<SEC-DOCUMENT>0001047469-19-005499.txt : 20190930
<SEC-HEADER>0001047469-19-005499.hdr.sgml : 20190930
<ACCEPTANCE-DATETIME>20190928030343
ACCESSION NUMBER:		0001047469-19-005499
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		30
FILED AS OF DATE:		20190927
DATE AS OF CHANGE:		20190928

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aprea Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001781983
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-233662
		FILM NUMBER:		191123878

	BUSINESS ADDRESS:	
		STREET 1:		535 BOYLSTON STREET
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		6095104718

	MAIL ADDRESS:	
		STREET 1:		535 BOYLSTON STREET
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>a2239779zs-1a.htm
<DESCRIPTION>S-1/A
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg17601_table_of_contents">  Table of Contents</A> <BR>
<A HREF="#fa">  Index to Financial Statements</A><BR></font>
</P>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT>


<FONT SIZE=1><B>As filed with the Securities and Exchange Commission on September&nbsp;27, 2019


 </B></FONT>

</P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B> Registration No.&nbsp;333-233662  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=1><B><BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=1><B> <div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>  </B></FONT><FONT SIZE=1><B>Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=1><B>


<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>


AMENDMENT NO. 3<BR>
TO

 </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>FORM S-1<BR>  </B></FONT><FONT SIZE=1><B>REGISTRATION STATEMENT<BR>
UNDER<BR>
THE SECURITIES ACT OF&nbsp;1933  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=1><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>Aprea Therapeutics,&nbsp;Inc.<BR>  </B></FONT><FONT SIZE=1>(Exact name of registrant as specified in its charter) </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="31%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="31%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="31%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Delaware</B></FONT><FONT SIZE=1><BR>
(State or other jurisdiction of<BR>
incorporation or organization)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B> 2834</B></FONT><FONT SIZE=1><BR>
(Primary Standard Industrial<BR>
Classification Code Number)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B> 84-2246769</B></FONT><FONT SIZE=1><BR>
(I.R.S. Employer<BR>
Identification No.)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>535 Boylston Street<BR>
Boston MA 02116<BR>
(617)&nbsp;463-9385</B></FONT><FONT SIZE=1><BR>
(Address, including zip code, and telephone number, including<BR>
area code, of registrant's principal executive offices) </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Christian S. Schade<BR>
President and Chief Executive Officer<BR>
Aprea Therapeutics,&nbsp;Inc.<BR>
535 Boylston Street<BR>
Boston, MA 02116<BR>
(617)&nbsp;463-9385<BR>  </B></FONT><FONT SIZE=1>(Name, address, including zip code, and telephone number, including<BR>
area code, of agent for service) </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="47%" style="font-family:times;"></TD>
<TD WIDTH="28pt" style="font-family:times;"></TD>
<TD WIDTH="47%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Copies to:</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=1><B>Geoffrey W. Levin, Esq.<BR>
Samir A. Gandhi, Esq.<BR>
Istvan A. Hajdu, Esq.<BR>
Sidley Austin&nbsp;LLP<BR>
787 Seventh Avenue<BR>
New York, NY 10019<BR>
Telephone: (212)&nbsp;839-5300<BR>
Fax: (212)&nbsp;839-5599</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=1><B> Richard D. Truesdell, Jr., Esq.<BR>
Derek&nbsp;Dostal,&nbsp;Esq.<BR>
Davis Polk&nbsp;&amp; Wardwell&nbsp;LLP<BR>
450 Lexington Avenue<BR>
New York, NY 10017<BR>
Telephone: (212)&nbsp;450-4000<BR>
Fax: (212)&nbsp;701-5800</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Approximate date of commencement of proposed sale to the public:<BR>
As soon as practicable after this Registration Statement is declared effective.</B></FONT></P>


<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act of 1933 check the
following box.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this form is filed to register additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>


<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this form is a post-effective amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>


<P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an
emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule&nbsp;12b-2 of the Exchange Act. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="102pt" style="font-family:times;"></TD>
<TD WIDTH="12%" style="font-family:times;"></TD>
<TD WIDTH="79pt" style="font-family:times;"></TD>
<TD WIDTH="12%" style="font-family:times;"></TD>
<TD WIDTH="96pt" style="font-family:times;"></TD>
<TD WIDTH="12%" style="font-family:times;"></TD>
<TD WIDTH="121pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Large&nbsp;accelerated&nbsp;filer&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Accelerated&nbsp;filer&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Non-accelerated&nbsp;filer&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;text-align:center;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"text-align:center;" -->


 Smaller&nbsp;reporting&nbsp;company&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT></font> <p align=center style="font-family:times;margin-top:0pt;margin-left:0pt;"> <FONT SIZE=1> Emerging growth company&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="25%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=1><B>CALCULATION OF REGISTRATION FEE

  </B></FONT>

</P>

<div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="30%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>TITLE OF EACH CLASS OF<BR>
SECURITIES TO BE REGISTERED</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>AMOUNT TO BE<BR>
REGISTERED(1)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>PROPOSED<BR>
MAXIMUM<BR>
OFFERING PRICE<BR>
PER SHARE</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>PROPOSED<BR>
MAXIMUM<BR>
AGGREGATE<BR>
OFFERING<BR>
PRICE(1)(2)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>AMOUNT OF<BR>
REGISTRATION<BR>
FEE(3)</B></FONT><BR></TH>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"><FONT SIZE=1><B> </B></FONT><FONT SIZE=1>Common Stock, par value $0.001 per share</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>5,750,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>$16.00</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>$92,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>$11,150.40</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=9 VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"> &nbsp;</TD>
</TR>
</TABLE></DIV>


<!-- end of user-specified TAGGED TABLE -->


<DL compact>

<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Includes
the additional shares that the underwriters have an option to purchase. See "Underwriting."


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Estimated
solely for purposes of calculating the registration fee in accordance with Rule&nbsp;457(a) under the Securities Act of 1933, as amended.


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Previously
paid.

 </FONT></DD>

</DL>

<P style="font-family:times;">


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT SIZE=1><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall
file&nbsp;a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or
until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine.</B></FONT>

</P>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=1>

<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p>

<P style="font-family:times;"><FONT SIZE=1><div
style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=135098,FOLIO='blank',FILE='DISK116:[19ZBM1.19ZBM17601]BA17601A.;55',USER='CHE106630',CD='27-SEP-2019;13:04' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<P style="font-family:times;"><FONT COLOR="#EF505F" SIZE=2><B>The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange
Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not
permitted. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;">

<FONT COLOR="#EF505F" SIZE=2><B>

Subject to Completion<BR>





Preliminary Prospectus dated September&nbsp;27, 2019</B></FONT>


</P>

<P style="font-family:times;"><FONT SIZE=2><B> PROSPECTUS</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>5,000,000 Shares  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>
<IMG SRC="g453739.jpg" ALT="LOGO" WIDTH="211" HEIGHT="138">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> Common Stock  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=4><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This is Aprea Therapeutics,&nbsp;Inc.'s initial public offering. We are offering 5,000,000 shares of our common stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
expect the public offering price to be between $14.00 and $16.00 per share. Prior to this offering, there has been no market for our common stock. We have applied to list our common
stock on the Nasdaq Global Select Market under the symbol "APRE." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are an "emerging growth company" and a "smaller reporting company" under federal securities laws and are subject to reduced public company disclosure standards for this prospectus and
future filings. See "Summary&#151;Implications of Being an Emerging Growth Company and Smaller Reporting Company." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=3><B>Investing in the common stock involves risks that are described in the "</B></FONT><FONT SIZE=3><B><I>Risk Factors</I></B></FONT><FONT SIZE=3><B>" section
beginning on page&nbsp;12 of this prospectus.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=3>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these
securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="74pt" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="74pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Per share </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1><B> </B></FONT><FONT SIZE=2>Public offering price</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Underwriting discount(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds, before expenses, to us</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:0%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>We
have agreed to reimburse the underwriters for certain FINRA-related expenses. We refer you to "Underwriting" beginning on page&nbsp;188 of this prospectus for
additional information regarding underwriting compensation. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters may also exercise their option to purchase up to an additional 750,000&nbsp;shares from us, at the public offering price, less underwriting discounts and commissions,
within 30&nbsp;days after the date of this prospectus. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
shares will be ready for delivery on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=2>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>Joint Book-Running Managers  </I></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="108pt" style="font-family:times;"></TD>
<TD WIDTH="7%" style="font-family:times;"></TD>
<TD WIDTH="199pt" style="font-family:times;"></TD>
<TD WIDTH="7%" style="font-family:times;"></TD>
<TD WIDTH="199pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=4><B>J.P. Morgan</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=4><B>Morgan Stanley</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=4><B>RBC Capital Markets</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>The
date of this prospectus is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019. </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=594032,FOLIO='blank',FILE='DISK116:[19ZBM1.19ZBM17601]BC17601A.;63',USER='CHE108067',CD='27-SEP-2019;09:01' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="be17601_explanatory_note"> </A>
<A NAME="toc_be17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Explanatory Note    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On September&nbsp;20, 2019, we consummated the corporate reorganization as described in this prospectus under the section titled "Corporate
Reorganization," pursuant to which all of the issued and outstanding stock and options of Aprea Therapeutics AB, a corporation domiciled in Sweden, were exchanged for common stock, preferred stock or
options, as applicable, of Aprea Therapeutics,&nbsp;Inc., the issuer of the common stock being offered in this offering. As a result of this corporate reorganization, Aprea Therapeutics AB became a
wholly-owned subsidiary of Aprea Therapeutics,&nbsp;Inc., a recently formed holding company with nominal assets and no liabilities, contingencies, or commitments, which has not conducted any
operations prior to this offering other than acquiring the entire issued and outstanding stock of Aprea Therapeutics AB. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
refer to these transactions throughout the prospectus included in this registration statement collectively as the "Holdco Reorganization." See "Corporate Reorganization" for further
detail regarding these transactions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
audited consolidated financial statements for 2017 and 2018 and the notes thereto, the unaudited interim condensed consolidated financial statements for the six months ended
June&nbsp;30, 2019 and 2018 and the notes thereto, and selected historical consolidated financial data and other financial information included in this registration statement are those of Aprea
Therapeutics AB and do not give effect to the Holdco Reorganization. The balance sheet of Aprea Therapeutics,&nbsp;Inc. at July&nbsp;11, 2019, included in this registration statement, does not
give effect to the Holdco Reorganization. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Immediately
prior to the completion of this offering, and with the consent of shareholders representing a majority of our outstanding preferred shares, all outstanding shares of our
convertible preferred stock, including the shares issued as part of the Holdco Reorganization, will convert into an aggregate
of 13,028,292 shares of our common stock. Shares of the common stock of Aprea Therapeutics,&nbsp;Inc. are being offered by the prospectus included in this registration statement. </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=435604,FOLIO='blank',FILE='DISK116:[19ZBM1.19ZBM17601]BE17601A.;27',USER='CHE108067',CD='27-SEP-2019;09:01' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_bg17601_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="BG17601A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="bg17601_table_of_contents"> </A>
<BR></FONT><FONT SIZE=2><B>  Table of Contents    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=1>
<A NAME="BG17601_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Page </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ca17601_summary"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Summary</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ca17601_summary"><FONT SIZE=2>1</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da17601_risk_factors"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk Factors</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da17601_risk_factors"><FONT SIZE=2>12</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dk17601_special_note_regarding_forward-looking_statements"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Special Note Regarding Forward-Looking Statements</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dk17601_special_note_regarding_forward-looking_statements"><FONT SIZE=2>75</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dk17601_use_of_proceeds"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Use of Proceeds</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dk17601_use_of_proceeds"><FONT SIZE=2>77</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dk17601_dividend_policy"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dividend Policy</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dk17601_dividend_policy"><FONT SIZE=2>78</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dm17601_corporate_reorganization"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corporate Reorganization</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dm17601_corporate_reorganization"><FONT SIZE=2>79</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dm17601_capitalization"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Capitalization</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dm17601_capitalization"><FONT SIZE=2>80</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dm17601_dilution"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dilution</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dm17601_dilution"><FONT SIZE=2>82</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dm17601_selected_financial_data"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Selected Financial Data</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dm17601_selected_financial_data"><FONT SIZE=2>85</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#do17601_management_s_discussion_and_an__man03466"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Management's Discussion and Analysis of Financial Condition and Results of
Operations</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#do17601_management_s_discussion_and_an__man03466"><FONT SIZE=2>86</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dq17601_business"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Business</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dq17601_business"><FONT SIZE=2>102</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ea17601_management"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Management</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ea17601_management"><FONT SIZE=2>153</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ec17601_executive_compensation"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Executive Compensation</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ec17601_executive_compensation"><FONT SIZE=2>162</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ee17601_principal_stockholders"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Principal Stockholders</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ee17601_principal_stockholders"><FONT SIZE=2>173</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#eg17601_description_of_capital_stock"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Description of Capital Stock</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#eg17601_description_of_capital_stock"><FONT SIZE=2>176</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ei17601_shares_eligible_for_future_sale"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares Eligible for Future Sale</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ei17601_shares_eligible_for_future_sale"><FONT SIZE=2>181</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ei17601_material_u.s._federal_income_t__mat02456"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Material U.S. Federal Income Tax Considerations to Non-U.S. Holders</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ei17601_material_u.s._federal_income_t__mat02456"><FONT SIZE=2>184</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ek17601_underwriting"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Underwriting</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ek17601_underwriting"><FONT SIZE=2>188</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ek17601_legal_matters"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal Matters</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ek17601_legal_matters"><FONT SIZE=2>196</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ek17601_experts"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Experts</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ek17601_experts"><FONT SIZE=2>196</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ek17601_where_you_can_find_more_information"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Where You Can Find More Information</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ek17601_where_you_can_find_more_information"><FONT SIZE=2>196</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#fa"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Index to Financial Statements</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#fa"><FONT SIZE=2>F-1</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Through and including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019 (the 25th&nbsp;day after the date of this prospectus), all dealers
that effect transactions in these securities,
whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers' obligation to deliver a prospectus when acting as underwriters and with
respect to their unsold allotments or subscriptions.</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are responsible for the information contained in this prospectus. We have not, and the underwriters have not, authorized anyone to provide you with any information other than what is
provided in this prospectus. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you or any
representation that others may make to you. We are not, and the underwriters are not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. The
information in this prospectus is accurate only as of the date of this prospectus, regardless of the time of any sale of the common stock. Our business, liquidity position, financial condition,
prospects or results of operations may have changed since the date of this prospectus. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>This prospectus contains forward-looking statements that are subject to a number of risks and uncertainties, many of which are beyond our control. See "Risk
Factors" and "Special Note Regarding Forward-Looking Statements."</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
investors outside the United States: We have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any
jurisdiction where action for that purpose is required, other than in the United States. Persons outside </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>i</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=4,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=421765,FOLIO='i',FILE='DISK116:[19ZBM1.19ZBM17601]BG17601A.;49',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_bg17601_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2>the
United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of
this prospectus outside the United States. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
this prospectus, unless otherwise stated or the context otherwise requires, references to "Aprea," "the company," "we," "us," "our" and similar references refer to Aprea Therapeutics,
Inc. and its consolidated subsidiaries, after giving effect to the Holdco Reorganization, and to Aprea Therapeutics AB and its consolidated subsidiaries prior to giving effect to the Holdco
Reorganization. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Presentation of financial and operating data  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise indicated, the historical financial and operating information presented in this prospectus as of and for the years ended
December&nbsp;31, 2017 and&nbsp;2018 and for the six months ended June&nbsp;30, 2018 and 2019 is that of Aprea Therapeutics AB. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain
amounts and percentages included in this prospectus have been rounded. Accordingly, in certain instances, the sum of the numbers in a column of a table may not exactly equal the
total figure for that column. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
audited consolidated financial statements for the years ended December&nbsp;31, 2017 and&nbsp;2018 and the notes thereto, the unaudited interim condensed consolidated financial
statements for the six months
ended June&nbsp;30, 2018 and 2019 and the notes thereto, represent the operations of Aprea Therapeutics AB and its consolidated subsidiaries and do not give effect to the Holdco Reorganization. The
balance sheet of Aprea Therapeutics,&nbsp;Inc. at July&nbsp;11, 2019, included in this registration statement, does not give effect to the Holdco Reorganization. On September&nbsp;20, 2019, we
consummated the corporate reorganization as described under the section titled "Corporate Reorganization." In this prospectus, we refer to this transaction as the "Holdco Reorganization." We expect
that the Holdco Reorganization will not have a material effect on our consolidated financial statements. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Industry and market data  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We obtained the industry, market and competitive position data used throughout this prospectus from our own internal estimates and research, as
well as from independent market research, industry and general publications and surveys, governmental agencies and publicly available information in addition to research, surveys and studies conducted
by third parties. Internal estimates are derived from publicly available information released by industry analysts and third-party sources, our internal research and our industry experience, and are
based on assumptions made by us based on such data and our knowledge of our industry and market, which we believe to be reasonable. In some cases, we do not expressly refer to the sources from which
this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is
derived from the same sources, unless otherwise expressly stated or the context otherwise requires. In addition, while we believe the industry, market and competitive position data included in this
prospectus is reliable and based on reasonable assumptions, such data involve risks and uncertainties and are subject to change based on various factors, including those discussed in "Risk Factors."
These and other factors could cause results to differ materially from those expressed in the estimates made by third parties or by us. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Trademarks and tradenames  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Aprea and other trademarks or service marks of Aprea appearing in this prospectus are the property of Aprea. The other trademarks, trade names
and service marks appearing in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus are referred to without the
&reg; and &#153; symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their
rights thereto. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>ii</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=5,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=58990,FOLIO='ii',FILE='DISK116:[19ZBM1.19ZBM17601]BG17601A.;49',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ca17601_summary"> </A>
<A NAME="toc_ca17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Summary    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>This summary highlights, and is qualified in its entirety by, the more detailed information and financial statements
included elsewhere in this prospectus. This summary does not contain all of the information that may be important to you. You should read and carefully consider the entire prospectus, especially our
financial statements and the notes thereto appearing at the end of this prospectus and the "Risk Factors" section of this prospectus, before deciding to invest in our common stock. Except as otherwise
indicated herein or as the context otherwise requires, references in this prospectus to "Aprea," "the
company," "we," "us" and "our" refer to Aprea Therapeutics,&nbsp;Inc. and its consolidated subsidiaries, after giving effect to the Holdco Reorganization described herein, and to Aprea Therapeutics
AB, referred to herein as Aprea AB, and its consolidated subsidiaries prior to giving effect to the Holdco Reorganization.</I></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Aprea Therapeutics overview  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a clinical-stage biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53
tumor suppressor protein. p53 is the protein expressed from the </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> gene, the most commonly mutated gene in cancer. We believe that mutant p53 is an
attractive therapeutic target due to the high incidence of p53 mutations across a range of cancer types and its involvement in key cellular activities such as apoptosis. Cancer patients with mutant
p53 face a significantly inferior prognosis even when treated with the current standard of care, and a large unmet need for these patients remains. Our lead product candidate, APR-246, is a small
molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes, or MDS, and acute myeloid leukemia, or AML. APR-246 has received
Orphan Drug and Fast Track designations from the FDA for MDS, and Orphan Drug designation from the EMA for MDS, AML and ovarian cancer, and we believe APR-246 will be a first-in-class therapy if
approved by applicable regulators. We have commenced a pivotal Phase&nbsp;3 trial of APR-246 with azacitidine for frontline treatment of </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant
MDS and expect initial data from this trial in the second half of 2020. Our pivotal Phase&nbsp;3 trial is supported by data from two ongoing Phase&nbsp;1b/2 investigator initiated trials, one in
the U.S. and one in France, testing APR-246 with azacitidine as frontline treatment in </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant MDS and AML patients. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the ongoing U.S. Phase&nbsp;1b/2 trial, sponsored by Dr.&nbsp;David Sallman of the H. Lee Moffitt Cancer Center and Research Institute, or Moffitt, we have observed an objective
response rate, or ORR, of 88% and a complete remission, or CR, rate of 59% in 41 response-evaluable MDS/AML patients treated with APR-246 and azacitidine, as of July 2019 and we expect a final CR
endpoint in the second half of 2019. In MDS patients, the CR rate was 61%, with an additional 27% achieving non-CR responses. In AML patients, the CR rate was 50%, with an additional 38% achieving
non-CR responses. In addition, 46% of evaluable patients were able to discontinue treatment in order to proceed to allogeneic hematopoietic stem cell transplantation, or allo-HCT. Allo-HCT is
currently the only recognized therapy believed to increase the likelihood of long term survival for </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant MDS and AML patients in remission. In
the ongoing French Phase&nbsp;1b/2 trial, sponsored by Groupe Francophone des Myelodysplasies, or GFM, under lead investigator Prof. Pierre Fenaux, we have observed an ORR of 75% and a CR rate of
56% in 16 response-evaluable patients treated with APR-246 and azacitidine, as of July 2019 and we expect a final CR endpoint in the first half of 2020. In MDS patients, the CR rate was 55%, with an
additional 18% achieving non-CR responses. In AML patients, the CR rate was 60%, with an additional 20% achieving non-CR responses. We expect the results of our pivotal Phase&nbsp;3 trial and the
U.S. and French Phase&nbsp;1b/2 trials will be submitted in support of marketing applications to the FDA and EMA. We are also developing a next-generation small molecule p53 reactivator, APR-548,
for potential use in multiple hematologic malignancies and other oncologic indications, and expect to file an IND with the FDA in the first half of 2020. We </FONT></P>
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=6,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=519545,FOLIO='blank',FILE='DISK116:[19ZBM1.19ZBM17601]CA17601A.;66',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_ca17601_1_2"> </A>
 <p style="font-family:times;"><font size=0>&nbsp;</FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;"><FONT SIZE=2>currently
retain global development and commercialization rights to all of our preclinical and clinical product candidates, which are summarized in the following figure: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g701865.jpg" ALT="GRAPHIC" WIDTH="672" HEIGHT="400">
  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Investigator-initiated
trial
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>With
or without azacitidine </FONT></DD></DL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that targeting p53 and thereby reactivating key intrinsic cellular functions has the potential to significantly impact patients' lives and treatment strategies for a wide
variety of cancers. p53 is a tumor suppressor protein that in its normal state functions to sense DNA damage and induce cell cycle
arrest, DNA damage repair, senescence and cellular apoptosis. Mutant p53 is an attractive target because it is widely mutated across hematologic and solid tumors and is associated with an aggressive
clinical and molecular phenotype. In preclinical studies and clinical trials, mutations in p53 and the apoptotic pathway have been shown to play a key role in cancer genesis, proliferation and
resistance to currently marketed therapeutic agents. Many approved and clinical stage oncology drugs are more effective with a functional p53 pathway. Our approach is to restore normal function to
p53, thereby re-enabling a cell's ability to undergo apoptosis. Accordingly, we believe that by targeting p53, our drug candidates may enhance the ability of other anti-cancer therapies to induce
cancer cell death. In addition, we believe that our approach may counteract resistance mechanisms that characterize many of the most aggressive cancers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe there is a significant market opportunity for therapies targeting mutant p53 because these mutations occur in more than half of all tumors and confer an inferior prognosis
relative to patients with wild type p53. Based on the importance of p53 mutations as disease-driver mutations, the sensitivity of hematopoietic cells to oxidative stress and continued unmet medical
need, we have initially focused our clinical development on hematological malignancies, MDS and AML, with mutations in the </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> gene. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MDS
is a collection of bone marrow disorders in which malignant hematopoietic cells prevent the production of healthy, mature blood cells. As of 2019, there are an estimated 200,000 MDS
patients </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=7,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=1028521,FOLIO='2',FILE='DISK116:[19ZBM1.19ZBM17601]CA17601A.;66',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_ca17601_1_3"> </A>
 <p style="font-family:times;"><font size=0>&nbsp;</FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;"><FONT SIZE=2>worldwide,
with 68,000 of these in the United States and 69,000 MDS patients across the five major markets of the European Union and Japan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AML
is the most common form of adult leukemia, with the highest incidence in patients age 60&nbsp;years and older. Like MDS, AML is characterized by proliferation of abnormal immature
white blood cells which impair production of normal blood cells. There are an estimated 213,000 AML patients worldwide, with 37,000 of these in the United States, and 41,000 across the five major
markets of the European Union and Japan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MDS
and AML can develop </FONT><FONT SIZE=2><I>de novo</I></FONT><FONT SIZE=2> or may arise secondary to progression of other hematologic disorders or from chemotherapy or radiation
treatment for a different, prior malignancy. Secondary MDS and AML carry a worse prognosis than </FONT><FONT SIZE=2><I>de novo</I></FONT><FONT SIZE=2> disease. Mutations in </FONT> <FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> occur in approximately
20% of patients with newly diagnosed MDS/AML and in more than 30% of patients with therapy-related MDS/AML. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Treatment
with azacitidine is the standard of care for frontline therapy in </FONT><FONT SIZE=2><I>TP53 </I></FONT><FONT SIZE=2>mutant MDS and AML, with an ORR of approximately 40-50%,
a CR rate of approximately 10-20% and median overall survival, or OS, of approximately 7-8&nbsp;months. There are no established curative pharmacologic therapies for MDS and AML. Allo-HCT is
currently the only recognized therapy believed to increase the likelihood of long term survival for </FONT><FONT SIZE=2><I>TP53 </I></FONT><FONT SIZE=2>mutant MDS and AML patients in remission;
however, many patients are not candidates for allo-HCT due to lack of sufficient clinical response to therapy, advanced age, comorbidities or lack of a suitable donor. Unfortunately, even for those </FONT> <FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2>
mutant MDS and AML patients who receive allo-HCT, the post-transplantation prognosis is poor: </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2>
mutations are associated with a 4-fold increased risk of death and 1-year relapse-free survival of only 30% following transplantation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Given
the poor prognosis for patients with </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant MDS and AML, there is a significant need for more effective therapies in this
population, particularly if such treatments have a favorable safety profile, and a mechanism of action that targets mutant p53 directly, and may be used in combination with existing or future
treatment options. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have assembled an outstanding team, which includes world-class scientific and clinical oncology leaders, to execute on our mission to create novel p53-reactivating therapies to help
patients suffering with cancer. Together with our board of directors, our scientific founders and members of our management team have significant experience in drug discovery and development and
finance. Collectively, we believe our team's strong capabilities position us to build a leading biotech company focused on developing novel cancer therapies to address the significant unmet medical
need of patients with p53 mutant malignancies, for whom there are limited effective therapeutic options. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our drug candidates  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our lead product candidate, APR-246, is a small molecule that has demonstrated reactivation of mutant p53 in clinical trials. Promising clinical
data support the application of APR-246 across a variety of hematologic malignancies and other oncologic indications. APR-246 is a pro-drug that is administered intravenously and forms the active
moiety, 2-methylene-quinuclidin-3-one, or MQ, under physiological conditions. APR-246 has been shown to induce apoptosis in cancer cells with mutant p53 in Phase 1/2 trials. We believe the mechanism
of action and current adverse event profile of APR-246 may provide the basis for its combination with both conventional and novel therapies, such as targeted therapies, chemotherapy, radiotherapy and
immuno-therapy. APR-246 has received Orphan
Drug and Fast Track designations from the FDA for MDS, and Orphan Drug designation from the EMA for MDS, AML and ovarian cancer. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=8,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=794647,FOLIO='3',FILE='DISK116:[19ZBM1.19ZBM17601]CA17601A.;66',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_ca17601_1_4"> </A>
 <p style="font-family:times;"><font size=0>&nbsp;</FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are conducting and supporting multiple clinical trials of APR-246:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B>Pivotal Phase&nbsp;3 MDS Trial-</B></FONT><FONT SIZE=2> We are currently enrolling a pivotal Phase&nbsp;3
randomized, controlled trial evaluating APR-246 with azacitidine as frontline therapy in HMA-na&iuml;ve </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant MDS patients. The first
patient was enrolled in January 2019 and we anticipate full enrollment in our Phase&nbsp;3 trial in the first quarter of 2020 and top-line data from this trial in the second half of 2020. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B>U.S.&nbsp;Phase&nbsp;1b/2 MDS/AML Trial-</B></FONT><FONT SIZE=2> We are supporting an investigator-initiated
Phase&nbsp;1b/2 single-arm, open-label trial in the United States, sponsored by Dr.&nbsp;David Sallman of the H.&nbsp;Lee&nbsp;Moffitt Cancer Center and Research Institute, or Moffitt,
evaluating APR-246 with azacitidine as frontline therapy in HMA-na&iuml;ve patients with </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant MDS or AML. We are collaborating with
Moffitt on this trial by supplying APR-246, in addition to providing financial support. The primary endpoint of the trial is CR rate and enrollment has completed with 55 patients. Top-line results on
the CR rate primary endpoint and median duration of response are expected in the second half of 2019. The regimen achieved an ORR of 88% and a CR rate of 59% in 41 response-evaluable patients as of
July 2019. In MDS patients, the CR rate was 61%, with an additional 27% achieving non-CR responses. In AML patients, the CR rate was 50%, with an additional 38% achieving non-CR responses. In
addition, 46% of evaluable MDS/AML patients were able to discontinue treatment in order to proceed to allo-HCT. By intention-to-treat analysis, and with a median follow up of 10.5 months, median OS
was 11.6 months (95% confidence interval: 9.2 - 14.0 months) with significantly prolonged OS of 12.8 months in responding patients versus 3.9 months in non-responding patients (p
&#60;0.0001). </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B>French Phase&nbsp;1b/2 MDS/AML Trial-</B></FONT><FONT SIZE=2> We are supporting a parallel investigator-initiated
Phase&nbsp;1b/2 single-arm, open-label trial in France, sponsored by Groupe Francophone des Myelodysplasies, or GFM, under lead investigator Prof. Pierre Fenaux, evaluating APR-246 with azacitidine
as frontline therapy in HMA-na&iuml;ve patients with </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant MDS or AML. We are collaborating with GFM on this trial by supplying APR-246,
in addition to providing financial support. The primary endpoint of the trial is CR rate and enrollment has completed with 53 patients. Top-line results on the CR rate primary endpoint are expected in
the first half of 2020. All patients are to receive the recommended Phase&nbsp;2 dose from the U.S.&nbsp;Phase&nbsp;1b/2 MDS/AML Trial. As of July 2019, the regimen has achieved an ORR of 75%
and CR rate of 56% in 16 response-evaluable patients. In MDS patients, the CR rate was 55%, with an additional 18% achieving non-CR responses. In AML patients, the CR rate was 60%, with an additional
20% achieving non-CR responses. Responding patients who proceed to allo-HCT are eligible to continue receiving APR-246 with azacitidine as post-transplant maintenance therapy. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B>Phase&nbsp;2 MDS/AML Post-Transplant Trial-</B></FONT><FONT SIZE=2> We are currently enrolling our single-arm,
open-label Phase&nbsp;2 trial evaluating APR-246 with azacitidine as post-transplant maintenance therapy in </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant MDS and AML patients who have
received allo-HCT. The primary endpoint is relapse-free survival at 12&nbsp;months. We anticipate full enrollment in the first half of 2020. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B>Phase 1/2 AML Trials-</B></FONT><FONT SIZE=2> Based on </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> data
evidencing synergistic activity between APR-246 and a Bcl-2 inhibitor, we have designed and plan to conduct Phase 1/2 clinical trials in frontline and relapsed/refractory AML assessing APR-246 with a
Bcl-2 inhibitor with or without azacitidine. We anticipate the first patient to be enrolled in the fourth quarter of 2019. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
second product candidate, APR-548, is a next-generation p53 reactivator with the potential for oral administration. APR-548 is a unique analog of APR-246 and therefore a pro-drug of
MQ. We have filed a patent application in support of composition of matter and methods of use intellectual property protection for APR-548.&nbsp;APR-548 exhibits high oral bioavailability in
preclinical testing and is being developed in an oral dosage form. We are currently conducting Investigational New Drug, or IND, enabling preclinical trials of APR-548 and anticipate submitting an IND
in the first half of 2020. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=9,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=331946,FOLIO='4',FILE='DISK116:[19ZBM1.19ZBM17601]CA17601A.;66',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_ca17601_1_5"> </A>
 <p style="font-family:times;"><font size=0>&nbsp;</FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our strategy  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our mission is to be the leading player in the development and commercialization of p53-targeted cancer therapies. The key elements of our
strategy are to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Rapidly develop and commercialize our lead mutant p53 reactivator product candidate, APR-246, in frontline combination therapy for </FONT> <FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant MDS
</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Expand the clinical opportunity for APR-246 by pursuing development of combination therapy for post-transplant maintenance in </FONT> <FONT SIZE=2><I>TP53</I></FONT><FONT
SIZE=2> mutant MDS and AML </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Rapidly develop APR-246 for frontline and relapsed/refractory </FONT><FONT SIZE=2><I>TP53 </I></FONT><FONT SIZE=2>mutant AML </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Advance our next-generation p53 reactivator, APR-548 </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Explore additional oncology indications for APR-246 and APR-548</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Maximize the commercial opportunity of our product candidates across global markets </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks associated with our business  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our ability to execute on our business strategy is subject to a number of risks, which are discussed more fully in the section of this
prospectus entitled "Risk Factors." You should carefully consider these risks before making an investment in our common stock. These risks include, among others, the
following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We have incurred significant losses since inception. We expect to incur losses for the foreseeable future and may never achieve or maintain
profitability. As of June&nbsp;30, 2019, we had an accumulated deficit of $71.2&nbsp;million. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.
We have never generated revenues and may never be profitable. Our lead product candidate, APR-246, is currently in multiple clinical trials and all of our other product candidates are in preclinical
research. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will enable us to fund our operating
expenses and capital expenditure requirements into 2023. We expect that the net proceeds from this offering and our existing cash and cash equivalents will be sufficient to enable us to complete each
of our ongoing clinical trials. We do not expect that the net proceeds from this offering and our existing cash and cash equivalents will be sufficient, however, to enable us to conduct through
completion any additional clinical trials of APR-246 or to otherwise complete the development of APR-246. Accordingly, we will need substantial additional funding, which may not be available to us on
acceptable terms or at all, to complete development of APR-246 and to fund development of our next-generation p53 reactivator, APR-548. If we are unable to raise capital when needed, we may be forced
to delay, reduce and/or eliminate our research and drug development programs or commercialization efforts. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We are substantially dependent on the success of APR-246 and cannot be certain that we will receive marketing approval for APR-246 or will
successfully commercialize APR-246 even if we receive such marketing approval. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> If we experience delays or difficulties in the enrollment of patients in clinical trials, we may not be able to initiate or complete clinical
trials for our product candidates on a timely basis. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results
of a clinical trial do not necessarily predict final results. </FONT></DD></DL>
</UL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=10,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=521274,FOLIO='5',FILE='DISK116:[19ZBM1.19ZBM17601]CA17601A.;66',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_ca17601_1_6"> </A>
 <p style="font-family:times;"><font size=0>&nbsp;</FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not
otherwise produce positive results, we may incur additional costs, experience delays in completing, or ultimately be unable to complete, the development of our product candidates or be unable to
obtain marketing approval. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We rely on third parties to conduct our clinical trials, some aspects of our research and preclinical studies and the manufacturing of our
product candidates. If these third parties do not perform satisfactorily, including by failing to meet deadlines for the completion of such trials, research and studies, we could be delayed in our
clinical development activities or in our efforts to obtain marketing approval of our product candidates. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The chemical structure of APR-246 is in the public domain. Accordingly, we do not own or license any composition of matter patents claiming the
compound of APR-246 and will not in the future own or license any composition of matter patents claiming the chemical structure of APR-246 as described in the public domain. Our patent portfolio for
APR-246 currently consists of method-of-use and formulation patent claims, and dosing, manufacturing processes, and crystalline solid form provisional patent application claims. If we are unable to
obtain or maintain patent and other intellectual property-related protection of our proprietary technologies and our product candidates, including APR-246, their respective components, formulations,
methods used to manufacture them and methods of treatment, if the scope of the patent protection obtained is not sufficiently broad, or if we are unable to successfully defend our patents against
third-party challenges or enforce our patents against third-parties, our competitors and other third parties could develop and commercialize products and technology similar or identical to ours, and
our ability to successfully commercialize any product candidate we may develop and our technology may be adversely affected.</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our commercial success depends in part on the ability to avoid and successfully defend claims that we have infringed, misappropriated or
otherwise violated the intellectual property of a third party. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our corporate information  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We were incorporated under the laws of the State of Delaware in May&nbsp;2019 under the name Aprea Therapeutics,&nbsp;Inc. On
September&nbsp;20, 2019, we consummated the Holdco Reorganization, pursuant to which all of the issued and outstanding stock and options of Aprea Therapeutics AB, or Aprea AB, were exchanged for
common stock, preferred stock or options, as applicable, of Aprea Therapeutics,&nbsp;Inc. As a result of the HoldCo Reorganization, Aprea AB, became a wholly-owned subsidiary of Aprea
Therapeutics,&nbsp;Inc. See "Corporate Reorganization" for additional information. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are a holding company. We conduct substantially all of our operations through our subsidiaries. Our subsidiary, Aprea&nbsp;AB, a corporation domiciled in Sweden, was originally
incorporated in&nbsp;2002 and commenced principal operations in&nbsp;2006, and holds substantially all of our intellectual property assets. Our executive offices are located at 535 Boylston
Street, Boston, MA 02116, and our telephone number is 617-463-9385. Our website address is www.aprea.com. The information contained on, or that can be accessed through, our website is not a part of
this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Implications of being an emerging growth company and smaller reporting company  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a company with less than $1.07&nbsp;billion of revenue during our last fiscal year, we qualify as an "emerging growth company" as defined
in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We may remain an emerging growth company for up to five years, or until such earlier time as we have more than $1.07&nbsp;billion
in annual revenue, the market value of our stock held by non-affiliates is more than $700&nbsp;million (and we have been a public company for at least 12&nbsp;months </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=11,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=513158,FOLIO='6',FILE='DISK116:[19ZBM1.19ZBM17601]CA17601A.;66',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_ca17601_1_7"> </A>
 <p style="font-family:times;"><font size=0>&nbsp;</FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:times;"><FONT SIZE=2>and
have filed one annual report on Form&nbsp;10-K with the Securities and Exchange Commission, or the SEC) or we issue more than $1&nbsp;billion of non-convertible debt over a three-year period.
For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure and other requirements that are applicable to other public companies that
are not emerging growth companies. These provisions include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reduced disclosure about our executive compensation arrangements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> exemption from the non-binding stockholder advisory votes on executive compensation or golden parachute arrangements; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting;
and</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reduced disclosure of financial information in this prospectus, such as being permitted to include only two years of audited financial
information and two years of selected financial information in addition to any required unaudited interim financial statements, with correspondingly reduced "Management's Discussion and Analysis of
Financial Condition and Results of Operations" disclosure. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have taken advantage of some reduced reporting burdens in this prospectus. Accordingly, the information contained herein may be different than the information you receive from other
public companies in which you hold stock. In addition, the JOBS Act permits an emerging growth company to take advantage of an extended transition period to comply with new or revised accounting
standards applicable to public companies until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption and, as a result, upon
completion of this offering we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies that are not emerging
growth companies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are also a "smaller reporting company," as such term is defined in Rule 12b-2 under the Securities Exchange Act of 1934, or the Exchange Act, meaning that the market value of our
common stock held by non-affiliates plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700 million and our annual revenue is less than $100 million
during the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i) the market value of our common stock held by non-affiliates is less
than $250 million or (ii)&nbsp;our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our common stock held by non-affiliates is less
than $700 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are
available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual
Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=12,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=600182,FOLIO='7',FILE='DISK116:[19ZBM1.19ZBM17601]CA17601A.;66',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_cb17601_1_8"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="cb17601_the_offering"> </A>
<A NAME="toc_cb17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  The Offering    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <P style="font-family:times;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->



  </B></FONT></P>


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2><B> </B></FONT><FONT SIZE=2><B> Common stock offered by us </B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> 5,000,000 shares</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2><B> </B></FONT><FONT SIZE=2><B>Underwriters' option to purchase additional shares </B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> We have granted the underwriters a 30-day option to purchase up to 750,000 additional shares at the public offering price,
less underwriting discounts and commissions.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2><B> </B></FONT><FONT SIZE=2><B>Common&nbsp;stock&nbsp;to&nbsp;be&nbsp;outstanding after the offering </B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> 19,209,865 shares (or 19,959,865 shares if the underwriters exercise in full their option to purchase additional
shares)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2><B> </B></FONT><FONT SIZE=2><B>Use of proceeds </B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> We estimate that our net proceeds from this offering, after deducting the underwriting discounts and commissions and
estimated offering expenses payable by us, will be approximately $66.6 million, or $77.0 million if the underwriters exercise their option to purchase additional shares in full, assuming an initial public offering price of $15.00 per share, which is
the mid-point of the price range set forth on the cover page of this prospectus. We intend to use the net proceeds from the offering to fund: (i)&nbsp;future Phase&nbsp;1b/2 clinical studies of APR-246 for solid tumor and hematological malignancies
as well as additional future clinical studies to be determined if the data derived from such Phase&nbsp;1b/2 clinical studies is favorable; (ii)&nbsp;continued research and development activities for APR-548, including ongoing IND-enabling studies
and a first-in-human clinical trial; (iii)&nbsp;the ongoing preclinical and clinical development of APR-246, including preparation and submission of a New Drug Application (NDA) in MDS; and (iv)&nbsp;general research and development activities,
working capital and other general corporate activities including the buildout of infrastructure to support the advancement of our product candidates. See "Use of Proceeds" on page&nbsp;77 for a more complete description of the intended use of
proceeds from this offering.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2><B> </B></FONT><FONT SIZE=2><B>Directed share program </B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> The underwriters have reserved up to 3% of the shares of common stock being offered by this prospectus (excluding the
shares of common stock that may be issued upon the underwriters' exercise of their option to purchase additional common stock) for sale to our directors, officers, employees, business associates and related persons of the Company. The number of
shares of common stock available for sale to the general public will be reduced to the extent these individuals purchase such reserved shares. Any reserved shares that are not so purchased will be offered by the underwriters to the general public on
the same basis as the other shares offered by this prospectus. See "Underwriting&#151;Directed Share Program."</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
<p style="font-family:times;"><font size=1></FONT><FONT SIZE=2>
</font></p>
</DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=13,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=372372,FOLIO='8',FILE='DISK116:[19ZBM1.19ZBM17601]CB17601A.;13',USER='CHE108062',CD='27-SEP-2019;09:53' -->
<A NAME="page_cb17601_1_9"> </A>
 <p style="font-family:times;"><font size=0>&nbsp;</FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <P style="font-family:times;"><FONT SIZE=2><B>


<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->



  </B></FONT></P>


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2><B> </B></FONT><FONT SIZE=2><B> Risk factors </B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> See the "Risk Factors" section beginning on page&nbsp;12 of this prospectus, as well as other information included in this prospectus for a
discussion of factors to consider carefully before deciding to invest in shares of our common stock.</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2><B> </B></FONT><FONT SIZE=2><B>Proposed Nasdaq Global Select Market symbol </B></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> "APRE"</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The number of shares of our common stock to be outstanding after the completion of this offering is based on 14,209,865 shares outstanding as of June 30, 2019, after giving effect to the
Holdco Reorganization which took place on September 20, 2019 and the 1 for 1.6045 split of our common stock which took place on September 26, 2019 and assumes the conversion of our outstanding
convertible preferred stock into 13,028,292 shares of common stock immediately prior to the completion of this offering, and excludes:</FONT>

</P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 2,761,794 shares of common stock, with a weighted-average exercise price of $1.66 per share, issuable upon exercise of stock options
outstanding as of June&nbsp;30, 2019 under our 2016 Stock Incentive Plan; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 2,488,206 shares of common stock reserved for issuance pursuant to future awards under our 2019 Stock Incentive Plan or our Employee Stock
Purchase Plan, plus any future increases in the number of shares of common stock reserved for issuance under our 2019 Stock Incentive Plan or our Employee Stock Purchase Plan pursuant to provisions
thereof that automatically increase the share reserve under the plan each year. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
otherwise indicated or the context otherwise requires, information in this prospectus reflects and assumes the following:</FONT></P>


<UL>
<DL compact>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the 1 for 1.6045 split of our common stock which took place on September 26, 2019; </FONT><FONT SIZE=2>


<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the issuance of 2,807 shares of common stock from the exercise of stock options on March&nbsp;25, 2019, which were registered pursuant to
Swedish law with the Swedish Companies Registration office on August&nbsp;27, 2019; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> no exercise of outstanding options or warrants; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the completion of the Holdco Reorganization; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> no exercise by the underwriters of their option to purchase up to an additional 750,000 shares of our common stock; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the conversion of all of our outstanding shares of convertible preferred stock into an aggregate of 13,028,292 shares of common stock
immediately prior to the completion of this offering; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the filing and effectiveness of our amended and restated certificate of incorporation, which will occur immediately prior to the completion of
this offering. </FONT></DD></DL>
</UL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=14,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=490939,FOLIO='9',FILE='DISK116:[19ZBM1.19ZBM17601]CB17601A.;13',USER='CHE108062',CD='27-SEP-2019;09:53' -->
<A NAME="page_cb17601_1_10"> </A>
 <p style="font-family:times;"><font size=0>&nbsp;</FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="cb17601_summary_financial_data"> </A>
<A NAME="toc_cb17601_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Summary Financial Data    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>You should read the following summary financial data together with our financial statements and the related notes
appearing at the end of this prospectus and the "Selected Financial Data" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of this prospectus. We
have derived the statement of operations data for the years ended December&nbsp;31, 2017 and 2018 and the balance sheet data as of December&nbsp;31, 2018 from our audited financial statements
appearing at the end of this prospectus. The consolidated statements of operations data for the six months ended June&nbsp;30, 2018 and 2019 and the consolidated balance sheet data at
June&nbsp;30, 2019 are derived from our unaudited condensed consolidated financial statements included in this prospectus. The unaudited condensed consolidated financial statements include, in the
opinion of management, all adjustments that management considers necessary for the fair presentation of the consolidated financial information set forth in those statements. Our historical results are
not necessarily indicative of results that should be expected in any future period.</I></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Years ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Six months ended June&nbsp;30, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Consolidated Statement of Operations Data:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13,392,631</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14,194,732</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,492,788</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,998,270</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,459,744</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,294,671</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,166,520</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,347,915 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,852,375</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>16,489,403</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,659,308</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,346,185</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income (expense):</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(182</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(188</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(7,439</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign currency gain</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>662,140</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>961,316</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>949,158</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,615,974 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total other income (expense)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>662,125</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>961,134</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>948,970</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,608,535 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,190,250</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,528,269</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(7,710,338</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(8,737,650</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss per share attributable to common stockholders, basic and diluted(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(13.17</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(13.45</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(6.68</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(7.43</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted average common shares outstanding, basic and diluted(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,153,069</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,154,368</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,154,107</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,176,417 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma net loss per share attributable to common stockholders, basic and diluted (unaudited)(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.65</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.62</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma weighted average common shares outstanding, basic and diluted (unaudited)(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,428,873</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14,075,669 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>See
Note&nbsp;2 to our audited and unaudited interim financial statements included elsewhere in this prospectus for an explanation of the method used to calculate
basic and diluted net loss per share and unaudited pro forma net basic and diluted loss per share as well as the weighted-average number of shares used in the computation of the per share amounts. </FONT></DD></DL>
 </DIV>

 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=15,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=472180,FOLIO='10',FILE='DISK116:[19ZBM1.19ZBM17601]CB17601A.;13',USER='CHE108062',CD='27-SEP-2019;09:53' -->
<A NAME="page_cb17601_1_11"> </A>
 <p style="font-family:times;"><font size=0>&nbsp;</FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table sets forth summary balance sheet data as of June&nbsp;30, 2019:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> on an actual basis (including 2,807 shares of common stock from the exercise of stock options on March 25, 2019, which were registered pursuant
to Swedish law with the Swedish Companies Registration Office on August&nbsp;27, 2019); </FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> on a pro forma basis to give effect to (i)&nbsp;the Holdco Reorganization described under the section titled "Corporate Reorganization",
(ii)&nbsp;the 1 for 1.6045 split of our common stock which took place on September 26, 2019, (iii)&nbsp;the conversion of all of our outstanding shares of convertible preferred stock into an
aggregate of 13,028,292&nbsp;shares of common stock immediately prior to the completion of this offering and (iv)&nbsp;the filing and effectiveness of our amended and restated certificate of
incorporation; and </FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> on a pro forma as adjusted basis to give further effect to our issuance and sale of 5,000,000 shares of our common stock in this offering at an
assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and
commissions and estimated offering expenses payable by us. </FONT></DD></DL>
</UL>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="74pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="74pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>June&nbsp;30, 2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Actual </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Pro forma </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Pro forma<BR>
as adjusted(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Consolidated Balance Sheet Data:</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60,994,738</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60,994,738</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>127,544,738</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Working capital(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>56,215,210</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>56,215,210</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>122,765,210</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>62,214,654</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>62,214,654</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>128,764,654</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,878,053</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,878,053</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,878,053</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible preferred stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>118,188,993</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stockholders' equity (deficit)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(61,852,392</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>56,336,601</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>122,886,601</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>

<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>A
$1.00 increase or decrease in the assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page
of this prospectus, would increase or decrease the pro forma as adjusted amount of each of cash and cash equivalents, working capital, total assets and total stockholders' equity by
$4.7&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and
commissions. An increase or decrease of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase or decrease the pro forma as adjusted
amount of each of cash, cash and cash equivalents, working capital, total assets and total stockholders' equity by $14.0&nbsp;million, assuming no change in the assumed initial public offering price
per share and after deducting estimated underwriting discounts and commissions. This pro forma as adjusted information is illustrative only and will depend on the actual initial public offering price
and other terms of this offering determined at pricing.

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>We
define working capital as current assets less current liabilities. See our financial statements for further details regarding our current assets and current
liabilities. </FONT></DD></DL>
 </DIV>

 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=16,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=584686,FOLIO='11',FILE='DISK116:[19ZBM1.19ZBM17601]CB17601A.;13',USER='CHE108062',CD='27-SEP-2019;09:53' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_da17601_1_12"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da17601_risk_factors"> </A>
<A NAME="toc_da17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Risk Factors    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>Investing in our common stock involves a high degree of risk. Before you decide to invest in our common stock, you
should consider carefully the risks described below, together with the other information contained in this prospectus, including our financial statements and the related notes appearing at the end of
this prospectus. We believe the risks described below are the risks that are material to us as of the date of this prospectus. If any of the following risks actually occur, our business, financial
condition, results of operations and future growth prospects could be materially and adversely affected. In these circumstances, the market price of our common stock could decline, and you may lose
all or part of your investment.</I></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks related to our financial position and need for additional capital  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have incurred significant losses in each year since inception. We expect to incur losses for the
foreseeable future and may never achieve or maintain profitability.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since our inception, we have incurred significant losses on an aggregate basis. Our net loss was $8.7&nbsp;million for the six months ended
June&nbsp;30, 2019, and $15.5&nbsp;million for the year ended December&nbsp;31, 2018. Our accumulated deficit was $71.2&nbsp;million as of June&nbsp;30, 2019 and $62.5&nbsp;million as of
December&nbsp;31, 2018. We have not generated any revenue to date from sales of any drugs and have financed our operations principally through private placements of our preferred stock. We have
devoted substantially all of our efforts to research and development. Our lead product candidate, APR-246, is in clinical development, and our other product candidates are in preclinical research. As
a result, we expect that it will be several years, if ever, before we have any product candidates ready for commercialization. We expect to continue to incur significant expenses and increasing
operating losses for the foreseeable future. The net losses we incur may fluctuate significantly from quarter to quarter. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
become and remain profitable, we must develop, obtain approval for and eventually commercialize a drug or drugs with significant market potential, either on our own or with a
collaborator. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our product candidates, obtaining marketing
approval for these product candidates, manufacturing, marketing and selling those drugs for which we may obtain marketing approval and establishing and managing any collaborations for the development,
marketing and/or commercialization of our product candidates. We may never succeed in these activities and, even if we do, may never generate revenues that are significant or large enough to achieve
profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the
value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business and/or continue our operations. A decline in the value of our
company could also cause you to lose all or part of your investment. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even
if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditures to develop and market
additional product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net
losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse
effect on our stockholders' equity and working capital. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of drugs that we do not expect to be commercially
available for many years, if at all. If we are unable to obtain product approvals or generate significant commercial revenues, our business will be materially harmed. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=17,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=428086,FOLIO='12',FILE='DISK116:[19ZBM1.19ZBM17601]DA17601A.;40',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_da17601_1_13"> </A>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our limited operating history may make it difficult for you to evaluate the success of our business to date
and to assess our future viability. We have never generated revenues and may never be profitable.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are an early-stage company. Aprea Therapeutics AB, or Aprea AB, was originally incorporated in 2002 and commenced operations in 2006. We were
incorporated in May 2019. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, developing our lead product candidate, APR-246,
identifying potential product candidates, conducting preclinical studies of our product candidates and conducting clinical trials of our product candidates. All of our product candidates other than
APR-246 are in preclinical research. We have not yet demonstrated our ability to successfully complete large-scale, pivotal clinical trials, obtain marketing approvals, manufacture commercial-scale
drug products or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful drug commercialization. Typically, it takes about six to ten years
to develop a new drug from the time it is in Phase&nbsp;1 clinical trials to when it is approved for treating patients, but in many cases it may take longer. Consequently, any predictions you make
about our future success or viability may not be as accurate as they could be if we had a longer operating history. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We may need to
transition from a company with a research focus to a company capable of supporting commercial activities. We may not be successful in such a transition. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
we continue to build our business, we expect our financial condition and operating results may fluctuate significantly from quarter to quarter and year to year due to a variety of
factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any particular quarterly or annual periods as indications of future operating performance. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We will need substantial additional funding, which may not be available to us on acceptable terms or at all.
If we are unable to raise capital when needed, we may be forced to delay, reduce and/or eliminate our research and drug development programs or future commercialization efforts.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Developing drug products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain
process that takes years to complete. We expect our expenses to increase in connection with our ongoing activities, particularly as we conduct clinical trials of, and seek marketing approval for,
APR-246 and our other product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to drug
sales, marketing, manufacturing and distribution to the extent that such sales, marketing, manufacturing and distribution are not the responsibility of any collaborator that we may have at such time
for any such product candidate. Furthermore, commencing upon the completion of this offering, we expect to incur additional costs associated with operating as a public company. Accordingly, we will
need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we may be forced to delay, reduce
and/or eliminate our research and drug development programs or future commercialization efforts. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
plan to use the net proceeds from this offering to fund our ongoing clinical trials of APR-246 and additional research and clinical development activity related to APR-246 and other
programs and for working capital and other general corporate purposes, which may include additional research, hiring additional personnel, capital expenditures and the costs of operating as a public
company. We will be required to expend significant funds in order to advance the development of APR-246, as well as any other product candidates. In any event, the net proceeds from this offering and
our existing cash and cash equivalents will not be sufficient to fund all of the efforts that we plan to undertake or to fund the completion of development of any of our product candidates.
Accordingly, we will be required to </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=18,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=327181,FOLIO='13',FILE='DISK116:[19ZBM1.19ZBM17601]DA17601A.;40',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_da17601_1_14"> </A>

<P style="font-family:times;"><FONT SIZE=2>obtain
further funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources. We do not have any committed external source of funds.
Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our
ability to pursue our business strategy. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will enable us to fund our operating expenses and capital expenditure
requirements into 2023. Our estimate as to how long we expect the net proceeds from this offering, together with our existing cash and cash equivalents, to be able to continue to fund our operations
is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than
we currently expect. Further, changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to
seek additional funds sooner than planned. Our future capital requirements will depend on many factors, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the scope, progress, results and costs of our current and future clinical trials of APR-246 for our current targeted indications; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the scope, progress, results and costs of drug discovery, preclinical research and clinical trials for APR-246 and our other product
candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number of future product candidates that we pursue and their development requirements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs, timing and outcome of regulatory review of our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the extent to which we acquire or invest in businesses, products and technologies, including entering into or maintaining licensing or
collaboration arrangements for product candidates on favorable terms, although we currently have no commitments or agreements to complete any such transactions; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs and timing of future commercialization activities, including drug sales, marketing, manufacturing and distribution, for any of our
product candidates for which we receive marketing approval, to the extent that such sales, marketing, manufacturing and distribution are not the responsibility of any collaborator that we may have at
such time; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing
approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs of preparing, filing and prosecuting patent applications, maintaining, defending and enforcing our intellectual property rights and
defending intellectual property-related claims; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our headcount growth and associated costs as we expand our business operations and our research and development activities; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs of operating as a public company. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Raising additional capital may cause dilution to our stockholders, including purchasers of common stock in
this offering, restrict our operations or require us to relinquish rights to our product candidates.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect our expenses to increase in connection with our planned operations. Until such time, if ever, as we can generate substantial revenues
from the sale of drugs, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and/or licensing arrangements. To the extent
that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest may be diluted, and the terms of these securities could include liquidation or other
preferences and anti-dilution protections that could adversely affect your rights as a common stockholder. In addition, debt financing, if available, would result in fixed </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=19,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=327406,FOLIO='14',FILE='DISK116:[19ZBM1.19ZBM17601]DA17601A.;40',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_da17601_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2>payment
obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures,
creating liens, redeeming stock or declaring dividends, that could adversely impact our ability to conduct our business. In addition, securing financing could require a substantial amount of time and
attention from our management and may divert a disproportionate amount of their attention away from day-to-day activities, which may adversely affect our management's ability to oversee the
development of our product candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technology, future
revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, reduce and/or
eliminate our product candidate development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks related to the discovery, development and commercialization of our product candidates  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are substantially dependent on the success of our lead product candidate, APR-246, which is currently in
multiple clinical trials. Our clinical trials of APR-246 may not be successful. If we are unable to obtain approval for and commercialize APR-246 or experience significant delays in doing so, our
business will be materially harmed.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our future success is substantially dependent on our ability to timely obtain marketing approval for, and then successfully commercialize,
APR-246, our lead product candidate. We are investing a majority of our efforts and financial resources in the research and development of APR-246. Our other product candidates are in earlier stages
of development. Our business depends entirely on the successful development and commercialization of our product candidates. We currently have no drugs approved for sale and generate no revenues from
sales of any products, and we may never be able to develop a marketable product. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;APR-246
will require additional clinical development, evaluation of clinical, preclinical and manufacturing activities, marketing approval in multiple jurisdictions, substantial
investment and significant marketing efforts before we generate any revenues from product sales. We are not permitted to market or promote APR-246, or any other product candidates, before we receive
marketing approval from the FDA and comparable foreign regulatory authorities, and we may never receive such marketing approvals. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
success of APR-246 will depend on several factors, including the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> successful and timely completion of our ongoing clinical trials of APR-246; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> initiation and successful patient enrollment and completion of additional clinical trials on a timely basis; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to demonstrate APR-246's safety, tolerability and efficacy to the FDA or any comparable foreign regulatory authority for marketing
approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> timely receipt of marketing approvals for APR-246; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> obtaining and maintaining patent protection, trade secret protection and regulatory exclusivity, both in the United States and internationally; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> successfully defending and enforcing our rights in our intellectual property portfolio; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> avoiding and successfully defending against any claims that we have infringed, misappropriated or otherwise violated any intellectual property
of any third party; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=20,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=893609,FOLIO='15',FILE='DISK116:[19ZBM1.19ZBM17601]DA17601A.;40',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_da17601_1_16"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the performance of our future collaborators, if any; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the extent of, and our ability to timely complete, any required post-marketing approval commitments imposed by FDA or other applicable
regulatory authorities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establishment of supply arrangements with third-party raw materials and drug product suppliers and manufacturers who are able to manufacture
clinical trial and commercial quantities of APR-246 drug substance and drug product and to develop, validate and maintain a commercially viable manufacturing process that is compliant with current
good manufacturing practices, or cGMP, at a scale sufficient to meet anticipated demand and over time enable us to reduce our cost of manufacturing; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establishment of scaled production arrangements with third-party manufacturers to obtain finished products that are compliant with cGMP and
appropriately packaged for sale; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> successful launch of commercial sales following any marketing approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a continued acceptable safety profile following any marketing approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> commercial acceptance by patients, the medical community and third-party payors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the availability of coverage and adequate reimbursement and pricing by third-party payors and government authorities; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative and competing treatments; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to compete with other therapies. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual
property rights and the manufacturing, marketing, distribution and sales efforts of any future collaborator. Accordingly, we cannot assure you that we will ever be able to generate revenue through the
sale of APR-246. If we are not successful in commercializing APR-246, or are significantly delayed in doing so, our business will be materially harmed. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may find it difficult to enroll patients in our clinical trials given the relatively smaller patient
population who have the diseases for which our product candidates are being developed. If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of
necessary marketing approvals could be delayed or prevented.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number
of eligible patients to participate in these trials as required by the FDA or comparable foreign regulatory authorities. Patient enrollment is a significant factor in the timing of clinical trials. In
particular, because our clinical trials of APR-246 are focused on indications with relatively small patient populations, our ability to enroll eligible patients may be limited or may result in slower
enrollment than we anticipate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patient
enrollment may be affected if our competitors have ongoing clinical trials for product candidates that are under development for the same indications as our product candidates,
and patients who would otherwise be eligible for our clinical trials instead enroll in clinical trials of our competitors' product candidates. Patient enrollment may also be affected by other factors,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> size and nature of the patient population; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> severity of the disease under investigation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> availability and efficacy of approved drugs for the disease under investigation; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=21,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=80215,FOLIO='16',FILE='DISK116:[19ZBM1.19ZBM17601]DA17601A.;40',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_da17601_1_17"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> patient eligibility criteria for the trial in question; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> patients' and clinicians' perceived risks and benefits of the product candidate under study; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> competing clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> efforts to facilitate timely enrollment in clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> patient referral practices of physicians; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the ability to monitor patients adequately during and after treatment; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> proximity and availability of clinical trial sites for prospective patients; and</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> continued enrollment of prospective patients by clinical trial sites. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether.
Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain
additional financing. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The reactivation of p53 is a novel and unproven therapeutic approach and our development of APR-246 may never
lead to a marketable product.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are developing APR-246 for its ability to reactivate the tumor suppressor protein p53, the protein product of the </FONT> <FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> gene and the
most commonly mutated gene in cancer. We are also developing a next-generation p53&nbsp;reactivator, APR-548, for potential use in
multiple hematologic malignancy indications. We believe that mutant p53 is an attractive target for novel cancer therapy due to the high incidence of p53 mutations across a range of cancer types and
the universally inferior prognosis for cancer patients with mutated p53. However, to our knowledge, no one has advanced a product candidate with this mechanism of action into clinical development. The
scientific evidence to support the feasibility of developing these product candidates is both preliminary and limited. For instance, even though APR-246 has shown promising results in preclinical
studies and early-stage clinical trials, we may not succeed in demonstrating safety and efficacy of APR-246 in larger-scale clinical trials, including our pivotal Phase&nbsp;3 clinical trial.
Advancing APR-246 as a novel product to reactivate p53 creates significant challenges for us, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> obtaining marketing approval, as obtaining regulatory approval of a p53 reactivator from the FDA or comparable foreign regulatory authorities
has never been done before; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> educating medical personnel regarding the potential efficacy and safety benefits, as well as the challenges, of incorporating our product
candidates, if approved, into treatment regimens; and</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establishing the sales and marketing capabilities to gain market acceptance, if approved. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If serious adverse or unacceptable side effects are identified during the development of our product
candidates or we observe limited efficacy of our product candidates, we may need to abandon or limit the development of one or more of our product candidates.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adverse events or unacceptable side effects caused by, or other unexpected properties of, our product candidates could cause us, any future
collaborators, an institutional review board, or IRB, or regulatory authorities to interrupt, delay or halt clinical trials of one or more of our product candidates and could result in the
(i)&nbsp;delay or denial of marketing approval by the FDA or comparable foreign regulatory authorities, (ii)&nbsp;approval with significant restrictions on distribution or (iii)&nbsp;required
labeling information regarding safety concerns, if approved. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=22,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=313164,FOLIO='17',FILE='DISK116:[19ZBM1.19ZBM17601]DA17601A.;40',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dc17601_1_18"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
general, our clinical trials of APR-246 include cancer patients who are very sick and whose health is deteriorating, and we expect that additional clinical trials of APR-246 and our
other product candidates will include similar patients with deteriorating health. Multiple patients in our trials have experienced adverse events, including serious adverse events. The most commonly
reported adverse events include nausea, vomiting, constipation, dizziness and neutropenia. Some patients in our trials have experienced serious adverse events. See "Business&#151;Our Approach."
In the U.S. Phase&nbsp;1b/2 MDS/AML Trial, serious adverse events, regardless of causality, reported for more than one patient were: febrile neutropenia (27%), lung infection (9%), infections and
infestations (5%), respiratory failure (5%), sepsis (5%), vomiting (5%), chest pain (4%), dehydration (4%), intracranial hemorrhage (4%) and multi-organ failure (4%). In the Phase&nbsp;1b/2 Clinical
Trial of APR 246 in Platinum Sensitive Ovarian Cancer (PiSARRO), serious adverse events, regardless of causality, reported in more than one patient were: device related infection (17%), vomiting
(17%), febrile neutropenia (8%), infection (6%), small intestinal obstruction (6%) and thrombocytopenia (6%). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some
patients have died during their participation in the clinical trials for APR-246, and there has been one death reported by an investigator as possibly related to both APR-246 and
azacitidine. We believe this death may have been caused by the underlying disease, other comorbidities from which such patient was suffering or the other co-administered treatments. Any deaths
occurring in our clinical trials, whether related to our product candidate or not, could affect perceptions relating to our product candidate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any of our product candidates are associated with adverse events or undesirable side effects or have properties that are unexpected, our trials could be suspended or terminated and
the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. We, or any future
collaborators, may abandon development or limit development of that product candidate to certain uses or subpopulations in which the undesirable side effects or other characteristics are less
prevalent, less
severe or more acceptable from a risk-benefit perspective. Drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential
product liability claims. Any of these occurrences may harm our business, results of operations, financial condition and prospects significantly. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The outcome of preclinical testing and early clinical trials may not be predictive of the success of later
clinical trials, interim results of a clinical trial do not necessarily predict final results, and the results of our clinical trials may not satisfy the requirements of the FDA or comparable foreign
regulatory authorities.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently have no drugs approved for sale and we cannot guarantee that we will ever have marketable drugs. Clinical failure can occur at any
stage of clinical development. Clinical trials may produce negative or inconclusive results, and we or any future collaborators may decide, or regulators may require us, to conduct additional clinical
trials or preclinical studies. We will be required to demonstrate with substantial evidence through adequate and well-controlled clinical trials that our product candidates are safe and effective for
use in treating specific conditions in order to obtain marketing approvals for their commercial sale. Success in preclinical studies and early-stage clinical trials does not mean that future larger
registration clinical trials will be successful because product candidates in later-stage clinical trials may fail to demonstrate safety and efficacy to the satisfaction of the FDA and non-U.S.
regulatory authorities despite having progressed through preclinical studies and early-stage clinical trials. Product candidates that have shown promising results in preclinical studies and
early-stage clinical trials may still suffer significant setbacks in subsequent registration clinical trials. Additionally, the outcome of preclinical studies and early-stage clinical trials may not
be predictive of the success of later-stage clinical trials. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
time to time, we may publish or report interim or preliminary data from our clinical trials. Interim or preliminary data from clinical trials that we may conduct may not be
indicative of the final </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=23,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=193305,FOLIO='18',FILE='DISK116:[19ZBM1.19ZBM17601]DC17601A.;41',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dc17601_1_19"> </A>

<P style="font-family:times;"><FONT SIZE=2>results
of the trial and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Interim or
preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the interim or preliminary data. As a result, interim or
preliminary data should be viewed with caution until the final data are available. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the design of a clinical trial can determine whether its results will support approval of a drug and flaws in the design of a clinical trial may not become apparent until
the clinical trial is well advanced. We have limited experience in designing clinical trials and may be unable to design and
conduct a clinical trial to support marketing approval. Further, if our product candidates are found to be unsafe or lack efficacy, we will not be able to obtain marketing approval for them and our
business would be harmed. A number of companies in the pharmaceutical industry, including those with greater resources and experience than us, have suffered significant setbacks in advanced clinical
trials, even after obtaining promising results in preclinical studies and earlier clinical trials. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
some instances, there can be significant variability in safety and efficacy results between different clinical trials of the same product candidate due to numerous factors, including
changes in trial protocols, differences in size and type of the patient populations, differences in and adherence to the dosing regimen and other trial protocols and the rate of dropout among clinical
trial participants. We do not know whether any clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety sufficient to obtain marketing approval to market our product
candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have multiple clinical trials of APR-246 currently ongoing. In the event that an adverse safety issue, clinical hold or other adverse finding occurs in one or more of our clinical
trials of APR-246, such event could adversely affect our other clinical trials of APR-246. Moreover, there is a relatively limited safety data set for product candidates that are designed to
reactivate p53. An adverse safety issue or other adverse finding in a clinical trial conducted by a third party with a product candidate reactivate p53, could adversely affect our clinical trials of
APR-246. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further,
our product candidates may not be approved even if they achieve their primary endpoints in Phase&nbsp;3 clinical trials or registration trials. The FDA or non-U.S. regulatory
authorities may disagree with our trial design and our interpretation of data from preclinical studies and clinical trials. In addition, any of these regulatory authorities may change requirements for
the approval of a product candidate even after reviewing and providing comments or advice on a protocol for a pivotal clinical trial that has the potential to result in approval by the FDA or another
regulatory authority. In addition, any of these regulatory authorities may also approve a product candidate for fewer or more limited indications than we request or may grant approval contingent on
the performance of costly post-marketing clinical trials. In addition, the FDA or other comparable foreign regulatory authorities may not approve the labeling claims that we believe would be necessary
or desirable for the successful commercialization of our product candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Before
obtaining marketing approvals for the commercial sale of any product candidate for a target indication, we must demonstrate with substantial evidence gathered in preclinical
studies and adequate and well-controlled clinical trials, and, with respect to approval in the United States, to the satisfaction of the FDA and other comparable foreign regulatory authorities, that
the product candidate is safe and effective for use for that target indication. There is no assurance that the FDA or other comparable foreign regulatory authorities will consider our future clinical
trials to be sufficient to serve as the basis for approval of one of our product candidates for any indication. The FDA and other comparable foreign regulatory authorities retain broad discretion in
evaluating the results of our clinical trials and in determining whether the results demonstrate that a product candidate is safe and effective. If we are required to conduct additional clinical
trials of a product candidate than we expect prior to its approval, we will need substantial additional funds and there is no assurance that the results of any such additional clinical trials will be
sufficient for approval. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=24,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=239517,FOLIO='19',FILE='DISK116:[19ZBM1.19ZBM17601]DC17601A.;41',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dc17601_1_20"> </A>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Clinical drug development is a lengthy and expensive process, with an uncertain outcome. If clinical trials
of our product candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs, experience
delays in completing, or ultimately be unable to complete, the development of our product candidates or be unable to obtain marketing approval.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must complete preclinical development
and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates. Clinical testing is expensive, difficult to design and implement, can take many years to
complete and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical studies and early-stage clinical trials may not be
predictive of the success of later clinical trials, and interim results of a clinical trial, such as the results of our ongoing clinical trials of APR-246, do not necessarily predict final results.
Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in
preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their drugs. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
do not know whether ongoing clinical trials will be completed on schedule or at all, or whether future clinical trials will begin on time, need to be redesigned, enroll patients on
time or be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including delays related to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> obtaining regulatory authorization to commence a trial; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which
can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> obtaining institutional review board or ethics committee approval at each clinical trial site; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> recruiting suitable patients to participate in a trial; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> developing and validating any companion diagnostic to be used in the trial, to the extent we are required to do so; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> patients failing to comply with the clinical trial protocol or dropping out of a trial; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> clinical trial sites failing to comply with the clinical trial protocol or dropping out of a trial; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> addressing any conflicts with new or existing laws or regulations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the need to add new clinical trial sites; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> manufacturing sufficient quantities of product candidate for use in clinical trials and ensuring clinical trial material is provided to
clinical sites in a timely manner; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> obtaining advice from regulatory authorities regarding the statistical analysis plan to be used to evaluate the clinical trial data or other
trial design issues. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product
candidates, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we may receive feedback from regulatory authorities that requires us to modify the design of our clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to
conduct additional clinical trials or abandon drug development programs; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=25,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=538426,FOLIO='20',FILE='DISK116:[19ZBM1.19ZBM17601]DC17601A.;41',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dc17601_1_21"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical
trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our third-party contractors, including our CROs, may fail to comply with regulatory requirements or meet their contractual obligations to us in
a timely manner, or at all; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we, our investigators, or any of the overseeing IRBs or ethics committees might decide to suspend or terminate clinical trials of our product
candidates for various reasons, including non-compliance with regulatory requirements, a finding that our product candidates have undesirable side effects or other unexpected characteristics, or a
finding that the participants are being exposed to unacceptable health risks; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the cost of clinical trials of our product candidates may be greater than we anticipate; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be
insufficient or inadequate; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any future collaborators that conduct clinical trials may face any of the above issues, and may conduct clinical trials in ways they view as
advantageous to them but that are suboptimal for us. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete
clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are insufficiently positive to support marketing approval, or if there are
safety concerns, we may:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> incur unplanned costs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> be delayed in obtaining marketing approval for our product candidates or not obtain marketing approval at all; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> obtain marketing approval in some countries and not in others; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> obtain marketing approval for indications or patient populations that are narrower or more limited in scope than intended or desired; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> obtain marketing approval subject to significant use or distribution restrictions or with labeling that includes significant safety warnings,
including boxed warnings; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> be subject to additional post-marketing testing requirements; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> have the drug removed from the market after obtaining marketing approval. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
drug development costs will also increase if we experience delays in testing or marketing approvals. We do not know whether clinical trials will begin as planned, will need to be
restructured or will be completed on schedule, or at all. Furthermore, we rely on third-party CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials, and while we
have agreements governing their committed activities, we have limited influence over their actual performance. Significant clinical trial delays also could shorten any periods during which we may have
the exclusive right to commercialize our product candidates or allow our competitors to bring drugs to market before we do and impair our ability to successfully commercialize our product candidates
and may harm our business and results of operations. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=26,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=153540,FOLIO='21',FILE='DISK116:[19ZBM1.19ZBM17601]DC17601A.;41',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dc17601_1_22"> </A>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may expend our limited resources to pursue a particular product candidate or indication and fail to
capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific
indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource
allocation decisions may cause us to fail to capitalize on viable commercial drugs or profitable market opportunities. Our spending on current and future research and development programs and product
candidates for specific indications may not yield any commercially viable drugs. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may
relinquish valuable rights to that product candidate through collaboration, licensing or other strategic arrangements in cases in which it would have been more advantageous for us to retain sole
development and commercialization rights to such product candidate. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The failure to obtain required regulatory clearances or approvals for any companion diagnostic tests that we
may pursue may prevent or delay approval of any of our product candidates. Moreover, the commercial success of any of our product candidates that require a companion diagnostic will be tied to the
receipt of any required regulatory clearances or approvals and the continued availability of such tests.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the clinical development of our product candidates for certain indications, we may work with collaborators to develop or
obtain access to companion diagnostic tests to identify appropriate patients for our product candidates. We may rely on third parties for the development, testing and manufacturing of these companion
diagnostics, the application for and receipt of any required regulatory clearances or approvals, and the commercial supply of these companion diagnostics. The FDA and foreign regulatory authorities
regulate companion diagnostics as medical devices that will likely be subject to clinical trials in conjunction with the clinical trials for product candidates, and which will require separate
regulatory clearance or approval prior to commercialization. This process could include additional meetings with health authorities, such as a pre-submission meeting and the requirement to submit an
investigational device exemption. In the case of a companion diagnostic that is designated as "significant risk device," approval of an investigational device exemption by the FDA and IRB is required
before such diagnostic is used in conjunction with the clinical trials for a corresponding product candidate. We or our third-party collaborators may fail to obtain the required regulatory clearances
or approvals, which could prevent or delay approval of our product candidates. In addition, the commercial success of any of our product candidates that require a
companion diagnostic will be tied to and dependent upon the receipt of required regulatory clearances or approvals and the continued ability of such third parties to make the companion diagnostic
commercially available to us on reasonable terms in the relevant geographies. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not be successful in our efforts to identify or discover additional potential product candidates.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical
development for a number of reasons, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the research methodology used may not be successful in identifying potential product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are
unlikely to be drugs that will receive marketing approval and/or achieve market acceptance; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> potential product candidates may not be safe or effective in treating their targeted diseases. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=27,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=758967,FOLIO='22',FILE='DISK116:[19ZBM1.19ZBM17601]DC17601A.;41',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dc17601_1_23"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research
programs to identify new product candidates require substantial technical, financial and human resources. If we are unable to identify suitable compounds for preclinical and
clinical development, our business would be harmed. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If any of our product candidates receives marketing approval and we, or others, later discover that the drug
is less effective than previously believed or causes undesirable side effects that were not previously identified, our ability, or that of any future collaborators, to market the drug could be
compromised.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical trials of our product candidates must be conducted in carefully defined subsets of patients who have agreed to enter into clinical
trials. Consequently, it is possible that our clinical trials, or those of any future collaborator, may indicate an apparent positive effect of a product candidate that is greater than the actual
positive effect, if any, or alternatively fail to identify undesirable side effects. If one or more of our product candidates receives marketing approval and we, or others, discover that the drug is
less effective than previously believed or causes undesirable side effects that were not previously identified, a number of potentially significant negative consequences could result,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> regulatory authorities may withdraw their approval of the drug or seize the drug; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we, or any future collaborators, may be required to recall the drug, change the way the drug is administered or conduct additional clinical
trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> additional restrictions may be imposed on the marketing of, or the manufacturing processes for, the particular drug; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we may be subject to fines, injunctions or the imposition of civil or criminal penalties; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> regulatory authorities may require the addition of labeling statements, such as a "black box" warning or a contraindication; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we, or any future collaborators, may be required to create a Medication Guide outlining the risks of the previously unidentified side effects
for distribution to patients; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we, or any future collaborators, could be sued and held liable for harm caused to patients; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the drug may become less competitive in the marketplace; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our reputation may suffer. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
of these events could have a material and adverse effect on our operations and business and could adversely impact our stock price. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if any of our product candidates receive marketing approval, they may fail to achieve the degree of
market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If any of our product candidates receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians,
patients, healthcare payors and others in the medical community. For example, current cancer treatments like chemotherapy and radiation therapy are well-established in the medical community, and
doctors may continue to rely on these treatments. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant revenues from sales of drugs and we may not
become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the efficacy and safety of the product; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the potential advantages of the product compared to alternative therapies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the prevalence and severity of any side effects; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=28,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=16108,FOLIO='23',FILE='DISK116:[19ZBM1.19ZBM17601]DC17601A.;41',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dc17601_1_24"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the product is designated under physician and other provider treatment guidelines as a first-, second- or third-line therapy; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability, or the ability of any future collaborators, to offer the product for sale at competitive prices; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the product's convenience and ease of administration for patients and healthcare practitioners compared to alternative treatments; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the willingness of the target patient population to try, and of physicians to prescribe, the product; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> limitations or warnings, including distribution or use restrictions and safety information contained in the product's approved labeling; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the strength of sales, marketing and distribution support; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> changes in the standard of care for the targeted indications for the product; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the availability of coverage by, and the amount of reimbursement from, government payors, managed care plans and other third-party payors. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We face substantial competition, which may result in others discovering, developing or commercializing
products before or more successfully than we do.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The pharmaceutical and biotechnology industries generally, and the cancer drug sector specifically, are highly competitive and characterized by
rapidly advancing technologies, evolving understanding of disease etiology and a strong emphasis on proprietary drugs. We face competition with respect to APR-246, our lead product candidate, and will
face competition with respect to any product candidates that we may seek to discover and develop or commercialize in the future, from major pharmaceutical, specialty pharmaceutical and biotechnology
companies. There are a number of major pharmaceutical, specialty pharmaceutical and biotechnology companies that currently market and sell drugs or are pursuing the development of drugs for the
treatment of cancer. Potential competitors also include academic institutions and governmental agencies and public and private research institutions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
are a large number of companies developing or marketing treatments for cancer, including the indications for which we may develop product candidates. Many of the companies that we
compete or may compete against in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials,
obtaining
regulatory approvals and marketing approved drugs than we do. Small or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large
and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient
registration for clinical trials, as well as in acquiring technologies complementary to, or that may be necessary for, our programs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
commercial opportunity could be reduced or eliminated if our competitors develop and commercialize drugs that are safer, more effective, have fewer or less severe side effects, are
more convenient or are less expensive than any drugs that we may develop. Our competitors also may obtain FDA or other regulatory approval for their drugs more rapidly than we may obtain approval for
ours, which could result in our competitors establishing a strong market position before we are able to enter the market. The key competitive factors affecting the success of all of our product
candidates, if approved, are likely to be their efficacy, safety, convenience, price, the effectiveness of companion diagnostics in guiding the use of related therapeutics, the level of generic
competition and the availability of reimbursement from government and other third-party payors. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=29,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=496736,FOLIO='24',FILE='DISK116:[19ZBM1.19ZBM17601]DC17601A.;41',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dc17601_1_25"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
most common methods of treating patients with cancer are surgery, radiation and drug therapy. There are a variety of available drug therapies marketed for cancer. In many cases,
these drugs are administered in combination to enhance efficacy. Some of the currently-approved drug therapies are branded and subject to patent protection and may be established as the standard of
care for treatment of indications for which we may choose to seek regulatory approvals. Many of these approved drugs are well-established therapies and are widely accepted by physicians, patients and
third-party payors, and, even if our product candidates were to be approved, there can be no assurance that our product candidates would displace existing treatments. In addition to currently marketed
therapies, there are also a number of drugs in late-stage clinical development to treat cancer, including the indications for which we are developing product candidates. These clinical-stage product
candidates may provide efficacy, safety, convenience and other benefits that are not provided by currently-marketed therapies. As a result, they may provide significant competition for any of our
product candidates for which we obtain regulatory approval. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are developing our lead product candidate, APR-246, to reactivate p53 for the treatment of various cancers. We are aware of other product candidates that are in clinical development
for the treatment of various cancers through the reactivation of p53. Although there is a subset of drugs that directly target the p53 pathway, there are many cancer drugs that claim to affect the p53
pathway by upstream or complementary pathways. We are aware of selective small molecule inhibitors that are designed to target the p53-MDM2 interaction in various stages of clinical development being
tested by F.&nbsp;Hoffmann-La Roche&nbsp;Ltd and Hoffmann-La Roche&nbsp;Inc., or collectively Roche, Amgen&nbsp;Inc., Novartis AG, Daiichi Sankyo&nbsp;Co.,&nbsp;Ltd, and Aileron
Therapeutics,&nbsp;Inc. If APR-246 were to be approved for the indications for which we currently have ongoing clinical trials, it will compete with currently-marketed drugs or drugs that may be
approved for marketing by the FDA or comparable foreign regulatory
authorities in the future and such competition will not be limited to drugs that act through the reactivation of p53. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our business and operations would suffer in the event of IT system failures, cybersecurity attacks, data
breaches, or vulnerabilities in our or our third-party vendors' information security program or defenses.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our business relies upon information technology systems operated by us and by our third party service providers. These systems may fail or
experience operational disruption, experience cybersecurity attacks, or be damaged by computer viruses and unauthorized access. In the ordinary course of business, we collect, store and transmit
confidential information (including but not limited to intellectual property, proprietary business information and personal information). It is critical that we do so in a secure manner to maintain
the confidentiality and integrity of such confidential information. While we are currently in the process of developing and implementing policies and procedures to ensure the security and integrity of
our information technology systems and confidential and proprietary information, we do not currently have any such policies and procedures formally in place. If we fail to develop and maintain
adequate policies and procedures for the protection of our information technology systems and confidential and proprietary information, we may be vulnerable to security breaches or disruptions and
system breakdowns or other damage or interruptions. We also have outsourced elements of our operations to third parties, and as a result we manage a number of third-party vendors and other contractors
and consultants who have access to or store our confidential information. We do not conduct audits or formal evaluations of our third-party vendors' information technology systems and cannot be sure
that our third-party vendors have sufficient measures in place to ensure the security and integrity of their information technology systems and our confidential and proprietary information. If our
third-party vendors fail to protect their information technology systems and our confidential and proprietary information, we may be vulnerable to disruptions in service and unauthorized access to our
confidential or proprietary information and we could incur liability and reputational damage and the further development and commercialization of our product candidates could be delayed. While we have
not, to our knowledge, experienced any material IT system failures or </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=30,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=549631,FOLIO='25',FILE='DISK116:[19ZBM1.19ZBM17601]DC17601A.;41',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dc17601_1_26"> </A>

<P style="font-family:times;"><FONT SIZE=2>cybersecurity
attacks to date, we cannot assure you that our data protection efforts and our investment in information technology will prevent significant breakdowns, data leakages, breaches in our
systems or those of our third-party vendors and other contractors and consultants, or other cyber incidents that could have a material adverse effect upon our reputation, business, operations or
financial condition. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs, business operations, a breach of
sensitive personal information or a loss or corruption of critical data assets including trade secrets or other proprietary information. For example, the loss of clinical trial data from future
clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Such IT system failures, cybersecurity attacks or
vulnerabilities to our or our third-party vendors' information security programs or defenses could result in legal liability, reputational damage, business
interruption, and our competitive position could be harmed and the further development and commercialization of our products or any future products could be delayed or disrupted. Moreover, containing
and remediating any IT system failure, cybersecurity attack or vulnerability may require significant investment of resources. Furthermore, significant security breaches or disruptions of our internal
information technology systems or those of our third-party vendors and other contractors and consultants could result in the loss, misappropriation and/or unauthorized access, use, or disclosure of,
or the prevention of access to, confidential information (including trade secrets or other intellectual property, proprietary business information and personal information), which could result in
financial, legal, business and reputational harm to us. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we are required to in the future and if we are unable to successfully develop companion diagnostic tests
for our product candidates that require such tests, or experience significant delays in doing so, we may not realize the full commercial potential of these product candidates.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may be required by the FDA to develop, either by ourselves or with collaborators, companion diagnostic tests for our product candidates for
certain indications. To be successful, we or our collaborators will need to address a number of scientific, technical, regulatory and logistical challenges. We have no prior experience with medical
device or diagnostic test development. If we choose to develop and seek FDA approval for companion diagnostic tests on our own, we will require additional personnel. We may rely on third parties for
the design, development and manufacture of companion diagnostic tests for our therapeutic product candidates that require such tests. If these parties are unable to successfully develop companion
diagnostics for these therapeutic product candidates, or experience delays in doing so, we may be unable to enroll enough patients for our current and planned clinical trials, the development of these
therapeutic product candidates may be adversely affected, these therapeutic product candidates may not obtain marketing approval, and we may not realize the full commercial potential of any of these
therapeutics that obtain marketing approval. Any failure to successfully develop this companion diagnostic may cause or contribute to delayed enrollment of this trial, and may prevent us from
initiating or completing further clinical trials to support marketing approval for our product candidates. As a result, our business, results of operations and financial condition could be materially
harmed. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with
third parties to sell and market our product candidates, we may not be successful in commercializing our product candidates if and when they are approved.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not have a sales or marketing infrastructure and have no experience in the sale or marketing of pharmaceutical drugs. We are not currently
a party to a strategic collaboration that provides us with access to a collaborator's resources in selling or marketing drugs. To achieve commercial success for any approved drug for which sales and
marketing is not the responsibility of any strategic collaborator that we may have in the future, we must either develop a sales and marketing organization or outsource these functions to other third
parties. In the future, we may choose to build </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=31,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=1044877,FOLIO='26',FILE='DISK116:[19ZBM1.19ZBM17601]DC17601A.;41',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dc17601_1_27"> </A>

<P style="font-family:times;"><FONT SIZE=2>a
sales and marketing infrastructure to market or co-promote some of our product candidates if and when they are approved, or enter into collaborations with respect to the sale and marketing of our
product candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
are risks involved with both establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform these services. For example,
recruiting and training a sales force is expensive and time-consuming and could delay any commercial launch of a product candidate. If the commercial launch of a product candidate for which we recruit
a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be
costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Factors
that may inhibit our efforts to commercialize our product candidates on our own include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our inability to recruit and retain adequate numbers of effective sales and marketing personnel; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> limitations or restrictions on the ability of sales personnel to appropriately market the product to physicians or other healthcare
professionals; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the lack of complementary drugs to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with
more extensive product lines; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> unforeseen costs and expenses associated with creating an independent sales and marketing organization; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> inability to obtain sufficient coverage and reimbursement from third-party payors and governmental agencies. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we enter into arrangements with third parties to perform sales and marketing services, our revenues from the sale of drugs or the profitability of these revenues to us are likely to
be lower than if we were to market and sell any drugs that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our product
candidates or may be unable to do so on terms that are favorable to us. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and
attention to sell and market our product candidates effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will
not be successful in commercializing our product candidates. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If the FDA or comparable foreign regulatory authorities approve generic versions of any of our product
candidates that receive marketing approval, or such authorities do not grant our product candidates appropriate periods of data or market exclusivity before approving generic versions of our product
candidates, the sales of our product candidates could be adversely affected.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Once an NDA is approved, the drug covered thereby becomes a "reference-listed drug" in the FDA's publication, "Approved Drug Products with
Therapeutic Equivalence Evaluations." Manufacturers may seek marketing approval of generic versions of reference-listed drugs through submission of abbreviated new drug applications, or ANDAs, in the
United States. In support of an ANDA, a generic manufacturer need not conduct clinical trials demonstrating safety and efficacy. Rather, the applicant generally must show that its drug is
pharmaceutically equivalent to the reference listed drug, in that it has the same active ingredient(s), dosage form, strength, route of administration and conditions of use or labeling as the
reference-listed drug, and that the generic version is bioequivalent to the reference-listed drug, meaning it is absorbed in the body at the same rate and to the same extent. Generic drugs may be
significantly less costly to bring to market than the reference-listed drug and companies that produce generic drugs are generally able to offer them at lower prices. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=32,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=571648,FOLIO='27',FILE='DISK116:[19ZBM1.19ZBM17601]DC17601A.;41',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dc17601_1_28"> </A>

<P style="font-family:times;"><FONT SIZE=2>Thus,
following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference-listed drug is typically lost to the generic drug. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA may not approve an ANDA for a generic drug until any applicable period of non-patent exclusivity for the reference-listed drug has expired. The Federal Food, Drug, and Cosmetic
Act, or FDCA, provides a period of five years of non-patent exclusivity for a new drug containing a new chemical entity, or NCE. During the exclusivity period, the FDA may not accept for review an
ANDA or a 505(b)(2) NDA submitted by another company for another version of such product candidate where the applicant does not own or have a legal right of reference to all the data required for
approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity
for an NDA, 505(b)(2) NDA or supplement to an approved NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA
to be essential to the approval of the application, for example, for new indications, dosages or strengths of an existing product candidate. This three-year exclusivity covers only the conditions
associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for product candidates containing the original active agent. Five-year and three-year exclusivity
will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the nonclinical studies and
adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. Manufacturers may seek to launch these generic drugs following the expiration of the marketing
exclusivity period, even if we still have patent protection for our drug. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Competition
that our product candidates may face from generic versions of our product candidates could materially and adversely impact our future revenue, profitability and cash flows
and substantially limit our ability to obtain a return on the investments we have made in those product candidates. Our future revenues, profitability and cash flows could also be materially and
adversely affected and our ability to obtain a return on the investments we have made in those product candidates may be substantially limited if our product candidates, if and when approved, are not
afforded the appropriate periods of non-patent exclusivity. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if we obtain regulatory approval of any product candidate, the approved product may be subject to
post-approval studies and will remain subject to ongoing regulatory requirements. If we fail to comply, or if concerns are identified in subsequent studies, our approval could be withdrawn, and our
product sales could be suspended.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we are successful at obtaining regulatory approval for APR-246 or any of our other product candidates, regulatory agencies in the United
States and other countries where a product will be sold may require extensive additional clinical trials or post-approval clinical trials that are expensive and time-consuming to conduct. These trials
may reveal side effects or other harmful effects in patients that use our products after they are on the market, which may result in the limitation or withdrawal of our drugs from the market.
Alternatively, we may not be able to conduct such additional trials, which might force us to abandon our efforts to develop or commercialize certain product candidates. Even if post-approval studies
are not requested or required, after our products are approved and on the market, there might be safety issues that emerge over time that require a change in product labeling, additional postmarket
studies or clinical trials, imposition of distribution and use
restrictions under a Risk Evaluation and Mitigation Strategy, or REMS, or withdrawal of the product from the market, which would cause our revenue to decline. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
any products that we may successfully develop will be subject to ongoing regulatory requirements after they are approved. These requirements will govern the manufacturing,
packaging, marketing, distribution, and use of our products. If we fail to comply with such regulatory requirements, approval for our products may be withdrawn, and product sales may be suspended. We </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=33,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=604017,FOLIO='28',FILE='DISK116:[19ZBM1.19ZBM17601]DC17601A.;41',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dc17601_1_29"> </A>

<P style="font-family:times;"><FONT SIZE=2>may
not be able to regain compliance, or we may only be able to regain compliance after a lengthy delay, significant expense, lost revenues and damage to our reputation. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if we are able to commercialize any product candidate, such product candidate may become subject to
unfavorable pricing regulations, third-party coverage and reimbursement policies or healthcare reform initiatives, which could harm our business.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The regulations that govern marketing approval, pricing, coverage and reimbursement for new drugs vary widely from country to country. Some
countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing approval is granted. In some foreign markets,
prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a
particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to
generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates
obtain marketing approval. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
ability to commercialize any products successfully also will depend in part on the extent to which reimbursement and coverage for these products and related treatments will be
available from government authorities, private health insurers and other organizations, and if reimbursement and coverage is available, the level of reimbursement and coverage. Government authorities
and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the
healthcare industry in the United States and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of
reimbursement for particular medications. Increasingly, the third-party payors who reimburse patients or healthcare providers, such as government and private insurance plans, are requiring that drug
companies provide them with
predetermined discounts from list prices, and are seeking to reduce the prices charged or the amounts reimbursed for medical products. We cannot be sure that coverage and reimbursement will be
available for any drug that we commercialize and, if coverage and reimbursement are available, we cannot be sure as to the level of reimbursement. Reimbursement may impact the demand for, or the price
of, any product candidate for which we obtain marketing approval. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product
candidate for which we obtain marketing approval. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or
comparable foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be reimbursed in all cases or at a rate that covers our costs, including research,
development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement
rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs, may be incorporated into existing
payments for other items or services and may reflect budgetary constraints or imperfections in Medicare data. Net prices for drugs may be reduced by mandatory discounts or rebates required by
government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United
States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates. Our inability to promptly obtain coverage and adequate
reimbursement rates from both government-funded and private payors for new products that we develop and for which we obtain marketing approval could have a material adverse effect on our operating
results, our ability to raise capital needed to commercialize products and our overall financial condition. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=34,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=813992,FOLIO='29',FILE='DISK116:[19ZBM1.19ZBM17601]DC17601A.;41',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_de17601_1_30"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Product liability lawsuits against us could cause us to incur substantial liabilities and to limit
commercialization of any drugs that we may develop. Our insurance policies may be inadequate and may potentially expose us to unrecoverable risk.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We face an inherent risk of product liability exposure related to the testing of our product candidates in clinical trials and will face an even
greater risk if we commercially sell any drugs that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or drugs caused injuries, we will incur
substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> decreased demand for any product candidates or drugs that we may develop; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> injury to our reputation and significant negative media attention; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> withdrawal of clinical trial participants; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> significant costs to defend the related litigation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> substantial monetary awards to trial participants or patients; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> loss of revenue; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reduced resources of our management to pursue our business strategy; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the inability to commercialize any drugs that we may develop. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
currently hold clinical trial liability insurance coverage for up to $3.0&nbsp;million, but that coverage may not be adequate to cover any and all liabilities that we may incur. We
would need to increase our insurance coverage when we begin the commercialization of our product candidates, if ever. Insurance coverage is increasingly expensive. We may not be able to maintain
insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Governments outside of the United States tend to impose strict price controls, which may adversely affect our
revenues from the sales of our products, if any.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In some countries, particularly member states of the European Union, or, the EU, the pricing of prescription pharmaceuticals is subject to
governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. In addition, there can be
considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may
further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU member states and parallel distribution, or
arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we, or our future collaborators, may be required to conduct a clinical trial or other studies
that compare the cost-effectiveness of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party
payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any product candidate approved for
marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially harmed. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=35,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=174162,FOLIO='30',FILE='DISK116:[19ZBM1.19ZBM17601]DE17601A.;36',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_de17601_1_31"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks related to our dependence on third parties  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We rely on third parties to conduct our clinical trials and some aspects of our research and preclinical
studies, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research and studies.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently rely on third parties, such as CROs, clinical data management organizations, medical institutions and clinical investigators, to
conduct our clinical trials of APR-246 and expect to continue to rely upon third parties to conduct additional clinical trials of APR-246 and our other product candidates. We currently rely and expect
to continue to rely on third parties to
conduct some aspects of our research and preclinical studies. Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it
would delay our drug development activities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our regulatory responsibilities. For
example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan, study protocols for the trial, statistical analysis
plan and other study-specific documents (for example, monitoring and blinding plans). Moreover, the FDA requires us to comply with standards, commonly referred to as Good Clinical Practice, or GCP,
International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, or ICH, guidelines, and regulations regarding the informed consent process, safety reporting
requirements, data collection guidelines, and other regulations for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and
accurate and that the rights, integrity and confidentiality of trial participants are protected. The European Medicines Agency, or EMA, also requires us to comply with similar standards. Regulatory
authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs fail to comply with applicable GCP
requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform additional clinical
trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials
comply with GCP and other applicable regulations. In addition, our clinical trials must be conducted with product produced under current Good Manufacturing Practices, or cGMP, regulations. Our failure
to comply with these regulations may require us to conduct new clinical trials, which would delay the marketing approval process. We also are required to register certain ongoing clinical trials and
post the results of certain completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and
civil and criminal sanctions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Furthermore,
these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their
contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in
obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also expect to rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of such third parties could delay
clinical development or marketing approval of our product candidates or commercialization of our product candidates, producing additional losses and depriving us of potential revenue from sales of
drugs. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=36,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=162,FOLIO='31',FILE='DISK116:[19ZBM1.19ZBM17601]DE17601A.;36',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_de17601_1_32"> </A>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are currently dependent on a single third party manufacturer for the manufacture of the active
pharmaceutical ingredient for APR-246. This reliance on a single third party increases the risk that we will not have sufficient quantities of our product candidates or drugs or such quantities at an
acceptable cost, which could delay, prevent or impair our development or commercialization efforts.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not have any manufacturing facilities or personnel, and we currently have no plans to build our own clinical or commercial scale
manufacturing capabilities. We currently contract with third parties for the manufacture of our product candidates for certain preclinical trials and clinical trial materials, including raw materials
and consumables necessary for their manufacture, consistent with applicable cGMP requirements. We intend to continue to contract for these materials in the future, including commercial manufacture if
our product candidates receive marketing approval. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
active pharmaceutical ingredient, or API, for APR-246 is currently manufactured by a single contract manufacturer. Although we may do so in the future, we do not currently have
arrangements in place for redundant supply of the API for APR-246. We contract with a different manufacturer for formulation of drug product, sterile fill of vials, labeling and packaging, and the
storage and distribution of APR-246 to clinical sites. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
expect to rely on third-party manufacturers or third-party collaborators for the manufacture of our product candidates for commercial supply of any of our product candidates for which
we or any of our future collaborators obtain marketing approval. We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to
establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the possible failure of the third party to manufacture our product candidate according to our schedule, or at all, including if our third-party
contractors give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between us and them; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the possible termination or nonrenewal of agreements by our third-party contractors at a time that is costly or inconvenient for us; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the possible breach by the third-party contractors of our agreements with them; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the failure of third-party contractors to comply with applicable regulatory requirements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the possible failure of the third party to manufacture our product candidates according to our specifications; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the possible mislabeling of clinical supplies, potentially resulting in issues including the wrong dose amounts being supplied or active drug
or placebo not being properly identified; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the possibility of clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug
supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the possible misappropriation of our proprietary information, including our trade secrets and know-how. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
facilities used by our contract manufacturers to manufacture our product candidates must be approved by the FDA or the EMA pursuant to inspections that will be conducted after we
submit our NDA to the FDA or our MAA to the EMA. We do not have complete control over all aspects of the manufacturing process of, and are dependent on, our contract manufacturing partners for
compliance with cGMP regulations for manufacturing both active drug substances and finished drug products. Third-party manufacturers may not be able to comply with cGMP regulations or similar
regulatory requirements outside of the United States. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements
of the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=37,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=93133,FOLIO='32',FILE='DISK116:[19ZBM1.19ZBM17601]DE17601A.;36',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_de17601_1_33"> </A>

<P style="font-family:times;"><FONT SIZE=2>FDA
or other regulatory bodies, they will not be able to secure and/or maintain marketing approval for their manufacturing facilities. In addition, we do not have complete control over the ability of
our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA, the EMA or a comparable foreign regulatory authority does not approve these
facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact
our ability to develop, obtain marketing approval for or market our product candidates, if approved. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil
penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could
significantly and adversely affect supplies of our product candidates and harm our business and results of operations. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
drugs that we may develop may compete with other product candidates and drugs for access to manufacturing facilities. There are a limited number of manufacturers that operate under
cGMP regulations and that might be capable of manufacturing for us. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
do not currently have arrangements in place for redundant supply of the API of APR-246. If our current contract manufacturer cannot perform as agreed, we may be required to replace
that manufacturer. Although we believe that there are several potential alternative manufacturers who could manufacture our product candidates, we may incur added costs and delays in identifying and
qualifying any such replacement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
current and anticipated future dependence upon others for the manufacture of our product candidates or drugs may adversely affect our future profit margins and our ability to
commercialize any drugs that receive marketing approval on a timely and competitive basis. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Although we currently plan to retain all commercial rights to APR-246 and our product candidates, we may
enter into strategic collaborations for the development, marketing and commercialization of APR-246 and our other product candidates. If those collaborations are not successful, the development,
marketing and/or commercialization of our product candidates that are the subject of such collaborations would be harmed.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As we further develop APR-246, we may build a commercial infrastructure with the capability to directly market it to a variety of markets and
geographies. Although we currently plan to retain all commercial rights to APR-246 and our product candidates, we may enter into strategic collaborations for the development, marketing and
commercialization of APR-246 and our other product candidates. Our likely collaborators for any collaboration arrangements include large and mid-size pharmaceutical companies, regional and national
pharmaceutical companies and biotechnology companies. If we do enter into any such arrangements with any third parties, we will likely have limited control over the amount and timing of resources that
our collaborators dedicate to the development, marketing and/or commercialization of our product candidates. Our ability to generate revenues from these arrangements will depend on our collaborators'
abilities to successfully perform the functions assigned to them in these arrangements. In addition, any future collaborators may have the right to abandon research or development projects and
terminate applicable agreements, including funding obligations, prior to or upon the expiration of the agreed upon terms. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Collaborations
involving our product candidates would pose the following risks to us:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=38,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=184551,FOLIO='33',FILE='DISK116:[19ZBM1.19ZBM17601]DE17601A.;36',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_de17601_1_34"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> collaborators may not perform their obligations as expected; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> collaborators may not pursue development, marketing and/or commercialization of our product candidates or may elect not to continue or renew
development, marketing or commercialization programs based on clinical trial results, changes in the collaborator's strategic focus or available funding or external factors such as an acquisition that
diverts resources or creates competing priorities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product
candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> collaborators could independently develop, or develop with third parties, drugs that compete directly or indirectly with our product candidates
or product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a collaborator with marketing and distribution rights to one or more drugs may not commit sufficient resources to the marketing and
distribution of such drug or drugs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of
development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product
candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> collaborators may not properly obtain, maintain, defend and enforce our intellectual property rights or may use our proprietary information in
such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> collaborators may infringe, misappropriate or otherwise violate the intellectual property rights of third parties, which may expose us to
litigation and potential liability; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we may lose certain valuable rights under circumstances identified in any collaboration arrangement that we enter into, such as if we undergo a
change of control; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development, marketing
and/or commercialization of the applicable product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> collaborators may learn about our discoveries, data, proprietary information, trade secrets, or compounds and use this knowledge to compete
with us in the future; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number and type of our collaborations could adversely affect our attractiveness to future collaborators or acquirers. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Collaboration
agreements may not lead to development or commercialization of product candidates in the most efficient manner, or at all. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks related to our intellectual property  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we are unable to obtain and maintain intellectual property protection for APR-246 or any other product
candidates we develop or for our technology, our competitors could develop and commercialize products or technology similar or identical to ours, and our ability to successfully commercialize APR-246
or any product candidates we may develop, and our technology may be adversely affected.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our commercial success will depend in large part on obtaining and maintaining patent, trademark and trade secret protection of our proprietary
technologies and our product candidates, which include APR-246 and others, their respective components, formulations, methods used to manufacture them and methods of treatment, as well as successfully
defending these patents against third-party challenges. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=39,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=650989,FOLIO='34',FILE='DISK116:[19ZBM1.19ZBM17601]DE17601A.;36',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_de17601_1_35"> </A>

<P style="font-family:times;"><FONT SIZE=2>We
seek to protect our proprietary position by filing patent applications in the United States and abroad relating to our product candidates as well as other technologies that are important to our
business. Our ability to stop unauthorized third parties from making, using, selling, offering to sell or importing our product candidates is dependent upon the extent to which we have rights under
valid and enforceable patents or trade secrets that cover these activities. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
chemical structure of APR-246 is in the public domain. Accordingly, we do not own or license any composition of matter patents claiming the compound of APR-246 and will not in the
future own or license any composition of matter patents claiming the chemical structure of APR-246 as described in the public domain. Our patent portfolio for APR-246 currently consists of
method-of-use and formulation patent claims, and dosing, manufacturing processes, and crystalline solid form provisional patent application claims. Our existing patents and any future patents we
obtain may not be sufficiently broad to prevent others from using our technology or from developing competing products and technologies. Any failure to obtain or maintain patent protection with
respect to APR-246 and our other product candidates could have a material adverse effect on our business, financial condition, results of operations and growth prospects. If it is later determined
that our activities or product candidates infringe, misappropriate or otherwise violate the intellectual property of third parties we may be liable for damages, enhanced damages or subjected to an
injunction, any of which could have a material adverse effect on our business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
patenting process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely
manner. In addition, we may not pursue or obtain patent protection in all relevant markets. During the course of business we have decided not to pursue certain products or processes and have not
pursued certain corresponding intellectual property. However, we may decide to pursue such products or processes again in the future. It is also possible that we will fail to identify patentable
aspects of our research and development output before it is too late to obtain patent protection. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
patent position of pharmaceutical and biotechnology companies generally is highly uncertain and involves complex legal and factual questions for which many legal principles remain
unresolved. In recent years patent rights have been the subject of significant litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are
highly uncertain. Our pending and future patent applications may not result in patents being issued in the United States or in other jurisdictions which protect our technology or products or which
effectively prevent others from commercializing competitive technologies and products. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art, including our own previously filed patent
applications and scientific publications, allow our inventions to be patentable over the prior art. We are aware of certain scientific publications by our inventors and other third parties that
disclose subject matter, including the composition of APR-246, relating to certain of our patents, that may be used by third parties to challenge the validity and enforceability of our patents and
patent applications. If such third parties are successful, we could lose valuable patent rights. In the United States, an inventor's own publication cannot be used as prior art to the inventor's
patent application on the same subject matter when published less than one year before the effective filing date of the patent application. Such a publication may be considered prior art in certain
jurisdictions that do not provide such a grace period. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States
and other jurisdictions are typically not published until 18&nbsp;months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions
claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. In addition, the U.S. Patent and Trademark Office, or USPTO, might
require that the term of a patent issuing from a pending patent application be disclaimed and limited to the term of another patent that is commonly owned or names a common </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=40,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=844647,FOLIO='35',FILE='DISK116:[19ZBM1.19ZBM17601]DE17601A.;36',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_de17601_1_36"> </A>

<P style="font-family:times;"><FONT SIZE=2>inventor.
Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our
employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors, and other third parties, certain of these parties have and others may in the
future breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Moreover,
the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if our patent
applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive
advantage. Our competitors may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United
States and abroad. Such challenges may result in the patent claims of our patents being narrowed, invalidated or held unenforceable, which could limit our ability to stop or prevent us from stopping
others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. In addition, some of our owned patents
and patent applications may in the future be co-owned with third parties. If we do not have exclusive control of the grant of licenses under any such third-party co-owners' interest in such patents or
patent applications or we are otherwise unable to secure such exclusive rights, such co-owners may be able to license their rights to other third parties, including our competitors, and our
competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our co-owned patents in order to enforce such patents against third
parties, and such cooperation may not be provided to us. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Given
the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after
such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours or
otherwise provide us with a competitive advantage. Upon the expiration of our current patents, we may lose the right to exclude others from practicing these inventions, including APR-246 based on
patent exclusivity. The expiration of these patents could also have a similar material adverse effect on our business, results of operations, financial condition and prospects. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our proprietary position for APR-246 depends upon patents that consist of method-of-use and formulation
patent claims, which may not prevent a competitor or other third party from using the same product candidate for another use or in another formulation.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Composition-of-matter patent claims on the active pharmaceutical ingredient, or API, in pharmaceutical drug products are generally considered to
be the favored form of intellectual property protection for drug products because such patents may provide protection without regard to any particular method of use or manufacture or formulation of
the API used. The chemical structure of APR-246 is in the public domain. Accordingly, we do not own or license any composition of matter patents claiming the compound of APR-246 and will not in the
future own or license any composition of matter patents claiming the chemical structure of APR-246 as described in the public domain. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Method-of-use
patent claims protect the use of a product for the specified method and dosing or formulation patent claims cover dosing regimens or formulations of the API. These types of
patent claims do not prevent a competitor or other third party from marketing an identical API for an indication that is outside the scope of the method claims or from developing a different dosing
regimen </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=41,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=177138,FOLIO='36',FILE='DISK116:[19ZBM1.19ZBM17601]DE17601A.;36',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_de17601_1_37"> </A>

<P style="font-family:times;"><FONT SIZE=2>or
formulation that is outside the scope of the dosing or formulation claims. Moreover, with respect to method-of-use patents, even if competitors or other third parties do not actively promote their
product for our targeted indications or uses for which we may obtain patents, physicians may recommend that patients use these products off-label, or patients may do so themselves. Although off-label
use may infringe or contribute to the infringement of method-of-use patents, the practice is common and such infringement is difficult to prevent or prosecute. In addition, there are numerous
publications and other prior art that may be relevant to our patents and may be used to challenge the validity of such patents in litigation or other intellectual property-related proceedings. If such
challenges are successful, our patents may be narrowed or found to be invalid and we may lose valuable intellectual property rights. Any of the foregoing could have a material adverse effect on our
business, financial conditions and results of operations and prospects. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Issued patents covering our product candidates and other technologies could be narrowed or found invalid or
unenforceable if challenged in court or before administrative bodies in the United States or abroad.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we seek to enforce a patent covering our product candidates or other technologies against a third party, that third party could assert that
such patent is invalid or unenforceable. In patent litigation in the United States, challenges to validity or enforceability are commonplace. Grounds for a validity challenge could be an alleged
failure to meet any of several statutory requirements, including lack of patentable subject matter, lack of novelty, obviousness, inadequate written description, indefiniteness, or lack of enablement.
Grounds for an unenforceability assertion could be an allegation that relevant information was withheld from or a misleading statement was made to the USPTO during prosecution. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, third parties may raise claims challenging the validity or enforceability of our patents before administrative bodies in the United States or abroad, even outside the
context of litigation. Such mechanisms include preissuance submission of prior art to the USPTO and re-examination, post-grant review, </FONT><FONT SIZE=2><I>inter partes</I></FONT><FONT SIZE=2>
review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (</FONT><FONT SIZE=2><I>e.g.</I></FONT><FONT SIZE=2>, opposition proceedings). Moreover,
we may have to participate in interference proceedings declared by the USPTO to determine priority of invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office,
that challenge our priority of invention or other features of patentability with respect to our patents and patent applications. An adverse determination in any such submission, proceeding or
litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize our product candidates or other technologies and compete directly
with us, without payment to us. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the United States, an inventor's own publication may not be effective prior art to the inventor's patent application on the same subject matter when published less than one year
before the effective filing date of the patent application. Such a publication might be considered prior art in certain
jurisdictions that do not provide such a grace period. For those non-US jurisdictions, reliance on non-patent exclusivity may provide sufficient competitive protection to exclude others from
commercializing generic versions of our products. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Such
proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. If we are
unsuccessful in any such proceeding or other priority or inventorship dispute, we may be required to obtain and maintain licenses from third parties, including parties involved in any such
interference proceedings or other priority or inventorship disputes. Such licenses may not be available on commercially reasonable terms or at all, or may be non-exclusive. If we are unable to obtain
and maintain such licenses, we may need to cease the development, manufacture, and commercialization of one or more of the product candidates we may develop. The loss of exclusivity or the narrowing
of our patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products. Any of the foregoing could have a material adverse effect on our
business, results of operations, financial condition and prospects. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>37</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=42,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=262330,FOLIO='37',FILE='DISK116:[19ZBM1.19ZBM17601]DE17601A.;36',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_de17601_1_38"> </A>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be subject to other claims challenging the inventorship of our patents and other intellectual
property.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may also be subject to claims that former employees, collaborators or other third parties have an interest in our patents, trade secrets, or
other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in
developing our product candidates or other technologies. Litigation may be necessary to defend against these and other claims challenging inventorship of our patents, trade secrets or other
intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to
use, intellectual property that is important to our product candidates and other technologies. Even if we are successful in defending against such claims, litigation could result in substantial costs
and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and growth prospects. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we do not obtain patent term extension or data exclusivity for any product candidates we may develop, our
business may be materially harmed.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our
U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Act. The Hatch-Waxman
Act permits a patent term extension of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a
patent beyond a total of 14&nbsp;years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for
manufacturing it may be extended. Similar extensions as compensation for patent term lost during regulatory review processes are also available in certain foreign countries and territories, such as in
Europe under a Supplementary Patent Certificate. However, we may not be granted an extension in the United States and/or foreign countries and territories because of, for example, failing to exercise
due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to
satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the
term of any such extension is shorter than what we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of
operations and growth prospects could be materially harmed. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not be successful in obtaining, through acquisitions, in-licenses or otherwise, rights that may be
necessary to our product candidates or other technologies.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The growth of our business may depend in part on our future ability to acquire or in-license any relevant third-party proprietary rights that we
may identify as necessary or important to our business operations. For example, our programs may involve additional product candidates that may require the use of additional proprietary rights held by
third parties. Our product candidates may also require specific formulations to work effectively and efficiently. These formulations may be covered by intellectual property rights held by others. We
may develop products containing our compounds and pre-existing pharmaceutical compounds. These pharmaceutical compounds may be covered by intellectual property rights held by others. We may be
required by the FDA or comparable foreign regulatory authorities to provide a companion diagnostic test or tests with our product candidates. These diagnostic test or tests may be covered by
intellectual property rights held by others. We may be unable to acquire or in-license such third-party intellectual property rights. We may fail to obtain any of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>38</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=43,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=770932,FOLIO='38',FILE='DISK116:[19ZBM1.19ZBM17601]DE17601A.;36',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_de17601_1_39"> </A>

<P style="font-family:times;"><FONT SIZE=2>these
licenses at a reasonable cost or on reasonable terms, if at all, which would harm our business. We may need to cease use of the compositions or methods covered by such third-party intellectual
property rights, and may need to seek to develop alternative approaches that do not infringe, misappropriate or otherwise violate intellectual property rights which may entail additional costs and
development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license to such intellectual property rights, any such license may be
non-exclusive, which may allow our competitors access to the same technologies licensed to us. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
we sometimes collaborate with academic institutions and clinical research organizations to accelerate our research or development, including our research or development of
APR-246, under written agreements with these institutions and organizations. In certain cases, these institutions and organizations may own or jointly own with us inventions that are created under
such collaborations and provide us with an option to negotiate a license to any of the institution's rights in such inventions. Regardless of such option, we may be unable to negotiate a license
within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution or organization may offer the intellectual property rights to others, potentially
blocking our ability to pursue our program and allowing third parties to compete with us. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
licensing and acquisition of third-party intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources than we do, may
also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More
established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities. In addition, companies
that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow
us to make an appropriate return on our investment or at all. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the
intellectual property surrounding the additional product candidates that we may seek to acquire. If we are unable to successfully obtain rights to third-party intellectual property that may be
necessary, we may have to abandon development of such program and our business, results of operations, financial condition and prospects could suffer. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to
protect our product candidates and technology.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recent or future patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and
the enforcement or defense of our issued patents. Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was
entitled to the patent, while outside the
United States, the first to file&nbsp;a patent application was entitled to the patent regardless of whether another inventor had made the invention earlier. In March 2013, under the Leahy-Smith
America Invents Act, or America Invents Act, the United States moved from a "first-to-invent" to a "first-to-file" system. Under a "first-to-file" system, assuming the other requirements for
patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. A
third party that files&nbsp;a patent application in the USPTO after March 2013, but before us, could therefore be awarded a patent covering an invention of ours even if we had made the invention
before it was made by such third party. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be
certain that we were the first to either (i)&nbsp;file any patent application related to our product candidates or other technologies or (ii)&nbsp;invent any of the inventions claimed in our
patents or patent applications. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>39</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=44,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=975239,FOLIO='39',FILE='DISK116:[19ZBM1.19ZBM17601]DE17601A.;36',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_de17601_1_40"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
America Invents Act includes a number of other significant changes to U.S. patent law, including provisions that affect the way patent applications are prosecuted, redefine prior art
and establish a new post-grant review system. These include allowing third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a
patent by USPTO-administered post-grant proceedings, including post-grant review, </FONT><FONT SIZE=2><I>inter partes</I></FONT><FONT SIZE=2> review, and derivation proceedings. Because of a lower
evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence
in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action.
Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party in a district court
action. An adverse determination in any such proceeding could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete
directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights, all of which could have a material adverse
effect on our business and financial condition. Accordingly, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent
applications and the enforcement or defense of our issued patents. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings
have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with
respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents
could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights,
which could be expensive, time consuming and unsuccessful.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Competitors may infringe our patents, or we may be required to defend against claims of infringement. In addition, our patents also may become
involved in inventorship, priority, validity or unenforceability disputes. To counter or defend against such claims can be expensive and time consuming. We may not prevail in any lawsuits that we
initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. For example, in an infringement proceeding, a court may decide that a patent owned by us is invalid or
unenforceable. There is also the risk that, even if the validity of these patents is upheld, the court will refuse to stop the third party on the ground that such third party's activities do not
infringe our owned patents, including finding that the other party's use of our patented technology falls under the safe harbor to patent infringement under 35 U.S.C. &sect;&nbsp;271(e)(1).
Even if resolved in our favor, these lawsuits are expensive and would consume time and other resources, including distracting our personnel from their normal responsibilities. In addition, there could
be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have
a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development
activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our
competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual
property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the
marketplace. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>40</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=45,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=182346,FOLIO='40',FILE='DISK116:[19ZBM1.19ZBM17601]DE17601A.;36',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_de17601_1_41"> </A>

<P style="font-family:times;"><FONT SIZE=2>Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised
by disclosure during this type of litigation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may not be able to detect infringement against our patents which may be more difficult for formulation patents. Even if we detect infringement by a third party of our patents, we may
choose not to pursue litigation against or settlement with the third party. If we later sue such third party for patent infringement, the third party may have certain legal defenses available to it,
which otherwise would not be available except for the delay between when the infringement was first detected and when the suit was brought. Such legal defenses may make it impossible for us to enforce
our patents against such third party. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
another party questions the patentability of any of our claims in our U.S. patents, the third party can request that the USPTO review the patent claims such as in an </FONT> <FONT SIZE=2><I>inter partes</I></FONT><FONT SIZE=2> review, </FONT><FONT
SIZE=2><I>ex parte</I></FONT><FONT SIZE=2> re-exam or post-grant review proceedings. These proceedings are expensive
and may result in a loss of scope of some claims or a loss of the entire patent. In addition to potential USPTO review proceedings, we may become a party to patent opposition proceedings in the
European Patent Office, or EPO, or similar proceedings in other foreign patent offices, where either our foreign patents are challenged. The costs of these opposition or similar proceedings could be
substantial, and may result in a loss of scope of some claims or a loss of the entire patent. An unfavorable result at the USPTO, EPO or other patent office may result in the loss of our right to
exclude others from practicing one or more of our inventions in the relevant country or jurisdiction, which could have a material adverse effect on our business. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we are sued for infringing, misappropriating or otherwise violating patents or other intellectual property
rights of third parties, it will be costly and time consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our commercial success depends upon our ability to develop, manufacture, market and sell our product candidates and use our proprietary
technologies without infringing, misappropriating or otherwise violating the intellectual property rights of third parties. There is a substantial amount of litigation involving patents and other
intellectual property rights in the biotechnology and pharmaceutical industries. We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual
property rights alleging that our product candidates and/or proprietary technologies infringe, misappropriate or otherwise violate their intellectual property rights. We cannot guarantee that our
product candidates and other technologies that we have developed, are developing or may develop in the future will not infringe existing or future patents owned by third parties. U.S. and foreign
issued patents and pending patent applications, which are owned by third parties, exist in the fields relating to our product candidates. As the biotechnology and pharmaceutical industries expand and
more patents are issued, the risk increases that others may assert our product candidates infringe the patent rights of others. Moreover, it is not always clear to industry participants, including us,
which patents cover various types of drugs, products or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in our fields, there may
be a risk that third parties may allege they have patent rights encompassing our product candidates, technologies or methods. It is also possible that patents owned by third parties of which we are
aware, but which we do not believe are relevant to our product candidates or other technologies, could be found to be infringed by our product candidates or other technologies. In addition, because
some patent applications in the United States may be maintained in secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically not
published until 18&nbsp;months after filing, and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications
covering our product candidates or technology. If any such patent applications issue as patents, and if such patents </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>41</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=46,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=681225,FOLIO='41',FILE='DISK116:[19ZBM1.19ZBM17601]DE17601A.;36',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_de17601_1_42"> </A>

<P style="font-family:times;"><FONT SIZE=2>have
priority over our patent applications or patents, we may be required to obtain rights to such patents owned by third parties which may not be available on commercially reasonable terms or at all,
or may only be available on a non-exclusive basis. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a third party claims that we infringe its intellectual property rights, we may face a number of issues even if we believe such claims are without merit, including, but not limited
to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> infringement and other intellectual property claims which, regardless of merit, may be expensive and time-consuming to litigate, may divert our
management's attention from our core business and may impact our reputation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> substantial damages for infringement, which we may have to pay if a court decides that the product candidate or technology at issue infringes
on or violates the third party's rights, and, if the court finds that the infringement was willful, we could be ordered to pay treble damages and the patent owner's attorneys' fees; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a court prohibiting us from developing, manufacturing, marketing or selling our product candidates, including APR-246, or from using our
proprietary technologies, unless the third party licenses its patent rights to us, which it is not required to do; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if a license is available from a third party, we may have to pay substantial royalties, upfront fees and other amounts, and/or grant
cross-licenses to intellectual property rights for our product candidates or such license is only available on a non-exclusive basis; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> redesigning our product candidates or processes so they do not infringe, which may not be possible or may require substantial monetary
expenditures and time. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>Some
of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties
resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a
material adverse effect on our business, results of operations, financial condition and prospects. The occurrence of any of the foregoing could have a material adverse effect on our business,
financial condition, results of operations or growth prospects. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may choose to challenge the patentability of claims in a third party's U.S. patent by requesting that the USPTO review the patent claims in an </FONT> <FONT SIZE=2><I>ex-parte</I></FONT><FONT SIZE=2> re-exam, </FONT><FONT SIZE=2><I>inter
partes</I></FONT><FONT SIZE=2> review or post-grant review proceedings. These proceedings are expensive
and may consume our time or other resources. We may choose to challenge a third party's patent in patent opposition proceedings in the EPO, or other foreign patent office. The costs of these
opposition proceedings could be substantial, and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent office then we may be exposed to
litigation by a third party alleging that the patent may be infringed by our product candidates or proprietary technologies. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not be able to protect our intellectual property rights with patents throughout the world.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Filing, prosecuting and defending patents on all of our product candidates throughout the world would be prohibitively expensive, and the laws
of some foreign countries may not protect our rights to the same extent as the laws of the United States. Competitors may use our technology in jurisdictions where we have not obtained patent
protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but where enforcement is not as strong as in the United
States. These products may compete with our product candidates in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective
or sufficient to prevent them from so competing. Many companies have encountered significant problems in protecting and defending intellectual property rights in </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>42</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=47,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=346529,FOLIO='42',FILE='DISK116:[19ZBM1.19ZBM17601]DE17601A.;36',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_de17601_1_43"> </A>

<P style="font-family:times;"><FONT SIZE=2>foreign
jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection,
particularly those
relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products against third parties in violation of our proprietary
rights generally. The initiation of proceedings to enforce our intellectual property rights or proceedings by third parties to challenge the scope or validity of our patent rights in foreign
jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business and could put our patents at risk of being invalidated or interpreted narrowly. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Many
countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of
patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are
forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations,
and growth prospects may be adversely affected. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Obtaining and maintaining our patent protection depends upon compliance with various procedural, document
submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other
provisions during the patent prosecution process and following the issuance of a patent. In some cases, an inadvertent failure to comply with such requirements can be cured by payment of a late fee or
by other means in accordance with the applicable rules. There are situations, however, in which non-compliance could result in abandonment or lapse of a patent or patent application, resulting in
partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case if our patent
were in force, which would have a material adverse effect on our business. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be subject to claims that our employees, consultants or advisors have wrongfully used or disclosed
alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously employed at other biotechnology or
pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees, consultants or
advisors or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their current or former employers. Litigation may be necessary to defend against
these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual
property rights or personnel. Even if we are successful in defending against such claims, litigation or other legal proceedings relating to intellectual property claims may cause us to incur
significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions
or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common
stock. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or
other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of
their substantially greater financial resources. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>43</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=14,SEQ=48,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=175924,FOLIO='43',FILE='DISK116:[19ZBM1.19ZBM17601]DE17601A.;36',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_de17601_1_44"> </A>

<P style="font-family:times;"><FONT SIZE=2>Uncertainties
resulting from the initiation and continuation of patent litigation or other intellectual property related proceedings could adversely affect our ability to compete in the marketplace. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning
such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The
assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that
they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of
operations, and growth prospects. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of trade
secrets and other proprietary information.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary
know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our platform technology and discovery and development
processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect and we have limited control over the
protection of trade secrets used by our collaborators and suppliers. Although we seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with
parties who have access them, such as our employees, consultants, and outside scientific advisors, contractors and collaborators, we cannot guarantee that we have entered into such agreements with
each party that may have or have had access to our trade secrets or proprietary technology and processes. Despite our efforts, any of these parties
might breach the agreements and intentionally or inadvertently disclose our trade secret information and we may not be able to obtain adequate remedies for such breaches. In addition, competitors may
otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Moreover, our competitors or other third parties may independently develop
equivalent knowledge, methods and know-how. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Enforcing
a claim that a third party illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts
inside and outside the United States sometimes are less willing or unwilling to protect trade secrets. If we choose to go to court to stop a third party from using any of our trade secrets, we may
incur substantial costs. These lawsuits may consume our time and other resources even if we are successful. If any of our trade secrets were determined to be lawfully obtained or independently
developed by a competitor or other third party, we may not be able to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or
independently developed by a competitor or other third party, our competitive position, business, results of operations and prospects would be materially and adversely harmed. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Intellectual property rights do not necessarily address all potential threats.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not
adequately protect our rights or permit us to gain or keep our competitive advantage. For example:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> others may be able to make or use compounds that are similar to the pharmaceutical compounds used in our product candidates but that are not
covered by the claims of our patents; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>44</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=15,SEQ=49,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=110909,FOLIO='44',FILE='DISK116:[19ZBM1.19ZBM17601]DE17601A.;36',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dg17601_1_45"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the APIs in our current product candidates will eventually become commercially available in generic drug products, and no patent protection may
be available with regard to formulation or method of use; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we, or our future licensors or collaborators, might not have been the first to file patent applications for these inventions; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we, or our future licensors or collaborators, might not have been the first to make the inventions covered by our issued patents or pending
patent applications; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> others may independently develop similar or alternative technologies or duplicate any of our technologies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> it is possible that our current or future pending or licensed patent applications will not result in issued patents; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> it is possible that public disclosures or publications, including disclosures or publications made by us, could be used in an attempt to
invalidate our patents; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors or
other third parties; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and
then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> it is possible that others may circumvent our patents; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> it is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue with claims covering
our products or technology similar to ours; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the laws of foreign countries may not protect our proprietary rights to the same extent as the laws of the United States; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the claims of our issued patents or patent applications, if and when issued, may not cover our product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our issued patents may not provide us with any competitive advantages, may be narrowed in scope, or be held invalid or unenforceable as a
result of legal challenges by third parties; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the inventors of our patents or patent applications may become involved with competitors, develop products or processes which design around our
patents, or become hostile to us or the patents or patent applications on which they are named as inventors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we have engaged in scientific collaborations in the past and will continue to do so in the future. Such collaborators may develop adjacent or
competing products to ours that are outside the scope of our patents; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we may not develop additional proprietary technologies for which we can obtain patent protection; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we may choose not to pursue patent protection in order to maintain certain trade secrets or know-how, and a third party may subsequently obtain
a patent covering such intellectual property; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> it is possible that product candidates or diagnostic tests we develop may be covered by third parties' patents or other exclusive rights;
or</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the patents of others may have an adverse effect on our business. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>45</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=50,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=790903,FOLIO='45',FILE='DISK116:[19ZBM1.19ZBM17601]DG17601A.;41',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dg17601_1_46"> </A>

<P style="font-family:times;"><FONT SIZE=2>Should
any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and growth prospects. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks related to regulatory and marketing approval and other legal compliance matters  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have never obtained marketing approval for a product candidate and we may be unable to obtain, or may be
delayed in obtaining, marketing approval for any of our product candidates.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have never obtained marketing approval for a product candidate. The time required to obtain approval by the FDA and comparable foreign
regulatory authorities is unpredictable but typically takes many years following the commencement of preclinical studies and clinical trials and depends upon numerous factors, including the
substantial discretion of the regulatory authorities. It is possible that the FDA and comparable foreign regulatory authorities may refuse to accept for filing and substantive review any new drug
applications, or NDAs, marketing authorization applications, or MAA, that we submit for our product candidates or may conclude after review of our data that our application is insufficient to obtain
marketing approval of our product candidates. If the FDA, or comparable foreign regulatory authorities do not accept or approve our NDAs or MAAs for our product candidates, it may require that we
conduct additional clinical, nonclinical or manufacturing validation studies and submit that data before it will reconsider our applications. Depending on the extent of these or any other regulatory
authority-required studies, approval of any NDA, MAA or other application that we submit may be delayed by several years, or may require us to expend more resources than we have available. It is also
possible that additional studies, if performed and completed, may not be considered sufficient by the FDA or comparable foreign regulatory authorities to approve our NDAs or our MAAs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
delay in obtaining, or an inability to obtain, marketing approvals would prevent us from commercializing our product candidates, generating revenues and achieving and sustaining
profitability. If any of these outcomes occur, we may be forced to abandon our development efforts for our product candidates, which could significantly harm our business. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is
expensive, time-consuming and uncertain and may prevent us, or any future collaborators, from obtaining approvals for the commercialization of some or all of our product candidates. As a result, we
cannot predict when or if, and in which territories, we, or any future collaborators, will obtain marketing approval to commercialize a product candidate.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The research, testing, manufacturing, labeling, approval, selling, marketing, promotion and distribution of drugs are subject to extensive
regulation by the FDA and comparable foreign regulatory authorities, whose laws and regulations may differ from country to country. We, and any future collaborators, are not permitted to market our
product candidates in the United States or in other countries until we or they receive approval of an NDA from the FDA or marketing approval from comparable foreign regulatory authorities. Our product
candidates are in early stages of development and are subject to the risks of failure inherent in drug development. We have not submitted an application for or received marketing approval for any of
our product candidates in the United States or in any other jurisdiction. We have limited experience in conducting and managing the clinical trials necessary to obtain marketing approvals, including
FDA approval of an NDA. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
process of obtaining marketing approvals, both in the United States and abroad, is a lengthy, expensive and uncertain process. It may take many years, if approval is obtained at all,
and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Securing marketing approval requires the submission of
extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate's safety and efficacy. Securing
marketing approval also requires the submission of information about the product manufacturing process to, and inspection of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>46</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=51,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=417292,FOLIO='46',FILE='DISK116:[19ZBM1.19ZBM17601]DG17601A.;41',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dg17601_1_47"> </A>

<P style="font-family:times;"><FONT SIZE=2>manufacturing
facilities by, the regulatory authorities. The FDA or other comparable foreign regulatory authorities have substantial discretion and may determine that our product candidates are not
safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit
commercial use. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
product candidates could fail to receive marketing approval, or marketing approval for our product candidates could be limited or delayed, for many reasons, including the
following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe
and effective for its proposed indication; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory
authorities for approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we may be unable to demonstrate that a product candidate's clinical and other benefits outweigh its safety risks; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA or other submission
and applications or to obtain marketing approval in the United States or elsewhere; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers
with which we contract for clinical and commercial supplies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the FDA or comparable foreign regulatory authorities may fail to approve any companion diagnostics that may be required in connection with
approval of our therapeutic product candidates </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the FDA or the applicable foreign regulatory agency may fail to approve the formulation, labeling and/or the specifications for our product
candidate </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes,
regulations or guidance or changes in regulatory review for each submitted drug application; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our
clinical data insufficient for approval. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
lengthy approval process as well as the unpredictability of clinical trial results may result in our failing to obtain marketing approval to market APR-246, which would
significantly harm our business, results of operations and prospects. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide
that our data are insufficient for approval and require additional preclinical studies, clinical trials or other studies and testing. In addition, varying interpretations of the data obtained from
preclinical studies and clinical trials could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we, or any collaborators we may have in the future, ultimately
obtain may be limited or subject to restrictions or post-approval commitments that render the approved drug not commercially viable. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>47</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=52,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=54187,FOLIO='47',FILE='DISK116:[19ZBM1.19ZBM17601]DG17601A.;41',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dg17601_1_48"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
delay in obtaining or failure to obtain required approvals could materially adversely affect our ability or that of any collaborators we may have to generate revenue from the
particular product candidate, which likely would result in significant harm to our financial position and adversely impact our stock price. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Failure to obtain marketing approval in foreign jurisdictions would prevent our product candidates from being
marketed abroad. Any approval we are granted for our product candidates in the United States would not assure approval of our product candidates in foreign jurisdictions.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to market and sell our product candidates in the EU and many other jurisdictions, we, and any collaborators we may have in the future,
must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time
required to obtain approval may differ substantially from that required to obtain FDA approval. The marketing approval process outside of the United States generally includes all of the risks
associated with obtaining FDA approval. In addition, in many countries outside of the United States, it is required that the drug be approved for reimbursement before the drug can be approved for sale
in that country. We, and any collaborators we may have in the future, may not obtain approvals from regulatory authorities outside of the United States on a timely basis, if at all. Approval by the
FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside of the United States does not ensure approval by regulatory
authorities in other countries or jurisdictions or by the FDA. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
June 23, 2016, the electorate in the United Kingdom, or the U.K., voted in favor of leaving the EU, commonly referred to as Brexit. The U.K. government communicated the notice of
withdrawal to the EU on March&nbsp;29, 2017. As part of the withdrawal process, the U.K. government and the EU negotiated a withdrawal agreement that was approved by the U.K. Prime Minister and the
leaders of EU member states. However, under U.K. law, such agreement also requires the approval of the U.K. parliament, and the U.K. parliament has to date refused to approve the agreement. While
negotiations are continuing, there remains considerable uncertainty around the withdrawal. As a result, the EU and the U.K. have agreed to delay the date on which the U.K. will leave the EU to
October&nbsp;31, 2019, although if the U.K. parliament approves the withdrawal agreement prior to that date, it is possible that the U.K. may leave the EU on an earlier date; however, failure to
obtain parliamentary approval of an agreed withdrawal agreement may, absent a revocation of the U.K.'s notification to withdraw or some other further delay, mean that the U.K. would leave the EU on
October&nbsp;31, 2019 with no agreement (a so-called "hard Brexit"). Absent delay or mitigating legislative measures by individual EU Member States, in the event of a hard Brexit the trade
relationship between the U.K. and the EU
would be solely based on World Trade Organization terms, thereby hindering current levels of mutual market access. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the U.K. and the EU do reach a deal on or before October&nbsp;31, 2019 (or any later withdrawal date which may subsequently be agreed between the U.K. and the EU) or if the U.K.'s
withdrawal takes effect on the terms of the existing withdrawal agreement, a transition period may start that lasts until December&nbsp;31, 2020. Based upon the currently proposed transition plan,
during this period, the U.K. would, with some exceptions, remain subject to EU law. It would also maintain access to the EU's single market. During this transition phase, the U.K. and EU would also
start negotiations on their future trade relationship. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
consequences for the economies of the U.K. and the EU member states as a result of the U.K.'s withdrawal from the EU are unknown and unpredictable, especially in the case of a hard
Brexit. Given the lack of comparable precedent, it is unclear what the broader macro-economic and financial implications the U.K. leaving the EU with no agreements in place would have. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>48</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=53,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=747748,FOLIO='48',FILE='DISK116:[19ZBM1.19ZBM17601]DG17601A.;41',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dg17601_1_49"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since
a significant proportion of the regulatory framework in the U.K. is derived from EU directives and regulations, Brexit could materially impact the regulatory regime with respect to
the approval of our product candidates in the U.K. or the EU. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would prevent us from
commercializing our product candidates in the U.K. and/or the EU and restrict our ability to generate revenue and achieve and sustain profitability. If any of these outcomes occur, we may be forced to
restrict or delay efforts to seek regulatory approval in the U.K. and/or EU for our product candidates, which could significantly and materially harm our business. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We, or any future collaborators, may not be able to obtain or maintain orphan drug exclusivity for our
product candidates and, even if we do, that exclusivity many not prevent the FDA or the European Commission from approving competing products.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulatory authorities in some jurisdictions, including the United States and the EU, may designate drugs for relatively small patient
populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a
patient population of fewer than 200,000 individuals annually in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the
cost of developing the drug will be recovered
from sales in the United States. APR-246 has received orphan drug designation from the FDA for use in the treatment of high-risk myelodysplastic syndromes, or MDS, and orphan drug designation from the
EMA for MDS, acute myeloid leukemia, or AML, and ovarian cancer. We may seek orphan drug designations for APR-246 for other indications or for other of our product candidates. There can be no
assurances that we will be able to obtain such designations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee
waivers. In addition, the company that obtains the first FDA approval for a designated orphan drug for a rare disease receives marketing exclusivity for use of that drug for the designated condition
for a period of seven years. Once a product receives orphan drug exclusivity, a second product that is considered to be the same drug for the same indication generally may be approved during the
exclusivity period only if the second product is shown to be "clinically superior" to the original orphan drug in that it is more effective, safer or otherwise makes a "major contribution to patient
care" or the holder of exclusive approval cannot assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was
designated. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
European Commission can grant orphan drug product designation to products for which the sponsor can establish that it is intended for the diagnosis, prevention, or treatment of
(1)&nbsp;a life-threatening or chronically debilitating condition affecting not more than five in 10,000 people in the European Union, or (2)&nbsp;a life threatening, seriously debilitating or
serious and chronic condition in the European Union and that without incentives it is unlikely that sales of the drug in the European Union would generate a sufficient return to justify the necessary
investment. In addition, it must be established that there is no other satisfactory method approved in the European Union of diagnosing, preventing or treating the condition, or if such a method
exists, the proposed orphan drug will be of significant benefit to patients. Orphan drug designation is not a marketing authorization. It is a designation that provides a number of benefits, including
fee reductions, regulatory assistance, and the possibility to apply for a centralized EU marketing authorization, as well as 10&nbsp;years of market exclusivity following a marketing authorization.
During this market exclusivity period, neither the EMA, nor the European Commission nor the EU member states can accept an application or grant a marketing authorization for a 'similar medicinal
product.' A 'similar medicinal product' is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is
intended for the same therapeutic indication. The market </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>49</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=54,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=62952,FOLIO='49',FILE='DISK116:[19ZBM1.19ZBM17601]DG17601A.;41',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dg17601_1_50"> </A>

<P style="font-family:times;"><FONT SIZE=2>exclusivity
period for the authorized therapeutic indication may be reduced to six years if, at the end of the fifth year, it is established that the orphan designation criteria are no longer met,
including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. In addition, a competing similar medicinal product may in limited
circumstances be authorized prior to the expiration of the market exclusivity period, including if it is shown to be safer, more effective or otherwise clinically superior to our product. Our product
can lose orphan designation, and the related benefits, prior to us obtaining a marketing authorization if it is demonstrated that the orphan designation criteria are no longer met. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even
if we, or any future collaborators, obtain orphan drug designation for a product candidate, we, or they, may not be able to obtain or maintain orphan drug exclusivity for that
product candidate. We may not be the first to obtain marketing approval of any product candidate for which we have obtained orphan drug designation for the orphan-designated indication due to the
uncertainties associated with developing drug products. If this happens, marketing approval for our product candidate may be delayed due to the first-approved product's orphan drug exclusivity, unless
we demonstrate clinical superiority. We may not be able to demonstrate that our product is clinically superior to a first-approved product with orphan drug exclusivity, i.e.,&nbsp;that it provides
greater safety or efficacy or a major contribution to patient care. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the
orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of the product to
meet the needs of patients with the rare disease or condition. Further, even if we, or any future collaborators, obtain orphan drug exclusivity for a product, that exclusivity may not effectively
protect the product from competition because different drugs with different active moieties may be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently
approve the same drug with the same active moiety for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a
major contribution to patient care or the manufacturer of the product with orphan exclusivity is unable to maintain sufficient product quantity. Orphan drug designation neither shortens the
development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if we, or any collaborators we may have in the future, obtain marketing approvals for our product
candidates, the terms of approvals and ongoing regulation of our product candidates could require substantial expenditure of resources and may limit how we, or they, manufacture and market our product
candidates, which could materially impair our ability to generate revenue.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Once marketing approval has been granted, an approved drug and its manufacturer and marketer are subject to ongoing review and extensive
regulation. These requirements include submissions of safety and other post-marketing information and reports, user fee requirements, registration and listing requirements, requirements relating to
manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. We, and
any collaborators we may have in the future, must also comply with requirements concerning advertising and promotion for any of our product candidates for which we or they obtain marketing approval.
Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the drug's approved labeling.
Thus, we, and any collaborators we may have in the future, may not be able to promote any drugs we develop for indications or uses for which they are not approved. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA or comparable foreign regulatory authorities may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy
of a drug. For example, the approval may be subject to limitations on the indicated uses for which the drug may be </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>50</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=55,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=591838,FOLIO='50',FILE='DISK116:[19ZBM1.19ZBM17601]DG17601A.;41',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dg17601_1_51"> </A>

<P style="font-family:times;"><FONT SIZE=2>marketed
or to the conditions of approval, including the requirement to implement a REMS or comparable foreign equivalents, like the EU Risk Management Plan, or RMP, which could include requirements
for a restricted distribution system. Manufacturers of approved drugs and those manufacturers' facilities are also required to comply with extensive FDA or comparable foreign regulatory authorities
requirements, including ensuring that quality control and manufacturing procedures conform to cGMPs, which include requirements relating to quality control and quality assurance as well as the
corresponding maintenance of records and documentation and reporting requirements. We, our contract manufacturers, our future collaborators and their contract manufacturers could be subject to
periodic unannounced inspections by the FDA or comparable foreign regulatory authorities to monitor and ensure compliance with cGMPs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accordingly,
assuming we, or our future collaborators, receive marketing approval for one or more of our product candidates, we, and our future collaborators, and our and their contract
manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we, and our future collaborators, are not able to comply with post-approval regulatory requirements, regulatory agencies or enforcement authorities
may:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> issue warning letters; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> impose civil or criminal penalties; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> suspend regulatory approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> suspend any of our ongoing clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> refuse to approve pending applications or supplements to approved applications submitted by us or our collaborators; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> impose restrictions on our operations, including closing our or our collaborators' manufacturing facilities; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> seize or detain products or require a recall. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to
comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our product candidates, if approved. If regulatory sanctions
are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
regulatory requirements and policies may change, and additional government regulations may be enacted for which we may also be required to comply. We cannot predict the likelihood,
nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or in other countries. If we or any future collaboration partner
are not able to maintain regulatory compliance, we or such collaboration partner, as applicable, may face government enforcement action and our business will suffer. Moreover, our or our future
collaborators' ability to market any future drugs could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval
regulations may have a negative effect on our operating results and financial condition. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>51</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=56,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=880550,FOLIO='51',FILE='DISK116:[19ZBM1.19ZBM17601]DG17601A.;41',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dg17601_1_52"> </A>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The FDA's and other comparable regulatory authorities' policies may change and additional government
regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates, which would impact our ability to generate revenue.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In December 2016, the 21st&nbsp;Century Cures Act, or Cures Act, was signed into law. The Cures Act, among other things, is intended to
modernize the regulation of drugs and spur innovation, but its ultimate implementation is unclear. If we are slow or unable to adapt to changes in existing requirements or the adoption of new
requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which
would adversely affect our business, prospects, financial condition and results of operations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States
or abroad. For example, certain policies of the Trump administration may impact our business and industry. Namely, the Trump administration has taken several executive actions, including the issuance
of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA's ability to engage in routine regulatory and oversight activities such as
implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. Notably, on January&nbsp;30, 2017, President Trump issued an Executive Order,
applicable to all executive agencies, including the FDA, that requires that for each notice of proposed rulemaking or final regulation to be issued in fiscal year 2017, the agency shall identify at
least two existing regulations to be repealed, unless prohibited by law. These requirements are referred to as the "two-for-one" provisions. This Executive Order includes a budget neutrality provision
that requires the total incremental cost of all new regulations in the 2017 fiscal year, including repealed regulations, to be no greater than zero, except in limited circumstances. For fiscal years
2018 and beyond, the Executive Order requires agencies to identify regulations to offset any incremental cost of a new regulation and approximate the total costs or savings associated with each new
regulation or repealed regulation. In interim guidance issued by the Office of Information and Regulatory Affairs, within the Office of Management and Budget, on February&nbsp;2, 2017, the
administration indicates that the "two-for-one" provisions may apply not only to agency regulations, but also to significant agency guidance documents. In addition, on February&nbsp;24, 2017,
President Trump issued an Executive Order directing each affected agency to designate an agency official as a "Regulatory Reform Officer" and establish a "Regulatory Reform Task Force" to implement
the two-for-one provisions and other previously issued Executive Orders relating to the review of federal regulations; however, it is difficult to predict how these requirements will be implemented,
and the extent to which they will impact the FDA's ability to exercise its regulatory authority. If these executive actions impose constraints on FDA's ability to engage in oversight and
implementation activities in the normal course, our business may be negatively impacted. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Any of our product candidates for which we, or our future collaborators, obtain marketing approval in the
future will be subject to substantial penalties if we, or they, fail to comply with regulatory requirements or if we, or they, experience unanticipated problems with our product candidates following
approval.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any of our product candidates for which we, or our future collaborators, obtain marketing approval in the future, will be subject to continual
review by the FDA or comparable foreign regulatory authorities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
example in the United States, the FDA and other agencies, including the Department of Justice, or the DOJ, closely regulate and monitor the post-approval marketing and promotion of
drugs to ensure that they are manufactured, marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent
restrictions on manufacturers' communications regarding off-label use and if we, or our future collaborators, do not market any of our product candidates for which we, or they, receive marketing
approval for only their </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>52</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=57,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=29671,FOLIO='52',FILE='DISK116:[19ZBM1.19ZBM17601]DG17601A.;41',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dg17601_1_53"> </A>

<P style="font-family:times;"><FONT SIZE=2>approved
indications, we, or they, may be subject to warnings or enforcement action for off-label marketing. Violation of the FDCA and other statutes, including the False Claims Act, relating to the
promotion and advertising of prescription drugs may lead to investigations or allegations of violations of federal and state healthcare fraud and abuse laws and state consumer protection laws. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, later discovery of previously unknown adverse events or other problems with our product candidates or their manufacturers or manufacturing processes, or failure to comply
with regulatory requirements, may yield various results, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> litigation involving patients taking our drug; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> restrictions on such drugs, manufacturers or manufacturing processes; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> restrictions on the labeling or marketing of a drug; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> restrictions on drug distribution or use; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> requirements to conduct post-marketing studies or clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> warning letters or untitled letters; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> withdrawal of the drugs from the market; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> refusal to approve pending applications or supplements to approved applications that we submit; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> recall of drugs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> fines, restitution or disgorgement of profits or revenues; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> suspension or withdrawal of marketing approvals; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> damage to relationships with any potential collaborators; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> restrictions on coverage by third-party payors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> unfavorable press coverage and damage to our reputation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> refusal to permit the import or export of drugs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> drug seizure; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> injunctions or the imposition of civil or criminal penalties. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Recently enacted and future legislation, and a change in existing government regulations and policies, may
increase the difficulty and cost for us and our future collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the United States and some foreign jurisdictions, there have been and continue to be a number of legislative and regulatory changes and
proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability, or the
ability of our future collaborators, to profitably sell any drugs for which we, or they, obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be
adopted in the future, may result in more rigorous coverage criteria and additional downward pressure on the price that we, or our future collaborators, may receive for any approved drugs. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the United States, the Congress and recent presidential administrations have enacted or are considering a number of legislative and regulatory proposals to change the healthcare
system in ways that could affect our ability to sell our products, if approved, and to do so profitably. Among policy makers and payors in the United States and elsewhere, there is significant
interest in promoting </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>53</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=58,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=847041,FOLIO='53',FILE='DISK116:[19ZBM1.19ZBM17601]DG17601A.;41',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dg17601_1_54"> </A>

<P style="font-family:times;"><FONT SIZE=2>changes
in healthcare systems with the stated goals of containing healthcare costs, improving quality and expanding access. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the United States, the pharmaceutical industry has been a particular focus of efforts to reform the healthcare system and has been significantly affected by major legislative
initiatives, including the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, "PPACA"), which contains provisions that may
potentially affect the profitability of our products, including, for example, increased rebates for products sold to Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans,
mandatory discounts for certain Medicare Part&nbsp;D beneficiaries and annual fees based on pharmaceutical companies' share of sales to federal health care programs, and expansion of the entities
eligible for discounts under the Public Health Services pharmaceutical pricing program. There have been judicial and Congressional challenges to the PPACA, as well as efforts by the Trump
administration to repeal or replace certain aspects of the PPACA that contribute to regulatory uncertainty that could affect the profitability of our products. Since January 2017, President Trump has
signed several Executive Orders and other directives designed to delay the implementation of certain provisions of the PPACA or otherwise circumvent some of the requirements mandated by the PPACA. In
December 2018, a federal district court in Texas ruled the individual mandate was unconstitutional and could not be severed from the PPACA. As a result, the court ruled the remaining provisions of the
PPACA were also invalid, though the court declined to issue a preliminary injunction with respect to the PPACA. In April 2019, in a brief filed in the Fifth Circuit Court of Appeals, the Trump
Administration took the position that the individual mandate was unconstitutional, that it could not be severed from the PPACA, and, as a result, the PPACA must be invalidated in its entirety. The
case is pending before the Fifth Circuit, and it remains unclear whether, and to what extent, the PPACA may be affected by the Fifth Circuit's and possibly other courts' rulings. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
Congress has not enacted legislation to comprehensively repeal the PPACA, at least two bills affecting the implementation of the PPACA have been signed into law, including the
repeal, effective January&nbsp;1, 2019, of the tax-based shared responsibility payment imposed by the PPACA on certain individuals who fail to maintain qualifying health coverage for all or part of
a year, which is commonly referred to as the "individual mandate." Additionally, on January&nbsp;22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that
delayed the implementation of certain fees mandated by the PPACA, including the so-called "Cadillac" tax on certain high-cost employer-sponsored health insurance plans and the annual fee imposed on
certain health insurance providers. Moreover, effective January&nbsp;1, 2019, the Bipartisan Budget Act of 2018, among other things, further amends portions of the Social Security Act implemented as
part of the PPACA to increase from 50% to 70% the point-of-sale discount that pharmaceutical manufacturers participating in the Coverage Gap Discount Program provide to eligible Medicare Part&nbsp;D
beneficiaries during the coverage gap phase of the Part&nbsp;D benefit, commonly referred to as the "donut hole," and to reduce standard beneficiary cost sharing in the coverage gap from 30% to 25%
in most Medicare Part&nbsp;D plans. In the future, there may be additional challenges and/or amendments to the PPACA. It remains to be seen precisely what any new legislation will provide, when or
if it will be enacted, and what impact it will have on the availability and cost of healthcare items and services, including drug products. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other
legislative changes have been proposed and adopted since PPACA was enacted. These changes include the Budget Control Act of 2011, which, among other things, led to aggregate
reductions in Medicare payments to providers of up to 2% per fiscal year that started in April 2013 and, due to subsequent statutory amendments, will continue through 2027 unless additional
Congressional action is taken. The American Taxpayer Relief Act of 2012, which, among other changes, reduced Medicare payments to several types of providers and increased the statute of limitations
period for the government to recover overpayments to providers from three to five years. These legislative changes may result in additional reductions in Medicare and other healthcare funding and
otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>54</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=59,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=177201,FOLIO='54',FILE='DISK116:[19ZBM1.19ZBM17601]DG17601A.;41',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_di17601_1_55"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;More
recently, the cost of prescription pharmaceuticals has been the subject of considerable discussion in the United States. Congress has begun developing legislation and the Trump
Administration has proposed and begun implementing regulatory reforms to further increase transparency around prices and price increases, lower out-of-pocket costs for consumers, and decrease spending
on prescription drugs by government programs. Congress has conducted or is in the process of conducting inquiries into the prescription drug industry's pricing practices. The Trump Administration's
budget proposal for fiscal year 2019 contained additional drug price control measures that could be enacted in future legislation, including, for example, measures to end Medicare Part&nbsp;B
coverage of medications and to shift those medication costs to Medicare Part&nbsp;D, to allow some states to negotiate prescription drug prices under Medicaid and to eliminate cost sharing for
generic drugs for low-income patients. While several proposed reform measures will require Congress to pass legislation to become effective, Congress and the Trump Administration have each indicated
that it will continue to seek new legislative and/or regulatory measures to address prescription drug costs. At the state level, legislatures are increasingly passing legislation and states are
implementing regulations designed to control spending on, and patient out-of-pocket costs for, drug products. Implementation of cost containment measures or other healthcare reforms that affect the
pricing and/or availability of drug products may impact our ability to generate revenue, attain or maintain profitability, or commercialize products for which we may receive regulatory approval in the
future. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
expect that these and other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and/or new payment methodologies, and place
additional downward pressure on the price that we receive for any approved product and/or the level of reimbursement physicians receive for administering any approved product we might bring to market.
Reductions in reimbursement levels and imposition of more rigorous coverage criteria or new payment methodologies may negatively impact the prices we receive or the frequency with which our products
are prescribed or administered. Any coverage or reimbursement policies instituted by Medicare or other federal health care programs may result in a similar policies from private payors. The
implementation of cost containment measures or other healthcare reforms may affect our ability to generate revenue, attain or maintain profitability, or commercialize our product candidates. We expect
that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and
services, which could result in reduced demand for our product candidates or additional pricing pressures. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
pricing of prescription pharmaceuticals is also subject to governmental control outside the United States. In these countries, pricing negotiations with governmental authorities can
take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that
compares the cost-effectiveness of our product candidates to that of other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at
unsatisfactory levels, our ability to generate revenues and become profitable could be impaired. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Legislative
and regulatory proposals have also been made to expand post-approval requirements and restrict sales and promotional activities for drug products. We cannot be sure whether
additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our
product candidates, if any, may be. In addition, increased scrutiny by the United States Congress of the FDA's approval process may significantly delay or prevent marketing approval, as well as
subject us and any future collaborators to more stringent drug labeling and post-marketing testing and other requirements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>55</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=60,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=56616,FOLIO='55',FILE='DISK116:[19ZBM1.19ZBM17601]DI17601A.;93',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_di17601_1_56"> </A>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may seek a breakthrough therapy designation for APR-246 or one or more of our other product candidates,
but we might not receive such designation, and even if we do, such designation may not lead to a faster development or regulatory review or approval process.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may seek a breakthrough therapy designation for APR-246 or one or more of our other product candidates. A breakthrough therapy is defined as
a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening condition, and preliminary clinical evidence indicates that the drug may
demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs and
biologics that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical
development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA may also be eligible for priority review if supported
by clinical data at the time the NDA is submitted to the FDA, and parts of the NDA may be submitted and reviewed on a rolling basis. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designation
as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for designation as a
breakthrough therapy, the FDA may disagree and instead determine not to make such designation. Even if we receive breakthrough therapy designation, the receipt of such designation for a product
candidate may not result in a faster development or regulatory review or approval process compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate
approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product candidates no longer meet the conditions
for qualification or decide that the time period for FDA review or approval will not be shortened. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


A fast track designation by the FDA for APR-246 may not actually lead to a faster development or regulatory
review or approval process.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If a drug is intended, whether alone or in combination with one or more other drugs, for the treatment of a serious or life-threatening
condition and nonclinical or clinical data demonstrate the potential to address unmet medical need for this condition, a drug sponsor may apply for FDA fast track designation. Although we have
received a fast track designation for APR-246 for the treatment of patients with myelodysplastic syndrome having a </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutation, this does not ensure
that we will receive marketing approval or that approval will be granted within any particular timeframe. We may not experience a faster development or regulatory review or approval process with fast
track designation compared to conventional FDA procedures. In addition, the FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical
development program. Fast track designation alone does not guarantee qualification for the FDA's priority review procedures. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may seek priority review designation for APR-246 or one or more of our other product candidates, but we
might not receive such designation, and even if we do, such designation may not lead to a faster development or regulatory review or approval process.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the FDA determines that a product candidate offers a treatment for a serious condition and, if approved, the product would provide a
significant improvement in safety or effectiveness, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an
application is six months from the 60-day filing date, rather than the standard review period of ten months. We may request priority review for our product candidates. The FDA has broad discretion
with respect to whether or not to grant priority review status to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may
decide not to grant it. Moreover, a priority review designation does not necessarily mean </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>56</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=61,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=783964,FOLIO='56',FILE='DISK116:[19ZBM1.19ZBM17601]DI17601A.;93',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_di17601_1_57"> </A>

<P style="font-family:times;"><FONT SIZE=2>a
faster development or regulatory review or approval process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. Receiving priority review from the
FDA does not guarantee approval within the six-month review cycle or at all. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our relationships with healthcare providers, physicians and third-party payors will be subject to applicable
anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to penalties, including criminal sanctions, civil penalties, contractual damages, reputational harm and
diminished profits and future earnings.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although we do not currently have any products on the market, we are subject to a variety of regulatory requirements, including healthcare
statutory and regulatory requirements and enforcement by the U.S. federal and state governments and the foreign governments of the countries in which we conduct our business. Even though we are not in
a position to make patient referrals and do not bill Medicare, Medicaid, or other government or commercial third-party payers, our relationships with healthcare providers, physicians and third-party
payors will subject us to healthcare statutory and regulatory requirements and enforcement by the federal government and the states and foreign governments in which we conduct our business. Our future
arrangements with healthcare providers, physicians and third-party payors and patients may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain
the business or financial arrangements and relationships through which we market, sell and distribute our products for which we obtain marketing approval. Restrictions under applicable federal and
state healthcare laws and regulations include, without limitation, the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>The Federal Anti-Kickback Statute</I></FONT><FONT SIZE=2>&#151;An intent-based federal criminal statute that
prohibits, among other things, any person from knowingly and willfully soliciting, offering, receiving or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in
return for, either the referral of an individual for, or the purchase, order or recommendation or arranging of, any good or service, for which payment may be made, in whole or in part, by a federal
health care program, such as Medicare and Medicaid. The term "remuneration" has been broadly interpreted to include anything of value. The PPACA, among other things, amended the intent requirement of
the federal Anti-Kickback Statute, so that a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it. The Anti-Kickback Statute has also been
interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and individuals, such as prescribers, patients, purchasers, and formulary managers on the other the other
hand. A conviction for violation of the Anti-Kickback Statute results in criminal fines and requires mandatory exclusion from participation in federal health care programs. Although there are a number
of statutory exceptions and regulatory safe harbors to the federal Anti-Kickback Statute that protect certain common industry practices from prosecution, the exceptions and safe harbors are narrowly
drawn, and arrangements may be subject to scrutiny or penalty if they do not fully satisfy all elements of an available exception or safe harbor. The Anti-Kickback Statute safe harbors, including the
discount safe harbor, are the subject of possible regulatory reforms. Any changes to the safe harbors may impact our future contractual and other arrangements with pharmacy benefit managers,
third-party payors, wholesalers and distributors, healthcare providers and prescribers, and other entities, as well as our future pricing strategies. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>The Federal Civil False Claims Act</I></FONT><FONT SIZE=2>&#151;Imposes civil penalties, including through civil
whistleblower or </FONT><FONT SIZE=2><I>qui tam</I></FONT><FONT SIZE=2> actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, false or
fraudulent claims for payment by a federal healthcare program or knowingly making using or causing to be made or used a false statement or record material to payment of a false claim or avoiding,
decreasing or concealing an obligation to pay money to the federal government, with potential liability including mandatory treble damages </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>57</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=62,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=99277,FOLIO='57',FILE='DISK116:[19ZBM1.19ZBM17601]DI17601A.;93',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_di17601_1_58"> </A>
<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>and
significant per-claim penalties, currently set at $11,181 to $22,363 per false claim or statement for penalties assessed after January&nbsp;29, 2018, with respect to violations occurring after
November&nbsp;2, 2015. Among other reasons, pharmaceutical companies have been investigated and/or subject to government enforcement actions asserting liability under the federal civil False Claims
Act in connection with their alleged off-label promotion of drugs, purportedly concealing price concessions in the pricing information submitted to the government for government price reporting
purposes (e.g.,&nbsp;under the Medicaid Drug Rebate Program), and allegedly providing free product to customers with the expectation that the customers would bill federal health care programs for
the product. In addition, the
government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False
Claims Act. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes "any request or demand" for money or property presented to the U.S. government. In
addition, manufacturers can be held liable under the federal False Claims Act even when they do not submit claims directly to government payors if they are deemed to "cause" the submission of false or
fraudulent claims. Criminal prosecution is also possible for making or presenting a false, fictitious or fraudulent claim to the federal government. </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>The Federal Criminal Statute on False Statements Relating to Health Care
Matters</I></FONT><FONT SIZE=2>&#151;Makes it a crime to knowingly and willfully falsify, conceal, or cover up a material fact, make any materially false, fictitious, or fraudulent statements
or representations, or make or use any materially false writing or document knowing the same to contain any materially false, fictitious, or fraudulent statement or entry in connection with the
delivery of or payment for federally funded healthcare benefits, items, or services. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>HIPAA Criminal Federal Health Care Fraud Statute</I></FONT><FONT SIZE=2>&#151;Enacted as part of the Health
Insurance Portability and Accountability Act of 1996, makes it a crime to knowingly and willfully falsify, conceal, or cover up a material fact, make any materially false, fictitious, or fraudulent
statements or representations, or make or use any materially false writing or document knowing the same to contain any materially false, fictitious, or fraudulent statement or entry in connection with
the delivery of or payment for federally funded healthcare benefits, items, or services. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>The Federal Civil Monetary Penalties Law</I></FONT><FONT SIZE=2>&#151;Authorizes the imposition of substantial
civil monetary penalties against an entity, such as a pharmaceutical manufacturer, that engages in activities including, among others (1)&nbsp;knowingly presenting, or causing to be presented, a
claim for services not provided as claimed or that is otherwise false or fraudulent in any way; (2)&nbsp;arranging for or contracting with an individual or entity that is excluded from participation
in federal healthcare programs to provide items or services reimbursable by a federal healthcare program; (3)&nbsp;violations of the federal Anti-Kickback Statute; or (4)&nbsp;failing to report
and return a known overpayment. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>HIPAA Health Information Privacy and Security</I></FONT><FONT SIZE=2>&#151;The Health Insurance Portability and
Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and its implementing regulations, or collectively, HIPAA, imposes
privacy, security, and breach reporting obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouse as well as their business associates that perform certain
services involving the use or disclosure of individually identifiable health information, including, among other requirements, mandatory contractual terms and technical safeguards to protect the
privacy, security and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security of
individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>58</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=63,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=250963,FOLIO='58',FILE='DISK116:[19ZBM1.19ZBM17601]DI17601A.;93',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_di17601_1_59"> </A>
<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>directly
applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in U.S. federal courts to enforce the federal HIPAA laws and
seek attorneys' fees and costs associated with pursuing federal civil actions. </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>The Federal Physician Payments Sunshine Act</I></FONT><FONT SIZE=2>&#151;Requires "applicable manufacturers" of
drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid or the State Children's Health Insurance Program, among others, to track and report annually to
the federal government (for disclosure to the public) certain payments and other transfers of value they make to "covered recipients." The term covered recipients includes physicians, teaching
hospitals, and, for reports submitted on or after January&nbsp;1, 2022, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse
midwives. Failure to submit required information may result in civil monetary penalties. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>The Federal Food, Drug, and Cosmetic Act</I></FONT><FONT SIZE=2>&#151;Prohibits, among other things, the
adulteration or misbranding of drugs, biologics and medical devices. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>Analogous State and Foreign Laws</I></FONT><FONT SIZE=2>&#151;There are state and foreign law equivalents of the
above federal laws, such as the Anti-Kickback Statute and the False Claims Act, which may apply to items or services reimbursed by any third-party payor, including commercial insurers
(i.e.,&nbsp;so-called "all-payor anti-kickback laws"). Similarly, there are state and foreign laws that govern the privacy and security of health information, biometric information or more general
personally identifiable information, including state health information privacy laws, data breach notification laws, marketing privacy laws, and certain comprehensive privacy legislation such as the
new California Consumer Privacy Act which govern the collection, use, disclosure, and protection of health-related and other personal information, many of which differ from each other in significant
ways and, with respect to state laws, are often not pre-empted by HIPAA, or govern data that we may have that is outside the scope of HIPAA, thus requiring additional compliance efforts. These privacy
and data protection laws are also evolving, requiring continual evaluation and investment in compliance programs. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>State and Foreign Laws Regulating Pharmaceutical Manufacturer Compliance Programs and Other
Practices</I></FONT><FONT SIZE=2>&#151;Some state and foreign laws require pharmaceutical companies to implement compliance programs, comply with the pharmaceutical industry's voluntary
compliance guidelines and the relevant compliance guidance promulgated by the federal government, or to track and report gifts, compensation, or other remuneration to physicians and other healthcare
providers. Several U.S. states and localities have enacted legislation requiring pharmaceutical companies to establish marketing compliance programs, file periodic reports, and/or make periodic public
disclosures on sales, marketing, pricing, clinical trials, and other activities. Other state laws prohibit certain marketing-related activities including the provision of gifts, meals or other items
to certain healthcare providers, and restrict the ability of manufacturers to offer co-pay support to patients for certain prescription drugs. In addition, several recently passed state laws require
disclosures related to state agencies and/or commercial purchasers with respect to certain price increases that exceed a certain level as identified in the relevant statutes. Some of these laws and
regulations contain ambiguous requirements that government officials have not yet clarified. Given the lack of clarity in the laws and their implementation, our reporting actions could be subject to
the penalty provisions of the pertinent federal and state laws and regulations. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Efforts
to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that
governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, guidance, case law or other applicable law. If our operations are found
to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines,
individual imprisonment, exclusion from </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>59</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=64,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=771318,FOLIO='59',FILE='DISK116:[19ZBM1.19ZBM17601]DI17601A.;93',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_di17601_1_60"> </A>

<P style="font-family:times;"><FONT SIZE=2>participation
in federal health care programs, such as Medicare and Medicaid, disgorgement, reputational harm, additional oversight and reporting obligations pursuant to a corporate integrity
agreement or similar agreement to resolve allegations of non-compliance with applicable laws and regulations, and the curtailment or restructuring of our operations, any of which could adversely
affect our ability to market our products, if approved, and adversely impact our financial results. Although effective compliance programs can mitigate the risk of investigation and prosecution for
violations of these laws and regulations, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and
could divert our management's attention from the operation of our business, even if our defense is successful. If any of the physicians or other healthcare providers or entities with whom we expect to
do business is found not to be in compliance with applicable laws, it may be costly to us in terms of money, time and resources, and they may be subject to criminal, civil or administrative sanctions,
including exclusions from government-funded healthcare programs. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our employees may engage in misconduct or other improper activities, including non-compliance with regulatory
standards and requirements, which could cause significant liability for us and harm our reputation.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are exposed to the risk of employee fraud or other misconduct, including intentional failures to comply with FDA regulations or similar
regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards we may establish,
comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial
information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and
regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and
promotion, sales commission, incentive programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which
could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this
activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in
compliance with such laws, standards or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a
significant impact on our business and results of operations, including the imposition of significant fines or other sanctions. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we fail to comply with environmental, health and safety laws and regulations, we could become subject to
fines or penalties or incur costs that could have a material adverse effect on our business.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the
handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our
operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from
these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources.
We also could incur significant costs associated with civil or criminal fines and penalties. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although
we maintain workers' compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this
insurance </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>60</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=65,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=569664,FOLIO='60',FILE='DISK116:[19ZBM1.19ZBM17601]DI17601A.;93',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_di17601_1_61"> </A>

<P style="font-family:times;"><FONT SIZE=2>may
not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our
storage or disposal of hazardous and flammable materials, including chemicals and biological materials. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations
may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Laws and regulations governing any international operations we may have in the future may preclude us from
developing, manufacturing and selling certain product candidates outside of the United States and require us to develop and implement costly compliance programs.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we expand our operations outside of the United States, we must comply with numerous laws and regulations in each jurisdiction in which we
plan to operate, such as the applicable anti-bribery, anti-corruption, anti-money laundering regulations. The creation and implementation of
international business practices compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly,
to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining
business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that
accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international
operations. The anti-bribery provisions of the FCPA are enforced primarily by the DOJ. The Securities and Exchange Commission, or SEC, is involved with enforcement of the books and records provisions
of the FCPA. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compliance
with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the
pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals
in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Violation
of the FCPA can result in significant civil and criminal penalties. Indictment alone under the FCPA can lead to suspension of the right to do business with the U.S. government
until the pending claims are resolved. Conviction of a violation of the FCPA can result in long-term disqualification as a government contractor. The termination of a government contract or
relationship as a result of our failure to satisfy any of our obligations under laws governing international business practices would have a negative impact on our operations and harm our reputation
and ability to procure government contracts. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA's accounting provisions. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are also subject to other laws and regulations governing our international operations, including applicable import and export control regulations, economic sanctions on countries and
persons administered or enforced by the U.S. government (including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury), anti-money laundering laws,
customs requirements and currency exchange regulations, collectively referred to as the trade control laws. We can provide no assurance that we will be completely effective in ensuring our compliance
with all applicable legal requirements, including trade control laws. If we are not in compliance with applicable trade control laws, we may be subject to criminal and civil penalties, disgorgement
and other sanctions </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>61</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=66,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=839414,FOLIO='61',FILE='DISK116:[19ZBM1.19ZBM17601]DI17601A.;93',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_di17601_1_62"> </A>

<P style="font-family:times;"><FONT SIZE=2>and
remedial measures, and legal expenses, which could have an adverse impact on our business, results of operations, financial condition and prospects. Likewise, any investigation of any potential
violations of these trade control laws by U.S. or other authorities could also have an adverse impact on our reputation, our business, results of operations, financial condition and prospects. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Various
laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information
classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the United States, it will require us to
dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain drugs and product candidates outside of the United States,
which could limit our growth potential and increase our development costs. The failure to comply with laws governing international business practices may result in substantial penalties, including
suspension or debarment from government contracting. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Security breaches, loss of data and other disruptions could compromise sensitive information related to our
business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the ordinary course of our business, we collect and store sensitive data, including personally identifiable information, intellectual
property and proprietary business information owned or controlled by ourselves and other parties. We manage and maintain our applications and data utilizing a combination of on-site systems, managed
data centers and cloud-based data centers. We utilize external security and infrastructure vendors to manage our information technology systems and data centers. These applications and data encompass
a wide variety of business-critical information, including research and development information, commercial information, and business and financial information. We face a number of risks relative to
protecting this critical information, including loss of access risk, inappropriate use or disclosure, inappropriate modification, and the risk of our being unable to adequately monitor, audit and
modify our controls over our critical information. This risk extends to the third-party vendors and subcontractors we use to manage this sensitive data. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
secure processing, storage, maintenance and transmission of this critical information are vital to our operations and business strategy. Although we take measures to protect
sensitive data from unauthorized access, use or disclosure, and are in the process of developing policies and procedures to protect our information technology systems and confidential and proprietary
information, we do not currently have any such policies and procedures formally in place and our information technology and infrastructure may be vulnerable to attacks by hackers or viruses or
breached due to employee error, malfeasance or other malicious or inadvertent disruptions. Any such breach or interruption could compromise our networks and the information stored there could be
accessed by unauthorized parties,
manipulated, publicly disclosed, lost or stolen. Any such access, breach or other loss of information could result in legal claims or proceedings, and liability under federal or state laws that
protect the privacy of personal information, such as the Health Insurance Portability and Accountability Act of 1996, or HIPAA, the Health Information Technology for Economic and Clinical Health Act,
or HITECH, and regulatory penalties. Notice of breaches must be made to affected individuals, the Secretary of the Department of Health and Human Services, and for extensive breaches, notice may need
to be made to the media or State Attorneys General. Such a notice could harm our reputation and our ability to compete. Although we have implemented security measures and are in the process of
implementing formal, dedicated enterprise policies and procedures to prevent unauthorized access to patient data, we do not currently have any such policies and procedures formally in place and there
is no guarantee we can protect our data from breach. Unauthorized access, loss or dissemination could also damage our reputation or disrupt our operations, including our ability to conduct our
analyses, process claims and appeals, conduct research and development activities, collect, process and prepare </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>62</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=67,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=511725,FOLIO='62',FILE='DISK116:[19ZBM1.19ZBM17601]DI17601A.;93',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_di17601_1_63"> </A>

<P style="font-family:times;"><FONT SIZE=2>company
financial information, provide information about our tests and other patient and physician education and outreach efforts through our website, and manage the administrative aspects of our
business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Penalties
for violations of these laws vary. For instance, penalties for failure to comply with a requirement of HIPAA and HITECH vary significantly, and include civil monetary penalties
of up to $55,910 per violation, not to exceed approximately $1.68&nbsp;million per calendar year for each provision of HIPAA that is violated and, in certain circumstances, criminal penalties with
fines up to $250,000 per violation and/or imprisonment. However, a single breach incident can result in multiple violations, which can lead to significant financial penalties. In addition, numerous
breach incidents could lead to possible penalties in excess of $1.68&nbsp;million. A person who knowingly obtains or discloses individually identifiable health information in violation of HIPAA may
face a criminal penalty of up to $50,000 and up to one-year imprisonment. The criminal penalties increase if the wrongful conduct involves false pretenses or the intent to sell, transfer or use
identifiable health information for commercial advantage, personal gain or malicious harm. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further,
various states, such as California and Massachusetts, have implemented similar privacy laws and regulations, such as the California Confidentiality of Medical Information Act,
that impose restrictive requirements regulating the use and disclosure of health information and other personally identifiable information. These laws and regulations are not necessarily preempted by
HIPAA, particularly if a state affords greater protection to individuals than HIPAA. Where state laws are more protective, we have to comply with the stricter provisions. In addition to fines and
penalties imposed upon violators, some of these state laws also afford private rights of action to individuals who believe their personal information has been misused. California's patient privacy
laws, for example, provide for penalties of up to $250,000 and permit injured parties to sue for damages. The interplay of federal and state laws may be subject to varying interpretations by courts
and government agencies, creating complex compliance issues for us and data we receive, use and share, potentially exposing us to additional expense, adverse publicity and liability. Further, as
regulatory focus on privacy issues
continues to increase and laws and regulations concerning the protection of personal information expand and become more complex, these potential risks to our business could intensify. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compliance
with U.S. and international data protection laws and regulations could cause us to incur substantial costs or require us to change our business practices and compliance
procedures in a manner adverse to our business. Moreover, complying with these various laws could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use
and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. We do not currently have formal policies and procedures in place, and have not conducted any internal or
external audits, to ensure our compliance with all applicable data protection laws and regulations. Additionally, we do not currently have policies and procedures in place for assessing our
third-party vendors' compliance with applicable data protection laws and regulations. Failure by us or by our third-party vendors to comply with U.S. and international data protection laws and
regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity and could negatively affect our operating
results and business. Claims that we or our third-party vendors have violated individuals' privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if
we or our third-party vendor, as applicable, are not found liable, could be expensive and time consuming to defend and could result in adverse publicity that could harm our business. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>63</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=68,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=787551,FOLIO='63',FILE='DISK116:[19ZBM1.19ZBM17601]DI17601A.;93',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_di17601_1_64"> </A>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Any clinical trial programs we conduct or research collaborations we enter into in the European Economic Area
("EEA") may subject us to European data protection laws including, the EU General Data Protection Regulation&nbsp;2016/679 ("GDPR").  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are subject to the GDPR, which applies extra-territorially and implements stringent operational requirements on controllers
(e.g.,&nbsp;sponsors) and processors (e.g.,&nbsp;CROs, laboratories) of personal data, including, for example, high standards for obtaining valid consent from individuals to process their personal
data (where consent is the legal ground relied upon), the requirements to provide detailed disclosures to individuals, restrictions on transfers of personal data from the EEA, short timelines for
personal data breach notifications to data protection authorities, limitations on retention of personal data, additional considerations where processing health data and other "special categories of
personal data" and specific obligations where third-party processors are engaged. Further, the GDPR provides that EU Member States may establish their own laws and regulations further restricting the
processing of genetic data, biometric data, health data and other personal data, which could limit our ability to use and share such personal data or could cause our costs to increase. The GDPR
imposes onerous accountability obligations requiring data controllers and processors to maintain a record of their data processing and policies. We do not currently have any formal data privacy
policies and procedures in place and have not completed an assessment of whether we are in compliance with the GDPR. The GDPR also grants certain privacy rights to individuals
(e.g.,&nbsp;the right to access or erase their personal data). If our or our vendors' or service providers' privacy or data security measures fail to comply with the GDPR requirements, we may be
subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data and/or fines of up to 20&nbsp;million Euros or up to 4% of the total
worldwide annual turnover of the preceding financial year, whichever is higher, as well as compensation claims for financial or non-financial loss by affected individuals, negative publicity,
reputational harm and a potential loss of business and goodwill. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. If so, this could
result in government-imposed fines or orders requiring that we change our practices, which could adversely affect our business. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks related to employee matters and managing growth  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our future success depends on our ability to retain our President and Chief Executive Officer, our Senior
Vice President and Chief Scientific Officer, Chief Medical Officer, Vice President of Business Development and other key executives and to attract, retain and motivate qualified personnel.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are highly dependent on Christian S. Schade, our President and Chief Executive Officer, Scott&nbsp;M. Coiante, our Senior Vice President
and Chief Financial Officer, Lars Abrahmsen, Ph.D., our Senior Vice President and Chief Scientific Officer, Eyal C. Attar, M.D., our Senior Vice President and Chief Medical Officer, and Gregory A.
Korbel, Ph.D., our Vice President of Business Development, as well as the other principal members of scientific team. Our agreements with Mr.&nbsp;Schade, Mr.&nbsp;Coiante, Dr.&nbsp;Abrahmsen,
Dr.&nbsp;Attar and Dr.&nbsp;Korbel do not prevent them from terminating their employment with us at any time. We do not maintain "key person" insurance for any of our executives or other
employees. However, the loss of the services of any of these persons could impede the achievement of our research, development and commercialization objectives. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recruiting
and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. We may not be able to attract and retain
these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific
and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our
research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>64</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=69,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=573718,FOLIO='64',FILE='DISK116:[19ZBM1.19ZBM17601]DI17601A.;93',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_di17601_1_65"> </A>

<P style="font-family:times;"><FONT SIZE=2>and
may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our employees may engage in misconduct or other improper activities, including non-compliance with regulatory
standards and requirements, which could cause significant liability for us and harm our reputation.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are exposed to the risk of employee fraud or other misconduct, including intentional failures to comply with FDA regulations or similar
regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards we may establish,
comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial
information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and
regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and
promotion, sales commission, incentive programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which
could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this
activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in
compliance with such laws, standards or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a
significant impact on our business and results of operations, including the imposition of significant fines or other sanctions. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We expect to expand our development and regulatory capabilities and potentially our sales and marketing
capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug
development, clinical operations, regulatory affairs and, potentially, sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial,
operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our
management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or
recruit and train additional qualified personnel. The physical expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability
to manage growth could delay the execution of our business plans or disrupt our operations. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks related to tax matters  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have significant deferred tax assets, which may become devalued if we do not generate sufficient future
taxable income, applicable corporate tax rates are reduced or if we experience an ownership change.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our total gross deferred tax assets as of December&nbsp;31, 2018 were $12.8&nbsp;million. Of that amount, $12.5&nbsp;million relates to
gross deferred tax assets in Aprea AB. Our anticipated activities are also expected to result in future significant net operating losses in the United States and Sweden resulting in additional
deferred tax assets. Utilization of most deferred tax assets is dependent on generating sufficient future taxable income in the appropriate jurisdiction and/or entity. The company has provided a
valuation allowance of $12.7 million on our net deferred tax assets as of December&nbsp;31, 2018, based on all available evidence, it is considered more likely than not that all the recorded
deferred tax assets </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>65</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=70,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=128132,FOLIO='65',FILE='DISK116:[19ZBM1.19ZBM17601]DI17601A.;93',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_di17601_1_66"> </A>

<P style="font-family:times;"><FONT SIZE=2>will
not be realized in a future period. Additionally, most of our deferred tax assets are determined by reference to applicable corporate income tax rates in Sweden or the United States. Accordingly,
in the event of a reduction of any such corporate income tax rates, the carrying value of certain of our deferred tax assets would decrease. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Moreover,
our ability to use our net operating losses and other deferred tax assets to offset future taxable income in Sweden and the United States may be significantly limited if we
experience an ownership change. For Swedish income tax purposes, an ownership change will generally occur when one, or several shareholders together, acquire shares representing more than
50&nbsp;percent of the voting power over a five&nbsp;year period (under special provisions in Chapter 40 of the Swedish Income Tax Act; 1999:1229). Such an ownership change results in the
forfeiture of tax losses carried forward exceeding 200&nbsp;percent of the cost of the change of control. In this calculation, capital contributions to the
company prior to the ownership change and in the preceding two&nbsp;years should reduce the cost of the change of control. Due to potential ownership changes under the Swedish Income Tax Act, we may
be limited in our ability to realize a tax benefit on our deferred tax assets, whether or not we attain profitability in future years. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
U.S. federal income tax purposes, an ownership change will generally occur when the percentage of our stock (by value) owned by one or more "5&nbsp;percent shareholders" (as
defined in the U.S. Internal Revenue Code of 1986, as amended) has increased by more than 50% over the lowest percentage owned by such shareholders at any time during the prior three years (calculated
on a rolling basis). We anticipate that we will incur losses in the United States in the foreseeable future related to our research and development activities. Due to potential ownership changes under
Section&nbsp;382 of the Code, we may be limited in our ability to realize a tax benefit from the use of our deferred tax assets, whether or not we attain profitability in future years. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, our ability to utilize any future net operating losses may be limited by the recently enacted Pub.&nbsp;L.&nbsp;115-97, commonly known as the Tax Cuts and Jobs Act of
2017 ("TCJA"). Under the TCJA, the amount of our net operating losses that we are permitted to deduct in any taxable year is limited to 80% of our taxable income in such year, where taxable income is
determined without regard to the net operating loss deduction itself, while allowing unused net operating losses to be carried forward indefinitely. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
these reasons, a material devaluation in our deferred tax assets due to insufficient taxable income, lower corporate income tax rates or ownership change would have an adverse effect
on our results of operations and financial condition. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may have taxable income as a result of the purging election we will make following the Holdco
Reorganization  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While not entirely clear, we intend to treat Aprea AB as having been a passive foreign investment company, or PFIC, for U.S. federal income tax
purposes prior to the Holdco Reorganization and treat Aprea Therapeutics,&nbsp;Inc. as having succeeded to the tax basis and holding periods of those shareholders in Aprea AB that exchanged their
shares for our common stock. Based on such treatment, and absent a purging election as described below, the stock of Aprea AB held by Aprea Therapeutics,&nbsp;Inc. would have retained its status as
stock of a PFIC with respect to all periods prior to the Holdco Reorganization (the "PFIC Taint") and therefore, absent a prior election by those shareholders to treat Aprea AB as a qualified electing
fund, Aprea Therapeutics,&nbsp;Inc., would have been subject to certain adverse U.S. federal income tax consequences with respect to distributions received on such stock and gain recognized on the
disposition of such stock. In order to purge the PFIC Taint on the stock of Aprea AB, and avoid such adverse tax consequences, following the Holdco Reorganization we intend to make a purging election
in the form of a deemed dividend election under which, for U.S. federal income tax purposes, Aprea AB will be deemed to have made a distribution to </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>66</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=71,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=30056,FOLIO='66',FILE='DISK116:[19ZBM1.19ZBM17601]DI17601A.;93',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_di17601_1_67"> </A>

<P style="font-family:times;"><FONT SIZE=2>Aprea
Therapeutics,&nbsp;Inc. of all of its current and accumulated earnings and profits as determined for U.S. federal income tax purposes. Because we do not expect Aprea AB to have had any
accumulated or current year earnings and profits, we do not expect the purging election to result in any incremental U.S. federal income taxes. We note, however, that earnings and profits are
determined only at the end of the taxable year and no assurance can be given that Aprea AB will not have any earnings and profits. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be subject to current taxation on some of the income of our foreign subsidiaries even absent any cash
distributions  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because we hold directly or indirectly all of the shares of our foreign subsidiaries, including Aprea AB, such subsidiaries are treated as
controlled foreign corporations ("CFC") for U.S. federal income tax purposes. For U.S. federal income tax purposes, Aprea Therapeutics,&nbsp;Inc. will therefore need to include in its taxable income
each year Aprea AB's "subpart&nbsp;F income," and "global intangible low-taxed income", if any, even if no distributions are made. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our foreign subsidiaries may directly become subject to U.S. federal income tax and be subject to a branch
profits tax in the United States, which could reduce our after-tax returns and the value of our shares.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently intend to conduct substantially all of our businesses and operations in a manner such that our foreign subsidiaries will not be
treated as engaged in a trade or business in the United States and will not be subject to additional U.S. income tax or branch profits tax. However, it is not entirely clear when a foreign subsidiary
is treated as being engaged in a trade or business in the United States for U.S. federal income tax purposes. Accordingly, we cannot assure you that the Internal Revenue Service ("IRS") will not
contend, perhaps successfully, that our foreign subsidiaries were engaged in a trade or business in the United States or are subject to more U.S. income tax than they currently incur. A foreign
corporation deemed to be so engaged would be subject to U.S. federal income tax, as well as branch profits tax, on its income that is treated as effectively connected with the conduct of that trade or
business unless the corporation is entitled to relief under an applicable tax treaty, which is determined on an annual basis. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The ongoing effects of the 2017 Tax Cuts and Jobs Act and GILTI could make our results difficult to predict.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our effective tax rate may fluctuate in the future as a result of the TCJA, which included significant enacted changes in U.S. income tax law
many aspects of which are not entirely clear and with respect to which guidance is mostly available only in proposed form. The enacted tax legislation included, among other new provisions, a reduction
in the corporate tax rate, new limitations on the deductibility of net interest, the base erosion and anti-abuse minimum tax and new rules related to the global intangible low-taxed income of our
foreign subsidiaries ("GILTI"). GILTI may require us to include in taxable income certain income of our foreign subsidiaries that are CFCs, though we may be eligible to claim foreign tax credits with
respect to some of the taxes paid by such subsidiaries. While the U.S. tax authorities issued formal guidance as well as final and proposed regulations for GILTI, there are still certain aspects of
the TCJA that remain unclear. We will continue to review the impact of GILTI and the other changes resulting from the TCJA as further guidance is issued. Any further guidance may result in changes to
the interpretations and assumptions we made and actions we may take, which as a result may impact the amounts recorded with respect to international provisions of the TCJA, possibly materially. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Changes in U.S. federal income tax law and other jurisdictions could materially adversely affect an
investment in our common shares.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It is possible that tax laws in the United States and other jurisdictions will be changed. It remains difficult to predict whether or when there
will be any tax law changes or further guidance by the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>67</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=72,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=950890,FOLIO='67',FILE='DISK116:[19ZBM1.19ZBM17601]DI17601A.;93',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_di17601_1_68"> </A>

<P style="font-family:times;"><FONT SIZE=2>authorities
in the U.S. or elsewhere in the world that will have a material adverse effect on our business. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks related to our common stock and this offering  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


After this offering, our executive officers, directors and principal stockholders will exert significant
control over matters submitted to stockholders for approval. This may prevent new investors from influencing significant corporate decisions.  </I></B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the completion of this offering, our executive officers and directors and our stockholders which own more than 5% of our outstanding common
stock before this offering will, in the aggregate, beneficially own shares representing approximately 70.0% of our common stock, not including any shares purchased by these stockholders in this
offering. As a result, if these stockholders were to choose to act together, they would be able to exert significant control over matters submitted to our stockholders for approval, as well as our
management and affairs. For example, these persons, if they choose to act together, would control the election of directors and approval of any merger, consolidation or sale of all or substantially
all of our assets. This concentration of voting power could delay or prevent an acquisition of our company, or other significant corporate decisions, on terms that other stockholders may desire.

 </FONT>

</P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which
may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provisions in our certificate of incorporation and our bylaws that will become effective upon the completion of this offering may discourage,
delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares.
These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition,
because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our
current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establish a classified board of directors such that not all members of the board are elected at one time; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> allow the authorized number of our directors to be changed only by resolution of our board of directors; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> limit the manner in which stockholders can remove directors from the board; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of
directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written
consent; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> limit who may call stockholder meetings; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a "poison pill" that
would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>68</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=14,SEQ=73,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=368449,FOLIO='68',FILE='DISK116:[19ZBM1.19ZBM17601]DI17601A.;93',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_di17601_1_69"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal certain
provisions of our charter or bylaws. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Moreover,
because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation Law, which prohibits a person who owns in
excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our
outstanding voting stock, unless the merger or combination is approved in a prescribed manner. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


An active trading market for our common stock may not develop.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior to this offering, there has been no public market for our common stock. The initial public offering price for our common stock will be
determined through negotiations with the underwriters. Although we have applied to list our common stock on The Nasdaq Global Select Market, an active trading market for our shares may never develop
or be sustained following this offering. If an active market for our common stock does not develop or is not sustained, it may be difficult for you to sell shares you purchase in this offering without
depressing the market price for the shares, or at all. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If you purchase shares of common stock in this offering, you will suffer immediate dilution of your
investment.  </I></B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The initial public offering price of our common stock is substantially higher than the pro forma as adjusted net tangible book value per share
of our common stock. Therefore, if you purchase shares of our common stock in this offering, you will pay a price per share that substantially exceeds our pro forma as adjusted net tangible book value
per share after this offering. To the extent shares are issued under outstanding options, you will incur further dilution. Based on the initial public offering price of $15.00 per share, which is the
midpoint of the price range set forth on the cover of
this prospectus, you will experience immediate dilution of $6.35 per share, representing the difference between our pro forma as adjusted net tangible book value per share after giving effect to this
offering and the assumed initial public offering price per share. In addition, purchasers of common stock in this offering will have contributed approximately 35% of the aggregate price paid by all
purchasers of our stock but will own only approximately 26% of our common stock outstanding after this offering.

 </FONT>

</P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If securities analysts do not publish research or reports about our business or if they publish negative
evaluations of our stock, the price of our stock could decline.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The trading market for our common stock will rely in part on the research and reports that industry or financial analysts publish about us or
our business. We do not currently have and may never obtain research coverage by industry or financial analysts. If no or few analysts commence coverage of us, the trading price of our stock would
likely decrease. Even if we do obtain analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or
more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The price of our common stock may be volatile and fluctuate substantially, which could result in substantial
losses for purchasers of our common stock in this offering.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our stock price is likely to be volatile. The stock market in general and the market for pharmaceutical and biotechnology companies in
particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your
common stock at or above the initial public offering price. The market price for our common stock may be influenced by many factors, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the timing and results of clinical trials of APR-246 and any of our other product candidates; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>69</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=15,SEQ=74,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=479574,FOLIO='69',FILE='DISK116:[19ZBM1.19ZBM17601]DI17601A.;93',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_di17601_1_70"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> regulatory actions with respect to our product candidates or our competitors' products and product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the success of existing or new competitive products or technologies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital
commitments; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establishment or termination of collaborations for our product candidates or development programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> failure or discontinuation of any of our development programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> results of clinical trials of product candidates of our competitors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> regulatory or legal developments in the United States and other countries; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> developments or disputes concerning patent applications, issued patents or other proprietary rights; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the recruitment or departure of key personnel; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the level of expenses related to any of our product candidates or development programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the results of our efforts to discover, develop, acquire or in-license additional product candidates or products; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> actual or anticipated changes in estimates as to financial results or development timelines; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> announcement or expectation of additional financing efforts; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> sales of our common stock by us, our insiders or other stockholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> variations in our financial results or those of companies that are perceived to be similar to us; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> changes in estimates or recommendations by securities analysts, if any, that cover our stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> changes in the structure of healthcare payment systems; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> market conditions in the pharmaceutical and biotechnology sectors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> general economic, industry and market conditions; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the other factors described in this "Risk Factors" section. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We could be subject to securities class action litigation.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the past, securities class action litigation has often been brought against a company following a decline in the market price of its
securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in
substantial costs and a diversion of management's attention and our resources, which could harm our business. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have broad discretion in the use of the net proceeds from this offering and may not use them effectively.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that do
not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could have a
material adverse effect on our business, cause the price of our common stock to decline and delay the development of our product candidates. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>70</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=16,SEQ=75,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=570107,FOLIO='70',FILE='DISK116:[19ZBM1.19ZBM17601]DI17601A.;93',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_di17601_1_71"> </A>

<P style="font-family:times;"><FONT SIZE=2>Pending
their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are an "emerging growth company" and a "smaller reporting company," and the reduced disclosure
requirements applicable to emerging growth companies or smaller reporting companies may make our common stock less attractive to investors.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are an "emerging growth company," as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We may remain an emerging
growth company for up to five years, or until such earlier time as we have more than $1.07&nbsp;billion in annual revenue, the market value of our stock held by non-affiliates is more than
$700&nbsp;million or we issue more than $1&nbsp;billion of non-convertible debt over a three-year period. For so long as we remain an emerging growth company, we are permitted and intend to rely
on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include not being required to comply with the
auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or Section&nbsp;404, not being required to comply with any requirement that may be adopted by the Public
Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor's report providing additional information about the audit and the financial statements, being
permitted to present only two years of audited financial statements and a correspondingly reduced "Management's Discussion and Analysis of Financial Condition and Results of Operations" disclosure in
this prospectus, reduced disclosure obligations regarding executive compensation and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder
approval of any golden parachute payments not previously approved. In this prospectus, we have taken advantage of reduced reporting obligations. In particular, in this prospectus, we have provided
only two years of audited financial statements and have not included all of the executive compensation related information that would be required if we were not an emerging growth company. We cannot
predict whether investors will find our common stock less
attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may
be more volatile. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. An emerging
growth company can therefore delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. However, we are choosing to "opt out" of such extended
transition period, and, as a result, we will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for public companies that are not
emerging growth companies. The JOBS Act provides that our decision to opt out of the extended transition period for complying with new or revised accounting standards is irrevocable. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are also a "smaller reporting company," as such term is defined in Rule&nbsp;12b-2 of the Exchange Act, meaning that the market value of our common stock held by non-affiliates plus
the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700 million and our annual revenue is less than $100 million during the most recently completed fiscal
year. We may continue to be a smaller reporting company after this offering if either (i)&nbsp;the market value of our common stock held by non-affiliates is less than $250 million or
(ii)&nbsp;our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our common stock held by non-affiliates is less than $700 million. If we
are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller
reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and,
similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>71</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=17,SEQ=76,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=405511,FOLIO='71',FILE='DISK116:[19ZBM1.19ZBM17601]DI17601A.;93',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_di17601_1_72"> </A>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We will incur increased costs as a result of operating as a public company as we become subject to additional
laws, regulations and listing exchange standards, and our management will be required to devote substantial time to new compliance initiatives.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a public company, and particularly after we are no longer an "emerging growth company" or a "smaller reporting company," we will incur
significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act of 2002 and rules subsequently implemented by the SEC and NASDAQ have
imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other
personnel will need to devote
a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more
time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to Section&nbsp;404, we will be required to furnish a report by our management on our internal control over financial reporting, including an attestation report on internal
control over financial reporting issued by our independent registered public accounting firm. However, while we remain an emerging growth company, we will not be required to include an attestation
report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section&nbsp;404 within the prescribed period, we will be
engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal
resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control
processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial
reporting. There is a risk that neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial
reporting is effective as required by Section&nbsp;404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounting
principles and related pronouncements, implementation guidelines and interpretations we apply to a wide range of matters that are relevant to our business, including, but not
limited to, revenue recognition, leases and stock-based compensation, are complex and involve subjective assumptions, estimates and judgments by our management. Changes in accounting pronouncements or
their interpretation or changes in underlying assumptions, estimates or judgments by our management could significantly change our reported or expected financial performance. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


In connection with the preparation of our financial statements as of and for the years ended
December&nbsp;31, 2017 and 2018, the Company and our independent registered public accounting firm identified a material weakness in the Company's internal control over financial reporting. If we
are not able to remediate the material weakness and otherwise to maintain an effective system of internal control over financial reporting in the future, investors may lose confidence in the accuracy
and completeness of our financial reports, and the market price of our common stock could be materially and adversely affected.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To date, we have not conducted an evaluation and testing of our internal control required by Section&nbsp;404 of the Sarbanes-Oxley Act. We
may experience situations in the future where our evaluation and testing processes required by Section&nbsp;404 of the Sarbanes-Oxley Act, or work performed by independent registered accountants,
may identify one or more material weaknesses in our internal controls over financial reporting that will result in our inability to assert that our internal control over financial reporting is
effective. During our evaluation and testing, we may identify deficiencies and be unable to remediate them before we must provide the required reports. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>72</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=18,SEQ=77,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=102780,FOLIO='72',FILE='DISK116:[19ZBM1.19ZBM17601]DI17601A.;93',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_di17601_1_73"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with the audits of our financial statements, we and our independent registered public accounting firm identified a material weakness related to our financial statement
closing process, primarily related to the lack of sufficient skilled employees with U.S.&nbsp;GAAP and SEC reporting knowledge and experience for the purposes of timely and reliable financial
reporting. Specifically, the material weakness identified relates to a lack of internal resources sufficient to prepare and review our consolidated financial statements and related disclosures in
accordance with U.S.&nbsp;GAAP and financial reporting requirements set forth by the SEC. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
standards established by the Public Company Accounting Oversight Board, a material weakness is a deficiency, or combination of deficiencies, in internal control over financial
reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected and corrected on a timely basis. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are working to remediate the material weakness and are taking steps to strengthen our internal control over financial reporting such as, for example, the recent hiring of Scott M.
Coiante as Chief Financial Officer. Additionally, we plan to further develop and implement formal policies, processes and documentation procedures relating to the financial reporting of the Company.
The actions that we are taking are subject to ongoing executive management review, and will also be subject to audit committee oversight. If we are unable to successfully remediate the material
weakness, or if in the future, we identify further material weaknesses in our internal controls over financial reporting, we may not detect errors on a timely basis and our financial statements may be
materially misstated. We or our independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which
could harm our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall. In addition, as a public company we will be
required to file accurate and timely quarterly and annual reports with the SEC under the Exchange Act. Any failure to report our financial results on an accurate and timely basis could result in
sanctions, lawsuits, delisting of our shares from The Nasdaq Global Select Market or other adverse consequences that would materially harm our business. In addition, we could become subject to
investigations by NASDAQ, the SEC, and other regulatory authorities, and become subject to litigation from investors and stockholders, which could harm our reputation and our financial condition, or
divert financial and management resources from our core business. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Because we do not anticipate paying any cash dividends on our common stock for the foreseeable future,
capital appreciation, if any, of our common stock will be your sole source of gain.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have never declared or paid cash dividends on our common stock. We currently intend to retain all of our future earnings, if any, to finance
the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock
will be your sole source of gain for the foreseeable future. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Sales of a substantial number of shares of our common stock by our existing stockholders in the public market
could cause our stock price to fall.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the
market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. After this offering, we will have outstanding 19,209,865 shares of common
stock based on the number of shares outstanding as of June&nbsp;30, 2019 (including 2,807 shares of common stock from the exercise of stock options on March&nbsp;25, 2019, which were registered
pursuant to Swedish law with the Swedish Companies Registration Office on August&nbsp;27, 2019). </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>73</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=19,SEQ=78,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=405278,FOLIO='73',FILE='DISK116:[19ZBM1.19ZBM17601]DI17601A.;93',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_di17601_1_74"> </A>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Of these shares of our common stock, the 5,000,000 shares to be sold in this offering, plus any shares sold upon exercise of the underwriters' option to purchase additional shares, will
be freely tradable, without restriction, in the public market immediately following this offering, unless purchased by our affiliates. All of the remaining shares are currently restricted as a result
of securities laws or lock-up agreements but will be able to be sold after the offering as described in the "Shares Eligible for Future Sale" section of this prospectus. Moreover, after this offering,
holders of approximately 14,200,000 shares of our common stock will have rights, subject to certain conditions, to require us to file registration statements covering their shares or to include their
shares in registration statements that we may file for ourselves or other stockholders. We also intend to register all shares of common stock that we may issue under our equity compensation plans.
Once we register these shares, they can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates and the lock-up agreements described in the
"Underwriting" section of this prospectus.

 </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our certificate of incorporation that will become effective upon the completion of this offering designates
the state courts in the State of Delaware or, if no state court located within the State of Delaware has jurisdiction, the federal court for the District of Delaware, as the sole and exclusive forum
for certain types of actions and proceedings that may be initiated by our stockholders, which could discourage lawsuits against the company and our directors, officers and employees.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our certificate of incorporation that will become effective upon the completion of this offering provides that, unless we consent in writing to
the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware)
will be the sole and exclusive forum for any derivative action or proceeding brought on our behalf under Delaware law, any action asserting a claim of breach of a fiduciary duty owed by any of our
directors, officers or employees to our company or our stockholders, any action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law or our
certificate of incorporation or bylaws, any action asserting a claim against us governed by the internal affairs doctrine, or any other action asserting an "internal corporate claim," as defined in
Section&nbsp;115 of the Delaware General Corporation Law. These exclusive-forum provisions do not apply to claims under the Securities Act of 1933, as amended, or the Securities Act, or the Exchange
Act. This exclusive forum provision may limit the ability of our stockholders to bring a claim in a judicial forum that such stockholders find favorable for disputes with us or our directors, officers
or employees, which may discourage such lawsuits against us and our directors, officers and employees. If a court were to find the exclusive-forum provision in our certificate of incorporation to be
inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could harm our results of operations. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>74</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=20,SEQ=79,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=784517,FOLIO='74',FILE='DISK116:[19ZBM1.19ZBM17601]DI17601A.;93',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dk17601_1_75"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dk17601_special_note_regarding_forward-looking_statements"> </A>
<A NAME="toc_dk17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Special Note Regarding Forward-Looking Statements    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our
plans, objectives and expectations for our business operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be
forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "due,"
"estimate," "expect," "goal," "intend," "may," "objective," "plan," "predict," "potential," "seek," "should," "target," "will," "would," and other similar expressions that are predictions of or
indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements
about:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> estimates of our expenses, capital requirements and our needs for additional financing; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the prospects of APR-246 and other product candidates, which are still in development; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> outcome and results of ongoing or future preclinical studies and clinical trials of APR-246; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the design of our multiple clinical trials, including the sample size, trial duration, endpoint definition, event rate assumptions and
eligibility criteria; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our expectations regarding the timing of data from our Phase&nbsp;3 and additional clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> market acceptance or commercial success of APR-246 and the degree of acceptance among physicians, patients, patient advocacy groups, health
care payors and the medical community; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our expectations regarding competition, potential market size, the size of the patient populations for APR-246, if approved for commercial use,
and market acceptance; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to maintain regulatory approval of APR-246, and any related restrictions, limitations and/or warnings in the label of APR-246; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the scope of protection we are able to establish and maintain for intellectual property rights covering APR-246; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> potential claims relating to our intellectual property and third-party intellectual property; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the duration of our intellectual property estate that will provide protection for APR-246; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> developments relating to our competitors and our industry; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our sales, marketing or distribution capabilities and our ability to commercialize APR-246, if we obtain regulatory approval; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> current and future agreements with third parties in connection with the manufacturing, commercialization, packaging and distribution of
APR-246; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our expectations regarding the ability of our current contract manufacturing partners to produce APR-246 in the quantities and timeframe that
we will require; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our expectations regarding our future costs of goods; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to attract, retain and motivate key personnel and increase the size of our organization; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to establish collaborations in lieu of obtaining additional financing; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the impact of government laws and regulations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our anticipated use of proceeds from this offering; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>75</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=80,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=238372,FOLIO='75',FILE='DISK116:[19ZBM1.19ZBM17601]DK17601A.;32',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dk17601_1_76"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our financial performance; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our expectations regarding the time during which we will be an emerging growth company under the JOBS Act or a smaller reporting company under
the Exchange Act. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
forward-looking statements are based on management's current expectations, estimates, forecasts, and projections about our business and the industry in which we operate and
management's beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our
control. As a result, any or all of our forward-looking statements in this prospectus may turn out to be inaccurate. Factors that may cause actual results to differ materially from current
expectations include, among other things, those listed under "Risk Factors" and elsewhere in this prospectus. Potential investors are urged to consider these factors carefully in evaluating the
forward-looking statements. These forward-looking statements speak only as of the date of this prospectus. Except as required by law, we assume no obligation to update or revise these forward-looking
statements for any reason, even if new information
becomes available in the future. You should read this prospectus with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially
different from what we expect. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>76</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=81,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=536364,FOLIO='76',FILE='DISK116:[19ZBM1.19ZBM17601]DK17601A.;32',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dk17601_1_77"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dk17601_use_of_proceeds"> </A>
<A NAME="toc_dk17601_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Use of Proceeds    <BR>    </B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We estimate that the net proceeds from our issuance and sale of 5,000,000 shares of our common stock in this offering will be approximately
$66.6&nbsp;million, assuming an initial public offering price of $15.00 per share, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus, and
after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. If the underwriters exercise their option to purchase additional shares in full, we
estimate that our net proceeds will be approximately $77.0&nbsp;million.


</FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A $1.00 increase (decrease) in the assumed initial public offering price of $15.00 per share would increase (decrease) the aggregate net proceeds to us from this offering by
approximately $4.7&nbsp;million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting
discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 1,000,000 shares in the number of shares offered by us would increase (decrease) the net
proceeds to us from this offering by approximately $14.0&nbsp;million, assuming that the assumed initial public offering price remains the same, and after deducting the estimated underwriting
discounts and commissions and estimated offering expenses payable by us. We do not expect that a change in the initial public offering price or the number of shares by these amounts would have a
material effect on our uses of the proceeds from this offering, although it may accelerate the time at which we will need to seek additional capital.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
intend to use the net proceeds from the offering as follows: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Approximately $20.0 million to $30.0&nbsp;million to fund future Phase 1b/2 clinical studies of APR-246 for solid tumor and hematological
malignancies as well as additional future clinical studies to be determined if the data derived from such Phase 1b/2 clinical studies is favorable; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Approximately $10.0 million to $15.0&nbsp;million to fund continued research and development activities for APR-548, including ongoing
IND-enabling studies and a first-in-human clinical trial; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Approximately $5.0 million to $10.0&nbsp;million to fund the ongoing preclinical and clinical development of APR-246, including preparation
and submission of a New Drug Application (NDA) in MDS; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The remainder to fund general research and development activities, working capital and other general corporate activities including the
buildout of infrastructure to support the advancement of our product candidates. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
expected use of proceeds from this offering represents our current intentions based on our present plans and business condition. As of the date of this prospectus, we cannot predict
with certainty all of the particular uses for the proceeds to be received upon the completion of this offering or the actual amounts that we will spend on the uses set forth above. We may also use a
portion of the proceeds to in-license, acquire or invest in additional businesses, technologies, products or assets. Although we have no specific agreements, commitments or understandings with respect
to any in-licensing activity or acquisition, we evaluate these opportunities and engage in related discussions with other companies from time to time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
net proceeds from this offering, together with our cash and cash equivalents, may not be sufficient for us to conduct through completion any additional existing clinical trials of
APR-246 or to otherwise complete the development of APR-246. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
amount and timing of our actual expenditures will depend on numerous factors, including the results of our research and development efforts, the timing and outcome of any ongoing or
future clinical trials, and the timing and outcome of regulatory submissions. As a result, our management will have broad discretion over the use of the proceeds from this offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pending
the use of the proceeds from this offering, we may invest the proceeds in interest-bearing, investment-grade securities, certificates of deposit and/or U.S. government
securities. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>77</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=82,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=983195,FOLIO='77',FILE='DISK116:[19ZBM1.19ZBM17601]DK17601A.;32',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dk17601_1_78"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dk17601_dividend_policy"> </A>
<A NAME="toc_dk17601_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Dividend Policy    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have never declared or paid any dividends on our common stock. We do not anticipate declaring or paying any cash dividends on our common
stock in the foreseeable future. Any future determination to declare and pay cash dividends, if any, will be made at the discretion of our board of directors and will depend on a variety of factors,
including applicable laws, our financial condition, results of operations, contractual restrictions, capital requirements, business prospects, general business or financial market conditions and other
factors our board of directors may deem relevant. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>78</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=83,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=605038,FOLIO='78',FILE='DISK116:[19ZBM1.19ZBM17601]DK17601A.;32',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dm17601_1_79"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dm17601_corporate_reorganization"> </A>
<A NAME="toc_dm17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Corporate Reorganization    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Aprea AB  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior to the Holdco Reorganization, the capital structure of Aprea AB consisted of four classes of equity interests: ordinary shares;
Series&nbsp;A preferred shares; Series&nbsp;B preferred shares; and Series&nbsp;C preferred shares. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Corporate reorganization  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On September&nbsp;20, 2019, we engaged in a series of transactions, which we refer to collectively as the Holdco Reorganization. As a result
of the Holdco Reorganization, Aprea AB became
a wholly-owned subsidiary of Aprea Therapeutics,&nbsp;Inc. and our consolidated financial statements will be reported from Aprea Therapeutics,&nbsp;Inc. We, Aprea AB, and the holders of all of the
issued and outstanding equity interests of Aprea AB entered into a Share Contribution and Exchange Agreement, dated as of June&nbsp;13, 2019, pursuant to which the Holdco Reorganization was
effected. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
May&nbsp;2019, we formed Aprea Therapeutics,&nbsp;Inc. as a stand-alone entity. The remaining steps to the Holdco Reorganization that were effected on September&nbsp;20, 2019
included:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Each holder of Aprea AB equity interests contributed, transferred, granted, assigned and delivered to us all of its right, title and interest
in and to all Aprea AB equity interests owned by such holder; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> In exchange for each Aprea AB ordinary share contributed by a holder, we issued to such holder one share of our common stock; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> In exchange for each Aprea AB Series&nbsp;A preferred share contributed by a holder, we issued to such holder one share of our
Series&nbsp;A preferred stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> In exchange for each Aprea AB Series&nbsp;B preferred share contributed by a holder, we issued to such holder one share of our
Series&nbsp;B preferred stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> In exchange for each Aprea AB Series&nbsp;C preferred share contributed by a holder, we issued to such holder one share of our
Series&nbsp;C preferred stock; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Each outstanding option to purchase Aprea AB ordinary shares issued by Aprea AB pursuant to the 2016 Stock Incentive Plan was cancelled, and we
issued to the holder of such Aprea AB option, a substitute option to purchase, on the same terms and conditions as were applicable to such Aprea AB option, shares of our common stock pursuant to our
2019 Stock Incentive Plan; except that with respect to vested options held by U.S. employees, we assumed such options and exercised them for newly issued shares of Aprea. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Immediately
prior to the completion of this offering, with the consent of shareholders representing a majority of our outstanding preferred shares, all outstanding shares of our
convertible preferred stock, including the shares of our Series&nbsp;A preferred stock, Series&nbsp;B preferred stock and Series&nbsp;C preferred stock issued as part of the Holdco
Reorganization will be converted into shares of our common stock on a 1-for-1.6045 basis. As a result of the Holdco Reorganization and such subsequent conversion, the former holders of all of the
issued and outstanding equity interests of Aprea AB will have received 100% of our outstanding common stock as of immediately prior to the completion of the offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>79</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=84,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=529204,FOLIO='79',FILE='DISK116:[19ZBM1.19ZBM17601]DM17601A.;94',USER='CHE108067',CD='27-SEP-2019;09:19' -->
<A NAME="page_dm17601_1_80"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dm17601_capitalization"> </A>
<A NAME="toc_dm17601_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Capitalization    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth our cash and cash equivalents and our capitalization as of June&nbsp;30,
2019:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> on an actual basis with respect to Aprea AB (including 2,807 shares of common stock from the exercise of stock options on March&nbsp;25,
2019, which were registered pursuant to Swedish law with the Swedish Companies Registration Office on August&nbsp;27, 2019); </FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> on a pro forma basis to give effect to (i)&nbsp;the Holdco Reorganization described under the section titled "Corporate Reorganization";
(ii)&nbsp;the 1 for 1.6045 split of our common stock which took place on September 26, 2019; (iii)&nbsp;the conversion of all of our outstanding shares of convertible preferred stock into an
aggregate of 13,028,292 shares of common stock immediately prior to the completion of this offering and (iv)&nbsp;the filing and effectiveness of our amended and restated certificate of
incorporation; and </FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> on a pro forma as adjusted basis to give further effect to our issuance and sale of 5,000,000 shares of our common stock in this offering at an
assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and
commissions and estimated offering expenses payable by us. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
capitalization following the completion of this offering will depend on the actual initial public offering price and other terms of this offering determined at pricing. You should
read this table together with our financial statements and the related notes appearing at the end of this prospectus </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>80</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=85,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=750645,FOLIO='80',FILE='DISK116:[19ZBM1.19ZBM17601]DM17601A.;94',USER='CHE108067',CD='27-SEP-2019;09:19' -->
<A NAME="page_dm17601_1_81"> </A>

<P style="font-family:times;"><FONT SIZE=2>and
the sections of this prospectus titled "Corporate Reorganization," "Selected Financial Data" and "Management's Discussion and Analysis of Financial Condition and Results of Operations." </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="74pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>June&nbsp;30, 2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Actual </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Pro forma </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Pro forma<BR>
as adjusted </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Cash and cash equivalents</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>60,994,738</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>60,994,738</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>127,544,738 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible preferred stock:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;A convertible preferred stock, $0.11 par value; 612,446 shares issued and outstanding actual; no shares outstanding, pro&nbsp;forma and
pro&nbsp;forma as adjusted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,483,044</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;B convertible preferred stock, $0.11 par value; 7,235,969 shares issued and outstanding actual; no shares outstanding, pro&nbsp;forma and
pro&nbsp;forma as adjusted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>49,742,942</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;C convertible preferred stock, $0.11 par value; 5,179,877 shares issued and outstanding actual; no shares outstanding, pro&nbsp;forma and
pro&nbsp;forma as adjusted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>61,963,007</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total convertible preferred stock</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>118,188,993</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stockholders' Deficit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock, $0.11 par value actual, $0.001 par value pro forma and pro forma as adjusted; 1,181,573 shares issued and outstanding actual;
14,209,865&nbsp;shares issued and outstanding, pro&nbsp;forma 19,209,865 shares issued and outstanding, and pro forma as adjusted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>129,974</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14,210</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>19,210</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Additional paid-in capital</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>19,971,732</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>138,276,489</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>204,821,489</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated other comprehensive loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(10,747,992</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(10,747,992</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(10,747,992</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated deficit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(71,206,106</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(71,206,106</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(71,206,106</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stockholders' equity (deficit)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(61,852,392</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>56,336,601</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>122,886,601 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Capitalization</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>56,336,601</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>56,336,601</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>122,886,601 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A $1.00 increase or decrease in the assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus,
would increase or decrease the pro forma as adjusted amount of each of cash and cash equivalents, additional paid-in capital, total stockholders' equity and total capitalization by
$4.7&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and
commissions. An increase or decrease of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase or decrease the pro forma as adjusted
amount of each of cash, cash and cash equivalents, additional paid-in capital, total stockholders' equity and total capitalization by $14.0&nbsp;million, assuming no change in the assumed initial
public offering price per share and after deducting estimated underwriting discounts and commissions.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
table above does not include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 2,761,794&nbsp;shares of our common stock issuable upon the exercise of stock options outstanding as of June&nbsp;30, 2019, at a weighted
average exercise price of $1.66 per share; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 2,488,206 shares of common stock reserved for issuance pursuant to future awards under our 2019 Stock Incentive Plan or our Employee Stock
Purchase Plan, plus any future increases in the number of shares of common stock reserved for issuance under our 2019 Stock Incentive Plan or our Employee Stock Purchase Plan pursuant to provisions
thereof that automatically increase the share reserve under the plan each year. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>81</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=86,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=626017,FOLIO='81',FILE='DISK116:[19ZBM1.19ZBM17601]DM17601A.;94',USER='CHE108067',CD='27-SEP-2019;09:19' -->
<A NAME="page_dm17601_1_82"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dm17601_dilution"> </A>
<A NAME="toc_dm17601_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Dilution    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between
the initial public offering price per share of
our common stock and the pro forma as adjusted net tangible book value per share of our common stock immediately after this offering. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
historical net tangible book value (deficit) as of June&nbsp;30, 2019 was $(61.9) million, or $(83.99) per share of our common stock. Our historical net tangible book value
(deficit) is the amount of our total assets less our total liabilities and convertible preferred stock, which is not included in our stockholders' deficit. Historical net tangible book value (deficit)
per share represents historical net tangible book value (deficit) divided by the number of shares of our common stock outstanding as of June&nbsp;30, 2019 (including 2,807 shares of common stock
from the exercise of stock options on March&nbsp;25, 2019, which were registered pursuant to Swedish law with the Swedish Companies Registration Office on August&nbsp;27, 2019). </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our pro forma net tangible book value as of June&nbsp;30, 2019 was $56.3&nbsp;million, or $6.36 per share of our common stock. Pro forma net tangible book value represents the amount
of our total assets less our total liabilities, after giving effect to (i)&nbsp;the Holdco Reorganization described under the section titled "Corporate Reorganization," pursuant to which all of the
issued and outstanding stock of Aprea Therapeutics AB was exchanged for common stock, preferred stock or options, as applicable, of Aprea Therapeutics,&nbsp;Inc., (ii) the 1 for 1.6045 split of our
common stock which took place on September 26, 2019 and (iii)&nbsp;the conversion of all of our outstanding shares of convertible preferred stock into an aggregate of 13,028,292&nbsp;shares of our
common stock immediately prior to the completion of this offering. Pro forma net tangible book value per share represents pro forma net tangible book value divided by the total number of shares of
common stock outstanding as of June&nbsp;30, 2019 (including 2,807 shares of common stock from the exercise of stock options on March&nbsp;25, 2019, which were registered pursuant to Swedish law
with the Swedish Companies Registration Office on August&nbsp;27, 2019), after giving effect to the Holdco Reorganization, the 1 for 1.6045 split of our common stock which took place on September
26, 2019 and the automatic conversion of all outstanding shares of our preferred stock into common stock immediately prior to the completion of this offering.


</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After giving further effect to our sale of 5,000,000 shares of common stock in this offering at the initial public offering price of $15.00 per share, which is the midpoint of the price
range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net
tangible book value as of June&nbsp;30, 2019 would have been $122.9&nbsp;million, or $8.65 per share. This represents an immediate increase in pro forma as adjusted net tangible book value of
$4.68 per share to our existing stockholders and an immediate dilution in pro forma as adjusted net tangible book value of $6.35 per share to new investors purchasing common stock in this offering.
Dilution per share to new investors purchasing common stock in this offering is determined by subtracting pro forma as adjusted net

</FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>82</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=87,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=339659,FOLIO='82',FILE='DISK116:[19ZBM1.19ZBM17601]DM17601A.;94',USER='CHE108067',CD='27-SEP-2019;09:19' -->
<A NAME="page_dm17601_1_83"> </A>

<P style="font-family:times;"><FONT SIZE=2>



tangible book value per share after this offering from the initial public offering price per share paid by new investors. The following table illustrates this dilution on a per share basis:

</FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Assumed initial public offering price per share</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15.00</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Historical net tangible book value (deficit) per share as of June&nbsp;30, 2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(52.35</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma increase in net tangible book value per share attributable to the conversion of our Convertible Preferred Stock immediately prior to the
completion of this offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>56.31</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma net tangible book value per share as of June&nbsp;30, 2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.96</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Increase in pro forma net tangible book value per share attributable to new investors participating in this offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.68</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8.65</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma as adjusted net tangible book value per share after this offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dilution in pro forma net tangible book value per share to new investors participating in this offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6.35</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A $1.00 increase or decrease in the assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus,
would increase or decrease our pro forma as adjusted net tangible book value by $4.7&nbsp;million, our pro forma as adjusted net tangible book value per share after this offering by $0.33 and
dilution per share to new investors purchasing shares in this offering by $0.67, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same
and after deducting estimated underwriting discounts and commissions. An increase of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would
increase the pro forma as adjusted net tangible book value per share after this offering by $0.98 and decrease the dilution per share to new investors participating in this offering by $0.98, assuming
no change in the assumed initial public offering price and after deducting estimated underwriting discounts and commissions. A decrease of 1,000,000 shares in the number of shares offered by us, as
set forth on the cover page of this prospectus, would decrease the pro forma as adjusted net tangible book value per share after this offering by $14.0 million and increase the dilution per share to
new investors participating in this offering by $0.98, assuming no change in the assumed initial public offering price and after deducting estimated underwriting discounts and commissions.

</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the underwriters exercise their option to purchase additional shares in full, our pro forma as adjusted net tangible book value per share after this offering would be $9.38 per share,
representing an immediate increase in pro forma as adjusted net tangible book value per share of $5.42 to existing stockholders and an immediate dilution in pro forma as adjusted net tangible book
value per share of $5.62 to new investors purchasing common stock in this offering, assuming an initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on
the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. If any shares are issued upon exercise of
outstanding options, you will experience further dilution.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table summarizes, on a pro forma as adjusted basis, as of June&nbsp;30, 2019, the differences between the number of shares of common stock purchased from us, the total
consideration paid to us and the average price per share paid by existing stockholders and by new investors purchasing shares of common stock in this offering. The calculation below is based on an
assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>83</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=88,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=322289,FOLIO='83',FILE='DISK116:[19ZBM1.19ZBM17601]DM17601A.;94',USER='CHE108067',CD='27-SEP-2019;09:19' -->
<A NAME="page_dm17601_1_84"> </A>

<P style="font-family:times;"><FONT SIZE=2>the
cover page of this prospectus, before deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="37pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="74pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="37pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares purchased </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total consideration </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Average price<BR>
per share </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percent </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percent </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Existing stockholders before this offering</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,209,865</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>74</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>136,926,976</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>65</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9.64</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Investors participating in this offering</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>26</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>75,000,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19,209,865</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>211,926,976</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
$1.00 increase or decrease in the assumed initial public offering price of $15.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus,
would increase or decrease the total consideration paid by new investors by $5.0&nbsp;million and, in the case of an increase, would increase the percentage of total consideration paid by new
investors by two&nbsp;percentage points and, in the case of a decrease, would decrease the percentage of total consideration paid by new investors by two&nbsp;percentage points, assuming that the
number of shares offered by us, as set forth on the cover page of this prospectus, remains the same. An increase or decrease of 1,000,000 shares in the number of shares offered by us, as set forth on
the cover page of this prospectus, would increase or decrease the total consideration paid by new investors by $15.0&nbsp;million and, in the case of an increase,
would increase the percentage of total consideration paid by new investors by four&nbsp;percentage points and, in the case of a decrease, would decrease the percentage of total consideration paid by
new investors by four&nbsp;percentage points, assuming no change in the assumed initial public offering price. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
table above assumes no exercise of the underwriters' option to purchase additional shares in this offering. If the underwriters' option to purchase additional shares is exercised in
full, the number of shares of our common stock held by existing stockholders would be reduced to 71% of the total number of shares of our common stock outstanding after this offering, and the number
of shares of common stock held by new investors participating in the offering would be increased to 29% of the total number of shares of our common stock outstanding after this offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The number of shares purchased from us by existing stockholders is based on 14,209,865 shares of our common stock outstanding as of June&nbsp;30, 2019 (including 2,807 shares of common
stock from the exercise of stock options on March&nbsp;25, 2019, which were registered pursuant to Swedish law with the Swedish Companies Registration Office on August&nbsp;27, 2019), after giving
effect to (i)&nbsp;the Holdco Reorganization described under the section titled "Corporate Reorganization," pursuant to which all of the issued and outstanding stock of Aprea Therapeutics AB was
exchanged for common stock, preferred stock or options, as applicable, of Aprea Therapeutics,&nbsp;Inc., (ii) the 1 for 1.6045 split of our common stock which took place on September 26, 2019 and
(iii)&nbsp;the conversion of all outstanding shares of our convertible preferred stock, including the shares issued as part of the Holdco Reorganization, into an aggregate of
13,028,292&nbsp;shares of our common stock, immediately prior to the completion of this offering, and excludes:</FONT>


</P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 2,761,794&nbsp;shares of our common stock issuable upon the exercise of stock options outstanding as of June&nbsp;30, 2019, at a weighted
average exercise price of $1.66 per share; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 2,488,206 shares of common stock reserved for issuance pursuant to future awards under our 2019 Stock Incentive Plan or our Employee Stock
Purchase Plan, plus any future increases in the number of shares of common stock reserved for issuance under our 2019 Stock Incentive Plan or our Employee Stock Purchase Plan pursuant to provisions
thereof that automatically increase the share reserve under the plan each year. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>84</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=89,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=759670,FOLIO='84',FILE='DISK116:[19ZBM1.19ZBM17601]DM17601A.;94',USER='CHE108067',CD='27-SEP-2019;09:19' -->
<A NAME="page_dm17601_1_85"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dm17601_selected_financial_data"> </A>
<A NAME="toc_dm17601_4"> </A>
<BR></FONT><FONT SIZE=2><B>  Selected Financial Data    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>You should read the following selected financial data together with our financial statements and the related notes
appearing at the end of this prospectus and the "Management's Discussion and Analysis of Financial Condition and Results of Operations" section of this prospectus. We have derived the statement of
operations data for the years ended December&nbsp;31, 2017 and 2018 and the balance sheet data as of December&nbsp;31, 2017 and 2018 from our audited financial statements appearing at the end of
this prospectus. The consolidated statements of operations data for the six months ended June 30, 2018 and 2019 and the consolidated balance sheet data at June 30, 2019 are derived from our unaudited
condensed consolidated financial statements included in this prospectus. The unaudited condensed consolidated financial statements include, in the opinion of management, all adjustments that
management considers necessary for the fair presentation of the consolidated financial information set forth in those statements. Our historical results are not necessarily indicative of results that
should be expected in any future period</I></FONT><FONT SIZE=2>. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Years ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Six months ended June&nbsp;30, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Consolidated Statement of Operations Data:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13,392,631</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14,194,732</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,492,788</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,998,270</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,459,744</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,294,671</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,166,520</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,347,915 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,852,375</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>16,489,403</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,659,308</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,346,185</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income (expense):</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(182</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(188</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(7,439</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign currency gain</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>662,140</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>961,316</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>949,158</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,615,974 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total other income (expense)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>662,125</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>961,134</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>948,970</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,608,535 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,190,250</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,528,269</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(7,710,338</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(8,737,650</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss per share attributable to common stockholders, basic and diluted(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(13.17</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(13.45</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(6.68</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(7.43</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted average common shares outstanding, basic and diluted(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,153,069</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,154,368</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,154,107</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,176,417 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma net loss per share attributable to common stockholders, basic and diluted (unaudited)(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.65</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.62</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma weighted average common shares outstanding, basic and diluted (unaudited)(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,428,873</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14,075,669 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>See
Note&nbsp;2 to our audited and unaudited interim financial statements included elsewhere in this prospectus for an explanation of the method used to calculate
basic and diluted net loss per share and unaudited pro forma basic and diluted net loss per share as well as the weighted-average number of common shares used in the computation of the per share
amounts. </FONT></DD></DL>
 </DIV>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="74pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="74pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>June&nbsp;30, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Consolidated Balance Sheet Data:</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,401,488</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>65,675,931</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60,994,738</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Working capital(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20,430,334</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>61,129,968</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>56,215,210</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,761,804</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>66,022,638</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>62,214,654</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,301,013</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,868,109</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,878,053</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible preferred stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>56,225,986</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>112,590,631</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>118,188,993</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stockholders' deficit</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(35,765,195</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(51,436,102</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(61,852,392</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>We
define working capital as current assets less current liabilities. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>85</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=90,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=221921,FOLIO='85',FILE='DISK116:[19ZBM1.19ZBM17601]DM17601A.;94',USER='CHE108067',CD='27-SEP-2019;09:19' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_do17601_1_86"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="do17601_management_s_discussion_and_an__man03466"> </A>
<A NAME="toc_do17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Management's Discussion and Analysis of Financial Condition and Results of Operations    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>You should read the following discussion and analysis of our financial condition and results of operations together with
the "Selected Financial Data" section of this prospectus and our financial statements and the related notes included at the end of this prospectus. This discussion and other parts of this prospectus
contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. As a result of many factors, including those factors
set forth in the "Risk Factors" section of this prospectus, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the
following discussion and analysis.</I></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a clinical-stage biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53
tumor suppressor protein. p53 is the protein expressed from the </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> gene, the most commonly mutated gene in cancer. We believe that mutant&nbsp;p53
is an attractive therapeutic target due to the high incidence of p53 mutations across a range of cancer types and its involvement in key cellular activities such as apoptosis. Cancer patients with
mutant p53 face a significantly inferior prognosis even when treated with the current standard of care, and a large unmet need for these patients remains. Our lead product candidate, APR-246, is a
small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes, or MDS, and acute myeloid leukemia, or AML. APR-246 has
received Orphan Drug and Fast Track designations from the FDA for MDS, and Orphan Drug designation from the EMA for MDS, AML and ovarian cancer, and we believe APR-246 will be a first-in-class therapy
if approved by applicable regulators. We have commenced a pivotal Phase&nbsp;3 trial of APR-246 with azacitidine for frontline treatment of </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2>
mutant MDS and expect initial data from this trial in the second half of 2020. Our pivotal Phase&nbsp;3 trial is supported by data from two ongoing Phase&nbsp;1b/2 investigator initiated trials,
one in the U.S. and one in France, testing APR-246 with azacitidine as frontline treatment in </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant MDS and AML patients. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the ongoing U.S. Phase&nbsp;1b/2 trial, sponsored by Dr.&nbsp;David Sallman of the H. Lee Moffitt Cancer Center and Research Institute, or Moffitt, we have observed an objective
response rate, or ORR, of 88% and a complete remission, or CR, rate of 59% in 41 response-evaluable MDS/AML patients treated with APR-246 and azacitidine, as of July 2019 and we expect a final CR
endpoint in the second half of 2019. In MDS patients, the CR rate was 61%, with an additional 27% achieving non-CR responses. In AML patients, the CR rate was 50%, with an additional 38% achieving
non-CR responses. In addition, 46% of evaluable patients were able to discontinue treatment in order to proceed to allogeneic hematopoietic stem cell transplantation, or allo-HCT. Allo-HCT is
currently the only recognized therapy believed to increase the likelihood of long term survival for </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant MDS and AML patients in remission. In
the ongoing French Phase&nbsp;1b/2 trial, sponsored by Groupe Francophone des Myelodysplasies, or GFM, under lead investigator Prof.&nbsp;Pierre Fenaux, we have observed an ORR of 75% and a CR
rate of 56% in 16 response-evaluable patients treated with APR-246 and azacitidine, as of July 2019 and we expect a final CR endpoint in the first half of 2020. In MDS patients, the CR rate was 55%,
with an additional 18% achieving non-CR responses. In AML patients, the CR rate was 60%, with an additional 20% achieving non-CR responses. We expect the results of our pivotal Phase&nbsp;3 trial
and the U.S. and French Phase&nbsp;1b/2 trials will be submitted in support of marketing applications to the FDA and EMA. We are also developing a next-generation small molecule p53 reactivator,
APR-548, for potential use in multiple hematologic malignancies and other oncologic indications, and expect to file an IND with the FDA in the first half of 2020. We have assembled a management team
with extensive experience in the discovery and development of novel oncology drugs. Our management team is supported by our world-class scientific advisors and leading </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>86</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=91,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=15389,FOLIO='86',FILE='DISK116:[19ZBM1.19ZBM17601]DO17601A.;76',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_do17601_1_87"> </A>

<P style="font-family:times;"><FONT SIZE=2>life
science investors in their mission to successfully develop p53-reactivating therapies for cancer patients. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Aprea
Therapeutics AB, or Aprea AB, was originally incorporated in 2002 and commenced principal operations in 2006. In connection with this initial public offering, we incorporated Aprea
Therapeutics,&nbsp;Inc. in May&nbsp;2019. We completed the Holdco Reorganization on September&nbsp;20, 2019, as a result of which all of the issued and outstanding stock of Aprea AB was
exchanged for common stock, preferred stock or options, as applicable, of Aprea Therapeutics,&nbsp;Inc. As a result of such transactions, Aprea AB became a wholly-owned subsidiary of Aprea
Therapeutics,&nbsp;Inc. For more information, please see the section titled "Corporate Reorganization". </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have devoted substantially all of our resources to developing our product candidates, including APR-246, building our intellectual property portfolio, business planning, raising
capital and providing general and administrative support for these operations. To date, we have financed our operations through private placements of preferred stock. Through June&nbsp;30, 2019, we
had received net proceeds of $136.9&nbsp;million from our sales of preferred and common stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since
our inception, we have incurred significant losses on an aggregate basis. Our ability to generate product revenue sufficient to achieve profitability will depend on the successful
development and eventual commercialization of one or more of our product candidates. Our net losses were $8.7&nbsp;million for the six months ended June&nbsp;30, 2019 and $15.2&nbsp;million and
$15.5&nbsp;million for the years ended December&nbsp;31, 2017 and 2018, respectively. As of June&nbsp;30, 2019, we had an accumulated deficit of $71.2&nbsp;million. These losses have resulted
primarily from costs incurred in connection with research and development activities, patent investment, and general and administrative costs associated with our operations. We expect to continue to
incur significant expenses and increasing operating losses for at least the next several years. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
anticipate that our expenses will increase substantially if and as we:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> conduct our current and future clinical trials and additional preclinical research of APR-246; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> initiate and continue research and preclinical and clinical development of our other product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> seek to identify and develop additional product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> seek marketing approvals for any of our product candidates that successfully complete clinical trials, if any; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establish a sales, marketing, manufacturing and distribution infrastructure to commercialize any products for which we may obtain marketing
approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> require the manufacture of larger quantities of our product candidates for clinical development and potentially commercialization; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> maintain, expand, protect and enforce our intellectual property portfolio; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> acquire or in-license other drugs and technologies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> defend against any claims of infringement, misappropriation or other violation of third-party intellectual property; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> hire and retain additional clinical, quality control and scientific personnel; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> add operational, financial and management information systems and personnel, including personnel to support our drug development, any future
commercialization efforts and our transition to a public company; and</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> operate as a public company. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>87</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=92,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=372429,FOLIO='87',FILE='DISK116:[19ZBM1.19ZBM17601]DO17601A.;76',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_do17601_1_88"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the completion of this offering, we expect to incur additional costs associated with operating as a public company. Furthermore, if we obtain marketing approval for any of our
product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
a result, we will need additional financing to support our continuing operations. Until such time as we can generate significant revenue from product sales, if ever, we expect to
finance our operations through a combination of public or private equity or debt financings or other sources, which may include collaborations with third parties. We may be unable to raise additional
funds or enter into other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to
significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because
of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to
achieve or maintain profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a
continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of June&nbsp;30, 2019, we had cash and cash equivalents of $61.0&nbsp;million. We believe that the anticipated net proceeds from this offering, together with our existing cash and
cash equivalents, will enable us to fund our operating expenses and capital expenditure requirements into 2023. We have based this estimate on assumptions that may prove to be wrong, and we could
exhaust our available capital resources sooner than we expect. See "&#151;Liquidity and Capital Resources." </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Components of our results of operations  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Revenue  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the near future. If
our development efforts for APR-246 or other product candidates that we may develop in the future are successful and result in marketing approval or collaboration or license agreements with third
parties, we may generate revenue in the future from a combination of product sales or payments from collaboration or license agreements that we may enter into with third parties. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Operating expenses  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our expenses since inception have consisted solely of research and development costs and general and administrative costs. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and development expenses  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts, and the
development of our product candidates, and include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> expenses incurred under agreements with third parties, including contract research organizations, or CROs, that conduct research, preclinical
activities and clinical trials on our behalf as well as contract manufacturing organizations, or CMOs, that manufacture our product candidates for use in our preclinical and clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in research and development
functions; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>88</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=93,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=599803,FOLIO='88',FILE='DISK116:[19ZBM1.19ZBM17601]DO17601A.;76',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_do17601_1_89"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> costs of outside consultants, including their fees, stock-based compensation and related travel expenses; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> costs of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> expenses related to compliance with regulatory requirements; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other
operating costs. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
expense research and development costs as incurred. We recognize costs for certain development activities, such as clinical trials, based on an evaluation of the progress to
completion of specific tasks using data such as patient enrollment, clinical site activations, or information provided to us by our vendors and our clinical investigative sites. Payments for these
activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our financial statements as prepaid or accrued research and
development expenses. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
typically use our employee and infrastructure resources across our development programs. We track outsourced development costs and milestone payments made to our research partners by
product candidate or development program, but we do not allocate personnel costs or other internal costs to specific development programs or product candidates. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research
and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in
earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will continue to increase
for the foreseeable future as we initiate additional clinical trials of APR-246, pursue later stages of clinical development of APR-246, initiate clinical trials for product candidates other than
APR-246 and continue to discover and develop additional product candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
cannot determine with certainty the duration and costs of the current or future clinical trials of our product candidates or if, when, or to what extent we will generate revenue from
the commercialization and sale of any our product candidates for which we obtain marketing approval. We may never succeed in obtaining marketing approval for any of our product candidates. The
duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the scope, rate of progress, expense and results of our ongoing clinical trials of APR-246, as well as of any future clinical trials of APR-246
or other product candidates and other research and development activities that we may conduct; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> uncertainties in clinical trial design and patient enrollment rates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> significant and changing government regulation and regulatory guidance; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the timing and receipt of any marketing approvals; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the expense of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the
development of that product candidate. For example, if the U.S. Food and Drug Administration, or FDA, or another regulatory authority were to require us to conduct clinical trials beyond those that we
anticipate will be required for the completion of clinical development of a product candidate, or if we experience </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>89</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=94,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=72244,FOLIO='89',FILE='DISK116:[19ZBM1.19ZBM17601]DO17601A.;76',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_do17601_1_90"> </A>

<P style="font-family:times;"><FONT SIZE=2>significant
trial delays due to patient enrollment or other reasons, we would be required to expend significant additional financial resources and time on the completion of clinical development. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are currently conducting multiple clinical trials of APR-246: our Phase&nbsp;3 trial in the United States for the treatment of </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2>
mutant MDS with azacitidine, our Phase&nbsp;1b/2 trials in the United States and France for the treatment of MDS and AML with azacitidine, and our Phase&nbsp;2 trial of post-transplant maintenance
therapy with azacitidine in MDS and AML. At this time, we cannot reasonably estimate the cost for initiating and completing other clinical trials of APR-246 and preclinical studies of APR-246, as it
will be highly dependent on the clinical data from ongoing clinical trials as well as any target disease subpopulations chosen for further evaluation. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General and administrative expenses  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in
our executive, finance, corporate and business development and administrative functions. General and administrative expenses also include legal fees relating to patent and corporate matters;
professional fees for accounting, auditing, tax and consulting services; insurance costs; travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses
for rent and maintenance of facilities and other operating costs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
expect that our general and administrative expenses will increase in the future as we increase our general and administrative personnel headcount to support personnel in research and
development and to support our operations generally as we increase our research and development activities and activities related to the potential commercialization of our product candidates. We also
expect to incur increased expenses associated with being a public company, including costs of accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with
exchange listing and SEC requirements; director and officer insurance costs; and investor and public relations costs. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other income and expense  </I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Interest income and expense  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest expense consists of bank charges and fees incurred on our cash and cash equivalents. We anticipate that our interest income will
increase in the future as we expect our investment balances to be higher due to anticipated cash proceeds from this offering. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Foreign currency gain  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our consolidated financial statements are presented in U.S. dollars, which is our reporting currency. The financial position and results of
operations of our subsidiaries Aprea AB and Aprea Personal AB are measured using the foreign subsidiaries' local currency as the functional currency. Aprea AB cash accounts holding U.S. dollars are
remeasured based upon the exchange rate at the date of remeasurement with the resulting gain or loss included in the consolidated statement of operations and comprehensive loss. Expenses of such
subsidiaries have been translated into U.S. dollars at average exchange rates prevailing during the period. Assets and liabilities have been translated at the rates of exchange on the consolidated
balance sheet date. The resulting translation gain and loss adjustments are recorded directly as a separate component of shareholders' equity and as other comprehensive loss on the consolidated
statement of operations and comprehensive loss. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Income taxes  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since Aprea&nbsp;AB's inception in 2002, we have not recorded any U.S. federal, state or foreign income tax expense or benefits for the net
losses we have incurred in any year, due to our
uncertainty of realizing a benefit from those items. We have provided a valuation allowance for the full amount of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>90</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=95,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=517251,FOLIO='90',FILE='DISK116:[19ZBM1.19ZBM17601]DO17601A.;76',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_do17601_1_91"> </A>

<P style="font-family:times;"><FONT SIZE=2>the
net deferred tax assets as, based on all available evidence, it is considered more likely than not that all the recorded deferred tax assets will not be realized in a future period. At
December&nbsp;31, 2018, we had $61.6&nbsp;million, $0.5&nbsp;million and $0.4&nbsp;million of foreign, federal and state net operating loss carryforwards, respectively, that expire at various
dates through 2036. Certain of these foreign, federal and state net operating loss carryforwards may be subject to Internal Revenue Code Section&nbsp;382 or similar provisions, which impose
limitations on their utilization amounts. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Critical accounting policies and use of estimates  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our management's discussion and analysis of financial condition and results of operations is based on our financial statements, which have been
prepared in accordance with generally accepted accounting principles in the United States. The preparation of our financial statements and related disclosures requires us to make estimates and
assumptions that affect the reported amounts of assets and liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on
historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the
carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these
estimates under different assumptions or conditions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
our significant accounting policies are described in more detail in the notes to our financial statements appearing at the end of this prospectus, we believe that the following
accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Accrued research and development expenses  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As part of the process of preparing our financial statements, we are required to estimate our accrued research and development expenses at each
balance sheet. This process involves reviewing open contract and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level
of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. The majority of our service providers invoice us
in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; however, some require advanced payments. We make estimates of our accrued expenses as of each
balance sheet date in our financial statements based on facts and circumstances known to us at that time. Examples of estimated accrued research and development expenses include fees paid
to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> CROs in connection with performing research activities on our behalf and conducting preclinical studies and clinical trials on our behalf; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> investigative sites or other service providers in connection with clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> vendors in connection with preclinical and clinical development activities; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> vendors related to product manufacturing and development and distribution of preclinical and clinical supplies. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
base our expenses related to preclinical studies and clinical trials on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple CROs
that conduct and manage preclinical studies and clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in
uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and
result in a prepayment of the expense. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In
accruing fees, we estimate the time period over which services will be performed, enrollment of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>91</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=96,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=834549,FOLIO='91',FILE='DISK116:[19ZBM1.19ZBM17601]DO17601A.;76',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_do17601_1_92"> </A>

<P style="font-family:times;"><FONT SIZE=2>patients,
number of sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we
adjust the accrual or amount of prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and
timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting amounts that are too high or too low in any particular period. To
date, we have not made any material adjustments to our prior estimates of accrued research and development expenses. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock-based compensation  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We measure stock options and other stock-based awards granted to employees and directors based on their fair value on the date of the grant and
recognize compensation expense of those awards, net of estimated forfeitures, over the requisite service period, which is generally the vesting period of the respective award. We apply the
straight-line method of expense recognition to all awards with only service-based vesting conditions and apply the graded-vesting method to all awards with performance-based vesting conditions or to
awards with both service-based and performance-based vesting conditions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
stock-based awards granted to non-employees, compensation expense is recognized over the period during which services are rendered by such non-employees until completed in accordance
with the FASB issued ASU&nbsp;No.&nbsp;2018-07, Compensation-Stock Compensation (Topic&nbsp;718): Improvements to Nonemployee Share-Based Payment Accounting. The new standard largely aligns the
accounting for share-based payment awards issued to employees and nonemployees by expanding the scope of ASC&nbsp;718 to apply to nonemployee share-based transactions, as long as the transaction is
not effectively a form of financing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
estimate the fair value of each stock option grant on the date of grant using the Black-Scholes option-pricing model, which uses as inputs the fair value of our common stock and
assumptions we make for the volatility of our common stock, the expected term of our stock options, the risk-free
interest rate for a period that approximates the expected term of our stock options and our expected dividend yield. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Determination of fair value of common stock  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a privately held company, there has been no public market for our common stock to date, the estimated fair value of our common stock has been
determined by our board of directors as of the date of each option grant, with input from management, considering our most recently available third-party valuations of common stock and our board of
directors' assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant.
These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants' Accounting and Valuation Guide, </FONT> <FONT SIZE=2><I>Valuation of Privately-Held-Company Equity
Securities Issued as Compensation</I></FONT><FONT SIZE=2>. Our common stock valuations were prepared using a hybrid method, which
used market approaches to estimate our enterprise value. The hybrid method is a probability-weighed expected return method, or PWERM, where the equity value in one or more scenarios is calculated
using an option-pricing method, or OPM. The OPM treats common stock and preferred stock as call options on the total equity value of a company, with exercise prices based on the value thresholds at
which the allocation among the various holders of a company's securities changes. Under this method, the common stock has value only if the funds available for distribution to stockholders exceeded
the value of the preferred stock liquidation preference at the time of the liquidity event, such as a strategic sale or a merger. The PWERM is a scenario-based methodology that estimates the fair
value of common stock based upon an analysis of future values for the company, assuming various outcomes. The </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>92</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=97,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=478069,FOLIO='92',FILE='DISK116:[19ZBM1.19ZBM17601]DO17601A.;76',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_do17601_1_93"> </A>

<P style="font-family:times;"><FONT SIZE=2>common
stock value is based on the probability-weighted present value of expected future investment returns considering each of the possible outcomes available as well as the rights of each class of
stock. The future value of the common stock under each outcome is discounted back to the valuation date at an appropriate risk-adjusted discount rate and probability weighted to arrive at an
indication of value for the common stock. These third-party valuations were performed at various dates, which resulted in valuations of our common stock of $0.92 per share as of May&nbsp;31, 2016,
$1.01 per share as of October&nbsp;2, 2017 and $3.18 per share as of December&nbsp;31, 2018. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to considering the results of these third-party valuations, our board of directors considered various objective and subjective factors to determine the fair value of our
common stock as of each grant date, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the prices at which we sold shares of preferred stock and the superior rights and preferences of the preferred stock relative to our common
stock at the time of each grant; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the progress of our research and development programs, including the status and results of preclinical studies and clinical trials for our
product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our stage of development and commercialization and our business strategy; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> external market conditions affecting the biopharmaceutical industry and trends within the biopharmaceutical industry; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our financial position, including cash on hand, and our historical and forecasted performance and operating results; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the lack of an active public market for our common stock and our preferred stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the likelihood of achieving a liquidity event, such as an initial public offering, or IPO, or sale of our company in light of prevailing market
conditions; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the analysis of IPOs and the market performance of similar companies in the biopharmaceutical industry. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
assumptions underlying these valuations represented management's best estimate, which involved inherent uncertainties and the application of management's judgment. As a result, if we
had used significantly different assumptions or estimates, the fair value of our common stock and our stock-based compensation expense could have been materially different. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Once
a public trading market for our common stock has been established in connection with the completion of this offering, it will no longer be necessary for our board of directors to
estimate the fair value of our common stock in connection with our accounting for granted stock options and other such awards we may grant, as the fair value of our common stock will be determined
based on the quoted market price of our common stock. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Options granted  </I></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes by grant date the number of shares subject to options granted between January&nbsp;1, 2017 and June&nbsp;30,
2019, the per share exercise price of the options, the fair value </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>93</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=98,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=769828,FOLIO='93',FILE='DISK116:[19ZBM1.19ZBM17601]DO17601A.;76',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_do17601_1_94"> </A>

<P style="font-family:times;"><FONT SIZE=2>of
common stock underlying the options on each grant date, and the per share estimated fair value of the options: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="83pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="47pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Grant date

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of shares<BR>
subject to<BR>
options granted </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Per share<BR>
exercise price<BR>
of options </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fair value of<BR>
common stock<BR>
per share on<BR>
date of<BR>
option grant </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Per share<BR>
estimated<BR>
fair value<BR>
of options </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>January&nbsp;3, 2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>91,456</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.92</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.92</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.66</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>February&nbsp;16, 2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32,892</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.92</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.92</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.67</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>March&nbsp;30, 2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>185,088</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.07</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.92</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.82</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>November&nbsp;24, 2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>353,788</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.01</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.01</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.74</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>July&nbsp;31, 2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,067</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.01</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.01</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.69</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>February&nbsp;28, 2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>984,596</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.19</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.19</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.23</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Income taxes  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We account for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the
expected future tax consequences of events that have been recognized in the consolidated financial statements or in our tax returns. Under this method, deferred tax assets and liabilities are
determined based on differences between the financial statement carrying amounts and the tax bases of the assets and liabilities using the enacted tax rates in effect in the years in which the
differences are expected to reverse. A valuation allowance against deferred tax assets is recorded if, based on the weight of the available evidence, it is more likely than not that some or all of the
deferred tax assets will not be realized. Potential for recovery of deferred tax assets is evaluated by considering several factors, including estimating the future taxable profits expected,
estimating future reversals of existing taxable temporary differences, considering taxable profits in carryback periods, and considering prudent and feasible tax planning strategies. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
account for uncertain tax positions using a more-likely-than-not threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on
factors including, but not limited to, changes in the law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new
audit activity, and changes in facts or circumstances related to a tax position. As of each balance sheet date, we did not have any uncertain tax positions. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Emerging growth company and smaller reporting company status  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are an emerging growth company, as defined in the JOBS Act. Under this act, emerging growth companies are permitted to delay adopting new or
revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from
new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may remain classified as an EGC until the end of the fiscal year in which the fifth anniversary of this offering occurs, although if the market value of our common stock that is held
by non-affiliates exceeds $700&nbsp;million as of any June&nbsp;30 before that time or if we have annual gross revenues of $1.07&nbsp;billion or more in any fiscal year, we would cease to be an
EGC as of December&nbsp;31 of the applicable year. We also would cease to be an EGC if we issue more than $1&nbsp;billion of non-convertible debt over a three-year period. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are also a "smaller reporting company," as such term is defined in Rule&nbsp;12b-2 of the Exchange Act, meaning that the market value of our common stock held by non-affiliates plus
the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700 million and our </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>94</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=99,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=858109,FOLIO='94',FILE='DISK116:[19ZBM1.19ZBM17601]DO17601A.;76',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_do17601_1_95"> </A>

<P style="font-family:times;"><FONT SIZE=2>annual
revenue is less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i)&nbsp;the market value of
our common stock held by non-affiliates is less than $250 million or (ii)&nbsp;our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our
common stock held by non-affiliates is less than $700 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from
certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of
audited financial statements in our Annual Report on Form&nbsp;10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive
compensation. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Results of operations  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Comparison of the six months ended June&nbsp;30, 2018 and 2019  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes our results of operations for the six months ended June&nbsp;30, 2018 and 2019: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Six months ended June&nbsp;30, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Change </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,492,788</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,998,270</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>505,482</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,166,520</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,347,915</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,181,395 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,659,308</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,346,185</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,686,877 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income (expense):</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(188</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(7,439</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(7,251</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign currency gain</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>949,158</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,615,974</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>666,816 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total other income (expense)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>948,970</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,608,535</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>659,565 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(7,710,338</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(8,737,650</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1,027,312</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and development expenses  </I></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Six months ended June&nbsp;30, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Change </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>APR-246</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,866,561</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,314,584</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>448,023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other early-stage development programs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>336,144</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>673,435</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>337,291</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unallocated research and development expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,290,083</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,010,251</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(279,832</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total research and development expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,492,788</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,998,270</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>505,482 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research
and development expenses for the six months ended June&nbsp;30, 2018 were $7.5&nbsp;million, compared to $8.0&nbsp;million for the six months ended June&nbsp;30, 2019.
The increase of $0.5&nbsp;million was primarily related to the advancement of our clinical product candidate APR-246. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General and administrative expenses  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative expenses for the six months ended June&nbsp;30, 2018 were $1.2&nbsp;million, compared to $2.3&nbsp;million for
the six months ended June&nbsp;30, 2019. The increase of $1.2&nbsp;million was primarily related to a $0.9&nbsp;million increase in legal and accounting fees. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>95</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=100,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=265643,FOLIO='95',FILE='DISK116:[19ZBM1.19ZBM17601]DO17601A.;76',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_do17601_1_96"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other income and expense  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency gain for the six months ended June&nbsp;30, 2018 was $0.9&nbsp;million compared to $1.6&nbsp;million for the six months
ended June&nbsp;30, 2019. The increase of $0.7&nbsp;million was primarily due to a strengthening of the U.S. dollar against the Swedish Krona during the six months ended June&nbsp;30, 2019.
Interest expense for the six months ended June&nbsp;30, 2018 and 2019 consisted of an insignificant amount of banking charges or fees and in 2019 interest expense derived from the new lease
accounting. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Comparison of the years ended December&nbsp;31, 2017 and 2018  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes our results of operations for the years ended December&nbsp;31, 2017 and 2018: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Years ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Change </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13,392,631</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,194,732</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>802,101</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,459,744</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,294,671</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(165,073</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,852,375</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,489,403</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>637,028 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income (expense):</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(182</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(167</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign currency gain</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>662,140</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>961,316</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>299,176 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total other income (expense)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>662,125</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>961,134</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>299,009 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(15,190,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(15,528,269</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(338,019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and development expenses  </I></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Years ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Change </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>APR-246</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,388,373</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,957,970</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,569,597</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other early-stage development programs</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,243,991</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>656,692</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(587,299</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Unallocated research and development expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,760,267</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,580,070</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(180,197</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total research and development expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13,392,631</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14,194,732</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>802,101 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research
and development expenses for the year ended December&nbsp;31, 2017 were $13.4&nbsp;million, compared to $14.2&nbsp;million for the year ended December&nbsp;31, 2018. The
increase of $0.8&nbsp;million was primarily related to the advancement of our clinical product candidate APR-246. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General and administrative expenses  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative expenses for the year ended December&nbsp;31, 2017 were $2.5&nbsp;million, compared to $2.3&nbsp;million for
the year ended December&nbsp;31, 2018. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other income and expense  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other income and expense for the year ended December&nbsp;31, 2017 consisted of an insignificant amount of banking charges or fees and a
foreign currency gain of $0.7&nbsp;million. Other income and expense for the year ended December&nbsp;31, 2018 consisted of an insignificant amount of banking fees on our cash balances and a
foreign currency gain of $1.0&nbsp;million. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>96</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=101,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=553655,FOLIO='96',FILE='DISK116:[19ZBM1.19ZBM17601]DO17601A.;76',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_do17601_1_97"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Liquidity and capital resources  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since our inception, we have incurred significant losses on an aggregate basis. We have not yet commercialized any of our product candidates,
which are in various phases of preclinical and clinical development, and we do not expect to generate revenue from sales of any products for several years, if at all. To date, we have financed our
operations through private placements of our preferred and common stock. Through June&nbsp;30, 2019, we had received net proceeds of $136.9&nbsp;million from our sales of preferred and common
stock. As of June&nbsp;30, 2019, we had cash, cash and cash equivalents of $61.0&nbsp;million. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Cash flows  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes our sources and uses of cash for each of the periods presented: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Years ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Six months ended June&nbsp;30, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash provided by (used in):</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(14,002,118</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,250,234</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(8,246,834</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(9,797,443</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Investing activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(3,702</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(4,734</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(6,189</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Financing activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23,343,863</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>56,366,742</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,415</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,621,480 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net increase (decrease) in cash and cash equivalents</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,341,745</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>41,112,806</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(8,250,153</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(4,182,152</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Operating activities  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The cash used in operating activities resulted primarily from our net losses adjusted for non-cash charges and changes in components of working
capital. Net cash used in
operating activities was $8.2&nbsp;million for the six months ended June&nbsp;30, 2018 compared to $9.8&nbsp;million for the six months ended June&nbsp;30, 2019. The increase in cash used in
operating activities of $1.6&nbsp;million was primarily attributable to an increase in our net loss of $1.0&nbsp;million and an increase in foreign currency gains of $0.7&nbsp;million. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
cash used in operating activities was $15.3&nbsp;million for the year ended December&nbsp;31, 2018 compared to $14.0&nbsp;million for the year ended December&nbsp;31, 2017.
The increase in cash used in operating activities of $1.3&nbsp;million was primarily attributable to an increase in our net loss of $0.3&nbsp;million, an increase in non-cash expenses of
$0.4&nbsp;million, resulting primarily from an increase in foreign currency gains of $0.3&nbsp;million and a decreases in stock-based compensation of $0.1&nbsp;million, and a decrease in the
components of working capital of $0.5&nbsp;million. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Investing activities</I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the six months ended June&nbsp;30, 2019 and 2018, we used an insignificant amount of cash in investing activities, consisting of the purchase of property and
equipment of $6,189 and $4,734, respectively. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the year ended December&nbsp;31, 2018, we used an insignificant amount of cash in investing activities, consisting of the purchase of property and equipment of $3,702. There was
no cash used in investing activities during the year ended December&nbsp;31, 2017. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
expect that investing activities will increase over the next several years. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>97</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=102,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=893917,FOLIO='97',FILE='DISK116:[19ZBM1.19ZBM17601]DO17601A.;76',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_do17601_1_98"> </A>
<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Financing activities</I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
cash provided by financing activities was $5.6&nbsp;million for the six months ended June&nbsp;30, 2019 compared to $1,415 for the six months ended
June&nbsp;30, 2018. The increase in cash provided by financing activities of $5.6&nbsp;million was primarily attributable to the issuance of Series&nbsp;C convertible preferred stock in February
2019 for net proceeds of $5.6&nbsp;million. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
cash provided by financing activities was $56.4&nbsp;million for the year ended December&nbsp;31, 2018 compared to $23.3&nbsp;million for the year ended December&nbsp;31,
2017. The increase in cash provided by financing activities of $33.1&nbsp;million was attributable to the issuance of Series&nbsp;C convertible preferred stock in November 2018 for net proceeds of
$56.4&nbsp;million. In October 2017, we issued Series&nbsp;B convertible preferred stock for net proceeds of $23.3&nbsp;million. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Funding requirements  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect our expenses to increase substantially in connection with our ongoing development activities related to APR-246 and other product
candidates and programs which are still in the early stages of clinical development. In addition, commencing upon the completion of this offering, we expect to incur additional costs associated with
operating as a public company. We expect that our expenses will increase substantially if and as we:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> conduct our current and future clinical trials and additional preclinical research of APR-246; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> initiate and continue research and preclinical and clinical development of our other product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> seek to identify and develop additional product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> seek marketing approvals for any of our product candidates that successfully complete clinical trials, if any; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establish a sales, marketing, manufacturing and distribution infrastructure to commercialize any products for which we may obtain marketing
approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> require the manufacture of larger quantities of our product candidates for clinical development and potentially commercialization; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> maintain, expand, protect and enforce our intellectual property portfolio; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> acquire or in-license other drugs and technologies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> defend against any claims of infringement, misappropriation or other violation of third-party intellectual property; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> hire and retain additional clinical, quality control and scientific personnel; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> build out new facilities or expand existing facilities to support our ongoing development activity; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> add operational, financial and management information systems and personnel, including personnel to support our drug development, any future
commercialization efforts and our transition to a public company; and</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> operate as a public company. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of June&nbsp;30, 2019, we had cash and cash equivalents of $61.0&nbsp;million. We believe that the anticipated net proceeds from this offering, together with our existing cash and
cash equivalents, will enable us to fund our operating expenses and capital expenditure requirements into 2023. We have based this estimate on assumptions that may prove to be wrong, and we could
exhaust our available capital resources sooner than we expect. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>98</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=103,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=909521,FOLIO='98',FILE='DISK116:[19ZBM1.19ZBM17601]DO17601A.;76',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_do17601_1_99"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because
of the numerous risks and uncertainties associated with the development of APR-246 and other product candidates and programs and because the extent to which we may enter into
collaborations with third parties for development of our product candidates is unknown, we are unable to estimate the timing and amounts of increased capital outlays and operating expenses associated
with completing the research and development of our product candidates. Our future capital requirements will depend on many factors, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the scope, progress, results and costs of our current and future clinical trials of APR-246 for our current targeted indications; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the scope, progress, results and costs of drug discovery, preclinical research and clinical trials for APR-246 and our other product
candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number of future product candidates that we pursue and their development requirements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs, timing and outcome of regulatory review of our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the extent to which we acquire or invest in businesses, products and technologies, including entering into or maintaining licensing or
collaboration arrangements for product candidates on favorable terms, although we currently have no commitments or agreements to complete any such transactions; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs and timing of future commercialization activities, including drug sales, marketing, manufacturing and distribution, for any of our
product candidates for which we receive marketing approval, to the extent that such sales, marketing, manufacturing and distribution are not the responsibility of any collaborator that we may have at
such time; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing
approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs of preparing, filing and prosecuting patent applications, maintaining, protecting and enforcing our intellectual property rights and
defending intellectual property-related claims; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our headcount growth and associated costs as we expand our business operations and our research and development activities;
and</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs of operating as a public company. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Developing
drug products, including conducting preclinical studies and clinical trials, is a time-consuming, expensive and uncertain process that takes years to complete, and we may
never generate the necessary data or results required to obtain marketing approval for any product candidates or generate revenue from the sale of any products for which we may obtain marketing
approval. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of drugs that we do not expect to be
commercially available for many years, if ever. Accordingly, we will need to obtain substantial additional funds to achieve our business objectives. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adequate
additional funds may not be available to us on acceptable terms, or at all. We do not currently have any committed external source of funds. To the extent that we raise
additional capital through the sale of equity or convertible debt securities, your ownership interest may be diluted, and the terms of these securities may include liquidation or other preferences and
anti-dilution protections that could adversely affect your rights as a common stockholder. Additional debt or preferred equity financing, if available, may involve agreements that include restrictive
covenants that may limit our ability to take specific actions, such as incurring debt, making capital expenditures or declaring dividends, which could adversely impact our ability to conduct our
business, and may require the issuance of warrants, which could potentially dilute your ownership interest. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>99</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=14,SEQ=104,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=203220,FOLIO='99',FILE='DISK116:[19ZBM1.19ZBM17601]DO17601A.;76',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_do17601_1_100"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technology, future
revenue streams, research programs, or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or
collaborations, strategic alliances or licensing arrangements with third parties when needed, we may be required to delay, limit, reduce and/or terminate our product development programs or any future
commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Contractual obligations and commitments  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes our contractual obligations at June&nbsp;30, 2019: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Payments due by period </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Less than<BR>
1&nbsp;year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>1&nbsp;-&nbsp;3&nbsp;years </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>3&nbsp;-&nbsp;5&nbsp;years </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>More than<BR>
5&nbsp;years </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating leases(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>310,973</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>122,783</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>188,190</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>310,973</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>122,783</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>188,190</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Represents
minimum payments due for our lease of office and laboratory space in Boston, Massachusetts under an operating lease agreement that, as amended, expires in
2021. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
enter into contracts in the normal course of business with CROs and CMOs for clinical trials, preclinical research studies and testing, manufacturing and other services and products
for operating purposes. These contracts do not contain any minimum purchase commitments and are cancelable by us upon prior notice of 30&nbsp;days and, as a result, are not included in the table of
contractual obligations above. Payments due upon cancelation consist only of payments for services provided and expenses incurred up to the date of cancelation. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Internal control over financial reporting  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the audit of our financial statements, we and our independent registered public accounting firm identified a material
weakness in our internal control over financial reporting primarily related to the lack of sufficient skilled employees with U.S.&nbsp;GAAP and SEC reporting knowledge and experience for the
purposes of timely and reliable financial reporting. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable
possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected and corrected on a timely basis. We are currently establishing more robust
processes to strengthen our internal control over financial reporting. See "Risk Factors&#151;In connection with the preparation of our financial statements as of and for the years ended
December&nbsp;31, 2017 and 2018, the Company and our independent registered public accounting firm identified a material weakness in the Company's internal control over financial reporting. If we
are not able to remediate the material weakness and otherwise to maintain an effective system of internal control over financial reporting in the future, investors may lose confidence in the accuracy
and completeness of our financial reports, and the market price of our common stock could be materially and adversely affected." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are working to remediate the material weakness and are taking steps to strengthen our internal control over financial reporting, such as, for example, the recent hiring of
Scott&nbsp;M. Coiante as Chief Financial Officer. Additionally, we plan to further develop and implement formal policies, processes and documentation procedures relating to the financial reporting
of the Company. The actions that we are taking are subject to ongoing executive management review, and will also be subject to audit committee oversight. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>100</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=15,SEQ=105,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=102989,FOLIO='100',FILE='DISK116:[19ZBM1.19ZBM17601]DO17601A.;76',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_do17601_1_101"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Off-balance sheet arrangements  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and
regulations of the SEC. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recently issued accounting pronouncements  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have reviewed all recently issued standards and have determined that, other than as disclosed in Note&nbsp;2 to our financial statements
appearing at the end of this prospectus, such standards will not have a material impact on our financial statements or do not otherwise apply to our operations. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Quantitative and qualitative disclosures about market risk  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Interest Rate Risk  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are exposed to market risk related changes in interest rates. As of June&nbsp;30, 2019, our cash equivalents consisted of bank deposits and
money market accounts. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level
of U.S. interest rates. However, historical fluctuations in interest income have not been significant for us. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Foreign Currency Exchange Rate Risk  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We face market risk to the extent that changes in foreign currency exchange rates affect our non-U.S. dollar functional currency foreign
subsidiaries' revenues, expenses, assets and liabilities. The financial position and results of operations of our subsidiaries Aprea AB and Aprea Personal AB are measured using the foreign
subsidiaries' local currency as the functional currency. Aprea AB cash accounts holding U.S. dollars are remeasured based upon the exchange rate at the date of remeasurement with the resulting gain or
loss included in the consolidated statement of operations and comprehensive loss. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
investments in foreign subsidiaries with a functional currency other than the U.S. dollar are generally considered long-term. In addition, we do not believe that we currently have
any significant direct foreign exchange risk. Accordingly, we have not used any derivative financial instruments to hedge exposure to such risk. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>101</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=16,SEQ=106,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=40972,FOLIO='101',FILE='DISK116:[19ZBM1.19ZBM17601]DO17601A.;76',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dq17601_1_102"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dq17601_business"> </A>
<A NAME="toc_dq17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Business    <BR>    </B></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a clinical-stage biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53
tumor suppressor protein. p53 is the protein expressed from the </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2>&nbsp;gene, the most commonly mutated gene in cancer. We believe that mutant p53
is an attractive therapeutic target due to the high incidence of p53 mutations across a range of cancer types and its involvement in key cellular activities such as apoptosis. Cancer patients with
mutant p53 face a significantly inferior prognosis even when treated with the current standard of care, and a large unmet need for these patients remains. Our lead product candidate, APR-246, is a
small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes, or MDS, and acute myeloid leukemia, or AML. APR-246 has
received Orphan Drug and Fast Track designations from the FDA for MDS, and Orphan Drug designation from the EMA for MDS, AML and ovarian cancer, and we believe APR-246 will be a first-in-class therapy
if approved by applicable regulators. We have commenced a pivotal Phase&nbsp;3 trial of APR-246 with azacitidine for frontline treatment of </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2>
mutant MDS and expect initial data from this trial in the second half of 2020. Our pivotal Phase&nbsp;3 trial is supported by data from two ongoing Phase&nbsp;1b/2 investigator initiated trials,
one in the U.S. and one in France, testing APR-246 with azacitidine as frontline treatment in </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant MDS and AML patients. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the ongoing U.S. Phase&nbsp;1b/2 trial, sponsored by Dr.&nbsp;David Sallman of the H. Lee Moffitt Cancer Center and Research Institute, or Moffitt, we have observed an objective
response rate, or ORR, of 88% and a complete remission, or CR, rate of 59% in 41 response-evaluable MDS/AML patients treated with APR-246 and azacitidine, as of July 2019 and we expect a final CR
endpoint in the second half of 2019. In MDS patients, the CR rate was 61%, with an additional 27% achieving non-CR responses. In AML patients, the CR rate was 50%, with an additional 38% achieving
non-CR responses. In addition, 46% of evaluable patients were able to discontinue treatment in order to proceed to allogeneic hematopoietic stem cell transplantation, or allo-HCT. Allo-HCT is
currently the only recognized therapy believed to increase the likelihood of long term survival for </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant MDS and AML patients in remission. In
the ongoing French Phase&nbsp;1b/2 trial, sponsored by Groupe Francophone des Myelodysplasies, or GFM, under lead investigator Prof. Pierre Fenaux, we have observed an ORR of 75% and a CR rate of
56% in 16 response-evaluable patients treated with APR-246 and azacitidine, as of July 2019 and we expect a final CR endpoint in the first half of 2020. In MDS patients, the CR rate was 55%, with an
additional 18% achieving non-CR responses. In AML patients, the CR rate was 60%, with an additional 20% achieving non-CR responses. We expect the results of our pivotal Phase&nbsp;3 trial and the
U.S. and French Phase&nbsp;1b/2 trials will be submitted in support of marketing applications to the FDA and EMA. We are also developing a next-generation small molecule p53 reactivator, APR-548,
for potential use in multiple hematologic malignancies and other oncologic indications, and expect to file an IND with the FDA in the first half of 2020. We have assembled a management team with
extensive experience in the discovery and development of novel oncology drugs. Our management team is supported by our world-class scientific advisors and leading life science investors in their
mission to successfully develop p53-reactivating therapies for cancer patients. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>102</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=107,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=526195,FOLIO='102',FILE='DISK116:[19ZBM1.19ZBM17601]DQ17601A.;69',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dq17601_1_103"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
lead programs are summarized below. We currently retain global development and commercialization rights to all of our product candidates: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g114644.jpg" ALT="GRAPHIC" WIDTH="679" HEIGHT="405">
  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Investigator-initiated
trial
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>With
or without azacitidine </FONT></DD></DL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that targeting p53 and thereby reactivating key intrinsic cellular functions has the potential to significantly impact patients' lives
and treatment strategies for a wide variety of cancers. p53 is a tumor suppressor protein that in its normal state functions to sense DNA damage and induce cell cycle arrest, DNA damage repair,
senescence and cellular apoptosis. Mutant p53 is an attractive target because it is widely mutated across hematologic and solid tumors and is associated with an aggressive clinical and molecular
phenotype. In preclinical studies and clinical trials, mutations in p53 and the apoptotic pathway have been shown to play a key role in cancer genesis, proliferation and resistance to currently
marketed therapeutic agents. Many approved and clinical stage oncology drugs are more effective with a functional p53 pathway. Our approach is to restore normal function to p53, thereby re-enabling a
cell's ability to undergo apoptosis. Accordingly, we believe that by targeting p53, our drug candidates may enhance the ability of other anti-cancer therapies to induce cancer cell death. In addition,
we believe that our approach may counteract resistance mechanisms that characterize many of the most aggressive cancers. Although we have observed single agent activity in preclinical testing of
APR-246, our current clinical program is focused on combination therapy based on the strong additive or synergistic effects we have observed in combination with multiple conventional chemotherapeutic
drugs, DNA hypomethylating agents, or HMAs, inhibitors of anti-apoptotic proteins and immuno-oncology checkpoint blockade agents. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
lead product candidate, APR-246, is a small molecule that has demonstrated reactivation of mutant p53 in clinical trials. Promising clinical data support the application of APR-246
across a variety of hematologic malignancies and other oncologic indications. APR-246 is a pro-drug that is administered intravenously and forms the active moiety, 2-methylene-quinuclidin-3-one, or
MQ, under </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>103</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=108,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=956446,FOLIO='103',FILE='DISK116:[19ZBM1.19ZBM17601]DQ17601A.;69',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dq17601_1_104"> </A>

<P style="font-family:times;"><FONT SIZE=2>physiological
conditions. APR-246 has been shown to induce apoptosis in cancer cells with mutant p53 in Phase 1/2 trials. We believe the mechanism of action and current adverse event profile of
APR-246 may provide the basis for its combination with both conventional and novel therapies, such as targeted therapies, chemotherapy, radiotherapy and immuno-therapy. APR-246 has received Orphan
Drug and Fast Track designations from the FDA for MDS, and Orphan Drug designation from the EMA for MDS, AML and ovarian cancer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are conducting and supporting multiple clinical trials of APR-246:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B>Pivotal Phase&nbsp;3 MDS Trial&#151;</B></FONT><FONT SIZE=2>We are currently enrolling a pivotal
Phase&nbsp;3 randomized, controlled trial evaluating APR-246 with azacitidine as frontline therapy in HMA-na&iuml;ve </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant MDS
patients. The trial has a target enrollment of 154 patients randomized in a 1:1 ratio to either the azacitidine control arm or to the APR-246&nbsp;+&nbsp;azacitidine experimental arm, with a
primary endpoint of CR rate. The first patient was enrolled in January 2019 and we anticipate full enrollment in our Phase&nbsp;3 trial in the first quarter of 2020 and top-line data from this trial
in the second half of 2020. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B>U.S.&nbsp;Phase&nbsp;1b/2 MDS/AML Trial&#151;</B></FONT><FONT SIZE=2>We are supporting an
investigator-initiated Phase&nbsp;1b/2 single-arm, open-label trial in the United States, sponsored by Dr. David Sallman of the H. Lee Moffitt Cancer Center and Research Institute, or Moffitt,
evaluating APR-246 with azacitidine as frontline therapy in HMA-na&iuml;ve patients with </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant MDS or AML. We are collaborating with
Moffitt on this trial by supplying APR-246, in addition to providing financial support. The primary endpoint of the trial is CR rate and enrollment has completed with 55&nbsp;patients. Top-line
results on the CR rate primary endpoint and median duration of response are expected in the second half of 2019. The regimen achieved an ORR of 88% and a CR rate of 59% in 41 response-evaluable
patients as of July 2019. In MDS patients, the CR rate was 61%, with an additional 27% achieving non-CR responses. In AML patients, the CR rate was 50%, with an additional 38% achieving non-CR
responses. In addition, 46% of evaluable MDS/AML patients were able to discontinue treatment in order to proceed to allo-HCT. By intention-to-treat analysis, and with a median follow up of
10.5&nbsp;months, median OS was 11.6&nbsp;months (95% confidence interval: 9.2&nbsp;&#150;&nbsp;14.0&nbsp;months) with significantly prolonged OS of 12.8&nbsp;months in
responding patients versus 3.9&nbsp;months in non-responding patients (p &#60; 0.0001). Analysis of peer-reviewed published data in </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2>
mutant MDS and AML suggests frontline azacitidine monotherapy provides an ORR of 40-50% for AML, CR&nbsp;rates of approximately 20% and median OS of 7-8&nbsp;months. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B>French Phase&nbsp;1b/2 MDS/AML Trial&#151;</B></FONT><FONT SIZE=2>We are supporting a parallel
investigator-initiated Phase&nbsp;1b/2 single-arm, open-label trial in France, sponsored by Groupe Francophone des Myelodysplasies, or GFM, under lead investigator Prof. Pierre Fenaux, evaluating
APR-246 with azacitidine as frontline therapy in HMA-na&iuml;ve patients with </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant MDS or AML. We are collaborating with GFM on this
trial by supplying APR-246, in addition to providing financial support. The primary endpoint of the trial is CR rate and enrollment has completed with 53 patients. Top-line results on the CR rate
primary endpoint are expected in the first half of 2020. All patients are to receive the recommended Phase&nbsp;2 dose from the U.S.&nbsp;Phase&nbsp;1b/2 MDS/AML Trial. As of July&nbsp;2019,
the regimen has achieved an ORR of 75% and CR rate of 56% in 16 response-evaluable patients. In MDS patients, the CR rate was 55%, with an additional 18% achieving non-CR responses. In AML patients,
the CR rate was 60%, with an additional 20% achieving non-CR responses. Responding patients who proceed to allo-HCT are eligible to continue receiving APR-246 with azacitidine as post-transplant
maintenance therapy. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B>Phase&nbsp;2 MDS/AML Post-Transplant Trial&#151;</B></FONT><FONT SIZE=2>We are currently enrolling our
single-arm, open-label Phase&nbsp;2 trial evaluating APR-246 with azacitidine as post-transplant maintenance therapy in </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant MDS and AML
patients who have received allo-HCT. The primary endpoint is </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>104</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=109,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=423647,FOLIO='104',FILE='DISK116:[19ZBM1.19ZBM17601]DQ17601A.;69',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dq17601_1_105"> </A>
<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>relapse-free
survival at 12&nbsp;months. Target enrollment is 31 patients and we anticipate full enrollment in the second half of 2020. Analysis of the historical, peer-reviewed published data in </FONT> <FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant MDS and
AML patients who undergo bone marrow transplant suggests that </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutation is
associated with a 4-fold increased risk of death following transplantation and a 1-year relapse-free survival of only 30%. </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B>Phase 1/2 AML Trials&#151;</B></FONT><FONT SIZE=2>Based on </FONT><FONT SIZE=2><I>in
vitro</I></FONT><FONT SIZE=2> data evidencing synergistic activity between APR-246 and a Bcl-2 inhibitor, we have designed and plan to conduct Phase 1/2 clinical trials in frontline and
relapsed/refractory AML assessing APR-246 with a Bcl-2 inhibitor with or without azacitidine. We anticipate the first patient to be enrolled in the fourth quarter of 2019. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
second product candidate, APR-548, is a next-generation p53 reactivator with the potential for oral administration. APR-548 is a unique analog of APR-246 and therefore a pro-drug of
MQ. APR-548 exhibits high oral bioavailability in preclinical testing and is being developed in an oral dosage form. We are currently conducting Investigational New Drug, or IND, enabling preclinical
studies of APR-548 and anticipate submitting an IND in the first half of 2020. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have assembled an outstanding team, which includes world-class scientific and clinical oncology leaders, to execute on our mission to create novel p53-reactivating therapies to help
patients suffering with cancer. Together with our board of directors, our scientific founders and members of our management team have significant experience in drug discovery and development and
finance. Collectively, we believe our team's strong capabilities position us to build a leading biotech company focused on developing novel cancer therapies to address the significant unmet medical
need of patients with p53 mutant malignancies, for whom there are limited effective therapeutic options. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our strategy  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our mission is to be the leading player in the development and commercialization of p53-targeted cancer therapies. The key elements of our
strategy are to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>Rapidly develop and commercialize our lead mutant p53 reactivator, APR-246, in frontline combination therapy for TP53
mutant MDS.</I></B></FONT><FONT SIZE=2> We are currently advancing APR-246 with azacitidine through Phase&nbsp;3 clinical development in </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant MDS.
We are initially targeting frontline </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant MDS, where there are few approved therapies, no approved p53-targeted therapies and a continued high
unmet medical need. We believe the data generated to date support compelling clinical activity in this underserved patient population. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>Expand the clinical opportunity for APR-246 by pursuing development of combination therapy for post-transplant
maintenance in TP53 mutant MDS and AML.</I></B></FONT><FONT SIZE=2> Allo-HCT is currently considered the only curative option for patients with </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant
MDS/AML, and even with transplantation the outcomes for these patients remain poor. We are currently advancing APR-246 as post-transplant maintenance therapy in </FONT> <FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant MDS and AML in the French
Phase&nbsp;1b/2 MDS/AML Trial and our Phase&nbsp;2 MDS/AML Post-Transplant Trial. We believe that this
approach may offer an opportunity to quickly expand the commercial potential of APR-246.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I> Rapidly develop APR-246 for frontline and relapsed/refractory TP53 mutant
AML.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;We are currently advancing the clinical development of APR-246 in frontline </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant AML
through the U.S.&nbsp;Phase&nbsp;1b/2 MDS/AML Trial and the French Phase&nbsp;1b/2 MDS/AML Trial. While these frontline trials are evaluating APR-246 with azacitidine, we also intend to evaluate
additional combination regimens with a Bcl-2 inhibitor with or without azacitidine in both frontline and relapsed/refractory AML patients. We believe that the treatment of these patients may offer an
opportunity to significantly expand the commercial potential of APR-246.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I> Advance our next-generation p53 reactivator,
APR-548.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;We are developing a next-generation small molecule p53 reactivator with the potential to be delivered in an oral dosage form. We intend
to </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>105</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=110,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=692066,FOLIO='105',FILE='DISK116:[19ZBM1.19ZBM17601]DQ17601A.;69',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dq17601_1_106"> </A>
<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>initially
develop APR-548 in </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant MDS/AML. We believe that an oral p53-reactivating drug will improve patient convenience and compliance, if
approved, including for patients receiving prolonged therapy in the maintenance setting.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I> Explore additional oncology indications for APR-246 and
APR-548.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;We are evaluating combination treatment with our product candidates in additional hematologic and solid tumor indications where mutant
and dysfunctional p53 is a driver of disease. We have preclinical models that show synergistic effects of APR-246 with a variety of anti-cancer agents including multiple conventional chemotherapeutic
drugs, HMAs, inhibitors of anti-apoptotic proteins and immuno-oncology checkpoint blockade agents. Based on our preclinical data, we believe there is potential to expand APR-246 and APR-548 into
additional oncological indications. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I> Maximize the commercial opportunity of our product candidates across global
markets.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;We currently retain worldwide development and commercialization rights to all of our product candidates. We intend to retain commercial
rights to our product candidates in the United States and may elect to build a focused commercial oncology organization to market any of our product candidates that are approved. Outside of the United
States, we may elect to selectively evaluate strategic partnership opportunities for our product candidates with partners whose development and commercial capabilities complement our own. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our approach  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Background on p53, a key tumor suppressor protein  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> is the most widely mutated gene in human cancers. Since its discovery in 1979, p53 has been
extensively studied by researchers and the pharmaceutical industry due to its central role in preventing the initiation and progression of liquid and solid tumors. p53 has long been referred to as
"the guardian of the genome" because it is the body's first line of cellular defense against cancers. Among its multiple biologic functions, p53 regulates a variety of tumor suppressive responses
including cell cycle arrest, DNA repair, apoptosis, and senescence. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;p53
is activated when DNA damage is detected and when oxidative or other cellular stresses exceed thresholds for normal cellular function. The result of p53 activation is to facilitate
the repair of the cell or trigger killing of the damaged cell, through a process known as apoptosis, before it can become cancerous and replicate. Given that the mutational status of p53 in a tumor
has a strong impact on sensitivity to commonly used anti-cancer drugs and radiotherapy, p53 is important both as clinical marker and as a novel therapeutic target. Importantly, mutations in p53 not
only diminish tumor suppression function but also often lead to the acquisition of new pro-tumor functions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
date, more than 25,000 unique </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutations have been reported and thus a key challenge in the development of p53-targeted therapies
is the vast number of mutations that compromise tumor suppression activity. Incidence of </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutations increases after treatment with chemotherapy or
radiation. The most common of these are missense mutations, involving the site-specific exchange of one amino acid for another, and account for 75% of all p53 mutations; however, even the six most
frequently mutated "hotspot" missense mutations in p53 collectively represent only ~30% of all missense mutations. Therefore, we believe that a therapeutic agent that targets a small subset of </FONT> <FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2>
mutations would be of limited benefit. To circumvent these challenges, previous drug development efforts have primarily focused on gene therapy delivery of wild type p53 or drugs that disrupt
interaction with proteins that control p53 activation and abundance. We believe the more effective approach is our direct conformational reactivation of mutant p53 and restoration of wild-type
structure and activity, independent of the type of mutation. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>106</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=111,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=45721,FOLIO='106',FILE='DISK116:[19ZBM1.19ZBM17601]DQ17601A.;69',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dq17601_1_107"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our approach to re-activating p53  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;One of the most attractive features of apoptosis activation as a cancer therapy is its potential to induce tumor regression rather than to
simply stop tumor growth. However, pro-apoptotic agents that cannot discriminate between malignant and normal cells carry a significant risk of side effects. This is an important issue with
traditional cancer treatments: radiotherapy and chemotherapy induce apoptosis only as a secondary effect of the cellular damage they induce. These treatments affect most proliferating cells without
distinction between malignant or normal cells. Our product candidates, in contrast, are designed to reactivate mutant, non-functional p53 to restore normal apoptotic functions in cancer cells without
triggering apoptosis in normal cells, thereby selectively enhancing the effects of other chemotherapy drugs in malignant cancer cells with mutant p53. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;APR-246
and the MQ, have been extensively studied. MQ-modified mutant p53 protein has been shown to induce significant levels of apoptosis, indicating that covalent binding of MQ
activates mutant p53 and induces a p53-dependent apoptotic response. Experiments by our founders looking directly at the conformational state of p53 protein in cells have confirmed that binding of MQ
stabilizes mutant p53 in the functional, wild type conformation. Structural biology studies performed by our collaborators have produced the first-ever crystal structures of several single-site
missense mutant p53 forms bound to DNA. These structures confirm both the sites of MQ binding to mutant p53 and the stabilization of mutant p53 by MQ in the wild type conformation. Reactivation of
mutant p53 via stabilization of the properly folded wild type conformation is the key step in our product candidates' mechanism of action. The following diagram illustrates this mechanism. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g412158.jpg" ALT="GRAPHIC" WIDTH="616" HEIGHT="139">
  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In </FONT> <FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> and </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> experiments, our lead p53 re-activating product candidate,
APR-246, via MQ, impaired tumor cells' capacity to respond to oxidative stress. In parallel to binding mutant p53, and as published by Liu et al, Nat Commun, 2017, 14844, MQ depletes intracellular
glutathione, or GSH, and induces reactive oxygen species, or ROS. Furthermore, as published in Peng et al, Cell Death Dis, 2013, e881, MQ has been shown to inhibit the reductase activities of the
redox enzyme thioredoxin reductase, or TrxR1, and convert the enzyme to a dedicated oxidase, thereby increasing levels of ROS. Additional results reported in Haffo et al, Sci. Reports, 2018, 12671,
have demonstrated MQ inhibition of thioredoxin, or Trx1, and glutaredoxin, or Grx1, which further augment oxidative stress, and ribonucleotide reductase, or RNR, which decreases the cell's ability to
repair damaged DNA. These effects on the cellular redox system, illustrated in the following diagram, may contribute to the anticancer activity of APR-246 as well as the selectivity for effects on
cancer cells versus healthy normal cells. Malignant cells have higher levels of ROS than healthy cells and are thus more </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>107</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=112,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=612802,FOLIO='107',FILE='DISK116:[19ZBM1.19ZBM17601]DQ17601A.;69',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dq17601_1_108"> </A>

<P style="font-family:times;"><FONT SIZE=2>susceptible
to increased stress that can trigger pro-apoptotic responses. MQ-induced oxidative stress is therefore an important secondary feature of the mechanism of action. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g385816.jpg" ALT="GRAPHIC" WIDTH="655" HEIGHT="298">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cell
fate is a function of the extent and severity of cellular stresses, such as oxidative stress and DNA damage. A network of proteins translates information about cellular stress into
biochemical signals and relays this information back to p53, the center of the network. p53 integrates these biochemical signals and becomes activated to initiate cell cycle arrest. When cellular
stress and damage are sufficiently high, such as with chemotherapy, p53 initiates apoptosis. MQ restores the ability of a cell to respond to oxidative stress and DNA damage via reactivation of mutant
p53 and induces heightened oxidative stress signals to which reactivated p53 can respond. The overlap of these features of the mechanism of action may in turn provide more efficient induction of
apoptosis. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Market opportunity for p53 re-activating product candidates  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe there is a significant market opportunity for therapies targeting mutant p53 because these mutations occur in more than half of all
tumors and confer an inferior prognosis relative to patients with wild type p53. Preclinical anti-tumor activity has been observed with APR-246 in a wide variety of hematological and solid tumor
models and cell lines as reviewed and referenced in Perdrix&nbsp;et&nbsp;al, Cancer 2017, 9, 172. Given the importance of p53 mutations as disease-driver mutations, the sensitivity of
hematopoietic cells to oxidative stress and continued unmet medical need, we are initially focused in our clinical development on hematological malignancies, MDS and AML, with </FONT> <FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutations.
</FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Myelodysplastic syndromes&#151;disease background and opportunity  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MDS is a collection of bone marrow disorders in which malignant hematopoietic cells prevent production of healthy, mature blood cells. Low blood
cell counts, called cytopenias, are a hallmark feature of MDS and are a principal cause of morbidity and mortality from infection and bleeding. MDS can develop </FONT><FONT SIZE=2><I>de
novo</I></FONT><FONT SIZE=2> or may arise secondary to chemotherapy or radiation treatment for a different, prior malignancy or following an antecedent hematological disorder. Treatment-related MDS is
associated with increased complex chromosomal abnormalities and carries a worse prognosis than </FONT><FONT SIZE=2><I>de novo</I></FONT><FONT SIZE=2> MDS. As of 2019, there are an estimated 200,000
MDS patients worldwide, with 68,000 of these in the United States and 69,000 MDS patients across the five major markets of the European Union and Japan. Globally, MDS prevalence is expected to
increase 2-3% annually in mature markets and 3-4% annually in emerging markets as populations age. MDS predominantly affects older adults, with </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>108</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=113,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=196139,FOLIO='108',FILE='DISK116:[19ZBM1.19ZBM17601]DQ17601A.;69',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dq17601_1_109"> </A>

<P style="font-family:times;"><FONT SIZE=2>approximately
75% of patients aged 60 years or older at diagnosis. Around 30% of patients diagnosed with MDS will progress to AML, with the rate being higher for patients with more advanced disease. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MDS
patients are segmented into different risk groups according the number of cytopenias, bone marrow blast percentage, and cytogenetic abnormalities. The presence of three or more
coincident structural genetic abnormalities is classified as a complex karyotype, which correlates with poor prognosis, low response to intensive chemotherapy, high rate of relapse and inferior
survival. Mutations
in </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> occur in approximately 20% of patients with </FONT><FONT SIZE=2><I>de novo</I></FONT><FONT SIZE=2> MDS and in more than 30% of patients with
therapy-related MDS who develop disease secondary to chemotherapy or radiation treatment for other cancers. Sequencing of a panel of commonly mutated genes, including </FONT> <FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2>, is standard practice in the
diagnosis of MDS. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Historically,
treatment response rates in </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant MDS patients have been poor regardless of therapy. Treatment with azacitidine is the
standard of care for frontline therapy in </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant MDS, with ORR of 40-45%, a CR rate of 20% and median OS of approximately 7-8&nbsp;months. There
are no established curative pharmacologic therapies for MDS. Allo-HCT is currently the only recognized therapy believed to increase the likelihood of long term survival for </FONT> <FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant MDS patients;
however, many patients are not candidates for allo-HCT due to lack of sufficient clinical response to initial therapy,
advanced age, comorbidities or lack of a suitable donor. Unfortunately, even for those </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant MDS patients who receive allo-HCT, the
post-transplantation prognosis is poor: </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutations are associated with a 4-fold increased risk of death and 1-year relapse-free survival of only 30%
following transplantation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Given
the poor prognosis for patients with </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant MDS there is a significant need for more effective therapies in this population,
particularly if such treatments have a favorable safety profile, and a mechanism of action that targets mutant p53 directly, and may be used in combination with existing or future treatment options. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Acute myeloid leukemia&#151;disease background and opportunity  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AML is the most common form of adult leukemia, with the highest incidence in patients aged 60&nbsp;years and older. AML is characterized by
proliferation of abnormal immature white blood cells which, like MDS, impairs production of normal blood cells. AML can develop </FONT><FONT SIZE=2><I>de novo</I></FONT><FONT SIZE=2> or may arise
secondary to progression of other hematologic disorders or from chemotherapy or radiation treatment for a different, prior malignancy; secondary AML carries a worse prognosis than </FONT> <FONT SIZE=2><I>de novo</I></FONT><FONT SIZE=2> AML. As of
2019, there are an estimated 213,000 AML patients worldwide, with 37,000 of these in the United States and 41,000 across the five
major European Union markets and Japan. Globally, AML prevalence is expected to increase approximately 1-2% annually in mature markets and 2-3% in emerging markets. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AML
patients are segmented into different risk groups according to cytogenetic abnormalities. The presence of three or more coincident structural genetic abnormalities is classified as a
complex karyotype, which correlates with adverse prognosis, low response to intensive chemotherapy, high rate of relapse and inferior survival. Mutations in </FONT> <FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> occur in approximately 20% of patients
with newly diagnosed AML, more than 30% of patients with therapy-related AML and approximately 70-80% of
patients with complex karyotype. Sequencing of a panel of commonly mutated genes, including </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2>, is standard practice in the diagnosis of AML. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Historically,
treatment response rates in </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant AML patients have been poor regardless of therapy. Treatment with azacitidine is the
standard of care therapy for frontline therapy in </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant AML, with 40-50% ORR, 10-20% CR rate and OS of 7-8&nbsp;months. Similar to MDS, allo-HCT
is currently the only recognized therapy believed to increase the likelihood of long term survival for </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant AML patients; however, many patients
are not candidates for allo-HCT due to lack of sufficient clinical response to therapy, advanced age, comorbidities or lack of a suitable donor. Unfortunately, even for those </FONT> <FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant AML patients
who receive allo-HCT, the post-transplantation prognosis is </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>109</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=114,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=967321,FOLIO='109',FILE='DISK116:[19ZBM1.19ZBM17601]DQ17601A.;69',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dq17601_1_110"> </A>

<P style="font-family:times;"><FONT SIZE=2>poor:
</FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutations are associated with a 4-fold increased risk of death and 1-year relapse-free survival of only 30% following transplantation. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Given
the poor prognosis for patients with </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant AML there is a significant need for more effective therapies in this population,
particularly if such treatments have a favorable safety profile, and a mechanism of action that targets mutant p53 directly, and may be used in combination with existing or future treatment options. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our lead product candidate, APR-246  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our lead product candidate, APR-246, is a small molecule that has demonstrated reactivation of mutant p53 in both clinical trials and
preclinical studies. Promising clinical and preclinical data support the application of APR-246 across a variety of hematologic malignancies and other oncologic indications. Based on its mechanism of
action of p53 reactivation and the complementary increase in oxidative stress, as well as its potential synergy with anti-cancer agents as evidenced in preclinical studies, APR-246 treatment may be
effective in a broad range of clinical settings. We are currently focusing our clinical development of APR-246 on hematologic malignancies. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Clinical trials of APR-246 in MDS and AML  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are currently evaluating APR-246 with azacitidine for the treatment of </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant MDS and/or
AML patients in 4 clinical trials, including frontline therapy and post-allo-HCT maintenance therapy. We plan to initiate an additional trial in the fourth quarter of 2019 to evaluate APR-246 with a
Bcl-2 inhibitor with or without azacitidine for the treatment of frontline and relapsed/refractory, or R/R, AML. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The Pivotal Phase&nbsp;3 MDS Trial  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our pivotal Phase&nbsp;3 trial commenced enrollment in January 2019. Patients are randomized in a 1:1 ratio to either the azacitidine control
arm or to the APR-246&nbsp;+&nbsp;azacitidine test arm. The primary endpoint is CR rate with secondary endpoints including ORR, duration of response, progression-free survival, or PFS,
leukemia-free survival, or LFS, OS, and proportion transitioning to allo-HCT. Serious adverse events, regardless of causality, reported in more than one patient as of September&nbsp;18, 2019 were:
febrile neutropenia 19%, lung infection (9%), pyrexia 6%, muscle weakness 4%, pericarditis 4%, pneumonitis 4%, hypotension (4%), sepsis (4%). There has been one death, resulting from respiratory
failure, in a patient receiving both APR-246 and azacitidine and reported by an investigator as possibly related to both study drugs. There has been one death, resulting from pneumonitis, in a patient
receiving azacitidine monotherapy and reported by an investigator as possibly related. The target enrollment is 154 patients and we anticipate completing enrollment in the first quarter of 2020 and
expect top-line CR data in the second half of 2020. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The U.S.&nbsp;Phase&nbsp;1b/2 MDS/AML Trial  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are supporting an investigator-initiated Phase&nbsp;1b/2 single-arm, open-label, multi-center trial in the United States of APR-246 with
azacitidine in HMA-na&iuml;ve patients with </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant myeloid neoplasms including MDS and AML. Enrollment commenced in May 2017 and was
completed in March 2019. The Phase&nbsp;1b part enrolled 12&nbsp;patients and was conducted as a dose escalation in a modified 3+3 design at dose levels of 50 mg/kg/d, 75&nbsp;mg/kg/d and 100
mg/kg/d, calculated by lean body mass. The Phase&nbsp;2 part enrolled 43 patients with all patients receiving a fixed dose of 4500 mg/d APR-246, a dose that our population pharmacokinetic analysis
has identified as approximately equivalent to the highest Phase&nbsp;1b dose, 100 mg/kg/d by lean body mass. A lead-in phase, beginning two weeks prior to starting cycle 1 of combination therapy
with azacitidine, was conducted only in the Phase&nbsp;1b part. The purpose of the lead-in phase was to establish the adverse event profile of
APR-246 in this patient population and to APR-246-induced p53 reactivation. The protocol specifies administration of APR-246 as a 6-hour intravenous infusion daily for four consecutive days, with
administration of 75 mg/m<SUP>2</SUP>/d azacitidine by sub-cutaneous injection or intravenously beginning on Day 4 after completion of APR-246 infusion and continuing for 6 additional days. The
image below shows the design of the U.S.&nbsp;Phase&nbsp;1b/2 MDS/AML Trial. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>110</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=115,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=236594,FOLIO='110',FILE='DISK116:[19ZBM1.19ZBM17601]DQ17601A.;69',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ds17601_1_111"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Design of the U.S.&nbsp;Phase&nbsp;1b/2 MDS/AML Trial  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g785591.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="220">
  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Baseline
characteristics of patients enrolled in the trial are shown in the following table. Patients with MDS, AML, chronic myelomonocytic leukemia, or CMML, and MDS-myeloproliferative
neoplasm overlap, or MDS-MPN, were allowed to enroll in the trial. Most patients were higher risk MDS (35/55,&nbsp;64%) or AML (11/55, 20%), with complex karyotypes, cytopenias and transfusion
dependence. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Baseline characteristics  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="102pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All patients (n=55) </B></FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B>Female / Male, n</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>29 / 26</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Age in years, median (range)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>66 (34&nbsp;-&nbsp;85)</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B>Age Category, n (%)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&#60; </FONT><FONT SIZE=2><B>65</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>23 (42)</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 <FONT FACE="SYMBOL">&#179;</FONT> </FONT><FONT SIZE=2><B>65</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32 (58)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>ECOG PS(1) at treatment start, n (%)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B>0</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17 (31)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>1</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>34 (62)</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B>2</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4 (7)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Disease type, n (%)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B>MDS</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40 (73)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:28pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>IPSS-R(2): Intermediate</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4 (7)</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:28pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B>IPSS-R: High</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8 (15)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:28pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>IPSS-R: Very High</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>28 (51)</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B>AML</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11 (20)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>CMML(3)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2 (4)</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B>MDS-MPN(4)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2 (4)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Therapy-related(5), n (%)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18 (33)</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B>Chemotherapy</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16 (29)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Radiation</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3 (5)</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B>Complex karyotype, n (%)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>47 (85)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>TP53</I></B></FONT><FONT SIZE=2><B> VAF(6)%, median (range)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>27 (1&nbsp;-&nbsp;79)</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B>Bone marrow blast %, median (range)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8 (0&nbsp;-&nbsp;30)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Hematology, median (range)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B>ANC(7), 10<SUP>3</SUP>/<FONT FACE="SYMBOL">m</FONT>L</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.19 (0.02&nbsp;-&nbsp;15.98)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Hgb(8), g/dL</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.6 (6.7&nbsp;-&nbsp;13.8)</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B>Platelets, 10<SUP>3</SUP>/<FONT FACE="SYMBOL">m</FONT>L</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>46 (0&nbsp;-&nbsp;845)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>WBC(9), 10<SUP>3</SUP>/<FONT FACE="SYMBOL">m</FONT>L</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.4 (0.6&nbsp;-&nbsp;30.8)</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B>Transfusion dependence, n (%)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>RBC(10)</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>36 (65)</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B>Platelets</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12 (22)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Eastern
Cooperative Oncology Group performance status </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>111</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=116,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=973735,FOLIO='111',FILE='DISK116:[19ZBM1.19ZBM17601]DS17601A.;77',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_ds17601_1_112"> </A>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Revised
International Prognostic Scoring System
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Chronic
myelomonocytic leukemia
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Myelodysplastic
syndromes-myeloproliferative neoplasms overlap
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Patients
treated for prior cancer(s)
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Variant
allele frequency
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Absolute
neutrophil count
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Hemoglobin
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(9)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>White
blood cell
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(10)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Red
blood cell </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
median age of all enrolled patients was 66&nbsp;years, consistent with MDS and AML affecting mostly older patients. Of the MDS patients in the trial, 36/40 were high or very high
risk by IPSS-R. Across all patients, 33% had documented therapy-related disease and 85% had complex karyotypes. High risk patients with complex karyotypes and </FONT> <FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutation have been reported to have
the poorest prognosis of all MDS and AML patients. The median bone marrow blast percentage was 8%. Hematologic
parameters were reflective of the frequently severe cytopenias attendant with MDS and AML, and were underscored by transfusion dependence at baseline in 65% of patients. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Of
the 51 MDS and AML patients treated with the combination of APR-246 and azacitidine, 41&nbsp;had at least one serial bone marrow biopsy performed and were evaluable for response in
accordance with trial protocol as of July 2019. In this subset of 41 evaluable patients, responses were reported in 29/33 (88%) MDS patients and 7/8 (88%) AML patients. In MDS patients, the CR rate
was 61%, with an additional 27% achieving non-CR responses. In AML patients, the CR rate was 50%, with an additional 38% achieving non-CR responses. Nineteen of 41 (46%) MDS/AML patients discontinued
treatment for allo-HCT, as transplant is viewed as a potentially curative option for patients with </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant MDS and AML. Treatment duration and
responses are shown in the figure below. The median time to first response is 1.9&nbsp;months in MDS patients and 2.2&nbsp;months in AML patients. By intention-to-treat analysis in all 55
patients, and with a median follow up of 10.5&nbsp;months, median OS was 11.6&nbsp;months (95% confidence interval: 9.2&nbsp;&#150;&nbsp;14.0&nbsp;months) with significantly prolonged
OS of 12.8&nbsp;months in responding patients versus 3.9&nbsp;months in non-responding patients (p &#60; 0.0001). In the subset of 41 MDS/AML patients, median OS was 12.2&nbsp;months
(95% confidence interval: 9.8&nbsp;&#150;&nbsp;14.6&nbsp;months). </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>112</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=117,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=474785,FOLIO='112',FILE='DISK116:[19ZBM1.19ZBM17601]DS17601A.;77',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_ds17601_1_113"> </A>

<P style="font-family:times;"><FONT SIZE=2><B> Treatment duration and response in evaluable MDS/AML patients<BR>
Data cutoff: July&nbsp;15, 2019 (n=41)  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g602177.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="354">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Treatment
with azacitidine is the standard of care for frontline therapy in </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant MDS and AML, with ORR of 40-45% and a CR rate of
20%. A limited number of peer-reviewed publications have reported the duration of response, or DoR, and PFS in this patient population; from the available public data, DoR is approximately
4-5&nbsp;months and PFS is approximately 4-8&nbsp;months. In the 41&nbsp;evaluable patients in the U.S. trial, ORR was 88% (95% confidence interval: 73&nbsp;-&nbsp;95%) and CR rate was 59%
(95% confidence interval: 43&nbsp;-&nbsp;75%). For the evaluable Phase&nbsp;1b patients, where the data is mature, DoR was 7.5&nbsp;months (95% confidence interval:
5.8&nbsp;-&nbsp;8.4&nbsp;months) and PFS was 9.3&nbsp;months (95% confidence interval: 8.2&nbsp;-&nbsp;10.6&nbsp;months) as of the data cutoff. These data are summarized in the following
figure. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Rates and Duration of Response  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g679196.jpg" ALT="GRAPHIC" WIDTH="615" HEIGHT="241">
  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Data
from Sallman et al, 2018 Annual Meeting of the American Society of Hematology, poster&nbsp;1817; Bally et al, </FONT><FONT SIZE=1><I>Leukemia
Res.</I></FONT><FONT SIZE=1>, </FONT><FONT SIZE=1><B>2014</B></FONT><FONT SIZE=1>; Takahashi et al, </FONT><FONT SIZE=1><I>Oncotarget</I></FONT><FONT SIZE=1>, </FONT> <FONT SIZE=1><B>2016</B></FONT><FONT SIZE=1>; Kulasekararaj, </FONT><FONT
SIZE=1><I>Br.&nbsp;J.&nbsp;Haematol.</I></FONT><FONT SIZE=1>, </FONT><FONT SIZE=1><B>2013</B></FONT><FONT SIZE=1>;
Bejar et al, </FONT><FONT SIZE=1><I>Blood</I></FONT><FONT SIZE=1>, </FONT><FONT SIZE=1><B>2014</B></FONT><FONT SIZE=1>; Falconi et al, </FONT><FONT SIZE=1><I>Leukemia</I></FONT><FONT SIZE=1>, </FONT> <FONT SIZE=1><B>2018</B></FONT><FONT SIZE=1>.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Duration
of response </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>113</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=118,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=37598,FOLIO='113',FILE='DISK116:[19ZBM1.19ZBM17601]DS17601A.;77',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_ds17601_1_114"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reported adverse events, or AEs, are mostly low-grade (Grade 1 or 2). Grade&nbsp;3 or higher AEs are mostly associated with the underlying
disease. In the APR-246 monotherapy lead-in phase there were no dose-limiting toxicities, no serious adverse events attributed to APR-246 and all treatment-related AEs were low-grade. The following
chart summarizes the AEs reported in more than one patient during the APR-246 monotherapy lead-in phase. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


AEs reported in &gt; 1 patient during APR-246 monotherapy lead-in phase (n=12)  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Adverse event, n (%)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Any grade </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Grade <FONT FACE="SYMBOL">&#179;</FONT> 3 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Nausea</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5 (42</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0 (0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Peripheral sensory neuropathy</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5 (42</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0 (0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Back pain</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3 (25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0 (0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Febrile neutropenia</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2 (17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2 (17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Anemia</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2 (17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2 (17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Headache</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2 (17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0 (0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Dizziness</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2 (17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0 (0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
most common AEs observed across all cycles of treatment in the trial, as of the cutoff date and regardless of causality, are summarized in the following chart. Only three patients
(5%) discontinued treatment due to AE. Serious adverse events, regardless of causality, reported for more than one patient were: febrile neutropenia (27%), lung infection (9%), infections and
infestations (5%), respiratory failure (5%), sepsis (5%), vomiting (5%), chest pain (4%), dehydration (4%), intracranial hemorrhage (4%) and multi-organ failure (4%). </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B> Most common reported AEs with APR-246&nbsp;+&nbsp;azacitidine treatment, regardless of causality (<FONT FACE="SYMBOL">&#179;</FONT>20%)<BR>
Data cutoff: July&nbsp;15, 2019 (n=55)  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Adverse event, n (%)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Any grade </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Grade <FONT FACE="SYMBOL">&#179;</FONT> 3 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Nausea</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35 (65</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0 (0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Vomiting</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24 (44</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1 (2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Fatigue</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>23 (42</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0 (0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Constipation</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>22 (40</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0 (0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Dizziness</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19 (35</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1 (2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Diarrhea</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19 (35</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1 (2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Febrile neutropenia</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18 (31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18 (33</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Neutropenia</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16 (29</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16 (29</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Edema&#151;limbs</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16 (29</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1 (2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Infections and infestations</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16 (29</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6 (11</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Dsypnea</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16 (29</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2 (4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Peripheral sensory neuropathy</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15 (27</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0 (0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Leukopenia</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15 (27</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14 (25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Thrombocytopenia</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15 (27</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13 (24</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cough</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15 (27</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1 (2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Headache</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14 (25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0 (0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Pruritus</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13 (24</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0 (0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Mucositis oral</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12 (22</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0 (0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Fever</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12 (22</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1 (2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Skin and subcutaneous tissue disorders</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12 (22</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0 (0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Tremor</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11 (20</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1 (2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Anorexia</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11 (20</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0 (0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Alanine aminotransferase increased</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11 (20</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1 (2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Lung infection</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11 (20</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9 (16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>114</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=119,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=1012622,FOLIO='114',FILE='DISK116:[19ZBM1.19ZBM17601]DS17601A.;77',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_ds17601_1_115"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
most common AEs, determined by an investigator to be possibly, probably or definitely related to APR-246 or azacitidine, are summarized in the following chart. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B> Most common reported AEs with possible, probable or definite relation to APR-246 or azacitidine (<FONT FACE="SYMBOL">&#179;</FONT>10%)<BR>
Data cutoff: July&nbsp;15, 2019 (n=55)  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Adverse event, n (%)

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Any grade </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Grade <FONT FACE="SYMBOL">&#179;</FONT> 3 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Nausea</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32 (58</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0 (0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Vomiting</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24 (44</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1 (2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Dizziness</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17 (31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1 (2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Constipation</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13 (24</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0 (0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Peripheral sensory neuropathy</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12 (22</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0 (0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Leukopenia</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12 (22</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11 (20</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Thrombocytopenia</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11 (20</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9 (16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Neutropenia</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10 (18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10 (18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Fatigue</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8 (15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0 (0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Tremor</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8 (15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0 (0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Pruritus</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7 (13</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0 (0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Diarrhea</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6 (11</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0 (0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Anorexia</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6 (11</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0 (0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fifty-eight
</FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutations, representing 49 unique mutations, were identified in the subset of 41&nbsp;evaluable MDS and AML patients.
Consistent with prior published findings, the majority of these were missense mutations (79%) and located in the DNA-binding domain (93%). Other </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2>
mutations sequenced in the 41 evaluable MDS and AML patients included insertion-deletion mutations (3%), splice-site mutations (5%), frameshift mutations (5%) and nonsense mutations (7%). The
distribution of </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutations by type and breadth of mutations by response are shown in the figure below. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I>TP53</I></B></FONT><FONT SIZE=2><B> mutations by type in evaluable MDS/AML patients<BR>
Data cutoff: July&nbsp;15, 2019 (n=41)  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g511473.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="151">
  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B><I>TP53</I></B></FONT><FONT SIZE=2><B> mutations by best response in evaluable MDS/AML patients<BR>
Data cutoff: July&nbsp;15, 2019 (n=41)  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g86732.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="151">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>115</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=120,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=485425,FOLIO='115',FILE='DISK116:[19ZBM1.19ZBM17601]DS17601A.;77',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_ds17601_1_116"> </A>
<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The French Phase&nbsp;1b/2 MDS/AML Trial  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are supporting an ongoing investigator-initiated single-arm, open-label Phase&nbsp;1b/2 trial in France by the Groupe Francophone des
My&eacute;lodysplasies, or GFM, under lead investigator Prof. Pierre Fenaux, to expand the adverse event and efficacy data set in MDS and AML patients treated with the combination of APR-246
and azacitidine. The trial was initiated in September 2018 and reached final enrollment of 53 patients in July&nbsp;2019. The median age of enrolled patients is 73&nbsp;years. Thirty-four of 53
patients (64%) had a diagnosis of MDS and 19/53 (36%) with AML. At baseline, 74% of MDS patients were very high risk by IPSS-R. Complex karyotype was found in 89% of enrolled patients. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
protocol specifies administration of 4500 mg/d APR-246 as a 6-hour intravenous infusion daily for four consecutive days, with administration of 75 mg/m<SUP>2</SUP>/d azacitidine
by sub-cutaneous injection or intravenously beginning on Day 4 after completion of APR-246 infusion and continuing for 6 additional days. Patients who receive benefit from frontline therapy and
undergo allo-HCT are eligible to continue with post-transplant maintenance therapy with APR-246 and azacitidine. As of July 2019, of the 53&nbsp;patients enrolled, there were 11 MDS patients and 5
AML patients that had at least one serial bone marrow biopsy performed and were evaluable for response in accordance with trial protocol. Responses were achieved in 8/11 (73%) of MDS patients with 55%
CR rate, and 4/5 (80%) of AML patients with a 60% CR rate, for a combined 75% ORR and 56% CR rate. As demonstrated in the following table, these data from the French Phase&nbsp;1b/2 MDS/AML Trial
are qualitatively consistent with data from the U.S. Phase&nbsp;1b/2 MDS/AML Trial. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Comparison of best response in French Phase&nbsp;1b/2 MDS/AML Trial and U.S. Phase&nbsp;1b/2
MDS/AML Trial  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="86pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="77pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>MDS

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>French phase&nbsp;1b/2<BR>
MDS/AML trial<BR>
(n=11) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>U.S. phase&nbsp;1b/2<BR>
MDS/AML trial<BR>
(n=33) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>ORR, %</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>73</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>88</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>CR, %</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>55</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>61</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>mCR&nbsp;+&nbsp;HI, %</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>21</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>mCR, %</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>HI, %</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="86pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="77pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>AML

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>French phase&nbsp;1b/2<BR>
MDS/AML trial<BR>
(n=5) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>U.S. phase&nbsp;1b/2<BR>
MDS/AML trial<BR>
(n=8) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>ORR, %</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>80</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>88</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>CR, %</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>MLFS, %</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>HI, %</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="86pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="77pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Combined MDS&nbsp;+&nbsp;AML

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>French phase&nbsp;1b/2<BR>
MDS/AML trial<BR>
(n=16) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>U.S. phase&nbsp;1b/2<BR>
MDS/AML trial<BR>
(n=41) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>ORR, %</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>75</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>88</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>CR, %</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>56</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>59</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>mCR&nbsp;+&nbsp;HI / CRi / CRp, %</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>mCR / MLFS, %</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>HI, %</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Serious
adverse events, regardless of causality, reported in more than one patient in the French Phase 1b/2 MDS/AML Trial were: Febrile neutropenia (23%), device related infection (9%),
sepsis (8%), pneumonia (6%), cerebellar syndrome (4%), lung disorder (4%), lung infection (4%), subdural hematoma (4%), urinary tract infection (4%). </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>116</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=121,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=955705,FOLIO='116',FILE='DISK116:[19ZBM1.19ZBM17601]DS17601A.;77',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_du17601_1_117"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The Phase&nbsp;2 MDS/AML Post-transplant Trial  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There is a significant unmet medical need for more effective therapies for patients with </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2>
mutant AML and MDS following allo-HCT given that the one year post-transplant relapse-free survival, or RFS, rate is only 30%. In the second quarter of 2019, we opened enrollment to our Phase&nbsp;2
MDS/AML Post-Transplant Trial to evaluate the benefit of APR-246 with azacitidine on RFS in </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant MDS and AML patients who have received allo-HCT.
The protocol specifies administration of 3700 mg/d APR-246 as a 6-hour intravenous infusion daily on days 1 through 4, with administration of 35 mg/m<SUP>2</SUP>/d azacitidine by sub-cutaneous
injection or intravenously on days 1 through 5. Patients may receive a maximum of 12 cycles of maintenance therapy in the Phase&nbsp;2 MDS/AML Post-Transplant Trial. Target enrollment in the trial
is 31 patients and the primary endpoint is 1-year RFS. In addition, we will evaluate the adverse event profile of APR-246 with azacitidine as maintenance treatment post-HCT. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The Phase 1/2 AML Trials  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have designed and plan to conduct a Phase 1/2 clinical trial evaluating the adverse event profile and efficacy of treatment with APR-246 and
ABT-199/venetoclax, the Bcl-2 inhibitor, with or without azacitidine, in frontline and R/R </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant AML. Bcl-2 is a pro-survival
protein that is frequently expressed at high levels in tumor cells and acts to restrict apoptosis. Inhibition of Bcl-2&nbsp;protein relieves its anti-apoptotic function, thereby augmenting
apoptosis. In preclinical trials, we have observed strong synergy when APR-246 and the Bcl-2 inhibitor are combined in the </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant AML cell line,
KBM3, as shown in the figure below, and believe that this combination may provide meaningful improvements in durable responses for </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant AML
patients with previously untreated and relapsed/refractory AML. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B> Strong synergy(1) is observed in </B></FONT><FONT SIZE=2><B><I>TP53</I></B></FONT><FONT SIZE=2><B> mutant cells treated with APR-246 and the Bcl-2 inhibitor  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g142480.jpg" ALT="GRAPHIC" WIDTH="585" HEIGHT="432">
  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Synergy
analyzed using the Highest Single Agent (HSA) method.</FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>117</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=122,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=513014,FOLIO='117',FILE='DISK116:[19ZBM1.19ZBM17601]DU17601A.;54',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_du17601_1_118"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the anticipated trial design, frontline and R/R </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant AML patients who have received prior HMA therapy will receive treatment
with APR-246 and the Bcl-2 inhibitor, and frontline patients who are HMA-na&iuml;ve will receive treatment with APR-246, Bcl-2 inhibitor and azacitidine. We intend to expand the number of
patients in individual arms of the trial, as warranted by adverse event and efficacy data, to enable a path to registration in frontline and R/R AML. We anticipate enrollment of
the first patient in the fourth quarter of 2019. The following figure shows the design of the Phase&nbsp;1/2 AML Trials. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Design of the Phase 1/2 AML Trials  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g504981.jpg" ALT="GRAPHIC" WIDTH="661" HEIGHT="244">
  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Intensive
chemotherapy
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>CR
with partial hematologic recovery</FONT></DD></DL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Clinical development in solid tumors  </I></B></FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Phase&nbsp;1b/2 Clinical Trial of APR-246 in Platinum-Sensitive Ovarian Cancer, or PiSARRO  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As part of the early development strategy, APR-246 was evaluated in clinical trials in ovarian cancer and this decision was based on the
anticipated market size and high prevalence of </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2>&nbsp;mutation of greater than 95% in high-grade serous ovarian cancer, or HGSOC. In March 2014, a
Phase&nbsp;1b trial was initiated as a part of a combined Phase&nbsp;1b/2 protocol in platinum-sensitive HGSOC to evaluate APR-246 with carboplatin and pegylated liposomal doxorubicin, or PLD. All
patients had previously been treated with platinum-based antineoplastic agents and all had accumulation of p53, as assessed by immunohistochemistry, or IHC, as a surrogate marker of mutant p53.
Archival samples were available for 29 patients, of which 27 had DNA of sufficient quality for sequencing and all 27 were confirmed to be </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
completed Phase&nbsp;1b part of the trial was conducted as a dose-escalation in 35 platinum-sensitive and partially platinum-sensitive patients. The primary trial objectives of the
Phase&nbsp;1b portion were to assess the adverse event profile of APR-246 with carboplatin and PLD, to determine a recommended Phase&nbsp;2 dose level, or RP2D, and to evaluate the
pharmacokinetics of APR-246 with carboplatin and PLD. Tumor response was a secondary objective. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
most frequently reported APR-246-related AEs were nausea, dizziness and fatigue, of which most were low-grade. A limited number of APR-246-related grade 3+ AEs were reported,
including neutropenia&nbsp;(37%), vomiting&nbsp;(14%), thrombocytopenia&nbsp;(9%), dizziness&nbsp;(6%), anemia&nbsp;(6%), fatigue&nbsp;(3%), headache&nbsp;(3%) and decreased
appetite&nbsp;(3%). Serious adverse events, regardless of causality, reported in more than one patient were: device related infection&nbsp;(17%), vomiting&nbsp;(17%), febrile
neutropenia&nbsp;(8%), infection&nbsp;(6%), small intestinal obstruction&nbsp;(6%) and thrombocytopenia&nbsp;(6%). </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although
efficacy was not a Phase&nbsp;1b trial objective, tumor response was evaluated. A 67% ORR was observed in 27 patients who were evaluable for radiological response according to
RECIST 1.1, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>118</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=123,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=834958,FOLIO='118',FILE='DISK116:[19ZBM1.19ZBM17601]DU17601A.;54',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_du17601_1_119"> </A>

<P style="font-family:times;"><FONT SIZE=2>including
11% with complete response and 56% with partial response. In addition, an 84% ORR was observed in 25 patients who were evaluable for CA-125 response according to Gynecologic Cancer
InterGroup, or GCIG, criteria. Reductions in lesion size and declines in CA-125 are shown in the following figure below. All patients who were evaluable by RECIST&nbsp;1.1 achieved a best response
of stable disease or better, where stable disease indicates lack of objective response but without disease progression. The median time between prior platinum therapy and disease progression prior to
enrollment in the trial, known as platinum free interval, or PFI, was 9.4&nbsp;months, and 40% of patients
had received more than one prior line of platinum-based chemotherapy. Two-thirds of patients enrolled in the trial were partially platinum-sensitive, with PFI 6-12&nbsp;months. The remaining
one-third of patients were platinum-sensitive, with PFI&nbsp;greater than 12&nbsp;months. The median progression-free survival, or PFS, was 10.2&nbsp;months across all patients and was
10&nbsp;months and 11.4&nbsp;months in partially platinum-sensitive and platinum sensitive patients, respectively. The median OS was 24.3&nbsp;months. This was the first clinical trial of
APR-246 with cytotoxic chemotherapy and we believe that the data demonstrated that the agent can be combined with carboplatin and PLD at standard doses. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g731568.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="264">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Data
supporting the carboplatin and PLD doublet as a treatment option in platinum-sensitive HGSOC were generated in the CALYPSO trial, a phase&nbsp;3 clinical trial sponsored by an
international consortium of 10 cancer research organizations. The CALYPSO trial enrolled 976 patients, randomized to receive either carboplatin and PLD&nbsp;(48%) or carboplatin and
paclitaxel&nbsp;(52%). All patients had received a maximum of two prior lines of chemotherapy; in the carboplatin and PLD arm, 88% had received one prior line and 12% had received two prior lines.
The median interval since last chemotherapy, or therapy-free interval, was 15.2&nbsp;months in the carboplatin and PLD arm, of whom 35% had a therapy-free interval of 6-12&nbsp;months and 65% had
a therapy-free interval in excess of 12&nbsp;months. The most frequently reported AEs in the carboplatin and PLD arm included neutropenia (80%), nausea (78%), fatigue (78%), anemia (66%),
constipation (55%) and vomiting (49%). The most common grade 3+ AEs included neutropenia (35%), thrombocytopenia (16%) and anemia (8%). In the carboplatin and PLD arm PFS was reported as
11.3&nbsp;months and OS as 30.7&nbsp;months. Median PFS in the carboplatin and PLD arm was greater than the 9.4&nbsp;months PFS in the carboplatin and paclitaxel arm (hazard ratio: 0.821, 95%
CO, 0.72&nbsp;&#150;&nbsp;0.94, </FONT><FONT SIZE=2><I>P</I></FONT><FONT SIZE=2>&nbsp;= 0.005). Response rates were not reported for the CALYPSO trial. Whereas the CALYPSO trial enrolled
a majority of patients with treatment-free interval exceeding 12&nbsp;months, our PiSARRO Phase&nbsp;1b trial enrolled a majority of patients with partially platinum-sensitive disease which is
generally recognized as a patient population with inferior treatment outcomes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the third quarter of 2016, enrollment commenced in the Phase&nbsp;2 portion of the PiSARRO trial and concluded at 211 patients. The Phase&nbsp;2 part was an open-label,
randomized, controlled multi-center trial to assess whether patients with platinum-sensitive recurrent HGSOC would benefit from treatment with APR-246 in combination with carboplatin/PLD chemotherapy
regimen. All patients were </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>119</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=124,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=1037542,FOLIO='119',FILE='DISK116:[19ZBM1.19ZBM17601]DU17601A.;54',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_du17601_1_120"> </A>

<P style="font-family:times;"><FONT SIZE=2>required
to have accumulation of p53 as assessed by immunohistochemistry, a surrogate marker of mutant p53. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patients
were randomized in a 1:1 ratio to receive either APR-246 with carboplatin and PLD or carboplatin and PLD only, with treatment to be repeated every 28 days for up to six cycles.
Enrollment was concluded in April&nbsp;2018. The primary endpoint for the Phase&nbsp;2 part is PFS, defined as the time from registration to the time of disease progression or relapse or death, or
the date of last tumor assessment without any such event. Serious adverse events, regardless of causality, reported in more than one patient were: small intestine obstruction (4%), thrombocytopenia
(2%), dyspnea (2%), nausea (2%), renal impairment (2%), vomiting (2%), abdominal pain, (1%) anemia (1%), constipation (1%), dehydration (1%), dizziness (1%), infectious pleural effusion (1%), large
intestine perforation (1%), urinary tract infection (1%). Upon receipt of final data, we intend to conduct a subset analysis of clinical and molecular characteristics that may influence response and
PFS in these patients, and anticipate completing this analysis in the first half of 2020. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Phase&nbsp;2 clinical trial of APR-246 in platinum-resistant ovarian cancer, or PiSARRO-R  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In July 2017 we initiated an open-label, multicenter Phase&nbsp;2 trial, PiSARRO-R, to evaluate the adverse event profile and preliminary
efficacy of varying infusion regimens of APR-246 with systemic PLD chemotherapy in platinum-resistant HGSOC. The trial enrolled 36 patients and all patients were required to have recurrent disease
with PFI between 4&nbsp;weeks and 6&nbsp;months, and accumulation of p53 as assessed by immunohistochemistry, a surrogate marker of mutant p53. The majority (69%) of patients had received 2 or
more prior lines of chemotherapy. Patients received either a 4500 mg/d fixed dose of APR-246 as a 6&nbsp;hour intravenous infusion (n=28, 78%), or the same or lower fixed dose over 3 or
4&nbsp;hours (n=8, 22%) for four consecutive days, followed by 40 mg/m<SUP>2</SUP> PLD on Day 4. The most frequently reported APR-246-related AEs were nausea, vomiting and dizziness. Limited
APR-246-related grade 3+ AEs were reported, of which only anemia (n=3, 8%) was observed in more than one patient. Serious adverse events, regardless of causality, reported in more than one patient
were: Intestinal obstruction (n=3, 8%) and infection (n=2, 6%). We believe the available adverse event data from the trial demonstrates that reduced duration infusion regimens with APR-246 are
feasible. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
part of the PiSARRO trials, we are collaborating with the European Network for Translational Research in Ovarian Cancer, or EUTROC, with the aim to identify predictive markers of
efficacy, tolerability and clinical pharmacology. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our second product candidate, APR-548  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are developing a next-generation small molecule mutant p53 reactivator, APR-548, a novel pro-drug of MQ that has the potential to be
administered in an oral dosage form. We intend to initially develop APR-548 in </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> mutant hematological malignancies. We believe that an oral
p53-reactivating drug will improve patient convenience and compliance, if approved, including for patients receiving prolonged therapy in the maintenance setting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
preclinical testing we have observed potency with APR-548 that is superior to that of APR-246 in a Saos-2 osteosarcoma cell line expressing an Arg273His mutant p53 and the MIA-PaCa-2
pancreatic cancer cell line harboring an Arg248Trp mutant p53. The half maximal inhibitory concentration, or IC<SUB>50</SUB>, in the Saos-2 cell line was calculated to be 5.6
<FONT FACE="SYMBOL">m</FONT>M &plusmn; 1.0 <FONT FACE="SYMBOL">m</FONT>M (n=3) for APR-548 and
9.5&nbsp;<FONT FACE="SYMBOL">m</FONT>M&nbsp;&plusmn;&nbsp;1.2&nbsp;<FONT FACE="SYMBOL">m</FONT>M (n=37) for APR-246, representing an
approximately 40% reduction in IC<SUB>50</SUB> with APR-548. In the MIA-PaCa-2 cell line, the IC<SUB>50</SUB> for APR-548 was calculated to be 6.0 <FONT FACE="SYMBOL">m</FONT>M (n=1)
versus 19 <FONT FACE="SYMBOL">m</FONT>M (n=1) for APR-246, representing a nearly 70% reduction in IC<SUB>50</SUB> with APR-548. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>120</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=125,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=991722,FOLIO='120',FILE='DISK116:[19ZBM1.19ZBM17601]DU17601A.;54',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_du17601_1_121"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Reduced </B></FONT><FONT SIZE=2><B><I>in vitro</I></B></FONT><FONT SIZE=2><B> IC<SUB>50</SUB><SUP>(1)</SUP> of
APR-548 in a p53 mutant saos-2 cell line  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g438810.jpg" ALT="GRAPHIC" WIDTH="510" HEIGHT="295">
  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Half-maximal
inhibitory concentration</FONT></DD></DL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
xenograft studies in which mice were implanted with a breast adenocarcinoma cell line, MDA-MB-231-</FONT><FONT SIZE=2><I>luc</I></FONT><FONT SIZE=2>, we tested the </FONT> <FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> efficacy of APR-548 when
administered by twice-daily intraperitoneal (i.p.) injection, or by twice-daily or three times daily oral (PO) gavage.
In these studies, mice received APR-548 for three cycles where each cycle consisted of 5 consecutive days of dosing followed by 2&nbsp;days without dosing. Tumor growth inhibition was measured on
day 33 post-inoculation, 3&nbsp;days after the final dosing in the final cycle. In mice receiving APR-548 via oral administration, we observed reductions in tumor weight relative to untreated
control mice. Results from these studies are summarized in the following table. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:57%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"140%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="140%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="47pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Xenograft Study

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>No. of mice </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>APR-548/dose<BR>
(mmol/kg) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Doses/day </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Dosing interval<BR>
(hours) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Route </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Tumor growth<BR>
inhibition (%) </B></FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B>#1</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>i.p.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20 &plusmn; 2</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>i.p.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>26 &plusmn; 2</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>#2</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
0.25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>i.p.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>15 &plusmn; 2</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>PO</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24 &plusmn; 2</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.75</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>PO</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>36 &plusmn; 5</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B>#3</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
0.50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>i.p.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>28 &plusmn; 6</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>PO</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>46 &plusmn; 8</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.75</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>PO</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40 &plusmn; 8</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.75</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>PO</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>28 &plusmn; 5</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>#4</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
0.19</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PO</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>3 &plusmn; 0.4</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.38</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>PO</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19 &plusmn; 3</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.75</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>PO</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40 &plusmn; 6</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>PO</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32 &plusmn; 4</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
xenograft study #3 we assessed APR-548 pharmacokinetics and confirmed that circulating blood concentrations of APR-548 exceeded levels expected to be efficacious, as determined from </FONT> <FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> results.
Results from this xenograft study are summarized graphically in the following figure. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>121</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=126,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=711649,FOLIO='121',FILE='DISK116:[19ZBM1.19ZBM17601]DU17601A.;54',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_du17601_1_122"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g1043123.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="312">
  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Twice
daily
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Three
times daily</FONT></DD></DL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In </FONT> <FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> studies in mouse and dog, we observed high oral bioavailability of APR-548 when dosed as either an aqueous solution or as a
solid in capsules. Observed oral bioavailability ranged from 75% to greater than 99%, and with no significant effect of feeding on absorption. Results from these studies are summarized in the
following table. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="69pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="121pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="87pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Species

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>No. of animals </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>APR-548 dose<BR>
(mg/kg) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Route </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Bioavailability (%) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Mouse (C57Bl/6N)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>PO (solution)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>80</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Mouse (CD-1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>PO (solid in capsule)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>97</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Mouse (CD-1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>PO (solution)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>99</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dog, fed</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>PO (solid in capsule)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>84</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dog, fasted</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>PO (solid in capsule)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>83</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dog, fed</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>PO (solution)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>80</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dog, fasted</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>PO (solution)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>75</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on results obtained through our preclinical </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> and </FONT><FONT SIZE=2><I>in vivo</I></FONT><FONT SIZE=2> studies, we have
initiated a series of studies required for IND submission. In our </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> studies, APR-548 has not demonstrated inhibition or induction or metabolic
enzymes at concentrations up to 300 <FONT FACE="SYMBOL">m</FONT>M. Studies testing APR-548 as an inhibitor or substrate of protein transporters have shown weak inhibition, with
IC<SUB>50</SUB> &gt; 150 <FONT FACE="SYMBOL">m</FONT>M, is limited to the OCT2 transporter. Additional studies have shown no significant effects when tested at
10&nbsp;<FONT FACE="SYMBOL">m</FONT>M in a screen of 87&nbsp;different receptors, transporters and enzymes, and no effect on the human </FONT> <FONT SIZE=2><I>ether-a-go-go</I></FONT><FONT SIZE=2> channel, or hERG, in a manual patch clamp assay at
concentrations up to 100&nbsp;<FONT FACE="SYMBOL">m</FONT>M. Metabolic
studies have shown that APR-548 is metabolized slowly and all metabolites produced in human cells are also produced in our mouse and dog toxicology species. Pivotal repeat-dose GLP toxicology studies
in both mouse and dog toxicology species have been initiated. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have developed a scalable, high-purity process for the manufacture of APR-548 and have completed physical characterization studies to survey the landscape of APR-548 polymorphs with
properties favorable for the development of an oral formulation to be used in clinical trials. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>122</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=127,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=635846,FOLIO='122',FILE='DISK116:[19ZBM1.19ZBM17601]DU17601A.;54',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_du17601_1_123"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Manufacturing  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently contract with third parties for the manufacture of our product candidates for certain preclinical trials and clinical trial
materials, including raw materials and consumables necessary for their manufacture, consistent with applicable cGMP requirements. We intend to continue to contract for these materials in the future,
including commercial manufacture if our product candidates receive marketing approval. We do not own or operate cGMP manufacturing facilities, nor do we currently plan to build our own cGMP
manufacturing capabilities for the production of our product candidates for clinical or commercial use. Although we rely upon contract manufacturers for the manufacture of our product candidates for
IND-enabling trials and clinical trials, we have personnel with extensive manufacturing experience who oversee our contract manufacturers. In
the future, we may also rely upon collaboration partners, in addition to contract manufacturers, for the manufacture of our product candidates or any products for which we obtain marketing approval. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
active pharmaceutical ingredient, or API, for APR-246 is currently manufactured by a single contract manufacturer. Although we may do so in the future, we do not currently have
arrangements in place for redundant supply of the API for APR-246. We contract with a different manufacturer for formulation of drug product, sterile fill of vials, labeling and packaging, and the
storage and distribution of APR-246 to clinical sites. We believe that these third parties have sufficient capacity to meet our current demand and, in the event they fail to meet our demand, we
believe that adequate alternative sources for the supply of materials for APR-246 exist. We intend to identify and qualify additional manufacturers to provide the API and other services for APR-246
prior to seeking marketing approval for APR-246. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that, because APR-246 is a small molecule, it can be manufactured through reliable and reproducible synthetic processes from readily available raw materials and then purified
and packaged for clinical use. We believe that the chemistry process is amenable to scale-up and requires only customary equipment in the manufacturing process. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have a service agreement and quality agreement with Syngene International Private Limited for the manufacture of API. We have a service agreement with Cobra Biopharma for the clinical
manufacture, labeling and packaging of formulated drug product. We have a manufacturing and supply agreement with Siegfried Hameln GmbH for the commercial manufacture, supply, labeling and packaging
of formulated drug product. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Manufacturing
clinical products is subject to extensive regulations that impose various procedural and documentation requirements, which govern record keeping, manufacturing processes
and controls, personnel, quality control and quality assurance. Our contract manufacturers are required to comply with current good manufacturing practice regulations, which are regulatory
requirements for the production of pharmaceuticals that will be used in humans. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Competition  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The pharmaceutical and biotechnology industries generally, and the cancer drug sector specifically, are highly competitive and characterized by
rapidly advancing technologies, evolving understanding of disease etiology and a strong emphasis on proprietary drugs. While we believe that our product candidates, development capabilities,
experience and scientific knowledge provide us with competitive advantages, we face significant potential competition from many different sources, including major pharmaceutical, specialty
pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions. Any product candidates that we
successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>123</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=128,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=74236,FOLIO='123',FILE='DISK116:[19ZBM1.19ZBM17601]DU17601A.;54',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_du17601_1_124"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
are a large number of companies developing or marketing treatments for cancer, including the indications for which we may develop product candidates. Many of the companies that we
compete against or may compete against in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical
trials, obtaining regulatory approvals and marketing approved drugs than we do. Small or early-stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial
sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or that may be necessary for, our programs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
commercial opportunity could be reduced or eliminated if our competitors develop and commercialize drugs that are safer, more effective, have fewer or less severe side effects, are
more convenient or are less expensive than any drugs that we may develop. Our competitors also may obtain FDA or other regulatory approval for their drugs more rapidly than we may obtain approval for
ours, which could result in our competitors establishing a strong market position before we are able to enter the market. The key competitive factors affecting the success of all of our product
candidates, if approved, are likely to be their efficacy, safety, convenience and price, in guiding the use of related therapeutics, the level of generic competition and the availability of
reimbursement from government and other third-party payors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
most common methods of treating patients with cancer are surgery, radiation and therapy with drugs or biologics. There are a variety of available drug therapies marketed for cancer.
In many cases, these drugs are administered in combination to enhance efficacy. Some of the currently-approved drug therapies are branded and subject to patent protection and may be established as
standard of care for the treatment of indications for which we may choose to seek regulatory approvals. Many of these approved drugs are well-established therapies and are widely accepted by
physicians, patients and third-party payors, and even if our drug candidates were to be approved, there can be no assurance that our drugs would displace existing treatments. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to currently marketed therapies, there are also a number of drugs in late-stage clinical development to treat cancer, including for the treatment of the indications for which
we are developing product candidates. These clinical-stage drug candidates may provide efficacy, safety, convenience and other benefits that are not provided by currently-marketed therapies. As a
result, they may provide significant competition for any of our product candidates for which we obtain regulatory approval. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are developing our lead product candidate, APR-246, to reactivate p53 for the treatment of various cancers. We are aware of other product candidates that are in clinical development
as potential treatments of various cancers through the reactivation of p53. Although there is a subset of drugs that directly target the p53&nbsp;pathway, there are many cancer drugs that claim to
affect the p53 pathway by upstream or complementary pathways. We are aware of molecules in development that also are being explored for p53 upregulation / activation in various stages of clinical
development being tested by CDG Therapeutics,&nbsp;Inc., Innovation Pharmaceuticals,&nbsp;Inc., MedVax Technologies,&nbsp;Inc., PMV Pharmaceuticals,&nbsp;Inc., and Senhwa
Biosciences,&nbsp;Inc., among others. We are also aware of selective small molecule inhibitors that are designed to target the p53-MDM2 interaction in various stages of clinical development being
tested by F-Hoffman La Roche&nbsp;Ltd and Hoffman La Roche&nbsp;Inc., or collectively Roche, Amgen&nbsp;Inc., Novartis AG, Aileron Therapeutics and Daiichi Sankyo&nbsp;Co.,&nbsp;Ltd.,
including testing MDM2 inhibitors in combination with a variety of other anti-cancer agents. Finally, we are aware of several small molecules that are designed to inhibit the activity of Bcl-2 and the
related protein Mcl-1 and relieve inhibition of the apoptotic cascade. Abbvie&nbsp;Inc.'s venetoclax has been approved in AML and chronic lymphocytic leukemia; companies with Bcl-2 or Mcl-1
inhibitors in various stages of preclinical or clinical development include Amgen&nbsp;Inc., Servier SAS, AstraZeneca&nbsp;Plc and Pfizer Inc., among others. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>124</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=129,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=59643,FOLIO='124',FILE='DISK116:[19ZBM1.19ZBM17601]DU17601A.;54',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dw17601_1_125"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
APR-246 was approved for the indications for which we currently have ongoing clinical trials, it will compete with currently-marketed drugs and will likely compete with other drugs
that are currently in clinical development, each as discussed below. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


MDS / AML  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The front-line treatments for patients with higher-risk MDS in the United States are combination chemotherapy or HMAs such as Dacogen
(decitabine) or Vidaza (azacitidine). We are aware of several ongoing clinical trials aimed at expanding the use of approved chemotherapy and immunomodulatory agents in higher-risk MDS, as well as
several new clinical programs testing novel technologies in this area, including product candidates from Abbvie&nbsp;Inc., argenx, Astex Pharmaceuticals,&nbsp;Inc., Celgene Corporation, CTI
BioPharma Corp., Cyclacel Pharmaceuticals,&nbsp;Inc., Eisai&nbsp;Co.,&nbsp;Ltd., Karyopharm Therapeutics&nbsp;Inc., Onconova Therapeutics,&nbsp;Inc., and Takeda Pharmaceutical Company
Limited. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Intellectual property  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We strive to protect the proprietary technologies that we believe are important to our business, including seeking and maintaining patent
protection intended to cover the methods-of-use, formulations, dosing, manufacturing processes, and crystalline solid form of one or more of our product candidates, including APR-246, and composition
of matter of our other product candidates, related technology, and other inventions that are important to our business. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
success will depend significantly on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions, and know-how
related to our business, defend and enforce our patents, preserve the confidentiality of our trade secrets, and operate without infringing the valid and enforceable patents and other proprietary
rights of third parties. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
third party may hold intellectual property, including patent rights, which are important or necessary to the development or commercialization of our product candidates. If it becomes
necessary for us to use patented or proprietary technology of third parties to develop or commercialize our product candidates, we may need to seek a license from such third parties. Our business
could be harmed, possibly materially, if we are unable to obtain such a license on terms that are commercially reasonable, or at all. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may seek to expand our intellectual property estate by filing patent applications directed to dosage forms, methods of treatment, diagnostics, and additional compounds and their
derivatives. Specifically, we have sought and will continue to seek patent protection in the United States and internationally for novel compositions of matter covering the compounds of our product
candidates other than APR-246 and a crystal form of APR-246, the chemistries and processes for manufacturing these compounds, and the use of these compounds in a variety of therapies. The chemical
structure of APR-246 is in the public domain. Accordingly, we do not own or license any composition of matter patents claiming the compound of APR-246 and will not in the future own or license any
composition of matter patents claiming the chemical structure of APR-246 as described in the public domain. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
patent positions of biopharmaceutical companies like us are generally uncertain and involve complex legal, scientific and factual questions. In addition, the coverage claimed in a
patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Consequently, we do not know whether any of our product candidates will
be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether
the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, circumvented or invalidated by third parties. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because
patent applications in the United States and certain other jurisdictions are maintained in secrecy for 18&nbsp;months, and since publication of discoveries in the scientific or
patent literature often lags actual discoveries, we cannot be certain of the priority of inventions covered by pending patent </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>125</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=130,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=238688,FOLIO='125',FILE='DISK116:[19ZBM1.19ZBM17601]DW17601A.;54',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dw17601_1_126"> </A>

<P style="font-family:times;"><FONT SIZE=2>applications.
Moreover, we may have to participate in interference proceedings declared by the United States Patent and Trademark Office, or USPTO, to determine priority of invention or in post-grant
challenge proceedings at the USPTO or at a foreign patent office, such as inter partes review and post grant review proceedings at the USPTO and opposition proceedings at the European Patent Office,
that challenge priority of invention or other features of patentability. Such proceedings could result in substantial cost, even if the eventual outcome is favorable to us. For more information
regarding the risks related to our intellectual property, see "Risk Factors&#151;Risks Related to Our Intellectual Property." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Patent portfolio  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of September&nbsp;18, 2019, our exclusively owned patent portfolio includes five U.S. issued patents, three pending U.S. provisional patent
applications, approximately 113 foreign issued patents and approximately 10 pending foreign patent applications. The claims of these owned patents and patent applications are directed toward various
aspects of our product candidates and research programs. Specifically, the claims of these patents and patent applications include compositions of matter for product candidates other than APR-246 and
a crystal form of APR-246, methods-of-use, drug product formulations, dosing, diagnostics and methods of manufacture. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


APR-246 Method of Use Family  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of September&nbsp;18, 2019, we exclusively own a patent family directed to methods-of-uses of APR-246. This patent family includes one U.S.
issued patent and approximately 33 patents granted in Europe (validated in Austria, Belgium, Bulgaria, Switzerland-Lichtenstein, Cyprus, Czech Republic, Germany, Denmark, Estonia, Spain, Finland,
France, United Kingdom, Greece, Hungary, Ireland, Iceland, Italy, Lithuania, Luxembourg, Monaco, Netherlands, Poland, Portugal, Romania, Sweden, Slovenia, Slovakia and Turkey), Australia, Canada,
India, and Japan. The issued patents in this family are expected to expire in 2025, not giving effect to any potential patent term
extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


APR-246 Formulation Family  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of September&nbsp;18, 2019, we exclusively own a patent family directed to formulations of APR-246. This patent family includes one U.S.
issued patent and approximately 40 issued patents in Europe (validated in Austria, Belgium, Switzerland-Lichtenstein, Cyprus, Czech Republic, Germany, Denmark, Estonia, Spain, Finland, France, United
Kingdom, Greece, Hungary, Ireland, Italy, Lithuania, Luxembourg, Latvia, Monaco, Malta, Netherlands, Norway, Poland, Portugal, Sweden, Slovakia, San Marino and Turkey), Australia, Canada, China,
Israel, Japan, South Korea, Philippines, Russia, Singapore, and South Africa. This patent family also includes approximately 5 pending patent applications in Brazil, China, Hong Kong, India, and
Thailand. The granted patents and pending applications, if issued, in this family are expected to expire in 2031, not giving effect to any potential patent term extensions and patent term adjustments
and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


APR-246 Dosing Family  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of September&nbsp;18, 2019, we exclusively own a pending U.S. provisional patent application directed to dosing regimens involving APR-246,
which was filed in 2019. This provisional patent application is not eligible to become an issued patent until, among other things, we file&nbsp;a non-provisional patent application within
12&nbsp;months of the filing of our provisional patent application. If we do not timely file any non-provisional patent applications, we may lose our priority date with respect to our provisional
patent application and any patent protection on the inventions disclosed in our provisional patent application. Any future U.S. patents that may issue from this provisional patent application
(assuming the necessary non-provisional patent applications are timely filed and all other </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>126</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=131,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=917481,FOLIO='126',FILE='DISK116:[19ZBM1.19ZBM17601]DW17601A.;54',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dw17601_1_127"> </A>

<P style="font-family:times;"><FONT SIZE=2>applicable
requirements are satisfied) are expected to expire in 2040, not giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate
maintenance, renewal, annuity, or other governmental fees. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


APR-246 Process and Solid Form Family  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of September&nbsp;18, 2019, we exclusively own a pending U.S. provisional patent application directed to improved processes for large scale
preparation of APR-246 and to a crystalline solid form comprising APR-246, which was filed in 2019. This provisional patent application is not eligible to become an issued patent until, among other
things, we file a non-provisional patent application within 12 months of the filing of our provisional patent application. If we do not timely file any non-provisional patent applications, we may lose
our priority date with respect to our provisional patent application and any patent protection on the inventions disclosed in our provisional patent application. Any future U.S. patents that may issue
from this provisional patent application (assuming the necessary non-provisional patent applications are timely filed and all other applicable requirements are satisfied) are expected to expire in
2040, not giving effect to any potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Combination Therapy Of APR-246 With A Bcl-2 Inhibitor  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of September&nbsp;18, 2019, we exclusively own a pending U.S. provisional patent application directed to a method of treatment using a
combination therapy of APR-246 with a Bcl-2 inhibitor. This provisional patent application is not eligible to become an issued patent until, among other things, we file&nbsp;a non-provisional patent
application within 12&nbsp;months of the filing of our provisional patent application. If we do not timely file any non-provisional patent applications, we may lose our priority date with respect to
our provisional patent application and any patent protection on the inventions disclosed in our provisional patent application. Any future U.S. patents that may issue from this provisional patent
application (assuming the necessary non-provisional patent applications are timely filed and all other applicable requirements are satisfied) are expected to expire in 2040, not giving effect to any
potential patent term extensions and patent term adjustments and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Next-Generation Patent Family/APR-548  </I></B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of September&nbsp;18, 2019, we exclusively own a patent family directed to next-generation p53 reactivators, including APR-548. Four
European pending patent applications have been filed in 2018 and one European pending patent application has been filed in 2019. In this patent
family, one European patent application is pending with claims directed to compositions of matter and methods-of-use of APR-548. Any future patents that may issue from these patent applications
(assuming all applicable requirements are satisfied) are expected to expire in 2039 and 2040, not giving effect to any potential patent term extensions and patent term adjustments and assuming payment
of all appropriate maintenance, renewal, annuity, or other governmental fees. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Intellectual property protection  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in
which we file, the patent term is 20&nbsp;years from the earliest date of filing a non-provisional patent application. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the United States, the Hatch-Waxman Act permits a patent holder to apply for patent term extension of a patent that covers an FDA-approved drug, which, if granted, can extend the
patent term of such patent to compensate for part of the patent term lost during the FDA regulatory review process. This extension can be for up to five years beyond the original expiration date of
the patent. The length of the patent term extension is related to the length of time the drug is under regulatory </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>127</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=132,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=827552,FOLIO='127',FILE='DISK116:[19ZBM1.19ZBM17601]DW17601A.;54',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dw17601_1_128"> </A>

<P style="font-family:times;"><FONT SIZE=2>review.
Patent term extension cannot extend the remaining term of a patent beyond a total of 14&nbsp;years from the date of product approval, only one patent applicable to an approved drug may be
extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Similar
provisions are available in Europe and other non-United States jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our product
candidates receive FDA approval, we expect to apply for patent term extensions on patents covering those product candidates. While we intend to seek patent term extensions to any of our patents in any
jurisdiction where such extensions are available, there is no guarantee that the applicable authorities, including the FDA and the USPTO in the United States, will agree with our assessment of whether
such extensions should be granted, and even if granted, the length of such extensions. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to our reliance on patent protection for our inventions, product candidates and research programs, we also rely on trade secrets and confidentiality agreements to protect our
technology,
know-how and other aspects our business that are not amenable to, or that we do not consider appropriate for, patent protection. Although we take steps to protect our proprietary information and trade
secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise
gain access to our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside
scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements
provide that all confidential information concerning our business or financial affairs developed or made known to the individual or entity during the course of the party's relationship with us is to
be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and which
are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive
property. However, such confidentiality agreements and invention assignment agreements can be breached and we may not have adequate remedies for any such breach. For more information regarding the
risks related to our intellectual property, see "Risk Factors&#151;Risks Related to Our Intellectual Property." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Government Regulation  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Government regulation and product approvals  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, including the EU,
extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution,
marketing, post-approval monitoring and reporting, and import and export of drug products. The processes for obtaining marketing approvals in the United States and in foreign countries and
jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Review and approval of drugs in the United States  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the United States, the FDA approves drug products under the Federal Food, Drug, and Cosmetic Act, or FDCA, and implementing regulations. The
failure to comply with applicable requirements under the FDCA and other applicable laws at any time during the product development process, approval process or after approval may subject an applicant
and/or sponsor to a variety of administrative or judicial sanctions, including refusal by the FDA to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of
warning letters and other types of letters, product recalls, product seizures, total or partial suspension of production or distribution, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>128</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=133,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=303327,FOLIO='128',FILE='DISK116:[19ZBM1.19ZBM17601]DW17601A.;54',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dw17601_1_129"> </A>

<P style="font-family:times;"><FONT SIZE=2>injunctions,
fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by the FDA and the Department of Justice or other
governmental entities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An
applicant seeking approval to market and distribute a new drug product in the United States must typically undertake the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA's good laboratory practice, or
GLP, regulations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> submission to the FDA of an IND, which must take effect before human clinical trials begin; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> approval by an independent institutional review board, or IRB, representing each clinical site before each clinical trial may be initiated; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> performance of adequate and well-controlled human clinical trials in accordance with good clinical practices, or GCP, to establish the safety
and efficacy of the proposed drug product for each proposed indication; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> preparation and submission to the FDA of an NDA requesting marketing for one or more proposed indications; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> review by an FDA advisory committee, where appropriate or if applicable; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the product, or components thereof,
are produced to assess compliance with current Good Manufacturing Practices, or cGMP, requirements and to assure that the facilities, methods and controls are adequate to preserve the product's
identity, strength, quality and purity; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> payment of user fees and securing FDA approval of the NDA; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy, or
REMS, and the potential requirement to conduct post-approval studies. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Satisfaction
of FDA pre-market approval requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity, and novelty of the
product candidate or disease. A clinical hold may occur at any time during the life of an IND and may affect one or more specific trials or all trials conducted under the IND. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Preclinical studies  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Before an applicant begins testing a compound with potential therapeutic value in humans, the drug candidate enters the preclinical testing
stage. Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> and animal studies to
assess the potential safety and activity of the drug for initial testing in humans and to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal
regulations and requirements, including GLP regulations. The results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and
plans for clinical trials, among other things, are submitted to the FDA as part of an IND. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity,
may continue after the IND is submitted. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The IND and IRB processes  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An IND is an exemption from the FDCA that allows an unapproved drug to be shipped in interstate commerce for use in an investigational clinical
trial and a request for FDA authorization to administer an investigational drug to humans. Such authorization must be secured prior to interstate shipment and administration of any new drug that is
not the subject of an approved NDA. In support </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>129</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=134,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=522712,FOLIO='129',FILE='DISK116:[19ZBM1.19ZBM17601]DW17601A.;54',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dw17601_1_130"> </A>

<P style="font-family:times;"><FONT SIZE=2>of
a request for an IND, a sponsor must submit a protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. The sponsor may be a company
seeking to develop the drug or, as in the case of an investigator-initiated trial, the sponsor may be an investigator who is conducting the trial. In addition, the results of the preclinical tests,
together with manufacturing information, analytical data, any available clinical data or literature and
plans for clinical trials, among other things, are submitted to the FDA as part of an IND. The FDA requires a 30-day waiting period after the filing of each IND before clinical trials may begin. This
waiting period is designed to allow the FDA to review the IND to determine whether human research subjects will be exposed to unreasonable health risks. At any time during this 30-day period, the FDA
may raise concerns or questions about the conduct of the trials as outlined in the IND and impose a clinical hold. In this case, the IND sponsor and the FDA must resolve any outstanding concerns
before clinical trials can begin. If the FDA has neither commented on nor questioned the IND within this 30-day period, the clinical trial proposed in the IND may begin. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Following
commencement of a clinical trial under an IND, the FDA may also place a clinical hold or partial clinical hold on that trial. A clinical hold is an order issued by the FDA to
the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the
IND. For example, a specific protocol or part of a protocol is not allowed to proceed, while other protocols may do so. No more than 30&nbsp;days after imposition of a clinical hold or partial
clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation may only resume after
the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or
otherwise satisfying the FDA that the investigation can proceed. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all IND requirements must be met
unless waived. When the foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain FDA regulatory requirements in order to use the study as
support for an IND or application for marketing approval. Specifically, FDA has promulgated regulations governing the acceptance of foreign clinical trials not conducted under an IND, establishing
that such studies will be accepted as support for an IND or application for marketing approval if the study was conducted in accordance with GCP, including review and approval by an independent ethics
committee, or IEC, and use of proper procedures for obtaining informed consent from subjects, and the FDA is able to validate the data from the study through an on-site inspection if FDA deems such
inspection necessary. The GCP requirements encompass both ethical and data integrity standards for clinical studies. The FDA's regulations are intended to help ensure the protection of human subjects
enrolled in non-IND foreign clinical trials, as well as the quality and integrity of the resulting data. They further help ensure that non-IND foreign studies are conducted in a manner comparable to
that required for IND studies. If a marketing application is based solely on foreign clinical data, the FDA requires that the foreign data be applicable to the U.S. population and U.S. medical
practice; the studies must have been performed by clinical investigators of recognized competence; and the FDA must be able to validate the data through an on-site inspection or other appropriate
means, if the FDA deems such an inspection to be necessary. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to the foregoing IND requirements, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it
commences at that institution, and the IRB must conduct continuing review and reapprove the study at least annually. The IRB must review and approve, among other things, the study protocol and
informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate approval of a clinical trial at its institution,
or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB's requirements or if the product candidate has been associated with unexpected serious harm to
patients. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>130</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=135,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=12525,FOLIO='130',FILE='DISK116:[19ZBM1.19ZBM17601]DW17601A.;54',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dw17601_1_131"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety monitoring board or committee. This group
provides authorization for whether or not a trial may move forward at designated check points based on access that only the group maintains to available data from the study. Suspension or termination
of development during any phase of clinical trials can occur if it is determined that the participants or patients are being exposed to an unacceptable health risk. Other reasons for suspension or
termination may be made by us based on evolving business objectives and/or competitive climate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Information
about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination on its ClinicalTrials.gov
website. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Human clinical trials in support of an NDA  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in
accordance with GCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any clinical
trial. Clinical trials are conducted under written study protocols detailing, among other things, the inclusion and exclusion criteria, the objectives of the study, the parameters to be used in
monitoring safety and the effectiveness criteria to be evaluated. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Human
clinical trials are typically conducted in the following sequential phases, which may overlap or be combined: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><I>Phase&nbsp;1:</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>The drug is initially introduced into healthy human subjects or, in certain indications such as cancer, patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism,
distribution, excretion and, if possible, to gain an early indication of its effectiveness and to determine optimal dosage.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><I>Phase&nbsp;2:</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage
tolerance and optimal dosage.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><I>Phase&nbsp;3:</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and
safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><I>Phase&nbsp;4:</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Post-approval studies, which are conducted following initial approval, are typically conducted to gain additional experience and data from treatment of patients in the intended therapeutic indication.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Progress
reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious AEs occur. In addition, IND safety reports
must be submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions; findings from other studies or animal or </FONT><FONT SIZE=2><I>in
vitro</I></FONT><FONT SIZE=2> testing that suggest a significant risk in humans exposed to the drug; and any clinically important increase in the case of a serious suspected adverse reaction over that
listed in the protocol or investigator brochure. Phase&nbsp;1, Phase&nbsp;2 and Phase&nbsp;3 clinical trials may not be completed successfully within any specified period, or at all.
Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health
risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the
IRB's requirements or if the drug has been associated with unexpected serious harm to patients. The FDA will typically inspect one or more clinical sites to assure compliance with GCP and the
integrity of the clinical data submitted. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Concurrent
with clinical trials, companies often complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the
drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing
quality batches of the drug candidate and, among other things, must develop methods for testing the identity, strength, quality, and purity of the final drug. Additionally, appropriate packaging must
be selected and tested </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>131</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=136,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=243977,FOLIO='131',FILE='DISK116:[19ZBM1.19ZBM17601]DW17601A.;54',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dw17601_1_132"> </A>

<P style="font-family:times;"><FONT SIZE=2>and
stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Submission of an NDA to the FDA  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assuming successful completion of required clinical testing and other requirements, the results of the preclinical studies and clinical trials,
together with detailed information
relating to the product's chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the drug product for one
or more indications. Data can come from company-sponsored clinical trials intended to test the safety and effectiveness of a use of a product, or from several alternative sources, including
investigator-initiated trials that are not sponsored by company. Under federal law, the submission of most NDAs is additionally subject to an application user fee, which for federal fiscal year 2019
is $2,588,478. The sponsor of an approved NDA is also subject to annual program fees, which for fiscal year 2019 are $309,915 per eligible product. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA conducts a preliminary review of an NDA within 60&nbsp;days of its receipt and informs the sponsor whether the application is sufficiently complete to permit substantive
review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application
is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA has agreed to specified performance
goals in the review process of NDAs. Most such applications are meant to be reviewed within ten months from the filing date, and most applications for "priority review" products are meant to be
reviewed within six months of the filing date. The review process and the Prescription Drug User Fee Act goal date may be extended by the FDA for three additional months to consider new information or
clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Before
approving an NDA, the FDA typically will inspect the facility or facilities where the product is or will be manufactured. These pre-approval inspections may cover all facilities
associated with an NDA submission, including drug component manufacturing (such as APIs), finished drug product manufacturing, and control testing laboratories. The FDA will not approve an application
unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required
specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, as a condition of approval, the FDA may require an applicant to develop a REMS. REMS use risk minimization strategies beyond the professional labeling to ensure that the
benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the product, seriousness of the disease,
expected benefit of the product, expected duration of treatment, seriousness of known or potential adverse events, and whether the product is a new molecular entity. REMS can include medication
guides, physician communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU may include, but are not limited to, special training or certification for
prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The FDA may require a REMS before approval or post-approval if it becomes
aware of a serious risk associated with use of the product. The requirement for a REMS can materially affect the potential market and profitability of a product. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA is required to refer an application for a novel drug to an advisory committee or explain why such referral was not made. Typically, an advisory committee is a panel of
independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation
as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when
making decisions. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>132</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=137,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=73573,FOLIO='132',FILE='DISK116:[19ZBM1.19ZBM17601]DW17601A.;54',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dw17601_1_133"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Fast track, breakthrough therapy and priority review designations  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The FDA is authorized to designate certain products for expedited review if they are intended to address an unmet medical need in the treatment
of a serious or life-threatening disease or condition. These programs are referred to as fast track designation, breakthrough therapy designation and priority review designation. In May 2014, the FDA
published a final Guidance for Industry titled "Expedited Programs for Serious Conditions-Drugs and Biologics," which provides guidance on the FDA programs that are intended to facilitate and expedite
development and review of new product candidates as well as threshold criteria generally applicable to concluding that a product candidate is a candidate for these expedited development and review
programs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Specifically,
the FDA may designate a product for Fast Track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or
life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For Fast Track products, sponsors may have greater interactions
with the FDA and the FDA may initiate review of sections of a Fast Track product's application before the application is complete. This rolling review may be available if the FDA determines, after
preliminary evaluation of clinical data submitted by the sponsor, that a Fast Track product may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of
the remaining information and the sponsor must pay applicable user fees. However, the FDA's time period goal for reviewing a Fast Track application does not begin until the last section of the
application is submitted. In addition, the Fast Track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial
process. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Second,
a product may be designated as a Breakthrough Therapy if it is intended, either alone or in combination with one or more other products, to treat a serious or life-threatening
disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such
as substantial treatment effects observed early in clinical development. The FDA may take certain actions with respect to Breakthrough Therapies, including holding meetings with the sponsor throughout
the development process; providing timely advice to the product sponsor regarding development and approval; involving
more senior staff in the review process; assigning a cross-disciplinary project lead for the review team; and taking other steps to design the clinical trials in an efficient manner. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Third,
the FDA may designate a product for priority review if it is a product that treats a serious condition and, if approved, would provide a significant improvement in safety or
effectiveness. The FDA determines, on a case- by-case basis, whether the proposed product represents a significant improvement when compared with other available therapies. Significant improvement may
be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient
compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority designation is intended to direct overall attention and
resources to the evaluation of such applications, and to shorten the FDA's goal for taking action on a marketing application from ten months to six months. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Accelerated approval pathway  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The FDA may grant accelerated approval to a drug for a serious or life-threatening condition that provides meaningful therapeutic advantage to
patients over existing treatments based upon a determination that the drug has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant
accelerated approval for such a condition when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, or
IMM, and that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and
the availability or lack of alternative treatments. Drugs granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>133</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=138,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=477095,FOLIO='133',FILE='DISK116:[19ZBM1.19ZBM17601]DW17601A.;54',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dy17601_1_134"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to
predict clinical benefit, but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical
endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug, such as an effect on IMM. The FDA has limited experience with
accelerated approvals based on intermediate clinical endpoints, but has indicated that such endpoints generally may support accelerated approval where the therapeutic effect measured by the endpoint
is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate clinical benefit of a
drug. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical
benefit of a drug, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Thus, accelerated approval has been used extensively in the development and approval of drugs
for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes
large trials to demonstrate a clinical or survival benefit. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
accelerated approval pathway is contingent on a sponsor's agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug's
clinical benefit. As a result, a drug candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase&nbsp;4 or post-approval
clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, would allow the FDA to
withdraw the drug from the market on an expedited basis. All promotional materials for drug candidates approved under accelerated regulations are subject to prior review by the FDA. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The FDA's decision on an NDA  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On the basis of the FDA's evaluation of the NDA and accompanying information, including the results of the inspection of the manufacturing
facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific
indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the
application. If and when those deficiencies have been addressed to the FDA's satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such
resubmissions in two or six months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not
satisfy the regulatory criteria for approval. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the FDA approves a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions be included in the product labeling,
require that post-approval studies, including Phase&nbsp;4 clinical trials, be conducted to further assess the drug's safety after approval, require testing and surveillance programs to monitor the
product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, which can materially affect the potential market
and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. After approval, many types of
changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>134</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=139,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=790817,FOLIO='134',FILE='DISK116:[19ZBM1.19ZBM17601]DY17601A.;43',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dy17601_1_135"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Post-approval requirements  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among
other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After
approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and
approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for
supplemental applications with clinical data. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state
agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and
often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements
upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality
control to maintain cGMP compliance. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Once
an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches
the market. Later discovery of previously unknown problems with a product, including AEs of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory
requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of
distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> restrictions on the marketing or manufacturing of the product, including total or partial suspension of production, complete withdrawal of the
product from the market or product recalls; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> fines, warning letters or holds on post-approval clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> product seizure or detention, or refusal to permit the import or export of products; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> injunctions or the imposition of civil or criminal penalties. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in
accordance with the provisions of the approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found
to have improperly promoted off-label uses may be subject to significant liability. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the distribution of prescription drug products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the
federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription drug product
samples and impose requirements to ensure accountability in distribution. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>135</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=140,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=223072,FOLIO='135',FILE='DISK116:[19ZBM1.19ZBM17601]DY17601A.;43',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dy17601_1_136"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Abbreviated new drug applications for generic drugs  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 1984, with passage of the Hatch-Waxman Amendments to the FDCA, Congress established an abbreviated regulatory scheme allowing the FDA to
approve generic drugs that are shown to contain the same active ingredients as, and to be bioequivalent to, drugs previously approved by the FDA pursuant to NDAs. To obtain approval of a generic drug,
an applicant must submit an abbreviated new drug application, or ANDA, to the agency. An ANDA is a comprehensive submission that contains, among other things, data and information pertaining to the
API, bioequivalence, drug product formulation, specifications and stability of the generic drug, as well as analytical methods, manufacturing process validation data and quality control procedures.
ANDAs are "abbreviated" because they generally do not include preclinical and clinical data to demonstrate safety and effectiveness. Instead, in support of such applications, a generic manufacturer
may rely on the preclinical and clinical testing previously conducted for a drug product previously approved under an NDA, known as the reference-listed drug, or RLD. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Specifically,
in order for an ANDA to be approved, the FDA must find that the generic version is identical to the RLD with respect to the active ingredients, the route of administration,
the dosage form, and the strength of the drug. An applicant may submit an ANDA suitability petition to request the FDA's prior permission to submit an abbreviated application for a drug that differs
from the RLD in route of administration, dosage form, or strength, or for a drug that has one different active ingredient in a fixed-combination drug product (i.e.,&nbsp;a drug product with multiple
active ingredients). At the same time, the FDA must also determine that the generic drug is "bioequivalent" to the innovator drug. Under the statute, a generic drug is bioequivalent to a RLD if "the
rate and extent of absorption of the drug do not show a significant difference from the rate and extent of absorption of the listed drug." Upon approval of an ANDA, the FDA indicates whether the
generic product is "therapeutically equivalent" to the RLD in its publication "Approved Drug Products with Therapeutic Equivalence Evaluations," also referred to as the "Orange Book." Physicians and
pharmacists may consider a therapeutic equivalent generic drug to be fully substitutable for the RLD. In addition, by operation of certain state laws and numerous health insurance programs, the FDA's
designation of therapeutic equivalence often results in substitution of the generic drug without the knowledge or consent of either the prescribing physician or patient. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the Hatch-Waxman Amendments, the FDA may not approve an ANDA until any applicable period of non-patent exclusivity for the RLD has expired. The FDCA provides a period of five years
of non-patent data exclusivity for a new drug containing a new chemical entity. For the purposes of this provision, an NCE is a drug that contains no active moiety that has previously been approved by
the FDA in any other NDA. An active moiety is the molecule or ion responsible for the physiological or pharmacological action of the drug substance. In cases where such NCE exclusivity has been
granted, an ANDA may not be filed with the FDA until the expiration of five years from the date the NDA is approved, unless the submission is accompanied by a Paragraph&nbsp;IV certification, in
which case the applicant may submit its application four years following the original product approval. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDCA also provides for a period of three years of exclusivity if the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence
studies, that were conducted by or for the applicant and are essential to the approval of the application. This three-year exclusivity period often protects changes to a previously approved drug
product, such as a new dosage form, route of administration, combination or indication. Three-year exclusivity would be available for a drug product that contains a previously approved active moiety,
provided the statutory requirement for a new clinical investigation is satisfied. Unlike five-year NCE exclusivity, an award of three-year exclusivity does not block the FDA from accepting ANDAs
seeking approval for generic versions of the drug as of the date of approval of the original drug product; it does, however, block the FDA from approving ANDAs during the period of exclusivity. The
FDA typically makes decisions about awards of data exclusivity shortly before a product is approved. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>136</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=141,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=278703,FOLIO='136',FILE='DISK116:[19ZBM1.19ZBM17601]DY17601A.;43',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dy17601_1_137"> </A>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


505(b)(2) NDAs  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As an alternative path to FDA approval for modifications to formulations or uses of products previously approved by the FDA pursuant to an NDA,
an applicant may submit an NDA under Section&nbsp;505(b)(2) of the FDCA. Section&nbsp;505(b)(2) was enacted as part of the Hatch-Waxman Amendments and permits the filing of an NDA where at least
some of the information required for approval comes from studies not conducted by, or for, the applicant, and for which the applicant has not obtained a right of reference. If the 505(b)(2) applicant
can establish that reliance on FDA's previous findings of safety and effectiveness is scientifically and legally appropriate, it may eliminate the need to conduct certain preclinical studies or
clinical trials of the new product. The FDA may also require companies to perform additional bridging studies or measurements, including clinical trials, to support the change from the previously
approved reference drug. The FDA may then approve the new product candidate for all, or some, of the label indications for which the reference drug has been approved, as well as for any new indication
sought by the 505(b)(2) applicant. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Hatch-Waxman patent certification and the 30-Month Stay  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon approval of an NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the
applicant's product or an approved method of using the product. Each of the patents listed by the NDA sponsor is published in the Orange Book. When an ANDA applicant files its application with the
FDA, the applicant is required to certify to the FDA concerning any patents listed for the reference product in the Orange Book, except for patents covering methods-of-use for which the ANDA applicant
is not seeking approval. To the extent that the Section&nbsp;505(b)(2) applicant is relying on studies conducted for an already approved product, the applicant is required to certify to the FDA
concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA applicant would. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Specifically,
the applicant must certify with respect to each patent that:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the required patent information has not been filed; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the listed patent has expired; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the listed patent is invalid, unenforceable or will not be infringed by the new product. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
certification that the new product will not infringe the already approved product's listed patents or that such patents are invalid or unenforceable is called a Paragraph&nbsp;IV
certification. If the applicant does not challenge the listed patents or indicates that it is not seeking approval of a patented method of use, the application will not be approved until all the
listed patents claiming the referenced product have expired (other than method of use patents involving indications for which the applicant is not seeking approval). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the ANDA or 505(b)(2) applicant has provided a Paragraph&nbsp;IV certification to the FDA, the applicant must also send notice of the Paragraph&nbsp;IV certification to the NDA
and patent holders once the ANDA or 505(b)(2) application has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice
of the Paragraph&nbsp;IV certification. The filing of a patent infringement lawsuit within 45&nbsp;days after the receipt of a Paragraph&nbsp;IV certification automatically prevents the FDA from
granting final approval of the application until the earlier of 30&nbsp;months after the receipt of the Paragraph&nbsp;IV notice, expiration of the patent, or a decision in the infringement case
that is favorable to the applicant. The ANDA or 505(b)(2) application also will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the branded reference drug has
expired. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>137</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=142,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=403177,FOLIO='137',FILE='DISK116:[19ZBM1.19ZBM17601]DY17601A.;43',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dy17601_1_138"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Pediatric studies and exclusivity  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the Pediatric Research Equity Act of 2003, an NDA or supplement thereto must contain data that are adequate to assess the safety and
effectiveness of the drug product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product
is safe and effective. With enactment of the Food and Drug Administration Safety and Innovation Act of 2012, sponsors must also submit pediatric study plans prior to the assessment data. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Those
plans must contain an outline of the proposed pediatric study or studies the applicant plans to conduct, including study objectives and design, any deferral or waiver requests, and
other information required by regulation. The applicant, the FDA, and the FDA's internal review committee must then review the information submitted, consult with each other, and agree upon a final
plan. The FDA or the applicant may request an amendment to the plan at any time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults,
or full or partial waivers from the pediatric data requirements. Additional requirements and procedures relating to deferral requests and requests for extension of deferrals are contained in FDASIA.
Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pediatric
exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing
protection to the term of any existing regulatory exclusivity, including the non-patent and orphan exclusivity. This six-month exclusivity may be granted if an NDA sponsor submits pediatric data that
fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to
fairly respond to the FDA's request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever
statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period
during which the FDA cannot approve another application. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Orphan drug designation and exclusivity  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the Orphan Drug Act, the FDA may designate a drug product as an "orphan drug" if it is intended to treat a rare disease or condition
(generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which there is no reasonable expectation that the cost of developing and making a drug
product available in the United States for treatment of the disease or condition will be recovered from sales of the product). A company must request orphan product designation before submitting an
NDA. If the request is granted, the FDA will disclose the identity of the therapeutic agent and its potential use. Orphan product designation does not convey any advantage in or shorten the duration
of the regulatory review and approval process. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the sponsor of a product with orphan designation receives the first FDA approval for that drug for the disease or condition for which it has such designation or for a select
indication or use within the rare disease or condition for which it was designated, the product generally will receive orphan product exclusivity. Orphan product exclusivity means that the FDA may not
approve any other applications for the same product for the same indication for seven years, except in certain limited circumstances. If a drug or drug product designated as an orphan product
ultimately receives marketing approval for an indication broader than what was designated in its orphan product application, it may not be entitled to exclusivity. Orphan exclusivity will not bar
approval of another product under certain circumstances, including if a subsequent product with the same active ingredient for the same </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>138</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=143,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=1007047,FOLIO='138',FILE='DISK116:[19ZBM1.19ZBM17601]DY17601A.;43',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dy17601_1_139"> </A>

<P style="font-family:times;"><FONT SIZE=2>indication
is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug
exclusivity is not able to meet market demand. Further, the FDA may approve more than one product for the same orphan indication or disease as long as the products contain different active
ingredients. Moreover, competitors may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a
different indication for which the orphan product has exclusivity. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Patent term restoration and extension  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A patent claiming a new drug product may be eligible for a limited patent term extension under the Hatch-Waxman Act, which permits a patent
restoration of up to five years for patent term lost during product development and the FDA regulatory review. The restoration period granted is typically one-half the time between the effective date
of an IND and the submission date of an NDA less any time the applicant did not act with due diligence during the period, plus the time between the submission date of an NDA and the ultimate approval
date less any time the applicant did not act with due diligence during the period. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14&nbsp;years from
the product's approval date. Only one patent applicable to an approved drug product is eligible for the extension, only those claims covering the approved drug, a method for using it, or a method for
manufacturing it may be extended, and the application for the extension must be submitted prior to the expiration of the patent in question. A patent that covers multiple drugs for which approval is
sought can only be extended in connection with one of the approvals. The USPTO reviews and approves the application for any patent term extension or restoration in consultation with the FDA. Similar
provisions are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our products receive FDA approval, we expect
to apply for patent term extensions on patents covering those products. We plan to seek patent term extensions to any of our issued patents in any jurisdiction where these are available, however there
is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and if granted, the length of such
extensions. For more information regarding the risks related to our intellectual property, see "Risk Factors&#151;Risks Related to Our Intellectual Property." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


FDA approval and regulation of companion diagnostics  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A therapeutic product may rely upon an </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> companion diagnostic for use in selecting the
patients that will be more likely to respond to that therapy. If safe and effective use of a therapeutic depends on an </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> diagnostic, then the FDA
generally will require approval or clearance of that diagnostic, known as a companion diagnostic, at the same time that the FDA approves the therapeutic product. In August 2014, the FDA issued final
guidance clarifying the requirements that will apply to approval of therapeutic products and </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> companion diagnostics. According to the guidance,
for novel drugs, a companion diagnostic device and its corresponding therapeutic should be approved or cleared contemporaneously by the FDA for the use indicated in the therapeutic product's labeling.
In July 2016, the FDA issued a draft guidance intended to assist sponsors of the drug therapeutic and </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> companion diagnostic device on issues
related to co-development of the products. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
FDA determines that a companion diagnostic device is essential to the safe and effective use of a novel therapeutic product or indication, FDA generally will not approve the
therapeutic product or new therapeutic product indication if the companion diagnostic device is not approved or cleared for that indication. Approval or clearance of the companion diagnostic device
will ensure that the device has been adequately evaluated and has adequate performance characteristics in the intended population. The review of </FONT><FONT SIZE=2><I>in
vitro</I></FONT><FONT SIZE=2> companion diagnostics in conjunction with the review of our therapeutic treatments for cancer will, therefore, likely involve coordination of review by the FDA's </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>139</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=144,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=983507,FOLIO='139',FILE='DISK116:[19ZBM1.19ZBM17601]DY17601A.;43',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dy17601_1_140"> </A>

<P style="font-family:times;"><FONT SIZE=2>Center
for Drug Evaluation and Research and the FDA's Center for Devices and Radiological Health Office of In Vitro Diagnostics Device Evaluation and Safety. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the FDCA, </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> diagnostics, including companion diagnostics, are regulated as medical devices. In the United States, the FDCA
and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket
clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an
exemption applies, diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution. The two primary types of FDA marketing authorization applicable to a medical
device are premarket notification, also called 510(k) clearance, and premarket approval, or PMA. The FDA has generally required </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> companion
diagnostics intended to select the patients who will respond to cancer treatment to obtain a PMA for that diagnostic simultaneously with approval of the drug. We expect that any companion diagnostic
developed for use with APR-246 will utilize the PMA pathway. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
PMA process, including the gathering of clinical and preclinical data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket
review during which the applicant must prepare and provide the FDA with reasonable assurance of the device's safety and effectiveness and information about the device and its components regarding,
among other things, device design, manufacturing and labeling. PMA applications are subject to an application fee of $322,147 for most PMAs for FY 2019. In addition, PMAs for certain devices must
generally include the results from extensive preclinical and adequate and well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA
approval is sought. In particular, for a diagnostic, a PMA application typically requires data regarding analytical and clinical validation studies. As part of the PMA review, the FDA will typically
inspect the manufacturer's facilities for compliance with the Quality System Regulation, or QSR, which imposes elaborate testing, control, documentation and other quality assurance requirements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PMA
approval is not guaranteed, and the FDA may ultimately respond to a PMA submission with a not approvable determination based on deficiencies in the application and require additional
clinical trial or other data that may be expensive and time-consuming to generate and that can substantially
delay approval. If the FDA's evaluation of the PMA application is favorable, the FDA typically issues an approvable letter requiring the applicant's agreement to specific conditions, such as changes
in labeling, or specific additional information, such as submission of final labeling, in order to secure final approval of the PMA. If the FDA's evaluation of the PMA or manufacturing facilities is
not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what
is necessary to make the PMA approvable. The FDA may also determine that additional clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the
trials are conducted and then the data submitted in an amendment to the PMA. If the FDA concludes that the applicable criteria have been met, the FDA will issue a PMA for the approved indications,
which can be more limited than those originally sought by the applicant. The PMA can include post-approval conditions that the FDA believes necessary to ensure the safety and effectiveness of the
device, including, among other things, restrictions on labeling, promotion, sale and distribution. Once granted, PMA approval may be withdrawn by the FDA if compliance with post approval requirements,
conditions of approval or other regulatory standards are not maintained or problems are identified following initial marketing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After
a device is placed on the market, it remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are
cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. A medical device manufacturer's manufacturing processes and those of its suppliers are
required to </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>140</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=145,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=496039,FOLIO='140',FILE='DISK116:[19ZBM1.19ZBM17601]DY17601A.;43',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dy17601_1_141"> </A>

<P style="font-family:times;"><FONT SIZE=2>comply
with the applicable portions of the QSR, which cover the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging and shipping
of medical devices. Domestic facility records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. The FDA also may inspect foreign facilities that export products
to the U.S. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The 21st&nbsp;Century Cures Act  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December&nbsp;13, 2016, then-President Obama signed 21st&nbsp;Century Cures Act, or the Cures Act, into law. The Cures Act is designed to
modernize and personalize healthcare, spur innovation and research, and streamline the discovery and development of new therapies through increased federal funding of particular programs. It
authorizes increased funding for the FDA to spend on innovation projects. The new law also amends the PHSA to reauthorize and expand funding for the NIH. The Cures Act establishes the NIH Innovation
Fund to pay for the cost of development and implementation of a strategic plan, early stage investigators and research. It also charges NIH with
leading and coordinating expanded pediatric research. Further, the Cures Act directs the Centers for Disease Control and Prevention to expand surveillance of neurological diseases. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
amendments to the FDCA and the PHSA, Title III of the Cures Act seeks to accelerate the discovery, development, and delivery of new medicines and medical technologies. To that end,
and among other provisions, the Cures Act reauthorizes the existing priority review voucher program for certain drugs intended to treat rare pediatric diseases until 2020; creates a new priority
review voucher program for drug applications determined to be material national security threat medical countermeasure applications; revises the FDCA to streamline review of combination product
applications; requires FDA to evaluate the potential use of "real world evidence" to help support approval of new indications for approved drugs; provides a new "limited population" approval pathway
for antibiotic and antifungal drugs intended to treat serious or life-threatening infections; and authorizes FDA to designate a drug as a "regenerative advanced therapy," thereby making it eligible
for certain expedited review and approval designations. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Regulations outside the United States  </I></B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Regulations and procedures governing approval of drug products in the EU  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of
other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of products.
Whether or not it obtains FDA approval for a product, the company would need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical trials
or marketing of the product in those countries or jurisdictions. Specifically, the process governing approval of drug products in the EU generally follows the same lines as in the United States and
involves satisfactorily completing preclinical studies and adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed indication, as well as the
submission to the relevant competent authorities of a marketing authorisation application, or MAA, and actual granting of a marketing authorization by these authorities before the product can be
marketed and sold in the EU. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical Trial Approval.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the currently applicable Clinical Trials Directive 2001/20/EC and the
Directive 2005/28/EC on Good Clinical Practice, a system for the approval of clinical trials in the EU has been implemented through national legislation of the member states. Under this system, an
applicant must obtain approval from the competent national authority of a EU member state in which the clinical trial is to be conducted, or in multiple member states if the clinical trial is to be
conducted in a number of member states. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>141</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=146,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=575193,FOLIO='141',FILE='DISK116:[19ZBM1.19ZBM17601]DY17601A.;43',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dy17601_1_142"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Furthermore,
the applicant may only start a clinical trial at a specific study site after the competent ethics committee has issued a favorable opinion. The clinical trial application
must be accompanied by an investigational drug product dossier with supporting information prescribed by Directive 2001/20/EC and Directive 2005/28/EC and corresponding national laws of the member
states and further detailed in applicable guidance documents. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
April 2014, the EU adopted a new Clinical Trials Regulation, (EU) No 536/2014, which will replace the current Clinical Trials Directive 2001/20/EC. To ensure that the rules for
clinical trials are identical throughout the EU, the new EU clinical trials legislation was passed as a regulation that is directly applicable in all EU member states without the need for
implementation into the member states' national laws. All clinical trials performed in the EU are required to be conducted in accordance with the Clinical Trials Directive 2001/20/EC until the new
Clinical Trials Regulation (EU) No 536/2014 becomes applicable. According to the current plans of the European Medicines Agency, or EMA, the new Clinical Trials Regulation will become applicable in
2020. The Clinical Trials Directive 2001/20/EC will, however, still apply three years from the date of entry into application of the Clinical Trials Regulation to (i)&nbsp;clinical trials
applications submitted before the entry into application and (ii)&nbsp;clinical trials applications submitted within one year after the entry into application if the sponsor opts for old system. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
new Clinical Trials Regulation aims to simplify and streamline the approval of clinical trial in the EU. The main characteristics of the regulation include: a streamlined application
procedure via a single entry point, the EU portal; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures that will spare sponsors from
submitting broadly identical information separately to various bodies and different member states; a harmonized procedure for the assessment of applications for clinical trials, which is divided in
two parts. Part&nbsp;I is assessed jointly by all member states concerned. Part&nbsp;II is assessed separately by each member state concerned; strictly defined deadlines for the assessment of
clinical trial applications; and the involvement of the ethics committees in the assessment procedure in accordance with the national law of the member state concerned but within the overall timelines
defined by the Clinical Trials Regulation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Marketing Authorization.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;To obtain a marketing authorization for a product under EU regulatory
systems, an applicant must submit an MAA either under a centralized procedure administered by the EMA or one of the procedures administered by competent authorities in EU member states (decentralized
procedure, national procedure or mutual recognition procedure). A marketing authorization may be granted only to an applicant established in the EU. In the case of pediatric patients, Regulation (EC)
No 1901/2006 provides that prior to obtaining a marketing authorization in the EU, applicants have to demonstrate compliance with all measures included in an EMA-approved Paediatric Investigation
Plan, or PIP, covering all subsets of the pediatric population, unless the EMA has granted (1)&nbsp;a product-specific waiver, (2)&nbsp;a class waiver or (3)&nbsp;a deferral for one or more of
the measures included in the PIP. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid for all EU member states. Pursuant to Regulation (EC)
No&nbsp;726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan drug products,
advanced therapy products and products with a new active substance indicated for the treatment of certain diseases, including products for the treatment of cancer. For products with a new active
substance indicated for the treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients, the centralized procedure may be
optional. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the centralized procedure, the Committee for Medicinal Products for Human Use, or the CHMP, established at the EMA is responsible for conducting the initial assessment of a
product. The CHMP is also responsible for several post-authorization and maintenance activities, such as the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>142</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=147,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=775673,FOLIO='142',FILE='DISK116:[19ZBM1.19ZBM17601]DY17601A.;43',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dy17601_1_143"> </A>

<P style="font-family:times;"><FONT SIZE=2>assessment
of modifications or extensions to an existing marketing authorization. Under the centralized procedure in the EU, the maximum timeframe for the evaluation of an MAA is 210&nbsp;days,
excluding clock stops, when additional information or written or oral explanation is to be provided by the applicant in response to questions of the CHMP. Accelerated evaluation might be granted by
the CHMP in exceptional cases, when a drug product is of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation. If the CHMP accepts such
request, the time limit of 210&nbsp;days will be reduced to 150&nbsp;days but it is possible that the CHMP can revert to the standard time limit for the centralized procedure if it considers that
it is no longer appropriate to conduct an accelerated assessment. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulatory data protection in the EU.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In the EU, new chemical entities approved on the basis of a complete independent data package
qualify for eight
years of data exclusivity upon marketing authorization and an additional two years of market exclusivity pursuant to Regulation (EC) No&nbsp;726/2004, as amended, and Directive 2001/83/EC, as
amended. Data exclusivity prevents regulatory authorities in the EU from referencing the innovator's data to assess a generic (abbreviated)
application for a period of eight years. During an additional two-year period of market exclusivity, a generic marketing authorization application can be submitted, and the innovator's data may be
referenced, but no generic drug product can be marketed until the expiration of the market exclusivity. The overall ten-year period will be extended to a maximum of 11&nbsp;years if, during the
first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their
authorization, are held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a new chemical entity so that the innovator gains the
prescribed period of data exclusivity, another company nevertheless could also market another version of the product if such company obtained marketing authorization based on an MAA with a complete
independent data package of pharmaceutical tests, preclinical tests and clinical trials. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Periods of authorization and renewals.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;A marketing authorization shall be valid for five years in principle and the marketing
authorization may be
renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the authorizing member state. To this end, the marketing authorization
holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing
authorization was granted, at least six months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization shall be valid for an unlimited period, unless the
European Commission or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal. Any authorization which is not followed by
the actual placing of the drug on the EU market (in case of centralized procedure) or on the market of the authorizing member state within three years after authorization ceases to be valid (the
so-called sunset clause). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Orphan drug designation and exclusivity.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Regulation (EC) No 141/2000 on orphan drug products provides that a drug shall be designated
as an orphan
drug if its sponsor can establish that the product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in
ten thousand persons in the EU when the application is made, or that the product is intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and
chronic condition in the EU and that without incentives it is unlikely that the marketing of the drug in the EU would generate sufficient return to justify the necessary investment. For either of
these conditions, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if
such method exists, the drug will be of significant benefit to those affected by that condition. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>143</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=148,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=767426,FOLIO='143',FILE='DISK116:[19ZBM1.19ZBM17601]DY17601A.;43',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dy17601_1_144"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulation
(EC) No 847/2000 sets out criteria and procedures governing designation of orphan drugs in the EU. Specifically, an application for designation as an orphan product can be
made any time prior to the filing of an application for approval to market the product. Marketing authorization for an orphan drug leads to a ten-year period of market exclusivity. During this market
exclusivity period, the EMA or the member state competent authorities, cannot accept another application for a marketing authorization, or grant a marketing authorization, for a similar drug product
for the same indication. The period of market exclusivity is extended by two years for medicines that have also complied with an agreed PIP. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
period may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for ODD, for example because the
product is sufficiently profitable not to justify market exclusivity. Market exclusivity can be revoked only in very selected cases, such as consent from the marketing authorization holder, inability
to supply sufficient quantities of the product, demonstration of "clinical superiority" by a similar drug product, or, after a review by the Committee for Orphan Medicinal Products, requested by a
member state in the fifth year of the marketing exclusivity period (if the designation criteria are believed to no longer apply). </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulatory requirements after a marketing authorization has been obtained.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In case an authorization for a drug in the EU is obtained,
the holder of
the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of drug products. These
include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Compliance with the EU's stringent pharmacovigilance or safety reporting rules, pursuant to which post-authorization studies and additional
monitoring obligations can be imposed, has to be ensured. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The manufacturing of authorized drugs, for which a separate manufacturer's license is mandatory, must also be conducted in strict compliance
with the EMA's GMP requirements and comparable requirements of other regulatory bodies in the EU, which mandate the methods, facilities and controls used in manufacturing, processing and packing of
drugs to assure their safety and identity. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The marketing and promotion of authorized drugs, including industry-sponsored continuing medical education and advertising directed toward the
prescribers of drugs and/or the general public, are strictly regulated in the EU notably under Directive 2001/83EC, as amended, and EU member state laws. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Authorization to market companion diagnostics in the EU.  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the European Economic Area, or EEA, </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> medical devices are currently required to
conform with the essential requirements of the European Union Directive on </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> diagnostic medical devices (Directive No 98/79/EC, as amended). To
demonstrate compliance with the essential requirements, the manufacturer must undergo a conformity assessment procedure. The conformity assessment varies according to the type of medical device and
its classification. The conformity assessment of </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> diagnostic medical devices can require the intervention of an accredited EEA Notified Body. If
successful, the conformity assessment concludes with the drawing up by the manufacturer of an EC Declaration of Conformity entitling the manufacturer to affix the CE mark to its products and to sell
them throughout the EEA. On April&nbsp;5, 2017, the EU adopted the new In Vitro Device Regulation (EU) 2017/746, or IVDR, which repeals and replaces Directive No 98/79/EC. Unlike directives, which
must be implemented into the national laws of the EU member states, a regulation is directly applicable, i.e.,&nbsp;without the need for adoption of EU member state laws implementing them, in all
EEA member states. The IVDR, among other things, is intended to establish a uniform, transparent, predictable and sustainable regulatory framework across the EU for </FONT><FONT SIZE=2><I>in
vitro</I></FONT><FONT SIZE=2> diagnostic medical devices and ensure a high level of safety and health while supporting innovation. The IVDR </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>144</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=149,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=384842,FOLIO='144',FILE='DISK116:[19ZBM1.19ZBM17601]DY17601A.;43',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dy17601_1_145"> </A>

<P style="font-family:times;"><FONT SIZE=2>will
not become fully applicable until five years following its entry into force. Once applicable, the IVDR will among other things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> strengthen the rules on placing devices on the market and reinforce surveillance once they are available; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establish explicit provisions on manufacturers' responsibilities for the follow-up of the quality, performance and safety of devices placed on
the market; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> improve the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> set up a central database to provide patients, healthcare professionals and the public with comprehensive information on products available in
the EU. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Brexit and the regulatory framework in the United Kingdom  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On June&nbsp;23, 2016, the electorate in the U.K., voted in favor of leaving the EU, commonly referred to as Brexit. The U.K. government
communicated the notice of withdrawal to the EU on March&nbsp;29, 2017. Since the regulatory framework for drug products in the U.K. covering quality, safety and efficacy of drug products, clinical
trials, marketing authorization, commercial sales and distribution of drug products is derived from EU directives and regulations, Brexit could materially impact the future regulatory regime which
applies to products and the approval of product candidates in the U.K. It remains to be seen how, if at all, Brexit will impact regulatory requirements for product candidates and products in the U.K. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Pharmaceutical coverage, pricing and reimbursement  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the
prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients and healthcare providers are unlikely to use our products unless coverage
is provided and reimbursement is adequate to cover a significant portion of the cost of our products. Significant uncertainty exists as to the coverage and reimbursement status of products approved by
the FDA and other comparable government authorities. Even if our product candidates are approved, sales of our products will depend, in part, on the extent to which third-party payors, including
federal health care programs in the United States, such as Medicare and Medicaid, and commercial health insurers and managed care organizations, provide coverage and establish adequate reimbursement
levels for such products. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that a payor will
pay for the product once coverage
is approved. Third-party payors are increasingly challenging the prices charged for, examining the medical necessity of, and reviewing the cost-effectiveness of medical products and services and
imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a
particular indication. Coverage and reimbursement by a third-party payer may depend upon a number of factors, including, without limitation, the third-party payer's determination that use of a
therapeutic product is:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a covered benefit under its health plan; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> safe, effective and medically necessary; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> appropriate for the specific patient; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> cost-effective; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> neither experimental nor investigational. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>145</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=150,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=79657,FOLIO='145',FILE='DISK116:[19ZBM1.19ZBM17601]DY17601A.;43',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dy17601_1_146"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate
the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable marketing approvals. Obtaining coverage and reimbursement approval of a
product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each payer supporting scientific, clinical and cost-effectiveness data
for the use of our products on a payor-by-payor basis, with no assurance that coverage and adequate
reimbursement will be obtained. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover our product candidates could
reduce health care provider prescribing and/or patient utilization of our products once approved and have a material adverse effect on our sales, results of operations and financial condition.
Additionally, a payor's decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor's determination to provide coverage for a
drug product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor.
Third-party reimbursement and coverage may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. In addition,
prices for drugs may be reduced by mandatory discounts or rebates required by federal health care programs or private payers and by any future relaxation of laws that presently restrict imports of
drugs from countries where they may be sold at lower prices than in the United States. It is difficult to predict how Medicare coverage and reimbursement policies will be applied to products for which
the company receives marketing approval in the future and coverage and reimbursement under different federal health care programs is not always consistent. If reimbursement is not available or is
available only at limited levels, we may not be able to successfully commercialize our products for which we receive marketing approval. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
containment of healthcare costs also has become a priority of federal, state and foreign governments and the prices of drugs have been a focus in this effort. Governments have shown
significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price
controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company's revenue generated from the sale
of any approved products. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for
which a company or its collaborators receive marketing approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Outside
the United States, ensuring adequate coverage and payment for our product candidates will face challenges. Pricing of prescription pharmaceuticals is subject to governmental
control in many countries. Pricing negotiations with governmental authorities can extend well beyond the receipt of marketing approval for a product and may require us to conduct a clinical trial that
compares the cost effectiveness of our product candidates or products to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in our
commercialization efforts. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the EU, pricing and reimbursement schemes vary widely from member state to member state. Some countries provide that products may be marketed only after a reimbursement price has been
agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular drug candidate to currently available therapies (so called health technology
assessment, or HTA) in order to obtain reimbursement or pricing approval. EU member states may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on
the profitability of the company placing the product on the market. Other member states allow companies to fix their own prices for products, but monitor and control prescription volumes and issue
guidance to physicians to limit prescriptions. Recently, many countries in the EU have increased </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>146</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=151,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=94286,FOLIO='146',FILE='DISK116:[19ZBM1.19ZBM17601]DY17601A.;43',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dy17601_1_147"> </A>

<P style="font-family:times;"><FONT SIZE=2>the
amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises
experienced by many countries in the EU. The downward pressure on healthcare costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being
erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been
obtained. Reference pricing used by various EU member states, and parallel trade (arbitrage between low-priced and high-priced member states), can further reduce prices. There can be no assurance that
any country that has price controls or reimbursement limitations for drug products will allow favorable reimbursement and pricing arrangements for any of our products, if approved in those countries. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Healthcare law and regulation  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to the
FDA, including but not limited to, the Centers for Medicare and Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services (such as the Office of Inspector General
and the Health Resources and Service Administration), the U.S. Department of Justice, and individual U.S. Attorney offices, and state and local governments. For example, sales, marketing and
scientific/educational grant programs may have to comply with the anti-fraud and abuse provisions of the Social Security Act, the false claims laws, the privacy and security provisions of HIPAA, and
similar state laws, each as amended, as applicable. Healthcare providers and third-party payors play a primary role in the recommendation and prescription of drug products that are granted marketing
approval. Arrangements with providers, consultants, third-party payors and customers are subject to these broadly applicable healthcare laws and regulations that may constrain our business and/or
financial arrangements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restrictions
under applicable federal and state healthcare laws and regulations, include, without limitation, the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>The Federal Anti-Kickback Statute</I></FONT><FONT SIZE=2>&#151;An intent-based federal criminal statute that
prohibits, among other things, any person from knowingly and willfully soliciting, offering, receiving or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in
return for, either the referral of an individual for, or the purchase, order or recommendation or arranging of, any good or service, for which payment may be made, in whole or in part, by a federal
health care program, such as Medicare and Medicaid. The term "remuneration" has been broadly interpreted to include anything of value. The PPACA, among other things, amended the intent requirement of
the federal Anti-Kickback Statute, so that a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it. The Anti-Kickback Statute has also been
interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and individuals, such as prescribers, patients, purchasers, and formulary managers on the other the other
hand. A conviction for violation of the Anti-Kickback Statute results in criminal fines and requires mandatory exclusion from participation in federal health care programs. Although there are a number
of statutory exceptions and regulatory safe harbors to the federal Anti-Kickback Statute that protect certain common industry practices from prosecution, the exceptions and safe harbors are narrowly
drawn, and arrangements may be subject to scrutiny or penalty if they do not fully satisfy all elements of an available exception or safe harbor. The Anti-Kickback Statute safe harbors, including the
discount safe harbor, are the subject of possible regulatory reforms. Any changes to the safe harbors may impact our future contractual and other arrangements with pharmacy benefit managers,
third-party payors, wholesalers and distributors, healthcare providers and prescribers, and other entities, as well as our future pricing strategies. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>147</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=14,SEQ=152,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=955985,FOLIO='147',FILE='DISK116:[19ZBM1.19ZBM17601]DY17601A.;43',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dz17601_1_148"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>The Federal Civil False Claims Act</I></FONT><FONT SIZE=2>&#151;Imposes civil penalties, including through civil
whistleblower or </FONT><FONT SIZE=2><I>qui tam</I></FONT><FONT SIZE=2> actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, false or
fraudulent claims for payment by a federal healthcare program or knowingly making using or causing to be made or used a false statement or record material to payment of a false claim or avoiding,
decreasing or concealing an obligation to pay money to the federal government, with potential liability including mandatory treble damages and significant per-claim penalties, currently set at $11,181
to $22,363 per false claim or statement for penalties assessed after January&nbsp;29, 2018, with respect to violations occurring after November&nbsp;2, 2015. Among other reasons, pharmaceutical
companies have been investigated and/or subject to government enforcement actions asserting liability under the federal civil False Claims Act in connection with their alleged off-label promotion of
drugs, purportedly concealing price concessions in the pricing information submitted to the government for government price reporting purposes (e.g.,&nbsp;under the Medicaid Drug Rebate Program),
and allegedly providing free product to customers with the expectation that the customers would bill federal health care programs for the product. In addition, the government may assert that a claim
including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act. As a result of a
modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes "any request or demand" for money or property presented to the U.S. government. In addition, manufacturers can be
held liable under the federal False Claims Act even when they do not submit claims directly to government payors if they are deemed to "cause" the submission of false or fraudulent claims. Criminal
prosecution is also possible for making or presenting a false, fictitious or fraudulent claim to the federal government. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>The Federal Criminal Statute on False Statements Relating to Health Care
Matters</I></FONT><FONT SIZE=2>&#151;Makes it a crime to knowingly and willfully falsify, conceal, or cover up a material fact, make any materially false, fictitious, or fraudulent statements
or representations, or make or use any materially false writing or document knowing the same to contain any materially false, fictitious, or fraudulent statement or entry in connection with the
delivery of or payment for federally funded healthcare benefits, items, or services. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>HIPAA Criminal Federal Health Care Fraud Statute</I></FONT><FONT SIZE=2>&#151;Enacted as part of the Health
Insurance Portability and Accountability Act of 1996, makes it a crime to knowingly and willfully falsify, conceal, or cover up a material fact, make any materially false, fictitious, or fraudulent
statements or representations, or make or use any materially false writing or document knowing the same to contain any materially false, fictitious, or fraudulent statement or entry in connection with
the delivery of or payment for federally funded healthcare benefits, items, or services. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>The Federal Civil Monetary Penalties Law</I></FONT><FONT SIZE=2>&#151;Authorizes the imposition of substantial
civil monetary penalties against an entity, such as a pharmaceutical manufacturer, that engages in activities including, among others (1)&nbsp;knowingly presenting, or causing to be presented, a
claim for services not provided as claimed or that is otherwise false or fraudulent in any way; (2)&nbsp;arranging for or contracting with an individual or entity that is excluded from participation
in federal healthcare programs to provide items or services reimbursable by a federal healthcare program; (3)&nbsp;violations of the federal Anti-Kickback Statute; or (4)&nbsp;failing to report
and return a known overpayment. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>HIPAA Health Information Privacy and Security</I></FONT><FONT SIZE=2>&#151;HIPAA imposes privacy, security, and
breach reporting obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouse as well as their business associates that perform certain services involving the
use or disclosure of individually identifiable health information, including, among other requirements, mandatory contractual terms and technical safeguards to protect the privacy, security and
transmission of individually identifiable health information, and require notification </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>148</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=153,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=782932,FOLIO='148',FILE='DISK116:[19ZBM1.19ZBM17601]DZ17601A.;42',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dz17601_1_149"> </A>
<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>to
affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended
HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in U.S. federal
courts to enforce the federal HIPAA laws and seek attorneys' fees and costs associated with pursuing federal civil actions. </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>The Federal Physician Payments Sunshine Act</I></FONT><FONT SIZE=2>&#151;Requires "applicable manufacturers" of
drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid or the State Children's Health Insurance Program, among others, to track and report annually to
the federal government (for disclosure to the public) certain payments and other transfers of value they make to "covered recipients." The term covered recipients includes physicians, teaching
hospitals, and, for reports submitted on or after January&nbsp;1, 2022, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse
midwives. Failure to submit required information may result in civil monetary penalties. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>The Federal Food, Drug and Cosmetic Act</I></FONT><FONT SIZE=2>&#151;A set of laws, which prohibits, among other
things, the adulteration or misbranding of drugs, biologics and medical devices. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>Analogous State and Foreign Laws</I></FONT><FONT SIZE=2>&#151;There are state and foreign law equivalents of the
above federal laws, such as the Anti-Kickback Statute and the False Claims Act, which may apply to items or services reimbursed by any third-party payor, including commercial insurers
(i.e.,&nbsp;so-called "all-payor anti-kickback laws"), as well as state and foreign laws that govern the privacy and security of health information or personally identifiable information in certain
circumstances, including state health information privacy and data breach notification laws which govern the collection, use, disclosure, and protection of health-related and other personal
information, many of which differ from each other in significant ways and, with respect to state laws, are often not pre-empted by HIPAA, thus requiring additional compliance
efforts.</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I>State and Foreign Laws Regulating Pharmaceutical Manufacturer Compliance Programs and Other
Practices</I></FONT><FONT SIZE=2>&#151;Some state and foreign laws require pharmaceutical companies to implement compliance programs, comply with the pharmaceutical industry's voluntary
compliance guidelines and the relevant compliance guidance promulgated by the federal government, or to track and report gifts, compensation, or other remuneration to physicians and other healthcare
providers. Several U.S. states and localities have enacted legislation requiring pharmaceutical companies to establish marketing compliance programs, file periodic reports, and/or make periodic public
disclosures on sales, marketing, pricing, clinical trials, and other activities. Other state laws prohibit certain marketing-related activities including the provision of gifts, meals or other items
to certain healthcare providers, and restrict the ability of manufacturers to offer co-pay support to patients for certain prescription drugs. In addition, several recently passed state laws require
disclosures related to state agencies and/or commercial purchasers with respect to certain price increases that exceed a certain level as identified in the relevant statutes. Some of these laws and
regulations contain ambiguous requirements that government officials have not yet clarified. Given the lack of clarity in the laws and their implementation, our reporting actions could be subject to
the penalty provisions of the pertinent federal and state laws and regulations. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
expect that one or more of our products, if approved, may be eligible for coverage under Medicare, the federal health care program that provides health care benefits to the aged and
disabled, and covers outpatient services and supplies, including certain drug products, that are medically necessary to treat a beneficiary's health condition. In addition, one or more of our
products, if approved, may be covered and reimbursed under other federal health care programs, such as Medicaid and the 340B Drug Pricing Program. The Medicaid Drug Rebate Program requires
pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of the Department of Health and Human Services as a condition for states to receive federal
matching funds for the manufacturer's outpatient drugs furnished to Medicaid patients. Under the 340B Drug Pricing </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>149</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=154,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=1017412,FOLIO='149',FILE='DISK116:[19ZBM1.19ZBM17601]DZ17601A.;42',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dz17601_1_150"> </A>

<P style="font-family:times;"><FONT SIZE=2>Program,
the manufacturer must extend discounts to entities that participate in the program. As part of the requirements to participate in these government programs, many pharmaceutical manufacturers
must calculate and report certain price reporting metrics to the government, such as average manufacturer price and best price. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Efforts
to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that
governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, guidance, case law or other applicable law. If our operations are found
to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines,
individual imprisonment, exclusion from participation in federal health care programs, such as Medicare and Medicaid, disgorgement,
reputational harm, additional oversight and reporting obligations pursuant to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with applicable laws and
regulations, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to market our products, if approved, and adversely impact our financial results.
Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws and regulations, these risks cannot be entirely eliminated. Any action
against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management's attention from the operation of our business, even if our defense
is successful. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, it may be costly to us in
terms of money, time and resources, and they may be subject to criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


U.S.&nbsp;healthcare reform  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the United States and some foreign jurisdictions, there have been and continue to be a number of legislative and regulatory changes and
proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability, or the
ability of our future collaborators, to profitably sell any drugs for which we, or they, obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be
adopted in the future, may result in more rigorous coverage criteria and additional downward pressure on the price that we, or our future collaborators, may receive for any approved drugs. For
example, the PPACA has substantially changed healthcare financing and delivery by both governmental and private insurers. Among the PPACA provisions of importance to the pharmaceutical industry, in
addition to those otherwise described above, are the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents, apportioned
among these entities according to their market share in certain federal programs identified in the PPACA; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> expansion of beneficiary eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to
certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers' Medicaid rebate liability; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> expansion of manufacturers' rebate liability under the Medicaid Drug Rebate Program by increasing the minimum rebate for both branded and
generic drugs and revising the definition of "average manufacturer price" for calculating and reporting Medicaid drug rebates on outpatient prescription drug prices; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> extension of manufacturers' Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care
organizations; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>150</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=155,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=724299,FOLIO='150',FILE='DISK116:[19ZBM1.19ZBM17601]DZ17601A.;42',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dz17601_1_151"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled,
infused, instilled, implanted or injected; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> expansion of the types of entities eligible for the 340B drug discount program; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establishment of the Medicare Part&nbsp;D coverage gap discount program by requiring manufacturers to provide a 50% point-of-sale-discount,
which increased to 70% starting in 2019, off the negotiated price of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the manufacturers' outpatient
drugs to be covered under Medicare Part&nbsp;D; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establishment of the Center for Medicare and Medicaid Innovation within the Centers for Medicare and Medicaid Services to test innovative
payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research,
along with funding for such research; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reporting of certain financial arrangements between manufacturers of drugs, biologics, devices, and medical supplies and physicians and
teaching hospitals under the Physician Payments Sunshine Act; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> annual reporting of certain information regarding drug samples that manufacturers and distributors provide to licensed practitioners. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
have been judicial and Congressional challenges to the PPACA, as well as efforts by the Trump administration to repeal or replace certain aspects of the PPACA that contribute to
regulatory uncertainty that could affect the profitability of our products. Since January 2017, President Trump has signed several Executive Orders and other directives designed to delay the
implementation of certain provisions of the PPACA or otherwise circumvent some of the requirements mandated by the PPACA. In December 2018, a federal district court in Texas ruled the individual
mandate was unconstitutional and could not be severed from the PPACA. As a result, the court ruled the remaining provisions of the PPACA were also invalid, though the court declined to issue a
preliminary injunction with respect to the PPACA. In April 2019, in a brief filed in the Fifth Circuit Court of Appeals, the Trump Administration took the position that the individual mandate was
unconstitutional, that it could not be severed from the PPACA, and, as a result, the PPACA must be invalidated in its entirety. The case is pending before the Fifth Circuit, and it remains unclear
whether, and to what extent, the PPACA may be affected by the Fifth Circuit's and possibly other courts' rulings. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
Congress has not enacted legislation to comprehensively repeal the PPACA, at least two bills affecting the implementation of the PPACA have been signed into law, including the
repeal, effective January&nbsp;1, 2019, of the tax-based shared responsibility payment imposed by the PPACA on certain individuals who fail to maintain qualifying health coverage for all or part of
a year, which is commonly referred to as the "individual mandate." Additionally, on January&nbsp;22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that
delayed the implementation of certain fees mandated by the PPACA, including the so-called "Cadillac" tax on certain high-cost
employer-sponsored health insurance plans, the annual fee imposed on certain health insurance providers, and the medical device excise tax on non-exempt medical devices. Moreover, effective
January&nbsp;1, 2019, the Bipartisan Budget Act of 2018, among other things, further amends portions of the Social Security Act implemented as part of the PPACA to increase from 50% to 70% the
point-of-sale discount that pharmaceutical manufacturers participating in the Coverage Gap Discount Program provide to eligible Medicare Part&nbsp;D beneficiaries during the coverage gap phase of
the Part&nbsp;D benefit, commonly referred to as the "donut hole," and to reduce standard beneficiary cost sharing in the coverage gap from 30% to 25% in most Medicare Part&nbsp;D plans. In the
future, there may be additional challenges and/or amendments to the PPACA. It remains to be seen precisely what any new legislation will provide, when or if it will be enacted, and what impact it will
have on the availability and cost of healthcare items and services, including drug products. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>151</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=156,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=259215,FOLIO='151',FILE='DISK116:[19ZBM1.19ZBM17601]DZ17601A.;42',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_dz17601_1_152"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;More
recently, the cost of prescription pharmaceuticals has been the subject of considerable discussion in the United States. Congress has begun developing legislation and the Trump
Administration has proposed and begun implementing regulatory reforms to further increase transparency around prices and price increases, lower out-of-pocket costs for consumers, and decrease spending
on prescription drugs by government programs. Congress has conducted or is in the process of conducting inquiries into the prescription drug industry's pricing practices. The Trump Administration's
budget proposal for fiscal year 2019 contained additional drug price control measures that could be enacted in future legislation, including, for example, measures to end Medicare Part&nbsp;B
coverage of medications and to shift those medication costs to Medicare Part&nbsp;D, to allow some states to negotiate prescription drug prices under Medicaid and to eliminate cost sharing for
generic drugs for low-income patients. While several proposed reform measures will require Congress to pass legislation to become effective, Congress and the Trump Administration have each indicated
that it will continue to seek new legislative and/or regulatory measures to address prescription drug costs. At the state level, legislatures are increasingly passing legislation and states are
implementing regulations designed to control spending on and patient out-of-pocket costs for drug products. Implementation of cost containment measures or other healthcare reforms that affect the
pricing and/or availability of drug products may impact our ability to generate revenue, attain or maintain profitability, or commercialize products for which we may receive regulatory approval in the
future. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
expect that these and other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and/or new payment methodologies, and place
additional downward pressure on the price that we receive for any approved product and/or the level of reimbursement physicians receive for administering any approved product we might bring to market.
Reductions in reimbursement levels and imposition of more rigorous coverage criteria or new payment methodologies may negatively impact the prices we receive or the frequency with which our products
are prescribed or administered. Any coverage or reimbursement policies instituted by Medicare or other federal health care programs may result in a similar policies from private payors. The
implementation of cost containment measures or other healthcare reforms may affect our ability to generate revenue, attain or maintain profitability, or commercialize our drug candidates. We expect
that additional state and federal healthcare reform measures will be adopted in the future, any of which
could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our drug candidates or additional pricing pressures. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Legal proceedings  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are not currently subject to any legal proceedings. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Facilities  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have facilities in Boston, Massachusetts and Stockholm, Sweden. Our Boston facilities consist of office space of approximately
2,295&nbsp;square feet under an operating lease agreement that expires in 2021. Our Stockholm facilities consist of office and laboratory space of approximately 3,980&nbsp;square feet under an
operating lease agreement that expires in 2022. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employees  </B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of September&nbsp;26, 2019, we had 14 full-time employees. Of the workforce, 9 employees are directly engaged in research and development
with the rest providing administrative, business and operations support. We are not bound by any collective bargaining agreements. We consider the relationship with our employees to be good. We also
use outside consultants and contractors with unique expertise and skills for limited engagements. As of September&nbsp;26, 2019, we utilized multiple outside consultants or contractors that
represented approximately 4 full-time equivalents to supplement our full-time workforce.

</FONT>

</P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>152</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=157,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=389814,FOLIO='152',FILE='DISK116:[19ZBM1.19ZBM17601]DZ17601A.;42',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ea17601_1_153"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ea17601_management"> </A>
<A NAME="toc_ea17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Management    <BR>    </B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth the name, age as of September&nbsp;26, 2019 and position of each of our executive officers and directors.

</FONT>

</P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="290pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Position </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Executive Officers</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Christian S. Schade</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>58</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>President and Chief Executive Officer and Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Scott M. Coiante</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>52</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Senior Vice President, Chief Financial Officer</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Eyal C. Attar, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>49</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Senior Vice President, Chief Medical Officer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lars Abrahmsen, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>61</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Senior Vice President, Chief Scientific Officer</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Gregory A. Korbel, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>43</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Vice President of Business Development</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Non-Employee Directors</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Scott M. Rocklage, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>65</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Chairman of the Board of Directors</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Guido Magni, M.D., Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>66</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Johan Christenson, M.D., Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>61</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jonathan Hepple, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>48</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bernd R. Seizinger, M.D., Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>62</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>John B. Henneman, III</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>57</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Executive officers  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Christian S. Schade</I></B></FONT><FONT SIZE=2> has served as our President and Chief Executive Officer and as a member of our board of directors since June 2016.
Mr.&nbsp;Schade has more than 30&nbsp;years of private and public pharmaceutical and biotechnology industry experience, as well as broad corporate finance expertise from his tenure in the
investment banking industry. Prior to joining Aprea Therapeutics, he was Chief Executive Officer of Novira Therapeutics, which was acquired in December 2015 by Johnson&nbsp;&amp; Johnson in an all-cash
transaction. Prior to joining Novira, Mr.&nbsp;Schade was Executive Vice President and Chief Financial Officer at Omthera, a NASDAQ-listed specialty pharmaceuticals company focused on the
development and commercialization of new therapies for dyslipidemia. At Omthera, Mr.&nbsp;Schade was responsible for all corporate finance, accounting and business development activities, and led
the sale of Omthera in July 2013 to AstraZeneca. He also was Executive Vice President and Chief Financial Officer at NYSE-listed NRG Energy, and from 2000 to 2009, he was Senior Vice President of
Administration and Chief Financial Officer at Medarex, a biopharmaceutical company focused on antibody-based therapeutic products for oncology, inflammation, autoimmune disorders and infectious
diseases. Mr.&nbsp;Schade played a pivotal role in the acquisition of Medarex by Bristol-Myers Squibb, leading the negotiations for the sale and the eventual merger-integration process of the
research, development and administrative functions. Before joining Medarex, Mr.&nbsp;Schade served as Managing Director at Merrill Lynch in London and held various corporate finance and capital
markets positions in New York and London for both Merrill Lynch and JP Morgan Chase&nbsp;&amp;&nbsp;Co. Mr.&nbsp;Schade currently serves on the board of directors of Integra Life
Sciences&nbsp;Inc. and has previously served on the board of directors of Indivior&nbsp;PLC. Mr.&nbsp;Schade received an M.B.A. from the Wharton School at the University of Pennsylvania and an
A.B. from Princeton University. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe Mr.&nbsp;Schade is qualified to serve as our President and Chief Executive Officer and on our board of directors because of his extensive experience in leadership and
management roles at various life sciences companies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Scott M. Coiante</I></B></FONT><FONT SIZE=2> has served as our Senior Vice President, Chief Financial Officer since August 2019. Mr.&nbsp;Coiante joined Aprea from
Agile Therapeutics, or Agile, where he was Senior Vice President and Chief Financial Officer. Having served at Agile since 2010, he played a leadership role in the company and in the development of
the internal finance and accounting infrastructure. Prior to joining </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>153</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=158,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=839503,FOLIO='153',FILE='DISK116:[19ZBM1.19ZBM17601]EA17601A.;60',USER='JTAYLORA',CD='27-SEP-2019;16:01' -->
<A NAME="page_ea17601_1_154"> </A>

<P style="font-family:times;"><FONT SIZE=2>Agile,
he was from 2002 Vice President of Finance and Treasurer at Medarex,&nbsp;Inc., formerly a NASDAQ listed biotech company that was acquired in 2009 by Bristol Myers Squibb. From 1989 to 2002,
Mr.&nbsp;Coiante held management positions of increasing responsibilities at Ernst&nbsp;&amp; Young&nbsp;LLP. Mr.&nbsp;Coiante received a B.S. in Accounting from Villanova University. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Eyal C. Attar, M.D.</I></B></FONT><FONT SIZE=2> has served as our Senior Vice President, Chief Medical Officer since April 2019. Dr.&nbsp;Attar joined Aprea from
Agios Pharmaceuticals, where he was Senior Medical Director and IDH Hematology Medical Lead. Having served at Agios since 2014, Dr.&nbsp;Attar played a leadership role in the clinical development
and approval of IDHIFA and TIBSOVO for patients with relapsed/refractory AML. Prior to Agios, he served on the clinical staff at the Massachusetts General Hospital Cancer Center, where
Dr.&nbsp;Attar was a member of the Center for Leukemia and Assistant Professor of Medicine at Harvard Medical School. He completed his residency in Internal Medicine at Brigham and Women's Hospital
and held fellowships in hematology and oncology in the Dana-Farber Partners Cancer Care Hematology/Oncology Fellowship Program. Dr.&nbsp;Attar received his medical degree from the University of
North Carolina School of Medicine. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Lars Abrahmsen, Ph.D.</I></B></FONT><FONT SIZE=2> has served as our Senior Vice President, Chief Scientific Officer since October 2014. Dr.&nbsp;Abrahmsen has more
than 30&nbsp;years of experience in research and drug development in the pharmaceutical industry, both with small molecules and biopharmaceuticals. Beginning with postdoctoral work at Genentech, he
has also worked at Biovitrum, Pharmacia&amp;Upjohn, Pharmacia and KabiGen. More recently he served as Chief Scientific Officer at Affibody from 2004-2010 and as SVP of Protein Therapeutics at Algeta from
2010-2013. Dr.&nbsp;Abrahmsen has experience from discovery research to preclinical development and has primarily focused on projects within oncology and metabolic diseases. Dr.&nbsp;Abrahmsen
received a Ph.D. in Biochemistry and an M.S. in Chemistry, both from the Royal Institute of Technology in Stockholm, Sweden. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Gregory A. Korbel., Ph.D.</I></B></FONT><FONT SIZE=2> has served as our Vice President of Business Development since July 2016. Dr.&nbsp;Korbel has 12&nbsp;years
of experience in the biotechnology and pharmaceutical industries. Prior to
joining Aprea Therapeutics, he was Director of Business Development and Operations at Novira Therapeutics, which was acquired in December 2015 by Johnson&nbsp;&amp; Johnson, and served as Director of
Research Operations subsequent to the acquisition. In addition to consulting for venture capital and biotechnology firms, he formerly served as Senior Scientist at Invtirogen/Life Technologies.
Dr.&nbsp;Korbel received an M.B.A. from the Wharton School at the University of Pennsylvania, a Ph.D. in Chemistry from Harvard University and a B.A. from Vanderbilt University. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Non-employee directors  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Scott M. Rocklage, Ph.D.</I></B></FONT><FONT SIZE=2> has served as a member of our board of directors since 2016 and as Chairman of our board of directors since
June&nbsp;2017. Dr.&nbsp;Rocklage joined 5AM Ventures in 2003 as a Venture Partner, became a Managing Partner in 2004 and transitioned to Founding Partner in 2017. Dr.&nbsp;Rocklage has over
three decades of healthcare management experience with strategic leadership responsibilities that led to FDA approval of three U.S. New Drug Applications (Omniscan&#153;, Teslascan&reg;
and Cubicin&reg;). He has served as Chairman and CEO of Cubist Pharmaceuticals, President and CEO of Nycomed Salutar and has also held R&amp;D positions at Salutar and Catalytica.
Dr.&nbsp;Rocklage formerly served as Board Chairman of Relypsa (acquired by Vifor Pharma) and Novira (acquired by J&amp;J). He currently serves as Board Chairman of Expansion, Kinestral and Cidara
(NASDAQ: CDTX) and is a Board member at NodThera and Nouscom. He was formerly Executive Chairman of Ilypsa (acquired by Amgen), Miikana (acquired by EntreMed) and Semprus (acquired by Teleflex).
Dr.&nbsp;Rocklage received his B.S. in Chemistry from the University of California, Berkeley and his Ph.D. in Chemistry from MIT where he conducted research in the laboratory of Richard R. Schrock
(Nobel Prize in Chemistry in 2005). He is an inventor or co-inventor of over 30 U.S. patents and has produced more than 100 peer-reviewed publications. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>154</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=159,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=298651,FOLIO='154',FILE='DISK116:[19ZBM1.19ZBM17601]EA17601A.;60',USER='JTAYLORA',CD='27-SEP-2019;16:01' -->
<A NAME="page_ea17601_1_155"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe Dr.&nbsp;Rocklage is qualified to serve on our board of directors because of his extensive leadership and investment experience in the life sciences sector and strong
scientific background. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Guido Magni, M.D., Ph.D.</I></B></FONT><FONT SIZE=2> has served as a member of our board of directors since March&nbsp;2016. Dr.&nbsp;Magni has served a Partner
with Versant Ventures since February&nbsp;2012. Dr.&nbsp;Magni previously served as a Managing Director of EuroVentures, a Versant incubator, where he was intimately involved in several biotech
investments including Synosia (sold to Biotie Therapies), Flexion and Okairos. Dr.&nbsp;Magni was
previously the Global Head of the Medical Science Department of Roche Pharmaceuticals in Basel, Switzerland. During his twelve-year term at Roche, Dr.&nbsp;Magni oversaw the development and the
registration of a large number of new chemical and biological entities including Cellcept, Pegasys, Mabthera, Xeloda, Herceptin, Tamiflu and Tarceva. Currently, Dr.&nbsp;Magni serves on the Board of
Biotie and AM Pharma, with previous board positions at Adolor Corporation and Anabasis Pharma before their recent acquisitions. Dr.&nbsp;Magni was trained at the University of Padua with a
specialization in neuro-psychiatry. He is the co-author of over 100 peer-reviewed papers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe Dr.&nbsp;Magni is qualified to serve on our board of directors because of his management and investment experience in the life sciences sector and medical and scientific
background. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Johan Christenson, M.D., Ph.D.</I></B></FONT><FONT SIZE=2> has served as a member of our board of directors since 2016. Dr.&nbsp;Christenson is a Partner of
HealthCap. Prior to joining HealthCap in 2001, Dr.&nbsp;Christenson was with SEB F&ouml;retagsinvest (the venture capital arm of SEB) to supervise its health care portfolio. He has senior
management experience from Astra Pain Control as Project Director and AstraZeneca as Global Product Director and member of the global therapy area management team of pain and inflammation.
Dr.&nbsp;Christenson received his medical training at the Karolinska Institute and received his Ph.D. in basic neuroscience in 1991. He served as a lecturer in neuroscience and also held a position
as Assistant Dean at the Karolinska Institute Graduate School for two years. Dr.&nbsp;Christenson has four years of clinical specialist training in paediatrics and paediatric neurology. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe Dr.&nbsp;Christenson is qualified to serve on our board of directors because of his management and investment experience in the life sciences sector and medical and
scientific background. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Jonathan Hepple, Ph.D.</I></B></FONT><FONT SIZE=2> has served as a member of our board of directors since April&nbsp;2015. Dr.&nbsp;Hepple is a co-founder of
Rosetta Capital&nbsp;Limited, where he has served as a Partner since January 2009. He has more than twenty years investment experience in the life sciences industry. He started his investment career
at Rothschilds Asset Management and he was also a partner at Seroba Life Sciences where he was on the boards of Covagen and Opsona. Dr.&nbsp;Hepple has held Board Director and Observer roles in
portfolio companies such as Catalyst Biosciences, Glycomimetics, Novimmune, Procertus and Tranzyme. He has served on the board of Clanotech AB since June 2013. He received his Ph.D. from Cambridge
University for cancer research. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe Dr.&nbsp;Hepple is qualified to serve on our board of directors because of his experience as an investor and board member in the life sciences industry, as well as his
scientific background. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Bernd R. Seizinger, M.D., Ph.D.</I></B></FONT><FONT SIZE=2> has served as a member of our board of directors since 2015. Dr.&nbsp;Seizinger is a board member in a
number of companies, including Opsona (Dublin, Ireland), Agennix AG (Princeton, NJ; Houston, TX; Munich, Germany) and TriMod&nbsp;Ltd. (Dublin, Ireland). He is Chairman of Opsona&nbsp;Ltd. And
acting Chairman of Trimod&nbsp;Ltd. From 1998 to 2009, Dr.&nbsp;Seizinger was President and Chief Executive Officer of&nbsp;GPC Biotech before it merged with Agennix AG. Prior to his corporate
appointments, he was at Massachusetts General Hospital and Harvard Medical School. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe Dr.&nbsp;Seizinger is qualified to serve on our board of directors because of his perspective and experience as a leader and board member in the life sciences industry, as
well as his strong medical and scientific background. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>155</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=160,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=249418,FOLIO='155',FILE='DISK116:[19ZBM1.19ZBM17601]EA17601A.;60',USER='JTAYLORA',CD='27-SEP-2019;16:01' -->
<A NAME="page_ea17601_1_156"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>John B. Henneman III</I></B></FONT><FONT SIZE=2> has been a member of our board of directors since August 2019. Mr.&nbsp;Henneman has more than 25&nbsp;years of
combined financial and operational management experience in the life sciences industry. From July 2018 until November 2018, Mr.&nbsp;Henneman served as the Chief Administrative Officer of NewLink
Genetics Corporation, a biotechnology company, and prior to that, served as NewLink's Executive Vice President and Chief Financial Officer from October 2014 to July 2018. From 1998 to 2014,
Mr.&nbsp;Henneman served at Integra LifeSciences Holdings Corp., a publicly-held medical device company, in various capacities. Before becoming Integra's Chief Financial Officer in 2007,
Mr.&nbsp;Henneman was Chief Administrative Officer, responsible for Integra's regulatory affairs, quality systems, clinical affairs, human resources, information systems and legal affairs functions,
the management of Integra's surgical instruments business, and Integra's business development function. Mr.&nbsp;Henneman serves on the boards of directors of R1 RCM,&nbsp;Inc., a publicly-held
revenue cycle technology and management services company, SeaSpine Holdings Corporation, a publicly-held medical technology company, and Alafair Biosciences,&nbsp;Inc., a privately-held medical
device company. Mr.&nbsp;Henneman is also senior advisor to Prettybrook Partners, a private equity firm, and a consultant to SparkMed Advisors&nbsp;LLC, which provides consulting and other
services to start-up medical device and biotechnology companies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe Mr.&nbsp;Henneman is qualified to serve on our board of directors because of his senior management experience at NewLink and Integra and his service on the boards of R1
RCM,&nbsp;Inc. and SeaSpine, as well as his extensive experience in the areas of finance, financial accounting, business transactions, and mergers and acquisitions, qualify him to serve on our board
of directors. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board composition and election of directors  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board composition  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors currently consists of seven members. After the completion of this offering, the number of directors will be fixed by our
board of directors, subject to the terms of our amended and restated certificate of incorporation and amended and restated bylaws. Each of our current directors will continue to serve as a director
until the election and qualification of his or her successor, or until his or her earlier death, resignation or removal. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
certificate of incorporation and bylaws that will become effective as of the closing date of this offering provide that the authorized number of directors may be changed only by
resolution of our board of directors. Our certificate of incorporation and bylaws will also provide that our directors may be removed only for cause by the affirmative vote of the holders of at least
75% of our shares of common stock present in person or by proxy and entitled to vote, and that any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of
directors, may be filled only by vote of a majority of our directors then in office. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have no formal policy regarding board diversity. Our priority in selection of board members is identification of members who will further the interests of our stockholders through his
or her established record of professional accomplishment, the ability to contribute positively to the collaborative culture among board members, knowledge of our business and understanding of the
competitive landscape. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director independence  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the rules of NASDAQ, independent directors must comprise a majority of a listed company's board of directors within one year of the
completion of its initial public offering. In addition, the rules of NASDAQ require that, subject to specified exceptions, each member of a listed company's audit, compensation and corporate
governance and nominating committees be independent. Our board of directors has determined that Scott&nbsp;M. Rocklage, Johan Christenson, John&nbsp;B. Henneman&nbsp;III, Jonathan Hepple, Guido
Magni and Bernd&nbsp;R. Seizinger qualify as "independent" </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>156</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=161,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=855235,FOLIO='156',FILE='DISK116:[19ZBM1.19ZBM17601]EA17601A.;60',USER='JTAYLORA',CD='27-SEP-2019;16:01' -->
<A NAME="page_ea17601_1_157"> </A>

<P style="font-family:times;"><FONT SIZE=2>directors
in accordance with the NASDAQ listing requirements. The NASDAQ independence definition includes a series of objective tests, such as that the director is not, and has not been for at least
three years, one of our employees and that neither the director nor any of his family members has engaged in various types of business dealings with us. In addition, as required by NASDAQ rules, our
board of directors has made a subjective determination as to each independent director that no relationships exist, which, in the opinion of our board of directors, would interfere with the exercise
of independent judgment in carrying out the responsibilities of a director. In making these determinations, our board of directors reviewed and discussed information provided by the directors and us
with regard to each director's business and personal activities and relationships as they may relate to us and our management. There are no family relationships among any of our directors or executive
officers. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Classified board of directors  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In accordance with our amended and restated certificate of incorporation to be in effect immediately prior to the completion of this offering,
our board of directors will be divided into three classes with staggered, three-year terms. At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected
to serve from the time of election and qualification until the third annual meeting following election. Effective upon the completion of this offering, we expect that our directors will be divided
among the three classes as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the Class&nbsp;I directors will be Bernd&nbsp;R. Seizinger,&nbsp;M.D.,&nbsp;Ph.D. and Jonathan Hepple,&nbsp;Ph.D. and their term will
expire at the annual meeting of stockholders to be held in 2020; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the Class&nbsp;II directors will be Guido Magni,&nbsp;M.D.,&nbsp;Ph.D. and Johan Christenson,&nbsp;M.D.,&nbsp;Ph.D. and their term
will expire at the annual meeting of stockholders to be held in 2021; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the Class&nbsp;III directors will be Christian&nbsp;S. Schade, Scott&nbsp;M. Rocklage,&nbsp;Ph.D. and John&nbsp;B.
Henneman,&nbsp;III and their term will expire at the annual meeting of stockholders to be held in 2022. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of
one-third of the directors. The division of our board of directors into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control of our
company. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board committees  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Audit committee  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the completion of this offering, our board of directors will have an audit committee and our board of directors will adopt an audit
committee charter, which will define the audit committee's principal functions, including oversight related to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our accounting and financial reporting process; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> appointing our independent registered public accounting firm; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> evaluating the independent registered public accounting firm's qualifications, independence and performance; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the compensation, retention, oversight of the work of, and termination of the independent registered public accounting firm; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> discussing with management and the independent registered public accounting firm the results of the annual audit and the review of our
quarterly financial statements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> pre-approving all audit and permitted non-audit and tax services to be provided; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>157</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=162,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=472302,FOLIO='157',FILE='DISK116:[19ZBM1.19ZBM17601]EA17601A.;60',USER='JTAYLORA',CD='27-SEP-2019;16:01' -->
<A NAME="page_ea17601_1_158"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> monitoring the rotation of partners of the independent registered public accounting firm on our engagement team in accordance with requirements
established by the SEC; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing our financial statements and our management's discussion and analysis of financial condition and results of operations to be included
in our annual and quarterly reports to be filed with the SEC; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing our critical accounting policies and estimates; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing the audit committee charter and the committee's performance at least annually. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the completion of this offering, our audit committee will be composed of John B. Henneman III, Bernd R. Seizinger and Jonathan Hepple. John B. Henneman III serves as the chairperson
of the committee. All members of our audit committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and NASDAQ. Our board of directors has
determined that John&nbsp;B. Henneman&nbsp;III is an audit committee financial expert as defined under the applicable rules of the SEC and has the requisite financial sophistication as defined
under the applicable rules and regulations of NASDAQ. Under the rules of the SEC, members of the audit committee must also meet heightened independence standards. However, a minority of the members of
the audit committee may be exempt from the heightened audit committee independence standards for one year from the date of effectiveness of the registration statement of which this prospectus
forms&nbsp;a part. Each of the members of our audit committee is independent under the applicable rules and regulations of NASDAQ. The audit committee will operate under a written charter that
satisfies the applicable standards of the SEC and NASDAQ. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Compensation committee  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the completion of this offering, our board of directors will have a compensation committee and our board of directors will adopt a
compensation committee charter, which will define the compensation committee's principal functions, including recommending policies relating to compensation and benefits of our directors, officers and
employees. Among other matters, the compensation committee will review and recommend corporate goals and objectives relevant to compensation of our Chief Executive Officer, evaluate the performance of
our Chief Executive Officer in light of those goals and objectives and recommend to our board of directors the compensation of the Chief Executive Officer based on such evaluations. The compensation
committee will also recommend to our board of directors the issuance of stock options and other awards under our stock plans. The compensation committee will review and evaluate, at least annually,
the performance of the compensation committee and its members, including adherence by the compensation committee to its charter. Upon the completion of this offering, our compensation committee will
be composed of Scott&nbsp;M. Rocklage, John&nbsp;B. Henneman III and Johan Christenson. Scott M. Rocklage serves as the chairperson of the committee. Each of the members of our compensation
committee is independent under the applicable rules and regulations of NASDAQ and is a "non-employee director" as defined in Rule&nbsp;16b-3 promulgated under the Securities Exchange Act. The
compensation committee will operate under a written charter that satisfies the applicable standards of the SEC and NASDAQ. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Nominating and corporate governance committee  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the completion of this offering, our board of directors will have a nominating and corporate governance committee and our board of
directors will adopt a nominating and corporate governance committee charter. The nominating and corporate governance committee will be responsible for making recommendations to our board of directors
regarding candidates for directorships and the size and composition of our board of directors. Among other matters, the nominating and corporate governance committee will be responsible for developing
and monitoring compliance with our corporate governance guidelines and reporting and making recommendations to our board of directors concerning governance </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>158</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=163,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=497333,FOLIO='158',FILE='DISK116:[19ZBM1.19ZBM17601]EA17601A.;60',USER='JTAYLORA',CD='27-SEP-2019;16:01' -->
<A NAME="page_ea17601_1_159"> </A>

<P style="font-family:times;"><FONT SIZE=2>matters.
Upon the completion of this offering, our nominating and corporate governance committee will be composed of Guido Magni, Bernd R. Seizinger and Jonathan Hepple. Guido Magni serves as the
chairman of the committee. Each of the members of our nominating and corporate governance committee is an independent director under the applicable rules and regulations of NASDAQ relating to
nominating and corporate governance committee independence. The nominating and corporate governance committee will operate under a written charter that satisfies the applicable standards of the SEC
and NASDAQ. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Compensation committee interlocks and insider participation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None of our executive officers serves, or in the past year has served, as a member of the board of directors or compensation committee, or other
committee serving an equivalent function, of any other entity that has one or more of its executive officers serving as a member of our board of directors or our compensation committee. None of the
members of our compensation committee is, or has ever been, an officer or employee of our company. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Code of business conduct and ethics  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We plan to adopt a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal
executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions, which will be effective upon the completion of this offering.
Following this offering, we will post a copy of the code on the Corporate Governance section of our website. If we make any substantive amendments to, or grant any waivers from, the code of business
conduct and ethics for any officer or director, we will disclose the nature of such amendment or waiver on our website or in a current report on Form&nbsp;8-K. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Limitations on liability and indemnification  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this offering,
contains provisions that limit the liability of our directors for monetary damages to the fullest extent permitted by Delaware law. Consequently, our directors will not be personally liable to us or
our stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any breach of the director's duty of loyalty to us or our stockholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section&nbsp;174 of the Delaware General
Corporation Law; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any transaction from which the director derived an improper personal benefit. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this offering, provides that we are required to indemnify our
directors and officers to the fullest extent permitted by Delaware law. Our amended and restated certificate of incorporation also provides that, subject to limited exceptions, we are obligated to
advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding, and permits us to secure insurance on behalf of any current or former director or
officer against any liability asserted against such person, whether or not we would have the power to indemnify such person against such liability under our amended and restated certificate of
incorporation or otherwise. We have entered and expect to continue to enter into agreements to indemnify our directors, executive officers and other employees as determined by our board of directors.
With specified exceptions, these agreements provide for indemnification for related expenses including, among other things, attorneys' </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>159</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=164,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=65723,FOLIO='159',FILE='DISK116:[19ZBM1.19ZBM17601]EA17601A.;60',USER='JTAYLORA',CD='27-SEP-2019;16:01' -->
<A NAME="page_ea17601_1_160"> </A>

<P style="font-family:times;"><FONT SIZE=2>fees,
judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding. We believe that these provisions of our amended and restated certificate of
incorporation and indemnification agreements are necessary to attract and retain qualified persons as directors and officers. We also maintain directors' and officers' liability insurance. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
limitation of liability and indemnification provisions in our amended and restated certificate of incorporation may discourage stockholders from bringing a lawsuit against our
directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might
benefit us and our stockholders. Further, a stockholder's investment may be adversely affected to the extent that we pay the costs of settlement and damage. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Fiscal 2018 director compensation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently do not have a formal non-employee director compensation policy. We did not make any equity awards or non-equity awards to, or pay
any other compensation to any of the non-employee members of our board of directors for their service as a director in 2018 with the
exception of Dr.&nbsp;Seizinger. Pursuant to a letter agreement with us, Dr.&nbsp;Seizinger is entitled to receive an annual cash retainer of $28,727, paid annually in arrears, for his service on
the board of directors. We reimburse our non-employee directors for reasonable travel and out-of-pocket expenses incurred in connection with attending board of directors and committee meetings.
Mr.&nbsp;Schade, our chief executive officer and a member of our board of directors, did not receive any compensation for his service as a member of our board of directors during 2018.
Mr.&nbsp;Schade's compensation for service as an employee for fiscal year 2018 is presented below in the "2018 Summary compensation table." </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table sets forth information regarding compensation earned by our non-employee directors during 2018. As noted above, Dr.&nbsp;Seizinger is the only non-employee director
who received compensation during 2018. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="59pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fees Earned<BR>
or Paid in<BR>
Cash&nbsp;($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total&nbsp;($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bernd R. Seizinger, M.D., Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>28,727</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>28,727</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>As
of December&nbsp;31, 2018, Dr.&nbsp;Seizinger held stock options to acquire 263,970 shares of our common stock following the consummation of the offering and
the payment of a subscription price established in 2015. None of our other non-employee directors held any other outstanding equity awards with respect to us as of December&nbsp;31,
2018.</FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After
the completion of this offering, our board of directors intends to approve a compensation policy for our non-employee directors. This policy will be intended to provide a total
compensation package that enables us to attract and retain qualified and experienced individuals to serve as directors and to align our directors' interests with those of our stockholders. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>160</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=165,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=93405,FOLIO='160',FILE='DISK116:[19ZBM1.19ZBM17601]EA17601A.;60',USER='JTAYLORA',CD='27-SEP-2019;16:01' -->
<A NAME="page_ea17601_1_161"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Following
this offering, we expect to offer our non-employee directors the following compensation for their service on our board of directors and its committees: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Director Compensation Element

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Board Cash Retainer</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Committee Cash Retainer</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&#151;Audit</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&#151;Compensation</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&#151;Governance</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Committee Chair Cash Retainer</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&#151;Audit</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&#151;Compensation</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&#151;Governance</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Annual Stock Compensation</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>150,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Value of Initial Stock-Based Awards for Newly Elected Directors</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>185,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>161</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=166,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=464108,FOLIO='161',FILE='DISK116:[19ZBM1.19ZBM17601]EA17601A.;60',USER='JTAYLORA',CD='27-SEP-2019;16:01' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ec17601_1_162"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ec17601_executive_compensation"> </A>
<A NAME="toc_ec17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Executive Compensation    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This section describes the material elements of compensation awarded to, earned by or paid to each of our named executive officers in 2018. We
are an "emerging growth company," within the meaning of the JOBS Act and a smaller reporting company under the Exchange Act, and have elected to comply with the reduced compensation disclosure
requirements available to emerging growth companies under the JOBS Act. Our named executive officers for 2018 were Christian S. Schade, Lars Abrahmsen and Gregory A. Korbel. This section also provides
qualitative information regarding the manner and context in which compensation is awarded to and earned by our named executive officers and is intended to place in perspective the data presented in
the tables and narrative that follow. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our current executive compensation program is intended to align executive compensation with our business objectives and to enable us to attract,
retain and reward executive officers who contribute to our long-term success. The compensation paid or awarded to our executive officers is generally based on a qualitative assessment of each
individual's performance compared against the business objectives established for the fiscal year as well as our historical compensation practices. In the case of new hire executive officers, their
compensation is primarily determined based
on the negotiations of the parties as well as our historical compensation practices. For 2018, the material elements of our executive compensation program were base salary and annual cash bonuses. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
preparing to become a public company, we have begun a thorough review of all elements of our executive compensation program, including the function and design of our equity incentive
program. We expect that our executive compensation program will evolve to reflect our status as a newly publicly-traded company, while still supporting our overall business and compensation
objectives. In connection with this offering, our board of directors has retained the services of Willis Towers Watson, an independent executive compensation consultant, to help advise on our
post-offering executive compensation program, as described further below. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Compensation of named executive officers  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Base salaries  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 2018, we paid annual base salaries of $412,000 to Mr.&nbsp;Schade, $192,505 to Dr.&nbsp;Abrahmsen and $226,600 to Dr.&nbsp;Korbel. We
use base salaries to recognize the experience, skills, knowledge and responsibilities required of all our employees, including our named executive officers. None of our named executive officers is
currently party to an employment agreement or other agreement or arrangement that provides for automatic or scheduled increases in base salary. Following a market review by Willis Towers Watson, the
compensation committee adjusted the base salaries of Mr.&nbsp;Schade and Dr.&nbsp;Abrahmsen to $500,000 and $220,000, respectively, to be effective upon consummation of this offering. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Annual cash bonuses  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although we do not have a formal performance-based bonus plan, each executive is eligible to receive a discretionary bonus pursuant to the terms
of his employment agreement or offer letter, as applicable. Under such terms of employment, the target bonus opportunities, as a percentage of base salary, for Mr.&nbsp;Schade, Dr.&nbsp;Abrahmsen
and Dr.&nbsp;Korbel are 40%, 25%, and 20%, respectively.
From time to time, our board of directors has approved discretionary annual cash bonuses to employees, including our named executive officers, based on a qualitative assessment of prior year
performance. Mr.&nbsp;Schade, Dr.&nbsp;Abrahmsen and Dr.&nbsp;Korbel earned cash bonuses of $181,280, $52,139, and $49,852, respectively, for services performed during 2018. Following a market
review by Willis Towers Watson, the compensation committee adjusted the annual bonus targets of Mr.&nbsp;Schade and Dr.&nbsp;Abrahmsen to 50% and 30% of base salary, respectively, to be effective
upon consummation of this offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>162</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=167,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=655627,FOLIO='162',FILE='DISK116:[19ZBM1.19ZBM17601]EC17601A.;72',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_ec17601_1_163"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Equity awards  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although we do not have a formal policy with respect to the grant of equity incentive awards to our named executive officers, or any formal
equity ownership guidelines applicable to them, we believe that equity grants provide recipients, including our named executive officers, with a strong link to our long-term performance, create an
ownership culture and help to align the interests of our award recipients and our stockholders. In addition, we believe that equity grants with a time-based vesting feature promote executive retention
because this feature incents the award recipient to remain in our employment during the vesting period. Accordingly, our board of directors periodically reviews the equity incentive compensation of
our named executive officers and from time to time may grant equity incentive awards to them in the form of stock options. None of our named executive officers received equity awards in 2018, although
each held outstanding equity awards as of December&nbsp;31, 2018 a result of prior year equity grants. In connection with this offering, our board of directors granted stock option awards to certain
employees of the Company, including each of the named executive officers. Accordingly, Mr.&nbsp;Schade, Dr.&nbsp;Abrahmsen and Mr.&nbsp;Korbel received stock option awards with respect to
306,085, 77,630 and 64,322 shares, respectively, and with an exercise price equal to the initial public offering price and which vest 25% on the one-year anniversary of the date of grant and monthly
thereafter, subject to early vesting in the event of a change in control or certain terminations of employment. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2018 Summary compensation table  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information regarding compensation awarded to, earned by or paid to our named executive officers during 2018. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="70pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and principal position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Salary<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Bonus<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option awards<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All other<BR>
compensation<BR>
($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Christian S. Schade(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>412,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>181,280</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>593,280</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>President and Chief Executive Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lars Abrahmsen, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>192,505</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>52,139</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>62,190</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>306,834</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Senior Vice President, Chief Scientific Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Gregory A. Korbel, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>226,600</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>49,852</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>276,452</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vice President of Business Development</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
amounts reported in the "Bonus" column represent discretionary annual cash bonuses awarded to our named executive officers.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of pension plan contributions for Dr.&nbsp;Abrahmsen.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Mr.&nbsp;Schade
serves as a member of our board of directors but does not receive any additional compensation for his service as a director. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>163</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=168,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=358263,FOLIO='163',FILE='DISK116:[19ZBM1.19ZBM17601]EC17601A.;72',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_ec17601_1_164"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Outstanding equity awards at 2018 fiscal year-end  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information regarding outstanding equity awards held by our named executive officers as of December&nbsp;31,
2018: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="73pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=12 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option awards </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Vesting<BR>
commencement<BR>
date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
securities<BR>
underlying<BR>
unexercised<BR>
option<BR>
exercisable<BR>
(#)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
securities<BR>
underlying<BR>
unexercised<BR>
option<BR>
unexercisable<BR>
(#)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option exercise<BR>
price ($/share) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
expiration<BR>
date </B></FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Christian S. Schade</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4/20/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>351,956</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>175,979</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.92</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9/14/2026</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/24/18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>43,454</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>116,995</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.01</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/24/2027</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lars Abrahmsen, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4/20/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>70,391</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35,196</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.92</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9/14/2026</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/21/18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,209</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40,948</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.01</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/24/2027</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Gregory A. Korbel, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7/5/17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>48,481</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>31,764</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.92</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9/14/2026</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2/16/18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,706</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17,383</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.92</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2/16/2027</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/24/18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,517</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17,550</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.01</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/24/2027</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Twenty-five
percent of these options vested on the Vesting Commencement Date, with the remaining options vesting in equal monthly installments on the first day of
every calendar month during the following three year period.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>These
options are subject to accelerated vesting in the event Mr.&nbsp;Schade's employment is terminated by us without "cause" or by him due to "good reason"
within 12&nbsp;months following a change in control. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employment agreements, severance and change in control agreements  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We entered into employment agreements with each of Mr.&nbsp;Schade, Dr.&nbsp;Abrahmsen and Dr.&nbsp;Korbel. These agreements set forth the
initial terms and conditions of each executive's employment with us, including base salary, target annual bonus opportunity and standard employee benefit plan participation. Except as noted below,
these employment agreements provide for "at will" employment. The terms "cause," "good reason" and "change in control" referred to below are defined in each named executive officer's employment
agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with this offering, we expect to enter into new employment agreements with the Company's named executive officers that will set forth the initial terms of their employment,
including base salary and annual bonus target levels. In addition, the employment agreements are expected to provide for severance benefits following a termination by the Company without "cause," the
expiration of the employment agreement term upon non-renewal by the Company or resignation by the named executive officer due to "good reason" as follows: (i)&nbsp;severance payments equal to
nine-months of base salary (12-months in the case of Mr.&nbsp;Schade); (ii)&nbsp;a prorated target bonus for the year of termination; and (iii)&nbsp;the payment of an amount equal to the
employer's portion of healthcare continuation coverage for a period of up to nine-months (12-months in the case of Mr.&nbsp;Schade), with the severance amount and healthcare continuation increasing
to 12-months (18-months in the case of Mr.&nbsp;Schade) for a qualifying termination of employment following a change in control of the Company. The severance benefits under the employment
agreements will be subject to the named executive officer's execution of a release of claims in favor of the Company and compliance with restrictive covenants relating to non-competition,
non-solicitation and confidentiality. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Christian S. Schade  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We entered into an employment letter agreement with Mr.&nbsp;Schade in April 2016. Under the terms of the letter agreement, in the event that
he is terminated by us without "cause" or he terminates his employment for "good reason," death or disability he will be entitled to receive, upon execution and effectiveness of a release of claims,
(i)&nbsp;continued payment of his then-current base salary for a period </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>164</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=169,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=540707,FOLIO='164',FILE='DISK116:[19ZBM1.19ZBM17601]EC17601A.;72',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_ec17601_1_165"> </A>

<P style="font-family:times;"><FONT SIZE=2>of
12&nbsp;months following termination and (ii)&nbsp;a direct payment by us of the medical, vision and dental coverage premiums due to maintain any COBRA coverage for which he is eligible and has
appropriately elected through the earlier of (x)&nbsp;12&nbsp;months following termination and (y)&nbsp;the date he becomes employed by another entity or individual. Upon a termination without
"cause" or due to "good reason," death or disability during this 12&nbsp;month period following "change of control" Mr.&nbsp;Schade is entitled to a prorated target bonus for the year of such
termination. Further, in the event Mr.&nbsp;Schade's employment is terminated by us without "cause" or by him due to "good reason" within 12-months following a change in control, the outstanding
options granted under the letter agreement will vest in full. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event that we terminate Mr.&nbsp;Schade with cause or he resigns without good reason, then he will not be entitled to receive severance benefits. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the letter agreement, Mr.&nbsp;Schade is prohibited from disclosing our confidential information and is subject to non-competition and non-solicitation restrictive covenants for
12-months post-termination. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Lars Abrahmsen, Ph.D.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We entered into an employment agreement with Dr.&nbsp;Abrahmsen in March 2016. Dr.&nbsp;Abrahmsen's employment agreement may be terminated
by us upon six-month prior written notice. Under the terms of Dr.&nbsp;Abrahmsen's employment agreement, we are required to compensate Dr.&nbsp;Abrahmsen up to 60% of his average monthly
remuneration during the 12-month non-compete period under his employment agreement. Dr.&nbsp;Abrahmsen is also subject to a non-solicit restrictive covenant for six-months following termination and
prohibitions on the disclosure of our confidential information. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Gregory A. Korbel, Ph.D.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We entered into an employment letter agreement with Dr.&nbsp;Korbel in July 2016. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event that he is terminated by us without "cause" or his employment termination due to death or disability, he will be entitled to receive, upon execution and effectiveness of a
release of claims, (i)&nbsp;continued payment of his then-current base salary for a period of three&nbsp;months following termination (six&nbsp;months if such termination occurs within the
12&nbsp;month period immediately following a "change of control") and (ii)&nbsp;a direct payment by us of the medical, vision and dental coverage premiums due to maintain any COBRA coverage for
which he is eligible and has appropriately elected through the earlier of (i)&nbsp;the date his base salary continuation ceases following termination and (ii)&nbsp;the date he becomes employed by
another entity or individual. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event that we terminate Dr.&nbsp;Korbel with cause or he resigns, then he will not be entitled to receive severance benefits. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the letter agreement, Dr.&nbsp;Korbel is prohibited from disclosing our confidential information and is subject to non-competition and non-solicitation restrictive covenants for
12-months post-termination. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Pension Plan  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our company policy is to provide a pension plan, the Pension Plan, to all of our employees in Sweden. Contributions for each employee are
calculated as an age-adjusted percentage of base salary. All contributions to the Pension Plan begin at the time of employment and cease upon termination of employment, with contributions distributed
to the participant at retirement. Other than the Pension Plan, the Company does not maintain any retirement programs for its employees. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>165</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=170,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=930057,FOLIO='165',FILE='DISK116:[19ZBM1.19ZBM17601]EC17601A.;72',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_ec17601_1_166"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock option and other compensation plans  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2016 Stock option program  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The 2016 Stock Incentive Plan of Aprea AB, or 2016 Plan, was approved by the board of directors and stockholders of Aprea AB in October 2016.
Under the 2016 Plan, we have reserved for issuance an aggregate of 3,402,418 shares of common stock of Aprea AB. The number of shares of common stock reserved for issuance is subject to adjustment in
the event of a stock split, stock dividend, recapitalization, combination of shares, reclassification of shares, spin-off or other similar change in our capitalization. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
board of directors of Aprea AB has acted as administrator of the 2016 Plan. The administrator has full power to select, from among the individuals eligible for awards, the
individuals to whom awards will be granted, and to determine the specific terms and conditions of each award, subject to the provisions of the 2016 Plan. Persons eligible to participate in the 2016
Plan are those employees, officers and directors of, and consultants to, the company as selected from time to time by the administrator in its discretion. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
term and per share option exercise price of each option under the 2016 Plan is determined by the administrator. The option may not be exercised until the occurrence of a "Trade Sale"
or "IPO," as defined in the 2016 Plan; provided, however, that option holders may also exercise their options when they leave their employment with the Company. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
2016 Plan provides that upon the occurrence of a "Trade Sale," as defined in the 2016 Plan, our board of directors may take one or more of the following actions as to some or all
awards outstanding under the 2016 Plan: (1)&nbsp;decide on a period for exercise of the stock options; (2)&nbsp;resolve to have these terms and conditions continue following the closing date of
the Trade Sale; (3)&nbsp;allow a grant of equivalent rights to acquire securities in a new company as the option holder had in us immediately before the Trade Sale in which case any rights under the
stock options shall lapse as a consequence thereof; (4)&nbsp;allow an amendment of the awards' terms and conditions to the effect that, following the Trade Sale, a new company assumes our rights and
obligations under the 2016 Plan and that the holder's right to subscribe for shares in accordance with the 2016 Plan shall relate to shares in such new company; (5)&nbsp;resolve to pay the option
holder in cash the difference between the share price in the Trade Sale and the exercise price, meaning that the stock option cannot be exercised into shares and that the stock option will lapse or
(6)&nbsp;any combination of the foregoing. The 2016 Plan provides that upon the occurrence of an "IPO," as defined in the 2016 Plan, our board of directors shall decide on an exercise period. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
administrator may amend, the 2016 Plan at any time, subject to stockholder approval where such approval is required by applicable law. The administrator of the 2016 Plan may also
amend, any outstanding award, provided that no amendment to an award may materially and adversely affect a participant's rights without his or her consent. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
2016 Plan will terminate automatically upon September&nbsp;30, 2026. As of June&nbsp;30, 2019, options to purchase 2,761,794&nbsp;shares of common stock were outstanding under
the 2016 Plan. In connection with the Holdco Reorganization and prior to the completion of this Offering, each outstanding option to purchase common stock of Aprea AB issued pursuant to the 2016 Plan
will be canceled, and we will issue to the holder of each such Aprea AB option, a substitute option to purchase shares of our common stock pursuant to our 2019 Plan. See "Corporate Reorganization" for
further detail regarding these transactions. Our board of directors has determined not to make any further awards under the 2016 Plan following the completion of this offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>166</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=171,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=118296,FOLIO='166',FILE='DISK116:[19ZBM1.19ZBM17601]EC17601A.;72',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_ec17601_1_167"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2019 Stock incentive plan  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with this offering, our board of directors expects to adopt, and our current stockholders expect to approve, the 2019 Stock
Incentive Plan, or the 2019 Plan, prior to the effective date of this offering. The 2019 Plan will replace the 2016 Plan, as described above. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
purposes of the 2019 Plan are to align the interests of our stockholders and those eligible for awards, to retain officers, directors, employees, and other service providers, and to
encourage them to act in our long-term best interests. Our 2019 Plan provides for the grant of incentive stock options (within the meaning of Internal Revenue Code Section&nbsp;422), nonstatutory
stock options, stock appreciation rights, restricted stock, restricted stock units, other stock awards, and performance awards. Officers, directors, employees, consultants, agents and independent
contractors who provide services to us or to any subsidiary of ours are eligible to receive awards under the 2019 Plan. The material terms of the 2019 Plan are expected to be as follows: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock subject to the plan.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The number of shares reserved for issuance under the 2019 Plan, including shares issuable upon exercise of
options
substituted for those originally issued under the 2016 Plan as well as stock options previously issued to our director, Bernd Seizinger, under a separate plan in 2015, is 5,000,000, plus an annual
increase added on the first day of each fiscal year, beginning with the fiscal year ending December&nbsp;31, 2020 and continuing until, and including, the fiscal year ending December&nbsp;31,
2029. The annual increase will be equal to the lesser of (i)&nbsp;4% of the number of shares of common stock outstanding on the first day of such fiscal year, (ii)&nbsp;5,000,000 shares of our
common stock or (iii)&nbsp;such other amount determined by our board of directors. To the extent an equity award granted under the 2019 Plan, including awards granted in exchange for awards under
the 2016 Plan or any
other prior equity plan of the Company (other than any substitute award), expires or otherwise terminates without having been exercised or paid in full, or is settled in cash, the shares subject to
such award will become available for future grant under the 2019 Plan. In addition, to the extent shares subject to an award granted under the 2019 Plan or a prior equity plan of the Company are
withheld to satisfy a participant's tax withholding obligation upon the exercise or settlement of such award (other than any substitute award) or to pay the exercise price of a stock option, such
shares will become available for future grant under the 2019 Plan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Plan administration.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our compensation committee will administer the 2019 Plan. Our board of directors has the authority to amend and
modify the plan,
subject to any stockholder approval required by applicable law or stock exchange rules. Subject to the terms of the 2019 Plan, our compensation committee will have the authority to determine the
eligibility for awards and the terms, conditions, and restrictions, including vesting terms, the number of shares subject to an award, and any performance goals applicable to grants made under the
2019 Plan. The compensation committee also will have the authority, subject to the terms of the 2019 Plan, to construe and interpret the 2019 Plan and awards, and amend outstanding awards at any time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock options and stock appreciation rights.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our compensation committee may grant incentive stock options, nonstatutory stock options,
and stock
appreciation rights under the 2019 Plan, provided that incentive stock options are granted only to employees. Other than with respect to options issued in substitution of awards granted under the 2016
Plan and other prior plans, the exercise price of stock options and stock appreciation rights under the 2019 Plan will be fixed by the compensation committee, but must equal at least 100% of the fair
market value of our common stock on the date of grant. The term of an option or stock appreciation right may not exceed ten years; provided, however, that an incentive stock option held by an employee
who owns more than 10% of all of our classes of stock, or of certain of our affiliates, may not have a term in excess of five years, and must have an exercise price of at least 110% of the fair market
value of our common stock on the grant date. Subject to the provisions of the 2019 Plan, the compensation committee will determine the remaining terms of the options and stock appreciation rights
(e.g.,&nbsp;vesting). Upon a participant's termination of service, the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>167</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=172,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=1002929,FOLIO='167',FILE='DISK116:[19ZBM1.19ZBM17601]EC17601A.;72',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_ec17601_1_168"> </A>

<P style="font-family:times;"><FONT SIZE=2>participant
may exercise his or her option or stock appreciation right, to the extent vested (unless the compensation committee permits otherwise), as specified in the award agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock awards.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our compensation committee will decide at the time of grant whether an award will be in
the form of restricted stock, restricted stock units, or other stock award. The compensation committee will determine the number of shares subject to the award, vesting, and the nature of any
performance measures. Unless otherwise specified in the award agreement, the recipient of restricted stock will have voting rights and be entitled to receive dividends with respect to his or her
shares of restricted stock. The recipient of restricted stock units will not have voting rights, but his or her award agreement may provide for the receipt of dividend equivalents. Our compensation
committee may grant other stock awards that are based on or related to shares of our common stock, such as awards of shares of common stock granted as bonus and not subject to any vesting conditions,
deferred stock units, stock purchase rights, and shares of our common stock issued in lieu of our obligations to pay cash under any compensatory plan or arrangement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Performance awards.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our compensation committee will determine the value of any performance award, the vesting and nature of the
performance measures,
and whether the award is denominated or settled in cash or in shares of our common stock. The performance goals applicable to a particular award will be determined by our compensation committee at the
time of grant. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transferability of awards.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The 2019 Plan does not allow awards to be transferred other than by will or the laws of inheritance
following the
participant's death, and options may be exercised, during the lifetime of the participant, only by the participant. However, an award agreement may permit a participant to assign an award to a family
member by gift or pursuant to a domestic relations order, or to a trust, family limited partnership or similar entity established for one of the participant's family members. A participant may also
designate a beneficiary who will receive outstanding awards upon the participant's death. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain adjustments.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If any change is made in our common stock subject to the 2019 Plan, or subject to any award agreement under the
2019 Plan,
without the receipt of consideration by us, such as through a stock split, stock dividend, extraordinary distribution, recapitalization, combination of shares, exchange of shares or other similar
transaction, appropriate adjustments will be made in the number, class, and price of shares subject to each outstanding award and the numerical share limits contained in the plan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in control.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Subject to the terms of the applicable award agreement, upon a "change in control" (as defined in the 2019 Plan),
our board of
directors may, in its discretion, determine whether some or all outstanding options and stock appreciation rights will become exercisable in full or in part, whether the restriction period and
performance period applicable to some or all outstanding restricted stock awards and restricted stock unit awards will lapse in full or in part and whether the performance measures applicable to some
or all outstanding awards will be deemed to be satisfied. Our board of directors may further require that shares of stock of the corporation resulting from such a change in
control, or a parent corporation thereof, be substituted for some or all of our shares of common stock subject to an outstanding award and that any outstanding awards, in whole or in part, be
surrendered to us by the holder and be immediately cancelled by us in exchange for a cash payment, shares of common stock of the corporation resulting from or succeeding us or a combination of both
cash and such shares of stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clawback.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Awards granted under the 2019 Plan and any cash payment or shares of our common stock delivered pursuant to an award are
subject to
forfeiture, recovery, or other action pursuant to the applicable award agreement or any clawback or recoupment policy that we may adopt. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Plan termination and amendment.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors has the authority to amend, suspend, or terminate the 2019 Plan, subject to any
requirement of
stockholder approval required by law or stock </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>168</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=173,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=687362,FOLIO='168',FILE='DISK116:[19ZBM1.19ZBM17601]EC17601A.;72',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<A NAME="page_ec17601_1_169"> </A>

<P style="font-family:times;"><FONT SIZE=2>exchange
rules. Our 2019 Plan will terminate on the ten-year anniversary of its approval by our board of directors, unless we terminate it earlier. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;New plan benefits.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The compensation committee has the discretion to grant awards under the 2019 Plan, and therefore it is not possible
at the time of
filing of this prospectus to determine future awards that will be received by our named executive officers or others under the 2019 Plan. All officers, directors, employees, consultants, agents and
independent contractors of the Company and its subsidiaries are eligible for consideration to participate in the 2019 Plan. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with this offering, our board of directors granted stock option awards to certain employees of the Company with respect to an aggregate amount of 807,353 shares, and with
an exercise price equal to the initial public offering price and which vest 25% on the one-year anniversary of the date of grant and monthly thereafter, subject to early vesting in the event of a
change in control or certain terminations of employment. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2019 Employee stock purchase plan  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with this offering, our board of directors will adopt and our current stockholders expect to approve the Aprea
Therapeutics,&nbsp;Inc. Employee Stock Purchase Plan, or the ESPP, to be effective upon the completion of this offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Generally,
all of our employees (including those of our consolidated subsidiaries, other than those subsidiaries excluded from participation by our board of directors or compensation
committee) who have been employed for at least 90&nbsp;days are eligible to participate in the ESPP. The ESPP permits employees to purchase our common stock through payroll deductions during
six-month offering periods. Participants may authorize payroll deductions of a specific percentage of compensation of up to 15%, with such deductions being accumulated for six-month purchase periods
beginning on the first business day of each offering period and ending on the last business day of each offering period. Under the terms of the ESPP, the purchase price per share with respect to an
offering period will equal the lesser of (i)&nbsp;85% of the fair market value of a share of our common stock on the first business day of such offering period and (ii)&nbsp;85% of the fair market
value of a share of our common stock on the last business day of such offering period, although the compensation committee has discretion to change the purchase price with respect to future offering
periods, subject to the terms of the ESPP. No employee may participate in an offering period if the employee owns 5% or more of the total combined voting power or value of our stock or the stock of
any of our subsidiaries. No participant may purchase more than 5,000 shares of our common stock during any offering period. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;250,000
shares of our common stock, subject to adjustment for stock splits, stock dividends or other changes in our common stock, have been reserved for issuance under the ESPP. Subject
to the adjustment provisions contained in the ESPP, the maximum number of shares of our common stock available under the ESPP will automatically increase on the first trading day in January of each
calendar year, commencing January&nbsp;1, 2020, by an amount equal to the lesser of 1% of the shares of our common stock issued and outstanding on December&nbsp;31 of the immediately preceding
calendar year, 250,000 shares of our common stock or such lesser amount as is determined by our board of directors. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
ESPP will be administered by the compensation committee or a designee of the compensation committee. The ESPP may be amended by our board of directors or the compensation committee
but may not be amended without prior stockholder approval to the extent required by Section&nbsp;423 of the Code. The ESPP shall continue in effect until the earlier of (i)&nbsp;the termination of
the ESPP by our board of directors or the compensation committee pursuant to the terms of the ESPP and (ii)&nbsp;the ten-year anniversary of the effective date of the ESPP, with no new offering
periods commencing on or after such ten-year anniversary. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>169</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=174,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=329592,FOLIO='169',FILE='DISK116:[19ZBM1.19ZBM17601]EC17601A.;72',USER='CHE108067',CD='27-SEP-2019;09:02' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ee17601_1_170"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ee17601_certain_relationships___ee102279"> </A>
<A NAME="toc_ee17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Certain relationships and related persons transactions    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since January&nbsp;1, 2016, we have engaged in the following transactions in which the amount involved exceeded $120,000 and any of our
directors, executive officers or beneficial holders of more than 5% of any class of our voting securities, or any of their affiliates, had a material interest. We believe that all of these
transactions were on terms comparable to terms that could have been obtained from unrelated third parties. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Series&nbsp;A preferred stock financing  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2011, the board of Aprea AB resolved to issue 145,469 Series&nbsp;A preferred shares in Aprea AB at a price per share of $22.22,
for an aggregate purchase price of $3.2&nbsp;million. In March 2016, Aprea AB issued 466,977 Series&nbsp;A preferred shares in Aprea AB at a price per share of $6.96 in connection with the
repayment of loans made to the Company by KDev Group (includes KDev Investments, KCIF Co-Investment Fund KB and Karolinska Development). These Series&nbsp;A preferred shares in Aprea AB were
contributed and exchanged for shares of Series&nbsp;A preferred stock in the Company in connection with the Holdco Reorganization. The following table sets forth the number of shares of our
Series&nbsp;A preferred stock owned by our directors, executive officers and 5% stockholders, and their affiliates, and the aggregate purchase price paid for those shares, in each case, after giving
effect to the Holdco Reorganization. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares of<BR>
Series&nbsp;A<BR>
preferred stock<BR>
purchased </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
purchase<BR>
price(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>KDev Group</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>579,647</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,753,978</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Includes
$3,249,627 in connection with the repayment of loans made to the Company. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Series&nbsp;B preferred stock financing  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In March 2016, Aprea AB, the shareholders of the Company and a number of investors entered into a Series&nbsp;B investment agreement for the
issue of up to 7,235,969 Series&nbsp;B preferred shares in Aprea AB in one or more closings. In March 2016, Aprea AB issued 3,322,762 Series&nbsp;B preferred shares at a price per share of $6.81,
for an aggregate purchase price of $22.6&nbsp;million,. In March 2016, Aprea AB also issued 590,445 Series&nbsp;B preferred shares in Aprea AB at a price per share of $6.81 in connection with the
repayment of loans made to the Company by existing investors totaling $4.1&nbsp;million. In October 2017, Aprea AB issued 3,322,762 Series&nbsp;B preferred shares at a price per share of $7.02,
for an aggregate purchase price of $23.3&nbsp;million. These Series&nbsp;B preferred shares in
Aprea AB were contributed and exchanged for shares of Series&nbsp;B preferred stock in the Company in connection with the Holdco Reorganization. The following table sets forth the number of shares
of our Series&nbsp;B preferred stock owned by our directors, executive officers and 5% stockholders, and their affiliates, and the aggregate purchase price paid for those shares, in each case, after
giving effect to the Holdco Reorganization. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares of<BR>
Series&nbsp;B<BR>
preferred stock<BR>
purchased </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
purchase<BR>
price </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>5AM Ventures</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,993,658</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13,783,254</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>HealthCap</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,661,382</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,490,331</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>KDev Group(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>590,445</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,108,818</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Sectoral Asset Management</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>996,826</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,898,961</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Versant</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,993,658</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13,786,556</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Includes
$4,108,818 in connection with the repayment of loans made to the Company. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>170</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=175,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=249214,FOLIO='170',FILE='DISK116:[19ZBM1.19ZBM17601]EE17601A.;107',USER='CHE106759',CD='27-SEP-2019;11:56' -->
<A NAME="page_ee17601_1_171"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Series&nbsp;C preferred stock financing  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2018, Aprea AB, certain shareholders of the Company and a number of investors entered into a Series&nbsp;C investment agreement
for the issue of 4,712,698 Series&nbsp;C preferred shares in Aprea AB at a price per share of $12.08, for an aggregate purchase price of $56.7&nbsp;million. In February 2019, Aprea AB, certain
shareholders of the Company and a number of investors entered into an additional Series&nbsp;C investment agreement for the issue of 467,179 Series&nbsp;C preferred shares in Aprea AB at a price
per share of $12.10, for an aggregate purchase price of $5.6&nbsp;million. These Series&nbsp;C preferred shares in Aprea AB were contributed and exchanged for shares of Series&nbsp;C preferred
stock in the Company in connection with the Holdco Reorganization. The following table sets forth the number of shares of our Series&nbsp;C preferred stock owned by our directors, executive officers
and 5% stockholders, and their affiliates, and the aggregate purchase price paid for those shares, in each case, after giving effect to the Holdco Reorganization. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares of<BR>
Series&nbsp;C<BR>
preferred stock<BR>
purchased </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
purchase<BR>
price </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>5AM Ventures</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>512,994</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,164,954</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>HealthCap</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>427,496</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,147,150</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>KDev Group</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>430,467</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,180,090</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Redmile(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,868,718</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>22,472,429</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Sectoral Asset Management</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>467,179</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,614,984</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Versant</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>512,995</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,197,369</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Includes
1,454,926 shares held by Redmile Biopharma Investments I,&nbsp;L.P. and 413,792 shares held by RAF&nbsp;L.P. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Registration rights agreement  </B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a party to an amended and restated registration rights agreement, dated as of September&nbsp;20, 2019 (the "Registration Rights
Agreement"), with our existing stockholders, including certain holders of five percent or more of our common stock and their affiliates and entities affiliated with certain of our directors. The
Registration Rights Agreement provides these holders the right, following the completion of this offering, to demand that we file&nbsp;a registration statement or request that their shares be
covered by a registration statement that we are otherwise filing. See "Description of Capital Stock&#151;Registration Rights" for additional information regarding these registration rights.

</FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employment agreements  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See the "Executive Compensation&#151;Employment agreements, severance and change in control agreements" section of this prospectus for a
further discussion of these arrangements. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Indemnification agreements  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this offering,
provides that we will indemnify our directors and officers to the fullest extent permitted by Delaware law. In addition, we plan to enter into indemnification agreements with each of our officers and
directors that may be broader in scope than the specific indemnification provisions contained in the Delaware General Corporation Law. See "Management&#151;Limitation on Liability and
Indemnification" for additional information regarding these agreements. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Policies and procedures for related person transactions  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Following this offering, pursuant to the written charter of our audit committee adopted in September of 2019, our audit committee of the board
of directors will be responsible for reviewing and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>171</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=176,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=61393,FOLIO='171',FILE='DISK116:[19ZBM1.19ZBM17601]EE17601A.;107',USER='CHE106759',CD='27-SEP-2019;11:56' -->
<A NAME="page_ee17601_1_172"> </A>

<P style="font-family:times;"><FONT SIZE=2>approving,
prior to our entry into any such transaction, all related person transaction s involving a principal stockholder, a member of the board of directors, senior management or an immediate
family member of any of the aforementioned individuals. In addition, our code of business conduct and ethics requires that our officers and employees avoid taking for themselves personally
opportunities that are discovered through the use of our property, information or position or use of our property, information or position for personal gain. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>172</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=177,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=180399,FOLIO='172',FILE='DISK116:[19ZBM1.19ZBM17601]EE17601A.;107',USER='CHE106759',CD='27-SEP-2019;11:56' -->
<A NAME="page_ee17601_1_173"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ee17601_principal_stockholders"> </A>
<A NAME="toc_ee17601_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Principal Stockholders    <BR>    </B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information with respect to the beneficial ownership of our common stock as of September&nbsp;26, 2019
by:</FONT>

</P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each of our directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each of our named executive officers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> all of our directors and executive officers as a group; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our common stock. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The number of shares beneficially owned by each entity, person, director or executive officer is determined in accordance with the rules of the SEC, and the information is not
necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any shares over which the individual has sole or shared voting power or investment
power as well as any shares that the individual has the right to acquire within 60&nbsp;days of September&nbsp;26, 2019, through the exercise of any stock option or other rights. Except as
otherwise indicated, and subject to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all shares of common stock held by that
person.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The percentage of shares beneficially owned is computed on the basis of 14,209,865 shares of our common stock outstanding as of September&nbsp;26, 2019, which reflects the 1&nbsp;for
1.6045 split of our common stock which took place on September 26, 2019 and the conversion of all outstanding shares of convertible preferred stock, including the shares issued as part of the Holdco
Reorganization, into 13,028,292 shares of common stock immediately prior to the completion of this offering. The percentage of shares beneficially owned after this offering is computed on the basis of
shares of common stock outstanding immediately after the completion of this offering (assuming no exercise of the underwriters' option to purchase additional shares of our common stock). Shares of our
common stock that a person has the right to acquire within 60&nbsp;days of September&nbsp;26, 2019, are deemed outstanding for purposes of computing the percentage ownership of the person holding
such rights, but are not deemed outstanding for purposes of computing the percentage ownership of any other person, except with respect to the percentage ownership of all directors and executive
officers as a group.


</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The table below does not reflect any shares of common stock that directors, executive officers and entities may purchase in this offering through the directed share program described
under

</FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>173</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=178,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=16009,FOLIO='173',FILE='DISK116:[19ZBM1.19ZBM17601]EE17601A.;107',USER='CHE106759',CD='27-SEP-2019;11:56' -->
<A NAME="page_ee17601_1_174"> </A>

<P style="font-family:times;"><FONT SIZE=2>


"Underwriting&#151;Directed Share Program." Unless otherwise indicated below, the address for each beneficial owner listed is c/o Aprea Therapeutics,&nbsp;Inc., at 535 Boylston Street,
Boston, MA 02116.

</FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="37pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="37pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage of<BR>
shares<BR>
beneficially<BR>
owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
shares<BR>
beneficially<BR>
owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name of beneficial owner

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Before<BR>
offering </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>After<BR>
offering </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>5.0% Stockholders</I></B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>KDev Group(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,444,837</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>17.21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12.73</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Versant(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,519,322</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>17.73</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13.11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>5AM Ventures(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,519,320</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>17.73</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13.11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>HealthCap(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,099,438</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14.77</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.93</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Redmile Group(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,868,718</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13.15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9.73</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Sectoral Asset Management(6)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,470,339</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.35</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7.65</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>Executive Officers and Directors</I></B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Christian S. Schade(7)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>553,327</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.75</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2.80</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lars Abrahmsen, Ph.D.(8)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>122,666</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Eyal C. Attar, MD</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Scott&nbsp;M. Coiante</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Gregory A. Korbel, Ph.D.(9)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>100,964</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Guido Magni, M.D., Ph.D.(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,519,322</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>17.73</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13.11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Scott M. Rocklage, Ph.D.(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,519,320</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>17.73</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13.11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Johan Christenson, M.D., Ph.D.(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,099,438</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14.77</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.93</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jonathan Hepple, Ph.D.(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,992,591</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14.02</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.37</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bernd R. Seizinger, M.D., Ph.D.(10)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>263,970</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.82</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.36</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>John&nbsp;B. Henneman&nbsp;III(11)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All directors and executive officers as a group (11 persons)(12)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,171,598</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>66.70</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>50.23</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Represents
beneficial ownership of less than 1% of our outstanding stock.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of (i)&nbsp;481,909 shares of common stock issuable upon conversion of shares of Series&nbsp;A convertible preferred stock held of record by KDev
Investments, (ii)&nbsp;37,169 shares of common stock issuable upon conversion of shares of Series&nbsp;A convertible preferred stock held of record by KCIF Co-Investment Fund KB,
(iii)&nbsp;60,569 shares of common stock issuable upon conversion of shares of Series&nbsp;A convertible preferred stock held of record by Karolinska Development, (iv)&nbsp;510,035 shares of
common stock issuable upon conversion of shares of Series&nbsp;B convertible preferred stock held of record by KDev Investments, (v)&nbsp;19,841 shares of common stock issuable upon conversion of
shares of Series&nbsp;B convertible preferred stock held of record by KCIF Co-Investment Fund KB, (vi)&nbsp;60,569 shares of common stock issuable upon conversion of shares of Series&nbsp;B
convertible preferred stock held of record by Karolinska Development, (vii)&nbsp;233,591 shares of common stock issuable upon conversion of shares of Series&nbsp;C convertible preferred stock held
of record by KDev Investments, (viii)&nbsp;34,321 shares of common stock issuable upon conversion of shares of Series&nbsp;C convertible preferred stock held of record by KCIF Co-Investment Fund
KB, (ix)&nbsp;162,555 shares of common stock issuable upon conversion of shares of Series&nbsp;C convertible preferred stock held of record by Karolinska Development, (x)&nbsp;767,056 shares of
common stock held of record by KDev Investments and (xi)&nbsp;77,222 shares of common stock held of record by KCIF Co-Investment Fund&nbsp;KB, or collectively, the KDev Group Entities. Jonathan
Hepple is co-founder and director of Rosetta Capital Limited, the investment manager of certain private investment vehicles that own shares of KDev Investments. Dr.&nbsp;Hepple does not share voting
and investment power over the shares held by any of the KDev Group Entities and disclaims beneficial ownership of all shares held by the KDev Group Entities except to the extent of his pecuniary
interest therein. Dr. Hepple is a member of our board of directors. The address for each of these entities is c/o KDev Group, Tomtebodav&auml;gen&nbsp;23A, 171&nbsp;65&nbsp;Solna,
Sweden.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of (i)&nbsp;1,993,658 shares of common stock issuable upon conversion of shares of Series&nbsp;B convertible preferred stock, (ii)&nbsp;512,995 shares
of common stock issuable upon conversion of shares of Series&nbsp;C convertible preferred stock and (iii)&nbsp;12,670 shares of common stock. Guido Magni, a partner of Versant Venture </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>174</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=179,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=853489,FOLIO='174',FILE='DISK116:[19ZBM1.19ZBM17601]EE17601A.;107',USER='CHE106759',CD='27-SEP-2019;11:56' -->
<A NAME="page_ee17601_1_175"> </A>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <UL>

<P style="font-family:times;"><FONT SIZE=1>Management,&nbsp;LLC,
does not share voting and investment power over the shares held of record by Versant. Dr.&nbsp;Magni disclaims beneficial ownership of all shares held by Versant except to
the extent of his pecuniary interest therein. Dr.&nbsp;Magni is a member of our board of directors. The address for Versant is 15&nbsp;Boulevard&nbsp;F.W. Raiffeisen,&nbsp;2411 Luxembourg. </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of (i)&nbsp;1,913,910 shares of common stock issuable upon conversion of shares of Series&nbsp;B convertible preferred stock held of record by 5AM
Ventures IV,&nbsp;LP, (ii)&nbsp;79,746 shares of common stock issuable upon conversion of shares of Series&nbsp;B convertible preferred stock held of record by 5AM
Co-Investors&nbsp;IV,&nbsp;L.P., (iii)&nbsp;492,475 shares of common stock issuable upon conversion of shares of Series&nbsp;C convertible preferred stock held of record by 5AM Ventures
IV,&nbsp;L.P. (iv)&nbsp;20,519 shares of common stock issuable upon conversion of shares of Series&nbsp;C convertible preferred stock held of record by 5AM Co-Investors&nbsp;IV,&nbsp;L.P.,
(v)&nbsp;12,163 shares of common stock held of record by 5AM Ventures&nbsp;IV,&nbsp;L.P. and (vi)&nbsp;507 shares of common stock held of record by 5AM Co-Investors&nbsp;IV,&nbsp;L.P.
Scott Rocklage, a Managing Member of 5AM Partners&nbsp;IV,&nbsp;LLC, the General Partner of 5AM&nbsp;Ventures&nbsp;IV,&nbsp;L.P. and 5AM Co-Investors&nbsp;IV,&nbsp;L.P., may be deemed to
share voting and investment power over the shares held of record by 5AM&nbsp;Ventures&nbsp;IV,&nbsp;L.P. and 5AM Co-Investors&nbsp;IV,&nbsp;L.P. Dr.&nbsp;Rocklage is a member of our board
of directors. The address for each of these entities is c/o 5AM&nbsp;Ventures, 501&nbsp;2nd&nbsp;Street, Suite&nbsp;350, San Francisco,&nbsp;CA 94107.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of (i)&nbsp;1,661,382 shares of common stock issuable upon conversion of shares of Series&nbsp;B convertible preferred stock, (ii)&nbsp;427,496 shares
of common stock issuable upon conversion of shares of Series&nbsp;C convertible preferred stock and (iii)&nbsp;10,559 shares of common stock. Johan Christenson, a partner of HealthCap&nbsp;VII
Advisor&nbsp;AB, is acting as advisor to HealthCap VII&nbsp;LP. Dr.&nbsp;Christenson disclaims beneficial ownership of all shares held by Healthcap except to the extent of his pecuniary interest
therein. Dr.&nbsp;Christenson is a member of our board of directors. The address for HealthCap is 18&nbsp;Avenue of d'Ouchy&nbsp;CH-1006&nbsp;Lausanne, Switzerland.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of (i)&nbsp;1,454,926 shares of common stock issuable upon conversion of shares of Series&nbsp;C convertible preferred stock held of record by Redmile
Biopharma Investments I,&nbsp;L.P. and (ii)&nbsp;413,792 shares of common stock issuable upon conversion of shares of Series&nbsp;C convertible preferred stock held of record by RAF,&nbsp;L.P.
(together with Redmile Biopharma Investments I,&nbsp;L.P., the "Redmile Funds"). Redmile Group,&nbsp;LLC is the investment manager to the Redmile Funds and, in such capacity, exercises shared
voting and dispositive power over the securities held by the Redmile Funds and may be deemed to beneficially own such securities. Jeremy Green serves as the managing member of Redmile
Group,&nbsp;LLC and as such shares voting and dispositive power over the securities held by the Redmile Funds. Redmile Group,&nbsp;LLC and Mr.&nbsp;Green each disclaim beneficial ownership of
these securities, except to the extent of its or his pecuniary interest in such securities, if any. The address for each of the above person and entities is One Letterman Drive, Building D, Suite
D3-300, San Francisco, CA 94129.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of (i)&nbsp;996,826 shares of common stock issuable upon conversion of shares of Series&nbsp;B convertible preferred stock, (ii)&nbsp;467,179 shares
of common stock issuable upon conversion of shares of Series&nbsp;C convertible preferred stock and (iii)&nbsp;6,334 shares of common stock. The address for Sectoral Asset Management is
1010&nbsp;Sherbrooke St.&nbsp;West, #1610, Montreal, QC&nbsp;Canada&nbsp;H3A&nbsp;2R7.

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of (i)&nbsp;160 shares of common stock issued in connection with the initial capital contribution to the Company, and (ii)&nbsp;553,167 shares of common
stock issuable upon the exercise of stock options exercisable within 60&nbsp;days of September&nbsp;26, 2019.



<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 122,666 shares of common stock issuable upon the exercise of stock options exercisable within 60&nbsp;days of September&nbsp;26, 2019.


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(9)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 100,964 shares of common stock issuable upon the exercise of stock options exercisable within 60&nbsp;days of September&nbsp;26,
2019.


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(10)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of 263,970 shares of common stock issuable upon the exercise of stock options exercisable within 60&nbsp;days of September&nbsp;26, 2019.


<BR><BR></FONT></DD>



<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(11)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Does
not include options to purchase shares of common stock, to be valued at $185,000 based on the initial public offering price of the Company's common stock,
approved for grant to Mr.&nbsp;Henneman, which grant is contingent and effective upon the effectiveness of the registration statement of which this prospectus forms a part. The final number of
shares will not be calculated until the price of the initial public offering of the Company's common stock has been finalized and will be computed using the Black-Scholes option-pricing model.

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(12)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Consists
of shares described in notes. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>175</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=180,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=462780,FOLIO='175',FILE='DISK116:[19ZBM1.19ZBM17601]EE17601A.;107',USER='CHE106759',CD='27-SEP-2019;11:56' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_eg17601_1_176"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="eg17601_description_of_capital_stock"> </A>
<A NAME="toc_eg17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Description of Capital Stock    <BR>    </B></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Following the completion of this offering and the completion of the Holdco Reorganization as described in the "Corporate Reorganization" section
of this prospectus, and the conversion of all outstanding shares of our convertible preferred stock into common stock immediately prior to the completion of this offering, our authorized capital stock
will consist of 400,000,000 shares of common stock, par value $0.001 per share, and 40,000,000 shares of preferred stock, par value $0.001 per share, all of which preferred stock will be undesignated.
The following description of our capital stock and provisions of our amended and restated certificate of incorporation and amended and restated bylaws are summaries and are qualified by reference to
the certificate of incorporation and the bylaws that will become effective as of the closing date of this offering. We have filed copies of these documents as exhibits to our registration statement of
which this prospectus forms&nbsp;a part. The descriptions of the common stock and preferred stock reflect changes to our capital structure that will occur as of immediately prior to the completion
of this offering. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Common stock  </B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of June&nbsp;30, 2019, we had outstanding 14,209,865 shares of common stock (including 2,807 shares of common stock from the exercise of
stock options on March&nbsp;25, 2019, which were registered pursuant to Swedish law with the Swedish Companies Registration Office on August&nbsp;27, 2019), reflecting the completion of the Holdco
Reorganization and the 1 for 1.6045 split of our common stock and assuming the automatic conversion of all outstanding shares of our preferred stock into 13,028,292 shares of common stock immediately
prior to the completion of this offering, which were held of record by 25&nbsp;stockholders.

 </FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders
of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of
directors by our stockholders will be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Other matters shall be decided by the affirmative vote of our
stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matter, except as otherwise disclosed below. Holders of common stock are
entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of outstanding preferred stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event of our liquidation or dissolution, the holders of common stock are entitled to receive proportionately all assets available for distribution to stockholders after the
payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of common stock have no preemptive, subscription, redemption or conversion
rights. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we
may designate and issue in the future. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Preferred stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the terms of our certificate of incorporation that will become effective as of the closing date of this offering, our board of directors
is authorized to issue shares of preferred stock in one or more series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges and
restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
purpose of authorizing our board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific
issuances. The issuance
of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes, could have the effect of making it more difficult for a third </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>176</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=181,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=587742,FOLIO='176',FILE='DISK116:[19ZBM1.19ZBM17601]EG17601A.;56',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<A NAME="page_eg17601_1_177"> </A>

<P style="font-family:times;"><FONT SIZE=2>party
to acquire, or could discourage a third party from seeking to acquire, a majority of our outstanding voting stock. As of immediately prior to the completion of this offering, there will be no
shares of preferred stock outstanding, and we have no present plans to issue any shares of preferred stock. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock options  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of June&nbsp;30, 2019, options to purchase 2,761,794 shares of our common stock at a weighted average exercise price of $1.66 per share
were outstanding, of which no options to purchase shares of our common stock were exercisable. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Registration rights  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are party to an amended and restated registration rights agreement, dated as of September&nbsp;20, 2019, pursuant to which certain of our
stockholders, including certain holders of five percent or more of our capital stock and their affiliates and entities affiliated with certain of our directors, have the right to demand that we
file&nbsp;a registration statement for their shares of our common stock or request that their shares of our common stock be covered by a registration statement that we are otherwise filing,
including, in each case, shares of our common stock that were issued upon conversion of convertible preferred stock. These shares are referred to as registrable securities. Such stockholders have
agreed not to exercise their registration rights during the lock-up period for this offering. See "Shares Eligible for Future Sale&#151;Lock-Up Agreements." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Demand registration rights  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At any time after 180&nbsp;days following the completion of this offering, the shareholders, as defined in the Registration Rights Agreement,
holding not less than fifty percent of the registrable securities have the right to demand that we file, a registration statement to register all or a portion of their registrable securities, provided
that the expected aggregate proceeds to be received from the sale of the registrable securities to be sold under the registration statement is equal to or exceeds $10.0&nbsp;million. We are not
obligated to file&nbsp;a registration statement pursuant to this demand provision (i)&nbsp;on more than one occasion within any six-month period or (ii)&nbsp;if at the time of such request, four
or more such demand registrations and underwritten takedowns, as defined in the Registration Rights Agreement, have previously been effected or deemed effected. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Form&nbsp;S-3 registration rights  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, if, at any time after the first anniversary of this offering, we become eligible to file&nbsp;a registration statement on
Form&nbsp;S-3 under the Securities Act, subject to specified limitations, a shareholder or a group of shareholders, as defined in the Registration Rights Agreement, may demand in writing that we
register on Form&nbsp;S-3 all or part of the registrable securities held by them. We are not obliged to effect more than one such underwritten takedown, as defined in the Registration Rights
Agreement, within any six-month period. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Piggyback registration rights  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If, at any time after the completion of this offering, we propose to file&nbsp;a registration statement to register any of our common stock
under the Securities Act (other than (i)&nbsp;a registration statement on Form&nbsp;S-3 or (ii)&nbsp;a registration statement relating to any employee benefit plan), either for our own account
or for the account of any of our stockholders that are not holders of registrable securities, the holders of our registrable securities are entitled to notice of registration and, subject to specified
exceptions, we will be required to use our commercially reasonable efforts to register the registrable securities then held by them that they request that we register. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>177</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=182,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=983430,FOLIO='177',FILE='DISK116:[19ZBM1.19ZBM17601]EG17601A.;56',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<A NAME="page_eg17601_1_178"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Expenses of registration  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the Registration Rights Agreement, we are required to pay all registration expenses, including registration fees, printing expenses,
fees and disbursements of our counsel and accountants and reasonable fees and disbursements of one counsel representing all shareholders, as defined in the Registration Rights Agreement, participating
in the offering, other than any underwriting discounts and commissions attributable to the sale of registrable securities, as defined in the Registration Rights Agreement. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Registration Rights Agreement contains customary cross-indemnification provisions, pursuant to which we are obligated to indemnify shareholders, as defined in the Registration Rights
Agreement, beneficially owning registrable securities covered by a registration statement in the event of material misstatements or omissions in the registration statement attributable to us, and each
shareholder, as defined in the Registration Rights Agreement, is obligated to indemnify us for material misstatements or omissions in the registration statement attributable to them. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Anti-Takeover effects of Delaware law and our charter and bylaws  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Delaware law contains, and upon the completion of this offering our certificate of incorporation and our bylaws will contain, provisions that
could have the effect of delaying, deferring or discouraging another party from acquiring control of us. These provisions, which are summarized below, are expected to discourage coercive takeover
practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Staggered board; removal of directors  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the completion of this offering, our certificate of incorporation and bylaws will divide our board of directors into three classes with
staggered three-year terms. In addition, a director will only be able to be removed for cause and only by the affirmative vote of the holders of at least 75% of the votes that all of our stockholders
would be entitled to cast in an annual election of directors. Any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, will only be able to
be filled by vote of a majority of our directors then in office. The classification of our board of directors and the limitations on the removal of directors and filling of vacancies could make it
more difficult for a third party to acquire, or discourage a third party from seeking to acquire, control of our company. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stockholder action by written consent; special meetings  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the completion of this offering, our certificate of incorporation will provide that any action required or permitted to be taken by our
stockholders must be effected at a duly called annual or special meeting of such holders and may not be effected by any consent in writing by such holders. Upon the completion of this offering, our
certificate of incorporation and bylaws will also provide that, except as otherwise required by law, special meetings of our stockholders can only be called by our chairman of the board, our Chief
Executive Officer or our board of directors. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Advance notice requirements for stockholder proposals  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the completion of this offering, our bylaws will establish an advance notice procedure for stockholder proposals to be brought before an
annual meeting of stockholders, including proposed nominations of persons for election to our board of directors. Stockholders at an annual meeting will only be able to consider proposals or
nominations specified in the notice of meeting or brought before the meeting by or at the direction of our board of directors or by a stockholder of record on the record date for the meeting who is
entitled to vote at the meeting and who has delivered timely written notice in proper form to our secretary of the stockholder's intention to bring such business before the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>178</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=183,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=458765,FOLIO='178',FILE='DISK116:[19ZBM1.19ZBM17601]EG17601A.;56',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<A NAME="page_eg17601_1_179"> </A>

<P style="font-family:times;"><FONT SIZE=2>meeting.
These provisions could have the effect of delaying until the next stockholder meeting stockholder actions that are favored by the holders of a majority of our outstanding voting securities. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Delaware business combination statute  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the completion of this offering, we will be subject to Section&nbsp;203 of the Delaware General Corporation Law. Subject to certain
exceptions, Section&nbsp;203 prevents a publicly held Delaware corporation from engaging in a "business combination" with any "interested stockholder" for three years following the date that the
person became an interested stockholder, unless the interested stockholder attained such status with the approval of our board of directors or unless the business combination is approved in a
prescribed manner. A "business combination" includes, among other things, a merger or consolidation involving us and the "interested stockholder" and the sale of more than 10% of our assets. In
general, an "interested stockholder" is any entity or person beneficially owning 15% or more of our outstanding voting stock and any entity or person affiliated with or controlling or controlled by
such entity or person. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Amendment of certificate of incorporation and bylaws  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Delaware General Corporation Law provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is
required to amend a corporation's certificate of incorporation or bylaws, unless a corporation's certificate of incorporation or bylaws, as the case may be, requires a greater percentage. Effective as
of the closing date of this offering, our bylaws may be amended or repealed by a majority vote of our board of directors or by the affirmative vote of the holders of at least 75% of the votes that all
of our stockholders would be entitled to cast in any annual election of directors. In addition, the affirmative vote of the holders of at least 75% of the votes that all of our stockholders would be
entitled to cast in any annual election of directors is required to amend or repeal or to adopt any provisions inconsistent with any of the provisions of our certificate of incorporation described
above under "&#151;Staggered board; removal of directors" and "&#151;Stockholder action by written consent; special meetings." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Exclusive forum selection  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective as of the closing date of this offering, our certificate of incorporation will provide that, unless we consent in writing to the
selection of an alternative forum, to the fullest extent permitted by law, the Court of Chancery of the State of Delaware (or if the Court of Chancery does not have jurisdiction, the federal district
court for the District of Delaware) shall be the sole and exclusive forum for (1)&nbsp;any derivative action or proceeding brought on behalf of our company under Delaware law, (2)&nbsp;any action
asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or employees to our company or our stockholders, (3)&nbsp;any action asserting a claim against our company
arising pursuant to any provision of the Delaware General Corporation Law or our amended and restated certificate of incorporation or bylaws, (4)&nbsp;any action asserting a claim against our
company governed by the internal affairs doctrine or (5)&nbsp;any other action asserting an "internal corporate claim," as defined in Section&nbsp;115 of the Delaware General Corporation Law.
These exclusive-forum provisions do not apply to claims under the Securities Act or the Exchange Act. Any person or entity purchasing or otherwise acquiring any interest in our securities shall be
deemed to have notice of and consented to this provision. Although we believe these provisions benefit us by providing increased consistency in the application of Delaware law for the specified types
of actions and proceedings, the provisions may have the effect of discouraging lawsuits against us or our directors and officers. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Listing on The Nasdaq Global Select Market  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have applied to have our common stock listed on The Nasdaq Global Select Market under the symbol "APRE." </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>179</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=184,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=293022,FOLIO='179',FILE='DISK116:[19ZBM1.19ZBM17601]EG17601A.;56',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<A NAME="page_eg17601_1_180"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Authorized but unissued shares  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The authorized but unissued shares of common stock and preferred stock are available for future issuance without stockholder approval, subject
to any limitations imposed by the listing requirements of The Nasdaq Global Select Market. These additional shares may be used for a variety of corporate finance transactions, acquisitions and
employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could make it more difficult or discourage an attempt to obtain control of us by means
of a proxy contest, tender offer, merger or otherwise. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Transfer agent and registrar  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The transfer agent and registrar for our common stock will be Computershare Trust Company,&nbsp;N.A. The transfer agent and registrar's
address is 150&nbsp;Royall St., Canton, MA&nbsp;02021. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>180</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=185,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=917230,FOLIO='180',FILE='DISK116:[19ZBM1.19ZBM17601]EG17601A.;56',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ei17601_1_181"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ei17601_shares_eligible_for_future_sale"> </A>
<A NAME="toc_ei17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Shares Eligible for Future Sale    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior to this offering, there has been no public market for our common stock. Future sales of our common stock, including shares issued upon the
exercise of outstanding options, in the public market after this offering, or the perception that those sales may occur, could cause the prevailing market price for our common stock to fall or impair
our ability to raise equity capital in the future. As described below, only a limited number of shares of our common stock will be available for sale in the public market for a period of several
months after the completion of this offering due to contractual and legal restrictions on resale described below. Future sales of our common stock in the public market either before (to the extent
permitted) or after restrictions lapse, or the perception that those sales may occur, could adversely affect the prevailing market price of our common stock at such time and our ability to raise
equity capital at a time and price we deem appropriate. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Sale of restricted shares  </B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on the number of shares of our common stock outstanding as of September&nbsp;26, 2019, and after giving effect to the Holdco
Reorganization and the conversion of all outstanding shares of our convertible preferred stock for common stock, upon the completion of this offering, we will have outstanding an aggregate of
approximately 19,209,865 shares of common stock. Of these shares, all of the shares of common stock to be sold in this offering will be freely tradable in
the public market without restriction or further registration under the Securities Act, unless the shares are held by any of our "affiliates" as such term is defined in Rule&nbsp;144 of the
Securities Act. All remaining shares of common stock held by existing stockholders immediately prior to the completion of this offering will be "restricted securities" as such term is defined in
Rule&nbsp;144. These restricted securities were issued and sold by us, or will be issued and sold by us, in private transactions and are eligible for public sale only if registered under the
Securities Act or if they qualify for an exemption from registration under the Securities Act, including the exemptions provided by Rule&nbsp;144 or Rule&nbsp;701, which rules are summarized
below.

</FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a result of the lock-up agreements referred to below and the provisions of Rule&nbsp;144 and Rule&nbsp;701 under the Securities Act, based on the number of shares of our common
stock outstanding as of September&nbsp;26, 2019, the shares of our common stock (excluding the shares sold in this offering) that will be available for sale in the public market are as follows:


</FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="143pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Approximate number of shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>First date available for sale into public market </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2> 14,179,428 shares</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>180&nbsp;days after the date of this prospectus upon expiration of the lock-up agreements referred to below, subject in some cases to applicable volume limitations under Rule&nbsp;144</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Lock-Up agreements  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with this offering, we, our directors, executive officers and holders of substantially all outstanding shares have agreed with the
underwriters, subject to certain exceptions, to not to dispose of or hedge any shares of our common stock or securities convertible into or exchangeable for shares of common stock during the period
from the date of the lock-up agreement continuing through the date 180&nbsp;days after the date of this prospectus, except with the prior written consent of J.P. Morgan Securities&nbsp;LLC and
Morgan Stanley&nbsp;&amp;&nbsp;Co.&nbsp;LLC. These agreements are subject to certain customary exceptions. See the section titled "Underwriting" for additional information. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to the completion of the offering, certain of our employees, including our executive officers, and/or directors may enter into written trading plans that are intended to comply
with Rule&nbsp;10b5-1 under the Exchange Act. Sales under these trading plans would not be permitted until the expiration of the lock-up agreements relating to the offering described above. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>181</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=186,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=213484,FOLIO='181',FILE='DISK116:[19ZBM1.19ZBM17601]EI17601A.;53',USER='CHE108062',CD='27-SEP-2019;09:54' -->
<A NAME="page_ei17601_1_182"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Following
the lock-up periods set forth in the agreements described above, and assuming that the representatives of the underwriters do not release any parties from these agreements, all
of the shares of our common stock that are restricted securities or are held by our affiliates as of the date of this prospectus will be eligible for sale in the public market in compliance with
Rule&nbsp;144 under the Securities Act. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Directed share program

 </B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At our request, the underwriters have reserved up to 3% of the shares for sale at the initial public offering price to those who are directors,
officers, employees, business associates and related persons to us through a directed share program. The number of shares available for sale to the
general public will be reduced by the number of directed shares purchased by participants in the program. Except for certain of our officers, directors and employees who have entered into lock-up
agreements, each person buying shares through the directed share program has agreed that, for a period of 180-days from the date of this prospectus, he or she will not, without the prior written
consent of Morgan Stanley &amp; Co. LLC, dispose of or hedge any shares purchased in the program or any securities convertible into or exchangeable or redeemable for our common stock with respect to
shares purchased in the program. For certain officers, directors and employees purchasing shares through the directed share program, the lock-up agreements described above with respect to the
underwriting agreement shall govern with respect to their purchases. Any directed shares not purchased will be offered by the underwriters to the general public on the same basis as all other shares
offered. We have agreed to indemnify the underwriters against certain liabilities and expenses, including liabilities under the Securities Act, in connection with the sales of the directed shares.

 </FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Rule&nbsp;144  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In general, under Rule&nbsp;144, as currently in effect, once we have been subject to the public company reporting requirements of the
Exchange Act for at least 90&nbsp;days, a person (or persons whose shares are required to be aggregated) who is not deemed to have been one of our "affiliates" for purposes of Rule&nbsp;144 at any
time during the three months preceding a sale, and who has beneficially owned restricted securities within the meaning of Rule&nbsp;144 for at least six months, including the holding period of any
prior owner other than one of our "affiliates," is entitled to sell those shares in the public market (subject to the lock-up agreement referred to above, if applicable) without complying with the
manner of sale, volume limitations or notice provisions of Rule&nbsp;144, but subject to compliance with the public information requirements of Rule&nbsp;144. If such a person has beneficially
owned the shares proposed to be sold for at least one year, including the holding period of any prior owner other than "affiliates," then such person is entitled to sell such shares in the public
market without complying with any of the requirements of Rule&nbsp;144 (subject to the lock-up agreement referred to above, if applicable). In general, under Rule&nbsp;144, as currently in effect,
once we have been subject to the public company reporting requirements of the Exchange Act for at least 90&nbsp;days, our "affiliates," as defined in Rule&nbsp;144, who have beneficially owned the
shares proposed to be sold for at least six months are entitled to sell in the public market, upon expiration of any applicable lock-up agreements and within any three-month period, a number of those
shares of our common stock that does not exceed the greater of:</FONT></P>


<UL>
<DL compact>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 1% of the number of shares of our common stock then outstanding, which will equal approximately 192,098 shares of common stock immediately
after this offering (calculated as of September&nbsp;26, 2019); or </FONT><FONT SIZE=2>

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the average weekly trading volume of our common stock on The Nasdaq Global Select Market during the four calendar weeks preceding the filing of
a notice on Form&nbsp;144 with respect to such sale. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>182</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=187,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=963221,FOLIO='182',FILE='DISK116:[19ZBM1.19ZBM17601]EI17601A.;53',USER='CHE108062',CD='27-SEP-2019;09:54' -->
<A NAME="page_ei17601_1_183"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Such
sales under Rule&nbsp;144 by our "affiliates" or persons selling shares on behalf of our "affiliates" are also subject to certain manner of sale provisions, notice requirements
and to the availability of current public information about us. Notwithstanding the availability of Rule&nbsp;144, the holders of substantially all of our capital stock and options have entered into
lock-up agreements as referenced above and their restricted securities will become eligible for sale (subject to the above limitations under Rule&nbsp;144) upon the expiration of the restrictions
set forth in those agreements. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Rule&nbsp;701  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In general, under Rule&nbsp;701 as currently in effect, any of our employees, directors, officers, consultants or advisors who acquired common
stock from us in connection with a written compensatory stock or option plan or other written agreement in compliance with Rule&nbsp;701 under the Securities Act before the effective date of the
registration statement of which this prospectus is a part (to the extent such common stock is not subject to a lock-up agreement) is entitled to rely on Rule&nbsp;701 to resell such shares beginning
90&nbsp;days after we become subject to the public company reporting requirements of the Exchange Act in reliance on Rule&nbsp;144, but without compliance with the holding period requirements
contained in Rule&nbsp;144. Accordingly, subject to any applicable lock-up agreements, beginning 90&nbsp;days after we become subject to the public company reporting requirements of the Exchange
Act, under Rule&nbsp;701 persons who are not our "affiliates," as defined in Rule&nbsp;144, may resell those shares without complying with the minimum holding period or public information
requirements of Rule&nbsp;144, and persons who are our "affiliates" may resell those shares without compliance with Rule&nbsp;144's minimum holding period requirements (subject to the terms of the
lock-up agreement referred to above, if applicable). </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Registration rights  </B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on the number of shares of common stock outstanding as of September&nbsp;26, 2019, after the completion of this offering, the holders of
approximately 14,200,000 shares of our
common stock, or their transferees, will, subject to any lock-up agreements they have entered into, be entitled to certain rights with respect to the registration of the offer and sale of those shares
under the Securities Act. For a description of these registration rights, please see the section titled "Description of Capital Stock&#151;Registration Rights." If the offer and sale of these
shares are registered, they will be freely tradable without restriction under the Securities Act.

</FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock plans  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We intend to file with the SEC a registration statement under the Securities Act covering the shares of common stock reserved for issuance under
our 2019 Stock Incentive Plan and 2019 Employee Stock Purchase Plan. Such registration statement is expected to be filed and become effective as soon as practicable after the completion of this
offering. Accordingly, shares registered under such registration statement will be available for sale in the open market following its effective date, subject to Rule&nbsp;144 volume limitations and
the lock-up agreements described above, if applicable. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>183</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=188,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=782232,FOLIO='183',FILE='DISK116:[19ZBM1.19ZBM17601]EI17601A.;53',USER='CHE108062',CD='27-SEP-2019;09:54' -->
<A NAME="page_ei17601_1_184"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ei17601_material_u.s._federal_income_t__mat02456"> </A>
<A NAME="toc_ei17601_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Material U.S. Federal Income Tax Considerations to Non-U.S. Holders    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a summary of material U.S. federal income tax consequences of the purchase, ownership and disposition of shares of our common
stock as of the date hereof. Except where noted, this summary deals only with common stock that was acquired in this offering and that is held as a capital asset by a non-U.S. holder (as defined
below). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
"non-U.S. holder" means a beneficial owner of shares of our common stock (other than an entity treated as a partnership for U.S. federal income tax purposes) that is not, for U.S.
federal income tax purposes, any of the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an individual citizen or resident of the United States; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a corporation (or any other entity treated as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of
the United States, any state thereof or the District of Columbia; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an estate the income of which is subject to U.S. federal income taxation regardless of its source; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a trust if it (1)&nbsp;is subject to the primary supervision of a court within the United States and one or more U.S. persons as defined
under the Code have the authority to control all substantial decisions of the trust or (2)&nbsp;has a valid election in effect under applicable U.S. Treasury regulations to be treated as a U.S.
person. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
summary is based upon provisions of the Internal Revenue Code of 1986, as amended (the "Code"), and regulations, rulings and judicial decisions as of the date hereof. Those
authorities may be changed, perhaps retroactively, so as to result in U.S. federal income consequences different from those summarized below. This summary does not address all aspects of U.S. federal
income taxes and does not deal with foreign, state, local or other tax considerations that may be relevant to non-U.S. holders in light of their particular circumstances. In addition, it does not
represent a detailed description of the U.S. federal income tax consequences applicable to you if you are subject to special treatment under the U.S. federal income tax laws (including if you are a
U.S. expatriate, foreign pension fund, "controlled foreign corporation," "passive foreign investment company" or a partnership or other pass-through entity for U.S. federal income tax purposes). We
cannot assure you that a change in law will not alter significantly the tax considerations that we describe in this summary. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a partnership (or other entity treated as a partnership for U.S. federal income tax purposes) holds shares of our common stock, the tax treatment of a partner and the partnership will
generally depend upon the status of the partner and the activities of the partnership. If you are a partnership or a partner of a partnership holding our common stock, you should consult your tax
advisors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>If you are considering the purchase of our common stock, you should consult your own tax advisors concerning the particular U.S. federal income tax consequences
to you of the purchase, ownership and
disposition of our common stock, as well as the consequences to you arising under other U.S. federal tax laws and the tax laws of any state, local or other taxing jurisdiction.</B></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Dividends  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have never paid cash dividends on our common stock and we do not anticipate paying any cash dividends in the foreseeable future. See
"Dividend Policy." If we make a distribution of cash or other property (other than certain </FONT><FONT SIZE=2><I>pro rata</I></FONT><FONT SIZE=2> distributions of our stock) in respect of shares of
our common stock, the distribution generally will be treated as a dividend for U.S. federal income tax purposes to the extent it is paid from our current or accumulated earnings and profits, as
determined under U.S. federal income tax principles. Any portion of a distribution that exceeds our current and accumulated earnings and profits generally will be treated first as a tax-free return of
capital, causing a </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>184</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=189,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=703709,FOLIO='184',FILE='DISK116:[19ZBM1.19ZBM17601]EI17601A.;53',USER='CHE108062',CD='27-SEP-2019;09:54' -->
<A NAME="page_ei17601_1_185"> </A>

<P style="font-family:times;"><FONT SIZE=2>reduction
in the adjusted tax basis of a non-U.S. holder's common stock, and to the extent the amount of the distribution exceeds a non-U.S. holder's adjusted tax basis in shares of our common stock,
the excess will be treated as gain from the disposition of shares of our common stock (the tax treatment of which is discussed below under "&#151;Gain on Disposition of Common Stock"). </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividends
paid to a non-U.S. holder generally will be subject to withholding of U.S. federal income tax at a 30% rate or such lower rate as may be specified by an applicable income tax
treaty. However, dividends that are effectively connected with the conduct of a trade or business by the non-U.S. holder within the United States (and, if required by an applicable income tax treaty,
are attributable to a U.S. permanent establishment) are not subject to the withholding tax, provided certain certification and disclosure requirements are satisfied. Instead, such dividends are
subject to U.S. federal income tax on a net income basis in the same manner as if the non-U.S. holder were a U.S. person as defined under the Code. Any such effectively connected dividends received by
a foreign corporation may be subject to an additional "branch profits tax" at a 30% rate or such lower rate as may be specified by an applicable income tax treaty. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
non-U.S. holder who wishes to claim the benefit of an applicable treaty rate and avoid backup withholding, as discussed below, for dividends will be required (a)&nbsp;to provide the
applicable withholding agent with a properly executed IRS Form&nbsp;W-BEN or Form&nbsp;W-8BEN-E (or other applicable form) certifying under penalty of perjury that such holder is not a U.S. person
as defined under the Code and is eligible for treaty benefits or (b)&nbsp;if our common stock is held through certain foreign intermediaries, to satisfy the relevant certification requirements of
applicable U.S. Treasury regulations. Special
certification and other requirements apply to certain non-U.S. holders that are pass-through entities rather than corporations or individuals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
non-U.S. holder eligible for a reduced rate of U.S. federal withholding tax pursuant to an income tax treaty may obtain a refund of any excess amounts withheld by timely filing an
appropriate claim for refund with the IRS. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Gain on disposition of common stock  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the discussion of backup withholding and FATCA below, any gain realized by a non-U.S. holder on the sale or other disposition of our
common stock generally will not be subject to U.S. federal income tax unless:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the gain is effectively connected with a trade or business of the non-U.S. holder in the United States (and, if required by an applicable
income tax treaty, is attributable to a U.S. permanent establishment of the non-U.S. holder); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the non-U.S. holder is an individual who is present in the United States for 183&nbsp;days or more in the taxable year of that disposition,
and certain other conditions are met; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we are or have been a "United States real property holding corporation" for U.S. federal income tax purposes and certain other conditions are
met. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
non-U.S. holder described in the first bullet point immediately above will be subject to tax on the gain derived from the sale or other disposition in the same manner as if the
non-U.S. holder were a U.S. person as defined under the Code. In addition, if any non-U.S. holder described in the first bullet point immediately above is a foreign corporation, the gain realized by
such non-U.S. holder may be subject to an additional "branch profits tax" at a 30% rate or such lower rate as may be specified by an applicable income tax treaty. An individual non-U.S. holder
described in the second bullet point
immediately above will be subject to a 30% (or such lower rate as may be specified by an applicable income tax treaty) tax on the gain derived from the sale or other disposition, which gain may be
offset by U.S. source capital losses even though the individual is not considered a resident of the United States. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>185</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=190,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=257771,FOLIO='185',FILE='DISK116:[19ZBM1.19ZBM17601]EI17601A.;53',USER='CHE108062',CD='27-SEP-2019;09:54' -->
<A NAME="page_ei17601_1_186"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Generally,
a corporation is a "United States real property holding corporation" if the fair market value of its U.S. real property interests equals or exceeds 50% of the sum of the fair
market value of its worldwide real property interests and its other assets used or held for use in a trade or business (all as determined for U.S. federal income tax purposes). We have not been, are
not and do not anticipate becoming a U.S. real property holding corporation for U.S. federal income tax purposes. If we are or become a "United States real property holding corporation," however, so
long as our common stock is regularly traded on an established securities market during the calendar year in which the sale or other disposition occurs, only a non-U.S. holder who holds or held (at
any time during the shorter of the five-year period preceding the date of disposition or the holder's holding period) more than 5% of our common stock will be subject to U.S. federal income tax on the
sale or other disposition of our common stock. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Information reporting and backup withholding  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Distributions paid to a non-U.S. holder and the amount of any tax withheld with respect to such distributions generally will be reported to the
IRS. Copies of the information returns reporting such distributions and any withholding may also be made available to the tax authorities in the country in which the non-U.S. holder resides under the
provisions of an applicable income tax treaty. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
non-U.S. holder will not be subject to backup withholding on dividends received if such holder certifies under penalty of perjury that it is a non-U.S. holder (and the payor does not
have actual knowledge or reason to know that such holder is a U.S. person as defined under the Code), or such holder otherwise establishes an exemption. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Information
reporting and, depending on the circumstances, backup withholding will apply to the proceeds of a sale or other disposition of our common stock made within the United States
or conducted through certain U.S.-related financial intermediaries, unless the beneficial owner certifies under penalty of perjury that it is a non-U.S. holder (and the payor does not have actual
knowledge or
reason to know that the beneficial owner is a U.S. person as defined under the Code), or such owner otherwise establishes an exemption. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Backup
withholding is not an additional tax and any amounts withheld under the backup withholding rules will be allowed as a refund or a credit against a non-U.S. holder's U.S. federal
income tax liability provided the required information is timely furnished to the IRS. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Additional withholding requirements under FATCA  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to sections&nbsp;1471 through 1474 of the Code, commonly known as the Foreign Account Tax Compliance Act ("FATCA"), a 30% withholding
tax may be imposed on certain payments to you or to certain foreign financial institutions, investment funds and other non- U.S. persons receiving payments on your behalf if you or such persons are
subject to, and fail to comply with, certain information reporting requirements. Such payments will include U.S.-source dividends and the gross proceeds from the sale or other disposition of stock
that can produce U.S.-source dividends. Payments of dividends that you receive in respect of shares of our common stock could be affected by this withholding if you are subject to FATCA information
reporting requirements and fail to comply with them or if you hold shares of our common stock through a non-U.S. person (e.g.,&nbsp;a foreign bank or broker) that fails to comply with these
requirements (even if payments to you would not otherwise have been subject to FATCA withholding). Pursuant to recently proposed regulations, the U.S. Treasury Department has indicated its intent to
eliminate the requirements under FATCA of withholding on gross proceeds. The U.S. Treasury Department has indicated that taxpayers may rely on these proposed regulations pending their finalization. An
intergovernmental agreement between the United States and your country of residence (or the country of residence of the non-U.S. person receiving payments on your behalf) may </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>186</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=191,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=974966,FOLIO='186',FILE='DISK116:[19ZBM1.19ZBM17601]EI17601A.;53',USER='CHE108062',CD='27-SEP-2019;09:54' -->
<A NAME="page_ei17601_1_187"> </A>

<P style="font-family:times;"><FONT SIZE=2>modify
the requirements described above. You should consult your own tax advisors regarding the relevant U.S. law and other official guidance on FATCA withholding. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a dividend payment is both subject to withholding under FATCA and subject to the withholding tax discussed above under "&#151;Dividends," the withholding under FATCA may be
credited against, and therefore reduce, such other withholding tax. You should consult your own tax advisors regarding these requirements and whether they may be relevant to your ownership and
disposition of our common stock. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>187</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=192,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=943876,FOLIO='187',FILE='DISK116:[19ZBM1.19ZBM17601]EI17601A.;53',USER='CHE108062',CD='27-SEP-2019;09:54' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ek17601_1_188"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ek17601_underwriting"> </A>
<A NAME="toc_ek17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Underwriting    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are offering the shares of common stock described in this prospectus through a number of underwriters. J.P.&nbsp;Morgan
Securities&nbsp;LLC, Morgan Stanley&nbsp;&amp;&nbsp;Co.&nbsp;LLC and RBC Capital Markets,&nbsp;LLC are acting as joint book-running managers of the offering and as representatives of the
underwriters. We have entered into an underwriting agreement with the representatives. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to the underwriters,
and each underwriter has severally agreed to purchase, at the initial public offering price less the underwriting discounts and commissions set forth on the cover page of this prospectus, the number
of shares of common stock listed next to its name in the following table: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>J.P. Morgan Securities&nbsp;LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Morgan Stanley&nbsp;&amp;&nbsp;Co.&nbsp;LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RBC Capital Markets,&nbsp;LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters are committed to purchase all the common shares offered by us if they purchase any shares. The underwriting agreement also provides that if an underwriter defaults, the
purchase commitments of non-defaulting underwriters may also be increased or the offering may be terminated. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters propose to offer the common shares directly to the public at the initial public offering price set forth on the cover page of this prospectus and to certain dealers at
that price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. Any such dealers may resell shares to certain other brokers or dealers at a discount of up to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share from
the initial public offering price. After the initial offering of the shares to the public, if all of the common shares are not sold at the initial public offering price, the underwriters may change
the offering price and the other selling terms. Sales of shares made outside of the United States may be made by affiliates of the underwriters. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters have an option to buy up to 750,000 additional shares of common stock from us to cover sales of shares by the underwriters which exceed the number of shares specified in
the table above. The underwriters have 30&nbsp;days from the date of this prospectus to exercise this option to purchase additional shares. If any shares are purchased with this option to purchase
additional shares, the underwriters will purchase shares in approximately the same proportion as shown in the table above. If any additional shares of common stock are purchased, the underwriters will
offer the additional shares on the same terms as those on which the shares are being offered. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriting fee is equal to the public offering price per share of common stock less the amount paid by the underwriters to us per share of common stock. The underwriting fee is
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. The following table shows the per share and total underwriting discounts and commissions to be paid to the underwriters assuming both no exercise and full exercise of
the
underwriters' option to purchase additional shares. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Without<BR>
option to<BR>
purchase<BR>
additional<BR>
shares<BR>
exercise </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>With full<BR>
option to<BR>
purchase<BR>
additional<BR>
shares<BR>
exercise </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Per Share</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
estimate that the total expenses of this offering, including registration, filing and listing fees, printing fees and legal and accounting expenses, but excluding the underwriting
discounts and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>188</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=193,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=396316,FOLIO='188',FILE='DISK116:[19ZBM1.19ZBM17601]EK17601A.;50',USER='JTAYLORA',CD='27-SEP-2019;14:08' -->
<A NAME="page_ek17601_1_189"> </A>

<P style="font-family:times;"><FONT SIZE=2>


commissions, will be approximately $3.2 million. We have agreed to reimburse the underwriters for expenses of up to $35,000 related to clearance of this offering with the Financial Industry Regulatory
Authority, or FINRA.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
prospectus in electronic format may be made available on the web sites maintained by one or more underwriters, or selling group members, if any, participating in this offering. The
underwriters may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the
representatives to underwriters and selling group members that may make Internet distributions on the same basis as other allocations. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have agreed that we will not (i)&nbsp;offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract
to sell, grant any option, right or warrant to purchase or otherwise dispose of, directly or indirectly, or file with the Securities and Exchange Commission a registration statement under the
Securities Act, relating to, any shares of our common stock or securities convertible into or exchangeable or exercisable for any shares of our common stock, or publicly disclose the intention to make
any offer, sale, pledge, disposition or filing, or (ii)&nbsp;enter into any swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership of
any shares of common stock or any such other securities (regardless of whether any of these transactions are to be settled by the delivery of shares of common stock or such other securities, in cash
or otherwise), in each case without the prior written consent of J.P. Morgan Securities&nbsp;LLC and Morgan Stanley&nbsp;&amp; Co.&nbsp;LLC for a period of 180&nbsp;days after the date of this
prospectus, other than the shares of our common stock to be sold hereunder and any shares of our common stock issued upon the exercise of options granted under our existing stock incentive plans. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
directors, executive officers and holders of substantially all outstanding shares have entered into lock-up agreements with the underwriters prior to the commencement of this
offering pursuant to which each of these persons or entities, with limited exceptions, for a period of 180&nbsp;days after the date of this prospectus, may not, without the prior written consent of
J.P. Morgan Securities&nbsp;LLC and Morgan Stanley&nbsp;&amp;&nbsp;Co.&nbsp;LLC, (1)&nbsp;offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to
purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of our common stock or any
securities convertible into or exercisable or exchangeable for our common stock (including, without limitation, common stock or such other securities which may be deemed to be beneficially owned by
such directors, executive officers, managers and members in accordance with the rules and regulations of the SEC and securities which may be issued upon exercise of a stock option or warrant) or
(2)&nbsp;enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the common stock or such other securities, whether any such
transaction described in clause&nbsp;(1) or (2)&nbsp;above is to be settled by delivery of common stock or such other securities, in cash or otherwise, or (3)&nbsp;make any demand for or
exercise any right with respect to the registration of any shares of our common stock or any security convertible into or exercisable or exchangeable for our common stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
restrictions described in the immediately preceding paragraph do not apply to, among other items, transfers or dispositions of shares of common
stock:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> as a bona fide gift or gifts or for bona fide estate planning purposes; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to immediate family members or any trust or other legal entity for the direct or indirect benefit of the party subject to the lock-up
restrictions or the immediate family of such person; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> by will, other testamentary document or intestate succession subject to the lockup restrictions; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>189</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=194,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=160681,FOLIO='189',FILE='DISK116:[19ZBM1.19ZBM17601]EK17601A.;50',USER='JTAYLORA',CD='27-SEP-2019;14:08' -->
<A NAME="page_ek17601_1_190"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to any corporation, partnership, limited liability company, trust or other business entity under the ownership of the party or managers,
managing members, partners, stockholders, all subject to the lock-up restrictions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> as transfers to affiliates, investment funds or other entities controlled or managed by the party subject to the lock-up restrictions; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction made to all holders of our common stock
involving a change of control; provided that in the event such tender offer, merger, consolidation or other such transaction is not completed, the shares of our common stock shall remain subject to
the lock-up restrictions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the exercise of outstanding warrants or options to purchase shares of common stock granted under any stock incentive plan or stock purchase
plan of ours, provided that the underlying shares shall continue to be subject to the lock-up restrictions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> transfers or surrenders to the Company of shares of common stock pursuant to any contractual arrangement that provides the Company with an
option to repurchase such shares in connection with the termination of the party subject to the lock-up's employment or service relationship with us, or on a cashless or "net exercise" basis or to
cover tax withholding obligations of the party subject to the lock-up, in connection with the vesting or exercise of such shares of common stock or other securities; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> transactions relating to common stock or other securities convertible into or exercisable or exchangeable for common stock acquired in this
offering or in open market transactions after the completion of this offering </FONT></DD></DL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>provided
that in the case of any transfer or distribution pursuant to the subclauses above, (i)&nbsp;each donee or distributee shall sign and deliver a lock-up letter in the form executed by the
party subject to the lock up restrictions and (ii)&nbsp;no filing or other public announcement under Section&nbsp;16(a)of the Exchange Act of 1934, as amended, or the Exchange Act, shall be
required or shall be voluntarily made during the restricted period (other than a filing on Form&nbsp;5 after the restricted period has ended); </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> and the establishment of a trading plan pursuant to Rule&nbsp;10b5-1 under the Exchange Act for the transfer of shares of common stock,
provided that (i)&nbsp;such plan does not provide for the transfer of shares of common stock during the restricted period and (ii)&nbsp;no filing under the Exchange Act or other public
announcement shall be required or voluntarily made by or on behalf of the party subject to the lock-up restrictions regarding the establishment of such plan. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have applied to list our common stock on The Nasdaq Global Select Market under the symbol "APRE." </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with this offering, the underwriters may engage in stabilizing transactions, which involves making bids for, purchasing and selling shares of common stock in the open
market for the purpose of preventing or retarding a decline in the market price of the common stock while this offering is in
progress. These stabilizing transactions may include making short sales of the common stock, which involves the sale by the underwriters of a greater number of shares of common stock than they are
required to purchase in this offering, and purchasing shares of common stock on the open market to cover positions created by short sales. Short sales may be "covered" shorts, which are short
positions in an amount not greater than the underwriters' option to purchase additional shares referred to above, or may be "naked" shorts, which are short positions in excess of that amount. The
underwriters may close out any covered short position either by exercising their option to purchase </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>190</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=195,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=810517,FOLIO='190',FILE='DISK116:[19ZBM1.19ZBM17601]EK17601A.;50',USER='JTAYLORA',CD='27-SEP-2019;14:08' -->
<A NAME="page_ek17601_1_191"> </A>

<P style="font-family:times;"><FONT SIZE=2>additional
shares, in whole or in part, or by purchasing shares in the open market. In making this determination, the underwriters will consider, among other things, the price of shares available for
purchase in the open market compared to the price at which the underwriters may purchase shares through the option to purchase additional shares. A naked short position is more likely to be created if
the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market that could adversely affect investors who purchase in this offering. To the
extent that the underwriters create a naked short position, they will purchase shares in the open market to cover the position. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters have advised us that, pursuant to Regulation&nbsp;M of the Securities Act, they may also engage in other activities that stabilize, maintain or otherwise affect the
price of the common stock, including the imposition of penalty bids. This means that if the representatives of the underwriters purchase common stock in the open market in stabilizing transactions or
to cover short sales, the representatives can require the underwriters that sold those shares as part of this offering to repay the underwriting discount received by them. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
activities may have the effect of raising or maintaining the market price of the common stock or preventing or retarding a decline in the market price of the common stock, and, as
a result, the price of the common stock may be higher than the price that otherwise might exist in the open market. If the underwriters commence these activities, they may discontinue them at any
time. The underwriters may carry out these transactions on NASDAQ, in the over-the-counter market or otherwise. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to this offering, there has been no public market for our common stock. The initial public offering price will be determined by negotiations between us and the representatives of
the underwriters. In determining the initial public offering price, we and the representatives of the underwriters expect to consider a number of factors
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the information set forth in this prospectus and otherwise available to the representatives; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our prospects and the history and prospects for the industry in which we compete; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an assessment of our management; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our prospects for future earnings; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the general condition of the securities markets at the time of this offering; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the recent market prices of, and demand for, publicly traded common stock of generally comparable companies; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> other factors deemed relevant by the underwriters and us. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
we nor the underwriters can assure investors that an active trading market will develop for our common shares, or that the shares will trade in the public market at or above the
initial public offering price. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other relationships  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include sales
and trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage and other financial and non-financial
activities and services. Certain of the underwriters and their respective affiliates may in the future provide various commercial banking, financial advisory or investment banking advice or other
services in the ordinary course of their business, for which they will receive customary fees and commissions. In addition, from time to time, certain of the underwriters and their respective
affiliates, officers, directors and employees may effect transactions for their own </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>191</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=196,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=144700,FOLIO='191',FILE='DISK116:[19ZBM1.19ZBM17601]EK17601A.;50',USER='JTAYLORA',CD='27-SEP-2019;14:08' -->
<A NAME="page_ek17601_1_192"> </A>

<P style="font-family:times;"><FONT SIZE=2>account
or the account of customers, and hold on behalf of themselves or their customers, long or short positions in our debt or equity securities or loans, and may do so in the future. The
underwriters and their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect
of our securities and may at any time hold, or recommend to clients that they should acquire, long and/or short positions in our securities. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Directed share program

  </B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At our request, the underwriters have reserved up to 3% of the shares of common stock to be issued by the Company and offered by this prospectus
for sale, at the initial public offering price, to directors, officers, employees, business associates and related persons of the Company. If purchased by these persons, these shares will be subject
to a 180-day lock-up restriction. The number of shares of common stock available for sale to the general public will be reduced to the extent these individuals purchase such reserved shares. Any
reserved shares that are not so purchased will be offered by the underwriters to the general public on the same basis as the other shares offered by this prospectus.

 </FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Selling restrictions  </B></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities
offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this
prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances
that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe
any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by
this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Australia  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus is not a disclosure document under Chapter&nbsp;6D of the Australian Corporations Act, has not been lodged with the Australian
Securities and Investments Commission and does not purport to include the information required of a disclosure document under Chapter&nbsp;6D of the Australian Corporations Act. Accordingly,
(i)&nbsp;the offer of the securities under this prospectus is only made to persons to whom it is lawful to offer the securities without disclosure under Chapter&nbsp;6D of the Australian
Corporations Act under one or more exemptions set out in section&nbsp;708 of the Australian Corporations Act, (ii)&nbsp;this prospectus is made available in Australia only to those persons as set
forth in clause&nbsp;(i) above, and (iii)&nbsp;the offeree must be sent a notice stating in substance that by accepting this offer, the offeree represents that the offeree is such a person as set
forth in clause&nbsp;(i) above, and, unless permitted under the Australian Corporations Act, agrees not to sell or offer for sale within Australia any of the securities sold to the offeree within
12&nbsp;months after its transfer to the offeree under this prospectus. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Canada  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in
National Instrument&nbsp;45-106 </FONT><FONT SIZE=2><I>Prospectus Exemptions</I></FONT><FONT SIZE=2> or subsection&nbsp;73.3(1) of the </FONT><FONT SIZE=2><I>Securities
Act</I></FONT><FONT SIZE=2> (Ontario), and are permitted clients, as defined in National Instrument&nbsp;31-103 </FONT><FONT SIZE=2><I>Registration Requirements, Exemptions and Ongoing Registrant
Obligations</I></FONT><FONT SIZE=2>. Any resale </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>192</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=197,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=763341,FOLIO='192',FILE='DISK116:[19ZBM1.19ZBM17601]EK17601A.;50',USER='JTAYLORA',CD='27-SEP-2019;14:08' -->
<A NAME="page_ek17601_1_193"> </A>

<P style="font-family:times;"><FONT SIZE=2>of
the shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Securities
legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto)
contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser's
province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser's province or territory for particulars of these rights or consult with a
legal advisor. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to section&nbsp;3A.3 of National Instrument&nbsp;33-105 </FONT><FONT SIZE=2><I>Underwriting Conflicts</I></FONT><FONT SIZE=2> (NI&nbsp;33-105), the representatives are
not required to comply with the disclosure requirements of NI&nbsp;33-105 regarding underwriter conflicts of interest in connection with this offering. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


European Economic Area  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In relation to each Member State of the European Economic Area (each, a "Relevant Member State"), no offer of shares may be made to the public
in that Relevant Member State other than: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>A.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>to
any legal entity which is a qualified investor as defined in the Prospectus Directive;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>B.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>to
fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD Amending Directive, 150, natural or legal persons (other than
qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the representatives; or
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>C.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>in
any other circumstances falling within Article&nbsp;3(2) of the Prospectus Directive, </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>provided
that no such offer of shares shall require the Company or the representatives to publish a prospectus pursuant to Article&nbsp;3 of the Prospectus Directive or supplement a prospectus
pursuant to Article&nbsp;16 of the Prospectus Directive. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
person in a Relevant Member State who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed that it is a "qualified
investor" within the meaning of the law in that Relevant Member State implementing Article&nbsp;2(1)(e) of the Prospectus Directive. In the case of any shares being offered to a financial
intermediary as that term is used in Article&nbsp;3(2) of the Prospectus Directive, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares
acquired by it in the offer have not been acquired on a non-discretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may
give rise to an offer of any shares to the public other than their offer or resale in a Relevant Member State to qualified investors as so defined or in circumstances in which the prior consent of the
representatives has been obtained to each such proposed offer or resale. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company, the representatives and their affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgements and agreements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus has been prepared on the basis that any offer of shares in any Relevant Member State will be made pursuant to an exemption under the Prospectus Directive from the
requirement to publish a prospectus for offers of shares. Accordingly, any person making or intending to make an offer in that Relevant Member State of shares which are the subject of the offering
contemplated in this prospectus may only do so in circumstances in which no obligation arises for the Company or any of the underwriters to publish a prospectus pursuant to Article&nbsp;3 of the
Prospectus Directive in relation to such offer. Neither the Company nor the underwriters have authorized, nor do they authorize, the making of any offer of shares in circumstances in which an
obligation arises for the Company or the underwriters to publish a prospectus for such offer. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>193</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=198,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=26541,FOLIO='193',FILE='DISK116:[19ZBM1.19ZBM17601]EK17601A.;50',USER='JTAYLORA',CD='27-SEP-2019;14:08' -->
<A NAME="page_ek17601_1_194"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the purpose of the above provisions, the expression "an offer to the public" in relation to any shares in any Relevant Member State means the communication in any form and by any
means of sufficient information on the terms of the offer and the shares to be offered so as to enable an investor to decide to purchase or subscribe the shares, as the same may be varied in the
Relevant Member State by any measure implementing the Prospectus Directive in the Relevant Member State and the expression "Prospectus Directive" means Directive 2003/71/EC (including the 2010 PD
Amending Directive, to the extent implemented in the Relevant Member States) and includes any relevant implementing measure in the Relevant Member State and the expression "2010 PD Amending Directive"
means Directive 2010/73/EU. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Hong Kong  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The shares may not be offered or sold by means of any document other than (i)&nbsp;in circumstances that do not constitute an offer to the
public within the meaning of the Companies Ordinance (Cap. 32, Laws of Hong Kong), or (ii)&nbsp;to "professional investors" within the meaning of the Securities and Futures Ordinance (Cap. 571, Laws
of Hong Kong) and any rules made thereunder, or (iii)&nbsp;in other circumstances that do not result in the document being a "prospectus" within the meaning of the Companies Ordinance (Cap. 32, Laws
of Hong Kong), and no advertisement, invitation or document relating to the shares may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong
or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the laws of Hong Kong) other than with
respect to shares that are or are intended to be disposed of only to persons outside Hong Kong or only to "professional investors" within the meaning of the Securities and Futures Ordinance (Cap. 571,
Laws of Hong Kong) and any rules made thereunder. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Japan  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The securities have not been and will not be registered under the Financial Instruments and Exchange Law of Japan, or the Financial Instruments
and Exchange Law, and each underwriter has agreed that it will not offer or sell any securities, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan (which term, as
used in this prospectus means any person resident in Japan, including any corporation or other entity organized under the laws of Japan) or to
others for re-offering or resale, directly or indirectly, in Japan or to a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with,
the Financial Instruments and Exchange Law and any other applicable laws, regulations and ministerial guidelines of Japan. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Singapore  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other
document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares may not be circulated or distributed, nor may the shares be offered or sold, or be
made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of
the Securities and Futures Act, Chapter&nbsp;289 of Singapore, or the SFA, (ii)&nbsp;to a relevant person, or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions
specified in Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Where
the shares are subscribed or purchased under Section&nbsp;275 by a relevant person that is: (a)&nbsp;a corporation (which is not an accredited investor) the sole business of
which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or (b)&nbsp;a trust (where the trustee is not an
accredited investor) whose sole purpose is to hold </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>194</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=199,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=14592,FOLIO='194',FILE='DISK116:[19ZBM1.19ZBM17601]EK17601A.;50',USER='JTAYLORA',CD='27-SEP-2019;14:08' -->
<A NAME="page_ek17601_1_195"> </A>

<P style="font-family:times;"><FONT SIZE=2>investments
and each beneficiary is an accredited investor, shares, debentures and units of shares and debentures of that corporation or the beneficiaries' rights and interest in that trust shall not
be transferable for six months after that corporation or that trust has acquired the shares under Section&nbsp;275 except: (1)&nbsp;to an institutional investor under Section&nbsp;274 of the SFA
or to a relevant person, or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275 of the SFA; (2)&nbsp;where no consideration is given
for the transfer; or (3)&nbsp;by operation of law. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Switzerland  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock exchange
or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of
Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in
Switzerland. Neither this document, nor any other offering or marketing material relating to the shares or this offering, may be publicly distributed or otherwise made publicly available in
Switzerland. Neither this document nor any other offering or marketing material relating to this offering, the Company, or the shares has been or will be filed with or approved by any Swiss regulatory
authority. In particular, this document will not be filed with, and the offer of shares will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, or FINMA, and the offer of
shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection afforded to acquirers of interests in collective
investment schemes under the CISA does not extend to acquirers of shares. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


United Arab Emirates  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority, or DFSA.
This prospectus is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA
has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein
and has no responsibility for this prospectus. The shares to which this prospectus relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares offered
should conduct their own due diligence on the shares. If you do not understand the contents of this prospectus, you should consult an authorized financial advisor. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


United Kingdom  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This document is being distributed only to, and is directed only at, and any offer subsequently made may only be directed at persons who are
"qualified investors" (as defined in the Prospectus Directive) (i)&nbsp;who have professional experience in matters relating to investments falling within Article&nbsp;19 (5)&nbsp;of the
Financial Services and Markets Act 2000 (Financial Promotion) Order 2005,
as amended (the "Order") and/or (ii)&nbsp;who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article&nbsp;49 (2)&nbsp;(a) to
(d)&nbsp;of the Order (all such persons together being referred to as "relevant persons"). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
person in the United Kingdom that is not a relevant person should not act or rely on the information included in this document or use it as basis for taking any action. In the United
Kingdom, any investment or investment activity that this document relates to may be made or taken exclusively by relevant persons. Any person in the United Kingdom that is not a relevant person should
not act or rely on this document or any of its contents. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>195</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=200,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=2574,FOLIO='195',FILE='DISK116:[19ZBM1.19ZBM17601]EK17601A.;50',USER='JTAYLORA',CD='27-SEP-2019;14:08' -->
<A NAME="page_ek17601_1_196"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ek17601_legal_matters"> </A>
<A NAME="toc_ek17601_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Legal Matters    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The validity of the shares of our common stock offered hereby is being passed upon for us by Sidley Austin&nbsp;LLP, New York, New York.
Certain legal matters relating to this offering will be passed upon for the underwriters by Davis Polk&nbsp;&amp; Wardwell&nbsp;LLP, New York, New York. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ek17601_experts"> </A>
<A NAME="toc_ek17601_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Experts    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The consolidated financial statements of Aprea Therapeutics AB at December&nbsp;31, 2017 and 2018, and for each of the two years in the period
ended December&nbsp;31, 2018, appearing in this Prospectus and Registration Statement have been audited by Ernst&nbsp;&amp; Young AB, independent registered public accounting firm, as set forth in
their report thereon appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
balance sheet of Aprea Therapeutics,&nbsp;Inc. at July&nbsp;11, 2019, appearing in this Prospectus and Registration Statement has been audited by Ernst&nbsp;&amp; Young AB,
independent registered public accounting firm, as set forth in their report thereon appearing elsewhere herein, and is included in reliance upon such report given on the authority of such firm as
experts in accounting and auditing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registered business address of Ernst &amp; Young AB is Box&nbsp;7850, 103&nbsp;99, Stockholm, Sweden. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ek17601_where_you_can_find_more_information"> </A>
<A NAME="toc_ek17601_4"> </A>
<BR></FONT><FONT SIZE=2><B>  Where You Can Find More Information    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have filed with the SEC a registration statement on Form&nbsp;S-1 under the Securities Act with respect to the shares of our common stock
we are offering to sell. This prospectus, which constitutes part of the registration statement, does not include all of the information contained in the registration statement and the exhibits,
schedules and amendments to the registration statement. Some items are omitted in accordance with the rules and regulations of the SEC. For further information with respect to us and our common stock,
we refer you to the registration statement and to the exhibits, schedules and amendments to the registration statement. Statements contained in this prospectus about the contents of any contract,
agreement or other document filed as an exhibit are not necessarily complete, and, in each instance, we refer you to the copy of the contract, agreement or other document filed as an exhibit to the
registration statement. Each of these statements is qualified in all respects by this reference. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
completion of this offering, we will be subject to the information reporting requirements of the Securities Exchange Act, and we will file reports, proxy statements and other
information with the SEC. We intend to furnish our stockholders with annual reports containing financial statements certified by an independent registered public accounting firm. We also maintain a
website at www.aprea.com. The information contained on, or that can be accessed through, our website is not a part of, and is not incorporated into, this prospectus. We have included our website
address in this prospectus solely as an inactive textual reference. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>196</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=201,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=490603,FOLIO='196',FILE='DISK116:[19ZBM1.19ZBM17601]EK17601A.;50',USER='JTAYLORA',CD='27-SEP-2019;14:08' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_fa17601_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="fa17601_index_to_financial_statements"> </A>
<BR></FONT><FONT SIZE=2><B>  <A NAME="fa"></A>Index to Financial Statements    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="FA17601_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="28pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Audited Financial Statements of Aprea Therapeutics,&nbsp;Inc.</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#1"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Report of Independent Registered Public Accounting Firm</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#1"><FONT SIZE=2><BR>
F-2</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#2"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Balance Sheet as of July&nbsp;11, 2019</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#2"><FONT SIZE=2>F-3</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#3"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Notes to Financial Statements</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#3"><FONT SIZE=2>F-4</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Audited Consolidated Financial Statements of Aprea Therapeutics AB</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#4"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Report of Independent Registered Public Accounting Firm</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#4"><FONT SIZE=2><BR>
F-5</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#5"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Consolidated Balance Sheets as of December&nbsp;31, 2017 and 2018</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#5"><FONT SIZE=2>F-6</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#6"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Consolidated Statements of Operations and Comprehensive Loss for the years ended December&nbsp;31, 2017 and 2018</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#6"><FONT SIZE=2>F-7</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#7"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit for the years ended December&nbsp;31, 2017 and
2018</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#7"><FONT SIZE=2>F-8</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#8"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Consolidated Statements of Cash Flows for the years ended December&nbsp;31, 2017 and 2018</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#8"><FONT SIZE=2>F-9</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#9"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Notes to Consolidated Financial Statements</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#9"><FONT SIZE=2>F-10</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Condensed Consolidated Unaudited Interim Financial Statements of Aprea Therapeutics AB</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#10"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Condensed Consolidated Balance Sheets as of December&nbsp;31, 2018 and June&nbsp;30, 2019 (unaudited)</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#10"><FONT SIZE=2><BR>
F-27</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#11"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Condensed Consolidated Statements of Operations and Comprehensive Loss for the six month periods ended June&nbsp;30, 2018 and 2019
(unaudited)</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#11"><FONT SIZE=2>F-28</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#12"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) for the six month periods ended
June&nbsp;30, 2018 and 2019 (unaudited)</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#12"><FONT SIZE=2>F-29</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#13"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Condensed Consolidated Statements of Cash Flows for the six month periods ended June&nbsp;30, 2018 and 2019 (unaudited)</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#13"><FONT SIZE=2>F-30</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#14"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Notes to Condensed Consolidated Financial Statements</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#14"><FONT SIZE=2>F-31</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=202,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=734429,FOLIO='F-1',FILE='DISK116:[19ZBM1.19ZBM17601]FA17601A.;19',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_fc17601_1_2"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><B> <A NAME="1"></A>Report of Independent Registered Public Accounting Firm

  </B></FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


To the Stockholder and the Board of Directors of Aprea Therapeutics,&nbsp;Inc.

 </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Opinion on the Financial Statements

 </B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have audited the accompanying balance sheet of Aprea Therapeutics,&nbsp;Inc. (the Company) at July&nbsp;11, 2019 and the related notes.
In our opinion, the balance sheet presents fairly, in all material respects, the financial position of the Company at July&nbsp;11, 2019, in conformity with U.S. generally accepted accounting
principles.

 </FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Basis for Opinion

  </B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The balance sheet is the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's balance sheet
based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company
in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 </FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the balance
sheet is free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.
As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's
internal control over financial reporting. Accordingly, we express no such opinion.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our audit included performing procedures to assess the risks of material misstatement of the balance sheet, whether due to error or fraud, and performing procedures that respond to those
risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the balance sheet. Our audit also included evaluating the accounting principles used and
significant estimates made by management, as well as evaluating the overall presentation of the balance sheet. We believe that our audit provides a reasonable basis for our opinion.

</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


/s/ Ernst&nbsp;&amp; Young AB

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


We have served as the Company's auditor since 2019.

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


Stockholm, Sweden

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


August&nbsp;20, 2019,

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>



Except for the stock split described in Note&nbsp;1, as to which the date is September&nbsp;27, 2019.

</FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=203,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=646103,FOLIO='F-2',FILE='DISK116:[19ZBM1.19ZBM17601]FC17601A.;16',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_fe17601_1_3"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="2"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="fe17601_aprea_therapeutics,_inc._balan__apr03217"> </A>
<A NAME="toc_fe17601_1"> </A></FONT> <FONT SIZE=2><B><BR>  Aprea Therapeutics,&nbsp;Inc.    <BR>    <BR>    Balance Sheet    <BR>    <BR>    As of July&nbsp;11, 2019 (date of initial capital contribution)    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>July&nbsp;11,<BR>
2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Assets</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current assets:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total current assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Liabilities and Stockholders' Equity</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stockholders' deficit:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock, $0.001 par value; 160 shares authorized, issued and outstanding.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Additional paid-in capital</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stockholders' equity</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total liabilities and stockholders' equity</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
See accompanying notes to financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=204,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=770655,FOLIO='F-3',FILE='DISK116:[19ZBM1.19ZBM17601]FE17601A.;11',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_fg17601_1_4"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="3"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="fg17601_aprea_therapeutics,_inc._notes__apr03929"> </A>
<A NAME="toc_fg17601_1"> </A></FONT> <FONT SIZE=2><B><BR>  Aprea Therapeutics,&nbsp;Inc.    <BR>    <BR>    Notes to Financial Statements    <BR>    <BR>    As of July&nbsp;11, 2019 (date of initial capital contribution)    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


1. Nature of business and basis of presentation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nature of business</B></FONT><FONT SIZE=2>&#151;Aprea Therapeutics,&nbsp;Inc. ("ATI" or the "Company") was incorporated in Delaware on May&nbsp;3, 2019 and the date of its
initial capital contribution was July&nbsp;11, 2019. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
authorized share capital of ATI consists of 160 shares of capital stock, par value $0.001 per share, which has been issued. ATI was incorporated with nominal assets and liabilities
for the purpose of becoming a holding company for Aprea Therapeutics AB and Aprea (U.S.)&nbsp;Inc. and for the purposes of consummating a corporate reorganization. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
September&nbsp;20, 2019, the Company consummated a corporate reorganization, pursuant to which all of the issued and outstanding stock and options of Aprea Therapeutics&nbsp;AB,
or Aprea AB, were exchanged for common stock, preferred stock or options, as applicable, of Aprea Therapeutics,&nbsp;Inc. As a result, Aprea Therapeutics&nbsp;AB, became a wholly-owned subsidiary
of Aprea Therapeutics,&nbsp;Inc. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basis of presentation</B></FONT><FONT SIZE=2>&#151;The accompanying financial statements are prepared in conformity with accounting principles generally accepted in the United
States ("U.S.&nbsp;GAAP"). Separate statements of income, changes in equity and cash flows have not been presented in the financial statements because there have been no operations in the Company at
the balance sheet date. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to the completion of its initial public offering, the Company will approve a 1-for-1.6045 stock split of the Company's common stock. All share and per share amounts in the balance
sheet and notes thereto have been retroactively adjusted for all periods presented to give effect to this split. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=205,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=451796,FOLIO='F-4',FILE='DISK116:[19ZBM1.19ZBM17601]FG17601A.;23',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_fi17601_1_5"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<P ALIGN="CENTER" style="font-family:times;">


<FONT SIZE=2><B> <A NAME="4"></A>Report of Independent Registered Public Accounting Firm

  </B></FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


To the Stockholders and the Board of Directors of Aprea Therapeutics AB

 </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Opinion on the Financial Statements

 </B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have audited the accompanying consolidated balance sheets of Aprea Therapeutics AB (the Company) as of December&nbsp;31, 2017 and 2018, the
related consolidated statements of operations and comprehensive income (loss), convertible preferred stock and stockholders' deficit and cash flows for each of the two years in the period ended
December&nbsp;31, 2018, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all
material respects, the financial position of the Company at December&nbsp;31, 2017 and 2018, and the results of its operations and its cash flows for each of the two years in the period ended
December&nbsp;31, 2018, in conformity with U.S. generally accepted accounting principles.

</FONT>

</P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;">


<FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Basis for Opinion

  </B></FONT>

</P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with
respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.


</FONT>

</P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over
financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness
of the Company's internal control over financial reporting. Accordingly, we express no such opinion.


</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting
principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our
opinion.

</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


/s/ Ernst&nbsp;&amp; Young AB

</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


We have served as the Company's auditor since 2015.

</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


Stockholm, Sweden

</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


August&nbsp;20, 2019,

 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>


Except for the stock split described in Note&nbsp;1, as to which the date is September&nbsp;27, 2019.

 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=206,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=974329,FOLIO='F-5',FILE='DISK116:[19ZBM1.19ZBM17601]FI17601A.;13',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_fk17601_1_6"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->


<P style="font-family:times;"><FONT SIZE=2>
<A NAME="5"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="fk17601_aprea_therapeutics_ab_consolidated_balance_sheets"> </A>
<A NAME="toc_fk17601_1"> </A></FONT> <FONT SIZE=2><B><BR>  Aprea Therapeutics AB    <BR>    <BR>    Consolidated Balance Sheets    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Assets</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current assets:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>24,401,488</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>65,675,931</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid expenses and other current assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>329,859</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>322,146 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total current assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>24,731,347</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>65,998,077</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Property and equipment, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>30,336</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>24,450</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other noncurrent assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>121</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>111 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>24,761,804</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>66,022,638 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Liabilities, Convertible Preferred Stock and Stockholders' Deficit</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current liabilities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts payable</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,661,813</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,739,337</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,639,200</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,128,772 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total current liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,301,013</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,868,109 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,301,013</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,868,109</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Commitments and contingencies (Note&nbsp;6)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible preferred stock:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;A convertible preferred stock, $0.11 par value; 612,446 shares issued and outstanding at December&nbsp;31, 2018 and 2017 (liquidation
preference of $6,483,044 at December&nbsp;31, 2018)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,483,044</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,483,044</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;B convertible preferred stock, $0.11 par value; 7,235,969 shares issued and outstanding at December&nbsp;31, 2018 and 2017 (liquidation
preference of $58,874,347 at December&nbsp;31, 2018)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>49,742,942</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>49,742,942</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;C convertible preferred stock, $0.11 par value; 4,712,698 and 0 shares issued and outstanding at December&nbsp;31, 2018 and 2017, respectively
(liquidation preference of $57,115,312 at December&nbsp;31, 2018)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>56,364,645 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total convertible preferred stock</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>56,225,986</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>112,590,631</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stockholders' deficit:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock, $0.11 par value; 1,155,366 and 1,153,061 shares issued and outstanding at December&nbsp;31, 2018 and 2017, respectively.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>126,838</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>127,091</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Additional paid-in capital</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>19,335,560</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>19,666,588</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated other comprehensive loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(8,287,406</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(8,761,325</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated deficit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(46,940,187</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(62,468,456</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stockholders' deficit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(35,765,195</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(51,436,102</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total liabilities, convertible preferred stock and stockholders' deficit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>24,761,804</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>66,022,638 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
See accompanying notes to consolidated financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=207,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=153140,FOLIO='F-6',FILE='DISK116:[19ZBM1.19ZBM17601]FK17601A.;12',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_fm17601_1_7"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="fm17601_aprea_therapeutics_ab_consolid__apr03368"> </A>
<A NAME="toc_fm17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  <A NAME="6"></A>Aprea Therapeutics AB<BR>  <BR>    Consolidated Statements of Operations and Comprehensive Loss    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Years ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13,392,631</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14,194,732</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,459,744</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,294,671 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,852,375</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>16,489,403</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income (expense):</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(182</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign currency gain</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>662,140</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>961,316 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total other income (expense)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>662,125</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>961,134 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,190,250</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,528,269</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other comprehensive income (loss):</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign currency translation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>495,160</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(473,919</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total comprehensive loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(14,695,090</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,002,188</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss per share attributable to common stockholders, basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(13.17</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(13.45</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted-average common shares outstanding, basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,153,069</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,154,368 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma net loss per share attributable to common stockholders, basic and diluted (unaudited)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.65</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma weighted average common shares outstanding, basic and diluted (unaudited)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,428,873 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
See accompanying notes to consolidated financial statements </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=208,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=11368,FOLIO='F-7',FILE='DISK116:[19ZBM1.19ZBM17601]FM17601A.;16',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_fo17601_1_8"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- COMMAND=ROTATED_TABLE WIDTH="150%" -->

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="7"></A></FONT><FONT SIZE=2><B>Aprea Therapeutics AB  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="37pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=17 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Convertible preferred stock </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Series A </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Series B </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Series C </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Common stock </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=3 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=3 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Accumulated<BR>
other<BR>
comprehensive<BR>
loss </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Additional<BR>
paid-in<BR>
capital </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Accumulated<BR>
deficit </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
stockholders'<BR>
deficit </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Balance at January&nbsp;1, 2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>612,446</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6,483,044</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,913,207</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>26,399,079</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,153,061</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>126,838</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>18,940,120</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(8,782,566</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(31,749,937</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(21,465,545</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Issuance of Series&nbsp;B convertible preferred stock, net of issuance costs of $47,047</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,322,762</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>23,343,863</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Stock-based compensation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>395,440</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>395,440</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Foreign currency translation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>495,160</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>495,160</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(15,190,250</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(15,190,250</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Balance at December&nbsp;31, 2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>612,446</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6,483,044</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7,235,969</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>49,742,942</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,153,061</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>126,838</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>19,335,560</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(8,287,406</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(46,940,187</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(35,765,195</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Issuance of Series&nbsp;C convertible preferred stock, net of issuance costs of $3,278,302</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,712,698</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>56,364,645</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Exercise of stock options</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,305</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>253</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,844</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,097</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Stock-based compensation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>329,184</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>329,184</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Foreign currency translation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(473,919</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(473,919</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(15,528,269</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(15,528,269</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Balance at December&nbsp;31, 2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>612,446</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6,483,044</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7,235,969</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>49,742,942</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,712,698</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>56,364,645</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,155,366</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>127,091</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>19,666,588</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(8,761,325</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(62,468,456</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(51,436,102</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>See
accompanying notes to consolidated financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=209,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=339100,FOLIO='F-8',FILE='DISK116:[19ZBM1.19ZBM17601]FO17601A.;14',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_fq17601_1_9"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->


<P style="font-family:times;"><FONT SIZE=2>
<A NAME="8"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="fq17601_aprea_therapeutics_ab___fq102440"> </A>
<A NAME="toc_fq17601_1"> </A></FONT> <FONT SIZE=2><B><BR>  Aprea Therapeutics AB    <BR>    <BR>    Consolidated Statements of Cash Flows    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Years ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash flows from operating activities:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,190,250</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,528,269</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adjustments to reconcile net loss to net cash used in operating activities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Depreciation and amortization</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,932</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,316</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stock-based compensation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>395,440</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>329,184</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign currency gain</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(662,140</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(961,316</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Changes in operating assets and liabilities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid expense and other current assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,041</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(19,452</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts payable</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>327,054</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>214,380</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued expenses and other liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,115,805</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>706,923 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:50pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash used in operating activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(14,002,118</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,250,234</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash flows from investing activities:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Purchases of property and equipment</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(3,702</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:50pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash used in investing activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(3,702</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash flows from financing activities:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from the exercise of stock options</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,097</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from issuance of Series&nbsp;B convertible preferred, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23,343,863</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from issuance of Series&nbsp;C convertible preferred, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>56,364,645 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:50pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash provided by financing activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23,343,863</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>56,366,742 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Increase in cash</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,341,745</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>41,112,806</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Effect of exchange rate changes on cash</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,394,568</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>161,637</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents&#151;beginning of year</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13,665,175</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>24,401,488 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents&#151;end of year</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>24,401,488</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>65,675,931 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
See accompanying notes to consolidated financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=210,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=186050,FOLIO='F-9',FILE='DISK116:[19ZBM1.19ZBM17601]FQ17601A.;6',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_fs17601_1_10"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="9"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="fs17601_aprea_therapeutics_ab_notes_to_financial_statements"> </A>
<A NAME="toc_fs17601_1"> </A></FONT> <FONT SIZE=2><B><BR>  Aprea Therapeutics AB    <BR>    <BR>    Notes to Financial Statements    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


1. Nature of business and basis of presentation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nature of business</B></FONT><FONT SIZE=2>&#151;Aprea Therapeutics AB (the "Company") is a clinical-stage biopharmaceutical company focused on developing and commercializing novel
cancer therapeutics that reactivate mutant tumor suppressor protein p53. p53 is the protein expressed from the </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> gene, the most commonly mutated gene
in cancer. The Company began operations in 2006. Its principal offices are in Stockholm, Sweden and Boston, Massachusetts. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basis of presentation and management plans</B></FONT><FONT SIZE=2>&#151;The accompanying financial statements are prepared in conformity with accounting principles general
accepted in the United States ("U.S.&nbsp;GAAP"). The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction
of liabilities in the normal course of business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since
its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, and raising
capital, and has financed its operations through the issuance of convertible preferred stock ("Preferred Stock") and common stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company is subject to risks common to companies in the biopharmaceutical industry. There can be no assurance that the Company's research and development will be successfully
completed, that adequate protection for the Company's intellectual property will be maintained, that any therapeutic products developed will obtain required regulatory approval or that any approved or
consumer products will be commercially viable. Even if the Company's development efforts are successful, it is uncertain when, if ever, the Company will generate significant product sales. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company's management believes that the December&nbsp;31, 2018 cash balance of $65,675,931, along with the gross proceeds of $5,645,248 from the issuance of Series&nbsp;C
convertible preferred stock ("Series&nbsp;C Preferred") from a new investor in February 2019, will be sufficient to fund the Company's operations into the third quarter of 2021. In the event that
additional funds are not available thereafter, management would expect to significantly reduce expenditures to conserve cash, which would involve scaling back or curtailing new development activity. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to the completion of its initial public offering, the Company will approve a 1-for-1.6045 stock split of the Company's preferred and common stock. All share and per share amounts
in the consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this split. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of significant accounting policies  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Principles of consolidation</B></FONT><FONT SIZE=2>&#151;The consolidated financial statements include the accounts of Aprea Therapeutics AB and its wholly owned subsidiaries
Aprea Personal AB, which was incorporated in May 2009, and Aprea US,&nbsp;Inc., which was incorporated in June 2016. All intercompany transactions and balances have been eliminated. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Use of estimates</B></FONT><FONT SIZE=2>&#151;The preparation of financial statements in conformity with U.S.&nbsp;GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets, liabilities, revenue, and expenses as of and during the reporting period. The Company bases estimates
and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company assesses estimates on an ongoing basis; however, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=211,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=521534,FOLIO='F-10',FILE='DISK116:[19ZBM1.19ZBM17601]FS17601A.;28',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<A NAME="page_fs17601_1_11"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Aprea Therapeutics AB </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Financial Statements (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of significant accounting policies (continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>actual
results could materially differ from those estimates. Significant items subject to such estimates and assumptions include fair value of stock-based compensation expense. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unaudited pro forma financial information</B></FONT><FONT SIZE=2>&#151;The Company is planning a proposed offer and sale by Aprea Therapeutics,&nbsp;Inc., a Delaware corporation
and successor entity, of common stock in an initial public offering (the "IPO"). Prior to the completion of the IPO, pursuant to a corporate reorganization, the Company became a wholly-owned
subsidiary of Aprea Therapeutics,&nbsp;Inc. In connection with the corporate reorganization, each issued and outstanding share of Series A, Series B and Series C convertible preferred stock of the
Company was exchanged on a one for one basis into shares of Series A, Series B and Series C convertible preferred stock of Aprea Therapeutics, Inc. Each share of common stock of the Company was
exchanged on a one for one basis in to shares of common stock of Aprea Therapeutics, Inc. Prior to consummation of the IPO, all outstanding shares of Series A, Series B and Series C convertible
preferred stock of Aprea Therapeutics, Inc. will be converted into common stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
unaudited pro forma basic and diluted weighted average common shares outstanding used in the calculation of unaudited pro forma basic and diluted net loss per share attributable to
common stockholders for the years ended December&nbsp;31, 2017 and 2018 give effect to the automatic conversion of all outstanding shares of convertible preferred stock into shares of common stock
as if the conversion had occurred on the later of January&nbsp;1, 2017 or the issuance date of the convertible preferred stock for the year ended December&nbsp;31, 2017, and on the later of
January&nbsp;1, 2018 or the issuance date of the convertible preferred stock for the year ended December&nbsp;31, 2018. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency and currency translation</B></FONT><FONT SIZE=2>&#151;The functional currency for Aprea Therapeutics AB and its wholly owned foreign subsidiary, Aprea Personal
AB, is the Swedish Krona. Assets and liabilities of Aprea Therapeutics AB and Aprea Personal AB are translated into United States dollars at the exchange rate in effect on the balance sheet date.
Revenues and expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is
included in the consolidated statements of convertible preferred stock and stockholders' deficit as a component of accumulated other comprehensive loss. Adjustments that arise from exchange rate
changes on transactions denominated in a currency other than the local currency are included in other income (expense), net in the consolidated statements of operations as incurred. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Concentrations of credit risk</B></FONT><FONT SIZE=2>&#151;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily
of cash. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit
risk as the Company's deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents</B></FONT><FONT SIZE=2>&#151;The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase
to be cash equivalents. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred initial public offering costs</B></FONT><FONT SIZE=2>&#151;The Company capitalizes deferred initial public offering ("IPO") costs, which primarily consist of direct,
incremental legal, professional, accounting and other third-party fees relating to the Company's initial public offering, within other non-current assets. The </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=212,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=23088,FOLIO='F-11',FILE='DISK116:[19ZBM1.19ZBM17601]FS17601A.;28',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<A NAME="page_fs17601_1_12"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Aprea Therapeutics AB </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Financial Statements (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of significant accounting policies (continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>deferred
IPO costs will be offset against IPO proceeds upon the consummation of an offering. Should the planned IPO be abandoned, the deferred issuance costs will be expensed immediately as a charge
to operating expenses in the consolidated statement of operations and comprehensive loss. There were no deferred IPO costs as of December&nbsp;31, 2018. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment</B></FONT><FONT SIZE=2>&#151;Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred. When assets are
retired or disposed of, the assets and related accumulated depreciation are eliminated from the accounts, and any resulting gain or loss is included in the determination of net income or loss. Fixed
assets acquired for research and development purposes are assessed for alternative future use. Depreciation is provided using the straight-line method over the estimated useful lives of the related
assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="141pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Asset category

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Estimated useful life </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Computer equipment and software</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5&nbsp;years</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Furniture and fixtures</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5&nbsp;years</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Laboratory equipment and office furniture</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5&nbsp;years</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Leasehold improvements</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Remainder of lease term</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment of long-lived assets</B></FONT><FONT SIZE=2>&#151;Periodically, the Company evaluates its long-lived assets, which consist primarily of property and equipment, for
impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison
of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is
measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. To date, no impairments have occurred. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fair value of financial instruments</B></FONT><FONT SIZE=2>&#151;Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability
between market participants at measurement dates. ASC Topic 820, Fair Value Measurement ("ASC 820"), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy
is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are
considered observable and the last is considered unobservable:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Level&nbsp;1 inputs: Quoted prices in active markets for identical assets or liabilities. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Level&nbsp;2 inputs: Inputs other than quoted prices included within Level&nbsp;1 that are either directly or indirectly observable, such
as quoted market prices, interest rates and yield curves. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Level&nbsp;3 inputs: Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market
participant would use in pricing the asset or liability. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly,
the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&nbsp;3. A financial instrument's level within the fair value hierarchy is
based on the lowest level of any input that is significant to the fair value measurement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=213,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=453286,FOLIO='F-12',FILE='DISK116:[19ZBM1.19ZBM17601]FS17601A.;28',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<A NAME="page_fs17601_1_13"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Aprea Therapeutics AB </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Financial Statements (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of significant accounting policies (continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Convertible preferred stock</B></FONT><FONT SIZE=2>&#151;The Company has classified convertible preferred stock ("Preferred Stock") as temporary equity in the accompanying balance
sheets due to certain change in control events that are outside of the Company's control, including sale or transfer of control of the Company, as holders of the Preferred Stock could cause redemption
of the shares in these situations. The Company does not accrete the carrying values of the Preferred Stock to the redemption values since a liquidation event was not considered probable as of
December&nbsp;31, 2018. Subsequent adjustments of the carrying values to the ultimate redemption values will be made only if it becomes probable that such a liquidation event will occur. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development costs</B></FONT><FONT SIZE=2>&#151;Research and development costs are charged to expense as incurred. Research and development expense consists of
expenses incurred in performing research and development activities, including salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of
equipment, contract services, and other outside expenses. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using or
information provided to the Company by its vendors
on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the
financial statements as prepaid or accrued research and development. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patent costs</B></FONT><FONT SIZE=2>&#151;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the
uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation</B></FONT><FONT SIZE=2>&#151;The Company measures stock options and other stock-based awards granted to employees and directors based on their fair value
on the date of the grant and recognize compensation expense of those awards, net of estimated forfeitures, over the requisite service period, which is generally the vesting period of the respective
award. The Company applies the straight-line method of expense recognition to all awards with only service-based vesting conditions and apply the graded-vesting method to all awards with
performance-based vesting conditions or to awards with both service-based and performance-based vesting conditions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
stock-based awards granted to non-employees, compensation expense is recognized over the period during which services are rendered by such non-employees until completed in accordance
with the FASB issued ASU No.&nbsp;2018-07, Compensation-Stock Compensation (Topic&nbsp;718): Improvements to Nonemployee Share-Based Payment Accounting. The new standard largely aligns the
accounting for share-based payment awards issued to employees and nonemployees by expanding the scope of ASC 718 to apply to nonemployee share-based transactions, as long as the transaction is not
effectively a form of financing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company estimates the fair value of each stock option grant on the date of grant using the Black-Scholes option-pricing model, which uses as inputs the fair value of the Company's
common stock and assumptions the Company makes for the volatility of its common stock, the expected term of its stock options, the risk-free interest rate for a period that approximates the expected
term of its stock options and its expected dividend yield. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=214,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=279797,FOLIO='F-13',FILE='DISK116:[19ZBM1.19ZBM17601]FS17601A.;28',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<A NAME="page_fs17601_1_14"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Aprea Therapeutics AB </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Financial Statements (Continued) </B></FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of significant accounting policies (continued) </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Determination of fair value of common stock  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As there has been no public market for the Company's common stock to date, the estimated fair value of its common stock has been determined by
its board of directors as of the date of each option grant, with input from management, considering the Company's most recently available third-party valuations of common stock and its board of
directors' assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant.
These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants' Accounting and Valuation Guide, Valuation of
Privately-Held-Company Equity Securities Issued as Compensation. The Company's common stock valuations were prepared using a hybrid method, which used market approaches to estimate its enterprise
value. The hybrid method is a probability-weighed expected return method, or PWERM, where the equity value in one or more scenarios is calculated using an option-pricing method, or OPM. The OPM treats
common stock and preferred stock as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a
company's securities changes. Under this method, the common stock has value only if the funds available for distribution to stockholders exceeded the value of the preferred stock liquidation
preference at the time of the liquidity event, such as a strategic sale or a merger. The PWERM is a scenario-based methodology that estimates the fair value of common stock based upon an analysis of
future values for the company, assuming various outcomes. The common stock value is based on the probability-weighted present value of expected future investment returns considering each of the
possible outcomes available as well as the rights of each class of stock. The future value of the common stock under each outcome is discounted back to the valuation date at an appropriate
risk-adjusted discount rate and probability weighted to arrive at an indication of value for the common stock. These third-party valuations were performed at various dates, which resulted in
valuations of the Company's common stock of $0.92 per share as of May&nbsp;31, 2016, $1.01 per share as of October&nbsp;2, 2017 and $3.18 per share as of December&nbsp;31, 2018. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to considering the results of these third-party valuations, the Company's board of directors considered various objective and subjective factors to determine the fair value
of its common stock as of each grant date, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the prices at which the Company sold shares of preferred stock and the superior rights and preferences of the preferred stock relative to its
common stock at the time of each grant; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the progress of the Company's research and development programs, including the status and results of preclinical studies and clinical trials
for its product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the Company's stage of development and commercialization and its business strategy; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> external market conditions affecting the biopharmaceutical industry and trends within the biopharmaceutical industry; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the Company's financial position, including cash on hand, and its historical and forecasted performance and operating results; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the lack of an active public market for the Company's common stock and its preferred stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the likelihood of achieving a liquidity event, such as an initial public offering, or IPO, or sale of the Company in light of prevailing market
conditions; and </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=215,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=658904,FOLIO='F-14',FILE='DISK116:[19ZBM1.19ZBM17601]FS17601A.;28',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<A NAME="page_fs17601_1_15"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Aprea Therapeutics AB </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Financial Statements (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of significant accounting policies (continued) </B></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the analysis of IPOs and the market performance of similar companies in the biopharmaceutical industry. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
assumptions underlying these valuations represented management's best estimate, which involved inherent uncertainties and the application of management's judgment. As a result, if
the Company had used significantly different assumptions or estimates, the fair value of its common stock and its stock-based compensation expense could have been materially different. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes</B></FONT><FONT SIZE=2>&#151;The Company accounts for income tax in accordance with ASC 740-10, Income Taxes ("ASC&nbsp;740-10"), which requires the recognition of
deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company's financial statements and tax returns. Deferred tax assets and
liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using
enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that
these assets may not be realized. The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position
will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is
calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions
as part of its provision for income taxes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss per share</B></FONT><FONT SIZE=2>&#151;The Company has reported losses since inception and has computed basic net loss per share attributable to common stockholders by
dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company
computes diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock and convertible preferred stock, outstanding
during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses
since inception, these potential common shares have been anti-dilutive and basic and diluted loss per share were the same for all periods presented. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic
and diluted net loss per share attributable to common stockholders was calculated as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Numerator:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,190,250</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,528,269</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Denominator&#150;basic and diluted:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted average common shares outstanding, basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,153,069</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,154,368 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss per share attributable to common stockholders, basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(13.17</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(13.45</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=216,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=27418,FOLIO='F-15',FILE='DISK116:[19ZBM1.19ZBM17601]FS17601A.;28',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<A NAME="page_fs17601_1_16"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Aprea Therapeutics AB </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Financial Statements (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of significant accounting policies (continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be
anti-dilutive (in common stock equivalent shares): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;A convertible preferred stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>612,446</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>612,446</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;B convertible preferred stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,235,969</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,235,969</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;C convertible preferred stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,712,698</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options to purchase common stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,897,206</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,844,188 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total shares of common stock equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,745,621</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,405,301 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pro forma net loss per share</B></FONT><FONT SIZE=2>&#151;Unaudited pro forma net loss per share attributable to common stockholders is computed using the weighted-average number
of common shares outstanding after giving effect to the conversion of all the convertible preferred stock into shares of common stock as if such conversion had occurred at the beginning of the period
presented or the date of original issuance, if later. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table summarizes the Company's unaudited pro forma net loss per share attributable to common stockholders: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year ended </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, 2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Numerator:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss attributable to common stockholders, basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,528,269</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Denominator:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted average common shares outstanding&#151;basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,154,368</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Assumed conversion of Series&nbsp;A, Series&nbsp;B and Series&nbsp;C convertible preferred stock</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,274,505 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma weighted average common shares outstanding, basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,428,873 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma net loss per share attributable to common stockholders, basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.65</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=217,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=72757,FOLIO='F-16',FILE='DISK116:[19ZBM1.19ZBM17601]FS17601A.;28',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_fu17601_1_17"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Aprea Therapeutics AB  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Financial Statements (Continued)  </B></FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of significant accounting policies (continued)  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recently issued accounting pronouncements  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In March 2016, the FASB issued ASU No.&nbsp;2016-09, Compensation&#151;Stock Compensation ("ASU&nbsp;No.&nbsp;2016-09"), which
amends ASC Topic 718, Compensation&#151;Stock Compensation. ASU No.&nbsp;2016-09 identifies areas for simplification involving several aspects of accounting for share-based payment
transactions, including the income tax consequences, classification of awards as either equity or liabilities, an option to recognize gross stock compensation expense with actual forfeitures
recognized as they occur, as well as certain classifications on the statement of cash flows. The amendments are effective for annual periods beginning after December&nbsp;15, 2016, and interim
periods within those annual periods. The Company adopted ASU No.&nbsp;2016-09 effective January&nbsp;1, 2017. The adoption of ASU No.&nbsp;2016-09 did not have a material impact on the Company's
financial statements. Upon adoption, the Company elected to account for forfeitures as they occur. The Company did not have any excess tax benefits associated with stock option exercises and therefore
there was no deferred tax asset recorded upon adoption. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
August 2016, the FASB issued ASU No.&nbsp;2016-15, </FONT><FONT SIZE=2><I>Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments</I></FONT><FONT SIZE=2>
("ASU No.&nbsp;2016-15"). This guidance addresses the presentation and classification of certain cash receipts and cash payments in the statement of cash flows. The standard is effective for annual
periods beginning after December&nbsp;15, 2017 and for interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU No.&nbsp;2016-15 effective January&nbsp;1,
2017. The adoption of ASU No.&nbsp;2016-15 did not have a material impact on the Company's financial statements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
February 2016, the FASB issued ASU 2016-02, "</FONT><FONT SIZE=2><I>Leases (Topic 842)</I></FONT><FONT SIZE=2>." Under ASU 2016-02, lessees will be required to recognize, for all
leases of 12&nbsp;months or more, a liability to make lease payments and a right-of-use asset representing the right to use the underlying asset for the lease term. Additionally, the guidance
requires improved disclosures to help users of financial statements better understand the nature of an entity's leasing activities. This ASU is effective for nonpublic reporting companies for interim
and annual periods beginning after December&nbsp;15, 2019, with early adoption permitted, and must be adopted using a modified retrospective approach. The Company is currently assessing the impact
of the adoption of this authoritative guidance on its financial statements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
June 2018, the FASB issued ASU No.&nbsp;2018-07, "</FONT><FONT SIZE=2><I>Compensation&#151;Stock Compensation",</I></FONT><FONT SIZE=2> which expands the scope of Topic 718
to include share-based payment transactions for acquiring goods and services from nonemployees, except for specific exceptions. This ASU is effective for annual or any interim periods beginning after
December&nbsp;15, 2019. The Company is currently assessing the impact of adopting this authoritative guidance on its financial statements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
May 2017, the FASB issued ASU No.&nbsp;2017-09, "Compensation&#151;Stock Compensation", which clarifies the guidance about which changes to the terms and conditions of a
share-based payments award require an entity to apply modification accounting in Topic 718. This ASU is effective for annual or any interim periods beginning after December&nbsp;15, 2017. The
Company adopted this standard on January&nbsp;1, 2018, which did not impact the consolidated financial statements as the Company has not modified the terms and conditions of any share-based payments
during the year ended December&nbsp;31, 2018. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=218,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=187899,FOLIO='F-17',FILE='DISK116:[19ZBM1.19ZBM17601]FU17601A.;20',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<A NAME="page_fu17601_1_18"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Aprea Therapeutics AB </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Financial Statements (Continued) </B></FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


3. Property and equipment  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment as of December&nbsp;31, 2017 and 2018 consist of the following: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lab equipment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>72,123</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>69,770</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Furniture&nbsp;&amp; Fixtures</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,313</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,313</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Computer equipment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13,828</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,689 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Property and equipment, at cost</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>102,264</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>98,772</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Less accumulated depreciation and amortization</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(71,928</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(74,322</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Property and equipment&#151;net</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30,336</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,450 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation
expense for years ended December&nbsp;31, 2017 and 2018 was $7,932 and $8,316, respectively. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


4. Fair value measurements  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's financial instruments consist of accounts payable. The carrying amount of accounts payable is considered a reasonable estimate of fair value due to the short-term maturity. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
accounting standard for fair value measurements provides a framework for measuring fair value and requires expanded disclosures regarding fair value measurements. Fair value is
defined as the
proceeds that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market
participants on the measurement date. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
fair value measurements are classified in the three-tier fair value hierarchy, which categorizes the inputs used in measuring fair value. These categories include (in descending
order of priority) Level&nbsp;1, defined as observable inputs, such as quoted prices in active markets for identical securities; Level&nbsp;2, defined as inputs other than quoted prices included
in Level&nbsp;1 that are either directly or indirectly observable; and Level&nbsp;3, defined as significant unobservable inputs in which little or no market data exists, therefore, requiring an
entity to develop its own assumptions. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


5. Accrued expenses  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses at December&nbsp;31, 2017 and 2018 consist of the following: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Professional fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>33,886</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>80,771</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Compensation and benefits</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>717,218</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>624,298</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,817,292</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,178,086</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>70,804</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>245,617 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total accrued expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,639,200</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,128,772 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=219,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=491941,FOLIO='F-18',FILE='DISK116:[19ZBM1.19ZBM17601]FU17601A.;20',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<A NAME="page_fu17601_1_19"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Aprea Therapeutics AB </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Financial Statements (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


6. Commitments  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating leases</B></FONT><FONT SIZE=2>&#151;In August 2016, the Company entered into an operating lease for office in Boston, Massachusetts that expires in December 2021. The
Company leased office space in Solna, Sweden under an annual operating lease that expired on June&nbsp;30, 2019. Additionally, the Company entered into a new operating lease for office and
laboratory space in Solna, Sweden that is effective July&nbsp;1, 2019 and expires in June&nbsp;2022. Base rent for this lease is approximately $125,000 annually. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rent
expense for the years ended December&nbsp;31, 2017 and 2018 was $242,263 and $263,518, respectively. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Future
minimum lease payments as of December&nbsp;31, 2018 are as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Years ending December&nbsp;31,

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>121,635</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2020</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>123,930</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>126,225</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Thereafter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total future minimum lease payments</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>371,790 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


7. Income taxes  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Components of the net loss consist of the following: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(15,185,931</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(15,713,032</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Domestic</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4,319</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>184,763 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(15,190,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(15,528,269</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
reconciliation of the effect of applying the federal statutory rate to the net loss and the effective income tax rate: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="16pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Statutory federal income tax rate</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>34.0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21.0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Earnings in jurisdictions taxed at rates different from the statutory U.S. federal tax rate</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> (12.0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Permanent differences</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> (0.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Changes in valuation allowance</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> (21.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> (16.7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rate change due to TCJA</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> (0.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rate change due to Swedish tax reform</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> (5.7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Effective income tax rate</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>0.0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=220,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=758086,FOLIO='F-19',FILE='DISK116:[19ZBM1.19ZBM17601]FU17601A.;20',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<A NAME="page_fu17601_1_20"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Aprea Therapeutics AB </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Financial Statements (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


7. Income taxes (continued) </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Significant
components of the Company's deferred taxes as of December&nbsp;31, 2017 and 2018 are as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred tax assets:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net operating loss carryforward</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,108,800</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,816,395</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Capitalized research and development</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,694</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,951 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Gross deferred tax assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,114,494</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,818,346</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Valuation allowance</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(11,053,983</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(12,661,874</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total deferred tax assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60,511</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>156,472</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred tax liabilities:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fixed assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2,297</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2,050</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stock Compensation</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(58,214</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(154,422</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total deferred tax liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(60,511</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(156,472</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net deferred tax assets (liabilities)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company has no income tax expense due to operating losses incurred for the years ended December&nbsp;31, 2017 and 2018. The Company has provided a valuation allowance for the full
amount of the net deferred tax assets as, based on all available evidence, it is considered more likely than not that all the recorded deferred tax assets will not be realized in a future period. At
December&nbsp;31, 2018, the Company has $61.6&nbsp;million, $0.5&nbsp;million and $0.4&nbsp;million of foreign, federal and state net operating loss carryforwards, respectively, that expire at
various dates through 2036. Certain of these foreign, federal and state net operating loss carryforwards may be subject to Internal Revenue Code Section&nbsp;382 or similar provisions, which impose
limitations on their utilization. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
valuation allowance increased in 2018 by $2.5&nbsp;million, due to the increase in the deferred tax assets by the same amounts; primarily due to net operating loss carryforwards.
Realization of the future tax benefits is dependent on many factors, including the Company's ability to generate taxable income within the net operating loss carryforward period. Under the provisions
of the U.S. Internal Revenue Code and Sweden tax law, certain changes in the Company's ownership, including a sale of the Company or significant changes in ownership due to sales of equity, may have
limited, or may limit in the future, the amount of net operating loss carryforwards that could be used annually to offset future taxable income. For U.S. and Swedish income tax purposes, the Company
has not completed a study to assess whether a change of control has occurred or whether there have been changes of control since the Company's formation due to the complexity and cost associated with
such study and because there could be additional changes in control in the future. As a result, the Company is not able to estimate the effect of the change in control, if any, on the Company's
ability to utilize U.S. or Swedish net operating losses or other tax attribute carryforwards the future. For Swedish income tax purposes, the Company has estimated that approximately
$12.5&nbsp;million of its net operating losses may be subject to limitations in accordance with the country's group contribution restriction laws. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company files tax returns in Sweden, the United States, Pennsylvania and Massachusetts, and all tax years since inception remain open to examination by the major taxing jurisdictions
to which the Company is subject, as carryforward attributes generated in years past may still be adjusted upon </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=221,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=753843,FOLIO='F-20',FILE='DISK116:[19ZBM1.19ZBM17601]FU17601A.;20',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<A NAME="page_fu17601_1_21"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Aprea Therapeutics AB </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Financial Statements (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


7. Income taxes (continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>examination
by the Internal Revenue Service (IRS) or other authorities if they have or will be used in a future period. The Company is not currently under examination by the IRS or any other
jurisdictions for any tax years. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2018, the Company had no uncertain tax positions. The Company has elected to recognize interest and penalties related to income tax matters as a component of
income tax expense, of which no interest or penalties were recorded for the years ended December&nbsp;31, 2017 and 2018. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
June 2018, Sweden promulgated changes to the Swedish regulations on corporate income taxation. The law will apply from January&nbsp;1, 2019. Among other things, the changes decrease
the corporate income tax rate in two steps from 22% to 21.4% as of January&nbsp;1, 2019 and 20.6% as of January&nbsp;1, 2020. U.S.&nbsp;GAAP requires companies to revalue their deferred tax
assets and deferred tax liabilities as of the date of enactment, with the resulting tax effects accounted for in the reporting period of enactment. This revaluation resulted in an overall reduction of
deferred taxes of $0.7&nbsp;million and a corresponding reduction in the valuation allowance. As such, there was no net impact to the Company's statement of operations as a result of the reduction
in tax rates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2017, what is commonly known as the Tax Cuts and Jobs Act (the Tax Act), was signed into law. Among other things, the Tax Act permanently lowers the corporate federal income
tax rate to 21% from the statutory rate of 35%, effective for tax years including or commencing January&nbsp;1, 2018. As a result of the reduction of the corporate federal income tax rate to 21%,
U.S.&nbsp;GAAP requires companies to revalue their deferred tax assets and deferred tax liabilities as of the date of enactment, with the resulting tax effects accounted for in the reporting period
of enactment. This revaluation resulted in an overall reduction of deferred taxes of $0.1&nbsp;million and a corresponding reduction in the valuation allowance. As such, there was no net impact to
the Company's statement of operations as a result of the reduction in tax rates. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


8. Convertible preferred stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has 20,000,000 shares authorized for all classes of equity combined. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Series&nbsp;A Preferred  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In June 2011, the Company issued 145,469 shares of Series&nbsp;A Preferred for gross proceeds of $3,233,417. In March 2016, the Company issued
466,977 shares of Series&nbsp;A Preferred as settlement of its outstanding bridge loans totaling $3,249,627. All 612,446 shares of Series&nbsp;A Preferred were issued to related parties. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2018, the rights and preferences of the Series&nbsp;A Preferred are as follows: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conversion</I></B></FONT><FONT SIZE=2>&#151;Each share of Series&nbsp;A Preferred may be converted at any time, at the option of the holder, into a share of common stock. The
Series&nbsp;A Preferred automatically converts into shares of common stock when 1)&nbsp;shareholders representing a majority of the outstanding preferred shares calls for such conversion or
2)&nbsp;at the closing of an initial public offering of the Company's common stock at a per share price of at least one and a half (1.5) times the average amount (EUR 16.05 based on all
Series&nbsp;C preferred shares issued as of December&nbsp;31, 2018) paid per Series&nbsp;C preferred share (as adjusted for share splits and similar) and aggregate proceeds in excess of EUR
50,000,000. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=222,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=1031378,FOLIO='F-21',FILE='DISK116:[19ZBM1.19ZBM17601]FU17601A.;20',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<A NAME="page_fu17601_1_22"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Aprea Therapeutics AB </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Financial Statements (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


8. Convertible preferred stock (continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividends</I></B></FONT><FONT SIZE=2>&#151;Holders of Series&nbsp;A Preferred do not accrue dividends. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Voting rights</I></B></FONT><FONT SIZE=2>&#151;Preferred Stock and common stock vote together as one class on an as converted basis. Common stock voting rights on certain matters
are
subject to the powers, preferences, and rights of the Preferred Stock. Holders are entitled to vote on all matters and shall have the number of votes equal to the number of shares of common stock into
which the shares of Preferred Stock held by such holder are then convertible. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Series&nbsp;B Preferred  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In March 2016, the Company issued 3,322,762 shares of Series&nbsp;B Preferred for gross proceeds of $22,609,485, or $22,290,261 net of
issuance costs. The Company also issued 590,445 shares of Series&nbsp;B Preferred in settlement of its outstanding bridge loans totaling $4,108,818. In October 2017, the Company issued 3,322,762
Series&nbsp;B preferred shares at a price per share of $7.02, for an aggregate purchase price of $23,349,617. All 7,235,969 shares of Series&nbsp;B Preferred were issued to related parties. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2018, the rights and preferences of the Series&nbsp;B Preferred are as follows: </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conversion</I></B></FONT><FONT SIZE=2>&#151;Each share of Series&nbsp;B Preferred may be converted at any time, at the option of the holder, into a share of common stock. The
Series&nbsp;B Preferred automatically converts into shares of common stock when 1)&nbsp;shareholders representing a majority of the outstanding preferred shares calls for such conversion or
2)&nbsp;at the closing of an initial public offering of the Company's common stock at a per share price of at least one and a half (1.5) times the average amount (EUR 16.05 based on all
Series&nbsp;C preferred shares issued as of December&nbsp;31, 2018) paid per Series&nbsp;C preferred share (as adjusted for share splits and similar) and aggregate proceeds in excess of EUR
50,000,000. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividends</I></B></FONT><FONT SIZE=2>&#151;Holders are entitled to dividends of 8%, compounded annually if not paid. No dividends have been declared or paid as of December&nbsp;31,
2018. The company has not accrued dividends on the Series&nbsp;B Preferred since dividends are only payable upon the occurrence of a liquidation event, including the transfer of more than fifty
percent of the Company's outstanding shares or the transfer of substantially all of the Company's intellectual property. Approximately $8,806,426 of accrued dividends that were payable through
December&nbsp;31, 2018 was added to the stated liquidation preference amount of the Series&nbsp;B Preferred, which totaled $58,874,347 at December&nbsp;31, 2018. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Voting rights</I></B></FONT><FONT SIZE=2>&#151;Preferred Stock and common stock vote together as one class on an as converted basis. Common stock voting rights on certain matters
are
subject to the powers, preferences, and rights of the Preferred Stock. Holders are entitled to vote on all matters and shall have the number of votes equal to the number of shares of common stock into
which the shares of Preferred Stock held by such holder are then convertible. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Series&nbsp;C Preferred  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2018, the Company issued 4,712,698 shares of Series&nbsp;C Preferred for gross proceeds of $56,725,342 or $56,364,645 net of
issuance costs. A total of 4,219,849 shares of Series&nbsp;C Preferred were issued to related parties. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=223,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=683255,FOLIO='F-22',FILE='DISK116:[19ZBM1.19ZBM17601]FU17601A.;20',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<A NAME="page_fu17601_1_23"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Aprea Therapeutics AB </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Financial Statements (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


8. Convertible preferred stock (continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2018, the rights and preferences of the Series&nbsp;C Preferred are as follows: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conversion</I></B></FONT><FONT SIZE=2>&#151;Each share of Series&nbsp;C Preferred may be converted at any time, at the option of the holder, into a share of common stock. The
Series&nbsp;C Preferred automatically converts into shares of common stock when 1)&nbsp;shareholders representing a majority of the outstanding preferred shares calls for such conversion or
2)&nbsp;at the closing of an initial public offering of the Company's common stock at a per share price of at least one and a half (1.5) times the average amount (EUR 16.05 based on all
Series&nbsp;C preferred shares issued as of December&nbsp;31, 2018) paid per Series&nbsp;C preferred share (as adjusted for share splits and similar) and aggregate proceeds in excess of EUR
50,000,000. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividends</I></B></FONT><FONT SIZE=2>&#151;Holders are entitled to dividends of 8%, compounded annually if not paid. No dividends have been declared or paid as of December&nbsp;31,

2018. The company has not accrued dividends on the Series&nbsp;C Preferred since dividends are only payable upon the occurrence of a liquidation event, including the transfer of more than fifty
percent of the Company's outstanding shares or the transfer of substantially all of the Company's intellectual property. Approximately $389,970 of accrued dividends that were payable through
December&nbsp;31, 2018 was added to the stated liquidation preference amount of the Series&nbsp;C Preferred, which totaled $57,115,312 at December&nbsp;31, 2018. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Voting rights</I></B></FONT><FONT SIZE=2>&#151;Preferred Stock and common stock vote together as one class on an as converted basis. Common stock voting rights on certain matters
are
subject to the powers, preferences, and rights of the Preferred Stock. Holders are entitled to vote on all matters and shall have the
number of votes equal to the number of shares of common stock into which the shares of Preferred Stock held by such holder are then convertible. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Liquidation preference  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon liquidation, dissolution, or winding up of business, the Preferred Stock holders are entitled to receive a liquidation preference in
priority to holders of common stock at the original issue price plus, in the case of Series B and Series C Preferred, any unpaid accumulated dividends as follows: </FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>If
a liquidation event occurs prior to the Company achieving a certain clinical milestone, Series&nbsp;C Preferred shareholders shall receive an amount per
Series&nbsp;C Preferred share equal to the original subscription price per Series&nbsp;C Preferred share (as adjusted for share splits and similar) plus unpaid accumulated dividends. Secondly,
after the Series&nbsp;C Preferred shareholders have received full payment, the Series&nbsp;B Preferred shareholders shall receive an amount per Series&nbsp;B preferred share equal to the
original subscription price per Series&nbsp;B Preferred share (as adjusted for share splits and similar) plus unpaid accumulated dividends. Thirdly, after the Series&nbsp;B and C Preferred
shareholders have received full payment, the Series&nbsp;A Preferred shareholders shall receive an amount per Series&nbsp;A preferred share equal to the original subscription price per
Series&nbsp;A Preferred share (as adjusted for share splits and similar). When the Preferred A, B and C shareholders are satisfied in full, any excess assets available for distribution will be
allocated ratably among holders of common stock and preferred stock based on their pro rata shareholdings on an as-if-converted basis.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>If
a liquidation event occurs after the Company achieves a certain clinical milestone, Series&nbsp;B and C Preferred shareholders, based on their pro rata
shareholdings, shall receive an amount per Series&nbsp;B and C Preferred share equal to the original subscription price per Series&nbsp;B and C Preferred share (as adjusted for share splits and
similar) plus unpaid accumulated dividends. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=224,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=277825,FOLIO='F-23',FILE='DISK116:[19ZBM1.19ZBM17601]FU17601A.;20',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<A NAME="page_fu17601_1_24"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Aprea Therapeutics AB </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Financial Statements (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


8. Convertible preferred stock (continued) </B></FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>Secondly,
after the Series&nbsp;B and C Preferred shareholders have received full payment, the Series&nbsp;A Preferred shareholders shall receive an amount per Series&nbsp;A preferred share
equal to the original subscription price per Series&nbsp;A Preferred share (as adjusted for share splits and similar). When the Preferred A, B and C shareholders are satisfied in full, any excess
assets available for distribution will be allocated ratably among holders of common stock and preferred stock based on their pro rata shareholdings on an as-if-converted basis. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
liquidation preferences apply to each series of preferred stock only to the extent the holders would receive less than three times their respective original purchase prices. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


9. Common stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has 1,155,366 shares of common stock outstanding as of December&nbsp;31, 2018. During 2018, the Company issued 2,305 shares of common stock to employees for aggregate
consideration of $2,097 as a result of stock option exercises. No common stock was issued during 2017. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
holders of common stock are entitled to one vote for each share of common stock. Subject to the payment in full of all preferential dividends to which the holders of the Preferred
Stock are entitled, the holders of common stock shall be entitled to receive dividends out of funds legally available. In the event of any voluntary or involuntary liquidation, dissolution or winding
up of the Company, after the payment or provision for payment of all debts and liabilities of the Company and all preferential amounts to which the holders of Preferred Stock are entitled with respect
to the distribution of assets
in liquidation, the holders of common stock shall be entitled to share ratably in the remaining assets of the Company available for distribution. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


10. Stock option plan  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2016, the Board of Directors adopted the 2016 Amended and Restated Stock Option Program (the "Plan"), which provided for the grant of stock options to the Company's employees,
officers, directors, and outside consultants for the purchase of up to 1,224,824 shares of the Company's common stock. During 2017, the Plan was amended to provide up to 1,946,849 shares of the
Company's common stock. During 2018, the Plan was further amended to provide up to 3,069,999 shares of the Company's common stock. Holders of stock options shall be entitled to exercise the vested
portion of the stock option provided that a trade sale, as defined in the plan, or initial public offering has occurred. The holders of stock options may also exercise the vested portion of the stock
option within six months of termination of employment. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock
options generally vest over a four-year period and expire in October 2026. The Board of Directors has the discretion to provide for accelerated vesting. At December&nbsp;31,
2018, there were 1,487,466 shares available for future grant under the Plan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company recorded stock-based compensation expense of $395,440 and $329,814 during the years ended December&nbsp;31, 2017 and 2018, respectively. As of December&nbsp;31, 2018,
there was $386,388 of unrecognized compensation cost related to nonvested share-based compensation arrangements granted under the Plan, which is expected to be recognized over a weighted-average
period of approximately 2.1&nbsp;years. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
fair value of each option award is estimated on the date of grant using Black-Scholes, with the assumptions noted in the table below. Expected volatility for the Company's common
stock was </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=225,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=74066,FOLIO='F-24',FILE='DISK116:[19ZBM1.19ZBM17601]FU17601A.;20',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<A NAME="page_fu17601_1_25"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Aprea Therapeutics AB </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Financial Statements (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


10. Stock option plan (continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>determined
based on an average of the historical volatility of a peer group of similar public companies. The expected term of options granted to employees was calculated using the simplified method,
which represents the average of the contractual term of the option and the weighted-average vesting period of the option. The Company uses the simplified method because it does not have sufficient
historical option exercise data to provide a reasonable basis upon which to estimate expected term. The contractual life of the option was used for the expected life of options granted to
non-employee. The assumed dividend yield is based upon the Company's expectation of not paying dividends in the foreseeable future. The risk-free rate for periods within the expected life of the
option is based upon the Swedish Government Bond Rate in effect at the time of grant. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
determining the exercise prices for options granted, the Company's Board of Directors has considered the fair value of the common stock as of the measurement date. The fair value of
the common stock at each award grant date was based upon a variety of factors, including the results obtained from an independent third-party valuation, the Company's financial position and historical
financial performance, the status of technological developments within the Company's proposed products, an evaluation or benchmark of the Company's competition, the current business climate in the
marketplace, the illiquid nature of the common stock, arm's length sales of the Company's capital stock, including Preferred Stock, the effect of the rights and preferences of the preferred
shareholders, and the prospects of a liquidity event, among others. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
assumptions used in Black-Scholes for the years ended December&nbsp;31, 2017 and 2018 are as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="86pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="37pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=4 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected volatility</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>71.9% - 75.4%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>71.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk-free rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.3% - 2.5%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected dividend yield</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected term in years</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.6 - 9.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=226,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=988919,FOLIO='F-25',FILE='DISK116:[19ZBM1.19ZBM17601]FU17601A.;20',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<A NAME="page_fu17601_1_26"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Aprea Therapeutics AB </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Financial Statements (Continued) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


10. Stock option plan (continued) </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
summary of option activity under the Plan during the years ended December&nbsp;31, 2017 and 2018 are as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="47pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="74pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
options </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted-<BR>
average<BR>
exercise<BR>
price per<BR>
share </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted<BR>
average<BR>
remaining<BR>
contractual<BR>
term (in years) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
intrinsic<BR>
value </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding at January&nbsp;1, 2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,237,292</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.85</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>66,498 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Granted</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>663,224</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.73</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercised</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cancelled/Forfeited</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3,310</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.92</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding at December&nbsp;31, 2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,897,206</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.46</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>360,691 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Granted</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,067</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.01</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercised</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2,306</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.92</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cancelled/Forfeited</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(74,779</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding at December&nbsp;31, 2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,844,188</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.82</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,382,781 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercisable at December&nbsp;31, 2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,807</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.92</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,388 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vested or expected to vest at December&nbsp;31, 2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,844,188</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.82</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,382,781 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
weighted-average grant date fair value of options granted during the years ended December&nbsp;31, 2017 and 2018, was $0.75 and $0.69 per share, respectively. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


11. Subsequent events  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In February 2019, the Company raised $5,645,248 in gross proceeds through the issuance of 467,179 Series&nbsp;C convertible preferred shares. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
September&nbsp;20, 2019, the Company consummated a corporate reorganization, pursuant to which all of the issued and outstanding stock and options of Aprea Therapeutics AB, or
Aprea&nbsp;AB, was exchanged for common stock, preferred stock or options, as applicable, of Aprea Therapeutics, Inc. As a result, Aprea Therapeutics AB, became a wholly-owned subsidiary of Aprea
Therapeutics, Inc. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
September 2019, the Company's Board of Directors and stockholders approved a 1-for-1.6045 stock split of the Company's preferred and common stock. All share and per share amounts in
the consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this split. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=227,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=896327,FOLIO='F-26',FILE='DISK116:[19ZBM1.19ZBM17601]FU17601A.;20',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_fw17601_1_27"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="10"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="fw17601_aprea_therapeutics_ab_condense__apr02689"> </A>
<A NAME="toc_fw17601_1"> </A></FONT> <FONT SIZE=2><B><BR>  Aprea Therapeutics AB    <BR>    <BR>    Condensed Consolidated Balance Sheets    <BR>    <BR>    (Unaudited)    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31,<BR>
2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>June&nbsp;30,<BR>
2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Pro forma<BR>
June&nbsp;30,<BR>
2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Assets</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current assets:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>65,675,931</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>60,994,738</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>60,994,738</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred offering costs</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>624,624</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>624,624</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid expenses and other current assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>322,146</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>291,991</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>291,991 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total current assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>65,998,077</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>61,911,353</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>61,911,353</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Property and equipment, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>24,450</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25,662</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25,662</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Right of use lease asset</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>277,531</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>277,531</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other noncurrent assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>111</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>108</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>108 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>66,022,638</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>62,214,654</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>62,214,654 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current liabilities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts payable</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,739,337</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,323,719</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,323,719</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,128,772</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,260,109</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,260,109</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lease liability&#151;current</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>112,315</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>112,315 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total current liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,868,109</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,696,143</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,696,143</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lease liability&#151;noncurrent</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>181,910</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>181,910 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,868,109</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,878,053</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,878,053</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Commitments and contingencies (Note&nbsp;6)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible preferred stock:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;A convertible preferred stock, $0.11 par value; 612,446 shares issued and outstanding at December&nbsp;31, 2018 and June&nbsp;30, 2019
(liquidation preference of $6,483,044 at June&nbsp;30, 2019)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,483,044</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,483,044</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;B convertible preferred stock, $0.11 par value; 7,235,969 shares issued and outstanding at December&nbsp;31, 2018 and June&nbsp;30, 2019
(liquidation preference of $61,127,463 at June&nbsp;30, 2019)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>49,742,942</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>49,742,942</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;C convertible preferred stock, $0.11 par value; 4,712,698 and 5,179,877 shares issued and outstanding at December&nbsp;31, 2018 and
June&nbsp;30, 2019, respectively (liquidation preference of $65,188,827 at June&nbsp;30, 2019)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>56,364,645</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>61,963,007</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total convertible preferred stock</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>112,590,631</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>118,188,993</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stockholders' equity (deficit):</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock, $0.11 par value at December&nbsp;31, 2018 and June&nbsp;30, 2019, $0.001 par value at pro forma June&nbsp;30, 2019; 1,155,366, 1,181,573 and
14,209,865 shares issued and outstanding at December&nbsp;31, 2018, June&nbsp;30, 2019 and pro forma June&nbsp;30, 2019, respectively.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>127,091</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>129,974</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14,210</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Additional paid-in capital</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>19,666,588</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>19,971,732</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>138,276,489</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated other comprehensive loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(8,761,325</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(10,747,992</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(10,747,992</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated deficit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(62,468,456</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(71,206,106</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(71,206,106</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stockholders' equity (deficit)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(51,436,102</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(61,852,392</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>56,336,601 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:27pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total liabilities, convertible preferred stock and stockholders' equity (deficit)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>66,022,638</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>62,214,654</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>62,214,654 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
See accompanying notes to condensed consolidated financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=228,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=699727,FOLIO='F-27',FILE='DISK116:[19ZBM1.19ZBM17601]FW17601A.;18',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_fy17601_1_28"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="11"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="fy17601_aprea_therapeutics_ab_condense__apr04119"> </A>
<A NAME="toc_fy17601_1"> </A></FONT> <FONT SIZE=2><B><BR>  Aprea Therapeutics AB    <BR>    <BR>    Condensed Consolidated Statements of Operations and Comprehensive Loss    <BR>    <BR>    (Unaudited)    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Six Months Ended June&nbsp;30, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,492,788</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,998,270</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,166,520</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,347,915 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,659,308</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,346,185 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income (expense):</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(188</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(7,439</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign currency gain</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>949,158</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,615,974 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total other income (expense)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>948,970</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,608,535 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(7,710,338</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(8,737,650</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other comprehensive loss:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign currency translation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,176,208</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,986,667</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total comprehensive loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(8,886,546</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(10,724,317</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss per share attributable to common stockholders, basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(6.68</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(7.43</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted average basic and diluted shares of common stock outstanding</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,154,107</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,176,417 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma net loss per share attributable to common stockholders, basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.62</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma weighted average common shares outstanding, basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14,075,669 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
See accompanying notes to condensed consolidated financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=229,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=827354,FOLIO='F-28',FILE='DISK116:[19ZBM1.19ZBM17601]FY17601A.;12',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ga17601_1_29"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- COMMAND=ROTATED_TABLE WIDTH="150%" -->

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="12"></A></FONT><FONT SIZE=2><B>Aprea Therapeutics AB  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (Unaudited)  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="47pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="53pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=17 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Convertible Preferred Stock </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Series&nbsp;A </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Series&nbsp;B </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Series&nbsp;C </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Common Stock </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=3 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=3 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Accumulated<BR>
Other<BR>
Comprehensive<BR>
Loss </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=3 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=3 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
Stockholders'<BR>
Equity<BR>
(Deficit) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Additional<BR>
Paid-in<BR>
Capital </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Accumulated<BR>
Deficit </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Balance, December&nbsp;31, 2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>612,446</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6,483,044</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7,235,969</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>49,742,942</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,153,061</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>126,838</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>19,335,560</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(8,287,406</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(46,940,187</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(35,765,195</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Exercise of stock options</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,503</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>165</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,250</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,415</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Stock-based compensation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>169,854</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>169,854</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Foreign currency translation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(1,176,208</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(1,176,208</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(7,710,338</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(7,710,338</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Balance, June&nbsp;30, 2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>612,446</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6,483,044</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7,235,969</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>49,742,942</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,154,564</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>127,003</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>19,506,664</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(9,463,614</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(54,650,525</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(44,480,472</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Balance, December&nbsp;31, 2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
612,446</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
6,483,044</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
7,235,969</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
49,742,942</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
4,712,698</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
56,364,645</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
1,155,366</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
127,091</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
19,666,588</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
(8,761,325</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
(62,468,456</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
(51,436,102</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Issuance of Series&nbsp;C convertible preferred stock, net of issuance costs of $53,509</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>467,179</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5,598,362</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Exercise of stock options</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>26,207</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,883</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>20,235</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>23,118</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Stock-based compensation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>284,909</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>284,909</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Foreign currency translation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(1,986,667</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(1,986,667</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(8,737,650</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(8,737,650</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Balance, June&nbsp;30, 2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>612,446</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6,483,044</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7,235,969</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>49,742,942</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5,179,877</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>61,693,007</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,181,573</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>129,974</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>19,971,732</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(10,747,992</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(71,206,106</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(61,852,392</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Exchange and conversion of preferred stock and common stock of Aprea Therapeutics&nbsp;AB into common stock of Aprea
Therapeutics&nbsp;Inc.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(612,446</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(6,483,044</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(7,235,969</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(49,742,942</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(5,179,877</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(61,693,007</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>13,028,292</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(115,764</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>118,304,757</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>118,188,993 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Balance, June&nbsp;30, 2019 pro forma</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>14,209,865</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>14,210</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>138,276,489</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(10,747,992</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(71,206,106</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>56,336,601 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>See
accompanying notes to condensed consolidated financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=230,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=86182,FOLIO='F-29',FILE='DISK116:[19ZBM1.19ZBM17601]GA17601A.;25',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_gc17601_1_30"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="13"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="gc17601_aprea_therapeutics_ab_condense__apr03146"> </A>
<A NAME="toc_gc17601_1"> </A></FONT> <FONT SIZE=2><B><BR>  Aprea Therapeutics AB    <BR>    <BR>    Condensed Consolidated Statements of Cash Flows    <BR>    <BR>    (Unaudited)    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Six Months Ended June&nbsp;30, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash flows from operating activities:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(7,710,338</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(8,737,650</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adjustments to reconcile net loss to net cash used in operating activities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Depreciation and amortization</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,263</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,739</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stock-based compensation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>169,854</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>284,909</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Amortization of right of use lease asset</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>51,853</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Foreign currency gain</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(949,158</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,615,974</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Changes in operating assets and liabilities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred offering costs</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(624,624</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid expense and other current assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>91,530</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>19,721</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts payable</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(51,369</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>640,719</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued expenses and other liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>198,384</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>232,679</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lease liability</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(53,815</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:50pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash used in operating activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(8,246,834</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(9,797,443</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash flows from investing activities:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Purchases of property and equipment</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(4,734</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(6,189</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:50pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash used in investing activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(4,734</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(6,189</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Cash flows from financing activities:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from the exercise of stock options</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,415</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23,118</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from issuance of Series&nbsp;C preferred, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,598,362 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:50pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash provided by financing activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,415</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,621,480 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Decrease in cash</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(8,250,153</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(4,182,152</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Effect of exchange rate changes on cash and cash equivalents</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(547,286</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(499,041</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents&#151;beginning of period</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>24,401,488</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>65,675,931 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents&#151;end of period</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,604,049</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>60,994,738 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Non-cash activities:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cumulative effect of change in accounting principle&#151;ASC 842 adoption</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>329,384</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
See accompanying notes to condensed consolidated financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=231,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=632883,FOLIO='F-30',FILE='DISK116:[19ZBM1.19ZBM17601]GC17601A.;8',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ge17601_1_31"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="14"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ge17601_aprea_therapeutics_ab_notes_to__apr03351"> </A>
<A NAME="toc_ge17601_1"> </A></FONT> <FONT SIZE=2><B><BR>  Aprea Therapeutics AB    <BR>    <BR>    Notes to Condensed Consolidated Financial Statements    <BR>    <BR>    (Unaudited)    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


1. Nature of business and basis of presentation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nature of business</B></FONT><FONT SIZE=2>&#151;Aprea Therapeutics AB (the "Company") is a clinical-stage biopharmaceutical company focused on developing and commercializing novel
cancer therapeutics that reactivate mutant tumor suppressor protein p53. p53 is the protein expressed from the </FONT><FONT SIZE=2><I>TP53</I></FONT><FONT SIZE=2> gene, the most commonly mutated gene
in cancer. The Company began operations in 2006. Its principal offices are in Solna, Sweden and Boston, Massachusetts. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basis of presentation and management plans</B></FONT><FONT SIZE=2>&#151;The accompanying financial statements are prepared in conformity with accounting principles generally
accepted in the United States ("U.S.&nbsp;GAAP"). The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction
of liabilities in the normal course of business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since
its inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, and raising
capital, and has financed its operations through the issuance of convertible preferred stock ("Preferred Stock") and common stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company is subject to risks common to companies in the biopharmaceutical industry. There can be no assurance that the Company's research and development will be successfully
completed, that
adequate protection for the Company's intellectual property will be maintained, that any therapeutic products developed will obtain required regulatory approval or that any approved or consumer
products will be commercially viable. Even if the Company's development efforts are successful, it is uncertain when, if ever, the Company will generate significant product sales. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company's management believes that the June&nbsp;30, 2019 cash balance of $60,994,738 will be sufficient to fund the Company's operations into the third quarter of 2021. In the
event that additional funds are not available thereafter, management would expect to significantly reduce expenditures to conserve cash, which would involve scaling back or curtailing new development
activity. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to its initial public offering, the Company approved a 1-for-1.6045 stock split of the Company's preferred and common stock. All share and per share amounts in the consolidated
financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this split. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of significant accounting policies  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Principles of consolidation</B></FONT><FONT SIZE=2>&#151;The consolidated financial statements include the accounts of Aprea Therapeutics AB and its wholly owned subsidiaries
Aprea Personal AB, which was incorporated in May 2009, and Aprea US,&nbsp;Inc., which was incorporated in June 2016. Management has concluded it has a single reporting segment for purposes of
reporting financial condition and results of operations. All intercompany transactions and balances have been eliminated. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unaudited interim condensed consolidated financial statements</B></FONT><FONT SIZE=2>&#151;The accompanying
condensed consolidated balance sheet as of June&nbsp;30, 2019, the condensed consolidated statements of operations and comprehensive loss and cash flows for the six months ended June&nbsp;30, 2018
and 2019, and the condensed consolidated statement of convertible preferred stock and stockholders (deficit) equity for the six months ended June&nbsp;30, 2019 are unaudited. The unaudited condensed
consolidated financial </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=232,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=940455,FOLIO='F-31',FILE='DISK116:[19ZBM1.19ZBM17601]GE17601A.;42',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<A NAME="page_ge17601_1_32"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Aprea Therapeutics AB </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Condensed Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (Unaudited) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of significant accounting policies (continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>statements
have been prepared on the same basis as the audited consolidated financial statements, and in management's opinion, include all adjustments, consisting of only normal recurring adjustments,
necessary for the fair statement of the Company's financial position as of June&nbsp;30, 2019 and its results of operations and comprehensive loss and cash flows for six months ended June&nbsp;30,
2018 and 2019. The financial data and the other financial information disclosed in the notes to these condensed consolidated financial statements related to the six month periods are also unaudited.
The results of operations for the six months ended June&nbsp;30, 2019 are not necessarily indicative of the results to be expected for the full fiscal year or any other period. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Use of estimates</B></FONT><FONT SIZE=2>&#151;The preparation of financial statements in conformity with U.S.&nbsp;GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets, liabilities, revenue, and expenses as of and during the reporting period. The Company bases estimates and assumptions on historical experience when
available and on various factors that it believes to be reasonable under the circumstances. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from
those estimates. Significant items subject to such estimates and assumptions include fair value of common stock and stock based compensation expense. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unaudited pro forma financial information</B></FONT><FONT SIZE=2>&#151;The Company is planning an offer and sale by Aprea Therapeutics,&nbsp;Inc., a Delaware corporation and
successor entity, of common stock in an initial public offering (the "IPO"). Prior to the completion of the IPO, pursuant to a corporate reorganization, the Company became a wholly owned subsidiary of
Aprea Therapeutics,&nbsp;Inc. In connection with the corporate reorganization, each issued and outstanding share of Series&nbsp;A, Series&nbsp;B and Series&nbsp;C convertible preferred stock
of the Company was exchanged on a one for one basis into shares of Series&nbsp;A, Series&nbsp;B and Series&nbsp;C convertible preferred stock of Aprea Therapeutics,&nbsp;Inc. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
share of common stock of the Company ($0.11 par value) was also exchanged on a one for one basis into shares of common stock of Aprea Therapeutics,&nbsp;Inc. ($0.001 par value).
Immediately prior to consummation of the IPO, all outstanding shares of Series&nbsp;A, Series&nbsp;B and Series&nbsp;C convertible preferred stock of Aprea Therapeutics,&nbsp;Inc. will be
converted into common stock, on a 1&nbsp;for 1.6045 basis. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
accompanying unaudited pro forma balance sheet as of June&nbsp;30, 2019 has been prepared to give effect to the corporate reorganization and automatic conversion of all outstanding
shares of convertible preferred stock into 13,028,292 shares of common stock of Aprea Therapeutics,&nbsp;Inc. as if </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=233,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=369750,FOLIO='F-32',FILE='DISK116:[19ZBM1.19ZBM17601]GE17601A.;42',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<A NAME="page_ge17601_1_33"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Aprea Therapeutics AB </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Condensed Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (Unaudited) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of significant accounting policies (continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>the
corporate reorganization and automatic conversion had occurred on June&nbsp;30, 2019 as illustrated below: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:57%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"140%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="140%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="74pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Series&nbsp;A<BR>
Preferred<BR>
Stock </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Series&nbsp;B<BR>
Preferred<BR>
Stock </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Series&nbsp;C<BR>
Preferred<BR>
Stock </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Common<BR>
Stock </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Additional<BR>
Paid-in<BR>
Capital </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Aprea Therapeutics AB as of June&nbsp;30, 2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,483,044</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>49,742,942</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>61,963,007</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>129,974</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>19,971,732</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adjustments to reflect:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exchange of common stock</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(128,792</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>128,792</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exchange and conversion of preferred stock:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;A Preferred</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(6,483,044</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>612</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,482,432</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;B Preferred</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(49,742,942</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,236</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>49,735,706</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;C Preferred</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(61,963,007</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,180</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>61,957,827 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma of Aprea Therapeutics,&nbsp;Inc. as of June&nbsp;30, 2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14,210</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>138,276,489 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
unaudited pro forma basic and diluted weighted average common shares outstanding used in the calculation of unaudited pro forma basic and diluted net loss per share attributable to
common stockholders for the six months ended June&nbsp;30, 2019 give effect to the automatic conversion of all outstanding shares of convertible preferred stock into shares of common stock as if the
conversion had occurred on the later of January&nbsp;1, 2019 or the issuance date of the convertible preferred stock for the six months ended June&nbsp;30, 2019. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency and currency translation</B></FONT><FONT SIZE=2>&#151;The functional currency for Aprea Therapeutics AB and its wholly owned foreign subsidiary, Aprea Personal
AB, is the Swedish Krona. Assets and liabilities of Aprea Therapeutics AB and Aprea Personal AB are translated into United
States dollars at the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at the average exchange rate in effect during the period. Unrealized translation gains and
losses are recorded as a cumulative translation adjustment, which is included in the consolidated statements of convertible preferred stock and stockholders' deficit as a component of accumulated
other comprehensive loss. Adjustments that arise from exchange rate changes on transactions denominated in a currency other than the local currency are included in other income and expense in the
condensed consolidated statements of operations and comprehensive loss as incurred. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Concentrations of credit risk</B></FONT><FONT SIZE=2>&#151;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily
of cash. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit
risk as the Company's deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents</B></FONT><FONT SIZE=2>&#151;The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase
to be cash equivalents. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>

<!-- ZEQ.=3,SEQ=234,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=904666,FOLIO='F-33',FILE='DISK116:[19ZBM1.19ZBM17601]GE17601A.;42',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<A NAME="page_ge17601_1_34"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Aprea Therapeutics AB </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Condensed Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (Unaudited) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of significant accounting policies (continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred offering costs</B></FONT><FONT SIZE=2>&#151;The Company capitalizes deferred IPO costs, which primarily consist of direct, incremental legal, professional, accounting and
other third-party fees relating to the Company's initial public offering. The deferred IPO costs will be offset against IPO proceeds upon the consummation of an offering. There were $0 and $624,624 of
deferred IPO costs as of December&nbsp;31, 2018 and June&nbsp;30, 2019, respectively. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment</B></FONT><FONT SIZE=2>&#151;Property and equipment are recorded at cost. Expenditures for repairs and maintenance are expensed as incurred. When assets are
retired or disposed of, the assets and related accumulated depreciation are eliminated from the accounts, and any resulting gain or loss is included in the determination of net income or loss. Fixed
assets acquired for research and development purposes are assessed for alternative future use. Depreciation is provided using the straight-line method over the estimated useful lives of the related
assets. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="141pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Asset category

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Estimated useful life </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Computer equipment and software</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5&nbsp;years</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Furniture and fixtures</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5&nbsp;years</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Laboratory equipment and office furniture</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5&nbsp;years</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Leasehold improvements</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Remainder of lease term</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment of long-lived assets</B></FONT><FONT SIZE=2>&#151;Periodically, the Company evaluates its long-lived assets, which consist primarily of property and equipment, for
impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison
of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is
measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. To date, no impairments have occurred. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fair value of financial instruments</B></FONT><FONT SIZE=2>&#151;The accounting standard for fair value measurements provides a framework for measuring fair value and requires
expanded disclosures regarding fair value measurements. Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at
measurement dates. ASC Topic 820, Fair Value Measurement ("ASC 820"), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency
of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is
considered unobservable:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Level&nbsp;1 inputs: Quoted prices in active markets for identical assets or liabilities. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Level&nbsp;2 inputs: Inputs other than quoted prices included within Level&nbsp;1 that are either directly or indirectly observable, such
as quoted market prices, interest rates and yield curves. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Level&nbsp;3 inputs: Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market
participant would use in pricing the asset or liability. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly,
the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-34</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=235,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=505112,FOLIO='F-34',FILE='DISK116:[19ZBM1.19ZBM17601]GE17601A.;42',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<A NAME="page_ge17601_1_35"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Aprea Therapeutics AB </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Condensed Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (Unaudited) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of significant accounting policies (continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>degree
of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&nbsp;3. A financial instrument's level within the fair value hierarchy is based
on the lowest level of any input that is significant to the fair value measurement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company's financial instruments consist of accounts payable. The carrying amount of accounts payable is considered a reasonable estimate of fair value due to the short-term maturity. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Convertible preferred stock</B></FONT><FONT SIZE=2>&#151;The Company has classified convertible preferred stock ("Preferred Stock") as temporary equity in the accompanying balance
sheets due to certain change in control events that are outside of the Company's control, including sale or transfer of control of the Company, as holders of the Preferred Stock could cause redemption
of the shares in these situations. The Company does not accrete the carrying values of the Preferred Stock to the redemption values since a liquidation event was not considered probable as of
June&nbsp;30, 2019. Subsequent adjustments of the carrying values to the ultimate redemption values will be made only if it becomes probable that such a liquidation event will occur. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounting for leases</B></FONT><FONT SIZE=2>&#151;In February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No.&nbsp;2016
02, "Leases" ("ASC 842") to enhance the transparency and comparability of financial reporting related to leasing arrangements. Under this new lease standard, most leases are required to be recognized
on the balance sheet as right-of-use assets and lease liabilities. Disclosure requirements have been enhanced with the objective of enabling financial statement users to assess the amount, timing, and
uncertainty of cash flows arising from leases. Prior to January&nbsp;1, 2019, GAAP did not require lessees to recognize assets and liabilities related to operating leases on the balance sheet. The
new standard establishes a right-of-use ("ROU") model that requires a lessee to recognize a ROU asset and corresponding lease liability on the balance sheet for all leases with a term longer than
12&nbsp;months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement as well as the
reduction of the right of use asset. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company has adopted the standard effective January&nbsp;1, 2019, using the modified retrospective method. The new standard provides a number of optional practical expedients in
transition. The Company has elected to apply the 'package of practical expedients' which allow us to not reassess (i)&nbsp;whether existing or expired arrangements contain a lease, (ii)&nbsp;the
lease classification of existing or expired leases, or (iii)&nbsp;whether previous initial direct costs would qualify for capitalization under the new lease standard. The Company has also elected to
apply (i)&nbsp;the practical expedient which allows us to not separate lease and non-lease components, for new leases entered into after adoption and (ii)&nbsp;the short-term lease exemption for
all leases with an original term of less than 12&nbsp;months, for purposes of applying the recognition and measurements requirements in the new standard. For the impact to the Company's consolidated
financial statement upon adoption of the new leasing standard, see Note&nbsp;3 to our unaudited condensed consolidated financial statements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified
asset(s), if any, and the Company's control over the use of the identified asset(s), if applicable. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the
present value of future lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-35</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=236,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=205600,FOLIO='F-35',FILE='DISK116:[19ZBM1.19ZBM17601]GE17601A.;42',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<A NAME="page_ge17601_1_36"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Aprea Therapeutics AB </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Condensed Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (Unaudited) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of significant accounting policies (continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>readily
determinable. As such, the Company will utilize the incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease
payments in a similar economic environment. As of the ASC 842 effective date, the Company's incremental borrowing rate is approximately 4.3% based on the remaining lease term of the applicable leases. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company has elected not to separate lease and non-lease components as a single component. Operating leases are recognized on the balance sheet as ROU lease assets, lease liabilities
current and lease liabilities non-current. Fixed rents are included in the calculation of the lease balances while variable costs paid for certain operating and pass-through costs are excluded. Lease
expense is recognized over the expected term on a straight-line basis. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development costs</B></FONT><FONT SIZE=2>&#151;Research and development costs are charged to expense as incurred. Research and development expense consists of
expenses incurred in performing research and development activities, including salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of
equipment, contract services, and other outside expenses. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using or
information provided to the Company by its vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the
pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued expense. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patent costs</B></FONT><FONT SIZE=2>&#151;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the
uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation</B></FONT><FONT SIZE=2>&#151;The Company measures stock options and other stock based awards granted to employees and directors based on their fair value
on the date of the grant and recognize compensation expense of those awards, net of estimated forfeitures, over the requisite service period, which is generally the vesting period of the respective
award. The Company applies the straight-line method of expense recognition to all awards with only service based vesting conditions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
stock based awards granted to non-employees, compensation expense is recognized over the period during which services are rendered by such non-employees until completed in accordance
with the FASB issued ASU No.&nbsp;2018-07, Compensation Stock Compensation (Topic 718): Improvements to Nonemployee Share Based Payment Accounting. The new standard largely aligns the accounting for
share based payment awards issued to employees and nonemployees by expanding the scope of ASC&nbsp;718 to apply to nonemployee share based transactions, as long as the transaction is not effectively
a form of financing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company estimates the fair value of each stock option grant on the date of grant using the Black Scholes option pricing model, which uses as inputs the fair value of the Company's
common stock and assumptions the Company makes for the volatility of its common stock, the expected term of its stock
options, the risk free interest rate for a period that approximates the expected term of its stock options and its expected dividend yield. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-36</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=237,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=28536,FOLIO='F-36',FILE='DISK116:[19ZBM1.19ZBM17601]GE17601A.;42',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<A NAME="page_ge17601_1_37"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Aprea Therapeutics AB </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Condensed Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (Unaudited) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of significant accounting policies (continued) </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Determination of Fair Value of Common Stock  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As there has been no public market for the Company's common stock to date, the estimated fair value of its common stock has been determined by
its board of directors as of the date of each option grant, with input from management, considering the Company's most recently available third party valuations of common stock and its board of
directors' assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant.
These third party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants' Accounting and Valuation Guide, Valuation of Privately
Held Company Equity Securities Issued as Compensation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company's common stock valuations were prepared using a hybrid method, which used market approaches to estimate its enterprise value. The hybrid method is a probability weighed
expected return method, or PWERM, where the equity value in one or more scenarios is calculated using an option pricing method, or OPM. The OPM treats common stock and preferred stock as call options
on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company's securities changes. Under this method, the
common stock has value only if the funds available for distribution to stockholders exceeded the value of the preferred stock liquidation preference at the time of the liquidity event, such as a
strategic sale or a merger. The PWERM is a scenario based methodology that estimates the fair value of common stock based upon an analysis of future values for the company, assuming various outcomes.
The common stock value is based on the probability weighted present value of expected future investment returns considering each of the possible outcomes available as well as the rights of each class
of stock. The future value of the common stock under each outcome is discounted back to the valuation date at an appropriate risk adjusted discount rate and probability weighted to arrive at an
indication of value for the common stock. These third party valuations were performed at various dates, which resulted in valuations of the Company's common stock of $0.92 per share as of
May&nbsp;31, 2016, $1.01 per share as of October&nbsp;2, 2017 and $3.18 per share as of December&nbsp;31, 2018. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to considering the results of these third-party valuations, the Company's board of directors considered various objective and subjective factors to determine the fair value
of its common stock as of each grant date, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the prices at which the Company sold shares of preferred stock and the superior rights and preferences of the preferred stock relative to its
common stock at the time of each grant; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the progress of the Company's research and development programs, including the status and results of preclinical studies and clinical trials
for its product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the Company's stage of development and commercialization and its business strategy; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> external market conditions affecting the biopharmaceutical industry and trends within the biopharmaceutical industry; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the Company's financial position, including cash on hand, and its historical and forecasted performance and operating results; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the lack of an active public market for the Company's common stock and its preferred stock; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-37</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=238,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=470465,FOLIO='F-37',FILE='DISK116:[19ZBM1.19ZBM17601]GE17601A.;42',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<A NAME="page_ge17601_1_38"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Aprea Therapeutics AB </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Condensed Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (Unaudited) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of significant accounting policies (continued) </B></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the likelihood of achieving a liquidity event, such as an initial public offering, or IPO, or sale of the Company in light of prevailing market
conditions; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the analysis of IPOs and the market performance of similar companies in the biopharmaceutical industry. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
assumptions underlying these valuations represented management's best estimate, which involved inherent uncertainties and the application of management's judgment. As a result, if
the Company had used significantly different assumptions or estimates, the fair value of its common stock and its stock-based compensation expense could have been materially different. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes</B></FONT><FONT SIZE=2>&#151;The Company accounts for income tax in accordance with ASC 740-10, Income Taxes ("ASC 740-10"), which requires the recognition of
deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company's financial statements and tax returns. Deferred tax assets and
liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using
enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that
these assets may not be realized. The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position
will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is
calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency. The Company recognizes interest and penalties, if any, related to uncertain tax
positions in income tax expense. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss per share</B></FONT><FONT SIZE=2>&#151;The Company has reported losses since inception and has computed
basic net loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period,
without consideration for potentially dilutive securities. The Company computes diluted net loss per common share after giving consideration to all potentially dilutive common shares, including
options to purchase common stock and convertible preferred stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such
securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive and basic and diluted loss per share have been the
same. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-38</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=239,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=180598,FOLIO='F-38',FILE='DISK116:[19ZBM1.19ZBM17601]GE17601A.;42',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<A NAME="page_ge17601_1_39"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Aprea Therapeutics AB </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Condensed Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (Unaudited) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of significant accounting policies (continued) </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic
and diluted net loss per share attributable to common stockholders was calculated as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Six Months Ended<BR>
June&nbsp;30, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Numerator:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(7,710,338</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(8,737,650</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Denominator&#151;basic and diluted:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted-average common shares outstanding, basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,154,107</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,176,417 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss per share&#151;basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(6.68</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(7.43</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be
anti-dilutive (in common stock equivalent shares): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Six Months Ended<BR>
June&nbsp;30, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;A convertible preferred stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>612,446</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>612,446</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;B convertible preferred stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,235,969</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,235,969</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;C convertible preferred stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,179,877</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options to purchase common stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,860,631</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,761,794 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total shares of common stock equivalents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,709,046</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,790,086 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pro forma net loss per share</B></FONT><FONT SIZE=2>&#151;Unaudited pro forma net loss per share attributable to common stockholders is computed using the weighted-average number
of common shares outstanding after giving effect to the conversion of all the convertible preferred stock into shares of common stock as if such conversion had occurred at the beginning of the period
presented or the date of original issuance, if later. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-39</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=240,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=197676,FOLIO='F-39',FILE='DISK116:[19ZBM1.19ZBM17601]GE17601A.;42',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<A NAME="page_ge17601_1_40"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Aprea Therapeutics AB </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Condensed Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (Unaudited) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of significant accounting policies (continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table summarizes the Company's unaudited pro forma net loss per share attributable to common stockholders: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="84pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Six Months ended<BR>
June&nbsp;30, 2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Numerator:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss attributable to common stockholders, basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(8,737,650</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Denominator:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted average common shares outstanding&#151;basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,176,417</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Assumed conversion of Series&nbsp;A, Series&nbsp;B and Series&nbsp;C convertible preferred stock</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12,899,252 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Denominator for pro forma basic and diluted loss per common share</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14,075,669 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma basic and diluted net loss per common share</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.62</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recently issued accounting pronouncements&#151;not yet adopted  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In June 2018, the FASB issued ASU No.&nbsp;2018-07, "</FONT><FONT SIZE=2><I>Compensation&#151;Stock
Compensation",</I></FONT><FONT SIZE=2> which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees, except for specific
exceptions. This ASU is effective for annual or any interim periods beginning after December&nbsp;15, 2019. The Company is currently assessing the impact of adopting this authoritative guidance on
its financial statements. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


3. Leases  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On January&nbsp;1, 2019, the Company adopted ASC 842 using the modified retrospective transition approach allowed under ASU 2018-11 which releases companies from presenting comparative
periods and related disclosures under ASC 842 and requires a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption (Note&nbsp;2). The Company is party to
two operating leases for office or laboratory space. The Company's finance leases are immaterial both individually and in the aggregate. The Company has elected to apply the short-term lease exception
to all leases of one year or less. As of June&nbsp;30, 2019, this exception applies to one operating lease for office and laboratory space, which is for a term of one year, and expired
June&nbsp;30, 2019. Rent expense for six months ended June&nbsp;30, 2018 and 2019 was $64,474 and $69,524, respectively, which are included in operating expenses. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further,
the Company has applied the guidance in ASC 842 to our corporate office and laboratory leases and have determined that these should be classified as operating leases.
Consequently, as a result of the adoption of ASC 842, we recognized a ROU lease asset of approximately $329,384 with a corresponding lease liability of approximately $348,040 based on the present
value of the minimum rental payments of such leases. In accordance with ASC 842, the beginning balance of the ROU lease asset was reduced by the existing deferred rent liability at inception of
approximately $18,656. In the
consolidated balance sheets at June&nbsp;30, 2019, the Company has a ROU asset balance of $277,531 and a current and non-current lease liability of $112,315 and $181,910, respectively, relating to
the ROU lease </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-40</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=241,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=115671,FOLIO='F-40',FILE='DISK116:[19ZBM1.19ZBM17601]GE17601A.;42',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<A NAME="page_ge17601_1_41"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Aprea Therapeutics AB </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Condensed Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (Unaudited) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


3. Leases (continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>asset.
The balance of both the ROU lease asset and the lease liabilities primarily consists of future payments under the Company's office lease in Boston, Massachusetts. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company is party to an operating lease in Boston, Massachusetts for office and laboratory space. The lease commenced in November 2016 with the initial term set to expire in December
2021. This office lease does not have any renewal options. The Company was party to an operating lease in Solna, Sweden that had month-to-month payments and expired on June&nbsp;30, 2019.
Additionally, the Company entered into a new operating lease for office and laboratory space in Solna, Sweden that is effective July&nbsp;1, 2019 and expires in June 2022. Base rent for this lease
is approximately $128,000 annually. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Quantitative
information regarding the Company's leases for the six months ended June&nbsp;30, 2019 is as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="208pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Lease Cost

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Classification </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Six Months<BR>
Ended<BR>
June&nbsp;30, 2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating lease cost</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>General and administrative expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>51,853</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Other Information</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating cash flows paid for amounts included in the measurement of lease liabilities</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>60,818</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating lease liabilities arising from obtaining right-of-use assets</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted average remaining lease term (years)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted average discount rate</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Future
lease payments under noncancellable leases are as follows at June&nbsp;30, 2019: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Future Lease Payments

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Operating<BR>
Leases </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60,818</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2020</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>123,930</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>126,225</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Thereafter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Lease Payments</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>310,973 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Less: Imputed Interest</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(16,748</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Lease Liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>294,225 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
most of the Company's leases do not provide an implicit rate, we use the Company's incremental borrowing rate based on the information available at commencement date in determining
the present value of lease payments. The Company uses the incremental borrowing rate on January&nbsp;1, 2019 for operating leases that commenced prior to that date. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-41</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=242,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=296194,FOLIO='F-41',FILE='DISK116:[19ZBM1.19ZBM17601]GE17601A.;42',USER='CHE108067',CD='27-SEP-2019;09:03' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_gg17601_1_42"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Aprea Therapeutics AB  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Condensed Consolidated Financial Statements (Continued)  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (Unaudited)  </B></FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


4. Property and equipment  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property and equipment as of December&nbsp;31, 2018 and June&nbsp;30, 2019 consist of the following: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31,<BR>
2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>June&nbsp;30,<BR>
2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lab equipment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>69,770</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>73,722</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Furniture&nbsp;&amp; Fixtures</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,313</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,313</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Computer equipment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,689</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,279 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Property and equipment, at cost</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>98,772</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>102,314</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Less accumulated depreciation and amortization</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(74,322</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(76,652</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Property and equipment&#151;net</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,450</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,662 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation
expense for six months ended June&nbsp;30, 2018 and 2019 was $4,263 and $4,739, respectively. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


5. Accrued expenses  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses at December&nbsp;31, 2018 and June&nbsp;30, 2019 consist of the following: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31,<BR>
2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>June&nbsp;30,<BR>
2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Professional fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>80,771</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>318,668</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Compensation and benefits</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>624,298</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>434,133</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,178,086</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,102,926</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>245,617</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>404,382 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total accrued expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,128,772</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,260,109 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


6. Commitments  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's commitments are disclosed in the audited financial statements included in this Registration Statement as of and for the year ended December&nbsp;31, 2018. Since the date
of such financial statements, there have been no material changes to the Company's commitments. Further, the Company's commitments related to lease agreements are disclosed in Note&nbsp;3 to our
unaudited condensed consolidated financial statements included elsewhere in this Registration Statement. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


7. Income taxes  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has no income tax expense due to operating losses incurred for the six months ended June&nbsp;30, 2018 and 2019. The Company has provided a valuation allowance for the full
amount of the net deferred tax assets as, based on all available evidence, it is considered more likely than not that all the recorded deferred tax assets will not be realized in a future period. At
December&nbsp;31, 2018, the Company had $61.6&nbsp;million, $0.5&nbsp;million and $0.4&nbsp;million of foreign, federal and state net operating loss carryforwards, respectively, that expire at
various dates through 2036. Certain of these foreign, federal and state net operating loss carryforwards may be subject to Internal Revenue Code Section&nbsp;382 or similar provisions, which impose
limitations on their utilization amounts. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-42</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=243,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=291423,FOLIO='F-42',FILE='DISK116:[19ZBM1.19ZBM17601]GG17601A.;32',USER='CHE108067',CD='27-SEP-2019;09:04' -->
<A NAME="page_gg17601_1_43"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Aprea Therapeutics AB </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Condensed Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (Unaudited) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


7. Income taxes (continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Realization
of the future tax benefits is dependent on many factors, including the Company's ability to generate taxable income within the net operating loss carryforward period. Under
the provisions of the U.S. Internal Revenue Code and Sweden tax law, certain substantial changes in the Company's ownership, including a sale of the Company or significant changes in ownership due to
sales of equity, may have limited, or may limit in the future, the amount of net operating loss carryforwards that could be used annually to offset future taxable income. For U.S. and Swedish income
tax purposes, the Company has not completed a study to assess whether a change of control has occurred or whether there have been changes of control since the Company's formation due to the complexity
and cost associated with such study and because there could be additional changes in control in the future. As a result, the Company is not able to estimate the effect of the change in control, if
any, on the Company's ability to utilize U.S. or Swedish net operating losses or other tax attribute carryforwards in the future. For Swedish income tax purposes, the Company has estimated that
approximately $12.5&nbsp;million of its net operating losses may be subject to limitations in accordance with the country's group contribution restriction laws at December&nbsp;31, 2018. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company files tax returns in Sweden, the United States, Pennsylvania and Massachusetts, and all tax years since inception remain open to examination by the major taxing jurisdictions
to which the Company is subject, as carryforward attributes generated in years past may still be adjusted upon examination by the Internal Revenue Service (IRS) or other authorities if they have or
will be used in a future period. The Company is not currently under examination by the IRS or any other jurisdictions for any tax years. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2018 and June&nbsp;30, 2019, the Company had no uncertain tax positions or related interest and penalties accrued. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
June 2018, Sweden passed law on changes to the Swedish regulations on corporate income taxation. The law applies from January&nbsp;1, 2019. Among other things, the changes decrease
the corporate income tax rate in two steps from 22% to 21.4% as of January&nbsp;1, 2019 and 20.6% as of January&nbsp;1, 2020. U.S.&nbsp;GAAP requires companies to revalue their deferred tax
assets and deferred tax liabilities as of the date of enactment, with the resulting tax effects accounted for in the reporting period of enactment. This revaluation resulted in an overall reduction of
deferred taxes of $0.7&nbsp;million and a corresponding reduction in the valuation allowance. As such, there was no net impact to the Company's statement of operations as a result of the reduction
in tax rates. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


8. Convertible preferred stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has 20,000,000 shares authorized for all classes of equity combined. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Series&nbsp;A Preferred  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In June 2011, the Company issued 145,469 shares of Series&nbsp;A Preferred for gross proceeds of $3,233,417. In March 2016, the Company issued
466,977 shares of Series&nbsp;A Preferred as settlement of its outstanding bridge loans totaling $3,249,627. All 612,446 shares of Series&nbsp;A Preferred were issued to related parties. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-43</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=244,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=506891,FOLIO='F-43',FILE='DISK116:[19ZBM1.19ZBM17601]GG17601A.;32',USER='CHE108067',CD='27-SEP-2019;09:04' -->
<A NAME="page_gg17601_1_44"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Aprea Therapeutics AB </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Condensed Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (Unaudited) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


8. Convertible preferred stock (continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of June&nbsp;30, 2019, the rights and preferences of the Series&nbsp;A Preferred are as follows: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conversion</I></B></FONT><FONT SIZE=2>&#151;Each share of Series&nbsp;A Preferred may be converted at any time, at the option of the holder, into a share of common stock. The
Series&nbsp;A Preferred automatically converts into shares of common stock when 1)&nbsp;shareholders representing a majority of the outstanding preferred shares calls for such conversion or
2)&nbsp;at the closing of an initial public offering of the Company's common stock at a per share price of at least one and a half (1.5) times the average amount (EUR&nbsp;16.05 based on all
Series&nbsp;C preferred shares issued as of June&nbsp;30, 2019) paid per Series&nbsp;C preferred share (as adjusted for share splits and similar) and aggregate proceeds in excess of EUR
50,000,000. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividends</I></B></FONT><FONT SIZE=2>&#151;Holders of Series&nbsp;A Preferred do not accrue dividends. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Voting rights</I></B></FONT><FONT SIZE=2>&#151;Preferred Stock and common stock vote together as one class on an as converted basis. Common stock voting rights on certain matters
are
subject to the powers, preferences, and rights of the Preferred Stock. Holders are entitled to vote on all matters and shall have the number of votes equal to the number of shares of common stock into
which the shares of Preferred Stock held by such holder are then convertible. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Series&nbsp;B Preferred  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In March 2016, the Company issued 3,322,762 shares of Series&nbsp;B Preferred for gross proceeds of $22,609,485. The Company also issued
590,445 shares of Series&nbsp;B Preferred in settlement of its outstanding bridge loans totaling $4,108,818. In October 2017, the Company issued 3,322,762 Series&nbsp;B preferred shares at a price
per share of $7.02, for an aggregate purchase price of $23,349,617. All 7,235,769 shares of Series&nbsp;B Preferred were issued to related parties. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of June&nbsp;30, 2019, the rights and preferences of the Series&nbsp;B Preferred are as follows: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conversion</I></B></FONT><FONT SIZE=2>&#151;Each share of Series&nbsp;B Preferred may be converted at any time, at the option of the holder, into a share of common stock. The
Series&nbsp;B Preferred automatically converts into shares of common stock when 1)&nbsp;shareholders representing a majority of the outstanding preferred shares calls for such conversion or
2)&nbsp;at the closing of an initial public offering of the Company's common stock at a per share price of at least one and a half (1.5) times the average amount (EUR&nbsp;16.05 based on all
Series&nbsp;C preferred shares issued as of June&nbsp;30, 2019) paid per Series&nbsp;C preferred share (as adjusted for share splits and similar) and aggregate proceeds in excess of EUR
50,000,000. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividends</I></B></FONT><FONT SIZE=2>&#151;Holders are entitled to dividends of 8%, compounded annually if not paid. No dividends have been declared or paid as of June&nbsp;30,
2019. The company has not accrued dividends on the Series&nbsp;B Preferred since dividends are only payable upon the occurrence of a liquidation event, including the transfer of more than fifty
percent of the Company's outstanding shares or the transfer of substantially all of the Company's intellectual property. Approximately $11,059,542 of accrued dividends that were payable through
June&nbsp;30, 2019 was added to the stated liquidation preference amount of the Series&nbsp;B Preferred, which totaled $61,127,463 at June&nbsp;30, 2019. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Voting rights</I></B></FONT><FONT SIZE=2>&#151;Preferred Stock and common stock vote together as one class on an as converted basis. Common stock voting rights on certain matters
are
subject to the powers, preferences, and rights of the Preferred Stock. Holders are entitled to vote on all matters and shall have the number of votes </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-44</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=245,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=52295,FOLIO='F-44',FILE='DISK116:[19ZBM1.19ZBM17601]GG17601A.;32',USER='CHE108067',CD='27-SEP-2019;09:04' -->
<A NAME="page_gg17601_1_45"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Aprea Therapeutics AB </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Condensed Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (Unaudited) </B></FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


8. Convertible preferred stock (continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>equal
to the number of shares of common stock into which the shares of Preferred Stock held by such holder are then convertible. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Series&nbsp;C Preferred  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2018, the Company issued 4,712,698 shares of Series&nbsp;C Preferred for gross proceeds of $56,725,342. In February 2019, the
Company issued 467,179 shares of Series&nbsp;C Preferred for gross proceeds of $5,651,872. A total of 4,219,849 shares of Series&nbsp;C Preferred were issued to related parties. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of June&nbsp;30, 2019, the rights and preferences of the Series&nbsp;C Preferred are as follows: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conversion</I></B></FONT><FONT SIZE=2>&#151;Each share of Series&nbsp;C Preferred may be converted at any time, at the option of the holder, into a share of common stock. The
Series&nbsp;C Preferred automatically converts into shares of common stock when 1)&nbsp;shareholders representing a majority of the outstanding preferred shares calls for such conversion or
2)&nbsp;at the closing of an initial public offering of the Company's common stock at a per share price of at least one and a half (1.5) times the average amount (EUR&nbsp;16.05 based on all
Series&nbsp;C preferred shares issued as of June&nbsp;30, 2019) paid per Series&nbsp;C preferred share (as adjusted for share splits and similar) and aggregate proceeds in excess of EUR
50,000,000. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividends</I></B></FONT><FONT SIZE=2>&#151;Holders are entitled to dividends of 8%, compounded annually if not paid. No dividends have been declared or paid as of June&nbsp;30,
2019. The company has not accrued dividends on the Series&nbsp;C Preferred since dividends are only payable upon the occurrence of a liquidation event, including the transfer of more than fifty
percent of the Company's outstanding shares or the transfer of substantially all of the Company's intellectual property. Approximately $2,811,614 of accrued dividends that were payable through
June&nbsp;30, 2019 was added to the stated liquidation preference amount of the Series&nbsp;C Preferred, which totaled $65,188,827 at June&nbsp;30, 2019. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Voting rights</I></B></FONT><FONT SIZE=2>&#151;Preferred Stock and common stock vote together as one class on an as converted basis. Common stock voting rights on certain matters
are
subject to the powers, preferences, and rights of the Preferred Stock. Holders are entitled to vote on all matters and shall have the number of votes equal to the number of shares of common stock into
which the shares of Preferred Stock held by such holder are then convertible. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Liquidation preference  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon liquidation, dissolution, or winding up of business, the Preferred Stock holders are entitled to receive a liquidation preference in
priority to holders of common stock at the original issue price plus, in the case of Series&nbsp;B and Series&nbsp;C Preferred, any unpaid accumulated dividends as follows: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>If
a liquidation event occurs prior to the Company achieving a certain clinical milestone, Series&nbsp;C Preferred shareholders shall receive an amount per
Series&nbsp;C Preferred share equal to the original subscription price per Series&nbsp;C Preferred share (as adjusted for share splits and similar) plus unpaid accumulated dividends. Secondly,
after the Series&nbsp;C Preferred shareholders have received full payment, the Series&nbsp;B Preferred shareholders shall receive an amount per Series&nbsp;B preferred share equal to the
original subscription price per Series&nbsp;B Preferred share (as adjusted for share splits and similar) plus unpaid accumulated dividends. Thirdly, after the Series&nbsp;B and C Preferred
shareholders have received full payment, the </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-45</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=246,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=775914,FOLIO='F-45',FILE='DISK116:[19ZBM1.19ZBM17601]GG17601A.;32',USER='CHE108067',CD='27-SEP-2019;09:04' -->
<A NAME="page_gg17601_1_46"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Aprea Therapeutics AB </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Condensed Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (Unaudited) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


8. Convertible preferred stock (continued) </B></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>Series&nbsp;A
Preferred shareholders shall receive an amount per Series&nbsp;A preferred share equal to the original subscription price per Series&nbsp;A Preferred share (as adjusted for share
splits and similar). When the Preferred A, B and C shareholders are satisfied in full, any excess assets available for distribution will be allocated ratably among holders of common stock and
preferred stock based on their pro rata shareholdings on an as-if-converted basis.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>If
a liquidation event occurs after the Company achieves a certain clinical milestone, Series&nbsp;B and C Preferred shareholders, based on their pro rata
shareholdings, shall receive an amount per Series&nbsp;B and C Preferred share equal to the original subscription price per Series&nbsp;B and C Preferred share (as adjusted for share splits and
similar) plus unpaid accumulated dividends. Secondly, after the Series&nbsp;B and C Preferred shareholders have received full payment, the Series&nbsp;A Preferred shareholders shall receive an
amount per Series&nbsp;A preferred share equal to the original subscription price per Series&nbsp;A Preferred share (as adjusted for share splits and similar). When the Preferred A, B and C
shareholders are satisfied in full, any excess assets available for distribution will be allocated ratably among holders of common stock and preferred stock based on their pro rata shareholdings on an
as-if-converted basis. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
liquidation preferences apply to each series of preferred stock only to the extent the holders would receive less than three times their respective original purchase prices. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


9. Common stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has 1,181,573 shares of common stock outstanding as of June&nbsp;30, 2019. During the first six months of 2018 and 2019, the Company issued 1,503 and 26,207 shares of
common stock to employees for aggregate consideration of $1,415 and $23,118, respectively, as a result of stock option exercises. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
holders of common stock are entitled to one vote for each share of common stock. Subject to the payment in full of all preferential dividends to which the holders of the Preferred
Stock are entitled, the holders of common stock shall be entitled to receive dividends out of funds legally available. In the event of any voluntary or involuntary liquidation, dissolution or winding
up of the Company, after the payment or provision for payment of all debts and liabilities of the Company and all preferential amounts to which the holders of Preferred Stock are entitled with respect
to the distribution of assets in liquidation, the holders of common stock shall be entitled to share ratably in the remaining assets of the Company available for distribution. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


10. Stock option plan  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2016, the Board of Directors adopted the 2016 Amended and Restated Stock Option Program (the "Plan"), which provided for the grant of stock options to the Company's employees,
officers, directors, and outside consultants for the purchase of up to 1,224,824 shares of the Company's common stock. During 2017, the Plan was amended to provide up to 1,946,849 shares of the
Company's common stock. During 2018, the Plan was further amended to provide up to 3,069,999 shares of the Company's common stock. Holders of stock options shall be entitled to exercise the vested
portion of the stock option provided that a trade sale, as defined in the plan, or initial public </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-46</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>

<!-- ZEQ.=5,SEQ=247,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=594459,FOLIO='F-46',FILE='DISK116:[19ZBM1.19ZBM17601]GG17601A.;32',USER='CHE108067',CD='27-SEP-2019;09:04' -->
<A NAME="page_gg17601_1_47"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Aprea Therapeutics AB </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Condensed Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (Unaudited) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


10. Stock option plan (continued) </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>offering
has occurred. The holders of stock options may also exercise the vested portion of the stock option within six months of termination of employment. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock
options generally vest over a four-year period and expire in October 2026. The Board of Directors has the discretion to provide for accelerated vesting. At June&nbsp;30, 2019,
there were 543,647 shares available for future grant under the Plan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company recorded stock-based compensation expense of $169,854 and $284,909 during the six months ended June&nbsp;30, 2018 and 2019, respectively. As of June&nbsp;30, 2019, there
was $2,271,127 of unrecognized compensation cost related to nonvested share-based compensation arrangements granted under the Plan, which is expected to be recognized over a weighted-average period of
approximately 2.9&nbsp;years. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
fair value of each option award is estimated on the date of grant using Black-Scholes, with the assumptions noted in the table below. Expected volatility for the Company's common
stock was determined based on an average of the historical volatility of a peer group of similar public companies. The expected term of options granted to employees was calculated using the simplified
method, which represents the average of the contractual term of the option and the weighted-average vesting period of the option. The Company uses the simplified method because it does not have
sufficient historical option exercise data to provide a reasonable basis upon which to estimate expected term. The contractual life of the option was used for the expected life of options granted to
non-employee. The assumed dividend yield is based upon the Company's expectation of not paying dividends in the foreseeable future. The risk-free rate for periods within the expected life of the
option is based upon the Swedish Government Bond Rate in effect at the time of grant. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
determining the exercise prices for options granted, the Company's Board of Directors has considered the fair value of the common stock as of the measurement date. The fair value of
the common stock at each award grant date was based upon a variety of factors, including the results obtained from an independent third-party valuation, the Company's financial position and historical
financial performance, the status of technological developments within the Company's proposed products, an evaluation or benchmark of the Company's competition, the current business climate in the
marketplace, the illiquid nature of the common stock, arm's length sales of the Company's capital stock, including Preferred Stock, the effect of the rights and preferences of the preferred
shareholders, and the prospects of a liquidity event, among others. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
assumptions used in Black-Scholes for the six months ended June&nbsp;30, 2018 and 2019 are as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="26pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=4 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Six Months<BR>
ended<BR>
June&nbsp;30, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2019 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected volatility</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>n/a</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>73.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk-free rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>n/a</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected dividend yield</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>n/a</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected term in years</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>n/a</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-47</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=248,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=964422,FOLIO='F-47',FILE='DISK116:[19ZBM1.19ZBM17601]GG17601A.;32',USER='CHE108067',CD='27-SEP-2019;09:04' -->
<A NAME="page_gg17601_1_48"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Aprea Therapeutics AB </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Condensed Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (Unaudited) </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


10. Stock option plan (continued) </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
summary of option activity under the Plan at December&nbsp;31, 2018 and June&nbsp;30, 2019 are as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="47pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
options </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted-<BR>
average<BR>
exercise<BR>
price per<BR>
share </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted<BR>
average<BR>
remaining<BR>
contractual<BR>
term (in years) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
intrinsic<BR>
value </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding at December&nbsp;31, 2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,844,188</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.82</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,382,781 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Granted</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>984,596</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.19</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercised</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(26,207</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.97</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cancelled/Forfeited</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(40,783</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.99</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding at June&nbsp;30, 2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,761,794</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.66</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,234,886 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercisable at June&nbsp;30, 2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vested or expected to vest at June&nbsp;30, 2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,761,794</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.66</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,234,886 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
weighted-average grant date fair value of options granted during the six months ended June&nbsp;30, 2019, was $2.23 per share. No options were granted during the six months ended
June&nbsp;30, 2018. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


11. Subsequent events  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On September&nbsp;20, 2019, the Company consummated a corporate reorganization, pursuant to which all of the issued and outstanding stock and options of Aprea Therapeutics AB, or
Aprea&nbsp;AB, was exchanged for common stock, preferred stock or options, as applicable, of Aprea Therapeutics, Inc. As a result, Aprea Therapeutics AB, became a wholly-owned subsidiary of Aprea
Therapeutics, Inc. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
September 2019, the Company's Board of Directors and stockholders approved a 1-for-1.6045 stock split of the Company's preferred and common stock. All share and per share amounts in
the consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this split. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-48</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=249,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=742372,FOLIO='F-48',FILE='DISK116:[19ZBM1.19ZBM17601]GG17601A.;32',USER='CHE108067',CD='27-SEP-2019;09:04' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><div
style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>5,000,000&nbsp;shares  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>
<IMG SRC="g453739.jpg" ALT="LOGO" WIDTH="211" HEIGHT="138">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> Common stock  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=4><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>Prospectus  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=3><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="108pt" style="font-family:times;"></TD>
<TD WIDTH="7%" style="font-family:times;"></TD>
<TD WIDTH="199pt" style="font-family:times;"></TD>
<TD WIDTH="7%" style="font-family:times;"></TD>
<TD WIDTH="199pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=4><B>J.P. Morgan</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=4><B>Morgan Stanley</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=4><B>RBC Capital Markets</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B> <div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div>  </B></FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=250,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=763568,FOLIO='blank',FILE='DISK116:[19ZBM1.19ZBM17601]HO17601A.;19',USER='CHE108067',CD='27-SEP-2019;09:04' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ja17601_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ja17601_part_ii_information_not_required_in_prospectus"> </A>
<A NAME="toc_ja17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Part II<BR>  <BR>    Information not required in prospectus    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="ja17601_item_13._other_expense__ja101988"> </A>
<A NAME="toc_ja17601_2"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;13.&nbsp;&nbsp;&nbsp;&nbsp;Other expenses of issuance and distribution.    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth the expenses to be incurred in connection with the offering described in this Registration Statement, other than
underwriting discounts and commissions, all of which will be paid by us. All amounts are estimates except the Securities and Exchange Commission's registration fee, the Financial Industry Regulatory
Authority,&nbsp;Inc. filing fee and the NASDAQ listing fee. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2> Securities and Exchange Commission registration fee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,151</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Financial Industry Regulatory Authority,&nbsp;Inc. filing fee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,300</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>NASDAQ listing fee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>150,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accountants' fees and expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>900,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal fees and expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,500,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Transfer Agent's fees and expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Printing fees and expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>300,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Miscellaneous fees and expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>299,549</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,200,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2> </font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2><A NAME="ja17601_item_14._indemnification_of_directors_and_officers."> </A>
<A NAME="toc_ja17601_3"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;14.&nbsp;&nbsp;&nbsp;&nbsp;Indemnification of directors and officers.    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;102 of the Delaware General Corporation Law permits a corporation to eliminate the personal liability of its directors for
monetary damages for a breach of fiduciary duty as a director, except where the director breached his or her duty of loyalty, failed to act in good faith, engaged in intentional misconduct or
knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Upon completion of this
offering, our certificate of incorporation will provide that none of our directors shall be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duty as a
director, notwithstanding any provision of law imposing such liability, except to the extent that the Delaware General Corporation Law prohibits the elimination or limitation of liability of directors
for breaches of fiduciary duty. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;145
of the Delaware General Corporation Law provides that a corporation has the power to indemnify a director, officer, employee, or agent of the corporation and certain
other persons serving at the request of the corporation in related capacities against expenses (including attorneys' fees), judgments, fines and amounts paid in settlements actually and reasonably
incurred by the person in connection with an action, suit or proceeding to which he or she is or is threatened to be made a party by reason of such position, if such person acted in good faith and in
a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or her
conduct was unlawful, except that, in the
case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable
to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances
of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the completion of this offering, our certificate of incorporation will provide that we will indemnify each person who was or is a party or is threatened to be made a party or is
involved in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=251,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=292493,FOLIO='II-1',FILE='DISK116:[19ZBM1.19ZBM17601]JA17601A.;119',USER='WWASSER',CD='27-SEP-2019;14:29' -->
<A NAME="page_ja17601_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2>investigative
(other than an action by or in the right of us) by reason of the fact that he or she is or was, or has agreed to become, our director or officer, or is or was serving, or has agreed to
serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such
persons being referred to as an "Indemnitee"), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys' fees), judgments, fines and
amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or
she reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was
unlawful. Our certificate of incorporation that will be effective as of the closing date of this offering also provides that we will indemnify any Indemnitee who was or is a party to an action or suit
by or in the right of us to procure a judgment in our favor by reason of the fact that the Indemnitee is or was, or has agreed to become, our director or officer, or is or was serving, or has agreed
to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or by
reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys' fees) and, to the extent permitted by law, amounts paid in settlement actually
and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or
not opposed to, our best interests, except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to us, unless
a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that
any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by us against all expenses (including attorneys' fees) actually and reasonably incurred by him or her or
on his or her behalf in connection therewith. If we do not assume the defense, expenses must be advanced to an Indemnitee under certain circumstances. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
plan to enter into indemnification agreements with each of our executive officers and directors. In general, these agreements provide that we will indemnify the director or executive
officer to the fullest extent permitted by law for claims arising in his or her capacity as a director or executive officer of our
company or in connection with their service at our request for another corporation or entity. The indemnification agreements also provide for procedures that will apply in the event that a director or
executive officer makes a claim for indemnification and establish certain presumptions that are favorable to the director or executive officer. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
maintain a general liability insurance policy that covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as
directors or officers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriting agreement we will enter into in connection with the offering of common stock being registered hereby provides that the underwriters will indemnify, under certain
conditions, our directors and officers (as well as certain other persons) against certain liabilities arising in connection with such offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insofar
as the forgoing provisions permit indemnification of directors, executive officers, or persons controlling us for liability arising under the Securities Act of 1933, as amended,
or the Securities Act, we have been informed that, in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act and is
therefore unenforceable. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=252,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=1016348,FOLIO='II-2',FILE='DISK116:[19ZBM1.19ZBM17601]JA17601A.;119',USER='WWASSER',CD='27-SEP-2019;14:29' -->
<A NAME="page_ja17601_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A NAME="ja17601_item_15._recent_sales_of_unregistered_securities."> </A>
<A NAME="toc_ja17601_4"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;15.&nbsp;&nbsp;&nbsp;&nbsp;Recent sales of unregistered securities.    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following list sets forth information regarding all securities sold or granted by us since January&nbsp;1, 2016, which were not registered
under the Securities Act, and the consideration, if any, received by us for such securities: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;&nbsp;&nbsp;In
March 2016 and October 2017, Aprea AB issued and sold an aggregate of 7,235,969 shares of its Series&nbsp;B preferred stock to five accredited investors at a
purchase price of $6.81 and $7.02, respectively, per share for aggregate proceeds of approximately $50.0&nbsp;million in cash. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;&nbsp;&nbsp;In
November 2018 and February 2019, Aprea AB issued and sold an aggregate of 5,179,877 shares of its Series&nbsp;C preferred stock to six accredited investors at a
purchase price of $12.08 and $12.10, respectively, per share for aggregate proceeds of approximately $62.3&nbsp;million in cash. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;&nbsp;&nbsp;In
connection with the formation and initial capitalization of Aprea Therapeutics, Inc., on July&nbsp;11, 2019, Aprea Therapeutics, Inc. issued 160&nbsp;shares of
its common stock to Chris Schade, our Chief Executive Officer, for an aggregate purchase price of $100. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)&nbsp;&nbsp;&nbsp;Since
January&nbsp;1, 2016, we have granted stock options to purchase an aggregate of 2,973,085&nbsp;shares of our common stock with exercise prices of $0.92, $1.01,
$3.18 and $10.95 per share, to our employees, directors and consultants pursuant to our 2016 Stock Incentive Plan. Since January&nbsp;1, 2016, we have issued an aggregate of 28,512&nbsp;shares of
our common stock upon exercise of stock options granted pursuant to our 2016 Stock Incentive Plan, for an aggregate consideration of $25,215 in cash. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
offers, sales and issuances of the securities described in Items&nbsp;15(1), 15(2) and 15(3) were exempt from registration under the Securities Act under Section&nbsp;4(a)(2) of
the Securities Act as transactions by an issuer not involving a public offering. The recipients of securities in each of these transactions acquired the securities for investment only and not with a
view to or for sale in connection with any distribution thereof and appropriate legends were affixed to the securities issued in these transactions. Each of the recipients of securities in these
transactions was an accredited person and had adequate access, through employment, business or other relationships, to information about the registrant. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
offers, sales and issuances of the securities described in Item&nbsp;15(4) were exempt from registration under the Securities Act under either (1)&nbsp;Rule&nbsp;701 in that
the transactions were under compensatory benefit plans and contracts relating to compensation as provided under Rule&nbsp;701 or (2)&nbsp;Section&nbsp;4(a)(2) of the Securities Act as
transactions by an issuer not involving any public offering. The recipients of such securities were the registrant's employees, consultants or directors and received the securities under the
registrant's 2016 Stock Incentive Plan. The recipients of securities in each of these transactions represented their intention to acquire the securities for investment only and not with view to or for
sale in connection with any distribution thereof and appropriate legends were affixed to the securities issued in these transactions. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=253,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=1017334,FOLIO='II-3',FILE='DISK116:[19ZBM1.19ZBM17601]JA17601A.;119',USER='WWASSER',CD='27-SEP-2019;14:29' -->
<A NAME="page_ja17601_1_4"> </A>


<P style="font-family:times;"><FONT SIZE=2><A NAME="ja17601_item_16._exhibits_and_financial_statement_schedules."> </A>
<A NAME="toc_ja17601_5"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;16.&nbsp;&nbsp;&nbsp;&nbsp;Exhibits and financial statement schedules.    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


(a) Exhibits.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following exhibits are filed as part of this Registration Statement: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2> ##1.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1781983/000104746919005375/a2239728zex-1_1.htm">Form of Underwriting Agreement</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>##3.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1781983/000104746919005057/a2239551zex-3_1.htm">Certificate of Incorporation of the Registrant</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>##3.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1781983/000104746919005057/a2239551zex-3_2.htm">Bylaws of the Registrant, as currently in effect</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>##3.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1781983/000104746919005375/a2239728zex-3_3.htm">Amended and Restated Certificate of Incorporation of Registrant, as currently in effect.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>3.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2239779zex-3_4.htm">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>3.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2239779zex-3_5.htm">Form of Amended and Restated Certificate of Incorporation of the Registrant (to be effective upon the completion of this offering)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>##3.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1781983/000104746919005375/a2239728zex-3_6.htm">Form of Amended and Restated Bylaws of the Registrant (to be effective upon the completion of this offering)
</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>4.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2239779zex-4_1.htm">Specimen common stock certificate of the Registrant</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>5.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2239779zex-5_1.htm">Opinion of Sidley Austin&nbsp;LLP</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>+10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2239779zex-10_1.htm">Form of 2019 Stock Incentive Plan and form of agreements thereunder</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>##+10.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1781983/000104746919005442/a2239760zex-10_2.htm">Form of 2019 Employee Stock Purchase Plan</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>##&#134;10.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1781983/000104746919005442/a2239760zex-10_3.htm">Service Agreement, between Aprea&nbsp;AB and Syngene International Private Limited</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>##10.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1781983/000104746919005442/a2239760zex-10_4.htm">Amended and Restated Registration Rights Agreement by and among the Registrant and the shareholders party
thereto</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>##+10.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1781983/000104746919005375/a2239728zex-10_5.htm">Form of Indemnification Agreement between the Registrant and each of its directors and executive
officers</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>+10.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2239779zex-10_6.htm">Employment Agreement between the Registrant and Christian S. Schade</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>+10.7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2239779zex-10_7.htm">Form of Executive Employment Agreement</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>+10.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2239779zex-10_8.htm">Employment Agreement between the Registrant and Lars Abrahmsen,&nbsp;Ph.D.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>+10.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2239779zex-10_9.htm">Employment Agreement between the Registrant and Gregory&nbsp;A. Korbel,&nbsp;Ph.D.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>+10.10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2239779zex-10_10.htm">Employment Agreement between the Registrant and Scott&nbsp;M. Coiante.</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>##&#134;10.11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1781983/000104746919005442/a2239760zex-10_11.htm">Master Manufacturing and Supply Agreement, between Aprea Therapeutics AB and Siegfried Hameln GmbH</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>23.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2239779zex-23_1.htm">Consent of Ernst&nbsp;&amp; Young&nbsp;AB, independent registered public accounting firm</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>23.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="a2239779zex-5_1.htm">Consent of Sidley Austin&nbsp;LLP (included in Exhibit&nbsp;5.1)</A></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=2>##24.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><A HREF="http://www.sec.gov/Archives/edgar/data/1781983/000104746919005057/a2239551zs-1.htm#EX24-1">Power of Attorney</A></FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>

<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>##</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Previously
filed.

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>+</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Indicates
a management contract or compensatory plan.

<BR><BR></FONT></DD>

<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>&#134;</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Portions
of this exhibit (indicated by bracketed asterisks) have been omitted as the Company has determined that (i)&nbsp;the omitted information is not
material and (ii)&nbsp;the omitted information would likely cause competitive harm to the Company if publicly disclosed. </FONT>

</DD>

</DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>

<!-- ZEQ.=4,SEQ=254,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=895071,FOLIO='II-4',FILE='DISK116:[19ZBM1.19ZBM17601]JA17601A.;119',USER='WWASSER',CD='27-SEP-2019;14:29' -->
<A NAME="page_ja17601_1_5"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


(b) Financial statement schedules.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No financial statement schedules are provided because the information called for is not required or is shown either in the financial statements
or the related notes.  </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="ja17601_item_17._undertakings."> </A>
<A NAME="toc_ja17601_6"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;17.&nbsp;&nbsp;&nbsp;&nbsp;Undertakings.    <BR>    </B></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(a)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement, certificates in such
denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(b)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant
pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as
expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in
connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(c)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
undersigned registrant hereby undertakes that:
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>For
purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement
in reliance upon Rule&nbsp;430A and contained in a form of prospectus filed by the registrant pursuant to Rule&nbsp;424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be
part of this registration statement as of the time it was declared effective.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>For
the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new
registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </FONT></DD></DL>
</DD></DL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=255,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=388375,FOLIO='II-5',FILE='DISK116:[19ZBM1.19ZBM17601]JA17601A.;119',USER='WWASSER',CD='27-SEP-2019;14:29' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_jc17601_1_6"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="EX24-1"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="jc17601_signatures"> </A>
<A NAME="toc_jc17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Signatures    <BR>    </B></FONT></P>

<P style="font-family:times;">


<FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Registration Statement to be signed on its
behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on this 27th day of September 2019.

 </FONT>

</P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="22pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="45%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2> APREA THERAPEUTICS,&nbsp;INC.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;CHRISTIAN S. SCHADE<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Christian S. Schade<BR></FONT> <FONT SIZE=2><I>President and Chief Executive Officer</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="jc17601_power_of_attorney"> </A>
<A NAME="toc_jc17601_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Power of attorney    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the
capacities and on the dates indicated. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="28pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="33%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="37%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="112pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  COLSPAN=3 ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Signature

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Title

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Date

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>/s/&nbsp;CHRISTIAN S. SCHADE<BR>



<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Christian S. Schade</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>President and Chief Executive Officer and Director (principal executive officer)</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>September&nbsp;27, 2019</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>
/s/&nbsp;SCOTT M. COIANTE<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Scott M. Coiante</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Chief Financial Officer (principal financial and accounting officer)</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>September&nbsp;27, 2019</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>
*<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Scott M. Rocklage, Ph.D.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Chairman of the Board of Directors</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>September&nbsp;27, 2019</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>
*<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Johan Christenson, M.D., Ph.D.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>September&nbsp;27, 2019</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>
*<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Jonathan Hepple, Ph.D.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>September&nbsp;27, 2019</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>
*<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Guido Magni, M.D., Ph.D.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>September&nbsp;27, 2019</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><BR>
*<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Bernd R. Seizinger, M.D., Ph.D.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>September&nbsp;27, 2019</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=256,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=66419,FOLIO='II-6',FILE='DISK116:[19ZBM1.19ZBM17601]JC17601A.;60',USER='CHE108067',CD='27-SEP-2019;09:04' -->
<A NAME="page_jc17601_1_7"> </A>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="28pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="33%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="37%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="112pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  COLSPAN=3 ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Signature

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Title

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Date

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>*<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> John B. Henneman, III</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>September&nbsp;27, 2019</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>*By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;SCOTT M. COIANTE<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Scott M. Coiante<BR></FONT> <FONT SIZE=2><I>Attorney-in-fact</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>

<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=257,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="1",CHK=580803,FOLIO='II-7',FILE='DISK116:[19ZBM1.19ZBM17601]JC17601A.;60',USER='CHE108067',CD='27-SEP-2019;09:04' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.4
<SEQUENCE>2
<FILENAME>a2239779zex-3_4.htm
<DESCRIPTION>EX-3.4
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 3.4<a name="12476-2-LI_Exhibit3_4_024437"></a></font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CERTIFICATE OF AMENDMENT TO THE</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AMENDED AND RESTATED</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CERTIFICATE OF INCORPORATION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">OF</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">APREA THERAPEUTICS,&nbsp;INC.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Aprea Therapeutics,&nbsp;Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the &#147;<b><u style="font-weight:bold;">DGCL</u></b>&#148;), does hereby certify that:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:24.5pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ONE:</font></b> The original name of this corporation is Aprea Therapeutics,&nbsp;Inc., and the date of filing of the original Certificate of Incorporation of this corporation with the Secretary of State of the State of Delaware was May&nbsp;3, 2019.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:24.5pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">TWO: &nbsp;</font></b>That the Certificate of Incorporation of this corporation was amended and restated on September&nbsp;20, 2019 (as so amended, the &#147;<b><u style="font-weight:bold;">Amended and Restated Certificate of Incorporation</u>&#148;</b>).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:24.5pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">THREE:</font></b>&#160; This Certificate of Amendment to the Amended and Restated Certificate of Incorporation (the &#147;<b><u style="font-weight:bold;">Certificate of Amendment</u></b>&#148;) has been duly adopted in accordance with Section&nbsp;242 of the DGCL and amends the provisions of the Corporation&#146;s Amended and Restated Certificate of Incorporation (the &#147;<b><u style="font-weight:bold;">Restated Certificate</u></b>&#148;).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:24.5pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FOUR</font></b>:&#160; This Certificate of Amendment has been approved and duly adopted by the Board of Directors of the Corporation.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:24.5pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FIVE</font></b>:&#160; The terms and provisions of this Certificate of Amendment have been duly approved by written consent of the required number of shares of outstanding stock of the Corporation pursuant to Subsection 228(a)&nbsp;of the DGCL and written notice pursuant to Subsection 228(e)&nbsp;of the DGCL has been or will be given to those stockholders whose written consent has not been obtained.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:24.5pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIX:</font></b>&#160; The following is hereby inserted into paragraph A of Article&nbsp;IV&nbsp;immediately before the first sentence therein:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 75.85pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Effective upon the filing of this Certificate of Amendment to the Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the &#147;<b><i><u style="font-style:italic;font-weight:bold;">Effective Time</u></i></b>&#148;), every 1 share of Common Stock then issued and outstanding or held in the treasury of the Corporation immediately prior to the Effective Time shall automatically be split into 1.6045&nbsp;shares of Common Stock, without any further action by the holders of such shares (the &#147;<b><i><u style="font-style:italic;font-weight:bold;">Stock Split</u></i></b>&#148;).&#160; The Stock Split shall occur automatically without any further action by the holders of the shares of Common Stock and Preferred Stock affected thereby. All rights, preferences and privileges of the Common Stock and the Preferred Stock shall be appropriately adjusted to reflect the Stock Split in accordance with this Amended and Restated Certificate of Incorporation.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">[Remainder of page&nbsp;intentionally left blank]</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="2",CHK=367986,FOLIO='',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LI_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 28 00:23 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:24.5pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">IN WITNESS WHEREOF</font></b>, this Certificate of Amendment, having been duly adopted in accordance with Section&nbsp;242 of the DGCL, has been duly executed by a duly authorized officer of the corporation on this 26th day of September&nbsp;2019.</p>
<p style="margin:0in 0in .0001pt;text-indent:24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">APREA   THERAPEUTICS,&nbsp;INC.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="9%" valign="top" style="padding:0in 0in 0in 0in;width:9.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Signature:</font></p>    </td>
<td width="40%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:40.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ CHRISTIAN S. SCHADE</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:   Christian S. Schade</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:   President and Chief Executive Officer</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="2",CHK=866303,FOLIO='',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LI_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 28 00:23 2019' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.5
<SEQUENCE>3
<FILENAME>a2239779zex-3_5.htm
<DESCRIPTION>EX-3.5
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 3.5<a name="12476-2-KG_Exhibit3_5_062449"></a></font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AMENDED AND RESTATED CERTIFICATE OF INCORPORATION</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">OF</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">APREA THERAPEUTICS,&nbsp;INC.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a Delaware corporation</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:49.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Aprea Therapeutics,&nbsp;Inc., a corporation organized and existing under the laws of the State of Delaware (the &#147;<b><i style="font-weight:bold;">Corporation</i></b>&#148;), hereby certifies as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:49.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The name of the Corporation is Aprea Therapeutics,&nbsp;Inc. The Corporation&#146;s original certificate of incorporation was filed with the office of the Secretary of State of the State of Delaware on May&nbsp;3, 2019</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:49.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">B.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>This amended and restated certificate of incorporation was duly adopted in accordance with Sections 242 and 245 of the General Corporation Law of the State of Delaware, as amended (the &#147;<b><i style="font-weight:bold;">DGCL</i></b>&#148;), restates and amends the provisions of the Corporation&#146;s certificate of incorporation and has been duly approved by the written consent of the stockholders of the Corporation in accordance with Section&nbsp;228 of the DGCL.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:49.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">C.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The text of the certificate of incorporation of this Corporation is hereby amended and restated to read in its entirety as follows:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;I <br>  <u>NAME</u></font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:49.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The name of the Corporation is Aprea Therapeutics,&nbsp;Inc.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;II<br>  <u>REGISTERED OFFICE</u></font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:49.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The address of the Corporation&#146;s registered office in the State of Delaware is 1209 Orange Street, City of Wilmington, County of New Castle, Delaware 19801. The name of its registered agent at such address is The Corporation Trust Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;III<br>  <u>PURPOSE</u></font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:49.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the DGCL.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="3",CHK=28020,FOLIO='',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KG_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 07:02 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;IV<br>  <u>CAPITAL STOCK</u></font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Authorized Capital Stock</u>. The total number of shares of all classes of capital stock that the Corporation is authorized to issue is 440,000,000 shares, consisting of 400,000,000 shares of common stock, par value $0.001 per share (&#147;<b><i style="font-weight:bold;">Common Stock</i></b>&#148;), and 40,000,000 shares of preferred stock, par value $0.001 per share (&#147;<b><i style="font-weight:bold;">Preferred Stock</i></b>&#148;).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Increase or Decrease in Authorized Capital Stock</u>. The number of authorized shares of Common Stock or Preferred Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority in voting power of the stock of the Corporation entitled to vote generally in the election of directors, irrespective of the provisions of Section&nbsp;242(b)(2)&nbsp;of the DGCL (or any successor provision thereto), voting together as a single class, without a separate vote of the holders of the class or classes the number of authorized shares of which are being increased or decreased, unless a vote by any holders of one or more series of Preferred Stock is required by the express terms of any series of Preferred Stock as provided for or fixed pursuant to the provisions of <u>Section&nbsp;4.4</u> of this Certificate of Incorporation (as defined below).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Common Stock</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The holders of shares of Common Stock shall be entitled to one vote for each such share on each matter properly submitted to the stockholders of the Corporation on which the holders of shares of Common Stock are entitled to vote. The holders of shares of Common Stock shall not have cumulative voting rights. Except as otherwise required by law or this amended and restated certificate of incorporation of the Corporation (as further amended from time to time in accordance with the provisions hereof and including, without limitation, the terms of any certificate of designation with respect to any series of Preferred Stock, this &#147;<b><i style="font-weight:bold;">Certificate of Incorporation</i></b>&#148;), and subject to the rights of the holders of shares of Preferred Stock, if any, at any annual or special meeting of the stockholders of the Corporation, the holders of shares of Common Stock shall have the right to vote for the election of directors of the Corporation and on all other matters properly submitted to the stockholders of the Corporation for their vote; <u>provided</u>, <u>however</u>, that, except as otherwise required by law, holders of shares of Common Stock shall not be entitled to vote on any amendment to this Certificate of Incorporation that relates solely to the terms, number of shares, powers, designations, preferences or relative, participating, optional or other special rights (including, without limitation, voting rights), or to qualifications, limitations or restrictions thereof, of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to this Certificate of Incorporation or pursuant to the DGCL.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Subject to the rights of the holders of shares of Preferred Stock, the holders of shares of Common Stock shall be entitled to receive such dividends and other distributions (payable in cash, property or capital stock of the Corporation) when, as and if declared thereon by the board of directors of the Corporation (the &#147;<b><i style="font-weight:bold;">Board</i></b>&#148;) from time to time out of any assets or funds of the Corporation legally available therefor and shall share equally on a per share basis in such dividends and distributions.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="12476-2-KG_PB_2_062508_6856"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="3",CHK=469531,FOLIO='2',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KG_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 07:02 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>In the event of any voluntary or involuntary liquidation, dissolution or winding-up of the Corporation, after payment or provision for payment of the debts and other liabilities of the Corporation, and subject to the rights of the holders of shares of Preferred Stock in respect thereof, the holders of shares of Common Stock shall be entitled to receive all of the remaining assets of the Corporation available for distribution to its stockholders, ratably in proportion to the number of shares of Common Stock held by them.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Preferred Stock</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Board is expressly authorized to issue from time to time shares of Preferred Stock in one or more series pursuant to a resolution or resolutions providing for such issue duly adopted by the Board. The Board is further authorized, subject to limitations prescribed by law, to fix by resolution or resolutions and to set forth in a certification of designation filed pursuant to the DGCL the powers, designations, preferences and relative, participating, optional or other special rights, if any, and the qualifications, limitations or restrictions thereof, if any, of any wholly unissued series of Preferred Stock, including, without limitation, dividend rights, dividend rate, conversion rights, voting rights, rights and terms of redemption (including, without limitation, sinking fund provisions), redemption price or prices and liquidation preferences of any such series, and the number of shares constituting any such series and the designation thereof, or any of the foregoing.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Board is further authorized to increase (but not above the total number of authorized shares of the class) or decrease (but not below the number of shares of any such series then outstanding) the number of shares of any series of Preferred Stock, the number of which was fixed by it, subsequent to the issuance of shares of such series then outstanding, subject to the powers, preferences and rights, and the qualifications, limitations and restrictions thereof, stated in this Certificate of Incorporation or the resolution of the Board originally fixing the number of shares of such series. If the number of shares of any series of Preferred Stock is so decreased, then the shares constituting such decrease shall resume the status that they had prior to the adoption of the resolution originally fixing the number of shares of such series.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;V<br>  <u>BOARD OF DIRECTORS</u></font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>General Powers</u>. The business and affairs of the Corporation shall be managed by or under the direction of the Board.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Number of Directors; Election; Term</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The number of directors that shall constitute the entire Board shall be fixed from time to time exclusively by the Board in accordance with the bylaws of the Corporation (as amended from time to time in accordance with the provisions hereof and thereof, the &#147;<b><i style="font-weight:bold;">Bylaws</i></b>&#148;), subject to the rights of holders of any series of Preferred Stock with respect to the election of directors, if any.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Subject to the rights of holders of any series of Preferred Stock with respect to the election of directors, the directors of the Corporation shall be divided into three classes as nearly equal in number as is practicable, hereby designated Class&nbsp;I, Class&nbsp;II and Class&nbsp;III. The Board is</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="12476-2-KG_PB_3_062515_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="3",CHK=855659,FOLIO='3',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KG_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 07:02 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">authorized to assign members of the Board already in office to such classes. The term of office of the initial Class&nbsp;I directors shall expire upon the election of directors at the first annual meeting of stockholders following the effectiveness of this <u>Article&nbsp;V</u>; the term of office of the initial Class&nbsp;II directors shall expire upon the election of directors at the second annual meeting of stockholders following the effectiveness of this <u>Article&nbsp;V</u>; and the term of office of the initial Class&nbsp;III directors shall expire upon the election of directors at the third annual meeting of stockholders following the effectiveness of this <u>Article&nbsp;V</u>. At each annual meeting of stockholders, commencing with the first annual meeting of stockholders following the effectiveness of this <u>Article&nbsp;V</u>, each of the successors elected to replace the directors of a class whose term shall have expired at such annual meeting shall be elected to hold office until the third annual meeting next succeeding his or her election and until his or her respective successor shall have been duly elected and qualified. Subject to the rights of holders of any series of Preferred Stock with respect to the election of directors, if the number of directors that constitutes the Board is changed, any newly created directorships or decrease in directorships shall be so apportioned by the Board among the classes as to make all classes as nearly equal in number as is practicable, provided that no decrease in the number of directors constituting the Board shall shorten the term of any incumbent director.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Notwithstanding the foregoing provisions of this <u>Section&nbsp;5.2</u>, and subject to the rights of holders of any series of Preferred Stock with respect to the election of directors, each director shall serve until such director&#146;s successor is duly elected and qualified or until such director&#146;s earlier death, resignation or removal.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Elections of directors need not be by written ballot unless the Bylaws shall so provide.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Notwithstanding any of the other provisions of this <u>Article&nbsp;V</u>, whenever the holders of any one or more series of Preferred Stock issued by the Corporation shall have the right, voting separately by series, to elect directors at an annual or special meeting of stockholders, the election, term of office, filling of vacancies and other features of such directorships shall be governed by the terms of the certificate of designation for such series of Preferred Stock, and such directors so elected shall not be divided into classes pursuant to this <u>Article&nbsp;V</u> unless expressly provided by such terms. During any period when the holders of any series of Preferred Stock have the right to elect additional directors as provided for or fixed pursuant to the provisions of this <u>Article&nbsp;V</u>, then upon commencement and for the duration of the period during which such right continues; (i)&nbsp;the then otherwise total authorized number of directors of the Corporation shall automatically be increased by such specified number of directors, and the holders of such Preferred Stock shall be entitled to elect the additional directors so provided for or fixed pursuant to such provisions, and (ii)&nbsp;each such additional director shall serve until such director&#146;s successor shall have been duly elected and qualified, or until such director&#146;s right to hold such office terminates pursuant to such provisions, whichever occurs earlier, subject to such director&#146;s earlier death, resignation or removal. Except as otherwise provided by the Board in the resolution or resolutions establishing such series, whenever the holders of any series of Preferred Stock having such right to elect additional directors are divested of such right pursuant to the provisions of such series of stock, the terms of office of all such additional directors elected by the holders of such stock, or elected to fill any vacancies resulting from the death, resignation or removal of such additional directors, shall forthwith</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="12476-2-KG_PB_4_062521_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="3",CHK=602574,FOLIO='4',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KG_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 07:02 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">terminate, and the total authorized number of directors of the Corporation shall be reduced accordingly.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Removal</u>. Subject to the rights of holders of any series of Preferred Stock with respect to the election of directors, a director may be removed from office by the stockholders of the Corporation only for cause.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Vacancies and Newly Created Directorships</u>. Subject to the rights of holders of any series of Preferred Stock with respect to the election of directors, vacancies occurring on the Board for any reason and newly created directorships resulting from an increase in the number of directors shall, unless the Board determines by resolution that any such vacancies or newly created directorships shall be filled by the affirmative vote of the stockholders, except as otherwise required by law, be filled only by vote of a majority of the remaining members of the Board, although less than a quorum, or by a sole remaining director, and not by the stockholders. A person so elected by the Board to fill a vacancy or newly created directorship shall hold office until the next election of the class for which such person shall have been assigned by the Board and until such person&#146;s successor shall be duly elected and qualified or until such director&#146;s earlier death, resignation or removal.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;VI<br>  <u>AMENDMENT OF BYLAWS</u></font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In furtherance and not in limitation of the powers conferred by statute, the Board is expressly authorized to adopt, amend, alter or repeal the Bylaws. The Bylaws may also be adopted, amended, altered or repealed by the stockholders of the Corporation by the affirmative vote of the holders of at least a majority of the voting power of all then outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class; <u>provided</u>, <u>however</u>, that, in the case of any adoption, amendment, alteration or repeal of the Bylaws by the stockholders of the Corporation, notwithstanding any other provision of the Bylaws, and in addition to any other vote that may be required by law or the terms of any series of preferred stock, the affirmative vote of the holders of at least seventy-five percent (75%) of the voting power of all of the then outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required to amend, alter, repeal or adopt any provision inconsistent with Sections <u>1.3</u>, <u>1.7(b), 1.11</u>, <u>1.13</u>, <u>1.16</u>, <u>1.17</u>, <u>2.1</u>, <u>2.8</u>, <u>2.9</u>, <u>2.10</u>, <u>2.13</u> or <u>2.14</u> or <u>Article&nbsp;VI</u> of the Bylaws.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;VII<br>  <u>STOCKHOLDERS</u></font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>No Action by Written Consent of Stockholders</u>. Except as otherwise expressly provided by the terms of any series of Preferred Stock permitting the holders of such series of Preferred Stock to act by written consent, any action required or permitted to be taken by the stockholders of the Corporation must be effected at a duly called annual or special meeting of the stockholders of the Corporation, and the ability of stockholders to act by written consent in lieu of a meeting of the stockholders is specifically denied.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="12476-2-KG_PB_5_062528_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="3",CHK=731173,FOLIO='5',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KG_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 07:02 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Special Meetings</u>. Except as otherwise expressly provided by the terms of any series of Preferred Stock permitting the holders of such series of Preferred Stock to call a special meeting of the holders of such series, special meetings of the stockholders of the Corporation may be called only by the Board, the chairperson of the Board, the chief executive officer or president (in the absence of a chief executive officer), and the ability of the stockholders to call a special meeting of the stockholders is hereby specifically denied.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Advance Notice</u>. Advance notice of stockholder nominations for the election of directors and of business to be brought by stockholders before any meeting of the stockholders of the Corporation shall be given in the manner provided in the Bylaws.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;VIII<br>  <u>LIMITATION OF LIABILITY AND INDEMNIFICATION</u></font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Limitation of Personal Liability</u>. No director of the Corporation shall be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except to the extent such exemption from liability or limitation thereof is not permitted under the DGCL, as it presently exists or may hereafter be amended from time to time. If the DGCL is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Indemnification and Advancement of Expenses</u>.&#160; The Corporation shall indemnify its directors and officers to the fullest extent authorized or permitted by the DGCL, as now or hereafter in effect, and such right to indemnification shall continue as to a person who has ceased to be a director or officer of the Corporation and shall inure to the benefit of such person&#146;s heirs, executors and personal and legal representatives. A director&#146;s or officer&#146;s right to indemnification conferred by this <u>Section&nbsp;8.2</u> shall include the right to be paid by the Corporation the expenses incurred in defending or otherwise participating in any proceeding in advance of its final disposition, provided that such director or officer presents to the Corporation a written undertaking to repay such amount if it shall ultimately be determined that such director or officer is not entitled to be indemnified by the Corporation under this <u>Article&nbsp;VIII</u> or otherwise. Notwithstanding the foregoing, except for proceedings to enforce any director&#146;s or officer&#146;s rights to indemnification or to advancement of expenses, the Corporation shall not be obligated to indemnify any director or officer, or advance expenses of any director, (or such director&#146;s or officer&#146;s heirs, executors or personal or legal representatives) in connection with any proceeding (or part thereof) initiated by such person unless such proceeding (or part thereof) was authorized by the Board.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Non-Exclusivity of Rights</u>.&#160; The rights to indemnification and advancement of expenses conferred in <u>Section&nbsp;8.2</u> of this Certificate of Incorporation shall neither be exclusive of, nor be deemed in limitation of, any rights to which any person may otherwise be or become entitled or permitted under this Certificate of Incorporation, the Bylaws, any statute, agreement, vote of stockholders or disinterested directors or otherwise.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Insurance</u>. To the fullest extent authorized or permitted by the DGCL, the Corporation may purchase and maintain insurance on behalf of any current or former director or officer of the Corporation against any liability asserted against such person, whether or not the</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="12476-2-KG_PB_6_062536_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="3",CHK=531074,FOLIO='6',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KG_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 07:02 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Corporation would have the power to indemnify such person against such liability under the provisions of this <u>Article&nbsp;VIII</u> or otherwise.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.5</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Persons Other Than Directors and Officers</u>.&#160; This <u>Article&nbsp;VIII</u> shall not limit the right of the Corporation, to the extent and in the manner permitted by law, to indemnify and to advance expenses to, or to purchase and maintain insurance on behalf of, persons other than those persons described in the first sentence of <u>Section&nbsp;8.2</u> of this Certificate of Incorporation or to advance expenses to persons other than directors of the Corporation.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.6</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Effect of Modifications</u>.&#160; Any amendment, repeal or modification of any provision contained in this <u>Article&nbsp;VIII</u> shall, unless otherwise required by law, be prospective only (except to the extent such amendment or change in law permits the Corporation to further limit or eliminate the liability of directors or officers) and shall not adversely affect any right or protection of any current or former director or officer of the Corporation existing at the time of such amendment, repeal or modification with respect to any acts or omissions occurring prior to such amendment, repeal or modification.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ARTICLE&nbsp;IX<br>  <u>MISCELLANEOUS</u></font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Forum for Certain Actions.</u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Forum</u>.&#160; Unless a majority of the Board, acting on behalf of the Corporation, consents in writing to the selection of an alternative forum (which consent may be given at any time, including during the pendency of litigation), the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another state court located within the State of Delaware or, if no court located within the State of Delaware has jurisdiction, the federal district court for the District of Delaware) shall be the sole and exclusive forum for (i)&nbsp;any derivative action or proceeding brought on behalf of the Corporation under Delaware law, (ii)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any current or former director, officer or other employee of the Corporation to the Corporation or the Corporation&#146;s stockholders, (iii)&nbsp;any action asserting a claim against the Corporation or any of its directors, officers or other employees arising pursuant to any provision of the DGCL, this Certificate of Incorporation or the Bylaws (in each case, as may be amended from time to time), (iv)&nbsp;any action asserting a claim against the Corporation or any of its directors, officers or other employees governed by the internal affairs doctrine of the State of Delaware, or (v)&nbsp;any other action asserting an &#147;internal corporate claim,&#148; as defined in Section&nbsp;115 of the DGCL, in all cases subject to the court&#146;s having personal jurisdiction over all indispensable parties named as defendants. Nothing herein contained shall be construed to preclude stockholders that assert claims under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or any successor thereto, from bringing such claims in state or federal court, subject to applicable law.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Personal Jurisdiction.</u> If any action the subject matter of which is within the scope of subparagraph (a)&nbsp;of this <u>Section&nbsp;9.1</u> is filed in a court other than a court located within the State of Delaware (a &#147;<b><i style="font-weight:bold;">Foreign Action</i></b>&#148;) in the name of any stockholder, such stockholder shall be deemed to have consented to (i)&nbsp;the personal jurisdiction of the state and federal courts located within the State of Delaware in connection with any action brought in any such court to</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="12476-2-KG_PB_7_062543_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="3",CHK=929541,FOLIO='7',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KG_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 07:02 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">enforce subparagraph (a)&nbsp;of this <u>Section&nbsp;9.1</u> (an &#147;<b><i style="font-weight:bold;">Enforcement Action</i></b>&#148;) and (ii)&nbsp;having service of process made upon such stockholder in any such Enforcement Action by service upon such stockholder&#146;s counsel in the Foreign Action as agent for such stockholder.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Enforceability.</u>&#160; If any provision of this <u>Section&nbsp;9.1</u> shall be held to be invalid, illegal or unenforceable as applied to any person, entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality and enforceability of such provision in any other circumstance and of the remaining provisions of this <u>Section&nbsp;9.1</u>, and the application of such provision to other persons or entities and circumstances shall not in any way be affected or impaired thereby.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:48.95pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Amendment</u>. The Corporation reserves the right to amend, alter or repeal any provision contained in this Certificate of Incorporation, in the manner now or hereafter prescribed by this Certificate of Incorporation and the DGCL; and all rights, preferences and privileges herein conferred upon stockholders of the Corporation by and pursuant to this Certificate of Incorporation in its present form or as hereafter amended are granted subject to the right reserved in this <u>Section&nbsp;9.2</u>. In addition to any other vote that may be required by law, applicable stock exchange rule&nbsp;or the terms of any series of Preferred Stock, the affirmative vote of the holders of at least a majority of the voting power of all then outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required to amend, alter, repeal or adopt any provision of this Certificate of Incorporation. Notwithstanding any other provision of this Certificate of Incorporation, and in addition to any other vote that may be required by law, applicable stock exchange rule&nbsp;or the terms of any series of Preferred Stock, the affirmative vote of the holders of at least seventy-five percent (75%) of the voting power of all then outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required to amend, alter, repeal or adopt any provision of this Certificate of Incorporation inconsistent with the purpose and intent of <u>Article&nbsp;V</u>, <u>Article&nbsp;VI</u>, <u>Article&nbsp;VII</u> or this <u>Article&nbsp;IX</u> (including, without limitation, any such Article&nbsp;as renumbered as a result of any amendment, alternation, repeal or adoption of any other Article).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:49.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Severability</u>. If any provision or provisions of this Certificate of Incorporation shall be held to be invalid, illegal or unenforceable as applied to any circumstance for any reason whatsoever&nbsp;the validity, legality and enforceability of such provision in any other circumstance and of the remaining provisions of this Certificate of Incorporation (including, without limitation, each portion of any paragraph of this Certificate of Incorporation containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="12476-2-KG_PB_8_062549_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="3",CHK=910325,FOLIO='8',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KG_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 07:02 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:49.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">IN WITNESS WHEREOF, the Corporation has caused this amended and restated Certificate of Incorporation to be signed by a duly authorized officer of the Corporation on this &nbsp;&nbsp;&nbsp;&nbsp; day of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Christian   Schade</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="44%" valign="top" style="padding:0in 0in 0in 0in;width:44.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President   and Chief Executive Officer</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="3",CHK=418222,FOLIO='',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KG_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 07:02 2019' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>4
<FILENAME>a2239779zex-4_1.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 4.1</font></b></p>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS#   . COMMON STOCK PAR VALUE $0.001 COMMON STOCK Certificate Number ZQ00000000   Shares * * 000000 * * * * * * * * * * * * * * * * * * * * * 000000 * * * * *   * * * * * * * * * * * * * * * * 000000 * * * * * * * * * * * * * * * * * * *   * * 000000 * * * * * * * * * * * * * * * * * * * * * 000000 * * * * * * * * *   * * * * * APREA THERAPEUTICS, INC. INCORPORATED UNDER THE LAWS OF THE STATE   OF DELAWARE ** Mr. Alexander David Sample **** Mr. Alexander David Sample ****   Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander   David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample   **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr.   Alexander David SEE REVERSE FOR CERTAIN DEFINITIONS THIS CERTIFIES THAT   Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample ****   Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander   Alexander David SamMple ***R* Mr. A.lexaSnderADavidMSampPle ***L* MrE.   Alexan&amp;der DavMid SamRple **S** Mr.. AleSxandeAr DaMvid SamPple *L***   MEr. Alex&amp;ander David Sample **** David Sample **** Mr. Alexander David   Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample ****   Mr. Alexander David Sample **** Mr. Mr. Alexander David Sample **** Mr.   Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander   David Sample **** Mr. Alexander David Sample **** Mr. Alexander DavidMSampRle   ****.Mr. SAlexaAnderMDavidPSamLple *E*** Mr. &amp;AlexandMer DavRid   SaSmple.**** SMr. AAlexanMder DaPvid SLampEle **** Mr. Alexander David Sample   **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr.   Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander   David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample   **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr.   Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander   David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample   **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr.   Alexander David Sample **** Mr. Alexander David Sample **** Mr. Sample ****   Mr. Sample is the owner of   **000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares***   *000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****   000000**Shar*es****0*000Z00**SEhareRs****00O0000**ShHares**U**0000N00**SDhares*R***000E000**DShares**T**000H000**SOhares*U***000S000**AShareNs****00D0000**Shares****0   THIS CERTIFICATE IS TRANSFERABLE IN CITIES DESIGNATED BY THE TRANSFER AGENT,   AVAILABLE ONLINE AT www.computershare.com   00000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****00   0000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000   000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****0000   00**Shares****0Z0000E0**ShRares***O*000000*H*ShareUs****0N00000D**SharRes****0E0000D0**ShareAs****0N00000D**SharesZ****00E0000R**SharOes****0*000*00**Shares****00000   0**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000   **Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000*   *Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**   Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**S   FULLY-PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF Aprea Therapeutics,   Inc. (hereinafter called the &#147;Company&#148;), transferable on the books of the   Company in person or by duly authorized attorney, upon surrender of this   Certificate properly endorsed. This Certificate and the shares represented   hereby, are issued and shall be held subject to all of the provisions of the   Certificate of Incorporation, as amended, and the By-Laws, as amended, of the   Company (copies of which are on file with the Company and with the Transfer   Agent), to all of which each holder, by acceptance hereof, assents. This   Certificate is not valid unless countersigned and registered by the Transfer   Agent and Registrar. Witness the facsimile seal of the Company and the   facsimile signatures of its duly authorized officers. DATED DD-MMM-YYYY   COUNTERSIGNED AND REGISTERED: COMPUTERSHARE TRUST COMPANY, N.A. TRANSFERAGENT   ANDREGISTRAR, FACSIMILE SIGNATURE TO COME President May 2019 FACSIMILE   SIGNATURE TO COME Secretary By AUTHORIZEDSIGNATURE C CUSIP/IDENTIFIER Holder   ID Insurance Value Number of Shares DTC Certificate Numbers   1234567890/1234567890 1234567890/1234567890 1234567890/1234567890   1234567890/1234567890 1234567890/1234567890 1234567890/1234567890 Total   Transaction XXXXXX XX X XXXXXXXXXX 1,000,000.00 123456 12345678   123456789012345 PO BOX 43004, Providence, RI 02940-3004 Num/No. Denom. Total   1 2 3 4 5 6 7 1 2 3 4 5 6 1 2 3 4 5 6 MR A SAMPLE DESIGNATION (IF ANY) ADD 1   ADD 2 ADD 3 ADD 4 CUSIP 03836J 10 2 </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="1479" height="897" src="g124762lmi001.gif"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="4",CHK=407205,FOLIO='',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LM_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 28 02:30 2019' -->

<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">. APREA   THERAPEUTICS, INC. THE COMPANY WILL FURNISH WITHOUT CHARGE TO EACH   SHAREHOLDER WHO SO REQUESTS, A SUMMARY OF THE POWERS, DESIGNATIONS,   PREFERENCES AND RELATIVE, PARTICIPATING, OPTIONAL OR OTHER SPECIAL RIGHTS OF   EACH CLASS OF STOCK OF THE COMPANY AND THE QUALIFICATIONS, LIMITATIONS OR   RESTRICTIONS OF SUCH PREFERENCES AND RIGHTS, AND THE VARIATIONS IN RIGHTS,   PREFERENCES AND LIMITATIONS DETERMINED FOR EACH SERIES, WHICH ARE FIXED BY   THE CERTIFICATE OF INCORPORATION OF THE COMPANY, AS AMENDED, AND THE   RESOLUTIONS OF THE BOARD OF DIRECTORS OF THE COMPANY, AND THE AUTHORITY OF   THE BOARD OF DIRECTORS TO DETERMINE VARIATIONS FOR FUTURE SERIES. SUCH   REQUEST MAY BE MADE TO THE OFFICE OF THE SECRETARY OF THE COMPANY OR TO THE   TRANSFER AGENT. THE BOARD OF DIRECTORS MAY REQUIRE THE OWNER OF A LOST OR   DESTROYED STOCK CERTIFICATE, OR HIS LEGAL REPRESENTATIVES, TO GIVE THE   COMPANY A BOND TO INDEMNIFY IT AND ITS TRANSFER AGENTS AND REGISTRARS AGAINST   ANY CLAIM THAT MAY BE MADE AGAINST THEM ON ACCOUNT OF THE ALLEGED LOSS OR   DESTRUCTION OF ANY SUCH CERTIFICATE. (Cust) (Minor) (State) (Cust) and not as   tenants in common (Minor) (State) PLEASE INSERT SOCIAL SECURITY OR OTHER   IDENTIFYING NUMBER OF ASSIGNEE For value received, hereby sell, assign and   transfer unto (PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING POSTAL   ZIP CODE, OF ASSIGNEE) Shares of the Common Stock represented by the within   Certificate, and do hereby irrevocably constitute and appoint Attorney to   transfer the said stock on the books of the within-named Company with full   power of substitution in the premises. Dated: 20 Signature: Signature:   Notice: The signature to this assignment must correspond with the name as   written upon the face of the certificate, in every particular, without   alteration or enlargement, or any change whatever. The IRS requires that the   named transfer agent (&#147;we&#148;) report the cost basis of certain shares or units   acquired after January 1, 2011. If your shares or units are covered by the   legislation, and you requested to sell or transfer the shares or units using   a specific cost basis calculation method, then we have processed as you   requested. If you did not specify a cost basis calculation method, then we   have defaulted to the first in, first out (FIFO) method. Please consult your   tax advisor if you need additional information about cost basis. If you do   not keep in contact with the issuer or do not have any activity in your   account for the time period specified by state law, your property may become   subject to state unclaimed property laws and transferred to the appropriate   state. Signature(s) Guaranteed: Medallion Guarantee Stamp THE SIGNATURE(S)   SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (Banks,   Stockbrokers, Savings and Loan Associations and Credit Unions) WITH MEMBERSHIP   IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE   17Ad-15. The following abbreviations, when used in the inscription on the   face of this certificate, shall be construed as though they were written out   in full according to applicable laws or regulations: TEN COM - as tenants in   commonUNIF GIFT MIN ACT -............................................   Custodian................................................ TEN ENT - as   tenants by the entiretiesunder Uniform Gifts to Minors Act........................................................   JT TEN-as joint tenants with right of survivorshipUNIFTRF MIN ACT   -............................................ Custodian (until   age................................ ) ............................. under   Uniform Transfers to Minors Act................... Additional abbreviations   may also be used though not in the above list. </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="935" height="1537" src="g124762lm01i001.gif"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="4",CHK=168703,FOLIO='',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LM-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 28 02:32 2019' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>5
<FILENAME>a2239779zex-5_1.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 5.1<a name="12476-2-LQ_Exhibit5_1_025201"></a></font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><img width="122" height="32" src="g124762lqi001.gif"></font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="56%" valign="top" style="padding:0in 0in 0in 0in;width:56.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SIDLEY AUSTIN   LLP</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">787 SEVENTH AVENUE</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">NEW YORK, NY 10019</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">+1 212 839 5300</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">+1 212 839 5599 FAX</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">AMERICA&nbsp; </font><font face="Symbol">&#183;</font>&nbsp; ASIA PACIFIC&nbsp; <font face="Symbol">&#183;</font>&nbsp; EUROPE</p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">September&nbsp;27, 2019</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Aprea Therapeutics,&nbsp;Inc.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">535 Boylston Street</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Boston, MA 02116</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Re: <u>5,750,000 shares of common stock, $0.001 par value per share</u></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ladies and Gentlemen:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We refer to the Registration Statement on Form&nbsp;S-1, File No.&nbsp;333- 233662, filed by Aprea Therapeutics,&nbsp;Inc., a Delaware corporation (the &#147;<u>Company</u>&#148;), with the Securities and Exchange Commission (the &#147;<u>SEC</u>&#148;) under the Securities Act of 1933, as amended (the &#147;<u>Securities Act</u>&#148;), as amended by Amendment No.&nbsp;1 filed with the SEC on September&nbsp;23, 2019, Amendment No.&nbsp;2 filed with the SEC on September&nbsp;25, 2019, and Amendment No.&nbsp;3 being filed with the SEC on the date hereof (as so amended, the &#147;<u>Registration Statement</u>&#148;). The Registration Statement relates to the registration under the Securities Act of 5,750,000 shares (including an aggregate of 750,000 shares that may be sold by the Company pursuant to the exercise of the underwriters&#146; option to purchase additional shares under the Underwriting Agreement (as defined below)) of common stock, $0.001 par value per share (the &#147;<u>New Shares</u>&#148;), of the Company. The New Shares are to be sold by the Company pursuant to an underwriting agreement among the Company and the Underwriters named therein, the form of which has been filed as Exhibit&nbsp;1.1 to the Registration Statement (the &#147;<u>Underwriting Agreement</u>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This opinion letter is being delivered in accordance with the requirements of Item 601(b)(5)&nbsp;of Regulation S-K under the Securities Act.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have examined (i)&nbsp;the Registration Statement; (ii)&nbsp;the form of the Amended and Restated Certificate of Incorporation (the &#147;<u>Certificate of Incorporation</u>&#148;) of the Company to be filed with the Secretary of State of the State of Delaware prior to the closing of the sale of the New Shares contemplated by the Registration Statement, filed as Exhibit&nbsp;3.5 to the Registration Statement; (iii)&nbsp;the form of the Amended and Restated Bylaws of the Company to be effective prior to the closing of the sale of the New Shares contemplated by the Registration Statement, filed as Exhibit&nbsp;3.6 to the Registration Statement; (iv)&nbsp;the form of the Underwriting Agreement; and (v)&nbsp;the resolutions adopted by the board of directors of the Company relating to the Registration Statement and the issuance of the New Shares by the Company. We have also examined originals, or copies of originals certified to our satisfaction, of such agreements, documents, certificates and statements of the Company and other corporate documents and instruments, and have examined such questions of law, as we have considered relevant and necessary as a basis for this opinion letter. We have assumed the authenticity of all documents</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sidley Austin (NY) LLP is a Delaware limited liability partnership doing business as Sidley Austin LLP and practicing in affiliation with other Sidley Austin partnerships.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="5",CHK=882173,FOLIO='',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LQ_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 04:50 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">submitted to us as originals, the genuineness of all signatures, the legal capacity of all persons and the conformity with the original documents of any copies thereof submitted to us for examination. As to facts relevant to the opinions expressed herein, we have relied without independent investigation or verification upon, and assumed the accuracy and completeness of certificates, letters and oral and written statements and representations of public officials and officers and other representatives of the Company. We have also assumed that the Certificate of Incorporation will be approved by all requisite action of the stockholders of the Company and will be duly filed with the Secretary of State of the State of Delaware prior to the sale of the New Shares.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Based on the foregoing, we are of the opinion that the New Shares will be validly issued, fully paid and non-assessable when: (i)&nbsp;the Registration Statement, as finally amended, shall have been declared effective under the Securities Act; (ii)&nbsp;the Company&#146;s board of directors or a duly authorized committee thereof shall have duly adopted final resolutions setting the price of the New Shares; and (iii)&nbsp;certificates representing the New Shares shall have been duly executed, countersigned and registered and duly delivered to the purchasers thereof against payment of the agreed consideration therefor in an amount not less than the par value thereof or, if any New Shares are to be issued in uncertificated form, the Company&#146;s books shall reflect the issuance of such New Shares to the purchasers thereof against payment of the agreed consideration therefor in an amount not less than the par value thereof, all in accordance with the Underwriting Agreement as executed and delivered by the parties thereto.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This opinion letter is limited to the General Corporation Law of the State of Delaware. We express no opinion as to the laws, rules&nbsp;or regulations of any other jurisdiction, including, without limitation, the federal laws of the United States of America or any state securities or blue sky laws.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We hereby consent to the filing of this opinion letter as an Exhibit&nbsp;to the Registration Statement and to all references to our Firm included in or made a part of the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 1.5in .0001pt 0in;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 1.5in .0001pt 0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Very truly yours,</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 1.5in .0001pt 0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 1.5in .0001pt 0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 1.5in .0001pt 0in;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 1.5in .0001pt 0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Sidley Austin LLP</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="12476-2-LQ_PB_2_025421_9970"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="5",CHK=254826,FOLIO='2',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LQ_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 04:50 2019' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>6
<FILENAME>a2239779zex-10_1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 10.1<a name="12476-2-KS-01_Exhibit10_1_094131"></a></font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">APREA THERAPEUTICS,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2019 EQUITY INCENTIVE PLAN</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ADOPTED BY THE BOARD OF DIRECTORS: September 19, 2019<br> APPROVED BY THE STOCKHOLDERS: September 26, 2019<br> TERMINATION DATE: September 19, 2029</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">I.&#160; </font></b><b>INTRODUCTION</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>PURPOSES.</b>&#160; The purposes of the Aprea Therapeutics,&nbsp;Inc. 2019 Equity Incentive Plan (this &#147;<b><i style="font-weight:bold;">Plan</i></b>&#148;) are (i)&nbsp;to align the interests of the Company&#146;s stockholders and the recipients of awards under this Plan by increasing the proprietary interest of such recipients in the Company&#146;s growth and success, (ii)&nbsp;to advance the interests of the Company by attracting and retaining Non-Employee Directors, officers, other employees, consultants, independent contractors and agents and (iii)&nbsp;to motivate such persons to act in the long-term best interests of the Company and its stockholders.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>CERTAIN DEFINITIONS.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;<i>Agreement</i>&#148;</font></b> means the written or electronic agreement evidencing an award hereunder between the Company and the recipient of such award.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;<i>Board</i>&#148;</font></b> means the Board of Directors of the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;<i>Change in Control</i>&#148;</font></b> has the meaning set forth in <u>Section&nbsp;5.8(a)</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;<i>Code</i>&#148;</font></b> means the Internal Revenue Code of 1986, as amended.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;<i>Committee</i>&#148;</font></b> means the Compensation Committee of the Board, or a subcommittee thereof, or such other committee designated by the Board, in each case, consisting of two or more members of the Board, each of whom is intended to be (i)&nbsp;a &#147;Non-Employee Director&#148; within the meaning of Rule&nbsp;16b-3 under the Exchange Act and (ii)&nbsp;&#147;independent&#148; within the meaning of the rules&nbsp;of NASDAQ or, if the Common Stock is not listed on NASDAQ, within the meaning of the rules&nbsp;of the principal stock exchange on which the Common Stock is then traded.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;<i>Common Stock</i>&#148;</font></b> means the common stock, par value $0.001 per share, of the Company, and all rights appurtenant thereto.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;<i>Company</i>&#148;</font></b> means Aprea Therapeutics,&nbsp;Inc., a Delaware corporation, or any successor thereto.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;<i>Exchange Act</i>&#148;</font></b> means the Securities Exchange Act of 1934, as amended.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;<i>Exchange Act Person</i></font></b><b>&#148;</b> means any natural person, entity, or &#147;group&#148; (within the meaning of Section&nbsp;13(d)&nbsp;or 14(d)&nbsp;of the Exchange Act), except that &#147;Exchange Act Person&#148;</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=301956,FOLIO='',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:28 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">does not include: (i)&nbsp;the Company or any Subsidiary; (ii)&nbsp;any employee benefit plan of the Company or any</font>  </font>Subsidiary or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary; (iii)&nbsp;an underwriter temporarily holding securities pursuant to an offering of such securities; (iv)&nbsp;an entity owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company; or (v)&nbsp;any natural person, entity, or &#147;group&#148; (within the meaning of Section&nbsp;13(d)&nbsp;or 14(d)&nbsp;of the Exchange Act) that, as of the effective date of this Plan, is the owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company&#146;s then outstanding securities.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;<i>Fair Market Value</i>&#148;</font></b> means the closing transaction price of a share of Common Stock as reported on NASDAQ on the date as of which such value is being determined or, if the Common Stock is not listed on NASDAQ, the closing transaction price of a share of Common Stock on the principal national stock exchange on which the Common Stock is traded on the date as of which such value is being determined or, if there shall be no reported transactions for such date, on the next preceding date for which transactions were reported; <i>provided</i>, <i>however</i>, that if the Common Stock is not listed on a national stock exchange or if Fair Market Value for any date cannot be so determined, Fair Market Value shall be determined by the Committee by whatever means or method as the Committee, in the good faith exercise of its discretion, shall at such time deem appropriate and in compliance with Section&nbsp;409A of the Code; <i>provided, further</i>, in the case of grants made in connection with the Initial Public Offering, Fair Market Value shall mean the price per share at which shares of Common Stock are initially offered for sale to the public by the Company&#146;s underwriters in the Initial Public Offering.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;<i>Free-Standing SAR</i>&#148;</font></b> means a SAR which is not granted in tandem with, or by reference to, an option, which entitles the holder thereof to receive, upon exercise, shares of Common Stock (which may be Restricted Stock) or, to the extent set forth in the applicable Agreement, cash or a combination thereof, with an aggregate value equal to the excess of the Fair Market Value of one share of Common Stock on the date of exercise over the base price of such SAR, multiplied by the number of such SARs that are exercised.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;<i>Incentive Stock Option</i>&#148;</font></b> means an option to purchase shares of Common Stock that meets the requirements of Section&nbsp;422 of the Code, or any successor provision, which is intended by the Committee to constitute an Incentive Stock Option.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">&#147;Initial Public Offering&#148;</font></i></b>&nbsp;means an initial public offering of the Common Stock of the Company registered on Form&nbsp;S-1&nbsp;(or any successor form under the Securities Act of 1933, as amended).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;<i>Non-Employee Director</i>&#148; </font></b>means any member of the Board who is not an officer or employee of the Company or any Subsidiary.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;<i>Nonstatutory Stock Option</i>&#148;</font></b> means an option to purchase shares of Common Stock which is not an Incentive Stock Option.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;<i>Other Stock Award</i>&#148;</font></b> means an award granted pursuant to <u>Section&nbsp;3.4</u> of the Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="12476-2-KS-01_PB_2_094228_2212"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=79133,FOLIO='2',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:28 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;<i>Performance Award</i>&#148;</font></b> means a right to receive an amount of cash, Common Stock, or a combination of both, contingent upon the attainment of specified Performance Measures within a specified Performance Period.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;<i>Performance Measures</i>&#148;</font></b> means the criteria and objectives, established by the Committee, which shall be satisfied or met (i)&nbsp;as a condition to the grant or exercisability of all or a portion of an option or SAR or (ii)&nbsp;during the applicable Restriction Period or Performance Period as a condition to the vesting of the holder&#146;s interest, in the case of a Restricted Stock Award, of the shares of Common Stock subject to such award, or, in the case of a Restricted Stock Unit Award, Other Stock Award or Performance Award, to the holder&#146;s receipt of the shares of Common Stock subject to such award or of payment with respect to such award.&#160; Such criteria and objectives may include one or more of the following corporate-wide or subsidiary, division, operating unit, line of business, project, geographic or individual measures:&#160; the attainment by a share of Common Stock of a specified Fair Market Value for a specified period of time; increase in stockholder value; earnings per share; return on or net assets; return on equity; return on investments; return on capital or invested capital; total stockholder return; earnings or income of the Company before or after taxes and/or interest; earnings before interest, taxes, depreciation and amortization (&#147;<u>EBITDA</u>&#148;); EBITDA margin; operating income; revenues; operating expenses, attainment of expense levels or cost reduction goals; market share; cash flow, cash flow per share, cash flow margin or free cash flow; interest expense; economic value created; gross profit or margin; operating profit or margin; net cash provided by operations; price-to-earnings growth; and strategic business criteria, consisting of one or more objectives based on meeting specified goals relating to publication, clinical or regulatory milestones, research and development achievements, market penetration, customer acquisition, business expansion, cost targets, customer satisfaction, reductions in errors and omissions, reductions in lost business, management of employment practices and employee benefits, supervision of litigation, supervision of information technology, quality and quality audit scores, efficiency,&#160; acquisitions or divestitures, coverage decisions, licenses, collaborations, joint ventures or promotional arrangements and such other goals as the Committee may determine whether or not listed herein, or any combination of the foregoing.&#160;&#160; Each such goal may be expressed on an absolute or relative basis and may include comparisons based on current internal targets, the past performance of the Company (including the performance of one or more subsidiaries, divisions, or operating units) or the past or current performance of other companies or market indices (or a combination of such past and current performance). In addition to the ratios specifically enumerated above, performance goals may include comparisons relating to capital (including, but not limited to, the cost of capital), shareholders&#146; equity, shares outstanding, assets or net assets, sales, or any combination thereof.&#160; The applicable performance measures may be applied on a pre- or post-tax basis and may be adjusted to include or exclude components of any performance measure, including, without limitation, foreign exchange gains and losses, asset writedowns, acquisitions and divestitures, change in fiscal year, unbudgeted capital expenditures, special charges such as restructuring or impairment charges, debt refinancing costs, extraordinary or noncash items, unusual, infrequently occurring, nonrecurring or one-time events affecting the Company or its financial statements or changes in law or accounting principles (&#147;<u>Adjustment Events</u>&#148;). In the sole discretion of the Committee, the Committee may amend or adjust the Performance Measures or other terms and conditions of an outstanding award in recognition of any Adjustment Events. Performance Measures shall be subject to such other special rules&nbsp;and conditions as the Committee may establish at any time.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="12476-2-KS-01_PB_3_094240_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=655843,FOLIO='3',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:28 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;<i>Performance Period</i>&#148;</font></b> means any period designated by the Committee during which (i)&nbsp;the Performance Measures applicable to an award shall be measured and (ii)&nbsp;the conditions to vesting applicable to an award shall remain in effect.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;<i>Restricted Stock</i>&#148;</font></b> means shares of Common Stock which are subject to a Restriction Period and which may, in addition thereto, be subject to the attainment of specified Performance Measures within a specified Performance Period.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;<i>Restricted Stock Award</i>&#148;</font></b> means an award of Restricted Stock under this Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;<i>Restricted Stock Unit</i>&#148;</font></b> means a right to receive one share of Common Stock or, in lieu thereof and to the extent set forth in the applicable Agreement, the Fair Market Value of such share of Common Stock in cash, which shall be contingent upon the expiration of a specified Restriction Period and which may, in addition thereto, be contingent upon the attainment of specified Performance Measures within a specified Performance Period.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;<i>Restricted Stock Unit Award</i>&#148;</font></b> means an award of Restricted Stock Units under this Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;<i>Restriction Period</i>&#148;</font></b> means any period designated by the Committee during which either (i)&nbsp;the Common Stock subject to a Restricted Stock Award may not be sold, transferred, assigned, pledged, hypothecated or otherwise encumbered or disposed of, except as provided in this Plan or the Agreement relating to such award, or (ii)&nbsp;the conditions to vesting applicable to a Restricted Stock Unit Award or Other Stock Award shall remain in effect.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;<i>SAR</i>&#148;</font></b> means a stock appreciation right, which may be a Free-Standing SAR or a Tandem SAR.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;<i>Stock Award</i>&#148;</font></b> means a Restricted Stock Award, Restricted Stock Unit Award or Other Stock Award.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;<i>Subject Person</i>&#148;</font></b> has the meaning set forth in <u>Section&nbsp;5.8(a)(1)</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;<i>Subsidiary</i>&#148;</font></b> means any corporation, limited liability company, partnership, joint venture, or similar entity in which the Company owns, directly or indirectly, an equity interest possessing more than 50% of the combined voting power of the total outstanding equity interests of such entity.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;<i>Substitute Award</i>&#148;</font></b> means an award granted under this Plan upon the assumption of, or in substitution for, outstanding equity awards previously granted by a company or other entity in connection with a corporate transaction, including a merger, combination, consolidation, or acquisition of property or stock or upon the substitution of Nonstatutory Stock Options for options of Aprea Therapeutics AB in connection with the reorganization of Aprea Therapeutics AB; <i>provided</i>, <i>however</i>, that in no event shall the term &#147;Substitute Award&#148; be construed to refer to an award made in connection with the cancellation and repricing of an option or SAR.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;<i>Tandem SAR</i>&#148;</font></b> means an SAR which is granted in tandem with, or by reference to, an option (including a Nonstatutory Stock Option granted prior to the date of grant of the SAR), </p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="12476-2-KS-01_PB_4_094259_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=942246,FOLIO='4',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:28 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">which entitles the holder thereof to receive, upon exercise of such SAR and surrender for cancellation of</font>  </font>all or a portion of such option, shares of Common Stock (which may be Restricted Stock) or, to the extent set forth in the applicable Agreement, cash or a combination thereof, with an aggregate value equal to the excess of the Fair Market Value of one share of Common Stock on the date of exercise over the base price of such SAR, multiplied by the number of shares of Common Stock subject to such option, or portion thereof, which is surrendered.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;<i>Tax Date</i>&#148;</font></b> has the meaning set forth in <u>Section&nbsp;5.5.</u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#147;<i>Ten Percent Holder</i>&#148;</font></b> has the meaning set forth in <u>Section&nbsp;2.1(a)</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.3</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>ADMINISTRATION.</b>&#160; This Plan shall be administered by the Committee.&#160; Any one or a combination of the following awards may be made under this Plan to eligible persons: (i)&nbsp;options to purchase shares of Common Stock in the form of Incentive Stock Options or Nonstatutory Stock Options; (ii)&nbsp;SARs in the form of Tandem SARs or Free-Standing SARs; (iii)&nbsp;Stock Awards in the form of Restricted Stock, Restricted Stock Units or Other Stock Awards; and (iv)&nbsp;Performance Awards.&#160; The Committee shall, subject to the terms of this Plan, select eligible persons for participation in this Plan and determine the form, amount and timing of each award to such persons and, if applicable, the number of shares of Common Stock subject to an award, the number of SARs, the number of Restricted Stock Units, the dollar value subject to a Performance Award, the purchase price or base price associated with the award, the time and conditions of exercise or settlement of the award, and all other terms and conditions of the award, including, without limitation, the form of the Agreement evidencing the award.&#160; The Committee may, in its sole discretion and for any reason at any time, take action such that (i)&nbsp;any or all outstanding options and SARs shall become exercisable in part or in full, (ii)&nbsp;all or a portion of the Restriction Period applicable to any outstanding awards shall lapse, (iii)&nbsp;all or a portion of the Performance Period applicable to any outstanding awards shall lapse and (iv)&nbsp;the Performance Measures (if any) applicable to any outstanding awards shall be deemed to be satisfied at the target, maximum or any other level.&#160; The Committee shall, subject to the terms of this Plan, interpret this Plan and the application thereof, establish rules&nbsp;and regulations it deems necessary or desirable for the administration of this Plan, and may impose, incidental to the grant of an award, conditions with respect to the award, such as limiting competitive employment or other activities.&#160; All such interpretations, rules, regulations and conditions shall be conclusive and binding on all parties.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Committee may delegate some or all of its power and authority hereunder to the Board (or any members thereof) or, subject to applicable law, to a subcommittee of the Board, a member of the Board, the Chief Executive Officer or other executive officer of the Company as the Committee deems appropriate; <i>provided</i>, <i>however</i>, that the Committee may not delegate its power and authority to a member of the Board, the Chief Executive Officer or other executive officer of the Company with regard to the selection for participation in this Plan of an officer, director or other person subject to Section&nbsp;16 of the Exchange Act or decisions concerning the timing, pricing or amount of an award to such an officer, director or other person.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">No member of the Board or Committee, and neither the Chief Executive Officer nor any other executive officer to whom the Committee delegates any of its power and authority</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="12476-2-KS-01_PB_5_094345_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=937285,FOLIO='5',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:28 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">hereunder, shall be liable for any act, omission, interpretation, construction or determination made in connection with this Plan in good faith, and the members of the Board and the Committee and the Chief Executive Officer or other executive officer shall be entitled to indemnification and</font>  </font>reimbursement by the Company in respect of any claim, loss, damage or expense (including attorneys&#146; fees) arising therefrom to the full extent permitted by law (except as otherwise may be provided in the Company&#146;s Certificate of Incorporation and/or Bylaws) and under any directors&#146; and officers&#146; liability insurance that may be in effect from time to time.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.4</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>ELIGIBILITY.</b>&#160; Participants in this Plan shall consist of such officers, other employees, Non-Employee Directors, consultants, independent contractors, agents, and persons expected to become officers, other employees, Non-Employee Directors, consultants, independent contractors and agents of the Company and its Subsidiaries as the Committee in its sole discretion may select from time to time.&#160; Participants shall also consist of persons to whom Nonstatutory Stock Options are granted in substitution for options of Aprea Therapeutics AB in connection with the reorganization of Aprea Therapeutics AB.&#160; The Committee&#146;s selection of a person to participate in this Plan at any time shall not require the Committee to select such person to participate in this Plan at any other time.&#160; Except as otherwise provided for in an Agreement, for purposes of this Plan, references to employment by the Company shall also mean employment by a Subsidiary, and references to employment shall include service as a Non-Employee Director, consultant, independent contractor or agent.&#160; The Committee shall determine, in its sole discretion, the extent to which a participant shall be considered employed during an approved leave of absence.&#160; Notwithstanding anything herein to the contrary, the aggregate value of cash compensation to be paid and the grant date fair value of equity awards that may be granted during any fiscal year of the Company to any Non-Employee Director shall not exceed $500,000; <u>provided</u>, <u>however</u>, such limit shall be multiplied by 1.5 for the first fiscal year in which a Non-Employee Directors commences service on the Board.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.5</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>SHARES AVAILABLE.</b>&#160; Subject to adjustment as provided in <u>Section&nbsp;5.7</u> and to all other limits set forth in this Plan, 5,000,000 shares of Common Stock shall initially be available for all awards under this Plan, including in respect of Nonstatutory Stock Options issued in substitution for options of Aprea Therapeutics AB in connection with the reorganization of Aprea Therapeutics AB, but excluding future Substitute Awards.&#160;&#160; Subject to adjustment as provided in <u>Section&nbsp;5.7</u>, no more than 5,000,000 shares of Common Stock in the aggregate may be issued under the Plan in connection with Incentive Stock Options.&#160;&#160;&#160; The number of shares of Common Stock available under the Plan shall increase annually on the first day of each fiscal year, beginning with the fiscal year ending December&nbsp;31, 2020, and continuing until (and including) the fiscal year ending December&nbsp;31, 2029, with such annual increase equal to the lesser of (i)&nbsp;5,000,000 shares of Common Stock, (ii)&nbsp;4% of the number of shares of Common Stock issued and outstanding on December&nbsp;31 of the immediately preceding calendar year, and (iii)&nbsp;an amount determined by the Board.&#160;&#160; The number of shares of Common Stock that remain available for future grants under this Plan shall be reduced by the sum of the aggregate number of shares of Common Stock that become subject to outstanding options, outstanding Free-Standing SARs, outstanding Stock Awards and outstanding Performance Awards denominated in shares of Common Stock.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To the extent that shares of Common Stock subject to an outstanding option, SAR, Stock Award or Performance Award granted under the Plan, other than Substitute Awards other than</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="12476-2-KS-01_PB_6_094414_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=223456,FOLIO='6',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:28 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">the Nonstatutory Stock Options granted in substitution</font> for options of Aprea Therapeutics AB in connection with the reorganization of Aprea Therapeutics AB</font>, are not issued or delivered by reason of (i)&nbsp;the expiration, termination, cancellation or forfeiture of such award (excluding shares subject to an option cancelled upon settlement in shares of a related Tandem SAR or shares subject to a Tandem SAR cancelled upon exercise of a related option) or (ii)&nbsp;the settlement of such award in cash, then such shares of Common Stock shall again be available under this Plan. In addition, shares of Common Stock subject to an award under this Plan shall again be available for issuance under this Plan if such shares are (x)&nbsp;shares that were subject to an option or stock-settled SAR and were not issued or delivered upon the net settlement or net exercise of such option or SAR or (y)&nbsp;shares delivered to or withheld by the Company to pay the purchase price or the withholding taxes related to an outstanding award.&#160; Notwithstanding anything herein to the contrary, shares repurchased by the Company on the open market with the proceeds of an option exercise shall not again be available under this Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:36.6pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The number of shares of Common Stock available for awards under this Plan shall not be reduced by (i)&nbsp;the number of shares of Common Stock subject to Substitute Awards or (ii)&nbsp;available shares under a </font>stockholder approved plan of a company or other entity which was a party to a corporate transaction with the Company (as appropriately adjusted to reflect such corporate transaction) which become subject to awards granted under this Plan (subject to applicable stock exchange requirements).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">Shares of Common Stock to be delivered under this Plan </font>shall</font> be made available from authorized and unissued shares of Common Stock, or authorized and issued shares of Common Stock reacquired and held as treasury shares or otherwise or a combination thereof.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">II.&#160; </font></b><b>STOCK OPTIONS AND STOCK APPRECIATION RIGHTS</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>STOCK OPTIONS.</b>&#160; The Committee may, in its discretion, grant options to purchase shares of Common Stock to such eligible persons as may be selected by the Committee.&#160; Each option, or portion thereof, that is not an Incentive Stock Option, shall be a Nonstatutory Stock Option.&#160; To the extent that the aggregate Fair Market Value (determined as of the date of grant) of shares of Common Stock with respect to which options designated as Incentive Stock Options are exercisable for the first time by a holder during any calendar year (under this Plan or any other plan of the Company, or any parent or Subsidiary) exceeds the amount (currently $100,000) established by the Code, such options shall constitute Nonstatutory Stock Options.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Options shall be subject to the following terms and conditions and shall contain such additional terms and conditions, not inconsistent with the terms of this Plan, as the Committee shall deem advisable:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Number of Shares and Purchase Price.</b>&#160; The number of shares of Common Stock subject to an option and the purchase price per share of Common Stock purchasable upon exercise of the option shall be determined by the Committee; <i>provided</i>, <i>however</i>, that the purchase price per share of Common Stock purchasable upon exercise of an option shall not be less than 100% of the Fair Market Value of a share of Common Stock on the date of grant of such option; <i>provided further</i>, that if an Incentive Stock Option shall be granted to any person who, at the time such option is granted, owns capital stock possessing more than 10% of the total</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="12476-2-KS-01_PB_7_094523_141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=275474,FOLIO='7',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:28 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">combined voting power of all classes of capital stock of the Company (or of any parent or Subsidiary) (a &#147;<b><i style="font-weight:bold;">Ten Percent Holder</i></b>&#148;), the purchase price per share of Common Stock shall not be less than the price (currently 110% of Fair Market Value) required by the Code in order to constitute an Incentive Stock Option.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:36.6pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notwithstanding the foregoing, in the case of an option that is a Substitute Award, the purchase price per share of the shares subject to such option may be less than 100% of the Fair Market Value per share on the date of grant, provided, that the excess of: (a)&nbsp;the aggregate Fair Market Value (as of the date such Substitute Award is granted) of the shares subject to the Substitute Award, over (b)&nbsp;the aggregate purchase price thereof does not exceed the excess of: (x)&nbsp;the aggregate fair market value (as of the time immediately preceding the transaction giving rise to the Substitute Award, such fair market value to be determined by the Committee) of the shares of the predecessor company or other entity that were subject to the grant assumed or substituted for by the Company, over (y)&nbsp;the aggregate purchase price of such shares.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Option Period and Exercisability.</b>&#160; The period during which an option may be exercised shall be determined by the Committee; <i>provided</i>, <i>however</i>, that no option may be exercised later than ten years after its date of grant; <i>provided further</i>, that if an Incentive Stock Option shall be granted to a Ten Percent Holder, such option may not be exercised later than five years after its date of grant.&#160; The Committee may, in its discretion, establish Performance Measures which shall be satisfied or met as a condition to the grant of an option or to the exercisability of all or a portion of an option.&#160; The Committee shall determine whether an option shall become exercisable in cumulative or non-cumulative installments and in part or in full at any time.&#160; An exercisable option, or portion thereof, may be exercised only with respect to whole shares of Common Stock.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Method of Exercise.</b>&#160; An option may be exercised (i)&nbsp;by giving written notice to the Company specifying the number of whole shares of Common Stock to be purchased and accompanying such notice with payment therefor in full (or arrangement made for such payment to the Company&#146;s satisfaction) either: (A)&nbsp;in cash; (B)&nbsp;by delivery (either actual delivery or by attestation procedures established by the Company) of shares of Common Stock having a Fair Market Value, determined as of the date of exercise, equal to the aggregate purchase price payable by reason of such exercise; (C)&nbsp;authorizing the Company to withhold whole shares of Common Stock which would otherwise be delivered having an aggregate Fair Market Value, determined as of the date of exercise, equal to the amount necessary to satisfy such obligation; (D)&nbsp;in cash by a broker-dealer acceptable to the Company to whom the holder has submitted an irrevocable notice of exercise; (E)&nbsp;in any other form of legal consideration that may be acceptable to the Committee and specified in the Agreement; or (F)&nbsp;a combination of (A), (B), (C)&nbsp;and (E), in each case to the extent set forth in the Agreement relating to the option; (ii)&nbsp;if applicable, by surrendering to the Company any Tandem SARs which are cancelled by reason of the exercise of the option; and (iii)&nbsp;by executing such documents as the Company may reasonably request.&#160; Any fraction of a share of Common Stock which would be required to pay such purchase price shall be disregarded and the remaining amount due shall be paid in cash by the holder.&#160; No shares of Common Stock shall be issued and no certificate representing Common Stock shall be delivered until the full purchase price therefor and any withholding taxes thereon, as described in <u>Section&nbsp;5.5</u>, have been paid (or arrangement made for such payment to the</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="12476-2-KS-01_PB_8_094556_7608"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=591335,FOLIO='8',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:28 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Company&#146;s satisfaction).</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>STOCK APPRECIATION RIGHTS.</b>&#160; The Committee may, in its discretion, grant SARs to such eligible persons as may be selected by the Committee.&#160; The Agreement relating to an SAR shall specify whether the SAR is a Tandem SAR or a Free-Standing SAR.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SARs shall be subject to the following terms and conditions and shall contain such additional terms and conditions, not inconsistent with the terms of this Plan, as the Committee shall deem advisable:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Number of SARs and Base Price.</b>&#160; The number of SARs subject to an award shall be determined by the Committee.&#160; Any Tandem SAR related to an Incentive Stock Option shall be granted at the same time that such Incentive Stock Option is granted.&#160; The base price of a Tandem SAR shall be the purchase price per share of Common Stock of the related option.&#160; The base price of a Free-Standing SAR shall be determined by the Committee; <i>provided</i>, <i>however</i>, that such base price shall not be less than 100% of the Fair Market Value of a share of Common Stock on the date of grant of such SAR (or, if earlier, the date of grant of the option for which the SAR is exchanged or substituted).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Notwithstanding the foregoing, in the case of an SAR that is a Substitute Award, the base price per share of the shares subject to such SAR may be less than 100% of the Fair Market Value per share on the date of grant, provided, that the excess of: (a)&nbsp;the aggregate Fair Market Value (as of the date such Substitute Award is granted) of the shares subject to the Substitute Award, over (b)&nbsp;the aggregate base price thereof does not exceed the excess of: (x)&nbsp;the aggregate fair market value (as of the time immediately preceding the transaction giving rise to the Substitute Award, such fair market value to be determined by the Committee) of the shares of the predecessor company or other entity that were subject to the grant assumed or substituted for by the Company, over (y)&nbsp;the aggregate base price of such shares.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Exercise Period and Exercisability.</b>&#160; The period for the exercise of an SAR shall be determined by the Committee; <i>provided</i>, <i>however</i>, that (i)&nbsp;no Tandem SAR may be exercised later than the expiration, cancellation, forfeiture or other termination of the related option and (ii)&nbsp;no Free-Standing SAR may be exercised later than ten years after its date of grant.&#160; The Committee may, in its discretion, establish Performance Measures which shall be satisfied or met as a condition to the grant of an SAR or to the exercisability of all or a portion of an SAR.&#160; The Committee shall determine whether an SAR may be exercised in cumulative or non-cumulative installments and in part or in full at any time.&#160; An exercisable SAR, or portion thereof, may be exercised, in the case of a Tandem SAR, only with respect to whole shares of Common Stock and, in the case of a Free-Standing SAR, only with respect to a whole number of SARs.&#160; If an SAR is exercised for shares of Restricted Stock, a certificate or certificates representing such Restricted Stock shall be issued in accordance with <u>Section&nbsp;3.2(c)</u>, or such shares shall be transferred to the holder in book entry form with restrictions on the shares duly noted, and the holder of such Restricted Stock shall have such rights of a stockholder of the Company as determined pursuant to <u>Section&nbsp;3.2(d)</u>.&#160; Prior to the exercise of a stock-settled SAR, the holder of such SAR shall have no rights as a stockholder of the Company with respect to the shares of Common Stock subject to such SAR.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">9<a name="12476-2-KS-01_PB_9_094624_8146"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=338408,FOLIO='9',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:28 2019' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Method of Exercise.</b>&#160; A Tandem SAR may be exercised by (i)&nbsp;giving written notice to the Company specifying the number of whole SARs which are being exercised, (ii)&nbsp;surrendering to the Company any options which are cancelled by reason of the exercise of the Tandem SAR and (iii)&nbsp;executing such documents as the Company may reasonably request.&#160; A Free-Standing SAR may be exercised by (A)&nbsp;giving written notice to the Company specifying the whole number of SARs which are being exercised and (B)&nbsp;executing such documents as the Company may reasonably request.&#160; No shares of Common Stock shall be issued and no certificate representing Common Stock shall be delivered until any withholding taxes thereon, as described in <u>Section&nbsp;5.5</u>, have been paid (or arrangement made for such payment to the Company&#146;s satisfaction).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.3</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>TERMINATION OF EMPLOYMENT OR SERVICE. </b>&#160;All of the terms relating to the exercise, cancellation or other disposition of an option or SAR (i)&nbsp;upon a termination of employment with or service to the Company of the holder of such option or SAR, as the case may be, whether by reason of disability, retirement, death, or any other reason; or (ii)&nbsp;during a paid or unpaid leave of absence, shall be determined by the Committee and set forth in the applicable Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.4</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>NO REPRICING.</b>&#160; The Committee shall not, without the approval of the stockholders of the Company, (i)&nbsp;reduce the purchase price or base price of any previously granted option or SAR, (ii)&nbsp;cancel any previously granted option or SAR in exchange for another option or SAR with a lower purchase price or base price or (iii)&nbsp;cancel any previously granted option or SAR in exchange for cash or another award if the purchase price of such option or the base price of such SAR exceeds the Fair Market Value of a share of Common Stock on the date of such cancellation, in each case, other than in connection with a Change in Control or the adjustment provisions set forth in <u>Section&nbsp;5.7</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.5</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>NO DIVIDEND EQUIVALENTS.</b>&#160; Notwithstanding anything in an Agreement to the contrary, the holder of an option or SAR shall not be entitled to receive dividend equivalents with respect to the number of shares of Common Stock subject to such option or SAR.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">III.&#160; </font></b><b>STOCK AWARDS</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>STOCK AWARDS.</b>&#160; The Committee may, in its discretion, grant Stock Awards to such eligible persons as may be selected by the Committee.&#160; The Agreement relating to a Stock Award shall specify whether the Stock Award is a Restricted Stock Award, a Restricted Stock Unit Award or, in the case of an Other Stock Award, the type of award being granted.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>TERMS OF RESTRICTED STOCK AWARDS.</b>&#160; Restricted Stock Awards shall be subject to the following terms and conditions and shall contain such additional terms and conditions, not inconsistent with the terms of this Plan, as the Committee shall deem advisable.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Number of Shares and Other Terms.</b>&#160; The number of shares of Common Stock subject to a Restricted Stock Award and the Restriction Period, Performance Period (if any) and Performance Measures (if any) applicable to a Restricted Stock Award shall be determined by the Committee.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Vesting and Forfeiture.</b>&#160; The Agreement relating to a Restricted Stock Award shall provide, in the manner determined by the Committee, in its discretion, and subject to the</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">10<a name="12476-2-KS-03_PB_10_094717_5554"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=10,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=82323,FOLIO='10',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-03_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 25 09:50 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#160;provisions of this Plan, for the vesting of the shares of Common Stock subject to such award (i)&nbsp;if the holder of such award remains continuously in the employment of the Company during the specified Restriction Period and (ii)&nbsp;if specified Performance Measures (if any) are satisfied or met during a specified Performance Period, and for the forfeiture of the shares of Common Stock subject to such award (x)&nbsp;if the holder of such award does not remain continuously in the employment of the Company during the specified Restriction Period or (y)&nbsp;if specified Performance Measures (if any) are not satisfied or met during a specified Performance Period.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Stock Issuance.</b>&#160; During the Restriction Period, the shares of Restricted Stock shall be held by a custodian in book entry form with restrictions on such shares duly noted or, alternatively, a certificate or certificates representing a Restricted Stock Award shall be registered in the holder&#146;s name and may bear a legend, in addition to any legend which may be required pursuant to <u>Section&nbsp;5.6</u>, indicating that the ownership of the shares of Common Stock represented by such certificate is subject to the restrictions, terms and conditions of this Plan and the Agreement relating to the Restricted Stock Award.&#160; All such certificates shall be deposited with the Company, together with stock powers or other instruments of assignment (including a power of attorney), each endorsed in blank with a guarantee of signature if deemed necessary or appropriate, which would permit transfer to the Company of all or a portion of the shares of Common Stock subject to the Restricted Stock Award in the event such award is forfeited in whole or in part.&#160; Upon termination of any applicable Restriction Period (and the satisfaction or attainment of applicable Performance Measures), subject to the Company&#146;s right to require payment of any taxes in accordance with <u>Section&nbsp;5.5</u>, the restrictions shall be removed from the requisite number of any shares of Common Stock that are held in book entry form, and all certificates evidencing ownership of the requisite number of shares of Common Stock shall be delivered to the holder of such award.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Rights with Respect to Restricted Stock Awards.</b>&#160; Subject to the terms and conditions of a Restricted Stock Award, the holder of such award shall have all rights as a stockholder of the Company, including, but not limited to, voting rights, the right to receive dividends and the right to participate in any capital adjustment applicable to all holders of Common Stock; <i>provided</i>, <i>however</i>, that a distribution or dividend with respect to shares of Common Stock, including a regular cash dividend, shall be deposited with the Company and shall be subject to the same restrictions as the shares of Common Stock with respect to which such distribution was made.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.3</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>TERMS OF RESTRICTED STOCK UNIT AWARDS.</b>&#160; Restricted Stock Unit Awards shall be subject to the following terms and conditions and shall contain such additional terms and conditions, not inconsistent with the terms of this Plan, as the Committee shall deem advisable.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Number of Shares and Other Terms.</b>&#160; The number of shares of Common Stock subject to a Restricted Stock Unit Award, including the number of shares that are earned upon the attainment of any specified Performance Measures, and the Restriction Period, Performance Period (if any) and Performance Measures (if any) applicable to a Restricted Stock Unit Award shall be determined by the Committee.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Vesting and Forfeiture.</b>&#160; The Agreement relating to a Restricted Stock Unit Award shall provide, in the manner determined by the Committee, in its discretion, and subject</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">11<a name="12476-2-KS-03_PB_11_094739_455"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=11,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=770574,FOLIO='11',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-03_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 25 09:50 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">to the provisions of this Plan, for the vesting of such Restricted Stock Unit Award (i)&nbsp;if the holder of such award remains continuously in the employment of the Company during the specified Restriction Period and (ii)&nbsp;if specified Performance Measures (if any) are satisfied or met during a specified Performance Period, and for the forfeiture of the shares of Common Stock subject to such award (x)&nbsp;if the holder of such award does not remain continuously in the employment of the Company during the specified Restriction Period or (y)&nbsp;if specified Performance Measures (if any) are not satisfied or met during a specified Performance Period.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Settlement of Vested Restricted Stock Unit Awards.</b>&#160; The Agreement relating to a Restricted Stock Unit Award shall specify (i)&nbsp;whether such award may be settled in shares of Common Stock or cash or a combination thereof and (ii)&nbsp;whether the holder thereof shall be entitled to receive dividend equivalents, and, if determined by the Committee, interest on, or the deemed reinvestment of, any deferred dividend equivalents, with respect to the number of shares of Common Stock subject to such award.&#160; Any dividend equivalents with respect to Restricted Stock Units shall be subject to the same restrictions as such Restricted Stock Units.&#160; Prior to the settlement of a Restricted Stock Unit Award, the holder of such award shall have no rights as a stockholder of the Company with respect to the shares of Common Stock subject to such award.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.4</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>OTHER STOCK AWARDS.</b>&nbsp; Subject to the limitations set forth in the Plan, the Committee is authorized to grant other awards that may be denominated or payable in, valued in whole or in part by reference to, or otherwise based on, or related to, shares of Common Stock, including without limitation shares of Common Stock granted as a bonus and not subject to any vesting conditions, dividend equivalents, deferred stock units, stock purchase rights and shares of Common Stock issued in lieu of obligations of the Company to pay cash under any compensatory plan or arrangement, subject to such terms as shall be determined by the Committee.&nbsp; The Committee shall determine the terms and conditions of such awards, which may include the right to elective deferral thereof, subject to such terms and conditions as the Committee may specify in its discretion.&nbsp; Any dividend equivalent rights granted with respect to an award shall be subject to the same vesting conditions as the underlying award.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.5</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>TERMINATION OF EMPLOYMENT OR SERVICE.</b>&#160; All of the terms relating to the satisfaction of Performance Measures and the termination of the Restriction Period or Performance Period relating to a Stock Award, or any forfeiture and cancellation of such award (i)&nbsp;upon a termination of employment with or service to the Company of the holder of such award, whether by reason of disability, retirement, death, or any other reason; or (ii)&nbsp;during a paid or unpaid leave of absence, shall be determined by the Committee and set forth in the applicable Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">IV.&#160; </font></b><b>PERFORMANCE AWARDS</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>PERFORMANCE AWARDS.</b>&#160; The Committee may, in its discretion, grant Performance Awards to such eligible persons as may be selected by the Committee.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>TERMS OF PERFORMANCE AWARDS.&#160; </b>Performance Awards shall be subject to the following terms and conditions and shall contain such additional terms and conditions, not inconsistent with the terms of this Plan, as the Committee shall deem advisable.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">12<a name="12476-2-KS-03_PB_12_094754_4141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=12,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=10119,FOLIO='12',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-03_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 25 09:50 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Value of Performance Awards and Performance Measures.</b>&#160; The method of determining the value of the Performance Award and the Performance Measures and Performance Period applicable to a Performance Award shall be determined by the Committee.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Vesting and Forfeiture.</b>&#160; The Agreement relating to a Performance Award shall provide, in the manner determined by the Committee, in its discretion, and subject to the provisions of this Plan, for the vesting of such Performance Award if the specified Performance Measures are satisfied or met during the specified Performance Period and for the forfeiture of such award if the specified Performance Measures are not satisfied or met during the specified Performance Period.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Settlement of Vested Performance Awards.</b>&#160; The Agreement relating to a Performance Award shall specify whether such award may be settled in shares of Common Stock (including shares of Restricted Stock) or cash or a combination thereof.&#160; If a Performance Award is settled in shares of Restricted Stock, such shares of Restricted Stock shall be issued to the holder in book entry form or a certificate or certificates representing such Restricted Stock shall be issued in accordance with <u>Section&nbsp;3.2(c)</u>&nbsp;and the holder of such Restricted Stock shall have such rights as a stockholder of the Company as determined pursuant to <u>Section&nbsp;3.2(d)</u>.&#160; Any dividends or dividend equivalents with respect to a Performance Award shall be subject to the same restrictions as such Performance Award.&#160; Prior to the settlement of a Performance Award in shares of Common Stock, including Restricted Stock, the holder of such award shall have no rights as a stockholder of the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.3</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>TERMINATION OF EMPLOYMENT OR SERVICE.</b>&#160; All of the terms relating to the satisfaction of Performance Measures and the termination of the Performance Period relating to a Performance Award, or any forfeiture and cancellation of such award (i)&nbsp;upon a termination of employment with or service to the Company of the holder of such award, whether by reason of disability, retirement, death, or any other reason; or (ii)&nbsp;during a paid or unpaid leave of absence, shall be determined by the Committee and set forth in the applicable Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">V.&#160; </font></b><b>GENERAL</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>EFFECTIVE DATE AND TERM OF PLAN.</b>&#160; This Plan shall be submitted to the stockholders of the Company for approval within 12 months of Board approval and, if approved, shall be effective as of the date of such Board approval. This Plan shall terminate on the tenth anniversary of Board approval of the Plan, unless terminated earlier by the Board. Termination of this Plan shall not affect the terms or conditions of any award granted prior to termination. Awards hereunder may be made at any time prior to the termination of this Plan, provided that no Incentive Stock Option may be granted later than ten years after the date on which the Plan was approved by the Board.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>AMENDMENTS.</b>&#160; The Board may amend this Plan as it shall deem advisable; <i>provided</i>, <i>however</i>, that no amendment to the Plan shall be effective without the approval of the Company&#146;s stockholders if (i)&nbsp;stockholder approval is required by applicable law, rule&nbsp;or regulation, including any rule&nbsp;of NASDAQ or any other stock exchange on which the Common Stock is then traded, or (ii)&nbsp;such amendment seeks to modify the Non-Employee Director compensation limit set forth in <u>Section&nbsp;1.4</u> or the terms of <u>Section&nbsp;2.4</u> hereof; <i>provided further</i>,</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">13<a name="12476-2-KS-03_PB_13_094829_8627"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=13,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=992561,FOLIO='13',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-03_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 25 09:50 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">that no amendment may materially impair the rights of a holder of an outstanding award without the consent of such holder.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.3</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>AGREEMENT.</b>&#160; Each award under this Plan shall be evidenced by an Agreement setting forth the terms and conditions applicable to such award.&#160; No award shall be valid until an Agreement is executed by the Company and, to the extent required by the Company, executed or electronically accepted by the recipient of such award.&#160; Upon such execution or acceptance and delivery of the Agreement to the Company within the time period specified by the Company, such award shall be effective as of the effective date set forth in the Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.4</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>NON-TRANSFERABILITY.</b>&#160; No award shall be transferable other than by will, the laws of descent and distribution or pursuant to beneficiary designation procedures approved by the Company or, to the extent expressly permitted in the Agreement relating to such award, to the holder&#146;s family members, a trust or entity established by the holder for estate planning purposes, a charitable organization designated by the holder or pursuant to a domestic relations order, in each case, without consideration.&#160; Except to the extent permitted by the foregoing sentence or the Agreement relating to an award, each award may be exercised or settled during the holder&#146;s lifetime only by the holder or the holder&#146;s legal representative or similar person.&#160; Except as permitted by the second preceding sentence, no award may be sold, transferred, assigned, pledged, hypothecated, encumbered or otherwise disposed of (whether by operation of law or otherwise) or be subject to execution, attachment or similar process.&#160; Upon any attempt to so sell, transfer, assign, pledge, hypothecate, encumber or otherwise dispose of any award, such award and all rights thereunder shall immediately become null and void.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.5</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>TAX WITHHOLDING.</b>&#160; The Company shall have the right to require, prior to the issuance or delivery of any shares of Common Stock or the payment of any cash pursuant to an award made hereunder, payment by the holder of such award of any federal, state, local or other taxes which may be required to be withheld or paid in connection with such award.&#160; An Agreement may provide that (i)&nbsp;the Company shall withhold whole shares of Common Stock which would otherwise be delivered to a holder, having an aggregate Fair Market Value determined as of the date the obligation to withhold or pay taxes arises in connection with an award (the &#147;<b><i style="font-weight:bold;">Tax Date</i></b>&#148;), or withhold an amount of cash which would otherwise be payable to a holder, in the amount necessary to satisfy any such obligation or (ii)&nbsp;the holder may satisfy any such obligation by any of the following means: (A)&nbsp;a cash payment to the Company; (B)&nbsp;delivery (either actual delivery or by attestation procedures established by the Company) to the Company of previously owned whole shares of Common Stock having an aggregate Fair Market Value, determined as of the Tax Date, equal to the amount necessary to satisfy any such obligation; (C)&nbsp;authorizing the Company to withhold whole shares of Common Stock which would otherwise be delivered having an aggregate Fair Market Value, determined as of the Tax Date, or withhold an amount of cash which would otherwise be payable to a holder, in either case equal to the amount necessary to satisfy any such obligation; (D)&nbsp;in the case of the exercise of an option, a cash payment by a broker-dealer acceptable to the Company to whom the holder has submitted an irrevocable notice of exercise; (E)&nbsp;any other form of payment that may be acceptable to the Committee and specified in the Agreement or (F)&nbsp;any combination of (A), (B), (C)&nbsp;and (E), in each case to the extent set forth in the Agreement relating to the award.&#160; Shares of Common Stock to be delivered or withheld may not have an aggregate Fair Market Value in excess of the amount determined by applying the minimum statutory withholding rate (or, if permitted by the Company, such other</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">14<a name="12476-2-KS-03_PB_14_094850_7906"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=14,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=128285,FOLIO='14',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-03_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 25 09:50 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">rate as shall not cause adverse accounting consequences under the accounting rules&nbsp;then in effect, and is permitted under applicable IRS withholding rules)</font>.&#160; Any fraction of a share of Common Stock which would be required to satisfy such an obligation shall be disregarded and the remaining amount due shall be paid in cash by the holder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.6</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>RESTRICTIONS ON SHARES.</b>&#160; Each award made hereunder shall be subject to the requirement that if at any time the Company determines that the listing, registration or qualification of the shares of Common Stock subject to such award upon any securities exchange or under any law, or the consent or approval of any governmental body, or the taking of any other action is necessary or desirable as a condition of, or in connection with, the delivery of shares thereunder, such shares shall not be delivered unless such listing, registration, qualification, consent, approval or other action shall have been effected or obtained, free of any conditions not acceptable to the Company.&#160; The Company may require that certificates evidencing shares of Common Stock delivered pursuant to any award made hereunder bear a legend indicating that the sale, transfer or other disposition thereof by the holder is prohibited except in compliance with the Securities Act of 1933, as amended, and the rules&nbsp;and regulations thereunder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.7</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>ADJUSTMENT.</b>&#160;&#160; In the event of any equity restructuring (within the meaning of Financial Accounting Standards Board Accounting Standards Codification Topic 718, Compensation&#151;Stock Compensation or any successor or replacement accounting standard) that causes the per share value of shares of Common Stock to change, such as a stock dividend, stock split, spinoff, rights offering, or recapitalization through an extraordinary cash dividend, the number and class of securities available under this Plan, the terms of each outstanding option and SAR (including the number and class of securities subject to each outstanding option or SAR and the purchase price or base price per share), the terms of each outstanding Stock Award (including the number and class of securities subject thereto), and the terms of each outstanding Performance Award (including the number and class of securities subject thereto, if applicable) shall be appropriately adjusted by the Committee, such adjustments to be made in the case of outstanding options and SARs in accordance with Section&nbsp;409A of the Code.&#160; In the event of any other change in corporate capitalization, including a merger, consolidation, reorganization, or partial or complete liquidation of the Company, such equitable adjustments described in the foregoing sentence may be made as determined to be appropriate and equitable by the Committee to prevent dilution or enlargement of rights of participants. In either case, the decision of the Committee regarding any such adjustment shall be final, binding and conclusive.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.8</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>CHANGE IN CONTROL.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>For purposes of this Plan, &#147;<b><i style="font-weight:bold;">Change in Control</i></b>&#148; means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&nbsp; any Exchange Act Person becomes the owner, directly or indirectly, of </font>securities of the Company representing more than 50% of the combined voting power of the Company&#146;s then outstanding securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control shall not be deemed to occur (A)&nbsp;on account of the acquisition of securities by the Company or any Subsidiary, (B)&nbsp;on</p>
<p style="margin:0in 0in .0001pt 1.25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">15<a name="12476-2-KS-03_PB_15_094910_3736"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=15,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=27462,FOLIO='15',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-03_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 25 09:50 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt 1.25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">account of the acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any Subsidiary, (C)&nbsp;on account of the acquisition of securities of the Company by an investor, any affiliate thereof or any other Exchange Act Person that acquires the Company&#146;s securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company through the issuance of equity securities or (D)&nbsp;solely because the level of ownership held by any Exchange Act Person (the &#147;<b><i style="font-weight:bold;">Subject Person</i></b>&#148;) exceeds the designated percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the Company or any Subsidiary, and after such share acquisition, the Subject Person becomes the owner of any additional</font>  </font>voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting securities owned by the Subject Person over the designated percentage threshold, then a Change in Control shall be deemed to occur;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)&nbsp; </font>there is consummated a merger, consolidation, or similar transaction involving (directly or indirectly) the Company and, immediately after the consummation of such merger, consolidation, or similar transaction, the stockholders of the Company immediately prior thereto do not own, directly or indirectly, either (A)&nbsp;outstanding voting securities representing more than 50% of the combined outstanding voting power of the surviving entity in such merger, consolidation or similar transaction or (B)&nbsp;more than 50% of the combined outstanding voting power of the parent of the surviving entity in such merger, consolidation, or similar transaction, in each case in substantially the same proportions as their ownership of the outstanding voting securities of the Company immediately prior to such transaction;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3)&nbsp; </font>the stockholders of the Company approve or the Board approves a plan of complete dissolution or liquidation of the Company, or a complete dissolution or liquidation of the Company shall otherwise occur, except for a liquidation into a parent corporation; or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(4)&nbsp; </font>there is consummated a sale, lease, exclusive license, or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license, or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an entity, more than 50% of the combined voting power of the voting securities of which are owned by stockholders of the Company in substantially the same proportions as their ownership of the outstanding voting securities of the Company immediately prior to such sale, lease, license, or other disposition.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">16<a name="12476-2-KS-03_PB_16_094932_9621"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=16,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=988264,FOLIO='16',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-03_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 25 09:50 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">Notwithstanding the foregoing definition or any other provision of this Plan, (A)&nbsp;the term Change in Control </font>shall</font> not include a sale of assets, merger, or other transaction effected exclusively for the purpose of changing the domicile of the Company and (B)&nbsp;with respect to any nonqualified deferred compensation that becomes payable on account of the Change in Control, the transaction or event described in clause (1), (2), (3)&nbsp;or (4)&nbsp;shall also constitute a &#147;change in control event,&#148; as defined in Treasury Regulation &#167;&nbsp;1.409A-3(i)(5)&nbsp;if required in order for the payment not to violate Section&nbsp;409A of the Code.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Subject to the terms of the applicable Agreements, in the event of a Change in Control, the Board, as constituted prior to the Change in Control, may, in its discretion:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&nbsp; </font>require that (i)&nbsp;some or all outstanding options and SARs shall become exercisable in full or in part, either immediately or upon a subsequent termination of employment, (ii)&nbsp;the Restriction Period applicable to some or all outstanding Stock Awards shall lapse in full or in part, either immediately or upon a subsequent termination of employment, (iii)&nbsp;the Performance Period applicable to some or all outstanding awards shall lapse in full or in part, and (iv)&nbsp;the Performance Measures applicable to some or all outstanding awards shall be deemed to be satisfied at the target, maximum or any other level;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)&nbsp; </font>require that shares of capital stock of the corporation resulting from or succeeding to the business of the Company pursuant to such Change in Control, or a parent corporation thereof, or other property be substituted for some or all of the shares of Common Stock subject to an outstanding award, with an appropriate and equitable adjustment to such award as determined by the Board in accordance with <u>Section&nbsp;5.7</u>; and/or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3)&nbsp; require outstanding awards, in whole or in part, to be surrendered to the Company by the holder, and to be immediately cancelled by the Company, and to provide for the holder to receive (i)&nbsp;a cash payment in an amount equal to (A)&nbsp;in the case of an option or an SAR, the aggregate number of shares of Common Stock then subject to the portion of such option or SAR surrendered, whether or not vested or exercisable, multiplied by the excess, if any, of the Fair Market Value of a share of Common Stock as of the date of the Change in Control, over the purchase price or base price per share of Common Stock subject to such option or SAR, (B)&nbsp;in the case of a Stock Award or a Performance Award denominated in shares of Common Stock, the number of shares of Common Stock then subject to the portion of such award surrendered to the extent the Performance Measures applicable to such award have been satisfied or are deemed satisfied pursuant to <u>Section&nbsp;5.8(b)(1)&nbsp; </u>, whether or not vested, multiplied by the Fair Market Value of a share of Common Stock as of the date of the Change in Control, and (C)&nbsp;in the case of a Performance Award denominated in cash, the value of the Performance Award then subject to the portion of such award surrendered to the extent the Performance Measures applicable to such award have been satisfied or are deemed satisfied pursuant to <u>Section&nbsp;5.8(b)(1)&nbsp; </u>; (ii)&nbsp;shares of capital stock of the corporation resulting from or succeeding to the business of the Company</font></p>
<p style="margin:0in 0in .0001pt 1.25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">17<a name="12476-2-KS-03_PB_17_094952_8715"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=17,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=872129,FOLIO='17',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-03_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 25 09:50 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt 1.25in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">pursuant to such Change in Control, or a parent corporation thereof, having a fair market value not less than the amount determined under clause (i)&nbsp;above; or (iii)&nbsp;a combination of the payment of cash pursuant to clause (i)&nbsp;above and </font>the issuance of shares pursuant to clause (ii)&nbsp;above.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.9</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>DEFERRALS.&#160; </b>The Committee may determine that the delivery of shares of Common Stock or the payment of cash, or a combination thereof, upon the settlement of all or a portion of any award made hereunder shall be deferred, or the Committee may, in its sole discretion, approve deferral elections made by holders of awards.&#160; Deferrals shall be for such periods and upon such terms as the Committee may determine in its sole discretion, subject to the requirements of Section&nbsp;409A of the Code.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.10</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>NO RIGHT OF PARTICIPATION, EMPLOYMENT OR SERVICE.</b>&#160; Unless otherwise set forth in an employment agreement, no person shall have any right to participate in this Plan.&#160; Neither this Plan nor any award made hereunder shall confer upon any person any right to continued employment by or service with the Company, any Subsidiary or any affiliate of the Company or affect in any manner the right of the Company, any Subsidiary or any affiliate of the Company to terminate the employment or service of any person at any time without liability hereunder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.11</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>RIGHTS AS STOCKHOLDER.</b>&#160; No person shall have any right as a stockholder of the Company with respect to any shares of Common Stock or other equity security of the Company which is subject to an award hereunder unless and until such person becomes a stockholder of record with respect to such shares of Common Stock or equity security.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.12</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>DESIGNATION OF BENEFICIARY.</b>&#160; To the extent permitted by the Company, a holder of an award may file with the Company a written designation of one or more persons as such holder&#146;s beneficiary or beneficiaries (both primary and contingent) in the event of the holder&#146;s death or incapacity.&#160; To the extent an outstanding option or SAR granted hereunder is exercisable, such beneficiary or beneficiaries shall be entitled to exercise such option or SAR pursuant to procedures prescribed by the Company.&#160; Each beneficiary designation shall become effective only when filed in writing with the Company during the holder&#146;s lifetime on a form prescribed by the Company.&#160; The spouse of a married holder domiciled in a community property jurisdiction shall join in any designation of a beneficiary other than such spouse.&#160; The filing with the Company of a new beneficiary designation shall cancel all previously filed beneficiary designations.&#160; If a holder fails to designate a beneficiary, or if all designated beneficiaries of a holder predecease the holder, then each outstanding award held by such holder, to the extent vested or exercisable, shall be payable to or may be exercised by such holder&#146;s executor, administrator, legal representative or similar person.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.13</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>AWARDS SUBJECT TO CLAWBACK.&#160; </b>The awards granted under this Plan and any cash payment or shares of Common Stock delivered pursuant to such an award are subject to forfeiture, recovery by the Company or other action pursuant to the applicable Agreement or any clawback or recoupment policy which the Company may adopt from time to time, including without limitation any such policy which the Company may be required to adopt under the Dodd-Frank Wall Street Reform and Consumer Protection Act and implementing rules&nbsp;and regulations thereunder, or as otherwise required by law.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">18<a name="12476-2-KS-03_PB_18_095015_563"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=18,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=223436,FOLIO='18',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-03_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 25 09:50 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.14</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>GOVERNING LAW. </b>&#160;This Plan,<b> e</b>ach award hereunder and the related Agreement, and all determinations made and actions taken pursuant thereto, to the extent not otherwise governed by the Code or the laws of the United States, shall be governed by the laws of the State of Delaware and construed in accordance therewith without giving effect to principles of conflicts of laws.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.15</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>FOREIGN EMPLOYEES.</b>&#160; Without amending this Plan, the Committee may grant awards to eligible persons who are foreign nationals and/or reside outside of the United States on such terms and conditions different from those specified in this Plan as may in the judgment of the Committee be necessary or desirable to foster and promote achievement of the purposes of this Plan and, in furtherance of such purposes the Committee may make such modifications, amendments, procedures, subplans and the like as may be necessary or advisable to comply with provisions of laws in other countries or jurisdictions in which the Company or its Subsidiaries operates or has employees.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">19<a name="12476-2-KS-03_PB_19_095021_9497"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=19,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=164534,FOLIO='19',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-03_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 25 09:50 2019' -->

<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">A</font></b><b>PREA </b><b>T</b><b>HERAPEUTICS</b><b>,&nbsp;I</b><b>NC</b><b>.<br> 2019 S</b><b>TOCK </b><b>I</b><b>NCENTIVE </b><b>P</b><b>LAN</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">S</font></b><b>TOCK </b><b>O</b><b>PTION </b><b>A</b><b>WARD </b><b>N</b><b>OTICE</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.7in;punctuation-wrap:simple;text-indent:-1.7in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">[Name]</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 1.7in;punctuation-wrap:simple;text-indent:-1.7in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">September&nbsp;20, 2019</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In substitution of your options with respect Aprea Therapeutics AB in connection with the corporate reorganization of Aprea Therapeutics AB, you have been awarded an option to purchase shares of Common Stock of Aprea Therapeutics,&nbsp;Inc., a Delaware corporation (the <u>&#147;Company&#148;).</u> The option is granted pursuant to the terms and conditions of the Aprea Therapeutics,&nbsp;Inc. 2019 Stock Incentive Plan (the <u>&#147;Plan&#148;)</u> and the Stock Option Agreement (together with this Award Notice, the <u>&#147;Agreement&#148;).</u> Copies of the Plan and the Stock Option Agreement are attached hereto. Capitalized terms not defined herein shall have the meanings specified in the Plan or the Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Option:</font></u></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">You have been awarded a Nonstatutory Stock Option to   purchase from the Company   [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] shares of its   Common Stock, par value $0.001 per share (the &#147;Common Stock&#148;), subject to   adjustment as provided in Section&nbsp;4.2 of the Agreement.</font></p>    </td>   </tr>
<tr>
<td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Original Option Date:</font></u></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</font></p>    </td>   </tr>
<tr>
<td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exercise Price:</font></u></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]   per share, subject to adjustment as provided in <u>Section&nbsp;4.2</u> of   the Agreement.</font></p>    </td>   </tr>
<tr>
<td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vesting Schedule:</font></u></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Except as otherwise provided in the Plan, the   Agreement or any other agreement between the Company or any of its   Subsidiaries and Holder, (i)&nbsp;one quarter of the shares subject to the   Option on the Original Option Date vested on the first day of the first   calendar quarter beginning at least twelve (12) months after the Original   Option Date and (ii)&nbsp;1/36th of the shares subject to the Option on the   Original Option Date vested or shall vest thereafter on a monthly basis on   each monthly anniversary of the Original Option Date, if, and only if, you   are, and have been, continuously (except for any absence for vacation,   leave,&nbsp;etc. in accordance with the Company&#146;s or its Subsidiaries&#146;   policies): (a)&nbsp;employed by the Company or any of its Subsidiaries;   (b)&nbsp;serving as a Non-Employee Director or (c)&nbsp;providing services to   the Company or any of its Subsidiaries as an advisor or consultant, in each   case, from the date of this Agreement through and including such date.</font></p>    </td>   </tr>
<tr>
<td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exercise Limitations:</font></u></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Except as otherwise provided in the Plan, the   Agreement or any other agreement between the Company or any of its   Subsidiaries and Holder, you shall be entitled to exercise the Option, to the   extent vested, from and after the earlier to occur of an Initial Public   Offering, Acquisition or Asset Transfer (each as defined in the Company&#146;s   Amended and Restated Certificate of Incorporation).</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=20,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=519706,FOLIO='',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-05_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:47 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Expiration Date:</font></u></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Except to the extent earlier terminated pursuant to <u>Section&nbsp;2.2</u>   of the Agreement or earlier exercised pursuant to <u>Section&nbsp;2.3</u> of   the Agreement, the Option shall terminate at 5:00 p.m., U.S. Eastern time, on   September&nbsp;30, 2026.</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">APREA THERAPEUTICS,&nbsp;INC.</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Christian S. Schade</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="43%" valign="top" style="padding:0in 0in 0in 0in;width:43.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President   and Chief Executive Officer</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=21,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=193336,FOLIO='',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-05_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:47 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Acknowledgment, Acceptance and Agreement:</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By signing below and returning this Award Notice to Aprea Therapeutics,&nbsp;Inc.,&nbsp;I hereby acknowledge receipt of the Agreement and the Plan, accept the Option granted to me and agree to be bound by the terms and conditions of this Award Notice, the Agreement and the Plan.</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Holder</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:justify;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=22,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=722963,FOLIO='',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-05_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:47 2019' -->

<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">A</font></b><b>PREA </b><b>T</b><b>HERAPEUTICS</b><b>,&nbsp;I</b><b>NC</b><b>.<br> 2019 S</b><b>TOCK </b><b>I</b><b>NCENTIVE </b><b>P</b><b>LAN</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Stock Option Agreement</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In substitution of options with respect to Aprea Therapeutics AB in connection with the corporate reorganization of Aprea Therapeutics AB, Aprea Therapeutics,&nbsp;Inc., a Delaware corporation (the <u>&#147;Company&#148;),</u> hereby grants to the individual <u>(&#147;Holder&#148;)</u> named in the award notice attached hereto (the <u>&#147;Award Notice&#148;)</u> as of September&nbsp;20, 2019, pursuant to the provisions of the Aprea Therapeutics,&nbsp;Inc. 2019 Stock Incentive Plan (the &#147;Plan&#148;), an option to purchase from the Company the number of shares of the Company&#146;s Common Stock, par value $0.001 per share <u>(&#147;Common Stock&#148;),</u> set forth in the Award Notice at the price per share set forth in the Award Notice (the <u>&#147;Exercise Price&#148;)</u> (the <u>&#147;Option&#148;),</u> upon and subject to the terms and conditions set forth below, in the Award Notice and in the Plan. Capitalized terms not defined herein shall have the meanings specified in the Plan.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Option Subject to Acceptance of Agreement.</u> The Option shall be null and void unless Holder shall accept this Agreement by executing the Award Notice in the space provided therefor and returning an original execution copy of the Award Notice to the Company (or electronically accepting this Agreement within the Holder&#146;s stock plan account with the Company&#146;s stock plan administrator according to the procedures then in effect).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Time and Manner of Exercise of Option.</u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Maximum Term of Option.</u> In no event may the Option be exercised, in whole or in part, after the expiration date set forth in the Award Notice (the <u>&#147;Expiration Date&#148;).</u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Vesting and Exercise of Option.</u> The Option shall become vested and exercisable in accordance with the vesting schedule set forth in the Award Notice (the <u>&#147;Vesting Schedule&#148;)</u> if, and only if, Holder is, and has been, continuously (except for any absence for vacation, leave,&nbsp;etc. in accordance with the Company&#146;s or its Subsidiaries&#146; policies): (i)&nbsp;employed by the Company or any of its Subsidiaries; (ii)&nbsp;serving as a Non-Employee Director or (iii)&nbsp;providing services to the Company or any of its Subsidiaries as an advisor or consultant, in each case, from the Original Option Date through and including the applicable vesting date. The Option shall also be subject to the following terms and conditions:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Voluntary Resignation by Holder, Termination by Company Other Than&#160; for Cause or Termination Due to Retirement, Death or Disability.</u> If Holder&#146;s employment with the Company terminates due to (i)&nbsp;Holder&#146;s voluntary resignation, (ii)&nbsp;termination by the Company other than for Cause, (iii)&nbsp;Holder&#146;s retirement pursuant to the terms of Holder&#146;s employment agreement with the Company or applicable regulatory requirements, (iv)&nbsp;death or (v)&nbsp;termination by the Company due to physical disability, the Option, to the extent vested on the effective date of such termination of employment, may thereafter be exercised by Holder (or, in the event of Holder&#146;s death, Holder&#146;s estate) until and including the earlier to occur of (i)&nbsp;the date which is six (6)&nbsp;months after the date of such termination of employment and (ii)&nbsp;the Expiration Date. Except to the extent the Option is vested and exercisable as of Holder&#146;s termination of</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=23,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=239896,FOLIO='',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-07_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:38 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">employment under this <u>Section&nbsp;2.2(a),</u> the unvested portion of the Option shall terminate immediately upon such termination of employment.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Termination by Company for Cause.</u> If Holder&#146;s employment with the Company is terminated by the Company for Cause, then the Option, whether or not vested, shall terminate immediately upon such termination of employment.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Change in Control.</u> In the event Holder&#146;s employment is terminated by the Company without Cause or by Holder due to Good Reason, in each case, within one-year following a Change in Control, the Option, to the extent it is then outstanding, shall become fully vested and may thereafter be exercised by Holder until and including the earlier to occur of (i)&nbsp;the date which is one-year after the date of such termination of employment and (ii)&nbsp;the Expiration Date.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Definitions.</u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Cause.</u> For purposes of this Agreement, <u>&#147;Cause&#148;</u> shall mean, in the sole discretion of the Board: (1)&nbsp;conduct by Holder in connection with Holder&#146;s service to the Company or any affiliate that is fraudulent, unlawful or grossly negligent; (2)&nbsp;Holder&#146;s material breach of Holder&#146;s material responsibilities to the Company or any affiliate or Holder&#146;s willful failure to comply with reasonable and lawful directives of the Board; (3)&nbsp;Holder&#146;s material breach of Holder&#146;s material representations, warranties, covenants and/or obligations under Holder&#146;s employment agreement; (4)&nbsp;material misconduct by Holder that seriously discredits or damages the Company or any affiliate; or (5)&nbsp;nonperformance or unsatisfactory performance of Holder&#146;s material duties or responsibilities to the Company or any affiliate. In the case of each of (2), (3), (4)&nbsp;and (5)&nbsp;as determined in good faith by the Board after written notice to Holder providing reasonable details of the alleged breach and not less than a 30 day period to cure the alleged breach.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Good Reason.</u> For purposes of this Agreement, <u>&#147;Good Reason&#148;</u> shall mean that Holder has complied with the <u>&#147;Good Reason Process&#148;</u> (hereinafter defined) following the occurrence of any of the following actions undertaken by the Company without Holder&#146;s express prior written consent: (1)&nbsp;&nbsp;&nbsp;a material diminution in Holder&#146;s position, responsibilities, authority or function; (2)&nbsp;a material reduction in Holder&#146;s base salary and/or annual target bonus opportunity; <u>provided, however,</u> that Good Reason shall not be deemed to have occurred in the event of a reduction in Holder&#146;s base salary and/or annual target bonus opportunity that is pursuant to a reduction program affecting substantially all of the senior level employees of the Company and that does not adversely affect Holder to a greater extent than other similarly situated senior level employees; or (3)&nbsp;a change of more than 50 miles in the geographic location at which Holder must regularly report to work and perform services, except for required travel on business of the Company; <u>provided, however,</u> that <u>&#147;Good Reason&#148;</u> shall not include, following a Change of Control, a reduction in title, position, responsibilities or duties solely by virtue of the Company being acquired and made part of, or operating as a subsidiary or division of a larger company or organization, as long as Holder&#146;s new duties and responsibilities are reasonably commensurate with Holder&#146;s experience. For purposes of the <u>&#147;Good Reason&#148;</u> definition, <u>&#147;Good Reason Process&#148;</u> shall mean that: (v)&nbsp;Holder has reasonably determined in good faith that a <u>&#147;Good Reason&#148;</u> has occurred; (w)&nbsp;Holder has notified the Board in writing of the first occurrence</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=24,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=266879,FOLIO='',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-07_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:38 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">of the Good Reason condition within 60 days of the first occurrence of such condition; (x)&nbsp;Holder has cooperated in good faith with the efforts of the Company, for a period not less than 30 days following such notice (the <u>&#147;Cure Period&#148;),</u> to remedy the condition; (y)&nbsp;notwithstanding such efforts, the Good Reason condition continues to exist; and (z)&nbsp;Holder terminates employment within 60 days after the end of the Cure Period. If the Good Reason condition is cured by the Company during the Cure Period, Good Reason shall be deemed not to have occurred.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Method of Exercise.</u> Subject to the limitations set forth in this Agreement, the Option, to the extent vested, may be exercised by Holder (a)&nbsp;by delivering to the Company an exercise notice in the form prescribed by the Company specifying the number of whole shares of Common Stock to be purchased and by accompanying such notice with payment therefor in full (or by arranging for such payment to the Company&#146;s satisfaction) either (i)&nbsp;in cash, (ii)&nbsp;by delivery to the Company (either actual delivery or by attestation procedures established by the Company) of shares of Common Stock having an aggregate Fair Market Value, determined as of the date of exercise, equal to the aggregate purchase price payable pursuant to the Option by reason of such exercise, (iii)&nbsp;by authorizing the Company to withhold whole shares of Common Stock which would otherwise be delivered having an aggregate Fair Market Value, determined as of the date of exercise, equal to the amount necessary to satisfy such obligation, (iv)&nbsp;except as may be prohibited by applicable law, in cash by a broker-dealer acceptable to the Company to whom Holder has submitted an irrevocable notice of exercise or (v)&nbsp;by a combination of (i), (ii)&nbsp;and (iii), and (b)&nbsp;by executing such documents as the Company may reasonably request. Any fraction of a share of Common Stock which would be required to pay such purchase price shall be disregarded and the remaining amount due shall be paid in cash by Holder. No share of Common Stock or certificate representing a share of Common Stock shall be issued or delivered until the full purchase price therefor and any withholding taxes thereon, as described in <u>Section&nbsp;4.1,</u> have been paid.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Termination of Option.</u> In no event may the Option be exercised after it terminates as set forth in this <u>Section&nbsp;2.4.</u> The Option shall terminate, to the extent not earlier terminated pursuant to <u>Section&nbsp;2.2</u> or exercised pursuant to <u>Section&nbsp;2.3,</u> on the Expiration Date. Upon the termination of the Option, the Option and all rights hereunder shall immediately become null and void.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Transfer Restrictions and Investment Representations.</u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Nontransferability of Option.</u> The Option may not be transferred by Holder other than by will or the laws of descent and distribution or pursuant to the designation of one or more beneficiaries on the form prescribed by the Company. Except to the extent permitted by the foregoing sentence, (i)&nbsp;during Holder&#146;s lifetime the Option is exercisable only by Holder or Holder&#146;s legal representative, guardian or similar person and (ii)&nbsp;the Option may not be sold, transferred, assigned, pledged, hypothecated, encumbered or otherwise disposed of (whether by operation of law or otherwise) or be subject to execution, attachment or similar process. Upon any attempt to so sell, transfer, assign, pledge, hypothecate, encumber or otherwise dispose of the Option, the Option and all rights hereunder shall immediately become null and void.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=25,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=898857,FOLIO='',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-07_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:38 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Investment Representation.</u> Holder hereby represents and covenants that (a)&nbsp;any shares of Common Stock purchased upon exercise of the Option will be purchased for investment and not with a view to the distribution thereof within the meaning of the Securities Act of 1933, as amended (the <u>&#147;Securities </u>Act&#148;), unless such purchase has been registered under the Securities Act and any applicable state securities laws; (b)&nbsp;any subsequent sale of any such shares shall be made either pursuant to an effective registration statement under the Securities Act and any applicable state securities laws, or pursuant to an exemption from registration under the Securities Act and such state securities laws; and (c)&nbsp;if requested by the Company, Holder shall submit a written statement, in a form satisfactory to the Company, to the effect that such representation (x)&nbsp;is true and correct as of the date of any purchase of any shares hereunder or (y)&nbsp;is true and correct as of the date of any sale of any such shares, as applicable. As a further condition precedent to any exercise of the Option, Holder shall comply with all regulations and requirements of any regulatory authority having control of or supervision over the issuance or delivery of the shares and, in connection therewith, shall execute any documents which the Board or the Committee shall in its sole discretion deem necessary or advisable.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Additional Terms and Conditions.</u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Withholding Taxes.</u> (a)&nbsp;As a condition precedent to the issuance of Common Stock following the exercise of the Option, Holder shall, upon request by the Company, pay to the Company in addition to the purchase price of the shares, such amount as the Company may be required, under all applicable federal, state, local or other laws or regulations, to withhold and pay over as income or other withholding taxes (the <u>&#147;Required Tax&#160; Payments&#148;)</u> with respect to such exercise of the Option. If Holder shall fail to advance the Required Tax Payments after request by the Company, the Company may, in its discretion, deduct any Required Tax Payments from any amount then or thereafter payable by the Company to Holder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Holder may elect to satisfy his or her obligation to advance the Required Tax Payments by any of the following means: (i)&nbsp;a cash payment to the Company; (ii)&nbsp;delivery to the Company (either actual delivery or by attestation procedures established by the Company) of previously owned whole shares of Common Stock having an aggregate Fair Market Value, determined as of the date on which such withholding obligation arises (the <u>&#147;Tax Date&#148;),</u> equal to the Required Tax Payments; (iii)&nbsp;authorizing the Company to withhold whole shares of Common Stock which would otherwise be delivered to Holder upon exercise of the Option having an aggregate Fair Market Value, determined as of the Tax Date, equal to the Required Tax Payments; (iv)&nbsp;except as may be prohibited by applicable law, a cash payment by a broker-dealer acceptable to the Company to whom Holder has submitted an irrevocable notice of exercise or (v)&nbsp;any combination of (i), (ii)&nbsp;and (iii). Shares of Common Stock to be delivered or withheld may not have a Fair Market Value in excess of the minimum amount of the Required Tax Payments (or such higher withholding rate as permitted by the Committee and which does not result in adverse accounting consequences for the Company). Any fraction of a share of Common Stock which would be required to satisfy any such obligation shall be disregarded and the remaining amount due shall be paid in cash by Holder. No share of Common Stock or certificate representing a share of Common Stock shall be issued or delivered until the Required Tax Payments have been satisfied in full.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=26,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=628269,FOLIO='',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-07_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:38 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Adjustment.</u> In the event of any equity restructuring (within the meaning of Financial Accounting Standards Board Accounting Standards Codification Topic 718, Compensation&#151;Stock Compensation) that causes the per share value of shares of Common Stock to change, such as a stock dividend, stock split, spinoff, rights offering or recapitalization through an extraordinary dividend, the number and class of securities subject to the Option and the Exercise Price shall be equitably adjusted by the Committee, such adjustment to be made in accordance with Section&nbsp;409A of the Code. In the event of any other change in corporate capitalization, including a merger, consolidation, reorganization, or partial or complete liquidation of the Company, such equitable adjustments described in the foregoing sentence may be made as determined to be appropriate and equitable by the Committee (or, if the Company is not the surviving corporation in any such transaction, the board of directors of the surviving corporation) to prevent dilution or enlargement of rights of participants. The decision of the Committee regarding any such adjustment shall be final, binding and conclusive.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Compliance with Applicable Law.</u> The Option is subject to the condition that if the listing, registration or qualification of the shares subject to the Option upon any securities exchange or under any law, or the consent or approval of any governmental body, or the taking of any other action is necessary or desirable as a condition of, or in connection with, the purchase or issuance of shares hereunder, the Option may not be exercised, in whole or in part, and such shares may not be issued, unless such listing, registration, qualification, consent, approval or other action shall have been effected or obtained, free of any conditions not acceptable to the Company. The Company agrees to use reasonable efforts to effect or obtain any such listing, registration, qualification, consent, approval or other action.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Issuance or Delivery of Shares.</u> Upon the exercise of the Option, in whole or in part, the Company shall issue or deliver, subject to the conditions of this Agreement, the number of shares of Common Stock purchased against full payment therefor. Such issuance shall be evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company. The Company shall pay all original issue or transfer taxes and all fees and expenses incident to such issuance, except as otherwise provided in <u>Section&nbsp;4.1.</u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Option Confers No Rights as Stockholder.</u> Holder shall not be entitled to any privileges of ownership with respect to shares of Common Stock subject to the Option unless and until such shares are purchased and issued upon the exercise of the Option, in whole or in part, and Holder becomes a stockholder of record with respect to such issued shares. Holder shall not be considered a stockholder of the Company with respect to any such shares not so purchased and issued.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Option Confers No Rights to Continued Employment.</u> In no event shall the granting of the Option or its acceptance by Holder, or any provision of this Agreement or the Plan, give or be deemed to give Holder any right to continued employment by the Company, any Subsidiary or any affiliate of the Company or affect in any manner the right of the Company, any Subsidiary or any affiliate of the Company to terminate the employment of any person at any time.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.7.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Decisions of Board or Committee.</u> The Board or the Committee shall have the right to resolve all questions which may arise in connection with the Option or its</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=27,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=489127,FOLIO='',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-07_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:38 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">exercise. Any interpretation, determination or other action made or taken by the Board or the Committee regarding the Plan or this Agreement shall be final, binding and conclusive.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.8.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Successors.</u> This Agreement shall be binding upon and inure to the benefit of any successor or successors of the Company and any person or persons who shall, upon the death of Holder, acquire any rights hereunder in accordance with this Agreement or the Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.9.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Notices.</u> All notices, requests or other communications provided for in this Agreement shall be made, if to the Company, to Aprea Therapeutics,&nbsp;Inc., Attn: Treasury Department, 535 Boylston Street, Boston MA 02116, and if to Holder, to the last known mailing address of Holder contained in the records of the Company. All notices, requests or other communications provided for in this Agreement shall be made in writing either (a)&nbsp;by personal delivery, (b)&nbsp;by facsimile or electronic mail with confirmation of receipt, (c)&nbsp;by mailing in the United States mails or (d)&nbsp;by express courier service. The notice, request or other communication shall be deemed to be received upon personal delivery, upon confirmation of receipt of facsimile or electronic mail transmission or upon receipt by the party entitled thereto if by United States mail or express courier service; <u>provided, however,</u> that if a notice, request or other communication sent to the Company is not received during regular business hours, it shall be deemed to be received on the next succeeding business day of the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.10.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Governing Law.</u> This Agreement, the Option and all determinations made and actions taken pursuant hereto and thereto, to the extent not governed by the Code or the laws of the United States, shall be governed by the laws of the State of Delaware and construed in accordance therewith without giving effect to principles of conflicts of laws.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.11.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Agreement Subject to the Plan.</u> This Agreement is subject to the provisions of the Plan and shall be interpreted in accordance therewith. In the event that the provisions of this Agreement and the Plan conflict, the Plan shall control. The Holder hereby acknowledges receipt of a copy of the Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.12.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Entire Agreement.</u> This Agreement and the Plan constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and the Holder with respect to the subject matter hereof and may not be modified adversely to the Holder&#146;s interest except by means of a writing signed by the Company and the Holder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.13.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Partial Invalidity.</u> The invalidity or unenforceability of any particular provision of this Agreement shall not affect the other provisions hereof and this Agreement shall be construed in all respects as if such invalid or unenforceable provisions were omitted.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.14.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Amendment and Waiver.</u> The provisions of this Agreement may be amended or waived only by the written agreement of the Company and the Holder, and no course of conduct or failure or delay in enforcing the provisions of this Agreement shall affect the validity, binding effect or enforceability of this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=28,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=372150,FOLIO='',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-07_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:38 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.15.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Counterparts.</u> The Award Notice may be executed in two counterparts, each of which shall be deemed an original and both of which together shall constitute one and the same instrument.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=29,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=244559,FOLIO='',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-07_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:38 2019' -->

<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">A</font></b><b>PREA </b><b>T</b><b>HERAPEUTICS</b><b>,&nbsp;I</b><b>NC</b><b>.<br> 2019 S</b><b>TOCK </b><b>I</b><b>NCENTIVE </b><b>P</b><b>LAN</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">S</font></b><b>TOCK </b><b>O</b><b>PTION </b><b>A</b><b>WARD </b><b>N</b><b>OTICE</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Bernd Seizinger<br> September&nbsp;20, 2019</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with the corporate reorganization of Aprea Therapeutics AB, you have been awarded stock options representing the right to acquire shares of Common Stock of Aprea Therapeutics,&nbsp;Inc., a Delaware corporation (the <u>&#147;Company&#148;)</u> in substitution of your stock options granted under that certain agreement entered into between you, Aprea Therapeutics AB and Aprea Personal AB on September&nbsp;4, 2015. The stock options are granted pursuant to the terms and conditions of the Aprea Therapeutics,&nbsp;Inc. 2019 Stock Incentive Plan (the <u>&#147;Plan&#148;)</u> and the Stock Option Agreement (together with this Award Notice, the <u>&#147;Agreement&#148;)</u> and, subject to the payment of the subscription price by you, are immediately exercisable upon the consummation of the initial public offering of the Company&#146;s common stock. Copies of the Plan and the Stock Option Agreement are attached hereto. Capitalized terms not defined herein shall have the meanings specified in the Plan or the Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stock Options:</font></u></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">You hold stock options with respect to [   &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] shares of the   Company&#146;s Common Stock, par value $0.001 per share (the <u>&#147;Common Stock&#148;), </u>subject   to adjustment as provided in <u>Section&nbsp;4.2</u> of the Agreement.</font></p>    </td>   </tr>
<tr>
<td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Original Grant Date:</font></u></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</font></p>    </td>   </tr>
<tr>
<td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vesting Commencement Date: </font></u></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;   ]</font></p>    </td>   </tr>
<tr>
<td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Subscription Price:</font></u></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$0.12 per share, subject to adjustment as provided   in <u>Section&nbsp;4.2</u> of the Agreement.</font></p>    </td>   </tr>
<tr>
<td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vesting Schedule:</font></u></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The stock options shall vest upon the earlier to   occur of (i)&nbsp;a sale or other transfer of any part of the shares in the Company,   in a single transaction or series of transactions with one or more bona fide   third parties resulting in that such person(s)&nbsp;or entity(-ies) together   with any person or entity acting in concert with such person(s)&nbsp;or   entity(-ies) holding (whether directly or indirectly) more than 50% of the   total number of shares (in aggregate calculated on a fully diluted basis) in   the Company or other holding company of the Company&#146;s business, or the sale   of all or substantially all assets of the Company (whether through a share   transaction or an asset transaction or the granting of a license constituting   substantially the entire value of the Company or (ii)&nbsp;a listing   (including, but not limited to, a spin-off) of the shares in the Company or   other holding company of the Company&#146;s business on a stock exchange or other   marketplace for public trading in shares, whether through a primary or a   secondary offering (the events in clauses (i)&nbsp;and (ii)&nbsp;are referred   to as an &#147;Exercise Event&#148;).</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=30,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=882388,FOLIO='',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-09_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:48 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exercise Limitations:</font></u></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Except as otherwise provided in the Plan, the   Agreement or any other agreement between the Company or any of its   Subsidiaries and Holder, the Option shall only be exercisable after the   occurrence of an Exercise Event.</font></p>    </td>   </tr>
<tr>
<td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="23%" valign="top" style="padding:0in 0in 0in 0in;width:23.0%;">
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Expiration Date:</font></u></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Except to the extent earlier settled or terminated   pursuant to <u>Section&nbsp;2.2 </u>of the Agreement, the stock options shall   terminate on September&nbsp;4, 2025.</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">APREA   THERAPEUTICS,&nbsp;INC.</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=31,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=116372,FOLIO='',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-09_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:48 2019' -->

<div style="page-break-before:always;"></div>
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Acknowledgment, Acceptance and Agreement:</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By signing below and returning this Award Notice to Aprea Therapeutics,&nbsp;Inc.,&nbsp;I hereby acknowledge receipt of the Agreement and the Plan and agree to be bound by the terms and conditions of this Award Notice, the Agreement and the Plan.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Holder acknowledges and understands that (i)&nbsp;the substitution of the Stock Options issued to Holder by Aprea Personal AB with the Option under the Agreement, or the acquisition of Common Stock upon the exercise of the Option may be treated as taxable events for United States Federal, state, local and foreign income tax purposes, including the application of the passive foreign investment company rules, and may be subject to tax withholding, (ii)&nbsp;it is Holder&#146;s responsibility to consult with Holder&#146;s tax advisors with respect to the tax treatment of the substitution and acquisition, and (iii)&nbsp;the Company, Aprea Personal AB, Aprea Therapeutics AB and their respective advisors do not provide any tax advice with respect to such substitution or acquisition.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Holder</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">&nbsp;</font></i></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Signature Page&nbsp;to Stock Option Agreement</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=32,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=133293,FOLIO='',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-09_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:48 2019' -->

<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">A</font></b><b>PREA </b><b>T</b><b>HERAPEUTICS</b><b>,&nbsp;I</b><b>NC</b><b>.<br> 2019 S</b><b>TOCK </b><b>I</b><b>NCENTIVE </b><b>P</b><b>LAN</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;punctuation-wrap:simple;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Stock Option Agreement</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .05in;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In substitution of stock options with respect to Aprea Therapeutics AB in connection with the corporate reorganization of Aprea Therapeutics AB, Aprea Therapeutics,&nbsp;Inc., a Delaware corporation (the <u>&#147;Company&#148;),</u> hereby grants to the individual <u>(&#147;Holder&#148;)</u> named in the award notice attached hereto (the <u>&#147;Award Notice&#148;)</u> as of September&nbsp;20, 2019, pursuant to the provisions of the Aprea Therapeutics,&nbsp;Inc. 2019 Stock Incentive Plan (the &#147;Plan&#148;), stock options to acquire from the Company the number of shares of the Company&#146;s Common Stock, par value $0.001 per share <u>(&#147;Common Stock&#148;),</u> set forth in the Award Notice at the subscription price per share set forth in the Award Notice (the <u>&#147;Subscription Price&#148;)</u> (the <u>&#147;Option&#148;),</u> upon and subject to the terms and conditions set forth below, in the Award Notice and in the Plan. Capitalized terms not defined herein shall have the meanings specified in the Plan.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .05in;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Acceptance of Agreement.</u> This Agreement shall be null and void unless Holder shall accept this Agreement by executing the Award Notice in the space provided therefor and returning an original execution copy of the Award Notice to the Company (or electronically accepting this Agreement within the Holder&#146;s stock plan account with the Company&#146;s stock plan administrator according to the procedures then in effect).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .05in;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Time and Manner of Acquisition of Shares.</u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .05in;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Maximum Term.</u> In no event may the Option be exercised, in whole or in part, after the expiration date set forth in the Award Notice (the <u>&#147;Expiration Date&#148;).</u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .05in;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Vesting and Settlement of Option.</u> The Option shall become vested and automatically exercised upon the occurrence of an Exercise Event, as described in the Award Notice if, and only if, (i)&nbsp;Holder is, and has been, continuously (except for any absence for vacation, leave,&nbsp;etc. in accordance with the Company&#146;s or its Subsidiaries&#146; policies): (a)&nbsp;serving as a Non-Employee Director or (b)&nbsp;providing services to the Company or any of its Subsidiaries as an advisor or consultant, in each case, from the Grant Date through and including the occurrence of an Exercise Event and (ii)&nbsp;the Exercise Event occurs within four years after the termination other than for Cause of Holder&#146;s service to the Company as a Non-Employee Director or advisor or consultant. Termination shall be deemed to be for &#147;Cause&#148; if the Holder (A)&nbsp;has acted in material breach of applicable laws and regulations, (B)&nbsp;has acted in material breach of fiduciary duties in relation to the Company, (C)&nbsp;has acted in material breach of contractual undertakings in relation to the Company or its affiliates or the Company&#146;s direct or indirect shareholders, (D)&nbsp;has accepted a position in or in any other way advising, promoting or investing in a company competing with the Company, (E)&nbsp;has solicited, or attempted to solicit, employees, consultants, directors, suppliers, customers or partners of the Company away from the Company, or (F)&nbsp;has suspended payments, entered into liquidation, either voluntary or compulsory, been declared bankrupt or otherwise may be deemed to be insolvent.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">1<a name="12476-2-KS-11_PB_1_234242_1526"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=33,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=533699,FOLIO='1',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-11_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:44 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .05in;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Settlement of Option.</u> Subject to the limitations set forth in this Agreement, upon the occurrence of an Exercise Event and subject to the Holder&#146;s payment of the Subscription Price set forth in the Award Notice, the Company shall issue or deliver, subject to the conditions of this Agreement, the number of shares of Common Stock acquired hereunder. Such issuance shall occur as soon as practicable following the Exercise Event (but in any event no later than the March&nbsp;15th immediately following the year in which the Exercise Event occurs). The Subscription Price shall be paid by the Holder to the Company in cash or, if permitted by applicable law, by reducing the Holder&#146;s other compensation from the Company. No shares of Common Stock or certificate representing a share of Common Stock shall be issued or delivered until the full Subscription Price has been paid and such issuance shall be evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company. The Company shall pay all original issue or transfer taxes and all fees and expenses incident to such issuance.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .05in;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Transfer Restrictions and Investment Representations.</u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .05in;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Nontransferability of Option.</u> The Option may not be transferred by Holder other than by will or the laws of descent and distribution or pursuant to the designation of one or more beneficiaries on the form prescribed by the Company. Upon any attempt to so sell, transfer, assign, pledge, hypothecate, encumber or otherwise dispose of the Option, the Option and all rights hereunder shall immediately become null and void.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .05in;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Investment Representation.</u> Holder hereby represents and covenants that (a)&nbsp;any shares of Common Stock acquired upon the exercise of the Option will be acquired for investment and not with a view to the distribution thereof within the meaning of the Securities Act of 1933, as amended (the <u>&#147;Securities </u>Act&#148;), unless such acquisition has been registered under the Securities Act and any applicable state securities laws; (b)&nbsp;any subsequent sale of any such shares shall be made either pursuant to an effective registration statement under the Securities Act and any applicable state securities laws, or pursuant to an exemption from registration under the Securities Act and such state securities laws; and (c)&nbsp;if requested by the Company, Holder shall submit a written statement, in a form satisfactory to the Company, to the effect that such representation (x)&nbsp;is true and correct as of the date of any acquisition of any shares hereunder or (y)&nbsp;is true and correct as of the date of any sale of any such shares, as applicable. As a further condition precedent to any acquisition of shares hereunder, Holder shall comply with all regulations and requirements of any regulatory authority having control of or supervision over the issuance or delivery of the shares and, in connection therewith, shall execute any documents which the Board or the Committee shall in its sole discretion deem necessary or advisable.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .05in;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Additional Terms and Conditions.</u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .05in;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Tax Consequences.</u> The Holder acknowledges and understands that (i)&nbsp;the substitution of the Stock Options issued to Holder by Aprea Personal AB with the Option hereunder, or the acquisition of Common Stock upon the exercise of the Option hereunder may be treated as taxable events for United States Federal, state, local and foreign income tax purposes, including the application of the passive foreign investment company rules, and may be subject to tax withholding, and (ii)&nbsp;it is Holder&#146;s responsibility to consult with Holder&#146;s tax</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="12476-2-KS-11_PB_2_234254_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=34,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=152130,FOLIO='2',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-11_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:44 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .05in;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">advisors with respect to the tax treatment of the substitution and acquisition, and (iii)&nbsp;the Company, Aprea Personal AB, Aprea Therapeutics AB and their respective advisors do not provide any tax advice with respect to such substitution or acquisition.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .05in;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Adjustment.</u> In the event of any equity restructuring (within the meaning of Financial Accounting Standards Board Accounting Standards Codification Topic 718, Compensation&#151;Stock Compensation) that causes the per share value of shares of Common Stock to change, such as a stock dividend, stock split, spinoff, rights offering or recapitalization through an extraordinary dividend, the number and class of securities subject to the Agreement and the Subscription Price shall be equitably adjusted by the Committee. In the event of any other change in corporate capitalization, including a merger, consolidation, reorganization, or partial or complete liquidation of the Company, such equitable adjustments described in the foregoing sentence may be made as determined to be appropriate and equitable by the Committee (or, if the Company is not the surviving corporation in any such transaction, the board of directors of the surviving corporation) to prevent dilution or enlargement of rights of participants. The decision of the Committee regarding any such adjustment shall be final, binding and conclusive.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .05in;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Compliance with Applicable Law.</u> The Option is subject to the condition that if the listing, registration or qualification of the shares subject to the Option upon any securities exchange or under any law, or the consent or approval of any governmental body, or the taking of any other action is necessary or desirable as a condition of, or in connection with, the purchase or issuance of shares hereunder, and shares subject to this Agreement may not be issued, unless such listing, registration, qualification, consent, approval or other action shall have been effected or obtained, free of any conditions not acceptable to the Company. The Company agrees to use reasonable efforts to effect or obtain any such listing, registration, qualification, consent, approval or other action.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .05in;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Option Confers No Rights as Stockholder.</u> Holder shall not be entitled to any privileges of ownership with respect to shares of Common Stock subject to the Option unless and until such shares are acquired and issued in accordance with this Agreement, and Holder becomes a stockholder of record with respect to such issued shares. Holder shall not be considered a stockholder of the Company with respect to any such shares not so issued.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .05in;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Option Confers No Rights to Continued Service.</u> In no event shall the granting of the Option or its acceptance by Holder, or any provision of this Agreement or the Plan, give or be deemed to give Holder any right to continued service with the Company, any Subsidiary or any affiliate of the Company or affect in any manner the right of the Company, any Subsidiary or any affiliate of the Company to terminate the service of any person at any time.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .05in;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Decisions of Board or Committee.</u> The Board or the Committee shall have the right to resolve all questions which may arise in connection with the Option. Any interpretation, determination or other action made or taken by the Board or the Committee regarding the Plan or this Agreement shall be final, binding and conclusive.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .05in;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.7.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Successors.</u> This Agreement shall be binding upon and inure to the benefit of any successor or successors of the Company and any person or persons who shall,</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="12476-2-KS-11_PB_3_234325_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=35,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=951710,FOLIO='3',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-11_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:44 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .05in;punctuation-wrap:simple;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">upon the death of Holder, acquire any rights hereunder in accordance with this Agreement or the Plan.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .05in;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.8.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Notices.</u> All notices, requests or other communications provided for in this Agreement shall be made, if to the Company, to Aprea Therapeutics,&nbsp;Inc., Attn: Treasury Department, 535 Boylston Street, Boston MA 02116, and if to Holder, to the last known mailing address of Holder contained in the records of the Company. All notices, requests or other communications provided for in this Agreement shall be made in writing either (a)&nbsp;by personal delivery, (b)&nbsp;by facsimile or electronic mail with confirmation of receipt, (c)&nbsp;by mailing in the United States mails or (d)&nbsp;by express courier service. The notice, request or other communication shall be deemed to be received upon personal delivery, upon confirmation of receipt of facsimile or electronic mail transmission or upon receipt by the party entitled thereto if by United States mail or express courier service; <u>provided, however,</u> that if a notice, request or other communication sent to the Company is not received during regular business hours, it shall be deemed to be received on the next succeeding business day of the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .05in;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.9.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Governing Law.</u> This Agreement, the Option and all determinations made and actions taken pursuant hereto and thereto, to the extent not governed by the Code or the laws of the United States, shall be governed by the laws of the State of Delaware and construed in accordance therewith without giving effect to principles of conflicts of laws.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .05in;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.10.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Agreement Subject to the Plan.</u> This Agreement is subject to the provisions of the Plan and shall be interpreted in accordance therewith. In the event that the provisions of this Agreement and the Plan conflict, the Plan shall control. The Holder hereby acknowledges receipt of a copy of the Plan.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .05in;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.11.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Entire Agreement.</u> This Agreement and the Plan constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and the Holder with respect to the subject matter hereof, including, without limitation, the Agreement on Terms for Aprea AB Incentive Plan for Bernd Seizinger, and may not be modified adversely to the Holder&#146;s interest except by means of a writing signed by the Company and the Holder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .05in;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.12.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Partial Invalidity.</u> The invalidity or unenforceability of any particular provision of this Agreement shall not affect the other provisions hereof and this Agreement shall be construed in all respects as if such invalid or unenforceable provisions were omitted.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .05in;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.13.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Amendment and Waiver.</u> The provisions of this Agreement may be amended or waived only by the written agreement of the Company and the Holder, and no course of conduct or failure or delay in enforcing the provisions of this Agreement shall affect the validity, binding effect or enforceability of this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .05in;punctuation-wrap:simple;text-indent:1.0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.14.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Counterparts.</u> The Award Notice may be executed in two counterparts, each of which shall be deemed an original and both of which together shall constitute one and the same instrument.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="12476-2-KS-11_PB_4_234354_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=36,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="6",CHK=984444,FOLIO='4',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-KS-11_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:44 2019' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>7
<FILENAME>a2239779zex-10_6.htm
<DESCRIPTION>EX-10.6
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 10.6<a name="12476-2-LS-01_Exhibit10_6_081643"></a></font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Execution Copy</font></b></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EMPLOYMENT AGREEMENT</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">THIS EMPLOYMENT AGREEMENT</font></b> (the &#147;<u>Agreement</u>&#148;) between APREA THERAPEUTICS,&nbsp;INC., a Delaware corporation (the &#147;<u>Company</u>&#148;), and Christian S. Schade (the &#147;<u>Executive</u>&#148;), is made and entered into as of September&nbsp;26, 2019, and will become effective, if at all, upon the date of closing of the Company&#146;s initial public offering of stock pursuant to an effective registration statement filed under the Securities Act of 1933, as amended (the &#147;<u>Effective Date</u>&#148;).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WHEREAS,</font></b> the Company desires to continue to employ Executive on the terms and conditions contained herein;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WHEREAS,</font></b> the Company and Executive previously entered into an employment letter agreement, dated as of April&nbsp;2016 (the &#147;<u>Prior Agreement</u>&#148;);</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WHEREAS,</font></b> Executive desires to continue to be employed by and render services to the Company upon and subject to the terms, conditions and other provisions set forth herein.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NOW THEREFORE,</font></b> in consideration of the promises and mutual covenants and agreements contained herein, the adequacy of all of which consideration is hereby acknowledged, the parties hereby agree as follows:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Agreement and Term</u>.&#160;&#160; The Company hereby agrees to continue to employ Executive, and Executive hereby accepts such employment and agrees to render such services to the Company, on the terms and conditions set forth in this Agreement.&#160; Unless terminated earlier as set forth in <u>Section&nbsp;4</u> herein, Executive&#146;s employment and the term under this Agreement shall commence under the terms set forth herein on the Effective Date and shall continue until the third-anniversary of the Effective Date (the &#147;<u>Initial Term</u>&#148;) and, thereafter, shall be extended automatically for successive one-year terms, unless either Executive or the Company gives contrary written notice not less than 60&nbsp;days in advance of the expiration of the Initial Term or any succeeding term of this Agreement.&#160; The Initial Term, together with any extension thereof in accordance with this <u>Section&nbsp;1</u>, shall be referred to herein as the &#147;<u>Term</u>.&#148;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Positions and Authority</u>.&#160; Executive shall serve in the positions of President and Chief Executive Officer of the Company, or in such other positions as the parties may agree.&#160; On the Effective Date, Executive shall continue to serve as a member of the Board of Directors of the Company (the &#147;<u>Board</u>&#148;) and, during the Term, the Company shall cause Executive to be nominated for election as a member of the Board.&#160;&#160; Executive agrees to serve in the officer positions referred to in this <u>Section&nbsp;2</u> and continue to serve as a director of the Company, and to perform diligently and to the best of his abilities the duties and services appertaining to such offices as set forth in the Bylaws of the Company, as well as such additional duties and services appropriate to such offices that the parties may agree upon from time to time.&#160; Upon the Effective Date, Executive&#146;s principal place of work shall be located in Boston, Massachusetts.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">During the Term, Executive shall devote Executive&#146;s full business time and efforts to the business and affairs of the Company and its subsidiaries, provided that the Executive shall be entitled to serve as a member of the board of directors of a reasonable number of other companies, to serve on civic, charitable, educational, religious, public interest or public service boards, and to</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="7",CHK=946185,FOLIO='',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LS-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 08:19 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">manage the Executive&#146;s personal and family investments, in each case, to the extent such activities do not materially interfere with the performance of the Executive&#146;s duties and responsibilities hereunder.&#160; Executive shall not become a director of any for profit entity without first receiving the approval of the Nominating and Corporate Governance Committee of the Board.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Compensation and Benefits</u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Base Salary</u>.&#160; As compensation for Executive&#146;s performance of Executive&#146;s duties hereunder, Company shall pay to Executive an initial Base Salary of $500,000 per year, payable in accordance with the normal payroll practices of the Company.&#160; The Base Salary shall be reviewed for increases but not decreases by the Compensation Committee of the Board (the &#147;<u>Compensation Committee</u>&#148;) in good faith, based upon the Company&#146;s and Executive&#146;s performance and the Company&#146;s pay philosophy, not less often than annually.&#160; The term &#147;<u>Base Salary</u>&#148; shall refer to the Base Salary as may be in effect from time to time.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Annual Incentive Compensation</u>.&#160; During the Term, Executive shall be eligible to participate in the annual cash bonus program maintained for senior executive officers of the Company (the &#147;<u>Annual Incentive Program</u>&#148;), with an initial target annual bonus opportunity equal to 50% of Base Salary.&#160; The actual amount of the annual bonus earned by and payable to Executive for any year or portion of a year, as applicable, shall be determined upon the satisfaction of goals and objectives established by the Compensation Committee, and shall be subject to such other terms and conditions of the Annual Incentive Program as in effect from time to time.&#160; Each bonus paid under the Annual Incentive Program shall be paid to Executive no later than March&nbsp;15th&nbsp;of the calendar year following the calendar year in which the bonus is earned.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Long-Term Incentive Grants</u>.&#160; During the Term, Executive shall be eligible to participate in the long-term incentive program maintained for senior executive officers of the Company (the &#147;<u>LTI Program</u>&#148;), with a LTI Program target opportunity and LTI Program Vehicles determined by the Compensation Committee for each year of participation.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Employee Benefits and Perquisites</u>. During the Term, the Executive shall be entitled to receive all benefits and perquisites of employment generally available to other members of the Company&#146;s senior executive management, upon Executive&#146;s satisfaction of the eligibility or participation criteria therefor. The Company reserves the right to modify or terminate employee benefits and perquisites at its discretion.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Business Expenses</u>.&#160; Subject to <u>Section&nbsp;17</u>, Executive shall be reimbursed for reasonable travel and other expenses incurred in the performance of Executive&#146;s duties on behalf of the Company in a manner consistent with the Company&#146;s policies regarding such reimbursements, as may be in effect from time to time.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Termination of Employment</u>.&#160; (a)<font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Term shall end upon the first to occur of:&#160; (i)&nbsp;the expiration of the term of this Agreement pursuant to <u>Section&nbsp;1</u> hereof; (ii)&nbsp;Termination due to Disability (as defined below); (iii)&nbsp;termination of Executive&#146;s employment by the Company for any reason other than Termination due to Disability; (iv)&nbsp;Executive&#146;s death; or (v)&nbsp;termination of Executive&#146;s employment by Executive for any reason.&#160; Upon the termination of Executive&#146;s employment with the Company for any reason, Executive shall be deemed to have resigned from</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="12476-2-LS-01_PB_2_081710_6510"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="7",CHK=85774,FOLIO='2',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LS-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 08:19 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">the Board and all other positions with the Company or any of its Affiliates held by Executive as of the date immediately preceding Executive&#146;s termination of employment.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If Executive&#146;s employment ends for any reason, except as otherwise contemplated in this <u>Section&nbsp;4</u>, Executive shall cease to have any rights to salary, bonus (if any) or other benefits, other than (i)&nbsp;the earned but unpaid portion of Executive&#146;s Base Salary through the date of termination or resignation, (ii)&nbsp;&nbsp;a lump-sum payment in respect of accrued but unused vacation days at the Executive&#146;s per-business-day Base Salary rate, (iii)&nbsp;any unpaid expense or other reimbursements due to Executive, and (iv)&nbsp;any other amounts or benefits required to be paid or provided by law or under any plan, program, policy or practice of the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Termination without Cause or for Good Reason</u>.&#160; If Executive&#146;s employment hereunder shall be terminated by the Company without Cause, termination upon the expiration of the Term following notice of non-renewal by the Company, or by Executive for Good Reason, then in addition to the payments and benefits described in <u>Section&nbsp;4(b)</u>&nbsp;and subject to <u>Section&nbsp;17</u> and Executive&#146;s continuing compliance with <u>Section&nbsp;5</u> of this Agreement:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the Company shall pay Executive an amount equal to 12 months of the Executive&#146;s Base Salary (the &#147;<u>Severance Payment</u>&#148;), payable during the 12-month period following such termination of employment, with the Severance Payment commencing as soon as administratively feasible within 60 days following Executive&#146;s termination of employment and the first installment payment including the portion of the Severance Payment that was payable prior to such first payment date; <u>provided</u>, <u>however</u>, if the Executive&#146;s employment is terminated under circumstances entitling the Executive to severance under this <u>Section&nbsp;4(c)</u>&nbsp;within 12 months following a Change in Control (a &#147;<u>CIC Qualifying Termination</u>&#148;), then the Severance Payment and period to pay the Severance Payment shall be increased to 18 months;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the Company shall pay Executive an annual bonus for the year of termination equal to the Executive&#146;s target annual bonus opportunity, payable within 60 days following the Executive&#146;s termination of employment, subject to proration based on the number of days in the calendar year that have elapsed prior to the date of termination;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>following the Executive&#146;s termination of employment, the Company shall pay to the Executive (or to the Executive&#146;s family in the event of Executive&#146;s death) on a monthly basis an amount equal to the monthly amount of the Consolidated Omnibus Budget Reconciliation Act of 1985&#160; continuation coverage premium for such month, at the same level and cost to the Executive (or the Executive&#146;s family in the event of Executive&#146;s death) as immediately preceding the Executive&#146;s termination of employment, under the Company group medical plan in which the Executive participated immediately preceding the Executive&#146;s termination of employment, less the amount of the Executive&#146;s portion of such monthly premium as in effect immediately preceding the Executive&#146;s termination of employment, until the earlier of (A)&nbsp;12 months after the Executive&#146;s termination of employment and (B)&nbsp;the Executive and Executive&#146;s family have obtained other substantially similar healthcare coverage; <u>provided</u>, <u>however</u>, if the Executive experiences a CIC Qualifying Termination, then the number of months set forth in clause (A)&nbsp;of this sentence shall be increased to 18 months;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="12476-2-LS-01_PB_3_081731_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="7",CHK=890397,FOLIO='3',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LS-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 08:19 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For the avoidance of doubt, Executive shall not be entitled to the benefits described in this <u>Section&nbsp;4(c)</u>&nbsp;for a Termination due to Disability, termination of Executive&#146;s employment for Cause, Executive&#146;s death, or termination of Executive&#146;s employment by Executive for any reason other than for Good Reason.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Section&nbsp;280G</u>.&#160; Notwithstanding anything to the contrary in this Agreement, Executive expressly agrees that if the payments and benefits provided for in this Agreement or any other payments and benefits which Executive has the right to receive from the Company and its Affiliates (collectively, the &#147;<u>Payments</u>&#148;), would constitute a &#147;parachute payment&#148; (as defined in Section&nbsp;280G(b)(2)&nbsp;of the Internal Revenue Code of 1986, as amended (the &#147;<u>Code</u>&#148;)), then the Payments shall be either (i)&nbsp;reduced (but not below zero) so that the present value of the Payments will be one dollar ($1.00) less than three times Executive&#146;s &#147;base amount&#148; (as defined in Section&nbsp;280G(b)(3)&nbsp;of the Code) and so that no portion of the Payments received by Executive shall be subject to the excise tax imposed by Section&nbsp;4999 of the Code or (ii)&nbsp;paid in full, whichever produces the better net after-tax position to Executive.&#160; The reduction of Payments, if any, shall be made by reducing first any Payments that are exempt from Section&nbsp;409A of the Code and then reducing any Payments subject to Section&nbsp;409A of the Code in the reverse order in which such Payments would be paid or provided (beginning with such payment or benefit that would be made last in time and continuing, to the extent necessary, through to such payment or benefit that would be made first in time).&#160; The determination as to whether any such reduction in the Payments is necessary shall be made by the Compensation Committee in good faith.&#160; If a reduced Payment is made or provided and, through error or otherwise, that Payment, when aggregated with other payments and benefits from Company (or its Affiliates) used in determining if a &#147;parachute payment&#148; exists, exceeds one dollar ($1.00) less than three times Executive&#146;s base amount, then Executive shall immediately repay such excess to the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Certain Definitions</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Affiliate</u>&#148; shall mean all persons and entities directly or indirectly controlling, controlled by or under common control with the Company, where control may be by management authority, or an equity interest of 50% or more (direct or indirect).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Cause</u>&#148; shall mean, in the sole discretion of the Board:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>conduct by Executive in connection with Executive&#146;s service to the Company or any Affiliate that is fraudulent, unlawful or grossly negligent;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Executive&#146;s material breach of Executive&#146;s material responsibilities to the Company or any Affiliate or Executive&#146;s willful failure to comply with reasonable and lawful directives of the Board;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Executive&#146;s material breach of Executive&#146;s material representations, warranties, covenants and/or obligations under this Agreement;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>material misconduct by Executive that seriously discredits or damages the Company or any Affiliate;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="12476-2-LS-01_PB_4_081744_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="7",CHK=798358,FOLIO='4',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LS-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 08:19 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>nonperformance or unsatisfactory performance of Executive&#146;s material duties or responsibilities to the Company or any Affiliate;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vi)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>violation of the Company&#146;s or any of its Affiliates&#146; policies including, without limitation, the Company&#146;s Code of Conduct and policies on equal employment opportunity and prohibition of unlawful harassment; and/or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the conviction of, or plea of nolo contendere to, any felony or a misdemeanor involving dishonesty or fraud</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the case of each of (ii), (iii), (iv), (v)&nbsp;and (vi)&nbsp;as determined in good faith by the Board after written notice to Executive providing reasonable details of the alleged breach and not less than a 30 day period to cure the alleged breach; provided that the Company may suspend Executive&#146;s employment, access, authority and duties during such cure period.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Change in Control</u>&#148; shall have the meaning assigned to such term in the Company&#146;s 2019 Equity Incentive Plan.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Good Reason</u>&#148; shall mean that Executive has complied with the &#147;<u>Good Reason Process</u>&#148; (hereinafter defined) following the occurrence of any of the following actions undertaken by the Company without Executive&#146;s express prior written consent:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the changing of Executive&#146;s position from President and Chief Executive Officer of the Company;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>a material diminution in Executive&#146;s responsibilities, authority or function as President and Chief Executive Officer of the Company;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>a material reduction in Executive&#146;s Base Salary and/or annual target bonus opportunity; <u>provided</u>, <u>however</u>, that Good Reason shall not be deemed to have occurred in the event of a reduction in Executive&#146;s Base Salary and/or annual target bonus opportunity that is pursuant to a reduction program affecting substantially all of the senior level employees of the Company and that does not adversely affect Executive to a greater extent than other similarly situated senior level employees; or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>a change of more than 50 miles in the geographic location at which Executive must regularly report to work and perform services, except for required travel on business of the Company; <u>provided</u>, <u>however</u>, that &#147;<u>Good Reason</u>&#148; shall not include, following a Change of Control, a reduction in title, position, responsibilities or duties solely by virtue of the Company being acquired and made part of, or operating as a subsidiary or division of a larger company or organization, as long as Executive&#146;s new duties and responsibilities are reasonably commensurate with Executive&#146;s experience.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Good Reason Process</u>&#148; shall mean that:&#160; (i)&nbsp;Executive has reasonably determined in good faith that a &#147;<u>Good Reason</u>&#148; has occurred; (ii)&nbsp;Executive has notified the Board in writing of the first occurrence of the Good Reason condition within 60 days of the first occurrence of such condition; (iii)&nbsp; Executive has cooperated in good faith with the efforts of the Company, for a</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="12476-2-LS-01_PB_5_081801_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="7",CHK=541018,FOLIO='5',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LS-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 08:19 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">period not less than 30 days following such notice (the &#147;<u>Cure Period</u>&#148;), to remedy the condition; (iv)&nbsp;notwithstanding such efforts, the Good Reason condition continues to exist; and (v)&nbsp;Executive terminates employment within 60 days after the end of the Cure Period. If the Good Reason condition is cured by the Company during the Cure Period, Good Reason shall be deemed not to have occurred.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:38.25pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Termination due to Disability</u>&#148; shall mean Executive&#146;s termination of employment as a result of Executive becoming incapacitated for a period of at least 180&nbsp;days by accident, sickness or other circumstance that renders Executive mentally or physically incapable of performing the material duties as President and Chief Executive Officer of the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Restrictive Covenants</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Confidential Information and Restricted Activities.</u> By signing this Agreement, Executive represents that Executive has carefully read and considered all the terms and conditions of this Agreement, including the restraints imposed on Executive pursuant to this <u>Section&nbsp;5</u> (collectively, the &#147;<u>Restrictive Covenant Agreements</u>&#148;).&#160; For purposes of the Restrictive Covenant Agreements, &#147;<u>Company</u>&#148; shall mean the Company and its Affiliates.&#160; Executive agrees that during Executive&#146;s employment and for the twelve month period after Executive&#146;s employment with the Company ends for any reason (the &#147;<u>Restricted Period</u>&#148;) Executive will not (without the Company&#146;s prior written consent), whether as owner, partner, shareholder, director, consultant, agent, employee, co-venturer or otherwise, (i)&nbsp;engage, participate or invest in any business activity anywhere in the world that develops, markets or sells any products, or performs or sells any services that directly or indirectly target the pharmacological restoration of normal function to wild type or missense-mutant&#160; P53 in oncologic applications; provided that this shall not prohibit any investment by Executive in publicly traded stock of a company representing less than two percent of the stock of such company, (ii)&nbsp;(A)&nbsp;solicit or attempt to solicit, or (B)&nbsp;take away or divert from the Company, or attempt to take away or divert from the Company, the business or patronage of any customer(s)&nbsp;known to Executive with respect to which Executive was involved in soliciting, in each case at any time during the twelve-month period that immediately preceded the termination of Executive&#146;s employment with the Company and with which, as a result of Executive&#146;s employment with the Company, Executive had business dealings or about which Executive acquired confidential information, or (iii)&nbsp;(A)&nbsp;recruit or attempt to recruit, solicit or attempt to solicit, hire or attempt to hire, interfere with or endeavor to entice away or (B)&nbsp;assist in recruiting or attempting to recruit, soliciting or attempting to solicit, hiring or attempting to hire, interfering with or enticing away any person who is or was employed by the Company or is or was an agent, representative or consultant of the Company within the six-month period preceding the termination of Executive&#146;s employment with the Company.&#160; Executive agrees without reservation that these restraints are necessary for the reasonable and proper protection of the Company, and that each and every one of the restraints is reasonable in respect to subject matter, length of time and geographic area.&#160; Executive further understands that Executive&#146;s obligations under the Restrictive Covenant Agreements will continue in accordance with their express terms regardless of any changes in Executive&#146;s title, position, duties, salary, compensation or benefits or other terms and conditions of employment.&#160; Executive expressly consents to be bound by the provisions of the Restrictive Covenant Agreements for the benefit of the Company or any Affiliate or successor to whose employ Executive may be transferred.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="12476-2-LS-01_PB_6_081809_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="7",CHK=200992,FOLIO='6',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LS-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 08:19 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Return of Property</u>. All files, letters, notes, memoranda, reports, records, data, sketches, drawings, notebooks, layouts, charts, quotations and proposals, specification sheets, program listings, blueprints, models, prototypes, or other written, photographic or other tangible material containing Company information, whether created by Executive or others, which come into Executive&#146;s custody or possession, are the exclusive property of the Company to be used by Executive only in the performance of Executive&#146;s duties for the Company.&#160; Any property situated on the Company&#146;s premises and owned by the Company, including without limitation computers, disks and other storage media, filing cabinets or other work areas, is subject to inspection by the Company at any time with or without notice.&#160; In the event of the termination of Executive&#146;s employment for any reason, Executive will deliver to the Company all files, letters, notes, memoranda, reports, records, data, sketches, drawings, notebooks, layouts, charts, quotations and proposals, specification sheets, program listings, blueprints, models, prototypes, or other written, photographic or other tangible material containing proprietary information, and other materials of any nature pertaining to the proprietary information of the Company and to Executive&#146;s work performed for the Company, and will not take or keep in Executive&#146;s possession any of the foregoing or any copies.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Developments</u>. Executive will make full and prompt disclosure to the Company of all inventions, discoveries, designs, developments, methods, modifications, improvements, processes, algorithms, databases, computer programs, formulae, techniques, trade secrets, graphics or images, audio or visual works, and other works of authorship (collectively, &#147;<u>Developments</u>&#148;), whether or not patentable or copyrightable, that are created, made, conceived or reduced to practice by Executive (alone or jointly with others) or under Executive&#146;s direction during the period of Executive&#146;s employment.&#160; Executive acknowledges that all work performed by Executive is on a &#147;work for hire&#148; basis, and Executive hereby does assign and transfer and, to the extent any such assignment cannot be fully made at present, will assign and transfer, to the Company and its successors and assigns all Executive&#146;s right, title and interest in all Developments that (i)&nbsp;relate to the business of the Company or any customer of or supplier to the Company or any of the products or services being researched, developed, manufactured, commercialized, marketed or sold by the Company or that may be used with such products or services; or (ii)&nbsp;result from tasks assigned to Executive by the Company; or (iii)&nbsp;result from the use of premises or personal property (whether tangible or intangible) owned, leased or contracted for by the Company (&#147;<u>Company-Related Developments</u>&#148;), and all related patents, patent applications, trademarks and trademark applications, copyrights and copyright applications, and other intellectual property rights in all countries and territories worldwide and under any international conventions (&#147;<u>Intellectual Property Rights</u>&#148;).&#160; To preclude any possible uncertainty, Executive has provided on <u>Exhibit&nbsp;A</u> to this Agreement a complete list of Developments that Executive has, alone or jointly with others, conceived, developed or reduced to practice prior to the commencement of Executive&#146;s employment with the Company that Executive considers to be Executive&#146;s property or the property of third parties and that Executive wishes to have excluded from the scope of this Agreement (&#147;<u>Prior Inventions</u>&#148;).&#160; Executive has also listed on <u>Exhibit&nbsp;A</u> all patents and patent applications in which Executive is named as an inventor, other than those that have been assigned to the Company, (&#147;<u>Other Patent Rights</u>&#148;).&#160; If no such disclosure is set forth on <u>Exhibit&nbsp;A</u>, Executive represents that there are no Prior Inventions or Other Patent Rights.&#160; If, in the course of Executive&#146;s employment with the Company, Executive incorporates a Prior Invention into a Company product, process or machine or other work done for the Company, Executive hereby grants to the Company a nonexclusive, royalty-free, irrevocable, worldwide license (with the full right to sublicense) to</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="12476-2-LS-01_PB_7_081817_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="7",CHK=890563,FOLIO='7',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LS-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 08:19 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">make, have made, modify, use and sell such Prior Invention.&#160; Notwithstanding the foregoing, Executive will not incorporate, or permit to be incorporated, Prior Inventions in any Company-Related Development without the Company&#146;s prior written consent.&#160; This Agreement does not obligate Executive to assign to the Company any Development that, in the sole judgment of the Company, reasonably exercised, is developed entirely on Executive&#146;s own time and does not relate to the business efforts or research and development efforts in which, during the period of Executive&#146;s employment, the Company actually is engaged or reasonably would be engaged, and does not result from the use of premises or equipment owned or leased by the Company.&#160; However, Executive will also promptly disclose to the Company any such Developments for the purpose of determining whether they qualify for such exclusion.&#160; Executive understands that to the extent this Agreement is required to be construed in accordance with the laws of any state that precludes a requirement in an employee agreement to assign certain classes of inventions made by an employee, this <u>Section&nbsp;5(c)</u>&nbsp;will be interpreted not to apply to any invention which a court rules&nbsp;and /or the Company agrees falls within such classes.&#160; Executive also hereby waives all claims to any moral rights or other special rights which Executive may have or accrue in any Company-Related Developments.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Enforcement of Agreement; Relief.</u> Executive acknowledges and agrees that the Restrictive Covenant Agreements and all other provisions of this Agreement that are intended to endure beyond the terms of Executive&#146;s employment shall survive the termination of Executive&#146;s employment and that any violation of any of the Restrictive Covenant Agreements will cause immediate and irreparable damage to the Company, entitling it to specific performance, injunctive relief and other equitable remedies.&#160; Executive specifically consents to the issuance of temporary, preliminary, and permanent injunctive relief to enforce the terms of this Agreement.&#160; In addition to injunctive relief, the Company is entitled to all money damages available under the law.&#160; If Executive breaches any of the covenants contained in the Restrictive Covenant Agreements, in addition to the Company&#146;s other legal and equitable remedies, the Company may cease any termination benefits to which Executive might otherwise be entitled.&#160; Any such termination of the termination benefits by the Company in the event of a breach by Executive shall not affect Executive&#146;s ongoing obligations to the Company including pursuant to the Release.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Notice of Intent to Resign</u>. In the event Executive wishes to voluntarily terminate Executive&#146;s employment, Executive agrees to provide the Company with four (4)&nbsp;weeks advance written notice (the &#147;<u>Notice Period</u>&#148;) of Executive&#146;s intent to do so, and, if Executive intends or contemplates alternative employment, Executive also agrees to provide the Company with accurate information concerning such alternative employment in sufficient detail to allow the Company to meaningfully exercise its rights under this <u>Section&nbsp;5</u>. After receipt of such notice, the Company, in its sole, absolute and unreviewable discretion, may (i)&nbsp;require Executive to continue working during the Notice Period, (ii)&nbsp;relieve Executive of some or all of his work responsibilities during the Notice Period, or (iii)&nbsp;shorten the Notice Period and make Executive&#146;s voluntary termination of employment effective immediately. Notwithstanding the foregoing, if Executive provides notice of resignation, in no event shall Executive&#146;s separation of employment be considered an involuntary termination by the Company, even if the effective date of termination is accelerated by the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Non-Disparagement</u>. Executive agrees during and following the Term not to make, or cause to be made, any statement, observation, or opinion, or communicate any information</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="12476-2-LS-01_PB_8_081827_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="7",CHK=947092,FOLIO='8',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LS-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 08:19 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(whether oral or written, directly or indirectly) that (i)&nbsp;accuses or implies that the Company or its Affiliates engaged in any wrongful, unlawful or improper conduct, whether relating to Executive&#146;s employment (or the termination thereof), the business or operations of the Company or its Affiliates, or otherwise or (ii)&nbsp;disparages, impugns, or in any way reflects adversely upon the business or reputation of the Company or its Affiliates. Nothing herein will be deemed to preclude Executive from providing truthful testimony or information pursuant to subpoena, court order, or similar legal process, instituting and pursuing legal action, or engaging in other legally protected speech or activities.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Protected Rights</u>.&#160; Notwithstanding anything in this Agreement to the contrary, Executive understands that nothing contained in this Agreement limits the Executive&#146;s ability to report possible violations of law or regulation to or file a charge or complaint with the Securities and Exchange Commission, the Equal Employment Opportunity Commission, the National Labor Relations Board, the Occupational Safety and Health Administration, the Department of Justice, the Congress, any Inspector General, or any other federal, state or local governmental agency or commission or regulatory authority (collectively, &#147;<u>Government Agencies</u>&#148;). Executive further understands that this Agreement does not limit his ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company. Furthermore (i)&nbsp;Executive shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (A)&nbsp;is made (x)&nbsp;in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (y)&nbsp;solely for the purpose of reporting or investigating a suspected violation of law; or (B)&nbsp;is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal, and (ii)&nbsp;if Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, Executive may disclose a trade secret to his or her attorney and use the trade secret information in the court proceeding, if Executive files any document containing the trade secret under seal and does not disclose the trade secret except pursuant to court order.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Breach</u>.&#160; Executive acknowledges that the restrictions contained in this Agreement are fair, reasonable, and necessary for the protection of the legitimate business interests of the Company, that the Company will suffer irreparable harm in the event of any actual or threatened breach by Executive, and that it is difficult to measure in money the damages which will accrue to the Company by reason of a failure by Executive to perform any of Executive&#146;s obligations under this <u>Section&nbsp;5</u>.&#160; Accordingly, if the Company or any of its Affiliates institutes any action or proceeding to enforce their rights under this <u>Section&nbsp;5</u>, to the extent permitted by applicable law, Executive hereby waives the claim or defense that the Company or its Affiliates has an adequate remedy at law, Executive shall not claim that any such remedy at law exists, and Executive consents to the entry of a restraining order, preliminary injunction, or other preliminary, provisional, or permanent court order to enforce this Agreement, and expressly waives any security that might otherwise be required in connection with such relief.&#160; Executive also agrees that any request for such relief by the Company shall be in addition and without prejudice to any claim for monetary damages and/or other relief which the Company might elect to assert.&#160; In the event Executive violates any provision of this <u>Section&nbsp;5</u>, the Company shall be entitled to recover all costs and expenses of enforcement, including reasonable attorneys&#146; fees, and the time periods set forth above shall be extended for the period of time Executive remains in violation of the provisions.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">9<a name="12476-2-LS-01_PB_9_081835_141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="7",CHK=573719,FOLIO='9',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LS-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 08:19 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Release</u>.&#160; Executive&#146;s execution of a complete and general release of any and all of Executive&#146;s potential claims (other than for benefits and payments described in this Agreement or any other vested benefits with the Company and/or its Affiliates) against the Company, any of its Affiliates, and their respective successors and any officers, employees, agents, directors, attorneys, insurers, underwriters, and assigns of the Company or its Affiliates and/or successors, is an express condition of Executive&#146;s right to receive termination payments and benefits under this Agreement.&#160; Executive shall be required to execute within 45&nbsp;days after Executive&#146;s termination of employment (or such shorter period of time as specified by the Company) the Company&#146;s standard form of general waiver and release agreement which documents the release required under this <u>Section&nbsp;5</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Survival</u>.&#160; <u>Sections&nbsp;5</u>, <u>6</u>, <u>8</u>, <u>10</u>, and <u>12</u> - <u>17</u>, and such other provisions hereof as may so indicate shall survive and continue in full force and effect in accordance with their respective terms, notwithstanding any termination of the Term.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Notices</u>.&#160; Any notice provided for in this Agreement shall be in writing and shall be delivered (i)&nbsp;personally, (ii)&nbsp;by certified mail, postage prepaid, (iii)&nbsp;by Federal Express or other reputable courier service regularly providing evidence of delivery (with charges paid by the party sending the notice), or (iv)&nbsp;by facsimile or a PDF or similar attachment to an email, provided that such telecopy or email attachment shall be followed within one (1)&nbsp;business day by delivery of such notice pursuant to clause&nbsp;(i), (ii)&nbsp;or (iii)&nbsp;above.&#160; Any such notice to a party shall be addressed at the address set forth below (subject to the right of a party to designate a different address for itself by notice similarly given):</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">If to the Company</font></u>:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">APREA THERAPEUTICS,&nbsp;INC.</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">535 Boylston Street</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Boston, MA 02116</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention:&#160; Chair of the Compensation Committee</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">If to Executive</font></u>:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Christian S. Schade</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">At the most recent address on file with the Company</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">With a copy to</font></u>:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sidley Austin LLP</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attn:&#160; Geoffrey W. Levin,&nbsp;Esq.</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">787 Seventh Avenue</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">New York, NY 10019</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Indemnification</u>.&#160; During the Term, the Company agrees that it shall indemnify Executive and provide Executive with Directors&nbsp;&amp; Officers liability insurance coverage to the same extent that it indemnifies and/or provides such insurance coverage to Board members and other most senior executive officers of the Company</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">10<a name="12476-2-LS-01_PB_10_081902_7608"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=10,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="7",CHK=494302,FOLIO='10',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LS-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 08:19 2019' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Entire Agreement</u>.&#160; This Agreement constitutes the entire agreement and understanding between the parties with respect to the subject matter hereof and supersedes and preempts any prior understandings, agreements or representations by or between the parties, written or oral, which may have related in any manner to the subject matter hereof, including, without limitation, the Prior Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>No Conflict</u>.&#160; Executive represents and warrants that Executive is not bound by any employment contract, restrictive covenant, or other restriction preventing Executive from carrying out Executive&#146;s responsibilities for the Company, or which is in any way inconsistent with the terms of this Agreement.&#160; Executive further represents and warrants that Executive shall not disclose to the Company or induce the Company to use any confidential or proprietary information or material belonging to any previous employer or others.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Successors and Assigns</u>.&#160; This Agreement shall inure to the benefit of and be enforceable by Executive and his heirs, executors and personal representatives, and the Company and its successors and assigns.&#160; Any successor or assignee of the Company shall assume the liabilities of the Company hereunder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Governing Law</u>.&#160; This Agreement shall be governed by the internal laws (as opposed to the conflicts of law provisions) of the State of Delaware.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Amendment and Waiver</u>.&#160; The provisions of this Agreement may be amended or waived only with the prior written consent of the Company and Executive, and no course of conduct or failure or delay in enforcing the provisions of this Agreement shall affect the validity, binding effect or enforceability of this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Withholding</u>.&#160; All payments and benefits under this Agreement are subject to withholding of all applicable taxes and other required deductions.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Clawbacks</u>.&#160; The payments to Executive pursuant to this Agreement are subject to forfeiture or recovery by the Company or other action pursuant to any clawback or recoupment policy which the Company may adopt from time to time, including without limitation any such policy or provision that the Company has included in any of its existing compensation programs or plans or that it may be required to adopt under the Dodd-Frank Wall Street Reform and Consumer Protection Act and implementing rules&nbsp;and regulations thereunder, or as otherwise required by law.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Company Policies</u>.&#160; Executive shall be subject to additional Company policies as they may exist from time-to-time, including policies with regard to stock ownership by senior executives and policies regarding trading of securities.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Code Section&nbsp;409A</u>.&#160; This Agreement is intended to comply with the requirements of Section&nbsp;409A of the Code, and shall be interpreted and construed consistently with such intent.&#160; The payments to Executive pursuant to this Agreement are also intended to be exempt from Section&nbsp;409A of the Code to the maximum extent possible, under either the separation pay exemption pursuant to Treasury regulation &#167;1.409A-1(b)(9)(iii)&nbsp;or as short-term deferrals pursuant to Treasury regulation &#167;1.409A-1(b)(4), and for such purposes, each payment to Executive under this Agreement shall be considered a separate payment.&#160; In the event the terms of this Agreement</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">11<a name="12476-2-LS-03_PB_11_081943_2034"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=11,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="7",CHK=569786,FOLIO='11',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LS-03_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 08:23 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">would subject Executive to taxes or penalties under Section&nbsp;409A of the Code (&#147;<u>409A Penalties</u>&#148;), the Company and Executive shall cooperate diligently to amend the terms of the Agreement to avoid such 409A Penalties, to the extent possible.&#160; To the extent any amounts under this Agreement are payable by reference to Executive&#146;s &#147;termination of employment&#148; such term and similar terms shall be deemed to refer to Executive&#146;s &#147;separation from service,&#148; within the meaning of Section&nbsp;409A of the Code.&#160; Executive hereby agrees to be bound by the Company&#146;s determination of its &#147;specified employees&#148; (as such term is defined in Section&nbsp;409A of the Code) provided such determination is in accordance with any of the methods permitted under the regulations issued under Section&nbsp;409A of the Code.&#160; Notwithstanding any other provision in this Agreement, to the extent any payments made or contemplated hereunder constitute nonqualified deferred compensation, within the meaning of Section&nbsp;409A, then (i)&nbsp;each such payment which is conditioned upon Executive&#146;s execution of a release and which is to be paid or provided during a designated period that begins in one taxable year and ends in a second taxable year, shall be paid or provided in the later of the two taxable years and (ii)&nbsp;if Executive is a specified employee (within the meaning of Section&nbsp;409A of the Code) as of the date of Executive&#146;s separation from service, each such payment that is payable upon Executive&#146;s separation from service and would have been paid prior to the six-month anniversary of Executive&#146;s separation from service, shall be delayed until the earlier to occur of (A)&nbsp;the first day of the seventh month following Executive&#146;s separation from service or (B)&nbsp;the date of Executive&#146;s death.&#160; Any reimbursement payable to Executive pursuant to this Agreement shall be conditioned on the submission by Executive of all expense reports reasonably required by Employer under any applicable expense reimbursement policy, and shall be paid to Executive within 30&nbsp;days following receipt of such expense reports, but in no event later than the last day of the calendar year following the calendar year in which Executive incurred the reimbursable expense.&#160; Any amount of expenses eligible for reimbursement, or in-kind benefit provided, during a calendar year shall not affect the amount of expenses eligible for reimbursement, or in-kind benefit to be provided, during any other calendar year.&#160; The right to any reimbursement or in-kind benefit pursuant to this Agreement shall not be subject to liquidation or exchange for any other benefit.&#160; </font>To the extent that the Severance Payment payable hereunder is deemed to be a substitute for a payment provided under another agreement with the Executive, then the Severance Payment payable hereunder shall be paid at the same time and in the same form as such substituted payment to the extent required to comply with Section&nbsp;409A of the Code.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">12<a name="12476-2-LS-03_PB_12_081949_8146"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=12,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="7",CHK=4156,FOLIO='12',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LS-03_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 08:23 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">APREA THERAPEUTICS,&nbsp;INC.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:45.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Scott M. Coiante</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Scott M. Coiante</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Senior Vice President,   Chief Financial Officer</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXECUTIVE</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:45.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Christian S. Schade</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Christian S. Schade</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President and Chief   Executive Officer</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">13<a name="12476-2-LS-03_PB_13_082215_7091"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=13,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="7",CHK=489270,FOLIO='13',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LS-03_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 08:23 2019' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>8
<FILENAME>a2239779zex-10_7.htm
<DESCRIPTION>EX-10.7
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 10.7<a name="12476-2-MM-01_Exhibit10_7_120103"></a></font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FORM OF EMPLOYMENT AGREEMENT</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">THIS EMPLOYMENT AGREEMENT</font></b> (the &#147;<u>Agreement</u>&#148;) between APREA THERAPEUTICS,&nbsp;INC., a Delaware corporation (the &#147;<u>Company</u>&#148;), and [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] (the &#147;<u>Executive</u>&#148;), is made and entered into as of [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 20&nbsp;&nbsp;&nbsp;] (the &#147;<u>Effective Date</u>&#148;).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WHEREAS,</font></b> the Company desires to continue to employ Executive on the terms and conditions contained herein;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WHEREAS,</font></b> the Company and Executive previously entered into an employment letter agreement, dated as of [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] (the &#147;<u>Prior Agreement</u>&#148;);</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WHEREAS,</font></b> Executive desires to continue to be employed by and render services to the Company upon and subject to the terms, conditions and other provisions set forth herein.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NOW THEREFORE,</font></b> in consideration of the promises and mutual covenants and agreements contained herein, the adequacy of all of which consideration is hereby acknowledged, the parties hereby agree as follows:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Agreement and Term</u>.&#160;&#160; The Company hereby agrees to continue to employ Executive, and Executive hereby accepts such employment and agrees to render such services to the Company, on the terms and conditions set forth in this Agreement.&#160; Unless terminated earlier as set forth in <u>Section&nbsp;4</u> herein, Executive&#146;s employment and the term under this Agreement shall commence under the terms set forth herein on the Effective Date and shall continue until the third-anniversary of the Effective Date (the &#147;<u>Initial Term</u>&#148;) and, thereafter, shall be extended automatically for successive one-year terms, unless either Executive or the Company gives contrary written notice not less than 60&nbsp;days in advance of the expiration of the Initial Term or any succeeding term of this Agreement.&#160; The Initial Term, together with any extension thereof in accordance with this <u>Section&nbsp;1</u>, shall be referred to herein as the &#147;<u>Term</u>.&#148;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Positions and Authority</u>.&#160; Executive shall serve in the position of [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] of the Company, or in such other position as the parties may agree.&#160; Executive agrees to serve in the officer position referred to in this <u>Section&nbsp;2</u>, and to perform diligently and to the best of his abilities the duties and services appertaining to such offices as set forth in the Bylaws of the Company, as well as such additional duties and services appropriate to such offices that the parties may agree upon from time to time.&#160; Upon the Effective Date, Executive&#146;s principal place of work shall be located in Boston, Massachusetts.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">During the Term, Executive shall devote Executive&#146;s full business time and efforts to the business and affairs of the Company and its subsidiaries, provided that the Executive shall be entitled to serve as a member of the board of directors of a reasonable number of other companies, to serve on civic, charitable, educational, religious, public interest or public service boards, and to manage the Executive&#146;s personal and family investments, in each case, to the extent such activities do not materially interfere with the performance of the Executive&#146;s duties and responsibilities</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="8",CHK=913819,FOLIO='',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-MM-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 28 00:07 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">hereunder.&#160; Executive shall not become a director of any for profit entity without first receiving the approval of the Chief Executive Officer of the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Compensation and Benefits</u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Base Salary</u>.&#160; As compensation for Executive&#146;s performance of Executive&#146;s duties hereunder, Company shall pay to Executive an initial Base Salary of $[&nbsp;&nbsp;&nbsp;&nbsp;] per year, payable in accordance with the normal payroll practices of the Company.&#160; The Base Salary shall be reviewed for increases but not decreases by the Compensation Committee of the Board (the &#147;<u>Compensation Committee</u>&#148;) in good faith, based upon the Company&#146;s and Executive&#146;s performance and the Company&#146;s pay philosophy, not less often than annually.&#160; The term &#147;<u>Base Salary</u>&#148; shall refer to the Base Salary as may be in effect from time to time.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Annual Incentive Compensation</u>.&#160; During the Term, Executive shall be eligible to participate in the annual cash bonus program maintained for senior executive officers of the Company (the &#147;<u>Annual Incentive Program</u>&#148;), with an initial target annual bonus opportunity equal to [&nbsp;&nbsp;]% of Base Salary.&#160; The actual amount of the annual bonus earned by and payable to Executive for any year or portion of a year, as applicable, shall be determined upon the satisfaction of goals and objectives established by the Compensation Committee, and shall be subject to such other terms and conditions of the Annual Incentive Program as in effect from time to time.&#160; Each bonus paid under the Annual Incentive Program shall be paid to Executive no later than March&nbsp;15th&nbsp;of the calendar year following the calendar year in which the bonus is earned.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Long-Term Incentive Grants</u>.&#160; During the Term, Executive shall be eligible to participate in the long-term incentive program maintained for senior executive officers of the Company (the &#147;<u>LTI Program</u>&#148;), with a LTI Program target opportunity and LTI Program Vehicles determined by the Compensation Committee for each year of participation.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Employee Benefits and Perquisites</u>. During the Term, the Executive shall be entitled to receive all benefits and perquisites of employment generally available to other members of the Company&#146;s senior executive management, upon Executive&#146;s satisfaction of the eligibility or participation criteria therefor. The Company reserves the right to modify or terminate employee benefits and perquisites at its discretion.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Business Expenses</u>.&#160; Subject to <u>Section&nbsp;17</u>, Executive shall be reimbursed for reasonable travel and other expenses incurred in the performance of Executive&#146;s duties on behalf of the Company in a manner consistent with the Company&#146;s policies regarding such reimbursements, as may be in effect from time to time.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Termination of Employment</u>.&#160; (a)<font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Term shall end upon the first to occur of:&#160; (i)&nbsp;the expiration of the term of this Agreement pursuant to <u>Section&nbsp;1</u> hereof; (ii)&nbsp;Termination due to Disability (as defined below); (iii)&nbsp;termination of Executive&#146;s employment by the Company for any reason other than Termination due to Disability; (iv)&nbsp;Executive&#146;s death; or (v)&nbsp;termination of Executive&#146;s employment by Executive for any reason.&#160; Upon the termination of Executive&#146;s employment with the Company for any reason, Executive shall be deemed to have resigned from all positions with the Company or any of its Affiliates held by Executive as of the date immediately preceding Executive&#146;s termination of employment.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="12476-2-MM-01_PB_2_105603_183"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="8",CHK=698941,FOLIO='2',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-MM-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 28 00:07 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If Executive&#146;s employment ends for any reason, except as otherwise contemplated in this <u>Section&nbsp;4</u>, Executive shall cease to have any rights to salary, bonus (if any) or other benefits, other than (i)&nbsp;the earned but unpaid portion of Executive&#146;s Base Salary through the date of termination or resignation, (ii)&nbsp;&nbsp;a lump-sum payment in respect of accrued but unused vacation days at the Executive&#146;s per-business-day Base Salary rate, (iii)&nbsp;any unpaid expense or other reimbursements due to Executive, and (iv)&nbsp;any other amounts or benefits required to be paid or provided by law or under any plan, program, policy or practice of the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Termination without Cause or for Good Reason</u>.&#160; If Executive&#146;s employment hereunder shall be terminated by the Company without Cause, termination upon the expiration of the Term following notice of non-renewal by the Company, or by Executive for Good Reason, then in addition to the payments and benefits described in <u>Section&nbsp;4(b)</u>&nbsp;and subject to <u>Section&nbsp;17</u> and Executive&#146;s continuing compliance with <u>Section&nbsp;5</u> of this Agreement:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the Company shall pay Executive an amount equal to nine months of the Executive&#146;s Base Salary (the &#147;<u>Severance Payment</u>&#148;), payable during the nine-month period following such termination of employment, with the Severance Payment commencing as soon as administratively feasible within 60 days following Executive&#146;s termination of employment and the first installment payment including the portion of the Severance Payment that was payable prior to such first payment date; <u>provided</u>, <u>however</u>, if the Executive&#146;s employment is terminated under circumstances entitling the Executive to severance under this <u>Section&nbsp;4(c)</u>&nbsp;within 12 months following a Change in Control (a &#147;<u>CIC Qualifying Termination</u>&#148;), then the Severance Payment and period to pay the Severance Payment shall be increased to 12 months;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the Company shall pay Executive an annual bonus for the year of termination equal to the Executive&#146;s target annual bonus opportunity, payable within 60 days following the Executive&#146;s termination of employment, subject to proration based on the number of days in the calendar year that have elapsed prior to the date of termination;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>following the Executive&#146;s termination of employment, the Company shall pay to the Executive (or to the Executive&#146;s family in the event of Executive&#146;s death) on a monthly basis an amount equal to the monthly amount of the Consolidated Omnibus Budget Reconciliation Act of 1985&#160; continuation coverage premium for such month, at the same level and cost to the Executive (or the Executive&#146;s family in the event of Executive&#146;s death) as immediately preceding the Executive&#146;s termination of employment, under the Company group medical plan in which the Executive participated immediately preceding the Executive&#146;s termination of employment, less the amount of the Executive&#146;s portion of such monthly premium as in effect immediately preceding the Executive&#146;s termination of employment, until the earlier of (A)&nbsp;nine months after the Executive&#146;s termination of employment and (B)&nbsp;the Executive and Executive&#146;s family have obtained other substantially similar healthcare coverage; <u>provided</u>, <u>however</u>, if the Executive experiences a CIC Qualifying Termination, then the number of months set forth in clause (A)&nbsp;of this sentence shall be increased to 12 months;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For the avoidance of doubt, Executive shall not be entitled to the benefits described in this <u>Section&nbsp;4(c)</u>&nbsp;for a Termination due to Disability, termination of Executive&#146;s employment for</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="12476-2-MM-01_PB_3_105618_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="8",CHK=547159,FOLIO='3',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-MM-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 28 00:07 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cause, Executive&#146;s death, or termination of Executive&#146;s employment by Executive for any reason other than for Good Reason.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Section&nbsp;280G</u>.&#160; Notwithstanding anything to the contrary in this Agreement, Executive expressly agrees that if the payments and benefits provided for in this Agreement or any other payments and benefits which Executive has the right to receive from the Company and its Affiliates (collectively, the &#147;<u>Payments</u>&#148;), would constitute a &#147;parachute payment&#148; (as defined in Section&nbsp;280G(b)(2)&nbsp;of the Internal Revenue Code of 1986, as amended (the &#147;<u>Code</u>&#148;)), then the Payments shall be either (i)&nbsp;reduced (but not below zero) so that the present value of the Payments will be one dollar ($1.00) less than three times Executive&#146;s &#147;base amount&#148; (as defined in Section&nbsp;280G(b)(3)&nbsp;of the Code) and so that no portion of the Payments received by Executive shall be subject to the excise tax imposed by Section&nbsp;4999 of the Code or (ii)&nbsp;paid in full, whichever produces the better net after-tax position to Executive.&#160; The reduction of Payments, if any, shall be made by reducing first any Payments that are exempt from Section&nbsp;409A of the Code and then reducing any Payments subject to Section&nbsp;409A of the Code in the reverse order in which such Payments would be paid or provided (beginning with such payment or benefit that would be made last in time and continuing, to the extent necessary, through to such payment or benefit that would be made first in time).&#160; The determination as to whether any such reduction in the Payments is necessary shall be made by the Compensation Committee in good faith.&#160; If a reduced Payment is made or provided and, through error or otherwise, that Payment, when aggregated with other payments and benefits from Company (or its Affiliates) used in determining if a &#147;parachute payment&#148; exists, exceeds one dollar ($1.00) less than three times Executive&#146;s base amount, then Executive shall immediately repay such excess to the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Certain Definitions</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Affiliate</u>&#148; shall mean all persons and entities directly or indirectly controlling, controlled by or under common control with the Company, where control may be by management authority, or an equity interest of 50% or more (direct or indirect).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Cause</u>&#148; shall mean, in the sole discretion of the Board:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>conduct by Executive in connection with Executive&#146;s service to the Company or any Affiliate that is fraudulent, unlawful or grossly negligent;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Executive&#146;s material breach of Executive&#146;s material responsibilities to the Company or any Affiliate or Executive&#146;s willful failure to comply with reasonable and lawful directives of the Board;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Executive&#146;s material breach of Executive&#146;s material representations, warranties, covenants and/or obligations under this Agreement;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>material misconduct by Executive that seriously discredits or damages the Company or any Affiliate;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>nonperformance or unsatisfactory performance of Executive&#146;s material duties or responsibilities to the Company or any Affiliate;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="12476-2-MM-01_PB_4_105641_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="8",CHK=382362,FOLIO='4',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-MM-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 28 00:07 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vi)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>violation of the Company&#146;s or any of its Affiliates&#146; policies including, without limitation, the Company&#146;s Code of Conduct and policies on equal employment opportunity and prohibition of unlawful harassment; and/or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the conviction of, or plea of nolo contendere to, any felony or a misdemeanor involving dishonesty or fraud</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the case of each of (ii), (iii), (iv), (v)&nbsp;and (vi)&nbsp;as determined in good faith by the Board after written notice to Executive providing reasonable details of the alleged breach and not less than a 30 day period to cure the alleged breach; provided that the Company may suspend Executive&#146;s employment, access, authority and duties during such cure period.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Change in Control</u>&#148; shall have the meaning assigned to such term in the Company&#146;s 2019 Equity Incentive Plan.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Good Reason</u>&#148; shall mean that Executive has complied with the &#147;<u>Good Reason Process</u>&#148; (hereinafter defined) following the occurrence of any of the following actions undertaken by the Company without Executive&#146;s express prior written consent:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the changing of Executive&#146;s position from [&nbsp;&nbsp;&nbsp;&nbsp;];</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>a material diminution in Executive&#146;s responsibilities, authority or function as [&nbsp;&nbsp;&nbsp;] of the Company;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>a material reduction in Executive&#146;s Base Salary and/or annual target bonus opportunity; <u>provided</u>, <u>however</u>, that Good Reason shall not be deemed to have occurred in the event of a reduction in Executive&#146;s Base Salary and/or annual target bonus opportunity that is pursuant to a reduction program affecting substantially all of the senior level employees of the Company and that does not adversely affect Executive to a greater extent than other similarly situated senior level employees; or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>a change of more than 50 miles in the geographic location at which Executive must regularly report to work and perform services, except for required travel on business of the Company; <u>provided</u>, <u>however</u>, that &#147;<u>Good Reason</u>&#148; shall not include, following a Change of Control, a reduction in title, position, responsibilities or duties solely by virtue of the Company being acquired and made part of, or operating as a subsidiary or division of a larger company or organization, as long as Executive&#146;s new duties and responsibilities are reasonably commensurate with Executive&#146;s experience.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Good Reason Process</u>&#148; shall mean that:&#160; (i)&nbsp;Executive has reasonably determined in good faith that a &#147;<u>Good Reason</u>&#148; has occurred; (ii)&nbsp;Executive has notified the Board in writing of the first occurrence of the Good Reason condition within 60 days of the first occurrence of such condition; (iii)&nbsp; Executive has cooperated in good faith with the efforts of the Company, for a period not less than 30 days following such notice (the &#147;<u>Cure Period</u>&#148;), to remedy the condition; (iv)&nbsp;notwithstanding such efforts, the Good Reason condition continues to exist; and (v)&nbsp;Executive terminates employment within 60 days after the end of the Cure Period. If the Good Reason</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="12476-2-MM-01_PB_5_105653_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="8",CHK=1027321,FOLIO='5',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-MM-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 28 00:07 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">condition is cured by the Company during the Cure Period, Good Reason shall be deemed not to have occurred.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:38.25pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Termination due to Disability</u>&#148; shall mean Executive&#146;s termination of employment as a result of Executive becoming incapacitated for a period of at least 180&nbsp;days by accident, sickness or other circumstance that renders Executive mentally or physically incapable of performing the material duties as [&nbsp;&nbsp;&nbsp;&nbsp;].</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Restrictive Covenants</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Confidential Information and Restricted Activities.</u> By signing this Agreement, Executive represents that Executive has carefully read and considered all the terms and conditions of this Agreement, including the restraints imposed on Executive pursuant to this <u>Section&nbsp;5</u> (collectively, the &#147;<u>Restrictive Covenant Agreements</u>&#148;).&#160; For purposes of the Restrictive Covenant Agreements, &#147;<u>Company</u>&#148; shall mean the Company and its Affiliates.&#160; Executive agrees that during Executive&#146;s employment and for the twelve month period after Executive&#146;s employment with the Company ends for any reason (the &#147;<u>Restricted Period</u>&#148;) Executive will not (without the Company&#146;s prior written consent), whether as owner, partner, shareholder, director, consultant, agent, employee, co-venturer or otherwise, (i)&nbsp;engage, participate or invest in any business activity anywhere in the world that develops, markets or sells any products, or performs or sells any services that directly or indirectly target the pharmacological restoration of normal function to wild type or missense-mutant&#160; P53 in oncologic applications; provided that this shall not prohibit any investment by Executive in publicly traded stock of a company representing less than two percent of the stock of such company, (ii)&nbsp;(A)&nbsp;solicit or attempt to solicit, or (B)&nbsp;take away or divert from the Company, or attempt to take away or divert from the Company, the business or patronage of any customer(s)&nbsp;known to Executive with respect to which Executive was involved in soliciting, in each case at any time during the twelve-month period that immediately preceded the termination of Executive&#146;s employment with the Company and with which, as a result of Executive&#146;s employment with the Company, Executive had business dealings or about which Executive acquired confidential information, or (iii)&nbsp;(A)&nbsp;recruit or attempt to recruit, solicit or attempt to solicit, hire or attempt to hire, interfere with or endeavor to entice away or (B)&nbsp;assist in recruiting or attempting to recruit, soliciting or attempting to solicit, hiring or attempting to hire, interfering with or enticing away any person who is or was employed by the Company or is or was an agent, representative or consultant of the Company within the six-month period preceding the termination of Executive&#146;s employment with the Company.&#160; Executive agrees without reservation that these restraints are necessary for the reasonable and proper protection of the Company, and that each and every one of the restraints is reasonable in respect to subject matter, length of time and geographic area.&#160; Executive further understands that Executive&#146;s obligations under the Restrictive Covenant Agreements will continue in accordance with their express terms regardless of any changes in Executive&#146;s title, position, duties, salary, compensation or benefits or other terms and conditions of employment.&#160; Executive expressly consents to be bound by the provisions of the Restrictive Covenant Agreements for the benefit of the Company or any Affiliate or successor to whose employ Executive may be transferred.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Return of Property</u>. All files, letters, notes, memoranda, reports, records, data, sketches, drawings, notebooks, layouts, charts, quotations and proposals, specification sheets, program listings, blueprints, models, prototypes, or other written, photographic or other tangible</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="12476-2-MM-01_PB_6_105713_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="8",CHK=282490,FOLIO='6',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-MM-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 28 00:07 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">material containing Company information, whether created by Executive or others, which come into Executive&#146;s custody or possession, are the exclusive property of the Company to be used by Executive only in the performance of Executive&#146;s duties for the Company.&#160; Any property situated on the Company&#146;s premises and owned by the Company, including without limitation computers, disks and other storage media, filing cabinets or other work areas, is subject to inspection by the Company at any time with or without notice.&#160; In the event of the termination of Executive&#146;s employment for any reason, Executive will deliver to the Company all files, letters, notes, memoranda, reports, records, data, sketches, drawings, notebooks, layouts, charts, quotations and proposals, specification sheets, program listings, blueprints, models, prototypes, or other written, photographic or other tangible material containing proprietary information, and other materials of any nature pertaining to the proprietary information of the Company and to Executive&#146;s work performed for the Company, and will not take or keep in Executive&#146;s possession any of the foregoing or any copies.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Developments</u>. Executive will make full and prompt disclosure to the Company of all inventions, discoveries, designs, developments, methods, modifications, improvements, processes, algorithms, databases, computer programs, formulae, techniques, trade secrets, graphics or images, audio or visual works, and other works of authorship (collectively, &#147;<u>Developments</u>&#148;), whether or not patentable or copyrightable, that are created, made, conceived or reduced to practice by Executive (alone or jointly with others) or under Executive&#146;s direction during the period of Executive&#146;s employment.&#160; Executive acknowledges that all work performed by Executive is on a &#147;work for hire&#148; basis, and Executive hereby does assign and transfer and, to the extent any such assignment cannot be fully made at present, will assign and transfer, to the Company and its successors and assigns all Executive&#146;s right, title and interest in all Developments that (i)&nbsp;relate to the business of the Company or any customer of or supplier to the Company or any of the products or services being researched, developed, manufactured, commercialized, marketed or sold by the Company or that may be used with such products or services; or (ii)&nbsp;result from tasks assigned to Executive by the Company; or (iii)&nbsp;result from the use of premises or personal property (whether tangible or intangible) owned, leased or contracted for by the Company (&#147;<u>Company-Related Developments</u>&#148;), and all related patents, patent applications, trademarks and trademark applications, copyrights and copyright applications, and other intellectual property rights in all countries and territories worldwide and under any international conventions (&#147;<u>Intellectual Property Rights</u>&#148;).&#160; To preclude any possible uncertainty, Executive has provided on <u>Exhibit&nbsp;A</u> to this Agreement a complete list of Developments that Executive has, alone or jointly with others, conceived, developed or reduced to practice prior to the commencement of Executive&#146;s employment with the Company that Executive considers to be Executive&#146;s property or the property of third parties and that Executive wishes to have excluded from the scope of this Agreement (&#147;<u>Prior Inventions</u>&#148;).&#160; Executive has also listed on <u>Exhibit&nbsp;A</u> all patents and patent applications in which Executive is named as an inventor, other than those that have been assigned to the Company, (&#147;<u>Other Patent Rights</u>&#148;).&#160; If no such disclosure is set forth on <u>Exhibit&nbsp;A</u>, Executive represents that there are no Prior Inventions or Other Patent Rights.&#160; If, in the course of Executive&#146;s employment with the Company, Executive incorporates a Prior Invention into a Company product, process or machine or other work done for the Company, Executive hereby grants to the Company a nonexclusive, royalty-free, irrevocable, worldwide license (with the full right to sublicense) to make, have made, modify, use and sell such Prior Invention.&#160; Notwithstanding the foregoing, Executive will not incorporate, or permit to be incorporated, Prior Inventions in any Company-Related Development without the Company&#146;s prior written consent.&#160; This Agreement does not</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="12476-2-MM-01_PB_7_105727_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="8",CHK=373917,FOLIO='7',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-MM-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 28 00:07 2019' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">obligate Executive to assign to the Company any Development that, in the sole judgment of the Company, reasonably exercised, is developed entirely on Executive&#146;s own time and does not relate to the business efforts or research and development efforts in which, during the period of Executive&#146;s employment, the Company actually is engaged or reasonably would be engaged, and does not result from the use of premises or equipment owned or leased by the Company.&#160; However, Executive will also promptly disclose to the Company any such Developments for the purpose of determining whether they qualify for such exclusion.&#160; Executive understands that to the extent this Agreement is required to be construed in accordance with the laws of any state that precludes a requirement in an employee agreement to assign certain classes of inventions made by an employee, this <u>Section&nbsp;5(c)</u>&nbsp;will be interpreted not to apply to any invention which a court rules&nbsp;and /or the Company agrees falls within such classes.&#160; Executive also hereby waives all claims to any moral rights or other special rights which Executive may have or accrue in any Company-Related Developments.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Enforcement of Agreement; Relief.</u> Executive acknowledges and agrees that the Restrictive Covenant Agreements and all other provisions of this Agreement that are intended to endure beyond the terms of Executive&#146;s employment shall survive the termination of Executive&#146;s employment and that any violation of any of the Restrictive Covenant Agreements will cause immediate and irreparable damage to the Company, entitling it to specific performance, injunctive relief and other equitable remedies.&#160; Executive specifically consents to the issuance of temporary, preliminary, and permanent injunctive relief to enforce the terms of this Agreement.&#160; In addition to injunctive relief, the Company is entitled to all money damages available under the law.&#160; If Executive breaches any of the covenants contained in the Restrictive Covenant Agreements, in addition to the Company&#146;s other legal and equitable remedies, the Company may cease any termination benefits to which Executive might otherwise be entitled.&#160; Any such termination of the termination benefits by the Company in the event of a breach by Executive shall not affect Executive&#146;s ongoing obligations to the Company including pursuant to the Release.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Notice of Intent to Resign</u>. In the event Executive wishes to voluntarily terminate Executive&#146;s employment, Executive agrees to provide the Company with four (4)&nbsp;weeks advance written notice (the &#147;<u>Notice Period</u>&#148;) of Executive&#146;s intent to do so, and, if Executive intends or contemplates alternative employment, Executive also agrees to provide the Company with accurate information concerning such alternative employment in sufficient detail to allow the Company to meaningfully exercise its rights under this <u>Section&nbsp;5</u>. After receipt of such notice, the Company, in its sole, absolute and unreviewable discretion, may (i)&nbsp;require Executive to continue working during the Notice Period, (ii)&nbsp;relieve Executive of some or all of his work responsibilities during the Notice Period, or (iii)&nbsp;shorten the Notice Period and make Executive&#146;s voluntary termination of employment effective immediately. Notwithstanding the foregoing, if Executive provides notice of resignation, in no event shall Executive&#146;s separation of employment be considered an involuntary termination by the Company, even if the effective date of termination is accelerated by the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Non-Disparagement</u>. Executive agrees during and following the Term not to make, or cause to be made, any statement, observation, or opinion, or communicate any information (whether oral or written, directly or indirectly) that (i)&nbsp;accuses or implies that the Company or its Affiliates engaged in any wrongful, unlawful or improper conduct, whether relating to Executive&#146;s employment (or the termination thereof), the business or operations of the Company or its</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="12476-2-MM-03_PB_8_105842_808"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="8",CHK=915077,FOLIO='8',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-MM-03_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 11:22 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Affiliates, or otherwise or (ii)&nbsp;disparages, impugns, or in any way reflects adversely upon the business or reputation of the Company or its Affiliates. Nothing herein will be deemed to preclude Executive from providing truthful testimony or information pursuant to subpoena, court order, or similar legal process, instituting and pursuing legal action, or engaging in other legally protected speech or activities.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Protected Rights</u>.&#160; Notwithstanding anything in this Agreement to the contrary, Executive understands that nothing contained in this Agreement limits the Executive&#146;s ability to report possible violations of law or regulation to or file a charge or complaint with the Securities and Exchange Commission, the Equal Employment Opportunity Commission, the National Labor Relations Board, the Occupational Safety and Health Administration, the Department of Justice, the Congress, any Inspector General, or any other federal, state or local governmental agency or commission or regulatory authority (collectively, &#147;<u>Government Agencies</u>&#148;). Executive further understands that this Agreement does not limit his ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company. Furthermore (i)&nbsp;Executive shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (A)&nbsp;is made (x)&nbsp;in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (y)&nbsp;solely for the purpose of reporting or investigating a suspected violation of law; or (B)&nbsp;is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal, and (ii)&nbsp;if Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, Executive may disclose a trade secret to his or her attorney and use the trade secret information in the court proceeding, if Executive files any document containing the trade secret under seal and does not disclose the trade secret except pursuant to court order.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Breach</u>.&#160; Executive acknowledges that the restrictions contained in this Agreement are fair, reasonable, and necessary for the protection of the legitimate business interests of the Company, that the Company will suffer irreparable harm in the event of any actual or threatened breach by Executive, and that it is difficult to measure in money the damages which will accrue to the Company by reason of a failure by Executive to perform any of Executive&#146;s obligations under this <u>Section&nbsp;5</u>.&#160; Accordingly, if the Company or any of its Affiliates institutes any action or proceeding to enforce their rights under this <u>Section&nbsp;5</u>, to the extent permitted by applicable law, Executive hereby waives the claim or defense that the Company or its Affiliates has an adequate remedy at law, Executive shall not claim that any such remedy at law exists, and Executive consents to the entry of a restraining order, preliminary injunction, or other preliminary, provisional, or permanent court order to enforce this Agreement, and expressly waives any security that might otherwise be required in connection with such relief.&#160; Executive also agrees that any request for such relief by the Company shall be in addition and without prejudice to any claim for monetary damages and/or other relief which the Company might elect to assert.&#160; In the event Executive violates any provision of this <u>Section&nbsp;5</u>, the Company shall be entitled to recover all costs and expenses of enforcement, including reasonable attorneys&#146; fees, and the time periods set forth above shall be extended for the period of time Executive remains in violation of the provisions.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Release</u>.&#160; Executive&#146;s execution of a complete and general release of any and all of Executive&#146;s potential claims (other than for benefits and payments described in this Agreement or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">9<a name="12476-2-MM-03_PB_9_105854_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="8",CHK=999378,FOLIO='9',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-MM-03_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 11:22 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">any other vested benefits with the Company and/or its Affiliates) against the Company, any of its Affiliates, and their respective successors and any officers, employees, agents, directors, attorneys, insurers, underwriters, and assigns of the Company or its Affiliates and/or successors, is an express condition of Executive&#146;s right to receive termination payments and benefits under this Agreement.&#160; Executive shall be required to execute within 45&nbsp;days after Executive&#146;s termination of employment (or such shorter period of time as specified by the Company) the Company&#146;s standard form of general waiver and release agreement which documents the release required under this <u>Section&nbsp;5</u>.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Survival</u>.&#160; <u>Sections&nbsp;5</u>, <u>6</u>, <u>8</u>, <u>10</u>, and <u>12</u> - <u>17</u>, and such other provisions hereof as may so indicate shall survive and continue in full force and effect in accordance with their respective terms, notwithstanding any termination of the Term.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Notices</u>.&#160; Any notice provided for in this Agreement shall be in writing and shall be delivered (i)&nbsp;personally, (ii)&nbsp;by certified mail, postage prepaid, (iii)&nbsp;by Federal Express or other reputable courier service regularly providing evidence of delivery (with charges paid by the party sending the notice), or (iv)&nbsp;by facsimile or a PDF or similar attachment to an email, provided that such telecopy or email attachment shall be followed within one (1)&nbsp;business day by delivery of such notice pursuant to clause&nbsp;(i), (ii)&nbsp;or (iii)&nbsp;above.&#160; Any such notice to a party shall be addressed at the address set forth below (subject to the right of a party to designate a different address for itself by notice similarly given):</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">If to the Company</font></u>:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">APREA THERAPEUTICS,&nbsp;INC.</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">535 Boylston Street</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Boston, MA 02116</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention:&#160; Chief Executive Officer</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">If to Executive</font></u>:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">[&nbsp;&nbsp;&nbsp;&nbsp;]</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">At the most recent address on file with the Company</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">With a copy to</font></u>:</p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sidley Austin LLP</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attn:&#160; Geoffrey W. Levin,&nbsp;Esq.</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">787 Seventh Avenue</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">New York, NY 10019</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Indemnification</u>.&#160; During the Term, the Company agrees that it shall indemnify Executive and provide Executive with Directors&nbsp;&amp; Officers liability insurance coverage to the same extent that it indemnifies and/or provides such insurance coverage to Board members and other most senior executive officers of the Company</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Entire Agreement</u>.&#160; This Agreement constitutes the entire agreement and understanding between the parties with respect to the subject matter hereof and supersedes and preempts any prior understandings, agreements or representations by or between the parties, written or oral,</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">10<a name="12476-2-MM-03_PB_10_105939_141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=10,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="8",CHK=847679,FOLIO='10',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-MM-03_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 11:22 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">which may have related in any manner to the subject matter hereof, including, without limitation, the Prior Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>No Conflict</u>.&#160; Executive represents and warrants that Executive is not bound by any employment contract, restrictive covenant, or other restriction preventing Executive from carrying out Executive&#146;s responsibilities for the Company, or which is in any way inconsistent with the terms of this Agreement.&#160; Executive further represents and warrants that Executive shall not disclose to the Company or induce the Company to use any confidential or proprietary information or material belonging to any previous employer or others.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Successors and Assigns</u>.&#160; This Agreement shall inure to the benefit of and be enforceable by Executive and his heirs, executors and personal representatives, and the Company and its successors and assigns.&#160; Any successor or assignee of the Company shall assume the liabilities of the Company hereunder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Governing Law</u>.&#160; This Agreement shall be governed by the internal laws (as opposed to the conflicts of law provisions) of the State of Delaware.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Amendment and Waiver</u>.&#160; The provisions of this Agreement may be amended or waived only with the prior written consent of the Company and Executive, and no course of conduct or failure or delay in enforcing the provisions of this Agreement shall affect the validity, binding effect or enforceability of this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Withholding</u>.&#160; All payments and benefits under this Agreement are subject to withholding of all applicable taxes and other required deductions.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Clawbacks</u>.&#160; The payments to Executive pursuant to this Agreement are subject to forfeiture or recovery by the Company or other action pursuant to any clawback or recoupment policy which the Company may adopt from time to time, including without limitation any such policy or provision that the Company has included in any of its existing compensation programs or plans or that it may be required to adopt under the Dodd-Frank Wall Street Reform and Consumer Protection Act and implementing rules&nbsp;and regulations thereunder, or as otherwise required by law.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Company Policies</u>.&#160; Executive shall be subject to additional Company policies as they may exist from time-to-time, including policies with regard to stock ownership by senior executives and policies regarding trading of securities.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Code Section&nbsp;409A</u>.&#160; This Agreement is intended to comply with the requirements of Section&nbsp;409A of the Code, and shall be interpreted and construed consistently with such intent.&#160; The payments to Executive pursuant to this Agreement are also intended to be exempt from Section&nbsp;409A of the Code to the maximum extent possible, under either the separation pay exemption pursuant to Treasury regulation &#167;1.409A-1(b)(9)(iii)&nbsp;or as short-term deferrals pursuant to Treasury regulation &#167;1.409A-1(b)(4), and for such purposes, each payment to Executive under this Agreement shall be considered a separate payment.&#160; In the event the terms of this Agreement would subject Executive to taxes or penalties under Section&nbsp;409A of the Code (&#147;<u>409A Penalties</u>&#148;), the Company and Executive shall cooperate diligently to amend the terms of the Agreement to avoid such 409A Penalties, to the extent possible.&#160; To the extent any amounts under this Agreement</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">11<a name="12476-2-MM-03_PB_11_110000_7608"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=11,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="8",CHK=152077,FOLIO='11',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-MM-03_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 11:22 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">are payable by reference to Executive&#146;s &#147;termination of employment&#148; such term and similar terms shall be deemed to refer to Executive&#146;s &#147;separation from service,&#148; within the meaning of Section&nbsp;409A of the Code.&#160; Executive hereby agrees to be bound by the Company&#146;s determination of its &#147;specified employees&#148; (as such term is defined in Section&nbsp;409A of the Code) provided such determination is in accordance with any of the methods permitted under the regulations issued under Section&nbsp;409A of the Code.&#160; Notwithstanding any other provision in this Agreement, to the extent any payments made or contemplated hereunder constitute nonqualified deferred compensation, within the meaning of Section&nbsp;409A, then (i)&nbsp;each such payment which is conditioned upon Executive&#146;s execution of a release and which is to be paid or provided during a designated period that begins in one taxable year and ends in a second taxable year, shall be paid or provided in the later of the two taxable years and (ii)&nbsp;if Executive is a specified employee (within the meaning of Section&nbsp;409A of the Code) as of the date of Executive&#146;s separation from service, each such payment that is payable upon Executive&#146;s separation from service and would have been paid prior to the six-month anniversary of Executive&#146;s separation from service, shall be delayed until the earlier to occur of (A)&nbsp;the first day of the seventh month following Executive&#146;s separation from service or (B)&nbsp;the date of Executive&#146;s death.&#160; Any reimbursement payable to Executive pursuant to this Agreement shall be conditioned on the submission by Executive of all expense reports reasonably required by Employer under any applicable expense reimbursement policy, and shall be paid to Executive within 30&nbsp;days following receipt of such expense reports, but in no event later than the last day of the calendar year following the calendar year in which Executive incurred the reimbursable expense.&#160; Any amount of expenses eligible for reimbursement, or in-kind benefit provided, during a calendar year shall not affect the amount of expenses eligible for reimbursement, or in-kind benefit to be provided, during any other calendar year.&#160; The right to any reimbursement or in-kind benefit pursuant to this Agreement shall not be subject to liquidation or exchange for any other benefit.&#160; </font>To the extent that the Severance Payment payable hereunder is deemed to be a substitute for a payment provided under another agreement with the Executive, then the Severance Payment payable hereunder shall be paid at the same time and in the same form as such substituted payment to the extent required to comply with Section&nbsp;409A of the Code.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">12<a name="12476-2-MM-03_PB_12_110008_8146"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=12,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="8",CHK=325575,FOLIO='12',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-MM-03_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 11:22 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">APREA THERAPEUTICS,&nbsp;INC.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXECUTIVE</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">13<a name="12476-2-MM-03_PB_13_110209_7091"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=13,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="8",CHK=491976,FOLIO='13',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-MM-03_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 11:22 2019' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>9
<FILENAME>a2239779zex-10_8.htm
<DESCRIPTION>EX-10.8
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 10.8<a name="12476-2-LW_Exhibit10_8_114515"></a></font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">APREA AB</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AND</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">LARS ABRAHMS&#201;N</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade align="center" style="color:black;"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EMPLOYMENT AGREEMENT</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade align="center" style="color:black;"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="9",CHK=851767,FOLIO='',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LW_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 28 02:08 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EMPLOYMENT AGREEMENT</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Employment Agreement (the &#147;Agreement&#148;) is entered into on this day between</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Aprea AB</b>, Reg. No.&nbsp;556631-2285<b>,&#160; </b>Nobels v&#228;g 3, 171 65 Solna, a company duly incorporated and organised under the laws of Sweden, (the &#147;Company&#148;); and</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Lars Abrahms&#233;n</b>,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; ,&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; , 114 22 Stockholm (the &#147;Employee&#148;).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Commencement date and term of employment</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The employment, effective with this agreement, commenced on March&nbsp;1, 2016.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>This Agreement supersedes all other written or oral agreements between the Company, or any associated company, and the Employee due to the employment. For the purposes of this Agreement, &#147;associated company&#148; means a legal entity directly or indirectly controlling or controlled by or under common control with the Company, irrespective of the country of registration of such legal entity. For the avoidance of doubt, this agreement is an extension of a previous agreement effective December&nbsp;1, 2015, Appendix II.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Position</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Employee shall hold the position of Senior Vice President and Chief Scientific Officer and be stationed at the Company&#146;s premises in Solna or at any other premises in Sweden occupied by the Company in the future.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company and the Employee (jointly the &#147;Parties&#148;) agree that the nature of the Company&#146;s business demands flexibility and that reallocation of duties,&nbsp;etc. from time to time is a constituent part of, and a precondition for, the employment relationship between the Company and the Employee. The position of the Employee implies that the Employee may be required from time to time to travel within and outside Sweden in order to promote the Company&#146;s interests in the best possible way.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Parties agree that it is essential for the Company&#146;s business and a condition for employment with the Company that its employees are service-minded and that they conduct themselves appropriately and act in all respects as good ambassadors of the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Working hours and other engagements</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The working hours comprise forty (40) hours per week exclusive of lunch breaks.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The position demands that additional hours are worked from time to time. No compensation shall be paid for any overtime worked since this, among other things, has been taken into account when determining the salary level.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>During the employment the Employee shall not, either personally or through any legal entity, be engaged in any other employment or carry out other work without the prior written consent of the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="12476-2-LW_PB_2_234631_2143"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="9",CHK=199440,FOLIO='2',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LW_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 28 02:08 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Salary and other remuneration</b></p>
<p style="margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Employee is entitled to a monthly salary of SEK 133,333. The salary is paid in arrears before the expiry of each calendar month</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>In addition to the salary, the Employee is eligible for a bonus targeted at 25% of the adjusted base salary. For 2016 the bonus will be calculated on a 12 month calendar period, notwithstanding the effective date of this agreement. Bonus payments are discretionary and will be based on achievement of Company and individual performance objectives.&#160; The Company reserves the right to unilaterally decide on any changes to, or cessation of, the bonus.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The salary and bonus target are normally subject to annual review.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Pension and insurance</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Employee&#146;s employment will expire by the end of the month of the Employee&#146;s 67<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font>&#160;birthday.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Employee shall be entitled to insurance and pension benefits in accordance with the Company&#146;s policy as applicable from time to time.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">6</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Work equipment</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For the performance of the Employee&#146;s duties, the Company will provide such equipment that the Company deems necessary from time to time.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Expenses</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Entertainment expenses incurred in compliance with Company regulations will be reimbursed and such expenses must be itemised and verified.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Expenses drawn on the Company&#146;s credit card (which will be available for the Employee&#146;s use), which the Employee has not accounted for in accordance with the Company&#146;s expense reporting policy within one (1)&nbsp;month of the due date of the credit card company&#146;s invoice, may be set off by the Company against the Employee&#146;s net salary.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Vacation</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Employee is entitled to 30 days paid vacation per each yearly period of service to be taken at such times as agreed with the Company. Vacation pay is calculated in accordance with the Company&#146;s policy as applicable from time to time. In conjunction with the cessation of employment, any vacation pay paid in advance may be deducted from any salary and accrued vacation pay.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">9</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Sick pay</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In case of absence due to sickness the provisions of the Swedish Sick Pay Act (Sw<i>. lagen om sjukl&#246;n (1991:1047)</i>) shall apply.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="12476-2-LW_PB_3_234647_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="9",CHK=140047,FOLIO='3',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LW_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 28 02:08 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">10</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Personal data and data security</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Employee confirms that the Company has informed the Employee of the Company&#146;s use of employees&#146; personal data in accordance with the provisions of the Swedish Personal Data Protection Act (Sw<i>. personuppgiftslagen (1998:204)</i>).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Employee agrees to comply with the Company&#146;s policies regarding the use of the Company&#146;s computers, e-mail system,&nbsp;Internet services and other software programs. The Employee is aware and acknowledges that the Company has unrestricted access to all material and e-mail correspondence and an overview of Internet usage that is saved in or performed via the Company&#146;s data system.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">11</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Intellectual property rights</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">11.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>All rights to any material and results within the Company&#180;s field of activity, and all intellectual property rights related thereto (including but not limited to all patents, inventions, trademark rights, copyrights and neighbouring rights, rights in computer software and database rights, design rights, trade secrets and know-how including the rights to registrations or applications for these rights), which are made, written, designed or produced by the Employee during the term of the Employee&#146;s employment shall exclusively vest in the Company, irrespective of whether such material, results and intellectual property rights are produced during or outside of working hours and irrespective of whether produced with the use of the Company&#180;s facilities. This applies irrespective of whether the Employee has been instructed or has taken own initiative to produce such material, results and intellectual property rights. The Company shall have a right to freely develop and alter such material, results and intellectual property rights and to licence and assign them to third parties, with or without a reference to the Employee&#146;s name. The above-mentioned right of the Company includes any patent applications for inventions that have been created through the participation of the Employee and which have been filed within six (6)&nbsp;months after the termination of the employment, provided that the invention falls within the Company&#146;s field of activity and that the Employee is unable to reasonably prove that the invention was made after the employment was terminated.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Employee shall not be entitled, directly or indirectly, to use or exploit the material, results and intellectual property rights referred to in Section&nbsp;11 in any manner whatsoever during the term of the Employee&#146;s employment or thereafter unless obtaining a written confirmation regarding such use from the Company. However, this Section&nbsp;11.2 shall not prevent the Employee from using such material, results and/or intellectual property rights to the extent such use is necessary for the Employee&#146;s performance of his/her normal contractual duties under this Agreement. In cases of uncertainty, the Employee shall always obtain written approval from the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Employee confirms that the compensation agreed in this Agreement for the performed work is reasonable and constitutes satisfactory compensation for the assignment in Section&nbsp;11 and hereby waives any claims for royalty or other compensation for the assignment, exploitation or use of the assigned rights, to the extent permitted by law. The Employee furthermore undertakes not to make any claims against the Company&#146;s, its subsidiaries&#146; or successors&#146; ownership or other rights to the assigned rights in Section&nbsp;11.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="12476-2-LW_PB_4_234702_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="9",CHK=111375,FOLIO='4',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LW_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 28 02:08 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Employee agrees to inform the Company in writing of all inventions, ideas, discoveries, developments or improvements wholly or partially made by the Employee during the term of the Employee&#146;s employment. Such information shall be given continuously, and without delay after creation.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.5</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Employee agrees and undertakes without any additional compensation, during or after the Employee&#146;s employment, to execute all such deeds and documents that, in the Company&#146;s sole discretion, are necessary or desirable in order for the Company to be able to protect, register, maintain and in any other way fully enjoy the Company&#146;s rights referred to under this Section&nbsp;11.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">12</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Confidentiality</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">12.1</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Employee shall not at any time during the employment or thereafter utilise, reproduce or disclose to any person or firm or company (unless required by the performance of the Employee&#146;s duties under this Agreement or by law) any information in respect of the Company or any of its associated companies that the Employee will gain access to through the employment and that the Company reasonably wishes to keep confidential.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">12.2</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Confidential information shall include, without limitation and in whatever form, information concerning the Company and its associated companies:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 71.3pt;text-indent:-.3in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>business, current and potential business relations, business plans, strategic plans investigations, finances and financial statements;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 71.3pt;text-indent:-.3in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>employees, terms of employment and other human resources matters;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 71.3pt;text-indent:-.3in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>customers, suppliers and distributors;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 71.3pt;text-indent:-.3in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>prices and pricing policies, marketing, sales methods, contracts;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 71.3pt;text-indent:-.3in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>trade secrets, know-how, methods, software programs, new products and services, safety devises,&nbsp;etc.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Confidential information shall not include information that enters the public domain, other than through a breach by the Employee of an obligation of confidentiality owed to the Company or its associated companies.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Employee agrees that the Employee will not, during the employment with the Company, improperly use or disclose any proprietary information or trade secrets of any former or concurrent employer or other person or entity. Further, the Employee will not bring into the Company any proprietary information or trade secret of any such employer, person or entity unless consented to in writing by such employer, person or entity.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">13</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Non-competition</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Parties hereby agree that the Employee in the course of the employment will gain access to company-specific trade secrets that cannot be protected through patents or other similar registrations and which may cause the Company considerable harm if used for the benefit of a competing business. The Parties furthermore agree that it is a precondition for the Employee&#146;s employment that the Company can disclose such</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="12476-2-LW_PB_5_234725_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="9",CHK=450747,FOLIO='5',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LW_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 28 02:08 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .7in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">information to the Employee in the knowledge that it will not be used to engage in or promote a business that competes with the Company&#146;s (or any associated company&#146;s) business. The Employee thus agrees to refrain, during the term of this Agreement and for a period of six (6)&nbsp;months after its termination, directly or indirectly, whether alone or as a partner, officer, employee, director or executive or consultant, from engaging, participating or investing in any business activity anywhere in the world that develops, markets or sells any products, or performs or sells any services that directly or indirectly target the pharmacological restoration of normal function to wild type or missense-mutant p53 in oncologic applications&nbsp;.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Subject to the exceptions stated below in this section, the Company shall, as compensation for the inconvenience that the existing non-competition covenant causes the Employee after the expiry of the employment, pay the Employee per month the difference between the Employee&#146;s average monthly remuneration (both fixed and variable) paid by the Company during the twelve (12) months preceding the time of termination of the employment and the (lower) salary which the Employee earns, or reasonably could have earned from any new employment or proceeds of any business activity. However, the monthly compensation payable by the Company shall never exceed sixty (60) per cent of the Employee&#146;s average monthly remuneration as set out above during the restrictive period of the non-competition covenant. For the avoidance of doubt, if the Employee, despite reasonable efforts to minimise the Employee&#146;s loss of income, does not obtain new employment or is not engaged in any business activity after the employment with the Company has terminated, the Company shall pay the Employee per month sixty (60) per cent of the Employee&#146;s average monthly remuneration as set out above during the restrictive period of this non-competition covenant. The right to compensation according to this section presupposes that there is a causal relationship between the Employee&#146;s undertaking in accordance with the non-competition covenant and the loss of income that is caused by its application. Compensation shall not be paid in case of the Employee&#146;s breach of this non-competition covenant.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>After the expiry of employment, the Employee is obliged to inform the Company of the level of the Employee&#146;s current salary from any new employment or proceeds of any business activity. Such written information shall be provided to the Company no later than on the 15<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font>&#160;day of each month. In the absence of such written information, it shall be understood that the Employee has not suffered any loss of income with regards to the concerned month, but Section&nbsp;13.1 shall still apply.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Compensation according to Section&nbsp;13.2 above shall not be paid during any period for which the Employee receives severance pay from the Company or if the employment expires: (i)&nbsp;due to the Employee&#146;s retirement; or (ii)&nbsp;due to cancellation of this Agreement with immediate effect or the Company&#146;s immediate dismissal of the Employee.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.5</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>During the term of employment, as well as in the event of either party&#146;s termination of the employment and as long as the non-competition covenant is in force, the Company may unilaterally subject to one (1)&nbsp;month&#146;s prior written notice either limit the application of the non-competition covenant or completely release the Employee from the non-competition covenant. In the event of a full release from the non-competition</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="12476-2-LW_PB_6_234747_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="9",CHK=686421,FOLIO='6',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LW_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 28 02:08 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .7in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">covenant, the Company shall be released from the obligation to pay compensation in accordance with Section&nbsp;13.2 above.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">14</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Non-solicitation</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>During the term of this Agreement and for six (6)&nbsp;months following the termination thereof, the Employee shall not, directly or indirectly, engage or participate in professional contacts with anyone who, during the twelve (12) months preceding the termination of the Employee&#146;s employment, has been a customer or client of the Company or any of its associated companies or is a potential customer or client who has been actively approached by the Company or any of its associated companies, with the intention of persuading such customer or client/potential customer or client to change the business relationship, to cease to do business with or to refrain from initiating a business relationship with the Company or any of its associated companies. The Company may through written notification release the Employee from this obligation in specific cases.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>During the term of this Agreement and for six (6)&nbsp;months following the termination thereof, the Employee shall not directly or indirectly solicit or attempt to solicit employees of the Company, or any of its associated companies, or use their services for any means other than for the benefit of the Company. The Company may through written notification release the Employee from this obligation in specific cases.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">15</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Termination of employment</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>This Agreement may be terminated by the Company subject to six (6)&nbsp;months&#146; notice and by the Employee subject to six (6)&nbsp;months&#146; notice. In the event the employment agreement extends beyond the end of the month of the Employee&#146;s 67<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font>&#160;birthday, such extension shall be governed by provisions of the Swedish Employment Protection Act.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company is entitled to terminate the employment summarily without notice in the event of the Employee&#146;s gross misconduct or material breach of any of the terms of this Agreement. However, notwithstanding such termination, the Employee&#146;s obligations pursuant to Section&nbsp;11 (Intellectual Property Rights), Section&nbsp;12 (Confidentiality), Section&nbsp;13 (Non-competition) and Section&nbsp;14 (Non-solicitation) shall remain in full force and effect.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>In conjunction with the expiry of the employment, the Employee shall deliver up to the Company all reports, papers, correspondence, documents and any other materials (including copies thereof) supplied, or entrusted to the Employee or in the Employee&#146;s possession in connection with this employment and/or relating to the Company, its associated companies and/or their businesses and the same shall at all times remain the sole property of the Company or the associated company as the case may be.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">16</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Amendments</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Agreement may only be amended by an instrument in writing duly executed by the Parties.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="12476-2-LW_PB_7_234757_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="9",CHK=397699,FOLIO='7',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LW_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 28 02:08 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">17</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Governing law</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17.1</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>This Agreement shall be governed by and construed in accordance with the laws of Sweden.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17.2</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Any dispute, controversy or claim arising out of or in connection with this Agreement, or the breach, termination or invalidity thereof, shall be settled by arbitration in accordance with the Swedish Arbitration Act (Sw<i>. lagen (1999:116) om skiljef&#246;rfarande</i>).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17.3</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The arbitral tribunal shall be composed by one (1)&nbsp;arbitrator. In case the Parties are unable to agree on the appointment of the arbitrator, the arbitrator shall be appointed by the Arbitration Institute of the Stockholm Chamber of Commerce.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17.4</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Parties undertake and agree that all arbitral proceedings conducted by reference to this arbitration section will be kept strictly confidential. This confidentiality undertaking shall cover all information disclosed in the course of such arbitral proceedings, as well as any decision or award that is made or declared during the proceedings. Information covered by this confidentiality undertaking may not, in any form, be disclosed to a third party without the written consent of both Parties hereto. Notwithstanding the foregoing, a party shall not be prevented from disclosing such information in order to secure its interests against the other Party in connection with a dispute or if required to do so by law, any applicable stock exchange regulations or the regulations of any other recognised market place.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 50.45pt;text-indent:-50.45pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17.5</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Company shall, unless the arbitrator holds that the Employee has caused the initiation of arbitral proceedings without reasonable cause, pay the arbitrator&#146;s fees and, if applicable, the fees of the Arbitration Institute of the Stockholm Chamber of Commerce. Other costs, such as legal fees, shall be apportioned between the Parties in accordance with the provisions of the Swedish Code of Judicial Procedure (Sw. <i>r&#228;tteg&#229;ngsbalken (1942:740)</i>).</p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade align="center" style="color:black;"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Agreement has been duly executed in two (2)&nbsp;original copies of which each of the Parties has received one.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Place:   Stockholm</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:   September 7, 2016</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Aprea   AB</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:46.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Christian S. Schade</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ </font>Lars Abrahms&#233;n</p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Christian   S, Schade</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CEO</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Lars   Abrahms&#233;n</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="12476-2-LW_PB_8_234818_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="9",CHK=976050,FOLIO='8',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LW_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 28 02:08 2019' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>10
<FILENAME>a2239779zex-10_9.htm
<DESCRIPTION>EX-10.9
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 10.9<a name="12476-2-LY_Exhibit10_9_105342"></a></font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">July&nbsp;15, 2016</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Greg Korbel</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3929 Netherfield Road</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Philadelphia, PA 19129</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dear Greg:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On behalf of Aprea (US),&nbsp;Inc. (the &#147;Company&#148;), a wholly-owned U.S. subsidiary of Aprea AB (&#147;Aprea&#148;),&nbsp;I am pleased to confirm the terms and conditions of your employment as set forth below in this letter agreement (this &#147;Agreement&#148;).&#160; Certain capitalized terms used in this Agreement without definition are defined in Section&nbsp;14.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Position</b>.&#160; Effective as of July&nbsp;15, 2016, you will serve as the Vice President, Business Development, of the Company.&#160; As Vice President, Business Development, you will have overall responsibility for the business development strategy and operations of the Company.&#160; You will report to the Company&#146;s Chief Executive Officer.&#160; It is understood and agreed that, while you render services to the Company, you will not engage in any other employment, consulting or other business activities, except for business and professional activities that do not interfere with your obligations under this Agreement and that are first disclosed to and approved by the Company&#146;s Chief Executive Officer or Board of Directors (the &#147;Board&#148;).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Place of Performance</b>.&#160; Your primary place of performance will be offices of the Company located in or around Boston, Massachusetts, and from time-to-time you may be required to travel to Company or Aprea offices located in Sweden and other geographic locations in connection with the performance of your duties.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Salary</b>.&#160; The Company will pay you a salary at the rate of U.S. $220,000 per year, payable in accordance with its standard payroll practices and subject to applicable deductions and withholdings.&#160; Your salary will be subject to periodic review and increase at the Board&#146;s discretion in conjunction with the Company&#146;s annual performance reviews.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Bonus Compensation</b>.&#160; You will be eligible for a bonus targeted at 20% of your base salary.&#160; For 2016, you will receive a prorated bonus based upon the fraction of the calendar year remaining from the commencement date of your employment.&#160; Bonus payments are discretionary and will be based on achievement of Company and individual performance objectives, as determined by the Board in consultation with the Chief Executive Officer.&#160; Payment of any bonus compensation shall be made in a single lump sum payment no later than March&nbsp;15 of the year following the year to which the bonus relates.&#160; Payment of your bonus compensation is not contingent on continued employment; if you are awarded a bonus, so long as you have not voluntarily terminated your employment or been terminated by the Company for Cause, the bonus will be paid to you regardless of whether you are still employed by the Company on the date on which the lump sum bonus payment is otherwise payable.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Benefits/Vacation</b>.&#160; You will be eligible to participate in the employee benefits and insurance programs generally made available to full-time executive officers of the Company, including 20 days of paid time off and the Company&#146;s standard medical and dental programs.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="10",CHK=386106,FOLIO='',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LY_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:48 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">6.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>At-Will Employment, Accrued Obligations</b>.&#160; Your employment will be &#147;at will,&#148; meaning you or the Company may terminate it at any time for any or no reason.&#160; In the event of the termination of your employment for any reason, the Company shall pay you the Accrued Obligations, defined as (a)&nbsp;your base salary through the date of termination, (b)&nbsp;an amount equal to the value of your accrued unused vacation days, and (c)&nbsp;the amount of any expenses properly incurred by you on behalf of the Company prior to any such termination and not yet reimbursed.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">7.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Termination Without Cause or by Reason of Death or Disability</b>.&#160; In the event that (a)&nbsp;the Company terminates your at-will employment without Cause, or your employment terminates by reason of your death or Disability, and (b)&nbsp;you (and/or your representative, if applicable) (i)&nbsp;enter into, do not revoke, and comply with the terms of a separation agreement in a form acceptable to the Company, which shall include a release against the Company, Aprea and related persons and entities (the &#147;Release&#148;); (ii)&nbsp;resign from any and all positions, including, without implication of limitation, as a director, trustee, and officer, that you then hold with the Company, Aprea or any Affiliate of the Company; and (iii)&nbsp;return all property belonging to the Company, Aprea or its Affiliates (&#147;Company Property&#148;) and comply with any instructions related to deleting and purging duplicates of such Company property (collectively, the &#147;Termination Benefits Conditions&#148;), the Company will continue your base salary for three months (six months if such termination occurs during the twelve-month period that immediately follows a Change of Control) (the &#147;Termination Benefits&#148;).&#160; Any severance payments due hereunder shall commence (and, if applicable, any prorated bonus payment shall be made) as soon as administratively feasible within 60 days after your termination of employment provided you have timely executed and returned the Release and, if a revocation period is applicable, you have not revoked the Release.&#160; Solely for purposes of Section&nbsp;409A of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), each installment payment is considered a separate payment. &#160;To the full extent permitted by Code Section&nbsp;409A, it is intended that any severance benefit hereunder shall be exempt from the requirements of Code Section&nbsp;409A by reason of either (1)&nbsp;the exemption set forth in Treas. Regs. Section&nbsp;1.409A-1(b)(9)(iii)&nbsp;or (2)&nbsp;the short-term deferral rule&nbsp;under Treas. Regs. Section&nbsp;1.409A-1(b)(4).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">8.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Termination of Employment Due to Your Resignation or Termination by the Company for Cause</b>.&#160; In the event your employment is terminated as a result of your (a)&nbsp;resignation for any reason, or (b)&nbsp;termination for Cause by the Company, you will not be eligible for any Termination Benefits.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">9.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Confidential Information and Restricted Activities</b>.&#160; By signing this Agreement, you represent that you have carefully read and considered all the terms and conditions of this Agreement, including the restraints imposed on you pursuant to Sections 9. 10 and 11 of this Agreement (collectively, the &#147;Restrictive Covenant Agreements&#148;).&#160; For purposes of the Restrictive Covenant Agreements, &#147;Company&#148; shall mean the Company and its Affiliates.&#160; You agree that during your employment and for the twelve month period after your employment with the Company ends for any reason (the &#147;Restricted Period&#148;) you will not (without the Company&#146;s prior written consent), whether as owner, partner, shareholder, director, consultant, agent, employee, co-venturer or otherwise, (a)&nbsp;engage, participate or invest in any business activity anywhere in the world that develops, markets or sells any products, or performs or sells any services that directly or indirectly target the pharmacological restoration of normal function to</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="12476-2-LY_PB_2_105544_9029"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="10",CHK=1009678,FOLIO='2',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LY_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:48 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">wild type or missense-mutant&#160; P53 in oncologic applications; provided that this shall not prohibit any investment by you in publicly traded stock of a company representing less than two percent of the stock of such company, (b)&nbsp;(i)&nbsp;solicit or attempt to solicit, or (ii)&nbsp;take away or divert from the Company, or attempt to take away or divert from the Company, the business or patronage of any customer(s)&nbsp;known to you or with respect to which you were involved in soliciting, in each case at any time during the twelve-month period that immediately preceded the termination of your employment with the Company and with which, as a result of your employment with the Company, you had business dealings or about which your acquired confidential information, or (c)&nbsp;(i)&nbsp;recruit or attempt to recruit, solicit or attempt to solicit, hire or attempt to hire, interfere with or endeavor to entice away or (ii)&nbsp;assist in recruiting or attempting to recruit, soliciting or attempting to solicit, hiring or attempting to hire, interfering with or enticing away any person who is or was employed by the Company or is or was an agent, representative or consultant of the Company within the six-month period preceding the termination of your employment with the Company.&#160; You agree without reservation that these restraints are necessary for the reasonable and proper protection of the Company, and that each and every one of the restraints is reasonable in respect to subject matter, length of time and geographic area.&#160; Any breach of any of the Restrictive Covenant Agreements is likely to cause the Company substantial and irrevocable damage and therefore, in the event of such breach, the Company, in addition to such other remedies which may be available, will be entitled to specific performance and other injunctive relief.&#160; If you breach any of the covenants contained in the Restrictive Covenant Agreements, in addition to the Company&#146;s other legal and equitable remedies, the Company may cease any Termination Benefits to which you might otherwise be entitled.&#160; Any such termination of the Termination Benefits by the Company in the event of a breach by you shall not affect your ongoing obligations to the Company including pursuant to the Release.&#160; You further understand that your obligations under the Restrictive Covenant Agreements will continue in accordance with their express terms regardless of any changes in your title, position, duties, salary, compensation or benefits or other terms and conditions of employment.&#160; You expressly consent to be bound by the provisions of the Restrictive Covenant Agreements for the benefit of the Company or any Affiliate or successor to whose employ you may be transferred.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">10.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Return of Property</b>.&#160; All files, letters, notes, memoranda, reports, records, data, sketches, drawings, notebooks, layouts, charts, quotations and proposals, specification sheets, program listings, blueprints, models, prototypes, or other written, photographic or other tangible material containing Company information, whether created by you or others, which come into your custody or possession, are the exclusive property of the Company to be used by you only in the performance of your duties for the Company.&#160; Any property situated on the Company&#146;s premises and owned by the Company, including without limitation computers, disks and other storage media, filing cabinets or other work areas, is subject to inspection by the Company at any time with or without notice.&#160; In the event of the termination of your employment for any reason, you will deliver to the Company all files, letters, notes, memoranda, reports, records, data, sketches, drawings, notebooks, layouts, charts, quotations and proposals, specification sheets, program listings, blueprints, models, prototypes, or other written, photographic or other tangible material containing proprietary information, and other materials of any nature pertaining to the proprietary information of the Company and to your work performed for the Company, and will not take or keep in your possession any of the foregoing or any copies.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="12476-2-LY_PB_3_105603_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="10",CHK=234694,FOLIO='3',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LY_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:48 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">11.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Developments</b>.&#160; You will make full and prompt disclosure to the Company of all inventions, discoveries, designs, developments, methods, modifications, improvements, processes, algorithms, databases, computer programs, formulae, techniques, trade secrets, graphics or images, audio or visual works, and other works of authorship (collectively &#147;Developments&#148;), whether or not patentable or copyrightable, that are created, made, conceived or reduced to practice by you (alone or jointly with others) or under your direction during the period of your employment.&#160; You acknowledge that all work performed by you is on a &#147;work for hire&#148; basis, and you hereby do assign and transfer and, to the extent any such assignment cannot be fully made at present, will assign and transfer, to the Company and its successors and assigns all your right, title and interest in all Developments that (a)&nbsp;relate to the business of the Company or any customer of or supplier to the Company or any of the products or services being researched, developed, manufactured, commercialized, marketed or sold by the Company or that may be used with such products or services; or (b)&nbsp;result from tasks assigned to you by the Company; or (c)&nbsp;result from the use of premises or personal property (whether tangible or intangible) owned, leased or contracted for by the Company (&#147;Company-Related Developments&#148;), and all related patents, patent applications, trademarks and trademark applications, copyrights and copyright applications, and other intellectual property rights in all countries and territories worldwide and under any international conventions (&#147;Intellectual Property Rights&#148;).&#160; To preclude any possible uncertainty, you have provided on <u>Exhibit&nbsp;A</u> to this Agreement a complete list of Developments that you have, alone or jointly with others, conceived, developed or reduced to practice prior to the commencement of your employment with the Company that you consider to be your property or the property of third parties and that you wish to have excluded from the scope of this Agreement (&#147;Prior Inventions&#148;).&#160; You have also listed on <u>Exhibit&nbsp;A</u> all patents and patent applications in which you are named as an inventor, other than those that have been assigned to the Company, (&#147;Other Patent Rights&#148;).&#160; If no such disclosure is set forth on <u>Exhibit&nbsp;A</u>, you represent that there are no Prior Inventions or Other Patent Rights.&#160; If, in the course of your employment with the Company, you incorporate a Prior Invention into a Company product, process or machine or other work done for the Company, you hereby grant to the Company a nonexclusive, royalty-free, irrevocable, worldwide license (with the full right to sublicense) to make, have made, modify, use and sell such Prior Invention.&#160; Notwithstanding the foregoing, you will not incorporate, or permit to be incorporated, Prior Inventions in any Company-Related Development without the Company&#146;s prior written consent.&#160; This Agreement does not obligate you to assign to the Company any Development that, in the sole judgment of the Company, reasonably exercised, is developed entirely on your own time and does not relate to the business efforts or research and development efforts in which, during the period of your employment, the Company actually is engaged or reasonably would be engaged, and does not result from the use of premises or equipment owned or leased by the Company.&#160; However, you will also promptly disclose to the Company any such Developments for the purpose of determining whether they qualify for such exclusion.&#160; You understand that to the extent this Agreement is required to be construed in accordance with the laws of any state that precludes a requirement in an employee agreement to assign certain classes of inventions made by an employee, this Section&nbsp;12 will be interpreted not to apply to any invention which a court rules&nbsp;and /or the Company agrees falls within such classes.&#160; You also hereby waive all claims to any moral rights or other special rights which you may have or accrue in any Company-Related Developments.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="12476-2-LY_PB_4_105614_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="10",CHK=981417,FOLIO='4',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LY_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:48 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">12.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Enforcement of Agreement; Relief</b>.&#160; You acknowledge and agree that the Restrictive Covenant Agreements and all other provisions of this Agreement that are intended to endure beyond the terms of your employment shall survive the termination of your employment and that any violation of any of the Restrictive Covenant Agreements will cause immediate and irreparable damage to the Company, entitling it to injunctive relief and other equitable remedies.&#160; You specifically consent to the issuance of temporary, preliminary, and permanent injunctive relief to enforce the terms of this Agreement.&#160; In addition to injunctive relief, the Company is entitled to all money damages available under the law.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">13.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Definitions</b>.&#160; For purposes of this Agreement:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Affiliates&#148; means all persons and entities directly or indirectly controlling, controlled by or under common control with the Company, where control may be by management authority, or an equity interest of 50% more (direct or indirect).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Cause&#148; means, in the sole discretion of the Chief Executive Officer:&#160; (i)&nbsp;conduct by you in connection with your service to the Company or any Affiliate that is fraudulent, unlawful or grossly negligent; (ii)&nbsp;your material breach of your material responsibilities to the Company or any Affiliate or your willful failure to comply with reasonable and lawful directives of the Board or written policies of the Company that results in harm to the Company or any Affiliate; (iii)&nbsp;material breach by you of your material representations, warranties, covenants and/or obligations under the this Agreement; (iv)&nbsp;material misconduct by you that seriously discredits or damages the Company or any Affiliate; and/or (v)&nbsp;nonperformance or unsatisfactory performance of your material duties or responsibilities to the Company or any Affiliate; in the case of each of (ii), (iii), (iv)&nbsp;and (v)&nbsp;as determined in good faith by the Chief Executive Officer after written notice to you providing reasonable details of the alleged breach and not less than a 30 day period to cure the alleged breach; provided that the Company may suspend your employment, access, authority and duties during such cure period.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Change of Control&#148; will mean the occurrence of any of the following events after the date hereof:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; the acquisition of the Company by another person or entity (other than an Affiliate) by means of any transaction or series of related transactions (including, without limitation, any reorganization, merger or consolidation or stock transfer, but excluding any such transaction effected primarily for the purpose of changing the domicile of the Company or any of its Affiliates), unless the Company stockholders of record immediately prior to such transaction or series of related transactions hold, immediately after such transaction or series of related transactions, at least 50% of the voting power of the surviving or acquiring entity; provided that neither the sale by the Company or any of its Affiliates of its securities for the purposes of raising additional funds nor any trading in the Company&#146;s capital stock after such time, if any, as the Company shall have a class of securities registered under the Securities Exchange Act of 1934 shall constitute a Change of Control hereunder; or</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; a sale, exclusive worldwide license or other disposition of all or substantially all of the assets of the Company other than to an Affiliate.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="12476-2-LY_PB_5_105634_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="10",CHK=467748,FOLIO='5',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LY_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:48 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">14.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Tax Matters</b>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">All payments and forms of compensation referred to in this Agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law.&#160; You hereby acknowledge that neither the Company has no duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or any of its Affiliates, or the Board related to tax liabilities arising from your compensation.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Anything in this Agreement to the contrary notwithstanding, if at the time of your separation from service within the meaning of Section&nbsp;409A of the Code, the Company determines that you are a &#147;specified employee&#148; within the meaning of Section&nbsp;409A(a)(2)(B)(i)&nbsp;of the Code, then to the extent any payment or benefit that you becomes entitled to under this Agreement on account of your separation from service would be considered deferred compensation subject to the 20% additional tax imposed pursuant to Section&nbsp;409A(a)&nbsp;of the Code as a result of the application of Section&nbsp;409A(a)(2)(B)(i)&nbsp;of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (a)&nbsp;six months and one day after your separation from service, or (b)&nbsp;your death.&#160; If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule.&#160; All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by you during the time periods set forth in this Agreement.&#160; All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred.&#160; The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year.&#160; Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.&#160; To the extent that any payment or benefit described in this Agreement constitutes &#147;non-qualified deferred compensation&#148; under Section&nbsp;409A of the Code, and to the extent that such payment or benefit is payable upon your termination of employment, then such payments or benefits shall be payable only upon your &#147;separation from service.&#148;&#160; The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section&nbsp;1.409A-1(h).&#160; the Company and you intend that this Agreement will be administered in accordance with Section&nbsp;409A of the Code.&#160; To the extent that any provision of this Agreement is ambiguous as to its compliance with Section&nbsp;409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with (or are exempt from) Section&nbsp;409A of the Code.&#160; The Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section&nbsp;409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the event that the Company determines in good faith that any payments or benefits (whether made or provided pursuant to this Agreement or otherwise) provided to you constitute</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="12476-2-LY_PB_6_105648_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="10",CHK=48184,FOLIO='6',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LY_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:48 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;parachute payments&#148; within the meaning of Section&nbsp;280G of the Code (&#147;Parachute Payments&#148;) and may be subject to an excise tax imposed pursuant to Section&nbsp;4999 of the Code, the Parachute Payments will be reduced to an amount determined by the Company in good faith to be the maximum amount that may be provided to you (after taking into account the value of the Restrictive Covenant Agreements, reasonable compensation for services, and any other available exemption) without resulting in any portion of such Parachute Payments being subject to such excise tax (the amount of such reduction, the &#147;Cutback Benefits&#148;); provided, however, that no such reduction shall apply if either (a)&nbsp;the Company&#146;s stockholders approve the Cutback Benefits (in accordance with the procedure described below) or (b)&nbsp;upon your request, the Company does not seek such stockholder approval and your net after-tax benefit, after applying the excise tax required by Section&nbsp;4999 of the Code with respect to the full amount of the Parachute Payments (without reduction), would be more than your net after-tax benefit after subtracting the Cutback Benefits.&#160; You shall be entitled to select which Parachute Payments (of those that are not considered to be deferred compensation under Section&nbsp;409A of the Code) shall be reduced hereunder; provided that if you fail to so select promptly, the Company shall select which Parachute Payments (of those that are not considered to be deferred compensation under Section&nbsp;409A of the Code) will be reduced.&#160; Parachute Payments that are considered to be deferred compensation under Section&nbsp;409A of the Code shall be reduced only to the extent that the complete reduction of the Parachute Payments in the preceding sentence is insufficient to eliminate the imposition of the excise tax imposed under Section&nbsp;4999 of the Code.&#160; Notwithstanding the foregoing, if applicable to the Company at that time, upon your request, the Company shall use reasonable efforts to obtain the approval of the Cutback Benefits by the Company&#146;s stockholders in the manner contemplated by Q&amp;A 7 of Treas. Reg. Section&nbsp;1.280G-1, it being understood and agreed that the Company does not guarantee that such approval will be obtained.&#160; If the Company seeks but fails to attain the required stockholder approval described in the immediately preceding sentence, you will forfeit the Cutback Benefits.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">15.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Interpretation, Amendment and Enforcement</b>.&#160; This Agreement, the Restrictive Covenant Agreements, and any other agreements evidencing equity grants to you by the Company and its Affiliates constitute the complete agreement between you and the Company, contain all of the terms of your employment with the Company and supersede any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company or its Affiliates relating to the subject matter herein.&#160; The terms of such agreements and the resolution of any disputes as to the meaning, effect, performance or validity of this Agreement or arising out of, related to, or in any way connected with, this Agreement, your employment with the Company or any other relationship between you and the Company and its Affiliates (the &#147;Disputes&#148;) will be governed by the laws of the State of Delaware, excluding laws relating to conflicts or choice of law.&#160; You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in the State of Delaware in connection with any Dispute or any claim related to any Dispute.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">16.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Assignment</b>.&#160; Neither you nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement (including, without limitation, the Restrictive Covenant Agreements) without your</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="12476-2-LY_PB_7_105658_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="10",CHK=618818,FOLIO='7',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LY_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:48 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">consent to one of its Affiliates or to any person with whom the Company or Aprea shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets.&#160; This Agreement shall inure to the benefit of and be binding upon you and the Company, and each of our respective successors, executors, administrators, heirs and permitted assigns.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">17.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Severability</b>.&#160; In case any provisions (or portions thereof) contained in this Agreement (including the Restrictive Covenant Agreements) shall, for any reason, be held invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect the other provisions of this Agreement, and this Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein.&#160; If, moreover, any one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, it shall be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it shall then appear.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">18.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Miscellaneous</b>.&#160; This Agreement may not be modified or amended, and no breach shall be deemed to be waived, unless agreed to in writing by you and a duly authorized officer or board member of the Company.&#160; The headings and captions in this Agreement are for convenience only and in no way define or describe the scope or content of any provision of this Agreement.&#160; The words &#147;include,&#148; &#147;includes&#148; and &#147;including&#148; when used herein shall be deemed in each case to be followed by the words &#147;without limitation.&#148; This Agreement may be executed in two or more counterparts, each of which shall be an original and all of which together shall constitute one and the same instrument.&#160; A facsimile or electronic transmission of a scanned copy of a signed counterpart signature page&nbsp;to this Agreement shall be deemed to be an originally executed copy for purposes of this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">19.</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Other Terms</b>.&#160; By signing this Agreement, you confirm to the Company that you have no contractual commitments or other legal obligations that would or may prohibit you from entering into this Agreement or performing your duties for the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="12476-2-LY_PB_8_105711_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="10",CHK=829539,FOLIO='8',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LY_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:48 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To indicate your acceptance of this Agreement, please sign and date this Agreement in the space provided below and return it to me by July&nbsp;15, 2016.&#160; We look forward to working with you.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Very   truly yours,</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">APREA   (US),&nbsp;Inc.</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Christian S. Schade</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Christian   S. Schade</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief   Executive Officer</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accepted   and Agreed:</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Greg Korbel</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Greg   Korbel</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dated:   July&nbsp;15, 2016</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">9<a name="12476-2-LY_PB_9_110227_141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="10",CHK=209773,FOLIO='9',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LY_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:48 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;A</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Prior Inventions and Other Patent Rights</font></u></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">None.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A-</font>1<a name="12476-2-LY_PB_1_110238_1139"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=10,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="10",CHK=413658,FOLIO='A-1',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-LY_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 23:48 2019' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>11
<FILENAME>a2239779zex-10_10.htm
<DESCRIPTION>EX-10.10
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 10.10</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Execution Copy</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EMPLOYMENT AGREEMENT</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">THIS EMPLOYMENT AGREEMENT</font></b> (the &#147;<u>Agreement</u>&#148;) between APREA THERAPEUTICS,&nbsp;INC., a Delaware corporation (the &#147;<u>Company</u>&#148;), and Scott M. Coiante (the &#147;<u>Executive</u>&#148;), is made and entered into as of September&nbsp;26, 2019, and will become effective, if at all, upon the date of closing of the Company&#146;s initial public offering of stock pursuant to an effective registration statement filed under the Securities Act of 1933, as amended (the &#147;<u>Effective Date</u>&#148;).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WHEREAS,</font></b> the Company desires to continue to employ Executive on the terms and conditions contained herein;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WHEREAS,</font></b> the Company and Executive previously entered into an employment letter agreement, dated as of August&nbsp;5, 2019 (the &#147;<u>Prior Agreement</u>&#148;);</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WHEREAS,</font></b> Executive desires to continue to be employed by and render services to the Company upon and subject to the terms, conditions and other provisions set forth herein.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">NOW THEREFORE,</font></b> in consideration of the promises and mutual covenants and agreements contained herein, the adequacy of all of which consideration is hereby acknowledged, the parties hereby agree as follows:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Agreement and Term</u>.&#160;&#160; The Company hereby agrees to continue to employ Executive, and Executive hereby accepts such employment and agrees to render such services to the Company, on the terms and conditions set forth in this Agreement.&#160; Unless terminated earlier as set forth in <u>Section&nbsp;4</u> herein, Executive&#146;s employment and the term under this Agreement shall commence under the terms set forth herein on the Effective Date and shall continue until the third-anniversary of the Effective Date (the &#147;<u>Initial Term</u>&#148;) and, thereafter, shall be extended automatically for successive one-year terms, unless either Executive or the Company gives contrary written notice not less than 60&nbsp;days in advance of the expiration of the Initial Term or any succeeding term of this Agreement.&#160; The Initial Term, together with any extension thereof in accordance with this <u>Section&nbsp;1</u>, shall be referred to herein as the &#147;<u>Term</u>.&#148;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Positions and Authority</u>.&#160; Executive shall serve in the position of Senior Vice President, Chief Financial Officer of the Company, or in such other position as the parties may agree.&#160; Executive agrees to serve in the officer position referred to in this <u>Section&nbsp;2</u>, and to perform diligently and to the best of his abilities the duties and services appertaining to such offices as set forth in the Bylaws of the Company, as well as such additional duties and services appropriate to such offices that the parties may agree upon from time to time.&#160; Upon the Effective Date, Executive&#146;s principal place of work shall be located in Boston, Massachusetts.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">During the Term, Executive shall devote Executive&#146;s full business time and efforts to the business and affairs of the Company and its subsidiaries, provided that the Executive shall be entitled to serve as a member of the board of directors of a reasonable number of other companies, to serve on civic, charitable, educational, religious, public interest or public service boards, and to manage the Executive&#146;s personal and family investments, in each case, to the extent such activities do not materially interfere with the performance of the Executive&#146;s duties and responsibilities</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=1,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="11",CHK=261486,FOLIO='',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-MA-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 08:32 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">hereunder.&#160; Executive shall not become a director of any for profit entity without first receiving the approval of the Chief Executive Officer of the Company.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Compensation and Benefits</u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Base Salary</u>.&#160; As compensation for Executive&#146;s performance of Executive&#146;s duties hereunder, Company shall pay to Executive an initial Base Salary of $350,000 per year, payable in accordance with the normal payroll practices of the Company.&#160; The Base Salary shall be reviewed for increases but not decreases by the Compensation Committee of the Board (the &#147;<u>Compensation Committee</u>&#148;) in good faith, based upon the Company&#146;s and Executive&#146;s performance and the Company&#146;s pay philosophy, not less often than annually.&#160; The term &#147;<u>Base Salary</u>&#148; shall refer to the Base Salary as may be in effect from time to time.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Annual Incentive Compensation</u>.&#160; During the Term, Executive shall be eligible to participate in the annual cash bonus program maintained for senior executive officers of the Company (the &#147;<u>Annual Incentive Program</u>&#148;), with an initial target annual bonus opportunity equal to 35% of Base Salary.&#160; The actual amount of the annual bonus earned by and payable to Executive for any year or portion of a year, as applicable, shall be determined upon the satisfaction of goals and objectives established by the Compensation Committee, and shall be subject to such other terms and conditions of the Annual Incentive Program as in effect from time to time.&#160; Each bonus paid under the Annual Incentive Program shall be paid to Executive no later than March&nbsp;15th&nbsp;of the calendar year following the calendar year in which the bonus is earned.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Long-Term Incentive Grants</u>.&#160; During the Term, Executive shall be eligible to participate in the long-term incentive program maintained for senior executive officers of the Company (the &#147;<u>LTI Program</u>&#148;), with a LTI Program target opportunity and LTI Program Vehicles determined by the Compensation Committee for each year of participation.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Employee Benefits and Perquisites</u>. During the Term, the Executive shall be entitled to receive all benefits and perquisites of employment generally available to other members of the Company&#146;s senior executive management, upon Executive&#146;s satisfaction of the eligibility or participation criteria therefor. The Company reserves the right to modify or terminate employee benefits and perquisites at its discretion.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Business Expenses</u>.&#160; Subject to <u>Section&nbsp;17</u>, Executive shall be reimbursed for reasonable travel and other expenses incurred in the performance of Executive&#146;s duties on behalf of the Company in a manner consistent with the Company&#146;s policies regarding such reimbursements, as may be in effect from time to time.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Termination of Employment</u>.&#160; (a)<font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>The Term shall end upon the first to occur of:&#160; (i)&nbsp;the expiration of the term of this Agreement pursuant to <u>Section&nbsp;1</u> hereof; (ii)&nbsp;Termination due to Disability (as defined below); (iii)&nbsp;termination of Executive&#146;s employment by the Company for any reason other than Termination due to Disability; (iv)&nbsp;Executive&#146;s death; or (v)&nbsp;termination of Executive&#146;s employment by Executive for any reason.&#160; Upon the termination of Executive&#146;s employment with the Company for any reason, Executive shall be deemed to have resigned from all positions with the Company or any of its Affiliates held by Executive as of the date immediately preceding Executive&#146;s termination of employment.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="12476-2-MA-01_PB_2_083038_520"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=2,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="11",CHK=484604,FOLIO='2',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-MA-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 08:32 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>If Executive&#146;s employment ends for any reason, except as otherwise contemplated in this <u>Section&nbsp;4</u>, Executive shall cease to have any rights to salary, bonus (if any) or other benefits, other than (i)&nbsp;the earned but unpaid portion of Executive&#146;s Base Salary through the date of termination or resignation, (ii)&nbsp;&nbsp;a lump-sum payment in respect of accrued but unused vacation days at the Executive&#146;s per-business-day Base Salary rate, (iii)&nbsp;any unpaid expense or other reimbursements due to Executive, and (iv)&nbsp;any other amounts or benefits required to be paid or provided by law or under any plan, program, policy or practice of the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Termination without Cause or for Good Reason</u>.&#160; If Executive&#146;s employment hereunder shall be terminated by the Company without Cause, termination upon the expiration of the Term following notice of non-renewal by the Company, or by Executive for Good Reason, then in addition to the payments and benefits described in <u>Section&nbsp;4(b)</u>&nbsp;and subject to <u>Section&nbsp;17</u> and Executive&#146;s continuing compliance with <u>Section&nbsp;5</u> of this Agreement:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the Company shall pay Executive an amount equal to nine months of the Executive&#146;s Base Salary (the &#147;<u>Severance Payment</u>&#148;), payable during the nine-month period following such termination of employment, with the Severance Payment commencing as soon as administratively feasible within 60 days following Executive&#146;s termination of employment and the first installment payment including the portion of the Severance Payment that was payable prior to such first payment date; <u>provided</u>, <u>however</u>, if the Executive&#146;s employment is terminated under circumstances entitling the Executive to severance under this <u>Section&nbsp;4(c)</u>&nbsp;within 12 months following a Change in Control (a &#147;<u>CIC Qualifying Termination</u>&#148;), then the Severance Payment and period to pay the Severance Payment shall be increased to 12 months;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the Company shall pay Executive an annual bonus for the year of termination equal to the Executive&#146;s target annual bonus opportunity, payable within 60 days following the Executive&#146;s termination of employment, subject to proration based on the number of days in the calendar year that have elapsed prior to the date of termination;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>following the Executive&#146;s termination of employment, the Company shall pay to the Executive (or to the Executive&#146;s family in the event of Executive&#146;s death) on a monthly basis an amount equal to the monthly amount of the Consolidated Omnibus Budget Reconciliation Act of 1985&#160; continuation coverage premium for such month, at the same level and cost to the Executive (or the Executive&#146;s family in the event of Executive&#146;s death) as immediately preceding the Executive&#146;s termination of employment, under the Company group medical plan in which the Executive participated immediately preceding the Executive&#146;s termination of employment, less the amount of the Executive&#146;s portion of such monthly premium as in effect immediately preceding the Executive&#146;s termination of employment, until the earlier of (A)&nbsp;nine months after the Executive&#146;s termination of employment and (B)&nbsp;the Executive and Executive&#146;s family have obtained other substantially similar healthcare coverage; <u>provided</u>, <u>however</u>, if the Executive experiences a CIC Qualifying Termination, then the number of months set forth in clause (A)&nbsp;of this sentence shall be increased to 12 months;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For the avoidance of doubt, Executive shall not be entitled to the benefits described in this <u>Section&nbsp;4(c)</u>&nbsp;for a Termination due to Disability, termination of Executive&#146;s employment for</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="12476-2-MA-01_PB_3_083050_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=3,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="11",CHK=547159,FOLIO='3',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-MA-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 08:32 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cause, Executive&#146;s death, or termination of Executive&#146;s employment by Executive for any reason other than for Good Reason.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Section&nbsp;280G</u>.&#160; Notwithstanding anything to the contrary in this Agreement, Executive expressly agrees that if the payments and benefits provided for in this Agreement or any other payments and benefits which Executive has the right to receive from the Company and its Affiliates (collectively, the &#147;<u>Payments</u>&#148;), would constitute a &#147;parachute payment&#148; (as defined in Section&nbsp;280G(b)(2)&nbsp;of the Internal Revenue Code of 1986, as amended (the &#147;<u>Code</u>&#148;)), then the Payments shall be either (i)&nbsp;reduced (but not below zero) so that the present value of the Payments will be one dollar ($1.00) less than three times Executive&#146;s &#147;base amount&#148; (as defined in Section&nbsp;280G(b)(3)&nbsp;of the Code) and so that no portion of the Payments received by Executive shall be subject to the excise tax imposed by Section&nbsp;4999 of the Code or (ii)&nbsp;paid in full, whichever produces the better net after-tax position to Executive.&#160; The reduction of Payments, if any, shall be made by reducing first any Payments that are exempt from Section&nbsp;409A of the Code and then reducing any Payments subject to Section&nbsp;409A of the Code in the reverse order in which such Payments would be paid or provided (beginning with such payment or benefit that would be made last in time and continuing, to the extent necessary, through to such payment or benefit that would be made first in time).&#160; The determination as to whether any such reduction in the Payments is necessary shall be made by the Compensation Committee in good faith.&#160; If a reduced Payment is made or provided and, through error or otherwise, that Payment, when aggregated with other payments and benefits from Company (or its Affiliates) used in determining if a &#147;parachute payment&#148; exists, exceeds one dollar ($1.00) less than three times Executive&#146;s base amount, then Executive shall immediately repay such excess to the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Certain Definitions</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Affiliate</u>&#148; shall mean all persons and entities directly or indirectly controlling, controlled by or under common control with the Company, where control may be by management authority, or an equity interest of 50% or more (direct or indirect).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Cause</u>&#148; shall mean, in the sole discretion of the Board:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>conduct by Executive in connection with Executive&#146;s service to the Company or any Affiliate that is fraudulent, unlawful or grossly negligent;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Executive&#146;s material breach of Executive&#146;s material responsibilities to the Company or any Affiliate or Executive&#146;s willful failure to comply with reasonable and lawful directives of the Board;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Executive&#146;s material breach of Executive&#146;s material representations, warranties, covenants and/or obligations under this Agreement;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>material misconduct by Executive that seriously discredits or damages the Company or any Affiliate;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(v)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>nonperformance or unsatisfactory performance of Executive&#146;s material duties or responsibilities to the Company or any Affiliate;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="12476-2-MA-01_PB_4_083100_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=4,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="11",CHK=382362,FOLIO='4',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-MA-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 08:32 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vi)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>violation of the Company&#146;s or any of its Affiliates&#146; policies including, without limitation, the Company&#146;s Code of Conduct and policies on equal employment opportunity and prohibition of unlawful harassment; and/or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(vii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the conviction of, or plea of nolo contendere to, any felony or a misdemeanor involving dishonesty or fraud</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the case of each of (ii), (iii), (iv), (v)&nbsp;and (vi)&nbsp;as determined in good faith by the Board after written notice to Executive providing reasonable details of the alleged breach and not less than a 30 day period to cure the alleged breach; provided that the Company may suspend Executive&#146;s employment, access, authority and duties during such cure period.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Change in Control</u>&#148; shall have the meaning assigned to such term in the Company&#146;s 2019 Equity Incentive Plan.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Good Reason</u>&#148; shall mean that Executive has complied with the &#147;<u>Good Reason Process</u>&#148; (hereinafter defined) following the occurrence of any of the following actions undertaken by the Company without Executive&#146;s express prior written consent:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>the changing of Executive&#146;s position from Senior Vice President, Chief Financial Officer;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(ii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>a material diminution in Executive&#146;s responsibilities, authority or function as Senior Vice President, Chief Financial Officer;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iii)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>a material reduction in Executive&#146;s Base Salary and/or annual target bonus opportunity; <u>provided</u>, <u>however</u>, that Good Reason shall not be deemed to have occurred in the event of a reduction in Executive&#146;s Base Salary and/or annual target bonus opportunity that is pursuant to a reduction program affecting substantially all of the senior level employees of the Company and that does not adversely affect Executive to a greater extent than other similarly situated senior level employees; or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(iv)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>a change of more than 50 miles in the geographic location at which Executive must regularly report to work and perform services, except for required travel on business of the Company; <u>provided</u>, <u>however</u>, that &#147;<u>Good Reason</u>&#148; shall not include, following a Change of Control, a reduction in title, position, responsibilities or duties solely by virtue of the Company being acquired and made part of, or operating as a subsidiary or division of a larger company or organization, as long as Executive&#146;s new duties and responsibilities are reasonably commensurate with Executive&#146;s experience.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Good Reason Process</u>&#148; shall mean that:&#160; (i)&nbsp;Executive has reasonably determined in good faith that a &#147;<u>Good Reason</u>&#148; has occurred; (ii)&nbsp;Executive has notified the Board in writing of the first occurrence of the Good Reason condition within 60 days of the first occurrence of such condition; (iii)&nbsp; Executive has cooperated in good faith with the efforts of the Company, for a period not less than 30 days following such notice (the &#147;<u>Cure Period</u>&#148;), to remedy the condition; (iv)&nbsp;notwithstanding such efforts, the Good Reason condition continues to exist; and (v)&nbsp;Executive terminates employment within 60 days after the end of the Cure Period. If the Good Reason</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">5<a name="12476-2-MA-01_PB_5_083109_5796"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=5,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="11",CHK=435981,FOLIO='5',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-MA-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 08:32 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">condition is cured by the Company during the Cure Period, Good Reason shall be deemed not to have occurred.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:38.25pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;<u>Termination due to Disability</u>&#148; shall mean Executive&#146;s termination of employment as a result of Executive becoming incapacitated for a period of at least 180&nbsp;days by accident, sickness or other circumstance that renders Executive mentally or physically incapable of performing the material duties as Senior Vice President, Chief Financial Officer.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Restrictive Covenants</u>.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(a)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Confidential Information and Restricted Activities.</u> By signing this Agreement, Executive represents that Executive has carefully read and considered all the terms and conditions of this Agreement, including the restraints imposed on Executive pursuant to this <u>Section&nbsp;5</u> (collectively, the &#147;<u>Restrictive Covenant Agreements</u>&#148;).&#160; For purposes of the Restrictive Covenant Agreements, &#147;<u>Company</u>&#148; shall mean the Company and its Affiliates.&#160; Executive agrees that during Executive&#146;s employment and for the twelve month period after Executive&#146;s employment with the Company ends for any reason (the &#147;<u>Restricted Period</u>&#148;) Executive will not (without the Company&#146;s prior written consent), whether as owner, partner, shareholder, director, consultant, agent, employee, co-venturer or otherwise, (i)&nbsp;engage, participate or invest in any business activity anywhere in the world that develops, markets or sells any products, or performs or sells any services that directly or indirectly target the pharmacological restoration of normal function to wild type or missense-mutant&#160; P53 in oncologic applications; provided that this shall not prohibit any investment by Executive in publicly traded stock of a company representing less than two percent of the stock of such company, (ii)&nbsp;(A)&nbsp;solicit or attempt to solicit, or (B)&nbsp;take away or divert from the Company, or attempt to take away or divert from the Company, the business or patronage of any customer(s)&nbsp;known to Executive with respect to which Executive was involved in soliciting, in each case at any time during the twelve-month period that immediately preceded the termination of Executive&#146;s employment with the Company and with which, as a result of Executive&#146;s employment with the Company, Executive had business dealings or about which Executive acquired confidential information, or (iii)&nbsp;(A)&nbsp;recruit or attempt to recruit, solicit or attempt to solicit, hire or attempt to hire, interfere with or endeavor to entice away or (B)&nbsp;assist in recruiting or attempting to recruit, soliciting or attempting to solicit, hiring or attempting to hire, interfering with or enticing away any person who is or was employed by the Company or is or was an agent, representative or consultant of the Company within the six-month period preceding the termination of Executive&#146;s employment with the Company.&#160; Executive agrees without reservation that these restraints are necessary for the reasonable and proper protection of the Company, and that each and every one of the restraints is reasonable in respect to subject matter, length of time and geographic area.&#160; Executive further understands that Executive&#146;s obligations under the Restrictive Covenant Agreements will continue in accordance with their express terms regardless of any changes in Executive&#146;s title, position, duties, salary, compensation or benefits or other terms and conditions of employment.&#160; Executive expressly consents to be bound by the provisions of the Restrictive Covenant Agreements for the benefit of the Company or any Affiliate or successor to whose employ Executive may be transferred.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(b)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Return of Property</u>. All files, letters, notes, memoranda, reports, records, data, sketches, drawings, notebooks, layouts, charts, quotations and proposals, specification sheets, program listings, blueprints, models, prototypes, or other written, photographic or other tangible</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">6<a name="12476-2-MA-01_PB_6_083118_2897"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=6,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="11",CHK=191084,FOLIO='6',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-MA-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 08:32 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">material containing Company information, whether created by Executive or others, which come into Executive&#146;s custody or possession, are the exclusive property of the Company to be used by Executive only in the performance of Executive&#146;s duties for the Company.&#160; Any property situated on the Company&#146;s premises and owned by the Company, including without limitation computers, disks and other storage media, filing cabinets or other work areas, is subject to inspection by the Company at any time with or without notice.&#160; In the event of the termination of Executive&#146;s employment for any reason, Executive will deliver to the Company all files, letters, notes, memoranda, reports, records, data, sketches, drawings, notebooks, layouts, charts, quotations and proposals, specification sheets, program listings, blueprints, models, prototypes, or other written, photographic or other tangible material containing proprietary information, and other materials of any nature pertaining to the proprietary information of the Company and to Executive&#146;s work performed for the Company, and will not take or keep in Executive&#146;s possession any of the foregoing or any copies.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(c)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Developments</u>. Executive will make full and prompt disclosure to the Company of all inventions, discoveries, designs, developments, methods, modifications, improvements, processes, algorithms, databases, computer programs, formulae, techniques, trade secrets, graphics or images, audio or visual works, and other works of authorship (collectively, &#147;<u>Developments</u>&#148;), whether or not patentable or copyrightable, that are created, made, conceived or reduced to practice by Executive (alone or jointly with others) or under Executive&#146;s direction during the period of Executive&#146;s employment.&#160; Executive acknowledges that all work performed by Executive is on a &#147;work for hire&#148; basis, and Executive hereby does assign and transfer and, to the extent any such assignment cannot be fully made at present, will assign and transfer, to the Company and its successors and assigns all Executive&#146;s right, title and interest in all Developments that (i)&nbsp;relate to the business of the Company or any customer of or supplier to the Company or any of the products or services being researched, developed, manufactured, commercialized, marketed or sold by the Company or that may be used with such products or services; or (ii)&nbsp;result from tasks assigned to Executive by the Company; or (iii)&nbsp;result from the use of premises or personal property (whether tangible or intangible) owned, leased or contracted for by the Company (&#147;<u>Company-Related Developments</u>&#148;), and all related patents, patent applications, trademarks and trademark applications, copyrights and copyright applications, and other intellectual property rights in all countries and territories worldwide and under any international conventions (&#147;<u>Intellectual Property Rights</u>&#148;).&#160; To preclude any possible uncertainty, Executive has provided on <u>Exhibit&nbsp;A</u> to this Agreement a complete list of Developments that Executive has, alone or jointly with others, conceived, developed or reduced to practice prior to the commencement of Executive&#146;s employment with the Company that Executive considers to be Executive&#146;s property or the property of third parties and that Executive wishes to have excluded from the scope of this Agreement (&#147;<u>Prior Inventions</u>&#148;).&#160; Executive has also listed on <u>Exhibit&nbsp;A</u> all patents and patent applications in which Executive is named as an inventor, other than those that have been assigned to the Company, (&#147;<u>Other Patent Rights</u>&#148;).&#160; If no such disclosure is set forth on <u>Exhibit&nbsp;A</u>, Executive represents that there are no Prior Inventions or Other Patent Rights.&#160; If, in the course of Executive&#146;s employment with the Company, Executive incorporates a Prior Invention into a Company product, process or machine or other work done for the Company, Executive hereby grants to the Company a nonexclusive, royalty-free, irrevocable, worldwide license (with the full right to sublicense) to make, have made, modify, use and sell such Prior Invention.&#160; Notwithstanding the foregoing, Executive will not incorporate, or permit to be incorporated, Prior Inventions in any Company-Related Development without the Company&#146;s prior written consent.&#160; This Agreement does not</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">7<a name="12476-2-MA-01_PB_7_083125_3020"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=7,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="11",CHK=373917,FOLIO='7',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-MA-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 08:32 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">obligate Executive to assign to the Company any Development that, in the sole judgment of the Company, reasonably exercised, is developed entirely on Executive&#146;s own time and does not relate to the business efforts or research and development efforts in which, during the period of Executive&#146;s employment, the Company actually is engaged or reasonably would be engaged, and does not result from the use of premises or equipment owned or leased by the Company.&#160; However, Executive will also promptly disclose to the Company any such Developments for the purpose of determining whether they qualify for such exclusion.&#160; Executive understands that to the extent this Agreement is required to be construed in accordance with the laws of any state that precludes a requirement in an employee agreement to assign certain classes of inventions made by an employee, this <u>Section&nbsp;5(c)</u>&nbsp;will be interpreted not to apply to any invention which a court rules&nbsp;and /or the Company agrees falls within such classes.&#160; Executive also hereby waives all claims to any moral rights or other special rights which Executive may have or accrue in any Company-Related Developments.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Enforcement of Agreement; Relief.</u> Executive acknowledges and agrees that the Restrictive Covenant Agreements and all other provisions of this Agreement that are intended to endure beyond the terms of Executive&#146;s employment shall survive the termination of Executive&#146;s employment and that any violation of any of the Restrictive Covenant Agreements will cause immediate and irreparable damage to the Company, entitling it to specific performance, injunctive relief and other equitable remedies.&#160; Executive specifically consents to the issuance of temporary, preliminary, and permanent injunctive relief to enforce the terms of this Agreement.&#160; In addition to injunctive relief, the Company is entitled to all money damages available under the law.&#160; If Executive breaches any of the covenants contained in the Restrictive Covenant Agreements, in addition to the Company&#146;s other legal and equitable remedies, the Company may cease any termination benefits to which Executive might otherwise be entitled.&#160; Any such termination of the termination benefits by the Company in the event of a breach by Executive shall not affect Executive&#146;s ongoing obligations to the Company including pursuant to the Release.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Notice of Intent to Resign</u>. In the event Executive wishes to voluntarily terminate Executive&#146;s employment, Executive agrees to provide the Company with four (4)&nbsp;weeks advance written notice (the &#147;<u>Notice Period</u>&#148;) of Executive&#146;s intent to do so, and, if Executive intends or contemplates alternative employment, Executive also agrees to provide the Company with accurate information concerning such alternative employment in sufficient detail to allow the Company to meaningfully exercise its rights under this <u>Section&nbsp;5</u>. After receipt of such notice, the Company, in its sole, absolute and unreviewable discretion, may (i)&nbsp;require Executive to continue working during the Notice Period, (ii)&nbsp;relieve Executive of some or all of his work responsibilities during the Notice Period, or (iii)&nbsp;shorten the Notice Period and make Executive&#146;s voluntary termination of employment effective immediately. Notwithstanding the foregoing, if Executive provides notice of resignation, in no event shall Executive&#146;s separation of employment be considered an involuntary termination by the Company, even if the effective date of termination is accelerated by the Company.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(f)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Non-Disparagement</u>. Executive agrees during and following the Term not to make, or cause to be made, any statement, observation, or opinion, or communicate any information (whether oral or written, directly or indirectly) that (i)&nbsp;accuses or implies that the Company or its Affiliates engaged in any wrongful, unlawful or improper conduct, whether relating to Executive&#146;s employment (or the termination thereof), the business or operations of the Company or its</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">8<a name="12476-2-MA-01_PB_8_083133_7748"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=8,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="11",CHK=354734,FOLIO='8',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-MA-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 08:32 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Affiliates, or otherwise or (ii)&nbsp;disparages, impugns, or in any way reflects adversely upon the business or reputation of the Company or its Affiliates. Nothing herein will be deemed to preclude Executive from providing truthful testimony or information pursuant to subpoena, court order, or similar legal process, instituting and pursuing legal action, or engaging in other legally protected speech or activities.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(g)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Protected Rights</u>.&#160; Notwithstanding anything in this Agreement to the contrary, Executive understands that nothing contained in this Agreement limits the Executive&#146;s ability to report possible violations of law or regulation to or file a charge or complaint with the Securities and Exchange Commission, the Equal Employment Opportunity Commission, the National Labor Relations Board, the Occupational Safety and Health Administration, the Department of Justice, the Congress, any Inspector General, or any other federal, state or local governmental agency or commission or regulatory authority (collectively, &#147;<u>Government Agencies</u>&#148;). Executive further understands that this Agreement does not limit his ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company. Furthermore (i)&nbsp;Executive shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that: (A)&nbsp;is made (x)&nbsp;in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (y)&nbsp;solely for the purpose of reporting or investigating a suspected violation of law; or (B)&nbsp;is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal, and (ii)&nbsp;if Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, Executive may disclose a trade secret to his or her attorney and use the trade secret information in the court proceeding, if Executive files any document containing the trade secret under seal and does not disclose the trade secret except pursuant to court order.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(h)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Breach</u>.&#160; Executive acknowledges that the restrictions contained in this Agreement are fair, reasonable, and necessary for the protection of the legitimate business interests of the Company, that the Company will suffer irreparable harm in the event of any actual or threatened breach by Executive, and that it is difficult to measure in money the damages which will accrue to the Company by reason of a failure by Executive to perform any of Executive&#146;s obligations under this <u>Section&nbsp;5</u>.&#160; Accordingly, if the Company or any of its Affiliates institutes any action or proceeding to enforce their rights under this <u>Section&nbsp;5</u>, to the extent permitted by applicable law, Executive hereby waives the claim or defense that the Company or its Affiliates has an adequate remedy at law, Executive shall not claim that any such remedy at law exists, and Executive consents to the entry of a restraining order, preliminary injunction, or other preliminary, provisional, or permanent court order to enforce this Agreement, and expressly waives any security that might otherwise be required in connection with such relief.&#160; Executive also agrees that any request for such relief by the Company shall be in addition and without prejudice to any claim for monetary damages and/or other relief which the Company might elect to assert.&#160; In the event Executive violates any provision of this <u>Section&nbsp;5</u>, the Company shall be entitled to recover all costs and expenses of enforcement, including reasonable attorneys&#146; fees, and the time periods set forth above shall be extended for the period of time Executive remains in violation of the provisions.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(i)</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Release</u>.&#160; Executive&#146;s execution of a complete and general release of any and all of Executive&#146;s potential claims (other than for benefits and payments described in this Agreement or</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">9<a name="12476-2-MA-01_PB_9_083141_141"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=9,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="11",CHK=999378,FOLIO='9',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-MA-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 08:32 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">any other vested benefits with the Company and/or its Affiliates) against the Company, any of its Affiliates, and their respective successors and any officers, employees, agents, directors, attorneys, insurers, underwriters, and assigns of the Company or its Affiliates and/or successors, is an express condition of Executive&#146;s right to receive termination payments and benefits under this Agreement.&#160; Executive shall be required to execute within 45&nbsp;days after Executive&#146;s termination of employment (or such shorter period of time as specified by the Company) the Company&#146;s standard form of general waiver and release agreement which documents the release required under this <u>Section&nbsp;5</u>.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Survival</u>.&#160; <u>Sections&nbsp;5</u>, <u>6</u>, <u>8</u>, <u>10</u>, and <u>12</u> - <u>17</u>, and such other provisions hereof as may so indicate shall survive and continue in full force and effect in accordance with their respective terms, notwithstanding any termination of the Term.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Notices</u>.&#160; Any notice provided for in this Agreement shall be in writing and shall be delivered (i)&nbsp;personally, (ii)&nbsp;by certified mail, postage prepaid, (iii)&nbsp;by Federal Express or other reputable courier service regularly providing evidence of delivery (with charges paid by the party sending the notice), or (iv)&nbsp;by facsimile or a PDF or similar attachment to an email, provided that such telecopy or email attachment shall be followed within one (1)&nbsp;business day by delivery of such notice pursuant to clause&nbsp;(i), (ii)&nbsp;or (iii)&nbsp;above.&#160; Any such notice to a party shall be addressed at the address set forth below (subject to the right of a party to designate a different address for itself by notice similarly given):</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">If to the Company</font></u>:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">APREA THERAPEUTICS,&nbsp;INC.</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">535 Boylston Street</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Boston, MA 02116</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attention:&#160; Chief Executive Officer</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">If to Executive</font></u>:</p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Scott M. Coiante</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">At the most recent address on file with the Company</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">With a copy to</font></u>:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sidley Austin LLP</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attn:&#160; Geoffrey W. Levin,&nbsp;Esq.</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">787 Seventh Avenue</font></p>
<p style="margin:0in 0in .0001pt .5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">New York, NY 10019</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Indemnification</u>.&#160; During the Term, the Company agrees that it shall indemnify Executive and provide Executive with Directors&nbsp;&amp; Officers liability insurance coverage to the same extent that it indemnifies and/or provides such insurance coverage to Board members and other most senior executive officers of the Company</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Entire Agreement</u>.&#160; This Agreement constitutes the entire agreement and understanding between the parties with respect to the subject matter hereof and supersedes and preempts any prior understandings, agreements or representations by or between the parties, written or oral,</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">10<a name="12476-2-MA-01_PB_10_083208_7608"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=10,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="11",CHK=193221,FOLIO='10',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-MA-01_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 08:32 2019' -->

<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">which may have related in any manner to the subject matter hereof, including, without limitation, the Prior Agreement.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>No Conflict</u>.&#160; Executive represents and warrants that Executive is not bound by any employment contract, restrictive covenant, or other restriction preventing Executive from carrying out Executive&#146;s responsibilities for the Company, or which is in any way inconsistent with the terms of this Agreement.&#160; Executive further represents and warrants that Executive shall not disclose to the Company or induce the Company to use any confidential or proprietary information or material belonging to any previous employer or others.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Successors and Assigns</u>.&#160; This Agreement shall inure to the benefit of and be enforceable by Executive and his heirs, executors and personal representatives, and the Company and its successors and assigns.&#160; Any successor or assignee of the Company shall assume the liabilities of the Company hereunder.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Governing Law</u>.&#160; This Agreement shall be governed by the internal laws (as opposed to the conflicts of law provisions) of the State of Delaware.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Amendment and Waiver</u>.&#160; The provisions of this Agreement may be amended or waived only with the prior written consent of the Company and Executive, and no course of conduct or failure or delay in enforcing the provisions of this Agreement shall affect the validity, binding effect or enforceability of this Agreement.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Withholding</u>.&#160; All payments and benefits under this Agreement are subject to withholding of all applicable taxes and other required deductions.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Clawbacks</u>.&#160; The payments to Executive pursuant to this Agreement are subject to forfeiture or recovery by the Company or other action pursuant to any clawback or recoupment policy which the Company may adopt from time to time, including without limitation any such policy or provision that the Company has included in any of its existing compensation programs or plans or that it may be required to adopt under the Dodd-Frank Wall Street Reform and Consumer Protection Act and implementing rules&nbsp;and regulations thereunder, or as otherwise required by law.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Company Policies</u>.&#160; Executive shall be subject to additional Company policies as they may exist from time-to-time, including policies with regard to stock ownership by senior executives and policies regarding trading of securities.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17.</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><u>Code Section&nbsp;409A</u>.&#160; This Agreement is intended to comply with the requirements of Section&nbsp;409A of the Code, and shall be interpreted and construed consistently with such intent.&#160; The payments to Executive pursuant to this Agreement are also intended to be exempt from Section&nbsp;409A of the Code to the maximum extent possible, under either the separation pay exemption pursuant to Treasury regulation &#167;1.409A-1(b)(9)(iii)&nbsp;or as short-term deferrals pursuant to Treasury regulation &#167;1.409A-1(b)(4), and for such purposes, each payment to Executive under this Agreement shall be considered a separate payment.&#160; In the event the terms of this Agreement would subject Executive to taxes or penalties under Section&nbsp;409A of the Code (&#147;<u>409A Penalties</u>&#148;), the Company and Executive shall cooperate diligently to amend the terms of the Agreement to avoid such 409A Penalties, to the extent possible.&#160; To the extent any amounts under this Agreement</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">11<a name="12476-2-MA-03_PB_11_083258_7507"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=11,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="11",CHK=255855,FOLIO='11',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-MA-03_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 08:37 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">are payable by reference to Executive&#146;s &#147;termination of employment&#148; such term and similar terms shall be deemed to refer to Executive&#146;s &#147;separation from service,&#148; within the meaning of Section&nbsp;409A of the Code.&#160; Executive hereby agrees to be bound by the Company&#146;s determination of its &#147;specified employees&#148; (as such term is defined in Section&nbsp;409A of the Code) provided such determination is in accordance with any of the methods permitted under the regulations issued under Section&nbsp;409A of the Code.&#160; Notwithstanding any other provision in this Agreement, to the extent any payments made or contemplated hereunder constitute nonqualified deferred compensation, within the meaning of Section&nbsp;409A, then (i)&nbsp;each such payment which is conditioned upon Executive&#146;s execution of a release and which is to be paid or provided during a designated period that begins in one taxable year and ends in a second taxable year, shall be paid or provided in the later of the two taxable years and (ii)&nbsp;if Executive is a specified employee (within the meaning of Section&nbsp;409A of the Code) as of the date of Executive&#146;s separation from service, each such payment that is payable upon Executive&#146;s separation from service and would have been paid prior to the six-month anniversary of Executive&#146;s separation from service, shall be delayed until the earlier to occur of (A)&nbsp;the first day of the seventh month following Executive&#146;s separation from service or (B)&nbsp;the date of Executive&#146;s death.&#160; Any reimbursement payable to Executive pursuant to this Agreement shall be conditioned on the submission by Executive of all expense reports reasonably required by Employer under any applicable expense reimbursement policy, and shall be paid to Executive within 30&nbsp;days following receipt of such expense reports, but in no event later than the last day of the calendar year following the calendar year in which Executive incurred the reimbursable expense.&#160; Any amount of expenses eligible for reimbursement, or in-kind benefit provided, during a calendar year shall not affect the amount of expenses eligible for reimbursement, or in-kind benefit to be provided, during any other calendar year.&#160; The right to any reimbursement or in-kind benefit pursuant to this Agreement shall not be subject to liquidation or exchange for any other benefit.&#160; </font>To the extent that the Severance Payment payable hereunder is deemed to be a substitute for a payment provided under another agreement with the Executive, then the Severance Payment payable hereunder shall be paid at the same time and in the same form as such substituted payment to the extent required to comply with Section&nbsp;409A of the Code.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">12<a name="12476-2-MA-03_PB_12_083309_8146"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=12,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="11",CHK=325575,FOLIO='12',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-MA-03_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 08:37 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">APREA THERAPEUTICS,&nbsp;INC.</font></b></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="46%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:46.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Christian S. Schade</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Christian S. Schade</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President and Chief   Executive Officer</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXECUTIVE</font></b></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="46%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:46.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Scott M. Coiante</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Scott M. Coiante</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="40%" valign="top" style="padding:0in 0in 0in 0in;width:40.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Senior Vice President,   Chief Financial Officer</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">13<a name="12476-2-MA-03_PB_13_083709_7091"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- ZEQ.=1,SEQ=13,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="11",CHK=70507,FOLIO='13',FILE="DISK121:[19ZBM2.19ZBM17602]12476-2-MA-03_ZBM17602.CHC",USER="JTAYLORA",CD='Sep 27 08:37 2019' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>12
<FILENAME>a2239779zex-23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#19ZBM17601_12">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A NAME="ke17601_exhibit_23.1"> </A>
<A NAME="toc_ke17601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Exhibit&nbsp;23.1    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ke17601_consent_of_independent__ke102315"> </A>
<A NAME="toc_ke17601_2"> </A></FONT> <FONT SIZE=2><B>  Consent of Independent Registered Public Accounting Firm    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We consent to the reference to our firm under the caption "Experts" and to the use of our report dated August&nbsp;20, 2019 (except for the
retroactive effect of the 1-for-1.6045 stock split of the Company's common stock as described in Note 1, as to which the date is September&nbsp;27, 2019), with respect to the balance sheet as of
July&nbsp;11, 2019 of Aprea Therapeutics, Inc., and our report dated August&nbsp;20, 2019 (except for the retroactive effect of the 1-for-1.6045 stock split of the Company's preferred and common
stock as described in Note&nbsp;1, as to which the date is September&nbsp;27, 2019), with respect to the consolidated financial statements of Aprea Therapeutics AB for the years ended
December&nbsp;31, 2017 and 2018, in the Registration Statement (Form&nbsp;S-1 No. 333-233662) and related Prospectus of Aprea Therapeutics, Inc., for the registration of shares of its common
stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>/s/
Ernst&nbsp;&amp; Young AB<BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Stockholm,
Sweden<BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>September
27, 2019 </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="12",CHK=932682,FOLIO='blank',FILE='DISK116:[19ZBM1.19ZBM17601]KE17601A.;14',USER='JTAYLORA',CD='27-SEP-2019;16:04' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<P><br><A NAME="19ZBM17601_12">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ke17601_1">Exhibit 23.1</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ke17601_2">Consent of Independent Registered Public Accounting Firm</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=JTAYLORA,SEQ=,EFW="2239779",CP="APREA THERAPEUTICS INC.",DN="12" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g124762lmi001.gif
<DESCRIPTION>G124762LMI001.GIF
<TEXT>
begin 644 g124762lmi001.gif
M1TE&.#=AQP6! W<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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MW2F4WCD1[AD1]:F>^%D?X^:>V-F>U'F?<;F=\7F?]=F?VRD0,'>@"9J@^0D
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M'4[B)CX"=: '%\"]). !\/]L!3K  7;^T!6P!67  :80"4Z0X1^@ E4@""K
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M]-@Q@S3_-@CB@C[Z < **V!(0Q-&1:*T4DLOQ31333?EM%.,;!C!BBHJ$ .
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M- (HL (D09)1V8(R,(7_[_*3#!"R$5@4^/.'0X"#-5&!)A@T,K(#.!B!>OB
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M0!/]L) >/ "W7'"($RK86P5V9#H87> &?5A $BQ0N0B-[PH*$D,@GNJ!*FQ
M!57@W >L8 3ZJ8 #-_C _XDNX($*;*$)_="$"A80A"2\H@YV(,(!/^"!#7A
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MT)\Z!?_>QTP4?DD$ -1 /_C Q]4!#FR ':#-UND&!PB!87R!*41"!GB "E3
M!>2 %<Q/C[P"!WC %QC! O1#$_C #7Q"#E#!#:C !_1!!J3=!=!"&O3!%DP&
M'7Z""[S"%DB !X0"7Z6A>[C 951!!JR6!YC&@2"&";R"!+E4VBV<$1 "!UQ
M;BD W^R&;U@<*9:B*9XB*C('QD%'/US!#=3#!XQ :77B&IR%%)C5"$!!$(S
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M90 .**<%D/]'$(3C!GS #8A!/\#!(-SB!AQ"%\"!!UA%$&P!SYE%=E$!!-B
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M!=LO8$% $<@! <>R2=W) X.P"(CP2!"$"5NR1PB-0NQ7$/]PC"6@IT3+Y<7
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MQ8N_XK@8@5^EFNR<4O]JY=T20][WS'P3Q,P$KM!JQ9Z$'%AW=W^W!&!V<QM
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MX  &+!#(+:C %)-XHR:<L(173$0)Z7G%%S1!H55-0@@>L%8- ' _,<!A UU
MT!+$\($D2*$+&^  *\EA@51J,PT;2$(%R*&)#!2) QZX@10.58$*Q   "Z 0
M=5SRN8. C3I!06E/F)A2JHA-($P4B3 D<09#< 9=F3" ,PSA_[R^6,$$)TA9
M,C F&!R08AB!.2K&C+I4P(Q"%A-4R$^&"J\X'",8 LO,9I#8,0/$8A*Z6($_
M^N&2K_8P&%:MR@@-8 5VY'2GZ(*)5K4@B;5$!' MN4E(9CJ5D[&M7>Z:XD!^
M<EB71*2FMSN*3I93OL!*]K#D2^GC8*)%F"1E:=U#['%R\MF+; <Y&4GL2CJ+
M$YXN=ER='9UV%'M8H\34(9]%UV>/6+IM\:2E2TO*;V$GE,I]120,F6)FZ<:9
M?KD4.4DYETG.E=G1L82UO$V=1IRG.;OE3;G=>>Y0P.O8PE%DBJ=56FBI%SSO
M0%>Y=7MN5$0 GK'--#N-ZXE)M*.33?\IY[ZLO=UHF>,NJTB%$<$X0Q*J HZ<
M9**M056K7DZCBC,@M6A#P,%G.&#4"1?'J*%8& >HZHS(&&6H'_S,,=8B 5C$
MHA7PJXI8R?J%L]*++P$3R'!$O!6J#%4"C) $4 ^K53?03(9%<2ZV6F(N<!6W
M*\X3&[MJ&E[2IDZ][R,*]=Q6'0 TT@<B'<$UL[" #>3@ U_80!6"4"PF5>$&
M0:C %OK0!PY0H0F:D )#3=$$#'0A"4&XPCPA\(*23F 0)-6G#0;A#Q-\L9$S
M2$(=#-$%*4QB TN0PA:"D 8Q7"$)-OA %>I0CS1@X%&:(,(--J")*E3 ""3H
M0P7>H"Q46PO_FX>B0I6.F6M=[YK7O?;UK\N4S#-=00<C0*4; " %*!#!"16H
M0C_\L855"T)26Q"$$38@B!$$ 152<'4@EM#'#/0!!W;@A#E-@0$_Z H K !C
M/]7CCPH1A%,Q8,4$^J&%%5Q!"J;H@PG$X((/A*@+L#)D'XQ0AP!=J@PF*(,,
M,7"H"T! $RY( P<H$00]Z ( 5SAIX?[J$K$5Y;LU&5W;$A)8['SW*PPV@@=&
M-Q$&;\,#16%P/3QPES/<(ABM8# >$A&'-SQPYSTO,- OZ')#P.\5-X]!(L[
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M9$ N,B#G) P.$@$8<,$9:H ![R(.;. .<$&";( !!0.%D$,N4.%?#BQB"L8
M6NRVRH-ER@G:<.I@2@9F!L*H .->#< .VC4(%$("N)4#), & V8!L+*&,++]
M4DO^1H<B*U-\>!!DPZ<L#?,'F0@R#4\\O*8(>=/W4K9CA;!YV#)OI&AI;+9C
M0=-<KA7P:#9D86_Z&%1D??.X@/9HA8\'IVN*;*I9038(98LO/];S3+;V".\L
M3[.\2E9DE4=FXT\[L 7:7BIH;VNFM,;]/#-:FW5HRU)OVH8BV^:U."]G$S9E
M_SA *!C!![+@!"2AJ80""$8P+-O57"M(Q%I2P_H@B"0H<?G@#8S*7FM"+G+!
MQ Z&&^X@%L0A8*AO 79 "S1A 83 'WP,,2# !*HN88= 6W4"&O0A%[+U;@<B
M;P7!!N> %GI,$HI#L!0"0V-6>9;6:Y40"E/S9=_F!Z&P*5 * $CJ"W"@ E2
M$P@A UA-CR3%"E1 # HI!PS1"!;@C/I #S! $*@@ W1A"PAI!4JA#$C .;!#
M!7) 3I1%0)0%!ISI!G(  TCE'09B$LI 17"@#,)M XC@"U<@S23 ""@! W0
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M XQ #R([2C#!"E#A CX!2C"[2&Y !PC)'_I@$L2@#C; "8Q !4;@ Z"@'Z1
M#'K) M( !C; X:J[2,)7I.P "A25C/1@@AURRS[OK6 6M/^^0CKZV</?4BCN
M0A\&01E03 ?]P:CT(13<X#%B 0,*HET-H<#68F.&3L)JG 1UYC/H8 ($8PY<
M',8OX(.@+C)>Z)733RH,X@[T(1+"01EP5T'#Z'3AA\5#X1!@' .TPJ@,8! *
M <6,P _2LR4;PC-*&C1_4&]$@HL\7 *D VMFX 7,Y@6T1O%:]GZ@X\[IO,_M
M'(HF@"D2LYNUR"F4-FV;R'XR[["&MRR'4\V'-FL[:_2""VF9]CB&%Z M/7-
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MQ17<X(,-),%@&=C C@;A@0V0:P2H\( ?-B"%#*2A"6*00!>ZD($MI(%90?#
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M!5*P!48@!7UF!,W$CCB ,A4 !8:  150,!A !T>2D$&@ A50!4VP3,-R7V(
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M0+6S.30W%[/5:(Y6/R)Q'/0DA")5I#VZ-+%X$K*9(K!#A,Q#G*0V/-@C-B;
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M-%'[W&FZH8!C4[)P96A>6\>PVR+L=!,^NK0O QN6R&OL9#<315JWALL'C1S
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M'"N@$MG%7RD?5[84')$AD)A7_=)\_#1"S(H-$OQ< >!O@3\]6@! 6#!I0U\
M_128$K2ECY0J,#YM27PED!T,'T;<D"+A4"E_F@A1RK!E 8<F*D9@@%(!@XH/
M6TPYX9N/)@1_N'7_Q2TA]P0)NG/[\TUXN' )$Q2HS,V;]_$%NL%- "Z\]W'_
M[+V9 Z?>/7APXLPA!(= /?EY[N"-EY\@0X0$"3* J_>'O5]R!=7]M?>N&SU]
MZXB#@+ )8DBO.MW$&R^Y (6#;C=_W@L.'!',>X\[#"40(3H1ZHNN.>@Z7._#
M!IN#S[P2LQO.Q/EP@T[%XL:CSCH17TS10>R.L^[#[$@$<<<!-[R..+^TT,<
M<6(Q()@E#7 R22>=9)+)**,41\HHIVRR2BNS1%+)*I6D$DLRR]Q2RS&A---,
M-;OTDLHQQZS2C7Y6+&[%ZY +\$[PBKM3.OWJ^Q/&!<T3C\@2=8-@NAES<[$^
M2/O$CL_FA)N/N LU#.[ !=Y;M,0:522N1>O&&T_"_^24 Q#12;F#8#L,_4.1
MN1S98W "6_5,3X%4-1U/)>N^,R\]!UTLL3C>3E3/QT&'4U;%$4'<U#IP?NP-
M-P!J * +*C*H8@/87!N! C$V6 "#$=*@0P4;2ADD'RKTJ "K-##P00*Y#*K+
ME" LN&*!N/SI9X$M)NBGSD'JE " 5R009(-2.*B@BH^V&%@7.^S8XH,;/MG
MAB::F $#)Z#XP ()-KC@*@S2N&&)#=:X8 -3!IX+E0RHB(DIGGOV^6>@@Z:I
M@ *$YDD1,"I)01&CF^;)J:.^^, .3E0( @ ]0-'JAB :$D./+TRP( A4*AC!
M""+ZT66%!0P1@X.UK# B%/^L#;+BDR \&&B2?MR0()0FC*C"$'\XR6&+)OAN
M1()!Q%!![[FLJ""N4"I80X<;G'""@P6"$*2?2>1MBP,]%M!C RAR^,")DR1V
MX10 ;+@-6A*!8]5'W$B,CM=*H64U-P9]1P[XXPKD]57DZ]013X%+#:Z?"5XI
M<((7 E;441&DGP#W 76+(1\#GX=61EQ[=Y:Z&"10@/<!G>U=-^EQCRXZ^$28
M(889%'A!OE[5:Y#^[L0@!B]0P"MF<"H>Z:9&>\H-.!(DHU>,IWBWJU0_0J"2
M5.'.=[F!GH$^1*G==.A#(_2/I8;S0>;E*4)^$8X( I3"!!7"2U6*TY:R%(LK
MU1#_25R2$I-P>"8>HNF&5^)2#8G(0S/)B4E'M.$2FXC$,.6P2:S S00>1#P@
MU2=WB8(6?IS5/@B5!U&]:AX6W2=&PHQ'>\CSBY!,%9T;O8\Z+S >?,XC 1_A
MSHX!O-_]YN.;39T0 @8"(ZN,Y2@)Q$ !BKS4%=47P5<-QX&1+,\ \\&K.DG0
M6,D)WZ&B [U7&,A ^NE>)C.)IT%1<D#3<R"R-&G([*0JA3UZ8'X$F9T%$B>"
M_G#@<%RH12+U@RIN^  ',)"#"T !%5801!7ZX0,.T*$"'ZB $?JP BJ\(@D<
MN$ 21H */>#@"QX@AQ7N]@$BP.$#;GB!#QC6""GH  H>__# !5R0@3+TH1]?
M,(0;RF"!/G1L!)^XP0+<8 31U8$2G+BF$P3Q"B.,0 <5@ ('#M&/*G#3-2Q+
M0A6:4)_9) $*"'%:24UZ4I0.)04E0*DBD'  F!Z 'P=0 Q+"D(*4YA0H5S"(
M1_BBAW9 (0,NP  =;F !#/B! QFP@NHJ((7[V" ..+@()PBQA0HT80$+Z!@,
MK'"#+KRB%/V R2L , -WK:$*$1V!'N[ECTGTH11?4,$$FF"V$50@"0!8@1$J
MD(L@!&)BD6A"7_I0@1O,ZP)V> 4GQ)!82E2A JS+00;Z ( 8T"0W'7+E^<CC
M2]K]YK-G[-3OV&.P,*(PC=@!CO_TBA5:+I;J%>M39'ZN)2!$J@I$@D*1<C)Y
MK$+Y!GB<;-%P;7<]8]6N0.>;'HJ 9YU3KD=4APH2!*1G(.D%YSGN:Y8"AT.=
M_*SJ3KGL37B_J\+;ZL:Y<<2-B#I$I#-Z-XNK$LX(&_@C6$[@2#H,AIBX),4;
M-M&_2=)A$&WX7QKND$IM:I(4 7Q@.34)3@?>$H&?U& *+PD;HF(@!-XKW3P]
MYT^=RFXA7Y3+7@&+=L5B%"EK]9Q$ 5(Y]W/MA, 86]Q1]S?K6V1X">/"&93O
M?8:4P!I5L@#\T!$\OZE.M4S\V41RYWA?W \A_5<\&=!651!R%(R$YY?OVG:[
M'28R?(;_I\)8XHI$3L:O<&PYO"ZW#P OV.<-TI"Z$03!"3D@@@K(6IH1Y* "
MGPM-*-:2 R?88:U4D !!!GHV00C""%WXP@M>=07!L>4&<M-%3+2@"4V$@@H<
M,((.K)!7#_BC#O)2 0?J,4TCZ*P?03";H"^PA'Y8[089<()D6V,$F"S &1^X
MP CX5I.9Z%39RV9V3D+P VA'^P=A$$%.4D!3G#8M!"^-:;>];08T5"($S5[V
M.SYPMQ%\H0"F\$$%+% 'M]1A$!Z@PC27  4[Z*$+I?$''&C]D0]TX6,)64-=
M1N"#5)?B%6*H$TWZ006*W: *G^!+7Z WB2\$P@3YV, '/E$!_WT"H \;2 )&
MVO(%&_2C#!O0!#E&:@6/;D#F2T@#N#H"+K[(KB_'&NXA346D#XDH.6?\<GG,
M#$L.BQ97A934:N\T/Q5^,%4_'Q!\>&5%%PFWZJE23G%UDQ_JP'*3/39/C+(C
M(_AH\4_<D4\!JQ=G_\PRMBQT5!Y]OO5A;2]824=>H8ZK(A)RD'Q+/O/9D\.L
M""%^BUP4[M-]3G?5JNB7 8I.#")L@!\F>$P_O/R$H8@E+1T13IP'O9/ E. M
MQ2+"F5<PYU4?)=9+&/,1OOR;#*"/6-[21[#,)2WW8V87Z>[Q:"</Y;<(S#V:
MBLS&']6P^)=TWW6WZ.*!(_K*GIQ>(O_W1*],4&[UU[!"HM="BH)>K]+3Q>[@
M*D9[S+Z@*O6GSJZV^^2;O-BA19WVGQF%]YE _K5.]QB1C_U8GE[Z) 4 @"N@
M BK8 IJQ @QXK"OHN#18 M60 @XHA4;K DV8F"HP!3'X G\0.3T8* J@@@GH
M@B8(@BNHC]N0@HD9 2MH A.XC7Y8@2X8A$E8 "W(@#78C,M2&RK8 "OH03&X
M@AB @"80! RH !50@:O8@"O0 PS8@!&@F0R@F<,P'7VA G+K0B]4-F[8A$W@
MAS$LPTJPMIA" J8!FA! @YB:*9F"*3B$0V]# B[(MB_T":@I"G_H@RHXM1%X
M!< 8 4YP@J/_@ALQ\( FZ ,=^( <J (36 @CT()^< &K28*LF@2:6( *:,0@
MZ(-0 )T^,(40=+A^,*>/L(.=20PM< -3D B^09<*6 $ *(!^$ ._X@!!D *Z
MF1N=$0/+V0Q2>P4]L(,@^( ,>!B)@P   (?9D8[>"1XTRR($T1VB6Q312B],
M 1#>8)0E Z;=\+ OZS+T(*0RRA/_>($7N+(=$R 9"+_PJ+HIZQ/K>H'T&0\%
M>$??LQ1>*0[J<2VX*P_V<0X]T: =>1&BPRWCN++[T!\7NRWMFB6K*Q]Z)*_C
MZ!7T^I&_ ![JB*YK9)ZF6Q[Y6B$<VRSG>)_G,!(% Z(E A,M2; <_SH]V7.B
MVO.O'2HBG&Q)"JNAEZP]U%L3VY.2UWO))XF%0L@D&$N@+](3A>00%,H-Z:$5
M^I@4 D$02#D^%^*0[^*/UP*D1*&0Z#$0%>N>?90?,OL3!^H49,D14E&0.9(>
MWA(O1Q&R B&/&5"R!LDN'>L>]1$E>$P..NJ[^/J-V7*5X<L1^E)(^(B@I*P4
M@U0?0+)(:'D%BRR1Z  .ZNNEK S!?'@FOPH"2K@!07""#/  'W""#<"$'$B7
M^QB$01 "'\@<)PBH#1 $FB"!$;2"%8"#4( H&_B%Q'"X+MBTNK#-9 . 0>B"
M4+@"'WBH@M #$@C!%;  (T@".@@"<3J+4/]8 !.H@C6P AW @" 8B _ @#K(
M' [( 1?0&7](@\@Q!9G(PYN(PSB<0_KD!_G,SYY0!!K@ 3)0PQW8A#/$B6NC
M0S/ PZ50!#?T-@:EP_ID4#,H 7'3SYO8PZ*P 8H9@7KX @"X -;9 J'JP,>1
M I;  %.8&3C8 AR0@#[@@+E@"#'0JH3 JYHS*T%8 (;+!V;4F[QB"TT0&%UX
M!7CA@"3H!S_8@ P5Q#JQ  X@!XD+! X0Q%)H@E>0 CN@@C2H@BL$-9.!@M9(
MIMJ,G6>$$?;)O3V)@17!CLDCD?,P2.;I%/4"D) ,OCSA.JXSGB-4EF$Y$?JY
M2.IH&&+A2 9I%D'_Q9"ERP[NV+TMB@\>"Q\S*I83P;I9<B$'ZK]3:24A\8W*
MG+OB4SKJ4,KE\SLWK5-$DD;S22[=D(_RD3_L"+Q).2%8/3Y-;0X1:B^Y Z9?
MZH="\*$"^\DJ8:+2N\DD(CTY&<J=-# L$3UD94D,*Q/2 U9@Q4DGT0)0B3L'
M226Z2Z$9@<?K@;^C"T?W026ONTC ZXWK R-%K160]*7HP-160J#84A^K%!X\
MO3H\>J'[@,Q:N=/N($ON"]150H_^F)0[,C]\9*0,2=3<<:'ZRLBY7%5U#3SR
M>15 HM6,1"-V;:_(*X^+'0Z5   XP !**$85F!@5P(!]^X T4(&.TP0B_]A.
M#^@#0= ,=PL$34@,$L !B;.#<9( %8"#3N-0 " !"C";B=N"(A4"78  3;@"
M31!$'[ #&+R!R]H6PPBT/%N!5S =)^B"+9A"J84"7<  3= 8*+B #U !*( )
M"# ;&'B)4J10!IU;F!**HO&)N^V)O.6)O:50F2 #- " 'M@$!*V):Y-#.53#
MI>"V!VW<-VQ0NCT , @#O[70H2B +LC2N7B% LC2#)"F9+2##8 #8%39#/@
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MU<HR"6"$6#@$94B&..  ")@%/N"$5\D$>B@$95 &4O^ @GZ$@#N  JB$AER
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M'\  06#"R)("** 8.H!"AM$L:B&0@U0A"T^.WQ+'%S*.CI0N;+7A 6&$,_
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M0,$(-Z1QA0UZ&&$#%4NH4(44_0!H00XJ7' #!K3D8$40&_3S2@566#'"!@#
M&*.,,])8HXTWXIBCCCL"  (8/[AR !(BU.@CD$(22:.100Y9Y(],)@EC#WOX
M,Z,K*=2HR ]_' !&&%7RN&,(!=R8P@%GGLG/ 6JBV>:92)2 A)PEJ.%FFG:B
M:488BH0A_P*?*?"I2 EJ$GHGFV@>BN8F!X39J*./TFC#!W9@4D$7  12104<
M6%&!$U;DX$036W@0Q <7&%&!/PO4 0 <4 11SP@?N. # $*L4. G(P313Q!U
M2$'"%_T L( ;_0@!8PA=$$O")$3H\6L_&U@!PP<H E  #LZY2,<&_O2A@@EN
M&('*!1DL\,H6A-@Q0AI+?""%!Q54$,0KQ<'HT +"I4656*OJ"U8,"U&$6D4
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MIS99,TW&7*<QDW6%*ER@15< @!%R@0$+6& #:?@ %%30A WTH0M4:,(%3+&
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M,P3;3B")CC@C"8QP!ALD (T/)#8BC/C%(G[1![O/X2,WT/LG*+* 3-"#8OV
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M?(83(E#VN1WU 4QQY!;G!!C!4!D#2D[F1 Y!;.'_1+R";P" I)F !("*U7$
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MT/P8)_@01':5#MS-T$+,W4(X B>T%BQ\PBA,#'%DPAET#.EDPC" @@P<[4+
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M.O7 /I0 %B!R"21K,G*#(2,R%BAR%#"R(R?R(E<;)4.R);^2(B@"#70R)Z<
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MG$H!R!&X$_Q9%4R"(&0!.;"(%6&1KRR!&&"IF?7#SDT'">A"/ZP R'W"=7B
M#VR 'R2!#_A /KR"&[S"*;C!!LRA)G0!!V# KLP*1;#")'# U-D 4_B )IAD
M@1,+'%!1&J2S#5R!RE*!&'Q94Z+"$IQ'588=W%Q%0PS9OL"/ JS=]N4-[_F%
MT":@ D65AO7>CTD >$??$[;%:,:%"*@W_]Z<# !WA@DXCA2ZQ0&Y!D'XMKU3
M6&,(E^D^3HH)UP6=:&GI1>+:[P@;3'"ZA<A7UP0KS+_0M04]?+X/1/NTMFE'
M'\9?+A8J5VQOKWW#!E5(5_8"S.?JM@G4#G>6Y^_*EV&'%V3KKO+^7WCE7]$3
M[]'_#N]\!.T,H._DPTI?CVP[EPG3^VJ,D%8$L&6(O7M"\&OEQEM8Z'[BE@/Z
MM0 )L&L8:&N =Y#9UFVXU<:K*(<"F>9D*.@^# #S&&"%D/<Y#]Q#H7#%9D94
M=U[0QG(N/ECLGMJDUE@(QT)D'U=.H,( O0H11 M^??;$G5@ P L @ V401I0
M0 8X 99*P0U\0?\@;<$>CT @V,>K.($/U,$D: )$",(I3L(KY,.24M$'I$$=
M.)T>7$$7^, 7S, K=,$,:($/4!T.H&(=6%T5B<%Q2$!):D(04(0N; "6.H$4
MU0<51/,'5($%] $55$ 5 -$26(!"(B5?9( =K$$]?+&E9U(@8RJF @0 @0,)
M%C0XL,>>$ 2%_$E!,*$(A@XA[I$XL.%#A!8G:A28L   'M<$NO((H,T?+%BB
M1"E1(LK)@S,9@CAP\P"2A0=3X,2Y"2>_FT*'%B5Z0)$9GT5O@E'$!.A2J0?"
M*.IY<Y-0?EFQ'BU*$VQ8L0<?C:5IP\J(-#D$^3/E) B4#SC2?#"$@<K_JRTZ
M<E@Q\@4 ARI5](@1V&^2D0UZ/)BJ _C+B!%67'PI4RJ)! X25@#8T._*BA4+
MC$SZ4F7$A\G];/B@TL>#BBVA/O?S-ZE"A2T<_)6I<J-*!14+!G7Q8"2#'@NT
M@G H<T6(!('^(%"G/@%"=>H+JG?WYV^!=>S6MUOW7EV"@N[A(; W[T\"? GG
MN7^?_[W]A D*^F5_WQX][2"00(()"O3O/.OB*W"^_B P$#OMWMONP1A>J"&&
M"6)X9P(''SQP004M-+ _"JDK4#\%,ISOO =?><' [*IS<('Y&%S/N_]NU.\5
M^OXC[T'][EO/Q.[FBQ&\'^,#T!\DO5O2/?1(_PRPO!P'?%!!\Z(\<3SOZH/R
MQP2U%,\Z$:RK+T$(7M G& /<?%,< ]ILTTTZ#8C3SCOEA'///?.LL\\WYP14
MT#?]-!11.]L4)Y9%$34TST$!73260 E5M-(YP83 S#3Q@R_+ZIS\403W;L2/
MO?#,DW)(4!%\[]3VJB1OP1@]37"^&<8#<M;XKGL%0AFP*]'$$]$C\,H!2_1/
M@AA>42!"Z@ $1T7]8K2M.R-'G)'"!6SM+H9\7E"@AGQB4(#%,/M#,;YU]>O/
M/04=)-# (:F\5;\8S-RN4]O0A$\&']O;][P._[VUR27#'!.[\$1 SQ\ ).C'
MAS[J4$$0(RK(@ H/FO_PH(X*]+#"B@H >*6)'$8PHH]^6(MCD"M>PT 332"P
MXX81*JBB'RF,((&$(/I8H)]3^N&@#Q(\P*&)?HQ 980JFH! #-?@H((#(YX3
M H 5RM!#YU<6T",-R2K0I&</#-'MAHL%\1H ?ZQ88V[#N#8+[[SUWML@(:*H
MA"!NS#C);\ '$ISPOP,?G"'%#V=\(XD2Z@< $ PW: <T!+*<[[X5$2$DFGK2
MRBBF#O#*)Z^(0GT,1<!@BO33<4(B!46 0GVIU7'JG/?>:8+C@[2JZ ( /3+
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M$I+*J(!Q">M  X+0('D%@77]4:,-Q:.Q)O "7RE)GV3\5T>#]*F%=>>>@5R
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M), '*&8!&HP(- &R!H$#?. *NL %1O_ !_PA'W! -5+#!1:  ]( [)(@")Q
M#TH!CJK@!3] "@3B;O:O=_+@ **"'S8K!)*/!I*/_!@B^7X@!9)O^@! "')S
M-X&O-W\S^8+S!WK3-WD <)"O;UQA#RHA):( $I# ^%A3(*YBN:Y+*C;!#-2
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MQ]#'"+27 YQ 9R+! X2  TSA;Y? !(!L,'S  [[@%01!#SA@!4IA!7;#,1=
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MDINI$)A#PV$%4M0$W*  AJ\*'30?=*&G%J /NJ 4!/\,#HS %/J 931A ZX
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M@X$N'.#P 085.*''*P!<D<4&=?A0!P=&!"$! !NLL($'?1"GBPVZ  "!$@4
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ML0BCXUX=]A*X4 ,<D3KT9P"X$#\[%EM9P4#_/I,72U-Z?79XG3$W>O$<D[$
M8V$6[I$TQ=5"PG%XOA$8'DAY<98Y<N$T"T!]T\=#E*47,Z 6KT! G3,6.9AG
M("0!M%$:2^$;-:!Z"!%"'^9"K_!BY!4=?*%YC><XP0<=@&,_,.,8X)$6:@,6
MCY=G7(&%2(,^TV=ZC_-X4=@Y1U1'9"%5 . #@C!S'W %'C (&U !63<)'
M1E !&Y #=I $@G E:?4*?8 C*B (', !@R &]O$*;F BZ](/35 &25 %8[55
MY& (1E &9414FY$A@B &9: )1" (2Q $FA"$DK@%%1 $AI +51 ((Z '#;(!
M@J '1A *?"0(-S "_T1 !/W2#Q>P45:@)8*"<M 8C=*(*40U;UL2 MB8C1"@
M"-9H(B# *CR 3-K42CO !&P2 FP")NSD4.[$3\'"COM4+*EB!O-43_1H!O=8
MCVJ0CPDGCZ@24?PPC<JB<JT$!Q_P"4XD!@"05H)0 1@0+AN@"4NP 0MP!1#0
M!)JP 6E0 3B ("I@!52@&^^P H+0!9CD 4'@ Z; :/V@&UO0!#YB"F6P!%3@
M E10!U10!E1@ 1BS&0"0:QB@"1()!U+0!2O0!4MVD1MP,OGQ 5NP!&+P!:]P
M!0LP"8)@"A;0!0#0!'J02#?0!4)P(84W7,G1-XI'%GAF&-)G7)@#9"6V&_](
M^%QN&6(S\!BGUV)04T%O8Q>&U5B LQC:X85?8V0MU&1"UA8*X!IP,1L:I'HR
MH !,)C]YTQR!89<MJ(&/84"Z95N2$8/"UYESID/+85Z'MV:8:5BYU3==H1V$
MHYI]I32;=WK)YX(VIF+.-3.(MV/] #P787X=01'UASO:@P\31E_VI0]2P9OP
MA3NE$PR% !'Y !3!,& 285^Q@!%*(1)%  <:MIW="9W=R1'C\!.+\#I.43JQ
MT)S\]6#*"11N((/.55E?IENLZ3.)@Q7F8SZ8<6,YDY=>*#F,XWM:.%@\HY99
M04+-X1ZA"3C-L15?%J Z6!?- 3B'(V9EB!8O4F/_!)&8G"4;57802R,VS36@
MQT>9F:,9DYDY=1E8)R9=NM$6[J%C>7-[;H$>3RB&7EB?$J"@;JEG=U% -D98
MEK&6.E:''Q $)W5V\N('%_ **S #)!,$4B!*3H R?I &?= /2.(P7U!J@O *
M&R &P;89>R@%)# (6M4%&X"1@> !'] '%E !?3 ? ' (&=D'_"((7R &5Z +
M9/0*% !X>L )J<1T"S #-K  4K "5$"1-H #4B (:= $D5&,:_ )*@!( EE1
M-*!0/'!N/_"IH'INW;BITM@#^_"/XR@I6+!P8+"JK10"/V!,>9".Z]2/Q */
MJ.*.N]J/L4(&: *LO?I0_^V4JZ::*03)2G!P U;P+!P  =#B!!M@ Z_@ GJ
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MZ)JY(0*'O3Y\.1]Y(SG+!1_BH896FSGL\U=Y 4@Q  !=H =TUP>O4 J#<,0
M K! E 1]T 5+\ $C0 N?9 =-$,P@8@,S4))4H L &P.E@%(9@ H8( 8W( 6>
M* 7-2(ABD 89@*\XH"Y4\ 54$,R/S H3T 5PT 09$*<8P*PZ\@H<T!48(BY6
MPFIQM0&3'"#^8"564 4J(,BLA(XBH @-_N .'N'+0DY@\&__>\($AR($M=HE
M;9!-!]<&&#XF(0 F= ()T:0&81#% - &L%I1B6(&AZ((_$8H74(#N@I1O&H&
MO8($BH & &4&[^BKQ)HJ;ZQP>WPF"AXFA*PL$' %+E !4/ !TL(!&/ !D[
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MAB/=>N&M,;-4X 6CQORMN^UTFZ"S!418JY_8C*)L-.."2VRR2+>CSS+!9)C
M,2W!9$]/YM9B5%++2C.S+LK,2XV]_2C%C$K0HH1@AO8 F " *U3PH L+-B"D
M'R+J\( .#-#:(/^.+_K P8@D.+B BAM&@"(-,2:Y @ ).#CDE7Y(P J5"E2H
M0 P?7MD  P\V6&(#$YIP JP1,JB@'QO<PA:<?N H@XZL<KC!E N"\*"""CAP
M0X^IDL! H"""$&0)'YH@N(ZI_-DB P[2F 0 (=("H!^01R:Y9)-/1CEEE5=.
MN8<]"A#B!S-2(/F$:]+BYF8A0*AD9)<5^0,,D$'@8N00?D#Z!QI^( ., GS>
M(ZT00':E9Y:O/KF' XH&66NK24[A +'Y$?L ?C8IF^RRF1BC[#"B.*"$'Y H
M>VLFT& "#+SQ!N/NN9E@ HD?T!"<;R;,J%MLM,<V>^S%#\ Z<LDG+_G_BBWL
MV***;/7(&*@F,!A!#PYNR($" &:89))^NN! DRH^4,$*"_I(HX(F,M!$@BNN
M6Z$"L*P0?9"@5GAEBP5\Z,((&UXQ80,C-E@#@PUNV&"!5U[I@X,-](!BA V2
MR& $#&Y((_L7^I'"!PFVOZ&B"D;8B8,OTI!">7_0 D RT-A4S,G]E8L/.";0
MC[E0!D[/(2  G],JV0"&/0I<RV1B<"?,M$<!?K(4FR8SEPR>:31OD<\&\R(!
M HYP,GXJE)A>\987O !.VU$ IY:S'1&VARV_*8QH^L.65^#0@9JB(9Q$ $',
ML.:"_)-4J^#")AY"AC_V@0L(Z127Y"C@/&D2_Q,3M42E3V&1BDC\HFCT@:,/
ML:)$;L"1A<01"QJ52 E:T(>+@J$B):"Q1T2Z$1L-P(H8P?%!BS@0BV@4H0G%
M"!<X\I !$JG(1K3(1\K(T"$=M$8;!4@9"%+"D #D(2V4<(IP4: (IRBI&D:)
M+UR<HGI*B9[G@%$T"BBA#3FHQ,]X<3*L8:5E]&+%Y?SEE@,$9:SD]"I04F8"
M,HS@F)@SP>[(10(OP.4)F51 MC2G/B)(S!(+4\,#:FJ#E(DE%&WSBB.*4S7*
MX:(!,\6>W&@)4P,TTS25=!]49K,OZYE!8)0#@!H 8&(?V$ 7!'$##!C, C>H
M  965XHN^.,*))A>!O\D&H@@5" #1IC$"C33AP40X09-T,0' 'H(#RR@"SZ8
MQ *NL $?Z(*$3=C !ZR@"0SHH0X+L,$,%K ""N@A#1]H%RKL\($*2*$/<%AH
M%P!@@0K@@*D5L (YNE"'#6RA"1V3@ 4R@ $,4(%R7_VJ(CHQUK&"%63<2-S8
MO@: -LPL!" X !A^$ 410 UFG4 ##8!&,Y )(0],^"L35O'7M;JL'T+X@]6(
M1K*8]4P(BOB!/\SJ,2P<  U(6P49S%#7DH5-;9M0&^,. %JQA0$,95,$X@Z0
MVKHI(@6*"(,B8"O;V+XV#"&8+6Q?.]O3,DYMH1UMXO@Q6>*FY1%FO<((TF#_
MA4\$ 0!]@ +M;)J!&VS! Y2P Q&^I1P2%* ?DR@J!T8P B=\8& >V,(25, !
M/8Q@#:C P//ZT8<-"&(05RA)R#:P@2:(01 <M:BX1F %*9 @ QDC5@9P@($J
MC, /:;B!(/IA/7_T8<)." 0'B)"#-*B "#T- @<DT(>SI$4Q=G$E<[*S1"M5
MQH!31.62:',GRI1*+N@Y87Y&>1L#@E%4&4R2CHTI%P*6*8BK2<QL8LR7?HB
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M/>B'*T@"">BZ+^@"D3&!,@B"-/  HX2"^*(7#.B"9N&-!?  'Q@PIB OG-@
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M,*B]Q0'-NDF!'TB!2DBK3=B$X5,$L4V]OY1:Y0M:E2E-RKD"LOR $<@6*?@
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M*)H=T&>S:@,UV 0D$ $AX('!>UH 2('?"DVSX=JR,0-%.*VO#0,F2-O0[!O
MN>@#B&B\63V'#BW2 DQY/IFWG9SDFI81^ ( X  7*"H=R%NIDX(K6( JN($%
M"#\I:#H]\(<L$ 1_\ ,7\($#PUT3$ 1O'O^H&] $'+B!*E !':@ .JB VX2
MB]*8K.N>"DB70< !(?!F#V@"'$B#I\N!$>B#"6"=+UB#-7BJ$: "/= #"="$
M)K"#-XBI<:F "_" <X4 $S.5Y-TQ6T%6,?$R+X&QU0#L+7JE-AQ0(931;WLX
MUYC2*E&,W(@EQ( F.)F ?.B4Y)5#<U*R='Q47)TW/<&,.6E"+G)50-P.MRC6
M2]8E/-FR'/4,7^N4'E0Q-*&5R8;D%L-%V[B-T,"3P! 4SM B5RU@,)*+*"U2
MX38*%K%3']&'0EQ$)5"&1@BU0IB0$F&%3Y2120J1#($1%78#[/:11G #2RR"
M'&Z13CLC1!PD553_D?*^-/16;R68M!.Q$"-6X57+1#<]!#?*AT(J@B&9@U"[
MD$;X1LOHCSAC;%&-T6>#9+>@,TW!C 8?[C":MS/4I<!@8LF8-B5)-FNZ$SG\
MT/Q8$\8PE1BC)7]LHH-+L]L04>0@2!J#U@NJ@>*NDQG[UA@HN/RPUAGO#-;^
MC!^7MQH]4M7H,MX0T%!UI[JP%1UO#U9ACL[P'VM]\ (U;0$]K%Q9@#HP IV>
M2B-0 3NX  &475V8:DZP93UX!4WHW.3AUP^X' \ 2N"42@XPF QP@A&0 D$8
M@8!9@91MERH( @JX@1M8 3' @2:0@#)(@@7(@";0 SOP@*QCZ9L*2I8S_QCP
MJP ?Z =32$T,6+^/I1Y=6+LJT '9\1B2QIH?^$S(<76@;8,_P (L* $L^ .R
MA<NTZ %$L"RVJKS)$H*=&:W!FQFS1+VTZEK1:KRXPIN'[LR_C +70EO1 BXN
M^('4:O:&IMI9)QF3CAP(>(7Q:CK>:((JR(!1[G-!H  GD( %0*B*4N<%="XC
M<(;YQ($@P('JTUTBV !TF9<T<(+,*<H;Z)Y*SYR)&H$+X(!ZR(6BO  <\ !-
M"()(MX!TEX*:Z(-!D-VOP]OW\7/978 % !TXL )#L(*,J (Q4*J^_D]M>\'D
M"#+>>!*\N%50[:)C7% R6Y)D6XMVTF+WQ24B/?^VS[C5V] Q#L^+&H!MT2"3
M _J-\/W#]9AC$:6-T9B@:8R5,M;D[%C0X#849!Q'%QP-7CH-.8SQ(8J@<S(.
M?L15%S1@"V?D9-029?546>I"+<UR+1Y0<#CCYHVV#94 %J81%\Z0?% U+8#3
M05N$1O!3/VJ102N$0E!O&5D$4W2C2*SA1-M$9:A%4_L0,B7A$I&16XBT U'\
M8Y@#6 L&"8$T%8Y$5<N0&4[31J*T&]$")*$/MLBG)@:,#T_0:KI&7GRE<(KD
M(^E[7]SB$4(S='*.S.CY:CJ@$3I&!SJ.V(Z5NN>A+SR-.>Z'&; B8RIZT8!!
M.^04/JPF%]*U"<@-A%3_?OO5$BL'_"@BUE,JXS@AUAKH;?YY!7\$B G^( PL
M" $<07\3"$*8(! "! D%#2XTN,"?B 4,#;[:".%B/P@ KNBYT66$&#L5+#BI
MTV^#BPI2*E0P=&,#B2\WC)#HTX1#!3T6%BS@U&2!D0H9/EQ0"@5'&B=!,VS1
MDT:%E350 J4QI;*JAPV"DKS44X&#!0X>XI1QXP%*A2!5;F"H8,1'OR!U;MHQ
M525(3"HBTXP84440@,2*%S-N[/@QY,B+%8'IA**RY,R:-W/NK%@(#4A(1'@N
M/?G/@4W\*D%.<>  O]>Q9=.>_?HV;MNX8;^.$B:,&=J\A8\)HPA);N'#=?,S
M_^W\>68;5:I\,/FR J4,4@)M\+2AB1@A&RP$^9#!SX4T%/I-*G-EP:$->C:$
MK<)!RA8,@:R,>#4B0QH;?%#%"%]D4$47T^F1 8-IY"!&#@P2\H$8&TCQ11_R
M=2&%!%\,0@4<2JG 01H?0#')%U?488H44&001'X9Z$'$*P!,D)@_!LE0D4<8
M,<30!"+TR) $"@PDT0L#:520" ;Y(T&1$@SYI)-2/KF0E4,:Z<]%$2D@44($
M0>ED/Q)@25"2!@%IY@M#BA##0P7%H "=%GF$D$%@#A22!',:"=$$9DHTD)<#
MS3 HD A)- &>89K)D9,0"4J1F!-%%.= C YY:8X$+?^PY48%+0ED19%2^1%!
M@?IHJD>:LFHJCZ8*2:F3C;XZY4:S;M3/(@88$,ROOOX:C!OY*'%L$4H4 4<1
MR;J!BSYN*,N*K\ "FVP1C02#BQ;&8MNLLLX.6VVU6BCKAK# !KMN,/HH<VP^
M1;"BA+'U%O%LNL(:$$LPZA8R[[?*"LQ*(0;H$V[!Z@(KCK#ZU*#FD7G&:JM&
MK;Z:49@*Y9KK0(W&RM"HENJYT<AY=IHIH9$*I.;'!7544)$M-Y1GEG:"62J0
M XGP,I%F AD#G!_=JG/$'BFPXT)$*B"SH'%"5!"/4+J:D)!.9RI!DT#B>F1%
M,S@*<Z0OJ+K1 DT:U(_39J[_/*353WMTLZDV]O-*%16H,,(&6YB"P1(;' *'
M!4U@8(4*?<BX01:#;,#E%WH,$@0<^-4A%(,?6$'%?WI00=,-_2QEPG1X9V"'
M"V)D (,=:5B  XQ27"%($SALT$<_/AAQ!08+<D!%&AEL4(8-&VP@!@9YFX(#
M%"-L(4@__N!P V$;0#?]9D)0?SWVFO'P!Q(I.-:#&DS0D#T 0KA"QB9Y;'^
M&:0UYMIM_&RRFVX'(('$#V",P008:##!A!I4HYS7($$13-A-_'8#AM\,,#6X
MF=]P#D"^YSSB.?ZXP@VL\($1G ( &+A $J# @0O Y0)&L$ ?KM"/)-@A%WZ1
M2?/Z_P$ "5!A ?WH R&LX %4N  5@N!/!IQ0ERWTPPF"J ,1YD(%)Q"! RO
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MP B(O($Z&&$2@YA!/[JP@DG0QP)I<,$&0K$!Y)IB YK8 IZ[L 6X0.$&5 "
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M($9:S615JXS-R?$)UMGBDWR))GF3T&P<J62)K>C:7TT5R?#5-K7*'O]>A(T
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M;F/"-6,V0B,TIE.Y_]W3G9(+F>H;H 8+/C@ A&+-DBS)AQ+$#+ C&RK$0,2
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MZM__R48!'1@7D',#S88:(%@8_[SS^^G&G2L8_2%0-]\&ET/'!>F=%=S *Q0
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M"!.:A@1%3&2D8\B:R4*24HU^Q)XR&YO("G"%--CD V( 0#]PBM-7D$,03N"
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M$V*WACF,D99F:,0@%JE*.7Q1+&)41!K"B!60Q!1N*O6G4QTVK0GD)!F3*YM
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M(B#AT?Z)!U@F"K@@!0H@;(0 "Q8* (0@U%J"U(1FI1QJ$SJBU%"MU1(JHK
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M;G_ @>$DT18OC"9CXT'&%/!F=.4N%#7@0[F0*#UF2P3,B)"Z2(]"8T[Z2#O
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M24)B)98AW#71KN &K* F-$$(O$D*:),"_" #!,$.=$$)"X-5I>HSG"HHQPP
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M 58@!A50!S>  3[@ 1NP1TK@  >KL"#(')*6K3ZI)V>4$<459A>@)Q!P:!?
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M_#2SN=?T+$QY)HE/S2WG(7B%L^<EJ$'/!803M*LT#=,K2_#MLM,OS,2$#7/
M_,S+H*[:AZ![YNM,[K+AJ)Q_-?@G6P[Z(2DO01H!#WP* 0=EP <^!8S/B8K
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M2YJS)G_YS5\O(2CB#R7XI[P,_; 3*%H(C"XG" X0A4UP(>3S$D(*6FVS@#H
M3_L7,Z T@7(U?OJ!B&("-=B$31@#-%"$ S"#_Y<)@SPH0 &$-5C[OY0YOUG+
MF!G(@>NS BKH!POX ",0A'[P 2C(A0K  0R(A T@D489JZ9JMR4+-WCKI*&*
M/2E+"&EYEJEZ,L#S,J/2*JZ@%L3),H6X09)#&R2#0J$BMZ$*JQX$MR"CJGX0
M =4QG_?1L/.I(R.9$KBHHA$3$L;@(P>K$O+Y"\C@H_N9/ \+(#G4GX!#*\YP
M,->0,;,@"ZX0L>>!GR:L%XQY$K&8K0;K,'P#BS8"DH;CB[)0N7MQ%,+H$J\
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M(0L2A[A5Y;=5Y;C%.O+2V@=UNO\#E5!<MEJ@0T57A.6A$V8%*H*3/0O_\CO
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M3I)-[NB<C+CPG8^-K?)N7/'!D4"Q<<23<3_^JV1CE(;X S/@ J%RA2C0OQU
M@S](@8(  3"(\GZ@<O;KAR>/\@+8<G<* 2_O!R;G@FAQ!3*HA! 8\S)O\H(8
M\R5O\IM0<R%0\S&?"CG_@R:'%CPG<R' \TKH\R8_"#EW\W[8\R4_\R-T,@B
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MD,*%1 C<H '7&")@*D0)G*(A!!:@"K%I#YF6"FH_BDQQ%Z2'A:"(JZW"]2H
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MW"YQXLL?<$B7"L0 @"1<P)/DT,,%G+""%7B@"I.H0?_1@N48JQV(+CLM))O
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M1EC,)F#!QZ@!$RR3(IC?,RF,-T4?/W@J (QEO0B!!UA!+GQ #F@" -@!%%1
M%62 *0@"(4Q"&9B $6R 9FP8A<W:K.V47:R/0SKDB6%78=P!7[B@)$#(!Y)@
MJ#&")%"4OK(!"K+%5-P!'[2@7KB:J)%@,@2#'<!%#\R&P3I#J#W-$ :5G5*8
MHV 7P41-H#%&8O"3/Q2!>5J)H= G59'LZZ!7H10*4NVB=#5AO;F.^^1GG7QG
MMEEA;NS)GJB7WB%A;"#B%(5&$_+.2X#_AC .$HI&US/:B7',5>ZL1OCLAWZ>
MT%&Q2\5F%[_QK%7!!WNTH3]P5?,0D?NT*\2)QB(XJ&JE8B@N4 ,ED,C="(&J
M;8Z<EBBN[69-R&69HL:MEF3![<IMHM8UVVBHAWI4R1KBSE-\9TOD$WFT#^FT
MQ@NLJ+G99H 0AP*@4!2N3E\I#FN J+HV#[GY[&VLSA("3\^>$!*^@%QI*(,8
MQY#:R0U%E<D>4<'U!LCBK"&.;I4T26[MQL[BU@1T[7M03WQ, -C)53Y0KE2P
M*_*BJ4[]4>:UQ$=6;"%U)!XQ8T@VQKIBUUT4R%A 1F(-B: -"46VZ3+RZ4T=
M#$B&Q<5:1Q%P_T H->H7&($3U$$?;$$&X( =8$ 05 5<?H 5E,$=^N"R"K"0
MM<$?4!XD;$()_$$4L.JGBBH/D,&3[< FI( >*F5"J!^L'@ 80$H8*)^FBH#%
M#!-3JD$UI0!71F4U21FD;$RR9O!3,MFR-NN[<,4$;,%<0L$5 $ 9V$$=.,$&
M8,!1B $<P($'=$$^, 4$WD7I!11(_B5V'1*>]J6BU<VF10@E $$BS($%L$/6
M7!J_,M377$TB%.Q+Z8,1L +";L$3.$(L+ &C":RHX0W7;$4#V@6=1E*8]AH@
M,09"DB]M*N>Z2<?$:2WA)LHX6JF5%)M4;8]S::UX,6=6G9UML.XD9_]0=8%.
M 7#)PF7/?UP/+SI*=2QN>]"<<4[G>>35P+UNLH'.RS*G9U#;$"5'Y.*6(V88
M54P'@M!<?_Q<S%IR>X H!,R@_:0<R\4(*,(<CL1M:1T0:*V(:65<*N8MW[YM
MW*9MVD+0@88<AC3"8KD/NSF']RYN?2VG:!S/O9G/*RBGP351S0DG\Z"SAOK#
MTT@*Y0K4:#C%E6H5Z@AG\^0;#\V.ZNK.:"RQTM3)+YN;WKUL.P\/;*BR\TQ1
MZF*G._>R9^0#!!2C7YR>G7I1]T9-8!A=Q<J%XZBKF)ZFEXJ81T;%(2TD^0*4
MXVPO9-C%]KYI?9U>20<FF-X47$A /FC"4;3_;[9L0#U<P 9P0AW8P0:4PDKX
M !0$ 1WPWP!+=5#RP#6LQ"JD@/,)012@@0BN*DQ<WU.*=<>,S+Q<&?Q51$<@
M 4*,P:Z& 0>O-3>9-5,RF3!-];TLP%&,P WX  #4P1+DC$QZ0#]<@!$$ 1&$
M0PTP15!-SA<-(4@>6@0*E.G]6EGHX$/%0BNXH",$0QQH@2H\K GV:T,!0!LD
M @N&U V, BD$0[=<#<+J0QR\ 5Q86E\,R5V(1<8R#64 Y$\UMKI*;+K2I@^U
MAVF@[FC\+HON!V[$UUI1EU$Q#[OIB9>0(9/&;&T$+@R11F.AV--R81=&UV^,
MH7G&1F<@X1)K:56 _ZQ\,6*@$)=^<O+6*K(^0VULI./"!<@KI.Y]K@;E'BY_
M.J.&&C*A!!9W] /9-E!F&=" -I !I8B#J^W=*BB"/E#9(O-E'1#=3K,J4I ^
M*$%RB.-R["S5,B-O\*YCX<=Z)Y5MC0_WF(EY^(<3O?AXA-=8L:AG%&?/!K,A
M*7)U>4ETH.>TO5=^<H>0BJU@J1?@1L=Y13*\X8D]LH<-5<G<-??V^"'IV.QV
MAPGEBIT"T-?DB"3&&DC$KA[%0MCU J+?!=)&;F2<^IW1]/&#I3E.PQ)#=AA8
ML E9I%XD3>\<\J6@6<9BG! KP%,%2($_-($=9,#/I$$5;,$2J  1G LYY/]"
M!9C+9$]U"G3"IH,!%FSZIGMZ)V#!U-YUO9S 'JP$"#2PD G!'RB$JV?U2UQP
MLI8,$XS!,8D?LFK?,*D!KGM,"J !$]SJQ<3?68_P-WGJ#+L+5[Q"%5A!%:R!
MS:2!%$C!$C@!NE1!N%#!*PQ-$5P&9?-:'?<39=CYY5&.G3^O8HDH8IRF3)AI
M\_71:<B$7(#O/[UH[TQ@K;%T9>-49C#;<1"/@@R*DAC*>.(XWG5;9^3X]'R&
MTZ$=S6Y0Q4J.))=C!^&HZER)PE<'Y^;5=J(.?31/?/5F<82\SFUMR+>)"-RB
MEL^G.Z+="B$\EC-<:X1G@E#89X2R+S=YG"C @_S_9RA".&AY'&J]W"EN7#2#
MHOXP^ (M/<O-R- W. &M[83[2"468'T7ARX?R##&)];[@UFA,W(03^J2!AP>
M',#W<[0A*7RTB6XHV_,T*8:6['3:U(% B6HPW6E8J03@4XINH8<2]&@T\7K:
M1N'_\I(HBG P6WGDN)6$QMF'/.1S3[WESNP4IVE,@/&2Q6(H#?@V6*#G=DB?
MJ5/DMJ\EEGW)N?;2FINOS_+F:51L&+7X6E00IA\W!N!U=.<S,:)5A9<+ J.*
M 15HP@9\P =L@"FTF108?U7HP0WT[P:4>DOXI/P=1/4CA")$_[U4-5RH^O,5
M\ 'L 7^!]?OI.DDH AB@_XRQ.^52QE_[P]^Q$CO*R##+^$,&Z 0,"()?9\ 2
M5, -J  ' $2=#!5,+8BA0 D   7Z,00@I(!" /TF2JPH1"'#B!@E1ESX4")&
MBB!)EE3(L1]'B!,Y6DQIL:+"$"!15IP9LV4(BAA1KGPI\2< G1$A*'GA#P)2
MI*\@0)B@-&E2J/U$Q)@0%>K4"1*P1H70[ZH$"5DA*$#Z% ( KELAQ/!'%F[7
MN'#]=40J%VO6N5E%1&6*%FF^"?W\C2P@ W#3NUS!XCV+M#%9L(G;*H[:."\$
M&6,O2TBL]*S4LT\7.%8PUI]GQUC%OB5K&:D(I!)@*B3\5BYGSOY*\UZ-^_4A
M __#@PTW7GRX..(&E"^/==PX\5C-H4-O/CVZ@>+4HP?#CCRY=O'1FQ<'#WXX
M]N79UQM0OYPZ<O,UY&9U*-$?0\V<F];O*D&!WY)2K1^G=I-K,JA4>XTMUJXB
MBZFL^I% -LL^BVJKT:3""JRQW$+P*HKR P"I%_JZ2P&T%IA+P+M<M,RBM[BR
M;$/@:FPQJH,@X.K#":^: 42G_$/**L*&;.O!(SWK)T7<%,A'AHJ( HHDC&XZ
MR;:6+$JKRIAT NE+GFS;",PR1P* 2Y_*-(FFAAZ*R*./T%PHJ#.[)%&FB3R"
MX I-*!!$ @[TN(&.(.P8J(D+5!"$(3&L^&0$#.JJC=+_2BV]%-/:(%"$4Q%"
MZ%213450Q,Y,33T5U53?5&B'*U5]U2)7:TOA 'X.N/6 37#5M59<N1B#5UQ[
M%;976XL=UEAB;4TV6%N#+?996*6]]!%I,>ICA"I&J(<* +;00X\-0%%!C!LR
MN*".0210H@@Z"X!31*$R$H*BFR@J ".'&DJ+7GQ'*O5?$D4RZ<R %?+'2I<>
M&HE>A>5]6,^&YSR)HIULD[.?*Q'&$LU\7NAJ@@?9LA$TL80$#:\8:D39GPD"
M+%#!DY/J:S (@-1K2)Q?@TPB''7V;\@ KY(J!HV%0"I EOT182V8R6)K9+R2
M;/E&I3Y42K4;%R2K-PRQ88TU_P4*3"K#JC'LCRZYAE;*39=(=NS$%E'.1Y]@
MD!,G%O2*>TZZ\<;#6SST C<.[_/&\RZ[[<3C;G#M^#;/<;^9@TYOP@^GO+WJ
MF'O.#9B[*K4N" I0[*RC77,,JJE93BII&;E":L4-G7(:@@4N3.W!K&*(7:F0
MX\IP*=A +O"5FKMJRN6DU9:@[8/S,=*?@V3(;/7JJ:=+I=-93'M[!826>4<(
MCCH>P-?C>N'UU<(:C$7C53XKGRGJTDBAM"*J&"B)2:*(2RXKPA]?#KM8O19V
M,0/FZTQI.B#^,K9 /34P)6>R5P%NDI9[,:R (!F=!/+A RDDP0=B$,,%1I !
M#-"! _\5J, ',J"0-(Q@!&G80*FF54,;WA"'.=2AJH3P Q_^,$XP$0*M<+6L
M6QEQ5TQ(@1J05<1A.9%8442BLIYH+&<):UD[G%:U8$41";SPA9H P 8VH (*
M?* )%@B"%#*0 4'DHP@)^<C1YFBI?!E03K6!TTGHEY%*_>1*,]DC3(+BQY"4
M2DM:LM3]#!E$@-6O!N.;39)D]IH3+8AZ3O'=:F1@EM5914$3^-#4?+:]PGRD
M>MQ#729?])=)"2%%1^M*#-*GE9OAQ4<G>UOP'J,TI[PBE+B<0-=P<[M*IDYX
M:UO9CE"CRM2Q"$U!/!B:=NE+Z^%"</#!G-_*H[GE"*YR[!G_''+RUAW)@8=Q
MYTQ/Y0Q7SLF%9SW?N9QV<#&!HS'2CX7Q"ED*T!H!@6R540L-7$00H<R@9D/&
MW$J%D/:SK'D&."AK#"DC6I9:'B\&?>D/FF*0I=-0-&>L])G;MK?*N#0)22AS
M&<E*Q")P($^D3XF,V0SZE@<]20%^I./!!DG#F$C3CQYQ9"(-:9$@*I*/A 0J
MFX3*,2&>RB-VLI,$:D %(XB! QO80ANAL($/?  #M*#"# $@A1A^(@.(U.):
MV=I6MVJ1&[F2ZQY$8"E:)2N*1^Q5%-"@""Y@@0M,0 ,3P,!$)S9+K_Q  AB8
M$(; ,@$)AIUB7O7ZQ .\%55<[&(6_UPP@D] H0O]J( 5;K"!)&! #SKX  ?$
M$(HKU*!=$YOF1=Q4L(],B223FA0!,;@Q _JT)!+3WVSKTK X^>NW8W*7E-JV
MQX8TC",!M%-2'/"QL]0R-4Z!2]FH1I>M=,@Q(1-;??(A@MLDA3Z/,=LN<W8F
MW!S)F25US2G34K.64=5S;TD1]$"6T;F$H'QCJQY;F"*@#(6,FE+KBNTRR>"G
M2=0IQ$3FBZ"B8.M5&"JUP0U_Y0N!0GQ3<B$VI]\,QYW">7-R=Q.GX<)9'<59
M3G/I!-SAGB.?$9.GQL.I08P2_#.X*,^:*+-=7%YA7K7E!J1" BCM< . "4P/
M*38HZ5/L&_^5WBCE!?:EBU50E^7;%%-\22G0RUCZ&Q8Q%"]1Z5E%R^Q,W23%
MNEA16=7$6[OMDJW' XH>5H L%:911C43@-),SA21F:@DJ&Z"%TAJ2Y)#2TFY
MAJD)<QGI$'OA1Z>&(>3#-(VEB.QV(35Y- &-6C^%R  ./CA$/R9A@13:H0)K
M"$(0JO#5,CS$":BPPAJV@-D;_N")OA;VL%,5 F-#  1TM2L4D7A%7$4A#"D(
MP[05T5@D'!&Q<KV5&9A0[12$@ DB2 $30F"&7>EU$U:T+!:)3:T:OJ(",'C4
M#+>Z@254P Y.^( 45% %%=@@CG)R"!V;FJ>/D!K379*5--T$D8W_+#HFAI%@
MV\24$3?YK^ K,?A*-*[ F\1)5E>"0!'B?-%)LLQDD*ED5$SV%87NZ$( 0DM4
M) G2#F?E(_ UZ<XEY) "^..E"A@?8RASE3BK-'PL2I& P(+2]C4%NS4J4&),
M?IEA8J4J'#[;@Z^WS-14W9E8&1U,"E/-O&B!..$L\>+BF4[#D<=R>UN/?-ZS
MXN_4W9V2XPXYE?-V%QNG[MZQL7;<\!!]RM=Z-E]-U8=V(Q_92 8ZNXWYS'+>
MLEM]1V9ANO=6.2"GX^4T6TLH\EYT%<U?Y7T=T3I[XRO229'(9RWZ4)9!-O,-
MBPVB<F':@$!*H0K'_#.S 5#\+-*&%# L_P4L"<-.0L"#;]?+^3*A0?*%,GV)
M3-]*UK?2\=&4@HV$@/I" #]-N"^4Y&/$^#+Q/O^2?^CR"V'Y]4M^2L(/_I&D
M7_T2 3]#-(X1&>2#%6Q@ >I #^P  PY0!4; #C0A#<)E(C[@44:@"8"KW2Z%
M!L  !3I! RN0V'I #93H]3@0 '@ $D(0)HA(6)ZELH0E"LQ@#)# !<> BIS(
M5I @#!0A!5( !W-0VG"P!'0%KXH(L?@!"&]%!'?('U[A!B[ "D;@"P# "6Y@
M#50@#=8@ SC@ RJ@C%Z!74!B?D(B8BB.@%2BX:C$(OH%#<?P8@;.X/;HX^ZD
MT-AD8YX+3^2E)?\N*(]"$.$0;D[\H09J0+U^;)^.J78NA)*TR\H@H,#\ <JP
M O4<<>D4L?7 06?6+/98;V>D0N"\PD  9$#(QFD8H[N\XD%RCW?\PD!8KRGH
M WK8YC[4PIY\ZETFPA]R"BS^Z%VH@C (XZ*.)T(X0Z!P1/$P\7A 0Y%N([\X
M9"+Z@1F;T1F=L3"8,1J;\2UHZ!FAD1JO41MW<1NS$7]<8ANG$1K%L1NOL2Y\
MBH',[N:$+\]2J9>B8@::27B8A#!(9# P)2G0A!DO)2*VPB5^KB$@XRRFQ\"2
M#B\83!*3Z2W>9Z!>YREH3RK:INQF8R_DYC=&@AC#+D 6P'ORBRL0BFS_+"/J
M:LJ?@*/*;,I\!B09<8.J\B&G'D((_B **D$(A, 59E((.F$F604-7('Z0  ,
M_B#Y@!(+AC(H/04H_T $"H HC\\F<5(F:?(II?(F*T$HJK(FJ_(AHG(J:S(J
M'Z(J0\ FS4 JN?(KNS(F<1(MM5)/*N+_?* 4^D$0JF #<B #$K *@F -/@ *
MEH!$!L$*K  5I. ("],P,:4'\@ 2#@ ,PF"IW&H'.J$Q,24%C*C9THT&*0N+
M-A-7D$")*H$)S,#<]D$-N"T,NLW<-C,(M8U8#A.') "L,J >Q*@)R$@/+$ %
MI' #]" (,L ':B A+$:0*#!5'A-3'(E2D HF_PJ.88QST_+H#*/S4H(" B*)
MF:PG,@(19)".._WL*0IC:CJ$*GIC0MH"=TJI/A9BO2[1S%Z/COPC+$HC1#3O
M':\.:SB#2<PF9%R.>O D-9S,!$F$*,Z1?:B);91"/]B"(>JB[/QS(N0'3?SG
M'_DG,6K*S 8D)5/)(EWD0(V*&=<KHN9+1$7C1C@D&F/DYT*41$%COA!$>][B
MYU2/1)SFRUI41;WN>NI182JF&HOQ0ED$0Q!*%3]1*DK#U&@(EO0C+9!B1I=4
M=*9N1_PA!.("(#7#GL[1Y^QD,1P49?S)Z4 C=Q"QF$I#DU Q-,3F-';IX/1C
M>]"L(N,"/T!40,SB*O\B)#24S$DF#$.>!J!0QN621)DPK"R*P'^$@ ?,H*Y&
M4-EV %$? @M$@ ? X"%*( 1Z  R$  L4P5(QM5(O%0N:SU,U55(!@%%%P% ;
ME511E0>4+57KJ@!.@%5/H%%+]2$.-5%IM545PE8!0%9OM5%/U5>#-8@B@JI\
M8!(68 N<8 ,R0-^D0 P^8 M,005*02',:@TN8 +OQ#6W501= 0QV  L.  T2
M]:TP]0"B !'$E0)14#/S:C5%(#6QC5B00!%ND DH"PPX)0RN;34M,[%Z95LU
MZU5" -YR(0F<0!>\A2]I+0.6P HP(*M<@ JZ$(]N2SHI1:K(Y"),Y4P4:6#_
MHE.J% 8Y+U8Y$:UB0=:IJ 0"'( ^3K)J/J2FR.)JN$LJ,(D1T49,RV)/24]H
M6F<]<<X2$>]G\>*X9 =&'3$?R"9]$+'EM).4+/3KFC0?S7!V=*+/,D-\/#$3
M+:3/,I'!7F%T]$) ZZ=_IHG-I$85;TZDY,)M?/0N:,1M7<\U[$0G*$QX<%8I
M=&*?$$9+!?5%!M%O'<-(='1/+ ]PNTYM6[3IA*<:&]0B[A$ S"M%#30O3,;V
M&'=V("!I_^F^$",9:X\BKJ)2ED8: 2094PY*>\=\F 08L29\=#;-D")&:?'"
MV%/R#F9HN>9CN&+W6H9]:DF@N,MEF$QF@O&]#LSD_[1""22T#11A3Q1!(3CE
M)+# '[@!#1RU 'K@>JG7>C'5'[07 $H@>[?W>Z\7 *07 )I7(CCE_D@E>ITW
M>LE5$9;R?*%7(9IW)-"W?B6B>>N"4R9%?_'W?==7$8K+D"  #G1!#Z#@!JH
M#I+@!C" A"[ $VY@"P1!(4RA#CA $#: 6RWE4SA%?S]XAX0 !"JA^?Z 'ZCO
MK7K@ ,) (9*-7&>%V9H(,P\ "0:+L<  #7[ ,_<U#U)3W0X -,, #=K5#$YS
MB7+%BE20L@*VAB3 !:S@ F[ !_KA !L8"G @%Z @$/JA#G)@ P+N79J*#5^O
M8VM#XSK-#.M0@XH*.I]SMO^2BB2D24L,IHUW8F2)LR/0A&6[5L$V26< ]6YG
M"J+T-/>RLRF8HI,2=W[2-G?-C'ZF-':](A\FB<\::O1.SA%A RDP8E*>HGX4
M1/,B8R5=;BT4HQ5% RD0(VZ!0P@F $ATSJ8*P[S4.#\L#TII&;[BQFZK2<-6
MS\<@.3_PUB;PA)6TAVAS.:H.EWN>&4&F])Z @N=^UIIP]"O.QD@<(BU"@.'*
M@FJ<V2N8A*+29BN,Z356SD;*AY.C@IN[>2+$;/0RAI-9]T52>4\KY'V.A'YR
MF4IQ-.PR[&"@V4;$1J;0XC2V+DK[5)= IG4%-WQ4!R\DH ANV25,]@S%%WS#
M-P3_V@ -A(!2P?=3/9I329I2/?J/DA-5[GBE4S:'TJ(H^B )$O "!G 0H& -
MTL .K! *," M,N"S1H!:2;@V@,V*B%J+%.$/;B5?A\V%K=*$-V&&3]"RG#A9
MF(#<QJU>;W#:IJT$\BH*ZI4)AI!8'"L%OEJ*F+A7;MA6H!A6, +>UB!;NF4+
M,$ %3"$# N$"Q(H#FL 3QGC'Y/A^_Z $"+NP2Z $N* C>J 3<&5<84(1;O*Q
M.8*Q^6JJ(SL*'G6Q=?*Q):*R.]NS=5*S)6(*9!*T%>*SI[J15,4?E* & !EG
M7B% "E(L#/<N(F2V;81]</9UK(MIBF1(=L,2Y79#H6)V_]7SE\,V,ZR+\XK)
M,RY*E,[":0H#P+9D 01&*38R*\:K=]9K:LHFS101YEQ/*KSG0'X90ZZ&0]BX
M+D+D\EH/OJNY#N_CO2.9O=:K(E[/G:-")_0VHG*1T)0[R."KI-RX8@3\1ZLF
MH.OC+?"D0"KM'-O1\Z+N9V+ NISINWK7/YX;S.)B1I3"E;/BN_AV=$3'-MA'
M;Z=N+9BG1@9CMU.#NR4:FB122E$&P8D9+T:YP\#A*FJF9FHJ23+T9!)ZPPE1
M+T3)FIVB"&@###%%"%! !'8 JJ%<R@$ !9I/L3LARJV2RKD\!*3<.7DH4Y1S
MV/HQ'ZQJ!*2@J[I@ P[0 KKJ O^VX(J]9;32'*EA0@1\B 9\Z,YQB!L6$PRH
M+\QWR!5N91,V8523$P6'>+(.P 5CT 618 ^J[=$YDUX508C3^@#&X :![5\U
M75C<6EH6( .LH KJH0X P!22X ,^(0F"  ?L8!*R8 MRP <"SM3F"$[B2MMX
MQ7P--0H.0 W^@ P<G5RY 1$V83&E^GXA0=ES1="1G1\@@1_V@/JX(=B7_=JS
M/5?(M0VB0-G3C?K:P-F7_=BY?1-8^&*#2)#T+U;R066XB[T4 &KQ@O;H FF
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ML%&<Y556:>OF,P' BC:NXHG4@BFMD],^#B,$<+AAR@IB]+-%$!F,4,<%%:C
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MF_TTBS'?K]4WUV *MUH.0T?C[Y0  6$"!'\$#19$2%#"PH,'$SX\", ?@ (
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MJ  ?2(,,L.U)/I-Z^  KF.3HYO=^#[$0 /@?0 /KMI \J&79DQ+$M1XS  -
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M*C3!TZTC.R)2#QQ )3 $#V1%.];CPD3=4PR$!"#7"'P"7S2!39C""&! #F2
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MG,P6J.-0T,;1I4 G8 $88$'_)]BCK3+%.W*!1KA"G=ZJKTH%/CX%!,#!!]R
M%4 !O#2!%=R $XR 36Q!'?@#%:B &YC=18@$+T4D:9"+-8T++YE6V8@D:0C8
MLGC$2,I>:<"D9,B;%0E%D0W+,)&&@_E,W8WD:513:*6=XC5>#2"6KC4'<E"9
M4DD*<MR'N'6EJA4B#=F5EAV;?H"9-[W"A]Y84L746V)>GL4EMW@4#?E##4S0
M\L7(*Q@L5=6-<X!#@Y!0!;4*=RC(?;2'.6G/Q4[6\&6?H)7>?4!)2!W: 4W
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M87HG_<PG)0 (-R1#8[9";;8F)0@$YB1"%%+"0)!S40"6?$9A.'\GD0A4(?<
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M3&2#RXE5T4 ,V&:044?N# 04P2O<RQ+TPQ?XP+QL0 9D  9402 (# !HPAJ
M,2"UZAM/]ZUN+'5?-\C,Q0S<!!@?I!A401KX11KD0A5,@AXD 0?83 V4\J)$
M4S!M!MFL)(*1%KDT&JK<=WVLZ\A5#;9^RTG(B$D,$X#'!B]9C?\6A82\KN0M
MX9VW4C9EM\;(^88VB8!:#7;PA8JF+%_=A.4$A*Q($8K!4D8.P5"&. K;>/@#
M627GX/5R $EWI,^DS!5?:XJM8%_VKD?WVL^AF"&?:.4^4ZR+,"^OW-[V:(B
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M%YH03RE:]U@E6]*06#&(2W&6M1P0?C!EH'&62Z%.@(?("S ZE^3'Z9&5#-2
M9\FY@\VK^L02OE)8)XC #G1B)RC"#G"!$'1""!2\1@Q\P2\\P>,BPSM\M> 2
M;J4<QM^V%D%XT!29L2P-JA1X^."K9908RJ>[1!"7'Q@!.4R"!VR $^# 3<C$
M$@RD)@S$#8P P+ J=O\\.PH!"&!!"7"!=0.]&P=K4PA8/^9%OV0 %.N!'>3
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M(48A))8 6@2C ROC#AAF!5M0(0BA)T9N,EX*:PC"(LQI"(O0'D""#S@A!@T
M:H1 38J06,R)$OI!!D ";_K@,QZ"V JA$0I!8!9B-<P)#[*-%6K@%9Q,HV)A
M"'7B"\^$*Q)B#L@P=L2-#\"F)^@)IGJC,D!")""@#7!M&'[_$$8Z*24<XI>>
M -<6@FNP!R6*JF#XX TN0A7TP1GD0'$@0 @2@=_Z;PHXL*N K%="22Z$@/U(
MA]"FPC.LZL>*D'GX;[)D();<+-!JHOP:@Y=^92R6H^EJXA6VA?T&(@:610%(
M WCNHJHXD>;^@EKZIB#4S'NP0BQ(Y07 P>=.KIDVA[,F !R<K*U2#LHR RW8
MK)CZKWMF0P&4(.G$2)%("_L"Y;0ZC/=D#</\(TW>1^L(\A^SSS)^*S]@K)
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M5G]@$S;A #H85T'814" #-XKA$U824)/1]1D!5Q@!&#@@P#@!IP@!S) !>K
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M[E<$H:NOH6R161!(.=M%EH0[2?\FVT^:@M4651/L%(*+-&U$UI)C,R1!$0K
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MXH1)33" A, +U!8A(=! #;X$P [,<-@=[.&+ML:UAW80!5[?^HL^%4$/T "
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M9WO1$!>T&<.%&4^V-G.$+V&Q8 I6)URV&<XU)#)19.>$-6R7E QE$NZB$0K
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M0W]DHKP^-'J!-!&K&:U0TA1(,<'>A:0&<8]4\28V V"SU&0F0YM)"A46@EX
M  [YT["MPC!9EHYS%+[:1!/_;#21\Q4Q!,N-;,$14Z(VF[&=.-(BS0<_>9R+
MG,$#)6"$!; #)8 $(B!K8V"$_?#'1B@2.X %@>S(2* (4I?'I:4Q"8,C1:?#
MK76Y]W2XM[%DEUM:D6M:$J $$Z +08 !20 [.;">'S "%E %@C@73: ?6W"U
MG,ALR,/+O P&N:*VD<@-=P4&;8 (=64&(AS,R]P=;!MR,^!65H *NM /3> $
M5: "']"T=( !JHP!7U #2A"S/,=ZP'3'0Z%+/\1\G>IA)$)+F22 -JMDJS'.
M'M9'K(1!/XLU%\2BO8%E1-<9+X$;$+!!!9 FKILS5O$U03F"2JF7&HBNL*26
M!K$ _]_H07+:$6B!+RU1-DT*I0J #<U$-'119)@D1A2!I$WQ @L,->]D$K5'
MDD\#-DS"7PTV:')BT%(9CW&&D4HJ*&^J%\[2%%WZ,_A$$QI-1O"7J+7GJP6<
MT_J*1U^QIPB;1.'!P=*)N$E3&>"1$7$$7K6G).T2LYRVD]%X2@M<NA*V8HQA
MU4'D?,'Z(.T2+1649TC62=_1&F$4=G;)U#!#+83WK%@#1[HKO##-%ZX4?M0$
M@LLRN/.%>-U*DA^)O7RT%*.G*EVM?V@T1/SR-.DD)X%'%1$E)7AA?\V$+E&&
MFGZ*L&O*:"HH ?"4Q/ $ (K1)3\S34AZ154AG7G1$BS#9O_EZ" OD6'[FA=B
MX\)>ZA!=I1B3*S#EY)VQB,XM>92DY!:*L$8B,2]'&4L2Q&TNPFVN\384U,^X
MMW0J:J.LQQ([&]X3C4A;"8VT51!#VP?Y< 4F!P47L 'NB0%+0 %B8 $6V@];
ML 7=(P7,;.!@VP:2##9[H\P''LS.K!X2L+=I  ."4 !Z  4?P&^0%;=+@ ,8
MT 6"^[]_&<',-Y6:'&,8$2^G^R2;D2'0/71[9^+078Q;YAL\EV+,5Q<K'G0F
M6BL)21!'HI<L[:UYC#) E*036<9M 11^>C.ADJ0JHP K9B9_FF8<@45]$A3;
M17<+'*A<,P$QP,,?@3+'LBIE["#_>A0">L)?5Q.;#$%#<HP5EP$QQ_0TL5GF
M/@P12;$(?= #6M 'E4,#"N</4R 'RN #'M F$\ -<N &/K "#\$-BZ %E+X(
M<$ 03[ (ELX*CU( 3^#H/M ':3+IFU[I*W 80G#I3*$$F^[JNJ#IE4[IK. !
M?U[I6G %^5,2;; ('L 4 " ,'   W, *)* L!2 ,</#GIGX%"U  DR[K6D#K
M$.#JF[X"*>$5HW#KEJX 2N !&Y+L_E#JID[KE]$#T]Z\E]X3B[ "!=$#BY $
M*<$-6K  D^X&;I#KSU@4AO[H@9XJU;X(5Z 5;=#JT:X%'C %WFX4R<[KU=[I
MA@0!JG[O_X( !*UNZHN@"PL@(TI Z,)0[5H ZQ<O[1YP09GNZ&[0[N(N\@*_
M*LNN!;AN%*5^ZZQ@ ^?.,'NAZAR 4NRN0IJ>\G_NZ[R>!5,2%'+P\I3>!T)
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M4YUJLA!$5:I1?6I5K7I5B3PB:/V(P0B\.@(? " #-_C $K;  2<D01!B6/_
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MU+TT>NYW;PMN;=.;GPB&5X7.JUF7R@<'C*"'H5[! Q@( B?$@ $QX. &0P7
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ME$#1!%V 5O(!5KB#$5@!!7@,37C.60O%\3@*R[JMBX *;0G_*4(1O)PLBH'
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MK Q:U!-/,<:*& FY]4L(H9HYB896;=(4R@CA'&!F7,A_[$< V<==A(#Q( B
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M5/3  50*4DHE#Z6>HDC %M3#".2 #P! !FQ 5BY $RR!'6# #?B )DR"">"
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M"R&ZQ]< E'E8V:_A&G$P"]P$Q2-*G(9$AT[)AD% RU:AF2ONCO7TFE8D:%?
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M"/7 /I1 %)C!YG'#)E1"PV*LIE3EH6Q%:U: $VP!5VX )GR %7# $FR $U2
M'G! !I1"/^2D'>C)"*S )V1 (.B"((B!G&S $E07KQ(L$>  3GS%(." &%3
M)"R !/1!&6P +80"5DQ''^" %*B &!@"GJ1!$AA!%\BE#;RF'BR!("07$>6
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MNQP(>_R@;KP3=T@GGD8/%V-;IX%.44"4N[1.QZ PL?_E6P UR<S5V[TI1]7
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M\-2BP:$*<&V"/S0!E[5  0-)J$/A / !*\!@!$L([6QC\@-^' #QAT?\X@_
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M! 1..96GU%'[(05,1!'00 BR&00J(9EZ(TEW>29T^?%Z^9?_8)B'>0^2Q!7
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M#V!@_21 %\+A"R8!K'P@ S1A"X(@%/QA+-ABN/V@"40X#4A8 JZ "LJ@+IO
M J[  [8 N,9/ @8A"+: "JAR"PQ!"K[ #>(Q$.8&J4C<"6S'!X) @"Y ^[Q3
M<:B@'\"A"M(@ZD +?H\<R7EB!PX *9+<R4OK"D: =*U $P#@!G+ "?32.V\
M%3RA'A-,+:K !Y*@(BK "("C'\H !_2 $O2@#HB@#T K+=:B @1A$#9@!?J@
M#P E-P @>1< !SC !](3O:Z PSG "5I.[$)A$%1"#%R@+'.@@/5@+=8@ TR@
M+!AL!"[ >=5"=6P A/CLH_[$QW#$@N)$_\3T8^/6['$M],SLQ!$_Q5/LT3V>
M>5S42!?;"3 *%$NT"(+<:3=0B#_:23>XR*9NI$/6@STN#"5"U%LNT%I*Z,2
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MQP4J]*-'/1\(5X$;=GP FQTYC& $!DO<P H $W1'EFB9!868/T&%%@($"DA
MVFG^K"8:J2^,2JJJF?^9*H*HF(8&VFF;0H"9! I,$%-GLH9FZJXQD)7IKP60
MFIH"KX0*ZV:F6JJK3A @E=2HJ$UK6:FKH59#L)H!X.L$H8*&E@1(45I#J)U=
M"IJMH\4*0% B/%LJ!/%BYJMI_13K;;2D@3NKN&0QX4H)?QQ06@BN1(%(&%A
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M0!<D*(0$W"J&*TSB QD(@A_LX*41W$<7XI3")%:@T4E48*D;D(('^O$%.VS
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MURS]:$,B#,,8G<C! %ZX):@6;O\O1FS! Q#@1B- X14%I(02[P* R1?+"(1
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M$'3:(A'_T. '/_@^]\=/?A!Q8Q\F-2D_*E'^]KL?1#PE$00T<0,[^ $*@@
M!9) B!&00P]00 <J0 Z^\290< 'BT0>OD $54 $Z$%DKT >EH <+0 )"L0%5
MT(!-D 1!\ %]0 (;X ,^< 5PH%$+< 6ZL %4L  <L 1Z( @<P% 54 4>X ^O
M8 )BH <;  $D4 'UL%1G]0I)H =6X 07  5)  <ND 9TX 09H /"$010H >G
M($R:Y@]($5_*9DN_%!H^ER^JPAF]Q(6P0AJFT2G,5BQ@""[+,C_-=5IDT3ZJ
M,EW(-0.Y<H<FY%V70AK3!5K0XF_T%2TQ4%M])P.A%7>F!0$O_Y J^3:&GB$J
M^8(IB/$.J9)&H)$4JD$6Y/("P/4IX&(KC.,/(H N[!*)T"(N'90JS.:'(K=L
M,B$:_-8J,;=+"J$9N[49R66)(;!]C!,"#B(4K\(NK\@K0J$9O/@I8U <S29"
M9Q9/EV(J"N$@PO,@JI%PH5.+J]%L,2$4\34?Q1%"0I$O$H(8FJ9]/A-=WBB-
MM[0I*Q(AI5$LOE@JI0)2#X(6)1-WLA(4\U&/MV@:MIA:#O(Z !"-()5I#J)<
MKL4L$,(I QDAHB4$VR<5RGB0B&&)T45:\5@K"C A8(@%W<);N]1:K2*+^WA:
MS8489\8I:-8/20$A('62"<=OZ[(:S?^H7+ZH:<BU+GT3CM$U6M>"&IJ12PH0
MB:B5&3V0"*%P#%OP"K#0%@:!%10!$E51%JB@ "\P"@(Q$0;1")P@!'=@!_[P
M K 0"X5@$"W1"M&2">Z0!"=P#!6Q!; 0"6[1"&( B(T$BV5!#XU #V(P!1A7
M%^X@"(:X$_1P#/3P!CE'EB"Q0B$' 6II T"0"$[P!);  4B1"@;P"4*$EJ.T
M2&41!\<0#">GE5+92.3H1U7 21/P!-!@!7R11E<A<Z>4EWO9!5#7F2;0 VYY
M#-2QA;5H+:<2&KLD&C+FC(3#30#@ RK  8@W C>  70 !2Z  1Z  0 (60JH
M F6@!U50#\+_(0&:, @5( &+M0!ZX)R?( 9)0 $8H$TAZ :",$S]8 -=((+%
MEP3/ER8,=0-&T$'V5 6#4 <D<)Z?  ,C4 94$($5T I0@ JTX $J, )04 =+
M, ("8@<<H)TRX0E.8 A0H GO%Z(B.J(B(@1AX H'P 5A$'X_ #4D^J+N%W\D
M8@-I, +YE%!2P%#/-WDY8 47( 6FT 45T"AKL %V)0$;8 %'& @;T 6OL %0
MVE5-, )!L %)X()+\ 'KX0$OP J -RE*H L08 ,K@ -YE0$<\ I=H +*MP"'
MT%0^T =?T 07$!MY)02E$ /EL085L $20 50D %5L 92 'T?4%$;_V #0L!9
M*\(9\C)?H+$IPPDMVH61="A:="A*RK4N^O(KJ=4/OY5<N9-W["-:(M0N ,>-
MF#&0H@@KP^,NMB0!+^!S6;BIQ'D:$P .6J@3Y$)W_3(J?@@:VE4MY'(:8\%=
MJ5%>\X4KN9(:91B,H8%+?(@INF)<V!(MM:5:(\0NPZF%T-4=:!@K:,:K:;89
M+TF/\@@KIZ&MHK%+[3,%H'J0:>:3<0@JIT*2W2$\]H@9H25C_S9NH#%:V?@@
ME^$MVJ>O>1<A-@4 '-*HT#):[FJPE@%2N_4@ML2OT$*.]:B&[U@:-&F0#A("
MM>(MGX*2]"@44^ @R]4^V4A?$\*+^9J-H_^%%A6[(@5KL?OR+LJ59N[%JP1+
MCPR;=T$1*KWT;RBY(F!X6J92*W[X*V2AC##[6O,U8UVXA?G6/OZ@JT&A"&$X
M&LVU+A( <-D%7/,% ;J*BGTW)<>2*Z/Q+C(0*L>Z+_)U*ZS%JR.I7)QUBG]8
M7:?1!@ZP7;XRD(BA739P%)U1C(1S&1(I=_ D+C(Q*Z78&?OXN(A+A\:57@!S
MA>8% 6U0 Z(2MMNX&KA( E8+&O%B*].:.XB(*='R2Y0B!%>P!84"?85: 92'
M 7 P">4A'0OP47V0I(%J66J:I!N@IB-  7U !40 ?2J@!QR@"PN@"ZPP%C3V
M0_V@"7V@@Q@0"!S_H DK(*B:4!V"U05)X -V8'B.Q5DK>$U\N@%P$'W7E :%
M)R0?4 54T \+4 4WD '(QVP-":, ',#MAR$"7,#D)Z,BX@]7P!O1H04 4 %.
M $Y;D 9V$ 1.4 %;P $^< , : 7WVP?D\0'YU(!;T$%^T 7]P 'U(0A-H F3
M  6[YP&E@(T1X@,3H'L9T 2"L 0^0 D5H <KT ]UT <>< 5&4"@PD 85\ 7]
MX 'Y:P504 &1 *'[RP%.  4YH .44 >058("92J1:!3;*K?Y"+E8*"H5.3BX
M%:W'M;/,EG##^2G<2*U' 8A*2U\,R86V\H9RURZ:BEO@ E^9,0$R<)-X_ZS'
MS_6)>[2JEM*ZRC8ON;2(>RR,HA$OU:@0I!$L2&&(TI4['/NQC>/&2 %:V>)O
MKXB0.B$"4Z#*K(PI"D #[Z((7LLIJQPQZQ,M2<N0W2$"^[J'-) "-+"SJ<6U
M_J (!9D'+]".> PM^%;)9 '+&!("OJ6/&=(/&6+'A['*TOR.>T0A+@HABD #
M'**RW0PU0F#,,4,#Z"JZIWG.XM@X,A/,VNR+0J AQ<S+-YLOJ\RPD<B%@?LN
M4V!3FS$%*5 WRO:N.K'-^0+,C&,I/+L:XPR&&2<"(5#1,$8OW:$(*](&XPS.
MI=+1<DB3IX%OX9H9-/#+:7A:4",5) T!>1#,N/\U*@1<0N#*RAGB#[4, 33
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M[#?.LLRUH"H5:,#/EU$PQIXQFV#L4#-A0D!KULPXC?\#\'T3U(BQS>^"M(H
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M@NN,$S@ZG$57+OWOK_/>GRYL6\(G*A $0=C!#A^PPR'ZD(0/K*$"6U@!!38
M #AP( @?_PB+$0# $"+X900?2 ('#.&&(.CB)KK0 @!2!P MF+!>7># !CQ
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M*P3#DA>$\V!@_P0/EW=R:VR/*$<=HL9@.=>)GNZ(U[_D_"X&(I# "UY1/^0
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MM4$5,^"&M/H3IJD)#4.!,- 4]!."]5(9ZYJ7O JNFZ@2XAB.59"N'>"",0
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MND# RAA/AW($+SBI46F?-BB204A)?SB?"9@!X< =?V"$.7@#Z!0G<E "[W2
M49"$5I  $8B!6;B!/A@%[+P2G,K.+M&=X,K'W2$>IBJG]TP=N0FT9J0>,PDU
MEW@T&CG'Y>(H!?"1*8L<Y>P<VI.?,FO.F[ W*O'1&2V>(DN>\NF<X, 2Z42.
M"6@=WOF)(C4>:K(.W/&<_YSP$?5I+*00 C24'#MK,S]3H2MQTA5J4_GT'CJM
MB<@HQS+!'3KULW^R"3%90^,!U#5T&9W(M"JITC+%B<C8E_FYTQXITD;5B>+K
MA[$KGD>SM]OY,^:PIM#2CS&QCGY0@#^[B?6A'S'5#\S9G*6"4Q^5U"%9TA/3
M4A-+JBE;GN=LOJ7BLE.MG3[;5?*!@&=:CM$94GUD/N<8*NJ!)FDZ#BU)1QY%
MCL_1$AF8'UP4F,_1U50UOF>M'@68 6AJ1D7%'RSI4VDULDM$GO895F+=KY:*
MC&R]CI\Y-";K'_I9SF9D)GUTU6L$D^0<NR]P@0N8R \( DJH %4Z)!4@AX3(
M ?\Q, $ Z (<, (], (_L(,;< %-> 4/8,R_N(%DN@%=.(5F@X O, *_< $K
M:"0C\ $?N0(.^((XT 0XP &*Z*$^@ #,8*(@<#EG"(4NJ(DE2(C6Q "(I05,
M0B( 0H4*J#=_J(#2T &P?$N>^ &B&(JL)8JM/8 IH-.J!5LUQ0(P"-NR?:.X
MM(HK6-G2Z ( P  ,( <I6((,V  5: ()H((K$@,5R( J$ -H6X OT(4*J <K
MR( NL #.7 !MXSG!*(4%H +GV2 J"(L*6(,J:(SCZ ,%.(0N&*53P "ZU(,D
M>"$92H,M& $IT(4K"(%!H (JJ !"6((TJ())6 (JD +_)S (BYP$#%@".
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M2!702TJ@A!LXW$DP@5?X@B[X"ZO<@"]8  #H R.JAPRPR2YH@BZ N!5:S0J
M 4P8@?\,D( 3DP X\-Q)6  ?H#AB HX%P+HEV((U& %-T((7\(=)$(2^58&Y
MY4V,L  56+6"H +?+1L]2(,UL (IN&.S!8"@P-JHX&FA(#B<!NHUA+&@)NJM
M0-NEN+M7L (G\ S?, *#A0(CV  I$H,^R(!@PK5^, $C,((O$ (C6 (8&H$F
MP(L"6 "_6.H^*(61CJ'D":Z:  L=J( ,<%06T@6L:P@3@ )B\@V; *0;J(.2
MMJ4R" 4?, &&$Z *((((V8*O^X ,< )TJP 2V*!+!)]_[)W:>:9MG::6FLY_
MQ"DZ@-8>$"A[DSSA:*C(69M1X X["(W.Z29*."GIF9(9()#_#^A0)6 %);"!
M%R 0'- "+4B&6%"!USZ.U^N1\0Q@1\ !.,B'&GB"+9NH=B(&5'CN[]2"*X#6
M?7F"14@$ R GZ"35Y]Q/^NDGCGHF("$G%1F&0] "[XX#_)B 3)B#[%PN,&$R
MY #&8I6FU_E57Y;28<UOF7%5/S,[(:"!]_2'*9@ &HA ,"(6 % $,IF""/PT
M!Q\^Y;U2G*"!:\I6>TD!2FFS;(( 15APQA*"%,"P/5O>,E$ 2L&)"B_Q-H@;
M&>^'+SKQ=+SQJE"$/L:9ECJ[:J*!<X2T*: !&N")'E]PO2)PD%)#E\ =$W>?
M$@\!1:CR$*B*XY!Q$3BJU"F6"I=P_T2#-#*A4R'8ED6M#$4(<<F]"46P"3.W
MLYA!54;&G02WMRJOEQX7 1HWC@H_<1:?5BM?FQ5ZG S'T2&G9@"8@A0P\6W.
M%?WH\.,0 9FY,QF \3E=&SXK#C^WEQ?G\P.NBA 05'8]<1I8TE%NJ>4*U*-B
M#C$AU?S&456'GVRB,CZ.'F&<@/2,9/-0@&EVSW^T*4OCGSG_G5!*U>!8+LJI
M 3A14/FLGP.4,Q[-TV82&."A'N 9,VR/LFL'GBG!]LK)Y'NM'RLQUS.>5P@0
M=N9\U#T6<"X)\B,[1SL>.S=X(.*L "=8 CN  RI8@D#0@1NH@"KH!X\-A7YP
M R-P B+H(/]/"()JFHVO6($@* 0;& 0.:(1OO#M!:*01J >AQ8D,$(10T 4?
M@*'2B)#D>04,, (.4 $G<-E^* 4C2!%RL#4=P  GV( %Z @5J (H.+4*&*5^
M^( /0 6Z+>JC1_JC$ )$^)BD=WJD..JE\(=74($DL'K._( +@((EN  ,>.PZ
M6($M2(,/T(%<\X ^V((F(%)5ZJ$*J$W)8,Q=6H!7Z(>43 (L=@D2B(F_&(%^
M!@ )6  )\ -=Z(,-\@#7K  /J-(Z6(* 'P$5\(/!(.M^(-JP( >^Y(0@4 ':
M'(D]2@/@Y<P9Z3-=/)[^H1',X9U[I-'P&0X.'E8%> +&0\"\"P'_AG*/$_"!
M5^@S(8"%^$XJ<Y($0M!4^,CY?O)1=:R[RKB#..C@XL"I-Q!6 ,X\ZAE3;I!^
M5<B%2Z7^WV$'-U!\Y.#]^";>2U6 Y^42;A@".X#2'U$%5("3.^A?"J:$A\8I
M)ZB<-:8.3&..+GD%Z9%2) ,(?P#\01@(P9\"!3$F0.@' 4*G/" JT>A7H%\(
M "(*;D33;R/!/P<0[8$@DJ0_(:[ A/C#12.$ @0A@8& Q%\_100U"A$! $"(
M?@!HH%$@(F@!$0XCKO)(@V#*%!!H(/GI*LRJ2A V:O2G=*L(($@@*/II<E.4
M321-[MFXLB67$"*$$&P#B8L0- #*8O07_U31P2D$I]S<N%4(@(@_P/Q4A/AG
M"@!MQOQ<]2/KU@) R?X4T::$/W^"'_[9!,FTZ;8.77ETZ?5Q")K]0(.$$%2P
MD(R:%7GDZA. *XF,RVH6HD@H;P#]0.19%<;?\1 Z!4.'@&;K3R%_2I9&I+8M
M!-;]7'.-:9=QU=^B_=%XE30P$H?'R0I%T;PF8)\0I!+MYW=5<Y7DI( ,/I4%
M4U74M;'=%-V-5)(_XKFTET,R04#3=4;%Y!4$H_DD!&$$B2 B00[Y(\$$+S#D
M#S[!&("/ 0;H\Z*,!@0#XXPSVM@BCL',"".-!LR18XTW&OECC?H0&6...M[X
MXI/Z!#,'D#%.>?_DCD8"J2.,3\98)#XZ*EDCE5;R>&23,J;9Y)(_>NFCC65^
MV>4<4<;Y9)UU;BGDFW1ZV:4^&/EWT$$X%4HH!!-( ( " &B"@QTJ0 '%!56H
M4(<4M%BQ1@X?7+" ((,DT0\)3F10A0L9B''%3WW<4,4(=?3CP0)-]-%'/PL@
MUL\&-VPZP@8 %!""$!#TD<0&?2Q@@A,C?%(!":V:6@$,&="Q0C^";!'$ FE4
M\($.5D!Q2!!B8' !%"I<<,$'&/AW!2&&<-"%4#_9>R^^^>J[+[_]^OLOP $+
M/##!!1M\,,()*[PPPPWK"T<%(UQP0Q?^F)*!%1MDT*X*=BRP1 56.+'_1 9&
M<+#!(39,LH$1P&)@P2"OX!2Q%3?H000$5/0C13]:^/=%%56DL<$6(U! KQM=
M7%'*%3CWN@8,%;S23S]P;(%I!A5LL8$/O.K"@1%++ %%T'UPL(4*&62 @109
M2*&"#0"\8)8("SP$%:$%'*0W3J$-RA"A> N4]T&,Q,()H=PX@DJBMITP1"L.
MW>&,(8P 0TE#!*421Q)0"2'$Y(9 I?@G'BCNA>"A]>!(*V8I;L2H.#$RS!NA
M^0/$'6<80KH)0 &N0.Z&K.Z%!(''E,DPA#STT^:CAD#011 8[@2!"JR>RZ %
M< .Y]))08@+50"3BC ?]S([X!#$HP)!%@8=&_ZA#)D(@P48, ?[0! P5WU!0
M4 $  A)^4((\C.4/(#!#)[CP!R;\H02=  $:&)*'/- @#%,)PPXB\[]K3($,
M7* )3B8@##24P#K]P,(.T-")B$2D! MTX"K,X(H?7.</8!!! 58QEQ*4X >0
MN 8WD.! $%R#(#M 0AX@DH<20.* KE @$TK0CS%T@H8%J2 -LFC!"@(  @=\
M@@=M*!  ]  ,)<1"%:\#@@0&AXE1[ 039$A#FFB&"<0:RPRC@(0GE "-/]B#
M4" 8AA#8AXEY,,,J%"C L=CG)B' 8@IH$$D+7L05UP C&,2HF1Y$L0UHF"$2
M4! 1+"QQ@4@00B=V@/_ 'V"!)C]A0@&$@ 4L_" *)> C$D*PB@/^!("#+*0!
M$0C%!D;D.D,)PS$E28,?X,059L D%FY(*!Z X92S3.$**U%%2$#BC42$R!QK
MHDMB8>$/>= C'QUXR!(!\ <AV"8D5A&%1"X0"^J\S@79$P8:3/ Y_7!F#SP8
M3<WT0P@TR.0U(+!+-/R!A:5\8QZN@<IP[DU^@X*  >!GD$%)H$0X$8I_[@52
M>R5*!NRC&DKKI9R.'D2D(,5)\5!4/'VI5#D$*9YFE",4X[&4("U5SD4&\A.+
M4$VG*ATCOE"J4Z.FU*A#50Z^!%+4["!5I80JWA@= M6GUK1>ABJ1O?3Q/,'_
MT<5X-]45 &I0-0M<( ,6V!C;3&$(#.C!#I3P!+!6L(%^?$$*&_C6!E10A;WZ
M8P%Z<-8(]""(5VQ %Y-@;#]LL %,5&!H(ZB"%.+F!L:*80-7\  .:':#J0%@
M X,U11ITP+6N;0 .&*C $IP A0I<@ 1+0-L(,G"QEXD!)S=HUPBD<*_'.(QA
M9!&!(I [!>4R-R/%?2YTH=L&$/Q&"'DX4'2SJ]WM.DP+X*I #KH @*MQX 9I
M",(:*B &/8A!O16H0- FX1\)! $#&'!"'T80,2I\ 0)IN,$(G%6'!62@'UOH
MAQO\$8HFW( "0@E"@P>A!0^$X@I&"$(@3""% *=A_P0+\(<//A#@$:S@ A@P
MA2ZF]HJ6?: *??A &4Z6@1M0P0GO%805MG %YU*-((IJJ> *%8+ T84@"UA?
M^Z"BY)3,[@V#4ESK!B<,2=AA MQ(1#TD<.4X?"$?11@%E1?0OI^<0!*#@ ,$
ME)"(.+Q!>X[80CX<H(0:S%G+CK##4"&0B3E P429B 4'&O*0\9G.$9^0@$->
MD) B$)H;JMA"#>A,YWPL@!MWB(,/\J$$,'LL*$%)U 20]P8().0)JLB%7\@,
MN7[ X@Q)2-0K],P'.DAO&+1.24A%H "LTB6D2X8?WW[R/ES[C6\'<8A40'
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MPP=<0<502PN. !%HBQM(P1?(S"!8@,3D"@;<@"D, @!(_\ 78( /^!788$*
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M7Z3$\/U$MX' N^V Q"F45,0'-YB!%+70'RP&%EA=)[C0*EQ#&WT&$W1""H!
M)I5 %/R!&G3"7N9E)^C;<J!!(04<$D!;&?U!4W!#%" "/Z@!%CQ'0>Q$0>P
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M3FH&!($%" 2LC, :[)4@#HP(_, RJ?_K#["KNSK7N<9K<?'  40&O8H -QP
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M/Q3A(V* &'S!"AA@/V1 @%6!)FS )*@S!X3#).3JO9 MI.( %72!*;R,!6Q
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MO&>7:!JO(M@E!,^[OB_,1A=, 7Q!N%A!+M3B"&8 *FQ $BS!"*2S)E#!/*]
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MAL!^R&X382A;'@BG"!K\ &T\Z <--C$VROVA$AEAX \@<8T#%NYPB9O< <B
MPKEYA"%;0<(?"&(0[4!@<$) P_,4%P((A$ !#!%!<Q(XA9*(@!N(X(>B(*$0
MF%R&?VUPVT968;8+^DMY"J *!&S8N?+$;6Z;Z(@(_K 'C+@"#6U  =<P4C7J
MK'&!(]%'@JAC%8;M4&$ &PG/8J.9'KVF)'GIS\"D0YTIE/^F:-39C6B:1AB1
M6,5K(SF,:#0S&Y2@9S@/6<U;WH*>MZ"F.8M$3+](LA_F)">1"&,(;A2I'=T@
MIV'^\M=R-ID9H '%D(1)SW=0!H!@Q,9B_F+9*AL&  D X LN" ('/E"!$8#*
M"14P0A\V\($,; $'),C"2)S  16<"0<;Z$*U7@$ 782K#T90 :@P4 $.+$!E
MRV%(LU:@!Q74H0)UR! &C,"F!;BA%%>P  Z@< ,Q$&$)1[$!!XQ0!E3@X +^
MB,0-G% '4T3(!1Q Z!;Z(8$*I&$$(T#2U#92*9%:Y0<'V,0!4+JLD:Z4I2VU
M4QO^L ^4'H ?!S"#1ER:4YWNU"K_EXK4%720!BM405]2(,<'JJ4"*J0A QA8
M0I9.5 4]7&$#@WC%!JI@!0Q80! 2N$*6)+ :*E1@ S[P 0>:( 4Q9" #&]"$
M(.#0#Q],X JZH.H6I% '9+W!!U2P@!X\L, %P,$',7@%!RRP 1U\8 D2& 0K
MTADC<WU!!5)(0QI,(88-Z*$*&)!"'_:EE\)DQY"MB>5I]$-+UJ@6-ZMTK5NH
M<T6$P8R6_\EDR&RF'KWL)S4SLUAW3+F<2_8G.V\)T$J"5Q_4QF9@$"C8&BW6
MW%N:S"P3HPYS3R-=A77E*PCS1\3:4Y.;A:>-L<FN=8P&GX>TIK6]E0]J5K.*
M[&$!"S^(_P(2>E""$G0"!-= S>;"((1.@+ $3#!#YO8&B?W^  W6F>  ^_&#
M%$ 8 B P0P_4P(0_0&(3*7#%'G: AA)$A SZ/<!^PT"\*)1@%?O-0Q3^$(5-
M1($+A&$"1OZ A#P$K@TEX+ :S(":'90@#! 8L(\)4@(NR$T-O!LP&H:B837D
M 0(3W$$4P,"X/UR#&R9%0@$$1(-.X"[(G;A=)RHQ8$C\(0_#*]XJ?H"$$.PM
M>_(- 19* $(DM $+8P !&:* 4C#\@,@")C0D\G#@'9^X>T]V"R20\+RY_( L
M%-E#&\BPBGUL8B+]B L9S#"%$J @#UA8!9K57& 7FR$$ ]XP%O_XL6*<X#G.
M0L"O?CNQE;(DQ+]9*T%"L!#H ^3!;3'VL46J++X#@($&$'8+09! !@Z/+9,\
MZ$2Q"6*&3JR""Z2&,;%#L H+=Z+4D)A*5 Z\"3"0.W#<T"\*^ELS$&"AR.3V
ML8$1S 1<,Y@D *#!A'\ X1V +02NX+)4]I8=D7QL.P @T(+4HR"5H$0D&)N
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M8-[)"PO@+3#&EXR+)41 "$J >\P !(CL#Z)G=!I"$80"#/[,#$J &]#@"9@
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M)>  .H, "E[ 'R:A"C[  H) !38 J^:. S;*#M) #R; 5S3!"39 #,Q*6U9
M#$R!"DA %_HAGF!@!"@  (-4$(A@ R;A%/K #?J %0Z!"A"J"S1!F]($0SP
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M]C8*!WR@'TA 3/2 ]O*B%$)!"O2@#S! $Z@  #1A4ZK &32A%)I@!9SE%3R
MF."I#UYA$,1 %](@!]; !:K  ZYJ XC !##@ ^+@"Q8( &"D K9@!0"@ E&!
M4__L8 %*01-J90N0*@."P .VH OB2"\^DV%8II8RAF=42PHE8#Q($S3?(S"[
MBUE70K7&PY#<XB,:QC N+N9>X)WA^06>0#(U@WT/!F.08X #I@PUIFI:L I-
M-6'0^06@(V(V!@MO:0QQP[BN2[5Z4S,.TP73V8$]TS<C<S/B-S48VC[V J0^
M,YW= LSR0@KA ^@VXHE(0@CFP[@"<Y%P8S:\\"N&HBR>!R,FDFL8IRS\(2K
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M"82@"3S $+)/0I9@G3!*HV[@ G3@H^R8,7X 8FFJTC5]TSE=C?'84&S@ ZQ
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ML6JH&(/_!G&*!D" !HP*-YV@"(]JLM!74V^204#:$G!&HQF4)N(C T:%%4+
M"-]Y%=9C M/6$TH@!XU !QE5%>*S %K%.2<P! 9@ +$P"2O0M:NB$A<4.Q[D
M8]H7)U@@6 \Q%3?Q!%@@ B) I+$B 6W 9>D',.A2$#Z1%-&B042A4MK'%2X5
M$IGV555! TA 5%;5:1DE*"MT*"TA$-9R43R!4X=B %UU*W[20;&K  "PELSD
M!$U 3KJT '6P!:AP UU0 (!4!0 0!R0P"+K  64 '*9 !%V GA)@"#YP"+HT
MGWT0",=Q'XKY(HE1!AL@:(1R!9, =>2F"43T!2O  :7  410_PKDY@%V,0D
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M-B@D6M3H4:1)E2YEVM3I4ZA1I4ZE6A3$ 3"*JF[EVM7KUZ*/N%ZI,*+*C2\
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M[#E6$@+@BD,D\$ 0*2(1HP]3!H>#L@7$J, #2IPP9(DE%JB#"$W*JN *&_3
M@ XG]-CB,@DJR"&'-2R %"SBBS?^>.2G8F23*-3((\GDHY=^>H7$HBK)*ZQP
M0A,H9@# C@_(J0"C%?H1 X<-3!@D"(YLGVN#)BKP8X'0@J" >U,$$4,3*JCP
M8)+W],,&0KB"%*ZP@2]H[@I4\,%@#F(Y $S"(U2XPD?$H (X,- -?>C#!JP@
M!CW<H I$N($>$-,$&Z1A"QQ8P!<"88JRI$$,";&!?O\JE![N0,@^A6*/#N/C
MC_.T24SY@97 0G4=,\$H21BJT ^[XZO.K*=1R0$19;IS12 N2#D.$A06[91%
M6#UH4^G187J@R,4326Q&"\C0?0#DJ>>(:#W9*M&,K@.@A70F!,L)C[$<,AGO
M2.P]BE!.&Q2Q(,X(80HBF)J1!!FY/3;MD%+DC")H@*<HC@D"2:,!9Z9 -<J$
M"C-- P - IDK$13 DE-X@2)$ *-%PBD$0X2.*QOYG/?D,)?&PE//O#.%%-#
M4(DRY7D.&0*JL2B217'2,1/4!A% TY52TLK4*+5(("YG.834RH5:]IP]$N68
MVE2()?$DIJ*D<I//:4,R P7_1N6(0$8!TDH(HBD";$)@D7>"V;+*R9Q.BA)
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M (DH_Y3@#X6%(@0Z,89.E("BZUD41O7HBBB85K51L!EMWPBA?LR!.SF,(GL
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M02XX",(@+.""LI5A 7UP"'7H<04/+,$(739!$,I@ [9YP!FZV8 A,% %'6S
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M)." #Z@"/5B!"7B!(+"O+U.!00 P(G@%'P"6^=H"(_" "AB$)5 T/4@"(_@
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MFZQ*S+RWY>S*A4N.ZKB0^.@'?2@0<$K'$O$'$2A)9/&C$]&U_."2'@T71%+
M.X*2,[*K3:F.HEH02UF/]8#(>R0B3DFCBJQ1.X*>/W*U BFU,&'(1(DC,Z(M
M]O"/;(*I*LK1^P"C(+(: "&7"OFT-0TE<9$ (2@;(I "(UC&;NR"#/]XA6OT
MC=K8@BH(1^U)@U<H"1^H(#$H($$@@0TPA3Y(G/P:!!]XA2TX0_B2 D#U@ \@
M@4#0@T6-CPU8 BJP&RD0A"70!4'0!;YYA=/X #UP@BI(@PV@F_RZQ@R @VXT
M@2XP @L0A ]H @!8@!NP@C7X(&9"Q*,@31%0A&ER5FH%"R&XN4W@@A\ S1]
MJ&K]UF_UAU?X@'HPBQ4  !P8 ;KA !*P"0^Z"\=!'YL CHOH@@K @$&X @BX
M@N]KH";(B2M8@%?PATFH R>H $,P@D'@@" P D/X  F@ O1YFR 0@R_H!W!X
MA2P0!$U(KT'H@E<@,XRX@ R0@"S@@!5HKH[_*(45>48_,())B LBV("S@ ,
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M  [((%-(@E?8 !]8 0EXA1W< COP@#I8@0UH+CV8!#>@#A.X@ _@@$C@@%?
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M90GT Q: P7?Z7G_"Y2J0'-N)@'B:YF6%W %40@D )AGP Q.4 !HD'PA$ 2(
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MT0#_2(T5P"KLPC)L+>:BB$C DCB!"@@$%7!A$CC:=W2!!TA!!33)L7ZC)BR
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M&'A _F3 "%0 %5B!(&CT">D"#@1!$%2 'E#""$C U!I!(-2!!)C /?6#('#
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M:GR^L3_*6)OLN<D$)+ U 15,L*,!V6I0/@8?7) R"">,4$$$(30PPPL/0_#
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M^=3G/OG9ST^UJE2ZN,$(+'4% &1 #Y2@P+@LH((-2 %3DQB$)N#IAPN@P@(
M*(4>KO"*)FS "*;P !4^$(0F-$&9J/B !ZI@A0QL( T5&,%#]:")-.BA"DU(
M0R"L\($EC* =&:#$%L2P@29TP0;@%$0I)+"!06P #N]:@A^L4 %3#,(4NA $
M_XV4Z80/*+,*<'B%Q>A&D*B<S68ZHUP98S,0D*C,:UXCS-$&DS*QJ<B*-'3K
MVB+7UKW*A#"5TQK=9%,2KZ7((#0KR&< ZU>!-)%DKXFK:\26L_E QVH$>4E;
MT@HSJH"GCU6C:V(#R['$G-5R#5JK;""4PK-)L0 _H('*3*:1LSJP02%H@PC:
MH B9T&"W";%?6Q2!V:K0H# .,6MJI?*9XBHD)S-0!"1*4#Q_@, ,_@C,;',"
MP$UX=Q-[, I@H0@!$<#M(+O-WRK(4+L#1*$2- C)%(RG'<!L @T F&T(,!<4
M)%0%N]KUC (/4()58 $+G?@# ,'0(+14(@2*4(@0BO_7&P >X'\8QC 8),RR
MA$0X!#M Q";*QX6HG*X?IVM/7T!@F2E XK\9"7!89M+B"VOX &K( PUR=Y >
M@" *%XZ"B6G"@Q2<*#/1@4[^@.Q>^)YNMR'&[W"1PC\A0*#%*7@"C$DSX^,I
MA"@EP (35M$)+ !0.XIP1?-L-K+@\??&%_X?&-BR5_.:Q&;VD\G]SCO %!O$
M?CI3FA#LIPC%="4WAE6MA%M$F,^\!\\9J\H!583&W+A5??,A&<\0>%GA-?:L
M;0U0&4M[M(Q53FPW@4Y\#&M8W4%';:HM&JL%K=GQ=&32CHX<=)1&P[E.^CWD
M ;5Y9 -%)\;U:DG#L\[,VNS_&I91:6U%T1>)K8!^S "G*L#!!49@"BE *0/Y
M8"4X,="'<9GB"N)TIZ-\:H-)4$ 3-\! $\AU25RF00P5J,((%E"C!7PBIANP
M@QTJX*T*V &E1NC"%BQPA84/@@I]\,<DC' %,;@T"1B8TR2V<(4J44$*&+""
M*6Z0;W(85 )IR("L-I ;Q?@S5(HP,QAF7G,LT+RX,-?YSGG><Y^+"J"CZL<K
M1H"*6!E4!5#@ "$\H((@S$@/8N# 6!=@!RA\803F,L]!#O&*H3NA AY(@ZRZ
M8(4;9,"D93!"/Y:P 2<LJ>0JJ ,&KH"!"DBK#B/XA";0-0)-8" .07CF)B70
M#Q,(_V$%%1BH"2YP@<+;H M$&%8%ZA D*"SA W58@*3$-[.ZO09[KDVA&R4M
MVD-VS'%WO37,TA?"E;D,.N2I6A;7>!VZ%<UYZ4N?R6#&5Z^5A&1<LQI@.7U[
MJ85':"VC_6!\S<:OH0S)L1.DQWAVV8_%YF=-JQGLVM.RPO Z!*L(PRHJ,06@
M%3=X0FA#")!@WKXL&!%[@,#JXA^53H A.5SHAP@4,W\T"*$$7L.!+L)T!F*
MU"_-AF=Y<@(,5@$,_@ -1" PP&<'U  )?N /.@$1R((&;")X),P?'$@(@B/G
MDF,3-A 2]F#+A$P[_F!UE.(@N.$ ]F *_FL*,,=W+ ,AA/_"A+A ! J =@#H
M?]0 #5*@N&PB)_*@#0)0"%;A!\B/*,"@>&@@#&B !HP0#43")Q ""TYP$\A
M#4;,,H  $LQ@_K@@!'ZP(X0 $=)B+X G:81"$4 G)(3AO7Y@QQ:L!$0 !+@
M!- @!'\0(;:G$P ("<(O#\A/"!R"LP:H+0!P__IA"GZ@O0Z@O4:L?(@##>9O
M- 8"<R A!4L@Q80""$\H:230O80,"\)@9%9AP?Y//U B-8+B ," !CJ!"?Z
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M>_1T1#=!#59A2/^@!,BB$V3B#T(4QJ:@!/X/!-C+,CPT#"#@2"&A1%=!1_,
MQEB437< 14_("G]@ R_LNPR1_Y*P$W[_U0PZP1740$WU\$_S8 .Q@%*;M!,@
MP<3"+R>BX$,?M0=*P#'RH$Z-@EF=]0?6M4PW55^M-6EB= >J4&%_PA6N@1MT
M;$<3[1:QP P8M45=H4B;%!3SH 18U R$H$G_E'_HT6O2*C=0KXXN33&"K;1
MZQ]7Q!UA5MF@38LN32JDSZS,L]5>X]*HB"'RDSX3Z6ATYO8V+:T^ZVA< B,:
MA#XC*V6&#;#X2FW>,;%:S:SD<VL$*6,**T-/B[;.:J]X[34BZVL8% !J  "^
MH (PH HNP*>V0!.:X.^6  )( "W1<@0L8*0FX158P1]>H4HBH:B"LP*43@\H
M  =\H ^^P ->_T$0=,$"8&4-9D07.* /DN +5N +.BD-MFD$*N #-B (C& 2
M^-8?.FH#-N 52+("0,I*) !*Z& 2.$ *EF +> D**N + & !]. 3,,$*YFDP
M!23"[N=T\.=^3.=^[G)XF]=YGS<P"U-45B#K1J >#,H"#$%=/$$0<( #]$ %
MM@ ##F$0.#((^L M-T!6ZF":WF00EL #I$ %0#<-;L F-V !N@  Q" +ZJ 4
MAM(.5J *B* /0F%19D!_;: 4., 'C*!&,L (X,$00*HC)B$4I" 28,H*.,$F
M%^ +B" 4+& 0,J TF\ 0.( (WBX#J&+S.F(W@F9JY&C5",EI3J9I5O\MC3PO
MM]SJ^KJ3V7*&'B_K0K'(KMH"S]I,CJ"/'W]O,.Z*'87/\\8'AT]"M/R(AL@F
M.ASKK5Z8@#2K*BAG9T"OTBIT)H*/:3+B'&="/)IVAOLA-8B"#*X! (&T![B@
M4\/P *XA!.J&VKZ"S(:5"?:P+UPA"J+ 2<FPP'A@#_C+-I! 4?< "+!@ TM@
M+OJ!&\B@_1!!#>+8%5J(=Y!"_YIU!\# &"U0+^IX$U=A_C;0#/0#"UR4CD8G
M2Z/'D+WG#]KK&OY@ S<P#VA0DZ, $7)Y#QC!$H^Q7\./__XK5:\!!"!AS?9@
M!&?"T$  #-;, KD!#;B!"?)K4ML 4!M'!K7_@V>(@A]L9UCMV&@8XX3^(,C4
M@ ;XP0Q  !':JQ+&  *P%!.AN0OW< 1=P2FLE ;^[QH P!BE4 BHF3',  FR
MHP>&5 BB@ Q8^;P,HLH*PPZ1@ :P@)VI*X\]<1/$-**CP!@W@0;V@"C4X%%#
M !*JXT=7.@5]0@B8H)/-8)F9]0^N 0@6K!(@( 7ZX0>6M)$9F@O&8'CPN)7_
M2,EL)EDA 06XH 0^PB6:><2\V784F9$5VBV@^?^,,04/R;;$)B&^3XTGC6F<
M"/=(KV2PAJZ<&&2:*-+HL]-RYFV&KX;T<\6V"/I8KVEIB+ VQB4*\HOVDV[:
M[-1HQH??JHNRR(Q _R)G3LTC)&<=#?O6"-*&)6UGEN8^00\ 7D0+Z$4%.( .
MG$"<]" -KLH#!J$?_  .DN "JB )!FH#0D&3<* ,. $.;F!^;RH2 & #/&&3
M%L ".& 25* //B -EB 25N *FDD* -<?!*$)7@$'/F +*H .TK(/2F'M_" 4
M<*0"BAL#+-</^B$4.* 4YLT(R&$#/EL0/,$0!"$(."(-=&#?,*6+H!>_\UN_
M]YN_%20W=&%,/E<7 (#>1N!@^J4.JF %,(D#=.0*3. =;@!+;@D*JD#B3, $
M7J$"JH4H<6 2?N(5,%,/X"!*-&D%+ !)^@$<,& )Q" ))D$")*X?5@ 'T/].
M$(9R TP 6/P!I%@3G.Z.=\5@!1: "@3A\L+J3 KW=HW !LB*UU[BK.RFUO;S
MKM :9'XOL?KS'[E/TM;J)MI*1;Q&V>3JUAZ-AM1F;$MK;-^#TMY#LI6-<2AG
M<N3SV<R*(:XC/L:#0;NX0;T#;GRM(#84B$^-:>33'=\Q]A"=:=(1!&:5'R:U
M'\9 +[@!#$(4P7B5J)T'S3,BIDN:!K9Y>)+9DA6Z'XZT!$89"QS5D6<U#\S@
M1)$ <WYBP2 A*W9@#W)"5EWQ>/Z01/]@D]LOFQ\P#\9 ",: 5[6C +@A_GQB
MS D,#/9@=8(#!"(B./102$?L0SLA"O@!HG74%4G_C&.-<:>I>14!<%*?X-8+
M;!4&>C' @$6Q%-BY85.QH/V$-+\*HG,H58Y^AZ1-6D>9P"&6L,7,(%U)+ K"
M]%0/X)!7)PJ$M 3*XI(++-5+H+U*&DB'9Q74 #*H.62!# FP69NQ0)U3?5%_
M!I1IH@LQ8Q5ZX!IV@ G(@!\Z001^AU+;H+W8V5YWH'RPX%&IM 0H]40?7K-<
M(=HI^1K0734Z(>-W/<$X5M6%(-@MW<"&U,YQ;V4A8!44>0>&>C%^\ F0H !,
MPUFI%0EV  VP0%17?156P0P @%<?'M4P!M EC?B^6C;*IK3PD_:0C++J$3RK
MG#WAIHP8U&DE[6P"J2)W_U8]B]@U6$1LV*8]FF^T]&KV2@O-3TT@6TVN5L3+
M8[9G8=;+UW-K,2UFHFUGU0KR8^!-;$D*/N #7  'I" #-($#-$$"NJ!0^@&<
M7, )MB"GMF %^@%8DF $^D$"EF )!D$,?F(%7J$.H,04Q$#B@N "@F ) . 5
MQ  #3,$'=,$#:K(?Z@ '3$$%#,$$'D7X^X$$UK8"*D#RL 3[!4$0/( 0#*'M
M8E\/MN#LTH 0)H%W*P @8%BQL@& P8,($RI<R+"APX<0(TJ<2+&BQ8L8,VK<
MR+&C1X8V*EBQ,Z(+@ U;-C2ALH&#&$V'-MS0M,6#CQ5==/GH$D2*APP5@C2A
ME?_A0Y,F)B;88 6NRQ4QNE10R2 (PP8)5"9U69#!P@9#@X1R<",&G!L;_KJ4
ML:-G0P8I@JQ@T"0%CBD?<-Q<60EGPP8C=*DL$6I*BJD-5P#8,%B@7PA_!2#T
M$^(/<C\(_AQ7QHRY7^;.$ I8#N&YLS\ G U>;OS8,V7,E?U! "!;]&S4J%E_
M+IWYL63(MT.@[I?;,V_9CCTW/@W@=6/0M'_+CH[[H._(T6TKEVU9"(#&E$=[
M!OY\>FCB0EBG1E[[\NC*!A][SZY\-N;(P U6IMROOVHAQODC1 F-3<;8;)F]
M!@!Q"_8'X&2WX9:9@_H58-!\$UK7#P@'I" @#6I@P4__"OV=P$\EQ.VP"1<%
M$N?/#@>8(<)E0B#!W$%"M 8"/TB($)YC?VPB C=D7$.;9CFJB,9D.Y(( #=J
M!.DA "JB2.4!7  @G&H+/LAA):<QZ%T!)ZRXX(5H9-@<;1<&&49]?QRP"1B9
MG8:9EAN.:% /(0HYV0XG&@2CE90)>L UO<'8XV3""1'DC-6=>9H_0* 1@J(S
M2A9"&W_LX2&1UX1VT&4P+MDD@'R6H"< /!Q0B6J#:F8A>1NZ>J9!LZ6(I63^
MK=D<C24@Q!]IW)V'JY:9?<=F <P^YUE"_=U)G'V^XNG;0?9AMY^=SV%KX;&/
M<8=?:.*>=UMXYT'&W73MX:G?_VN5&4?N9OA1QV9KD]XI8)V4E;=@9,O95R>_
MO25WX;.@X5<::G4^R]AJM7T&L)V5/??M9;+>YQ[ L'7F6YWUPL9=;O?!!L $
M!71!Q18JZ+%$!AQLT$<3' SR2A.:0+7 %S[T08440>@Q0LLJ5)'&%AGT\X(N
M?2S@0S^(36+(%G5LT44_6:55!A5-&%*7%!!L ,<$NL#1CQ1EI#'"!A^(H<<:
M/:G0AP]?2-#%%UT,PD$&1&S1AQ1U9%"''F)845@_"XPP@AT$,5CM1QS]<,#D
M_$QNN>7\* +YYIQW[OGGH(?NT",906"#'DGT0<0, *BPA2%57+#X#9Y@P($*
M8E3 @?\>'HAAB@I!0%'!#2,$14?Q2VP H"D23-)'$AOTTX0'TQLQ?1!F!\&!
M(#>@A,$51MBPP0*3</#*(/UP8,0&(P3"@1/U%*_#$H)LX 0&@FQQB I^T,%!
M$!^X00:,@(HMF,(.'+B"/Q;#,(:IRSWYD8QH #0QT1 K-9BA#+'V5:$,^H-8
M_8A,<A1FK.QX4#0B%$T(/WB940&G6!,;H:9:^"\$D48T[-)6R9CC,=JP)S/C
MHLT-+00;>/&G8^KB#[,6Q$+<E&PYPI&@@6Y%FR.R<#^N"6%P%C8J%8: ,D(0
MP0?A,YQ]"8A!E0G!Q$AS$"!"0(T=<V$+1;4@" BA29GAU*'_GB6Y2LRF2F,D
M30@@$*0L^8,&!]@#<1C4GR_VPQ6;B (8\O #5T1A$Z_ZDF-J"( GD&$/,P+!
M)J8D!$CL,32#BDP?'<>9">8)$DQ8!1-FR004P:@$8)"E+#LARTK,IUH](,,F
M\D #$ B3"9"8D\)(,QM(.LE1_+C&"@=E*#]6\8..PA)J0@!)25+2DIC\#@1:
MM0?,"#*$4W ,A[SY@U60P57J=-6=E-7)3XI E"3R1QM,*<W3Q*J:]MFD!"'
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M!2X0B.AQB;OXS[_^]\___C?$NQ?A#U=0 >V0!L0% 7;06W_1!!5@!*JG"7:
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M$T!A 17P>3G0$H)P 0N@!TYP>SB0 540/1S0#RW3#ZBC!U3  9- 8>5G 3?
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M+KM\ '##B#I&"*2"D,3P;(U ULC %)$VH$**%?2@HHO9,OC,@RL\,.B5+4S
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M+,#;]MI#V.#TF_,VVF_3#\$W]Z[[C5UDXU>_?@$!J%_ZF&.L MCG3_L:T/W
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MQ7I4K\-:V)X'4Y$X7C[_,H]^@^%^?!$Y'/9OBC)$GA^7JY B2'$/1?##$-%
M32D.48PL>>,MG:M6]5)PJ4),@RA+*<-_ B)V.%Q>:,FQR?<Q#H)E[61LG1%(
MB3Q0_L:UJV2I*ES;%6^1@?,?$MXGN>H\Y+<*=L].4>E:,*3F*^>5'RTZZUM0
MA%^0_H3<2)(+G6?$EH+L9R)(01B[Q(84,NOK*P6=-YVHY):!U)2/?EBOKEN(
M"P<PT 6#;. R09"":;I "U-L800(_0 'F$J!SW3!!DVXP@8FX8?(5&8+?<B
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M#P0!,C #+L6"/>@'+&@#2#B /20.: V!$NB'*+X&$("$";T&(0!""$@!(1C
M*#:#$L"4'F "^G,%,HA")"@S#/J7=6&"5?B#)]W%+R'C* B#/XC",=B!/5A
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M56 "8?V!3K!D,)=4.ZU2'JV0*\0"3-T!,^#_A@S$@C>/CCBOA#F/8T5E C1
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M()J4(DL.J #^'0' BYKHZ(,K^$S1% .K4.T;H.N12X,O\ !-N (.8"WY_O\
M(J#PD!*IM-P .OB $9 "36@"4_"!+LB'BLR-] >(#Q4J&,)AI ^ #5_J;*GS
M(8,1.Q4VD-O@#X $  !"]/-7 ((_?QTA](-0P!_(DB=%@@0I1&0!E1=! H
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M AWLP $5"(P#'!!$/\0@B"74(0E0J((1Q" !,;RB'Z^8A!Z6 (!); P#-\@
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M\$1:.0Z%GH2<LLBG-Y$)#&*=1+<I7$\1(IAK3APKOQMR32](V=T2.:((&J3
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M$O0#"N2!&;B":/(>]C%!TF%!">1!%"!!#Y1 "70""%S#18  $H1!/Y@F:H)
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ME,(NO4(90 &^"H(5L"(4+$""A,)-)D&R&4(>_^VK)N! &53 $C2!'2S!4VZ
M1FR!%=1#%=0!M]DCN9B+N9"+SAX /]BCS_XLT :M1N!CNW2!K("B)A3 !JQ<
M12X!HU'!IFT ->F!$\1;$EB #P! %[RD0$++!R1!&K@ IVS "MB 34A '_2!
MJ$A!R<$!%7  %=C (="!&(!<'W" !%S'%7C 2\X:J0A5#LSL!DR"![R"%%B
M(%" '70,#JC ),#!%_0!)]$"O6T!!^C!._3#"VP/KMK.J@*0YZ(1%A%(&BT/
MA-S-UQS/Z%"=]BA(DI 1KAX1<PCBYG@J XD56U'K\:!NE>%-=I"=D)1&9 ")
MG$Q=[Q2%Y,3'.Z9-&/]2$6 A'51-6&D 5NGHA4^ P)FZP@%<Q':X B1$ 8D>
M0 GP0.R! !F8P6HB01N8P=]%P0% @AG4!PB@: F8[S6  "2$P87V@^?!EA#\
M !B8;VZV 1KT !>LIG9"  3&K_"T+H&5!!.L B2XPB;LY?A% 2*DP!\L, WL
M00B @!KDINSM06@0WOL"YT?,IQ"4P"J<+_Z& 1:P)QI(10H(P7ON !D,,!IP
M Q<(!PCL 1"X+P,_$))!  AT F@RP1@@B/=&P2;T R(<@!ETL!'GL&?.7C\@
M* 1&0?Q^Q"I\$ N[</Y>:!N4  W_;P!;,1#LL!++Z![TPP*+Q%^-CTVLPBK_
M_$&@CL%C? 1RNIX)3W'Y1D%NBN<UM('Z0B B,# (V!8:N.#Y[D )Z.\U\&]-
MU#  FZ\9H$$;C($!(S"&QG'GA _EK$)_8D$/[V4_U/ .'  93'* [# 8!(@K
MJ$$4,W!D)!UV1(4=EX I8\$D6G(:BS L6R$(U_+S<H\@3H]OM(63L1"7',8:
MO4=^',]1=(^<=!U-D$6LH@GA)&L:<97SA,[L7-$2G8@3_<W:2%WKM!52U-",
MP,^+%)'R* 4< 878<)V*6 4+=0U1A,57Q.JTCE$4:80"],,7$($4#%43<, 6
M:,(@O$(3--PLV4$&B($8;$ ^Q-0&B $1W$ @W),3_[!2+W9!%ZP 2>!B'WQ!
M%U#!)&A"%Z0*2?=B'7S!*QC"03J2J*A $U1 QCX$-0F"$TR"%/@#'+2T)M33
MLE1 H/2!'GPB0UL !D@!!TR"$%Q+-;&<T&H&SI;+S6[UN60U6(>U6(\3T;)+
M'QC!*J5!HV1:#EA !=3!#2Q 'ZP 1"CC#5@2GB3(%Z0B!QA"$T"!"TB$$P2!
M'=S %D2$!/C#) 3!)#"22* B#D0">< !#@C")%AC/YC"#=C!&JA H%7 /64;
MWZ:B"<AQ&52!!6Q!OCF!'F  $4B !V  P]VU+!E55>)0\= S[LB(W;#)65I%
M-;,$CID5F P=YO 5J5;%KO]^%E7<#V0QQ9PH,U<,UEG(W5,TQ:]VSH),KV?5
M:IZ=F'4 XIR%JAR_S5[D!9 ]Q=5=R4;PEE/05>^((0!T0@<SPKFLPFL9<O&]
M*&_N !C4;Q240&CP'1-<ZFEZ9G>@ /OEP1_\@&7&'FC^L$: @(3^0/VB[QKW
M@)H:JH'F@6?63WKPQBK4]R88<6<1, !P W__@7\#^&J.02?\Z0=;.(*7WW];
M^&]RPQMOZ)^2Q!$;)W*6  $;L&EB@6>2LF@,MUH! !.0[PYPP0PO<@CH-S<<
M  2 GHJ^IXL79XSOY_*5 ((+@8*O:/UN9^PA@2N$J(]7^)87,!<4N7->*9-
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M[HY'[%#GL;:F9$3"!RK "#1A$B1 "O0 SJJ@#V:@R9P(0&XR X( S+8@%*[
M)\3@"VQ #'2!"G@S(;[@-'>( RP ![H@#0@P#1RO0 "O5S>@4)S2 C1!$^#
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MP71!!A^L+^) $\K !_9$$ :!"#2A"U!Y 8Q "F[@!IQ@0NR  S#@"Y#%F9T
M"IR@6:3 "#@@_=I( DI"M33M.9&I39\.J39.-?RJ3_V*G,+IL5;-GS F0\G'
M/X$W(;'3_U!_=)R.S53]ACD@ -;>)5^0RB+Q]'R89SHU==_N342E=UR>+F X
M!M>8%#4*1M<F9]P6<BW,#EXZ3G;AM'BJ$ZCZBFHRQ^H>(EJH+;94;F0N)CE<
M.J0RPVZ.+GCD)6PIXCA(@WN))RDJYJ>4S3G;ZB**9GRN9PS7\&_E252E<]0Z
M!V->C62L9TU'@IN4#G=]BB.63=&&PY[CV6-*^*KWS6DP:DTKE2FRIC?HSJ1N
M#G0NIV""A]<>XP_EJ0M38JP41]H@;=XFK9R[S:]_C7UYBJG3SG@"!CFB,3XG
MN*F6T7+L[JJ[#=E\,%"-)V5P0Q+5NCZ[+68(Z]8FF*XSFVEF)__3(IC5IJ*J
M2%4Z:X,F\N4\0,W1'@NJS#8D(*#!>H0J_6$%5( #TJ /KB (^J$,., ))J@.
MZOB(X6"&ND 38C,(P-D#RD *^B <6&(09NF/*8 $YL/()" -/,#T/&DB?& 2
M^,L/ML )?%9H^^''A"42%G +""$)RF GK^ 5JL":B> "M3L)TF +%*(*AFP$
M2"CZ&CG!%7S!&5Q+=G($/@'"%XPRATP%/& 22& 0TH *X."]*& $ODN-@@ #
M1F!8)P"^!"$Q>7,2Q, "NJ /3%)B8J#PQ* LY\,4< "',T (X&#- , $0J$+
M/$ ,I ! I-84Q, -:*D)?"3W/L$*TL#_ BH@,0>! YI #YK $'3A]_0 /S)@
M\LAYHL4.MN+)[7ZGI-9'<E.++,*-T3 #+YRI>X^#!]GG=WBG*NRP'TVU,TRQ
MI^&V/8V06T1W-YKWJ7%119_G@';CGEX'-9 JSEO&*D"Z)L03.GW1JY9M=MW%
MFKSJ-2JN=&UB%@5TTW-"MT8WB"R8U#?*,!#4= "[I8^4;E#&/O$:=_FP-$CT
MLQJ;VA!F2O'<*ZX"@&-#TW00MB<#-LB%9)9*'0_R.;VT&L_J(EAFLZ]-7>;.
MTGQ==LF"4R4B?<>B2#\-*YS1-3HJU%N#94Q+<<-"=_VPHR+#-_C0%'&.942T
MK@'J@#'J">')_["V:7H1M#H 7K"$BMJ%4:/D6=3,%':P34S'4"A@&ISF;K<Z
M35KX':H+DBSJ*1WKSJCJPN*"". KYGSGL=H(7:&>O5LHXCL<%PJCYQ21"=YQ
M!F[+T69:KPOJP D !94FX0MNX$>,SP1&< .LP J<P ^8R+HGX!2.-<5G;Q+2
MV =6P T>8O(L8!#\N E6X NNW!"J8(KV$B+TS =L'DH.H0[J8%A/H0]>P4>^
MO Z&OH<^H+TV  [*=0LNC ,2SPGJ8(K\(8->I"T;// %?_!+C&#%I"IB( U8
MJ&L!0"@G* 'CB&GMP&&=P -N8)5RX ,P8 V:%@"2X,4'P2;%H(VS(/\)IL@3
MNN+!B&0%#JTJ)"#%5X"9^Z&Y)Z+_J(1DG<C")V$%! %8$ 4#7,0*EF $]* .
M0B$#X. & H'P]& #=$7"%D (9"AAWD:;TB9V9ITGHD=P4EMPDF-,#P<"HB<]
M\!%]6D:D'UNH;LZDN:?8P[K>L1,T_$:E"]C0^TVTS7 SJEJQ&4NU4PWK  ("
M '\"_0$8*!! @7XA""[TYT^(OWX0"@AL>/"@1"$A^OE;6( @@((2+7K,B%%@
MQ94&*_;C*%)(@8,56SZT^/&E0X4&#T*4J'*BQ)$9^Q$%T.\FPY,)D;K,6##B
MQXHT%PHYF'3J2*L&17(%@'$HU8%'EV;L:33_(X"2$""Z;.AQJL6';2EZ#(D0
M85R"?$>Z%5E3HEVW6Y.J5)MVK4&+:KOZ7(B2(F2$C&D2/5F5HL_"@L=.%5FX
M8\?/!Q]"+=QVI-&)/4/.+#BW'T.'=ZD:7-V6;]*X=3N"-?IZXNB56W.S5;MR
M=E#*+H>NGHET]- 0E&=O=HFV,$[)!5&Z#?E7L\B&DVM"6"HU=NZ""4U"'$B1
M=$?3OO&R7.BR+G;"/N6R]*B34%IA19YD\>FDTWH3M;7?6R+IUE9(0!%E@Q$W
MC)"#&$9XT(\*%3BA2R1B^%!%!JCD4 41>FP(0!]^"+)!$% $T4<2=0BBP@(K
MR 9 /OTLT 4'8NS8_Z(*''211#_Y8.5/#$M0X40?'-01B"8^<.#'CJ_H<4,=
M-]R00085;. $#II L084"Y@PR ;.6''#!W7XLP"7:5@AAEIZ[LEGGW[^"6B@
M@@Y*:*&&'HIHHHHNRFBCCAKZR*)7;+$!'19< 0"E4#BA @X;]+.!%16D<84I
M5R1!#A5>4E'%)'TLP,$&5+PB11^Z-$'%%^ (4D<0X+3EQ@(^VC (5DA- H "
M$$C "@ 2S%#'%9J\HXD%IL"A"15B7+$!"?UTX>D%'TZRP0)!?/'*!Q5\P$$_
MDQC!J0H8X(#I*S1)19!A(<75&403X71>2.N9=-Y?APTDD3_4]?7@OX'U9/]3
M2PM"M&]J-3T6\,22*;R4A#T-A.]<NDEHV&[W M5QQAF+M9EPAN5$G67$726Q
M7P/A%%%2ED%,G4<, HC349ME5?)\#^Y&'71(;<6:5"_;G-B]?@DGV'9XZ>S7
M?$1;W=-3Q9FT$'7=,4T34TA5QE/, W544U8^A7 50CFG]2^!6..E4%,*G<4>
MPH2UA3)?;8?$=KY]$9=SOON"M^!=G_TE'=9[GYU6 3%#<+!$,3O\T4Q7I4:9
M5$(DYO9OA!MU\6EO[Q;V9=!5UI5#'!/^N4]Q ^;XZ#A)EU%L.0,,TL-1_U[0
MULGEO-GJ)4V,,]YBDY4W?&R#S=!IQ,WT4$,*@WS_5+ZJX>Y::@+RG973?%&L
M$NPV =[5RT %739$+PO<%?VZ=S7Z:#X+#%Y\"P8?G:P,[GQ984M7VF*T@AUN
M*D0SRBL*X ,I6$ %=4@#.7Q @@S@H )+^((I." (*03A AG@0)<FX $.:$(*
M7<A 'S;0!$U\X0HDT,45(/(*5D@@'P70@BY\T@\M4*$?2E  *Z9 D#YHXA5P
M^((8I+"!/DRB"S'LPRLD( 8]),$.%G!"$_S0!Q5H2P]5^, *X'"#2=!!!1O
M0!.<584TB&$$&XC;H^Z(QSSJ<8]\[*,?_XC'2"GJ%1F 0@8^L(!^B,$*%]C@
M!S#0#Q.$R0.:4($1:!7'_S10P [@N$(^_)"$#:A $W681#](T(5!B&$#_I@!
M*_RA"SJ]Q"BKX9'/FI6/%0! $%28!!4D$(10),$(8L  "!?PBCXTX0,YL$(.
M@K""4G" %G0PDP3\D8$1W& +85K! EJ$E<[0+U]PR4UQ"',XNH0//Y2AW.@
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M!]$%%3 "&? )?0  (O0D5/!A@; $,$(.Y/ !(X !<. /?9" 6_ *6M %LP>
M@J )(-L$*^ &+] /$M %P/> (P #(Y &CFD*1$F:I*DN&6 #+7L%/_L%96 !
M0: )1=M>7] %_3 (0.DMFA"8-5L%?0 '%F""5&"UQ;0%IP  ,=!LJJ$]O:&&
M\4$_J"$W[[,_UF%4OO@7:#<8UO$5"R>-V/%M2[.'-*6&HC,@,Y4SY;070@B/
MH26(M'%5D^@:L_^$;Q$R'G%W$5H%/15I.IFA4L-X$4H(&;E&5";S4W0SC;X1
MC.]A._C)- R7'I"E<5J#4BKW4XKJ5%P!6<PUB611()HFBSC%--BQA3+EN+WS
MC0+*-)V(&(/U/4RZ%!8S65*!'0G#&B9J:F?+4#LX&(UU$H[J5"A1:VB1B0=U
M&OHC-)C%%?"T;XNHMI[%A B2$[T8<$_8/Y^Q4DKCM[8K%"&0$,VXA'ZXGZ_C
M5U#W4R!S$WEE%JG&<#GH/#H5%TH36"('%NMS&6^E$SWU;.8[N9C:M0#U%S!A
M$J-S.^Z1<J=:AYXJ51&"MGSA4JD%N5E(JK_AP;:3<E5HAU7X'<Q[==W_&%*:
M 7HM5 =.X -4D 8?( 4<L )Z4 '9.GWTMP$CH =B8 -:$"M=0 0A* :#\$(+
MH L2L  3,,09&Y@P4+."B0%54)I5H .!B0IZX(%THFBWV00;T 5B0(.3L )?
M8 .:<"$L. $D,@)V4 %:%DH4@"M4@'XP)!L9T [A%PB)84<':\B'C,B)G!%\
M:2A7D,4CX , @ &4, CD8 1#&RM&( &>0H*/U \6DH ].PEQ< A7XH%7@ &1
M< I]\",:<@,;8 >FI["[F@3\=P,[IDU.H E >0/K!0!?X"[8%$)]$ J3$ K4
MMP1<4@$^8)M0P&*O7">< $)E9 09< %+X $ __"<"!6AU*5 5J,@I08@! 08
M>.,T8/I;1O-UHT5PG,.D!I6F_(F/W1:B _0O89M A?B\X*$R>P4Z(;5O*147
M>]5L.@&IQ$9W<QJF8]-5T7DR=H6'(Q&'6),<)KI7,=H4IT,]^J@V.D,U>WM.
MNH-1& QR&X.,[Y0_7GND(ITWD/-5)F,Z.C<?=J,?M!LAV)87B3-SX=%K2;@O
MY*R@M%4\^*2GZCLX+'$QT+8TB4&B9Y$RT -/4QJ>#,2FPXC0H3LQ+)T_U+51
M6ZHGQ5L]94?1.!6-RKL:(MH:YTRBI9-2W8/2=%J'QD9J5\$RAW%3%4,R[9C4
M_Z8:-I./VJ@U)Q-6H/_JG_JI=VH[=^&6BQP3:XZZB_LF,?'Q3K_C,D/7U,@C
M'!:*MVC]I3QXI_B$O L%<0#S,H15 P!@F9UB!.3@!T% !#@ >U7  6$T DE[
M(2,@!?W "J$0"EKV!77@"?V  5\P":#7#Q00F!) "Q>BL*V9!!Z@@*.9 U#@
M 0I; 7Z@S3[P!2H  750!YKP@:% #SXB!>KRKCCB"2RF1;?JVH*P31509((
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M[/(=I,3%=A')WL(F2Q^Y1I8QW7$*:C3C%_J8CCBF61Q4GI)8W-+E*OAAB (
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M%7Q@116O#-2'$1Q 84<536Q0:"E4""*H!U!PV0\'1JCPP0@88&#%&O\9V !
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M#WKXA!4JH(<N+* ,77 #.#8@DPWHH4O^T8,I%M"/<$C@ KH(Q2M>880*U*.
M'J#(!ES@A OX!P.3Z ( !M&'#1@A":_2@0KZX80*0*$":W!"!L)C@81DP @C
M2$,3K&3$(R(QB4I<_R(3F^C$)SII D:PPPCJ!X 280 ^\#&%#Y* JOY4P0H<
M>,4@C'"%?ASB AB0P@@L((:!+* "-_C !5:0GR]X0!, 4,!!^D"F"G!J3[[J
M1SZZ4*!^P"$)&8!!!?IPE25LH (6D (&"O6%06R@'V(8P1KX \$N^( 66<2
M!7#%*P!,H':H,UM*,*.UY9$%=3,)RW3H ARQR80;CFB%/[C!K950YI:<8XM5
M*C*OLKS&+9LI5EZ*Q3Q66H<B# F7$.Z BH>)39FQ*<II<,FLR^%%+6H1#N+
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MP2=4  GT@P2L'P=(01,,T210P0)\P17\GA1009>(01_0P0WP5P78P1*@0AI
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MB,0VRO_B16)$0/J%-(8 ,\:C0OK#%$2-.&6;3QQC*6(C+U*D.T8C,P( #12
M2P+D4OJD-2KD-<95TBC4.XE *9ZB1.;.<(335NA&5B0.: 6456S.2)E30854
M\KS&4J2%$#!$3H13 3C67YD&21@/<JA$7AP$7<0%;OP&6RT/[WS=OE36/:I&
M]DSF4@U5S;FE7,Q2V10F8VU/2K#$=+S26DB $)A/#W6'^*6!%/C!>WU '00"
MF;S"%RR '\2?'DB2"MA!!KR"/R0!#O2'G_2!'Z2!)FC"*UA0YVT!)VW(%OC
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M2/1 *Z1%1V,]0_^ 27<"!+PL/]]S/_=#)Z#T/,^S0;<!%K@TTB*!NSKTM98
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M&/0#RFM\:4>!6JNKTT/ #J@]77RC3[C]QP-U8G\\R;;VTN$]$$RUR_-]"12
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M ($))/I!%8U26UT%#2%^  $-EP (80<T.OD!BWZP@ "+/*) (H15\L BBCS
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M2&$2K\B "F38A?$L9@N!P  &AI(!0ES !MU#B)Y0MA&(+ 1E(5"(A_J$,HZ
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MXAC5L4_6<1V]\2,AP!K] 1Q)*;9>+P0X,B(CDAKUQ!F% !H5 6O 427U1!$
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M%5,$Y,Z.((3@#_;@#WZ 6W#U;(1@:LYF5TJ@5B'@#]0@6%8!5Q7A)#X2342
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M^IVRL61+!0R"I)@2U ]"'R,5UN3HLJ%*/:5V%BR0DF.$E2"$*EC)\:%/ 0D
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MH ,1+F"%#[RM'QA( PS *K>XQ?;ZV,^^]K?/_>X7[A4*^2H5 -"$_O;7"9R
M@A[Z(061?, (%"@%!SA1^'YH81"T^, %G+"%KJ3! U(P"290"%>P !YP>R(Q
M I@  ]+W6R(Q>JKW"6A#$:JS $:@"670!!M0.74 !1O0!(.@$R.0!BK@ 4U@
M! JA$%)3 5! !T%0 48@#U:0!E<  #8P9".$%G&A0G\$+2"T@_3R1P.W%[-"
M4U/F0?^3/\;R&JE6'D@H_U$F-5 !$T1*N$ 2M2PUQ%)P0U0LE(3P\QL,E81'
M95#)PAQ">!L/M4!:F%/#(H461A9Y@3\PQ$ 5E5,<%@(0X'7[05!PUP_NYAI]
MF (AT 8B, 7&) 08!P"*,%/JY&BKL E,  F;D )M0 9FX J;L J0L <BL ..
M]@>0B A[D(>TU 8I4(@IH B*P&AJ &8[8&=%!P%7AH>*((N3Y&G&1(AN1G+S
M1A[[(0+<@&YFP 6IH0B"A(NU:$PAD'4 , 7?5G?3) 3/2%"OR(FU6(MUP0/D
M!F8T,&Q<0(J*H'75B''56'9N!@$TX(D'('"T) R>9HB$V _AJ([V00/+:&<I
MD/]U99=U4T #X1@"U7B*5R8"Z8A':-!F;4&(NOAV;_<$B+ )0)=UBN!US^AN
M<*.'Y<@#H72,9N!UEM(/Q\B)(*0(F@:/6H>1!V &95< FQ)I,5<4//"(3&1F
M/) "\IAL6-!L(09JKG8 8&!)ND@#WY:')^!I1?=V(A"3>(0$<*>0)TD#\IA.
MFQ%3=N&4@ZAU9N9UMJ&#08:&!S2(/Q J9L $8+ #P487.R A3\");0 )ZI%(
M^@0"[X$K^<@/J\ $=TF0=HF79,!RH1(%3, %-#!FPD &8'"7Q-@#G"B70J<&
M?2@$*,!$0("7)0"87+ #_, $FFE/G#9F$( (8.!+SK;_@ZNP"I5)EFJBF:N@
M!F$ ':[ 1,1! _P0!G7A(&W)!*(Y;IMPF(&I9G<9F"(@#&IPF'=T10#PFH*8
M9F9PEY  !OZ0EKXQ;L/YFZ'D%D\P9H,I107R(77(&/$#4350-1DP8#>  4%
M754 !V5@,1:# 500!#5A!Z"S!75@!X2  1EP Z:P!1XP"*^0#Z%P!?[  3C0
M>B(!7E8P?0^8>#9A,>3  ?TP Z&P/(.0!%L0!$: .OQ7!Z4P" !P 1]@!TOP
M!1:@%<-3!43@$RI !^TW CE0!1G0%^;S58%@6MYWHSB:HSJZH]Z'.('S"A_P
M"6GP"9K@#Q@ .1NP!6E@!92W_P#T915+L )'(:(?,%<U$U6FH >K8P$;8 @;
ML %?4!$3\ J:T 1Z(!)5D*!6,! PD'B?\ $5( 57$ -N\0H^8 $6( @8LP7C
M4P<?L(&"0 14L 5+0 $X\ I0(Q)%<P4;: 5,:@HJ@ $6\#X34!L>]BLUI$,*
MI6K1X6&PD7!CX4]L@45[=V/T R(<I&'[PBT/11D6QALYE!=_9!<;AF/Q,W 8
M-4T6QA>K6JOII!S&P2W:\AG/LAH!I&-J!QUE@6&L@24YE$%JX1I"H!Y8D"%H
M "'7JB.?HB.@LFZ;((KG40DP8A]D,05I07*=L&V N8E/P&YJ< #SQG4_4)E1
M *]NA/\%$=(/*/ #F<*OH+@)H[@*G6!G2+ 8F6%,BP@!K\@/>R!(WTH&B)!M
M!\ /$+"O:(!N48"M!:(=F@BOWQJP=E())6!I?XBP601L4_*N!P ):E A)Y(C
M[KHD[/9,FX"OWAJQ>I0'F)B2%(%F!8!F-(!''P**];H'H!BQ'2(A_XJOUSJQ
M3+NM9+0)+.L* [M'$. 60A!*\G8 Q)BU''( HBA(_! %V5:O*= )4:(KZY9'
M3PLAZZ:R:)L=]5H"%&&N!0!F4Q)I$( %$.MI1UNS$>(*J^!I&1*U:J K$D*M
MVT8&>] )89 A6,"N#VE):+:(4)1G#4NTV>9GZE$"\!JX;P+_(26 1R6 !NSV
MD.J1(4CP1&@6 L9D2?N1M^#ZMT\+9<+:+]8"(BM"&31@!J6QNXK9B6,0%MR0
M;]MT GO@93N !#S@NU0C!,C;9;M; +L;;YQHE@PD&&+V V;@*UER(F,1!>,!
M0+OK#\W[D3H5O,L+-Q!@!DCE'R#@*?VP ]<@0VEI%]RP!^-; ,*IDO]1">L+
M-^Y+OUW6#\*P:414  0\%KO;!N)[(JHBOXIIOIZ"&=%+-981O"=@B6:V _G!
M=P$S:Q31%V#1!4>J AO0?%8@!;KP"BJ@$)>W>4: GWJP F) !71E"E) !7I0
M!T8@!II@ 3[P!6T1 S;@ P21>FT:_Q+@!0/A50%;L $V\ (4D0\^( 6:L %Z
M<%DZC)]U( 9?T <C: H5L &O0#$B(08>X 8;8%5_FGDJ4#+D9Q68\#(\>L=X
MG,=ZO,=ZXZ-_TP]P< ,ZD &H0!0%VGI.( @84 7OL 2N4P6&$,4+<*904 4>
MX#)T%02KPPDX0* X  <FH DL413)L0)F>GPZ<'QH.@);[ %"! "3T 4<X %.
M8 1)( B(I0DX\ 8;X 1U\ 8^@ $8,!(>8 2F8 <W4,M7( 8XL 1T@ &[TWH1
M]CX8I$(.=5!UX41'Q1;6["Y9>%(@MJH^9H8<YBP8%L*,&#]&6%''\AL3Y,W9
MK$)H.%3MG/]!HY%!-W0M+H5"C"%B<-BJ[,Q+0+4<6U@9$ 1!YGQ-[K09V9R$
M-D0<GN(*>R $$OTIFX8%4[ A$CVM0D<#?227-CDHL90'9 0&G0 "9#"V8.#1
M:?8#B! %45 )0J#1>\"R_" "%8W1$;UI?Y#27?<?[%;33# ?\]J<@%("K&AQ
M'DT#/]"-): &$!G1=K:)_= )BK =6+ 'W""T'OT?2! &$\)HF5G21\V*?<0#
MU=C4GF+5)= /[&8&?\#3!P#3_* &$("V^9AL:[(#]7H (8"VD)!*^(INP\G4
MF+D'3-V-V]$)]Y'2F[:SGN;6;; =.1(&3#VO_ #7X/'7)"TH>N3_1B @F$T=
M1DN=EI PFV,BT<>Y!]_$TR$P)FA;C?$;!CV 1_6+!9W-!#8[;TA@V R;V#30
MUA+];=OA"FK #XQ;U1"0N)TPMBD0OS\0 I! !G8MC)"@VQ&"U'KTU@29 CL0
MW';6UNRV"1"PT2APT:]X#1W2U,_]U1Q"(#E"1DSP!_Q: JL@F&&P X((W(L=
M2K@!A=;<43PD&/?+OVHP<8E$2GL0 MQP(71W< ZR@WUQP!CGCZ*V!RF0CW]0
M"761EI/$B<V;X320%FOI"I)DK/^!!OD+N_<; A2>C^[V& I^;M9A2>YD0/<K
M!#R X8I  Y!0)<^IXIQ8 "> '9YBFXB _P9%)QH[7N%)B=@9;I--KN%7M"(K
MKIP2UPE@\+TUA(A0GH_[HI@ Z1V$! *5D%%?N5(BI 0 X ,X *<?0 D<@ $O
M,PD>D :H0 )&T >:@PH7< -PX $8P %CE01B0#1'(04>(.@+H N*T0_\=Z8Y
M8 5&D,K]E5MUL !TJ 630 (+0 '7E0&6Y:4?P $JT <K4 $7@ J80 6O4 %)
M8 >DDQ.<0P1.H!0C8 23!0#.%1*[SL? 'NS"/NS8Y\=_\^H+F 94X ^9AY\Z
ML 4FL !B4 &JTQ,C4 >.:@<5D 9;H E3G*<;(,1)BC,^T.V"L'E<]0*,$0-=
MH M#[ .G< 5*5?\ $Q #_M %GJ<)C$H%72 %/9PY." (_P5?Y3>"8*4)/9S%
M6[ %<+  7=!Z&& *7WJ#U(PPLNJL.,8@PAH9_W*K==$<T?KH=Y&KVR(:__+?
M+U30(;QD<=>#KKI#IZ$O\S*J*%3R^E-P+69A.-8:R+HHYD'0*S14 G--R$(O
M+0(M&K]-RX%P+F]A(,8>6' - / 'J$;U,P(!VT'U_8 %+48<*K<E6X_2-M(&
MVZ8&*.V\$- &@S0%B%"P,M+39/0D6B\E$G+>0/"N)T(1^<AM84\&42 AZ 8)
M%A+9P\$G[8%'*2 CZ'8-.0T![.$*];MMLF8I3?0F8_ $>:0&%]*6!U#_(?7J
MNV$Q:&9 %UC0'LL](9X&^7EKM)+(!5Q/+*-FU\GF9^=AB24  :<=!099::16
ME5B]MWC$T_7*L%OO^%L_JS1@:9XB(6*/!)B?DC] !C*M0 3U%I$+D8%2OW_0
MU[?M^$+ !"$@^G ' J!H!A+BB1>"^_P ": H]0 @^H0A!,9/]9VF!L,K*L&_
M]2* !5O_&YLT'0#1*<J!$OY<;>*'! (D?I!^#-RS<!,7 ! *A/BS20T2(1GY
M^?MSK5_(?EB>'"!8P%_%%$)VH$$#A",(,E$40B*8ATR8 OU4"ND'P%\;-/U0
M% "@4FC/ A  ] LA5$A% %4!@$!3=<>>54Q6__TI^F23" !3\F Y ,8J!%>5
MJ@:%L&/3GQ)@^YTX\ ?1IC!!0V -VF./B!.;ZI9( :#'W$I!A4:%\"<Q"K<N
MT:R42Q?L6PB"R;8!D1',3W]3 ?O#^X<,7[A_*@EQQ:7 RX5A=E"<$GH3&-1Y
MZZ80-K=NT1UY]U:67,"U$&%JL)2 1!R-4M3"[?Y\,I@'FMHOA4+U"0'N3_!(
M8_0[M0$*A@\5,ICHL\6*#Q]TJ@02-")0F@H8FDSH0Y! 3*DC PZ:V$"0+S;8
MP(<K--$DA@5><,H?&ZYP@[XOKK!AI7X4D."5!3G80 PJJ.! BB8.K&,#"S@D
M@0(I1D@C@PJ"D.(#)_^HV* **6Q8H D]]'/"E"_Z\4</5$:HH@FKJIKJ22FG
MI+)**Z_$,DLMM^2R2R^_!#-,,<<DLTPSKWQDS 6,R*4**Z@ H((*4 FB BGZ
M2<*($2KH0P45%N@C"$/J7*(=(TQ9( DQ,HAOQQOTV*"? Z70Y)5^W/#'GWZT
M$.2I$/H1@@JX(,@GA"NNF&2#.FS(0(\,B B$E@TX^,)2*7"@ HH;X.! !0\X
ML,*)#6!@D@,2/E#/BAP&Z:*?&)X,P9^>A%A)6JA6LL@B4$LKS:=M*UKI4P#$
MY?9;;3_MZ:V>K!4BVHIZBK:G"BUZBBIK/Z66*G>=LFBEI/HY%TG2IMUWJ7__
M\W4*7W^KXG=:IZJRMMIIK;7*KV_M?7=;H-Z%6"B/ : VW88U%M>JJ# &+V3P
MQ@T*A#S0  $K$%:!F8FL7(:99G"K @&,3L+ 0HBZ\K!)B$[^@.0P$9!J8Y7&
M> !#A!V80.(/+-"@"XF9N9L:B1T0.0 )=D,[8!,D@'B.Z!*,RN,/,USA)Z+P
MJ.HH;@AB)H,@F/- XJJ706 "ISW\@4"(GET)8XP>4%K%IK_R2!KNP4%>?/!^
M7$;B<B;^.&"CF4OH' D:RD;BI\7) ..@LB'  @2;^G&E[=5*[Z=R"$H+86KN
M.-]C:U?*7H5FS<7&EVPUT!"Z)-<Y AN2*/(  TF5__G=@0Q^4IA9:ZQ^WV05
MK'*W6;$#]G#%9\ZY0+Z$Y>_.HX2!U%BI<K):7D7KW\WX06:PU8 $B=QI%@_/
M4J<3LPD-;&9@7PE*(#D(T& 3FTA!NK@'N!)H9!5CR(/,: 8$G)A!4T !02>P
M0 ,L]&,,RC,#1SK1MBC\@#=-"<K8;.8OH'RJ8.A"TLX X!T \. :FNK'2PK@
M&1HD1@AM@(1;I,5#(2C"-B*I%P1XL(=^P"XK3GF)3[BQA]QY,(J"Z<1TJM*&
M/'0&)2CYX56*(@0?>JA>2"%B8OJ!Q-=4*RY7]&$577&9(9YQ$S]\B1!ZH(9.
M@*&(5>%@&&@PN:!,,2A5%/_"(O4X'6YLX@#\., UI%@44$4A!=OY8 @D62]N
M#7$L/,B<8+# A811)6'88DH.)W"I#^3@ DFH0A#ZL8$1C& 00<A '180! YX
M( .$Z$,%C' %0-7!"'700X%PL(4@O((#I=@ %18P 1LXI1^36 $I8S (3['B
M=E\XQ8HX((@R&"$-03 "$7 0!$$L8 5ZJ$(2+I"!!3C!"2: @AWJ4(4*Z, (
M'A#$#?H A0_<@)P V$(:TH"*.YW)HA?%:$8UNE&.=M2C&4T3F( R Q?H8 1&
M\$$_;O"!$5B@ ALP@2 :J@D.&($#?7 &I$QJHS2\XA54:$(=YJ&""BRA5UM8
M0*3_=.D3"3R%!&*HPU,TY8])](,$#*O* HA@@BU\H0F:X,0%JF"(%96B4V+X
M0 9R\($/<,((>N" ,CFPI!&LX!4WL, (<N#.IH837%.I4 U] A25H M;'NO7
MW+K5E,<\A;'^B IDW^4O&Q+VD9$E;+^B$A2D'-:;Y &MIA[K,<8.%F"/\1;"
M/H8MGRS6)QV[G0Y!!I6*A$<EM*U*:96"6,12ARJYI=;&UC59>VTV76\I&;?R
MY:W-BNMALWW+4ZIX6MHJ=DI5Q&J]'!M#QU0,L/7"KL=B"*55', ,2]-6[<H&
M!C!T!7!>8<+\*I>"(M:W;643 1#_P(_&0+=B_1C=6*32_]W%^:8$6+#:<]!"
MQ:I4SEM(\>;HJ(@4'IBW-+_3I% D+)X*4_&1%WG+07@3@L6IH;[VS<A8O!5@
M,/2L*R^.;_SB!DGL/I)S:LFM9Z4BD10XQC&+,<R!#Z- SGFQ(YMPBU5*(Q7Q
M\2,JHT/@W-[2X>D"3#4H40,8?D"6A6GE $4!67'ZMN0"C.Z'L#&;"'SBX'Y0
M^;IH5@O%'JE=*CG&LHSUYEJ4O+&5026XKP498 !P@@G?K2B> 8'8YA@%LE1D
MD#T&P!X=21U"^Z0-46B,/P S1"XZLE\ $ L-/ D5K!0@-E5L R(2\Y+22%(I
M$/;'8D20:&EQ@]%S*P!65B*,/?\\!0)1Z,NIYZCJ+&KZ %Q(-%P8S0,S"*R!
M7JQ0I4$-[)X]10C$!O,3&)W%GS [4W]NBF>$,9V['?L[*B%/<7_[K"^XP HC
MX(!"_9'7-)! "A4@T0TF\>X;4*("%T!H%S: @3JD@0(K.% 3ON"!?O0AADY9
M  E"X?#OV& 03?744TSP"@E\H0Q2X  'MO"!)613$U?P  6J((8;5* )&'BI
M'R#E 29MX15]N$%^;G #40' "!6@42F>U-V/%MWH1T=ZTI6^=(]"@)H%[Q3,
M1[ %/XB!$AN0TQ6:L 4)L-4.O;0",+=@@2\D 0X8P, &EB"%-#2!"G"0 CQ?
MX2%_E"'_#F+ P0:NH LX?'P#>D"28_I@!#$P: 49R, &"'&!#4P"#A-H@@5N
MH (Q]'+J%1"#*7"@BQ[IP10;< ++1V %.EP! ,]"2A4GUEO"4054\7H]+ ,K
MK82-)["IU?&_,A8MH(2+7;9][>H5-K#83PM*LO>8N'CO^]^:BRGT8MGJM97;
M\7 W2@Q3"KY@N[.420MBIY56ZB>F,FM[?US'_;XK\;SZBCV)7I%U/;56$J7K
M9ZNW_1KNR4R6PVPII6'/+0X(TI;@&ITS,D"40+)P.R-,,L TFQ8D.H Z^AB3
MX08U4+%\@1(>P"1+0L"R.:,]0 KQ&9QL8:W*R10SLAP.V@VG_\"+P1&DN($L
MVO.U2-N$-1H=!CS L,DO&RJP'#PCMT!!"(B7IF@*PUE!).&7I1A ADB!PXJ?
M'.3 #]04#N(O[W)";A@?LI ??9&>'H#!\P,5&EB%O#DCQ.BN(ZNC GB"U<BO
MVC)! %#!T>@,&$3!1GN2GC@([GB7"B'"]GL+VN._T9H^J7H2&<R8=*&8V0"S
M'4@C18RU3;BP,Z*(I0BB*+!$_Q$&'(Q 1O0^83@ORY 6P?"'/#HLSZ@>2RP!
M$0 "3V(9P, *BQ & ^2O=!%%V$# %YH75F.C- H!7IL"3U**/:*!RQ "(8 $
M+OB+6RP 7FN86#3 2F#$::DP" */1/\K0)1 QFN,0&=$P$I0"L'(G<OH!P[B
M AT[%]J3EY5X!0"(CPJX 0H0!"EP@@RH!PH @#+  !,8!')( ROXA#JH@[22
M G^8 1]8@D#P!!6@  I8@BW0!#MP@DF@.XAJ@B 8!$$XE2L8A#J8!"/(H:I8
M@4GXJE(0@X4T!2K @"7P@0[9@ S()158@Q%0JP]8  P O"90)A68E33HI318
M@J!XR VXNBYCNJ(TRJ-$RJ14RC+IAU<P@AN @ASP 0#8@*]#JF"J$2-XNU+P
M #U0 0Z@@$\8@0]8@RJ(!"J  !ZA!3M0@0R@@Y1L$EHP H?SAU#X@@6P@@UP
M 0N@@PJ@A#3_L  <6 (2Z*JGT 0C0#L+\),E8!,5F 02Z4J@<X\;L (H"((M
M\ $I" 42,((F,((M$$I-N $#N0'3FP#LJY:YN;W"&C#=JA![(:S%JI#(,BS>
M0LV,D8INF2P\^[[0<B7;\A <<JS7M+\\T\W VKYJT3-N\1CFS,W'L"R(J9#J
M"D'54BYO20JG6!?"RD[QLJ$)C"+&PBHGA,WN:B#(HH&F2 $(:*"F$*4"F (1
M" &R$ +ZLD/6,JS,$H$V4 0 :(/]5(3W_)3U?$\((-#T!)D?6 U6DL\BZ@=%
M*+ ?H %%F- *I0%-"8$?Z)P?R(,,P@E63$_T!)L12T]0403"(8RR_ZF$'NO/
MMU@<%1NZN-@$*IK/%KQ0 \T6^NH<(:2!T5&#VVD##1V+'_@!NVDS\TI"R2H-
MT=C/XE #+O@!)KBO44N!$(BD,D,)#J4O&I!012JBN!@?N" NMO@R(0#0^!R*
M!O4'6Q/ )GS/:12!I8$*$6@7VU&$A8A )8/-ZH"@W,G"?CC0IB@.*E($]13"
M.Z4!W2@;+E"$!X4R3:F((XNSLM#0B/@4N4 R*1J?!H*R]00  CU1216!!F)1
MZ@K!UQR7BKA3$5 $LHA/ 6U5C,&8XH2A4T6W$+Q-[*P(&M"SZ8S/W)*N.3NM
MI&"*;H&,V7JLY:J*.TV]&)J*[AHO\0 5=?^Y/:B@@1A"%Q+<F(SKB0\SSMA\
M$C,M5L=24M7[,-V4KF;UE,N:+>SLEL"K(L,J  C[&,UJK>7"K-=2  #P 2*
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M@8_UAXS7DPRP [;B!&.)ZP4 @$FP@RIH*%0P@B7 @<J[@298B2T8@4]8@RV
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M07@,%(F0,2"BT)RK^P<9OY'T&4E":!7"5UB(!  $ (PDE?^##8[48(-2^5-
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M %*#&0I1.R2;+,?0[##ML</LKC_?SUO)@]$)#X0BE!*\91,B ,'YS+ #, "
M!R"QD1!<@1?KP8XAE3E "9!0NQ*H!S8 H,XFU* 9" @&+B+ '0J.%X6)\&-Y
M$'!@5FXG.PW*+W9,0$(!5[$*W+5-3;W#P@]*L DR,&4/0,"=*RY8 O&8Y6T;
M@L ,C;*)%-2.@K&CS ZU-!40Q"0/8WC):MHBA%7\ 'D[R(P9'O_$/Y]<SX9H
M ,%WP-!&^]TN0V_C1GJP0 /$1*$$(* /%HP'"1&N@H%0@4#D %!&?E1%#;+C
MH!I@U\;KE0 C7&B,]WZ NS\PQ0S],)]Q%NB@LJFH?0BTHI#D9B +[4U'JH-
M"&C A#P<! (_",$/<IG+,-BR'XK092Y%X,L\K(*7'?KE#_+P@Y%, 9@_$ $
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M9$C6"YFW&9@ A@+ N][U%@'&ZVT<:*I(&%&H-R086+T&/2$**<"0O%=1@BB
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M'RP :^% !9R?'6A"!B@+POC !FR _]7#!T#+"-3!%\#!"MB #VR>!_1!'6R
M#_3!"L"!)M2!^4$!HO2?&/B !33!;)I5$*0!9H[ !^)7:-;,%31!!DQ-^6V
M&'3!%FPG]QE,&A >8%$?>J:G>JXG>[9G8DF $=B!]FT  .C!$KC 3NT*!UC
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MB(Z$0*+ZVTXH:BPYAB)\2!O<G$(4@!# $X)$8R-J!GT(XR)VAZI&1!@H@C"
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M2&1 ',RH$T"*!TC $H3"!D2"'BQ /Y1"$W" 4LT>*LCG!JB (-#!:9*?(&Q
M*/B ! R"$3A!C6[ &F" 'CB!_QCP;A#DP/U90&.40:?D@!1$F'M&L 1/, 57
M,+A8W[FL7P7D OE] 0!LP7]"@1Y P;,4C!X@BIX<BAXD@0>,Q%Y9P?UF0'Y:
M@0Q#P194@!YTP0*LP"1D@10<@B%0Z!=, @Y,0@D*@B9L01?XP"&00#]H0@5\
M@AWX[@>$2A7DB0H < 5P@! L@ 1L )V0\ A<0!4,PA4(0OBA'P900*/ 27Y%
MH9(D#I"L2)&\C=MP89\*H2HU&-O,B$R>(8S]H17B*0_N\2@Q3TCRF($<64@%
M<H^X32(GH48.(A,BB9214N4LJ2 [#I;]9!L>(=Q\6^'PX"0OSN40)+A5$__D
M@3UJDO\KN'(>"$5U1($:N$(>,&4)"!O";H@B , 4J$FF5<=W( )"5L<?N+(F
M]4,*!1(K&P\S;Y(:$+,KA $9 28 J*TO9;,0!+,:*$44&(8: %$G %$@)?/W
MN(4FG?,35 <D[,'WK$(EC$$I];)90!,]FZPP;\(WOT0X_T KN\4-34$GQ/(K
MHS,6% 8)[8$K5,(T(T'[/.HVCV&,!/,F],0P(^0YV_(_0\ Y5S,*^#-"%\9"
M-S2B?H:P"1LPCQE&7#0$I! ZO_0JNT4LGW-AA$!AO+,FA48!"-LV_RRM8FPQ
MZS,9$'-+Q[(S8T$S)[,MH\'W'/0>3,$@_0$UY[14[ 0 V'/_57\B0F*!4+<S
M1R,S&E1S0?./)CES2%L'-:/&HX; %/0(- F38P"U",!$3WAU4S>U\3PNX4B(
MJAU9I(ZA5L8(@Q#E%N&$5Z8:6G!2P%U(&X! =8Q<^PA#:T@%UJX/)Y4 3OA#
M8W/'R$&$"&CE5!R%;[SM-X;!#FPE)$390H/J5")K+6(V75)(53K&UW'2S2)B
MGC5MC.Q/43P=U 6<99= Q/'@_K#K ?Q!3P@(<E#B0O?#"?Q%:HL2%,&$K[ZJ
M8C/J<0LW8SH0<F?<'#HI-X:.C<1  ?@ !JA &O N\8F!%.C"\M&)%7R 'NB!
M$P. !^A!/33!&V3 !5! J7Q +D !_P:L@1&0@PTL@"Z40A<,P@;T@1CXPR1L
M0"DP2Q=HGH%.0A?X@PELP.!%[P68514TP<GX@17(U2L @ GT@::, -ZYER9,
M @<, ATP2GIC@ 60Q U_@A6<IP7WN(__.) _'P9G<!IP0A\X@8A2P ?4 R48
MP:YD@!-T# ;85@:( 240P05\*&5*@:)HWQJ,@"'8P0W<EN,M@(,L0!9\1A]@
MP :\ O^E[P+X "=PC#\$%4;V@2!\0074@PJ*@0JBE0H(. =\U6E&#0=\P)C[
M2Q]P "IL0'@BY_UU :8P3J&E#8Y-"(7)R)"T29B =Y?2;HF8:3(2R9V::>D\
M";:XR)VNB?^!P8@4/ENY3=B(A?J#T"&20MB#D0B)45F*A0D50J&/M ^.?0FJ
M0S!L,)B;;MB#K.GE\$B## 6"9,57H, >"$$GB(#"7NP/6(]-,P$!3<]+, $Y
M^Q$7:.T/T%,L\8!+8 4 =((BE #_5#NU1U"U7_L.4!$5(0$O_8&W#[1#_\$J
MC#M3\D 8:.U"\,#; H:T@V4GA, 7806]MS2V,VH*5$\8($>_3P]R_(\F_4$>
M< $/G#O%.ZRZQ[O)NSM^?,57#/1"T)-D[+NW>[QPBSNX"P08F#L-G/O%P[O*
M2[L(D 96*'P_? \O(7P>=((Y\?NWYD$EB?NV:X7RY#P]2?W%ISS_0JZ\(B!!
MM$>[,N=!K?& (E3/#]1$QL\\$/T%%F %-UWLU"^$U=/[R2N"4*R\UP, /PE=
M'@" TB,U))2 TV,!N=\[4#*JS@^%T$,\"N!'PS]\O7M])9JVOF/\TE<2%QRS
M2PC$%)U%P8O\4)@\Q%_[I;=/E6 9B2C27V (1&$M8TB&5! E3$J)D/!3@40!
MQZI)V,Y9"=R;CYU%K94$[7^E/XSM5"C"$Z3V<U/;'F !&/2 :#NDZQ0C94<%
MMV%M,E:M+L[E-X;36=0EER[F/D''G:&!9#^(WG )2SIL7?(/3D23_,B/M@D=
MM85SN:O9J%7"V KB":3_B@A#&JE_F*@Z_T 4Z"?$7P%_  [Z@P!@ H O&#ZD
M66*%@Y4-@CS@R' #API"3CPT,?)EP08,22Y4(%1A!)T*.2I\6,&!A+]^-E;T
MZ[>B3B0)I4IU"951DP<  +)PT+F@3I\M+-/4T5,!R@A4?6A)\:#)R!9#=:"H
MR)$CC9$^28)\X%#%288/4 8=[ .%3A)-_8[FU;N7;U^_?P$'%CR8<&'#AQ$G
M5KR8<6/'CP,_8OS.""HG(WP "-)NQ 8794?HR2"A'Z<D"YS<P !C1)-^-@75
MJV"EPA*QM*7HY%"GWY(@4NK<J")&SX(%_4@L,!7$R!(B@L3 6<#AU4X<+*L$
ML8/*RJ<+05YW8?]M(8<=#H:^]EOP-,>'#R,$5>$0I N ?$?["02P$,! FP4@
M,(@@(?!:R,#^!,ROH(7\(0@A(1 Z" (%'U00PJ,:S.^U_0S:#Z$0*.PGA+SR
M<Y!! @M ,< - \S+0  ?+*A!FQP\B,0".,P/1!@E]## A? "0$!_=F1PQ D%
M2I*_HP3:<401$0*P0P;Q8[)' P_*[\ &\[(1R0P%1$.(/ZZ!@,PQK^D'"QSW
M"R$%(79  XU^2@!!#3,@0*(?2 XH(8\HPM@/+YW:%)-,-2$P]!HTS2P3BX3Z
M@>#-'\!  X@Q0"!C420@@(0?/Z.HI+\5\1-B3C(;%0*+/%5-\]!'1P3_0(@W
M=P #"2'JC&)3(?B$Y$]1@PQ2UE/+1'5511N%X-'_)(4@3DO1 "&**#CELP1%
M=C"CDDAM0@@O() U-E%&C>V62!X@^ $+2['(E-I.^\0V5!!?TTF@1/LY5%Q%
M\W64S?T4$8)2+-3,U(QJ^Q2!!D#Q,BA6 @G6U]4R40B!6" >S<O-$$  8XR"
MR3"CA$X__?5!$G52L]]&^T$!"0!6'0. 5Q5Z, 5GY535X!)"X!//;+<%,B%9
MQT!SY8RA-/)D)O&3L@<U1/"G#5?0X&8/$42,\Z@>]@AAAS1A[ <$)(CD)HJH
M!Z+!#+S:@"2%KU\;T9^Q"S);!*Y%: /0H\Q^_WM.C@_@HN,"$4EA;C3R.@%L
M"=7&ZXD_1&V0AI<!T-OP?K+MD4B$QL9KAST(!0$-'D"W"400.13=IL_Q,EM4
M5[C0J0U$*N%A3@A "'QL /46@70%O0;=80!8#\'L,+04DD$+(]VO6P!(LV$M
M#*S(H0HC*M!#D^G.FNL&3D; (3<3/'!"#ZOLZ",#%SXP@HY(5^C#'U->$4,%
M(Z1P@HI7/%A@A2Z6( 4<;& )"Q #!*:C$ZE4H0)I,(05H' #*SBA#SK!0/:(
MH ,HG"4).='$%K#WGC10+PE4.,H@H%"1)D"&A2UTX0MA&$,9SI"&,)3,8A9P
MOD^,X O^4,%L3/$!%?] 80-B:,("B&"$*KCD W:8C1@D,(@F!($E;=&#"IH@
M!2JLH(AZT$,@TG ^3XS@!F*X@1XXT(<-?& +5%1!$*IP@S1LP A&X, 77F&2
M,F2@ BH0RP8L,(A!>, *5L@ ;48@A3KVP0,JN"(&G$"1*EA!$_5IR%%"4#.%
MZ">3/HJ2YCBTHDR:J#\@(F6 &@0B!@D-0U%Z4:2:5" ?W0M#_HF109JTH!PM
M*2%2$A&+.!FL K!I00(Q$8_\DR0VV1(O/4KF0DZ7'[T<2);-J]F*A! K'!E3
M0OKY$4( @#H;33-)OQ2;Z$# !"2 ( ](V $3YN0AL74""S3 @JKJ9 93"8'_
MG7^( J4*(B5LLG.=JT <" S*SFC!DZ!# D#'7/$#,6$AG_T8 ^[R\ <S@( +
M&L-D?T PMG1&*P]S^@$Z$ZI.88D-#)T(P\<H"H)%B:F?4<@#&%ST+WZN8IWJ
M'"D_VYG.=;8SE5G#0B?4E:]<E:!E)37335OTH@D15*@C]9I/?6I04;+T#S0X
M%:ANU8EV*NNFT@S!,!>RTYX6% U>0VE!]907?K94HF/*U:T(2E8PK+1*"&5K
M5>&IUI$V3U803<''_E""'5!+"&+U)Z7Z(]>#@ BP"QU#'D3WT*#R%)R4!0,6
M*(7/Q;[,%24-09W 4)!?>DBS"V6KB&843ED^+[*=_YP0#<@P+20HX@E7PTMF
M 8 W'AR N,2MA!!<0=Q-<&%&!1!&<??!!0@,M[@'.&YR#[!<?^!-"#WX@W*9
MJ[5^  $28(A""F0K.CC%4P@TJ*YU3U!<[7(HOOP@;FH'0KKF#B1KB/.'XJ 4
M)_?*-U"VC5-^RW20;$WAO.E%P^0.0EXN(+>X8'!N@@E$W>)6XFL)R5;4$")5
M'L'(>1YZ01IN8(H,7& #%Y "!S0A@0V<,1 C&($*JK"%%>CB!AE(@F@$L88/
M9, "D^B"#<2P!3UL00HLP< 2UA (*.C!""L@P?DPL($JJ$ *5?@B!HPP"#'\
M+P,;R  Y/B (.^2@#XJD0O\2,C "*#"PRT:PP )T\88/ !(B8MDS7J0P BN,
MP (U-/2A$9UH12^:T8JYH6)L$,=!;P  @;Z!>ZIP 1UDP BE,,$@ML >#D A
M*QS @1%T80<ND[$?KU!**5Q @4]PQA"?J,></S#H0*1&!6FPPGLR$ 08?& B
MA73"((+0!Z5L8 05H(,3--&$4W- #W0)@@XJD %!=@'4?/SU;%@BB!E KTK)
M$V@I+30CN17I0PA2&O-XA"+-G>XH*G*E0W<$IA9Y:$H5VM$O#6)N?\.[2"3&
MT9,\N3EFM1M,D162NN7][W^7$T-4^N;F&!1P$J.[WT1B'NI(=114?DA#3[*)
ML"[_U*4*]2=ED1V47ZB4(8?S%3\MYQ*8:.YP @D)1RO]5_,&U7*1DZA*X92K
M7@8R\[SH1R\=0GK-6;XAA.,E5I.5)Z$09/41#5-('%*XT7<>]!RY')P8EZ?,
M954E",&H *HL\82(+DQ_9 DPPBHW7R"T=C;%:DE$+_K,F\G:O02)[DP2UCBO
MY/*6V[W>#3L0-9NN=OZZ&ZTK?[KR9/4:>W.)30%'40@(U ,1(&A$J-L0RDX^
M* !%;>=L'SR!%B\B&DB3X@ 0@2(,'[;^$ CGA==0U*.D^GQW*$C$YZ^4LG0D
M7/9]\BD#T]>/3W;-\Q="J]50 6APD&$>!$6$@KLLL11*_W!:G$<0L-$$6NV"
M*GS@TC?X(9@QX -0IZ$*%A@U#@1!1]=0H [U"%\_DH #X, ( N$&/J&05& $
MT@ 5/J "4&'+L$@%K  51J \5B,!>ZP"+@ '.& ^^N%\C, )[* ?!L$(+N(&
MEH #+* "R"$#0L$'P&S*XJS9&O &_. HC.#2<B #&JT'?? '@3 (A; O'BTQ
M(&"21@ &OJ#2ON,"G  #5&P#ZD %! $./" (,@ #NNP&-J ?6"$?^J$,/B#^
MND 0MD %[*#9T' $MFP-*J *3" -6&*-4(TE*H *G*@"H0 &O*,J5*,)!N$*
MEF #-F 0?* ?=.$*7N$Z1B (+/\@ _S@"N"@"Z3 %%0@ Z@@#=HB-9S !LA-
M>8))M>+-F08DF59KJT(IESQ$ETY$GE3./VSI0$!$1@3"2[AI%<7/F#*)EL;O
M%E\I2:IDWYS)0W9Q\L;IK%P$07Z)($8QFYAFZ"QN]TR'ZE1++[CD1#2$&6/Q
M7[AIY]+JFF1KG%H)2'+IW$[G7T3.FU9Q0'ID+Z#)%UV)+V!11@AB16R$\&J$
M&<'I]6B$1A@O1QP$Z3I)FXQIFCBD'HV.7F $FF"1&0/JFQA2MLP/%7]I%D-,
MH'*)'4N1FX8$0!8$MCP2(%4K'S=)E(HJFV8$FO8BY<IN\+S%)OJNXF@)=9Y.
M%F'1[W;_$9I@4E;$,1DG:Y-R$AU;:>YP$4@LTB"'IIB:1YR0KA9CSD&*T7E0
M3I>RD2I):2]*;_M>A!DSCO&T!*U\*?C,+R =#D,R<F@@<IN:9.FD2K8\29L&
M8I1DQ#^RJ>1,$4)F44KDQBWC4K6$$1>S9$60+^#"Z9KHT;8*LQQG";92\37*
M:4(4  "HC1:&Z,E, 0-83!.JL'XR0 RJ((XXP -\P 9(<!(L@ K>8(V@( U&
MP Z6( T-J0*RS0,^H I&P 24; %"XP->X0*:S0Y8$Q/HX '/<,^@8P.D8!#Z
MH0_<( :R8"I&0 S*[!6N0!!53 R>; /"8LJ6 "\L( D3*2:'_W \R;,\S?,\
M8X@$W&/03"C;R.(&4"';,@ .-H (2* ?IJS'VD,,@D ,P$DGB* "@L!\1F ;
M1J#_V' $4L,'^F?4.* !AR@(.$ "?FP+ I0E,J .!DTU.&"-C(+E5D %DH"!
MK" E<  .=L(,M?,"FH"!W".,5H"UOO+QXBUY/.Z3!J3=!'/D=M2A4(GW.$1C
MTBU&*F0AH43E8NOBG,?T]G+H/(Y'Q&^6N,1&V0U*;A1#4*0711'G3(])>.GZ
ME$;?(FN;T$US" +DQL\:5ZN;F,5P0H & "0%VDX1^J$-1.!-;X9.O2[>IBEO
M;L]/XQ0"WA1 X%16LJ]9WE1J[A0"\O^&!E*@'W O\,0T2Q0A;Q0A!"X5:P85
M4>%44G"DO0"D4AEU]4* !T0 ^Q0D09JN3D>O#12!42M55NXT43?U9D2D4FD5
M4*?K46F@Q'0I0T#$516U4NT4]#KU9C!54+,O5"$  CI55QT54LGQ0!9R/TX5
M5OUT4VM569LD^]I+4>U45E( 3D>/1$!/FIAD"N[451G550'@9O8#6;,O63%U
M00S'3NT40'@@!<I54-9Q%?&U5?\T487 60.55@NU60*64/D5=<Y5Y0QD8=M5
M!""@4H5 "$X54^_T53W2WJQ4'GDDWU1$2;ING'2"WB %F7;$6[9)0M 2(W]/
M>8:&0&+%+CO_#C^>A.M8UDRU)%@20M[RL9GD;>:21&0K<NPHA$G8[1=_5-VD
M<>#6L4"X*1JW)'E^I$,B,QQ&@(_XZ *,  K(X8V4HA]0K G>8PL6( 5?KA\$
M:-2$# 8"01!N8 XQ  <8J0^(0 4,@?X\((7Z@ 3Z(,4"C27J(!"PS07@@0AN
MX!#,Q1\XH(!(M'U6J!]V8P/TP G>0@.SK0*D $+TH![>0PK0<W1)MW1-]W3[
MXP4J0 >LP [J SC20 P^P!2J((!4  /20 5X@Q U(0WL8 ,J@ M+X2!8H0FH
M0 P(\3,_4SJW8,SZP!0VP!1T(<X.R3TRX'FQDP,6P +P1\MLC,B@_VT22N$5
M[,,(^&@2[" #,D %OV ^2L%RH2 #EJ"-GJPSMX!\+^FL)+6<;*N;K/8Q;Q$Q
M,VY%[)$CL6F<;C%)59$_CG)+R ^;B+3O=C0>"Z)I;M(LA9852ZE4AB;P(#*"
MEXDL&]/T%OA3C2ZG "Z#Q\X=.>E*(@H-7CBBL. /NN8/U  +\F 5P@ )IL @
MIJ!!L$9/ 2!@O@L1-@$1#@ 1]@ "7ABIT,")A6 5)*J)?Z $:-A,;ABS2NI4
MI152O1A$1&!,DG@3(.&(ESB&ISB-$<>)D6J&E_@/-@&II!@-[A12;0+W< ]@
MKAB.D1@2NF:.V?@'D."%0Z 3XJ2-B_AJV/]ICKGX5;U8$8!X3-[X /A$B2'
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MXA6,X(JHL K2P .2(*F#  >F(LXJH QT8@M\@(!>$PLO8 O61P_D2 ^N_P
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M, (!"- 00A;*1"HH^ $:@#!!_Z"EA.T9C@XATKZ$$-&(:$!A$+7#A ,F$"%
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M,0%%?.(*,(DF*VDE+PD 0XESI;)'L,*225D)PA %$P0).-E !W$"!_ '6]E
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M&. "J[<!4I!=)+ $"] /_WJ  5_ -G[@"7TW GE7 1[P"=^559JU 7)E!U5
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MT"JQWE$D%P8TP):=H @F(AMS4M'+@13P!@;9FAFSGA:* M2U;M BTBI\P0_
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M)/^@ 1'XKNP*3#<"MKJLK;(S$/6@%$KTRTHTS.Q"M3FJ_\1*_$3#[ [LP"X
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M8-'NH0#>(0(]"(57  !6^!P%VH(+H/\$#Q@$)K2 )IC1"] !%DR=)%@"0\@
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M /BA%]]Y_N7G7GY0]2.>?NDE^&"##>+7G8,1@M<@>P T*-YV^^FWH'KR]0=
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M3D,4<$(-^+9_Q_<')%L*<XWIV8I(8WSNL4?@?6*''?\??0;VUP^(&%[)WI4
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MU)--GUTE/ 5(6_!VR1_QG(B;R H/CM##G6H*:#NS!$$>D-"=$"#)%6&@$QJ
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M=^RD>[6<]VU'>$*-/8' ;T$ ",BGE\3)?=Z8")0EH81!&T!""2#"88% )12
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M?E(0HELP\25#54</**'? !<$>%U/,>T55 CBU11  +6%X <PQL@S#V.18/4
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MY  5-KE!/XC0(RGT80FA$,05_'&Z&^3 "G"XP!)N,((MQ"845)" "B[@ 15
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M$#3!"%ZA#H1'\I: $'3  H2">I+@$(P@")+ 'ZX !RK !$SO C8 %9H %2H
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M]'($@DL,)*#_"I[H!CKL--) #V)R!=3Y BP 6U5 $*0  ^A@$@($*D13#SB
M EBS%#J" SSH"Z1 /_Q!$-19__9R"9)Y \I@8#W@U'WK H2'?[8 *)8#[Z1
M"H8+7UNO"?Q"#.P@/+[=H<O=W,\=9;&R,29 -X3'?*A@!*R@"@Q!#%0  W"@
M'01!#/C"O%H!S'*  W2 \;[@$#I6][RY @(S"/@2!S30+W" /G!@$MR+!)8B
M T(A/8*D#UP2 Z@@"?1 #Z# :8-@$+[@"EQR!#8@"< R!Y)'%_SK"X*G"FJ"
M ^H@@-+ $$ZA'Q*'TOY<LY*FL AW: K9K*]0"/MC0L:*EC_7S%6M_ZW8?+(
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M36Q&&!2X<<3C5PI8%].R4H11@-V3;$M%/$G!*)DQ&>L$5.>2<T7A&"%  RD
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M,"KC4EXHC4?HA7]P (BP!^&R"9"@!G_P ]WB"GF !JZ +=^"!=\R-"A ,'^
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MHS3 @_D;+C$# 3<:PF;:-EQ0P#R8PC<,PP#0"2&P-B@0PT)@P4)PHV' @SN
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MARM( A?  #'(  [H Y2L@";8(TCQHBZ8! Q0@?SJ@A;3+ 49@=T2 Y4;@33
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M@T%H!-2$C7YHA%+H@_09A%#8 N%3D,R:!%=-@A% !3G)@2:8@$%P T]0 4X
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M&L[8#R4U+0/BC;,R]GLJ77+6=&^W(::GIVF7"7TFW:$VTH&C_[PT#:@1)M.
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M?,$6C L4Q,0DO$,_;, [G$(9=,$*0,!'0<0(D(!DK$"%*?_+"#2!#_B /VS
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MY_'$CPC%R+997.ST!L@MS[DD:7(J8GABCG.^4(.N(QS*D(<6#L?Y9Q[2TQ4
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M#G# 12S-!-ADP(;"H\'@%X0%. 0!'!A!KQ0FJ5A 6 \"TGSK!>B!/W@ )YB
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MP!I4@(ZE@;)2@0G00K-6@=7$7C],PA8XP4,,S4PL0!)4 0R(5!9D 12D&@=
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M50W.E48;^A-Z/]RC&(&,(0A"8'<-%;Q\$*#,(-A *.! *3D!0$"!(BA0DWX
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M(K$CSZT<K9IPLN[&PX]*-><3L+\3N:LO/PKS$]"_ %-4+T8Z[0Q43Q7M3-!
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MB1L4?^6++[3HP@@]K+@A;L%?\6 0/2C1PP)_J,C!CI+_/C!*A2!&^. * ";
MT[OS"K#RSUHC]&[1$+Y<MWI&H;>/VD>UY[9' $V,L"/IJ;KP6CL=!&]$[;K%
M,=WOOG3+3/6Q=9]:!.,O$R$>"[WO_O14I!WO("M=_[N2AZ#T/O!1ZTI%*M^R
MXD,^$=6G?$W*4P-/=:'Y7 ]'#83/ ]7#P/V9R(+B >#R5L0\+)6H2JBJ2K(J
MM:1J5<M(['N5>7ZDK0M-2'H:J>'VU),A:JTK2!"\$_,8M:@;_7"#"\2/$NUC
MI2C""D'LB:"EM)(_(6H(2O_A7(XV6$7.^5!5XRN0>/[D0!MB<7_7Z1^ TN3"
M"3J05:3:7ZWPJ*$UFD^-&D3C_P[1A4% !@F-*EK0EJ9TH?4<1%&+W*$-3_4G
M"D)22##BT8*<B"E7>21(B PA?N)'*6=9$CV6S%8F%U@HCE PDR8TTA.IN"#]
M[,].1"QD*I$' %U4P EUJ( >[%"&(#AA!('H@RDB80<[X( $"UA /\00A U@
M A45F$0?-J +P8GA W;P0"@P4 &"5"$)AC#!JS;I#P\D00]2$,0-@E &#]CA
M U\ P R^H L;A!,5(U"!(,3 $@]XP B#P$ 5,O"*G%"" QNP@U&<0$R:^2,N
M,%B#&,J648UNE*,=]>A'O7*VLUP!-FNH!T:E8 4],$T,5+!"&IH@!H1E ')'
MV8 >2/^P@91LP)T3N((//" !EOA@!$O()@>V8($E-&$## O""B3P!9]201 ;
M" 0%-,$:06@":7I8 79>< 4WQ. 5<&CJ"*R@"0D,PE\-V<)H3.&$#%AA84[8
M #D^@#4; * V]:-2MA14JD/&JI*06E:*6(38%V&H 'PJU+E"Y+T&=O!5PEJ5
MJ)8U6>XHBD>&XI2QS!0"!I&16] ZEX">9"<S>=)$\1M@$*M52 =AZCY;Q&R)
M.#):&W8)M^+S#[;T1!7UM4M+^=HL:LV4P<L"24S9J:P=B32H!ATHA;8B+)[8
M.)ZI4<M4D!TL+!4+2OL(84[GJU.$LD5<$TG1?X0ESY& Y2/_*396@19<%+,F
M=%TFA8=((=J5M4XEVM&*CTG2>A6?E 0M EYE6@AQ59DRVT8LP8A/\+$5>C]X
M%1E-%D0V.F.V-J1(<WW+4PA>DO3RQ2O2W.I4$)(D&55<Q&J)+[ SW):EWB0@
MU&YM?@Q,#_.29*<5\6E-,N1(N@(D+_^!1[3AA6V"^'.G=:&W@TJ45XH/$@,A
M="$0>JB"&%2P 5.DH6^F@(,-:%J!-)B@% OPS>$PL($K^$,75! <4[;0A*IV
M804?>,._,/ %*EQA A+(1Q^N, E-Y&4#M]$;%321 2-PK#JK>TM3=R:%.5/
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M"?#O-;*F%)K*KC*@"2A S.QI IX--C9 .75V9WFV9\6".<<"+M0F#:@#-_I
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MJ9/,&EOW#G^6[NVX9^9Z:(U.1I<M8 M62@S(< N^X JJ )!- 3[[81 :8@/
MX04VP"XG0A!,P0\LX LV8*\J-C,X '%^$W)DYR0: @;0*A>PV.&.YP4F00LT
M<P.JR@]L>1)> 0(RX!-N@&9T&0."X WRY@M*1P66JI+CS)X6P,M>BMX\N;[M
M^[YW5@*@P!#Z@ .4T F<4! NP 6,H&&H8*5TH )4[7/T< $$H0_$F CX^P*^
MJ=G_:J C5J-OY2(-\ ^MYN%!/T$N9&;@), CM( 5KH *C.85X*T)2$ 0-!8
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MR/KGM0R]1_T.B']Q'XOT7@)+?R;WR64,R"#K($16"W" $UZ\#J*M"@:J##[
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M=D2Q1S/MFU-1;"_$[:N&$7N3V)4N"Q;18+$<+J4$H76OV,CR_=.^$Y&ZZ%4
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M)46SE*",Q5]/*0DF/UD03+:-D999%5[*12U5?60TU\H5Q=Q5JHPQI&&8',U
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M!-$%/N #'/1=27$:&X :@L#_">JX 6(@"#Y@ SQ$51Q 0QE@(!L0=9H@"",
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M4U!#K?013U^Y8 0KZB&T#@\X:((#*?I!!0,B_(""@Q X,"*.!8PP8@,.*)'
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M-$*CT>B[KP"B-Y(+F &\OB-%YY,,)>*[Q+.UD:F86X.>.5J85S@Y*5"!;[F
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M&P4C1[T(P5S4RD"+Q="*\ @)4)R >J, )V 5P/DD?KH )W@%3]B"/@@$'/
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MBD8=>;-BIZ*]KE[;5.+ASQ2].F4]T7!BWFHWI[6M4*&_X(5S\P7.6^'$?C(
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M6(,=:*$#*:C@!GJP P9RD 859. &4+# ".R@@BWH 0?]P #\7C&I#^"' Q+
M@1%\((@T5 %#%9!"!8SPA7Y8<0M!P, 2,J "%QC!%!!80 6LD -4; !*LIPE
M+6MIRUOB,I>ZM*64EF2#-%!"#%)8 ?\ MBB&#%1!"AFP@Q2V((9^3&(+*JA
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M*XEAT#<0!"(Y  $.>, \]V;BE:I@ BBHH+\VZ((@%)6&):B  Y30A*L9$H/
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MT<G8$^0*5*$%!67;Z%Z98&2;!^7-[>YO4[ %(R*8KNP(M A!\]8/BUKP ;W
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ML7#U5U15# F'1->T7S[9V2H5W()E;4O6<(=E3#EWW&IV49%J"E\% -0  /C
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M@ --&.$5@2B##ZCPBE 4R1]2N  Y;M G5>D@ TX(1!8PL $+],$*%[# ();
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MY*(Q3/_"&=4"J@2D$'>""OV0("0  ."@#N! #%X!#J EP@(&_TJ!"DI$"BQ
M"FQ $Z0 #G2A#[H@D:Q #SX@EOIAO>#.6(C  M3%#JRE6#9@"RA $*1@"W2)
M F-IEU!H$-9$#TZD @3A%:[@"C9 %SB 'S%@"2R@S"H ^I8 %9Q@$NJE#S1!
M KM@)=Z,%C" "AP%*'=/*(>2*(O2*".E]S8%+70A#E!!##[@"H1 $$A #!;@
MS(S  C( 7'2)8&K)_MS,6#9  F0"N6Y@"W* $XS !\JLS2C2 ZRO E A86Z
MSHI,D@:!!%9$_JH@$CQ!"JY P7#@ VZ@"=) #/IA 112$%;_0 ]NH )<@,?&
MY5DX((I4@/86H"0Y0!?6L3K8YB>21M(RHS-^1H'2)AB-0W>N0I^DY^><HMR$
M[=W,C7:ZYVM>8^(F#61DKN'N@GQV@M($SC1?#F^R#2M@!PT_QN%2328>K6\V
MCGSN9C("H[&XQSFK(RD\AC<N8^.8 Q0#)V= ;3O!0]$.KF8\1C,62S?PXRT
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M-L $I, 0*B 7@F!/!2$0]I0(["#0+, $?, /C( *M+(?^%0/JL (K& +! $
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MPD[HR2:A5[[@(F$23EYA"YP: +AE Y; !Z!L!?S! Z"  E2@7BZ C'U)RM(
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M('5V2"4!CC!4WHL?>%J9PDX:L1^F=&#^/M3#^JQ2A<)Y1V:Z( 4+Z.%ML+'
MT3+PBDGDPP,2" +,.&$1*6R! _T0A&DRP($N4 $#@S#+*U9@ Q]0@0I2,(4@
M_+$!99J% ^TLRQ?Z,$X)4 $T1Q,$[@C7CSJ(I2*",((>ZN /">1C$O!$VB0@
M8H0M8 0#=9 " "1 @318X086^YI&-\K1CGKTHR#]2=B2<H4*C$ ''Z " "K@
M!R,L 37_*O! 3#-@B@U( 62A^,(2"-$'(U0@"!]X13]T881!F* )53 ITSA
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MDX%LV1WFWI)^[ILOEJ[S)#*YUY25ZN)X=HLH%NNHR.YJ[$0!X(8M<.(#AN#
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M49<7*J__2"G_8@T.<3TZ6N('XZC 0Y[Q1<B#,;.4WG0FBA*UX\-QE.:#V^'
M-X3<DZ(HB4XE!(G/0TI<'AC/XQO@C,^5E\*C]. ++$<"2[(X*F_BSR2=L&-'
ME@X\? $$::VV:V^,<DQ@D\@;0RBB^.=T*GK@F1.J+!(R[JDG4XU3N=XSB;9/
MUL*NU*7,'T%62]EXC+HLUT-='1F=R:T2<Q8?.4+?LR?JWDLN=78;6<<6Y^U9
MAR(E-]D>#^[QD6LZ+6H])*6CDZGTDFHB^>M[O\GB%H*&Q:$N8[2B&7&K3-[Z
MC>%)CT7N07][XK%8?$0@]&<EP45!8O9(X.<J=Y1=$P  /E !&5 1_T:@ E4
M/'[  7!P'Y/@&"Y0;0M@-PL@'%<0"J[&;SZE QN0!,6V.'VP5T1P!9/@:A^P
M!CD0"$UP!7!@ D0 3XMV Q6C R,P F+  7TS"$K0#Q*P !9 !7U@!SJP.!4P
M"3:1!8*0!6E@"&F  0(W G; ,3%W Q9E!QN@;-!VAFB8AFJXACXA;48A!*^P
M!<!# 3:0-K\&!8*  9H@AX% !39P!1/P:+J1 Q+8#WUP%1[@!B9W!9I0!G"
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MO'1'[C-&;'UUGIIV H)"ZV5_@*U+;]=]0LK58FW8($Q"@'=)JP0]-)+2NLK
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MJN*B,NLW[Z34TK$-P=)R).>"DO(I*[/TZ4;$,AS*RB!+T<(#XH3XT@0AI"R
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M!0[HAXF$R&>4!+G0BZ<,!E18BC; #4I0A$1P AL*!9C<"F(@R&+B#2&0 TG
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MW[."^UO4=X;G>);G>=8_"+@"I2("TP& @X+E?M@ )T"%$:@ ## "'] )3>"
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M.PB$$<BH'," )C#"@3:$*L !"_ '&_@"'PB"E1J)+[@;*/#DIKD!JA($"=@
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MH4H F8*AXI;(*H"9_@I *, 1UAQ*_>P*F>NOHA""J'2>&-*J(@ :R4C-T6?
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MN>A'<]@ &$8HXR&@((CZ4A&+)3RA!FVLP00DTXJ<]"04693!'8QR DO49D+
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M5RUF/TA@!"+<H )U&,$(5."!#/1#$%?PP!;Z4 <Q>*JTZVT" %Z1AC1\XK3
MZHAAXR__^=.__O:__[6DU84*M/\3MC?K#>2 "BS )*P .7P %0C")/@#!8P
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MR$$L!(%!>40B#&8_<.9&BD9F) TNQH$?0*8S>:7G%$002 !:9I,2_UU3+%B
M$N2#') "V52.'YSF8:[&.!E&.1E&/]A-+% !<NJ2X:3A6\H"9DA&+N2$QB&1
M17P%)03)>72GC:S&7)0:WFRA\9P'0P54TU24\> G@>S($H%DKBW-CNQ%?_Y%
M#!2 +BP!'8S #63! DC!!@P"4<V@9WT %'Q &@1!$JR?%-A #)R"#VC"SVR
M*4A!$'3!$B1!. R>#4! Q!C""&0 !YA"EQA"!>@5RE3$ KA!B0I"!9H5'-2!
M#^C"5F6 %9R@(*3!%A!"!51!/\Q@'RC5('R!!W# ".B $S@!!D" !Q@!*MQ5
M(."?F9XIFJ:IFJ[IL"#6LVA4/<"*#O#2!?\8R@@(U01TWVF9P'#UP0WHP07D
M0 5,P@=4@29)0 R&0E)90!]DP140065) ?RY 0!XP"#<J";XQPJ8U0I0:C]8
MGDU4BA@(0I9NP 68 @<$:4YL  5(P0A40 70005L01<,0A.\0@5D@ 3T@\5L
M@ N$RQ)H4I501DX(%$X\7FM$7GP=*'3DEQ $CK,A'F'X!!WLY7<> V>H@ F8
MCX*)1WERAP5XCA",@B10Y#@,D73%19C)1&$X!1@]JR"JV53 @M;$@I:HH02]
MW&:$PKD2DP_I0B)PABFXG-TQA@%8P-X]0<#&0@:L18ATB"KLF@V$T$$@#;G:
M1QGT@6T( TIRQ^?_,5M!F,5^^)!>?)@_A%B%1>=F9&Q<?$^SVD8J"!!)H)F:
M < 3R('6&,"]RD]% ($<R,)FA&MTB \RZ@1+#$8(D"LIL@*ZG@4^'$:-&, 9
ME,W/!JWG)%LJ$5YEM$$J2,)F#(+&ZAHI]BL'(&,$55D;T"MWW&O"@443L,,0
M9,2 +&+$QD$?A \H@)B('4C: D/0XLR4S,2 ^,736*S!Q@%X*E,F'(-IE,&D
M(<78),$\_H29645)?$$BM(2V"H$<[&0D .Q2("--U&S&!6Q:*%%.R 6DS:),
M9 @55D0FP(1JV AE< -).L86,%+ T9N+*"T^]%SOX(T0*"Q8&( 20FPK_R2)
M[9J& 30!(XE-*42L >2>B"3(:SC&'(#MT<R$:R3"[,3"%E $=BJF-GE8T;%3
MR-6;K"4#/GQMB>%G84R"*OPN!6Q;#WBO:80O9=PO]N8>\N)3\(68 7#'Q/6(
M1_ O9WPL,C&K%VX9=C8'+W&#[ 0#/@S"<1!)18R$!&L-[FHL -SO:8!O9I@3
M\I[=;I3=$(0"*9C&Y[4A6,Q!*>CN9"R2BYC/N\E'C]0%=8 (QT%3F-4F<F64
MX;%(Y%5-Y,D%?MTBLD;>?*4N +P  +B5H9S6%NPJ%.@!!WP!#@3,&KCJJ_Z@
M$?"2! C"*ZR4%*!JK]1!KN@"8N1#/UP@F@@"1_\$@13T =T  "L(1S]0@2F$
MS J\P@6HJ$46# !(P+D(P@W\J1T<%17@P!=DP0TL <YLP09@'T=]AC]@ !1@
MGQ2PJ2=_,BB'LB@OBYL^BPV, ":L0050 0"4@12H@!A\P0U0 :_"JA1T@0J\
M@B#HP1(X@14$014T01] P KX !4D00$&@699Y!4( I;BC!OX0YS8P""<AVU,
M0FK=1!Y#P"N(P14$P15\@050 1Q0@0^,ZLCT@Q;@@ ]<0!50@@](@2Z[ ?A5
M 193BL:H  9(@1YTP1,?CQ9:5"DQ#44QS9#PX9- G&U5S1:F4DFDG/$D29*<
MA[.V@00XR8_L*K!(30?_20C'*8TU(X;QW=H$U$1?""Z!6-1&>+3WD-MW(,9P
M0 !UB305SI!(JW1.W%/N"($,:-+>C$0;3$ B(48;)$,Q652QHMJ!'%1\ H8"
M_$62C#33+ U/V(BC 0L4_<WK#/5$#4L;R( P,0T56I00S$2P#$F>S@C\O>Y4
M2 CK0,!0Z(U*@[0BJ2=8BX=Z:O182\B4Z UC;D16@)'KT,_K(B@51B2Q0 D$
MP'6X,742711(]H,(R,!2EY),+/9\_$V2U 1*UT4J^0.5"<$$/!054K;Q'8CQ
M6=1S@!$WE$1M7 A^5@:%\$Y'<(,EX'"P"($"[%60:$0^#+6P2.3[T4!/W6(&
M_WMT#9" <$PT!W%$&R#2L A!#533X$6E1SRW)B'VE$S)%-2 -AEP%/V(WB#-
M4^_%?@!+?3[WI'B$00F31]# 4,-7E]6 )A6/1T  ?1^WL-Q7/QR2!!BH6-M&
M=P/WC,SU?.3I/4F-(FD%'*$:1N^$;1!W MTC!/SV%6+U2*@38N (#;S":FL$
M=-,(7Z>20(-01G#06GLV8F1X7"PW1FNX>!A>X':T;QJH/QEH1&Y0!^47\C2K
M1=4  'R!5YD5!>C!_F2 H=2!&U !FF2 $VR '>B>!;S" MQ)I31!.6> *6!@
M'^C4KDH *TA GGZ!%EBS%NC5#%2X"/3%*VA"'W# DO]+@1O43!!, A6L@ 1X
M@*PD 08$0IWG\A*X@2;8E17 P0K<P"0L 12PC)Y(P ?<U2?HU2A/.J57NJ73
M7RDW2P'80!6D ?9-BAAXU0=4GYXLP =@@"!L:AQX0'I=P ALP19@R@P0@1A8
M@"#\U%R]^2!HPM"\PA<4@!O\]U+#5W:#$01,0![_MC\TWR3LE"E$0A*,%P;4
M 1'T S@0 05\0 ZD015\0<TD 2<X >*"D1YH5Q5<@!WT02)5R;P)B5+_<-(D
MWHY,C;M#AUU(U _+!+P.#F/:FG=4QGS!%Y3<]'>\K'>()$-1-(T<-(\4_-P:
MJVTMD9X9\(NO-7)\AT%I]4#_O:Y[ST<2ST28\4<[' A4YI>4"-3#7W5*1^3%
MZXW=+:9(8Y1Z,LE!TP3E$9X0*U'!,XVMX3S2(*CJ#BYXWYK-U_RQ!@OBM;SB
M!3==:/?&VY;D)4^P.%1-G'> PG0&'^O<,BOJ&C&]<[81"U[3*Y-X0\D6]D-H
M\,% %GV8_?M<)$F10$T/*($<T(X'[#BSWL74IFXJ]%,&W_15.Q2/8+B3R#>&
M%RO&P^?\9%1"*2M,8[31TP5\!<N+RP6R#OYA3TU]$3$2F[5M(,G)(SZX$?:C
MG;W84YXPC039O[3@<H21S/O@H7?'*<G6XSQA(Y2QBIGD[X?K%_QP-#T1&VOL
M)^O)_\^$OCEX 7C^X)F]73A4&[ E+\8GB]<%BZ1NPQ?T@;[N=P@N0\E7L3I4
M\"N>K1&_$F.P$@E][FS$!$!@&K"7$:#?*\Q+$'B *4R"\'5Z!=@!:GE $'!
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MP.Y/3&^Y5;B!%%ZQ@%=<@16:H,)KD*>+)4C@XKKHA^\SX &?;*$W=B"'!ZZ
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MV(*YF&L-4"$#I.<3FJMZJH *)L,&OD "+" )]*#_J71A,29A!=S !L3 >L0
M CQ "LB!N3)@$)* HB2O\9; 8YK -%0@ YP "MY*\+ B! KG;_0&[++.*H0
M!*[AKZJB)$\R*U02):FB);4")K%")FO%%0Z #/:N[_XN\*:B  +K&GAI!P[@
M[J9""&@@"@0+# )/"/9F;Z: !J9 <'AI*G9@$X@2L0[@&E+ILD:2(YN"\+[B
M"F[ "C"A'C3!)PBA JP' Y8@"#8@%)+ "# @9I8  ' @*:S@:7[A-:3 (%8
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M'M&-JI0B2#1<<"20\ 3-?#/(#M1$]P,5(<"!@%.5HA!/PT4[.2W%E%,[DNT
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M!OHV\Y( ;R?##1: ,?H@"<I@ [K -9-B"Y(@!E;@"I8@":1@$@+R/YA/#W!
MI:'&;'7 C"4@ W3!,Z2@"IK@?)P@ T9+@*#D3XPXQ+C$01^WVR@"1#VT4,]D
M4IF3"2N&072$D7!I8MA3Q1ZQ3]7#)X_U.\SD/VX(.DOT618A,<IZ1B! #H)
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MFU3H=@T(@H P=$U$VV)Q??N/ 34TA%KL2&=L3.*E%? WB7N)"LUCEWSR#LY
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MH0L5H$(2LCF6"9@D7:^ PYO@T 0B;,!+%6B"/UQCPBOH03PZRL K3 #!+62
MV1BXYA:@D L5_"D#M%A[!GJH4N4UA2MNF4I93A*RD/UL)5&;R+%P$8="'(,/
M=+A9)B0!$E+$@1,Q&0(N#&  *$#@#L$_!C"XUH_CXZ(1I. #\W\_#.[W+B.Z
MSS[RN1\+.JCK^08(&\9Z((E@T*,1PZ>#/U(QC#=0A'6HN)E/[B\+H5 (P6
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M'QEB=1RB"/DYGL\9!4O'!.,9GELD!#3 =.LA!&2P"<J9 OT)'^DA!%%P %$
M(14"(8!\Q.LQH3!R!2XP E!P V-G!)3@!QMP Q= '4% "$9@!R3@ 4GP21C0
M#S@P" L@")^4!$Z RVE!I+GQ 8(P"#A !T[@ 190""5EQ*,% /D0!X;A!%(P
M"'K00HLAFB#C!)[_P$)P5TRA, @>P*(94"T>T 0WL 1)D ,?X,EBX 050 XZ
M%7MFR2FHIC+^%S6T=A9Z@RKP&H>Q$ 29 (KBHZN<P#BZ:*Z24 I7D"X,P8 3
M09'I1[:E PLYPR_9AX^?P@ASP G96DVX>+9E<:B<H#8+&0*PD+-BPX#&$[+6
M*@1!"SO]4*P0(-*&@$\3,04JM5'_M;#6"@'00RTL+3T]]JPW$]):D0I.6105
M?=$_?;"2(P0]< R"VH^QT+@7P<]OT+3FX@QLX"V],@5;40 ]L+W0(SU88;00
M,-5*P0A0#;$FI@KM\"P/[0'\S'Q>\<\??;@O+16 ,Q:PXQ_3 E\ET1)G_TT'
M34L11IVM:?'0AL PFEK0Z8*MZQ*(9\ &&+U_9TL4<%T19_T&DAW2  ;7)OW6
MZ9<6NIK90U 2B>,/'4TOF3 '=* Y6-T\YE(W:9U:+XV!BFW0L!(R$\$(P! V
M5[,L'2TJ0L#/'%"(G+JNSOHTT+.0*B<)N:#:C0L7-)!-,_TI7GW5!F,W<.T5
MPHVH<Z-R\24LA#T$NIA]GTL1'5V2=L J9QT$1DT>[%V(Y"U3N2"$=^"M+KW3
M&*.JC=L54YV+ "72;YU_4=':&CL6ATH'9-L5"5'0=G/>P^#1_9U_&JO0T\(&
MH&,RG<(ZRNM[E"TO 7Z #/YE>&@5N=I^V-,S@_^]VN+CW\^:%F:#W%9]X8R3
M"T:=3S1@ S3V4#5-+=!3O1WM$V?-"?2LXQKQ!-M;V%WQTAJ[AD3E,^0QM/-<
M/563VS4C-U61%E"3Y7/#/>TC P#@ V4 !42P2AE0PI-2!95A DN0 ]FF"Y&P
MS;10;+<<!'X (E-: 5>J!W5 !"00"DYD2/UR$9,0"B00!$[PRWI))WJ0T1R
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MI0L5I)#BBSXJ&.&3*GXK0()!*OA@A"BID, "#/R18HL-,J!B 4TJV&"$-%3
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MR,K@7-Y1A<NMC"8PVQ- 6_C%W4##G\(0LL3(!+58"Q5P"XI0"!R@HJMK!<&
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M#$!GS.@'].,9)RC9"7 #&]"%?GB!T*("0>49_9-9 %B"=YB$%X@!#A"#*ZD
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M_J7Y_F_$VCS36)X'$0(:\"*)$A N%Q0DT6\%=/)V*9TS?Q"(FO$]&BC.LXC
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M_?QI?&GQHS^553&.1&EU(TN8F8:]B=IQ9%&1!3#:G#J6:<LV$C+%XG#1YTX
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MNP!PHX89(B4&PB9@L"M$%&B@V\,!4;"\<LSU0O!#'DP(_.2Y0I"QLPC<''
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MO6=NOSO6[ Y9.BNB )DX@,*6JBZJ799A.N.9=:A&V:IM@A\< Y$04%""%-!
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MES@7NG YM?Z?+%((.#_VB!)*3 @3"E,B%<"$;/](B^D]37P'24#2,5X%!/2
M*F1#AN$2<#/%3'C!L?6%\^_N%D=@ !&J9PT_<>P&30!$/W\%_ GQYP\ 0@
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M&UYQ6$!I R<J((*#?EYY10( /)" A%<,Y,"("S8P98$^3)#B!EU>,44*,6P
M8 ,H.*"C E,2E**?##[( 0<,NI""%BMR2$.%)53XX(8/-NBGGQO.&V%'PH0<
MDL@BC3R2,"$467+)%!1Q,@41ABQ D1!<02.$++/$;<HJK^2H2BJ[A  %)+3<
MDBDAJ;02RS.Y5--+-, ,04PXR333S30)X^: /@_@IT\D0#B "R0-/5++PY#L
M_\'/1M% LJY#^?03T$8+/1333(=\1-,AN[@!AC3L> > #*#(Q8XMTK# C@VL
MR& !*G3$ ,@^X)ADA$]&J&*05V)HH@DXZO#@%1^JJ*()*03Q) -!!/%AB2^^
MN"($&R30Q0=!-EC @B7($:2.#-*PX@-BJ?"#BB:HZ&<%'*P8800]OK#A%2/2
M$",-*C01Y 8[H,C@@@\R0 6#"S!8 0 %FA*L*L1F.XPUUOSQ:&+3I#L()H%@
MNL,*$_I9R:J0+J)8((^4.RVFF(Y:R;3G#J,J,$65NBJ$X9SSJB7$$C)9)K=N
M=IABL_:"N*W47DJY*)-9$[HM@LPBR&:S*(: 8Q/:XO_HZL)F:^,.9ZPNR"N0
M*_/H**>\@LHJE7F"VBL 0'ZY,K430QOLH]AVSN:R$Z)IKLH>1BA-LUXBJFV+
MGE9HMKTGKDPFK!GJ6B?G]JZK8:=W\HILF82XXPR="K*(,+BX(FSFA4!:.260
M478[);5>KNTYS @"2BC5),Y,Y!-4:<4X@:CNO*+J&D^(K^+)?OLE(0]'NVC5
M*-[<BKK0IKKCG;.^NF&1AT.]%6YV%P+BU.I.>W-G/#BJ9M/NP,1CD.$*V7F8
M>P;+9KD^JOAITTORZ"P]]4Z\+;:)B4,4]3F&+$X(A1G<W])VNH4  7()C!D$
M(!B-CWVF@(1I6,Z,EHE@V"'_00F$Q1PHL1"SX"PP&%L;]3S&E)K-X@QLL-GL
M$",TG2T.+ " (/MX%+26T<1B,;M:4F H0[R)3SE%,\A+Y@8TP1B->.(S&4PJ
M-C.'P44A"NA'%S#P+SM\8 ORN4 5+&"##:3!%!DP@@=L\(4;C.!=%2#'M9J
M 70=: MK>-4&." %*2S! SX0@QOF!8 )M/$0FLC)$C8@A3XX@0)IT$,92. !
M4\ A Y/H@@3(880UP$L/5*"7$:R@ BN(TA15Z"(&MK %._@+'E0PY ?&!:1.
MW1*7DP)4I2IU*2*%0!&:JE*FAIDI8 HS<X8ZIJ':P 1G.G,53$A!#[B0 EP>
M"IA,_W*2(FC 32DEZ9G.A 0_*A$I(O$@#UA@0AC\-Z1F1I,)\'1F-:]9SR)Q
MJIZO@.,6ZA$$ &SA R/(A1.", (=Y$ %!,4!*J!@L%<HZ -!T$%X-'$1061
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MP0)"6X8*V&$2A;$ #L*S 3L8(4%+0 4M4'&##-2!$CG(004H45-4@%$*A;F
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M4"(6@*$.AV$),M ,.Y (W$82KI"$ ( )NY (+B@6<*$1<&$8.$$(4B$6"@0
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M9KF7?QF7=3F9>=F7F3F8&T6;06]->X ,?$D(OKE(N$$-^F0/0@ %J+E(>.
M*B&<W9D,D&#TFEF;M=GR7!E)\.F:=*$*2OD&N@  _.6-5$D%H$ /+@ .1@ *
MDL!3MP "C  3/(X$^J$4_YS%DJ5@!:1 #\1@$MBE"BK H 0A"01A!&[@C9K
M YS%" #U?#U@'N E!S:@#]P@"2:!"&X CI,S")8@% " "$#Z!D)+#SY!#(+
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M4/09EZ[ J6T*H$5.!53 %#[)5-_O!M( %:S D5+$47$Q/BG@"[9 !0)A":3
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M!1^OMRN\1%G(0AIW$ ==,$ZN(4$ H$X]$0>"  '"H I&0%;](Q\88"/^! K
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M$E)J E3:/W<!E+RD%"540%&%>_]C@P6T2]+D/^_QK(U5)QRU$9,@,&Y(!!R
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MX )&8 H+H GM&@1)P%MZ0 (K8 1-( ;G- E]\ (U\VJ#4+JE5092L )6!0#
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M5ED^%\#B3% Q <IRB[PZTE%$)\WZDR%  S6@(ME44!O1@EP%#L5VBW5Q?34
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M0R#Z1P$,F$(*7<" (":Q)@ ,H@F<V ('2@B'0=1A$H.(U&HXL($,=&$+5,C
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M-(F/9Z(/3YR9=^*[==.C#3&H4Z*5@W@J;4FF>$(HEC(4) $U$C'%8K(4<BD
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M@RI( ](#0<[A!O?3/Z48"Z@H !JX0(5(SN5$"/-RSN=4A.B4$N4D"^B,"B$
M 3(H':VX!A$(3H[80.^C ;< SX08SK!0B@2KKC903_=S/PD+3X800;L@P0\8
M 1WP 0"H@/E!',FX /R1@D%XA05(@G[H S\PA"6P A48 >^H@$#H!S_P@3X8
M##D<L_/8 #W H30P!"A8/"K0 T[( 0__, 4FA +(TP/A\ =!"(4,2((M& 1!
MJ#(X]!_\V0([B(3%X@0/"+Y^@ ,IJ(!Z6 ,HZ*U)"(*],H+ZF0!>@9*BV[5$
M:4I *[150[B2FS:D'+M!.[@,X8\IH<IJ QF$^SA509@B08TBB;=$*YE;\I6@
MXP\T/252,3J/ RIX(1*7<Y),8Z3^R"HRJK5L(1>+[(]D81=B@HLDJ8]"]39S
MXZ:B*RIWF3D-8;=/&9 F0:@=:125>Q!V\K9$41-N.10I70]W 16 ^;B)V50H
M\2 +8=4]41=;-*93'93,,1=443B[.QE(4[N2\S1!BU/_\"EW/+A7?92#T":O
M$CI-E:A%*Q)#_W/)J/PI\S@F>@L\:/(U/4G6@2,2 ,%55/DX&5'(//DZ_=@6
M8X*5'4DZH6L6GD,T,"J7LU-%,ME%0MHIA%D6:,I(:/*C3$&Z-<*6>7D2-S&1
M#0$9/9HY-K(D,,6XF8M7 >'747,59'M6AT.IG3+*B>'%4&NU-+J2>Z'5(PFD
MB24C(S'8A&.37[V2_Y   *""&CPR4T"LR:N##9@-N.2 (/"#-;L 3, ?[$#0
M0;B")AB$(#B<Z#(!(\ !(J  *$B"-- #0Z@ <L" &_" ,$L"*%C,2"!0 +":
M"J #(RB#*Q@$$NB'*]"#&P ,.TA;06B<!?" L9F$.EBS&\@ )TM!'?\P@B88
MB$%HCA'8@LR93ZEH@X=@@CPHGTWX0(80@A\X3ZD0@CQ0!+)HW,?-3B:PW F3
M7,IU7(50A/.<W,%-3_CDA^-$B#8  >Z)")AH"/ ;SPT,O]--7<.EW;887*FH
MS[F0 *>E SN(VR'= CAXV@+"T5!P QJ3FR10,QW(!=9<H"10 4TP 0\(@B"@
M!1K;K'XH R?3@19,@AQP@L (@GI A=]R BMHK!'(30 @6Q_@@#H0@RL &S$@
M L.# OQ1G!]:@--3 7^(!"-XKARX 52 !^IMC@H(#[+TJ(.%$W1<D"FMI6<!
MN*(4UF5M*DZ2(Y<RQZ TMCL)2&&%"QTIR:__>[10<B8ZI:1I$E:,JAA$4K@L
M2BFZLR)7#$12R42$R*)=9*KS0*N#/-D%1JM#Z8J4>I.!6:>@:DFT>Z>B2K<V
MN3=X^Z.?"JIBE.$^];0U =7S4,@;MD=Y:JJ6W*@MMK@Y>I2 B:.E4C54"CI<
MTRA]Q&& V<6G?)AT@A9CD^"MQ)F86<EO.9DP#KEE8;>.J<AY"19JPJ9S49>[
M2*J.<JHA1KN'<59&>>*W2C<:=B-+<2-II"-A+2-QHR8.7K59/&1L&KN$&59!
M:A1L#!FMHB2+FI63+48\3CCRXV0-J19'$J06=L=3720*'@BV(A>N.J>/6I.,
MTB)H&2,^5K6X6\FF_Y+3D:GC#XFYE=0B59X/KSS*%\9E7D(UH^0T&@& "2A+
M%ZA+#\B,^TF##_A? - :05@ (E"<&S.@_%FM'>J#+Q0#WO"!?M"$&MPS*\@%
M"Z@ *'"!#["##[B "IC"-;",>L"!S3J$#2"'ZET"&Y" /H "#G"Q-/B$XK("
M0?  (KB;?L !N\6?-$@@*Q-@O^@'#D \&KU=\:$*), G",04 S,(\YI.3%F_
MG+9I@[B*^=+I]0EJZ=QIH.YI%_GIN\!I@U"$UQ$!(?C<P2W<B?">[%&(-OB!
MPTT!P>W%T74_L#@ ^30O&I@"LT;K*9CJF Y.#\ !3%@"5/@" (C>P7&"-/\0
MA#1( ]2D@"[(H,/I C23@@O0F@*R@KJI@P40A"58/D&8 "W$P\ LLM3$@ ](
M U! !1PPA0J@A>]0@1(S!%THT$G@ "HHPBMP:>7Z@ U8 @I0 =;<@MV\ >G=
M@#3P PRP@@MP@A0< 0N(O/K9PS1=&0\ZV%N5$$)#J0H1DAWP 0^8F&-JJ(]%
MN"G-*&J[)7LL%1_)EERTE_2   7P!VY0AB 0JF9Q- [15S5ZQCLU1)+A-SM1
MJ#F2&;!C%(-AV$C3U:Y;A"\P 5A%%SUYE398A*\!DFID%::+JVK=QP(8A:\9
M$7[#JS:0 _*N6/,V%STZ%CEP@PW?<$'XCZ#2MI[_4CDAD(,E *BZ^Z)EN51W
M^Q<!>:M.%I9FB=-KZ8HV1L@VEA=ZFT9Q"K2;A+HJY1 !WX"RF<?C+@\(:'"P
M635)5%?E#@$)/X9!,(1+$0+PY@8W"()>Q!9,X_%-@8 >D(-"P 71=.1&LZAE
M(F/H;CM0Q%5GW/)KD?$RNF2E"Q,30*IXZA@IW94C.8\K)^^-X\6IZXHK&3>3
MU1(YB/(D6-42/DH(F/!#*XL)%[J221-ND(,Z\-0ZB0EJNTE2XH_RKD>?XI:"
MS5)Z A!'C_(:D(,N</0_'Y1<+!-7R;KZ:'4C48 MN?1"/9B4Q2N7P/)=9S64
M 5,?[A9O_K<E%D1$6]E"_SG&1&K9%5 !V'(#*: %T_2,#+  "7B%)C""+MC0
M$7 N%1 #E/X '3.L#:B#?IXX.("#"M !#/"AUL.]#*@"4UB@)=@".@R$Y.J#
M+O"'5X@$70#"N4&B#]"!O3:%-IN\XQ-;.%BQ+:@#*[ "U&P"*DB#)8AV@I""
MS+(#"_!JMF:_AP#/'6!/]#R?/#C/JV#=XU&*$D!YCB"#E0<)]W/YT%5YKVCY
MEX^)F,?YM=#YF^<)FM_<G9=YD("P S #"$"! \C<P:4*-/ PUSGZIOAX "A<
MB5B%B)B(HA_.\SL_?M _II!/D"^(W)6+5Q"B*EB#+X" )'0"&-0#*,B!$;B?
M$?^8A (H QP8\JN!YQ94WR2P@^9(@SY8@#*8N":+@^<:@23 @218@BL(@DD@
M B/P SU8@27P@T&(A U8RR"@LHOV@"_H@Q78@BJX 4I( A@ W"+C $K0!7\H
M@T'0A24H:<H+#!SK@SX(!"M8TAADIIY3)5(195Q^IYA9.N^&!3XXT"O:)F[6
MXZ/DX5R.E6=BNTF"D9)DIE#Y%C.!A4\P@9(BN7A$YCU*UT2T(E<FH[$3RQY)
M$[N*N6.^)!_^R8XS8CK:IS/P@%RRN&H3_CO _QH'B!#]  #P)U!@ 0C]# *
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MT(\K9& +9_\;FA3$$ 0*9$ %; / %NXT BFX:V,N;940SI4N,H1!7>V*5QM
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MEIS-1F"%!\:C<!<;1 A"WV\# =<:XRT.>;(SC9U1TKBI@(<A_5 " +YP PS
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M$NP9A+YE=ZU$-LH(?V0(7/@AV?6&*37/4I0< $R CNC!9M&!%="!YG& +NA
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MU5@H O_%W[#&2PAN# 2L0 7X'BH(QR38P0@(E#1M =LTP06(2M[8@04 31<
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M"%P$)J0/*N 8+&SX'.AFZ:[F_BQO(33O0]Z 1OFE=7[$T9X1GF'N2+J' 2G
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MJ.-N37_"<ZXR %*)Y0T'Z^O!4D:1HU2J)W3K[#/I_+&.L_08F\U) 5-C1)+
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M']B'\CN*8;WJ(+ A&'AH22C_V@:)X!*'8\2H=1>5$<+VKBY75UY&?SD&#!8
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M*9TR*:52*Y'R ,P  K"R!+22&S2M=TJ@W6J2>#8!"6I&"'9@$\R-> Z@$H2
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M#FBA'\[T#-B 3*"B0KN 7;'4Q480/_NA0ZN@J[S@,ABE+*:BL8R3+7)A/2&
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M5I[#] 3LF51!."A 1E#:HI6Y8.+)'60#"NLK,8PQ5^[O_R E%C! 1B"Y,^9
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M[I\@!A: 7-;4=;RM9HA^HJ9>&K,>:U\ ZP5I%XN>3'41Z+%>^9C^D'C>*=J
MJR _!&K&:/P#:2#1W4Q?K3"$5S0Q6]XM['/4].'KI:,6*[K:H*;0M/0>^/QH
M]W61J5:GHMH@$6+$\PWJ,C*+=?9=#[=B^@-)48;__T H2AJA/N>_8I+TW@8R
M:IXT$>+S00(XKTDP:3X 1?L/OJMG2^"[\SX 8-\IWT BZS(N,$/BOIW@I%<
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M"1@@%WU0!90 )140"$+("7J@9&YVA4M@!76@3@.7!*4@!8) !1P@"(30)3=
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MPGN-IWCN=77>HU=C57;SD1%,V99A63PO&5Z_$S:@4RYJ&6'NQ5/,833_)46
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M)OS"'6)S+@S##N'"*9+!.XQI><")H70=VM&GV^%)/$P=E>I$KU !:= .!00
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M<Y(_24V5 O42Z?5H-4JD7S$W$A4 R* ?7]B"&-(@A@MP0 6F0(44/K"!#&1
M"A?80!+@L(5!5( 2%9A;'=(0.14L3A!Z$,,'(&>$)9"#"EL(PA8TD8$T4 &C
MD_A5$#AJA25\( ,88"D.NK %"Z3-:T&8%[TJL 5RP*$/8K# V= F5"L$ 0,<
M0-T6?D4%K&1@!!__0,4A&$DUM!ZL!WE@@L]<IM8]=(AE*. "Q>(Z,"& H*X,
MNZO A$!7NYXUKWOEJUR9,EB!]6 /@M7KP+@1-,@>@!\'V,0FP)#6F^V :0#0
M;-"08+2#/#9H)=@9:#&[&*4QS6>G96UK _:*#WP"!E78   PD*D1Y((<4# "
M1NE0 2E4( L;J$/>DK !0@AB"R.H@!.<-8(;;* ?"[  M3C0+2)( 0H6@,(%
M*J '#CBA#T1(@MQ4\%M"B-0(%MB $59@!--A[1,CL ,G<E /,4#!"=7B6QW(
M=@-E]4$%5LC!LES**3$8Y 5^4A0R[Y*0!CKQGXL2R7+\P0A)I,$#X,&B_P$H
MP2'B(7* S/DD0EBBQ-N\,WBD06*@\F271?Y(DUY1RC-=(@0(O,\0O2$BG6*R
M$T32Y0XPZ <W5*$_>X[H)G>@YAII-" D$DH[G^2&(S#AG9;<9'NA&1]3X*0>
MB=QD%F<P1$"38YT.%8H@J8C#,<Z0!.^UI#QN3(V(EC@4AD20F@\1@B,(L4%8
M[H2;,%C13-RXE)J\\T<]&(("U\AC$FUOD'<(8L#\*>5"%8 ;C<YRG4AC6-8X
MF30%N$E&/-0A(MYF4N$;3$QZ<&21U$A!,,P%CTG-*&$RNA6?Y BEXU<31#+&
M1.TY9$<VW0J0\*G$B<118:;<PE/3!4-(_,ZG=?^$D.Q%T H2"+)T<A+D36KE
MSD]RR4=((P1=%T6N1.+P<!1S(H*06C3?+B2"E@,::%NX(=(>5(>2PJB0R/G>
M5.K''3!1Z#E%9=J5$4F'JHR):GHHW<2$"O#2@Q$?$<HB=QK?J*-<T!FMISYR
M<B&0;BR])>Z;0R-6LEU>TB>&:\>8!5VP#8P !2F,8 L?N !XE["$QQE!!4&P
MP I6R@$HO")K-W#"#490A0H0H1\^Z((%C$"$)JA "C5]E;,V8 @G^,$0*C "
MVI2E+-Z*00_$I4(_!%$%K.5@"3JXP1H\  5J"2()U=V 'O20 2@L@0-ZV'D:
MYH9@QX3B!CKXP!8,Z]K_TW)##?LX@!E$X(I-K)9@$4-#"A01 M K @1JT+S*
M.O_YT(,@\R4[/>A#P(/1E_X@$4."YUTO^M6SWF6W5[WL:>]Y"(1^%;D/&1-6
M87PFN *RF\@8Y)G"#3)L@@LA:-@F.O$'Y@NL (KXP1\BBX4PR!ZM0(ML^0GK
M_*A-C6I$]$ :Y"L( .37$%"8/P<JT 0<K"X)&$C")#9@@W[@@#Y !3'@EK^K
M@@^X@7D1C&W9*AP0@]Z"@B8@!Z1S @YP@1NH%3'@&R>H #&H BK @3+P SWP
M@'[H@RIP.N9R*OH#00[@@'[0!"D(!5>1*"NP GGPE?/* #] A20P"(. M^AQ
M_XC5P!-< K)_\R<B- Q-2P0RDXXJLP,3B"8:Z LMZ .-@(!%L %&< ,?Z ,(
MV &_P$(MY$*_X !M$H:_N(*(X(9%6 $U= ,VA  E8 7Z$ 8M$"*AZ <Q] LX
M\*,MC$,VQ!)!]#7YT4(V# $W9$.-V$(MA(-^R(1C, )6$ 8 $L1O8XM1F$16
M8(<AR 5!I"0(Z &_^()7\(_@^0I'B(;>*)!\&(5P@,%^B$,Y9(@"Z8-0=(PV
MV LWZ ((T$)'B ,M@ , B$,M> 6>6(1\D ,W^ P>444K8(1@H 3K$41A.(4I
MC"*_N$*-N$5,U(M)7(0D$0(@8H,K(:(A881)U(570/^W;7R%!RD2"*#%*UB(
M-0J!$U"%*;(/AR!%-^#&SC@&>M %+ R- KF"B5C$AEB$46@T001$.(BF?O!'
M4RPG50!%OZC'>C(L?[Q"1:'']O"'*G0#4\3'2\Q(93HUDVP%3&P)&MA&(<K'
M )I'OV"%]^DB?Z#(4VS$96S&Y, 26NM"GZ3#4^ Q/'R>/:3)C.R042S%G6Q*
M+R2!P^ .DGS*18B!11A#G6 $5:!$#S ->G0(-WR%7(RF)W!*^QC)BH2)!Z$U
M3"2*CNR#A'!#&Y #'S"(E_S')*B.N&2(10C&+R!&94+'U.##OX!$D'##ONB"
M*CF+C.0VA\C+*PR41>B#/KS_ IA@!$<P EV02C;Q"U^4B2^*GM!RA#US"+=<
MRB);A"L @"E8A+ZX @EHC8 3GPDIE!IQCYX 'MZ9D4,Y)A*!L&.*(Z:4DRM)
M##R1'B 9GMVACP^:BQ@ @%>  E,( CMX%?OKN210@3Z@!1^8*.E< 0^P@B1H
M.L(CJ=$Q E"8K@T0A,$SA _@@'*I .L,+R.X 16 @PL@@AN@@RW@ !RPE@T(
M NE:@""H NBJ@K+#@358 D.H @\@ JG< )W" $X0 P[(P!$ &^L, A4(E8.8
MNP_( 5- O];B@7W@ AH@@S#@@4U @\<[K#9P!3(HOQ(0/P\) 1HM/R3 42'8
MT<CJ_U&"<0X0J-$@Q5$ F%$CA2PA]:LV*%(;1=+#XH$HH"PPD%+6XH$#0(.#
M ($#N(8HVE*#>;U5J-').C^T$@(L*(%.P((U95,W;3X3?1KU0ZM7J *X@X':
M6BZYX3D+6 ):R !3>)8R6 %=\(<KT(-4@3H[L --> 5-J ,G< $ID((-:((*
MV  /Z ,_, 4Q* -:: +5"2ZF\SLQZ)8M<(*UH8)7X( 96!8QV( EJ( T@(,@
M@ ,/T(0/,#PI< $]^)=^F(3$,06_&1LQ: (+^( /6(,,T -=J)00 @D-T3@^
MX8R06(ZI4+?H^1]4 "BCF8A,D(10: 12X ,ZL$A<F(-"D/^$.%"&6%C7-X,A
M7(B#0CB&8:"#7TP%8 B%0B"%YAG%(<"%6"#76% !+!J&-S V1T"%!7@4"$@%
M VB$?FV><@K882!8*. (?1U7"X*?#M&T.]@&$\2P(+HC8*"#-0(".9 $7&@$
M5AB"6)@#C'4*GUC9EET$58B%@26%6" $APC7<26%.'@##H$D170$*^BB6 I8
M X@%*"@ 6(C8B<U8>;U8GH6"K[@#>CV&8&@';D@&GBV$)0A7>A5:4,!'IG7:
M/@( #*.$*H/0'Y(%?@4&7("?2&39?HT#Y*A:<IV#)7A8EOT%&(PE8*!&:?,3
MAEC9=^6 <&W9<N4$PCR/+))8?Z7_6GWTGT8S&IAH7'(U5PB !N1I!!7@#VX(
M603!,)$U21]0A6"P6J>MV%8P#,X5VB3XGW1MA&.8@S_SB"K!,%S(6T[0V'V=
MVHB8W3C@@'R,6=S5W=[ #'D=V-PEA.+%VW*E \S=-7W]74DP@'HP0>,E6GEM
M6D(((3G['YTE6#H(@52(A<_PD(5= )&;W*EUC,;-6Q@$6G(]WKL-VCC@A%A2
M!8%5AF/P7#G@6<%]6)F=7T:[W=Q=@NEU7/TU7E!(BEVR79GEV3^[6PB6B_#U
ML/H5VC=0B-F]UZ\-6Y^]#UC2"(BEW.8QBT2 7F#(  EPGZT-AC18  CPW;P5
MC.<E6$)0_]E@:%D.:(-$^-U&Z-K9_(\-8J$J2]K3L."9=;(7+H0C3@,3L!^6
M$(W>030NXUWF0*AI6Z7O<+<J&9"2^S3?P!(G8B FF8D[D3/_&)\HF0D%   ?
MP-0UJ( +:((-L(,Z^,\FH()!T 03@ "U8[H*$*H-T(05$ -!(!4J: (Q$,$@
M6( 5J -=&"I:*9<MJ(<U"(30^>,F4)=!=@(2Z /EN@$QL%0]"!4JX-0-V(+E
MJ@/FVH"KT(4RP(! "!PJ()L,\)0/D(<,* .LT(,*@(%/^)<YQ2SHJX2_0@(A
M( ,P+1@J!8,?^(&7(36#X0$RL.8?$('/V^9NOF9P3J*!X69O!O_G$#"M@#D!
M-?#F*7@K:B8#-/@!F0GGA1$"I9FL*UUFU#H )/ 0+#B B=%2-&"D'F""M@*
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MU5ZXV0=L5JH*$<)CTUF96UF/*9NJK[FQ%:N5)GU8$  O ."#'A>,8(<5&WR
M0088:++$ @MD4$$:(WS;ARFZZ"6!!"9L<(,3&7S_,$*WINB;PP94-+$"!W"8
MLD$0^ :!P08<])'$!V)(48&^4-@A\0A;.*&'%!)X,$$_$GSA@P>';+'&!QHO
M(($8@FRPA1@9@'M!!5!4(,5%4ECQ215-(':;SS\#';300PO-S0%';\+/ 4C0
M2;1M(2CRPQ]11%&)TU!+3;750V,]==5."Q&UUUL/'7;67Q.M" A8D(&VSST<
MK?31<Q_ A=-W$[T#W7:#4#?0/-3- QEAT$ &&G@C/G3?9"?>>.*/..ZS/S.,
M4 6[8@"P01U)+%%''1BXD($*6P2A5Q)00)'N!S9[ *D11F 0A >"&+'$%B/4
M$\0:(Z01Q @W;-%/!<-O_R"Q#Y7?(,8%]<@S<[XJ0#%"#AC@@ ,''DB!@1$^
M $""!R08,4(%0:A@K@>O:&N'"A^H0$L03G!P@R 2 ' * +[&5%*FNK9J$JJN
M_4]+SRD+ "35"BG)ISXAB4,23!("1@"%,*W(D@3=HI16]$ 2E& +=8"RD&20
M8@[Z,$ ]DB()*!S(&2:  )K>P(TAH# FLOI@"/%!0I=(8H(.L0HL&+@7!^VD
M)-Q(1#M>2(<[H.()JJ!$B [8D:Y<T$.S\$M9+@6$1+!&@EF:3RH,8 !\!..+
ML:"$E$HB);? Y1.%\DD.;P,!&H!P#C9LR05O,\76I"*,<RB%'P"P%;]T,1A@
MM/_A&"7(EBT6I !Y#,8(O;B1*29A+R$!I!=MJ(\P4D*+]].(";:"B;*$(#%4
M#"5&[@>6E43#!#U,PK @2 GY[*0'<9PC#B<HD EN*B,,S!(+@=(1*H*H/,3P
M@D"6D A4""23;12,2U1AH!O=Q&<7%,)>K.(S"'2QDEX<(P!D&<(1MB05?'C#
M75!51V9F:3OD60L/XV"('T70F3U\IVV>E,TO;E.9$[2-6WYC*2&< #R6<F4!
M;2(0%*[E6=X4H0%4",VL\ 2;L7C#_7+CCSR*T)*%' (3P>)*I[!*EKB0A1=+
MJ$4K3=$#T RF$.XYPF#,H:-9"H$6V4E)07H1DW6\J#;_#:"/6"QAE6;\Z!W\
M4M&[;,I7PD@&+AJI$SE(PHNE$,1:\FB /5(UFS@-1B%SZ(\0.*@C<A$"5+TX
M"$$@559;+(EMTF@"2]4T!'>48 A2(0F8#L(/;F&K_I:UJEK!"JR^ M&T;&6K
M!,X4J9;ZS6]0E2FW=*B?KFEL7\N(E?Q1*Y&%;9"F>-DJVX!E!4;@A"#JH (.
M7"!=4F@"!Q9@ D% 80FXJP 1%M Z?X2B"67H@P<F@0,56*XKG^B6'6Z@AS3T
MXP;2,\'PF+L["=",N%7X0!)043DQU&P!'"C#%G!0EM8100^_6\(2J&H(.&P@
M$%6 @AXXH ).!($#..BC/VZG_Z\F1"Z_CH-:"/I+ROR&302)"S#B"%Q@10CX
MP G&&X*!)@0L0+@$G8CPA!FGW[3]( \)AEK0N$&&2@C!%6@00A3V<&&@08T&
MBE QB_MFMQ/#^#:0N[ $C&"'-&"">TVH@AT^0(0T>$ %?H!"$/IA 0Q@8%O5
MU4$@^F&$4+P" R:K0A7Z085 >$ /:_"6] Q1C^FJP+HC,(48JL )^U[ "M;U
MEW+5G ,K!&$0'+B"<B^PA2MP(!)&Z(,+9M:'#-C8"%3P /E@NX1Q&2%=8K@"
M .CW-),,*R95E"QF\U>G#,G'@66!RS:N@L"<>&"5!BG@&"GBG'ZD)R6WI @4
MMGB63/^J(A(^8 4V%!/%L/@% G"Q0V\N)6F!A&+6$BBJ!U[(E+7,HB6PX ,'
MY/,D4M[%/*.(@PU$,NUF1W$K3XG*L6?"AK5(24I<68"Q+V//6%"A!NI6M\<Z
M^QRX(.4QJ;8-L&<M@SO$J#GE>9)E&*$,2<3A#:"^4;K538,:N&0IKKF4/[82
M!Q^X(>+),, 2Q,D!9B5;I>A>M[HE8.RG)5LU,%A @CH2(\@VK3)<Z<<JL>)*
M7M5&( ]GQ;U;8FI_7%!_MDD% W/$B&!L4#$P+T\JG#'M/E@[#AP0B'J8R0U)
MV*$?J;")E6[#[08]Z6<$KX$":O"$&G@\UK.N=3@G.BN9</O_-E;Y55L5+J6,
M\YR5=WGU"[T@3E8RDS%4R,?!:^" !9SS?KC9%:I5 85- 4@EJLA%)@*.E;84
M?N;WCA'/%6(90Z%E6 ;9>M?5#7A+$$)6K]Z*IX#]!9IC)]7%$@D;\%/.^VV=
MXR2?8<X-<NZ"J_L%Y':FE6YDBKZK6Z5\B.1P7FWRJ^#*5O4Y@2/B</H8**8\
M2@"A362U5%+8)/;K?D4/EF*E^3AJ-JB9/O9!0:UC98GM<+&"! A8^]08NU!"
M* +UWQ"F&<[*KX4%K2DU99+'3XN61 M&^)^T+-RT<%"L/)JE/0=?,0OD_=]>
M+$ME02"K?-8 Y0, V$ %W "^.,$'_Q@"'3C!HJT .8C!%E@!'03!%E2 'U"!
M"VQ /]A9!1C!!;Q"&6R ;'W !PQ7#E ![\Q,&EB.(5#"%AC"#=Q8]&#"#6S
M[XS !V1 \MC9*S3!![B ':#0)&R/(-R %1 "%^H!>]E $(B!"F2!(-@!+7S
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MT1F84"O4!A!! #1$PC&P!ENPA4/<2'X(@1#T1<+I$,OYA?'U0QLX0DO<!J]
MT#&,'&.0@FR@6@Z!U6HDQ3I-D@<0RE[%1C^,!RX!@#FTQ*N%T@-- @=8%K*D
M$2B=% !TI$KTA5?LDX,PPB\8@JJ=T%;$R,]1@DP @# 4PM(YTYS_A)N^E4=4
M5,$HC-%;.,): AUNL- DK, M[1M(;D570-3ZL4H!_%=!P(9L?-140).M# >$
M8$9,:M%)04<F  5H39W $1M$)14C6()/F@!0RD8&C24G$>:K111+L -YW$]*
M_<Q9+$$I,<(D],%GW@]<Y)LOW22^"<,RS<?/3--4B(0)$)1;3-W2Y1!!J00Q
M3"7045.D""9A\@1D,<M=$$9=8$3<A44<',,6T,]E211%1><VF%!;K@5L2@(A
ME 5LU(->,A%&Y*9SUD53]! 'P&17M-1$M55,/ATN]4-*O5Q3X!M]_LA5S@ES
MD =8/0E;AM)!7.=2],2K%4H!A0,', 83_U6538 :1 6+9X[3</CF:9HE-0UG
M*Y0E?3CE<P+=5U$H'-R26\A52Q2)"81 )NCF_520866:U77*6UG)3LD52*9'
M)OP"?3 '1?I/*%D)K] *Y-7'&9F1B#K@8?&$X $D6U@IKRP<-;E18B$0IMQ*
M&6GG5TD@I3T'Y"6(EM3&*VA@$U3 !EA!%6( Z9B"#6P #E1!!EC!'(Y+$O3I
M#4@ #A3,!U2 )@B")KS"!FR 'E1!!5@!!8R %- ,IDIJ'6B"$9"#'5A #D !
M!JCC<1F7!5!!'^A"$&@"#FR!*9!JEN& #_R9Z*3!%EBJ+O+I"MK!%E@ $^9
M!FC"_32!%?PI!?^$XHGI#=U<PX+A30\@@;,Z#;1"(M% J[1:*QI@Z]!<*^+T
M0 ELZVVL6"*J6+4.HM'(S0&DZR98V"8FS=%$*R * 1/0:[W2ZQ]LPB<FZ[Z^
M @Y  >><8B"HHQV(:@8<3"38%NJL@*1F@ Y40 8  !RL@ =4P!JP(>I\P.L<
MA@U$PB!X  XT@1Z(@7*I@!'405GTP0HJ(R70P23< !5(P"#$8#](09\9P;U
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MOP4X-FR9U&]"/Q^3!@WR(,&#KCBF-N#H!V")'A=I/'RR4F4DE ]IJ'RH$ 1
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M*IME&P\*X,:2)/BZ+KC?A%BL!@WC&JTNM)ZH#2VIABL O-@DK.R\QFS[23'
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MO0M@=E0H'G5D'\F8)HYR@D![_!/$^U"QF:9ZU[L0)JVN]FK5=@%,3OTU1R'
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M#D1#$$@@"+9@@*Q@ Y(@%Y9B+I= +5XA#L)'!>0&%;ZF"G# #YH+\\J B9J
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M S3A:W! #*I@"0Q(\C!@ S"  OP@#5)LLF!@!#P #">@%,1 $'P 29L +')
M!X:60Z6@ L2@"XAK ?H@#9 6\A1K;3=@":!4+38 9D:@"0JP/W.'!PX@"OX
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MCG2K]A4RRL<"BA@C@MUHL&]1 !C_NG39KW'!R!T)HOVXM:_#NC_]]6"(L1\
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M@($I>GS1Q08+&-&F%154844.:?#9SRM4$(L!!E*(44<9&S@1B@W]2# )HR/
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MAAT<(&"W4403B\,NL5YQ6@4PZVW(JB^U)I%::;TB6W7CUGY1JPU,R&M>77$
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MKH5 "L/ "1! K,":%; 0!SNH$*K 1=7:"/4Z!U @ 8R08T* K+X3"L? J_4
M3'*Q/I*0"__##8G 9SC6KN7Z;>AC0A1!8+A0KW'P!NTVKH7PL%S_!$2K9*X(
M2!0#,JNA8*MQD*<B6Z]\P GKTVG75F$;"PSU"J] 4*W7*@@$%@DT^P:ZM*N\
M2@D>UK+ ()_IHP"IH ^AD RTJK'L"K3VN@0&06#<JK2\9@ ."[$5\F8&D0IS
M$ H%"P4[BPO#$+1>VP\->PR28  5]D*29@#!\&VS6JNW"@JOT;!8BPONX '(
MBK%Q4*Y1:P)$.PDVFSHDJ[.2%@S!H&"9( LSRZPR1+B6&V<PVP\;NTJW&@0
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MHIUC3,TT"_1&2LS&1)2(T3#HP TX?H:5-;G0"A>C3) XL9DI_-2E_%$A*RP
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M<!X,@#0I>(5$'('_-:B'+?"!!?B F-&$?/@",=@"^;&##." BM282? !</"
M]&&=$8 ![=&>#*B##+@!*\"$3]"!#_B >M #*O" %_ !7>B"#5 !'! #/;B
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M; (2F 1=*)\MJ *F[)[_E;290#"%[>$>>%T#*ZB F)2 *_!#XX0""]B +<"
M!Z,$-_@"&] #':B"B94"(UB=F.D"*K"60% !%3@>/1B$MP@9*T"%###&>\PS
M(?@!'>,'-!!'G8&:-\L<J,D#Q E:S#G:H8V"RSF<K0D#PU&<'>.'9?2;32@:
MG"T095S& VA&K#V<'@ <+,""$C@ 2"B!,&-:KQV=?"2=@K !DYT=,0" %<"
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M0 A5Z"D<2(;'RP7+N"LV8(B:^B=19W,($%-?FP)>P@<ZOTT(2/12D-)3%8X
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M80)PU=/HU)=6BS)5Y+('&2XHA82E:M;LCGV5R*XE<RWGV;AR9?]>*[GC0 H
M=RO)[>OW[TI_K_1\VD@R31 H%UR,R&%G204?*D98&;'Q"P05'T9(Z;< P*M)
M'%3@4!&)0Q=_>NJAJD!N19))G%:\ZN>O@&TA'CR\,I+DE1,],$;42[/@T(8F
M'+8L$3.I3S\2?6Z,2(.AWZ"-U5WH*O.!@YT<.CY 4>'DQA4 +TI"P!T"  3X
M!2#X@]!OOC_;\>O7WW^?OC\*3" !??W09Q(-^4@ 0 '^O&=2&S5,T$\((9SD
MCS]"8!B" A0"8"!*^ %07PA/U/!9@_F9",Z(< ' (85"1#C!A_SE9]^'\R%H
MPV?TO5=@ACG&)X00$D@@S!4Q_#B! C+_O-#/?1@* :))^97T1#XQ*&"?C@!"
MV=\3+YB D@1; MF/,"M\6*-^#C)8DA#S00"!",(H\0Z31N8GC T2]%> $&&^
M0J>6"FQY&P F?A8"A?THFI)](=3PRI0EN5@F!._E),0+[87 C80CAE# C^Q-
M  $--<"5TZ?Y>/"A$+/48P*&!!:P$@1"0%#$*R_21Q^6.>'6GD>68BD!E+;=
M-RI]MW*9:(=P_IH?AO79QF@;3RQXI8(?MG''-A[<^MY)0B@0@T=S4AAM21&^
MNE*%'F9+@DI0/F%#?"N==*M)3_3J(P#<)-(.7'.F>^.3)Z'D8IPF]HI?LP!:
M:JF._-DGQ!3Y_RR0H;*X39R3@T(DV*-'Z9(:X;8!_@I?A@Z2"N*S0G##RKM"
M0&/$JQ3NVFMN(<XI I="T,BRABK6X$&E*/T8I(9SUL!*#%- , 6!'BD+GWV_
M+C !DPH(D\\*/F(Y)@#?.N/!@^D*4<.)<OJ#9;Y=.GHTHR .:V;2$5N;(L@0
M,/FK"(8:/&5^$%OLX'__E83A?Q;/9UNZHLIW4H'SI>A??2,>R.B#TR:.7]&_
M-MC>XHS>V"#A!OKS-^.83RMJHX<W2JR&'CXI66(:Y6"%&!<,TD\:(U0PG![^
M=*&'%3<$X8%M7902A I2-(%#%Q)H0MT(-VS0#P=&<. !=/!]R+T'*_]XWX\4
M.8PPW!<>U%'&%AN84@<55'PH01 54 9'/ZLU]H$>^I<&052F E:X0! \T822
M1,(R%5@@8"(8%R$P815,J" DU,"7IRA"$5A  @T4L91-@*%8*A%"![L2PC^0
MD%]C440//DB#%9+0A"]4Q!_0$,(>L+"$+$%A#$$XA1&"P84E"0$,L:!#&OHP
M)@= PZV$(!.<2/ L;8A"%&A AA+\X0 ;K&($N;&)/>0$!)O@BQG! ,8ULM$#
M!K3")Z@ O _<P +ED8(=.$(_'*1!!1GAGP<VX 0*4$ /FEA /_I A0QLP0/A
M\$<3_F>!((@!?@M8P@9\T 4/%.(5@O#!!KK_,(DM-($(@CB('D8@AGYT 0>3
MV, &;. 9']P@ VDPA122 ( E9" 0X3$"%980/#M@  H88$@5FM '\8T(-Z%K
M'89$M[(#]4<$$C@5@51GHP+UHVG=/&*7:G2C_#!J3A"0 -!^=:IS$@APYS0G
MG?PFSSEMB4#M-%A[NNF1$$2S6#"SFGWJ@YM^ LEC$#A7D]XYK6;Q1S_WS)Q
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M(>!@.>9 '3H!/.+  E# *PS"%?CC%P" %G1!(X!I*7C !R3!=SC!L66 $:R
M!R0;!SQD&NA!\%2 !?0#%;S"063COBW'"#R&N^7 9MA!;0  !MA!!M3#%B3>
M,,:%&-$9I2&:5\B%(LRF2[3!I<8%$O7%I\9%!TT0#S!!)S!!&(S9+H8 " @%
M#X!!+48J!W50"O" (J3 ( JCK+Y$,4:0!U"&%>A %X2 $63 !@3"!E3!!V0
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M#V"Q%J<Q (# HNV!KGJ:$&"!%]%QGE6Q$Q< -\S$F@':H3DQ3/0J8(A:&-[
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M%7%X2> 0%OP!%D@:%T'"&<FQ$R/R7[Q":V "[_2#$F\ %(RCBUV *:3!)*Q
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MK(?WAT_69CBIG+K@+W2%4\2(@ RDS<V/4]E*9W4=4?BZ)T>!SMXPZ*FXU\]
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M_.,CX?P9 8!MPSU\52M"_C1IP^B2OY'L;P+]]3?)?.<&3E[!"%3F!JB@'S+
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MHB=ILJ+<-*$+2F$2^F L/@ &;L!#7T$3I" #4$')A P.*H (NL#V*C -_Z
M1B]F"Y: Q_IK R8"!U#!"E"!8\Y3^(1@!_8A"OX@"C9A%2#A +KK(OA6= !7
M<.'+(OC6;\E #12W<!EW'TJ@!,B ##K!^"2W(AKW#QXW<@VW;ST7<C7W(A0B
M^[+/M?)V=2E"$<+ /%D7(])S;B1 PSB4"@# "-( 1',  ^!3$_H@ XXG!S3,
M!%Y!#TKA"OSA C! >9H*^ !@ 6X !JJ $$P@"_S!!SA@!<JM'TP@)^IA#:K
M!%8I C>@+/J@'^:A>,H2+N#S!BX "BRF'\1@$ XP1'\B>;9 $%:4$OZ+$Z
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M$##+"N! "B8A'WS !P9OR4QA"S9#":T@:;8 #OR!P99&"U;C"A K \CA!J3
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MA1Z&. ).S' #%'@%2PQ2BGQ81A-?&$@_7M$%(TS"#OWHTQ"E4)X)F*("%ZC
M%L[9#Q],P@.:\($3/D&>%30A"^9TPA9DJ8(;F*(.-E!504XC0*A(0 024-V]
M2">4SEQ,:)9K_Y?V]G64WMW$,*19C%*DPC:BP<9\82N93%1R%80LX"SEF2A.
M"M.ND-%+,D%IBVOP0E"'A*8M0E/?SP"@F<P(+"$GW8CJ7D*:OJ!48@K9GD*D
M9;Z+J(QE^-I+S>SUKHE,]'R D9I<L'6Z>170(G.#3?P<<YJ&3$ B;".;W%0V
MUI@Q9BI[R=?@A/(XFUZD;QZ*EYM6A["9$"\T$[F:96BGK\>Y;VL=:IEG*'*V
MGK#.;CSQ:T0T2M<.[55Q)1K):09#5L.&K69V2QK10%H K 9&<-+BB47\-R^H
M7NUHYL+91[6ZVH*:3FH-R6Q+'Y8[P=G+'UAE#%=R]YG!;39X1+7+*_^$%C:+
M2-6D_@/H7(QGKL5=1+2YPTEK4!<9HTB57M?EWT'<HIB#2, M4;&:6W]WNO0R
MQB!K^Q:_X,68_DVTM8O3VD=:-M7%U79_#\4+5=L5FI<H0 @VF&(&!'&>#& @
M!U/4A'FJ0 @J;. 5DYC$##! Q2I\8 U-F$%Y'C@"%!*A"U4H!15>80)23<)C
M!9G$ B+R"A4T08-]J, G,+B$@?3!0<R*D!1>(85U6H *3JC")/JA'5=F8 -Z
MH$ 0SK,!5 + 0=;9 "BOC*8A2:U$6D:3(A2Q91)].<PCZO*9S#RB'AS 1638
M! VB@(;587G.=*YSB43Y)@EDP IVN(&5MS#_ CM@P,]).) 3;A $332*6140
M @=PL!$GU,$.4(!")+Y *CV,P HCX  )/!"J/H3B%7N9P#_I%H+T<.!!??"
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M[6:-<(IH(-"FG& "D&TK^V7FHZM)HN==BDNV>ON5X.'O0?K^X7:-5\]CYD4
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M4$T(.(%_!@"$;H5ZHM>[()KHTZCJ8YE^ 0?&P8F%3JJ#*&BF@TQ8F -Y_UZ
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M7(" ZD 3() >'!,R 9_O]< F^,4.[ &5M0$B5(+_6&Q"".Z &D@IE2J&DP(
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MU1R40A9@"*T,E5+& ,X"@ C(P"R<+E5MU;&I[0AZ;G,N0C*,FP%4RX)Q@G7
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M'+R!#$@13'&X/O@X%)P7*IR5'$C";0^"($P A)1Q'1.)"&B:2FU02EV/@8B
M@V#<*1&[D$1(L5.0M^X2E6BG'E_[!35(C^Q-Q'V0N"M[<YS,5X<0")UQ!6V'
M&^C! GR$#<Q *6Q .[3&!I3$?SA3_P9P@E,,*1SXPP*$@B8/5'IXP$#-0"GW
MPR1   =00!^D0<QM !%L@2%P)D.81*M- @=L@ 1L@!]P@!2DQB!81XI"@1[8
M 0>DP04( M+UPPI,@HOJP2!HP@I<P4>8@!V4PL' @16@P@TT1$!#4N.M10]
M@BV!P)QNA>O-A=$CO=)K#!8T/94J0AO\@)=JC.NM!3=$02=9/=:7'M.G@")
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M/@ D6-*?:N&ZS"AK)0"+J&9KZ.>+"C#0Q(@K%I!B S@P6$""%?K88 DK*OB
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M48$;E"(L&+#""$8@ALK=&,=B*P -%$&#Q9EMQSW^,=F"[&/&*0+)(AARW$+
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MA-0B@8XJX?"-X<Z@#]K (@1!&+@/.6X._'+"*Q0"%B O$9). NQ/[8[IC^Q
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MAX56]H\Z,"48^N1&<D(M(F,A^/^ #-'. ,[ !N[ GE;$ ##A+:9@1O0A%J3
M V!D!XZA@0R@"7:M!3G3 &+A,X/E4I9.%EAC-!(C.@Q!!'H@$0P 'X)A$)*
MMR)# :3JG*!A#H)A#LJ@,HI/&$1S#NP@!J8P&/1A-/'JL7XHK;*C%2Q*$NS
MC1 *-@U 'X)!#Y) !(;"6KC/ .8@(V(  C@).PU@$*Y@@Z A&'RS#)0A%O)C
MC+IE6X0A-@W ,]^"+8KI#8<E$V0AX3P.!<6)!F)3.;?3UXH$ )X &O!3.;?
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M=K_F(BDG'XP@#3@@#=S <XB@#JC@%0;!"7(!"CS #J[''P0!!QYH$' @"9Q
M#P[L P2A"ZH@ YK 'Q9@$L / %0@%*B@>3C "&#F"DC@ TA &!^($_K )3?
M"JH@"<K@TO3E"XRB%&AA"YYW!(S #JI $-X ![AG$$JA#_#E!F#2O\3 ".J@
M'XC@!K; S5[ :^Y039%"#9$B65+CV!!Q#I')9*N#/M$%E*)%_A#"+MGP7"!
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M^;*K$P(<B&L[ * +Q& 7-2$(/F"_JV #=* "',P&W*!__&$%<-P.,"#!3>&
MKV?%2* ?@H#0*B )]& 2-*$.7@%L?2 NQ& ##O\A"5[A9BQ@.ZN@ @+!S5[!
M _"K BP@:4WF C  !\K 4@ @!MR@#_SA"[3Q W+ O7I\ ZI #/3+'VR@#Q:
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M55=57'PBIQ9?"O I&H9G#:K6EH'*A9R*4ZD685!S+BIEID+JA1-/0RJJU$X
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M-M '0?AC$DT8A.,T00(?3 (.D[#!*TS0A"I\X -B&*@=</^0@8HD00^>RR
MKO"L.BRT"E*HP!(2M@$B9( 3&1!#V+AEA$]880T;L)I2ETH3]@C!%60X@%2E
M6@*E]0RJ4Y4J$JP*@*=&-:M;K5@;0/#5J8:58E[-ZB;.:I^T@I6K3(VK7.=*
M5Z56;6HVN$$:8& %?F[ #GIPVP9N$#98-:&E@<N!>)K@ W56A -&6,,2*N !
M#-1#;5*0'2!G@CAR;  #L^N'&#P@!4%D=@&H-9 05F "*-"A A_0A!AN@($1
MW( #33""!_P1BE)P@"%)&($>,+"%+ BB#VF00@:JX(2R#<);F:D)3L[7$R4&
MKP#@@$IZ1@.J.]&%?*+"$6J8&<O_019R33%P'VURB)8\"<6\:(+?C%1DO:#4
M@)L_X8J$>!>#JQ!J*&/*!P,G((,I9:HL-&D4>#%I$^I=\HF7A$UD<F*>X,47
M,1/ )6JHQ)DQ.6HI+;PO4](BP;TH0$E._$EP-.2H$[%/E!7\B7.J(QPJ*F Y
M6F$?<:B(%6RNJ#;5?2,DTP04"CYE11H"TAO=R!,"J<9XU<W/$]."'%#R1C[!
M=&-M$H3E::IX8N1##UK.TT0L8G%\$7+QEP=$'>TTM2K$D<^0W6@H]C#Y*AD^
MYF6 (H(/"B?(32F3>,?LYSG6]RDY><YQ&N4]GJC*+$R>"H9;(X$RI= L.=))
M5Z)Y'['H_R@H@M%N$^>"H:!HT+MRSI.D=R<ELB@/ C6('T]JX!>^",5[_2!4
MH#ZC@+[ :8-G:4MK2HC(J32J*#+2C&2$P!90B2^5@F+T5 B8XTL.YS(-Q$G)
M_C=#F_!8,>"=E*0I.1L *   /H"7%.R SQN((11]& 0&<!"X$1B!$KHP0K7N
MF00.-$0*&$E##C*0+$&L $(>Z <'.+ !"@A"87 0A"":( 4B<, ?"W!+$ 11
MK!%\@ ,XN( 5*N"$/GQ WQ(8Q!?$L#4QP" 'M+A!'Z2P@BUP8@M5"!T'2E$4
M*RQD!($X8EV'CK&8?8QI1E]RT15! P<M+>E,@P#3G;YT&BB=Z/]8S[K6M_ZT
M L#A S!8PPB"4 !-W+-S*M!#!IKP!1OXX[-=T(0=OE!0/<C$ Z\P104L@(H+
M+.%U&:#"5B8A!3A0_ -V8)L**I"!/BQ@6AF@2 8F3P$Q2$X7_;"!%)I CAM,
MRVUZL"AJM7!9,:0A RN@@A2HX"OE9F #&_AX%69W!0#,X#U9Z@TYM7.31^-H
M2/V@I""YRQ1_*-/"W'&,$)8YXFH:^,7O*4"E97":0_O$,;PT2RH+\YODN/J]
MII9 ".2BR,@$"C' =/6G@3.9;,*R*;J!RO/.<D$J@R."0'$E4R8\3IZTN2?N
M\Q0.]F(&$GS5P4,)8F D5D9O\DSTM3O_#G)MV5%"J:$J! 0]/6050%8#W -&
M,[1A!0!+V<$><P9%.V)"((@6%:-B>Y$:W"-D<G0@J))_2.&")7@>&F9EY"-D
M!T)!:E(5"80::R:#7C$;)R)G*C9G^6<D)J1_1X$D%&,4+V)NLZ0FLA%&.%%F
M-3$^\Y$CC48=J=&#,T),UU84(7A,N_$BJU$="F!GV?$BC@$4KT9E@((44=)H
M0T)ESJ,CI30;(H)* GA.,!(:Y:43$60505$6GB0IQ2=-(K ;.O$[CC%.+R("
MN7<BP9%?$)!Q0O@945%@;D%_RQ-+PC<D1/([_> E"N065O%\9=A=;() GC9B
MPX04NE=E#&05__DP4W#P.O'B;X E" O  9,P"4D@!120!!HQ"/U@.C8@!O4@
M" A%,!N0 1:U FY@"J^0!AN0!AAP QF@ LGE>(%0!2H@!3<@!58@CA(0!)/0
M!_[0!:\W E(@CD%0 5!P.0GG$&G  10P"::5,!+0!=BR!9I  5NP 5:0!(<
M !*@!R,  Y\@!EQ7D19YD1B9D1JYD5C''ASP 6F "C?P#OV CE4@!BUA,&*P
M!"-1 ;=5!3DP6/3B#WI@!+'C D%P 56  1;0#PBS #Y #A^@ O9T RJP!C=
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M5EMOQ3577?]WY;5767OXHX1@AX7D@!)2\#5999=EUK)'>FWL%2@,X< )$S>
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M#N"$0UB2)<" DJJ $1@!)QF$#$ 8$N@#$BP%"]"$4+ !"W "'("2!3"%4O
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M-- $*9""#+ "230%(J!:*/ 3.\@40;@".*"",I# #4B"0;@G/RB%7J.".;,
M#M@ '_"#+NVU@]H4;)H$_>.H&Q#!*[ !*F72-61!)L'0+9B$# @$32B##?@$
M0L@ . B$)%BS*BA"?] T2U3"Q0!*!M7<S?65 N"& ]@$-$@-(0 !,D""ON+<
MS7507GF%2[0"O06 &UB"&T"3)J@ <DA-*<A-._" 03"%J;V ;1D8VVTG'/"7
M*6M-KM4R#HB$((B$#4@#^R,"0>#=#0B"0.!2XVT")_& ,O@"%Q"#.M@"?_"
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M(0UPR( >NK"%.EB "A](@@OA8P(IK* )6\B>!S;0AR:,3Q,;\,&';+""?BQ
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M!K@N3&^ 9]L1:%S!%WR?DT%!(&"(&$@/%9A"$ 2W08A%/7R > ZVQ$_\;/3
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M!2-8($M?T 0&LI@!08S@ G0D@@D@M[&W3.PB+Z@9Z;HU@Z5T3F:%44#OBJ:
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MQ9X;9?\&=;A!"E\1"N&JOPHJT$,]G("#&W"@'_O-P!)6#P4]Z&$2IL#!)(2
M YS _XQ !7(!CEP@-1CB"XQ@#<#N!CA!$&BA?*B '%YC"YJ@"E9@!#R  VP
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M$7YG02IN:1"*6_0-8D 42 =&#FEF8J#"7IZI5/Y*_W0P5&>2!VF6#BP$]*L
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MF"!J,!)7G_2%<DU*T)CD6@! "Y:@\\1@D/3 7 4!MZJ @2Y ?JZ@"_9Q$&Y
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M#*,,K<G_=]PP2JL4,]H4 &0  #8V?J"@"5; #IS@!C  -_4/!SQ !XS@^OR
M5.7$"2[(-2 O"$S!!0BDAC5A?># ""+!"51 RS2A"31! DRA#IPA%&;@%;I
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M(D&,BG.U8BV"\=A^M"WJ$R.2Q60R!P(2(]0HK2KL.E%KYF\+IH,G(](I!WU
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M35!?4;QY),%; 2+T2G?/%?60<?W@Y0,.56S @2!ZI%%!#AA4H(<%_7P1RA<
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MCP0U-]0?Q<EYC!-O]1%7W>\/YSS^1R"%WM7L:5<$P0LC@6]:<4,CQY+5M4'
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MWLD!8F "&? *_-(/2V (=F $57!J.U(!KP<!'* )1. #_<(!??^  5*0!&X
M$@NP*QZP!1Z@+4%0!AR0 ?WP 890GGU0,_W@!E(P"4D 0G6P 5?P0:1G2AR
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MVVJ3'R;,0*\P\3-LN#.1$[QY UN0 6+0F^UD1=OR+7$<X4J8 Q5@ XXV":4
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MV$"3/N PX94FZM@B$ STX* +,8QM0H\-%NC"B K$4($06C8 8 $]1AA!!U,
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MPP<VL($,IE645UR!"((( A&(L "QY < ,;"!&[CFJT%XH!]E6(!(X: "*6S
M QQH0M-N((5^2($#-_A"$[PFA2 $0045J, -,F"!HMCL$R,0 V+*\S*TIE6M
M:V6KQ800!314K !MB (7%!$"'D "#$+8 1E"UE; !C:M,6/9.T:P!BO X L
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M#ON0%2 [/Y@%*\ &6/""EJW8$7B%AS,[ (!)0Y@(!<@$(S"$AQ.VQ>R#._B
M/M"-IR,R6$,AZ3#=_2(%6OS=2L0'*U@ V:7="O&0(+NXDSN&4Y1-X6D.:&*,
MDGU#? @&&'@"50B% 9,$6B369#2 ^<6$">C,I9#=_R00R-7H"("4"$[Y,X%D
M.^@AU2B"# 7N.TR98$BYBMOY%/-9M'/[@BJX@ KP "+0*B,8A 4P AFM@'8P
M G!(@CJH "/@@$D(A2#(PPMM D$P HZZ%EUXA=HI Z[2@2VMAP4U&#O]A#7
M+1QH @%<@1X&@ 6,8:OB@![DA%!(EM9C'!+0 R,8 =YR@04H!1S( +Q9@"V
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M@BU( Q4-@B_H @P8@0U(T2 0B$G@&8&)@2]H/IH*<T-56RTH"DTH&#%@P1&
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M!2-(T84_W*;AXB0D6*")"A;8F\$D2PA2!;2O7/2=>@K)9]YW$DC C2K!&&!
M,,'HTXK-!L31QQTY4R(!+#DSYQY;I.2LLSYQ!/%S,*U <((D!I"3B %K:%V*
M*@8XXP$W0^1,M3!DXT*)/R)( ($P5_/<M %%)R2$1HO)'4P<=/@C_S75J>1\
M1A(R)*+/'/K$0@DWQ.2,LP%>&Q!+;E_'8<,L.1/2ST* &U"/!!U9'3DE /@3
MNN0_RYTS;55?[73.B8/4MC\*I*(/V"9<Q/D9AD PP1-:&]"*1A/TDPK.S*57
M72IS@-T<!$,;X,7;6!^CSP=:D_.U.QZ$KG/3B2M-W00Q:*ZT=M/1_!)(JV74
MIC]VAZ^^^O$K1'HA^F@!  1**%"^YM_)P2;^>$(R<$$/4#"B+\)(1BPV1!@A
M] -4^M/.^D32OC3U8RATJ%E2X'*;H/1C%%)8 $D8\@(%)(0B6I (2B*XFNK$
MSWSED=G[%,*2DZ"*5A&LSDNFTYT*:B016__HSF)RH;ED#*(/ X1&/3P @41D
M #&9L 0=EC.8YTTM! DY 3!4XS:W@&0H2: 90>IBB270;(I)@(T(GL>N?K1A
M%):@1$U6, $A7&XOEKB) CXW 48,PR=3"" ')M V6'P"=R$8RA)JXA,:#*T5
M0G!DWP*8A)95;8];M 04AO*6[T##"'!8R"A4H3A1<*(?!'&"?C+1"(10!71N
M@<LFF],66GR1 RU4 "!] H$ OH$;IY".^?H80W_(A(84A%G,9I@0H_3N?^'K
MG4+($L.8Q6 [_M@/ '11APVH@ H?(-@&B+ !"8A!#_7X@!7T   ;3$('%;"
M$P$P@0U,H@O@I(+_#:X @0V,X!,CV$(_+%"&/G" "$%XQ0*N\ I!U($#22 '
MF/10A19MP!_YN((8J+"!()3BG/IYQ20LFH$7],,(5;#"A#0A@2$YP0(?V((I
MED"%(#1A/UNPU@5\H"9()2NHR>K!'B0(@FM<! 1Y2I,0>%!4E)Q@#^]#Q*C.
M1 -%_&%0BL#J)L"P33GM 25"4$.=[@2&-7%#4D+XPS4F=:>EVDE5)5C5JK
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MQP/X<H(@]""(X'C  W  $\LVH(,658 #*R""$5:@(3C0[ K$%8,N.! *#I!
M$!EHD0LV,/D%#.D5P/9'C(C@!"*X-CB:N%B7)M&/)1BA E#P  >JL 47;&%B
M_P!802XXD80KZ =-C5U_G+BA!BXHH@ \@,19?^ K1-%_JXJ Q*)ZI=>+S FL
M".  PA5*M $B@,%6@0 9F,$/K,(FY!"M$!6@E(H9A$$(\,#]I4D;,$$',D$>
M?& 'YD$* !5RA, )<MOZM0$*T$D)LM\+PN!B/5:Q%, 5W  J5,$': ( - $E
M4(L4?$ &@),8;  $!$(5B($GX$ 7V, K-,$6<$L]L L <( 1;,$Y^8 $Z($>
MT,@2),$&-$$3()0F:,$5V(",:8$/F,(*!*$4N L&W,!X40$$7($/3,)X+4 _
MG()*C4 &5($FO$(,3$(:.($=;($/",(D$*$I0&$@F/_"!MA!&D!+#&!2?"1/
MNRE$$3@"XE "83P/SGG/ZP0!(UQ-+%0%!&0",,2"%'C *(1#(V! VXR"[50.
MB 6/VUR-K>T,T(P#I'F P>',A9D.);P"=+%%*2X!?=!8-*T-=(V"&\!BVRP/
MT"3!B-F.))%BY-!!/PA#/@Q-XOS,,"!0HP'-;MR!LC69H7%.V)@'?AD %+ &
MW1T8?L6""I!B,,2"'8":Z=!"C<&0?/0#+. ,.T( (\B"DVU3#PP!/HX.>EA'
M-IJBYJ0B+DC!*]R:D\'%,(:.K4%8'/0BV'#/U>"""L1 V]B;-G6$,;5-#$'
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M[  9', F%*"Q\, ^E  3I( BO* B?)64&NJASLH,%@L<5/\ 2]F!\8G!"%1
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M@)GE3!D\V\1J@1,Y'F'HC@? Q>^XJQLL@KP^#6C4SYE 3R1,+-8>!E)4K18
M#U.<P$)^@,#FS UL'=@8@IGAC,0R+2M\6P_)9N]\1&!>UG2:1$KDI%8<TWF<
MVJG)V[G@)(TI@3[@@DC4 +R"TA8 G'7DQ6 H! UH#.E<Q ZQ0B%<'2Y8;0U,
M)6YFIOXH0!$86^>Z 0T(&VBB!%"H %QH41M P[\=KD? 6'N$@ ,HKNP$'@ME
M;KT!9N#*CWN,YG=HA)JLIN%F)GH.3T1L9DA,AP+<Y]\R1!^1A TI1#\DS[;-
MY)I0QR4*_ZX$B$!\@(0(?*=\-,32$8]Z0L"G)<3OGN3=7J^[R4Q-^JXTL1GC
MD1H%*>/GT%="D ].M(<_-%/,/.UZ&#"^J65Y0J_V&M+\*.;A!>[@[22-I0>H
M:5,_U,#DP:$>J$ @(-0(Y,"]H!\4B# &0, D+,# U,@-?(!$_);FG,MX!8$=
MZ)8>7&L&U&HI^  'O,)HV>$&J&@=U %M6$"KME-G! >UK(8>?(!XX0 < , @
M](,4N, (P.,5>,#!Y,"0; !HL6H=T)=%38B9H(FZ(>KZA8": LNMH H:L\D)
M"HLBS*F;I*":4&50"<$/@$ 4'  _'$ )@$$8B  <DPH/=" %TO]Q&C-R(ZN)
MHA(+'"R)I.;/#2P!%- "$6Q!/6# ?V: *02!,Y!J!5"!)@R""?2#&&! $!C"
M!^A"/[3H%:P&!51!'P1!'SB!'BR!'FP!\$F B " #ZS'*PA!'UQ \:VH'R!4
M$E2 )L#%)-SR DP".> R% 1!ZH6"#91!!>1 $V" "92!$P1!%9@6MO3J!]P
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M[S+2$@1 PQQT(BA9@>R\,4K,CAN(92$4@4G(A?!&-@0T;I@90",H@0LQ! #
M BKHAVC"@A'T 7[&ET)H@3XH@_XF1$^>!%[;]6MG[_H<'DB0SMZRB0S/9#1Q
MA/W"S* M'OT QC(&IMWH3WKX)>G@6]]!%_$N]^STIE3P+EFX1&0R7U5_1'#N
M[:;EK0P-YF:W_PP-]:YKZ\?V*H1XB(1\8G!'%'!+6"],^(_YAL\,)#=WUT !
M\*Y@/I,"G&?P>L0+R(#21)X_A,,'+($=U($*L)<-0P$.7($4-"H>?DP_R*J
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M0 \R), &#D$"&F,%FD I^R E]J8*<D ''*DD_YK@RM( "J @%VX@JSB+,XG
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M$.9 &<9+&'Z!%=S@B:"!#IP#&CA!".0@E/MA"EPFO*_"';V C D!.SK%'9*
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M"GIBL$4:=6 P0AHV %!#0=U%U]P$$4EKK3\*Q'!M=!-E5%VTS54'04;;2@"
M4]\JUVU#MCDDP;>T+>"/"+9A*X$((#4%[K8W&51 =R%(N]AUUT:K9 $6WH1P
M=PK(D)$0Z=:K[6,8;50M0^E"5UT_!537)$(;/022P-=]-,$$_Q_M6W'#$J1,
M,'20D:NR8BC3[."3&RWLU"OC+N:=<MT-O._/02LD0C"-. CN3;/$X<8Q^LPQ
MB!M7O )S(7.X,9!3$$#SQD>I !:","0.S:]R/83C@1R3)*,,!0CU8(E9#"F
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M1 YT0 @CZ'$,%7"^KB!UB+R^1PF<; &T!_F7W611@^7< 0H2=L;X[D 9Y2A
M'P9H?@T,H(Q]W<P@"PGNG/GEYLUJS*8T$T8RMA>+"R".&\D(ACZ",8@DR&!U
ME+B>,^QQAS-@,!<( 1(# 3J?84.(4Q&M$# O\1G!8&(E 04+\1I+\3VRH#UQ
M( A_,1$%9 5/X @ZICG1I0P&T H-UP.J$ =!4$ P,0>?47R0\2X]07B^4X(G
M^ 8G0 KZH _M9P+?\QD&@((ITSY>4#%.\4(&H/^#&(! 3Q%_\U=_(2!!]^,,
MV!!DC" 7#D%>*002W- 52Q!"(= /]C6$"91C'A 2L; $$7$35=@74] 1K8 [
MY/6!3]$5C#4[TN)4T $.1\579Y-TX(%$324SCF,PK%  7> ):; %M)(#(T L
M&: "E'(!(W !AL !$F!R5R %-Y #.I &OW);!*<']? ):Q $FG J+(<X_; %
M#N(0UU00!? *"\ !IF !?: I,# "<.,/#F4%ZE8!-Z )78 #H> /'& (4' >
M $ %&9 !55 H%1!1@.8$E.(/5G"-(R &XK:-W-B-0A %FY 'BI "KK )8-"-
MZ)B.4$)N6[(":R B([#_)DV0 1:  =<(!19P 7;0!%)P!7Y@!YIV PM@ [AB
M QL !5;0C$;0!38P 9J@!QNG(J^P!"0P"9K ( ,!3IBS %\0@ MB! GW"AM0
M3R,@!?W0D&#4C':P 91BD"OP!3?P 3=@"AY0B_,8"-%4 6G@!+6R <VB1#Q'
M=GS55)J%+G'%,][Q4DSG%M[A%M(B$=SR5LD5+5#I=#=!=8H1*C>!E,"W+6B%
M,,JQ,*'7.$2G& UW(="",'LW+D(T 92C,4X7&1.!AXP3 _4R,.%7E?RB$) 1
M/$M"$&>G$$SR$. G FAY,PUW+AK!,0LA$6^5+BE#E&=#,&2Y5( (-(B3F'T7
M_RU:H ]_%0(U@ MND%&I,P_^!%PWP0KZ4 @.T0,5=@5/D QTT'<!4Y8\E%/7
M(@Q"]@L6%78.41!"<'VXH'5"X B4T \G8 ETD)S] QU%T BXH#"%@ ]:EU-.
M0GJ9)WX: U/:.73*03E/4 .NTE80()Y;01M*PC$(DW8$T1 ',04UP$N&%QE?
M* &'R9C^<"%RZ55B)P1*8 ,IDW:A@C#],%K0D1WXHG9XN3$8X1;?LG;582Y.
MHA .\02)HG8A4 0O0(0;078?D0\.-%K *9[ E3!GU3-?]U0!XY@;D1SG&1E8
M60#$]0304'S0,1!-MQ$A, $%$':CQ1P2P$LORG1&1?]2T6*5M1%73,E#$Z%#
M/<4= *   ' *>H >%_ !4'!%@9 !6[ !'B (M58!@_ *D]"15& *D^:,@P
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M]8 !AE"I*L",.+ B0N GU)T=E24!"K7_DI0(!QY@!_70!?X@!BPI[TV  9R
M<P=RUOV (G^V!5=0!DM0(QFP'D%@!3?@ A8@OY-8!4FRVA!OJD+P Y 0VFA0
MVE<B!&WP!R7 \1S?\0=@!J\4\20_)3:0 81@*A9%*Q>0 3I0)[F6!DW@ ;KP
M 8&0<>0$!UG]9W7T"J]@ 8*Z!'W@ 51@!&E  1L@"'A-!%VP 5_P!1N@"P#
M"A+@ VZ 3#7YD&+P:EM@!7JP N P"1SPJ(W4!V%D!?6@!U10-7KP*W6ROEN
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M!!W]J,L\P(A@I.$5D9I%*RJ:C&"4PF6&0)P_8L!4E$Y I5MH:3^@T0H(,,(
M1BV$)%AJDQ,,P:A(I0,$3F")0R#-#4*%@$\',54[/$T4G.#&'1:KC)I"8*S
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M5&@"W_*/_ &2%%/ !63  Q("+)@/ZQ "'D@!;6O "R2@%2L/(= %.LN@%0"
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M*U"?#["#Y^@'5##!>O ="<3 ]G3/]P2 'C@ ?D"#ZP !,D"" @@V^.3/[]#
M\F@Q!UF#,,D %5B"V!F0##"%#7 PU1@!*6@I0AL!"H .*6@",:  3P@$2I""
M("B#*Y"-!?_P@< (A WX#]RH@LO;@ K0@>O,@1FCOBV@@AA@+P\(A""H@"7
M@2="HOE;@/,; 1@3A!:T@P^8,BJ "]S8 "C802DXDJ\"%X90 ,VS'(5XQ,QI
ME: 3I87"-!FH")YH-EXC"(?PPS6)B:E0F%=@)%SC$TDT@86H1%%[A$=(@BP8
MM4?H/DJ8AFIX!%U!-0AX@SM]-0ZX4YL+@5$[-74@@E$S!+GQB1= ')? G('
M)D*"")<XE*H0%$SS!X-Q*)V("'"!2(?A%3'1%&&)">@0 1D0E,QQB-:BMT"R
M"F%#N'\:554!-T53J(:KBGY0!@-8BPE0ALRL"<M2!51XMW"1MX7_B4Q>G4>
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MW0Z/M.@#"B:0&0  ""'='- #%0B"2? +,AJ!5TB"+>  %4B#?IB!Q:"$&Z"
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MK $4C( 18!.LI('.8( AU('%=($)&,(*;%SI6$8_A()&08P-A )8_!B+>4"
MG<(@C  A)(&K<,('-,$AY-(S+2%(;<#.J(#)< "A5$ ?"$)) 8I++543Y$ 5
MI($/+!B\):(B+B)&<,,!\,,!1"(D1N(!<,&Q<,,FD%L(_$ !4!LD6"(CAN)
MR1NS7 &NY JK8,#_".C %F!4'2Q!HER!!32!/U# T%@!#-R )MA!&HA!%\!!
M$(B!%,S*E8A!$D@!)^" !U#;192"$8C!%GS!#+R"#4B!!8C!()P81O0!#J@
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M(1@ 27 8+ 1'@]4 +@Q8(\P!U=WE7_P(.$B>1MR6[<U$"#!%4"@)5>1E(RD
MVH >(BG2!&8J;.J%0C8&2#B7UV!-)2%K(76FR5U$W!6)#-1=3>!J^R68LLY7
M\XE /L F48&D;,"@U+V$UL!JKWX@D1 3Z]WK9'+J7A $CL 9]D#23, $US5M
M_W "0#Y021+\R1:L@"KI 1140#^4 J,8 1'D2Q5 P;ZD017T 0!003=6 "J
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MR7U!!4@ HFC"#;@ '1C"!8B9QAUN%>B %4A:]K;#QDF *="M*61 %01!$N#
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M)*.ZL0AUL@C!%>R+ON";'NA !1"!!TC!!0S*)R"U&\ )END2H=A+%6R!$7C
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MA4CT EL];$/2@6 &S<.@6D% !BK\WW6ZHR?_?_3J)OT00H\ ( ,>XN17-0+
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M(OS8=V 3LB%X4G2H%T!0"!*V)#$K665;N;<?(H!S &=)'1'0AV'@B0$NLRC
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M8Z! YC: !&!& C; "/0@"8)+!;; #IR  FR- HJMU! ##/O@%92."@9A$E:
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M"W"N>$[&M[: ?3*@'>#F RX %39 $'S@$BW " +!"3Y!Z$; 0/MJ \2  GQ
M/R6@%.#@"[K@%5A!"\EP$!8@.-[A2]EQ 0J@-=) ##;@I>+_;D*9L6@D:@%\
MP <$M0HH02W2( TLH N00PJL( .@P!$K  Z8A5GH@R<'#TC6Y5:*4H](A)SZ
M2X0DR?+ZSDKBXP@O,SN,\].RXRH/SS,+!C\40 8Z: #7:R9S\Y(PD#MBY0C5
MPTUNE;T<)KRF20%QL/"(9"A_I(7HZ\;83"A/CU@L\,\D*=!6)%9 =0&LPP"-
MDP5QTQ^"@?BT0PD@C9JN8PJ,<_WF0/Y^I!]JP/H>I8WJ)))<Z)':[U_;K_XV
MJ8UP04\HY4Z*9) JY38C1!GP@3H8P1T,(3O*:&*OPY9>TP D)3>SDE:5T]':
MQ3M4[SAQ,UE%U0#+4EM[=3U"TS.S_V,I<:CU,HE"SB,\"&CQ("^$Y.PIA7 V
M6S7X.C9H*P^!6(\DC])E+S9$Y,, LXM51]*%M&,!)^@T+=*3Z@,\5-)@BC*5
M)E(75. "TF )JH!!,4 *KF!\?LL.$,,"-,$'!N@&MB W]  *1$(,1*(S,G$#
M].X+)J$+OO05-F !C& +)L$(/, -2* +ON 4)D$3:.(*JE0%*& $UD %C. #
M6,<)Q( @^V "?. +-H "/N,#Y $5C. *+" (J@ YE@ 5I& ,RP,'U,(*)J'>
ME/1V<=<HN($,HJ 4(:%OUHHH:-1$VR 7*X&'&FY%;_$'$.%P^H'B2N"J3/3C
MBJ(+ZL>>=/\! #3!"G) ;-.@U!9# @QA"8+ $%; #@:U LI L_K!%,[G \AA
M RA!)$:@#&JB#TC 'P3A%7HJW51 !38" %8  C94#XA@!59 $/(WMP"@"RZ"
M>^D (ZS@!K!.LQQXVSY!!3S@GS!@;%2@"JH ?5#!0%_C"B1RB6S%/<0R@6#2
M5K +6;()5DXRG:@5-C70,G>0FI3U.C2$5/S!AH[2@)PR2(#I/D3R9Z6(6Z6R
MA*J2*DMR]5:D/?JA7-D#EV+%-UT3.J73,LT#ABE)! B(.J@889BSDT*S(NTK
M--EE0FJP2SJ2C;_CAE>02[8R/7!!^WZ20IY #B2A%:ID4'#RA/+_@8_HDB_I
M:#H&Q0#$H?T6.2W[Q$=DS$_D9#KHI$\"B3K^DD&2.!RX:#H881M:J <LP6*O
MI?GHR#%-0&@!;;Q2\"FIU9),<XF/Q$, *"BI$E3# X*.& $?Q ;P0USU#D/6
M; 9RZ;G48X6)68$F;U8G<_'LY26GZY55.3IK\TC>)()8T@5_! BAU9H?I&5#
M")G619HMY 48!)T:)$C".06#Q#^2Q<;D(X;3@SR,I$:4Y I6( U, 15P*M>V
MX Z#P F"8+72@ -N  <.0;/> 0,"@Z]"HZ_T@'V")[>R0'\Y@7"7X KZ0",X
M0!#4DS@X8 &(8%CTKA\LH.B 41!PZA-&_P #!*O<0J$".. #B" )!,$)]F(%
M8N<S+L,"\&JPJB -ONYQ7B1WC?JH=R)(2W$3-N$5B6)OPF!&4D 1DC2IN('@
M=$(1,,<FR,H5B=KA@O<3J9<HNH!R,<$*3#@EK, 43 T#"&$#], ?.$ /MD"Q
M<N "S$<%)N#95'<$G" #M@!L,\!LOX *G '<]."W*,&>2JL)5J ?OF +"MI#
M!8$@FX .!V$%J@ZP&Q)3!U6AFF 27@%NZ*<*,* ,MN 5%F #PA8#G& +_*!^
MQ,"$H8.4S(D_3.B%PB51*L29\8,RV\4]XN/";I4$FQ6'*#,J7=:<9.];DU4"
M,&B=D;B5YYAA-_^O@[JX8-IKOUR(DQ!O1' )@F"VNP/OA Z& OM%/88;2_PC
M:;U$NHNIA3FM6Z>#:3LS/9Q6GH6V '"!^*; 3QIA0HY/$D)AH5SH+>7/032K
M!EBAR!RY*/W54(J%?34+/' !4L*/_/15"=[/3O !B$O(8:]#E#DA.T;A%PQA
M].PDDM+(6P7P6(V6/Z3#_WP/.M4K55]E8++60<(9@IS+NQ#H:L'% D-H/4B0
MBYF;.@H/9Q%-G+0#76S3Q4=( -UC9<U)GOV.1'C2@10P5KK9FS@$44SV S.)
M]VH9@ZK[6ZVI.^P[0K9UABT( &* >V)G U#A A(T T"!?4P!!YK@,$S_;032
M@ C69NG(X;+09K S@ IRI@F,H!3$("3PPK0N8 N:X'1*80N@H!]50 H^P"_B
M20JZH ^H0"*>;6PG-PE\8 MTX==T0 5&P 58^[(3T4 W'0.L8 -B8@.@)0VL
MP KJ@:B0>MB)_2:X0A$4@>."0@A6X0"D:A7_!@NDEZVT8D?;8*MKH@?&X-]N
M0JM/=*R7O0!68"V":P4 (-)S 'T$W0I>:P->X=L<TJ^AP F6P /B  =TX=<#
MP314*PDTM PHX-<E:@3B-K8^U-3TP"XP-P=4@ A<1K*\S0F,@+!Z9U!'0!#F
M01>X,!+Z  K$X'\_H"%Q  >NH E> H1K X0__R )3 ZY="6\7EA:0:\#X]A7
M.["3 NA#\OLI2R^\D*6ZD.6<6Z^9LGM$=@E$%FB%T^->+G-*E'Y#GMXH X3I
M+\2]!(^8STP"=OE:8A:=!(:<N2OV./-:A!R9S@/ TKM<@#X'CUED\^,]AAY(
MQ#@K,8T]O%E<^P[OCSD[P@$70L ?6$$90%P[1H$40N$8W@ \E" 8RH2:7J &
ME(##%;^/\E(Z(IG&BHE. C8NZ[*-  63VZCN20A,_ <"4F$83"&33K_$L4,+
ME,%2 ##%FK[O*A-99[_GJ?DZX-OSL!B]1#\(Q2./EW4!7X$\^$Y:A5 TEWMJ
M?_CO<)]$;C [PFGZ9__?]B% !*8)^X=P0ZKR^I4>.-'^%>RE]-!E49J)*(&^
M*+M_T3*3['W^2(YXAR'L)+7,(S^695E864@% !0  #R U #BPX@15K9\R%"&
MB@\C6]+<R"!(!885/D9\,+%E@Y4<1DPD6?'*2(8*.:Q4V?#)CIT*&:#4V^(I
M0Y4T=CY8N6!JQ(81+@1*,>(AJ(</%?34T;- CY$-<*"H"))AQ)8M.'Q0*7/A
M0QJB.5 ]% 2@GYT,5C!M ( 6@)"T;-NZ?0LWKMRY=.O:O8LWK]ZV(13Y543#
MKXB\/38-1@L"R10::BKM?8RV#99-7 JD%0*"#)>V!;BA"?&V30K(I-T^@AS_
MHDN:3R/J41$B9823+1Q4F(!"I Z1?CZ<-,F@PH^1*E+ZE2KURLZ:+8,R]&NB
M@@.."J@N6$E#I,J(3W6J:/\"I4J7@14PV+DQ<&?*E17J&%FR8LN-=GJZK#!B
MH<^-''8\V!F! 6TD$!%$'U ( L4&M-CA@@I7 #!!6/Y ,.&$$DQ (00*2%!A
MAOYP2*&%$V#8H3\+>)BA!!)H*(,_)5)XHC\D0M"/BB262&*,$%P(3H803/"B
MB!#L&.2.(Z(XX0LW0O#*CT7Z(X*'44(I)8536HEEA5.*X.*665(XP0L0Q/ C
MB2I....$"O3S(889Z@CDCRBBB*$$&R*)HIUIXJGF_Y%/7BG#!"!J2:$$7!:Z
M9Y <HHEDC#JZ",$,C?(Y80Q/\CDGH1,JH\^$C9Z@RB!!2  -(2@J@(\6%9ZH
MP!SZ&(#/BAU*H(P!!@2C*@2L!&. /KE>ZH\;MPYK:['$DBC$)+P:4,.;4QIJ
M(90%X%)(AQ (4P>4PG! I(\9QN#KHTAZ>>FALT):X: +7.E/#%P^:::%'O;H
M#[WT@IBHAQSVL^.%$]++YX7=7BJPNAY.V,^1 J,H0HT;RBBNB&IZV,_#3NZX
M9L9-HDLON8>:ZV.)18:(:86,QB KA3$L&6,,#[_X8\)NOC@!P!_*VB&9]>8Y
MXX\ #TJRH'*:[&&,"&\()/^P95J8,J0G A # %?H<8,*502A@B%!<+"U!TTL
MD<8%'!!2 0Y!"!+'!OU(\4$5'SBQ0B0248<)%)^@@H%WGP@RTT47I-$/>B/0
ML<4(55MA!2H56%&!!4O<T,<25>BQA1TA4#%(%V)LH8,*G!RTQ" +"!(1!PC6
M,0+8Y=5X@PZ86"%&/Z7-3GOMMM\^.S<'',#/[KNCD1</>[!UPAXB"$'&:+C3
M)<0.49AQ/ ^01!%&:)!LXMAEF66_?%ZG06;#=@/9 , 6*FR0009-2+6%&%^_
MTD\0J!Q4]@8+D.!//VZ( 4<27]2!O@J,  9!T,$(UF"'-!"G'V*0B29N4 $J
MI*'_"5* @PH$D@$[:&<#4&@-!3:P 2IT 0X<\$$^_&&"5[Q"@"-001KRTP\.
M;& ++1E!$_2 @328X@8;> 74T%(D0:GH32]ZU,I*YB$SB>!._])7TWXTQ'^A
M25$8 @>CTE6B5^2K0C)0 ,G2)30T(4U*2A,9$D>&+@@LH$1'E-3&Y 1%DBW
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M/:R%&0=PL3?Y XC 6P" E26@".O:%M_S&'"P.!Q@!5\  $% !X:@ DD !4'
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M?R$C S40 Z(= Z7] J4MVK"6VN1I(B!#VC70, I VO^E/=JR+=L_AB)'R$E
M0R%"4&@<);YB?5'R4KO%F3 '2L-:8HIE="B6XF:8TJ?^Y#.1W7!Y9"Z(G2$J
M%HE0]M8%*KI^ C(8$BAWK2'E5-XKDM;!>]594HA0&D1BDD=SW=4IHTGQ1Z':
M%D2J>V8\)ME1S8;=3:96K"\AY4Y#H[WY='XF<RBR$R%78 0UD3XJL 3U2!.3
M8%<7D&!$8 2Q$017^P%!<%P?T 32MP23D'M6M7FR*>%:<3XJ0 <;H)G,M01
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MU<A63AK<$ 5@T!<]4%HTN^AL 1!"A$ "HRB$(DA(  B)4@G PX?<#DR<R._
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M4T/7N*#7F*/E++*3P BT5X4-O-4)-VB"$<CQ@7(OX6AIN( AMO"O2$@!%!G
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M -QH1A78#0K &15XA3*X@9,9@0K@A*E)@P\PA9*:A/M)CK!Z20KP!%C= %.
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MG"($*R YX:H#HD%30N W*3"%3MV \NFO^=H"5+A&F\J!F,2ZF$R"]/J[#+B
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M*O#%-.B#+RBIY<B $;  ([B!24BK_H(-#$ %4["#L<Z,$;4#/3@%QWT(H)V
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M9D,+#"1"D)XN@!&G&KU $:*AICD0J:&Z(4L-!84@A*:QQJA ,+AXBA"BP4*
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M0!)%); %G_YC0@ @051.B0' %BIL((6*#<Y/CA,D]*.)BDU\8@2!6( '_%$
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MB!;<4LKX2!W_0H,NG,,MI($$]( R-!HE,((4C((=L$D/'$,=M$$R<(*F90/
M0 .N/4$BQ,(QM,*X&!M%O, XT0!%^-G/I!)%X (PB,L+X$,A% "LH!,HL8E^
MEM&O48K0N(F?F<I&V<B?N* +$BB%"LQ[_EBSA&"EF!P5 1PP892, :FP (S'
M7%FPR @EY<R0E-F>U-&E>4M&J$F1Y-&2U4"0O0F>ADIZ>@FF@12CP&?#H4R0
M;M27B">W"0G E9.W6$2<;,S#85J@\":5G$F6,I1B= %>% : H @E;( 0U($5
MK)@.C$ 0&,$@:$)9<,!WZ $16 $=U%<%E(%669@/T! &2,$2Z$$@_ZA $V#
M0)D"7$F!'BQ!@QD(5PQ4!KC "/@%*M !6!C">+U 5U1 $.1 #IC0!70! /B
M_HE!'5Q=!N2 7"K1%KS>&DB!;]WDO-(KX D!&23797"#^2@"Z2&"&?P "%C>
M<0@!)"!!"BA""+"&(H! XCD&-Z#!]30&#UQ><$ "&5!7< CL5=9D6&[&*Y1$
M#7W6!@#6]&% #E0!%:Q %]0!!6" &(B!'2R!!>! $_C#%2!8!F70%L!!5 AD
M/\#!DO2#!YB5=F# !FA"%W1D?%%!7"1!'\ !%7@ H]A $'3!Y&3 \;T/!EB
M#_2!#2"F_UP !VR !0Q1$@3!!J20%:2!$_^H1!.P0OO8YC]]8A4J(Z%XG#PM
M2:?JE)XZX$0\8C2JX*H@H$L]Q*HD!-TLIS<FH!WE+8Z (!/1R1?-F]7D$X[P
M"(XM2438D8RP28U-T9EQR7@^R;J9T8T(6E)U#*8*"8"N6SM]D1^QFQ!F8A8%
M4J!!G)6AB; D'+%L88V\THXU(D(D8A050!$PF:!11#\4@CYHP1Q52ATR BY8
M "-L@03<@0KT S00 @0D0B,X04/L0"-PP!WVVO:&[QYV[RAP *_A6C)6U#$
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M+P.S]SA&#U2L37IL9BA$!6""5/A /TB!$]P %%1 ]AE!$YA 5&3 #:RK$7P
M!RR 5MGE5UD!TN% +JS!ZQ$!@D0"!R"1$7Q!*<37U/K ($3"(+R"5G5!*)3M
M() *!W1(!O0!Y:@D#HA8&IC"#0Q"5FG5!N  T>7 "%Q AWS!!52 !7R %*A
M( @T"<BM$N6,HOY8/\&30YR)G1PGPB!JH P)IG[,<M*(&L6TPE#,KQ6$I0JB
MN,&GCS02GSP:GT2:RSPQU#A9T'2)!+2/ER JD\RG()9IU-Q)"GL9R=T1Q[V)
M)!T<Z[KG(A9:)!J;0W U[\[*Q5U;IQ!,F@ 2!/^ 0Y(\Q"4BRI&L2YKD SXH
M \E9V9T\*/UR8[.D0BMP@R.\029\@@G 0BDDPS%T;RK40S)!P!W$02,TPA+T
M0"$D P4DTZSY@S T0B%\:)JX22/T$HRXBI/&]:\4 +_XF)4\"8+"2RE1D9%H
MVZS@,(;F]"R!TJ#M8A(/24\S,)5L3,ZPK@[247*Z*2>A+LPX9Z/*-!P]&:0M
MD:'BB)FHF4%TF0(\')85&4\ADL]H&U UW)"06<BU-J>4"A$G!,4],6W3"=UH
MRB8J'-(@RIA,!%HDQA?0 1V@0F=YPKIN <]E$ Y(P;1^0!]HU6A6 "IP@%MM
MP1:@@F'L5P7<0"3LLP__$%^'F8 '+,#:V(0$F$!F1@(5A,(7,,HD<) GY-PG
MV $.G*/L:,X*#)0$U!!0%%A4? %[58#W.8',IJUB#,((6 $JE (J$WF1;P;A
M;<(F'$"2A]YF- ]JH-;",I5RC0;J*49T92QC0*PQ-T8()+.14X8$5  4I$$5
M: ( X( U2T$5++0@O )>^8<.E*,.Y'@_=,L7?,7H6 $'D(.(<8#LI '*AI 8
MK, "3$(<<, @>( $+  .)$$_?,'IR,2'U,$K?(#> #D'6$$.?  \9@ =;, 6
M?$ 2A)4T7SISW  E2+B!)T%AA=862/@1]1]INZ<+E[;@;F+-<$D&E\LAV>X!
M_[L3CUA$I '42<W@111[2D]2&\U("4>$1M 1Q00WG]@TF:5)#:BBFR84RJ@;
M'NU3%JT;"$_ 3\\3TSS*E@B,>@;CH+4@HHV1;A.<P%RBC"P@3+71K^_BDQR[
M.SE1GNXP4S4"/LS@4>E3FO2# AB /MC -NX,O1#90#S!*S2\J]$(P+0IFJF+
M0X2 L%#)N03B,"YP&RV"\TJ1.?5BOF,B\#YQ"8.\6B-@?"I5C7C*!4O\ L_(
M0A'W!%PB QN*W0KAL^L9&]FN*.Y)..%3YV:$"!2)"/28@F;GX2;+;^KI#(+@
M<.[M!K<\!O,;K$@2W[ZWI4S;QVG1(@G-MQ<)UL#31?^IFYN \$7)$U/YB0]$
M A2TY ?003VL %P803?KQ05\0!P4>A](0 9]E0DY9%,D@70 >0Y@2!W\>1Q$
M@BGH 0%Y@->:P.GD\TL(0A!X0 U)A0K(SA;H@05 @0I\6.DL0!)XIS-4@!VX
MU0UD@!YL  ?,E0JT;0[ Y.X 0!.,4"A;%Y@#?_ GA\(JK#!KAB+81@@@C_)
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M(@V8TL,&UC""/FRA"W\R@29"Y0,IK.$#IAJ!*3)0!T].HA^#P,$7X, J%6
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M80U6B\3*5A"$)DR" WL#P"1&H()/W  *0R.)%3A )RCD0 4ZR &S*W#)?JS
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MLEC[7E!Q55^P$0=4QKY=F.>1@Z_I"-Q&,G'_,3] (:BA]&""-K7-"C#@ YH
M  3!%"(!#H8&!C( H00!"JP@#2J (?SA"O0D%#A@95Y!(_K@HI0EJSI& *T
M"C( "H;%$#K&"88"#N)@ P0A"$P@R/1@"P1"T9(I;L1  \6 ""!@ T8  ^H!
M!C! !;:@'XP@XX*@7IS@$U#A!A@BV)X0"J-0"KNE#?X "5*@!Z(@#Q0! GY
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MQ.W*2S94;/'4L8.0X[5<;XNZ\;BVKGZ*XP4,H!%4+'/49S<4 !>F(RJ (T4
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M[+3B-8Z$)R_ HHTZX_78;HI0@Q]A*S!>X#1@C"/G9_U>CUT-TRO\9RER3SE
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MOL #C+ "M@ :1P 53 $'3 %#OX!H2F(#Z !H1F )I"!O]$A_H::TH/)4.1*
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M 4!_KL %=$99\D0,7  #^J$)]& !*, (;FD$,AT*$FD!F!W=JN#_XJ#%DSC
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M$$7LX\PAEI&9JD10/PX6P@WRQTCZR98>+:B?1[YG@AK<Y(!$P"55:M-4#02
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MM0 23.(='.#I#8CPUB1LP;D9X, &^K&$&RS<(R8@1\YOT(]!1(\#1!A!#D:
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M@@N9E"L8.%%D1AY:0!H3H(-:$ +OT4EH=!X6E4$'TVB-ABLFF&AN@E#*I"I
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M@ ]MADH, HL LFG4]"M_E$>LPB^^)IWO@9F[E![Y0A^U5BWFU$>N*'X#^DG
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M!5M@J5)P%\GW 18@$!MPE2"SX'9_]T41 H_C.(W3.!19 -RP!X?3%'L0!A#
M U&@WP# 6%& !6"0!U?1K*35%5\1%I./]P#0X$$Q%J]PER,@!OWP\Q@ !3FP
M!BZ0!C1%!=8=7Q]P SX  *9 -H Q$/DP"#Z@Q'40"2[7#X^!J4B</G  E/U
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MKI& RLDK;*F8'O901;SIDID4K:<R\6@RL6E.8M+40\1D:"?/5B<X(]VC,BG
MWR/2D);H'2((L$<GS@,3B#H)R)Q4Z=XK0LR/)J1)E3_[02G7='RQS2A-KE4"
M -""9"]0V0Q8@6=2V (5*K#=##3A,'K00QK6\ $C-($$"\":'3;PBBO4 5=5
MZ-D2]& !39#@"GVPP4%L %P."(($?M@ #I9@ Q54P+0;R$<?G-N$HDE@$#@@
M1STH< ,]+& !3=@NJ#:0@<ENX0,9D (4[""%--#K756P0@8H$"RY'=;RE\=\
MYK_*C3$,%@!"X('%]L6#C0FKL&DE+"3_T) "183 ]8H @1H\;_J[YL%>'3M
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MR &_T8,)H()7P("I\CDK^"?V\X!!6(%7D"T,P( @Z(,J2(+R"P4J&(1!T 4
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M?&D8D#D +HA?ZS48H'2!-8B7#0  #K""!<P!*." "]"!"E"!)@@"'' ;#L"
M?MB +FB""G !><F!"(:#00@'"=X6,6BM+=B""G""*Z"'80%!%/8!*>B')D"Z
M#! #*M 4'.B"%<"!^>N#>JB 3Y@M&K8 '.@#JW&"&] $(J"""]! 00"5$?B
M)." =V@<85D/1O%(OR4@_\TAG58HL3BP@3OXG$Q,A3EXQ22XC2)!0=Z)@R!0
M0@CX,!Q0'7)0G5*XG214!<[)G0^30B'ALS.3PO>!1-B0V%ELPR68@#'TG%R(
M 1R+@ZF0(-))0>/!(LZ1X^7AA%>P,'V( T'P8E!,B$UT()QX@5&PQ>"(PC>
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M,"SKKSHS "/8=#CUG$'XBD,(AR"P."AY 7V+@1B0@\X)-.78U5ZYQ_O9T^C
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M$7IP=Q.:512:HWCG:%HX:A/>R/:#F$L \($MD&P.< (K<($ =8(* &!!P(#
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MA"N,Q&*8VT+W( " 0?BC'T+P!SCZ 0=T):$"1!M!&4K+@>RE2W<JJ(,>C+"
M('B L!?HAP\R< $=0"$0][/##3! "<$"( ,P@(@41$NYZ5*WNM:]+G:5EI&C
M80YS.SB Y)Y6 $4HHG%GXX'?EB8$2&PB#)ACV@GVL#04F%=I(0 !&<@0A3 P
MK0=("('2>I#>[%;-<I1[A0MP9X<N ( <=:#M_Q(R4 %3Z($*?=@ +7!'M"X
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M@^SAR%Q8YCW=IO9;M@W17FEE6M-4J#^ Q:&&+DI4KUI41?VA3%#E:4@W$M4
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M!^&/V'L)K/[UL[_]50O!#K+F-Q <+FJ#.P :CI8V)"0N:2 HP1]<PX A30A
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MC:#'3W&F/F]*035F36FE",1 4\GKS (39H)+P8[()Z/=O4**T7I%W(K6%13
M%QA!%=2!$ZQ!$!!!$]R+]AF,'?3#CYF"/W1!!H@P=U[ *7A$'Q0A%4\ %:S
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MU+0!%GP-_?*H9$<\"/ #&:@! 1<\ (1VU4B $5R %5C!!A1 ?T*!"NA!!JA
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M#?*&@I6\^C8W*6%),"+BAGRT!2,A2(D""L$;7!A "PX)@>Y.F]?<%2(8P3!
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M&PP@*$$WT\3..I%AG,8<P[.535!N&Q2AH.0J>M)@!S6FX0-KF-4&DM!%08S
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M?(:TTD[M_S#O<JYF-*XB-BHP+5@F+R*H*AAO;^A";JYBFQRF"_3@!JC@!BJ
M Y*@"AS$")9@!0RA#D; ",J@#W(.J((@"([E W!@GU[!13ZA I)@ 3C ![I@
M$DKA%0"@,5J.. I  D)A YR "MK, W( !E#$:'X*!P+I NJ ".AL"P;! P;A
MJ52@#^XL#2R@I *&5J@@5L*L'RJ*BZAEW_001T* 4K*$'_0- +@A"L! UX8)
M#   4O1-")H)#!1!UXBIU>J-1D;)3PZ '[S)F\!@3EI-"!#!$16A3LS@G9"I
M1D0)EUH-"RQ%$1311H2 "6 Q%O,@%L,MUT+@%K$$#4* $\DIF/\ @ >(B9Z6
M#=IVJ9?T[9AJ$0#: !("<49V !'4P)4@94_VL!H%I=] :0$N8%U&H Z$0#G\
M@$3L8#V<  IN0 H6P ,,(59,P1]V< GV@P,H@>=N9D6VP,RJ( APP B<( @\
M@ H:89O>),YHA!4&@0/@@ .:P B,P!1N8 0J0!?J402(  /*ZB"[P @&00*V
M8 3(8>060 ]T0 SJP 4^  H"R0D^H +2:J4 8"F$:S,F O54C[=$PS74;[E8
M8\5>B">8"P*P@L/RJK?ZZB841SA.8VHR#.SVAH, !V+B C7DKG%H@B9,@\.&
M R[B8@%C8&QPB"C23X2,Z^KPZFUB$C/_B%*N;F(".(AGNN['>.)F($-M[B8J
MWLN#(*NO%H>O2 ; JC*W\L:]2&\H=$+UBNMEEDNY[,NWR+*Z"B &M("\RLMS
M"D$+6,$!;*#P)B(?\F$1W* 0]&$.7"(8E,$@#D^U#G/'=%(K?\-P_)(Q+P>_
M+$@O<[+P>&OU6HQBQD*Y9,N$MD9[0,QXQH(PLG(UR\<LA5(S?\,LGX\GG/,G
M<_,TNG+P0 LS($!_R-)BDI(AU$8OJV(XX>ZM@F8 OZXR>F/QGE)ZJ.("=8MD
MWB]Z5FQ]?*LL9ZO%% ]JT.(MZ+/Q4@( 5LH']( .Z" #QC&(5 "+_,P0-N ^
M^D 3C& 2P(&+_VZ  U1 $%9 ,V9D"_+H YQ #P*4#DB@%$J!1O"-1G*J"06A
M#HP !Z3 H@BF'OWA%>H "CAA!+@L"2:!XSR@#&2%!*;J0/JQI.P@'Z%@T%9$
M$*S #LZ1((O-&O404EH)1X9I$S2Q 'A@$FVIF[*D35H-$6I1"&[Q2VYQ3$LT
M2[-$4G:@!-!-2O>A2X0D"KRI&7$*1WA1&?_ $OTDGT)%"'@)!4J !G;M *!D
MG68DU6IDUFKMUE"-V*0DVFYD&?>!H 1J$^3422W5H&:@BY2H5:#@ M(@ RQ@
M RY !:0@ S1A P2!!9T 51?@$*Z@#K9 "I;H!LKC%;H@'_JA#RI@!/^"8!*V
MP (R8 /(P08V  Y^RD:X11=>(40$H0FZP +$(!!&  <6X!5TX10\X K0 P8S
M  =6X*HD  ,T 0IP0!""(%HS(!!4  HLX#HRP F6P ;\<^KP\V=BJ"^T3V0^
M*P2]TVUH"_&0IRE$2_[H#_ML8L5LH[ZV9N[:JWD8Q[\JS"X&B\0\#X5L*(,B
MJ\14[  ;:"Z6[S3[-3]);##2;O$<1S$UHRE(ENU40RD:$+)J2(+X"BATHGL"
MAP1!]CTA)R@$]F/);NQ0CWFH)A^T0!EP 1B@RP Z9P[P01D*H1 FH1",=B"(
MKW.(KS)9X0E"]O.21_L.;RY&!GOVJX401_/_;-9QC$MF(T?Y,.()M& 1M$ +
MKL \@V-HG@=FPI-RQH)Z"-8H*<BP&.)CQ!;Z\$I[^-:R& <H-=8V3$P_A6SL
MYH<L!N,M:P)CO:?]%O:U\/,PMB[TA"<I+JQBV78F&??"/&@F/,,H';=ZC"=K
MJ,NO+N-TB:,&^N$*5.!3K6,)H, 4TJ"CND 0C" #@L 4DJ +ON 5)B$-F@ B
M'[0?5N *=LBITL #@M4(- $_/" <G/!8UPH %H#--H!>*J +FL #TJ ";FXE
MX(!!]""/E'?.-$$72.!!,L (ND ,!C0#,D %E@,#,L BEV!&$FD-UL"3+M5)
M^12@;D37WD1&\(27_Q+%4!Y15 @%5,JTU2ZXH,KI ,S@#[# VLR-U^AIE2KQ
M3RQ13UT1$AQQ47A-$A>1F-+I%A$%!/8@&;EAEW"$!Y+Q@'FX5"2  D;@$SY!
M# "@"BY@"52 $X#(#@(AC#;@"OPH5JB@0-)1#(C. [8@S.! $[I@FYJ@8)P@
M"4S!"*B@"K:  SP  CB !" @,U^A#R" >F4E _3 "3A@!0PFRA; !S1AKRS@
M5IS@ IR )^+ !G  (M,  V2*$ 2!K&X@DO:W"KY%"+;C)1^7?'XF=EOS<;GB
M^MZS-SIW_\@&-0R/AFRB([!"OKYR]21W[C!0)]=R/"O#,H0V:V1F-4BF'_]$
MP ;PCBIW2W",DOXTXVFL!GZ81BH)RV5]+&=4"Y7IZ@7,9@90(RS9YFCHDV6>
M(GL,0\=@RSA%K&25<_*Z.?Y\@S>'<IQ_8OU^6:X4$\.8(NL*US?B#_E>H C>
M5FJGU@#,Z[R4H9_?M@9LQF>8\RR)RZ_L2F\)#/6XN2YJC+C<.38;8GD83*X8
M(1@F01F.(1:@P+#D>9.[SS3,V9LWF2KD<L(*0YHQR+]4IG'64BK<TRVDF6EZ
MF;!\,C/^DB@$[#T;)RX+XP5JX'^&DR: AS#>2W#:LC$48 :$LF*TPBP6Z'5%
MJRZPYFW.0K]PR"SZYCZK[F>[ I[GZC?"D_1@"P#_HN0+C" 7, ")8R4-@F )
M/B1\K2 -J@ <)L%'^T"0B< 0RI<$! $+A< &M@ #%J .., .SK@"H( #TK$/
MG.9_WEB-,6!"RV +* &-%]0&%L $=*$.%H $M@!?5. "., $0LH$]""(<, "
MR*4?MP"(5" (1G4+D@H MM$*=&!;>CBW=7NW+=76?JD-2J!2=>0170$-(*
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M-M0'@QYR'/R4*66*U21=I2:)X? !AXH^'C)4J)"F'RL237!4V #!0R0C'ZI
MP6%AMO\4*!QN&/G2A(B@TVDP)'&2P0=;S!:@%3HTT1D "B[(8(,./@AAA!).
M2&&%%EZ(888:-L@-&0<<8 8$KFPBPH8\5 ) ""DH4L"$;>S 1(Q,K!AA&SPP
M 0(3>82A2(1"_$"&&2((P0,D9H01(9!1E+B#D2AN"*6$CT0)  1;U!&$%'
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MO1L*AU5?]$%$(!MPX)D4RZ\I!0"38+"!$TML@,,6IFR@B=GX  .V\@&5#HC
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M +X, L$U% 2"%3((OA#F;_ AM(,<XG<'42A!"$?_ T28(05$(@,(43_>5^0
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M!'9G!$O  9/@ 3 H!+JP L=C"CAP6=W'/'&4!O.S)EL79C'8!U?P6E)P=X)
M!??G 1X@!4: =5]D@/[@ Y$@*'#D ;I@!'K@!$G  7J@6S@0@S$   4P$A(S
M& 17$ K %0D5-_-RC6?!%U4!.I !GG_C4#QC%N#P_P(*UQ(/^%1_DS9@PQ)
M<3<S,3-\$4T-4W,]$7*X]DZO-IY=A2P\DU;BXA&!D1<M<6NX!J&W=FN<]@)D
MH0 *AXP,,X1YM8CD^!*M%G+]^3$]*&[C=FBTUFS)LFT\-U<?*C#6-FR7F#(K
M.I\W8W,$ZC+<1FRM5#/2<E;&9J*#R(B<2&H/@5 RXVYPDU)GH2\;U3D$<31U
M%1.,( OZ8*6A$ 1JP0V)\ F"DYYXB!AXH2RDR% 0@S,]$Q$ 6B\M416;9J$L
MH0 0BFLA:E2& W0.QS-$PU9?RC:3AFLQ( )$D:=X:!/=A"[Z!!;)Y!:<6&BS
M9$]\P17B&1FATVRKA%</D?\7<UHQ=TINX/D2?05Q)E-N]=F$/S,4 ) /1U<!
MIF$('.!F1H @U15WDR4!'+ $-X #KW (@] :T.DE<. "'A ?5\ *-C !)E &
MW:4FGP #@O()]0 K,& %"&@$I;!9,_ %,P!^)* '1) !A^ !)! )FA */F #
MRJ,)@@ .<4 .GW #:5!W7Y0!@D $'K"J%= $!;  %  %5H"O#$)Z@RFP QM>
M(? #!TL#/[ BBK BST<AW  )4HD$+2($ /8@/1"Q_+!#!= #$V1#KN A4GD
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M%O]++,ISPZ3_\CT_+0A7NP61V&CT 4RF L]I"OZP 1_@ W6TE QH!5  10M
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M?HP0I)\-,KB! RG_+.A'##LX@*(*,;8PPA0 -"EEDB5\H%**)@;AX-$K( #
M!"T 74"020 M -!:;<TG1G^N>"4('YK LH])/-C@BE!> :")'#:PHPH5/,B
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MA3*4$0X_X U=@1-*2%":/P@P-6WSZ2EP>G,6<#AG/WP-'.!84YY[9HXC %
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M#1B(+P@%2=,#4_" (' "4Z@"*3 "4UH!&XA!/1@$+7)#)0D%(_]!+"@@!Q.
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M#@&4),$!#'""0! $4T@#%?B6#?"'29B$I-@ "NB#)AB!#Q #%!'3.B"" )D
M%/2)BTT_C?5=J$,7DAI&PU"[E,S8P?N7:BL:@F:79D:<]),O[Q!>GP$WBUV:
M"9@8$4@"CN"(B2C!I\#RWV ;UKCRBWK(\^Q6??R-AB0"=9#9??7FM7-7N?^D
M26NFJ7<!:*4-:9,5CX0MSX6VR(S,N8+^&W\<V*<".KA9V++2NHAK"C+OBIC%
MROX8.WNU9D/W9X.UV+OIY@"2.6G.V?]Q6N'5V(\+.4!/9FG>6;W+<0926# ?
MO+_11JZ)]*<B]5PF<V!N<T>W9OT)/QV_NYRMNIADV9^$=<.)RJ T.9ECV7M%
M66;WY([\Y_)<]B<0A9+HVLR"AE XAD&(B"> !CI("LN2@,P#+7HX!GJ@ Q/@
M/:)@!'=PO2=PA%!HA$;XA4+ !7EO!">0K6,(AA;DC=;,]@/+/:$(W% @!1:S
MK'[ =GJH]DRH@E?@/'_PS&P?!#CP -Z; !)@!'K_4(98N/<@T N%(_61<@Z&
MR!K^43RWT/2N^0RH0$@VY_4B5S8J7[S@+3EP#M:LBT[74(".:- F$ 0/X8!!
MT80T: )7885!Z((*'00*4($,$*0,4 $CP/ #C(%1)(U7N"(GJ ,CLP IVP(,
M, 4'YJ7[7H(,VP(\-(%\*(4^&.T%@(/Y='I/R@ + +(JZ(,K.#) <> E& $=
M,(4-.,4F6((ZJ(,8<8(,8,- $"(9$8+O?GS(C_PE%>$^LI%!&8$K 0 CX !2
M3"$B@ (G,($+H$0AH.,KC ,+S8(JR((T\@0Q^( FH(73/(0O&#$J* ,?V((/
MX( MYOQ7P.E($ 1G@! 0_\(!*5B#*O"'00@08/J"$.B'0? $+*J#'*B"0-"#
M/H "X6X4(Z"P*O*$%:@#0M @*NB#+#"P4^B'&OE%JW@%8*ZGML2ZMZ.YZ, 9
MF%)HG$2@LMJ-E4/89R\K@)#@#P(X?Q(@+( P,.% A /!39CP8L:K"1 .-O2G
M$:%#""(V&I2 $<*$B@<93A@X4(1 D/X^'O0(P6/+EPP/PE0IXB)!2H]()(2I
M$*- A#L7//2(%*-%@S,7B$!JU*"_E!RC#IT)CJ/3H%(3<FTZ<NM4@B^++IQ9
ME:/2HPJM%MWJ=&!1K!T+\AR:5BY1A2RS8HV:=B[2OW.)JA08-['"MWJO(A7[
MV/^I4,%,'T,%*[6@T*I)L:X%';=QS*^5O2I]+/:SUYQ].S:U>#=MQZ^.G5Z=
M^_0M7<"V.T[M>WBVPY-*%YY]2=ET[86=X0ZT>AMC0H;-';*D:P*I5*<SSG(5
MW#CMBWY#^ZG,F]Z\1JH8TV>>0B)]0P@UEC9N;+Z[0MQ37B6V7T0R2(!>;N.M
ME1EC!XE4T@L3'%104^.-]))1%9XT7'4=I<=75BI%]$)%/-U4E&/=%;6931&]
M!T ,_?B@!Q$<E+*!'5=XXH0@=E001#^3&.$#"49LT,\&'T@Q0A5!7)!!&8(
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M3WJX009N]?\)*WS "67H1YL&D0$<V*! '.@'NS80BB;0N D;N("EC+6%&XQ
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MP9+=P 4(P@84C))P  Z$@KDT@2ED7P5P@#(MP18(@@]P0#U@@ <%01-PP"#
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M%_2#%;1F']R)!52!'Y2!& 'L!7! D?#EPC)LPSHLG/EEJD! '[12%5C!!@!
M'2C)!J1!KFW #-F /S2!'7@ !42,I0Q"/WS!!KQ"$$11DW2F#7S!%_C#%=R
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MI!D'7( 11,H&:,(,-%LD69K*4L$53$*Q<,#!<%H&)* /3$(&2$&Y6O*6\"L
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M@*4H=+!V6IGH@1A(P ;HG@WI@A3$ ,#\F2;8@2$?@BF+ 25L@"E(0;W :PX
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MJ& #N!5#!:0@!BF\8A+!O4(0I) &$ABA"E((Q49KJPDQU%8/4- #="WK 5/
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M"DXB"/1@<P1#!8P Z4A@"YR@#IP "D@1!JH@"(XK YJ@"R3  VJR"Z1@ 2C
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MI(LZ9&_C9%)V: J7EL[<HXO.I#XRLT<<N@;^[,\"#3PG\SVGR&FG2)RI1,G
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M" R3%5.]7#F>?E0KBT.IE3=#@:U;)-D[1+0VK+<YULO7UHO9R(L/ :R#1(
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M152#K++."A)!M:JT4*ZV7K32K;WJVE*OL+X*K*RX'GM021KA:I&O(=&Z[++
MSCHMLKT:^ZNUT!(+$K; _RJA$K4#341LL2N5N]*TWFJK+47);BNM0?0*^ZI
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M<X +1.D&&&AJAH<+DU@ QZ /^F Y]E&/__J@>#TYEF19EF9YECCI?XV 9,H
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4+/NR,!NS,HL@+CNS-GNS&!L0 #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g124762lm01i001.gif
<DESCRIPTION>G124762LM01I001.GIF
<TEXT>
begin 644 g124762lm01i001.gif
M1TE&.#=AIP,!!G<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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M=^_]]^"'+_[XY)=O_OGHIZ_^^NRW[_[[\,<O__STUV___?CGK__^_/?O__\
M#*  !TC  AKP@ A,H (7R, &.O"!IXN !"4(@ E2T((1J* %-8C!#GKP@Q)$
MP#0L6  ,EI"$(P2A"D'H@!1*L(46A.$$'X")%=JP@YXXA@5SN$,=3I"'/_3A
M#?^'Z(,:3M '/K @$I68Q"$2L8D27.($,>$)"QZCBDZ\X16MB$4);G&*7<RB
M"J>! 0N2T8QEG. 9U9A&,8XQ 6:$HQH18$8ZNG&%'+S@!C&8QSMZ4(06!.0$
M!2G!$T[0D'Z,@ Q?Z$)%-G*1CDSD!VG8PTH&49(>!*($-1F!(C(1DQV48A2A
MV$E2BC("5,3D%[T8QE5&P)6N!"4J'X#&6K)1EK:4X!IU*4=>XG*/P)Q@'_LH
M3#X:,Y"-E&4!]&'!!#32F21DYB\CT (A4M.:E)P@)&7I"2-NTIL1Z.8.P2G.
M:7KB"4H$IR>G2$I9IA*,7+3@.W\Y3U2&L9['H.4TC^'_@ GJ8QK]E. _ QJ!
M@?H3H-,L*"+U84>!]K*@#\7E,(]9S(0B0)J%Q&@$EMG,9R;3C="<8#4M.%*1
M6K.DO^1D.;\YSH2N-)SD1.<1P>E.4F+"IO=L93O=6,^>YE2>893E-/3I1:(:
M5* (G:8^%LI4"S(TH1FDJ!XKFL&S($ _5WU.5@>R58%T%8)@#:M8QTK6LIKU
MK&A-JUK7RM:VNO6M<(VK7.=*U[K:]:YXS:M>]\K7OOKUKZ,I@@^^"MC"&K9>
M#3!! A B@0-@ "0-@,!CMQ<".VC"$ULMQ3S4D(\ Y&,..?!! DKQ",YZ=A^2
MD(() $!:?GC6LW.8PR$6"X 0_Q3"$(,MB #D08C.^G8.DN!#(G) @8&,  R&
M6,((2OO:S\[!#0UX1&]A.X<^4&"K"WC$%)Y VQ'(0PVPY8<9VO#8$6RA$\V-
M[2LDL 4>>""K B@"#FA A.G^5A(Z*$$6#G'5!I3 %ZZM[G4%(H .#$(-L07$
M$FA[$ 3(8A$HP$ F<*"#R0J@"EG000$ <( 2#"(  9!$(WI 6.E=&+RH,,!
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MCZ#$ \B]Y>4"8NH%&4$Q2$$! 1 X$\F]:@6<GH<NH**\6VC$$@:273I0P+P
MS[JA@0T 1?. #P??0K\SWH81L  0^19(8H.   & (0MX%\@!)-OJ#BP"#89?
MA!%47H +WUH"8/B#( @261,PW7F*-L,#%C (90ODQZ1@>=VK4 945+D1?."
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M42"9A)H6*I:HC/_:J([ZJ)#J+5J7#_O@HOD0E2%P#D8) -E@!@Y062_:67.
M"DU68!XH"3"@AC&@F7Z0?P!0 83@J5=U8;Z0#!*PF^ U!>]97O)@B,)WAPSG
M!7KWEE6@8/$F#SJ0<PN@"*[J?"BPDC  "I?&8!6@!<I8$,N*A'/ #YK !S7
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M6P.G &W(7BBP"6SPKUWY:ML;@RR@ 4F 9^I7:'=8 1K@ =]:![W& 7_G!2S
MF1M6 ?U; &#@L2/P 1LPBT3PC T0!E\L$.SJOZ26 ;2FG9R)  L@!G4@ 3>0
M 7R0!Y. "'\0C!R S5BG !F@ P@0 T; :QQ !']0<0=;S@_\ ASPS1 V !Q
M6PJ*".S\ <H,!2X;?V(@LP-<!E=7=T5P!'P  1PP!(M IN![=U\@GX!  26
M!3 09F1P!<=V /:9#H&0T5>0 !$=>Y. ?])6:M%W!1L]9P=0!6K0M .\"'S_
M$ N1]@H.A@7 =H!4Z62)H ,<  I@<&6RD 7^602$.PI.@($"H )KT 864,^!
M4 L( +@K760. +@V" !PVP*A1P,F$ .*X*G9@(&FJ0,Y1@1E0&N5!0-7, E8
M75F'P &T& CZ6'?5@)J<Z@2:,'6 ZPEQ/!"=^@"C@ ,H$,@Y0&*LJ0@I< 77
MF]@ \,>';0&"W --]JM78 *@H ALMLAXAF9?  "CD 4H< 6PFP,>8 #"Q[,
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M&H2!/2Y*1SHN< 7^B8UK%O)/!SQBF/]]]:L!8*"$=0XPBN6%+0"DZ(^A*%&
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MNOL2"=#:#CU%5BCY6*<!SOY"$0#:D.Q(@ AL2,( H( (#5# V?!; .4? !I
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M(+..TT"2L!,<\)8J\ 4IT)-0T0'.H85U BU"&@RGB8S.08 <Z0,*2)[$* ]
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MD')%6%N!$+L!((,!.-M!,(2+$PNRH&F8:%M/XL N5W(Y#Q6QXP PF,W'48!
MD 0T4XE4(A0)\8!28(')\ (<Q27#>"8OD D6D)0<T8 DN (E?^[E? X6F(/\
M^3,H4().(0.$#*_\;+-&P9X/8(,)*O,K.-,/FO4!V(4C.,@<*8.KE+4-X ,(
M&'31X( !,()%H)XOJ";OJ  CT !,_X!%. 3NB@_1B',EZ,H/^G6.:  D&(!/
M:,TKN(+DZ('RP(%X)*]+V (>.(X\4((0,@ER_0,:L  H. (ID  ;:$TO@ (C
MR (^B(5PUS4ON ()J,NO='<.F(1\!\G_#K #H,40!8%>.*GQ*I!W>02#^>:
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MPH*!)]KQ1S(,!:DA_RDO()&(@3+5 $:()?O7"<D9!MECGV"0LFA71 E@9$9
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MF2A 1QGY8 @YH+,6#.F$2CLH0H^FDS\L@@2%,$.;0A *)^0C  %H!)0*H88
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M/@G<CC#-N 7)D#38O"4BO9V#J G%_0% %4R!#P@*H9S2.<!-S]1-50@ )/(
M4;#?IJ@% M!4%YA!#UC;FGG-(5@;!&I$%?2!BX!!'Q +*1U!!B0!&0S!OR&!
M%NR< AS!(.3 Y+! XRR( =Z1*<5 %BA*8PS6(#T3"VA $GA!"302<HB&Z-S
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M#0R$Q<J@ C-E@N142A7\@;.:!<8QQLHAV9(V1Y->BW-<%:("PBX$:62@6:P
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MC6P;T)TL"$ #&VC@BTZ,RT'L=H# H:P#=1C:<N2B@0:J0 DZR ,;M,8U2KP
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M3E< ,'0.CZ^C 6DXP )*#.D 1M%:"-QE%,DLH%4%\*0E<P>KXZGREJW;B?5
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ME6(+G=BSIELT AN^" TI"YCO<=*U7=AL2$G3 02&X(I\Z@ )I8Y4(-S=!X[
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MR S(T.(%/ K&N7)""CA "\8+K[K #):@!/K@_O)3V1A" 71M7!($%-@ #6)
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M_UJ2;M$@D@QQM3XP$RH&*<FG"]G+F]XU$S0H >1"M-;#"]QC%%IT"4+@"%+
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M$D ! @% _Z/CJDH"HKKR5>PP"93 [,%-<!#D[Z9 #Z(XFPY[ZS6A]8*7$.8
M$/B@(_Z>'_Q@"E: <0F_$S(PSXJ;:)*$6Y  Q1/..G[T58 DSN?&%YP@E7$#
MV[9^\;V "$+.ZU8@NN+- ]8M S.0G^;&V%+Y6-=&"8 E<=G4R)?@-*]7"B;"
M;50BTW+@8&!S:SAG2**:3N.B >? ZZ!$_+I\#C+0Z[A'XXSN'N: $OKEO8I@
MDAS#6D A%/+AZ/)A"HHBY)2P,,5Y[?\ A-:9)UA-ET; 'K3M\AE# 0!BC2<
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MD4PIC^B Q"23#"+% %<(58$=DCPA0)F3%)+F #EA!, H7>APA6(Y] "6(1Y
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MP<9&U3@3T*8!'!B $AY&!E"(X5\!RX .)- NB,'K"@<84 6,D*\.MN$_^;)
MN%Z!@06 @5X FT@A5%."L)&,@IZ 3AD 4<7_(OBB7I%)AQ0D0 0V"*D!1=
MP!S$QC+PH(H:3%D>E$#&B,21!P,900F<P$?A%4)#'8@;L]8D"T*0XBCT(44+
MIF<W1.# !^V[0JKFUH7Y#4"2>=.1 .+1"3-8ITUF>*-!"J ".^C ;F 0W)->
M"<M8ZB@;AH@>0<2$"@3(PA>^2 9D*M %)[@!EY"Q$BH$D!DN? **!!G!(]R
M&6<&!RS0;.86I*""01!"=7GB00\JP(9!78L%M, ,05C5!G-6 1 #.$(ZE30"
M>:#@* O0 @JH%!DMT, J,6!#&U1P!#]42R-*\,4K++ %&/R*!79HA%GZF80-
M(&9 P)IH/$A "]HL_T ,$ZU2:[HF "*LP <+"(.O"!*;B994H3KJ  %(0( U
M?J .T5O !W0 @0]DX(T*<(Y5;,HRI-A@.?YZ8S.)H(&NA4 ,4L! %;2P!*0:
M%4-$Z /3)D)3'2V@J@5 PB< L=,&?. ,!F/#&VU*"5!@P0<'J()]FEF"/IC
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M'B@!)5IP %9;1S%2: &:_Y-$\QC(.=**S9P:_M#7!YVCDZ<U7 QD&Q%9@%8
MW;EL*10A!3!PTT%6FLDY[7 (6#'J()"C^H!P.U7;4ET M'U4/#5=I=A5Z9D&
M",%O!X3+*DBIT54Z6WASY,RJ:*2XA">(TET-@"HT8A+%[?B OH<$+>Q@$!@I
MU!*4KBX'R2)=5!H%(':A[&L5P5 U8 %BF,V%(?B32OWT0#UQ58)%J(M<%YA$
MN[TT##@(900W2($)U$W[#5Q #-MV3>9-&)'8R(?=%S#"AX=]@PVXB%T<'GC!
M51SWB"A W"W3B+A/6 -_ W$1>C@0$HCP!Z@200O1.]DA;+"!*WR@J4?3 @$6
MT?\#-7!^$@<'^V9Y$M$!6L '5941!=('CN-)/.=S0%<"., +:P,=@' VCG5G
MF\ &.] %3Q!BC@0WAL.!CS<@7[-6$<&!GJ063U %.7 4Q+4+:P G5>!(;2<1
MD@9I/=B#V8!UE*83"$!+DY %M[8%?/!,GM8?>]>$W?0 3 AJG^:$"!"##U!Z
M.9 $;. %)6 HH^!-5(4;4X &Y8=.YL0J!& '-K$0;V).\:0#]/0(3B 5 2 )
M\=47;&@& 58!K:(%;0!$27 $)K8%)[%1;9 '_!)K%Z $TM&&P5%1/^5?DD@8
MH"$%NZ !!!1I!0<!+- );$B&+<,;:K 4<X 1"I !@'C_ QG0 Z@X7WWF'0$@
MB\V@ QUW !T0"&K@!U*P?3?PB:#A!WT 1)^X$%-0+<,!5>H1&EKV-;FXBPWD
M(%@A!GPP5!;P :^0!RS0 P;SB7/@C5Q!>225'WR6.<0X!_<P![5@%6+55!I$
M2:/@B/NPB^P#CU'Q'48E !P"&ON@(68#7 KP"#(X:)7X'120:%EWA%Z3#;(H
MBV\2$?% "%*B)*45::'0$?O@$F;@ !O1$0PAD:EE!N28):$P%@LA)0FQ$K(H
M2D*82WG75R'A$K*("DQXA4J2#3Q  :'67-4$%FK %'8H"+0A *5F2P#061<0
M%A[!7->"%IGG 2*R!&#8 Z:'_W0/P@:/D77N$@B_& ![6 !\\0>+L A=("PQ
M$#14(@O\DC8$:0;K%@,:T"]AD )'\6YP4$4(]@!O20LGU(=PD $TD ='@ :@
M4&%44@$E=$("0V"$<(ZY4937<@-U8!;008PVT0PH( '1 1HD,6X[LF]\]C(&
M)SMBT ?6J %18&(=( 8$\#%%@ -_0 *!\ =2< 7I< 8M4 (;$'-04 <"5)H?
ML#88D@E?%'[X$2 G(R1QX02-D21BU0<I G/TP0,#P 84\!^"R ?P"!H.D0,O
MX($4  9N$YXIT@7W(0"L%I4* 1KWJ'3F"39N-R&G!!8^$P.,\ "98 8O<$HJ
MT 6=!/\YDN6# ?HD49(D8B)H%8 #2R /R1 #/' )M*:3B1=-\C %?W 'OF &
MPT>%B8<!4DDEI4:=@A!/=$ $WD0E]+$GHAALYD1<%^!.C?<L0<4J%G9A+# _
M@9E?R48#1  ''& NA7AMOE)/;<!&@+ #QN)ZY1<9._13WW9A89"C**4%T(=2
M$N5"^7)',%"4I3!3X!9Y@S %=T"6M( $ T.._M(UJ"B:33-R(8>F?18R?*!#
M(2=4K8EQGK0)LE*5LI,.<) .NM-&0] '&# "-J %=24%DZ %,;=_,]<T?Z4S
M)R(@/!*F?^ +M3 U D<$"7F>:>8@7[-TPM-T(5:A@B8 %7#_#@#*:HKVGRQH
M"'1D@R52#-HP7?-@=G279P"0#=C 6@ J$7"G(W5'6N>0=ED$7'E73;E#=U,'
M>#H1@Y-V>11JH1@:/1(J.]&U) 90:I 'ADD078WW/1"@!?T"!E(P!(:B=.)T
M%:!'>X @B#>*7QGA3(  !P3 !R: %6P@7<(#"&W0>@B$H\N6"5TPK3FP>PA&
MEV!@?"HPI<D'!QR% 25  E%  E0* &5JL0+SL-?G246@?1C2I0$S,"KFI9!"
M?@/24TYFLD&1'Y-  #0 !3  !:W9!2NP Q?P!1*0%95Z$9WA*QI4@,]I&GRU
M)#M[!W^  [5 )5]C!*T6?>&S"('@_P>8NGI7P *'T 'L=3:0*GIL\ (AD @I
M0 0DN'3Y^%A*IZIY=IZA2FF*$*:+X MT@!!9$%J*0 =%D(.H=:JU):!]NR2E
M)ED+(%P H'6>D V-L$R>UD*HYI*_A 4P\#P5J"YB@@;1Y%P%0%S#4EE2  J<
MT -?,0A=8 9+4 6\*!'5D$<:\0BT8!6F-P!84(;P) \L=3_(5D_[E"=L4(8*
MX$^@H %&  <(I0,7! ,O<(A? 6$Y< $2I:0,-D_"\WNWQ*0K"U)5H %/4 KU
M%@-:$*6146^0$@;YXP5#< 1GP %AH&4EHE/ZMV+C5XNF00#&-1$VQD9)=7EM
M=!3_H67(N/\$^(NR?_I>2G"L>@1_>D!)FX %AX$ 3J,!UF%3+R>B(6,X;K4$
M?_5&[%@ Q5,%5&,WGS B7-L=<S01=+LD:XM8Q#4XCN4!>D*?"7D5P&2>DZ-F
MH'5A@79+-CR1@S!E.E@0(<G#.B(+K142\<.LNV8'>9,)'[EW46=,7_%WE"9<
MKX57@T +_ D')&.LQ>1<D %=>[DD"L )?&!.2<&Y_B22>Y<6%H< Q.4+.> #
M"N!.ON9<I2)L2)$)&G!?[^18AR  ]_-.>.6D=MS M=N ;, 6]Y,_B1.O=;E]
M>+D B,!2F7,J8K '7[D%79 # 0:^G2G)-!"R(!:99E$*>-E#SY'_'R5[8:<<
M6$>P 7V@8?;G0GW  >D 4WR0FWS01D;%1EF0!), !4CT!1"' 1)0 FLP!2H+
M9 -<(O71>YO48V!P(2I M!CB6'VS"^EPE45 "120"8U@!$)V-FC6@93@ !-A
M9B@"-O=Q: 50@DFW=&]&"DIZGF&3*D1@"#T0 YR006P6S_P9PV;@J'XKT*)W
MS\W:5[3D R$ "6^2.SH9:L-!"EAX+?+05,XT?1;-$T40-#S!.[10 Q:'&:/0
M"IH *(,0%'$BF"W#*H>  5CQN!;PATHJ$<66$>ADAJDG $"S!"'@3VE3!CKP
M L.0 D'J  T@!L(&(89P+$%%4>0'9/P%_RGP=A5IB1B;$*\- *7VDGO&!;(<
M2V'R6P5ZP <:U##RA@82@+ ]-'UZ%DY[\0%N.E-3U0 01T>+X 9'LP%\0-=P
MF@6K82+V(0$04'Y'8P=@=+&*8+!"959SEJA'( C<P0+U<B]-A32!]7,_$YP.
M] J$91J)4 L2@,#P*1&R@ 6250&*==I8DM.@%<0 JH,H&G4$(0NO2F.^ %L-
M8 ^"IB1E%VEZBX.L)=I(40VDX"(,1@I?6UNX"EM$<=S-! FZO5L5, BAMY.Y
MXE ($$^@91 :9K?R^DPU'5T'>!4E,&8:_ ?Q%6PRC2%;0";C"AGQ4 B:\!C-
MIBXF(F%5\ ?IE/^/77 (F?=ZS;8$MS?8HT "O9:/AHP!SX(K -X!&B!.S*8!
MMR;4=!E\^"H+), 6 F#5Q3L,;AD(P(%/)X,GLH!?%B"7J"P1V;=]GRPP/Q37
M3$+6+2WB=S102* $KBQ6*? "1-!0#X!_7K#7YX0(R2 @)(X"O)F_Y(',-AYU
M!R#8%_8)R-PM.E "?;W !Y,WW:&TB9$(KU "@#!8A,!'_MB" X)FC#2<9$MB
M1!""H)HD+KU&6303 A +ZRAVY?4(KZ "<L9L <!VD8.B4S;0@_YJA+ 4 8 *
M?-$?" I96V 4QN1I.\&4_2$F:QUY;IP[&9$[PN$9=#@%>QD"G-! !R#_#Z8&
M(82QBV88%J !%%^;E/NP$&,'AW(H%K*X#W307KBK$>6;!_[4&8Z!*#" 4,6[
M47O@)9JQ XTHBZ#1"Q0 +,0H"<9'428UV 7B$A=Q%-E;!Y((U1Y%&+#.#ZJP
M"*PH?OZ& 7G@$_P@+(0Z4]&#BOA )5)$B@'@&!BB'C(2[FW@O_CA&"4 53?0
M(5%A!H=0"K?1$4$#'W.G0;5P84 #, W@5@YL5_OQV'&2"*@>(,,Q8S85( ]R
M!,"5@;N0!=$S'"%8CU$Q!;$]PDGBCY(1()"A '8+"AVRCW[ H H!ZWM()4.Y
M[';(U09*>'2GP[U=6*K5 @G1$#;!#PP/*6#0_Q*.J1$D>8Z@40LAX9^%T)*[
MU;A^=ZR;+D72,0>BY$S'I#>FII.SLYZ@00>#_32$L8<8@$[@VI1<*!Q@D ./
ML6.@<3W"80.# !K  ??Z9!5P? :Y+L^CX M.H.Z*5[MI2D%*,)=UP0:' !U9
MI6!5A(N$@>V'N&Q5D 7!L?.G;A&O@!+?"T^AW-4\E0&8J9ELJ K'.A&! !I3
MH'@Q,(<O<0;!\\!1QA\&DXSVFSFZ&1$U$+Y1X KV4B"9W2T0 1\5?S+ )47B
M20CH: BP)7%P,F<\0 #DC 1J,P(QL(&=0)#&N GDC%*)$" <DO0YL!J?I!!1
M8?,J AIAOQH7JU@"@/_"5Y$).3  64!NCP 09@JHL,,O0( IM!  8-C0X4.(
M$25.I%C1XD6,$IDX6'BQ 80$&46.)%E29(,@(4U>%(!2I40!$ 5 "-)Q)<66
M-1DN&-#CYL0#('\.)5K4:,29)HZ*G(EAZ4.:2YO:;$B3:LD&)JXN=8DUY=.,
M71U*@+ 5K,0&-GRPA #AK$2S6*L\>5O7[EV\>?7NG1B7+UR& IB0\?O7\&'$
MB14O9MS8\4,!L0@_!EN#C%/*F35OYMS9\V?0H46/)EW:]&G4J56O9MW:]6O8
ML67/IEW;]FW<N77OYMW;M^T1Q0+L,YA/D@\%YWQTS&;&00@[Q(G[2?8P1"'_
M@W-(I*  X+H:@_RH2UC @E  0$M""HB1R,D<*5\65F#CP68(+6U4CEKTQXE!
MXB0YI($M4' J!B7>:X2"D!9X1 ?,8@#$"P06 ..\1OAXJ2$!D&#!B0 :40^
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M$1_-X!G=\\*39(4C#,21!%IX/-$@*91R2(%$#LK220"0V(*0.3)4J<5%MFU
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MD#[8A6##$2,@PA@(A#[P@O[;%2+HM7):K$E@ ^N;"!5(L<!HH3:8*@Y !!X
M!4; J(@HG1Q8EYZ)'S7LGN]!!D,@ /#Q'BYPGXE",$5@IP8KF(3:H%W  >9A
MJ'4IA4%XA7S_:T/K2+'FX," (89P28#F (5P^98RW H/@[C1&@3_F:H'>@'D
MVY!C>H0G^)@>,("(Z:E1@*"%4*&:BYBF<J.*\3[,N[X!^""GD"0]4Z$M$X '
ML1J\X0(B$)&KJ ! <+%L2(\%T*N&<PBB2X$;0:(!+ % X ,>:9:)2$8XXQ4-
M:(-"BR,<V8 V2"TXF 0C0 '4JC3U@J,1?+NN.X.= X 'K!T%, (T2*T-G(@&
M@$$9_( 8K"T\035;PX ;X#L 0#0?A @@7(L9'!4%2 <B7#Q%*Z8\P((GC$(.
MP16%G,(V##0Z\!M5.;TG.3U9\+TVX\+_RL(0XJ:=8(%&*($XG$.-_W,?>+3#
M+$B"<-D]"U.XW_NP(8F..7"5?-"$YR@$\& 40U@"JE" RWD=#$( ^BE*?IB"
M&+.0\Y@"2LD&'K"V@O& #4)*_LD/E<#*D-%%9)&'6U.JLV(#6L /6I!&/B!%
MU"("7W""*="!Z<,1^+,)M#+ 1_B/@V"F?1F&%+":4NB1[-@'36B#MP(;?Y$$
M,",2  &2[IA 1I,H)<BNIY.D1^,2 *E+#' [P!.TNT2"<GP7-YNZ*IF5$$')
M$1C(, D\#:" *C@<.#D(A'@%$VB1.,F./K" =$!!I( U0.O!=TDM0/@$0@ 0
M/X"\#G$/DT')72/"<BJ"UDL>VI.)"N#"2/\+A7L(@'L0#U+( WMARCMSK>\I
M *KPI@IK"&\RA"$P!% X/0?Q CNT@S]8A#LHA(&J$U)HGXBJ $9X@'RC@$.4
MJ(,2/8?(!G4!OG*K $[PA 'E* O028BQ@^6 " :-"7AY'49!J*=$D0 X#HCX
M&$]P$#=(@.6CF <("14JJ]I3 ]L, $WH ;&TB6S(@@L(!!@U",K)P$= ,K,T
M*ZR1!!!ZB%'(RX:@#P-4A-T$DH9+,AA0"@\K@WT8C@"H(:D!4;YI.JPYB#GP
M@R!1@0VH3  04\QL PD0-$\H3#6HTJA,.0U4':*[QR&!P")D 7>L$N!I!-9T
MS9D;2!,PG"7X@#C_01'4<8 _<9TYZ ,..$'#"HQ, K0/8*<JI(07"!W,D03<
M9 _GU#.8P,CH+,Y,H(3R5*AMRAEH6X)1V$U,,9C,,TG?<1W8>8#F"8\0H8!1
MP %0R#4'X0.95(!Y>(*D(U S>($B( 4,4(%+F1D9+57. #XWF#CZ43&#0;&!
M24!-C*XN.(3)DAA\)((N<(/X"9FSRH(>4 $.TKX/4@EM6PM6Q Q>/,L>DQ /
MJ('<DC\-&((8LHD&(#"9*U<7PR$#9+JA P,ZM2+,N#\#]#J+))$W.Q,>28$'
MR!%OA$=#*X%!^ ,2\(4RN2/-R@,CJ(/NF$'5Z3HZ'2TCP ?31(17L,=E_U2H
M'72T!ZA!3JHE1(A-F"5( @'.']2"&*.26MC(#P"$(>@DR+JD:8H!1%#)1M/(
M<CJC76 \BK#6OC,]Q*/.^$30GCE69\5)#N$H(L@!"U $5*@ 2KB$>3@&@N "
M K@ +SB3X) $$K@#0B"%@@K0=JF%[U'#=M&&N,BQ*;B#.W "\/$.1O"$X*"#
M7I'$Y-L>4$2P#U,)%,.H;""%@PE6G)"'*?B#._ %YW"^CI %")JY!VD0B6&.
MBA%=KPPA0*A%?BH_IWF978RJ4?&>0MH*$0K8G:D!%@"S,",[Z$,Z$N #A*4(
M!8PC!6"!%+C"BLT1%"""0 C<Z W'S/*"/%""*/\ED43;B3!PQJO) !TP34-S
M67R$@E6SQYG]--SB@SQ(!YQM$8)<@-]\5/4*0H,46F;"M5J:)&L[@!AP+S-T
M"+.C"TBA0BDTX,#H@%P9L5SK/*VEVBA#/2^T "+@ID[)@2]0!#>( 4JH 9F<
M5@!]@!+1VPH#%ZWUC$OLB.2(,8:HW(,Q,>43F(4X.*1$,1<#@"H(DL!0LEWE
MONZ!-Q/H2IMP$&[=* WP"9I[3;/D +V"%0&0!RX NBI#  4X@B[( 0\8A3[
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M3$B/"JDJI7A7TH7C*OB#DE.5 G2KW%J(1-$$#P@!0.X.#PEIA^ /;H5M-$@
M.@OCH1L&D=V5 @D3^AB0+;#&!-2K2O&0P00 6*LYL_\[@TG(@)ZJ@N%%1QR.
M$I?M$$3 0H@P.SCN$"70N1<D2/^S!51#@LBZ.IH%2+-S PF R(= D$KV7R5P
M9?CR68;@W3H2@%.B /SND"-HV5VRH=(9Y8<HCZHI2##(2@4.YB35SBB#-+\;
M0W.M" 6B Z4(@2T 'RK!F>K!YH+QA HH!$GPA!!XN!"@4'2A S7TL%H(@0!E
MB$S@A_54*'O0ANZ!@'?</2>VAUJ0 !S7M4QP@HX*E[O) SM ; Q]!"E'OHY(
MQ0>PX;@0 !>>.7F@@YCA4^\ -SDM71*Q18:(AXKQ'AYX'U79UAI85RYSE*N"
M5]HE;>Y "M]. /@*UPHAV.+_!E[^XZL";(#>?5EX?+HSD6X3J.X#.8)QUI:%
M8#L^\&XH\>E!$^\C+N^:1N\Z8L&7]2-4 ZRK\[0E&$@.A#7C,E]GO>Y*,3O_
M'H4@[!H6B/ "EVI=@_4*7I&T<'#( -6")+7N&).LA(S.XSKH99X*CP@(WB8)
M9EJLD8)>>0!EG0(?>/%#F$GMR7'OX?&<#&#0N,0DA>'X.1@[*$J;Z<BK.5V^
MZ@(=J#$8990 Z,@8&(0 ">DZ(008-0,;0H *( 2_M"P,H+/_")L'6$6S5.)%
MJH*YY(=F(.ADM+()MX_V:-/EA&3X&@0CJ;F-/F.B^V@226X<R0 #[)&#N))>
MR,+D_[7-.0 $"ICT)@0/29B1(EB!_4$")4B!D)5!,. A,#@1,)W%(,H:C:EH
MMWM92-G-Y^R>V00U$5PL/"E4%%&%8V"/0#"2CH/461> Y(51,)VM*F \7L&Y
M"[F'.2@3LQ#QZ5@0VB)OG, 5<9EK5B.%$@B%DP\ ZK#HGU$<.I#3"_D1,]"5
MQ<XQ\ 'A-; V^HEECB)#@38#OBT&<"X%2(BHAI#\ZA@Q>PX8P*.A2\".'YD"
M3(SGA^.?B]LH@X&.FD$1==^)![&)^%F"$# 1JMF?%O4X=O<IIM?W%#F$@FHY
MB1H$'8" -?/RB7[B<EA&VM)XA"#HBWY<_Y.'Z2ZS,PLA#?\ &!8HU.X,_(=0
M@$<X>3]P^>X;!!29>1,  YN7P U8 25@QYOU@I\W"#!MK?Q.!!B5!.!%7Z"V
MD@" CPPJG,/Y (!P]0  @ 9$%GDHTBE  'X!5#T1$".0PRDZ,! 48$.+CXQ(
M6*CAYT?*P ,EV'@BV*!$%SY@"-V;D^,)P9HU!<@Z0A. @ 5;U.P+T&B@30 '
M1BUT.--HC%!S'.Z;@HIG#"PT)89RV-!/,IQ=4A(<9>=/C@<+%-$I@,0J@!!8
M#E7(XH#@65(%5(1B&#1 ,@1%_P(.+'@PX<*&!?L]K-)$8IL0@@@P?  "QJ(&
M!C<PH;@@9<*9&V\.+=IF@R"@1Q__GGSZ,NK6 "1 2""YLV$!-1@3GES9-6^"
MNO\>:+"[=^3(AZL<ZZU\N6_:J 4(-\Y<,'3<TZ^7/GV])FSMVPW#'B[X0!#Q
M@B5DEGY8@ #GW]_#CR]_/OWZ]@E[OZ]_/__^UTL-89Y_ Q)8H($'(IB@@@LR
MV*"##T(8H83*L3:AA1=BF*&&&W+8H8<?@ABBB".26**))Z*8HHHKLMBBBR_"
M&*.,,])8HXTWXIBCCCOR>%\ID"0C&T'9&)+2"(J0,E=;@_"SCR2+P$$! ",\
MXH9L1Y)B@@#5 )7//OQ(<@B5:& 40R).S-$(!;*Y=1%!\?"P! 0OS0&(!Z M
M,(@3#N5C_T@/LL7  IJ +('  H^H$< <?Z3PA9!T/;)G/O<8XL$"6J!060QW
M_"%I /G,H4,-F%:F AM/U/#3'(NNX$6JB?(#:A]2UK0 $;[PDT,;&#4@#ZR?
M2F'!%@NQZD4"(]R0@K"=Y/.I4!08-$@ 4V0J6+0/9=K !W40I8 1.A0 0 UT
M\N"!!#=H0!028IP1+D$C*,30%(#P@<$!1#C%)P\=V4I( +HF($ 1Z=+U@108
ME)!50_GDX,,!'>@I"0R:*; */T]=S -8 F121BWN+@#&%#N968L 2"3R2F(U
M#$-'90=4H<8<?BP"@P,X$<+GM#OQ5$49::F4B20[A? ('7YA-?_S(BOTP!->
MSH+)<RF*7!SK'%/X(, H%$DBQ0LV'=EDLV#Z$,(:'1%4!2DMA&!'U:M.91-.
M@00PDF9MZZS)"WC'>H\FE\R#2L"R<#WQDE4SU%=19J*IIE\A2!OK/IIL7(T3
M^W@))AQ8M"$DG)[DV=!3<[PRW+C^-L*'H8CF<W$ !P/ ^!RSKB[SHBDLD4 I
MB"X\AQ0O?7IQJ!@( (:=?OF4**M+2) )H8G)0D(;C2&Q!2%U>G#EL*,W<PC2
M)13B;#Y^ +)!'4JJD $:#8"Q4+//%I7J]8 82]#I_^X*@$]3N)$8RO3?(&=3
M^$,=I"2 #G2A?T8A AN:!@ %I.,,DSC_ AK\AX@SF*X(OIA6ID:0L*!,@035
M\L@JON0L-=6@!!NTR' JQJ>+Y8 "-D")2HA B3QT0F<CJTD-[&%"+Q5)%CF[
MF@@K@[):)$8B7=@)S))DIKK-BB 5",789 (*MSU%44^8XJ=":#,(<<PN&:F&
MR0 @1*Q)<1!HX( %)I$(*3A@=PJL0"%&A@ DD $*@^#" +P0!"JY00!5^ ,*
MKO 10#0-<H8H% !&P0,O;($+7H@%&'+ 2((4+05)N$(?,3**+L#@"ARHI ="
M<(10FB /+%"333*9!#)T,@0LR)\9V0"'*[@1$*^D@"Q'& ,V>* &+*B#%R P
M"41H( DL2"8G_Z_PA<8@:P-\L,!!O+< 1)" !I,8P!6N ($MI, +'.  (NPD
M@!MDX H?8(,V.?D%@VR !A8H 2!0X*ZB>/ (;>! "1;AAAILBU8*R( ]/Z(!
M<1Z$!MOJEAC 59,&%($-?(  !ZH)KRS 8!+-Q  2RND%)!SD%1*(*%$6$(8S
M2* $6;B %S3JS1@< 046R,,1#B:!6 P #*#D9F4:D GR#40BA5@*O-2@,9AE
MH2-'R0)8IE0"'-!@ +M0PL$0&,H!D.$*2C)*%9R0 ["$H(Y7Z6J1"!*#-<!@
M  /X! XZ(@M0-M,+FLF(++Q !#N\ JLOR(0AY D*)&T5)UXH@1W*D?]5!U3@
M;!FI@B;8%@H=#&";9"!*1C(Q!1J,4Q%F>$#;,NK. G26D]PLQ2 .(<C+CC,1
M+E. '=*ZS2O,=;$X*.1'&I%(+&2@I63P@@0RPH0!Z)&/5P %%FCA+D?V()-J
MY22MZ+*%@XZR7*9< 3>Q2@&M832S:I)E'43) 46H:0'+;"<W8W$%*"0"$!<@
M@PD2H(!$E(%,^AMF,3G  D2&0 EG^%I^4;!5F/9!G)]8Q"$2X)-L1E:N*\O#
M )2PB$+F00SGD^(&T% *,2Q"F[OEP&XDHH0 CQ(0$0D4=(EP!W")MPQ]F(L@
M[= (N[*!I24X@@9 !P85#P1>.,"@_BY8 R+_(+(@1"!83:I'/PY,\!404.DT
M^>G/QC0 I^D(! RR2DD>\ $)4*CI5J,\@ ^ 4J,8J (;'G 9]E%B%X% P22R
MJM6'XI0(7;CE%22 P#98@)^!4)D@.U%6GLBB$Y3(<29(88%$P&"<JYS+63/J
MA0%\(0:MK2YL5;"&)D\B$";+SX$JL$1,GN,JF2B'(DK7EE G9A0YZ $@ Y8)
M.I2Z,JU^5Y60, @KO6L+4@B"6PA!!RG)@@>[ *9?1C#+W81 "YUKY1'<-"4P
M]($#G-/4J1I3"F4/YU+5DH@&[C2"87RQ(%L8H2RZG2H85*8"B[@ J0*S #'8
MDR<?B$(<P;W5*85A_\( J, &=*"MW&[KW@T(@W]Y4H0H4)8T[&H!3TI0!Q-\
M( -*4D!#_PT6;:U #$1^]\=N$O&2BJ$/&"!"!A*^$AKR9!04S$.9Z<*N%Y1
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M)-LN=$'K.9(7*$(]F<9?N,6RU80L9,$E-1(@# #_IA1;)L1)8R0;"DQ>LM$
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MFE* =!J"#T2>SKS"1U*)FT".$S $0VA"X@'%4PS-Y&EG ' G!K2G@TH"+71
MMYW&[CC!^TS!]"2/LTA"!?&$?2I)N2'B%DQ,>V81M?166[! &72G?K;!/?F>
M5VX!FER,%#27;V2"]#&HOPSG''"G!+3/IZR*7BI OYU&]=W3_5D ^*5#';S
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M@!T^/1V+5<$22>#6&H6J7<$6N$$'],%JHHH]A% @^,+1<*GB,E4,VN_<J1T
M&$"A[<8!#.2CM@4DV..^Q69- "3;7'!@5($A/&H'@\)I%H7>[1S;HD*:-N0(
MGT,)%X6J)5QRN@4M#,;<LLD\/$%BP DO&2YA"&X7Z  2Z!-HQ$ 6D"?'#M,5
MY,$BR%<:OB0<LE@F=,$?W($O-(('J&[HQE2'%0'3+([GWI/_?JX/(M";8(P
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MD231P0$ 2A$#A0Z3(^B 3.KXKX$/!"0(B0U0&&$+0OA[;S2P0!FDJRG0X$T
M)!)Q3Q(I.EQ C#X*Z. .'02 8@,O;J@CH=-*_]@@,H*(U""*%0'HX B!3HOA
MB,!&!(HP/_J@0 (;V(AR!"*R,.U++*H$ (DMG,@GO-HX2U G =3TI*!,Z"@A
M%/=RFX(OJ(H[J@,L]!1@%$+\>(K$(L9"@@U _7J$E!:J(,0J2:(+*XLY!5 !
M+[WF>$4%R&RJP Y4$AN1UEIMO1777'7=]<(&#LRU 0B&XU4 7WF]]0!A<TU6
M@F-K#18Y9W4M-HA9:TTV6IM\M;8@" :2=M=@34+"BV&WS95:;L%=E]UVUQ4
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M0Y^JJ 8S_<=*CZ!#8B!E"(7NK *$Z-NL1H$#'5R! T3 @2 4, @XD&$ 5Q@
M=ZQC"!_49!0Y6 (2)C&)030BIOOB3 UZ^M,!D.$%SSD$<F1!G=*E8  Q)8,)
M[ B5"K !#@/P A@Z\J4NP/\ I6#@@=\4$ A)P&\!+("#%TR0!Q8 @@*E8($&
M:#  (G1!!U,,&)A2X 4.?& 1T5D>"9+@A4FP%6 P8@,-)C&$+@AI!#?(  4:
M$(8,>,$"?UW$$TKQ 5'*] I?2$ ,E* !+R A'<*L 0<F881%P&  GU.!$4QK
M 2(L0@<0^, &^)!9P!["-T>@ 6N/$#E: 3./"?E((7@0&6"6 1 )D2<;G$L$
M#7A"70>PP2+X (&4+L(-Z\O"!6(:4]XXL)D<*$$@,.@G-N@I10#%R1,ZD(7N
M7J$$Q?W(5P][6*%&)19VM<,K8IJ'4MGDB#+\JE8/^\6^O' *?.  :;TX@FK4
M8H+_,NE0!=;@B;N8(4I'; &'84"&2<#4!(]I0V;SD(BS_*T*4Z"!"6*@"!#[
MQ0ZPE6GUR&B'D=:J C;M2Q7^@ (.<$ 1]QN!(E(0UASTH$=%Y4)4_[N3DJ+@
M"D#1:>G "@%0)$(*&.W=(U90UT]TP0US.\(*M#J 25!6'J;E !C>A  F]#01
M^AP $HY0AR4<^:T6BL$BFCQG'GA S5(DCHL@P((,7&#'GQLL8QUK(%HEA;?X
M700:$K#:22AA$1=@*YCD?%LT#(2T?9US1VH@AC.,KPB!C5AR8D!;OP*6%FU:
M! HF$5,OI$@+W9US8!O @0$@H@MKO0(1M-"#%[*!UV0(_ZV?M. #!2"BU."M
MR7.CJ[Y83"(="U[V>,OK!0?3RH$\D/ D[O."#G1AQ>H-A!#_)HLLP+<$2"1B
M(G3  5"PP(NT.H!8%'J3-42[P:<IPON.# 9# $H \5##PW>2C;'T3 #5D((B
MS.D8+/3O-/)XQ6/@1)Q!$.)L%G] 399SB*K2JF3+.;7'VY XZH1 "ZJ\U54K
M(H"K#K-TS2%(Z/KP@).L0 DPP"C.:3 L6;"A#35@@<X5YX'X;>$,>DT*%RC@
MRW,G9P%A"!&"-M & 8 !2J4(@Y94X*(:K/V+*8*2E=+1H,AF($K 1(A-2J '
M/J@H2B'8P!EJ\ $O^4E+8 <#=/^="P9?+.XFGP"$$72"!$1(X4A&N701]@Z
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MX(M.0@L\H 1N3WV(8$60X!/T( .. E)(#RF^$/OB*93Z!$S<P/9FKP4$K@/
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M'F3%*AO*\Z"  -*A#4(@G>9($RPD!#AA"1BJ!W(J2O(/("_M$7;$,0;A,P(
M-#2!<1PG(IIAF$:$<O9A'S##N!2G*U,/ZF*@F6!$!VCJ$8!C)-J@ &X'K;8
M?OHB!D@@ G>B HX #:1N/TQ)S!1#&I&C!U\ [>+*3OAC?C  E>[ABG0 %#(
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M"-9 ;LAV%&O%XA:4($:!![(2K 9W0PU0"S@M+,_SA!MF??!*1"JP0Y;C#*Z
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M.0!8FJ!3AO  3V21*@A, @J!T  -!O "%0SB505@PB2<IX$D>,$$(W@$#(A
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M<&%P<\'1 "6X$0ZW 8?U9HM0<Q\@A,%!4DU4=E6U,@I@!#67#HN@!VB =9]
M AO@!3?@<S]! H)F@N_8 %"@!03 !OOUCJ-U!'!  #I ?R%A _M(!(KU15G8
M GU%$U=%5V44-'7%!NG@,V#TD9*Q&<7G$X44%6=7.(D!!HHX?)DA$EDP!.TT
M62T@"UD0,F6! SN B& A"U-  )03-USPB"J0!4E B1A$.)WR!!7@-<GW"+5
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MP*LJ";Q7/,35*A)*\-(%*5IN-05"DT0A@ZT$)!)2&"_56CRR%SA:HQF;P 8
M.@J^\ =T-=9?5 0Y, F!/"'UM78YL(>Q]G194,HQ0 A=P)3_H/>4]%D*^?T7
M3=EN!-L3H@<#O40$.. #(< (&W$GK8 -F\/*8?&5K7P,H/%[G4<''E@,N)I\
MU-5NV<8353 %6/&4F%4"FZ4 "*DO@] %9D !T=>M\B %R+R8JDC8]CM:FU6*
M(<"0L30$QVP^*1(/?7 %6F"H<:4%M/ [1^ +/""UR9@OHY "GWU(V?A_U30
M:D5Q);<'><,"79 #9*O;E6HXW>BFBL:V@^Z.Q%T!!$ +TSD #E5$57 5D^'0
M+ERX2E 3BRLL7C $/6<"Z?@5V (767>/CXN#8"4L>64N1 4Y-; #;A#=%S#=
MYB(72P %KE#*1?#$9V !Z? R5CR&_X\[%^KL:5NV"Y\0&6XL6J-@!U.0K?C-
MUBMQDC^A?R7 K3XQ"G<U41\0&<=KAQ10 HU@!*C@3,_+H5DT>O&2>&L0ZP-
MXHBQR58BB: X&;SC:X]XOWYXOST^&=70>^*VP>A"4"F!&;5,BJG'"8) 7X6@
M"3W0< E<!=TT&6#P$++X;PF,+D>  S>TF2Z5Y=939 M,'B[7?Y+5,C$Q6FQ
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M&#05Z )YS*, %)'R12E0PH4@HP5P&:0*8 L!^1]CHA*L(!&O:(BEX@J 3,
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M0&"S'Y$?!=B #=  B8@! EB$%="4"A"2<(F!#3B$!A"##$@*$T"">EP_<LN
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M%9N"1?@#0A@D 2B&6:H7WT0=TZK)%OU<#P #'8B!/@"%60RM:BB#1;@# *2
M@[E3Z*B,ARE929&'/^!=7Y@/*M,)&T@')<B46N+=V,V!P'*R9FT#/-& '2"N
M]BR!+M"!@B 0G+D-#RF(4A"#>0P.I*R!'^G.5BV!$(N")-B:>A&2]7O+6QU(
M"2@!$B" >G3_SBH(A"E WJ,0S "R5?E! B/XU5H53 D0$\4,C0$F C49A2.
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M& (U29LNR($ W@DVH(%)F(0C2 $+" ,[>2DAM6 //@(M6&0[/()#"(N/ !4
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M/$KM PM8;@MP6OB(AT$P! \@)H8 %"<S#X).T@5, 9BAD>DVQS;@WAT]8!3
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M#X(BED,@'1 9:+4G,*UD0\!NT8U^M ?_D* $VW?!RA[I !9"3>=/ \(#(_@
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M5L2 !HB/ZX11%OT/#,1 T4" %WB' FC!(;A.&V 1)78? HR &,  $G@%!H3
M!BQ"(SQ;#7#/:<C""O"!5?3"$GP "[13 30-+)9?U-2!!;QB,8*1FJ4#"L 5
M(OP!(+P53"&!$: !)WU '4S"_B" Z\  U41-'XC!&;P .1[&"!B0!7Q 'SC
M]_4!!Z3#L(U &L',0+Q;.F@ /-X )5C )V"-*,4"V"  -5T $4#.0-#,$)3A
M&^E%!_2!"9"-"8"!\#P21Y2 R@C P($%091-!G%$%:C, 51!&YI%&/^^0 GD
M@ .4I":5@.'$0!8P'7-E00_$P%:81 Y00!7@#0#$0!0004RN =,!AN%4 %&J
M %&2A HPPLJLU0,(0#88PB[D0 MD BFT0!GA(P!4@56&!0I@Y>"$ %'&@R%0
M1@B<@R=4@"&T %F"80X0@1G81 5\8D+9G2<H ",413;D@!F>@P^<!S5DGGPE
M0 6((0!D T4EU&%Z0@RHS&AY#QM WAFV 1D6Q1/!WT*0H4(HP 6 02-0QA/!
MX60B@%@<P53(UQGR1 4L EGT3%"48AN 0B96#0N@P"AH0-=IT!+$1PB4#P"4
MXB%T@/H@ !,L$\F]3BQ.C66@01YL .0M0&'_8!%96 8*3(*S!:<69  )3 TM
M0D:U20TV&D;3H  H(",W6D 8H(!*"L9"+. AC +8\4$:70$TMN(-' $)G($#
M*,!]?DT=X&,,I ,:Q$ AJ(('V$ &M.,[+@#82( !M:<%T",G41 %O)L#?,W<
MY,8"@ %(V@ 6D& !."$EO  <51O9$*'B<*1">L0HB"3;J-A$SHT-S,W%"$R)
MQ-ANT-@2%44%X, 29((OY,-;S,%#O! 6L 0U2,%S-(0.Q  E[ (/!"F3,H0B
MO((*:,$ :($12 &B+8',-&1@B@4?@,$K>,=J(@A=)4(9H%D,],'/", 6'$'P
MM>(P'% &P%\5#$(^_\Q!8YPIE^5!!O"!*LI3(OB!)*  *JIB"<"!0HS ,&3
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MMNM&=@#6+H0*=($'4&PK@D2^_UD/1)L!,AA"5,; "GG$2*Y,/." )[RE681
MH&?#U26F(0R!5<J#S%[S0JP596!EGU.&+!@Z0&O$"LD"*?CL&D">W65Z5PHM
MT4*T(8P?8)ZL^(0A'\"Q662P"4 T'6! XE#&C^J8F&<"<!]1$HEM%J"!88:/
M39LFX Z'30]SJ+T?LOMA'XA5"'3!'TP% &2")&L!2PCUS\AFW'3!(; :_R@
M?JL ";0!1DI0;HK/*&0!"I0 %RR!26ANM8E!':ABWZ(N!Z"NWN(W$R 4!F"?
M#E@ 6Y-X%X2UZ:+N?&@U!V X KSN&5@ (I1-#7!C/_J"^<9,I_DR(>C%J[X
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MG3-F M&),@#I02H %@"C$0I44.*,%AH8 L4<SRB@BD$ (0#()!0)P ] !&F
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M(.C_+\F(+CRF"'( %-9 UPX@$TAA*>;A&# S%! 3,4GA;$ZI P)!#>:@$7I
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MXVL:Z($<9!$ P;X^)@'<# 5 8;]$+;_<.+MJ(!VVYPL.[ R\P_P(A#C!4@
MQ2VSQFD!0P&P@-[^D!.60,ND@ B\A",F2X-(&(2G8A2R( FR@ _   9  <(4
MX?@:^0A(H ^62 ;284)20W:O"0:>A_]#Q* -0B, ^.%*7@$4&&X]BHM(B8"?
MT8"^((?[ '2)P< %4X#1]$S.D* /L\M.LH][*//11N #=BZ]1N'Z0",*>$Y
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M3F( J;Z@LTK;<Z@IH$V+I$B !D(.6JE'/8P/%$QN"8YKS1"(N-  0/=@A?)
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MWCQG\^C7IW_OOCV204_FUZ<OP'X%]?K-JS /P'Y/_/=$@.:%<*!Z(="'X#$
MA# /*AM-.&$ %%Z(888:;@A &0)P"&*((FXD0 ,F4&CBB!B6& 1""36  0(N
M)O0A  ((  $&&C;0(H@PSCABB3H.), !0ZJHT?\!,"+)9)-./@EEE"8"&24
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M0AO%8!!2 $4&:('+*HV@"(LXQ)D2ET-AD@J.E9*CEO(S@$D,H@\#\$)Y4C"
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M@ %9\("99,5"3"FIA21@02AR7@)"S*)6$2W@?U%00@Z6@(0CZ"$=73BEC6P
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M"Y0P.?/&< #P;DN0":\@0T>E!$Z 20$P!VY 3'2F@%B@<._6<',6(%G@ 15
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M!67 $\.0 AO*!SBY ,G' :2' ?[#>]!W96\X"EZJ3I@Y$*>9!$8@%"J0 1>
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M9 P@94Q4"8&&DZ*&T=)'2)(C0'( $, G">$B;>)+,:(A?70 ]#4A/#(CHT
MGZD1<3PA$*"S@1P$B$PA=E(D@#PG@(PC$G#'NCLN2S(A?'( 5(0C+?HB!SLB
M?SPCCAPB RLNY+0F$W( --( Y/@D)6(G/ ++>SQ#F!PI>J,OEXS+&E$#);!R
MH*PB:^PDQ-S+QXPIQHS,^[1'9K;,@0P%?#"(STS-U;PQ).L%;T,"=4 L$O^
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MHP %-D # C(H *!5%)!0 @56;?*4ADTR. 2 &DS(*J48"."CA$(:\2!%"\1
M ZXZ/(4!@P6.&C:$HP1=()U%]/!I 1;.@""=%%Y,YPP)/JC_XT=BQ>C/M3HH
M*$(#05-"(AT=!&B  PC:>BLN$XCHHX4@^\"@@PWX( )=@0_>@ 8P7D%@)0V^
M((*2%A;XY!5]^2T!$ <.*(&2%T8F I '!+!!@P?"I$^ &+#H(:4#;@.%D1?
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MP<SP(P F7"%SUI/%(F#PA1BP@18_:@ 4$B&%^<U* [2H0A]D1< \U"$=&O"
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M@D76RR24-D""(_")$&"#-HB'/CBGH#J5\,@J# B!(TC9+.DAH\ *>HJ56=F
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MF2BLA7RFF=_+T8WBSG]V;P__<!#G33UE3N2('4<)0>7D@"M A QXTRFI@2N
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MYT< ::KL-XX=!@ZE$),<F!Z0MQH%/> #E8F"$OUW6>%28.D@0@ A)+!B5X.
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M@=5)=3!(&7-(\>MFG;56@"QZU&8# ;G]22H O\76 !B^_/%'%RDD%QMS*4A
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MQ$!GF4 %H-P@DV244BUYG.8>8^K4IT*51?!,0#Q>001'74$+7AC%(4IPTGC
M@05\2$ (SD $%+S@@2EX:53;"I:3U*8!UY.%$=S0 3=$QQ>^2,8R0_"(?.QC
M#K6022V$N)80D=*MBETL8\V2#=M95 5WD (HM$ !&W3U$ 6PZ"?PE TI$$&S
M#W1I8TN;1)HN  SL^BDRI+#0$8 !%?'0V4(!@(0E2* #@VV+-$U&3=,"-[C
M_[WG"ZKZ@F*\X@!B6 (\2Q#/QX)".A3B*H)&@5;A8E<F.FA7(E31!2F80!:^
MZ)T1[O"*/'3A"14X @G8X E9(G,M!O#8R2"*W?OB]ZDC$ ,%:LC$IS15,L/H
MP1GS&U4!U$ ,'7I.@%&#Q#_M,<$+9LM2?=M@ V,XP[VLP$G'$H,VI%7#C#W
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M&_W76F3#D=%, 61#(W3(*!Q9.>8&.E* DX$"&PR&DZ7#D.D?%H!@%CR! 53
MIR$!#2!(!60!"/9!#^R0 G@!#>TC+:C (CQ!W+2!"AQ!GRR $NA%7LB&!IC:
M:Q@!&_"!Z9Q4!=1!%%C<FR"A&+1! A3&$7"!792":""!W.2)%K1!'NB!74"
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MA*P%B,U! @0  !4RT,B3(0FB"UY*:%C28!B<*T3@4 A19TF-+3P\ ) %QY-
M@0H(7. @AD\> C1,<,#0X$.&B7!VP5D"0$$4#S%6QB*R(LD%%!8^Z R"),.3
M!E"B.  @H$@&+Y,RM$%"  6'$ADZ/MW*ARH-"#6(&$E)X F !4,(8&TI <(G
M'1:VI@708 B:&I]0Y$F78< 0&&\A;&E$82T,"U#,FEB:0BX'$S'2N1&PJ<YB
M-S7  /*T5 <H)7W3G6EQ%TR.SWE>-2""ZFZ>/I]R]! 0(Y 4(J^N?*AS:;<%
M"_^.=W/(8\0-@J=(E-#@\$&*A!)2+$A6_C2&'2D81DFY8D,#A>X<P#^014?
M@D=SB63Y9,C';?33)4.04*5<?0PB^??W_Q_   4<D, "#3P0P0057)#!!AU\
M$,(()9R0P@HMO!### ^LXI7],GFEA%=>$&B4#OG+!@XMED"@1 P$B.6+$D?D
MKX(S*(CGC\,J2&$W$P"(Q00918KG%1\K@.$+J/A(0*088*#@1R+Z" DJ&DIX
M4BTR3#AR"9[8X*, )Z%L$@;;D#"A QA"$B@&D.[B8 @X'L I"D%BN, '.G>
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M?!2H CS5THDG& 8 (X4K+NCS3Z=P2B<+L3W:84R>DB" IK_RO&T'0P&(H7(
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M59C"*_QTA@(@X1,TV$TF_M"7<'D+"8AHKJ#OLEUZV>4V&IA:!S3P@GOQAYT
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M?V1^Z#;MN1X _Q<T ! O  >PH/+A'C)N__(A -1- !'/VPYO  DPWQ30 .<
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MLZ@!7 )&H$4R9C.+S.]/B( 2>J P'_-"&J (_RCA"G8 -P\ LR[@IPX  @8
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MGT(78/G#3XP@Y R!"#K6(P"V&FH!;]H!+D,@=;.!B@&@ Z!X'P"V G+@-"H
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M#R"DAX"*13=S!4 >OE@@AC1@]Q( JH$4@(JI>_LT_M43_^2!@F![2'W N %
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MG=X#8][=G=_W'=[=G0BZ0 ->!F8"7M_]'>$/OM]A9N !(=\9'N ;7N+??1$
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M'NM@S 4H@@<^0 (1T"L3 4! OH"X A%>L5CYHO\AC UP+ >@L($=I( # \A
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MZ/1G/- #5<!]!1 #-'!K,# $.K!@"^ *:90$0X5%B74)8) %M% %!%![?4
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M<_ 24_ $"K *<Y #P+;E>&X4E58+S54#BI ,50#@5?"+56 (?, !'2!F]"T
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MBQJP@")2.8AD"* 8=&!()NA0 TK^+90+>$0C/E&Y$-B!"Y:<R>=4$85 2*$
MZG& ,D%2A>T(I!2/J.0J:X#.YV'@<V9X7@V[  <PX( &1,#!"N0"B"\080U<
M( (EI"(+9_FS5PL  ^7ZPC>_*:$1N_!%#O2P.PJ4 C>L,P1BF,@"0$0A$8WH
M@0JP!P<67"@$@U %29>WA?S)CP)0H85(I[""CRZA"H'(C?7VME.>]M2G/TT)
M.7WBGB>$X!Q/B(P"V-"#"C#"_P<GRT$/1@$(NA"5*U7(@2>8DXU&8*@^?*A
M%I":"4!X0@#RT$$,V##6LIY5!R4 A%>UT 859$%%%3!@PTK@BRSJ "2*H04R
M-."#Q+  !=&#SP(&, DM& $03!I("+2  H:H0 ,>B \+,I"%BU$&!4C8P,4V
MN &DED(,4<A#!@4 @1IF8"&>C842.AM:# Q#AQT46!CJ (H,J$@!BH*@&&"
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M)WJ.&!@?#[ !:_]Z@ 6H1J-+/-C8EFL<NW0@,&XDB!A0@C,8#BG2 ?.ZCM5
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M:<W"IO*!$% $)U #["V_,C@$_PN,,D"!+2"$.?@#'/  BRJ#KZL"FM6V@5
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M4(*P1_FT/WNT5WNW/WLE>/H52'DCN(.NK_N[9WF[QWN4_Z\@NE][5>6"DR>
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M&M-J(#_J3:N)3KS*"#[@BSX\8 &)  0! E$+.@D #%W@0@F<, 5 #" 0&B!
M(CA4@=QDD0[_+ZA !3^! UHPSQ<DX,,6L!@(*0S0%V4 A ^F5H0N ,(3%?"%
M&;(HA7I!2I$DK, B,D" +J A 0M0!" ND(A&&%(#?$ $&[)HB"M-10%'D&07
M8% "0BZA 5OX P&.H %//&H1L31<!MH0 Q)LB2HC $,D9=F#$"1B"G X B!(
M.;)!1 H)2IB"'I#)!R(LXI@:4!U5%L""*:Q "1IH)1&ZH <C $(0(PCG.*TD
M)E 8 046$,,9C] 'TXV@!(L89Z1BD(@_H*!4 A :+)7@!T 881%N&-D12' 2
M,$VE V+P@0)8  @*Q(  %QC"&3C  AY$9*!&^(,;&D Z"8#!HR M_T])"0I2
M>:T@'8LX@P0R\4<C^.(/X\R")_0)"#$8])]'&&<7(D0L,#3**C' @A[=(($J
MJ(&@-25H%I90A3D 8@='>(4 9#$(D@2"#AC(1H"R6 L)5*,6"!! $>A H%(\
M A4'R,04?# ">21C%!P"0QG@X(!1J"&1@U!K]8;A"RYX0E4 D(4A"DN*5*&J
M*K+HZRZT&()!-&('6I1 ,9(!@"I(X@D"H.L(,)D.+2) %F(L)%78JD<I,*\,
M5G*.++( AT^LX0DQX(%P..6#-39"D1@8V&QQ0(-PSI* =\"!!GKPH8@1<)I=
MT, 0LM"#4K# EGM\8R"FD($]MF@J5>J!"O^RNX(K"@EAE*JJ>*_8@U]B49[=
M!4 (LKN0/@PS$'[@ >%(D %Y#K.8>@B$+P"1@2Z<@49M@  +-)".+J# !$6H
MIC"1( 82[""5IGLBAIL8@G/\*!-"G2ROJ++AG!IB"0"H0!ND4@$<>"*V)I8%
M#GI0A48\P$_^:A4MJC!1^,HI!E&U3@BT8)P*L($/I8WJ*'8<9 ]0;Q3)]0J,
M%!"L$[.!%BM"1"-,/#!L3L7)/K!Q#;0TLFO>2@PHR(,&GH  )/!+"WI(IG5D
MD68$E$(,4># $=*D@ V0)YMB:$,"]CRF$&R !'!>0!C&=!PS8P#1,,A#+A$P
M@F$\.M(BK<,[24#_ C1@0 5&.(0 (& ".L7 ".1I0!'J0($/U"%$U1,4!#X@
MA0(L(!T938<.),UJ5W\%!3$(1 [&88,,< "CY\33!^8ITCX0"J9$H$0+VC-/
M8A6!$@X8P0TH\0(.(*H]VB8"(!R !##4PBN(&.Z>1L:&+Y!; (^:-;&>/;[[
M@4$*9XVMC$'T;@2$@ 6'J *( .#CG+8!857(@0,.7F.%CR('% C!(YY E;?2
M00**\$,R6M4# PVP4P 8A2%V W)75V -JJ,0?^(1<@NUP$(2RD9BX6N'.WS8
M#I[(1,6+$8!DE (+4C4#J$*P!D^HO+Q3\7#0L?"$R4K<;MEH! 5L_+W=_ZQ8
MN3A07:N>D FHVUA)B/H0*-A@X@\]X#=1]94**/&%)/\H2[K,@IJ)K&:J ,<+
M"F!#W/'.Q"Q9^0B'0("N:!&#;R)@ 4I(,=VU< A:LT"7BD= ##8@<>HZ_N].
M]D ]X9"'.NA2#TSB6@Q6H!WL1"$/>IA9#1:7X=5/*P2<^%$U7L&?4LP#%4R\
M>XL#?MC1[L,0/KCMCPCH@QHH0HPPN#$6#I$))^PC ,YWPVT]1CXMV&JY_#[;
M?P+0_#F\@DO:-+Z_#( $(@2B#)+@@ZZ4\ KAQ(R4==H"(:9P_"SQH0!5H!<
M)@T'(GQ3Q(GHJ_MM%AS\R*2E  =\"0+$C*)5C_\8[($E19KA_8$O\,,^S$$
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MA8@ "-W)+18 9(,F,%;_JLABK(@/ )0")/"#-HA%*0R")^: *))B#%CB\@4
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M"\1C#9@9$K03F3P-!VS F"A &!28&*"!A-5!1_+!/V7 DA8L##3:PYK #6C
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M!O AD((.H<@!*GB1*J! 6B/80AOR4 Y$",1,,0B23I2@ 1I8( ,\@L$73/@
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MRRH0(@"2< ,&9/&*2X1M"CSHP2AT($,Y!:(+?^ !+6J@")EL00V^R($1H 2
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MC01D21 )5!LB$M!V0<P=G08<&]U!V#9#G*WK8A<DW@BIMT$,%1UU0]G8"6F
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M08;/7VP)";Q@3?*@:%X%<#ZE!QJ@ S8 !O2F!(8O"=CE &)@]@*$!]D*+CP
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M$?1 "8</0 7TP0)40 E4"1.A$_I3"8^ ! JT."*T=P140@'G/YU %>! 5@C
M0I700P$'1#N40@>T%33T0TDT1'6N0E?T0UNT0PE!%5B4JER41E741G-&%59
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M *(@-BR !;:,N02@9P>@#D"A""Y@ ]07M/@&J4BF8,I!$;9L$;Y5O]B1)S>
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MP%TG5IH0 9TU( FD\1, P<F,[V.O8Q<H4_@0-@;$H%_F9 @$Q8-)1@$GR&]
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M#"DY@ AP=T9*80O0V9&V:Q^:X0X^Y$2VK0I\(0"FX$(&X1X$?0F0J ,6P1<
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MA0Z+_M'($('DX,%A?$X! Q&4PL"!(G_PL 1457@!60-;_($"$BR4\8JHE;X
M51&?]+'$IVV4.D4;$(#QAP[#XJ!#"3LD@@,7L](WA!%_P "%$G](88*L4Z !
M60U@X- '!3&P\ >.8/@""!\E=3! 1.@%TLA]7;S2(KH9[&"$'6= YMM09 P
M"KF-)$$$ 8%<*-X?@'CQ+0P80$%#24@,T287-$ !QPXI<M#&@42P%,L>&RF0
M""!+E-"%&\HQ!X *BC2RQ"A=</&)#S648!#+2'07G!8$'") #5=T=P""+V12
MJX$=H%!2 T2\8BHJL8 GX1:\)/]3@SRJ2$TU " 2\,H(8!@8@P:?D&VV@2'
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M '"J4.R]+3\&6>#%=,5V?;>I@ W??M4?_GW)+  G$P% (RFJP8\YY$"%74F
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MD Y\@"L , HH<%RN0!+_NB(%2] !"I@]_$)B3-8;%_ )!R-#9/ 4HW !#[
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M6EF @2 %L!#,H2)30$HT( ;_Y1$(A& F8PP3"%(BVW64O6O'=XS'6]&N5R$
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M!:^;!SK0D0/Z 3VPNB^Q7>Z'AGGLTS_=NR2Z%<TF6QY R:OS!UT ,T5 */'
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M4!Z-*( -2T @_@H7/@=V;'64DD46EC"04F#!!P98  <2L  H1.$*9,! #:[
M :<L"@ U@ (!:& " 51A#3#@P!4.N  RO* !5X#"!4S0@#Q$@0_2.0 'OM#
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M2"L]D( &D,$$':G!)* 0"+E<P00JT,!X/)+O?7=D 6+PXT<:P/#''F48*(!
ML<O3@%@<<=D9IU],1@ %#1A8) *P 1M$7BD!C,+<%T$"(V/ B ?$@Q0G)T@Q
MWY<-4D1<.Y)6-[U"W:T0/((0=!"((TFZ"2%B0  =Z$(=*+  $\25 SOP0D(:
M@$(^),1\)FC@".2A Q4J0 ,HV,4+!W* 6 Q!B@UAX06^D( 1Q&+?!\@#U3E0
M0R0,X (" 0#=G:+0&+ A UX0>-\Y\,-87&$ 7Y! @\U>D IHH> (.(#C$VX0
M)/_T9Q=U((W;#2MW! "1ZN&LO%,TW@"D5WVQJ5<ZZ"L/%8''CP-YN,!X9#^
M)'P! C8P^P':+A#?7R$/0_ "!+; !@],,?A)60(0]WZ0(QY@AY3?Q ZDN( /
M9"'K"FG[%P;2_;Z;4"D6(,, J@[""US0L)M0NTOS#8HH&)R /?3""D\X!#[0
MSP!M)P(E)#F0?+,Z,D" _?N"!;@""2B"+D"!$LB!*\"_/QJ!(L !%'B!*N*
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M*,@VM@*$)'2GJY. 3=" _P- (JB% A  I/L$ KTV-M@G]XDA]QF!$I"" NV
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M' 420 $+@/\ $Y"V@1@!5XB"%I"%%5!* ;@!IR.(4AC=2W %Q[Q-)(!=HCB
M#NB/H 4 !1"#@KM4*ERL&& !0! $X#6"/Z"!#W!6:!V".J#.:OV %#"!Y"T
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M=*06@@.9Z+AU.4I-CB1S$:BPPV5'(%((XJF9$@CH"B)F6I0:U&B'G639L!5
MD,V0IPHY"H203)E4O)Z 'H3-#<!)  &Z?P,/+GPX\>+&CR-/KGPY\^;.GT./
M+AVYA !^IF//KGU[V!H#, "HP*9-!Q(>/)I($';4BB5$"M&Q, S%1S0)%&2@
MU4!+FQIB4,2P$ (+B'$!!$J@4( "&Z  7DLA9(#&@!EDL$B#(X0!PR09M(%
M Q_48<$&.A1 H X.<C2"*U% 8,09+2R0 0P<1(B _P @OM#2AW4\T$ >2P!
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M!6Q0%ANPH0> LD"D6%(##GR"!WRP *,>( ,_54,*)HB%_P4@,+,K>BYRM0.
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M.H"4@Z,"5'&ZZ8%?/>N-P_/63Z<!2*# 72 8UAMR0+]=J$,) $&#(3B0)0T
M110@'DH('M\$DLM #Y+MI@N@.F1=T  %$B" 3>S @0?@P"0&4'D?[0#Z,=""
M!I8@ 0B8P+3 1W4#8L$!*%R@\BTY !*RS_Y8=-\+8*'_^CWD_DGL0.6M'?WM
M0!1\@03@WP!X00+07_%=@0D@(/RA6EI= ?Q]098X$  <0 T, ?05QA@!H/XA
M01AD@0<\$O__Q5]A>(<"H@C_1<$"%M$5Y,$.+*#'H=L7Y% 166 HU<D5T" &
M%-$01 $?6)_ << .$*$&<B"BY)[10$$4 (E+-, 5D)K N0H2?,$HD((/\H&#
M',T02D #% $.T, 6/:'^'4 >=(\59LD+^A$93$*#E(_0P5X=VB%'R);ZW"%T
M"  8P, +Q$,7G$@1P,$D,%=$  )E3($>!$(C+,$(;,$B$, 1:!-^Y,IW70 4
M# (@="&612(!* &)+< 1D, B<*($% $)9( 2<,$ )((?Y  -2$ 8+ (<L( J
MD$ @9,'A90 *@,$BK( 2 ,(2+( 2+*(P)EY##!4P"B,QLH ?\  *_Y16%=Q!
M, *"!RS )RQB__2'*^A FG1!!N $'" "+%X !I2 )!X!#@#"+K B03Q!5U7-
M$?S!'^@!)2[!14Q$3@@821C!'[@!7$3CS+S$3>0$7KS91[F$#03""A! (-2"
M&%8-0;R";['%3A!&0\A"(@!".OS!<%5!&:@"05B,'4P%1$K 7Y3$7 B "F"!
M3/@"I_!%.BP"6P3<(Z ")V5.EB7#8N3 0R*&C$U&(-"!!(R$5L0%922#@"&&
M8=!!W8S&(,Q--M"+%8F/ZNUA5J[>ZVGE<GA*"BQ!)A!"?&R!11!,#1R0"HR'
M ;5!'FB #^ 7@/ 3 E2 QC",6PC<OGP7&O\8S 5D  TD0 5H0*Z4@AALP"+
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M&!S"2>_T23= P\T>7P66KEE><!P %7-$LWV<KY&=,UGQ17,UP$E=5V-Q4NW
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M  3&P!H(/XB:U8! A; )9 %-H (33!&\&M2# 6\(7NI$9SH@6$$&(OA:U&0
M! 8P8($"%( 5%AB[,4Q. NS;8-TBD36\*:T2>/B?"")A!<39XH('B" >D <
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M*!LXD,B9XJAO."K_QG [*\PB>%O\&@,@"-2V%E$.1_T@_\+'2XCLKVSL3(
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M[?$.H-@,2NZ77BZIE94WD-ON5K8,2 ,:G7?O\.F6M[/-H-;LAM&L_5F)Z3Y
M0K-V70/D>;ECD/A)M4>V2DYST&"<Y>24^-TR6H&$#R:;^1[\71DP3=OC'@,5
M=*A<(>BPI[Y%P%%C<5(!),Z^H$[Y%BLQBUA$(@Z.E'D1>PA+J8:X?I&S O\"
MEFJ^!(A4"/I%IQ)MR,[PP:]N<B#B2A/\X&(G6 :5B(0EB%C#RK71%%)U]K,7
M MAQ4XW)1GY#'%IM5F4JP!0]7$ <E)@&OY=U($ZN*MT/, (1Q.$-3?C!U!!O
MU7?S<*ASGP45_HEX?(H/!$V0W)0';_F'$L^LF=\>P04HRC=\S=Y9JYL<MQH'
MOD?WN[/ LQ5HB7A&&S$.E5!&]< , N@]=.[Q/.HN[?;@N1?7T5M$/-9"74D@
MO"$20*S;&]+0!*B9\?3/V^51ZV9]@1R@P*T5P45%T$ $G'SN/[A<U@$ TS[F
M37:>MX5CG2< ) !]=N.C\.DL#,NP>U#KIJ9JHN__#>1@<&H Z +(:ER/C4YG
MJWZ F69A[=CN(+#'(&:I BWP;33P;=PG;QI@=GSH -S'V1K@@/+& Q-"  JG
M=SBP("2@>Q2B<.8& 290("3@P#J0(5AP(%BL<%+P^[K'V7ZPDEXNT<IF!$7'
M!HG(XG90;@PBOXJN=6;0U:"&( P@!AW"![-0( XL"Y\0EKB0 HE"G,0M)%QP
M+!XL#D @@"9BA+2.(@3@!RXO(?1O#/M"#!\#<I@ #14B"2E";_HP".^0*!)'
M$)GP$)4F=P[1WH!PCO G(>*&)A: A$80))*HZ%20<31P:[#&"!\"$TT"R"Q0
MAP *>>H&H-QGCOIFCM@F_VU@RA8FCQ ]8HL,S"& K/T:8N\\)R)N*Q,1R P5
M8N!HH@&^:9HNT05^\2 J# B_S[2$X-,>8JE( G'>"'LB)Z<8 *[^IX@B"P (
MR10.3';"T2"VJ(&LH($8<18?PHU^*GK(29%&@,HH;_%FZ-8(0H5>[G3:IV_^
MJ;#<)A_U9@QLP>^XQZ<"2&_D[*@4*:H\40$ Z'JV1H. )WWRRHBH2:Z0;;\4
M*8DF)]" Y^8PB<&>**W$@;M "L3PT8@LKHJHJ8@H"I.$0&M2APEB)^&$#B$1
M[*<N"M3&*/YLX0W@Z'\8Z:@.#A]_SXA :'%.2/62$7*H:7RPAN6.ZHW*IACC
MBO^0(H%U#&)QD.>@I*Z LI)U"&D6R+$@1J@>N$;QJL>&8HD*.JA]$&=YDJAJ
M)(<7UQ&6@.F;TK*#F@QV3@BO).>2S$=T%&!V]J?)<L?>1"OH9$>.M@F;1  $
M<H><K("9F(JB"O R10>,HDZUK&]_Y RQ0A.>*,JV J@S-\_>4JJ;UM!R!"*V
M6&YRW$BC&&XE0^FWC'+K, B@V*>F(#*YX,Q\?&IIOD:EV&>B1,"-#"S$*$JD
M<@H$Y$GVV">G)D>-?"X%BXB.(DH<%@ $MNFGBJ@!G:HZM6J?MJEN0* @ZL8L
MV2:L3LK5)JFMO#"IL&>+^$<;8S!RJ(F+PNJNWHN(TI+_ 8*I&0EQV@9KR*IF
M=Y@J<)#GLD0)A'+0AT1@H%)K>.+*S5#0M$#NC)JJ:B9/;Y*H$KZ)HHJ+0D4'
M+C5GX(QK!$W'\8ZG@WCSFB J? YIR=Z+G3(Q<;[+.I>KI'SJ?VC'$R\G<_K)
M;I GIF[4(MFH1R]IW#A.,C](:ZR@"5OTMKC'T40..94(L?2K=Y8*N7YJ^&[N
MI'QKA.#J  9)!$S2M\#OID!H/8\.(4@,D^"SY'S("NI!LM#1/EV@@5Q@*_W/
M%&(*V1J L^I'=I@*?):0 F7A?#CK_QB@$I:'?:S/?)HHAOI& #C+;>QF ?BG
M;^Q&4X^L,R_K0Q>H$CSH#3#S_X3*AD(WIXC>8!9 "P!\2P%2-8*^*:!JZ8,H
M,H+J;K;B#;3")S8)*Z^0S6Z M+  (+_HKNA , Y$2;54;=S2#>&$T[P^*,W.
MKX4T[;T"R[I X TTB&J&S#I1C<^&[W!:M*2JBERCSG.\RTP+S-,J08. 0#PE
M<GM24&EF04(OK-7V<^M&S$-]Z.AZIV[X!U +8FJPJH"&2@X23':HH'[PLB!6
M9\DBP;"N9P1@1[\48*QFP<V&I^BF;<E2JP'R;B!,50"VB9R6S+<*[ "&!Z\*
M;W9.2,J,"T6!YY]&;[;>"Z;&"4:S!KP*KGFT;1CG+<WPL;#$2:/D0,V<R<.F
MB7'T9O^:).N]J& $\ "^>-0UF0O.$@K)=BE?OPCV6FZ"B-:T#B!+)Z=L:THC
M!6+@B#/B@HW3:NJ]MFA6;:ZIX%5\;*$>X'!S^+0<2:N2OI75W 9^]K3;SM(%
M%'86SK)K%*=^3NF+\.#F;J=B+78@N&CNH"8"<Z^87*\ P0D)@N_R# _Q0("*
M9/'[#J\ 1Q!V@:#<\@@$T\[U$"\W24MI4A*!2%>UU'9T@3=K?\A9:V 6+,]]
ME";Z"HA],E%[$&]$P8G@I#:Z-&^KXLE]*@_QTLUS"\MS*R&/(N@-Q-<%ADT(
M$&"+WB#[M@CH8A>!1,"Q"A!>=<CZW(@!'^PNJ:KZ%&?P@"C_ZBSAYO!L[II@
MI:HJ^D)*OY1/&1?7 !@@4&7'[T@I=B*!:0RI/J6M'MIO/K^O/M5NU;:)6:,O
M<,[/];R&8IN+<]<S!@MG/?$G#_/&!2UQ(& P(6@X>S00"Y6P S^'!R^P0'40
M(6KPZNSS"3]G!)%8Y)"P;#Z'B >B<(JX=WX8(6 0;YQM!.,JAH5X;2QQ;7S8
M"I0!$@MB%1=BBROBYF9!?JZ.! & 45>X(=11*.38(NAX>@QP*B*GS/Q0&2O0
M?I8FY>!X-G X*O0FB&&B</K8* Q  & )9+J,CD5BCJIFC'$BSCYGCA29(%@N
MDZ6&A!8B%)FG<2[0D4:9<#8Q)])4_R%NR7U4V6^LK(_>&"4BN6%FC)9!XG=D
M0!P&C"?N&&\&;2&\\WEX.1*;#R&ZDHSC]MC()AE!XDP/V27@1P49J(>V*% C
M0AXI+,$H,'(@:=3:D,3:T(* )Q^QD,TRL9P7X(3P"<B6C(3FZ")A2HG$=XZD
M4G1N3H.L8)$\["!]-_5<ZL$0DH)&:($N4GS6N2X1<NL.#Y]B:\$D0)+*AH(>
MKA*""(!4+8XN9] RFH@$$Y,63Z1>]986;R63Z(U<(!FCDBC_AVRN$8\<*9#@
M-')HB&H 4OW$YVY0L1)3AX@6J]PN"16M-8Z.%*>QD*7Y1H7T^92L*JB1,)'B
M(-"B;]<$*?^W\AD&3RXNO_6]*EDE^@::'>:0<.ITA*G)ON8RK6F!^ YW3">@
M_(R(#G-53^>D^L91EVR;9"%P099$<Q4P,<S>NHDRQU646$_<_DF;5O(AR\AV
M+5JFOLDU_ZFQT4GB+ JC"NJ"P,B1CI&(0$ 9.BBD N>A#OCRV(<ID1,Y;:HH
MY^VD:,IM02JC]$JZ= J=>FI-\2>_CE6K:)M-E1,(LNQP@8?D3(LZR[;NU/"J
M>DJJ3 <ZO8;"".G:D-NI+))R!]4_39*=?$IE78VZ[0KPR,M\?,QT!M5\LGD,
MN4AMV(F1"ZM%QV!2T1L #@N#.K1!?9A3:U6UA$INN:=EF:J=P%?_.1L(+G\1
M<L9GW73:C)H0X:S2(Q,MHIA*E8+KFK3KA""\I);L1/.ICI)UFF3@DYEUFFYI
M>7 TOJ2KZ/:(XP03A ZI*#6(">8&3+EK%JK3?ZGZJ.:KC1C@7]MOO0K+3&L<
M/LE-<<W'=&('V;1S7HN[ZSJLC&JHR%M*Z_S4L#PL2'$(>/)&J@Q5RFM(ZNJN
M;F;A3@4V;U!,;Y3<C'[@4C<W)F;I!"MF!;DFAE;' $:@L&[5@V 'SI7FQFS.
MS:$JVP[,44V6(%ZV97]+OVV!J31*98NH"2 /-NLA6AT/#[JYRA8+O+2(, '
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MANC)@'5Y^8&>XH"X0O5J70SP8@+&%0=Q*"HO&9/%X?!%23H* %FG4J08A;<
M$"1K<E LZ>TLLITXF((*RJ,= ,;P1C>&"P +F,4;N*.,FBW/9\ $ !(V$@D\
M9/1XBMJ.)?2RG<1]DIUWZP@K:9D9F&U$(15ST] Z*2T1["\SD:A'1M$4IK2N
M*:F>X98(1 !"()3)7G(0P'<TF)>ROH$*.VR +("P*YS98JH):4 </01.<CKV
ML9"EE2RN)P!;:"\R8LDA PW@%IQY\%13+%C):E"/,8!G>UW\P60[PP0H<A$
M74+_K02\^!0W'2"H<2.H%X%GE-2Q;HZ--!:@<"O'3X;04)3DW0CNR,>=XH]K
M?V02@5PJT[8<[F B2!S'"'DJ%] .:"%C)+"F1<DQ$,@M3+CC3AFP/EQ9H9-W
M\2&\,%)58(9IDK:[;\$\EBMC46&VWU(&J-PB@&QE2Y% (-9_BVB)!=PM+QP9
M&IID0,".30T($&2 )0 @-]_M%,-4O:<$9$=&<6@$!%X\(@B"AX!J\2FR,(ZQ
MC&<<$\7&X0U-K,#^EE()4VP$GF\P2"54NS]@1>0@%0DJ%48@@C?$H6P*V#&H
MXM"$'U>VC\6,0TP5L@"#5(1:B:JAXI",O#HN[PUEZ]J-_T,&@"$]&:=Y]$PQ
MWR X%PAO:C$3'I/M!H1Z-)0K%XE#)2I2K1LW,:?5,6-FWI"&2A25RTV.A,+X
MU^0X)*IK%*'.U":"K$UKF:>BE$,-9ODR+7L)5P?1]+G0S#Z&FMJ' C:LDY&U
M'2<_F6Y.GD4V+S+K4X_LUK4^"+($*&ED>>[&U $MMR9"'8'$02\2<3+68JE8
MLP$H.S3L"F6\2>-N>_O;06$-2PS@G-,D9D&E>?%<PN,4;XZ&,!TQ"V78?2.T
M(,#<J<J-6CI3&7/;!2^.?,IDFL*5['6&+E<!@+Q'HABJ\/OA#)_*OL^R%HH3
M7#*=0<I@E-FLL41\,262  ?2<?\$ D#@(W)J0!*.0 (C; C<,(^YS&G%[1ZU
M5)+=B11)9SXB 7#@#_D(P!P"P &//(4  >!' (*N;IX[_>E0CWI-]$J%IL^[
MYE+?CP1PD*$ W,,)16>+0@9 (3]02$-93[O:I6XD)&&]S10#2=O9_!,D61T_
M;@I4AR8N$KW2/3%V-H#KI)@3%XMUH>H^@+4YM"$#[, )BQA 8Q5B@2[DXP^[
M@,!) G#WM7O^\R_4[/6P/@+,Y>NF#^W\2Q2 7! 5[^W\ 2_#(6.@,.W/6ZG)
MB0N@."F1@0<NIC61!-+#\$7DPQ<G!\ .*#1YT#O_^;2"$KE\193PW258AYO%
MTL1EB^S_MAE1W)IA8N3ZLNU7*[L5ZR2S%M(D2UV+44<"EU@FABR\[*Q)5KA6
M@7$J?U#12Y?]8A'34W] !2ZPQ"P,84T'H"Z\$S_[HC'%Q&8@8W_K(G[B(GY,
M,$,Y8RE28H$G SR:81$5@TR;TGL9&%:^8W]'0RUIU4<AR#+1(65-85H%\2>>
M$2Y60B A>#% 8B5RL1VZ8DP$LQWK\GNET2MS%4P30R!N52('P ]_4!17<!Y7
MT!%#0"$- 'U:N(7E5#?&D@9R #A,\ 8_,#J]LC<^A#][\S:QTSB[4C<*M1 R
M0#J"TQ!: A'J@FOX0X9YPTM:=A$" Q&PTQ'Q) =S&#OPHB?'_W-;(/ R,;-^
M'$9HJ6-IO2,PKW-'2! VS9,Z7K0];Z1:PJ-8#  [J&,LLV, 1 $=X#,+Q@."
MR<15V:58(O ]N1)?(7,^]^(\SN,"T]%>8[ PZ3,NM ,\JI->#=1 P#B+D4!X
M(9$74B0"LU ?534UD1&,#%4O5L",3^,^]6 X&V-0*50:)A0+$G011!0'XV(*
M+Q<B$!  B]",9.<+6=@1RW</Z\B%^)B/*+)#U]$$=90H?O->5]1..B1%P$),
MSP12EH47IA=0),1%!ZE$5\1 >-& "B%2ZB(XNY(^8[!$7%$]9O9%5H(0->!2
MI[(LPW)%!6=29L1 C>1&&94Q%V%7V_^#4.LR):ACD7-D/'.547@Q2K%!+1.3
MDW%H7:F$*<Z!*=L#)#\65['C%IV$8D538)OS P6V8E#)D7XC?A=!/B* !YWD
M%LGD7;77*F$2:_8"C%J"+UTC+'JU93A#2*VE+\G46E$U!@+6  G&EITH#B?R
M=<GG$;'@!TXP %F!BH_'>?JXF(Q)(I,E>/X( )&P,QDE)@H 'H5"0Y.)+$AA
M"^>")@>)BNR$>@3%27Z341U#D;#U)GYDD^ES3,^240HU1UWD DP@3PS5*&DT
M7Y& FH"B$*FW7MMC9DW"84^E%)OF3XU2:U!44Q.D1D^E%TIA1J+9-6J%$+!D
M4Q_U1G<4)@S_H!2AU"7WM9(2)1UO9 F,Q&&_$U\K9IZ\U59P$RH%X4\\E4>8
M8B#.>%_LQ#'14RU2$@G" @"RXQC^J33'9$UQR3^Q5"UG) 0FPTG>@F\,XA@2
M8!Z^('D*(0'IX ?[$(4?$04!@':-.:(DVA'95AJ4(1[UM #N4$>QU40'V4Y4
MH&,T%%L645GHF21^8H&$Z$ZE&3<PND<_^A3 D@;:XV@&(%(+]E.L1YS2.0*^
M<R3+2 5(T!Q38X&N8Y4@*#P<9E(A1$=M86K.94;3%0D'XU*L!R0R\%X= S2/
MMEXN:CS8)2IZ221( B2=E"U6^3Y*,8):XD4%9D:$M!'5HJ4-5#(%_W0W%Q$]
MZ*5A+:9A@&J616&65H"60Q.@525XE>"6DKI >24#(,0Q5FE:=YD0T*%!0!4)
M=",.$OHA O '9^<'OD A<W $(7&% 7"/);JKO&H<CK0 _G@ D1 UMB!L!/(&
M:D59P]H_!Q$9S'IC?>2/#D-EZ:,4]P0TR*9#I0DIWM(Y-LAK6D8IK^5%2& 0
M-[:<K-@L9U8VD#,1. 9GU3$UPF9F!B$^DP-L(+!FO'@0T6, #,!IBN1E2>(9
M(.!D"E,M3C9)"R$"DR2OMS8U%%$)MRB>J]9IJU8)4C0Y%!$]%=MJN=9(W3(1
M$($K7B9)XJ!W^<E B?$RSK%,(OM>2+89E/^Q)6C6*^#C93);&M1V:"*K2S*@
M,"?2 "3@"W/@!/?@!W<0=B"Q?$Z@=[WZM&O7?/G!;0-'$@O7&AW!.K!W +H*
M%Q4W$LWB;E6K-'<!;Y3Q<J;!%A(')@^'<:B!M@:@&GD!/U<W;U#!;YD1/>E&
M<6Y+<*1A !* %3%A*:YR%@)G(!WG$4CQ8KF7(X(A<A#0M0H! 4DP!+ 'M9C+
M<Y?+(PV -R("7!RR'(NE$Q"F>CVQ'3F7N:J[NMTF 5*[JV/['U7G$V$K'M=A
MNN"VN<!1'Q(@ 1 0N1FZ%9'+M1EZ "80N8![&0K'M;Z[%;V[O"_7O,+;NP>0
M?+W; +I*O=%+O K_%Q9<^[N ,;W5BP%AT0!!,+SA>QG)2Q1;80&12[W#"P%!
M\KP+4;R^"P%@T;M/H;_""[RL*WP?\100P $<$)@FH@!) K%QR!-Z)1<(_&+2
M)1-0PDWY<B7Y@BV+9Q/88249G!COE1Q&D26O(<(Z86?9T36CVQ6VU<% 15YL
MP016&U\ELX408 ($? 408 !!0, \'+X<< 4\_+LYG*$%?,,_7, 'P '*"P #
M_,-7 ,0' ,0^# %.R\2QH!H#K+XFT  8<,0X7,-.3," "\1A?+_UD0#8FP"Q
M\,0\[,50S,38"U9$S,8%/,!*@<;'Z\4<$!7L^[\GXKM #+XH0C""]R?M__8<
M/N,1#\7"2_%3,/%0L")W<08J?_1O/*%8X#-+*@%2N8')MC/"FHP3N**-;$&J
M*I$9:<2J??<=@-8J(V%[&O%,( (8<C)YN:&[OR%R'& 5'& "!Q $)B !"3#,
M1$' D9L /VS#62$!7P !7Z#$0G0%>;S$PCS R,O$'( !!C# 02 2OFL"X 0!
M. P8!E#$^(O,V2P ]TN^I7&\"="[QPO,O L!Y_N[0E3#5-P 6YP 2&'/'@&Y
M@($!-OS#^(O-!(P!"E?# H#+?MP?(B?% *#$HK$H33,VY$))UE1](% V&7@1
ME> 6BG(WD+/1/%I297-;UM(LN<@ $NL8]&>5[_]B!2J]+GC#*"JS<Y"V*]02
M'8VB )>6T@]38!>3/.P2)@T5,]1B@%9",TM!+S'#,5&#,B\S"_>2@D.S,A (
M/9V!:J:P/1CE'!M(++Y#*7J%)E:R%1&#,AT!'>N21T18-"=X@4^#U;($ LMH
M%"_891Y$A&!J-5:B+Q/A@F&3,@R4KU&AUZ,:-JWC-<NB*X+45G34JL<A)]6K
MJQQP!SL@T;BK&\@\Q&:1Q6=A EALPT^1 #AL 29 %.@LSMPD 5= H280"V8L
M$N7LOY-KPSEL *@MS:I-O^?+%5V\(?0, ;% %(!K B: PX21?(*L$!@PQ)1!
MQ<HD %U\!5^ PP@@SC__S,=+W- APA6Z#-VV;;O=Q9%-(%$>Q(:C(P2AHUKU
M\)7P5 ^[)E#*Y-,"LS=BX3KX\VR+(SO:,XLA]"?S-U0CL]%6,#K:LSD.Y4^K
MTSJ7HT0086#PHBY/.5.Y4BR*8XBL6#W; SZ^(SLB0&%T2TE<$CGPLM$W.2\?
M+DG5LS!SE5Z9;#R6EAM!=;.Z9CU XSXVGBN%JQ!(N3R U#W"R#_2T4D/](W0
M2"R-@D BY$#\PT!S=%,5U.05!HQP<RJC3#<<\YQO^$#>,D>#$E?/21"FI: 3
M9 MO8"R8^9Q&>"!7< 1^$"$&W!$64"$X0 !B9Q^BN<U [,O]W,:[+ '%K4SQ
M_^;+1#S0&-  W S,:R$6M7T6 QS,(X',AMX1O\OH"1"YXBS-2TS/6=$ !1P$
MQKO+\JP0F7[0(0$!"+T0O_O/!/S/X@S&SSW0@>P8#.W=]R%R)N#JM_X:LO!E
M"+!9!F!9562FL30TS@H>?G),,@U64>-#U_(4P%,7R&(5(#B0&V5,'N'32B&;
MO4*&611G<]38@N019)IN#7 Q%9$KO)5N36I'>'07(P0^+L76&2,#]5D=T]X1
MMB,!K*A'E:!6V3*++D4\B\0Z HI,=21*G=RH#GHJV0(\!A.IYK76$M\M0<9)
MZ?,S@'J?BL>+B5(X'7-^83D\^,*+!@6ANV(%'$$@U?\#0AAD3 <D#OVC\<;.
M*SD;)K, -->DR5.3L8G%.]UG+*HJV<0A 7X0=%U  I,'&)1[!P]B!/S1+#;\
MQ%0<!$#\S+YLO.NHT!G:S$#\Q-+\W!P0!*[1V:=A 1P0"RK1RR]'SQ)PO B0
MS=F]QF7_%"8@ZL[-QGTN >?+N\A=P*D>QYXQWH+,O@0=][)>PV)O]KA.(@UP
M!?.H3")GHN-Q)+:@,+( /WEQ+F$CF[0%G-'3 'M2659@>F[3!!1UWD3J)GEC
M630$6@B+!S(@#J5BPE/3!&D0-GPX+F\@1?[)45*&9P5W$+DY1T+CXX0T+S9)
M483F4D@0'?>.4'=F6_PNGB#_H Q3LZG*F5[:E6B=])W&Z2^X\G?@554[Q5--
ME48Q,TLF3!G_NCW/ @3K[T4*BB9VAK#+(D6Y(@=!5!   60, RM4  !@(L(@
M$X*1\# @R,0*G@8,FH@0,4O(&#D"F)ABB&<,B :1@$"T-$:$$  -%!X4,$9<
M#2 L7;($$%/< 09R6D9R81*B%2$&#AY%FE3I4J9-G1K8X>3/I(-&#QY8:B1?
M  E.O7X%Z]6 ! -E(7"0 .&+U8,2.+ % ,$$!P17KP292_8L! A7NB8]P $#
MUJ-!T#I-^Q: 51,0  2>BZ$K @DFKAQ($-?Q50Y!$B1P&P3OW\17, @P*D%U
M7,]'__DB-2#W[^,O5R @@&"!@X4#77O+);PX['#BQ8T?1YY<^7+F.942%L!T
M]M&T)AK4/7JE07/N1P4P^ %@01,&LPX(B/1C9 (!(ERH3- @CL,##689E!')
M5/">+>L5/4JE PZ() X0SK/%"O#$JV>,. PZ2H;[!+"E$A ,(%"]'PY8P!0A
M9,#H!PD:J,DJ$*E +PT\!@1!#A 94.@ $'X 40@9Y7!!A)-Z:Y$)C7*$2(B8
MY!@##Q3'L**L@Q(2<I:.QC!)" 209&)&)@% 4D&6!AK(1A'D".Z@!GID0$H9
M< 1/ !<86%/(-<,<HPF-(GE#P1\\8@#"BNY<4\N8S&O EO\WPML33\(*'6,6
MAGY @"$JK"!II9A &D,9+!7EJ$B>&%W /08L.<"%>@@[(-%-$8H$IU)G^4X.
M!%QBR%67J,"NN^1F:R" /\($0()T"%BJ@7S\X,#6[@Q (+ @C#K@LB @2  N
MOLA*( C;#DO ,A-,6':Q*SB8%JY>P4VJKP/$1>H $V*1UC'<ON6 @W/CNNP@
MOK"3H-Z#&C/LW-BL6_>OL[#" (+@GHV6.GF-0B"6N2#H"H-XX_WK (B-Q3AC
MC3?F6#FKK#+XK[K0A<TU#FQ+R@ .,B.Y8Z\6>".2)M1KXHU*?!JAP#@ %2&.
M-^2011P#&A@5@!%^_EB!.):.0P[_MD;H^6>7?#ZPAJ6ECL/#".E\ P0'KY:#
MB0)_#E4$&8#P&4SO&/!9!"O07MI%/!A:&@04HZZ$1A'&@)ML$2X"#\HW@*""
MR9@V/(K),<$<8Z WX@!"Q+_QD!1)"02O*8&OWU@1A MA8J >(/ 0THHQ2N5:
MB$4!L$+MHSJ58TP\)#C;Y_ 66V#!-1EZO&LJ2C7%( %J_SFSG(+RV;R@'N_(
M"F4J>ASR#Z_6J*<Q*A$'":;!%'OI_:Y20,X:Z(R#T:/"CZ,_$JD8_XWB73X.
M JF\.XH$/ZY*RHE\AI@._N$2.,M<P 5 >%W!-AB"5[R"@  !Q@MB\6*9 ]$B
M+K?TKX)._Q'  (\2F\'TZBS/NH( H66OU8SK-/:"EEPX\##0G&5B)X3 =:KR
MFJ0TX%LB;$Q;]M) P?#*?S\$8A"%J)3HE 4T$SM9O&I5,GO!"P-+49D/A\B4
M!AA%%@>"BP3"5$4J/@@V&&I9%:WBKZ-PL2ED? Q<!O2<>0'&*@*85ZTHHT:L
M(  [8#R('.M"EI:!98U*6>)CPM1& /P 0$VI"P+@"(!$%@>.?3S*'YDBR72%
MZ9%LK.11[,A(F& F71@D9%(">15(3O$H&-"54CC #U]$IUP!<,(53!D6+4K@
MC@9(P+EF8T0))*!6H#'>=,8" .,!TH=D^0JOSH.48/:FF%5!RO\BJ\(R+?9F
M@ZK1XE'80TMK]HHMOJR*:EPY2W*6TYS+.8O#;E,KODC17L7:X%+<,LYS*B5H
MI62* 100"67P"I_-^>=P @I%L9 3CNZL9T(5"C\!_"$ 1D!* QP: !(HA0#W
M*,-F%CK%@9ZSHQL%:4A%:ARC3 QE2,GA* %@K?[%LRHK;&E"T6B< T!HI#?%
M:4YUJE ##( ?9?C#MP:P"%C^81_I@(D!KE"&?/QAI_#[Z%.E.E6J#K$KX.J+
M1MM"KI;&BY;P,EBOROF=2@#!:4TY)$+.ZI68=*V?:!VH 'Z7E.^H! B1,,GO
MRN02O,Z"<*&B$PB*LH ?V+0X5#" 1 S_RY3#B:LB=S4K%1I0D(U.UD:+70XE
MD>,1UUU%!K<CS@$^ZY+[5)6(2C'"/O;!#UA2% )#"  L_>"+ .S#"4>H@7-,
MNUO>]M:W(2TB_@Z@F[DTQ2V7V6,>5[B48NXR,%[03E*Z\D;_+> _3 "M4A10
MM"5EMRE$LP)VF[)=S#9E 5Y$RIE<$(?P%FYH]?C!>7_ !";\;B3A'0-\O^/=
ML"Q@%O-=R5?:XS2XC$D$3,C1W@*\T$[!R%+<J0@(FB,A2[J@O%XY !,V@M[?
MRO,*1R ! ;9S$ [X(;;WB*TL.[QB%K?8Q?##S<0LH!2X?"L6TG4@_I#B%HW6
MI0$GNY@I1V 1__?,EV\_>&RDFK!6PAI@ 0J*G+B^<Y'/,D$EL>/;@2VRHL0Q
M(,I-%D!XMQR<]L17:V4L7X=P(I[(P80C5%B '&S:@#6)0#U?PDKN@&"%4G4M
MRV;%RF,1EY">O36B,UJ2"&!D$R\C3L]@RC 0[#RT1F^QTBWQ<MC>@Q$4Y2C*
MH5K(?+V,-I8(H &(._70^ 9I"R,$R6LJ$T*R)H3'*F2ROW/!#]A2:X,T@&\@
MB(,04(VDHM3 RWP6K:0'5&=561D(,V,6GUN"[+,I1$TVD;94GYF3*^Q@ "-^
M<;A=1D^8E%O<YS;GN[H24\"XI3$4(Z8*79F8#]I&-9FQ8P =6,L@RO^@"1OQ
M6A/&0 65,$31_[:*+/!@@#A900;_@8L MJLWB^1))4+H"=L.J;3Y!GLD _KO
MPW7]NON<5PY6*,C0_LN$IJ'<R@<ZGT;L UH9_.QZ(C&KC\*[Y_7B* [NR3G/
M]UPETS5-7/XM"D_V1CJ7'/A+"0F;6?LT$"M@!.I*:KH+S.H2!B0D>5I'D\/+
MM*B8X*'.(%CXDLK$D]AA!.."3=-(A% @&[4$!(KJ24+,P[>JSQE&"3%%A'-4
MCS:5*@X<8?N:B 0$*X.$ 74Z%(S&\#U,;T@&XH@)XR=O99^P_,+H-J4KR1U-
MT,]R]*5'?1 O2% /3T*$,)E+7<@EG,3$RX#_\%3A%09PA1L+!W[6/4 ,Q!$T
MK,CB9P;I4' N;P 97&@$@G7L?IJO*0#(('V([1!B#](3 [1*4^@QLV%E8*3S
MGF0,NFZ *9 ,.0:<OR<V1;H (F<\)HV@?#$QG4"L8 L<:<1P2$*\ZH,(,&D5
M7O&O-$# -U"=,@$1(N&T#,L//#@;P4J %ZDZNSF(]Q"> U 0_(B#?PLS]Q"!
M&0FTRH$[.?B2,6* N1D[:TN(@;@32,&X'S >7[.4#&,"(+B/0)D9P* "3_.3
M'"P5<=@3C@B4/3N &@BPBE"0!SN((7,1<? .&0@\\.@41ON!_O@(A$J]T',.
M<HN.,-2M+NP.T2,]_S)$PXW!D+0XCEXBL6_Y"P<R@:U2#&LA ]L+ N\(C)-A
M-XVQ+H;S&A"@O[\ADOU(N OY. !(E:.[C^:#$<)(" L1%0@I,Z/@D@,Y@/]2
M@-**$(7(/DYJB?+Q$5HYB$VT*95 D1DQ$3E+OSLA" :(!$4##Q\1@AQ!K%=D
M *R0@6/#BO-3DC)"M,19B2Q#">31$:>I",@1 8> ",2I/LK*B5U<B \T$S[S
MM<%9P/!8P351"2<$@#H#$UM$B%>\$[E;D*M@@ ,1@3?0$4P4@?^H%>C1D5D0
MQX3(,$4#@5AY#,'1D5Y+$()(EYX8OXA*$" 8FE1IB7]T%2;@KI&")%XY/?^%
M$L/3BL@T+,,S'$.+U$CN. SZ82+$V+>X*"X 2*+&L(P0B@\3F W<@(!O Z(%
MV(DK*I+N.S\ 0((&:4@9Z*<*$)KV2"LQV0]9D(,5/ ]?[)#)LRF%.X A^P'B
M*XGY.K.#6 "[4;.(^J^JO H\:PFS,H 1^"^KJ!+)^J]2T1M:H9(9.1,A 4 Y
M\[Z] @%# \;L8A(DJ)R!8$N,0+GZT)&50  9R+8K;)4<$1)_ T'303G)8H#G
ML;/O,+N,\XDRLH5Z\(F;^$:WZ8DP X(U :V*4(;_NX^@&$'XJYR:B+O]"!2R
M,<*!BXEZT$*WX0BD@,++BZC'PX.6>,V2P+B%(Z__G:(G>AJ1/G1(Y0@.H_C%
M27(I':,._ DDU/C(YM2QBCQ.MJ(NY$P9UNLHZ+"*F)HNL4K.I6!.>8*FB@'/
MU-"Q[22S/OJ+S.A-=!%/NJ*?[GLCDK&@MJ Q[B0-Z7H,W8)(?)H. 3B+YL@7
MM)B-9D&+)+(8KSHIE;F];://C &^(DE'HX 9.K&"&J@$[KHGQ//)!F@"[1./
M^RB21#ROM#FO>H 0GDB>WAB;02F)#BTC_^-$,;DNC2#()DB#FY%0P3H?NYFY
M_9( ML%&"0 "UC02_/O1I2&<F+@:*[ /)OLOI+A"P\/&!>@;'%E' [&RQVFS
MJQ <'<6<13. W7D\ [$O__>YF3ZQB,?,B?*@%=&Z&K7TF8O .$OPCNL!@3&%
MG*K[@2%+.TRKA,!"L+&!N<D;D)Y @#&MB>YIFA]UE3+J"1>8A5I1DTHPB,32
M&5=!@DKX0" ():K* 'Z8@PR SH6"BY9ABU)]"M\CJ:9@T.'H'Y+QH3[Z)ZPH
M3E6%HE$5,.+HP^T$"^!D"I4""W'IOF#-3R5I&2[$3UMEO8S!#*]RS^*(#0/B
M"R3P@I.IEQ+JBWP)#A<*DZBR%;GJ* &0LUGMHU#JU&CR19HBI/-#UD@*$V#M
MIJMHUTEJHTOJI. 8$ 8=$+;0K$QR5PSCB&(:)NSHUZ4H6+JB) Q)IGH] &!M
M"O^/V(ET>:9Y32A^O:9/1;$CF"HI^ACFZ%CE.+U3A2:,\=9E'5EE':*2=5B:
M@E9:(@Z'+=F.<0O;R[%I.8ZA42&L.AE:Q9 D(DEP"0+5X(N3VMC/J\_NF)7E
M:  Y6+.<BEF->:RF=3&>2(\.0Q<#B(4,\ 4_(( NN =@X:VKU;& 4J-</=GZ
M?-J/S<_J?([H9"RV)5F4+:B.F55;^:A_PMNF^*>5]0JWL(!8P"::58SD>":V
MZ MYV1<#,B"3!!=?W4BFF"OA/-?'#:T&H%C>LMP6&]:#((  N(<CB(X["( -
MR"DX4HW>J ]H4J8&P( &Z,_^^8UX;5#5R$YD&@N+X;?_TX68LCC=U:!=ZN!=
M9.H5W"65V:VEW=6BW855;,JF7A$9UG5=9JFF6J)>6G6*\] BR2",Y'4,817>
MLB@+BVG=WA5>&N.CJTB+WTU>LEA?;$)=VE4-UFVI[1R+U##6:H(8LEBFV<7=
M8:*.]HW5YO4F# F96NJ-\)6N+&J)_"W9^D6*@B$QQSV.QMBDX=6+6%"A&9/;
M>FH/#WU8A7BCE7 ![DFLM1H.)N@LB8!(!QFYY6""Q,HVXU"LT+I<I<A<,8'&
MK[ LRD7#6-@ /_@#)8 G!/!:B,HI[HTAWBBCYE67WPBK2!+@H$T+"/C%V%@W
MZS"*OMB.:GD6T3"*9T'=L8" _RY&W85!H=@(LFEY%O?U(#&68KV &+G0*CTT
MF _2C"N.X]]@W0*VF , W'85V@;@"S&^C9"1KG9JBV>!F 9H# C 8 $^9"K6
M(3$^4">>E@'1HLYH)]5P&,MMJ;"JC"I:8]>8XMY@PX;%Y/QE9'!#XAABBF<1
MCCI>9'X9&/;=)9MUX_RE8@DNCK/@9>+H2*2P/;_876_Z92$2@$KXR:48 8B#
MB32#2LEJX>$XDSESQA?MK.2P#UJ[YN*XDK!8'.0(9[7CKTEJ-1X&/:L8@-HB
M 5[Y S_06-YT%WC:%UR9#95$BB>VEZI0R5U;%D$V@?, EX ^" "J%4^*I!&*
M"P""@/\.B@W/^#%D:HT[]HV+T2*!G>CZF-]N<M]ZP5H,,(M>FHYX#3+ 2)?9
M&)$QA@D:HHZS>**>?2(4$H#R/<XI7K<@@PQ7 B!\GJ'-2):KT&"E:*''0 N&
M5E4)R,.KT*A-WBJ"7@PW=$,F&HN.A(R6=MZJZ":SZ(S4^,^K8!=S:PX,^!9F
MZ0Z53I?;^Y9O2=R+D4_JE&$HNYTJJ8DED30 <42$@XF@B++JPXA!"=,[_3>)
ML(4ER[5[K(GZ@+(DX>L]8[Z7D,KYRC\^&X.N,6P;\;6G2VP7:!&L $*>> -Z
MM!&&B)SZ6!,D1(J$0,(<U!%4J[13.X]:G.S[P Y!JP]>+)O_P[:^X)'*O92V
MQX(TU48R(>@T'5EF=#:M[[27+MB'/^B]:'KG#'C.IX6?S1!03@Z.](TI"* G
M@\D,7JD6 PA:B%&7]"7E/.J-D6EC>QF+@HF8,1[C(/"7Y@UH[DT8+2).8G+=
MPIC?J#88T;#9BP$@?E.2$L*FKRBA<2EI]N;7 QA?! @"P,TC1H;O/LRE PB"
M!LBE;CF(P9 6ZS4 "$YO-I2.0C88\)YC*\X)"%:-9S$!MI" YGX,W]C5-6;)
MZ0C:/UI#I(!O:TJ SMBQL_78Q!BG&C98O\ Q/E(-">( #*Y58Y&%F0D?U6$O
MEI/R'[A)*7^/-  0??*_?U. /8N3_Q_X<M.9&1#)KSL[F_ JGYJ3@XEK/BMP
M<RX["#/_&9%CN1_0.BO0.AIAQ^EQD<]>+SQWF_72\S7?FZ'CN?21$&6P"BI5
M<Q<!@GS,N1Z1.DGYDK>1@QI4-*T[QAP,NXNCTK42&WK,N4U'NZF#""LDB(LS
M;A:3 "- ,5^( F_;@1U(APPP JV]ARX@ 2,P@EX_9B#*SH9- .VX<,-8HK2(
M!:+=\.G C5B8H'(![]A( -U XSW2<)*<"P/2H@*"%M?-WU@0C;NHELQP(3XT
M !9:C,"X@COLC8GN%09]\8DQ@8)9H(:>V7C!C!^;&$6>F#F>))0&CC+BZ0W7
M;FN2C5.:EO]=A9;CE60QF8YNAY?2:%P4,JXQ5LDX3FKJ((RAP:J<92:-JJ6A
MB:G4P RLD(MQB@_1B.D<7PSP[J4JNJ!Y5VB,@8Q@5XIU@_:<?PNX.$FL ++X
M*&GN& D,$2Q;  &4BX3]2WHK6'I;T#4!T(@Q:@ K4^8O,1J-<)NN1$L0L#[1
M @'^,XI5=T<;R3 K&)3FLRDS/Y#]VF:"&/O&P4 %,!+Y$((?W9"JMX*FH<4<
M6?I>;#^[.53%%B0$:QK!K#Z5R,7$O[@!FTJ:RQ-,6WP9:)RZ-HIQ%H\ 8XC0
MUCH0X'0AB \[*PG!POE6!RG#S0<GB"W;VHHR0#'5\@,GN ?6XH?_K2#R(=)N
MDHP6<V^IL8#P,I*B"I*6:G%P1HX%#,B+Q7CX7EDDKA;I?<]P"[=#]_YB]@WW
M@N$B<=J@DFY>%^?Q<>&6 5)I?'FF>T-J*BZE#MHJ[O_]MLC>WVA_039DIM@+
MX'@68X7@8=^E@L&E8@)QY@((" (1' @21 * A D30$!H  .$A <@0C!@T8 $
M$PH3-+ H :'"D D.'##04$)#A28_'EAX "2 D0@AD#01,:$$#C!#\NSI\V>#
M*S=_$NT9ZPH&E0HAD!D* "4' 0""<+A25:@!GU*+$I4ESH  ($QL 6$PAH$0
ML@S6"HGT RP((5D!,*D$9$R3'[;>"A#A_V(O6!%"QLB188J*+#QNP9X=@^>
M  8_ZI9]\T/&8X5,0## 0R7RCP:SA#"0 YDP82H 7("@,L+4#P"2F<2),^:-
M'":CD8B(9%J ##F$A8">NV!6' 9QY+B0HUH& R"F 4"W(KAO;A"Q$[JPTA)
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MQO32H31])%!!'.S(4XU?<AH$H;DNF"7?&)RX*:,<KC@5E2A!@,"A8.^$4:,
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M#Q:0!HJ-?Z;RT:>!%H";+\D@+^-?@&#4GT(L0"1D1E$0H %:W+\T0"08BVB
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M]O$]&,%-\!X'_$$^+ (HMM33]%,</0]D/@7C/._C/&I"Z:U'8%YX2<0_<85
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M'X0R@(&_XAB*@3<6B@.OAT:(!(\#G)M1!B9=> ,O(,T\H($ZCQ))!+= ^!&
MWF:Q,Q(YW,*C@;JJ?$,D$%SPS<_+X@@4B>?28!2(60@2QTX1&#5SRC@ZQ4,
M*YC$D200L/+M )Y,<0L($-\@:!8$#A BLHP8,$4(S7[P;;%8?;OL#1 LZZT>
M07&MIU%QJON3I%F$2*"C) 5@8@R2A!#R1+*64FBC:0]8]5J%$F+ ,,UX[-!
M 238((!\G @@ "?DBU?>>?W_6$0C=?GMU]]_ 0Y8X($)+EC #1F4 ((&FBTO
M 0?Y33$.$424C H#,%[Q!Q>RM,4X31M( RNGH.HKL7TOFX@)A0X0(4G+1@"A
MKEED"TZ6)L3ZH2,299@H+V%O<NHDC 4HBJN'>G;S#3EDJ$<. 9#\<BC@[E1F
MWP/J;+K)D)11P&F4>P,Y3*(4;6(D((82[N0%V"KT4,7R-'NFM/4ZN3##^F*
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M1G,V4)?"MZ2AP.2'=G96G_S8V28# 9EW=&&";N79V\C@*7[^9*'^53275-<
M1IA7E3<2B^K-(<QSN%< =F#E,X^:U*6^;P(F! $$[-9 >7G(%?^"X&@"I80K
M17O*:-#V3CF4R I#68"-4 63,=!EUQ$!MJT8@#9ATT61EQ&!$(T]!A# U J]
MADJO]]4 @:+-!8 YD0QD!D9L"\ %=#.  H8% A&\9 ')!F*[<_TG8O](VV,0
M@=[LC1)<ZYC<S];W&$[$!"M$TSB<LI45N++OA^ :D#+(F4;(+14#$ 4(S?[6
M8H!028>[$\>#8H);U$)L[6E;W]7>%5TJ2'%%CD:'R59DM2I9;93;^]8BEW?%
MXT#3['6;+I7D.2"WXV0V,:#G#Z%X37Y>&(S,J %C0-UP(; #^EI& @2X@R\\
M[(<[D& 2IO;ZU\'N51-< 7T2L!"&)&#_=L>6YR$<T)ZL_V- *BQ 10:A&.=8
M%CJB/--/[RM+"]O7A'JLQ"=I6)-/?P*$HLQ$(0I4C7?H6&>D5:(JSYG.46HW
MD3&Q<(G.:0)CCJ.HGOQ@=F512T]Z$M,EU:,G<3$.08:UM+PX/#-+HR?9^">6
M!X)I*K&O26 88Q*I0#PM-4F\!+V8MV&1RBG;D<GBTE*787FJ6)MC4R7^"!TC
MC>8U<6B5"*!%DI^T1@2M(<E,M ($GR3D@;%AR@,-#[KT#XN/'<S\D=*?5*8P
MOOY944V@;B3L!'  ";  $<35'N)".(#LQHX,U(P#&@ J_,-"Y&K-^D4B?J H
MHHA$=F861&9]_X[E9IX. $20G.Y'9RZH:$2F9^JIG:R !34H(I@D(C*(H,[M
MD*SID98"?F+"1A[#U=!M*'K&H]P"A%!*7)SFW.!D:6I@%EHC3Y;&X<3!3S9N
MW2!E380D]ZP&W9""?J+0-[QB*!I@[K)+.$ @4-8"!*H%<""E"5#%I6(J>ZS%
M^ZZH.&C(-_(I;-BD*LK/<[8K7)A I Z@6HH#BZ+CC2PG]U@O#D"D'@@B(U:D
MI0"J-V8CIO:(.GJ#=9(D3<R/$6NICZ8E R="[XA+T=CL%&G, %5Q%5G1/UQ,
M/"Y$0B# !#B %OEK/]3J =6L?    JY@Q1@$4').[@# *SCC)9 D*/_V)SPH
MB 0;CT6\A$3^YS&:418H)5).IW[TYRG69V;NBH+N9$W&9$Q,;RALP1O#8T<
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M%W !8^TA,&9"!DO-^HM!0J I%JN67"*\<.: [J<M-\(:M4E$#("",(8IFLD
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M;1S.HSZE*0QO;\*%B(! <:*C20>*08FJ):2T,ZC4H+!(*T1 2P^IH1X:<H-
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G_=NU/7C!?=S)O=F[O=S1/=UYW=?5O=W=G=;/M=C??=[I'=0# @ [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g124762lqi001.gif
<DESCRIPTION>G124762LQI001.GIF
<TEXT>
begin 644 g124762lqi001.gif
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=;5 RJK-G20N6D/GO[;CGKOONO/?N^^_ ;Q00 #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g453739.jpg
<DESCRIPTION>G453739.JPG
<TEXT>
begin 644 g453739.jpg
M_]C_X  02D9)1@ ! 0$!K@&N  #__@ \35),3%]'4D%02$E#4SI;4%)/2D5#
M5%]!4$5874%04D5!7U1(15)!4$555$E#4U\T0U],3T=/+D504__; $,  0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$(
M (D TP,!(@ "$0$#$0'_Q  ?  $  @(" P$!            "0H'" 8+ 00%
M @/_Q !'$   !@$# P("!P0'!@0'   ! @,$!08'  @1"1(3%"$5,0H6&$%7
ME]4B(U%A%R0W.7>1MQDR<7*!MB=VL=(U.%)8>*'P_\0 '0$  00# 0$
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M%I_5-/M!9Y_&K*WY@6G]4UB'31[&I_RFL^@B?+]'Y)H]HV'XZ9]2;^_Y?O\
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M3!(*UPZ!E"-4YXM:F%B'/#H\=:.H11)0Z:B:J*J9S$4263,DNBJ0PD4162.
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M?9YGDES6FJ;6S+.B'MUO"^H8(DA]DL7T2%64K._VVQD0(XZ$0 V-:C!MXMV
M/ \_P]]7@OHV&_USE+%MAV0Y*FCN[GA"(&T89>/URF=3.&EWZ#.2J1%5E17=
M+XQGG[1*-2#O,E3K#$,$"%:UQ0Q:/NMN=AVYB5V@[NL$;@8]XX:QM'OD4G=D
M$%#D"5QM8E0KN1(I8A>2JIN*G)23I JA#D3D6,>Z @J-DQ! ZNX.#/<'MZE
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M3<&[K<]XCH:3]E2<>Y'E:Q6$)N5-+2:<6T:L%D$GLJX3;J2#D#.%.Y<R1#G
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MWBV3;NW[XIT%'#M-$Q72F#J"RPNB0*FJ693Q*.DR6QR4]@*'71*2[!+DQY#
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M"H81,<1%JLCTX=S#K'^S7$=0)?:U"DB'N4@+&2!8P7;8K[,60),/*+@!6'S
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ML=(F):OS%3DY.L2CB)>OZS8$4V\Y NEVPE.M%2R"22+]F;]TX3(4APX -<(
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M^B7Q/5T/"CPZB+B%=F0-Y&<YE@Z*L.W;'.59.CMK&]61(G,PJZU%G_+_ *
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M$.#=E5*T=1--7ZN0$8=8@.%%Q-1$Z&O]Z?M,_P#,-^_TGO.NRQ)_N%_Y2_\
MH&J/?:RRNR]I4.%C5!520!Y#*X.7G,F%DSH,9A4V1$%"'&,\;454(24Y[TW"
M)4MO]F_'H/H+C*7HI+%9I*4')$XQHPH\.89PU^/<DODC8]R[*QD=&M78I$U^
*M---4XU:'7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g701865.jpg
<DESCRIPTION>G701865.JPG
<TEXT>
begin 644 g701865.jpg
M_]C_X  02D9)1@ ! 0$!GP&?  #__@ ]1$E32S$Q-CI;,3E:0DTQ+C$Y6D)-
M,3<V,#$N3U544%5473$R-#<V7S%?05!214%?-$-?1DQ/5RY%4%/_VP!#  $!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1
M" &0 J # 2(  A$! Q$!_\0 'P !  $$ @,!              <%!@@) 0H"
M PL$_\0 <A    4# 0$%$ L*"0<)!08' P0%!@<  0(($0D2$Q75%!87&2$Q
M-U%55E=VD966TS-!8764E[2UMM+6-398<X&2L='4YA@B-%-4<9.RLR,E)D5&
M=X8D)S(X0E)FH;<*1&-E>"@Y0V)R=$=DA8BFP?#_Q  = 0$  04! 0$
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M%D*18O59AEY#TX0"GPC#Y-SPC%[^9NY\P-JJ>#_U*KKPDU3=C/8KK/R4/<D
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M<J2^R',K'%]3(N =P$6\D-%U)AAI$ G:9#&4 /09SP)$$'/"G#H\V3]2%?\
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MU+W1$,V;#PU@S3C@&;-!X8V64:UL<,#(N&&-K<0]2V.&-L;>Y:OS]-.W1/\
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MJZ6?+@'4Y2(&2YTB; !,E1PA@\,\;[*D];Y(\S5,F!JH*J,=.Y<?\?GRX$Q
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M3>AA)?@Z?_H0ZN2*^N1Q A]QDKS:2]13B!#[C)7FTEZBL\?ROLD B <!8\0
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M0 !/F$!B/9_D\"P9!G'>:8$PD9 Z4$,B@B- R,Y*8V29&2HVV61D0;3.^OE
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M96O[5[7M:]K]>U[6O7,_")OZP.-]O+ZTN(]M_)OZD7/+JYFO_)\K_P#3KO\
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M5E.ILHBLEGX\><POIHDP5P:Z,E+,Y("2V'T6P3+E]X(BXHB&FDFXEY#6Q0;
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MI&'%096'/.7&/,BLNZB'# !8HENX:/P% VJ)9UO&%4O<\W4U'6U,-8;F"JG
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MOBE*5#=:W2E*4TTI2E--*4I332E*4TTI2E--*4I332LG='\TYP7.[1=)LR(
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MU9;U&\F?<]K?[QH\^E)"M;F,77SF(RF&N$T*F6Q]S&V300@\:]ZNRLXDF8,
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MIII2E*::4I2FFE*4III5@RKV,I"\2W-\SG*OZK!E7L92%XEN;YG.4TU?('L
M/XH/^YC6O#7=KZ*Z+%Z!VSFRF.XSTZ'Y,*$W!*$]LO3I'+2"C-LI+E.B.*07
MTBK"*":7 U4-.0R.>);,VH86+XC9"#!85L/ ]@!_%!_W,:@:3M-D9R[*\(3
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MXYU(TQF.V-28[1:RP+FH+W1/U@3JGS3.#I55D !-)702N;5:K<8*  1%S2R
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ML-+JHN(T=YKJ K)1)6;99R*#:7 @S:^53RZ8"GYG%H1-)F2(YN<1%5*!3K+
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MMRXU@K#;=[P-Q+X;RPV^_B\%ON$WW\7>[>I5!<@0H)0H&.$* )9R,B]PQPA
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M(R<^5!-", 1>SI =.=TDGLR#]B"_%!?X>->=^KCO;[,L=^&)O,K6RPX4'/A
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M6MMO:W;O:W5J_JL&5>QE(7B6YOF<Y337Y@7HXK @VZ%;YO\ Y(/JV/Q]LO\
MQ,>M_IQM\MK7[=K7ZE>SGT<?@K?/P^/OMQ5_ >P _B@_[F->VFFH\Y]''X*W
MS\/C[[<4Y]''X*WS\/C[[<5(=*::CSGT<?@K?/P^/OMQ3GT<?@K?/P^/OMQ4
MATIIJ/.?1Q^"M\_#X^^W%.?1Q^"M\_#X^^W%2'2FFH\Y]''X*WS\/C[[<4Y]
M''X*WS\/C[[<5(=*::CSGT<?@K?/P^/OMQ3GT<?@K?/P^/OMQ4ATIIJ/.?1Q
M^"M\_#X^^W%6%(#L73)%MV&C=XDK!O\ 88N&9DZQLL1A G&3%#*AV+/(?*PY
MK/#$ #(7$(KB*)C<T9+!;1*R J-Y,^Y[6_WC1Y]*2%-->RST<>RW_-6^>M;_
M -_C[[<5SSZ./P5OGX?'WVXJ0L>M;^JWZ*YIIJ/.?1Q^"M\_#X^^W%.?1Q^"
MM\_#X^^W%2'2FFH\Y]''X*WS\/C[[<4Y]''X*WS\/C[[<5(=*::CSGT<?@K?
M/P^/OMQ3GT<?@K?/P^/OMQ4ATIIJ/.?1Q^"M\_#X^^W%.?1Q^"M\_#X^^W%2
M'2FFL?'$ZUT5]1T/G'#Q % Y\^"*"G6-<<YOT(M;+F?(-Y9E\>!M_'&YK'+;
M["]K%>:1M\#C('/HX_!6^?A\??;BOS.CLB1C_P ;?,):I,IIJ/.?1Q^"M\_#
MX^^W%.?1Q^"M\_#X^^W%2'2FFH\Y]''X*WS\/C[[<4Y]''X*WS\/C[[<5(=*
M::CSGT<?@K?/P^/OMQ3GT<?@K?/P^/OMQ4ATIIJ/.?1Q^"M\_#X^^W%6"Z'6
MNBNV-1LXX>)<0NMN3,(L*=8UQCN63+6@L@BV03R$!QS"P$S,B7-BE0[@@B8@
M9CF;X%\L@:C9W??K%?O^YOH*OTTU[N?1Q^"M\_#X^^W%.?1Q^"M\_#X^^W%2
M'2FFH\Y]''X*WS\/C[[<4Y]''X*WS\/C[[<5(=*::CSGT<?@K?/P^/OMQ3GT
M<?@K?/P^/OMQ4ATIIJ/.?1Q^"M\_#X^^W%.?1Q^"M\_#X^^W%2'2FFL?I,=B
M\9:)D(:-WB0PXY: G-!HZQLP=^$\F^*&#?$H\3(_"&<\,2P-\0<L,1A0\A\P
M2]A1PK^N\W%:^5K16^;VMEE:U^;X]ZNS*_5ZCYO;R7O;M7O;JUZI8^\HS[_,
MGZ<-NI'MUORY?IO334>\^CC\%;Y^'Q]]N*<^CC\%;Y^'Q]]N*D.E--1YSZ./
MP5OGX?'WVXISZ./P5OGX?'WVXJ0Z4TU'G/HX_!6^?A\??;BG/HX_!6^?A\??
M;BI#I334><^CC\%;Y^'Q]]N*LB2W<OF8Z?9<:-7D1"&:+B"$.F3K&R+% Q$H
MUAF9'Q*/$R:R! QRN()B6+&![X8WL$")GLQO/56!*W8PD/Q*<_S,<JL>6//&
MFL6@W K<&';G'<]]@8=MMC35V7V88]6VUQVOLOU[;;6OV[6OU*\^>!6[QG/\
M*:GVCJY@_8@OQ07^'C7G4S@2VC\X?DC]"^[_ %//Z1V\TZ@?L%_WG=W^U\_S
M]VK6YX%;O&<_PIJ?:.G/ K=XSG^%-3[1U=-*KR%^U/YE_P GG]([74#]@O\
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ML1.2;T?6940RPC0LX64?<P#>=[M>;?DS4^-#0;GPQ1'4FEV6FK#;*&L@D-9
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M>>/OTU 8?L07XH+_  \:\Z\ _8@OQ07^'C7G4V'R1YH^[7+]*P=W09U:EF?
M)-5TN KP;O%E*/D]_+S1:1A]/1GPR:'5LI =+/:B>S9'65-;)" ()&XS?C>0
MG DI:DI+"6TE 0AF.3QZW0O6O/&E]]62(X;32#8#=TA3MJ2>+P7$I.>"\<5F
M$^HTC9LH*"U#3P9N()!)7I$25!<N9/9CN3!6 !)&$P@WU@<;\TD;J\1C9G.1
M_JFEB6AV4A3_ "[ Z>\\WLPR;45AH&&<I63'\I*A8%7-1ZU2BD@%T1LCOQ.1
MDM;757,!4=#9148XX3,VPW#&<$L'FJV,HY>M<LD2*3;5.0>=8XYZME5ABURU
M@<SA1$O(5"3;*(6)A.FN9*F0WJ;++ZC$K@3>"V\RX9'8U<K@C@1*8#GF%P1E
M K.2(9UCI%\B;K\)DRGL\@7TNGB4N:9V")%1Z"V<QV2^(U?\.R&I2;*$@'CC
M4+O]H'F\]R,;!O VDKS81V XSZX5448B55PD)O8E(<L:ZFC-K*DF0G?K48QN
M>TC2-",KO0[I,9Y:00G>UF%K D2>8OT^P^<82DU'H6CYVI*((V'2W6HZW&K-
M((L>!5GX4! &4]K2AKIEP_I(W1>?R,:M%H+&E)V3"@0UD*O)\A)#U2F*PV,\
MD!7=)1O+5R!Q2R#>1010P0%\)NK02BG@HAO$,@H'CL;3!NL4<180$4)CTJ/7
M%]0W*CS37BU,7=%#R7(PYPFC$"D;D]H*B<$J9J)XXU-1C>3<,TDJVB" 8'=C
M279 ("")P3BF]%V7<ZXFOP/PU89<_P#"RK8X,(#UDBI0OA(@P65W!U;E)S6B
M+ \8**MN#/Q) Z9XU%J43,U?6*]K4-LE=D2@K#5%O*S$ES(J:L0V'942U')'
M6;,,(,P[JRK+$.)T@M&5T5\+K)TZXA,%O08VAX-D-H.@J^ -5SHU&R""@*8D
M,S2R4$LUE1I,E!>;7+)KC-DT)M-EY<\BB&F4[3?;=-6VQ]-Z(=PF-B,Y!4-"
M4(N"*@(2CP@008\DC3DYL]2TFJ2FN,M4=2:K0]*6#<L -BK -QD.(N*BN!*5
MTQ4P3R62^FO6_J+F[5PBPHI-./B$4D7]NA9=TN].)6 <*BSM,LS-*(8K2TQ(
M-.+(TFJR<8>2&IO-8YB4!7@95@PDM/0$Y&6C-[67M=FJ]-DY]1HFHFFY<!4)
MT@_3NV9$:Z9(KDC?3]+DUZB3,;)$8R>ZQ76@ID_2&APSB2D]ZHD;"1^#'[^4
M4V,'(-AFIDCF=IOJG#+6-'AG@U#&5:MIH"NNQ-8"R-C'0:]TD*61*GR1-EEQ
M463%5B'6J=!7H/%I%=B<CE6##6+ I-@&PHK@_8IZPR0SSK[!@4ET0-B^FISS
MS7W.LA)B3H@TU)$S"RH+*Z/&Y1(D+&:DLVDR.5=:8K*I-43UL-0)DU!0)IX@
M6)5OKZA8X><3?#35HRK+&9RRB8S2K0TUMTZU+J:3&SX,,&#'*DB1Y+;NDZ(6
M*7D,]* 3-@9,G]+D[4B=<IA8S:L)Q";DJ(VLT(E9#T(NQT2SD[5L-ON;(ZW+
MVQSDT(ZF9<GP.66S-)*.!7?&Z7IJ>!5S1(CN1$8ZLW=3.GYN3BEMW HYG*[3
M@RZP154ZWSJT76<2KI2<T-QV1T(4^*0M#.(N&LREN8S-Q-% 3:L7;%:J\)BO
MXSEBIL4E8@ RJM<>A$\D0'*Y?3Y^E9BOM\?D:AKJ5%&]D])2%M8$_G)75AP$
M9213!,2!GV[SN!0?+)+ZFP&J(X/Y"4\965]-&]5;JB.#^0E/&5E?31O5!;']
MG?\ [EO_ "%J14O[94_XE'_5#4[P+V&8R\2T+Y'A4N5$<"]AF,O$M"^1X5+E
M0W71]*4I332E*4TTJRY(['K[\371\Q'ZO2K+DCL>OOQ-='S$?IIJOH7W%2?>
MQ/\ D8%56J4A?<5)][$_Y&!55III2E*::=?KUQ?'&^S;C:^SJ6VVMU+=2^RW
M:ZMK7_):N:4TUXWPPOU\<;_UXV[=[]KMWO?^N][^W7-K6QM:V-K6M;K6M:UK
M6_JM;J5S2FFE*4III5@RKV,I"\2W-\SG*OZK!E7L92%XEN;YG.4TU?('L /X
MH/\ N8U[:]0'L /XH/\ N8U[:::4I2FFE*4III2E*::4I2FFE*4III6+>L6/
ME25H.5XZ13R>FJKN<[!22)Y5L9NG%1\WBCC6%-V)A#&>"MB#E:_ A9Y[Z^/4
MV;;VRDJ-Y,^Y[6_WC1Y]*2%8&4QM7,8S(8F\!,I92E:Q]P ,E&=6X@Z[Q!@3
M!K(E,*!,9@AF8(9B8C5FPA=E#JSHDE6%,2V(F1F5M"0.(*-I&9$IVF)WB>V-
M:6^E1S9?JVDB*^K_ /D>'(M.E1S;X2(K_,>'(M;Z\>M;^JWZ*YKC?M=/!;\%
MY'[9R']7N]-YU&/63P_^[/\ K;_Y^[[_ 'YUH3Z5'-OA(BO\QX<BTZ5'-OA(
MBO\ ,>'(M;[*53VN?@M^"\E]M9#^KW??[\Z>LGA_]V?];?\ S]WW^_.M"?2H
MYM\)$5_F/#D6G2HYM\)$5_F/#D6M]E*>US\%OP7DOMK(?U>[[_?G3UD\/_NS
M_K;_ .?N^_WYUH3Z5'-OA(BO\QX<BTZ5'-OA(BO\QX<BUOLI3VN?@M^"\E]M
M9#^KW??[\Z>LGA_]V?\ 6W_S]WW^_.M"?2HYM\)$5_F/#D6G2HYM\)$5_F/#
MD6M]E*>US\%OP7DOMK(?U>[[_?G3UD\/_NS_ *V_^?N^_P!^==?90W,.8DY:
M0$,:0HSS,N'C;F44,-U\ #Q.2#.C\T;](Q$_RH8EL N#QR_CVOONI5=Z5'-O
MA(BO\QX<BUN@='9$C'_C;YA+5)E/:Y^"WX+R7VUD/ZO=]_OSIZR>'_W9_P!:
M?W?Z_=]_OZT)]*CFWPD17^8\.1:=*CFWPD17^8\.1:WV4I[7/P6_!>2^VLA_
M5[OO]^=/63P_^[/^MO\ Y^[[_?G6A/I4<V^$B*_S'AR+3I4<V^$B*_S'AR+6
M^RE/:Y^"WX+R7VUD/ZO=]_OSIZR>'_W9_P!;?_/W??[\ZT)]*CFWPD17^8\.
M1:=*CFWPD17^8\.1:WV4I[7/P6_!>2^VLA_5[OO]^=/63P_^[/\ K;_Y^[[_
M 'YUH3Z5'-OA(BO\QX<BU0U+<PIB3%5O)(TA1F(8<AQ0)%! L'7P( B<D'%D
M7,SOTC'/>"%R0H0?!8Y9<-EAOK6PWU[=@BHV=WWZQ7[_ +F^@J_3VN?@M^"\
ME]LY#N_VO=]_OSIZR>'_ -V?]:?W?Z_=]_OSK2YTJ.;?"1%?YCPY%ITJ.;?"
M1%?YCPY%K?92GM<_!;\%Y+[:R']7N^_WYT]9/#_[L_ZV_P#G[OO]^=:$^E1S
M;X2(K_,>'(M.E1S;X2(K_,>'(M;[*4]KGX+?@O)?;60_J]WW^_.GK)X?_=G_
M %M_\_=]_OSK2G%>Y</5"D1H+DCO1@KC+15LHKKJ&B ./,^LA)N5SA5+M913
MBA2Q,Z?!*A*5Q!K973[F@PL<A!,=FZNUMEK6MUK>U;K?DM[5NU;VNM7-*Z%P
M;P#PSP%5N5.&Z1U0R#PL6V/L.MO::E])02YY&<*4,G*U1, !M<<1S-.9W6,P
M]##K:JBJ5BXX-DF9L,I$>48DSF2Y1C>1'?:)(Y\I3I2E*F6MGJ-Y8^\HS[_,
MGZ<-NI'MUORY?IO4<2Q]Y1GW^9/TX;=2/;K?ER_3>FFN:4I332E*4TTI2E--
M*L"5NQA(?B4Y_F8Y5_U8$K=C"0_$IS_,QRJCY8\\??IJ P_8@OQ07^'C7G7@
M'[$%^*"_P\:\ZFP^2/-'W:Y?J,) A.'Y7N=RDV,F2_KJ+)7(V/W=:$56+G(^
M<RVWW*XF49N8]E;2VX6HV5M32\O\@:4D!*-9_P <F'LL9[:2-,4C-PFT7O!$
M;.)M)[Q><@$D@TAB%"Y=Y20,='DA>Q'2C:<>R'D7-2/XO\B(;S1GL7.#DW.F
M*I+/F:V1%*S%9"^B%0B]<1""(T0FT]4),AD2-, P869#,B1!RE(S(S,Q,QJR
M=>NSGYT)/J1$'SJ N>(F"B#YAGFB)B)B"WB)B)\NH=#T]02$B2JV0H@CT%MS
MF+@-,;>!;9,%"DL0-!(M?#)W) 5L$]1M9N)J>B<'@7+A9)Q,L!D'E8+'*K0?
M>CK2I)ZNH+TAZ>HH>2RKJ2\KK2DNM<(R975%T(C8;CA,+^08X&"]@KHS)9A,
MV36<#Q#?M)M* !0%50TT^7R1I7I>2R*6=5.0O*;M,=15NPMFTK6F8YP9!1$I
M2E4QOVJ2I<^X6 B.O7,>4T),>SW)*60]A$4=DC,=A&91V?YQ$7E*9F+6C!\.
M,!QV>#'C!D--UXCOPUBXT%"+$%FQF47(BO&2!^;L-HUQGTZVX@N-TB97ODKK
M*.G'C&T4MC>H?PT':+ 0)#+%]+4)E Y9*#$I*S)LT F9>@ [I+O@3)9/%C 1
MZYVST*%7< JD3))7*.0L LDSY<^%B-;+*E57E,FDC-61OJ-G3YS7<L@9]%DN
M3SD+8DNDXB<OFF>FTB8&QS)30JU8X@3KH(1YI@24LHB2#IE,1(S$<P>X+;RA
M[F>SLUB^EZ)='J*[6F_4C3'"2:]&(DH" S'.48:6"K-I#:R*8;K=2$H6UN!!
M3T=".'4HF5% &"YC/'L!\1LSQL0>1X<@:%]/39.LV#8O9D4M926C+B44-E).
M*62/K9HN7)B*1R^0I@R9'"($R280#&,9EDE()$49) (I)(H2!EFE4?D\E97*
M;.1OV%%"Q)3[EARRA)&:8);&$$PDF,)43$],F,D.63/>H5JZR@P0D#C?8P4
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MVFFE*Q'UUZB5W2AI4EB?FTC-Q?6V 5:8A%.=YU73FQ>[D?S49PYY=.()4ZM
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MHATGF;LLG"BBAI);!P.D,(JAL\ZX$&RE<X2$5#B58S*W5II/EQ1PQ$K3!J%
MDF5%.%,VDP3:G#G&V;$GJ%WC/#*DU85 9 $;Z(W"+#8#M-.U%4%$%W-\PF!
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M"-O<]'F*W%9E2*QKC"BIJ!27_=QXO -KCIBM&R&M#B(P)Z[A3'&EF&V(GG3
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M?3S&)XDQ$:,"IP \DKB>?*F 8\;Z,S,1"IH'?M\@&2%L)<8T(/5P--D!EAU
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MKKJJIJB&KH:DGKY$R?-VP5KES @&4OM!H-E@MA#9;,1"+;:K:3PDM!0DS 7
MBF$ LQ!,2X'#BCF!+YC"C&!S!D<<T;-#CFC8XYD847.)\07>![-"!X<PN7QN
M2G(]0F7+?C%6,9%7IP@1*W89URLP#IDH*1*7[6)2::U?7W&XHU;4JUA+NMO)
M-9SKA$+VY(B6&7/)[%,SOM[KW>TP 7'2E*AFM9I2E*::5M,W+"07$ERJ\8U+
MD3:BUW6V!'0?%!M?(!NK+:&+DRJH/?*^\!+K)13NC#WPM84<V DV_CA@"7#U
M9_EM;W;WV6M[M[^U;MWKL-;F[!V$<0U:1%<GP3LERY5;M<8*^)@@S"EAL&J0
MMP@>.8?&& QIQ&+89;T6RH2P$M?(IA>W:O !A<KE?"3B+6.<=9.%"QDLG9$8
MF/$>D54ZDP4<I3D#LA5Y9]V"V-L+]TC>)5P;5L6,Y68@I *HF^P<1O'2D97*
MYW[)ETG"]O+ R1QVAK8M2E*_1[7;M*4I332E*4TU&\L?>49]_F3].&W4CVZW
MY<OTWJ.)8^\HS[_,GZ<-NI'MUORY?IO337-*4III2E*::4I2FFE6!*W8PD/Q
M*<_S,<J_ZL"5NQA(?B4Y_F8Y51\L>>/OTU 8?L07XH+_  \:HKA=[69)0JLN
MUV-AFIXJF1322LZW(AM9.&63@E^+4TJHKY].)#JAP4+*Q%/"'S.&\@\[%P!=
MYGO:T'[$%^*"_P /&M=FZ*Z(7#K89T9HC4=[%92_':\^5(DM/A ="X&2P?C&
M,,DTI))=!4[HRD.F!#6,*3-?+3=+1?B7D.W5 PU;"76<NCX>M0MY"I6R=Z<;
M1;)#8NP@K'0B%&2YE(3!$)MA:B*-Y6)RSE/DY"Y-;8]-=K*R/&7C RM'/"^>
M9(8+W<]D<HR1;?\ Q<O+O&^\3HHPQI#5(Q>.EL^VX?SC-N"&I >\/!NP@3YR
MQEIX&Y0$?ZV1*.@N[8_''>YDX]T]Z"G6_F06!1%1)5"8=L+8V0F::-S_ $<6
M'323'VG<B(*>( P(.4=:1>RVHMZ4%"=$\"+1;O 3!Y'4J6%%2D?$!O9+PX;C
M-#FC&&9?/$G6M)>W$=?6'),"O;4 V<A7CF]7&TW,:9K^"<:VZGX]XZ?BTTIB
M:29()2+E*%Q3D=EFNHM-I-_%17&B>32MLT,RU2_',GO7<I7V^SR&I'7UIE:V
M3M;=FI+**P-/BNV&W%)>VIPUJ7L[M%R:7=%\8WDLTHF;-1P/-Y8"F74:(I#\
M4P %-,P0!IS",$$+!7A&RD+L6#LW(BIE4Q%IM4)=>D(>46&NDC@C/DM3"O%&
MSSM!T::&7BDB9@:XFL(6F9;6.96+)@%<W+$K$-@B!CF7$LZH["$@6P%W0SHN
ME&1UF8W:CPJ[9"9S?YC>#JSD%/R#1D0-)6VP24Y'1T=ZE6M8RB(BLXD!N.]_
MHHBTU$X^JIS=7$D+?A PXUG!N=B"GHNIUIMMC)9>+YI8^DEN2BGMQQ YMB1X
MS&4]+C!;:2>&.9$+M%I),@++*1WW>PS3#9:^HKYA9,)^-E,+$Q6W',S@C(>+
M4D^+TQ>2F&\TQREU.(3IIGS.^5+74AZSVH)-Z:17BBD^8Y#*(>$5.] 4#)M7
M.)YP580#!(D#9!'R%9>YTFDW3$+IY>CLBU6 6M=:7K(<Y!K1BHHL5"(6&H%M
M3@M0J@,%475,4DVQBB&:922*H'CB:73S144ZE&2H(Y$6V<<.IK*#UZYFXN;J
M,65587JL)P(L8-HX6R'I-+1@&HJ"0@H3@&J8?-R>XF\3"F,14272*SU"Z+"9
M=D5RO>1D"@UE) ;"WDMN8#$=MYC;&E7<^FNHIRNUHZ@$F>E1WMB36@,5>111
M#=;ECES'W^UEB)B9EZ'BN20UWDK*3T*-R*BP#.P<RD97#B"8/CXBVBO2^N[F
M?*BRRFKIJ9S&'4D**X;U--LL1:#M02[*9#+4)!CR$G"L'%XR&7;#D;8+KD8-
MMM=8&Q62C77U-PJA+)+.IAR^+;JW'5W++BB@RC39&R*V8M>8SU1"!6+UI&4D
M(4OK<?>K1/;K<S;JR3 $;YQ!>P$<BD%4P&CM!0;@3F:;?&Q73!=(R[T-:!+Z
M-LE Z*\&6^E@[IP@^"LE(BP1&Z.84(B<<R+R@XU,T*H'E$ZDN\.26TG'$7FO
M$X&69!;$V>.8V1L4SW>9A%XC).'CC.9?*,- TJ?4R-=+@788CJW"L"X6=.F-
M=BU$U,J))K FK-4CXKQ=*S7#U&IU*T0?7;L@S I6MFRH60<O,V6"4P)07,)3
M R);XX@2-N+8",4?R>W67=.:[33HG14A&BS4,(87(Y6(E?P2(Y6S%2>AW,24
MP[08W9-"0I_(--R%4B,45U%TR0R*03X'&5G%+NY/(KX632V=B\HY8Y#C*8A7
MP4;,G7;@2UIPAY#%B_G5D9%(7:+LD.+X.DM NG1HUUI9=]V.\R8*TUE7$^,%
MC"N&YD:JAS*A([AU-P$[=1([C?(N,I*<(R813EEB2E",BP X&$N-TK*0Y!O-
M6*62^29[3ZS8L36.U&ZK(ZP&\BR^.]%E>#]STW**6GB&89A[43&QZ(V-!K-A
MG36BK42O$R[X,%CU!CCBY[%1"$BI[ <CRDYY1@A')O>+@:2Z\UEA&#$>,E?:
MR*7Q"-;,YX0-Z^KQMQ"2HK2ES8RN0<8S+D$::TG@%DZL#.6R N74FPJ6G*ZU
MRDNK>QA]58 ^3#T8F608#-5 0>PS FWENF(,D>992,LA<P,03%ODZ^W"(YBC
MV=66%($9+9I;;N2ZY6L=LIM]Q-%P(+L9JP80':TW2T7<E(;I:KH;BP5%(K"
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M[T"1_M%6X:E/8*\%/Q23]JYWN^5.Z-/6EP[\&A]/;_KZT\]*11/#LO>@2/\
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MW O;.^.5\K "[;8WPWMK97RQORJ(X/Y"4\965]-&]5FPL80^=S[$LGM8R8[
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M1BSB';"=D="1S"L 4/#IH)W.U@A#@),R(#CMO@#EE>U[:W6UNMB*B-AD2'-
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M]OJ\AZ*-(#N8I@5.?Y$JV Y:>0</QXZ&ZF*CY72KC/(2@T5J7W0DGC &2?B
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MB+@S6EP0#J]2IQOQ.JM64XPNDN](P^R=\F]"D%=<J]TRJ;8%B_&NI=)CEL:
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M?>I]IF'J4M,*:HM4AIL(NU<,N-34W:TR\4/T9RH[14L[,Z)7:NOE$,Y"#G4
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M)>WQ-BO5??Z%,GV1&5*@K*C!ALF)E:P,8EI3S!T^8C B "#79*C5NH_RI;6
MCG= **8,]EF)! Q,<TD,S$1V3,[#O D43JU2]R@5B\A2"JW>+#:3+*@[H$)I
M?+LDHZ2"SII6-5R]&BA#SL8B.&62$!'58>*-Y]CY ))RY9'5G0"998EAQ!E
MACV:W'J=UYJ'28+ATUPWB<:THM,&*HM-R0?B1-5'3H3?.DP&6" Y]EHJ@&^I
M3>;J39!EHH$WRH8",WR.^5WN]A#ZJ;I\'ZCY Z)KOCO1:Z]96HLLI:1V<>E3
M";3SD>[E:VI!;E**FN\)(B8E/*ZU;!/:*F,^)",2K"B<=;#/2GNW&4FV20B
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M[>6U-MNW;RVIIKFK+DCL>OOQ-='S$?J\]MNW;RVJRY'O;H>OKJV^\UT>W_\
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M##W^6\QM;';?9MJ3NAO?O]DGTJOR?5.@7L,QEXEH7R/"I<J&ZZ/J-.AO?O\
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M\;6M:UKY7O>][[+6MC:^5[WOLMC:][WV6VUZRYHJ;  -%#14X5,@X&"QHH9
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M#&QR4R6X_FYB"$B(>QCD<*8#@%<S93 T9P,"EBN9HO@:,A%+!W-BEBV0EAS
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M\\:;Q[\>G_YCY]>^E>CFHK_2BWP@'Z].:BO]*+?" ?KTWCWX^>--X]^/3_\
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MQAO1\TD!F(8ZXL#6'55D=*;B>FD1E12&QQS.GQ ,C1C>!8""W#!!P#LYC/\
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MK)GG GZ^FFJK4;.[[]8K]_W-]!5^KTX]1>ZR9YP)^OJ.G8KI6;SB[/!33\L
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:"W],?J%K)IB7CE7W,_VE'Z)_:A_WCY]?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g114644.jpg
<DESCRIPTION>G114644.JPG
<TEXT>
begin 644 g114644.jpg
M_]C_X  02D9)1@ ! 0$!HP&C  #__@ ]1$E32S$Q-CI;,3E:0DTQ+C$Y6D)-
M,3<V,#$N3U544%5473$R-#<V7S%?05!214%?-$-?1DQ/5RY%4%/_VP!#  $!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1
M" &5 J<# 2(  A$! Q$!_\0 'P !  $$ @,!              <&" D* 04#
M! L"_\0 =1    4# 0$%#A '"@H%"@0' 0,$!08  @<($0D2$Q<Q%!46(5%6
M5V&1E9?1U-48&3,W05-56'%V@9:QMM+6(C5SDY2TM1HC-$>'DJ&RQM,*)"8G
M,C9"15)W)3A&<O H0T1B9&5F>+.W.53!\4AU@XBDN,?_Q  = 0$  @(# 0$
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MM;J3[YE3\P8%YAJ$-S@TV8YU.Y8R]&LELC]*&O'.F++V:6&+,65XK@X9/+H
MIAY;(PO&5INTO,3@[ Y6OJTIRD,@26M39L(6+#RR"#+3+ILC[EYC"7R65N>G
MK4)!H]'PR#IHP'$,<2V3WYO<%VJ[4)C,N8*-/S7G3#[&&.7]+"Y(0Z,;KDY2
MW-\80H4"Y0O5G+FZU$X1NI:9X$M(UNUH>I<#<-5GTZE:V^S'"NF6:H#;:A*%
MR%1%B\)&5@)ZS*04X@6Q-J"4P1W:&H^%74]*KZM1XMUMRK-AZ%(+7;R7E-8&
M&TX)[5UB@>@0](;$V)DES">5@3-$>GM;J3[YE3\P8%YAIZ>UNI/OF5/S!@7F
M&O;F.Y+&P*Z1RJ4ZML.-6$\=Q*6O^6<JG0?)IKKCUVC&5HIAMNCZK$2!"OGS
MTGR!+YFSJL<RE(6D9)%&$SV]* ;#FF]M/_+)N>^-7K!]DE8)PDF\PN9M2I1>
M0HW*G*W&#TJQCK&TI:=,?3:',Y\1L>'B..L?SF].JYD>%+"I<AN1.'/!N5,P
M-CIK]'P"FJL^MPCPQ<39O+TZ'(X-4M*;3$V']*PZWIU92VK57EC:T&5Q:W56
ME6Z-I+#SR_POK)XOXGUNN:*Q6^FSB-IM:@&(5U4J1;:PU$QL #^6$$:GKAG4
M48CZWI[6ZD^^94_,&!>8:>GM;J3[YE3\P8%YAKV)'N8C5C>4S5M59FB>;FR'
M->Z!P.2DPQKGF,E\/SSHFPQQF.S";=+(ZZA*V8SGM'ST2MH!.RR)4"^/7O38
MFM"0A32[<O1;<NH<#&:IL6.N8HR3)@SYCF*XWS+)I5A1?%<7(\H.)%J5%'"V
MK(C46G7$1-=+FEZCT089;<*5_>VYKLO<[>ZZO@$9'./"G"W2FD_4!9/!D3/8
MZIN5:>Q Z5-JLNNU,*)ENO7!K;%158GLLI$^A6?# $D$\1Z[)KLHJ&,<2% C
M8L17*NH6S=A+3:#89R(8P@6IYL@!2SE[WT]K=2??,J?F# O,-/3VMU)]\RI^
M8,"\PU%NK#0TV:4<2RXU^E1<QRC"M8[A@59(8VI/3P1[@*C3)C3.T>=&YB<$
M8N2-\-43ZPEQ4&NBM,665>WI@5%$%N:K&U5CT/@GP1\14!U/2N!^$K%%C"!+
MRX:TU4/&! Q<L3JPSI, P,)8('RS[(!G>,A-8XK\)6A6XHZCQ9Q JU"@::AU
MJZ<KYBD96<B_EYP)<B4#)#O_ "2F._,NAF[M[J3:4;<&IE2 VE&76CT P'I#
M;9<(#L%AV#L$ '8/2ZM3-J%W:G=*L>YQRI"(MJ/7HHY%YDY,[*C40V%+SDS>
MFL3B228M5LAJI3?:-]XB<H,O-NV_A7"   8(3O43OR)O_P!.ZKC]77_6>SI_
MS%>?_II:Y=X,?!S&OZ:B.!N$X2S1M<<Q,:!ID+-J;W#H)80=FY2-06'BLICF
M 6L@9B#*)Y1Q]QN6AZ@^>+.(9<K4M*6MDZM=YQ6ROJDL""ZV\"PE*(QB=B)8
M3/\ )C:^ST]K=2??,J?F# O,-/3VMU)]\RI^8,"\PUB(K,MN>&BO3OG[ 4SR
M[FYG?W.UAU48EPD[NI6J+%.E^-8ZQ=.(,\RB:945O&68\\L\\>H3:U7.*3'K
M0<1()&WVJN8"KB6U;>.OQ+P?X)>%=*/5]2\'_"YU@?6K\E;A[0^J3;3@0J(F
MT-5$1SG&\L>&_B"".1 N^@<4>$;B'4(TZEQEKJW=!UB3=J^J2 KKA!G,PB7-
MF=AC^2LMN\BY1B2CH/3VMU)]\RI^8,"\PT]/:W4GWS*GY@P+S#7JY(W/7$ZK
M!K#DS!F?&Y^DJ+"VH7.2R)21BEJA5E3%^'M9,RT]->0X:\,[!T-1*QVAUL%>
M$<+7J7A\D+I=(UJ.UL1\[DY\DKMQ0R$CGL%A0:A,?G#,8[FMR&P_'\Y8)O?)
M,&.&-6Z1PB(8OEZR.2F92)^'*#.ZQ1K5&Q"1KF!GD3HX1EL,2(4+C7N3P +#
M>UPMPK0.+.KU)1=X,%+X;H?.6H3*XTH_8 H)<HM_OP[K")L+<E<WU/#&1#".
M(M=L@5?3+0MK\1FQ<JU4P74V+MD3,RW9;(B/O<S!%L!K(J ]/:W4GWS*GY@P
M+S#3T]K=2??,J?F# O,->FY[DCDB/X^R7-91FO&4971-YU'-L#CS]'L@L-N2
MT^F)2".<'*7J2LK &+GB3+K%C1CB)SMG*?90]MRIO4%M!9K>L76Z8BP#A^>Z
M(]7F?5TEGQF9,".^GY.QQ0IH9VS'J:/9=R>,/->5;_SW<GR4O:I C=$]T>OC
M\701DPA$Z%/LF-7FMS7(HT?P'7*YVJ'"/"6H)5JVD:*XJO"E4H5>UK4%:72A
MA-H*"$=L;TGV(*5)8IR"*;(="=)FJ>%FN\*]OB7B"HP]/U#4PA^OOCGK:93*
M_8VA=HYELUEBU2MN=BVJ:,=(X/+E_3VMU)]\RI^8,"\PUR&[M;J0(A_Y3*GE
M#_L# O,-8AZYMY0^$/IJX1X*_!I,Q'I!X0[YC_\ ;VE_5<J_JB<=_G?Q'[G_
M )O>]S;^>_\ 3'TYG6S/NU6Z5PQW@2./ZD%Z4A^PEAB:N=IT,A2P3I%,H(V/
ML@667*62^X@I6YJC3BD96]2H[! A*445:%M0_P"GM;J3[YE3\P8%YAJP[4A_
MK#BK_P"6?3A_]K&2K>:AN'_!CX.K&BZ:Y_ O";FLJK)C&:!IAF93ON1$5:9*
M?+,Y+Z[Q_P ;HU>\E/%G$"U+?(@L-6NB(QL!;0,.B(C?W(B,R[^GM;J3[YE3
M\P8%YAIZ>UNI/OF5/S!@7F&H0W.#39CG4[EC+T:R6R/TH:\<Z8LO9I88LQ97
MBN#AD\N@"F'ELC"\96F[2\Q.#L#E:^K2G*0R!):U-FPA8L/+((,M,O9>]S2T
ML9!?YE%,0Y]30)_7YVT4X3@IDDEQ.H2&QO+>I7#.29+-=/SE/L*QPI@G+I$,
MH1EE9+<PH+FR)LC$2]D.*5U=["2C:YK%#P*:%J]O1]1X T '4:M2W:L(X3TN
MVA2KEBM75)*JJ=?V&;0,-G8NC( X5M8Y1*R9TR]X5-6TVKJ5/C'5R7;?9KUT
MNUZ\AAG44UI_?',"KO/9B" [1U8(ER2Q!@G,*^GM;J3[YE3\P8%YAIZ>UNI/
MOF5/S!@7F&NEA6Y13Z982@F83,VXUA]TOF>*8RYLL]CTYB##%FC+69W7"#1+
M#<A/B! TR1I89$U7.\D5QUG4QPEG5I4[5+'1]YI:D\C'[C#D9LR%,(Y)<WQ>
M(06%1;$3VZY D^*<G-R^QXS9-9?"(:QA!2RU!JQH).@LDE3_ )#CDLDD&;(0
MF3NA;FL>C54<0]&AZ'E++*F:%P4+*CWUGA'"0F0OKNK5VJ" TDI<?6N55JA/
M4Z\N"4=2)F8[*=X9V@AB];XDD+"DO44\0D,=)RG/!A\UZ.F(JJN-LLY>E"SZ
MG+M.U)^GM;J3[YE3\P8%YAIZ>UNI/OF5/S!@7F&HTTE:4L/S#4EEG3]GTC),
MU<<>RH(DID6!IY 8IBB'1.-3Y1&LUZC,CYNG+#(HVQXDQ5#D_1G&P4,Z)+D=
MP6M<>-?F0Y8F(7X_)RUQMCFTQ989)0FD/9Y9)6J)3*U"8V6RZ+MKXO11V56M
MIPB<W6R-F(1/((31$Q("T"+A$;*L5#@SP2ZEJ=S2ZO '#!.I4]/OD\N&-+BH
MZKJ2I=58AT(F9Y@B?_J@J&$+11+IKVNA"W.*?"10T^KJ-CC#7!59M6J8JC7+
MLV%/I' .!J^K$1L0]\K-G)$A+>GUD]3*=Z>UNI/OF5/S!@7F&ID].HW2KT/7
M&#Z)!?T4\>?01S;T&0G@.ASBRZ).8N8.<G,G"\^/\9YMX/FO>?XOPO,_[U6"
M2KC/_P"$7_\ N@__ .+5VUGP9>#I,Z5TN!N$U]76*26<F@:8/44<G!K/:M[(
M"VCF&>Z=HWSG1N/N-G3J?5XLX@9T=(N.7S:M=+D:$H@&#NZ=B'>9@H[XGQ3E
M]?I[6ZD^^94_,&!>8:>GM;J3[YE3\P8%YAK$15P.DW&$;S;JDTWX:F1SHGB.
M6,[8GQO*%#&IL1O)$>FTX98Z\G-*HQ,LL3N13>X'F(3KDBFTM3:7<*<[9P=T
MA>\&_@OT^E<OV. >$^A2JV+;NGP[I9,Z591N9R#->((^0"Y1WC>=HWC??(^G
MQWQ_=MUJ:>,.(8;:L)K*D]8O"'4<P%AS%UNX>:1YI]R-YR_;T]K=2??,J?F#
M O,-/3VMU)]\RI^8,"\PU</DW<\=&R"5OD=2RIVPP]Q?#6NZ<R^(FZE,<:KK
MX4S:;VV+K,09JE#IA&(E.3.U3H]QE"=ZPBL0&S8XY@+1I%;>H+6FW01&MQ^G
M<JD.:&-ISO!3R,;(&-VA<@LQUE$(YDUKDVFE-JH8%-[ZL;4+1 UKACM>W-@1
ME>XR.9E2I5>GNC5T>37R.^A53\ ;Z\V+/!O#6F -;MD]MX1HF!5XO_<TF*LZ
M=5OTWB%J5<Q(LM#H/39$BKD3 N=D?#"AP)1Q3K-Z3L35&:_$%L)ZT5!NP!*M
MNK/ B3!1RFH2ARV(*!;$#/7^GM;J3[YE3\P8%YAIZ>UNI/OF5/S!@7F&NSC&
MXWY7F,/T^3*/9DQXX-&;X^BE[H\)8I/'*'02+CAA]SA)%">=L*-ZCLWDD%CL
M=<(U*X(G-BTMLG%Z5K8VYZ8P<9(VVKS[3)CW3MJ:Q[CG,DZ=LKX=?XG%\G.[
M]@-(C:I^JADC9'E>3&UK#.;U)&,)NV/;0+)/$\J!V"!-'-TJO2O1*=(B52E+
M3/ 3J;[-32^%N#]1NU:ERX=*MPI6AYJHFY3P7U].2HGRU#04DFB;N0F+@E"3
M(C;.H>%VBI%B[Q%Q#4JOLU:HV6Z\^5BRT"&*(H5:8SIB+5=4Q H"3$9]D0Q-
MROI[6ZD^^94_,&!>8:>GM;J3[YE3\P8%YAJUG7?I\A.G'-3#%L;G.Q\'G.%L
M.9EC]R^;1O*C4GMRA$BGQV:H9F&'LL;C&882POI;FQL.2F>.LB>0<[U91J %
M2 ]0HLNJQ:1P!X*]:TRCJU+@+A.:NH5E6D=3AW219 -&"Y&0*#"#"=P/D,PY
MAGD,QV*834^-/")I.H6]-M\7<019I/)#>36+Y!)!([$,RT2Y2B!*.81*(G8A
M$MXC-HP;MWNFSAB_43)U.I-;>\X\Q4PRF*J+81!["T+TOS/BV&J5)Z:QC A>
M5>P2AY2VIEEAI!9R@I998"E,3?;9^/\ A#.ZX (_^5/?RC_%GCC[OU;#%/6/
MU?\ _(F*_P#^R&#:QY7<H_"/TU%U_!IX/"U/7E%P1PK*T:C66D)T'3.50%HF
MCN(%QV;8!)KFLD8VB389_P HIF?3N'>,.*7Z#ICW<0ZPUS!M=1K+]DV'R77@
M/,1,F9Y0$1C>>X8B/%F:K]T,[KA[Z>_P9XX^[]/W0SNN'OI[_!GCC[OUA4K(
M[N6^F3!^K#4RZXTU#O$N8,8-&$LK9#='F%/2)@>6QSBA4<2,;@:X.#>YI1:&
M]=( 7O*4U/:"I"E,LX<G8(W8]:X&\%^@Z3J&LW>!.&BJ:;59;L#7X<TQSR6J
M-R%*N@/487B (*)(IVB=YC+)0U[BK4+E>DC7M2AM@X6$LOO$(G:2W,N>>48@
M9F9\^_CG+COW0SNN'OI[_!GCC[OT_=#.ZX>^GO\ !GCC[OU)\YW*[%6-]/F'
M'"0A-1U%VX6W0B7:@6=?-P9XNPSG3AI6)U-XO;&!G31%T<&LYMCDDAQTJCS@
MI-+EQJHQ#>[Q=.JM6IO%F;<4S6Q1DN:0#-,/QYC]&TN-^%HUEB]\=WG(CWC3
M2[B/-^64<BR0UH&N&8VL=)5D!=#<6VR4E4=*'\$;#>2@(M2.[E34M\!#6*$^
M$^&JZK';NS67<+Z>2+,4=1+3C-'9Z[VFMQ =M#94*RT\&6V$H *!F2]/<"<C
MK.HL-<)ZBXU%PF$NKK? EU#&(,),$F,SOUYA<1,SWQK^Z&=UP]]/?X,\<?=^
MG[H9W7#WT]_@SQQ]WZEB&;A^@:,E:?67-&IAH,QOG/'>;92GF6)H!,G-GL>\
M8Z6G+4>@+A615#1*<<S^,$)T2YJEBM.L89<E61*2,*.')U3HP/ML+8OW&Z89
M548XAS!J8Q%QU2-BTCSW).(;H9DNU?B/%6M&2L,:Q!.5TQ5HD40FBXDV909S
MF$(C2ZUWCS?+$UA;DYJVIV+(SCZ@109QP]PK" 0FQ-F>$/O$I=;N4(/GC2ID
M5KN465FM,02#G55=266JXGUCU09CV.I:F101#(#J924$*ZSMICK;;DNRLPC>
M2,8;,1, <YV/[H9W7#WT]_@SQQ]WZ?NAG=</?3W^#/''W?KT8QN.[Q-3T<KA
M^J;&4GP-9B26Y.D&9&C%N7+ES2OA6H6[3$\PANQ(O0M\UD+H;E&TR]L>RU34
MRJH<C728[F2^Q UN?59$W'7)..M/FH7/1N?,/3I)I]E65&)Y9\4-TNR:S.+;
MBV4QF/B\O$YB1#BDQQ?D)ODEDKQLGG$=1Q]X8VY=8^3...0ITIF<:_@%)ZJT
M:!PB-AUI-($LX3A;(N/=V<*K19I0RBP+M@>EW396YUD\5 U1%C)G'PB9SJ>J
M<JUL:4_=.9W4L(.6#]^]D!#$\A1O!R!Q$[P65'^Z&=UP]]/?X,\<?=^G[H9W
M7#WT]_@SQQ]WZPJB&P1#J"(>S['P[![H -<5>/4P\'/YC<)_L#3/JWVWGR;0
M'IKXE^'=5^>O_P!?D_O]^<W,-PQW6_7_ *R-?<:POJ&SRKF^.%&+\G2A0P)X
MC$8YP[S'VYMYTJ#7!B:4:ZXI+<O4&\RB=P!IO!&&677$EB"L;G^#(_\ XIT4
M_P"1V9_V>PTKX,]$7H^E</\ A$^Y^AZ;1TBC]PM,?V33JJ:=?K,.W#&]&N"U
M]0X 8,^7<H&(F=HSWSP<W;>H\.18OV77']NM+ZUAA-9R *N4><YF>4=YVC?:
M-Y]_-=C=9+!'=*]<6P;?^LME/EOL#_M"H'D&X!]GN[0Y0&K1,79DRAA95,UN
M,)<KB*O(6.)GB.8J$!;4>:]8[R$WEM<QC1MSBD6BE3O2$DH@U:W\R.J7>6F(
M%Z0X.$K[6.,-&&D6=8]ATRFFF/ DKELFCS8]2.32+$\(>'Y^=UR>TU8Z/#JN
M9CUKBX*C/PU"Q6<:H.N !O,NV!LKST NA_WH>FOP*X^\PUXIEUSX[EVZS[H8
M?DMQRTYZD'E^F;[,,ESF4W26(8LD<8FKUF/&6.\.9013R!/<*702<Q&;XUQ-
MCF+OL!E<;=X,H31%H7DQXAX*-<C?5LW5K= K<BR#*EVHQ[/E\KR"1DR3&*XK
MC)9'GZ0IL0+L $M;M"54..A:_'I>%'%5BX,3*&"_%HPH2&,8>*9&CYG^Q;Z
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M(F.GUG<FVVW59MMU"S?9X"N*71(M\)-]@E)20FB\4%)]/GF8G4]ID^F'-O\
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MA1;=,H 2#V__ "9$8B1\4P,1.\1GR9A/($1$5*7:([1_QI/RC_\ U*<,G_\
MS*7]*3_WE?69]"9I;][C@SP5POS/3T)FEOWN.#/!7"_,]3GKGJ_YF-_;X^3X
MF\L_J\N1_I%3\*.]S_P(>3?_ ,9Y_P!7Z]'3_!CS"K]U/BEMAQ)EPX.S1LM+
M.*,NZ3>P[1WME]P[ ]D=G2I6]'%\%X5QM,X9),>8CQK!9#SY<FWGY$(1'8Z[
MBWK(?*3%2$7%J;TJL4BDQ,GO/3\+P1MY!-U]EPEV""OEKPO\8#Q_Q=]WUZ?.
MEC]RZ5+LI6NV3O6)Y2SK17JQL?5VY>E['E_E3OW>P<$:>.D:)V,7%8B+;V]0
MEPJ=S%6X\D&V.[;Q\W?OXN[>;Q\"^LSC+XEL7ZG94N5$>!?69QE\2V+]3LJ7
M*\VRV8I2E,8I2E,8KQ'^H'?DC/ZEU>6O$?Z@=^2,_J74QE#8J];+'OQ+C/['
M1U7U4#BKULL>_$N,_L='5?4QBE*4QBE*4QBE*4QBE*4QBN!Y/EM^D*YK@>3Y
M;?I"F,C7$'K>1[X'7]NNE274:8@];R/? Z_MUTJ2Z8Q2E*8Q2E*8Q2E*8Q2E
M*8Q2E*8Q7 \GRV_2%<UP/)\MOTA3&1IB 0XO(]TPY'7V?_?KK4E[0ZH=T*UE
MY/J^U*1&5S",1O++XTL+%,IBV-+:0UQ8PE$@2RAWL3IBS54?4*3+2K/P;;SS
MS31M  N,NV!LZ3T<.J_LU2+O1#ONU7S9:]$_P55LV*IZ)Q01UGM09!6TF1(D
MLE92,EJXSRS(E([C$[;;Q$[QE'9Q[I2V&LJNH22S()F%UMID9D9VWLQ.V\=V
M\1.WN1FT'M#JAW0IM#JAW0K5\]'#JO[-4B[T0[[M4]'#JO[-4B[T0[[M5@]=
M-P1\!<5?-M(\GQQY_H\N=/5 TG\DU'Y.M]:S:#VAU0[H4VAU0[H5J^>CAU7]
MFJ1=Z(=]VJ>CAU7]FJ1=Z(=]VJ>NFX(^ N*OFVD>3XX\_P!'EQZH&D_DFH_)
MUOK6;0>T.J'="FT.J'="M7ST<.J_LU2+O1#ONU3T<.J_LU2+O1#ONU3UTW!'
MP%Q5\VTCR?''G^CRX]4#2?R34?DZWUK-H/:'5#NA3:'5#NA6KYZ.'5?V:I%W
MHAWW:IZ.'5?V:I%WHAWW:IZZ;@CX"XJ^;:1Y/CCS_1Y<>J!I/Y)J/R=;ZUFT
M$(AU0Y;?9#JA4<8A$.+.$],/]7T7L]J^M<3T<.J_LU2+J]-HAP\G:&,[*]!K
MUG:H&5O1M37F%_1MZ BQ,D2EM42NL((+VC87;<;'3#;@MWP[!,,ONV=(;A
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MK5\]'#JO[-4B[T0[[M4]'#JO[-4B[T0[[M4]=-P1\!<5?-M(\GQQY_H\N/5
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M )1 3SC.XE?<7J"P*;%39T5G##U\)(<W-D.F%N3H0,7*>F9.8L=V:]^Y^<[
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ML0SNZOH8UV=*\]ED>T0$RHQ6R5"1(+D).XC9(8")EL2OG C$>4XFY=5G#"B
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M603..,-.<.C$<EKJ9&,AN^09S+H-%\N$/3@[$J\?%67M-DQL5HS+HP>/M4[
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M/\[^S:.SBWZH]=?P\O;Y=G2Y*Y]:EI'N\8:E^RZOD_I7G^C'J>5?A)_S=?\
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M3B@QGUDQ_P#00^W3&2/M#M]P?%3:';[@^*HXXH,9]9,?_00^W3B@QGUDQ_\
M00^W3&2/M#M]P?%3:';[@^*HXXH,9]9,?_00^W3B@QGUDQ_]!#[=,92^;.F5
MCT  1'HZNZ6P=O\ J;+NU_X^2HYWE_\ PW?S1\5>_EW&T#:BX,*"*,J7FR97
M)50$I=YS0FZ%)0I DT0OVW%@H3$';W: ;\JP?8$!H+H$AG6PS_HYG]]5ATF3
M[,?*(S'7+O(Y&=^17N0!>Y[N_C[MO=RH:_"YN+YR8,]G#;D6)QMU&>.2:$[^
M/NY?<\<[[15V\O\ ^&[^:/BIO+_^&[^:/BJD>@2&=;#/^CF?WU.@2&=;#/\
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M)3!"J2]V0$Y(HB?'M)3,>+>=MYU!,F"%N1\CW7"%MH9"FP#=<(6V -\L=[;
M&^X0M"Z^X!M+M$=]?=MML 1#95%B.]N&R[\&\-NVR[\&^W8(@(76CLN 0$!
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MTP;; Z=]P6C;:'3N$ H%UMW)=:(]/: " B&P=@@( ([! 0V" [! >D( /2K
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M#MIA>8-;DCL@UU+L+[78/J#7 7F$S"(:Q)6!$,#=&$%L:&I4&""&/Y.K,-F
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M1Z67='(#7'#[$IO1S:9M2:Z]TD]HE-[6_JT2!,'!/I876)DQ5A5MUP77W!:
MWW77"-PUMZ W23V%F#OM+/O#3UK/&_P[PK\YU?R?$_G^CRX]3[5?RS3_ .W9
M^K9K%[!Z@]P:;!Z@]P:V=/0&Z2>PLP=]I9]X:>@-TD]A9@[[2S[PT]:SQO\
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MUU1OOZU>5TZ"X?UJQOO$U>24Z"X?UJQOO$U>24QCHTA_75&^_K5Y73HSB [
M"51L1$;0  ?6H?9#V 5[:=!</ZU8WWB:O)*=!D0#8(16-@(#:("#$U![(>R"
M3;3&1UB>61=+ & E3)&%.=:#H-Q1[RVDFV[Y[<[K=\68JMN#?6C;<&T.G;<
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MIU_,')V/XGW?X#R_T=JGKGO!Y^0<5?L[3/)\<^7Z)]['I]T3\5J'R"?K.;*
M\GRV_2%1QB#ULX3\7T/T7UKZ^F*ZM.OYAZ6S_L!$^4!V[?X#76,VOW5+'VI
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MQZ/[69^G+]VK*;Q#[<7_ %<?WC,?^/\ QW1KC8'4#V/8#V!VAW!Z8=NN1'8
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M5 =H#\@],.W5NB_2-IC=89'<>..",6K81$C<A'1N+J8<TFL[*;EEKDK)DXQ
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MQY_M'?I]] D[ZQ)Q\S9-YJIT"3OK$G'S-DWFJMP3>AU;OY]_VJ;T.K=_/O\
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M0\@;.D'('L<HU(^]#JW?S[_M4]:C1_/6U^PU>3XT\_V\3U.T_"K?F@_6//\
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M@3"Y!(N4 CF,RY8G8 'O(IV@8[YF(SN1@'+SF(<Q" \Q0/,93 B [S&Y%,Q
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M;<2C,M$BQ0=M) E#K+!372VPXN:12A9N:4 !,.16L2,N18D9;#/* D4[#$S
MC !YC(0&)B)(B@1B2F!&-YF(W(I@8CW9F(COF,EVE?A,9:L2I5J3?*$BU*C7
M(U)-E]Y*E$XEV'(%1-^]#?D+2C2[TAFP 4;\+2M]?MM#S6E&WW!;84;?<.\
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M&:JO)7+5ZX]3B4Q[NF&K:+9@E,DF\[-%CA&DYHP45$<D,YY6.%^K7%6H# .
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MZ=@=ONCXZXN -@\O(/LCU/AKGUJ6D?GAJ7[+J^3^E>?Z/?[GJ>5?A*Q\@O\
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MZ]*E-H]Z/U9 YY@4*+;+"[5*BTLJ\#"B[3SK2RC $;@,+L"\+2S+;A&ZTRP
MOMN$;@$!$1'FU4JL$!L5JK!"VZT!L4GV"%M]PWWV@-I@"%MY@B9?:'2N,$3+
M@&\1NKP4IM'O1^J,9Y ..M&\;3CK1,OM,,&TTP!,,LOX2PPP0N ;S+#!$RR^
M[;=:8(WVB%W3KR K6   "Q8 !=OP %:@ "\+M^%X !FP+PO_  PO -\%^V\!
MWPB->O2FT>]'ZL9Y0//MOL-M//M-+ +2S0.- TNT &T+2S O"\NT+1$ MLN
M  1  V".W]WK%A@WB8L6&"98!9@F*E%XF%AO@ LP;S!$PL OO ++Q&T OO
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MMO\ I77;-NRVT.G=<.P+0Z8B 5@F:M'FJ_'.HQ! <4O,RQKI_<7;13#IKF3
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M4WB'VXO^KC^\9BE*5*Y Y VHW [;J(QVCABB6R+'LBC$^Q_EK&^18HG:U[[
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M-A%RI:!3*MJM96\6&AB'J<#@44 TE$LB%@K,A%A!,P!% E,3,1G4X@];R/?
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M6(G2#0260?"N3)D\SW$^*\@)8.,FA,6?(_,LH:D6+3&7AV5*WXP$3++(U,Y
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M=2N_'$,^,RGZF3"E%WXXAGQF4_4R84KSS5?;<_HP_P \]#T#VA/Z=G^$,G+
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M>;Z<9 ^XX]\0\WTI3&.,@?<<>^(>;Z<9 ^XX]\0\WTI3&.,@?<<>^(>;Z<9
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..[;S/?L/NS,S[GOY__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g412158.jpg
<DESCRIPTION>G412158.JPG
<TEXT>
begin 644 g412158.jpg
M_]C_X  02D9)1@ ! 0$!A0&%  #__@ _1$E32S$Q-CI;,3E:0DTQ+C$Y6D)-
M,3<V,#$N3U544%5473$R-#<V7S%?35547U U,U\T0U]&3$]7+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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MQOO%G\1S1M*R>1;@>X:[) FS-0<AD:D&5)(7VMVJA4>QT& B%=9F$60';]C
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M1*(R(L=4R8[_ +%%BI<R_)<\T,MK5C.,5W&<9QC./CC.//&?TXSS%F+G<?'
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M>&UMHN\D>:3NK>!(XH]\LDDK[$&^1W=LNS$]@EF.69G8XR[L6=L *"S$DD@
M#D]  . *\5H;=:=8=;;=8D-J:D,/-H=8D-+QG"V9##B5-/LKQG*7&GD+;6G.
M4K2K&<XY.#X(G?JXZ W91>F-\-SSG7'=A>56-00RTI^;G0NX)$6<:"U>K2'<
M/28>IML>YE1354<>6*H^R?H!558@"[R9@Q(0.73Z_P!8L-W[+=5:=4&77[8?
M[5=<% 6V%^S?:75MP5+8)\DA?J3Z6P-+IMHL4Q?JQZ!XB8KSSY>E6VI((]Y
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MU#%]?9)6"T4V;<H+P%9RN!Z.','95C'QYC[@14YRJP(9+W>:1,P8L9Y7.R:
M\#".:T;J\[L_?O8O2&WWZRS(L&O=?2M"EJ)3O:RY+P($^)M.F+7(G6<17U"X
MEP(XM!&+-M+9=T?*=@^ZN*DUU!XEO2K;9=P71MB1&B,E2GI:\AL^[MH;QZG)
MQHE75&(8N"PGUN2B1V3"@1&TK=ER6&\97R0>)*BSHL:9"D,2X<MAF3$E176W
MXTF,^VEUB1'?94MIYAYI:'676EJ;=;4E;:E(5C.<69D "H8L\YR<M\SX?#QJ
MQ(XYCN>5;@A=H&$"KG!)PO.25')/F/A H4\)7N+4V6DZ4\3:T#6(_DEH;LO1
M,*2G#2<YRE*"FDMGZ64UY>>,?[U.>>?4OX>?IY<SJ#X8F]M6]F&.S_:?MBSV
M!ME; *"4L+7Z3;:[#:=4.-B8DNRGMB;+V?8B0NNPK&>=JU7%RQ0P89,SC4A^
M9(RVSB:?CF)E<@@MG(P>!G!Z\XSSX\\^-6"WA4J0@&TY')QD=#@G&1CCRI\N
M...5U?5-+F!0 9.-'"8\,(&17IQ$J6FQAPT?#CHRX_+G3YCK$2'%81C*WI$A
MYIEI/Q6M./CS";KE!I9/LCVSVXG;6G]F67:A_68G6\>A7H#<+'4.OFK=754<
M-JAMB#GWT4RG>%HW9=W(<9XD(PN\PIZIZ)\UR#"BK\93NT[H#>6CJ3=J1^&>
MD%(9E6X077(B!X!PV%NY,3LQT7A@@-OT6ISZS7JA'"'(7T1795R.6Y.'3H<'
M('QLU?Q"['L0_HA<RCZ>U9L _:=$48+B-LLNSV&K>TMVU2984;'T37WJ[#3>
MM":M),Q1.ST'2$%J[B0>R8)*!'B57,6;\Z]O?3EK?8SM>NDVGHXOM>[*6 B_
MQ!VKB[0Z58S6SNK/=)I.ASQR7&I/IL80W2SW6GF1YHPO=VLD%[/Z&QT2&[M#
M,^H)!=29]7M3;RR!O:4(99U(6,2$^SA9  #DEU9%W9>.6ZT_;R&P=3:POI:-
M&AD[OKRE6XC#AMNM1(D^R5D69F1HK3[TA]J,Q)FNMQVWGWG4,I0EQUQ>,K5<
M7GT0CK(B2(=R.JNC8(RK ,IPP!&00<$ CQ ->?(()!Z@X/Q%....95%?-,1)
M=B26X;S<>6Y'>1&D.L^\-,2%M+2P\XQZV_;-M.Y0XMGVB/:H2IOUI]7GC5RV
M;X'>RNSMIM^U+#9BF@-_NU,<Q;=E6&VQ]Z4[L9M!F3#C.V6[TR&1#E(U7#UX
M:L14K-62>H;@+'$A56727*G2!05W:6XYQK_0[?4=5T/5I;S5H)M EU"6WM++
M5+NSTR_.HV36,BZSIT$BVNK1VT;&>P2\2065V!<P;9 2;XKAX8YHU6(B<1@N
M\:/+'W;B0&&0@M$6(VOM(WH2K9%:&]Z\&'Q-Z)-F1(W7ZG;;BQY:V(QW36\:
M _!(1O7E+,Y8;;[^H#HG+Z/)UP>IHMF'C*FLD)>48=<N)J/P*/$-V:9@QKZ(
MU'UHJCOL5E;%>KO%VY=H+*G48=0'UCJM[%=)S<L>O+"S&X@<-AW*7),>8VA<
M1W>$\L9^>//CG6V+[_K3UB7&-P^.!G^/M6!O1'P[M!] J.6!:OCF+7L&Z+@R
M]I;LOBA<[96Q98W#^!, A*$CA0>NTVM(E26*C0*H,$U4 F1.)>Y3K,9L-A,9
MY<<<SJDDDY)))ZD\D_.G'''%13CCCBE....*4Y'#XNUQLM$\-;N0?J)::!.9
MTI80+)T:^Y%(!(-PF"Z<:,0I;2D.PY(P$?)S&IC3C;D53.)"'$*;PM,CW+3[
MWU/1=[:8VIIG9L9$K7VT=?VRB7)I;S<;*:[9@DP64DLRW?)$*5!CR%3X<W*D
M>YRXK$KUH]CZL*5^:LF+&@I3!A1VHD."E,*'$8;2TQ$APTXC1(C+2$I0TS%C
MM-1V6T)2AMMM"$8PE.,8YY5KU4B^H=EG]+V\VU8SU?EDFJ?L*&&-A:EV!HHM
MUMD=N75$DV,%M6NMG(CL5ZRJKF"8^K6APD*;G3P/X/V Y2>:%O<VUY"EQ:7$
M%U;R;N[GMI8YX9-CM&^R6)GC?9(C(VUCM=64X(('8P1P05. 2&!5AD C(."#
M@@X(\:<NUUVN=@UQV?ZI7^I.99M-8[2]?6@RD)4MR0S>-HUS5EI$I2A25*18
M:+?K77I*,9_*C%7<^7J2A2;38QE6<XQC.<X2I6<8QYYPE.,J4K/E\DI3C*E*
MS\$IQG.<XQC.>3(>"=T<MO9OL)0^U=B#2X76+K]8EW.H6F;&4@1O7=8AJ5!J
M,&@ONX]C9=?ZF)ORK;:[L/PZ!F;&%4ZKU@H4GUR\MA=A>2,>!&:JF95C;)'M
M*0!YDC''PZ^ZMVU']SC'RQC*DX^/G\$JRG'QS\<_#&/G\?T_'GESC&/+&,?'
M/ECR\\Y\\Y^W.?SYS^?/Y\_'G/+ZYE....*4XXXXI3CCCBE.4LX##V8*7KEA
M%CS@ ^,G!3@4M$8("BX@I%=A$A9.!*;=BSAY"&^]$F1)+3C$F.ZXRZA2%JQF
MJ<<4J)('X)70,%LH'LUG7MLGSP%B8L$.M&+Z;*4V4V-(9+U^MF@TK"I%AJ=9
M+>1$* .DB$7#V,LDE$8:W(RY3;)61=I%.B2:9"6E.LRHTN#*?@$AI",[A^(3
M%D(JVY, C$?QAV/*CK2M.<K:7AR.Z\RYV#CF(50" !@]16;.[$%F9BO0DDX^
M&:M"#TK40]EC6V2\7/&X),D>@/&)$!$*#930]P08M48,%&!@R;03$.O"9)]R
M Z30-DS8461'8(3D2;3=O^INCNT^OL0-PTMZRRJ,R8L-0*!B<ZOV@3-P-=5.
M'#C8M:)>15C9CLCS064F6+(H3%D.PLD( Z7%RWYPKY9\L^6<?'&?C\\?''GY
M>6<X^'QQY_''GC\_&U0",#!ZCSJ-[!@P8AAC!!P1CRQT_OYUH+=*_%=V%U:U
ME&7H?K;UEHZ]FB*G:KA)<B;GLQ,C+0!C_1@C!BS;:(%(U<K#4N5#KM=8?9%B
M,2)S[,7WZ?/E2.Q]J?&8[*;CTCNBH'=>:* 0;_1#P>Q3*O7[C'DNO31#X:)9
M,,&KF;&XL5?CR_>1Y7,1"WD0HD(Q])"XK,-O&_Q >O=9Z;]K]EZNJ96*6T8<
MOAF7INXBQQ=%*JQ.REBI0MUA,VY\>S4F=J:I,8+B M3'G"1$GKYJM>URW;!=
MJ!C,22@R$7'$PI6-F0/*0)HHG$7E3:GH)",["FQ\JQE*VE.1WG6\+QY+;5G"
MT^2DXSC3AN+:Z60VUQ!<I#/-;2M!+'*L=S;OW4]O(8V8)/!(ICFA8B2)P4D5
M6!%=(1@A79"'9%;+!@3N4%6]KD@C!4\@C!!(.2&C((0:."#&6XPP+ A"!T=E
M*$-,P!<9J!":;0WA*$I1&CM)QA&,)SY>>,?'GV\MK3+$_"?BZ]MDCV5Q$QDQ
M1DN2WB+'V %@M>B'8ZXI6<LS)R8#;*;4"CN.E )5N2_(CY$RQ\^1<KEV,?O6
M8.1_IY>[Y4Y] JS&J+;=:["JZG6[=KO;^GKQ3WX_K]Y8LX/9U5P-5&]GG"\O
M2$2Y0[T8]2769[S"T.-NK;5Z$I4I6$H2I:E>?I2A.5*5Y8\\^E*<95GRQ\?A
MC/P^/)"?")T!7^UW=+4I6P$TP]+Z;N+6QW#K\,BBM;HV[K24\<J6F*#:U#I%
M0M$^FV45%V#MP3&)2I$0'6(M6:BOS29URO4RW%M;F 7$\$'K%Q':P=]+'%W]
MS+N,5O#O9>]GD",8X4W2/M;:IP:A\['(!.U&8[020!QN.,X )&6Z#J:WRJ;3
M0-)#N!@$9]J.^4+F)TF;-F$RA0P8(/SRI8J5(/R9Y C.ENK==D27UY;0EF)&
M2Q"BQ8S,=]^\'OH1LK8QG9-KU!+D$3YAP\3KHNZ6NO4ITG.D8E6);59 DQT6
M*/MSZ&W+4!BNL@#"T.+6+:7,(+ER=XQY8Q^?[?A\?TY^&,8\\_//EC'QYSS<
MVK@# P.GNKEJ[J259E+<$@D$\YY(]_/QJB.5L$X"Q6<B8"*^D>T*;#L1FXP]
M@='8;C1H<6-&2TW$CQ&&66X;<7#.(>&&,Q?8J8:RBQKO5C4<[8D/:9X.[9[M
M 8:B13M@9"S"C<&.D1A@>X99"Q3TH=C\'P2YP^66?AGGPPN59&#$J!&>;R-X
MX*J<9 ..GRJ S#(!(SP<5UFY4VL;!J=DHMS#Q+#4K<#*5NR Y^',Q"P0S#>'
MDH$C++C3R428K[K>76'6I#*\I?CO-2&VW41U=:/"4ZH]5]R"M[:_SLLWL &!
M,@A,R[W&(9@PL&F)HUTLF&-KX-4DS"KQ(C6!\J;(E,LB)TMYV*^9?66Y)WQR
M2H."0#C^_P"]2'=590Q"M_4!T/QIQQQR:QIQQQQ2G'''%*<<<<4IQQQQ2G''
M'%*<<<<4IQQQQ2G'''%*<<<BFW7WMV?K3LI9=%":E4)\'%_TD*JAN8,L#R\5
M0VS25[B9.R(IAB)FRPE['I2*,Y&;C16L&<X*P"?L,J7R=8UJPT.WBN=0>1(9
MK@6R-'$TI[YH9ID5@O\ 2'$#(K'@RM&F<N*]AV+[#=H.WVHWNE]G(;:>\L--
M?5KB.YNHK4>HPWMC97$L;2\2&V-_'<SHN62SANKC!6!@<Q]W=.NJ'91Z)*[
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03CCCBE....*4XXXXI7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g385816.jpg
<DESCRIPTION>G385816.JPG
<TEXT>
begin 644 g385816.jpg
M_]C_X  02D9)1@ ! 0$!F@&:  #__@ ]1$E32S$Q-CI;,3E:0DTQ+C$Y6D)-
M,3<V,#$N3U544%5473$R-#<V7S%?4D5$3UA?-$-?1DQ/5RY%4%/_VP!#  $!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1
M" $J H\# 2(  A$! Q$!_\0 'P !  $$ P$! 0            D&!P@* 0(%
M! ,+_\0 3A    8#  $!! 4'" <&! <   ,$!08' 0(("1$2$Q0A%187,5$*
M(D%A@9'75EAQDI68TM89(S)7E['1&"4S.:'P)T*WP2A267*"@]/_Q  = 0$
M 04! 0$             ! $#!08'" ()_\0 3A$  @(! @,$! <*"P8'
M  $" P0%$082(0<3,5$4(D%A%3)6<8&1L0@7&$)78Y25U/!256)REI>AP='6
MUR,D,S9#4S=V=X*3M;;_V@ , P$  A$#$0 _ -_@
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M
M
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MB]XK?2B97+HISU>GD_>$8?(,LA<,QT3!G)3(*?I>(6T>U1^UI50[4[-4O:Z
MS(7.L)&[G(P-KTV3,I$C;XD:JWU?W1C>)&B0_!+]L',["X,;4Z*LK-4NR G9
M,ND;.3JD/5E+5.JK8](F4)TJTU-[V,^N/7\?G\\9QG]N,_/']&?F-<:L.&^R
MGFB&BG)W&YS$HHDG_0K"ICQ=NQ6&J2J1L;R'\AWM FA@)J.S'=!"$#%S1&KG
MAR&+Q.2^M?9:WNO(LY*6I[CKI)-B*/L+3%F%EC+ A*;&*.M+<Q,K:3L9L2WM
M#0C);VQ"3L=N8;L4D1)B$Y>33##,Z%XR9OOOG;;('K@
M
M                                                   Q7ZZ8.Q9'
M7+,BXFL2B*TM(J9-ZE]?>@Z]F-DPU5!=&A[+<FMM8X5)XHZ)9&<]FQ]2D<SW
M Y"2W)'-*:DW/5ISB,J  $'_ -EGY07_ #MO&#_=-Z"_C2'V6?E!?\[;Q@_W
M3>@OXTB<  !!_P#99^4%_P [;Q@_W3>@OXTA]EGY07_.V\8/]TWH+^-(G
M0?\ V6?E!?\ .V\8/]TWH+^-(?99^4%_SMO&#_=-Z"_C2)P  $'_ -E?Y07_
M #MO&#_=-Z!_C2&:L_*#,YSG/6WC!SG/WYSR;T%G.?T?/_XT_/Y"<  !!_\
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M&<XQ]_K^S&<_\L9 '(#C&<9_']N,X_YXP.0   _]_P#O\/V@
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M]:.B;=BM(U-*8L3)YW$HN9")1/9>V-Z.=.TF:X@>42OV2O2A0EV3;4/!O(#
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M*XML=;$*Y-J8E,-3;ZD*TYQ.NZ<PPC?&F-B=]R\Z[9KP
M   $3?F'YNK2]>7D;]*:H:K'G4#MOG1NA#@8R+'B0QQ@G_55 L-J$,N6[U6I
M6Z10,ER;I9DK7W1L<T7:K=RT&JK.<7[<EG4_(]>7\DXW2:GE5-U96M$\3<'Q
M:C(HFKZSXWO3<&MRS(FNG934EE<>029RGMFRW:U#9E&XC7F]=IF$TMV5.JM
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MQ:W:1-#.J4X1)WI<P8-*>264Y?GZ/+>/@<M>SCKL@^+^,UV(QDX
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MR0\>1:J'--8E -_725N:4*"XHW)Y21+8)U8U6O6MARF-WVPR*=2I]F^(;MP
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MXQN4)NV'_DCG^W#(+9$F<)'7M76(]1Y"PV96TW3K+"I>:SQ@-E+\2Q1Z3X3
M9X<.<+2/@ZMV.AZRMF.RBD62TI%.RV^8U,A(LG=CF\$..FD=+FL/E,88-719
M?2E;8<?D:Z#.1,8JUPUHI"QF-\?B\Q:+'=2>,JP+P_[3$!A-KTQ':0ZXD;Q9
M4Z:[2YY46Y9M+72[4<RT4Y6ISM+=K-BT;9'QTC<:879#K.(A)ED'EFKV_15U
MV(=D;(RX-S#R_P#1;55\%L]=-J/J]:9P-4W5SS W'BWK"]FZ?3V;/G1:-]BF
M+3J.TD,;YZAZ72G8VT$/%F(9"<TY?7Z8+%JYC8%2(F=EHNZ:NE?V3(W:GY-
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MRR-$+\(\LR%R5V:]SFNWQEC<4N'HFK*KC<0;XS+Y)T 5!9MR; Z37P^09M%
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MSG'X9'(
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M6:ON[H GBNR;(:Y!6]Q6%!^.JVL6I8DQ[/[Y;;I8YW*#9/MVZ\4AKZOT5O\
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MVLTP9Y%&HO$F-AD3
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MC!KGL47LKSIC(P<8QZ8QC\,8Q\_GGY?CG](Y'1" WNV^G5M].BZ^2\@  !0
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M8^@
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M&I>,FIRZ_BK=037LW?-+;QVY7X--]@ !V8@
M
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M5N_%O=OJV8JVQV62F^F[Z+RBND5]"20  $DM@
M
M                                             $5_F%YJF/0/'#_+
M:93Z:]-\I2V+]=<QN19?HNUMFBU1DG^JQ!I1!BO9-94-+E%=K4)1I!*[ZQ)=
M%>^2B<8Q*@.-L>N,XQ]_RSC[_3UQGUQZ^F<9]/7'SQZ_/'R'Q97"V$ZK(QG7
M9"5=D)).,X33C*,D^CC*+::?1IM'U";A.,X^,6FOH?A\S\'YKH1D\U7[".I^
M?Z=Z.K@W&\+NFO8Y8+*GSMID]HR^(]=W>-KM-##<$.44?BG6,N2???)A"YH/
MT,_.P+WB)CC%D_[&?:O9WC<6Z[-U>+WE5WKQDE-QN4CTH^^),H27=6C#IN:?
MC5)3U[:KC$J'4[WB=BF)2\PG0I3C82SCP[Q;H5G#?$&I:3)2[JB]SQ)RW;LP
MKTKL6>_XTNYG&%C716PLBOBM++='M*/Q9)2C\TENOJ\'[TUX@  :X#G&N^^V
MNA>F3#-]M="R]?GL89OG&NFFN/T[;[9QKKC].<X$9OC^:=.Q/(OUMWDMV^E*
MAY?2K?'IR.HWUWW;'-YC;FDE?7UL,VIN"M=_K!8^[)6;4])BS]%+/$'9$2KP
M5J:2+B^2+I"3<Q<D6%+:T3Y=+YL5;'.?^9HX3C4Q=(^B;S=-(#6*9$F]K!BG
M+ N<5LU6ZE:F9*;XNI-,TR7C89^<'\HQGB'D6AN7HNHT<BJF@+6RR*18QGWT
MQGR_8U]L><+-]R23S5LSG;I()&>8IURH_P"\"RS-]LE8R._=B7#ZG=J'$M\.
ME">FZ>VO^K9&%F;='?P<*G51&2Z-7WQ?6)9R)\E32?K6/EV_D+9R?TOEBO-.
M7D9<  #T48T
M
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MR[?/:S(G9*.^[C!QCX11CLFSGM>SWC#U(]-MU'?=[?RI-OSV:3ZH  #.E@
M
M
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MZ8'<>Z3"^(
M
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M&U#KZ>GR^[.=ML?_ ,ML[?\ W'8="O7W9?K\\^QIZY_'/LX]1W'L8PP
M
M
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M@=@
M
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MQ](?1_OO];\%\3\+[S\_W7M?,>R O$$
M            #XG!R;VE(8O=%R-M1$Y*U-6+U1"-*5L>>6F(U,4*#"R=,G*#
MB2"L;;XR8<:65I[6^^NN?M_]_N^\4W6^VZW23:]J3WV>WD]GMY[/R*\LN52V
M?*VXJ6SY7**BY)/P;BI1;2ZI2BWXH .,9QG[LXSZ?+/IG&?3/X?(<BI0
M
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M=.H/T,-(*VTN-IIKIKKIIKC777'IKKKC&-=<8^[&,8],8QC]&,8QC&/EC&,
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M@NPW.A58NKM'"FS5YWB*=0[.DF31@F7+U+\8!(
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M/$-CZDB&M3+,G-><\*7R>Q5H,@SBG13]E<7UE1R&--9[VT:+ ,IP
M                        ,X]<>GS_ &9SC/[\>F0
M
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M62^,:1L,>43L\:M<LP
-              #_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g785591.jpg
<DESCRIPTION>G785591.JPG
<TEXT>
begin 644 g785591.jpg
M_]C_X  02D9)1@ ! 0$!IP&G  #__@ ^1$E32S$Q-CI;,3E:0DTQ+C$Y6D)-
M,3<V,#$N3U544%5473$R-#<V7S%?4$A!4T537S1#7T9,3U<N15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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MMUP:B;#VB.LQ!2,-!.Y9'D5F:T2&OXDY&Q_+JTG'MZR4N"5 >>2>+*8(Q&F
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MR*ZJV\5D6K*43J'U^HM*X:U@K=<#XY1ROY*NN)#3\986VMI2]MQ[.U65.VN
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M'C!\H/YV/KYYF_IL^J;^.+//U3J7V=\>FSZIOXXL\_5.I?9WQ\$KM!\^[/\
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MF--[)YK^THK*Z84H0IY/3]EAJI8]UC$+$86Q#&K BJ0#R]JD:8"Q))S3L^;
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MY<XP/,-48CA<;]\!:@<<$!\&[^9F%!?&WSH)B;GZ0ZJ:6J(OJ3 GFB#);"J
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MJRIN&$X/EEJ3V)U]'@#"(90'26OB)E3JE. 9P+")OPK&X+QX$'!:%(H,R,&
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MFWSWIQ(); 5TV;9]"X.CF)K\5&X(H*L)'''6+R5[<WX1)D0:"V:4MCC*2WW
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MLI J:FACEP8+#F>=)HA&(FQQ5X0DM.0F0LBSC(LYP$(,9SG. !\7A!C.>^
M\0A"\ ,?8@\0A"\.,>(0A=\YL-LV]VV<MN8=R8\*%!5BC[@ EE6Q7*M*["[/
M3MJD;-DB)*++2MUZQ*.U-=2N1,D4+/5]MHQN!+!W"MW#3;]UY8#U.AT&@T2Q
M#!E*1B&-2L4-=!@B&F?,SE'3CCCFYZU73EY/3J_T@&CWY7.NO][$6Y9MR\GI
MU?Z0#1[\KG77^]B+<HMT?U9W%^@LO_X^QJXV]]_\)^EL=^]IUT/<3[;K:O\
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MG/80<XS@6,^L.<9QG&,\UXUQ,3'A,<)^2=....--...:8$'.18P(.<ASV'C
ML9R#.<=\8'C&<Y#G./7C L8SG'KQZN-/_P!>76O''-,9QGOVSC/;.0Y[9QGL
M+'JR'/;.>P@Y]0@Y]>,^K.,9XTUKQS3.0XSC&1!QD7?PAR+&!"[8[Y\(<Y[B
M[8]>?#C/;'KSVQS7C3_]^35QVJNKEL;?71"Z9J>,21X6R.2Q-JE$F98C():R
MUC%Y+*&J+JK&G94>3'GM$*CBAU)5/3LK-1I"209+$K*,&#/.KWS0-L:VV*\5
MI;\#F<$?T"MV$T%S2(2"&'2J-H) \1YOFD?;I&C1+5L6D"AD6'LSH2$](J*
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MW^$R4\BIY*LT?Z$6=?\ JH5]_A,E/*S>?]':W^-=N?O+-3-J_P!//_X7S/\
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MG;&:0O",/,QD+^-W#G,Q9L9$[CQL5LI7S%&K4KQ+9*B-&ED*JUJJRFN)U3(
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M03IN;86X5UIG%6V"ZN86%EE6]RC'."U:R6MENW'3M.G@)PXNN5KC;,67LF$
M93D9"RL$RLB?$W:XRMPFDXH+BQWI9I35R,+(9IQ--M.E\X:GZNZ[XM*T^F-!
M)5%JX51/!-'U7)9,MN<IQN!2URE7)1.)=2-X1REI<K"53Q8H=D3=E<5*'G+6
MB/CKZJK@T+-A(.A3PI[9I;&J#K.*6M:#K2+EKR@V2M1A&_)I=?,5J]SC$-/;
M(J_FB2Q9I><1EG]\^(B<\C0)O+EE\L99;IN2-O#!(8[;=H,$@BD5!!8N^LEA
M3!I>HU"2S##BX;'G9O>D[@QQ,!QQIH(VUJ4C*$PTP84.!&#SGBY]9UE6L\)Y
M#:5B3RRW](W%-"1]L.922;O25I(4*59#6F=90YNJ\AM)5+%BDI 4H D*4*U)
MX"0FJ#ACC;=V)?PN=Q&0;<I6*F*PMW&"8=]C)/9;R-RX,V'O8Z'U$*>M::TL
M6/>)L7+,6[$TV4\V;WC2RN'R-%56TBSD,G5O%!Q4FDH*]2LB82M0+E-AK%,-
MCH RE/1K)FND7C8D+T?^TTZN'Y+E)_XEHER+I3_-JOZE3_TC.2BZ/_::=7#\
MERD_\2T2Y%TI_FU7]2I_Z1G+S;G]9.T'_$&*_P!&[9U79W[S[&_1%W_4.4UZ
MPVF?VH.JWY-]&?W6Q3ERG+:],_M0=5OR;Z,_NMBG+E.>2F8^^V4_2-W]Y;KT
M8Q7WKQO_ $%/]W7IQQQRNU/TXXXXTTXXXXTTXXXXTTXXXXTUQ3XQL\F97>.2
M%M1/+"_M;@RO30Y)RU;>Z-+JC.;W)N7)3<"*4HUR)0>E5$&!R6<0<86/&0BS
MCG$0:!PFL8A'*_KF(QJ!P6'M*1ABD-AS&V1J+1ED0%X)1-#!'V9*B:FAM2%8
MP6G1-Z1.G+#C[$OOG.<]LXXTTXXXXTTYA<_PK+_.5I=_P+>7_<M8\S1N87/\
M*R_SE:7?\"WE_P!RUCSO#^3E_;#M7_EY[_3N5UU+VX?V:[@_O8K_ ,QC]0\=
M'7[=,/Y-6X/^'"?\BN3?^51_[FD_]L5R5'HZ_;IA_)JW!_PX3_D5R;U)4><?
M'YFD_P#;%<]#L9_7O=O^']F?O>[M?C#(?U*VW^F]Q_NN UE*=('7VOF750Q5
M<"RBFA%U&K1E] +R;DL.$P2:EZY0Z!32"ERJB&27+TCI.YFNV:FD6*PVQDD1
MOFT32!+58<%+=DGYZ*$;]Z-:\6Q,YC#K1LV&U-8ULT)K=J9"Z.;+ )M'8A+(
MGUDL"SK#?([7+[8S52%7R1&XNV#,2-MS-ID2EC;$L3HD6$3KC.K9Q-7)/$4C
MC,)4X):^2^90%*ND3PL3P9%[J"?/,X80I6F%15+[MB$\^;L &\GW6$)S\'GV
M<GYJ^@V\VS:LGY:]I-D6S*IP5NRK+=?%KH,J75P5F."]S4922XG)[BN7G&KE
MBTWQJE2TTU6H-,4&#,%U[F^RW.Y:UN%S\I@LG5W1EJ>1R./RV-LFNJG%6+B<
M>G&V1<XJEIV$=6P][(UTUK45T,FF:+#1M*V_%=H6&QU?"J5C<K1?@,?8ITKF
M/N5X-S;Z:K+C;J2!0V4+R:GY"I4<UJ)<T.\BU8$D\C+IF:\L+IJT[QF\E]"1
M^7]4FS;QA<Q*N":0JNK89J^C$9F\%K%ZI2M'Q0UR*1R1PVW?1.:IGBR$!;<W
MM;<F(2G*"D2;D1FC=;+:SDW4'ETS9DR>X]/M-]A72*LKJG)4F16X12B/T0[2
MP*120H*,75XCE\G7M)YB0P+>\J6EW+&0>C2G8CM=;(L1]<(P[OD^F[T[0D!)
M4,='>6R!S<H@4G>3Y$G*BJ]:XGJXX61(52E^) RG(0E/:E0[@P%Q/-4CJE36
MRUAU#:LEM8XX-D.-A12R(';;/8CF^O*.V87;<?7QZ>L<W=P.)<B7G/ %A+T2
M^!<_=A#)FIG?2E)BM#C!EJ.P]P5%[U?&6K7RW7W:T>+4IM12SQU\^CC4O;8-
M?=[^VXK[=L--=<(74JLD("&D4&-Y8.RW:RCQCJH[?EZ(OL8M[#&[3"'7&K6H
M6=6OF9L9=0B;9YK+AXD<+Y99;>T%UQ0Z+JIU3M?S]QO.!4CK79<P4R>66C$+
M8)DEQR-GCCP8XTS-:Y2U'/*4?%;TW--1/='3YRG"IQ5I53D;*2<K""NN:[:(
MUFCU[KY]N;4C:R_+AN38F^:!ED?IZ1+:_F^JG\2L59G8M4OA3VQ8B;C/W9<O
M<'9T;;LD43C"2*M:LDDM.K)RX*(F56P]_KJ]CM2K;SN1;5D16M[E%:W66?-E
M,%C;BT*0+&E>QQ0U[RQ-:QJ6%%K6P]"@3Y;5H<+&_"10$(P[FW8K8)F26.@:
M+UN5K0W&<I4VZD;[1G*1/::E8$8%BJQ2R'X 9JK6%F&E+%<C]T52LDTPA2<:
M0,1><@;.WR.*M8XMWDTW9Y^5"VV[FXN=T.LI"<?-RK:K/K5%6I9E(I4I0CF2
MC%L-U5]RRS'[ZMI>Z*+T[=*(5B%4)2%;&S7[R+F-9;BN]3UN<Q')2*Q9ZKOY
MQUU<*<%=*^LOE:3")N<*23:.R2"-UB-+'*H8]S&/KF))(Z_D3NH:&JPV,2[!
M"1\B*H:)P-3OC2L5,BP;:O)1N9H$XS@Y'+KTQM3'JS[ IDFC;SIE/K5MMI72
M'\<\YLR2N+;NE#MC;:8:YEQC"UN$9:(W#Y![BN1]@P=;4[FZ)T\6R7AY2^6Q
MDP&-.^RN42@IB(DTED$C(B\?11*,D/[VYO1,<BK:8I-;HPP%.:I46RQQO-6*
MS4+$V!2M2,Q4I&F2%"4'9'45YV+V"D3/7L>D%[7,^,-2+TCK5;*\6E.7)JK1
MT;_#[G.<!0K'TY/$'%NP  6Y>P 0+&\  %H3TY8< Q=;HVYNO.>Y)X[<D81U
M,+0VYI-R*%,8RY0<FP*465A<*:-6WC&5\A#4(]U&Y&K 7*=>#J=OYW;F(C)A
M=P<Y0+)5RJ]Y"FQ@"%>RMB28U1E6&+3T70;3E;6]R"H\BKV&P-],7@U.(.K;
M1],4A&IY6D!A.YM5TGE:_P Y23B<NKY#KS)A;_8Y;LKC:=F9UL@4I"W1IC06
M-T:8Z A.E,&\9$J&=VJ%:FLEI;WW95=PQ*QTD:V G^\=;:L6JY&N<48I+LC7
M,GF1L&$5("&1/&IX6=-&I#!II'V\DE"D?)DV 4%LYV4I8(IB)5*$LG*FZ62R
M!--"'[$J)EZ=[<R943)PN&78,D*D9:H+R7( NN<N>'H"T+GAQSE=A5A5_E><
M^IM6T5BB-JU=E6"J50Z1O$PB"E3-I.>?%)=(G<F02"51DXYU&8P25]?DY#X]
M/[0)&[NKR02ZN"Q0O*+4!YL[5S<]*:.=E#_>JO -R#SNOR(7DQ:LJRR[1/ES
MCG(%4-R;#2!M:+*BGB8<"-R8GB<W,1U5QN LNNHD:R*94V=%!XXTBJ%K&*<6
M!6U(006)2SQY3F94W2D!Z@[WZQXJJKY?(X[3-B:IT3L7*W=&Y32M)QM+8D<C
M[KL)3/NHJ;AQEMRLC\V?Z_Q7)2@]7EO97ER" _QF* ?CJ#3:C'GJ);LTN],4
MQL^I]3V[<6?P>HH#(53--KM!0,F5((54+3)$J%>]IU"Y.H*"_N,=1*Y"<W1U
MS,8PJCC0F&V$TUM):M.VA%;3+>G&P'"(V=F\4$8L222Q]ACI=Z%L<4T8MF4,
M(7P@J336,.RU-($CNZ&&+W16VIVYX6JF=2O1J*3,5DV)%IXFM.,SN7QNS4;\
MME22PH[(G5@FB23.2A4K<7]')&A4B=4;LO5+5IRM8E4DF'B5J0&>(HXPL4$=
MK;I(+R3S<*N,VC7PHYQ3;0OR&1BX^UWEXQ8FU4*I)W14ZLT3KIS112*&4XX3
M9W'MT9IM'%DRNO<C<G.+:%<@I4HJ)K]%)2KH6!=(UR-3UD#F8Z.\CROXZR:K
M2UDHZRDNJTRG&MDQB5.4STP83/%-56!:EDQ0Z$R.QME);&(@P6+(ZMIF8;"V
M$-P5NJQ##4,+JTN4.9XF97-%+>CPJRMI\?TIM3WC878.HV$VQ&-CT[VKKZ67
MZXR:9J K,:#SG751;;X[)<+$+,N0R2$3N+O,++DA#26[JFZ61P3R2%T3#,'
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M:&F_;U8:U>*98[IMIEI^0'*%#]5338\Q;:X>3U9GE59CG"$;R3&UGGAO8U:
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MJ;SS@W'U\1;QMA>01(4;RV;@VMFTX]U.GR('&,3@K^*MF:K&0=2RG+8L7.A
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M4[.2,ET:J[=Q-=EBR8L5, L&3,<6K'GY>)<.,3=X#&IRM\JSHM&(5+=F$T1
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MLV*ST#DU.B%4VN;<O2F")4H7!N7$IUJ%:F-"(I0D5$$J"# B+-* /&<<_'D
M\8SG(18QCX\Y#GMCO\7?/;DKL].@4TWQT?B%W.$=EBF/Q73:K=O'263-KDK&
M\S-A<2FZQVR=S]$Z&-KL?'X&JC,)G#[B4N8DJV/N2)3(<+&H_"3M@)/K;8-:
MQ!MD=2:LP=98.IVX4TG<B@,4;(]-8G8U-6%/D>OZ:'#]]1ID7E 8G&F4!#(2
M7[LW@2[8.FN9<L7-;BFO6[Z96K8IS<'=L=_J5[5@Z3%M2@'JREB&5Y9"VVTL
MJX>W8K$*P)L/QZR$.]$::4-FK=9R*59FJJ*=AR4#96R&NE441D&]*36AJWY!
M"'#S' $JV0R70@60\ )-,&66648,PT8"RBP $(9IA@L +++ '&1#&8/. @ #
M&1#%G 0XR+.,<YK,5E&%4A1"C<@"MB*=>JEB/+*YX519*U.29F=%,D3Y2^68
M4[8\+$;2XG.P$92%S5IF]4,I8H*)'.%+ZUIB*+)!;(ZUUEB-4T=MDCDU-2:J
MIQ'GF2V;05:4M<]EU]')DJ;)K)%3T\V[,8/61.7.7HF2QWB6/,R9QM)#7$1-
MK'U@1;"T:U7S+VABH7$'M+I\QQ2&[CY7&PW]9VTDKM>CI;L'#'4E9.#)B[/C
M;.13-&Z0(4-RQQF!Q6(RED/*-=53J^5T=I86.[33Q+9&Q9QM3GL6JT+&QD+"
M!*L+DL8IMVM4;+G4%$=KFAO >G5<<S8V"*H?WC++DDHM68A%=LD2:R3D62#(
M P0VP,+"R<0CE)<R7.X1&'AMKFPGF.G3!H@4V=8DF4/251*FR)2%PC2=5&F0
M4FD:8Y_1MQS04HC\;"*0OI)BP)C,Q!$\.84K=C*G'3_"+OV\(N_?(>W;/?Q8
M^,/;M\>/NX^/'W>2]4_+H;*-3:/K!Y.K03I'X-U37QG;E2YD9)(?8:^NJJQ4
M">1*3WQMRX9E\B4'MK4TR$);7-"F-$UGEN#>PFE%W*/U.:7+;:CC?64:H)S,
M-K>^U"UDB#Y&;-;S-_VE1707>E(K&;3GM7Q2::[P:+J9*^:LMC]-2*]M=^#(
MB5<IL)S:6J).!_:3[G7+E3(X6[P4_-BAU,18A=;$7LE4!]UK&":XN!0AX2NN
M0+@SCBP%]0OE.PXNUJUBGEJ@]1.-)J[)P+B??K4W&JNN!A<]W;9)7\Y8B6\H
M3'(1\D8_2) N<EJ5N;D2M>X+E29 A0(4QZM:M7+3RTJ-$D2)RS%"E6K4FE)D
MJ4@LP]0H-+))+&:,(<[5B)8W+%C<X)%2!P;E*I$X(5R<Y(M0+$)QB=<D6I5
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MP]Z<8U+(H]-TCC4B9E(D3NQ/S2I+6-KNV+"_\HF7HE10#B3P]\]\9"/ RQC
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/D %A0L14 D $?4(M?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g602177.jpg
<DESCRIPTION>G602177.JPG
<TEXT>
begin 644 g602177.jpg
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MTDT\\MQN3ET493$LA2@H,M%ZF..EM&83M'%KMDI9[HZ,O=Z<@_@.JGH 0/\
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M?P74WU:^&/U%6 [N%N_]8NU'H*8V]F=.[A;O_6+M1Z"F-O9G7V)AT  5'%0
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M1-[WOSD61Q.-R]$C;I.RMS\WH'QADJ1$ZI2UJ0E^B[PDD$==@ISK")$M9'U
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MEL-XAB%Q>2DDC<^-PVHSNA 6K78]G"=N),$*UNC<3T^LQ"DE*&U[W-,3CN:
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M4[3F*50$3Z:G7)VD5Q@)-YK0FW&7>PJP(M&^*H2C3$J^'O(U:HHD!:A5??\
M@A5U!H;<A'7**VJZ6"X[]^X07Z&W/O<K=ZH?[4#87]_X)7IJX _7T[4#87]_
MX)7IJX _7U5ZJ_/5>8$Q,4.996$)0$2577*MG5_&*6U@J4JXN5$] 2$@ 1$5
M2FU^L.M/S>CW$J'&F0PDRFDN0E$% <4X-9J7EFVBM)<6-IJ:Y2 %*4<S-/:/
M\4SR=\B]8%"/>JIVC_%,\G?(O6!0CWJJA;M0-A?W_@E>FK@#]?3M0-A?W_@E
M>FK@#]?47N#WP15>CVPS'#Y3J\O5:+YK57] ,7]']:LMX/R'7Y!$T]H_Q3/)
MWR+U@4(]ZJG:/\4SR=\B]8%"/>JJ%NU V%_?^"5Z:N /U].U V%_?^"5Z:N
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MWR+U@4(]ZJG:/\4SR=\B]8%"/>JJ%NU V%_?^"5Z:N /U].U V%_?^"5Z:N
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M2O5&J3$2 @M",:<A2;;IA(-+MM<<<4"41U2EU1V,UIQ[(1Y1BSM&5<IP9+C
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M  #!7_$VF]SZI.*G'U.W45_//# ]8$H]UFG;J*_GGA@>L"4>ZS7R^Z#Q_P#
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M:2UP\6[7/>RFKN<FS/E+N!_YR&3V<4[G)LSY2[@?^<AD]G%0KVO2CRO?#/\
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M640V5E2)'PJ=J")$VKX6]!?$)2409$4G/(6* !)565"%<)=@C)Y&!M>H/A>
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MG1VY:4E4./+?6EEAF;;9;"G77'5AMM 4XM:R I1OP:I<X*Q-KGJK5]%E3G'
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MP-G/JA?I3.?L_GO^D1=?M9>'W]#.&1Z3O$6]IM>VAU;X?:Q60D^"'#&(NH-
M58TW9[B+!+!T8N71#%?)P;!M:_*_.X@V[W?O;PVH[W0O1_Q5."G\G[E'(/\
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M0%MTTG4D:"1*SV=N$-82W@7@ GZ24I+)./+-T'I60TTD@I;;!&8(0D$'N7!
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M >JB!4<:7] R2!M9Y*G@\23O#>>C3O:5^\8*U*Q7K4K< 8;4ND,BSP7##I#
M6Y-#TT.>9+#8(#'1<V/0)(LD6M<NE$?;XP*:+V)Q:DDA<X>RN)C>G4*Y+>0(
M1*?9TPIU8)N[+N,.N ))>&C0_#^)=6!E]C>D7BPDW7?IUI%8[^U79;@LXV-_
MM5TW3/V-?/2[%Z_KK+[HLXX@66:D:IQ<[I<EPI19O;T2E"C6KEMR7P?4J-(K
M=&U*H4G] 24I<$) QV-5D!,K$KX=V+'!,D;CL@91NQ-['*X,V,I2G'H4;?BF
M<3V/Y+E>,TZT./;/)K4[R^*L*X4K5NBG(:).@LA;I<D*5+QJO0<N'/C!MCS
MCQY+)C%Y'%3L-@C\B</@L^B0I,0M42B;>>8W*XI=N<'-7$HT/G=P2J&H4F5!
M=E#:-" ;8)"+/-.RN"WI1(TZ')\0O>-/K='%*D]X1I6]U=':!Q#)2 J+."@X
M".8$'P^=Q9SLLC!SJEL<Z%MG3.N91R0'(<?9MQ'E5I9'K'N18A*T4BA;#D1J
M UOB$;@?"9,TMKXQR0]G-.*=V]L<&IX;%@#7%"E$26N2V4A)&>6$5)Q\+#6]
M3*DDU=%DYD$DNZA=7QPD2J'NH'TP3KC*1K0W;!PPIE8#G&4XHCDB-<HPVL[J
MW+%CPE8%S.@NR$,7/L/\/K"F&90&7,"Z4/+X7CU7CLITD1</5.X&]R@^.\=N
MCIU\01%M>0N#A&,6Q!.>D(7)V'JQ,K6=9Q7-1$MJ$603Y_P4K;[NZ7,V*5+3
M9E*DEW1/D2'G-OP>.5$HBGSJ\MY$DNT&+%*=(6XV.NC&I/() <(P\D(_CAV8
MP(<8F$DR]CE>UJ$KLI.D;?-8PMC#:)HO&;&HG:0IG8UK;7%8&7,9K6@4J *7
M(E7TU* 80<Q5?C/#&UOBDUCLV;028]?&6G$C<W%.=H>X"Z?AB$8PQS$U_7!1
M#Q.B*RF(8BB#:^M3,L:F5Q-LZK0($YSAT*?Y\DX6^N<BOTTQPG*<XN+H(HG
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M9:]T+>_<A?#"F\0F.,Y)?:.4+A8[4-ZI,])XDG13<-RXW\%7I.V2AR>9"H*
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MTD$$5N=A!S[L=<-[7\%["MH%RO:_AMROW[=^W>J$MT8WL;N;AQ+B%PSOC;$
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MF^0SZ*('^-18()EAN8K6;%I37(F;+F/'LR3L#LUR/IYLA-,G2%='U^4(IFB
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M(A]NT[:O.7SF]^JKXB'V[7H]GG,?U_S'U5&UWV]7] SOF8P8"P9]F0QF# 6
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M:4@"QN298    W)[@N<KQ](EL7K4E"*'HM6M12$I34*BI2B2@ )2%%2B2+
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MU#O_ ,5:V$L6^@UP)5E5W!N.M&.&JNN1?IJZA1\48)DIA<A-/2DQ,2JE-54
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M>C<NMIT,C#@2(TSJM4Z-UE9QAPU:T*GUW+A_ZR.JYC6*(S(BPM"&&LZIO29
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MU0SMB(XR[@8UMHUW1C%U6- B$HZ9=(GN4[=NPA'/J4I2$13G%1-TN(\A*,;
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M]K]AXN]N7AOR&"]P]ZPK7[]2,VY&S6)<0%SX5'$Y)17%_;SB-C]ACS2P\O\
M""2/8<=C.5^_T'+O\O#:]9E9>BW%R5;:Y1E6,=2N*$HU<=US*;CF$D;#YDBB
MUA2@A<?1NA-[*\Z*W4@)4M)>EQI)I(RUW3S!D#*(.*Z#]'X2TTU;%$_-4^>T
M&XPPBEBG/3R)W$E#I4M)S*VYB4EQ(RTS3\03Z1//)FE/LMJ4V2S*3+BEH+:
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32$*4I2$*4I2$*4I2$*4I2$?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g679196.jpg
<DESCRIPTION>G679196.JPG
<TEXT>
begin 644 g679196.jpg
M_]C_X  02D9)1@ ! 0$!F@&:  #__@ \1$E32S$Q-CI;,3E:0DTQ+C$Y6D)-
M,3<V,#$N3U544%5473$R-#<V7S%?4D%415-?-$-?0D%2+D504__; $,  0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$(
M /$"9P,!(@ "$0$#$0'_Q  >  $  @(" P$             " D"!P8* 00%
M __$ &X0  $#! $! @<*!0T*"@8%#04#! 8  0('" D1$A,4%B$QF-@*%1E1
M4E=9DM'7%QA!EK<B-S@Y5F%Q=WB!D;'2)R@R-E.3E[;!\",D)4)R=GFALK4F
M1TE5U=8S0V>(N#5(6%IB='6"AZ>SM.'_Q  5 0$!
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M8)SKF' @U)P$YF!7D#()L&X9D>6X":@(+Y)MH6Z'YCHZ2AID.I(<"I8V6%O
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M=53QWPUDOE%&-3R>&L"YY./$]XDXHZ91N02N,YJN"AX:99$W@I8,'*8Y+O&
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M(KK=W&_@4%U>XCF%SM*HNU%U@N06[-6:YW# .CQS^DL'VA"8W/HC( <GXC.
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MF,=KQ=\9M'WT5-QZ62V"2V*E5QC]['I7"SCH(697)!UW0LDQ=V0;&0Q!FO\
M\<"E!RSMJ.(Y/!C/2<YX1:=V#*I9)S[N<6PE!0W+48Z-DB ^.Q79IV+QZ'N]
MM1!LB(N2$;!1#1@9XB_6*O@;(EF2-(Q[WV+DG;G?FK-8@M31=2-!'QHRH_D$
MFEI^1R9XV(2232B8''L@D!TV]9,1;)1V[?OLTF[=@-'C!8QNP#BF#(8/9M4@
MV)X-/_)X?5Q^RHV<H-KVU%K_ -\W>IC.V0$G>LX&2CT>D$0"%B96?%!4'BD2
M&-949!X&"LZ/25M'!K=J];(MEE\W15\-'X*/DI+5P&;:WC<_)ZZ*2'$@JKK&
M>([&CK9J^S:LEY(UBLKB3+,VUQPRP+,&#.8$2;)BO?%)N?9AC.%_&A3:@B]Q
M2V=J)BWC/&[36I#6MM3:UA$LBVDE<513F(D81QYV CHB5B J-C9.2B4(M*T&
M;():1(Y*2*.+M#[=W:ZBS5.;G@T_\GA]7'[*CSK3C)KS56P3^PXR\EJCPLWF
M;,-'2A^SN(P9EL>?J;2V"SAH1%BTNP2F$_4M(RBA5X:<ME$6PL*N*!-D!6$B
M:#0/(_?<5XV:XQV/+1]W(=65Q"'Y.UB@.-Q\*]FAQL '&IC+9&[8@XE$F+QT
ME<Q(""JF#2RK=%!J[=NF[?.*O'S<_'TQMTYL[6&AI-#RG+DWJ7':NV2>01B]
M-[A;\80>S->PN<1I:4/BK8K'=$W#A;'@(Y2-W,^!#8.7^2F1G*9VWM.1O<@J
M,,3A*1@"D'FX+8L)E,3(M1\@BTPCR!-BR+L+DQQH(]Q5$FS8=\-.A"XIZ-+/
M$EF5UO%UT-1:WX8:EU5(X4<B1">(C8(W#N@T+?2GQ^'+S,+KC+4K?998<J.Q
M?DYZO <\P3PDN5L)6RSN6P!I&L<"& 2T\&G?_F8?5Q^RG@T_\GA]3'[*SI05
M83OD]QPF>[H$6D>E2TJV[I39>V(IQD+N345;'%=G8SD'Q-V>BT$82M)[!&QA
M[L#!FP,SX/9B;U^F5E(I%%UB'8E+!-2;$&[:@(6<L012.7?N#HHI'3MAN9>/
M2.)R(M$92 ?JB7A$8Y<!I("*CKO!SYTQ>X-\'C1=1!?"]: .\'-0R"<379#P
MK/$YO+"#0P-DK<V&Q+P4RRG,5V*T+10@M&EWKMXPDL*C> ?&=.)LTCL6'Y:_
MCC41 'KZ,N9&ZQUT U/!P<"C2Q9T+"8/U+D#Y)4P=,%3)9^?/GSA-7!+)^;D
M!\J3-%G>**":Y!^XS1;MT?!HIASKP:?^3P^I:_\ 5:JYN4VX=(;5C/);B'MW
M3FQIE&)*#TYHX]',UO(-CN5+E\;G&M18.&2AM( TB#@1[F)'DI1/,\@23%LU
M>/8@N?<,4_&+'*CILGC#KG9YN52@PZE(F4R='2.24BCQI%D0C)?CU-Y?L+6$
MBC23T<3&M2XF23<ZH3Q)L"PF0C54@YH4\&67;. T#I#FWJZ7N=;0*!:ZG@N'
M8/HCIXD;**A/%=;;(<Q&5D0FMI V5..C)9<>-U^L()2<+[\"DS!N+(8N7R1$
MN0"6$6OVVM>WHO:U_P"FH<P3@UI/7$G@\DBBDV8I0ET%/7CBDHNZCDOGT? S
M.-B]FS=LL.R)'IPF,GLB\9>8%6(4@^S$$R )R1CD?<C9CVMV6[+>BWFM0*4I
M0*4I019Y@OH"4TV5TML6 FMI@N4GOWQISUT$-6BZTQ:[-@LR\J0SN7>^8A2)
MCLH$%ESIW(&K] DRLV3P$WN5796K8/'L[ Y7HK3LAUH() ]?E-9PA>&@3V&=
MCH"-X1P<V$ 3=EGA+/WW!LD$A)._OD2QR>LE\L"#[#+%TM[VW-01W<(B/#S1
M.21XK#9>)GL+ED0)-Q<DBDM#LRHMN7%JD!Y@0XR7"GCH1\R,ABHUX+,/45F=
MU;H+H<BUQK^,:I@$,UI"V:S")P*,!(C'6CEVX(.TA  >@-8^.D7F:CPB^S10
MQ5>D'BJKM\[46=N5%%UL\KAS+P:?^3P^KC]E:KWAM 3H_46Q=NEXU)98,UU$
M#DN?1R%BT"LF,-08]=^NR%-7+E@P36410SNH^*D!P@:WQ6?E2#)@V<.$]KUQ
M&?PH+LF"S/7DDL[RCT\B<DAAZP]UDR?7#2D*^ E+,GF.&>31W=@0<6;.<<,\
MFZW<5MCE?#LN$)-(;)T9 MLS.!ZET<>AHW>&\LI9M#83-8/>/G>3^U^/8'?I
M/,P.>21W(%'I7406,>^<D%"T8TG(<Q4?:-<U\R;YI8-X-.__ #,/JX_949 ?
M$W64>V@&VD,(3A)\%>!#R444E2RT'>3B/:E4T4)V&1!9M+K.I>WU/GA#LEL2
M2(1=LU8%5@:A]@S+(R>H/AR,ED CQTZW EI*X"ABA9".QUNP7D!Y8:Q7>)!0
M2!)Z,'K&"N:.+ 8D_)#V:CYPA@Z>M$+J.$ZN9/RHX_VV^RW#->/4I_#EQVB^
MZ(1)Y<V)QLU^"K3ZY?C^[W&Z"'1$ERC<W:Y2&8ZV'R2.A&KV4#)#!)X$QP:N
MXXFA([0)?'<)A$Y/$U#$ACJ<GCQJ/9GXD76 2H'@:&N1N9>-'6^.;@+(!N+F
M[P,60PS6&D46SU'&ZB&%0Q9]/72Z,2B,*(R/9IL#$1)R'X-WIZ-#KR#6$E-0
MB32'54GQC,,C[<I#C<I@ .2EWB2#.<DR[F1*OIFX;R@^V?A.RV"=[=O@\/3>
MW^!CZ;7O:_Y/1VV\WQVKSX-/_)X?5Q^RLK6M;S6^.]_Y[WO>_P#3>][UYH*]
M^:FR^/RK+\ /*;4:TSTW/Q#Z8N/'R\<R:R5]HX*8Y!.51$,'R@?/RK" .-7@
MGIJ1H,F045*3\%%+JOF10RZ#R>TWMJVTT)@R+0DSKV8P*1LH]+8@?(1TR[8.
M#<4CLZ!O&Y>+DB@A^T)QR5#%LKI.,%V9-(H.61O9FDZ=<-VOQ0UQNF3Y&M@E
MYZ:CKCWO=$=9*2Q7\&Y Z'CLLBXB3W!K,ER0HT/%R]_G;R=.!1)$HP &S0HF
M6!#WB?/M/Z: Z<%'F0P]+Y>7E1Q"0R>83TNU.RL\08QP!$!7O@09# [.S81&
M8P$#CVK0<U2Q2:*/'%G)1^1?.PVWX-/_ ">'U<?LK3N^-S1/C_K&2[-E(XN;
M1!LG"@B*1=JS>RZ:'TVCIZ-BD38/G8]FZ.E+,G&:.3Y^P%#6;9Z9-D1@0:1(
M-MRUJ;<>CM7;[BJD/VI$!4K$V2.8CLWS?#(B!=2&,&X:4*QXAW;N0QA:-2,V
M(Q(L\L%K,B3QMGX1NX624"*?&S9>B-<G1G'+1VF2D UBM/MBBA9L:Y&+Q3#>
M$CCB/)[9\95'/#KV5(O";?8!R0*G<FR@1W(V,E$M<6;1J(6(V!>#3_R>'U<?
MLJ,$'XCZLU[L(7L"-N9<WQ IY.@4*5/IYP01*%]=QK4[^<M0R8U%\K+B6OXH
M,CKMZ]+NQV*;@T19BFA@^9(/914'HOW+,:R=D'=L<&K%JX>.<\4KJ98(-45'
M"V5DT\<L\[XI)YWMAACEGE>UL<;7O>UJJ!A_,WC(8/&.8<+T,5-;:FVHG 6:
M'(Y*8>4G0OCQHF+9;X4;ST5>4)C8N2CS7:.3V-P==JG*I&;DG@47>8-OF697
M!/F:!%D[8.?#>+O6KAFOXLZ<LG'@72.:"O@'C-9N[:+>#4R\$Y:KHN4%.ZJ@
MJFKAAGC!(AT[M,F&I+([,MU'9&<%9Q&13HOL:[V:2/6:^N<=5O-6G3"@.R)*
M(D(AX9)^_68^73J0NWDV4F=YFZ6.W"<HI^.-C!Q@9FFY'%6+,DP<62R3LX9/
MVR3MHO;!7#!3"RK=9-3N*889X][NYXVRM>UO>O@EC:][X8=EK7O?]1CZ+>>_
MY*_%BQ:#&30<P;I-&+!LW9,VJ.-L$6S1JC@W;-TL+>;%)!!--)/&W^#AAC;S
M]G;7LWM:]KVOY[7M>U[?O7]-!5?OKE-Q0GFPCVNME:WQV:0XG[6C6R8TV3D,
M52D0OD'K=?7^,!)QV$*RL)*5\4Y+NN-Q@%*G3)[&VQ]T9<R=B*BC%G)G\^=/
M;.9[9BKX[Y-DHD8!2^9P.4Q@RJ->/0DI@LC?QLTW3("7#H:3&/%F6!4(3:JX
M7?A2 ]RZ:#GRCH<TT/->!^BI[+IE+#^$QO>9%I-+E #&2XL $>V5+8M#X<8V
MG&4$!MB8Z<W"P2,^(.')<@ %DV3DR/CR!0L7=/I"ZHU8!U#%58N"?GC63^22
MV9'Y%*2"!.1R25SB1D93)3A=VT9#&%EWI4FO9LQ%C!@<2.19" XU@,8M&J0;
M(\&G_D\/JX_949>4^V,-2:\R>/=0&]P@9:OA B$5C4@AP4V;)SAXPA\=AHAA
M*S0*QPM-R1ZX9DV9/6Z3/"SE^5>CAR"SU&3M<#FFN(O/R&OR,F:K/5-:SEKL
M6--\5K)M,92PCLDC8UX_1NGGXZF-:RDB^8H7S3Q0+HCB-KW68I6N$6^+&S=0
M@[1'B[JC4Y75>N=?:_EP/1+/)V))QHSKCCK.QFC9<W W:'#9@6.BLG>@&8+R
ME6\=DT<*,#[52^5B#5I-WP:?^3P^KC]E1\UQQH@&L=BR'901_+B)<LE-V@,7
M(#N!./Z_%[,GMMG;$#01A@/:.!0J8SI%@>*-"+XQXK<0(%A,Q00<W&XR&H-"
M\BM[1CCEKNVQ)4.LY#YR>*Q11ZY+ 8Q' 3F6ET0S,[,Y=)7C$'$H@-<+89FI
M"054398*()IM7*[A)+*)G'_>O'TUN8KL'7FA9C!#_+\[J=EL':AM$.S=2S;@
MSBF.V[ XC*0&$H*/F[B+<?V3<1E)A+!.-9G&F(-!P4S72-+33V_IN,[F$Q=@
M??R (2@TYCVR83)XL_:,3T6FD9P(-QAIA8H-- WW_)Y<L,>#3P0N)>L"3I)P
MQS4\"LCI/5?!S2NG9'"#D,5G2([7MAA.-P\G+W!6(H3D9J]?35MF.1[IG=^Y
MG+W6SQ_'"+NY7 "[\?=&;QY,_DD42"8?@T[_ /,P^KC]E+IIVMV^#P^KC]G]
M?F^.LZ7MVVO;X[=E!5!/>5/&>9[\UR2D.D#LNW3I79>XH9Q?+J$XPD>OL?&=
MQ#B7N"[<2C*L'D"%$'&SV":1S8(>S4YKAN;E8-I9\U%#2EA>F=H MTZZ![$!
MBB09J5<R$4]"FT6F!0+((?*#4*E05YFQ7=L'*@B41TP.Q>L'3A@02;)OF2RC
M5REE?0,AX)Z;DT]EFSB9.?7G4A+LSX63(R 7@7@)QC/H7LEN2B9'..JOG>2$
MGUY#DF+&=.9J)$10-CK\(/&P)\2C;R1^JM8Q;3D" Z[AR;_$&!L26Q<%GZI0
MN4*G3)&22,\8(+6PN\,2*2&"QXLNFBW;J$"+F[5JU:V1;)!L"Z:=K7OX/#S?
M%ACV_P!55]<F=G:@V[#^3/%/:>EMD3:)R"/:MTI)(VIGY!L]PL^5Q^6:M9BH
M?(TCX>1"HV.= C6,GGV?O&BS8M'[^'+2!=@E9S816@]C\<X)LPI)3Q9]*P\B
MD;?3>.!Z-FTQY  2T-/9'LC6YT!@Z8$&")09)Y054)8$F)03(1:E@9L6]$YN
M6KD(V0KG[J=PE$&F$'G<4@";@5KV02XW8*X9:_V2G&)Z8OK8T.&&2YLJ\!LM
M8&A9B2!4B0'WU(QC >^+,BSPD+5SJ-\"-#Q@M%7K1.9$ L91&O'4+/2?(Y$9
M;-!@2> ,-E2]@0'JD"L[>,-E3#,L2;%APHP_(,R1(&X? 0"XQ035I2E I2E
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M2@4I2@4I2@4I2@4I2@?[_P!/II2E I2E I2E IV6MZ+>GSW_ '[_ !TI0/\
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M_9?LOZ*_:E!7:'Z>$5: -7#SNW]F2HYH"(P>'<>SY1E V:>IVFOY'"Y,**M
M :*L!4I/'7.OXJ)F!&4V(>^T>'JC!2$>6?O'ZWM7Z<&DU[GCSXK)'VT">,&-
M -PN!\*SV%KS9,'V1M#;*6R]>DLXMFUC)D]--LR;.0@&S3*'DHWX&)K@LPCH
MN@2L&[^'9>_>Q[+>:]^];LM?XKW[?-3O8^;]5C^J_P 'SV\_\'G\_P#-04M]
M9&/@XWQZXJ#@ <2#9*=4SILOE684:S%,U'SSEO %'CS)JR211NX=*6MFNOEC
MFLK>UKJJ*96[U728^B__ $L__'E5.?6M_6'XI?\ :A=-#_\ %I :N,Q]%_\
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M#%SI U$EVQ&(QU\0C4.L>BTI)20@HV&E'[.8W5D)L0^MSI0:8_%]U-^Y?/\
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M,1B-HBQBN^G'%IEKQF=&$E3!P7H&;0@,GMITX>)-IXY: 'P)2[OL_P!^V_\
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M%LY7'Q,A:CC3&V=F99BW+-':34BVQ44P0>(88+IX**86S[BF>.7+Z4"E*4'
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M#YY,0)-MDV9D8.+LTGPPFDT)LFS]LF2"D6I@,130=I*I8/A)9BR*#'>.%G#
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g511473.jpg
<DESCRIPTION>G511473.JPG
<TEXT>
begin 644 g511473.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@ _1$E32S$Q-CI;,3E:0DTQ+C$Y6D)-
M,3<V,#$N3U544%5473$R-#<V7S%?34E34T5.0T5?2U]&3$]7+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( )<"K ,!(@ "$0$#$0'_Q  ?  $  @(#  ,!            " D'"@$%
M!@($"P/_Q !R$  !! ("  ($!@H*"@D."@L% @,$!@$'  @)$1(3(3$4%1A!
M4=4*%A<987&!D92A(B165UB2E;'!\",R-#="4G2WT=(X2&)V=Z*SMN$E)B@U
M-CE'9(2%EL+3\2<S15-R@I.RM>)&569U>(.7I;C&UO_$ !8! 0$!
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M@.... XXXX#CCC@.... YT=F^/OM</?:M\7YLOQ,5^U[!;UOQ5\>? )'Q/\
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M '1Q:>IZ-A*)**MTQ(%7V]8J&#GF73JC-ER/S3$XSD)@M]MN*YA(C#*<+O\
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M2FC:Y&LDAZQI'M-!!SV(K\1<Y&23S&(SZG9V]U>M=G[.ZYHU-JME"U<C4]I
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M"$F$:!3VLM8:ILU$6<"R>MW<NJ7.9=NZ7:G=#.G^QNHT,RJ^W9*W$+$H>TM
M/TLSER90F/#G&A#A^LVPNAF8EVL7^.;GRI?8QQR=.OQ$ML;IU?1NO\+1IRP
M;5M?M5JO49=^GB=5E+G-J=H"7LD8'5'&ZVI&M1QV4_7ARF25F9<9CQ&IC,="
MIK[&,ACH)X4>D(6P;,6-V._G]7EZ#K:O,:N>NMFBC#MZIYW>MH/;8V7(8()8
MO-X-6O=Q.WAR&(0=BNVB"T1;ARV8=>B <GI\,[JDB1-PW6[NR%L<<O!V)4(N
MU=@P*;ML63)V<U%"[8KH\[$A7P+7RMTMLNOBC.'(4)-@(0I#,T;\'A,0UV;X
ME.[.NHF\U&QZR 7"P:KG:?UBBP[6VB! ;*V)MF\]=BG9NV1#5/TOJZ7J\,Q3
MZ("+"YI&LV6-7B!..X:A?!0D)U$SS$SQ>MS%!L6^TOKKJF5K C0=@;+'33V]
M[!'MBZ]IG2^@]\[*AOC ^JB81)2?5=Y)KE)4T:7"<L-2E$[(X+"&HJ81,([U
MUSF?O3OFL<IOA_\ 62DZX-ZU'TTI.A',%4N6\O:C\O:(9LH'&5_#50V@S,AW
M6D-CP@01 @_:@6"*Q\"S-FJG$YQ2=/\ $CO"ZZ5CA8\5C5DN:U$4K,U^??+V
M[(L6)L7;D&P,6?#-@CQCL*WQ-Z;.CVX7+C_%9]NP,8F0\J! ,C*\+)XTFRHX
M;;9 3HK70--+M288>1>=OAQDP*#A[,W-KHB%O%43,AF6]FD4:@58J[4&Y===
M*#SIF(&182U*BCKO\V/$A[)N2"[F1E4*TK:6ZI$70]AAHL06X5>L"-O=.0SU
M;OH8M0!K4VJ3ZWV6D,1</"0>P50JW-;-2A!<SE54%8PGMAQF*>:7"[;2FCZ#
MH2J2ZAKYNR+@$CTVREB-ONUNV#93!N=$'C79Q2SW4R<-RU,C! L9$87,3%AP
M1\9B.PWE+BW,P<IZ\)S?78S;5>M8;LIM2L;$M3>I.LNX \>%6,5>S0F=ZT:P
M6JTSY\7+[:7:NNVP2 "KL01D<>"^()H"-(<Q!4RBX7A3CCC@.... XXXX#CC
MC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCD->UGB$=+^D#M2B]J^
MQ&OM,$+W\,74Q%EE$IAPS#'N-LSRS(*O#3)F. A2'FXTRQ38,8'%E+Q&=GID
M>;7 F5QSSE0M]6O]7KUWI%A#6RGVP,-L58L]=(Q"X&P 3$1J<*,ARD%U^&0&
MD(;S4F',C/.,OLK2M"\XYZ/@.... XYQG.,8SG/NQSG&<9QC./=G'GC\6> X
MXXX#GC]A7VI:KH=TV;?3,:N4?7E4L-WN)^8EU<4)5ZH(EG3Y:0AAMU]QD>+@
MRI2VV&G7W<-^K9;6ZM",^PYX/:>MJAN76FP=1[ %I.43:%*M&OKF'R\[%^-*
MM<0LVOGH*)<=2),-V2,(26V9D9;<F(\IN1'6EUI&<!1#T'^R-^IG?/M/%ZNU
MS6>W=4&;FD\K3=NV/]J.0NR7P$&8:<#2!]?,D2=(L9.O0)QH.).8DMS$0Y I
MV?&-X9'O[#6,XSC&<>W&<>>,_3C/-7_IO]C0ZQZ/=C&.T>ONRMOV;==92R1K
MKW3ME:_K<&JU@E+B31&6]G%@$Z26O;[E7(D04,_6QU&E B4UNW,"2LT>V&D[
M&FKMA.[ "E'25;)4ZS54[*J5QK))Z-/2'L@\>*)R61AN%A,&P@Y, R-(!CD5
MJ)F>/F,YFC1)-J<*AKU]_P 2-_-/6'Q[G)G'*UMN>+WX=>BNR8WJ9M+LW3*M
MNV82# R-??A6*:#J1^R)@KKH&]W<<(ETVDF3*"4%R/ LAN [%9F1'ROQ:Q+C
M..V4>_'X_/']&>%K'%3KWN\<WH3X>NY NA-YV+8IS94P0)L5F":LU_)O:-;U
M\]Z3@0M?9""0M$!96$T^5@@@N#MG=$-H)Y"HBS!JITQ=ZWND;9ZHBMG:].C+
M;0[T_H>]4>T#/3<'F0!S:.N#==/#LOM,R&</PY4:9&4ZS&FPW%>@XW&E-.-H
MH>\6G['(L/B!=OGNU>I>QU>U3+V()I@3;]8OE(+VQF,]2 L&JCK7KZ57RPG*
MILRM0!T8A6+!AB LH,01C'H[9&5#8LGA:WQTSZG:XZ/3%*.5:B =65K2>R8D
M13"KJ"U]LC7,ZPC;\*0](16-APVI4LVM^"X[4[6-R_+#K"$XLBL,DQKM_-^>
MG[GSPY/+&F+'C&/+RN5=\O+'EC&/N#:/]F/+W?@QCZ/P<[&7_P!\%"_\"1[_
M )8'SK_#D_O,63\%SKO^8;1^>1!\1KM.3Z36W>O:<'4&[V>TUU.L]C 5>4[)
M8%$#T\U4*X$?L,B%G$V/5A10U%+V9Z&MJ7@'!FMQ9$5]QN4R5>#G&,^S.//'
MT9Y09W$:;9[)[O6RVAEQX"#D/.,IPTMZ1G6VOF<R'5MX2IR1EF/'9R^O*G<L
ML,-97EMEI**V_ <\=;N#WA[@63J_VC&Z_N0VUZZN>R*5<=?4?%%FT"91Y8A9
M "<A1"A.$7IY>";1#%%)_H'1AR,/B2R)9!=7P:R?N1_LD=U_[VP7^;JB<)$U
M_5X%"8CPZ+3F8S+,=B/4JXPPQ';;98988"PFVF66FTH::9:;2E#:$)0VTVG&
M$X2A/LHJZJ_9"_4;M3XFNY_#SJDF) @UA& &B-UR#L5=7W_LBGHG_=8IU;C^
M@EJ,@<MG+FMBK<R4QL6)7[3)@^H\ZZT7M4D7*[6R,&TWJ=<8,:@42C3]@[*,
MP(9,;KT+9PSWQ7&KM;(*]7=+X;BB2"A<2='73:TQZ!RV+,I3#II^E3IK]C6]
M7NHGB:[)[U!IC-BUY!8%6;K'I8LT\0;T[M6PLD$['MQ&;)8;B%V@TA69&HH[
M;:DU==E*ON1V9]:K,W!5I'?/Q3NF?APL4-KL[L,D&L.RW)ZZ?2*;4S=^NI,.
M)?BQC-G?K]?8>=&5@7)F1HKQDH]#8F37,CA""1!MV,W[*W[OT_V>Z;P-X:4M
MP39.J-B,Z^LE-M0QIQ< C'C[.JR4J5#(QH\\49!F(+T2>,)PH1FO'1[\27&A
M$H2T-T_>.1X$VQ_$VVKJ;?6BMO437VPZ;0ON47"N;59LZZ@<J$*PEK-7C8,G
M5AQHB*L(DC83<0F/?%+&G1TF&ZB6.G#,?#I$=8NK!KPUNC54Z.V<HC8<?!)V
MU@-S@XDL<'LMVL>RP^R=A54U59\R?/I[@9]\KBESV9I(1:JZ/;=)+KUK]<((
MDQKM_*>V:>G\"#*[1G94F'&D21NJ2#HZ0^RVZ] <GT[JM%G.0W%I4J,Y,C-H
MC2G&<H7(C)Q'=4MG'H<MID3(L53.),AAC,AY$9CUSK367I#F,Y;CL^L4GUKZ
M\)5E#+?I.JQC.4HSC'*H.G.?1[,VO/T:E>^;.?;]JO5KRQY8]N?//ECRQ[<^
M['-3K[(LUAWK[(][A%\U+0^Q&].K\"MU2G=>#.DZEL"Y4,)>P;>&=JQ0RJ%&
MELQ+FJ]N90]?GTQF";,6 ' 6A[%1*Q1);N\\'Z%N,^?MQQR&7AW@.QE6Z0=8
M:YVV(RRG8T-J&JC]K3"4]@L:^V&/&6EB+9"T9QY@O;!P;XJ'VPLW(E))V2*4
MF_"Y67\R')F\!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'
M''' <XSC&<9QGVXSC.,X^G&?9GG/.GL)=( ":.K'ERR PDD66+ 0'2ITD@="
M?FJ'A1C&</D2\U+&8HR SG#LR<ZQ';_9N8X$;:1ISK"$[2;>V=38M>5V2*TN
MEIV9#CV>:1)5VM61<Z.(L#-(>)/AZ3.V?]HT6+:K2%#BRVSF=:52/:2!IJB@
M4P)*DPX<OF HN,'$LB"44R,40@19V1I:&EY$0I S*9>^!$8J)+Z6)\;U4J.E
MYU+3R,.+PK1UZ07GQ>0'C.6?NQNSHYVVKVFNTMCD:KVL!DZZ(."->:7ER&AN
MG'I&,?"59CZ4<B@2A.3%CXEO0Y5X?0K&2TA*MHSQ&=#[0["TWKA5-4&[A3;%
M6^V>M-@2=CTEZ/DGJ^/5*=LUT3L&<+FD1L&TUNOW*95LV*GD,R1]M#R98&?%
MS$GO2(P3=/:[U]:V9D6STJH6*.2)B3$^,>K0$PS/+U]#* 128R2'RFY9((AA
MA(F=(0Y+&)9:3"=CI;1A/W&*93(T=$6/6*TQ%0W-CHC,@P[4=+1*+&@D64LM
M0T-8;GPH<2+-:PG")<:+&CR$N,L,H1KXZVJ/BLUY"$2*9>]:7*T[AV]>@E:U
MU8=8V;0T.ZV_N7L6R;C+;O+W!QR[SM66WK[- 6#KO'K*HYD:X4<$$(L*^Q$N
M<^X7HOBZ5:F:^AC;1V'V,2PCKY<[%'EVO0PTT5V!8-$99W/1SMK&*K"J=1@&
MY!L5Z#+'UZ^U('/*D,E:=<*=(C?$X; SE1J3J3:':[7W$V2;%GV+#@84M)TA
M"1%:AS3:51,I*S(C<"&W%DD,29$=,.,AEQ"8[6$=_AF/CVX0UYY5E><^@WYY
M6O*%*7G/H^>5*4EM2E>?I*SA&<YSG"<XH"H^I/%GN.SBH';&Q-F5G617?%=^
MZ 3H]KHE74[KY5^WN0GDM0VEBY62SC:>UK2=ID(7@"ZEK0LN;'@?%X!=M&W6
MPS_%-:J\:"0*M<55BON;$4TGI]DL<L.S];,0T6*N9T#C9]4U8.IMZ$!9%SOX
MP#N:,BP%P.F"M5LIDB09WG8PUKJ/W.AT^/ML:I;:2KTTH1A7H8;]-*4X5Z"5
M*SA'I8QC/HI4I6<)\_1PK*LXQC.<^?\ 3D6.EU?WM6.N5%#=D"QDOMB/,NSQ
M5VR3 9*R0:].O=EG4('82=</6P21,U^B2*Z&G3&K;<)CCD+""]RMYAN?92DI
M^ XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.4^>-]XA&S?#<Z32]VZ<I
MP.T[*MVRZ=J*JD;;!GDZ;2)MOBG2$BXV,6.E#WC'P*" DCP 5PH-B$K*1%MS
MI+D-I^%,N#YBW<^D]4=B-:VG3V[J#6MG:QNL% ZT4NW#FR@0O&9DLS8JGF%Y
M0XQ+@S8\><.(0WHQ ;/CQYL"5&E,-NI#7S^QZ?%V['>)% W]KSLO6*I-N6D8
MU%L S:= J\BI!;"&ODVQP4URU $SR @9:1<H"Y+%20[L2.; N/+?%QI8MV7.
MV6)#OJ&'7O0<<]4VMSU;*,N/.>@G*O5LMX\LN/+QCT6D8]JW,I3\_((:V\/C
MKWU9I7Q9TGU_4.L5@$S)QN/.J F7-$W1]_+<B57]MQ21"68V%6)ZH[;#/QD9
M38ZEA2IE#.5R4N5B;VPJZV/LPC4U9?ER]?TJ[:&IN\=C#:R6G8LEB9N[GP&)
MK49<(V!)"NU>.^W/>LAT0Q"M5A@X@BALZKLN%'9@AJ(]7OLFON]MWQ#]8:]M
M6M=4N]>-R;[ :8B:BK--,N[$IH.UW9JFB#0B]*/Y(6:_!L+8(V(:2$(KQ-UH
MP/'B@268<N/OF8SYX]OO]N,^SR]N,^6<XQYY\L9SCSQ[<^SD#Z+X87A_ZSWW
M\IZ@=3=,U+>J9$B=%OP.K)@R19.7"2/E&08-N3FK #LF)A;4@Z$!#S#N7Y;J
MYV7YDIUZ>&,8QC&,>[&,8Q^+'"177;OK/7AUU<\<<<*<_/N^RQ--U89W*TMN
M6/O>BJM]\TS5Z.7T@7G'TW:F5^HVFX/C-GQV@X,S!8UZ>DG"(^>B2Y$/9/AG
MWZ^'LC3LY(W]!'FJ'X\G@?6_O%OC5W:74NZ*I1;*:BZEZZ72I[$#'R 1_)*_
M30]+N5?*5QQV7&=&OW>4Q8Z_+'X;(Q(L::.,0)B7HTMY2>N>G;WBN*\'/458
MT9X:/4;75.W+7=_5P=K%!N!M6G2I<JDV)=P/&K<0C4K)!#)&/4JZ2-S*V"AE
M(L I%AB<-$Q@J=B0.B^8[0>-9X<?3W?$3KCO3?\ %KNSVW1"+9 $5&WVP+K5
M!Z+%G!W=F62N!YX>FXF#YD8HMF?(<F0!#S1<I&@C7&Y*Y'^'_P!00G1+I]I/
MJD#L\^[1]55B7 *7 A%^+G[/9K";*VJVFHXK$F8@*-FV(X26'"HE2?BL7B'#
M=E2WVGI+NL/XI/V.7;NSGB$KW3K#L35J/3NX5[F3[P$N=5/F[+K^T5[6GQA<
M2E2=%SVAEH%G0=)5*!!R[E=6%/2L0I,\B(]%488Q$;4PC'MC'>6YD**C#HL<
M;"D(18.8@0R@HJ-E,S1Q(:0C-3(!"!,C+<CRX4V(\S)BR6'%LOL.MNM+4A:<
MY[#F.=/ZT!Z8U-K'4%9?(2:WJK7M,UO7Y)9[$DI(!T:N#:P*?(R$I0E^<]!&
M,.RW4(0A<A;F4(2CT4XR-PK7N^R./$!G]-^D!'5^N#DL5O3M:X6U749@67(C
M'ZCK[$%*]KWV"_ 5\,'3(8*9%JE?)-^I7&L-IBS8KZ) SV9[\"_OTGOGT0UX
M?MYJ--WQIYB/J+>0];ZOC=X_68Z8E7O4Z'(5\+1'V35&!MAQ-RE4.0>^V&#'
M?6\/D-M7 D 88LXVZ3$C"#C*%-M.3A\.8MI"E84I#:Y+#JD(4K&%*2C.$YSC
M&<XSG&,\Q/?](@[-F%8*=*;UILVNQY3=0V%6Q WX8.1*<:?E [")RW'@7"D&
M'V&/M@J196&9.$((AIH&RPQ1\<&;>.1XK_8W6PW7>I+-M[8NL-96'9]7 $QH
MFS7@!563)LC ANSX%58M1:"0+-MSI/JXL=KX7,0T[':D94^KS7(9*L*QA2<X
MSA6,9QG&?/&<9QYXSC./9G&<9QG&<>S./;CV<#GFN']D*>+-V#\-6F=?ZGUM
MJ]51?-^S]@OR=FWRNRK2!IP37#=45($@:^F</&%KA8)%J8>0LV])'B0(PG*0
M*GRWX[T'8\Y%SM?UKZH=J**"U7VXUSK?9E++6\8FI@=A9;BO*O68TYX8FG%&
M)PL[ L\D=%*-H17248C/%-D8SR9$#X2UD3M?]5[^!3XCFU/$HZ>F]H;MJ]=!
M[1UIM,WJ2T&Z; DB:E=UC:Y6[0.LPX++FD7*^3<'65B!8@;,Z7!CDX:IPY<>
M$19@0[.-/?\ =%V!\O9G[N$S./9G/M^Y;JK/NQ[<XSGWXQ[<\CP3ZQZCZ>:2
MDV3J92ZUHF+HJA'3<.H4T7B-2[[4:O%)VHG2;\*R\I\XX97\8/#+V],7>:R=
MF*+1#,X;*.U\Y(/32_6'-^.^6<>MW2\_A.?;E.7M4ZG=2G\.4^GA/T*SCV8\
ML^7 _-?\4SK-UB1XR6Z=:.]V*8)UWN/L$4LV[-@EJ7L,ZYUMM&R#S9385 M)
M$6(E@K.4KA(E-9$EQ11(>IPGQ8S8D@))"$W7?T7>R6XH_3OI-M[=U5 D=H1^
MO/7X_=*X"3/S+F7%J@4KUX5N>7AH<RJ*21 B2S1F*RYEL>N<1CM+RA"<_G)>
M*C1.@['C*[KKS6XMNP=$63L++G=IK $U\(,R=;[ L1UJ;O 'K8A)M4.5;*X,
M.S"V2AJ8"BRJ@0D'Q@,?=&J]"S)_3RK0*FOZ^!UH-&&F:"]4!0,9#?PT9$%*
M@L%&'P(KV)B7V2HZ>"RPT[\*2\W/BO*]>A:'EHR\LQ6LUGQERSVG]JT]?!*\
M?7NCW5[TB^LG9*MZGLM/VO5]AVBMFM;4@I326KR%(!*L[47UN#YUFQT2?$2Z
M%>G6!'Q["*20$G!B0B=(AJV)N^O_ &ST9G_]H;%^/^[:'S^^JO"GZ'=?BEFM
M77'KY3>OFQ+(ZB2C9^J698>^UV4T[)?:352Y:4;C P:W93B2E*C0/M%LD+#8
MFS5HN)::A-X;[#6NR6ZIZ%EV]X;,LP39&WJ29*!X;HT:;F4#8@.F9/1A3STI
M8G)QH(V4D"DRY; V5*?AQ)4B(RPZHU?+[9S\./\ O+V/S]_VYUWS_P#Z#:0Y
M!'Q6]B;-U0/[57_3^O1.TK_7^D>QLB:4?JS%Z!3QQ1^LA;44-TB6U(A7(35J
MD1-VJ=5Y\66.,L!EQ"4.8/5*C.SN\.3^\Q9/]^==_P PVC^0A\49/9%3G9?Y
M(CQ5CL2GIG>W-<N5Y;#5JP\W.JKEG33'9.4MM79=+39$U!Q"D2D6#,#(]:"/
MP-6"3E.>6F?3=K1?8FVR]HA>\^W-;UG7@2R:RV'IH[9-I;"^TT;@_K@C5S(M
M^D1X%YC0F)8>LW0J3G"WM<MR4@R)") /BQ41^NR'L[)W<C_9([K_ -[8+_-U
M1.:Y'V)MGM"[W/W0NDR;)GK"G6QQWL:@@]ERK/[4D3H6-3O.-S5*>5M%;R+4
MXN8PC,]=538$&75-J@IYL;]R/]DCNO\ WM@O\W5$X(UN,HRV[8U6>Z'_ +ZF
MV/\ @\ZX?\S+3S^G<7NWUKZ&ZH5N3L[L>%KZGR"S-=!MI'D[!9+999,65.CU
MVI54%%G'+ 67#A2ICK,.+F/!@QWIQ&5#B-J>Y_/0_P#?4VQ_P>=</^9EIY5'
MXL_A[6;QJ-24@3J.WA]3C](6TW:]5[/V */$*WN,I81+=:L0X:"#OQBH;7"8
M49J0(V=*@EIE@+0T+JU9E4Z1FQFQ-=%JO33O/UD[]:N?VYU@V3#O]7&F%URR
M0WAI2N6JG6-N(Q/R"M]3/Q8)L 1=@R6)\+X5&S#)0'FY@V7,CY4XGRO=S_M-
MK#Z?MTF^7\B/9S^K&>0Q\$CPFB_A5Z6VC7;SM 3M':V[;D"M-UG5(82$T6OC
MJD&E!:O7*TT:7DP4=CI)%YY>Q3XXM9)^='AQP\&(,:5(F=W<_P"TVL,?3<YN
M/Q?]0W_Z>%C>_,JZZLQDGND56'Y9".&NUBU/3;7%'3Y(U9ZH& G7-\[69TN&
MMJ9\2GL#8L,W$COL9*#/A J2XH?-FQY%\PP:.$"QPL5!B#!@V##'CAPZ,S!@
M#X$1AN-#@PX41#$6+!AQT-L1HD=IJ/&8;2RPTVVE*<404;V]B*%_PCZ6_)_U
MN:#SY8_!RU_<M@N!"XZJTU4SSE+:V='O!2S7<:TW)M FKT&#6Y) /3DRFW!P
MJQ69ZR1H+5JGL$?M:'QY\L8*>-OC"(H-,GN-]DT]V](>(=MW75%UGJUGKYH;
M=5CT].U-::@7>V!?AU*L:ZR>.$KS',LDJQ;K&\U*(4X8(#NAA;$@!$*C["N1
M-D/;V8,G@T&$F,0YH[!0; )8@$F/@I&%B?#9EXASXV<J^#S8N'L,2V?//JI#
M;C?^#R",[PK?#R)[EJG84KU,U"4W-2UAY(2_DPLTD9<+ 5+<%64^U.)R!MPN
M,62YF=BYW" >MD@DADE*,R)[#$AN7E4W!J6\V(]3J3L_7EOME44XBTU>KW:L
M6&Q5IQI_X*ZBP!!!283#+1)\V',$HL;*9']A7Y.Y]#A(KK-\>N&&C(_'''"G
M''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<#X^@G_ !<?
MF]GY,>['Y.<YQC/OQC/S^W'G[?IYSQP./13YXSY8\\>><9\L>>,J]^<?1Y_/
M]/S\>6/HQ[/+R]F/9Y>[\WS?1SGC@/+'O\L>?T_J_F]G'ECZ,>[R_)]'XN..
M XXXX'@]H;*I^G=>W':%^*H"TZC5\C8SY#+;DA]$$<PIW,8? 82N66,$7O4C
M0@4>T^3-F9D 0,C29\Z,PY%#K9V>VE<KW/U-V:U>.T;M2V5I[<^EZO#)S"\.
MTZ3G38T5^NF#,K&(GW>=+R2 4-ORIB?2#"I=FK1RH2C-:).3HTCM[Z<J^_=3
MW+4]O<FQ!-I@Q513(IQ#)RJ68"4@V6E7BN/N)<9CV>B7(."N-9D2&GXS!T'
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M><_VF/RXSC'YLI\_P^?G\^/9Q\KH'C_ Q_%5G^;' FOQ]']?/VYY"GY7(/\
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M$R']+'T_US\WX_;CV>_VX^G'.J9/@Y)F?78Y@6_8!4 <4* V"$1TP-&F'9[
MD@0%MO*G0H11X639'2Y,=J/.='SFHKCKD20EL.VQ[,8Q]''&,^?MQQP''',8
MQMV:<FVLS1(>U]:R[O7&2,BP4Z-?*F_:@4<0UZ\J^9KK1=9@6R-8QZX@[/A1
MT0FO[)*4RC&58#)W',+BNQW7P[7+1< N]-.%ZG1V84BZ6<7M"BD:[4&"2G4#
MW[0;AGWQ=?9G+9>1#<+RH:):FG$Q\NJ;7A.3P%B 6L(,LE7-";'734)DD'/
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IXC])8#]KTB)[RUO@JW/VI$A2Q8N#\'K$G/P@I7(,9B7+R[:MQQP/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g86732.jpg
<DESCRIPTION>G86732.JPG
<TEXT>
begin 644 g86732.jpg
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MGMU,TF[WL?'/#JD)J=ONUB$U*1,>@)N5K%U ,7DU>M?#8TJ*U-+(9DSWX1!
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M+I,V:5@?&M4V9JPB:;:+&M1;0"84:IA DVDL)G0[)1+)ANV4PZTF5'"G'''
M<<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'//VQ-C55
M[&FH+@M6M0$PFLN%,94-18,C96 BR"4I4K,%!3,14S&$YSF-AW'EGW9]!QG/
MECS]N?O8]_ TTNHE>[BL=W=8L-C=TQMW#=F YV]9=V;N^8Z*O((I5MF5LDD1
M4FLSJH6"J,XKJF);XLE.=KV=<I<6V.]3LR]S<=E9=1U8#ZS6*QTX[8MO1A.Q
M+=5JI2+>:KFLV]8;2,/38T+8(\O78.9=^%:^#.%G1)*1&R3]0S&]7+>=:RJ
M[%:CLM@' 1%@)/9.$9(BMV&35;C HEJ*Q<.Y=&U+8,\''HUFFKPP]F T#/3/
MC?#$G(11+X+)]3FJ5+BPF%R9DB/&CMIRM;\EYEAE"<8SG*E.O+0VG'H^?FK*
ML8QCS\\XQP->J/2^XUZDZCG=\-2;L[,:= Q1Y^X4&K5:F"",39&W>K&IS<U1
M/6VO3]0AW>BZ9W4SNO7=6CS5G+%0C%O!F"AJR,A(5V"^%<Z9]GIEU7N>-IVR
MU.M5G=?0"Q-4,@85L7N+7M5:UU;J6!=QFJNT1;;OQ(1D4^SB71>Z:B<JAE>S
M*O$VH- W$J>/ YLV^#;_ &4TGHL<'G[(N*("K"8+ 0 .MUZT;#MYPK7ASQ:Q
M1@U&UT#M=Q*)K J.Z1L\F&#>B5J E,DV_ :=9RYB>/X@W46;8AU=@;542;*3
M]6"FK>-H.RR.JXQ;=HD :U,),;BATY_58$G?!]JK*J[!.6\=(E2SP<8MMDF0
MC1'"8=HY[TXZ=7TW/6_:PGV[U=L.J;KJP3K$"UML /?=22*'.FFCUK)'M9R@
M+Z32;W$A29DF 'MOQ1:5UU#U!B.3PK0FR8NCY$#7ALSJ+W"LFS]G6D+;C;>K
MR/B;:9W2*TUBOT!31_5X6C:1"6C9C.Q)=BQ:!@D:3#6-]VH(8BS)#M<E1XX>
M5$+H>DVZWC?6K=<N[&9N%C6*5J;4$S>^P,I#F9Z:[J^$Y:VW;&_D= E?"UN*
MH]K^"B(&)1F7@)+S&@._T+UF"Y_B&]0X#FJ&_KNP)RMVZEI&\];?%@*RD,6#
M5FQ=BZYU13;:O,82OXIBFKWM6F V81C$$FP[,(R)4-F,"-.01&-,\//-B'K5
MI3<(/6'AEZ[V13'A3'73KR.-[6R2*AR2@>[ZIIVKZ@J=:3(@%9V2T]N+==ID
MGB4+X:'9R&C/8(+D2H7I08V9TOW-8-?=GM.HZ< ]@;QOAKO?8 ?=P_?M=BE6
M>H[[I^W<:E"#)OQZ[LPI;VH=SI>CR.H[X! Z7J5=J>;*Q9) P-5H[MO%K[:Z
MVJF\?L?L5W;=FO,$71#EI(4K4=WME%H +8Q&RC:L8O\ ?1(QVKU$=*53[),E
M/E"#?Q>-$22$M#<?U:E_1UY[7ZN[-L$)^MH.PF1+08):J\>N.N+73*_?Z/97
MR4>OWC7ITX/8%VZM%'!4K*71\OXT@,K'R2XH=&+B79I58G7CH[V9Z_=JZO8E
MQ*_;:"2OVL+E:-H5,-I34 .-KBN]=>QFOY.J3^D-=UFL#5;"IVV+[73Z=N5N
M,3([%I%E$5XG/#0M:K%$[U,>['G[_+'GSGC@.... XXXX#CCC@.... XXXX#
MCCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@.... XXXX#CCC@
M....!^5IPI.<9\O+./G]WX\?/C/NSC/LSCSQG&<9SCE ]:^IPO#OJ/::=VKJ
MV-R@[!'N<_9E.UV(OX^-K;7.RI)618(%LJ [-9?-I36;&\BP5>J'C9JGC)\>
M/$D@B(%AH,FQ/Q+]_P"V>K70[M'V!T;5F[CM;5NJ35EIH9\3*/18Y%,H>/D6
M:<&AX]>5&TD9/GW,D-])#4V" D,25HBK?6G52^IW?%Z[W=G.[!_KQV-V]/[
MZYONNKQ>63EH&TX:6UO;*UF 0%?)PE5@H%AT!:XKQ 4FF/,3?4JCM%P2H\44
M8]<3":7E'N&Y#HNZ6NSCKW7KL^.*675FPR>M2-H%Q%"XMRP,KE4L<.TN <J>
M9KY A!M4=@L)A39HULI#ERACD<?+C#H. +L4M1;M!9=0U6PR:2O9FOJ<3L%X
M%MLR+(#K% 595%!E/;EL/0!MFLJ[E%B0[5.9GHJT:#,G0@\\L^.DB\O]?O\
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M]_E[?P\<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP'''' <<<<!QQQP''''
M<\[;ZZU;JI9JH_,FCF++7S5?>(#7?4$8+)H9*&.S(#WEG#4V*W*4_$<SCR1(
M;;5GW>?/1<_F\ZEEIQY6,Y2TVMQ6$XQE6<-H4O.,8SG&,YSA.<8]N/;Y>W'
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MZZU'L]WKI*/-L Z&QL]ZKV%,OX0LX<K$JFVNI6"94+G7'IS!>$,L8X>**/\
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MLD/Q-Z';9S&V%]B+I3[SV5ZYA%R=;;4H57LUH"%;':%7ZF:O8KMO'5BI4&6
MS'(2K<4G=>"0B$.'4HRFU6%U6S,^ASH+Q>B52GB"VPMA(VI-IDY$C9X3?-*%
M:_=H<_2 8#7M4BJ3$CQ7AO8NL;H2_;['O.+6A(0U%AFIT*WRA!\=KT87I^?6
MP[Z6/I_[OP_1^/G.,XS[O\_\_F^GE!EEZS>)X(W<-;U5L>ZMZZ$WO? :@'=B
M[^EVFH476%KD%I^NK':@[AOZX5YME8E'$LUX;L"#O >9# Q5:-1]<*"1+6=F
M?X:VINV>I];WL=VLM=G-F"=GK+]6#VRZB[\0$Y&Z_K@F_&H!V$8M<V, O6P8
MINT"0Q.XDWF$2'BK-=UZV:51@@62<<<<!QQQP'''' <<<<!QQQP'''' <<<<
M!QQQP'*;?'.\0#;GAR]().Z-&UH,9V3;MH4O4@ _:!CQJJZ^5;HQTA)N9D.R
M_%27D,, %AZZ+F2XHV78BP_)!<B.PH=.N2YC7;^G-6[^US:=1;HH=8V9K2ZP
M,#+32K@+CF )F(A]J6PF5#D8SZ+\.9'CSA\V.MB<.GQH\Z!)C2V&GD!KM?4[
MOBV]G?$9B=A===GQ-</VG2D>AV01MJG55JH0S(N^3;' ^2EM"#G' $:PC7:_
MD@&FAVA^"@5V7\,'^O'IFRMFF0[ZAAU[T''/5MK7AME.%O.>@G*O5LHSG&%O
M.>7H-(SG'I.*2GY^08U_T Z^]9J2T)Z8:_IW5\^#DD3(XG1@BW!=GD2ULRIH
M+:L"9->(;%JI5<1B.['+E<G:XG^GJ0;K)-'PESZA%PL79MK4M7)RWJ-2;KH"
ME;NV0&JQ(@T<M"KPO,%C7,.W,J&DP-.C/-SW["0%-1+/:(>8(EDC7H"C#184
M:>W5;ZI9[];<\1/5-"M53UG/T%N/L"#TZWH^M4)>;;4P%LNB:; F@+S\9)LA
MV_5U*VR9ADQZP"5EQ"\)H.'CXC.P]^O&<YQ[??[<?1[L^7G^#/OQ][D'Z3X:
MW0S7&^G.SM$ZHZ5J>]EN/R&MA@J;"'DQ\Z5#1 DE0XYE6*\#-R8:<QY)L,&@
M%WT/2?635*E25.SA]WNX2DZYZWQ....%.:G7U0?XR&M_#6W!UYH.M1%KL78:
M^3ZA;M]0:/>[)K^1]B>--FX;@"=/#/-0I>P;J238H&K#KC#Y2AMCK&13+B1"
MK$.;MB\HU\:#PHNL/B-0^K%EW6,(#++K#L;IZK2+15O5P+);-/;&OXJO7[41
M(LE2'8X$ZX1B%X!-*)!&LE(LN4#^#N&"7KPM*ZK['TIMWKGIG:775V,]I"_Z
M\KENUL['BO0U*JYR$F?%S.C25NS&S*7G9*#^9[T@@Z=02>GR9<QQZ4]CNX]]
MNKM#);%&6*[6S'UHRID)LHP#TOO&V5.F%*Z&@6&Q1#EUJFN#51C+KX0G!)G7
M,&ELAXLC#A!R/ZMW")05.I5RBU.NT>G!AU;J52KXFKU>NB(S<(0 KP(>P*"A
M1<-E*6XHX6-BQH4..WC"6H[#:<>><9SFIO9ND.U8%?9[KW0I'7LC3N\-K['V
M0+;K><V>,LU%@W_4U6JQ:*2KX2KE!!64&4S)FCW(9V&P23ZEIY(]Y3SN M_A
MS(I")%GPGD28<V.Q+BR&\YRV_&DM(?8>;SG&,Y0ZRXAQ&<XQYI5C/ESZ>=-7
M!2P8 (&6\F0L2(%C%OI1EM+RA\"/#4ZEO*EY0EU3&5X1E2LIPK"<JSG'GGN>
M!7+XH'9/:/6+K?$M^HLQ!MJMNQJMKOY8SQ<4S&H<"P0CLYVQ-#9WK!D@O*DA
MXE<KV34:2%:-&XKLV-,=;BCYL2/"/[G;[WQ<-K:AW+8W-DL4RH5V]AKV2'!A
MMH#*.6"<!74[(JOCA(XI%)IB/&:Q.>%PR;#8TW#DR"<5$)4.ZRXTVI["K!JE
MWJM@[?4K'"6..UJR"X9D(7@N*0XJ*0&SV7XDIK#C;;J,.-Y4T\TT^TIMYIMQ
M$=(/3;2U$K4,=H2J@M 6D#)(%*M=-=@H$8A#+$DL8G-6B+)PMN^U@RF)#B6&
ML6=^7&FP(L50N4$,C ID6$K\YQCWY^_^#'TY^C'W\^SG/-3/OAW;[6Q]V@8R
MMIVO1M7CZIU)=Z<,H!V13Z_8,VJGP35JO6),Y4A^W16+A,+UED:<?,A $8#%
M$$ACQ23.ED-C?IU?=F[0ZO:-O^XQ2P^RK5KP$6M<=T8L(]+FOMN(C&WPJT-9
M#2;(-;@V*0(PQ'0,>*KA-QV&V$,MA)7E.?BM]U-U=8\ZAH>E'1U7-[-A7@^2
MV$3K\.ROC8%(E52'BO5D682\!R9)NV?$\D0*0B>1P8>I,(?B3-P0@W&<P#O_
M %#UYW@%K.O.P=:I-K'FK)C%)#VJ>V++RK9#%$2+B*3/C$15B;L"0$(O)EM5
MF<B>\ BE,S&W134W"0B5X7O;;8O:[3%UF[60'FW?5VP54$E: <",&B6N/)J=
M>MP\A/ Q'7(82PQ8Q_ \S"'I9&/Y8B$X,2"B>N#&F!I[_;'V!_PX3,_/GVXU
M;JK./9CVY]OS8]_,(770&N^M.I2]_P"N%>#Z@*:7HM@L3 FN0/\ 0WL&M5F*
M1M92D[&'OO+E61@ZXW.7!N$B;F[U@W.6:%G7(\@T%.9LTRKUAW?;OEZ/KMU/
M/X3C/I>CZ[5.IW<)QG/EA64^GC'GY8PK.//RQC/EP/\ /@\23PT==6[Q4]V3
M0792%$Z^[5WP?MV^-A3:=8S1_15BN-@<);<J8Z#'5EG9#-2)2BC46P"78\&K
M-NX#V)J7)JI1R3OK=E]QIZ?](=Q;NH==D[.;Z^]>[%=:C7\3G9R[<S0J3F0
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MAJTNJ*,,YF)J^#\4O,<;D0&L[&_<C^V1W7_>V"_R=43A/^<KC3+WQE9[H?\
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M.,XSG&<9YHJ>*K]3S]HNQ7B46?8^J-HZP7K3N7=R=FD&M@&CL:R:L)C*,/\
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MO[CVK^;_ "DCIEWMOFU[C;-3]B]8Z@'7H/U]ZW]F0-DT28V)\CI]$[&1+.W
MJ5C [&?FV #?:D7JDSX0]$*SP5D 3HA0<B(['E-N6$9VG0_UMO8^GRE2/+/_
M #\\#IN]'8+4>P]%2J_2;9FRFU68/*2,$UZV2YBHS,$VAYY+" /IY;;4ZTE:
M\8RE*G$)SG"EHPK,NI>T&C I';CQ6^1H+9O:"2PI4@':V\3AR=9:R$YF1_,!
MYN1_C(42A^LQC"?A$)]O&<J;5Y8SQM.A_K:>^]_34C'EGZ?Z['&=IT/];3O[
M:DY_[><>S@>WN'9G2$_L'I&S1+S'? @:/O0>9*M@[4J&-FG5:F6&C2W?B'&&
MGB>!!/X$A6,9D? )6&O34RM.,\?9>]=?V3!O[CVK^;_(H_73H>?]S3OLQY>V
M7(_C7\WT??\ =]'&=IT/];3V/^%2/XUYX'L=C=E])%=V]=+ /O,>6&K!';#M
M@(LA+2J*);*:Z=@#7)SF06,,)GSE8AQ<KQCU\G/J6?6.8RG$-]M;=U^: :]9
M%&I<]\=O/L,?G-1:S;G7(@6R[CP=!$Y", /2:AE1*DSX+Z\81(C9]:UE24K]
M"2_UTJ)[/]#3W[:D>W_G?P<?73H?ZVGOP?"I'E_C\#S71;?^IM>:I.B+M:E5
MHG*M@26Q!+5ZUQ9+D:-IK4 1Y]+2@.5^J;+!R@]2\XPG$N!+9QG*V',)^R9V
M"U&YW4&7Q%LRJGM:A-AG;%BO6SXJ;+/Y$+9'JE_$/J\2G<-.^@UY^FKU:\>7
MIX]'G<_73H?ZV7?VU)_3X^NG0_UM.X_X5(_C7G@>VT%V8TC61FSFCMY8%N%M
M];IL U$L':6U30AJZS)P@I'Q@$K+D(C$<1(B2,?T-]K.%MJ4GVXKA[3[)J5M
MWMM>QUJ65-@S( /'%DQU5MTF'.?9HE,A.LQGFP.4N.-S(<N,M&/)27XSS2L8
M<;6G$Y\;3H>/]S3V?PRI'Z?.?KIT/];+O[:D_I\#N-3]CM,!+YL\D5NK4&"6
MH.BQXV4^#M"&9LX'3;-%,1(Z_B//K'ADJ5&CSD)QG,5Y]MI[T'58;SD'1/:7
M1%=TEJ$ ;O\ %&F0NM*0*+#I8.ULRH!$?6QT6;#DM* >DV_&D-.,O(5C&4.(
M4G./9YYQ/]=.B9Q_M:=_;<CS_)ZSYOP<X^NG0_UMO>?T_"I'G_C<#WVO>S6C
MQ>W-^G)][CQ1-D,:U?!SG@=J3'*-#=<CAQ!R&Y\0YP^F'/:<AR,H\\,R$9:=
M]!S'H\QQVS[#Z>N@G7S-7N"3;HVV2I<] ^OVZ2J)%6(=83(?2U7U+0TIY:6\
M+RGRRO\ 4XSG/GY?3]=.A^_Y-.Y_#+D>?^/C^#G'UTJ'^MM[]M2,?]K@09J&
MQZC!WE2CTN:38#0[YJB=+).56WHAQH0@'IF,2EOOK (;:CP'@99J4ZM24-*'
MRO3SCU2O*Q:Z=E])$=]Z(LL*\,2 5=J6[X9PHV#M.88N4;'ZY2'8F.Y!8]4Z
M36.GHAI5CS?5$D):]-32TX\A]=.AX_W-.Y_X5(_B7Y<?74H?ZV7?VU)_3X'N
M=)=E](U\OOAXO>8\!JQ;YL]@".2 =J0DH%DTW7L*.3A_U!SEZ$]+'SHS<A&,
MM./1)"6UK]4O.,DZ)V=0K?N/?CP"SCY>;,?H,RNQY.)(J:>AB-7@8966%@&(
MX^:6BBY<=Z,1DCF)+,%YO+<M;"_U/,"Q]K4-#B5YK;V,85CS5F4^KR\LX^92
MO+/E]&?P9SGF1[7*KMKUH1,0'5PUCH3Y>M%HWDP8JUI&-JDAC B4K"W8!$>0
M:9=4IE7JIT/,D?-;DCYLN*\$]..>$U?9Y5TUKKVXD&V&)ULH]2LTQF-C*8[,
MH]7QQ62TPE:E*2RV_+<2TE2E9PWA.,YSG'GSW7GCZ<?EQP.>.<>>/IQ^7''G
MCZ<?EQP.>.<>>/IQ^7''GCZ<?EQP/XR9,>''?ERWV8T:,TX_(D2'6V6&&&4*
M=>>>>=4AMIEEI"W'77%)0VVA2UJ2E.<XAAN?M7UZ):SVA7!.U*T<*D=?78:/
M:KV25CCSYTZKEHT.-!( AY$;-<DR7&V&<0YC_K7EI;;]):L)S$7QC-R6.BZR
MTUK(+(<AA]R[((CKD['>6TX5K=- 8.YJ\GT%)RX)-F)@MXS'\\(GP!2Q,M+H
M\C-8=Q[HVW" %)$KE5YHJ^_'0K"GY+S332,)3Z*&F65H;1A./9A*4X3C'EC&
M,8]G L!UIVUZ]A]=4$42V2/B$1U)J,&=$?#6I#T:9%KHUB3'>1@!GT'F'VW&
M76\Y])MQ"T+PE:5)Q[;[,?K;^RB*_<BU?S?Y#/Z[ +]8H[]M2_\ Z_(&=L>V
MW8W6^X.JE&T50>KKM9['[9;TE(E;CB[GG6&N6]-)V!LF18F54"R"A<FK9K-&
M4(9'K8<-XL,],M;V13:FL!:+L?M!HHMN/KR>'7Z++$5HQM%X]/8"6I<84R4U
MJ1&CG9KGQ#C#")I%QN%&RO\ U:2XAEK"UYRG&>OLQ^MO[*(K]R+5_-_FLSJ3
MQ(.X^\!V_K%4M)=<*N!UB1[$1ZA/O.G.V[-1,1M"[.L%1<8E[A@VQG7EF.G@
M-8(R,!*GEB8/.O?TRA$ 058Y8+U"[,;"VUUUU;MC=E T[%MNU*A6=E#ANI,7
MZ)6@]1O-8"66N!I^+R8*EY-H&-$I44]-BRL!I3J(ZQC+2,.^D%LB.X?7!><8
M1L\6K.?9C&!%J\\_@_J!_G^+F::=?Z7L$>Z3I5G"V:%'=1'EN""#$M<"4MI+
MZ8A&,A6)8V9EE2'O@A!B-)]4M+OJO5J2K-:D#;U=9D-K=HT)*?33Z2FI3^5I
MQYX]J/6.+3Z6/;Y>ECRS[//F3"!\35-J:'NU8B-1"5\M0[79U4?.8GQ]4;2.
M,.L1#C;'HH)O5TY!@EP#TS#CPM])-B$ZU%+D([X6'<Q/L#>FH=6RV!U^V%6*
MV5DQT2XX6:12\=>A.+6TB<V#@HEF,P5NMN-)F_ <1%.H6VE[*TJ3C)<Z8F'
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M$VT=FRM?$M2!!=;?M1S;&UAFN!@QB6U!<8C8JENN]A)L/R<MPW248%3I<,%
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MR+:85EK3M+@@99>D0 T4E&L%P$3V(4=V1A;=/5X\$U_6C>KM=F:YJ@B++:O
M$Z@"G!M<E C2&!)"D#9 ]R'698YIMMN,Z):C9QAIO+GK%-H4GSD2[]-1R8.!
M>B]0BU"[^]M<4X/U]5HCHG:#Z<I7L,8IL7A,*Y)SZ*FS36$R&U-MY3CR;0G!
M,;Z3USA.;2>R%;>U/1-D.A\UV=:@TAXQ7?A69^*_80YHM6;*$1/4TQF<R-L
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M5W:UKOJS72MQ.H^J3%NO6H-0;7M2-C7 P/9ON]=9UR#=Z-K]DR-UD::.']+
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M>SV^WYO;P(4?:X>B?W*>D_S*@?R\?:X>BGN^Q4TGY?1\BH'\O)K^ECZ?^_\
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MB/%3I&,("#&I,]^.PX0,%ID08+A(<S*(D)4>%#:>DOM-*"(_VNSH[]RYIO\
M-")^GSC[77T=^Y<TU^9\3]/DT,*QGW9_%[?/V>?S>_WXSC\/L]_'I8\O/S]G
MO\\>WV?3[/F^_P"[@0O^UU]'/N6]-?F?$_3X^UU]'/N6]-?F?$_3Y+,'::U9
MTE55NP!+ D$<)UDVH(5@%DA[&$>3',@"JA\B0D<;$OK0R3$S,L$![JTMS(S*
MU83GON!"[[77T=^Y<TU[/=_H0B?I\Y^UV='ON7=-_FA$_3Y-#G\WGFH[3K[[
MK;+#+:W7GG5I;:::;3E;CCCB\I0VVVA*EK6M6$H3C*E9QC&<\"&7VNOH[]RY
MIK\T(GZ?'VNOH[GW]7--9_XH1/T^9A@=FNN12I6&_#=^:5(46I3((ZU72#M:
M@S*G6B!-U#(Z!8+'&L+H8+-GO.-M0HI.;%?ENN(;CH=6I.,\R>S/7.&*IQV9
MOO2T0+L1<AN@%Y.UJ"P+O*XDU V4BGD7;"B'9U1B+C<"0D(_.4S-6B*[A#ZT
MMY$TW8=^UU]'/N6]-?F?$_3X^UU]'/N6]-?F?$_3Y+LX>"5D,4L5C,"P%?"0
M))0R<-D(8D.)&0VE/S")(H0>C08$&(PA;TF7+D,QV&DJ<=<0A.<X\'6]XZ8N
M(@ ?J6VM96<%:K*Y3*P:KM_J)P38[>U#D$':J!)"S$N$8LC<")+FN 1S\DLB
M)%D250\,,N.)# /VNSH[]RYIO\T(GZ?'VNSH[GW]7--Y_P"*$3]/DEXNS];S
MD5ER%?Z5,;NIDM7:<N+;*_(1:SX%)-1P)6E,D5I/%PR0IA188)S,G#DBB2ID
M=G$"5EKOG++76;#$J3IX,W:IXB:?@UIPK 0?F@ALN$/(F8@54C!.0)@3B0^%
M-),Q5PHDN?#C2'VWI3#;@1)^UU]'/N6]-?F?$_3X^UU]'/N6]-?F?$_3Y+@)
M8P%EB/3ZZ;$'H,8D5#2)H4E"*Q&"X(C)$&Q;TH>_(8:(ART.6,*P7'$RAQ"+
M(A3&F9+#K2.D*['U^"/1*L;O%0#V:>L(W!KI2S!!YV8Y9II ;7$10\R<R2D+
ML! 24@@TLQ5Y+3!L^*/Q)D0Y+;01B^UU]'?N7--?F?$_3YS]KLZ.Y]_5S3>?
M^*$3]/DSL*3G&,X^?VX]F?/\GOYUQDT(KHDD>/E!X0(&@2RI<P7FQ1@L4,@,
M+DSB)(C.=8AP($*,VY(ES);[,:,RA;K[K;:5*P$0OM=G1W[ES3?YH1/T^/M=
M?1W'NZN::Q_Q0B?I\F3'E1I;#,J*^S)C2&FWX\B.XAYA]AYM+K3S#S>5-O,N
MM+0XVZVI3:VUI6E64JQG/]O2Q]/\/Y/P_3CYOGX$,,^'7T=S[^KFFL_AJ$3]
M/G'VNOHY]RWIK\SXGZ?):0;16BAH[6QM@"$+#5TB564#!+0)9JO)/1GIH11P
M5'D.3Q"3$.._+%*(QXV",9EU^'E]IM:T][P(7?:Z^CGW+>FOS/B?I\?:Z^CN
M??U<TUG_ (H1/T^31XSGR]_ A=]KKZ.?<N::_,^)^GSG[79T=]WV+FF_+Z/D
MA$_3YD=7;SJDB28AJ[,]?$RZ\R3D'XJMU:S3)!L!9[(LP^88S:,.C&11.1''
M$G)J&$09S[,24IJ0ZAM7R+[F=0FXL&<YVGZX(A$VY;HZ6O>>K4Q9[4";D;.=
MA2%6O#,MN&1QF!*7'6XF/-QF*]E#^/5\)--Z=^G[@\%]KKZ.?<MZ:_,^)^GQ
M]KKZ._<N::_,^)^GR0VP-T:@U/$#S]I;4UQK6%8GY$8!+O\ >:M3(IN1%C)F
MRF!$BREAC)-Z/#6B6^U!6^XS&6A]Q*6E)7GT8:[TVQ589>*_:ZV<IAJ#$)A[
M:'.B2=8+#9ZD(A$!E@@S'Q$^#,6ZVF++B37H\A;B$,N+4M.,E16^UU]'/N6]
M-?F?$_3X^UU]'?N7--?FA$_3Y-#SQ_GC/S>_\6/GS[L<>ECZ?+\.,X_'[?F^
M_P"[@0O^UU]'?=]BYIKR^CY(1/T^/M=?1S[EO37YGQ/T^3.6XAM"EK4E*$)R
MI:E9PE*4IQE2E*5GRQA.$XSG*LYPG&,9SG/ECG5@; "M0479*R9%6*O'(,8F
M%.@B,,N&+C9C:7HA 65'/28!"#*:4EV-+AR'H[[:DK:<6E6,Y"(OVNOH[]RY
MIK\SXGZ?'VNOH[]RYIK\SXGZ?)6GKE4JMAA5FL]>KJ9,L3 C*.FQ8A,B<>*Q
MP0.$SDC*C>MEF3<N*'%1F_2>(E9+ Z&A^:\VPKT?GC/\GEGS_)[_ )O+\/L]
M_ AA]KLZ._<N:;_-")^GSC[77T=^Y<TU^9\3]/DQ"!(>(@32I6=$&C!T220(
M$9\EF'!@083*Y,R;-F25M1XD2)':<D29,AQMB.PVXZ\XAM"E8_ LL+.#!QH,
M1@E@Y>#$*"BHR7'GC28V?';EP2 ^?$<>B3H4V(ZU*B2XKSL>3&=;?8<<:<0O
M(0_^UV='ON7=-_BJ,7'\#G,N:MZR]?=)S))+4^G-=T I+95%D%JU5Q@\NY$7
MG&7(?QLEE9%N&XK"5.Q&I3<9U24*<:7E*<XSGZ6/I_S_ )?;CV>_RSC/S\Z>
M/8@$LV1K48T)D6,1 &%2P!@C#=-C!9IXC'#$B(EM]1"# +/B"K(R9*C,QI[P
MV>U$=>7#DI:#N?=QQC/G[<<<!QQS$<;?VC)MS.:YA[FU1+V!662DBR4>-L>F
M2+A7XX1C,HS(-UADXLZ)8$Q4JDDW9\".@?'QEZ6IEO&58#+G',#".T_6:P5>
MVW<#V'T8;IE!;'O7JW"-NZ\)UBEM%ENMBW;;8(5C?$5MLDXP\W 69F0D35LN
MHC9=4VO&,MUFTUJZ !-KI]@"6JKGX#!0%9*V6'G@!H9)3Z<8@),BI$L:2@R$
M?JV)<*2_'=3[6W%8QGR#NG6FGVULO-H=:<0IMQMQ.%H<0M.4+0M"L92M"T*4
ME:%8RE2<Y2K&<9SCD/C/A\=(CY2:9*=5]&OD2#RY$R0SKX%!Q(?<5E3CRV!\
M>)%PZXO*EN+0PC+BU96KS5G.<R(#;3UG8[G9]<U_85'.[!I+$*5<J*&MM>*7
M*I1B24*'2+/5X))\Z 8GI<;5#=+0(;<K"T994OTT^?LV)T.4J2B-*CR%PI&8
MDQ#+[3JXDI++$A4:4AM:E1Y"6),9Y3+V&W4M2&7,HPAUM2@AC]KAZ*?<J:3_
M #*@?R\?:X>B?W*>D_S*@?R\FOYXQ[_/\/EGR_+Y>7E]_P!W.CS:*WBR8IV3
MX7Y6J"*LN*O\:P/E'FNI()%*/8!_"/C3XE244D;DK\$^+\3U)AYD8DJ2UD(B
M?:X>B?W*>D_S*@?R\?:X>B?W*>D_S*@?R\F61)#Q$":4*SH@T8-B29Y$C/D,
MPX(^##8<DS)LZ9)6U'B1(L=IU^3)D.-LQV6W'7EH;0I6.!I,<8'0"XF?#)BB
MD**2&$QTIB</(#YK#<J'.@S8KCT67"EQG6I$65'=<CR&'$/,N+;6E60ALGPX
M^BJ<^:>JNE4YQY9QE-+@IS[/;CVX5C/).Z]UCKO4U>9J>LJ15J#6F'G)* =1
M!CP W,IU*$/3'8HYAA$B8\EM"7IDCUTI["$I<>5A*<8]SYX_[O;Y_3[O?]'Y
M<?3CG36"R5ZIC'#5H.AZX'9DCX;I8\4@AAC4LL1BB!45R>2?BQ&Y),K.AC1[
M"WDNS9\N-#BH=DOM-+#NN81VWULT#OG(Y>Y=.ZZV7($(6R*FW*J"39$8PXM3
MCD> 3E1U$8<9UQ67'(K$IN,XYG*UM*7GTN9CDSX4/X/F7+C1?A4IF#&^$OM1
M_A$R0K*&(K'KEH]=)?4E266&_2==RE6&T*RG/E]7I8S[L^?N]WGGV9]V?9\V
M?FS[L_-G@0H^UP]%/N5-)_F5 _EXQX</13'MQU4TGC/TXI4#^7DU_/'O^;W^
M?N_S\OG^CY^=*-LM=,D#PD0=#%"E6GQA=F&CBD&<0KI*8-B&8@\["BR'90>;
M*$3X)2/$)-19#PZ9$G--JBR675A$+[7#T3^Y3TG^94#^7C[7#T3^Y3TG^94#
M^7DU_/'T_P"?^?M_![?=SI35EKM<^*OE ># \'34"MA,F"D 7@Q82N74BP0O
MX=(C_&)DDIEY, 7#]?/F*:=Q&CNY;7Z(1,A>'=T<'2F)D3JQI-M^.ZEYI2J.
M,>;PM&<9QE;#Z76'4^SVH=:<;5CSPI.<9SC,NQ 40 &0 @,6.#!A41B +$BH
M,4<,&P8S:6HT(? AM,Q(42.TE+;$:,RTPTC&$MMIQCRYV6,XS[O\_/Y_P??Y
MSP'O]_*#.\'AW;LO7:CL)V&ZMZHT6&NNV.@L3KA2=LEH-0"VRB[]V-OP@.V#
MO-QYH7'L3EDU_P!?K.7.C++")IL5EG!1U&C3&&I67F7'!?9!6M^%%W*Z_O\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g142480.jpg
<DESCRIPTION>G142480.JPG
<TEXT>
begin 644 g142480.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@ _1$E32S$Q-CI;,3E:0DTQ+C$Y6D)-
M,3<V,#$N3U544%5473$R-#<V7S%?0T5,3%]624%?-$-?351.+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M=P=1Y/+C@]^22D) YX\>_P W '/YOJ3Y5SY.L.Z!RX#RKPH^_'//N??\OZ<
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MGD^P^AU]?[ 6MWY^G ]OIV^WWT/^/'((VL?E/:W-B+G^HO\ ;"7,-[SR$^.
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MB"&,62&!%CCBC"I&BKB[4=;&$6.%AI%OV;V#;V/)W)(.[7:Y-SO8%YJWMO\
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MR(^"V\A8/@_*HJ20./E\>?>V9+E])EN:F#-(7I\KS>!\IS<Q@&$4E2T6BJ4
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M*J5:,(9JSEDFR>M(#K_\W>FN2F5/FHW /T!W[WM[!2/Z'_+C@6)'W&W:WW+
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M%T<,.,>LAZ4J7&RVI75)LX>""%%(W5J>>>//L?KXX/GD<ZP/^DG,'\(^H%#
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M*AX'*B1[\\^!$*FQM*6TR'@(L0*\N. !V1SY(9;![EE7G_5[/;G@^-*14V%
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MASR[R"1R2./'GGZ>_GC@\^PX/ORY?\J1_P#"OZ>P^OM['GZ^//[?71_*D_\
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M[29"Q#P;'-VMP9Z:&SL-IJO);:K,K!<<<H*:TLT5+]HQ*5&8<3L9?Y%MH?\
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M+O)/'"/+ -D%E1  J !2H %@H^@^O?"E?E,,)!4L!7NE*2%*\\]Q' /=S_K
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MWQ@/L?\ M]O[=-%C-1CV07.XT>RA[67@J]S*RS1&QVGAR+FJOJK&,3GU<[<
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M5OY9A3G$:ZS-ND>ICQ;(<U/_ /I3897^C\@>/CHY!42"/N22DGMY\?3C7/\
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MD#4N>NLZ.7 \Q0K7[O&0C D]RHC?W_:7YWQT782CW#CO''T]_KP!S]/O[@\
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MA)"AX /T/!'/@#E7T/ !]N4<B2ZG@=P( X5]_< >2"3S]2#P$\<\ :_9,O\
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M_P#%_8Y_TK;M_P#6&-^@_P !^PU=!JE[T%O^+]QO_I5W;_ZPQOMX_NU=#HO
M^P_+%4O[Q_\ ,<&DOFT9<W$<HAMP;>T<EXY?16ZS'[<T%[9+D54IE$"EO/QM
M<*:WF*6(U9;&P@_RV:ZQ-_&1?@EY"HTELW@*M,/RJM12JR15AC5_!3CJ;=S'
MU7YEU,N.*1-\RI#M&;4N?@!<-K0Y6&0)R%)4P% =P;_W_0\_8XH'(^X^G?[C
M\Q]QSC[PJ.Y$P_%8KL&VJW(N.4D9=9?6HOKRM6Q616EU]S>"98"YMH2D&-96
MPGSA8S&GY@F2@]\=Q3:2^$0E5N'8K6JICCJJ_'*."K'U6[F0&B5#JHD=5*;U
MY;CMT:HMF ;=UQ;EF8YG+6I3Y)5&@X'V'''^GY# \G[_ -]S^9^^#3<;H5SU
MI0U49BCRK(%HS/")BH6'Y4,/LX[4'*:N8]:S+0V]+^+Q^G;9599)0?BGSDE+
M&FTG\MM/QO\ +Y#CZ;7=.E7>T%5$;PU><*CYM@EI_*499(PTPDU&655BK)3:
M1G67)J<53'-^K'E*4SDJ8!HWFW6IRD'A_E-_;^^ Q_H?MCE?F7[C^]RH_FP'
MUPY"3R.1YY)\_P!ITS&_6:MX-MU=7+<M<:>TU\*%\)92OXTIM]E)("T@I[ Z
M1W(=2EQ*%?#"PA:7H X_O)_O).JO>N;<)R78U6$1@TEJ*@RWE(=4M<A+X26U
MJX*6^Q/LE*4D\]W+BAX$=ZMSI<@R"NS L%F"+34@/\=95,(8% YN&8R'FRQL
M3QBQ=0U_ZNRFKF5BLKQM#$02&#R*06!&XT)J:^VX N"1BOIZ4[/FRYKZE*>E
M/+>6I1Y)4XM1Y]O(\D^ 0#SS]=*."D):)]R2!].? '/T'CG_  (_727C\JXY
M\<$>?(]N?I]O!\'_ '\Z5S *64_HGG_N/]__ ':NGA'1D4L4C7+,@=F.[,["
MY8^^HF^YO<^][:5=43%II/8LWOON/^7<_G?"3R1X)9<[^. A7!//@<<J)^GT
M]@#SSPK[ZBE7W8MKW-=O)3X",JH9\BL6MOE*+FO29$9HI*3P\X$A".WD\$
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MLDD]1.CQM(P554PL!%!&@LL,,48"0P1JJ11JJ1JJJ )_DTBJ  0 K*Q[D!@
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M($@/$R'Y0/Y;[8RIX,TR1=?Y4P0*139GPMN<NJ!:_P#?>^]\>A G\J?^:/\
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ME/Q]F2G,<SK95-'<<J$1W7IP[+Y+ZR&]_55L:YO[L]TL=*G1[A%#NRK??;W
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M2-8L;C8D#2/H0XV.^.S#3RM(X\\\@#SX_L)X/OQY/OR/;C2J/RL_;A/Z> /
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MSP2%I2D#CA/'"DJ45$=QY/!*>2"-4G[TSN^7*'<>.Y25]WCCL)4YP$)X[5*
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M-/R9]"'L@L D*4GO7,^(R3SR V!X *=1R@1E29"4@#M1\ZRKGM[1[#Q]5'@
M?7S]M33(U+4T^9R@I)F<OQ*AN8Z-%$5!%]/]V59F7GS9Y"=R<>+J=[5M+D=*
M0\>3Q"B.BQ6;,JB3S\SJ.P)-2Y@OL!'3+:P&,]5Q/A-(?/+;Y4EUI]ETI=0
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MOF *2H\\DGN\=Q)/)\\\E7W/M[#QIP<O>^/*8@Q/$"I;3#B\'E*EI #[O/)
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M'U!( 5NSN\L)''"0K(XZ@D> .$\@#Q] ??5S_ '_ (\_WZI?]!?_ (O['/\
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MXY/N/8C]]"7!R?"AQ[>1Y'OP?(_;P??Z'75^8#N')'@<_,>2??CV/Z*^GO\
M3V$J//@ \)X'CP./IY]_*O/G]CXXU:Y>AO\ Z17G^*9 =O9Q86(M[;&P &WI
M3//=[["U@K=@!N#?W)Y._OSV_B@@\*5X)!')\?H.#R?KR1]].53V,+(\<EXW
M;/\ 9.IHLJRH9BQW+[&&E/2*]1Y[EI+:%?"2 25#@#D^&K*CY)'CD_0>"0?
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M;5\9MN936T)8D5E[5O)[HMC"DI[D.-R6P%@I5W(62TH)6E0*OQ&VGVEI4T\
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MN+]U*///'G7;O[QZX>:0AL1JV&/@UT%L%+<=I/"0L^ %N+2.YQP\E2B0?&L
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M[W2XT\@\>X[FU\$<@ \*'#<'['\L5)\Z_P"9?S&*\O07_P"+]QS_ *5MV_\
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ME#G"PH<<GD<@^/'/.F)S?:'(MN(T;)*VQB9SMM<.=]+G./*5*A=JS_5,7+2
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M0%[_ /JGJX^W'3.9?\[#Z7(VL<1/K6$1Y!4$"UYZ4<^\JG_3&]*G\J?^:/\
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MFN[\#9?=B&D6CF789EUG:Q:B-<T^.5D:7.N:&0Z\Y*6(,:3+>;0M,5A3GRB
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M' LADQ).72<;P[:K%\?K;+/\P3"9KLEW$NWY>0W%.J1"L5S'Y#DT6S:-&F&
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M*4.>Y '<.///GG[?O]/?GZZW)Z#\9X*ORXC4&*9"JO33DHR,-(*V;UQL3P"
M.=N+X#SOHVHHYVEC66EJ%)*S0@H38BWF+L& (N=6Y[$=J?-XNE$E$AV%%'PN
M]QQIQ$<%/L3\,A*.4IX(3W.'Z$\#QJL_<;86PJ79278#C:T=W>DM>%)')"DJ
M* GLY! 4GZCP/'C:QD8LSD ,:-%3+6]\JFDH"VU C@]_C@ 'R2HA('/GCQIJ
M<GV&VV@.KM+^BBY3<-(48E(E014-/ ]S?XY]':IU"7"2J.V2@@^5*!UM=TUX
MGHT<=I'G=@-,"E?,9K#ABP0*;$F1F"C[^G%OH<TS*@NF;QH*6/9J_P"6&UU
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M:^NJ:NMJ*JLA,LQHBY3T^=.F=HT:88-><AZS#H9_B;\0=*2KLZ>MMSP#Q_\
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M/@\^W/'W2OGL,V?YC)\<. _?DCS^HX5X^GT/[Z@3/?=D>MQZ-REJ[BGJ&VO
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MM0Y-YG79PF;9?3Y75T<==D<!\R"GCJIDS.GDTE?BHLREDE%3.%8JL=8CTPB
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MVF4S:?&2*9^QBQ\?ASLDO7T:-,,&C1HTPP:\W;UNR!_$K8V3Q_[GG;+WY_\
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MTL7RZ\[+G+7+D/\ Q%GYE2G._P"'X!X:00$^4@<$ ;!9+UU-G2+3O5)19?(
MLK+Y<]54@VV!<204BG_&4FG(-U:!P&$@ROJ/*TJ8_B8D?-:>QB\TR10QN0 V
MDKY3U*WN& <0M:S"5";TI5V"=)UG9K@5^!V^PUHPRY74N355K9753;-J/:RK
M-:R8MTNRUJ 4Y/A?#+04OA"D (*0W"V3S;;QENUEQ6+S%9:@:W+\?=%G0S6U
M>4<RXX4(KQ'YXTH-/-D?,D:E;N%L;,KE.A<!WM[E#YF>%I'MP 4A2CXX!(X
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MLLM4B4U(U=\6?TFZ'*A4Y#X>209GF?KAJ>H2/-RVB(]+"@&R5TZW.F<$TJ$
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M#RZ-0PZQNO3I^Z'JW;8[PS,[O<WWIRF9A>R^SFSNVV8;Q[T[MY)506[6]K\
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M<<_E%;;284:PN8UA8,M24,,;&H(4.1]U#S]TJ*3_ +QX_37.OAO\I_Y[G_\
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M=@"QL 7D>UY)'+2.WJ=V.^.U%BAC$-/&L,"\1HH07L 2UB2[&V[,Q9N3OC@
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M-5%&0&;DK=9CLB/EMMG]#NLCH&KMX>L?K"]4?<7JKZ;MG]L=T<TO.GB-T9[
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%TPQ__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g504981.jpg
<DESCRIPTION>G504981.JPG
<TEXT>
begin 644 g504981.jpg
M_]C_X  02D9)1@ ! 0$!F@&:  #__@!!1$E32S$Q-CI;,3E:0DTQ+C$Y6D)-
M,3<V,#$N3U544%5473$R-#<V7S%?1$]315]&24Y$7S1#7T9,3U<N15!3_]L
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M.7.!LK8E*#A'<G="0T96IL;P-45B8V9UAZ'!_\0 '@$!  $$ P$!
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M7,;L*VHY7&QJN'D1(DWP&-6"9D$_'/Q.D%'.W."&$?E9\F?' ].KRV=]@QT
MM<W%[YFL!KF9#:]AS=\(H^92>':QV8"99:@NW!4ZF[N'&L-6<2KF81J&$U&
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M<0?7<A-=A2UTKE5=CVJ@42R4 8G9=)-!0M9!"#3,%*$/DZ5AI5UU9D.@ISK
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M\8KJXES6,X@I]Z,]N^4$9#JBYN0;9!1%E1NFQ]6&)UFVN+5DFA..QW/DJ]H
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M=S>_A)F0N+/B-P)Q5I7Z: ]0,:KED"KO62&6FVC;8O[Z@<MM:%HJ-TWJ@Q0
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MK&]!ZCI5S'VKG*FFCKT2>^RWW/79\D<>9\>7R7E7.KXUBIQKU775DNL/"NU
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M7_Q/7^GT3J4#CD7_ ,<+T3_&/+/HKL3] <?'"]$_QCRSZ*[$_0''U:\(?*?
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M/JB4'U!)!FS=>0GCI)I'7V8B-85ZK4$0KN.KZ/'=(U=8\PL)Y*S1I:P3EG1
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MSK@Q!LKW.%N$LWA>*^!<G?17"E9XNX5&NY5VG8EP7+Z+-5ZUI<;"KO4ELBZ
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M&!-VH<:)T0VUV:(#6Z33*6VJB6-M=\;[>>3*3(C+;<BDIV\F\SOX>K7?X#
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M.8A%;4ECE:I+*1AEF&)# PS(?J 3JFR;:.R*$,1DN=DC! "(J\\&3"F<"=)
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ME)R6HNTQ37D:1Y5]- #'3A7BJNI1ETQ8V!YV 1_PAS/-S$4E,ZN'7G_/F_\
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M %TC5>0XS*I-<?;"QZG6:N]Y@R*BWBC!KL(3:G2:N"K4$-9#UL$]131HM5G
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MSX9_KR2/V9^3PS_6Y^7Q]GASC[96L7'R]283],LC_HYY2 GHQU:&PZXY&3K
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M>BY:#K-SQ@OL;L.**-A!ADQT;O(BPY%DN)\E7NHJXSAO(9)-JE3LJNL3DJ*
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M[TY+_J-_SJX6W[&:_P!RMOY!/GL3W*?\%QQ_6<._W<WKR)[J'^,<%?U7$/\
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MF6U>Z>Z8==/1!'#=73-8 ZW\I):!BYMXY6?927''P(;U\O)H+KUWJ^;1^-,
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M7VXI*""815OP@LXR4>US%1%6V QL""PY:5^]]<./;PNR-Q9YAHX?XW8G]QK
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M4W2TU3SKKCP<<^O(H@;+;75?)-0A$I)QE5"$,L,AJJ\STUO;-B0>X8@W+57
MYD4!M\G2?)5UUNFB(6YSH:*0BP<N! 2MCXCJ,2N$025%,@HVO,(B7'OF/TN6
MB<-G<OO2:3C>O6='PE\9@\E8QM&;G65WSG*T%ITF$@N3T<<RI:&&B):R7K9
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MC+ CQG9T/1FYPB&.2$"Z@2@I/42)>O9=[I.-PR:&E\^A^YS>I^V@6$-KD.R
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M=J_9#4QPXL+W'LU@SM7/)Y8[JQ3Z<TI34@Z-^KST]J*Y8+88]CV/N38BX86
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M5,:BV+C_ (!VZ16_6<M[ZFS_ 'DS_BC?^;Y3J3Z(]O:?:/&L51GR,W^88_\
ME\_M'COJ_"Y5?XRH!_EI&?TIQ\+E5_C*@'^6D9_2G-"KU-G^\V?\4;_S?'J;
M/]YL_P"*-_YOCJ3Z(]O:?:/&O=(^WG_=_P#Z^?VCQWU?A<JO\94 _P M(S^E
M./A<JO\ &5 /\M(S^E.:%7J;/]YL_P"*-_YOCU-G^\V?\4;_ ,WQU)]$>WM/
MM'B[I'V\_P"[_P#U\_M'COJ_"Y5?XRH!_EI&?TIQ\+E5_C*@'^6D9_2G-"KU
M-G^\V?\ %&_\WQZFS_>;/^*-_P";XZD^B/;VGVCQ=TC[>?\ =_\ Z^?VCQWV
M4[7K!7SO16+!%/-\/.]',8WOYOG>/F^=YI//AX^;GP\?E\,^'R9XYHQP1JTP
ML7\&C3'_  (OY&K?'_UA3[R?'*]3U?G_ /UJR:\1.W/,[>KYO7\_M'CMI^5-
M_P#87N[_ .&O_P#:;#^:U'7?LR,H^'6W I!6SRPH[;3J NR>!-J2^I#(I:OG
MQH@-]1D4):*F]DGKDQGUY!)ZR160;>JN-'3=RHGILK^5-_\ 87N[_P"&O_\
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M1SO'7CZ(M(C*7#$(BBN@VCT^WAZ=O-Z=O)MZ)U;!3_\ :VWVW\_CX1OM$?\
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9SYWZ[Q\-?!QQS$7V4^WFU3F+[:?RSK__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g731568.jpg
<DESCRIPTION>G731568.JPG
<TEXT>
begin 644 g731568.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@ ^1$E32S$Q-CI;,3E:0DTQ+C$Y6D)-
M,3<V,#$N3U544%5473$R-#<V7S%?3$=?-$-?0T],7TQ)3D4N15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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M&,!#C&.??Y\\[DVS6:RV79.[.3R5V_W0\!$+5B2985 \%2)7$:*/-5%"J H
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M>KH]WT_&3K=MPM29SVPI3YSV[]L'DYSV^WVP9[W'IJ3OV])3]^_;MYY/?O\
M:[>9[_W/?YK$=?*FHMKCH*Y2^KT;7$99)MNHDY)I/#6)OA<@8XQ)V*:'&P)
M\1_"9Q]RZ0UI3F ;@*4Z TP(!Y0%B*!G,@_V/M?_ /1(?LA?:&-^[;_HH?;+
MVP]RS1[>?5$^HC[M_JJ>ZCR_;?W>>V/J]T'B]N/,_P )]L_%^U\B,&RKLVW-
MN[C%RLL.XMSV-L0UBDIEK3UTI.UJ5P.AX6%U>E$\\=!Y](U)I=U58LWF\(:T
MYEPF!BSLLX9.[GBE,P\GC7GK61>Y/GMYIZAX#CQOURL2X]]21CU=_6>3CU?;
M]9GO?=YQZ:D]7^$I_7V[?MY/K[^]V_;/7W^QS4R]CNU4R[(ZU6/*;8$FG+S
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M\<<ERJJ*J(JHB*%1% 5551PJJH "JH      X XUMP         .  /   >
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MX+^S'Z6<I_ P6NJ7/?[OWZ/*O[U_4!?8L/P1]BOE)%?1%7O)1Z>_&7W_ /\
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M%11H+FB*-^B%$)?:!+)0N9#-Z.021AN+38(*+)P &-9-YZ>_5DL?8FR+0NJ
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M?E7-)<KRS-N9*6U9S).[8!]]&]M M^<*#\91!5839\XW]J_;!^*5_?&?L_\
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M>*K*K6+&>S=9BLMFI2@2:U>@Q,BM%32M%*9<@L]HITTJDSVU&&EE!$,P80
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MZ\1Z<54='[C2.$64)HJ[R%_<(VK-;F!0[AD.9&VM[@:<RN)C.)I2.BE"NPL
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M9>&6,[1:F[I:G/+NXM[,4]S^BWJPJO.=W-:2W(TB"SZ6.GK,H)-6J$Y&%:Q
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MR_ZKL[_G(I/_ )]YUZ6; V9"8V]2R0ZQ6*0R1] <YN9J*<T\Z*P)$_A\T2=
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MS,B)- $P L8E#QQTG\=O^'U?W?5X_E_+RY'XJ_%\;?\ =\?^?JXCM]5>Y?\
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M2F,*.'J9]9.#55(-W[,/2E6[;#D/71.KFT/8M8:<NV$U_<L8U,W.>:9*6O\
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MU)I@T<#+([JR%U;E_:S@I,OM2:_43JR>W91FJ?2#UR10*RY&KR/.*6*#3<H
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MFJ)O#*]IZ,RVX6'5NUY2P78[RY[#7A]W49HW"-LK-(E+"R5"97:56U)W^1)
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M/<B$QW:%N9R"5)GQ4/G<,8^GEK<?$'_2#^?'./$'_2Q_NSWSGO[W;&/7GO\
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M6,XQ[_W/NYYA45-K<X+Q]6&Z ^6263G(9<T=S,EI"4OGF=XKG&3AB)RL,%C
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MQYG$X-%HY*[ <4PS1IU\WD;,THGF6+4XSSQ$*G]:X'E".-$ P(C!Y%CK8O\
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MY<>(M$ODM?/S-[1$9-&WMOCP#Q9SHGK:[H3&7CAZ/1)?N8P%A3E@NC3F.WY
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M(ONH:.,HX6JQ_P#VLE=NY2R5/RRX.(CT]+<\#9B?==GCNZ&%Q:'CA[=ZUD[
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M[VNLA[@4+K4!:1R"CPDC;)$8*G*:6YA9LICAH,JE+FZF#6J?3'$TL*<DC/\
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M&/TZKTM^*WZ#_EZQ^G4B..1W_93TU_\ $9U_,O=?]GG'[*>FO_B,Z_F7NO\
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M(;&U:3Q^GA1WTJE0>I@?$R8/ZK6];":8&<41N-&"\@_P<1&N5!NIHS0G9),
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M)*K$:X+U0C"C?;FY>IL@-", 4Q;/JR\.Q)A7@[B$>8OOAB&08$?8("RB%(!
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M5ZJV\VQ>L5B0"'4C=NLU=L3]!F&0V$5:=9SA^GM>)W"SRFY-9V9PYRV*T&7
MGF*1R?QINK67/4:MR>S!D$UTIB>2E83&VW'-./&P5E]16R(3$IS!7F#5YMW/
M;<L!"OCT-:*J>JJ8F5TJPL^NHFZZ<QB<339*MYLEC=56-;D5VGEZ**2QC<P/
M[X-K<4=3(/H]4@RR)+LFPTE6KS"E+Q?6L"NI01%Q8:Y01UPD\PF\W105EVBF
M-H:7[.Q1]HJQUZ=[8*]J]?+Z\52*5QVS43$P3-]?T3C%&FK =UKEF\,J&BYU
M66S%'ZUM4LN"#%RJXKS88ZM@BR"NE<V!)D,=2P><3BO'EZ<I[*VR&- ([%YB
MSV&W,2Y[<FI: ;(XG _:IMGIC<.DUGW.R3[6 ^SX1'+]8"K(A<WE#MJN5853
M%REK1RM?,YRP1%T0UVB=FE"YS@W)KPU1I&0^HV^<2MO; 219AOJ9R6755JG3
M"IM=VAKD3'<],>V3= X.)\E[[[BXW)I6[D4"A<*"V@)ALLBXHD;8K?)'2KW/
M$7K>$3#_ *TPIP$FE[5VZHTML07IUVU*[6G-1(IT]5[L?;*&T%B*(SR%DQ>4
MMTQE]<3NX'.N*GKV(VRY(X2?'7BS9#&:B:4TS3)E9.&>0K!G.3TTU@GI?;;6
MO>=DVM 9Y?#5=S1'Z?J*Q4"IW>]2I).VF4RU]G+)+2FMUTE>I)5(:E'EA;"(
M<">+D5J+W),[NX4[C$EC>K(,F]VQ$PW ;Z9*S7<6JY'N/,Z0320RB-EP1RQX
M5"(K.53G'XULI*F5#0@[F0RB/J&*00%M  W+I")<TQ*0/BGR2Q?ITELW',D$
MLLJ:K"#Z]9JWKRCHDQSQ'!?JTU]-JR<Y.*PX(H;8MJ5J/(ZOJYK1ND./B-6S
MB&.:X CP2EA0Q-B=$Z5YB%KY4BN>=6NQ[&AK95SC*ZRV/NV8V--E\7B,:CCI
M3:]'-:D3$5+#W342&R^4W1$IZVM566[=D+V-E"9)*HO*$LODC^BDR.")6FI!
M]6#?O874ZVJ4@M,6I34=8ITD@:V?1U=KM==XWG$6-1;)?NNMEK0PUQ2U[(*K
M9:@B=K/<LA!RA@MHIBKV<3B!J'QJC<A50N5O4LO>^JAU>AU@:OW%J[7E@2"Q
M86UM\VV4ED4AU225L>8E+GAJ:FU=*Y*UI5N)-)F^+J7=L8'=?.!U6"=K*\)<
MYJWL?CAAU.E=GR+:N(TK5,DCR.67+KND@49;S&2",K(V6!*'ZZV"*BV L.P]
M+MCV-?6$^C*NR8O :Y26-6\CD*AIN:.1UH>5L\$\-,F.J5+WZH-7Z5?4LA;8
MXJBUWU>L>DD$@1+M+'9OA<#GLI=@T>6OH/9U'7+_  L,7-M ,K<*U5%1NLH#
M,6[,PA9ZPN4(FFOTU6V@NBT>FU;EXRRTZGS;<!;=JF]OM5=F+R&O6%=4KM-4
M49D5@K*7%(*[?T4=*:$2N6N%2FR*/+&I((Y 2N> NC7C%/21WJOC=B9[*O%B
MO4-6P&+JH@NB#-'2&AV1,9\Y<Y;+8P"N;(B+$V,-E5*X4@ZU&M3RF4J,3YSL
MH<]5A:&:#'1A-B2E7)[\J+IZV[*[$L.KXC<Y,#V/MUFMS"*.S*/1XMY3S*<5
MM85L.=8U16,;L^21^/F1YWL>2PZGV F7'-IXT[&_KQG.+Y'?H[Q:S$K+=ME*
M$Z&.U1:[XR/CE$I 3"TUL8VDCICO#M@Y),(Y!M5=1":\(5I6&!QTJ'RFN7"1
MK7"/'R<D,6:W0IM=6FL5P+J"[&S3?6&:VQV\]8K(9'?;/8V#VO6T(K6S&^=T
M+55"9G2=IC;C9*L$@@,XFLP9WZE7>;-3F76$LKR3'N_M$7.89($_M)]7JB;H
M[BT);CQ%M>IA'&*$0G7MDMZ=";-4[.V.?XODXR^EONILV:19T20:C:[=)!5E
M?Q$MTFS4X$K:_>;VGR-W9'>KV4M;U#78%R6UU3I_9+'*X9(WNGK(O.NK2GJY
MOB\;99#J(OD4TBT/J^K8WG42 6+-Y3 KMKB+0:=SX>T%H1B*SBHITA.?'%#(
MFNOVCI75DJMPOC=6MJM96BKIA8#OK^P,E)II2R1)M8(/;TBG-I2)D#L9*IWI
MYL+&IA55AI*T5NU=U"?9,"72IRJ*TT31#W=\>&N7,;34Y.JGLSMA06L-13'4
M1-%Y+?\ 8-IQF*,D':(*_76.PU2ZJK#FIK%"XS'T?MX^1E(Z1E'*9P_MH$+\
M@IQ@F#O&A@E.6A*?XZX[27Y,NE=8VR%@R>/QB\X;"-JUH'BX8J@KU?7SS4DH
MLIEC:'8B 1E(I987/H05&4"2UHM&TBQI3/+>K*;O3"5/C-^%UE -YFKE2-,Y
M''WF/J+WARV<QALB6'&:REEB5;67+WYPIU6MHW9O->O< #'C;7D4O/@(1QZH
M83/DIEB0G*H3Z/L]:5G,*#Z25EP*P'"@((=&*%V9<F%8<RQ2>TG$JYD&+'E5
M=&V2FA52PJ&VAAO@SPQJ+8=H[221KL%[$_N.(;*CW11E_::Q/TBMO=GMDY9L
M1&=C[#KF:+:_9JT<6=IB,>8HI(8<H?Y9<,=,9)E%&\A%+X9+A16$PU58D2M=
MDB\@0VJ=-72MFA;0SS6<@=/@5/O7M=*MUX-4+HKCDAI6=;9;,U*ZR9/K/==<
M0V(,-'L^P7N1A=<;&R8M[J+8>3RH5?,.9T4VJ:XE$)FT+L)MC*&>Q82PN,91
MZ537:TL<KJV!GQ9!K38,;J>LTSC8)<!5;,DSBC76TV2PX=;2N&ZH:BO4?C4%
M<9$@:('7]C0A[ED=<CYBZH#XM%Y"SQHN&VG56&3?JEVO;4.9ZO42"M+\V6=[
M6G.8S$8LRR&JIDYVU5\5643"7+42NIPXV FLF($5S=%ZQ;8FQ6-XE-=VLT2:
M6S3$P98^S--=]ZJN_5[:N[%-4'KBUI7'23Z0BTT@$'KRI*WLY@<I^=+;)'+'
M?:U=,HZZ3^*T8SP6&AFZA=0SBEGK36U?7M-7%.!/%VM<38SU"+YMNAJ%C,[I
MJV=3JSFSC/6-I\&TL@PP1"QF@^,2=Z=X'5,E53F!,:*VUZ=I]T4)/EBQ9$US
M5'WM)(RF-O5'2V.UX]1TRTYAN<DHRIGZ*>ZJXM<8=#8NV.#' V.(-\]>E^RB
M9(W;'3J>Z:7XBE\)L*MR;.102IV2Z:NET@CD6O2,QR/"56%[JRI8=6*Q'.IJ
M3H^6-\G''L,5_,[P[!B,90K[%4L<6J"W9,\O-7.;IKYM$W5\KKUO9E-E3"8.
M%=HTK-4\2G* ZPHC[8X4KFFOOZY[$6[8O2R;;Y?KRHEXV"9:$GZJ=W.YE,<(
MU^C]V5HFD3/.S9*]M[Q)803!(#-HX[1^5V1&'1SKQW3,;G.HPEQ%%:%L+QAT
MO-O[WV:L'9ELNJ=TO("HT1 )?$894L]J&TB8"WSJ>WLUIF]/.Z3<GU@<H0MA
MT+@14;!8+SBW%4M;["?'IH:X6[P@!F2T[+;U9]+>[C;BF%0L5JF4GM'/'V>+
MV*)6-7B4,S-LB9QV3V237U-1.'6Z^#B[TS++5?XS01+39DJ,?W=-6LD+>!-3
MSU/I8FW',V6Q;;GCJK75\[LT%JBN&BQ#H$YWQ"7VE9#9L:M>!S@Z&ZK:FND)
MBT3ERTIDBU4S:'/<@B\B13>0D'QIIEB*/%--=)K'?RU+0VSCE0DVOJ@DBA6T
MELUHIK^.,=UCMJ=5%$(_L2V1:91"2S9O:H3)RR)_4H(_9;S &=VAD/F<9DL&
M+G:A8>V ><3]3+>C8W76YYPR5YM#K#2D"KNC(O9_N8L"GYI/IE+)4;']@9<C
MB3K9)KPS5=!'*R7NHHO$(C7CD;FPYQ7ZJV)=5OMG/(<Q1UR^#J4UV;<6^CL<
M4\P280_4[8[:V6.:]UA-?1^'QV)W%)K_ *_85VKT.<M-:^M)FF;G/6>3P.Y[
M<C>T%@PN5RJO;C3R9YLEQE#$"-^?4<:[6L[;]ZUDKMRKYY_9"Z[U3&6^"2N'
M5\55#I,V24WY,&MLVO<[*TXV&9;:B[I%XE,Y?5-4LULU?,@-M9VUB',K1(7E
M#9*)IJ:?4:V,MNAFW6205M>%5T:S2JRYJ78K[8M32^]FQ[C<;H"R[#0-(:\K
M\YFLL<12R"--[Y8L\C#G&C*X@+8[3"1.R%E0+TJJ5>GU]_LE:!B5L&NU6/S@
MO>)]$WIZI*4R>;5.[/\ 6U@R>NGQR@4JF$.@KX]QU>Z1=4K0K1L1K:()V2V*
M13!C W2UZA7U8;-?*;K_ %PFS%,TD17L-YN*MS415C;/JP>Y1#1-N'S5\J20
MO% ;0(*^1PN+E.DNMF2+ZZ;D26EVJ9M[A9D12J#2G^5VA=0S:B]5ZUK>Q66M
M([,&Q78#X[L]2MD.;(<C#-[+F,X;>XJ]KFH8,\2L]GD3>IL&4Q&KH#'9=/3I
M')6F+M:-T**RTU,'CCCC33CCCC33CCCC33CCCC33GJ+T"-T1+&UP3$K$"]*H
M1+4B@&#4ZI(K),3J4YY8OK3"3R#3"C0"]0RQB#GU9Y[?'&FJZIWTP]6E>I-@
MZ<T77L0U>JRQI_7EE/B*EX8Q,B0R60&Q:SGP78QD\)+:J<'PNK8_&W%<?^WA
M:0%Y*SDU(GQS&EG]*]AL;8Z4VJ7?UCQJC+4V%U_VOO/5=!%Z]<(%:-]ZUMT.
M0U])#I@Z,Q\SCD7>3ZOJ1WL>%MQRI%,G>N&D_"]H3.TB2.EKI@LA ,6/?" 0
ML=_>[X#G.._-3BU.LUM#6FU.RC$JLBJ$T"H?J-U?J2TT:^Z:7N"-R:G9X^T6
MPO\ 94ZZAR&P$VNM%R.+I[7D+N2QV P&*CS(HREJ6PY'-&D/&FK;M1^EHQ:N
M6K6TX<+]LFXH7K;5MK4IJ#6,TC\):VV@:VN>;Q^7S1 ;)XZW)9'93^0V0V&5
MW%Y!)C46&"OX\!K]K%SLXN+V=:WV[_;_ #YQ^C/*797UMZ%@FQ=EZ\RZG;H0
M/4!B&TDN;#6MSH^33>8)=1H(]6/8GD4)'[?77Y"6Z;1A@<3Z.?++KV'MUL&X
M1&M/H#:\L3BYX_;NOEKXOHZ'VU]22:IW>S;D,IBJXT==NGH8//G5%49=X2&1
MHME![#EZV,+#"H.:6T3=!*[+9)DQ6::16944<7]20,;35\7;'W?SY_KX[8^[
M^?/]?*(X7U=FR\957TYJ)7Z+0-E,VB3K&4SE!6E\L))(+VM'?JO;E@,Q4I+*
M11EF5,+CJBUL*631MRF#:Q.B-U=64B>L$E;G%O\ 1C'7[H4RHE-R6KK=LS2$
M<?=<*IV@IA)/@T4:X7M75P6K#:+AX8>;'[H<VB&NCE:L]BK85]5]SKQI+A[P
M19#BZ-D12NBQOIP/D'\_Z#]&FKZNV/N_GS_7QVQ]W\^?Z^0>T5WPJW?&"6#*
M:^;5D<?ZCLI74]FQ-3+ZRL5*QRTF,1N:MY\?LBF9I8=6SZ,/\1ET?>V>11"7
M.)0,JEC&]I&62LSNSHY46A/&ZK:VL"RW=(K7-->PF63ES1-_E97+&Z(1]QD2
MY*BP>,LGTM2E;324WG# 5YYA?F""#Q9XX'R#^?\ 0?HTUWGMC[OY\_U\=L?=
M_/G^OE-&K%K=3^U*YU=VME$GT\D]<[/P-NL=^UE1P^;5=)*9C%J5<ML2FD,2
MV$4V%8Y%N2YB7&1..6<B<JHBC;($CU)Y+"O:8,60M#U]#0_:+;BPMJ+HUROF
M9Z]7FEJ:DZWF%QV!K= I1"81K=M1+Y&[)9/IP?(G^Q+!36ZYQR(I"Y;F1>7"
MII%F],@'8$2;3YXP-S0X'R#^?]!^C35P_;'W?SY_KX[8^[^?/]?.>..!\@_G
M_0?HTUQVQ]W\^?Z^.V/N_GS_ %\Z19L[;:NKF>V4\IU2MHKZ%RN<.J5#@ EJ
MEMB+ XR%>G1A-$$L2H](VG%)\&""#)PP>/. ]^50ZGVIU/[8@.JFU<RE>G+]
M6&T,/:[#E&M2"&3JMI-2T+M:LEU@TX1#]@E%@6("W)G'E1L19;1;W&HXTW2%
M([RI]@P6K,9;6QZ<#Y!_/^@_1IJY7MC[OY\_U\=L?=_/G^OE-^@^WNU$XVWV
M&U!VN=*ID$YJFEJAMX]W@5-V?KZVMLRFLMGD1LVO*I;+AE+[(]F:,KUQCD>2
M1_:>,L\4CCX].ZF/.;7[;'I2$%R/' ^0?S_H/T::X[8^[^?/]?';'W?SY_KY
MSR*N\6S:33/4'8_:=7&5,TQ0]/S:R4D02G*$@I.[1YH./8V%0XI4;B<T-[J]
M#;T3H^!0+0L;8<L=S4IQ2(8,N!\@_G_0?HTU*GMC[OY\_P!?';'W?SY_KY4>
MCN#=W4AN(OO?"\]09?J\V45.K)V%<X!6TSI&6Z^S6+L[+(F=OJPAXLRW![#0
ME_4N+E <('<B SW#X7$7IIP\*).;$DOWNEGNC=FY31MZX7S"X564II[;!PKF
M(UE%W1,]OL&J=^HVDK<@+)9CTA>'9M>K/1D62Y-\\7L844=0RI \15G+5EQD
MYR6.!\@_G_0?HTU:EVQ]W\^?Z^.V/N_GS_7SGCC@?(/Y_P!!^C37';'W?SY_
MKX[8^[^?/]?.>5 36]]W-B-M-N=?-2["H.@HWI9':>:7J07-2\LNQWN>[+FK
M(=Q-;( IHMFI45>51%H>OBC6[/;<3,)0_O[R]FMYK2GCF$:]P/D'\_Z#]&FK
M?NV/N_GS_7QVQ]W\^?Z^:YEM]0W=R"[3PV,6N-MU9USB4,T=0W#:[7I7:VTV
MOS_=^Q#LYI[&B#+M>GMVF6F#5X@?UU?U3$[((K&R$31*I@%XGR..)4.$Z[8S
M#GOCOW[^L6/O=A9QV]_/K#V[9S]G.,YXX'R#^?\ 0?HTT[8^[^?/]?';'W?S
MY_KYSQQP/D'\_P"@_1IKCMC[OY\_U\=L?=_/G^OE8>S]^;,O^Y-+Z.:M26JJ
MF>)/0MH;/W#>%KU\[VY[FZ\@D[@M71:$5O6C58%:I'>8S2;S;TEYD<EDX&2)
MQ1A5C3M+L].S>!/6MM[U+=_=;'6!ZWOQE*MVPD1U[V%V:M^VJGU;V(V@K&5U
MO55M%5I5SVHK*"2YGD.O\/?FG"V;['OCK,K7>:F"A2Q*M&>Q'^1-1)3@?(/Y
M_P!!^C36S+VQ]W\^?Z^.V/N_GS_7S'M1S7ZI%55I8?IL3<_=W7\+F?MC WE?
M(X.O]U,::WWTV&R%U:(^YOT45>G^?''EQ865>Z,QB)<M:6U2>:B(R'QP/D'\
M_P"@_1IKCMC[OY\_U\=L?=_/G^OD .J?LQ8VG/3XVMV;J0B-J;'IFJ7&91 B
M7MBAYC1CPF=F="5AX:TCBTJ5R/!2\X0DY+BD&,S!><&^K(15;1WJ3;+1:C[G
ML-IOF&[4V.9)]8J-IB&3CIG;:].R$QJY]J;P8:7@<HG$UOJ?/1UDP%E<'XYT
MEC!79"1\1MS*$9CHVA?VY26X'R#^?]!^C36R1VQ]W\^?Z^<\I,>[/ZC=8;%5
MSI?/-D=99-+]LJ9L^>T#L<PZFR9E(J6Q];Y'5*VWX78= ';/N1=DP6=5Y80U
M-?2]IM*$NT+E*,ULE".2%*&L2G'^G#UU=-MZ3,N,.\NGU?X!<&QU3XCG_1X3
M&4=\Z^["V?0HG[VVSN_'_P#VL%6XI3AL]KLX9,/.&;T]U] ]LU==-7Y\<<<:
M:<<<<::<9QC.,XSC&<9QVSC/KQG&??QG'V<9XXXTU'0O4+5@JU<7H3KM2Q-S
M8?U,JQ:A-;Q0J?XDBTDI.N?L2LML"]8=EQ)! %R_"OTA9Y! E)AHB"L@]RWM
M4M9K_=&I[O"@:>MQY8VT;,SNMC5Y%Y>XMC2-P+=LMJ%:^-JQ0F0A=BBG4M,4
M8$HER+ O*"!6$)V,_P#'&FL5S^CJ;M6$(*ULNK8!/J^:CV14V0N811ED,9;5
M4:+\F/JD#,Z)%*)&I9"OVIK4)R2SD)61%IQE@&+&?"!T32U75XIJ2N*HKN"U
M:L)>4ZJN8I#V)BA!Z:0DC3/J4V+MR(AF&E=TQ@TSBFRC\A6G&(@XL16<@YE?
MCC36 Z@U6UJU^<'IVHVA:BJ%SD:!"V2!PK>OXU#ECVWMGE^UR-V4,3<B-<$Z
M )1):,I4(T*8D@@DG "2"@ ^:7I_JH3;/U>"=<J2)NOV\4R;ZK)-9Q$JQ/=
MM+**7//NP+:@OOMDN 01Z<K]-\Y8,@@Q2(TP@H0)'<<::P!;NJ6LU_NS0^WA
M0%/6V]L#<8T,CQ8M=Q>7NC0UFK<.0V]N7OC:L5(TF''&' !!!H"REW=66$"C
M.3,]JL&BZ8MB#(:RLZJJ^L&NVPYE4-T(F<19))%D"B.%>0P*$3([(U2!*>S$
M9R2V'$$ ,1$B&40( !C"+*O'&FL20V@Z0KRMG*FX+4=;Q*I7A(_-[K64?AC
MUP)R;Y0F,12-O7Q)(A+8U:!]1&FHW9$<B&E7I#!I5)1A L@SUZH-6-:]?G!Y
M=:,H:HZ@<I"B2MS\NK> 1J&JGE"A,":C2NA["WHAKB4I@0"( IR9@ORRPA[!
M+!@.?..--1U;-1-6F6U3+R9]=Z7:KE->WF2F6FVUO%$4_'()'Z5F0/(Y6F;"
MWD3D^C7+#GA7E7DYS4*CU"T1QYHS,_O;>INL-]OK=*+MU\INV9(T-1#&UO\
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M<8(2-:I),RKQQIK%;)1M-1NJ5%%,-5U\T4NJ8GV,*:H;XBQIJ[41N3Y79D3
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M2M4A5E6,<<::<<<<::]5<A1.B)6VN2-*X-Z]*H1+D"Y.2K1+4:LD:=4D5I5
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MSCMWQGOZO#G&!9SZL8SGU<QNLN&MV^VXY1*R4)2+9EM>3&UX[#!HW3+@YU]
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BCCCC33CCCC33CCCC33CCCC33CCCC33CCCC33CCCC37__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g438810.jpg
<DESCRIPTION>G438810.JPG
<TEXT>
begin 644 g438810.jpg
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M"<Q*MU!JSTT^> \Z]N<7]H \I>M!UD/'+4^P-7!">S[&B/E?\KQO=TMP3/O
M5JY[B]V"P]@]CE?:Q<^V-@;XE^<ZM&Y9C82.O4L3@)L[@YPPG(+$PN+N+N+,
M3,0OQSP[/\K!REJ2EC,C=B8"EJ4;=J,9&=P*2O7DE!C82$G!R!F)A(7=N68F
M?Y:7GY]CTT>_A_-'%[]^W;[UFX_CW[=O]H/;XY83IK<6NM_ZSJ>X-36 +5KR
M\,G,C6+ $9+PX23-I)/8EPK[MG6,;+-/+D(YXW\#UBW4-Y/F$*9(Z9S_ .8.
M*@>8/94G?S.W?S"]@$3#X>X^+T[B'IW^/8>W?-P?IMU;J72/"#CX]T7LWC+"
M:H<5>;-38J\UZROK6R8%N]I(Z3FG;*#>-%G!Y,KY9(S=RJF#11N0P@J50I:;
MJNTW\Y>GK6X:D<<50IQ>O',)N8S01LQ/)/*W5VD)^&%GY9OEF;A]=:+N^5V;
M)VJ5^#'Q10T#M 52*Q&;R#8K1,Q/-:G%PZS$_#"S\L/WN&=GV/\ &5/GI?6)
M*0YB[?X<J&*0YBIA5;845#%*(E(!C5OPE$X@!0,80*41[F$  <\T$+UI.W^W
M#B,'V>P27I]GZ09?5M-7"XRGKW)UI/UX<1OX!)?]P8]R=:3]>'$;^ 27_<&$
M5PN,ICD&O6R:+%3;27%F43,F!Q<,D6R*1#B8P"B8LDS9+BH4"@<3$2,D)3E
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M!!(?91644'VD!>8&Z:DL<FXN"_(.LLT2F,XGM5/Z-OF#0232!5=VHC49F.M
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MB-<UX#AGLUZ\62R%:;[6S%QA>];>)V"C0IUJIQC+D&LV/=&;FC[M>!Q$V++
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M=LW2C1<"+)).T#B44U4SGU-XG\DY+<\AD:.6EA&>M7FMP0QQ0Q=X'LP!&0D
M 1E ,KQ2_D_,<CMR3\>F_JY^D#8_ILSFH9G#YB_M7C+8=8H8F]E[E2K#:QGD
MC%U*<>6CM>UA :]#:8HKN?P==Y9O;&&8QCD\.,IS6?3FX^<R=5 "VC^6X[+B
M6RQ#H4'EA3V=O*JW3#L#8FUJ&2N71J(D[E]HD8R<.8_@4./<I@4_C^;*VMJ(
M@H\LN+VP:%&-E 2<[:TL8^]=1 AY@@,M*%@&[78E38@4R8"28J3D2&,?NL)2
M&,%AN<"4!^;X_$0]!'[!$/40^SX9O5>/5BW5.[]1[R@"V?4>Q*GL&%_0@NZK
M,PU?K1ZAO@VEXXIB2<,\+_\ :,I9FS=)CZ'2*.93 0'U >X?2&0ZVQP:T1LR
MP&O\-%3&F]O)F,NSW%I"65UQ?2._T1RJR[B&3)#VQ$RW@.X9VJ)ED7)2 D<2
MD$<PZ;8/-+BNHH&W:P'+[2C$5#J;5U/"-(#?-6B4S=Q=W74J2J,+>$F;<AC.
MI"A+MWYDTU':\<8Y@1 BR/S[Y=1?$/1<I:VAVCO9EL,YK&J8%P!%2O+,JW\:
M\Z^;&$3*0-19J!,RP^ 4W*Q8V&\::\N@8-+Z/OEVB[TTV:QL\RCL-E:27AO<
MC.5%)P+>63&9&PK.3#XEWRTH91VZ XBDY!59LJ06RITQW%W^HN"O471B-O/D
M66Y30$6%7;G;WF^0#JG%,Z6?NX*:IL;/PBU6G%'ICFDT9:':2KLS5N5=5RW9
MM/+^?^=.<"?^0W_]Q=H?^,<T)Y)\>;UNV;KV:63PE+$XP1^RJ\M[)1V0G+TS
MGO3-!C9 "T<H",;QRFT,4,70FD*4B^E7TF?5#]./T]>/\IB=@U#R%L.[;A)*
M^ZY.IK^J6\5/CHWFKX_7:#Y#;JL\^'KTYIIK+6J4!W;]ZZ\T95HZ<<.7.$?*
MN Y<Z,@-B-/9(^Y1O@K>S*PW5\1J]=6+9$[[R$CCYP0DXBHE.UU<_C \8]*U
M.J9XP>D3E[X2^H]@[C\_;L/[X>O[O?(PZ$X<<>N,DO8)O25(>4M[:8YI%V A
M+E=9MA*-8]R=W'F<1=AL$K' \8JJN0:2";5-\W0=O&J;@&SM=(\G\W'@(\U%
MAZ$.PG2ES$, PW9\?)+)5LR1\@-D'FKU3$YP89)H_1$(YB,8W>-A=>#O)5C0
M;F\;'=\85L]1T6]D)+NOXW9:].ME\56M",\F*F&CD\O!+!CK!S5*-E[TL]BE
M%7EM,%DI16/]@:HUEM:*/![,U_3;_$'3.G[ON-:B+&V3!3^V,@65:.3-U/@)
M56YTE"& IR&*8H"$-7/ **U\LK+<3MU[8XQ28*^T)5:$G%]C:8=*^$_B)(ZF
MV XE8M%!4PE*/R?DH4[=/Q V!,W@$MA6,F%1E7*/)+D[QX-[-ROTDG>: S(
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M+49PHU @BCHPU;MEBKE(C]W5>5D=C3*=$BG,+*,[1'0[FP7,M;2;K,Q/.+D
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MS^V9S+8V>2M-'8KR2TK]Z>N<D$\830F4;E'(+&#L[,[,8QE@6LDS@0 ?C_\
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M/;K)GYV;^<:/-QY'6((Z\M-[^4OWT2V_Q?)N2K4?[K]TA1:\)?;/E#YOMGO
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MF>V=+[;K[R5<5?C%84:Q:FM7W/"; D5*Y8!K\G5KL$FG7&S61]STTB\;]_C
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MV:VHSBT;+T[>(C:$<VO%>G)K5"TQ+Q]DCGR</.M6#R(1CW9W$BI"XTZK/&2
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MORVIWZZZU_'T3_3,?+6G?KKK7KZ!_9Z)^(_ /_7/GR(GYVMP2^J_JG^)7/\
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MC/0&#R1Y?$T<C+1N8R:U )SX_(5Y:UNI.WW9H)8IHXI. E$FCEZ",\?2:/\
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M)C/R)BAZ"8H#\>PB >GT^HYR)B@ "(@ #\!$0 !^?T'Y_3UPBYSH2G?W:_\
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M4E$;BU>T5%JAR%U*Q,"SF#\)1!#[Y%01(>2H4PH0SA;R30KCVU,(]@I8+@0
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MNYZ,E]0;[JY )<]%[$%O'72,4(3Q*RE;5 Q6%\J*WA,K'VFL'=M5VHHKO&[
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M6"!&S*/CX]DD@T9,F;=--!JT:HI-VZ)")(ID3(4H4G_<WO\ <3^!W^ >Q?\
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MI!$_;T:4 RW+]LQ>.I2@GLR\1Q$[6XT#DMIW9VV=I:4IEK;2VP-/DASW&,2
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MW2%A)R[QP$+!(7/X$8DSD+? O\,K3M6 K8 ]?:M:EM#F-6PF?E>:,(W@LY.
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M(CV]/AEX&,(J/_P;WHG_ %#J'^,7>WY5L?@WO1/^H=0_QB[V_*MEX&,(J/\
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..A$QC&$3&,81,8QA%_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g1043123.jpg
<DESCRIPTION>G1043123.JPG
<TEXT>
begin 644 g1043123.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@ _1$E32S$Q-CI;,3E:0DTQ+C$Y6D)-
M,3<V,#$N3U544%5473$R-#<V7S%?4D5$7S1#7T-/3%],24Y%+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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MK(LJ()#N=4FM>WLJ[>CWCM\!M/O;M!MA=6[;H$PZMJPIR 8^HP@!@ W=$HB
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M]]X59JWZ%$HD6]/NT[)LRDV:M^G<Y'T[M.P@B39JVD/KV$$2G*8HB [S.?\
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MB[5)A60<0B:@=C$4B N6,]GC-^,.M:[V/(?3^(WK28J[=N;5^Y1]GV4NU65
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M$;6I6LZ=3L=$V7\M#^1Z.QO!(WL;]4A,UN!6+:[%W&:]3R*/>#5L<2IP%09
M1P]#&6%T .XR8-H:@$XE#"+2QP-[6"PN7MK\>8%)Z9XX1AHY$\89[R4;-]'<
MTM?)2>U0DA;I5;<GA-Y5^BH^OM$">GH;/UI".'IG=D;?*8S(8=M+N>F]0&O=
M]G*YV+<F?I#RR>T\0F<[D$R::#ER;M+DUE7IPBM**J^6I9Q"]4/=./$:XOS"
M2S2+Q3TQZ[V%8H=&B&UP$1611G<F?9:")5K;^J/")E!\WW2_C#*Y0?-]TOXP
MPBCA8:$CKQ<M!O/K$_HRI[-TD*'D-X4621FTB7S]#EVDUF*/K& HYF*OWGTQ
M06&2 !Z@^12-O #ZX@YLJ%< CT$0ZCX?KY!$,\VVLX/]5+6(?,\QZ2-(AZW1
MR!W1>4! >O\ Q_E\@]?8];+%QH6@OX\4:HZG,<*EKY/N'8/79Z)115K0J0/Y
MA X*$VT#@(=0, @/E <[[+.P<<L%>SX!54IXO*]1_)73?=N)D?\ >T;[[33U
M ^;U3H]L5F_&,9T%W$QC&$3&,81,8QA$QC&$3&,81,8QA$QC&$3&,81,8QA$
MQC&$3&,81,8S'4MF<FCSCK1,M73":ICHR*#NC"XPM&BT[S;-I!1')(90S+14
M$+K)M/L(D.F F[6!-ISAL(7J5M=!A\!J*D5!B#FL(IJ.LKI<YU[6IZ&"HG+=
M&EPB+6_K$7"$V^X$_,LBY01 /.(!]L0#\>0IIGD7<,Y3R_;(J(DRHS+)U+4B
M-&O$[+K2:B%.;8U.19Q(V;:N<VX2ZR*%K27<BV>% -A4FSP9-NM[M@K;M>/V
M9V;D3B<LF5<L5MV-R)TV/"$O,-UX1)9+IBG'!]EL<8I;R A>B2%:#,,D2Z'1
MK:4^AR;Y \:=+>95IT;MBDEFR;RKPG*JCBKL*&(B"6-\K3783B.']RR9\#@V
M2KIHJ>1PD8[N89I79O=$ 7M%K@X7%]/*"/G6_?O%Z=>\7ITZ]>H=.G7IUZ^Q
MU\GV\ 8H]>@@/3S]! >GV^F<1SWS?Y2N? F#/J_DY<#/(&[C+R)BTUG[1<NA
M<X:7JL.V?XN\;O36T7?"5*%DLW=#Z1DLBK9EY+LFQ!OLF/;GN<*]3*YR!W;D
MF[[A'8>YE[0_D3QPI#D[/>5_%>.<8:GMR1NT_NP>2JVAN1<LM:P8KJK9FN-8
MH?)/K06%5$=;YVLK28S!_7Q#:S))"S:&IIFHI]GTBDMVF4-YA^T/XLKE#>8?
MM#^+"*/E!_3U[^_Y-?X,CF2$R/=!_3U[^_Y-?X,CF2$RG%^;;\/TBIR=^>9O
MT0N-;MB8G7:KM%T4+=IW;0,E\0B$1^TZ@XB1^A>7G)N7(WRH[+HB0/.WC2Y$
M9^0M.Q%71=C2Z*:[/C+?<L8*XJFJ>QV%QJ9,PK73L@1Z="=(FT)B'UI]*?1J
MT:]GAO"$TZ]1":B']$"*@3EUE*4X[Q'=W@'PH]_O9I:Y"\#>*//+F=--]K<@
MIPME7'A@HY[<J2JAB@M#RF$#+FR6K(@_R+D]$JZ9^3<I99ZE9'S:BA\1O5EA
MS$9E5)UK*#ALT')NL(0-9"$*)A*0I2E$YS[#"!0  [VPYC'.;H =3G,8YAZF
M,8QA$1J*"UZ=IAVA<&[-[C5)KR?H>[6Q-M:-Y&N*6C#B5NDL_61MG4R>7N>]
MQ!N>!B\ KN&-SM-;*GRUI6-<2CC<4#Z%KT[L#0Z8J>^TT=6'E&Z52LH4W]+[
M'^6=3<$7^_0LO5KE*?E#<-,L5PL#:W4VHA&G6Y50T[)E!*X?IZ:R$<A).Y5J
M,T0%WB[0ZOVG*/:"=F;QT[1.OWV-VVEDS#/-E36944&M>'3";L,@@4>M8T?4
M2W5J8&"71^*S)M='")QE>XQN<-KXP.FUC;]2Y'L3Z1U&Q @[):#,W(-AL=DO
M"TTE#M5YU%RI<.,+CI9)1'WWDO1U,LU'U_8[C;<K!ZM]0U)XY$X/*'N(+Y"Y
M$?+%AC/*E+YKUJ'AK<B*<3[MUDY/P+9L.740::GGT6PQ2  C*(L;H(B/3KT
M1Z=?6$?,&2$]'(O;B7X1J^7D>)"E3J.3L"TJ=&I3J+3<\$-:C63<3O%D\6*!
MA+L*8O>[IC!WNG7H8P>81S/WB5F]R6SX E_BLI,SKR6M;MAUW\5G(JCK69>_
M>#5[8_?T+Z?1R+VXE^$:OEX]'(O;B7X1J^7GS>)6;W);/@"7^*QXE9O<EL^
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M2@)N@ '40Z]  .O0,R1P4YWXY4=[6]25^J_]7=RK'/"I;\3JRU_7>'_6H_\
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M(" @(#YA#.-RN!$]AUX4PB8II["2F*;Z(IBFE#2!BF*/4#%, B!BB @("("
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M>&2U.$8)0XW78E1RES7 TM4UL,$X(S2)6YX>S.C?U)V.-=32MSLUL%8QY%K
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M V6O X/8K>R.NW1Z%VNC0BF+2\IFQPV)OS/L6HM6A2?1^4FVCK^AS+/BYO\
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M#*Y0?-]TOXPPB\? @ZQ-I#V=:L/_ .XK<A?'Y&L?HWS9:=H#X:,6NY21H !
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MH4==*:56P'B7/8+:,V00OM%]JOGU,U$RJ]W3\@+,=>77%RD(3!Y)'EZ&32M
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ME8F%UK^/;&_3HC\-72FP@<6T.J9+L#:FT; V^'*?3J.7=W U^&*;64Q=O<
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MUK2:R%]@I"%*4/(4H  !G!(I^EE/ZGW_ +D?._#C-ZF_C][R-4?$-AS(?8T
M'%<JK@'^;\-UB_\ 2:CJ"PKV>!(R>X.[$^S./=%%AUMRRKXA;O9<?PT\_/\
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M9U8$\(F(<N_0/T/<W:=9RF*8H&#',U'KQ_<]?E-Z*THD/0HCU-XPF:1#W0Z
M _1>B.[T /+UZ9(P/-]TWXQRQ4;RW*2M>WN7T^"X#)"\6!:^2OQUQ<T\3@ZG
MB((&MNM) V3MC'C.8\.8YKM3F/S@YI&JQ&@C58J(?$;<\/\ 74DT3=.OT3&,
MV3*8C*]6Y:OUFW2.-IF5K>'C7T4E$Z63+DVZ4(MANH[$CSHV=1 P&-*;Q&W!
MY.XJZ>;IXR<OG?W_ &<B['9>JB'+6>U^MU:T\7M**QV71M5U#5J_)$CC1L1R
M9F)J(3IL6OL.0(G[7L.8#;-43=3!WC:MG27.=W#(QZC[:(HHH9J_&S3,CTQL
M@@Q[$Z1L<=P"&P/I7P $ CM-M( )ZU(_\B(>V.D?2D4TKG7#B^-C'![N+.DC
M='-<:#VP'1J%I\1MWF[BKR?]Y.7K?X7CQ&W?W"K\(N7L]?;?LY=L9WLUOBMW
M#TXAN7:N>4[RK3XC;@\Q%7E_[Q<OG> 8VX/,15^$7+YW][V,NV,YS6^*-P].
M(;DN>4[RK1XC;O[A5[/U2<O7\_\ TO\ GY_/CQ&W?W"KR>4/ZY.7SO\ GYO-
MEWQG&:WQ6[AZ<0W)<\IWE6CQ$V]>O<5=?/\ 5)R]GK[;]G'B-N\OT"KR_P#>
M3E\[^QY?9]?+OC&:WQ6[AZ<0W)<\IWE6CQ&W>7Z!5Y?/_7%R];_"\>(FWR_0
M*O+Y_P"N3E\[R[XQFM\5NX>G$-R7/*=Y5I\1MW]PK_"3E\[RGB-N_N%7FZ?5
M)R\P>;_I>7?&,UOBMW#TXAN2YY3O*M'B-N_N%7FZ?5)R\WPO_P"./$;=YNXJ
M\W3ZI.7VO;?L9=\9SFM\4;AZ<02YY3O*M'B-N\GT"KR>0/ZY.7V/_>_L!E08
MVX/,15^$7+UO\+R[8SC-;XK=P].(;DN>4[RK3XC;O[A5^$G+YWE/$3;TZ=Q5
MT_7)R^=Y=\8S6^*W</3B&Y+GE.\JT QMP>8BK\).7VO;?L8\1-HAT[BKS]?J
MDY>?X7EWQC-;XK=P].(;DN>4[RK1XC;NH#W%74/^\G+YWCQ&W?W"KS]?JDY>
M?X7_ #'R^?+OC&:WQ6[AZ<0W)<\IWE6CQ&W>7Z!5Y?/_ %R<OG>/$;=_<*OP
MDY>M_A>7?&,UOBMW#TXAN2YY3O*M'B-N_N%7X2<@]GV%?V1QXB;1_P"0J]CZ
MI.7D^U^:_)EWQG.:WQ1N'IQ!+GE.\JT>(VX?^0J\W3ZI.7F^%X\1MP_\A5YN
MGU2<O,/^%Y=\8S6^*-P].()<\IWE6@6)M'SD5?A)R^=Y0S&W=!^@5>0/=)R]
M;S?]+];^?GR\90WF'[0_BSC-;XK=P].(;DN>4[RH\T 0NI7>FLG>[I+ZFA2]
MXYSFZ V1SIWCG,8YQ_\ :,8QA]<<D/D>Z#^GKW]_R:_P9',D)D8OS;?A^D5*
M3OCS-^B%PH<UF2_9OR.D>RZ:OM>=<@N,48X^0:O[BO+C9V-,:C-J26=3V4,=
M5V%:4JFUS:M4%JZ=VQL+%ZD(EB%O,S7(F9<MC\)C-EJ72+[^ZE.&PNC47<8I
MMP:R!M,42B!MH% -I@$I-8#UV]\1$"$\H_V!?,'*YVO-87W6EA<P[=C5576L
MX6771M5CSK=H1+N#JKT^P:JV->P+20O==[@6XZEW,,.6'8I8Y,<8FF@^C::9
M5.W1JP@6/BSJ@1@0$J<-8 ! T:>X ;A4% G@B=P"J!$1WE*7H4-PB8=H &P3
M")A$:B@OIQC&$4=7OU44#]YN>_&F*Y(K(ZO?JHH'[S<]^-,5R164X]<O[0_0
M8IOU,]H/G<N>/M9O5$0WWH6GXW2O-0CQ_;Y!OUJGO[TC>;>^UF]41#?>A:?C
M=*\U"/']OD&_6J>?O6-YMUDCX$9.?X3]LTZU,RG\-<HO\4^QYE*'C9ZHJAO?
M@KOXT-N=>V<A/&SU15#>_!7?QH;<Z]LQCPT>RN"^]\_UDK)7 U[&XQ[NA^KA
M,8QF%UF9,8QA$QC&$3.?CM<?KYUI[TW^N+[G0/G/QVN/U\ZT]Z;_ %Q?<R/P
M4^&5'[DK_JSECKA3\#JSW7A_UN-:ILR13?UWZG]\ZOOC>S9C?,D4W]=^I_?.
MK[XWLV;/5_K&M]R5/F7K6>@]?47NNF\\Q3V[?'ZF\6_UTN']YP+.<G.C;M\?
MJ;Q;_72X?WG LYR<\&N&_P#2;E)_A'V#A:_3CV)WZ!,B/VF4W^;,<7XJ?I93
M^I]_[D?._#C-ZF_C][R-4?$-AS@/4_2RG]3[_P!R/G?AQF]3?Q^]Y&J/B&PY
MD3L9_97*KWOPWZS4K"G9X>#W!U[\X_\ 4<.6;L8QFWB\UDQC&$6D#M@OJC0?
MZDL?]WAN:7LW0]L%]4:#_4EC_N\-S2]FVO!IX$X+S5_VG6K5'A)\,\9]M1?9
ME"O9UO\ 7&KO^_\ A'QI:,VS=NUZG:HO?OU?$*89J9K?ZXU=_P!_\(^-+1FV
M;MVO4[5%[]^KXA3#-<^S'\ JOWHJ_M+"EM;V!?Z9<F/[QT?V9BJY;LH;S#]H
M?Q97*&\P_:'\6>/[=8YQ\Z_1$W6.<?.N[/@_ZCWC'[QM:_%9NR4V19X/^H]X
MQ^\;6OQ6;LE-GI]DYX/8#[S87]1@7@)EKX996_WFQ[[5JU'JO_5 <@OUJI_X
MO/F2%R/5?^J Y!?K53_Q>?,D+EVC[T^WD\XY?.2=\/:1^;:F,8R:@F,8PB8Q
MC")GE)T$D&%2X(<UL;W+!C$@",,\F/LUQQUD0LZWQ&VO^S4)=I&5>Z^A$;L?
M4/A"M^Y2).A@ 0]7F.+BU-6^IK-TOLE"&,FVO9MJ>)>+JJ8@BK7LB[L1PD@O
M:'9I6LX,*,VYV%U2;=2IO!&*Q/L)NTZS 1<V/8RT@QU1R8A+O6?&63T^_/O"
MEX:><+A95"?D+HXMR=2V=#7+5'>/&]=,Y,1/"I!NV2EAEM;5,AVTHT0^IJ9D
M6J3ZI#L0-;KU*YRG=A-J:X!<44KU\XI\4J*7NO$$5-07U"NSWLCB5=G+VOH8
M]56TO%D)K4F4TE&J>L[HE7PV>V;$I0V0VRG-ZF,+L%;%DJ'8Z:F_JQPB90?-
M]TOXPRN4'S?=+^,,(H^R#INJB,-WD$7:;P-M[I@$>\7;9K7NW%Z#U'J.A/NZ
M=?-TZ^8,D'_/[^1T>?RR*4^G 1'T3:L7\A>H]X$3D_N@]>GK%! )QZ^0.[U'
M,,SWG]55>\O8)Q!=VEYV269(&CP\QUK&C7'8](),F<5<6C;DEW*2N>Q6]:&\
MHBHUD(1)M<6G6.K>568^KYB*MI:7&,3GJYF0-?%@.%Q.?<!\SA75$48(!.<Y
MU:=)LUH!<XAH)%\P/)O'<IZK$*; ,-J<4GPW"\0QNNBI@PNI\*PR/MU=6O#W
MMO' QS+M:72R/<R*)DDKV,-KY@21FJW:^W&X["HU%6--56VUJ2D.*A3NA]AN
MD)D\>2CK#Z-3-H19CI#TNHYM>CT8ZI-RG=HT:3;M<NJ>MF%7G6T4M:O%RAQB
M$Q;]B]HWK$FU NU@F6*6Y:B7H=_Y:D7MS@C5(5J<PG#6I3[ U[-NH2;#XWNV
MN839\@CT#L!EU/\ $++AD_@+XU;]JC011W-D9FK;LU[TNW2H2K$"B+J%Z)6G
MVZE*18FT[M!RF(/7Y^&30SL'%FBV=B;4S4WH*\9-(I$I!)K,X=S:9X6[ ,8Q
MCJG-W,N<ENTQA-N6*]^T1^CZ!]1@[J%V3^,4I;5'$\(RSJ(V2$Q^HQAN.87!
MC9A TRF<5\U1-^K$P3RZ'/D.;\6T5D>.O =!^#JG#2\LS7^J37TM3$QTA=HC
M[2ZEJHH].=(71,'<MC[J3>,8SA7A,8QA$QC&$3&,81,8QA$QC&$3&,81,8QA
M$QC&$3&,81,8QA$QC&$3&,81,8QA$RAO,/VA_%E<H;S#]H?Q811\H/Z>O?W_
M ":_P9',D)D>Z#^GKW]_R:_P9',D)E.+\VWX?I%3D[\\S?HA<1O.+B1R7:N3
M]PN=KRM1R-Y/,,.HASX4V$]=C3Q[O/\ IBI0<13J([*;EC%:N$'J1KJJ:>AH
MTN"9+X[MKQ@4(;27JY0SK6]DU=MB<-@:=0;1 VT-9 VF 0$#;0* ;3 8-6@#
M ;9WC 8-.H# />#60! H<5':H0VFK/[5"WXG-^6/$7CT];JKI*$N<CY?+)I&
M+AB4>M>$Z$#$]\,E\5DQVF7-U<26-Z[>B3<ZJZO<8CRL,=]DKA+XEMCVG5VL
M:2>"U$UCL/M$A0(.W8)1V;!*'='9L$A2%'8<0$VP2D*43B82E* @ 5%!1FY+
M\RN-7#]LBSIR'M!O@!)KOD6J*-FMAE\QDKZEAS*,CFKV@B, CLKE6V+09@[C
MU.Y>9F)%H2U;TJ^4O#0F6)-F[R[+V@7#B1W7%^/4?OV$OEJS1EBCY%F=H\=N
M3"]Z9Y ]]IP9H0V"C9]U<'E\TK%,HLB)00\NUS:20#1MF;-'EL<(+CD1>UGB
M?-.PXQ5]=<1./BBQ6:>:;)B'(JXH385#UOR!K2DI&RM2!_KOCO*KP<D[1$IG
M=RHJ1JDEA^+7W1!8I&E+DU,*Z<[H@Z1^$M<< N43):M=U?'N-D8ICC>LYU\.
M^T"239';4'>]]!0WC]Q%JJI''B"OB[8ZKI7,)ZS3"GFB M,^BQWJMI%6TI>I
M$NE"1S1'87@BWH/8@/**!B ]0&FYZ("'F$/33%?+DBLC7(T^W=R;@.K4KWHC
MA3<[Z[DI4IC] D\7*) !6F5:NX(B!NO@@/U*7NG*'> <\>*5_P"F-X_R+'_(
M^46$ATEFD_E-8+?%9RD%3?J9I_4'+RG9Z6YES_\ :S>J(AOO0M/QNE>:F'&,
MI'-[:'_:X/J98RZU&I'H0.VQ(W'UK#Z3+2*T)=)R*BK2)T^A5WSE':GT:M0"
M3NB8VUWM6T^U-R$AQ-RU2N,-1M)@VJB)";"AZ:Y27P8 C2I-7<ZE$X".L3]X
MQNIQ#H :Q<W$R'BCGR-R?;*P.:*2*0-=8V?%4/DC=H)&<Q[6N:0=#@"-(6H>
M6<TD&6&4#X9"QQJY8RYN@F.2GCCD;I'>O8YS7#C:XM.@D+-7&SU15#>_!7?Q
MH;<Z]LY!N.!#;.0M%:R[#Z3'MVOB%W:PUCLU&-)VT V$#:39K$Y!\I0V:SD$
M0^B*8.H#UO"U+A$1],;QY1$>G@6/R=1\WD9P#R?:S%'#22,5P6S2?YOGU$?U
MG:0LJ<#7L9C.FW\NAT:?ZN+GX/X*]XRQ^*5_Z8WC_(L?\CX\4K_TQO'^18_Y
M'S"N<[Q';V_O<_H=&9OA'3U>ECLO?,98_%*_],;Q_D6/^1\>*5_Z8WC_ "+'
M_(^,YWB.WM_>Y_0Z'PCIZO2QV7OF,L?BE?\ IC>/\BQ_R/CQ2O\ TQO'^18_
MY'QG.\1V]O[W/Z'0^$=/5Z6.R]\SGX[7'Z^=:>]-_KB^YOK\4K_TQO'^18_Y
M'S03VLJ;<FN^MB;ERI>8U4=X-JHB0AR!Z<'T.X4$:5)K$O7R]3D,?J(_1]WH
M 9(X*"3EE1W:1_)*_22#_1G:-!)Z/NQSPI^!U9I_I>'\O]:CV+5CF2*;^N_4
M_OG5]\;V;,;YD:GBB:W:I*4YM9C69 "AL(!1.032YG #E Y3D$Q!$#% Y#%$
M0#O%,7J4=H*_UC6^Y*GS+UK/0>OJ+W73>>8I\=OC]3>+?ZZ7#^\X%G.3G13V
M\Z7>G;N, [G%8N#8ZV^)2JB(2!I[J2"B/@_0:)((]X# 4WA._P"0H=T2^7O<
MZV>#/#=IX3,H]!'L1H-O["POD)&W7QCCN!^G'L3OT"Y$_M,IO\V8XOQ4_2RG
M]3[_ -R/G?AQF]3?Q^]Y&J/B&PYP'J/I=1^I]_[D?.]CC8V+=G'2@MA']UTE
M/2E5&+JUZ682:P&",'0A!V-)]@E+Y@'9LV'Z '>.8>HYD3L:21BN55FD_P W
MX;JMH_E-3RD>G(L*]GAX/<'>D#^><>Y?ZEAW(.+^%U(;&6/Q2O\ TQO'^18_
MY'QXI7_IC>/\BQ_R/FW6<[Q';V_O<_H='FM\(Z>KTL=E[YC+'XI7_IC>/\BQ
M_P CX\4K_P!,;Q_D6/\ D?&<[Q';V_O<_H=#X1T]7I8[+Z7.V"^J-!_J2Q_W
M>&YI>S<IVNR7>F<*&#<X*UXF26+W15D1$'7W5$0$>YZ"1I 'O]X -X0-@AW"
M]T2AU =->;;\&>G(G!;BVBOT&W]IUO)<=*U0X2?#/&?;4/V91+V=;_7&KO\
MO_A'QI:,VS=NUZG:HO?OU?$*89J7KHHFL2OB@82":>PHH'+T$Q!-*&D .4#
M8HF((]XH&*8O4 [Q3!U =K7;H)%"?CS4A]KFM6E-=Y.FM21O*0G>@<N$!**1
M"E.(E HE#O',7H8W4HF[I@UT[,?P"J]!]B*O3HT?SEA6V^ZZVN[ O],N3&FW
M^\='HTZ?YLQ;TT\JY?,H;S#]H?Q97*&\P_:'\6>/XUCG'SK]$+=8YQ\Z[L^#
M_J/>,?O&UK\5F[)39$+A,VK-O$'C,<CZZ)RFH^MS!IU:F@=>L#1E 8"$'<U[
M=HE( @0H[-AS]TH=XPCU')0^*5_Z8WC_ "+'_(^>GF3KC^+^!=P3_,V%Z;M_
MJ-/Y7/Z'1X"Y:C_?+*W2/";'N7^U:K9Z6YKX6K_U0'(+]:J?^+SYDA<CG6VK
M9HOOD!JVJ=RLY6JH.JA05.7:?K'WP0 P)=";2 %\P=W44>G]D)C=1&1F7B/O
M3Q=W)H_\QW)H7S<G?#VD?FVIC&,FH)C&,(F,8PB9X2T"+]E;3\C7#T%@N9X3
M+"-T#==^E,V35<:/.14<1<5*C0JT)T$F4#J8UF_<F4:M29?M.?1M*4=9O=Y!
M'M'^4<\X><5)==]=QR)N[ZTRFMXRJDEC)9POJRJ6"=3MCB4@N2U6^LVUVL!Q
MKJLFMT42:3H8FCUN*E*FUD4.C U"XOS:1:6NQR0LAN2U+^E1#<-E.<*[/]T@
M5]?DQUYSIA[7P,N9+8E;+]G&JE%W+J:2*,-<$FK=M4Q ]:Q),^3QH;N-C#+7
M2?K8+(62-MG4GG/GV6':KW]S=O48!93=Q_%O>:BLRQ)+5]0Q2\6*V.(3[7MH
MQ6 0Z+<C'JX-[8@D'],9'GYQL:JM3?!ZWE+>RL2LHQ>4QL-LQ3]!8AU#H ]/
M-][KY?,(=!$.H /K#Y?6PBP1..3W'^M;-04[/;8AL3LEPJ:?7L2+/;F")4AI
MVKU38CG=DOJP^OQ7&HA'U+LFT[WF1+VM,L/I=/%AEQ61Z,WV+C1R_P"./,*,
M/LNXYV@U6.S1=W;6:1$TM,GC#VRJWIA;)9'5#E%ILQQF4)&>611X:Y3#9#M9
MBL$RC+@CD$6<W=HWD6#H+Y$]COS:L7EC>5JHKOH^Q&OE/Q?[2VFYU9TAIQ[B
M<O@<;Y%0>JH+QLX^;U WS)3O%?UPV1<NF,R"+0)$V1[6W6W(9A%Y--[K3/;#
MLP[/VG.1:*Z>2W)[D/33-QQ=;BK/B'3$?I=KL&(V(I3$XT0ZQ=<GL1R=H#M<
M8EH22N46POC$(2ZGA3(1K^!1Y;)VR-."\D=;B*3-GSYLK>O*^F3L05"*(JYQ
M-3H=9^YN=5$:A\U*TM"4>YLZK'A^=&EH1% ACG6+TY"%,8P!ENK_ (>50ZU\
MW*[MK.$S>WI>Q2)?:$Q=V)N5R/?)[*.1WFK>VR0A!=$2!E6&3L$54(%FA2QM
M,?9@:=R/8F*88S6-'+5E?*+CRQ'KB<S&I@UL+T:1(T>A56L>,RRA]>)&>5[3
M[]:) ZMZ]N853>E<$ZM3(C UZT/A02[M*;:L"-PZ!_7?<'D#J'H-%UZ^OU_*
M?/U\_3R9\+D^9\4Q?*V3$<'GI:>DQJ.BP\UK(WQU\$6$82Q]? UW<.ADEA/J
M=X#G,#I07!SWL;]@S$,6R;PFGBHIJK":W&:G\*OQ&@Q&-DM3A<,'J?#H(Y*"
MJ=4TS6U4V+&NIJ@0F69E*V2(341S8-1F32B)R2.4Y93JK?9K2\_ASM#9PZ[-
M?C"T*2GAUU9,LJ<-H%U>BI;%763I879&PFKKN>$;-)]P:=,R2Z]>;^)?7^ET
MJ@#><(T8OGZ_V+HY%  'V    .GDZ= #R9B_FK"MIZQ26L@=W!'-:>?&N11U
MU1($AP,U.;NU-LI8'K44A!41EU1>A'%<4QR@WNK$R/\ K$JEGTG+[GB."Y9Q
MRJG850L;PTQ]0C#5O2I#&4 B>71,1PUB;03\S.)-95B7N%\'Z'VZ^X?:7IL/
MW<)QBDH,I,>R0D-0:ZNH,"RIHR8I'Q2T=*_%<#K#-5'\DVHI\["*=D3GNEGB
M::@DD2 6+'GTV(XE0XU2,9 ^KP^J&+T\<#H:>#&'3T;9I*0,C;3BGQ&. 8B(
M(.ULHIZF>BCIXJ6"E=+*'&6OT&X>Z^[X&B_B?Y_LX]!N'NON^!HOXK/J[GQ3
MO;LT:^?=M5ML.4=/4KIC+7Z#</=?=\#1?Q.5%&X>L[[O@:+R?M.+GQ3O&S;S
M[MJ6'*.GJ5SQEK]!N'NON^!HOXK'H-P]U]WP-%][_BO_ (_9Q<^*=XV;>?=M
M2PY1T]2NF,MGH-P]U]WP-%_%!_/['DQZ#<.GU7W?;]!HOXKIB[O$.]NS;M.[
M:EARCIZE<\9:_0;A[K[O@:+^*ROH-P]U]WP-%_%>?]C[&+GQ3O;LV\^[:EAR
MCIZE<\9; 1N'KN^X?-_T1%]W_FO7_F&4]!N'NON^!HOXK )XVD?"W9MY]VU+
M#E'3U*Z8RU^@W#W7W? T7\5CT&X>Z^[S#_T-%]__ (GUL7/BG>-FWGW;4L.4
M=/4KIC+9Z#</=?=\$1?Q/^W'H-P]U]WP-%Y?VK\6+GQ3O;LV\^[:EARCIZE<
M\9;/0;A[K[O@B+^)\W[/G\OL/0;AY/Z[[OL_F1%Y?VGR8N?%.\;-O/NVI8<H
MZ>I7/&6OT&X>Z^[X&B^]_P 5_P#'[./0;A[K[O@:+V>OZ%]S[7V?+BYXFG>.
ML^@2PY1T]2NF,M?H-P]U]WP-%_$_Z?M]<KZ#</+_ %WW?8_,B+R?M.+GQ3O;
MHU;>?=M2VT=/4KGC+8*-P]U]P?X&B_BL>@W#W7W? T7\5BY\4[V[-O/NYDL.
M4=/4KGC+7Z#</=?=\#1?Q6/0;A[K[O@:+[/_ .Q_GT\PXN?%(^$;-O/NVI8<
MHZ>I73&6OT&X>Z^[X&B_BLKZ#</=?=YO::+[_P#Q6+GQ3O&S;Q:=VW0L.4=/
M4KGE#>8?M#^++;Z#</=?=]KT&B_BONY04:\ 'J[[A\@_]$1!_P#\<7/BG>W9
MM&W=M2VT=/4L'T']/7O[_DU_@R.9(3(\T"!BJ[T*8X[#!?<T QQ I1./BR.=
M3"!0 H"/L%  ^QDALC%^;;\/TBI2=\>9OT0N?SG7VU&GB#RAF](::/JZ6LE7
MUTGFTM7SF_&"L[6FSD$/8K,\0T]7#K#'8LH2N4&7N48KB0.$C2);2OY!NI&.
M)$+JUO#TDW_Z=GAM6O:!3D#80IP)L(;7L*!@ P%V:S@!]>PH#TV:S !B' Q!
M\I1SD+YK<NJ$LWGY1UM<>N6/#-C'1%Z1ES+9W-BT.+EK\>Y%%U,H?T:,G%:G
M K^7<N6FSRO#<O(OF]>W!Q[KY1,T.D70\L=6_=O3=>X>;UO.;S?;']GV?L]<
MJ*"KC&,(HZO?JHH'[S<]^-,5R161U>_510/WFY[\:8KDBLIQZY?VA^@Q3?J9
M[0?.Y<\?:S>J(AOO0M/QNE>:N\VB=K-ZHB&^]"T_&Z5YJ[S<;(+P/P#W"WSL
MBT^RX\+<>]W'S,2S5QL]450WOP5W\:&W.O;.0GC9ZHJAO?@KOXT-N=>V8EX:
M/97!?>^?ZR5EC@:]C<8]W0_5PF,8S"ZS,F,8PB8QC")G/QVN/U\ZT]Z;_7%]
MSH'SGX[7'Z^=:>]-_KB^YD?@I\,J/W)7_5G+'7"GX'5GNO#_ *W&M4V9(IOZ
M[]3^^=7WQO9LQOF2*;^N_4_OG5]\;V;-GJ_UC6^Y*GS+UK/0>OJ+W73>>8I[
M=OC]3>+?ZZ7#^\X%G.3G1MV^/U-XM_KI</[S@6<Y.>#7#?\ I-RD_P (^P<+
M7Z<>Q._0)D1^TRF_S9CB_%3]+*?U/O\ W(^=^'&;U-_'[WD:H^(;#G >I^EE
M/ZGW_N1\[\.,WJ;^/WO(U1\0V',B=C/[*Y5>]^&_6:E84[/#P>X.O?G'_J.'
M+-V,8S;Q>:R8QC"+2!VP7U1H/]26/^[PW-+V;H>V"^J-!_J2Q_W>&YI>S;7@
MT\"<%YJ_[3K5JCPD^&>,^VHOLRA7LZW^N-7?]_\ "/C2T9MF[=KU.U1>_?J^
M(4PS4S6_UQJ[_O\ X1\:6C-LW;M>IVJ+W[]7Q"F&:Y]F/X!5?O15_:6%+:WL
M"_TRY,?WCH_LS%5RW90WF'[0_BRN4-YA^T/XL\?VZQSCYU^B)NL<X^==V?!_
MU'O&/WC:U^*S=DILBSP?]1[QC]XVM?BLW9*;/3[)SP>P'WFPOZC O 3+7PRR
MM_O-CWVK5J/5?^J Y!?K53_Q>?,D+D>J_P#5 <@OUJI_XO/F2%R[1]Z?;R><
M<OG).^'M(_-M3&,9-03&,81,8QA$R)?-ACD4LH&00B#<JG/AI94\D$+A55WF
MTML-?5;39TEE#<V0:+#&YR@6L\G33Q^W)8DKCJ;:U/SNG=-B6//;.[F2K=<M
M,C3ROX[Q+DO5!(/+I_/ZKUQB<UY;D=LBLGB+,<RA$TJ&6ML^B,C;%\WBLUB0
M:VU[9DV]>GD$9=6M6A#>G5Z U;#'*1:3.Q*M*36+R/YOH;4YN/=Y6A%Y)&&-
M%4S?R/K>^:N?8E$85 :\E=]UPL8J<JN2[(V-M1:50A =.V,:2,;]Z^,SQHDD
MS!//'_I)S2-V='%AIIZVT,1DTJNDJ/@?74UX0<0F6W-M=M2>YZ-=VV@;GL?E
M#%],5J^N7J::5SP^5W02U8C<957D9/3A5J(4<WF4FV9NYPB90?-]TOXPRN4'
MS?=+^,,(O'0$ ]*;1]@BOV?=%;_,/8];/99XZ >2)M =>OT"OR__ ,16_B\V
M>QR+.\;[5OS!2=WSN+NCH^%?EOU:M^G;HW:]>[3N(;3MU;B%V:MNK: Z]FO9
MK.!B'U["&,0Y#%$IBB)3 ("(9KJ[-*T'&7<?(Y&9&H'<ZLBN<DCZC881,X19
MAL:31/=HZCU[RJ..[:*%;I*(%3(')@.!":U>HH;&3>;[I?\ _8,U1\*XPO+7
MUE,$5\ CG5/WI+I+"M"PPITBQGF:1'L?(JYF HFTL4K=FF3(=^\ V"@=TJ)Y
M[NU4T!IRT8W33104>.4D3YZS"\093&GB%Y:S#:^BKI\2HHQK?,YN&05M+&"T
M2UU#2PN>R.5[A<Z)HJ,/QFG#07TE-28UG'6(:7$*7!I6-/$))<H*9[@.^,$=
M^]!&UW&>1A4S:IPRE=FTJA)O3J=[8]LKAK#0\1Q]1=TKDPO20#&%*Y(-A@ X
M 8^A4G/H7H=RA J3*-OKLN5+54];3PU=),R>GJ(VRPS1F['L<+@CC!XBUP#F
MN!:X!P(%JUIC&,KHF,8PB8QC")C&,(F,8PB8QC")C&,(F,8PB8QC")C&,(F,
M8PB8QC")C&,(F4-YA^T/XLKE#>8?M#^+"*/E!_3U[^_Y-?X,CF2$R/=!_3U[
M^_Y-?X,CF2$RG%^;;\/TBIR=^>9OT0N(OM"+4D'%7E9?=7I+WYWV'6>C=#'R
MR26'VJ$%X_-1M9:A0W&J@\#@B?B9/++D4*<:N0/39#71MMJ&3:VIG![.K:'.
M"N;18SRX]N)# <H&#KT-Y0Z@(#T'RE'H( (=2B ]!#J'7H;Z+KG%QV@%TM/'
MKE?,J9G=M7S>K53\;@,_?W.\[ZX.L=JSN20QD8KOB;!4U;R;@-)ULJ1M[%*G
MYIII^62AM43'D0=\J>O-<;?3O\GT]H^LP'(4P ( ;Z( ,42&#O>7H8ABE,0P
M=>AB& #%, E-U, B-107]XQC"*.KWZJ*!^\W/?C3%<D5D=7OU44#]YN>_&F*
MY(K*<>N7]H?H,4WZF>T'SN7/'VLWJB(;[T+3\;I7FKO-HG:S>J(AOO0M/QNE
M>:N\W&R"\#\ ]PM\[(M/LN/"W'O=Q\S$LU<;/5%4-[\%=_&AMSKVSD)XV>J*
MH;WX*[^-#;G7MF)>&CV5P7WOG^LE98X&O8W&/=T/U<)C&,PNLS)C&,(F,8PB
M9S\=KC]?.M/>F_UQ?<Z!\Y^.UQ^OG6GO3?ZXON9'X*?#*C]R5_U9RQUPI^!U
M9[KP_P"MQK5-F2*;^N_4_OG5]\;V;,;YDBF_KOU/[YU??&]FS9ZO]8UON2I\
MR]:ST'KZB]UTWGF*>W;X_4WBW^NEP_O.!9SDYT;=OC]3>+?ZZ7#^\X%G.3G@
MUPW_ *3<I/\ "/L'"U^G'L3OT"9$?M,IO\V8XOQ4_2RG]3[_ -R/G?AQF]3?
MQ^]Y&J/B&PYP'J?I93^I]_[D?._#C-ZF_C][R-4?$-AS(G8S^RN57O?AOUFI
M6%.SP\'N#KWYQ_ZCARS=C&,V\7FLF,8PBT@=L%]4:#_4EC_N\-S2]FZ'M@OJ
MC0?ZDL?]WAN:7LVUX-/ G!>:O^TZU:H\)/AGC/MJ+[,H5[.M_KC5W_?_  CX
MTM&;9NW:]3M47OWZOB%,,U,UO]<:N_[_ .$?&EHS;-V[7J=JB]^_5\0IAFN?
M9C^ 57[T5?VEA2VM[ O],N3']XZ/[,Q5<MV4-YA^T/XLKE#>8?M#^+/']NL<
MX^=?HB;K'./G7=GP?]1[QC]XVM?BLW9*;(L\'_4>\8_>-K7XK-V2FST^R<\'
ML!]YL+^HP+P$RU\,LK?[S8]]JU:CU7_J@.07ZU4_\7GS)"Y'JO\ U0'(+]:J
M?^+SYDA<NT?>GV\GG'+YR3OA[2/S;4QC&34$QC&$3&,81,U"=MDPNCOPX8')
M;#(]8]-P;DYQALOD_7DPL2G:OB$YXV5W:[1*[-BTHD]]SNM:IV,CN#:R)E4?
ME\Q:FJ4&-ICZH%:9?O1[MO>:Y>T[H&T+^H.#IZHDE(QY]ISD?Q_Y).FGD<[/
M[)2DCCM!3Q/8CC&[ =(ZQR%:A9EJEK;U@+-K7M1HE;<G6J-FGT-KV%(M;782
M4<6OD"VPGKA9942>Y[")P-?<PI;R8XV<EJT3\;MMPN3]07%'CBY53R%N!^@=
M-PRN'.-;T\<BK&S5\Y22'.[B]/3PZZ(OL/T?YSF]BER)L!PFUD<46:4\/+FH
MZO7/D;:^ZT^$C1R/E-/0:R+=Y![;;_(;3W+,*QB''9SU,R:W)"DCT/K:6R>5
M:F*-)W5U;VA.1=X7HRPB90?-]TOXPRN4'S?=+^,,(O'0#^U)H_\  K]GW16^
MSY<]EGCH#_:FT_\ @5_PBMSV.19WC?:M^8*3N^=[8_.J#YA^QY?O>7-<?'7<
M,(Y.6G%=XE3:)PKMU(74<>Z7QY6]M++&;-&OS=[>OKCDBQ*M91 O5*R;^YWM
M:<>[L=S6M>7HFLKLE5AI->_8:(*JVY/:]*9(.[>OAK0UK^/_ "82I@)T/N!C
MJY7!YB=-K*8V]R0-A^AMI=896>,[#Z\B^=1BEQ1@&ESA25#8*JS?ULW#*W$)
M+#3W%]5U<\ (?C5+A[B S'Z7$,G;$V:ZJQ"G]4X*U[M4;'928?@@DD=W+&9Q
M-E-26UXL5/(S>!N^N)SP-&A,M4[4IED=EZ%( ^A6F:-&K:G.NTIRB;4W/2'>
MED#,4YBHUFU&;<W[\53SD^GI]I2[;7KZ6,COO7:4.@(_Z!D4;>  IMJQ<PR(
M5" NS6D2ZSJMC6\(6E[[IB:]:+>4-F\DHDJE.L3)U:3?J5)5.G4H3*=&PF[0
MI3[M9=NA1IW:Q-KVZM^HY-NO80QB'(<IBB(" YYR80:(3]LTLTTCK5)6M.O3
M.>A"[I2*T^I>C$WH=40A^G=VD+LV:Q$! -FK9LT[ /JV'(;XW&L#Q84V(5&1
M^)PX+C%6U\K65<#:O!*BKD<TNJJJB[6]\%0YN>YU30NB,\KA+70UN:UHM+VN
M&<!W+P2"' Z'#00X'2"+6(T&^M?='9,P2UI2/D;=D#RU+=.K=H6MRO0KTB7;
MJ)M ASI]FPNK<0IP#;IV"7;J.!B'*4P"&7W,2O-(UTZK3.Z)EV1*0B40+)(*
MO60Q[ZCY.]O51_:BU+PZ  #J<TZW2<  NS68ODRU&8+KB8":.S!BL=MU '=9
M[!0%89".K4'DTIYE%4I4&W:<H=/"NL3WG.?R[50 )C!V6XGC="T#%<%-6QK1
MGUV 3BL;9H&=+-AM4VDKXLXZ6T] ,7DX@YR7(UC=IZ->ZZS?C,'ENQ*Q &NS
MH=*ZVVDZ!M='!%Z8H:)S#]".J81DK@@TZS%^B SRG9CE !\)K)T'IEEED#%)
M$.MTCSRUOC;N_P"*7M#@D<D9_)U^A4H]N[5UZ><HG P>80 ?)EPH,<PG$Y'0
MT=;$^J8W.EH9@^EQ&%O+48=5L@KJ<?MZ>- 0>K4?A!TA7?&,9=5RF,8PB8QC
M")C&,(F,8PB8QC")C&,(F,8PB8QC")C&,(F,8PB90WF'[0_BRN4-YA^T/XL(
MH^4']/7O[_DU_@R.9(3(]T']/7O[_DU_@R.9(3*<7YMOP_2*G)WYYF_1"X'.
M-?,%?S9M'C.]<L^?M305[FM),MRWI9-A<9Z":^0?%Z[&B\GN-L?$WA!:#Q4C
M8[TDFL"(.D;E<C?9":WI]##13?*X,^L+[8.]U:N^(/M]?*/L>R/4/( >;S>S
MY/*(CY<IW0]DW^.?Y6?UE103&,811MDI59N3L#!'M3ZMWY#L]'OJM&Q1J[OI
MGB_T/@]2A*?O";N?1>%Z 4#!W#"("&=_!2/VZR?@M?\ RQF$'OU44#]YN>_&
MF*Y(K*3!<R:3^<XB1^JP\7-N)51QL&:!W@U^V/5TE<[/:ME6EY"0X%VU+NW?
MD2-(E,D3[4VL-?IKE7T(DW*51A/W^\/>#8!1*)0[@" B.L7-HG:S>J(AOO0M
M/QNE>:N\W'R"\#\ ]PM\[(M/<N#?*['M7KXZA;_J8EF?C@&P>0U%!I$A=PV[
M7P:C;2F/K+L],[;W#;"$/K,<@&Z"8A=FLQ@Z@!RB(&#K>\%(_;S)]C^M:_S>
MM_UQG))QL]450WOP5W\:&W.O;,2<-(OBN"Z3['SZB1_2=GIK66>!HVPW&= /
M\NAU[(!\_&K)X*1^W63\%K_Y8QX*1^W63\%K_P"6,O>,PMFCE=\8[-NSI/*L
MS7V#=S=72>563P4C]NLGX+7_ ,L8\%(_;K)^"U_\L9>\8S1RN^,=FW9TGE2^
MP;N;JZ3RJR>"D?MUD_!:_P#EC'@I'[=9/P6O_EC+WC&:.5WQCLV[.D\J7V#=
MS=72>563P4C]NLGX+7_RQF@GM9BKBW?6P+]J3=M_(HZD,D3[DVL">G!]\AB;
ME*HQC][J/> Y0Z" =WJ'4>A'.?CM<?KYUI[TW^N+[F2."EMLLJ/2X_R2OUN)
M_HSAR[-Y*QSPJ'_<ZLU>N\/^M1C_ $WDK5-F1J= XV[5(:Q*4_Y)D [ACE,<
M@']-S/W!.4IB&,0#=!,4IRF$H" &*(@(8YS)%-_7?J?WSJ^^-[-FS]?ZQK?<
ME3YEZUGH/7U%[KIO/,4ZNWG*X%;N,'HW>BW%%UM_P/H5+O3&*7T)!.^.WPRQ
M6!Q$O<[O<[G=-WNO> 0[O.KG1MV^/U-XM_KI</[S@6<Y.>#/#<+<)F48N3[$
M:S<^P6%G7\.X <2_3CV)WZ!<B?VF4W^;,<7XJ/I=1^I]_P"Y'SO9XUZW\>.E
M!#I6,Y=(TI50ZB[6U8;84GI$8>Z!SD==93F /()BZ]8"/40(4!  X)E/TLI_
M4^_]R/G?AQF]3?Q^]Y&J/B&PYD3L:!?%<JM?L?ANHD?TFIY%A7L\#;)[@ZU>
MS./:Q_P6'+*?@I'[=9/P6O\ Y8QX*1^W63\%K_Y8R]XS;O-'*[XQV;=G2>5>
M:U]@W<W5TGE5D\%(_;K)^"U_\L8\%(_;K)^"U_\ +&7O&,T<KOC'9MV=)Y4O
ML&[FZND\JT:=KL5P*X4-Z/W(]PBDL7P8HTN],!?R^(=_OAN5JQ/U#N=T2B3N
MCW@$# ("&FK-T/;!?5&@_P!26/\ N\-S2]FV_!GHR)P3FK]?OG6K5#A)\,\9
M]M0_9E$O8UUWOR1*^[@E _I]A7<$P"8H']-#3W1,4!*)B@;H)B@8HB'4 ,41
MZAM:[= CD7CU4HK%"'=J_)O)X,$J/>F.'YPY;W!.;:N5%-]#WP,4I"_1"40-
MT 0'5/6_UQJ[_O\ X1\:6C-LW;M>IVJ+W[]7Q"F&:Y]F.+Y!56O1A%9QG^TL
M*UC4;6T<Y6UO8%G_ .,N3&KPCH_LO%NO> N6[*&\P_:'\65RAO,/VA_%GC^W
M6.<?.OT1-UCG'SKN=X3:WT>(/&84ZMI)I&CZW$A=S<LV;"E]+"#N@;9K=-13
MF G=[Q@UD 3=X0* = R4/@I'[=9/P6O_ )8R.G!_U'O&/WC:U^*S=DIL]/,G
M&C\7\"TN]AL+_6/]2I]NSI/*O 7+4_[Y96Z!X38]Q?\ -:KJZ2HYUL"DM]\@
M 5[-&W?XJJ#OG3Z=FC2/YWWSH!=6W>H.7H'D$1VF[P^4 +U[H2,R/5?^J Y!
M?K53_P 7GS)"Y>(^]/MY/..7S<G?#VD?FVIC&,FH)C&,(F,8PB9%WF%PYH/G
M91[]Q[Y(11?+JV?71@D)T+3)Y'$'5NDL3<"N\6D#:\QEQ;EA%S$[:]3@F2K1
M7LJS;K#0\-+FA-L2'E%C"+6APBX.W'PJL.W&]-R@WWOQXMEY7V,:.6O5479[
MZBUM&8*X@J)P+;-7JH37,H@>V 0%"S;HSMHR-/J-Q;VMWURA>=0]:5NR_&,(
MF4'S?=+^,,KE!\WW2_C#"+','\>#&&L4PM/@1*L\'X<%8[>[XS7=WOCK'N";
MN]WO=WR=[KT\G3/6?GC]ED^\O_VY:8#_ &IM/_@5_P (K<]CE-C>Y;W3N]''
ML"FX]T[0#W1UC7I&OGMIYSRJR?GD]ED^\O\ E9&OD@UO[,TQBZ-;:V/)Z=<G
M%QE;,E2+5^V0T[*6X6*VV7T"8-GH\$3&""<IFXNO:=Q<82B0DUG.I*4TK\_D
MY";"&(<I3D.42F*8 ,4Q3 (&*8H@(&*8!$#%$! P"(" @(AG;I)O4M1',6F5
MC<YDL+G6;-3RL=#40.< 2ULT#Y(BX#.:'ES;. *Z]1&9H71M=VM_</BE:.ZA
MGB>R6"9HN+NBFC9( 38EMCH)4)*)ESE6#TV\<7IU:5;#N:]TAXR3=6M5+FNQ
MJB\$1P1PI"[#OV%63*IFY4E:MB+PV]7(*^"-2U**@2OXH9A?GC'S"R?>7_*R
M!,X@<1J]!LIJVDZLO&:0R)*[4U:")?O:W?C7.U"\5#+&%$IT%!5"69L?%([Z
M<L(N_6WL)5AZUDQM;21D!XP_RJY2\M^$%;L*Y=#(3R+:G.6M$:8+5U@^Q]ZV
MH]VA2KUM=CP:/(%#;IE;WI3^+V67Q-WTQMT<"[%"J*-2G<D;%5JQ-HR;B=-,
MZ>HP+,,N'XC#&Z5S:=I:!2U4,0>]D]-G-B>6AXCL&SNMVJIJLAX%A,W"GBM'
M1X(_#Z7+G$*B.FQ7 L0K(,.I\1Q![2^3&<*KZQT-&6UYC?4U=!-+#,:F227"
M8IX)I<.PC:M^>/V63[R__;C\\GLLG^*O^5D=8%S&H69';&9TFZ"N9VL1(]JV
MN[1T.=;2] X*$^K8H;-;7.T$>W.QT^_8?014T@L2K (&]+LV:CE,,G]*C2HU
M:]^C;KW:=I V:]VHY=FG9K,'4IR;=8FUG*8/*!BG$!#S#E6"HIJIN?35+)F\
M9BE:_-/(X DM<.-K@' Z" ="^5Q3!L7P284^+X76X;,;EC*VEFI^VM!'=PND
M8UDT3K7;+"Y\;VNSF.+7 JTF+(3 (&\1B!@$# )5P@8!#IT,'7H8!#J @/4.
MGD]G,4O%)QQU7'>$K*TQ5_-]%Z8H*X/<,>AV=1'PNY2Q;4NA>?J(]2NJ1?J.
M B4^HP>;.6,H5V%8=B<;8\1HJ:N9&[/B%5!%/VJ3BEA,C'.BE&MLD9:]ITM<
M" 1:S8ZVM-N4<W5KVE8$TQR^HL79XEF\4L!!K)T3M4]:E3.]$(3REU!,8SK#
M2IV& .X&]PB^TYAZ#MV^<^?,>XY(P@!+&@#U!NYT\*\)FY?.(@ =/)L-(8F"
MM2AU&'R 9X9&WNB/4X@4!-DA,=/Y^;+7^ JJDTX/CF(T;6CN:3$7G'* GR_5
M\GX6:T#0V*EQBEB:+ ,L $U:MQT@ZM=S?<1NT+'T;F2:8)?1D5DL)D*<  VP
M[0X;5YM'4>G=4ZD^X^Y,<!ZE'6HUZMA3?0F( ^3/3?GC]863[R_]D.]GDI+4
M-<2Q5XQ=XHVE> $Q];^U!N8)%JV#Y2[-;^Q;6YV Q# !R]Y6<H&#J)1ZB ^9
M+7=C1KJ>$6TZKDY>IR,-GMB>:(3& >@:=+^AV,$J2:A)]"!U+@\&((=X=9_-
MG'JS**CT5N#QXE$-!J<#K8VSN &F23#,5=2-@:.*.#%,1E-B&M<;79Q'ZH/-
M;9K!MR<IUGE64_SR>RR?XJ_Y6/SQ^RR?XJ_Y7^W,6^GRT8[U+,:F4NZ74( =
MZK!]12;28INO38:./I8W)"" !UV:4>AU,7J!=9MH^>ZM%WUD[+"-6V3:(\]F
M'NBP3)(OACV&T![HZB-TF3->[>?KY %+Z((?R"0Y@$!RI'E+@CI&0U%:[#:A
M[@UE-C$-1@\TK[AN; S$HJ7U5W1 SJ5TS':VO<-*9PV#G%M5N6W)TE>]_/'[
M+)]Y?_MQ^>3V63_%7_*R\:]FO:0NS6<FS6<H&)L(8#$.4P=2F*<HB4Q1#S"4
M1 ?6'/[R_  @$.<00""#H(.D$;"%S?8-W-U=)Y59/SQ^RR?>7_[<?GC]ED^\
MO_VY>\9SF^4[>E]@W<W5TE63\\?LLGWE_P#MQ^>3V63[/D7_ "O)^SE[QC-\
MIV]+[!NY+=6GG*LGYX_99/O+_P#;C\\GLLGWE_RLO>,9OE.WI?8-W-U=)Y59
M/SQ^RR?>7_[<?GC]ED^\O_VY>\8S?*=O2^P;N;JZ3RJR?GC]ED^\O_VX_/'[
M+)]Y?_MR]XQF^4[>E]@W<W5TGE5D_/)[+)_BK_E8_/)[+)]Y?\K+WC&;Y3MZ
M7V#=S=72>563\\GLLGWE_P K'YX_99/O+_\ ;E[QC-\IV]+[!NYNKI*LGYX_
M99/O+_\ ;E!],?0>HLGF'KT!?^Q]%E\RAO,/VA_%C-\IV]+[!NYNKI/*H\\?
M_">BKS\-W/"_D]33PG@^]X/O^+(YU[G>^B[OL=[R^SDA\CW0?T]>_O\ DU_@
MR.9(3(Q?FV_#](J4G?'F;]$)C&,J*"8QC"*.KWZJ*!^\W/?C3%<D5D=7OU44
M#]YN>_&F*Y(K*<>N7]H?H,4WZF>T'SN7/'VLWJB(;[T+3\;I7FKO-HG:S>J(
MAOO0M/QNE>:N\W&R"\#\ ]PM\[(M/LN/"W'O=Q\S$LU<;/5%4-[\%=_&AMSH
M_P"3O-BC.(RB&I;C<9,AVSO2_;V (]%7*2%V:XYL:]3D*LR 0!()#O"(-)=O
M4=X&V"0.FHV<X'&SU15#>_!7?QH;<EGV^'U:XP?K=;O[\K_-:NRRRCQ#)/ 8
M\>PL4[JZBH:80BJC=+ 14XU2TLF?&R2)SOR4S\VTC;.L3< @[:=A-D1@O"+E
M[29'Y0/KF83BM;B)JG8=/%35@-#DWB6(P=JFF@JHV U%)$),Z!^=%GL&:7!S
M9Q_\,_PB_3!97_V6R/\ VY_.SMHN$&O7LV&D%E]W5K/L-TJR2"/=UD$YN@=?
M*/=*/0/7'R9R$Y\ZSZ36?J-7^]]F>=__ $A\O_\ NLG_ /TZJV?\QV=//?UP
M;V$_ X7-!J\M=) ]F\-Y1_R+9TGE7^B-&W]NE4>8I.T&W':I$S-;ZVG4:3I]
MYV]X0)W%$;<GV?EFC:9,IU#LTG^CU'$Q#?1%'+UF+:.^LO4GO8U_\46;,I9N
MU1RNGI*6=]L^:F@E?FBS<Z2)KW9H)) N38$FPXRO*7$:=E)B%=2Q%QCIZNI@
MC+R"_,BF>QF<0 "[-:,X@ $W( U)C&,[*Z:9S\=KC]?.M/>F_P!<7W.@?.?C
MM<?KYUI[TW^N+[F1^"GPRH_<E?\ 5G+'7"GX'5GNO#_K<:U39DBF_KOU/[YU
M??&]FS&^9(IOZ[]3^^=7WQO9LV>K_6-;[DJ?,O6L]!Z^HO==-YYBGMV^/U-X
MM_KI</[S@6<Y.=&W;X_4WBW^NEP_O.!9SDYX-<-_Z3<I/\(^P<+7Z<>Q._0)
MD1^TRF_S9CB_%3]+*?U/O_<CYWX<9O4W\?O>1JCXAL.<!ZGZ64_J??\ N1\[
M\.,WJ;^/WO(U1\0V',B=C/[*Y5>]^&_6:E84[/#P>X.O?G'_ *CARS=C&,V\
M7FLF,8PBT@=L%]4:#_4EC_N\-S2]FZ'M@OJC0?ZDL?\ =X;FE[-M>#3P)P7F
MK_M.M6J/"3X9XS[:B^S*%>SK?ZXU=_W_ ,(^-+1FV;MVO4[5%[]^KXA3#-3-
M;_7&KO\ O_A'QI:,VS=NUZG:HO?OU?$*89KGV8_@%5^]%7]I84MK>P+_ $RY
M,?WCH_LS%5RW90WF'[0_BRN4-YA^T/XL\?VZQSCYU^B)NL<X^==V?!_U'O&/
MWC:U^*S=DILBSP?]1[QC]XVM?BLW9*;/3[)SP>P'WFPOZC O 3+7PRRM_O-C
MWVK5J/5?^J Y!?K53_Q>?,D+D>J_]4!R"_6JG_B\^9(7+M'WI]O)YQR^<D[X
M>TC\VU,8QDU!,8QA$QC&$3&,81,8QA$R@^;[I?QAE<H/F^Z7\881>/@/]J;3
M_P"!7_"*S/8YXV =?2DT=?/W%?L^Z*WV?+GLLBSO&^U;\P7+N^=SGYTQC&27
M"^%S:VUZ;ES0\($3JU.:3>@<FQR2)US>X(56LVE4C7(E6O<F5I%.DY]2A,HU
M;-.[48VO80Q3" ZLN5]8<KZ&@3('!%^F+@S+Y@U)'&J5"*/SM/!&X?#;TBJO
M]\SUJ'1CAFURUID,@C&UQ<FEE;MY-\<)&T6A27-K>.@#YPZY=L(Q>7":J.84
M])7TS9&R38;B,(JL/JBT$-[?3O[DO8'',E86RLN0UX:Y[76W$\,BQ*G?$9JB
MCG+"R*NHI33UM.'%I=VF=O=!K\T!\;LYC[ EN<UKFP>?+KC^R.I(]R_X]R**
MI2)$9WQZ>H,W7/2^U<*8A5*PLFB::6:6)$=4&WP8R]DC^U/K.0ISB!3;<ML+
MX_<7)RD"1\:+/?J^UB<=NQ;QNN9:CC^H3F[XIU<"%PDU?:.FSH.U(IAVG84_
M4NPA>H@,\N@?^GD_%F#IMQIH>PG$SW**MB:B1CL#:$L:4!HO,B;"F Q=FJ8Q
M;:RR;4<A@ 2F(Z@(" #[/7K3PY/8BXR5>'244YN1-1]KJXH_)@@JWQ5<6H=W
M^%GVMW+0!97K#<>RPP*)U/A./5#J)Y';:&:>>FAJ-%B:N.#MV'58L3>.;"2'
M7.<2L:^D#E]#0 8C?->VJCU")-31=E9#'WDZ?J $)LG54N+4F\,0G4/1.ZO5
M)SF #[2F$3&'^@N[D/$@$MC\4Y \I$Q@(ID%%6'$;&1;B@ "93HC,K/7,T G
M3O""9.TN*@0*!2>$V'+KRXFXY3"-@<U6<D[KB!>H^ 99DXLET1G27IT)I\%9
M#6Y2\J<H>0-22;(S 4I0U[-8]\3U$G,F,=X V<>K>1:"AW/#:YW2[^J$.]U[
MY]?Y++";<8 ( "72WZ>O?/T*'=UYU_P# =.'919E^]@JY9F2'4 )'8I3U--'
M:UR(L2 U]U97+\='2G^?<BL%Q BX=54= ,+<UM])B9DI6X,)7V/<R5>$5)OI
M<QQO?X-7-WCXA4:T$]D4CIMUV&*3Q==D"FM6" G$"E[KM*V1''=Y1-U*&Q,]
M;]9NZ8Q3FUAWLD7%9Y")TA*YPF81>8-QR%V$7Q:0-,@1G(< ,4Q5#2L5ZA 2
MB @/>#J ]<C[OO&RVQ-O363Q.M;4DV .A2H@#K75NL>[4<X$,)4**2,LJ4IA
M 3&[AX:&_P &7\L3%,)2#'Z4+.SLD+CZ(L.M6*KI+MW$V;'B84W/Z%D!51MG
M4IQG.J,0\PJ._KZCLT2+88>X4XG'7W#"_ F4S?S%/28J!?UD72!MK6SYL/FQ
M:._+^2C'( N?PQP=55A-^,F3<FMSYI:'%XW'C$5%B--DE/$SQ<_$*IP&DN=Q
M[+NH>N/3[?D_'TRN0$BU95-(#>B* YG6DS")"&2-L5O^/7*PZ $HEUE\06KJ
MLH=>OJ'4=.K<E,80[IC="@4,A^DCF3&"&%@O>H[)(!^NM+:-,N4:<#:A'R$V
MR*LYHA;PV@0.@[R0WNB<PG'0!2AK-;Y9*^F>8ZS":N)[>^[6Z![0.7-FDIJD
M\PIK[%W(\'P"M:)<+RSP=['6S(<5H\7P^J<3:P<ZCHL7PF,>4_%PWRK:5+C+
M6[L;+($9V]^:&QZ0;!Z[$+N@2.20X^;Z),MT[])O)[)/M9%HUE\N8X<NN1<:
M(5.=)!*&UPJ*]6X51R@(]_82/VE$H&0O0@=XNH)%NV"<?!@80#PIOV#EBE:3
MFU3^@N3-?!I(4RE:KJ19/F?4)NHFZ.]/N=B)A)K .I]IRZR '3R]?(%"2MH)
M6/BJF/;&\9LC*VBJ(X' VNU[ZB!L#QJOW;FZ-9LI_B;CKP#1LPS%2[2R+!\>
MP/%JIXXB*##\1J,0:3<69)2L??06@Z%DK90\*1G-OAZN55PJ,<3B>!R9R9T'
ME'O"48XJ.Y10Q!, &$AF+H(]?*'4>O\ 'I>O%@Z"S3Z*3A,4>Z"*>1G:Q.8Z
MP$O0!DD-VE2B<"@)?";(D?O";O'ZB'T7B&GFMQ7=E)$6R[89'' XZR^+)]O7
MULZD/L'H37M:[ 01I=JV&$! I-F@IC" ] \G7,^QV:0^7IRJXG*HW)TAPZD5
M1Y]:7I.<OG[Q=[8L5:S!T\O4##EGBP+)QY)PF08:^]Q^+^)2X?#GW'=R45#.
MS#YW:!?U323 Z;@W*M>(9/8[A(OBF!XOAC>(UV&UM$W?/#$#HU;%CO\ )(GK
M+_;?3DF+I(8Q#N<!=6>=H3"40 -I6XNUDE $V=>I2$8=YR /0W>$HCGV-U[U
M4N5ZVQ5+4D;>#B!/$LT3+X4[!M$>[X$$4I2M6S;L[W0H!H'< F$ *(B.9=Z@
M/G#V?.40_&&6]Q:VIZ2G0NS>WNR+;U#8C<4B9>EV@(" @=.JU[M1P$.H" D'
MR=0SL'#\H:;UGC\58S7F8YA<$TIM;N&5.$28,R(&Q&?+1U;Q>Y#SI5H-^(CX
M1?DY"-OPGB"^I.I3J].M0DWZ5*?:4#:MZ?:3?IV%$.H&)MU&/K,40\PE,(#Z
MPCG[YAW?0M7!NV*F:/;8<NV /1; GE[@^XIA$1$XZXPX-B/:;J/7\O2[2CT
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M3S&>/#G\O?WF$>N?P$"Y9LFH19N059RS84G0NNP*'WI=NTX#Y!4.$"LF-:0
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MRDHM7],I<4 O;3:LHHR2!HMG"]]-B=#\9L3?Z_R>R%Q;GP>KR?)T<N3.)8:
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M-[>RZ&[0TM94A%[U;V[86[)H[6=.P%- IHKOSA5J([J9U6-X1]XH^Y^>M?\
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MGK@9V4"/A%;$3F**TXC*X'2E!6AQDX^1&-4<TUK,FFJ;2O)DO%R47G9*":2
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M.*PB**)PF8#)E$A<J_CQ8+J6+#1]@D$W"/JIQ(YS>"+[.S_+;?EY_8  >8
M/L97"+\_!%]G9_EMOR\U,]L#S@E7"WCW"DM/SFL8!R*Y"6NQ5%2TJN7?X6M(
M@J1M;O84_G,Z0[-VHRB,,,!B+NT <NW637*Y7$=!S&,JUZMFVK(NVDT\6&*\
M:_O2WY- XW<5-TW=F^!OLXL@L<UPFG)*[5D6\9JGCCO(T$91,NAP9JS:)39*
M]H]$1M,M;8]Z86U%)E"!R(N?>R>UFY$<AY?0LCXF7++J=KBS.S5BG,'3$*^X
M 69S_F#[=SE<,WK"34])$-6J=+K7B*+R6);H&M=GA>RM:Z2(G-&F>D3AJ\(3
M$%V=K%VCD(DEMH7Q_54Q>-?0;@$PPSC(BX?C:U&27EARCX\PB<R3C[;W)QUL
M&(L]($>[CD2Z#L#W)K2;/2TT"G<$>^;+-*1N>=_E-TOV=_'G7.>;]3OU4PZ'
MV VS=;)[Y+>>URI<6&Q+K?;3F1V=^?)VX53&(^]7A*)"^;-<=,U-:24/;DV(
M2)/1>YO-CZ>[^R-L:M^5$SL*YN)4EJ3F<NC-6\E98]\EH3NKRPI!$*M21V*1
M,TB-8Q([$IFPUHWH79G30Q?'94BUH$<Y2CK=4>A\U$6-^8'/>TES!$JZ[/HJ
M&Z^1K-R/CE2<F(?5\7BEYRB@8RD@UI2"=[7"+3NY..\(![TS. H("V.<QLZ+
M,&A0X+%F[9O7ZT+6KA=$>W(89W;W9VTK7EU5%*M%C2^ ,G-6Q;+;V"A)PS2&
MU(7<_I$I>)4&[V/+G>'V8V3JN=.NYO"2*2L-=^B('$6R2/LDM1K3(]UEB\3>
M-')JIZ7CTI3OTTB=8A%II1MH0NZ;0C]E1[=HA2B*LTUA7(2N)VR6CN5R:"/:
MUL>Y*DG2HT^8WI6:1*GS6XGW;/W9.#/$J.1B@(='Z/A;/'N+S_%I11R-M3*T
MZB&/D-CTEB\><3NQ51GF3[DK;+Y%N4C+G%^!T?'+9)77T;(]2=TU$6IKLJNT
MLY5<P.23]![T8X^QU;.:*LB[J6<=-/2FKVV6I(3R==ZI0K:!L!YG\GU\C:A/
M5;A7DND=@N,8KQ];W>91!R1QTT?FR9.SQSHSM1^:KISP8(-8DED"[CO/>T>Y
M6\*2II3PV=J]HJ(1BLY/>$8J#=!>;+9.E;?.KQD4HKF'0]+6SW !129[>Y1'
M][JS.K2A=%.]#CUV>_$CBS/G&S*1K-=%92HC$A@S$+E8]I36/5S I9.!L>45
M]3<-G4TDD0I:!/TZ\!(W:%54QQ*.*W! T:]K<*5F:4R/#!."?9T5%=QK;?=9
M6BPXC*;HYJH(K8_)NX'FMH%*9 ^KW2YN2S!0DWM9=4$/4M<BG2Y8ZV2VP%#H
M@[M)?1#:XL:U=JV&(M5G'7FOVE?+.#Z+,@?)VB*>W5/V6'"WFG-8I8?&U%-H
M#;-J7^R<G'J7M\CE#=:%?R6JX+J"CFE*93&U3GO94KLL==.K;XN,@<MOW!B\
M[WY)">\)VW[6"B[RXJ<(>05%0\(IL:S5Z]W-74WD-R5^ZSS8LW*['?V1Y21-
MS5+SI&%,Q,C['&S0PZU&Q<]/N'(WV6?9=7C!8>ZP",*IW4314T$XTI&^L.55
M^GI^=55QP?)Y'8E5]D,$!N-)"+B:J_?9/8<;=FRQT<KWJ%3E(&"4>C@*H1DV
M>-C]74:?(_4#.ZP]@D.B%[WR+UJW*V=J==-?1)6RQ=2Z,$13'3J21&,K7:.Q
M]0J;D -+*H=&1LVF2G7(-.TB]N4H%#H'>'R]?HC&,/WS"(]/L=>GWQRN,81,
M8QA$QC&$3&,81,8QA$QC&$3&,81,8QA$QC&$3&,81,8QA$QC&$3&,81,8QA%
MJQ[7N?\ *NB^'-M<G.+=\16H77C95UGVS*HM*Z08K>16TFCL?3+F2+%<GF5Q
MW; 2I521=M4/+<B?MRTBXNK8BU@C(.Z)4BYY<E.%-X(^-UQR5XYZ6]-F;B2U
M0)L@U75-Q;9%,MY76;RQ9(VH4.RV<R_2E21MGX][D,J%Q,"/4VZ4S\S%6O"U
M<S9NRNRF:WY$5+8E&V_'O395]K1%Z@L\C7C1X9?'D6D*0Z)W;/&T?7M;VW>B
MTQS:_1;6XHEVCKWTZG4< -F)I[PGXTV9<\9Y!S6N?'-MP]332R/2OTU3)!XO
M4<?W2VWFIMGB5MD"1@4^E5RO2T5'=5MF\CSZ9O!/Q7/2T,FMN(M2[+V_$2/7
M6ZQIKQ'N&OVZ70QK>*'2/%A5$Z;+=F8\H6#AS*H0I6L;ZK0UX6)W:_E5*)-(
MMJMO7U6W.,^UHDRW7HB6^4SIVH2-Q[./DES7CM5/L<FM#IK7AAJUE:G4]L3I
M<$-7HXS$2,$XCI-#3/JIF4@DD.=F>P(N37H<(L[*?"(VQ_;7-I0YN6=E]PA7
M0)EK;;3BG1%8S&Y/%XOK;;*M=G?8JCEM_,'*-Q=8O+FB;H99')<@ON+L%D1>
M;LKTAE\->6M,GBKTT-7A&_9>Y'V?''=TXA7=PQ9FF3,]:7PS6GKFC^]SF<V7
M8RZ;6SL5NC_:3K8EFR:5S:33]-*MJ*5H'V1R)PWZ'1H:]6HVI"C3IM1%K)A7
M:MWI1ER<@JFY,U4[6W759\KV_BG&^3$"V5Y!6,]FI.!<!Y);HBZ5<=U4R[=I
MDLI:+)<U$N2$4-,/03*#1X2/A6MX5HI$\:^T&NNYKGX7O-A4ZII*EN>O'&UI
MQ4E=29ZALTGT?E55H*WMJ'S5QF< <UK*#!=M'6D[J]L&>4Z>10-]JS0._ILE
M#BC22?1=GEQ\D<+UMESQ-#9$\DUK1KDA;LS;'*<PINL#D\V<?6SC=(+=0Q=O
MFJTD122"N4&YKT0) ZJXPT$5 J#0N?M(ONZZQCA)"XG??'6SF5V!#67$7BX]
M<;..--:VY6KT009@IA#3+YTXS=U>G!]DSB>M:JKFN(N@<M/AF5OU3=W='>0.
M$OT Q$4W,8QA$QC&$3&,81,8QA$QC&$3&,81,8QA$QC&$3&,81,8QA$SF[[6
M2I;2O#DM<%1Q6/KI9(++[*2=-/'&%KGQ!'FNT9-$^6U;SCEM2T8<WW7I8],L
MMFGF>G8H[ZM[HB/OBN\^Q8;0QI7-S;6,(O>UI&;7=XGVGRV-</>2=;1/GY)+
M.UT)56EHKJIY+'UD&X"0*M'Z?3C<ZNKC'J'?+[LF,.,+K5SD+=)DZJ4,;#*I
M<R-3,\[W!5Z#LN*QY$5E7/*&#Z(ARBAW'E@IZBX?Q=9^6L?J&+\D6ZRHQ4$M
M9;:CZ%14++&CN%31E46JV6MW-^TF.69I[%-"%AX/XEW&8PBAG5W$+M!X17E*
MV&:Q>T!=;=CM,]C#8[]%IER?N"7QX_(B9\CD\:[2E+*(?(IXXLDE;6+CZQH2
M3*M9!J=:TBS>ZNTDB\7URU>9YUX=;>(?:@-%#Z9H2PNT4673HXCZ[/W1M=R=
MN1Q+NY?M/-DNN-(=,=46*+(72P\8#KV0:I,FV59+8DJ3/4[C$GFC:BD!&,(O
MBY*\=.TFN&&7_6WI YGRBR9DDYLMG*=1.[$=95Q0LZ(2+D'%GWA8W\/8$[6&
M]Q-C<XK#6R,K&KTAPR!O4<@S=9C+="Q?*')KT+LF65QGY\*K#@7*6NZONEI2
M62OY3WIS%KV%NCI7O(:PJ0GG.;CFKA/&"L[ 3OL7?:WMM'Q.J.#+=[:A6L+W
M,F2NI55\?E< =)F60HV,(L 5]R"6._*)>P\CK=Y&S"-):9[:]X[0,[OR#63C
MAO,*E@TG31"K#5=4#59<OC=;,E9P)W25J5H>*NKMWCTO6+8C)4,DL@791G4/
MV<S9:3-P#X4M%VZ7!/;C7Q3H!OL9,\$5ZWY++T=6Q=.\I9&"X15#)4JC7Z'D
MAMW=,=]U.!^X0# 0K&$4SL8QA%S6=K-35CWIR>NVJH\PN$GDEE=E2J;N-<+W
MNS>T-]M.]=<SX+:/-"D8YN?MB1DW2NU*H8*!BZM$K=$6A9&UVT[N46%&XKF[
M)E=1:U'BM>TY-&N&_)&LXWV@\PN191=8)4$#JJ7QD8MP%K2JGV93X7A\?HG0
MDFO2RX._QRL')W9I"F<)0GCLGFK.VLSN9QV,81>E[,.O.15=UORJAZ:%\HX?
MQ]8:CI")<4V;EK&*?A_)-+84:IJ5-5KL6G?4+8PJ'&L(\Y?D8LM=.4EU@H3S
M'18>B$*CP'1'MYX2UGQ'[0^!H(7+_P D'G\_S>NJ_P"Q.G[<W3+D[<TICLKN
MJ:WGK8.T[332&OMB.$?E3*RTJVH23*NW=.H@$/0;U;]$6'1*%JIWVL818I:^
M(?:=M%%)9T$_[1===Z+B2@L_TM+N4-Q.*/=R^8^:^S2R)31118(LBCQ;QAW*
M&4]5;2&J.31#;J>9G#I+-DJ.1I[5R)X[]I5<$&O^L]M?\T979$O:^;+3RM5V
M#8+G*N*]I1U]Y$Q%\X5H^'4#=IXYQ1C<XO!V]C6MFVO(97JE@@S?8S'<P.TL
M<F8!8PBRC8W&?GD%AUKRG@E6W@T(K%6\H[WYH5W7RU3 ^1=A4S9?.KCFYPWC
M/6T\0/T:>Z_MECXJ55 E:MI0/#*_S:.5C+JK89E G29Z7]OC]7U\OLDY'N[3
MR*M;D',F%NHCMJWKM"M;_P CAG'$";5K#)<FA=3$JNF&RSI3&80UUS"'U#6I
MV;=5U>KXY*-RV+R-I?[%UR%=I8PBZG> ".RF_@KPS0W*1XU6VCXK<?4UFZI&
M"LLCTSO14\3U2C1) 7%(L&1Z'<JG2_F4$)M,[D6F.0AA,4)=8QA$SF8Y\5K9
M=F<Q>9;!JKYPMB4,-6]D/?-55,Q:VUQD]S\5>.'.";65R]K*#-4H=FN..C_M
ME+:PN,JC!U:-)*-ZNH6=[/L4.<?Z,812UX-MUD5E67* \WXDV^F9N4O);G#R
M[J>GY/#HJ5%"H$DW5J:&UQ:C)LD+@U5_8?(*8:)%8L+A*1$\%V;7:2N$M4QZ
M2Z56A;KWG_ VQZWXQ<%9M)JLYHN?(9TW\F>3O).6<)6FB-T[8>:_*&G6A.".
MPZNL^.R)N>X;%DKBYT)"71B6((U7T3@<:B\VT[X2][U*!C"+8-;U%<R+TJWL
MCJWMUYN.!2#QMI4=H.NXI6Q***2-:]LX16P=6T+992DEBZA!!U?(W5"VA,@B
M2_Q)XVW-VN/F2-Q4*Q/KZI;BMVC;A ^-45LZ=\\]07'#.S$F7+I<Y<C;7T2=
MBLADMGD;IY<,S'*44[TR.I&Q\JXE31^THW53I%V38SF8GQJ3)YCZ(D1F,(O&
M1?COVH-?4E$W;8_]H9*W:;5\]ZN4D:T\AYW)+740&N^TJ@38CC]!*)S8)VZM
MKL>>!FV6Z8^\P9QBTPG\81."]?(E]KK&J0FNB3CGS0M"0,<<D]2\J0I:[G6\
M.+T%<KS<ETYN2K.$5L\V^(=AOS5>\O>7R8S'0=32-8\DFV%;;/DS_.DT2?:Z
MCLPD O!T:,K&$6 BUQSIXD0:[76\%_(BMJ"G=^RMXJ]-5-PZ:&;JMX_SGM;)
MM(.0E%H]99Y"(^V\I^4%=3N'SGCI>#G(DLFD57O;W1%:2&J)>B3[9I(;A-93
MW;%F<!7.*N5SRV1H.U:[3X:\<>0$^>K8LZ(<"H)2MH0"?1Y_L)?*)D=\A+#9
MKK0<-;#C*Y@V:9JFA#<XR1YES7O>-S&$76<7KW2][^RZ!U^WT\O[.5QC")C&
M,(F,8PB8QC")C&,(F,8PB8QC")C&,(F,8PB8QC")C&,(F,8PB8QC")C&,(F,
H8PB8QC")C&,(F,8PB8QC")C&,(F,8PB8QC")C&,(F,8PB8QC"+__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
